drugbank-id,name,type,description,state,indication,mechanism-of-action,food-interactions,targets
"['DB00001', 'BTD00024', 'BIOD00024']",['Lepirudin'],biotech,"['Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches.[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine at position 1 (N-terminal end).[A246609] \r\n\r\nLepirudin is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT), an immune reaction associated with a high risk of thromboembolic complications.[A3, L41539] HIT is caused by the expression of immunoglobulin G (IgG) antibodies that bind to the complex formed by heparin and platelet factor 4. This activates endothelial cells and platelets and enhances the formation of thrombi.[A246609] Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.[L41574]']",['solid'],"['Lepirudin is indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction without ST elevation. In patients with ACS, lepirudin is intended for use with [aspirin].[L41539] Lepirudin is also indicated for anticoagulation in patients with heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease in order to prevent further thromboembolic complications.[L41539]']","['Lepirudin is a direct thrombin inhibitor used as an anticoagulant in patients for whom heparin is contraindicated.[L41539,A3] Thrombin is a serine protease that participates in the blood-clotting cascade, and it is formed by the cleavage of pro-thrombin. Active thrombin cleaves fibrinogen and generates fibrin monomers that polymerize to form fibrin clots.[A246624]\r\n\r\nLepirudin binds to the catalytic and substrate-binding sites of thrombin, forming a stable, irreversible and non-covalent complex.[A246609] This blocks the protease activity of thrombin and inhibits the coagulation process. Each molecule of lepirudin binds to a single molecule of thrombin,[L41539] and unlike [heparin], it is able to inhibit thrombin in both its clot-bound or free states.[A246609]']","[{'food-interaction': ['Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include chamomile, garlic, ginger, ginkgo and ginseng.']}]","[{'target': [{'id': ['BE0000048'], 'name': ['Prothrombin'], 'organism': ['Humans'], 'actions': [{'action': ['inhibitor']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1703'], 'pubmed-id': ['10505536'], 'citation': ['Turpie AG: Anticoagulants in acute coronary syndromes. Am J Cardiol. 1999 Sep 2;84(5A):2M-6M.']}, {'ref-id': ['A1705'], 'pubmed-id': ['10912644'], 'citation': ['Warkentin TE: Venous thromboembolism in heparin-induced thrombocytopenia. Curr Opin Pulm Med. 2000 Jul;6(4):343-51.']}, {'ref-id': ['A1707'], 'pubmed-id': ['11055889'], 'citation': ['Eriksson BI: New therapeutic options in deep vein thrombosis prophylaxis. Semin Hematol. 2000 Jul;37(3 Suppl 5):7-9.']}, {'ref-id': ['A1709'], 'pubmed-id': ['11467439'], 'citation': ['Fabrizio MC: Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass. J Extra Corpor Technol. 2001 May;33(2):117-25.']}, {'ref-id': ['A1711'], 'pubmed-id': ['11807012'], 'citation': ['Szaba FM, Smiley ST: Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood. 2002 Feb 1;99(3):1053-9.']}]}], 'textbooks': [None], 'links': [{'link': [{'ref-id': ['L41539'], 'title': ['Health Canada Approved Drug Products: Refludan (lepirudin) lyophilized powder for intravenous injection'], 'url': ['https://pdf.hres.ca/dpd_pm/00004023.PDF']}]}], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Prothrombin'], 'general-function': ['Thrombospondin receptor activity'], 'specific-function': ['Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.'], 'gene-name': ['F2'], 'locus': ['11p11-q12'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-24'], 'theoretical-pi': ['5.7'], 'molecular-weight': ['70036.295'], 'chromosome-location': ['11'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3535']}, {'resource': ['GenAtlas'], 'identifier': ['F2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M17262']}, {'resource': ['GenBank Protein Database'], 'identifier': ['339641']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2362']}, {'resource': ['UniProtKB'], 'identifier': ['P00734']}, {'resource': ['UniProt Accession'], 'identifier': ['THRB_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.21.5', 'Coagulation factor II']}], 'amino-acid-sequence': ['>lcl|BSEQ0016004|Prothrombin\nMAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC\nVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV\nNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE\nCSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA\nQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG\nDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI\nDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN\nDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP\nVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST\nRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY\nGFYTHVFRLKKWIQKVIDQFGE'], 'gene-sequence': ['>lcl|BSEQ0016005|Prothrombin (F2)\nATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC\nCTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG\nGTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGC\nGTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG\nGATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT\nGCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG\nAACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT\nGAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC\nGACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA\nTGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA\nGGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG\nTACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA\nCAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC\nTTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT\nGGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA\nGATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC\nCAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT\nCTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC\nGACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG\nCTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG\nGTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT\nGACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACCAGGTACGAGCGAAACATTGAAAAG\nATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC\nCGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT\nGTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG\nGTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC\nAGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC\nCGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA\nGGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC\nCGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT\nGGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT\nGGAGAGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00594'], 'name': ['Gla']}, {'identifier': ['PF00051'], 'name': ['Kringle']}, {'identifier': ['PF00089'], 'name': ['Trypsin']}, {'identifier': ['PF09396'], 'name': ['Thrombin_light']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular matrix']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['Golgi lumen']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['growth factor activity']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase activity']}, {'category': ['function'], 'description': ['thrombospondin receptor activity']}, {'category': ['process'], 'description': ['acute-phase response']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, intrinsic pathway']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['cellular response to mechanical stimulus']}, {'category': ['process'], 'description': ['cytosolic calcium ion homeostasis']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['multicellular organismal development']}, {'category': ['process'], 'description': ['negative regulation of astrocyte differentiation']}, {'category': ['process'], 'description': ['negative regulation of fibrinolysis']}, {'category': ['process'], 'description': ['negative regulation of platelet activation']}, {'category': ['process'], 'description': ['negative regulation of proteolysis']}, {'category': ['process'], 'description': ['peptidyl-glutamic acid carboxylation']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['positive regulation of blood coagulation']}, {'category': ['process'], 'description': ['positive regulation of cell growth']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of collagen biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of phosphatidylinositol 3-kinase signaling']}, {'category': ['process'], 'description': ['positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of reactive oxygen species metabolic process']}, {'category': ['process'], 'description': ['positive regulation of release of sequestered calcium ion into cytosol']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['proteolysis']}, {'category': ['process'], 'description': ['regulation of blood coagulation']}, {'category': ['process'], 'description': ['regulation of cell shape']}, {'category': ['process'], 'description': ['regulation of gene expression']}, {'category': ['process'], 'description': ['response to inactivity']}, {'category': ['process'], 'description': ['response to wounding']}]}]}]}]}]"
"['DB00002', 'BTD00071', 'BIOD00071']",['Cetuximab'],biotech,"['Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF).[A227973] EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelial tissue development and homeostasis.[A228083] EGFR has been implicated in various types of cancer, as it is often overexpressed in malignant cells [A227973] and EGFR overexpression has been linked to more advanced disease and poor prognosis.[A227963] EGFR is often mutated in certain types of cancer and serves as a driver of tumorigenesis.[A228083] _In vitro_, cetuximab was shown to mediate anti-tumour effects in numerous cancer cell lines and human tumour xenografts.[A227963]\r\n\r\nApproved by the FDA in February 2004 under the brand name ERBITUX, cetuximab is used for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with a BRAF V600E mutation.[A227963,L39045] It has also been investigated in advanced colorectal cancer, EGFR-expressing non-small cell lung cancer (NSCLC), and unresectable squamous cell skin cancer.[L31418] Cetuximab is administered via intravenous infusion and is used as monotherapy or in combination with other chemotherapies, including platinum agents, radiation therapy, [leucovorin], [fluorouracil], and [irinotecan].[L30448]']",['liquid'],"['Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy.[L30448]\r\n\r\nCetuximab is also indicated for K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with FOLFIRI, a chemotherapy combination that includes [leucovorin], [fluorouracil], and [irinotecan]; in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy; or as monotherapy in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.[L30448]\r\n\r\nAdditionally, cetuximab is also indicated for metastatic colorectal cancer that is BRAF V600E mutation-positive (as determined by an FDA-approved test) in combination with [encorafenib] but only after prior therapy.[L39045]\r\n\r\nCetuximab is not indicated for the treatment of Ras-mutant colorectal cancer or when the results of the Ras mutation tests are unknown.[L30448]']","['The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and a type I receptor tyrosine kinase expressed on both normal and malignant cells. It has been investigated as a therapeutic target for anticancer treatment, as it is often upregulated in cancer types, including head and neck, colon, and rectal cancers.[L30448] When activated by its ligand, EGFR undergoes a conformational change and dimerization to form homodimers or heterodimers with another member of the ErbB family of receptors. Dimerization of EGFR activates the intracellular tyrosine kinase region of EGFR and promotes autophosphorylation, initiating a series of downstream signalling cascades, including cell differentiation, proliferation, migration, angiogenesis, and apoptosis. This EGFR signalling pathway is often dysregulated in cancer cells, leading to aberrant cell growth and enhanced cell survival.[L31418]\r\n\r\nCetuximab is a monoclonal antibody that binds specifically to the EGFR on both normal and tumour cells to competitively inhibit the binding of epidermal growth factor (EGF) and other ligands that are produced by normal and tumour tissue epithelial cells.[A11, L30448] Upon binding to domain III of EGFR - which is the binding site for its growth factor ligands - cetuximab prevents the receptor from adopting an extended conformation and thereby inhibits EGFR activation, as well as phosphorylation and activation of receptor-associated kinases (MAPK, PI3K/Akt, Jak/Stat).[A11, A228078] Inhibition of the EGFR signalling pathway ultimately leads to inhibition of cell cycle progression, cell survival pathways, and tumour cell motility and invasion.[A227963] Cetuximab also induces cell apoptosis and decreases matrix metalloproteinase and vascular endothelial growth factor (VEGF) production.[A228078, L30448] _In vitro_, cetuximab was shown to inhibit tumour angiogenesis.[A227978] Binding of cetuximab to EGFR also results in internalization of the antibody-receptor complex, leading to an overall downregulation of EGFR expression.[A227973]\r\n\r\nK-ras is a small G-protein downstream of EGFR that plays an important role in promoting the EGFR signalling cascade: in some malignant cells, K-ras can acquire activating mutations in exon 2 [L31418] and thus be continuously active regardless of EGFR regulation.[L30448] Since mutant Ras proteins can isolate the pathway from the effect of EGFR, K-Ras mutations can render EGFR inhibitors like cetuximab ineffective in exerting anti-tumour effects.[L30448, L31418] Cetuximab is thus only limited in its use for K-Ras wild-type, EGFR-expressing cancers.[L30448]']",[None],"[{'target': [{'id': ['BE0000767'], 'name': ['Epidermal growth factor receptor'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A227973'], 'pubmed-id': ['15821783'], 'citation': ['Harding J, Burtness B: Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc). 2005 Feb;41(2):107-27. doi: 10.1358/dot.2005.41.2.882662.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Epidermal growth factor receptor'], 'general-function': ['Ubiquitin protein ligase binding'], 'specific-function': ['Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin.Isoform 2 may act as an antagonist of EGF action.'], 'gene-name': ['EGFR'], 'locus': ['7p12'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['646-668'], 'signal-regions': ['1-24'], 'theoretical-pi': ['6.67'], 'molecular-weight': ['134276.185'], 'chromosome-location': ['7'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3236']}, {'resource': ['GenAtlas'], 'identifier': ['EGFR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X00588']}, {'resource': ['GenBank Protein Database'], 'identifier': ['757924']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1797']}, {'resource': ['UniProtKB'], 'identifier': ['P00533']}, {'resource': ['UniProt Accession'], 'identifier': ['EGFR_HUMAN']}]}], 'synonyms': [{'synonym': ['2.7.10.1', 'ERBB', 'ERBB1', 'HER1', 'Proto-oncogene c-ErbB-1', 'Receptor tyrosine-protein kinase erbB-1']}], 'amino-acid-sequence': ['>lcl|BSEQ0001530|Epidermal growth factor receptor\nMRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEV\nVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALA\nVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDF\nQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGC\nTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV\nVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFK\nNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAF\nENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKL\nFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCN\nLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM\nGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVV\nALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGS\nGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGI\nCLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAA\nRNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY\nGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPK\nFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQ\nQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTED\nSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLN\nTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRV\nAPQSSEFIGA'], 'gene-sequence': ['>lcl|BSEQ0019007|Epidermal growth factor receptor (EGFR)\nATGCGACCCTCCGGGACGGCCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCG\nGCGAGTCGGGCTCTGGAGGAAAAGAAAGTTTGCCAAGGCACGAGTAACAAGCTCACGCAG\nTTGGGCACTTTTGAAGATCATTTTCTCAGCCTCCAGAGGATGTTCAATAACTGTGAGGTG\nGTCCTTGGGAATTTGGAAATTACCTATGTGCAGAGGAATTATGATCTTTCCTTCTTAAAG\nACCATCCAGGAGGTGGCTGGTTATGTCCTCATTGCCCTCAACACAGTGGAGCGAATTCCT\nTTGGAAAACCTGCAGATCATCAGAGGAAATATGTACTACGAAAATTCCTATGCCTTAGCA\nGTCTTATCTAACTATGATGCAAATAAAACCGGACTGAAGGAGCTGCCCATGAGAAATTTA\nCAGGAAATCCTGCATGGCGCCGTGCGGTTCAGCAACAACCCTGCCCTGTGCAACGTGGAG\nAGCATCCAGTGGCGGGACATAGTCAGCAGTGACTTTCTCAGCAACATGTCGATGGACTTC\nCAGAACCACCTGGGCAGCTGCCAAAAGTGTGATCCAAGCTGTCCCAATGGGAGCTGCTGG\nGGTGCAGGAGAGGAGAACTGCCAGAAACTGACCAAAATCATCTGTGCCCAGCAGTGCTCC\nGGGCGCTGCCGTGGCAAGTCCCCCAGTGACTGCTGCCACAACCAGTGTGCTGCAGGCTGC\nACAGGCCCCCGGGAGAGCGACTGCCTGGTCTGCCGCAAATTCCGAGACGAAGCCACGTGC\nAAGGACACCTGCCCCCCACTCATGCTCTACAACCCCACCACGTACCAGATGGATGTGAAC\nCCCGAGGGCAAATACAGCTTTGGTGCCACCTGCGTGAAGAAGTGTCCCCGTAATTATGTG\nGTGACAGATCACGGCTCGTGCGTCCGAGCCTGTGGGGCCGACAGCTATGAGATGGAGGAA\nGACGGCGTCCGCAAGTGTAAGAAGTGCGAAGGGCCTTGCCGCAAAGTGTGTAACGGAATA\nGGTATTGGTGAATTTAAAGACTCACTCTCCATAAATGCTACGAATATTAAACACTTCAAA\nAACTGCACCTCCATCAGTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCC\nTTCACACATACTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAA\nATCACAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCTTT\nGAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTCTTGCAGTC\nGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGATAAGTGATGGAGAT\nGTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATACAATAAACTGGAAAAAACTG\nTTTGGGACCTCCGGTCAGAAAACCAAAATTATAAGCAACAGAGGTGAAAACAGCTGCAAG\nGCCACAGGCCAGGTCTGCCATGCCTTGTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCC\nAGGGACTGCGTCTCTTGCCGGAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAAC\nCTTCTGGAGGGTGAGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCA\nGAGTGCCTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC\nCAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGAGTCATG\nGGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGTGTGCCACCTGTGC\nCATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGAAGGCTGTCCAACGAATGGG\nCCTAAGATCCCGTCCATCGCCACTGGGATGGTGGGGGCCCTCCTCTTGCTGCTGGTGGTG\nGCCCTGGGGATCGGCCTCTTCATGCGAAGGCGCCACATCGTTCGGAAGCGCACGCTGCGG\nAGGCTGCTGCAGGAGAGGGAGCTTGTGGAGCCTCTTACACCCAGTGGAGAAGCTCCCAAC\nCAAGCTCTCTTGAGGATCTTGAAGGAAACTGAATTCAAAAAGATCAAAGTGCTGGGCTCC\nGGTGCGTTCGGCACGGTGTATAAGGGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATT\nCCCGTCGCTATCAAGGAATTAAGAGAAGCAACATCTCCGAAAGCCAACAAGGAAATCCTC\nGATGAAGCCTACGTGATGGCCAGCGTGGACAACCCCCACGTGTGCCGCCTGCTGGGCATC\nTGCCTCACCTCCACCGTGCAGCTCATCACGCAGCTCATGCCCTTCGGCTGCCTCCTGGAC\nTATGTCCGGGAACACAAAGACAATATTGGCTCCCAGTACCTGCTCAACTGGTGTGTGCAG\nATCGCAAAGGGCATGAACTACTTGGAGGACCGTCGCTTGGTGCACCGCGACCTGGCAGCC\nAGGAACGTACTGGTGAAAACACCGCAGCATGTCAAGATCACAGATTTTGGGCTGGCCAAA\nCTGCTGGGTGCGGAAGAGAAAGAATACCATGCAGAAGGAGGCAAAGTGCCTATCAAGTGG\nATGGCATTGGAATCAATTTTACACAGAATCTATACCCACCAGAGTGATGTCTGGAGCTAC\nGGGGTGACCGTTTGGGAGTTGATGACCTTTGGATCCAAGCCATATGACGGAATCCCTGCC\nAGCGAGATCTCCTCCATCCTGGAGAAAGGAGAACGCCTCCCTCAGCCACCCATATGTACC\nATCGATGTCTACATGATCATGGTCAAGTGCTGGATGATAGACGCAGATAGTCGCCCAAAG\nTTCCGTGAGTTGATCATCGAATTCTCCAAAATGGCCCGAGACCCCCAGCGCTACCTTGTC\nATTCAGGGGGATGAAAGAATGCATTTGCCAAGTCCTACAGACTCCAACTTCTACCGTGCC\nCTGATGGATGAAGAAGACATGGACGACGTGGTGGATGCCGACGAGTACCTCATCCCACAG\nCAGGGCTTCTTCAGCAGCCCCTCCACGTCACGGACTCCCCTCCTGAGCTCTCTGAGTGCA\nACCAGCAACAATTCCACCGTGGCTTGCATTGATAGAAATGGGCTGCAAAGCTGTCCCATC\nAAGGAAGACAGCTTCTTGCAGCGATACAGCTCAGACCCCACAGGCGCCTTGACTGAGGAC\nAGCATAGACGACACCTTCCTCCCAGTGCCTGAATACATAAACCAGTCCGTTCCCAAAAGG\nCCCGCTGGCTCTGTGCAGAATCCTGTCTATCACAATCAGCCTCTGAACCCCGCGCCCAGC\nAGAGACCCACACTACCAGGACCCCCACAGCACTGCAGTGGGCAACCCCGAGTATCTCAAC\nACTGTCCAGCCCACCTGTGTCAACAGCACATTCGACAGCCCTGCCCACTGGGCCCAGAAA\nGGCAGCCACCAAATTAGCCTGGACAACCCTGACTACCAGCAGGACTTCTTTCCCAAGGAA\nGCCAAGCCAAATGGCATCTTTAAGGGCTCCACAGCTGAAAATGCAGAATACCTAAGGGTC\nGCGCCACAAAGCAGTGAATTTATTGGAGCATGA'], 'pfams': [{'pfam': [{'identifier': ['PF07714'], 'name': ['PK_Tyr_Ser-Thr']}, {'identifier': ['PF00757'], 'name': ['Furin-like']}, {'identifier': ['PF01030'], 'name': ['Recep_L_domain']}, {'identifier': ['PF14843'], 'name': ['GF_recep_IV']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['basolateral plasma membrane']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['early endosome membrane']}, {'category': ['component'], 'description': ['endocytic vesicle']}, {'category': ['component'], 'description': ['endoplasmic reticulum membrane']}, {'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['endosome membrane']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['Golgi membrane']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['membrane raft']}, {'category': ['component'], 'description': ['multivesicular body, internal vesicle lumen']}, {'category': ['component'], 'description': ['nuclear membrane']}, {'category': ['component'], 'description': ['nucleus']}, {'category': ['component'], 'description': ['perinuclear region of cytoplasm']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['component'], 'description': ['Shc-EGFR complex']}, {'category': ['function'], 'description': ['actin filament binding']}, {'category': ['function'], 'description': ['ATP binding']}, {'category': ['function'], 'description': ['chromatin binding']}, {'category': ['function'], 'description': ['double-stranded DNA binding']}, {'category': ['function'], 'description': ['enzyme binding']}, {'category': ['function'], 'description': ['epidermal growth factor-activated receptor activity']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['function'], 'description': ['MAP kinase kinase kinase activity']}, {'category': ['function'], 'description': ['protein heterodimerization activity']}, {'category': ['function'], 'description': ['protein phosphatase binding']}, {'category': ['function'], 'description': ['protein tyrosine kinase activity']}, {'category': ['function'], 'description': ['receptor signaling protein tyrosine kinase activity']}, {'category': ['function'], 'description': ['transmembrane receptor protein tyrosine kinase activity']}, {'category': ['function'], 'description': ['transmembrane signaling receptor activity']}, {'category': ['function'], 'description': ['ubiquitin protein ligase binding']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['activation of phospholipase A2 activity by calcium-mediated signaling']}, {'category': ['process'], 'description': ['activation of phospholipase C activity']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['cell proliferation']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular response to amino acid stimulus']}, {'category': ['process'], 'description': ['cellular response to epidermal growth factor stimulus']}, {'category': ['process'], 'description': ['cellular response to estradiol stimulus']}, {'category': ['process'], 'description': ['cerebral cortex cell migration']}, {'category': ['process'], 'description': ['digestive tract morphogenesis']}, {'category': ['process'], 'description': ['embryonic placenta development']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['hair follicle development']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['learning or memory']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['morphogenesis of an epithelial fold']}, {'category': ['process'], 'description': ['negative regulation of apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['negative regulation of protein catabolic process']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['ossification']}, {'category': ['process'], 'description': ['peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['phosphatidylinositol-mediated signaling']}, {'category': ['process'], 'description': ['positive regulation of catenin import into nucleus']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle']}, {'category': ['process'], 'description': ['positive regulation of DNA repair']}, {'category': ['process'], 'description': ['positive regulation of DNA replication']}, {'category': ['process'], 'description': ['positive regulation of epithelial cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['positive regulation of fibroblast proliferation']}, {'category': ['process'], 'description': ['positive regulation of MAP kinase activity']}, {'category': ['process'], 'description': ['positive regulation of nitric oxide biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['protein autophosphorylation']}, {'category': ['process'], 'description': ['protein insertion into membrane']}, {'category': ['process'], 'description': ['Ras protein signal transduction']}, {'category': ['process'], 'description': ['regulation of nitric-oxide synthase activity']}, {'category': ['process'], 'description': ['regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['response to stress']}, {'category': ['process'], 'description': ['response to UV-A']}, {'category': ['process'], 'description': ['salivary gland morphogenesis']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['single organismal cell-cell adhesion']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}]}]}]}, {'id': ['BE0000901'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor III-B'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A11'], 'pubmed-id': ['16336752'], 'citation': ['Snyder LC, Astsaturov I, Weiner LM: Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S71-80.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor III-B'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.'], 'gene-name': ['FCGR3B'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': [None], 'signal-regions': ['1-16'], 'theoretical-pi': ['6.71'], 'molecular-weight': ['26215.64'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3620']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR3B']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X16863']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31322']}, {'resource': ['UniProtKB'], 'identifier': ['O75015']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG3B_HUMAN']}]}], 'synonyms': [{'synonym': ['CD16B', 'Fc-gamma RIII', 'Fc-gamma RIII-beta', 'Fc-gamma RIIIb', 'FCG3', 'FCGR3', 'FcR-10', 'FcRIII', 'FcRIIIb', 'IGFR3', 'IgG Fc receptor III-1']}], 'amino-acid-sequence': ['>lcl|BSEQ0010635|Low affinity immunoglobulin gamma Fc region receptor III-B\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI'], 'gene-sequence': ['>lcl|BSEQ0010636|Low affinity immunoglobulin gamma Fc region receptor III-B (FCGR3B)\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['anchored component of membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['mitophagy in response to mitochondrial depolarization']}, {'category': ['process'], 'description': ['positive regulation of defense response to virus by host']}, {'category': ['process'], 'description': ['xenophagy']}]}]}]}, {'id': ['BE0002094'], 'name': ['Complement C1q subcomponent subunit A'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A202103'], 'pubmed-id': ['32117299'], 'citation': ['Deveuve Q, Lajoie L, Barrault B, Thibault G: The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass. Front Immunol. 2020 Feb 11;11:168. doi: 10.3389/fimmu.2020.00168. eCollection 2020.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Complement C1q subcomponent subunit A'], 'general-function': [None], 'specific-function': ['C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.'], 'gene-name': ['C1QA'], 'locus': ['1p36.12'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-22'], 'theoretical-pi': ['9.45'], 'molecular-weight': ['26016.47'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1241']}, {'resource': ['GenAtlas'], 'identifier': ['C1QA']}, {'resource': ['GenBank Gene Database'], 'identifier': ['AF135157']}, {'resource': ['GenBank Protein Database'], 'identifier': ['4894854']}, {'resource': ['UniProtKB'], 'identifier': ['P02745']}, {'resource': ['UniProt Accession'], 'identifier': ['C1QA_HUMAN']}]}], 'synonyms': [{'synonym': ['Complement C1q subcomponent subunit A precursor']}], 'amino-acid-sequence': ['>lcl|BSEQ0016678|Complement C1q subcomponent subunit A\nMEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR\nTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI\nRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR\nGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL\nIFPSA'], 'gene-sequence': ['>lcl|BSEQ0016679|Complement C1q subcomponent subunit A (C1QA)\nATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG\nGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC\nAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG\nACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC\nAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGAGCCCGTGGCATCCCGGGAATTAAA\nGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT\nCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG\nGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC\nTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG\nGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG\nGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC\nCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC\nATCTTCCCATCTGCCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF01391'], 'name': ['Collagen']}, {'identifier': ['PF00386'], 'name': ['C1q']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['collagen trimer']}, {'category': ['component'], 'description': ['complement component C1 complex']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['process'], 'description': ['cell-cell signaling']}, {'category': ['process'], 'description': ['complement activation']}, {'category': ['process'], 'description': ['complement activation, classical pathway']}, {'category': ['process'], 'description': ['innate immune response']}]}]}]}, {'id': ['BE0002095'], 'name': ['Complement C1q subcomponent subunit B'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A202103'], 'pubmed-id': ['32117299'], 'citation': ['Deveuve Q, Lajoie L, Barrault B, Thibault G: The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass. Front Immunol. 2020 Feb 11;11:168. doi: 10.3389/fimmu.2020.00168. eCollection 2020.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Complement C1q subcomponent subunit B'], 'general-function': [None], 'specific-function': ['C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.'], 'gene-name': ['C1QB'], 'locus': ['1p36.12'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-27'], 'theoretical-pi': ['8.87'], 'molecular-weight': ['26721.62'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1242']}, {'resource': ['GenAtlas'], 'identifier': ['C1QB']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X03084']}, {'resource': ['GenBank Protein Database'], 'identifier': ['573114']}, {'resource': ['UniProtKB'], 'identifier': ['P02746']}, {'resource': ['UniProt Accession'], 'identifier': ['C1QB_HUMAN']}]}], 'synonyms': [{'synonym': ['Complement C1q subcomponent subunit B precursor']}], 'amino-acid-sequence': ['>lcl|BSEQ0016676|Complement C1q subcomponent subunit B\nMMMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKG\nEKGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQ\nKIAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNL\nCVNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANS\nIFSGFLLFPDMEA'], 'gene-sequence': ['>lcl|BSEQ0016677|Complement C1q subcomponent subunit B (C1QB)\nATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGC\nCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATC\nCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGA\nGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCA\nGGGATTCCTGGGAATCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGC\nCCAGGGGCCCCTGGAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAG\nAAAATCGCCTTCTCTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATC\nCGCTTCGACCACGTGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTC\nACCTGCAAGGTGCCCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTG\nTGCGTGAACCTCATGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTAT\nGCCTACAACACCTTCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAG\nAACGTCTTCCTGCAGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGC\nATCTTTTCCGGGTTCCTGCTCTTTCCAGATATGGAGGCCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF01391'], 'name': ['Collagen']}, {'identifier': ['PF00386'], 'name': ['C1q']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['collagen trimer']}, {'category': ['component'], 'description': ['complement component C1 complex']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['process'], 'description': ['complement activation']}, {'category': ['process'], 'description': ['complement activation, classical pathway']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['inner ear development']}]}]}]}, {'id': ['BE0002096'], 'name': ['Complement C1q subcomponent subunit C'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A202103'], 'pubmed-id': ['32117299'], 'citation': ['Deveuve Q, Lajoie L, Barrault B, Thibault G: The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass. Front Immunol. 2020 Feb 11;11:168. doi: 10.3389/fimmu.2020.00168. eCollection 2020.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Complement C1q subcomponent subunit C'], 'general-function': [None], 'specific-function': ['C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.'], 'gene-name': ['C1QC'], 'locus': ['1p36.11'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-28'], 'theoretical-pi': ['8.58'], 'molecular-weight': ['25773.56'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1245']}, {'resource': ['GenAtlas'], 'identifier': ['C1QC']}, {'resource': ['GenBank Gene Database'], 'identifier': ['AF087892']}, {'resource': ['GenBank Protein Database'], 'identifier': ['33150626']}, {'resource': ['UniProtKB'], 'identifier': ['P02747']}, {'resource': ['UniProt Accession'], 'identifier': ['C1QC_HUMAN']}]}], 'synonyms': [{'synonym': ['C1QG']}], 'amino-acid-sequence': ['>lcl|BSEQ0011520|Complement C1q subcomponent subunit C\nMDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP\nGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS\nVFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV\nLLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF\nLLFPD'], 'gene-sequence': ['>lcl|BSEQ0011521|Complement C1q subcomponent subunit C (C1QC)\nATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG\nCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC\nCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA\nGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA\nCCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC\nCCCATGGGCATCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA\nGTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC\nAACGCGGTCCTCACCAACCCGCAGGGAGATTATGACACGAGCACTGGCAAGTTCACCTGC\nAAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG\nCTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT\nCAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT\nGTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC\nCTGCTCTTCCCCGACTAG'], 'pfams': [{'pfam': [{'identifier': ['PF01391'], 'name': ['Collagen']}, {'identifier': ['PF00386'], 'name': ['C1q']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['collagen trimer']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['process'], 'description': ['complement activation']}, {'category': ['process'], 'description': ['complement activation, classical pathway']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['negative regulation of granulocyte differentiation']}, {'category': ['process'], 'description': ['negative regulation of macrophage differentiation']}]}]}]}, {'id': ['BE0002097'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor III-A'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A13078'], 'pubmed-id': ['17704420'], 'citation': ['Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor III-A'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.'], 'gene-name': ['FCGR3A'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['209-229'], 'signal-regions': ['1-16'], 'theoretical-pi': ['8.21'], 'molecular-weight': ['29088.895'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3619']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR3A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X52645']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31324']}, {'resource': ['UniProtKB'], 'identifier': ['P08637']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG3A_HUMAN']}]}], 'synonyms': [{'synonym': ['CD16A', 'CD16a antigen', 'Fc-gamma RIII', 'Fc-gamma RIII-alpha', 'Fc-gamma RIIIa', 'FCG3', 'FCGR3', 'FcR-10', 'FcRIII', 'FcRIIIa', 'IGFR3', 'IgG Fc receptor III-2']}], 'amino-acid-sequence': ['>lcl|BSEQ0004112|Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK'], 'gene-sequence': ['>lcl|BSEQ0011522|Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A)\nATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCT\nTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTG\nCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCA\nAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACT\nCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAG\nAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCGACGACAGT\nGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTGCAGCTAGAAGTC\nCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAGGAAGACCCTATT\nCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACATATTTACAGAAT\nGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCAAAAGCCACACTC\nAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAATGTGTCTTCAGAG\nACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCATCATTCTTTCCA\nCCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCAGTGGACACAGGA\nCTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGGAAGGACCATAAA\nTTTAAATGGAGAAAGGACCCTCAAGACAAATGA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['regulation of immune response']}]}]}]}, {'id': ['BE0000710'], 'name': ['High affinity immunoglobulin gamma Fc receptor I'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13079'], 'pubmed-id': ['7547242'], 'citation': [""Negri DR, Tosi E, Valota O, Ferrini S, Cambiaggi A, Sforzini S, Silvani A, Ruffini PA, Colnaghi MI, Canevari S: In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. Br J Cancer. 1995 Oct;72(4):928-33.""]}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['High affinity immunoglobulin gamma Fc receptor I'], 'general-function': ['Receptor signaling protein activity'], 'specific-function': ['High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.'], 'gene-name': ['FCGR1A'], 'locus': ['1q21.2-q21.3'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['293-313'], 'signal-regions': ['1-15'], 'theoretical-pi': ['8.08'], 'molecular-weight': ['42631.525'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3613']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR1A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X14356']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31332']}, {'resource': ['UniProtKB'], 'identifier': ['P12314']}, {'resource': ['UniProt Accession'], 'identifier': ['FCGR1_HUMAN']}]}], 'synonyms': [{'synonym': ['Fc-gamma RI', 'Fc-gamma RIA', 'FCG1', 'FcgammaRIa', 'FCGR1', 'FcRI', 'IGFR1', 'IgG Fc receptor I']}], 'amino-acid-sequence': ['>lcl|BSEQ0001416|High affinity immunoglobulin gamma Fc receptor I\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT'], 'gene-sequence': ['>lcl|BSEQ0016183|High affinity immunoglobulin gamma Fc receptor I (FCGR1A)\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAATTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00047'], 'name': ['ig']}, {'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['clathrin-coated endocytic vesicle membrane']}, {'category': ['component'], 'description': ['early endosome membrane']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['receptor signaling protein activity']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent']}, {'category': ['process'], 'description': ['antigen processing and presentation of peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['interferon-gamma-mediated signaling pathway']}, {'category': ['process'], 'description': ['intracellular signal transduction']}, {'category': ['process'], 'description': ['phagocytosis, engulfment']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}, {'id': ['BE0002098'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor II-a'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A13078'], 'pubmed-id': ['17704420'], 'citation': ['Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor II-a'], 'general-function': [None], 'specific-function': ['Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens.'], 'gene-name': ['FCGR2A'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['218-240'], 'signal-regions': ['1-33'], 'theoretical-pi': ['6.78'], 'molecular-weight': ['35000.42'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3616']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR2A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M31932']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182474']}, {'resource': ['UniProtKB'], 'identifier': ['P12318']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG2A_HUMAN']}]}], 'synonyms': [{'synonym': ['CD32', 'CDw32', 'Fc-gamma RII-a', 'Fc-gamma-RIIa', 'FCG2', 'FCGR2A1', 'FcRII-a', 'IGFR2', 'IgG Fc receptor II-a']}], 'amino-acid-sequence': ['>lcl|BSEQ0037156|Low affinity immunoglobulin gamma Fc region receptor II-a\nMTMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSHLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN'], 'gene-sequence': ['>lcl|BSEQ0019233|Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A)\nATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCATTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['innate immune response']}]}]}]}]}]"
"['DB00003', 'BTD00001', 'BIOD00001']",['Dornase alfa'],biotech,"['Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme. Dornase alfa cleaves extracellular DNA to 5-phosphodinucleotide and 5-phosphooligonucleotide end products without affecting intracellular DNA. In individuals with cystic fibrosis, extracellular DNA, which is an extremely viscous anion, is released by degenerating leukocytes that accumulate during inflammatory responses to infections. Enzymatic breakdown of this extracellular DNA appears to reduce sputum viscosity and viscoelasticity.']",['liquid'],['Used as adjunct therapy in the treatment of cystic fibrosis. '],"['Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5-phosphodinucleotide and 5-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Extracellular DNA is a viscous anionic polymer and its breakdown appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction. Dornase alfa does not seem to have any effect on non-purulent sputum.']",[None],"[{'target': [{'id': ['BE0004796'], 'name': ['DNA'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A12'], 'pubmed-id': ['8792953'], 'citation': ['Cramer GW, Bosso JA: The role of dornase alfa in the treatment of cystic fibrosis. Ann Pharmacother. 1996 Jun;30(6):656-61.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes']}]}]"
"['DB00004', 'BTD00084', 'BIOD00084']",['Denileukin diftitox'],biotech,['A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.'],['liquid'],['For treatment of cutaneous T-cell lymphoma'],['Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.'],[None],"[{'target': [{'id': ['BE0000658'], 'name': ['Interleukin-2 receptor subunit alpha'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1717'], 'pubmed-id': ['2786749'], 'citation': ['Kiyokawa T, Shirono K, Hattori T, Nishimura H, Yamaguchi K, Nichols JC, Strom TB, Murphy JR, Takatsuki K: Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia. Cancer Res. 1989 Jul 15;49(14):4042-6.']}, {'ref-id': ['A1719'], 'pubmed-id': ['3124610'], 'citation': ['Murphy JR, Kelley VE, Strom TB: Interleukin 2 toxin: a step toward selective immunomodulation. Am J Kidney Dis. 1988 Feb;11(2):159-62.']}, {'ref-id': ['A1721'], 'pubmed-id': ['18684057'], 'citation': ['Duvic M, Talpur R: Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. doi: 10.2217/14796694.4.4.457.']}, {'ref-id': ['A15'], 'pubmed-id': ['17187516'], 'citation': ['Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interleukin-2 receptor subunit alpha'], 'general-function': ['Interleukin-2 receptor activity'], 'specific-function': ['Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T cells.'], 'gene-name': ['IL2RA'], 'locus': ['10p15-p14'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['241-259'], 'signal-regions': ['1-21'], 'theoretical-pi': ['6.49'], 'molecular-weight': ['30818.915'], 'chromosome-location': ['10'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6008']}, {'resource': ['GenAtlas'], 'identifier': ['IL2RA']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X01057']}, {'resource': ['GenBank Protein Database'], 'identifier': ['33813']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1695']}, {'resource': ['UniProtKB'], 'identifier': ['P01589']}, {'resource': ['UniProt Accession'], 'identifier': ['IL2RA_HUMAN']}]}], 'synonyms': [{'synonym': ['IL-2 receptor subunit alpha', 'p55', 'TAC antigen']}], 'amino-acid-sequence': ['>lcl|BSEQ0018991|Interleukin-2 receptor subunit alpha\nMDSYLLMWGLLTFIMVPGCQAELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKS\nGSLYMLCTGNSSHSSWDNQCQCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQAS\nLPGHCREPPPWENEATERIYHFVVGQMVYYQCVQGYRALHRGPAESVCKMTHGKTRWTQP\nQLICTGEMETSQFPGEEKPQASPEGRPESETSCLVTTTDFQIQTEMAATMETSIFTTEYQ\nVAVAGCVFLLISVLLLSGLTWQRRQRKSRRTI'], 'gene-sequence': ['>lcl|BSEQ0018992|Interleukin-2 receptor subunit alpha (IL2RA)\nATGGATTCATACCTGCTGATGTGGGGACTGCTCACGTTCATCATGGTGCCTGGCTGCCAG\nGCAGAGCTCTGTGACGATGACCCGCCAGAGATCCCACACGCCACATTCAAAGCCATGGCC\nTACAAGGAAGGAACCATGTTGAACTGTGAATGCAAGAGAGGTTTCCGCAGAATAAAAAGC\nGGGTCACTCTATATGCTCTGTACAGGAAACTCTAGCCACTCGTCCTGGGACAACCAATGT\nCAATGCACAAGCTCTGCCACTCGGAACACAACGAAACAAGTGACACCTCAACCTGAAGAA\nCAGAAAGAAAGGAAAACCACAGAAATGCAAAGTCCAATGCAGCCAGTGGACCAAGCGAGC\nCTTCCAGGTCACTGCAGGGAACCTCCACCATGGGAAAATGAAGCCACAGAGAGAATTTAT\nCATTTCGTGGTGGGGCAGATGGTTTATTATCAGTGCGTCCAGGGATACAGGGCTCTACAC\nAGAGGTCCTGCTGAGAGCGTCTGCAAAATGACCCACGGGAAGACAAGGTGGACCCAGCCC\nCAGCTCATATGCACAGGTGAAATGGAGACCAGTCAGTTTCCAGGTGAAGAGAAGCCTCAG\nGCAAGCCCCGAAGGCCGTCCTGAGAGTGAGACTTCCTGCCTCGTCACAACAACAGATTTT\nCAAATACAGACAGAAATGGCTGCAACCATGGAGACGTCCATATTTACAACAGAGTACCAG\nGTAGCAGTGGCCGGCTGTGTTTTCCTGCTGATCAGCGTCCTCCTCCTGAGTGGGCTCACC\nTGGCAGCGGAGACAGAGGAAGAGTAGAAGAACAATCTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00084'], 'name': ['Sushi']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['drug binding']}, {'category': ['function'], 'description': ['interleukin-2 binding']}, {'category': ['function'], 'description': ['interleukin-2 receptor activity']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['activation-induced cell death of T cells']}, {'category': ['process'], 'description': ['apoptotic process']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['cell proliferation']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['inflammatory response']}, {'category': ['process'], 'description': ['inflammatory response to antigenic stimulus']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['negative regulation of defense response to virus']}, {'category': ['process'], 'description': ['negative regulation of immune response']}, {'category': ['process'], 'description': ['negative regulation of inflammatory response']}, {'category': ['process'], 'description': ['negative regulation of T cell proliferation']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['Notch signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of activated T cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of T cell differentiation']}, {'category': ['process'], 'description': ['Ras protein signal transduction']}, {'category': ['process'], 'description': ['regulation of T cell homeostatic proliferation']}, {'category': ['process'], 'description': ['regulation of T cell tolerance induction']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}]}]}]}, {'id': ['BE0000651'], 'name': ['Interleukin-2 receptor subunit beta'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13080'], 'pubmed-id': ['15811959'], 'citation': ['Foss F, Demierre MF, DiVenuti G: A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005 Jul 15;106(2):454-7. Epub 2005 Apr 5.']}, {'ref-id': ['A13081'], 'pubmed-id': ['16516670'], 'citation': ['Foss F: Clinical experience with denileukin diftitox (ONTAK). Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6.']}, {'ref-id': ['A1721'], 'pubmed-id': ['18684057'], 'citation': ['Duvic M, Talpur R: Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. doi: 10.2217/14796694.4.4.457.']}, {'ref-id': ['A15'], 'pubmed-id': ['17187516'], 'citation': ['Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interleukin-2 receptor subunit beta'], 'general-function': ['Interleukin-2 receptor activity'], 'specific-function': ['Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2.'], 'gene-name': ['IL2RB'], 'locus': ['22q13|22q13.1'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['241-265'], 'signal-regions': ['1-26'], 'theoretical-pi': ['4.68'], 'molecular-weight': ['61116.59'], 'chromosome-location': ['22'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6009']}, {'resource': ['GenAtlas'], 'identifier': ['IL2RB']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M26062']}, {'resource': ['GenBank Protein Database'], 'identifier': ['307048']}, {'resource': ['UniProtKB'], 'identifier': ['P14784']}, {'resource': ['UniProt Accession'], 'identifier': ['IL2RB_HUMAN']}]}], 'synonyms': [{'synonym': ['High affinity IL-2 receptor subunit beta', 'IL-2 receptor subunit beta', 'p70-75', 'p75']}], 'amino-acid-sequence': ['>lcl|BSEQ0016166|Interleukin-2 receptor subunit beta\nMAAPALSWRLPLLILLLPLATSWASAAVNGTSQFTCFYNSRANISCVWSQDGALQDTSCQ\nVHAWPDRRRWNQTCELLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMA\nIQDFKPFENLRLMAPISLQVVHVETHRCNISWEISQASHYFERHLEFEARTLSPGHTWEE\nAPLLTLKQKQEWICLETLTPDTQYEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAALGKDT\nIPWLGHLLVGLSGAFGFIILVYLLINCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDV\nQKWLSSPFPSSSFSPGGLAPEISPLEVLERDKVTQLLLQQDKVPEPASLSSNHSLTSCFT\nNQGYFFFHLPDALEIEACQVYFTYDPYSEEDPDEGVAGAPTGSSPQPLQPLSGEDDAYCT\nFPSRDDLLLFSPSLLGGPSPPSTAPGGSGAGEERMPPSLQERVPRDWDPQPLGPPTPGVP\nDLVDFQPPPELVLREAGEEVPDAGPREGVSFPWSRPPGQGEFRALNARLPLNTDAYLSLQ\nELQGQDPTHLV'], 'gene-sequence': ['>lcl|BSEQ0016167|Interleukin-2 receptor subunit beta (IL2RB)\nATGGCGGCCCCTGCTCTGTCCTGGCGTCTGCCCCTCCTCATCCTCCTCCTGCCCCTGGCT\nACCTCTTGGGCATCTGCAGCGGTGAATGGCACTTCCCAGTTCACATGCTTCTACAACTCG\nAGAGCCAACATCTCCTGTGTCTGGAGCCAAGATGGGGCTCTGCAGGACACTTCCTGCCAA\nGTCCATGCCTGGCCGGACAGACGGCGGTGGAACCAAACCTGTGAGCTGCTCCCCGTGAGT\nCAAGCATCCTGGGCCTGCAACCTGATCCTCGGAGCCCCAGATTCTCAGAAACTGACCACA\nGTTGACATCGTCACCCTGAGGGTGCTGTGCCGTGAGGGGGTGCGATGGAGGGTGATGGCC\nATCCAGGACTTCAAGCCCTTTGAGAACCTTCGCCTGATGGCCCCCATCTCCCTCCAAGTT\nGTCCACGTGGAGACCCACAGATGCAACATAAGCTGGGAAATCTCCCAAGCCTCCCACTAC\nTTTGAAAGACACCTGGAGTTCGAGGCCCGGACGCTGTCCCCAGGCCACACCTGGGAGGAG\nGCCCCCCTGCTGACTCTCAAGCAGAAGCAGGAATGGATCTGCCTGGAGACGCTCACCCCA\nGACACCCAGTATGAGTTTCAGGTGCGGGTCAAGCCTCTGCAAGGCGAGTTCACGACCTGG\nAGCCCCTGGAGCCAGCCCCTGGCCTTCAGGACAAAGCCTGCAGCCCTTGGGAAGGACACC\nATTCCGTGGCTCGGCCACCTCCTCGTGGGCCTCAGCGGGGCTTTTGGCTTCATCATCTTA\nGTGTACTTGCTGATCAACTGCAGGAACACCGGGCCATGGCTGAAGAAGGTCCTGAAGTGT\nAACACCCCAGACCCCTCGAAGTTCTTTTCCCAGCTGAGCTCAGAGCATGGAGGAGACGTC\nCAGAAGTGGCTCTCTTCGCCCTTCCCCTCATCGTCCTTCAGCCCTGGCGGCCTGGCACCT\nGAGATCTCGCCACTAGAAGTGCTGGAGAGGGACAAGGTGACGCAGCTGCTCCTGCAGCAG\nGACAAGGTGCCTGAGCCCGCATCCTTAAGCAGCAACCACTCGCTGACCAGCTGCTTCACC\nAACCAGGGTTACTTCTTCTTCCACCTCCCGGATGCCTTGGAGATAGAGGCCTGCCAGGTG\nTACTTTACTTACGACCCCTACTCAGAGGAAGACCCTGATGAGGGTGTGGCCGGGGCACCC\nACAGGGTCTTCCCCCCAACCCCTGCAGCCTCTGTCAGGGGAGGACGACGCCTACTGCACC\nTTCCCCTCCAGGGATGACCTGCTGCTCTTCTCCCCCAGTCTCCTCGGTGGCCCCAGCCCC\nCCAAGCACTGCCCCTGGGGGCAGTGGGGCCGGTGAAGAGAGGATGCCCCCTTCTTTGCAA\nGAAAGAGTCCCCAGAGACTGGGACCCCCAGCCCCTGGGGCCTCCCACCCCAGGAGTCCCA\nGACCTGGTGGATTTTCAGCCACCCCCTGAGCTGGTGCTGCGAGAGGCTGGGGAGGAGGTC\nCCTGACGCTGGCCCCAGGGAGGGAGTCAGTTTCCCCTGGTCCAGGCCTCCTGGGCAGGGG\nGAGTTCAGGGCCCTTAATGCTCGCCTGCCCCTGAACACTGATGCCTACTTGTCCCTCCAA\nGAACTCCAGGGTCAGGACCCAACTCACTTGGTGTAG'], 'pfams': [None], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['interleukin-2 binding']}, {'category': ['function'], 'description': ['interleukin-2 receptor activity']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['interleukin-2-mediated signaling pathway']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['negative regulation of apoptotic process']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['protein complex assembly']}, {'category': ['process'], 'description': ['Ras protein signal transduction']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['viral process']}]}]}]}, {'id': ['BE0002102'], 'name': ['Cytokine receptor common subunit gamma'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13080'], 'pubmed-id': ['15811959'], 'citation': ['Foss F, Demierre MF, DiVenuti G: A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005 Jul 15;106(2):454-7. Epub 2005 Apr 5.']}, {'ref-id': ['A13081'], 'pubmed-id': ['16516670'], 'citation': ['Foss F: Clinical experience with denileukin diftitox (ONTAK). Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6.']}, {'ref-id': ['A13082'], 'pubmed-id': ['11707860'], 'citation': ['Foss FM: DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clin Lymphoma. 2000 Nov;1 Suppl 1:S27-31.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Cytokine receptor common subunit gamma'], 'general-function': ['Interleukin-2 binding'], 'specific-function': ['Common subunit for the receptors for a variety of interleukins.'], 'gene-name': ['IL2RG'], 'locus': ['Xq13.1'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['263-283'], 'signal-regions': ['1-22'], 'theoretical-pi': ['6.31'], 'molecular-weight': ['42286.68'], 'chromosome-location': ['X'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6010']}, {'resource': ['GenAtlas'], 'identifier': ['IL2RG']}, {'resource': ['GenBank Gene Database'], 'identifier': ['D11086']}, {'resource': ['GenBank Protein Database'], 'identifier': ['219890']}, {'resource': ['UniProtKB'], 'identifier': ['P31785']}, {'resource': ['UniProt Accession'], 'identifier': ['IL2RG_HUMAN']}]}], 'synonyms': [{'synonym': ['gammaC', 'IL-2 receptor subunit gamma', 'IL-2R subunit gamma', 'IL-2RG', 'Interleukin-2 receptor subunit gamma', 'p64']}], 'amino-acid-sequence': ['>lcl|BSEQ0004122|Cytokine receptor common subunit gamma\nMLKPSLPFTSLLFLQLPLLGVGLNTTILTPNGNEDTTADFFLTTMPTDSLSVSTLPLPEV\nQCFVFNVEYMNCTWNSSSEPQPTNLTLHYWYKNSDNDKVQKCSHYLFSEEITSGCQLQKK\nEIHLYQTFVVQLQDPREPRRQATQMLKLQNLVIPWAPENLTLHKLSESQLELNWNNRFLN\nHCLEHLVQYRTDWDHSWTEQSVDYRHKFSLPSVDGQKRYTFRVRSRFNPLCGSAQHWSEW\nSHPIHWGSNTSKENPFLFALEAVVISVGSMGLIISLLCVYFWLERTMPRIPTLKNLEDLV\nTEYHGNFSAWSGVSKGLAESLQPDYSERLCLVSEIPPKGGALGEGPGASPCNQHSPYWAP\nPCYTLKPET'], 'gene-sequence': ['>lcl|BSEQ0016682|Cytokine receptor common subunit gamma (IL2RG)\nATGTTGAAGCCATCATTACCATTCACATCCCTCTTATTCCTGCAGCTGCCCCTGCTGGGA\nGTGGGGCTGAACACGACAATTCTGACGCCCAATGGGAATGAAGACACCACAGCTGATTTC\nTTCCTGACCACTATGCCCACTGACTCCCTCAGTGTTTCCACTCTGCCCCTCCCAGAGGTT\nCAGTGTTTTGTGTTCAATGTCGAGTACATGAATTGCACTTGGAACAGCAGCTCTGAGCCC\nCAGCCTACCAACCTCACTCTGCATTATTGGTACAAGAACTCGGATAATGATAAAGTCCAG\nAAGTGCAGCCACTATCTATTCTCTGAAGAAATCACTTCTGGCTGTCAGTTGCAAAAAAAG\nGAGATCCACCTCTACCAAACATTTGTTGTTCAGCTCCAGGACCCACGGGAACCCAGGAGA\nCAGGCCACACAGATGCTAAAACTGCAGAATCTGGTGATCCCCTGGGCTCCAGAGAACCTA\nACACTTCACAAACTGAGTGAATCCCAGCTAGAACTGAACTGGAACAACAGATTCTTGAAC\nCACTGTTTGGAGCACTTGGTGCAGTACCGGACTGACTGGGACCACAGCTGGACTGAACAA\nTCAGTGGATTATAGACATAAGTTCTCCTTGCCTAGTGTGGATGGGCAGAAACGCTACACG\nTTTCGTGTTCGGAGCCGCTTTAACCCACTCTGTGGAAGTGCTCAGCATTGGAGTGAATGG\nAGCCACCCAATCCACTGGGGGAGCAATACTTCAAAAGAGAATCCTTTCCTGTTTGCATTG\nGAAGCCGTGGTTATCTCTGTTGGCTCCATGGGATTGATTATCAGCCTTCTCTGTGTGTAT\nTTCTGGCTGGAACGGACGATGCCCCGAATTCCCACCCTGAAGAACCTAGAGGATCTTGTT\nACTGAATACCACGGGAACTTTTCGGCCTGGAGTGGTGTGTCTAAGGGACTGGCTGAGAGT\nCTGCAGCCAGACTACAGTGAACGACTCTGCCTCGTCAGTGAGATTCCCCCAAAAGGAGGG\nGCCCTTGGGGAGGGGCCTGGGGCCTCCCCATGCAACCAGCATAGCCCCTACTGGGCCCCC\nCCATGTTACACCCTAAAGCCTGAAACCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00041'], 'name': ['fn3']}, {'identifier': ['PF09240'], 'name': ['IL6Ra-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['cytokine receptor activity']}, {'category': ['function'], 'description': ['interleukin-2 binding']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['interleukin-2-mediated signaling pathway']}, {'category': ['process'], 'description': ['interleukin-4-mediated signaling pathway']}, {'category': ['process'], 'description': ['interleukin-7-mediated signaling pathway']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['Ras protein signal transduction']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['viral process']}]}]}]}]}]"
"['DB00005', 'BTD00052', 'BIOD00052']",['Etanercept'],biotech,"['Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).']",['liquid'],"['Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older.[L14862,L45523] It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is also used to manage the symptoms of psoriatic arthritis and ankylosing spondylitis.[L48526] ']","['There are two distinct receptors for TNF (TNFRs), a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75). The biological activity of TNF is dependent upon binding to either cell surface receptor (p75 or p55).[A216522] Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation. Notably, etancerpt is only capable of binding to the active trimeric form of TNF as its binding site is located in the cleft between subunits.[A77626]TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses.[A216522] Increased levels of TNF are found in tissues and fluids of those with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. ']",[None],"[{'target': [{'id': ['BE0000704'], 'name': ['Tumor necrosis factor'], 'organism': ['Humans'], 'actions': [{'action': ['inhibitor', 'antibody']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1723'], 'pubmed-id': ['10206649'], 'citation': ['Park YC, Burkitt V, Villa AR, Tong L, Wu H: Structural basis for self-association and receptor recognition of human TRAF2. Nature. 1999 Apr 8;398(6727):533-8.']}, {'ref-id': ['A1725'], 'pubmed-id': ['10338381'], 'citation': ['Sandborn WJ, Hanauer SB: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 May;5(2):119-33.']}, {'ref-id': ['A1727'], 'pubmed-id': ['10357816'], 'citation': ['Grell M, Zimmermann G, Gottfried E, Chen CM, Grunwald U, Huang DC, Wu Lee YH, Durkop H, Engelmann H, Scheurich P, Wajant H, Strasser A: Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J. 1999 Jun 1;18(11):3034-43.']}, {'ref-id': ['A1729'], 'pubmed-id': ['10375846'], 'citation': ['Moreland LW: Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis. Cleve Clin J Med. 1999 Jun;66(6):367-74.']}, {'ref-id': ['A1731'], 'pubmed-id': ['10405518'], 'citation': ['Calabrese LH: Rheumatoid arthritis and primary care: the case for early diagnosis and treatment. J Am Osteopath Assoc. 1999 Jun;99(6):313-21.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A247970'], 'pubmed-id': ['31092047'], 'citation': ['Clark IA, Vissel B: Neurodegenerative disease treatments by direct TNF reduction, SB623 cells, maraviroc and irisin and MCC950, from an inflammatory perspective - a Commentary. Expert Rev Neurother. 2019 Jun;19(6):535-543. doi: 10.1080/14737175.2019.1618710. Epub 2019 May 24.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Tumor necrosis factor'], 'general-function': ['Tumor necrosis factor receptor binding'], 'specific-function': [""Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Upregulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective (PubMed:23396208). Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line (PubMed:22517918).The TNF intracellular domain (ICD) form induces IL12 production in dendritic cells.""], 'gene-name': ['TNF'], 'locus': ['6p21.3'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['36-56'], 'signal-regions': [None], 'theoretical-pi': ['6.92'], 'molecular-weight': ['25644.15'], 'chromosome-location': ['6'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:11892']}, {'resource': ['GenAtlas'], 'identifier': ['TNF']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M16441']}, {'resource': ['GenBank Protein Database'], 'identifier': ['339741']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2635']}, {'resource': ['UniProtKB'], 'identifier': ['P01375']}, {'resource': ['UniProt Accession'], 'identifier': ['TNFA_HUMAN']}]}], 'synonyms': [{'synonym': ['Cachectin', 'TNF-a', 'TNF-alpha', 'TNFA', 'TNFSF2', 'Tumor necrosis factor ligand superfamily member 2']}], 'amino-acid-sequence': ['>lcl|BSEQ0001404|Tumor necrosis factor\nMSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQR\nEEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELR\nDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRE\nTPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL'], 'gene-sequence': ['>lcl|BSEQ0021837|Tumor necrosis factor (TNF)\nATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAG\nACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATC\nGTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGG\nGAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCT\nTCTCGAACCCCGAGTGACAAGCCTGTAGCCCATGTTGTAGCAAACCCTCAAGCTGAGGGG\nCAGCTCCAGTGGCTGAACCGCCGGGCCAATGCCCTCCTGGCCAATGGCGTGGAGCTGAGA\nGATAACCAGCTGGTGGTGCCATCAGAGGGCCTGTACCTCATCTACTCCCAGGTCCTCTTC\nAAGGGCCAAGGCTGCCCCTCCACCCATGTGCTCCTCACCCACACCATCAGCCGCATCGCC\nGTCTCCTACCAGACCAAGGTCAACCTCCTCTCTGCCATCAAGAGCCCCTGCCAGAGGGAG\nACCCCAGAGGGGGCTGAGGCCAAGCCCTGGTATGAGCCCATCTATCTGGGAGGGGTCTTC\nCAGCTGGAGAAGGGTGACCGACTCAGCGCTGAGATCAATCGGCCCGACTATCTCGACTTT\nGCCGAGTCTGGGCAGGTCTACTTTGGGATCATTGCCCTGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00229'], 'name': ['TNF']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['membrane raft']}, {'category': ['component'], 'description': ['phagocytic cup']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['recycling endosome']}, {'category': ['function'], 'description': ['cytokine activity']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['function'], 'description': ['transcription regulatory region DNA binding']}, {'category': ['function'], 'description': ['tumor necrosis factor receptor binding']}, {'category': ['process'], 'description': ['activation of cysteine-type endopeptidase activity involved in apoptotic process']}, {'category': ['process'], 'description': ['activation of MAPK activity']}, {'category': ['process'], 'description': ['activation of MAPKKK activity']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular response to amino acid stimulus']}, {'category': ['process'], 'description': ['cellular response to nicotine']}, {'category': ['process'], 'description': ['cellular response to organic cyclic compound']}, {'category': ['process'], 'description': ['chronic inflammatory response to antigenic stimulus']}, {'category': ['process'], 'description': ['cortical actin cytoskeleton organization']}, {'category': ['process'], 'description': ['death-inducing signaling complex assembly']}, {'category': ['process'], 'description': ['defense response to Gram-positive bacterium']}, {'category': ['process'], 'description': ['embryonic digestive tract development']}, {'category': ['process'], 'description': ['epithelial cell proliferation involved in salivary gland morphogenesis']}, {'category': ['process'], 'description': ['establishment of protein localization to plasma membrane']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['extrinsic apoptotic signaling pathway']}, {'category': ['process'], 'description': ['extrinsic apoptotic signaling pathway via death domain receptors']}, {'category': ['process'], 'description': ['glucose metabolic process']}, {'category': ['process'], 'description': ['humoral immune response']}, {'category': ['process'], 'description': ['I-kappaB kinase/NF-kappaB signaling']}, {'category': ['process'], 'description': ['inflammatory response']}, {'category': ['process'], 'description': ['intrinsic apoptotic signaling pathway in response to DNA damage']}, {'category': ['process'], 'description': ['JNK cascade']}, {'category': ['process'], 'description': ['leukocyte tethering or rolling']}, {'category': ['process'], 'description': ['lipopolysaccharide-mediated signaling pathway']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['necroptotic signaling pathway']}, {'category': ['process'], 'description': ['negative regulation of alkaline phosphatase activity']}, {'category': ['process'], 'description': ['negative regulation of bicellular tight junction assembly']}, {'category': ['process'], 'description': ['negative regulation of branching involved in lung morphogenesis']}, {'category': ['process'], 'description': ['negative regulation of cytokine secretion involved in immune response']}, {'category': ['process'], 'description': ['negative regulation of extrinsic apoptotic signaling pathway in absence of ligand']}, {'category': ['process'], 'description': ['negative regulation of fat cell differentiation']}, {'category': ['process'], 'description': ['negative regulation of gene expression']}, {'category': ['process'], 'description': ['negative regulation of glucose import']}, {'category': ['process'], 'description': ['negative regulation of growth of symbiont in host']}, {'category': ['process'], 'description': ['negative regulation of interleukin-6 production']}, {'category': ['process'], 'description': ['negative regulation of lipid catabolic process']}, {'category': ['process'], 'description': ['negative regulation of lipid storage']}, {'category': ['process'], 'description': ['negative regulation of myoblast differentiation']}, {'category': ['process'], 'description': ['negative regulation of myosin-light-chain-phosphatase activity']}, {'category': ['process'], 'description': ['negative regulation of osteoblast differentiation']}, {'category': ['process'], 'description': ['negative regulation of protein complex disassembly']}, {'category': ['process'], 'description': ['negative regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['negative regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['negative regulation of viral genome replication']}, {'category': ['process'], 'description': ['osteoclast differentiation']}, {'category': ['process'], 'description': ['positive regulation of apoptotic process']}, {'category': ['process'], 'description': ['positive regulation of calcidiol 1-monooxygenase activity']}, {'category': ['process'], 'description': ['positive regulation of cell adhesion']}, {'category': ['process'], 'description': ['positive regulation of ceramide biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of chemokine (C-X-C motif) ligand 2 production']}, {'category': ['process'], 'description': ['positive regulation of chemokine biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of chemokine production']}, {'category': ['process'], 'description': ['positive regulation of chronic inflammatory response to antigenic stimulus']}, {'category': ['process'], 'description': ['positive regulation of cysteine-type endopeptidase activity involved in apoptotic process']}, {'category': ['process'], 'description': ['positive regulation of cytokine production']}, {'category': ['process'], 'description': ['positive regulation of cytokine secretion']}, {'category': ['process'], 'description': ['positive regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['positive regulation of fever generation']}, {'category': ['process'], 'description': ['positive regulation of gene expression']}, {'category': ['process'], 'description': ['positive regulation of hair follicle development']}, {'category': ['process'], 'description': ['positive regulation of heterotypic cell-cell adhesion']}, {'category': ['process'], 'description': ['positive regulation of humoral immune response mediated by circulating immunoglobulin']}, {'category': ['process'], 'description': ['positive regulation of I-kappaB kinase/NF-kappaB signaling']}, {'category': ['process'], 'description': ['positive regulation of interferon-gamma production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-6 production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-8 biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of interleukin-8 production']}, {'category': ['process'], 'description': ['positive regulation of JUN kinase activity']}, {'category': ['process'], 'description': ['positive regulation of MAP kinase activity']}, {'category': ['process'], 'description': ['positive regulation of membrane protein ectodomain proteolysis']}, {'category': ['process'], 'description': ['positive regulation of mononuclear cell migration']}, {'category': ['process'], 'description': ['positive regulation of NF-kappaB import into nucleus']}, {'category': ['process'], 'description': ['positive regulation of NF-kappaB transcription factor activity']}, {'category': ['process'], 'description': ['positive regulation of NFAT protein import into nucleus']}, {'category': ['process'], 'description': ['positive regulation of NIK/NF-kappaB signaling']}, {'category': ['process'], 'description': ['positive regulation of nitric oxide biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of osteoclast differentiation']}, {'category': ['process'], 'description': ['positive regulation of peptidyl-serine phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of phagocytosis']}, {'category': ['process'], 'description': ['positive regulation of podosome assembly']}, {'category': ['process'], 'description': ['positive regulation of programmed cell death']}, {'category': ['process'], 'description': ['positive regulation of protein complex assembly']}, {'category': ['process'], 'description': ['positive regulation of protein complex disassembly']}, {'category': ['process'], 'description': ['positive regulation of protein kinase activity']}, {'category': ['process'], 'description': ['positive regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['positive regulation of protein localization to cell surface']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of protein transport']}, {'category': ['process'], 'description': ['positive regulation of sequence-specific DNA binding transcription factor activity']}, {'category': ['process'], 'description': ['positive regulation of smooth muscle cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['positive regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['positive regulation of translational initiation by iron']}, {'category': ['process'], 'description': ['positive regulation of vitamin D biosynthetic process']}, {'category': ['process'], 'description': ['protein import into nucleus, translocation']}, {'category': ['process'], 'description': ['protein kinase B signaling']}, {'category': ['process'], 'description': ['receptor biosynthetic process']}, {'category': ['process'], 'description': ['regulation of branching involved in salivary gland morphogenesis']}, {'category': ['process'], 'description': ['regulation of establishment of endothelial barrier']}, {'category': ['process'], 'description': ['regulation of I-kappaB kinase/NF-kappaB signaling']}, {'category': ['process'], 'description': ['regulation of immunoglobulin secretion']}, {'category': ['process'], 'description': ['regulation of insulin secretion']}, {'category': ['process'], 'description': ['regulation of tumor necrosis factor-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to glucocorticoid']}, {'category': ['process'], 'description': ['response to salt stress']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['sequestering of triglyceride']}, {'category': ['process'], 'description': ['transformed cell apoptotic process']}, {'category': ['process'], 'description': ['tumor necrosis factor-mediated signaling pathway']}]}]}]}, {'id': ['BE0001087'], 'name': ['Lymphotoxin-alpha'], 'organism': ['Humans'], 'actions': [{'action': ['antibody']}], 'references': [{'articles': [{'article': [{'ref-id': ['A11581'], 'pubmed-id': ['11302411'], 'citation': ['Johnson CJ, Reilly KM, Murray KM: Etanercept in juvenile rheumatoid arthritis. Ann Pharmacother. 2001 Apr;35(4):464-71.']}, {'ref-id': ['A11583'], 'pubmed-id': ['15005015'], 'citation': ['Gudbrandsdottir S, Larsen R, Sorensen LK, Nielsen S, Hansen MB, Svenson M, Bendtzen K, Muller K: TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2004 Jan-Feb;22(1):118-24.']}, {'ref-id': ['A11584'], 'pubmed-id': ['15033655'], 'citation': ['Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P: True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha? Ann Rheum Dis. 2004 Oct;63(10):1344-6. Epub 2004 Mar 19.']}]}], 'textbooks': [None], 'links': [{'link': [{'ref-id': ['L4237'], 'title': ['Enbrel (Etanercept) FDA Label'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103795s5503lbl.pdf']}]}], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Lymphotoxin-alpha'], 'general-function': ['Receptor binding'], 'specific-function': ['Cytokine that in its homotrimeric form binds to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR and TNFRSF14/HVEM. In its heterotrimeric form with LTB binds to TNFRSF3/LTBR. Lymphotoxin is produced by lymphocytes and cytotoxic for a wide range of tumor cells in vitro and in vivo.'], 'gene-name': ['LTA'], 'locus': ['6p21.3'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-34'], 'theoretical-pi': ['9.36'], 'molecular-weight': ['22296.57'], 'chromosome-location': ['6'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6709']}, {'resource': ['GenAtlas'], 'identifier': ['LTA']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X01393']}, {'resource': ['GenBank Protein Database'], 'identifier': ['34445']}, {'resource': ['UniProtKB'], 'identifier': ['P01374']}, {'resource': ['UniProt Accession'], 'identifier': ['TNFB_HUMAN']}]}], 'synonyms': [{'synonym': ['LT-alpha', 'TNF-beta', 'TNFB', 'TNFSF1', 'Tumor necrosis factor ligand superfamily member 1']}], 'amino-acid-sequence': ['>lcl|BSEQ0010761|Lymphotoxin-alpha\nMTPPERLFLPRVCGTTLHLLLLGLLLVLLPGAQGLPGVGLTPSAAQTARQHPKMHLAHST\nLKPAAHLIGDPSKQNSLLWRANTDRAFLQDGFSLSNNSLLVPTSGIYFVYSQVVFSGKAY\nSPKATSSPLYLAHEVQLFSSQYPFHVPLLSSQKMVYPGLQEPWLHSMYHGAAFQLTQGDQ\nLSTHTDGIPHLVLSPSTVFFGAFAL'], 'gene-sequence': ['>lcl|BSEQ0010762|Lymphotoxin-alpha (LTA)\nATGACACCACCTGAACGTCTCTTCCTCCCAAGGGTGTGTGGCACCACCCTACACCTCCTC\nCTTCTGGGGCTGCTGCTGGTTCTGCTGCCTGGGGCCCAGGGGCTCCCTGGTGTTGGCCTC\nACACCTTCAGCTGCCCAGACTGCCCGTCAGCACCCCAAGATGCATCTTGCCCACAGCACC\nCTCAAACCTGCTGCTCACCTCATTGGAGACCCCAGCAAGCAGAACTCACTGCTCTGGAGA\nGCAAACACGGACCGTGCCTTCCTCCAGGATGGTTTCTCCTTGAGCAACAATTCTCTCCTG\nGTCCCCACCAGTGGCATCTACTTCGTCTACTCCCAGGTGGTCTTCTCTGGGAAAGCCTAC\nTCTCCCAAGGCCACCTCCTCCCCACTCTACCTGGCCCATGAGGTCCAGCTCTTCTCCTCC\nCAGTACCCCTTCCATGTGCCTCTCCTCAGCTCCCAGAAGATGGTGTATCCAGGGCTGCAG\nGAACCCTGGCTGCACTCGATGTACCACGGGGCTGCGTTCCAGCTCACCCAGGGAGACCAG\nCTATCCACCCACACAGATGGCATCCCCCACCTAGTCCTCAGCCCTAGTACTGTCTTCTTT\nGGAGCCTTCGCTCTGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00229'], 'name': ['TNF']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['process'], 'description': ['apoptotic process']}, {'category': ['process'], 'description': ['cell-cell signaling']}, {'category': ['process'], 'description': ['defense response to Gram-positive bacterium']}, {'category': ['process'], 'description': ['humoral immune response']}, {'category': ['process'], 'description': ['lymph node development']}, {'category': ['process'], 'description': ['negative regulation of fibroblast proliferation']}, {'category': ['process'], 'description': ['negative regulation of growth of symbiont in host']}, {'category': ['process'], 'description': ['positive regulation of apoptotic process']}, {'category': ['process'], 'description': ['positive regulation of chronic inflammatory response to antigenic stimulus']}, {'category': ['process'], 'description': ['positive regulation of glial cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of humoral immune response mediated by circulating immunoglobulin']}, {'category': ['process'], 'description': ['positive regulation of interferon-gamma production']}, {'category': ['process'], 'description': ['response to drug']}, {'category': ['process'], 'description': ['response to hypoxia']}, {'category': ['process'], 'description': ['response to lipopolysaccharide']}, {'category': ['process'], 'description': ['response to nutrient']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['tumor necrosis factor-mediated signaling pathway']}]}]}]}, {'id': ['BE0000710'], 'name': ['High affinity immunoglobulin gamma Fc receptor I'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A202010'], 'pubmed-id': ['27463856'], 'citation': ['Hofmann HP, Kronthaler U, Fritsch C, Grau R, Muller SO, Mayer R, Seidl A, Da Silva A: Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel((R))). Expert Opin Biol Ther. 2016 Oct;16(10):1185-95. doi: 10.1080/14712598.2016.1217329. Epub 2016 Aug 16.']}, {'ref-id': ['A203909'], 'pubmed-id': ['19128982'], 'citation': ['Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T: Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009 Feb;45(2):124-31. doi: 10.1016/j.cyto.2008.11.008. Epub 2009 Jan 6.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['High affinity immunoglobulin gamma Fc receptor I'], 'general-function': ['Receptor signaling protein activity'], 'specific-function': ['High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.'], 'gene-name': ['FCGR1A'], 'locus': ['1q21.2-q21.3'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['293-313'], 'signal-regions': ['1-15'], 'theoretical-pi': ['8.08'], 'molecular-weight': ['42631.525'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3613']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR1A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X14356']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31332']}, {'resource': ['UniProtKB'], 'identifier': ['P12314']}, {'resource': ['UniProt Accession'], 'identifier': ['FCGR1_HUMAN']}]}], 'synonyms': [{'synonym': ['Fc-gamma RI', 'Fc-gamma RIA', 'FCG1', 'FcgammaRIa', 'FCGR1', 'FcRI', 'IGFR1', 'IgG Fc receptor I']}], 'amino-acid-sequence': ['>lcl|BSEQ0001416|High affinity immunoglobulin gamma Fc receptor I\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT'], 'gene-sequence': ['>lcl|BSEQ0016183|High affinity immunoglobulin gamma Fc receptor I (FCGR1A)\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAATTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00047'], 'name': ['ig']}, {'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['clathrin-coated endocytic vesicle membrane']}, {'category': ['component'], 'description': ['early endosome membrane']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['receptor signaling protein activity']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent']}, {'category': ['process'], 'description': ['antigen processing and presentation of peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['interferon-gamma-mediated signaling pathway']}, {'category': ['process'], 'description': ['intracellular signal transduction']}, {'category': ['process'], 'description': ['phagocytosis, engulfment']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}, {'id': ['BE0002098'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor II-a'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13085'], 'pubmed-id': ['15457442'], 'citation': ['Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6.']}, {'ref-id': ['A13086'], 'pubmed-id': ['15526004'], 'citation': ['Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7.']}, {'ref-id': ['A202010'], 'pubmed-id': ['27463856'], 'citation': ['Hofmann HP, Kronthaler U, Fritsch C, Grau R, Muller SO, Mayer R, Seidl A, Da Silva A: Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel((R))). Expert Opin Biol Ther. 2016 Oct;16(10):1185-95. doi: 10.1080/14712598.2016.1217329. Epub 2016 Aug 16.']}, {'ref-id': ['A203909'], 'pubmed-id': ['19128982'], 'citation': ['Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T: Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009 Feb;45(2):124-31. doi: 10.1016/j.cyto.2008.11.008. Epub 2009 Jan 6.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor II-a'], 'general-function': [None], 'specific-function': ['Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens.'], 'gene-name': ['FCGR2A'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['218-240'], 'signal-regions': ['1-33'], 'theoretical-pi': ['6.78'], 'molecular-weight': ['35000.42'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3616']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR2A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M31932']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182474']}, {'resource': ['UniProtKB'], 'identifier': ['P12318']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG2A_HUMAN']}]}], 'synonyms': [{'synonym': ['CD32', 'CDw32', 'Fc-gamma RII-a', 'Fc-gamma-RIIa', 'FCG2', 'FCGR2A1', 'FcRII-a', 'IGFR2', 'IgG Fc receptor II-a']}], 'amino-acid-sequence': ['>lcl|BSEQ0037156|Low affinity immunoglobulin gamma Fc region receptor II-a\nMTMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSHLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN'], 'gene-sequence': ['>lcl|BSEQ0019233|Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A)\nATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCATTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['innate immune response']}]}]}]}, {'id': ['BE0002099'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor II-b'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A202010'], 'pubmed-id': ['27463856'], 'citation': ['Hofmann HP, Kronthaler U, Fritsch C, Grau R, Muller SO, Mayer R, Seidl A, Da Silva A: Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel((R))). Expert Opin Biol Ther. 2016 Oct;16(10):1185-95. doi: 10.1080/14712598.2016.1217329. Epub 2016 Aug 16.']}, {'ref-id': ['A203909'], 'pubmed-id': ['19128982'], 'citation': ['Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T: Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009 Feb;45(2):124-31. doi: 10.1016/j.cyto.2008.11.008. Epub 2009 Jan 6.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor II-b'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis.'], 'gene-name': ['FCGR2B'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['218-240'], 'signal-regions': ['1-42'], 'theoretical-pi': ['6.12'], 'molecular-weight': ['34043.355'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3618']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR2B']}, {'resource': ['GenBank Gene Database'], 'identifier': ['U87560']}, {'resource': ['GenBank Protein Database'], 'identifier': ['4099445']}, {'resource': ['UniProtKB'], 'identifier': ['P31994']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG2B_HUMAN']}]}], 'synonyms': [{'synonym': ['CD32', 'CDw32', 'Fc-gamma RII-b', 'Fc-gamma-RIIb', 'FCG2', 'FcRII-b', 'IGFR2', 'IgG Fc receptor II-b']}], 'amino-acid-sequence': ['>lcl|BSEQ0004116|Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI'], 'gene-sequence': ['>lcl|BSEQ0019237|Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B)\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTG\nCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCC\nATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTC\nAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGC\nGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTGGAG\nTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTC\nAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAACTTC\nTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATAGGC\nTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCACCG\nATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCTGTA\nGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATTTAG'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['viral process']}]}]}]}, {'id': ['BE0002100'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor II-c'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13083'], 'pubmed-id': ['10800083'], 'citation': ['Hart SP, Ross JA, Ross K, Haslett C, Dransfield I: Molecular characterization of the surface of apoptotic neutrophils: implications for functional downregulation and recognition by phagocytes. Cell Death Differ. 2000 May;7(5):493-503.']}, {'ref-id': ['A13087'], 'pubmed-id': ['7535196'], 'citation': ['Ranheim EA, Kipps TJ: Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell Immunol. 1995 Apr 1;161(2):226-35.']}, {'ref-id': ['A203909'], 'pubmed-id': ['19128982'], 'citation': ['Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T: Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009 Feb;45(2):124-31. doi: 10.1016/j.cyto.2008.11.008. Epub 2009 Jan 6.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor II-c'], 'general-function': ['Transmembrane signaling receptor activity'], 'specific-function': ['Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells.'], 'gene-name': ['FCGR2C'], 'locus': ['1q23.3'], 'cellular-location': ['Cytoplasm'], 'transmembrane-regions': ['224-246'], 'signal-regions': ['1-42'], 'theoretical-pi': ['6.9'], 'molecular-weight': ['35577.96'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:15626']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR2C']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X17652']}, {'resource': ['GenBank Protein Database'], 'identifier': ['32074']}, {'resource': ['UniProtKB'], 'identifier': ['P31995']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG2C_HUMAN']}]}], 'synonyms': [{'synonym': ['CD32', 'CDw32', 'Fc-gamma RII-c', 'Fc-gamma-RIIc', 'FCG2', 'FcRII-c', 'IGFR2', 'IgG Fc receptor II-c']}], 'amino-acid-sequence': ['>lcl|BSEQ0004118|Low affinity immunoglobulin gamma Fc region receptor II-c\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR\nAPTDDDKNIYLTLPPNDHVNSNN'], 'gene-sequence': ['>lcl|BSEQ0011523|Low affinity immunoglobulin gamma Fc region receptor II-c (FCGR2C)\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCCGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG\nAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT\nGAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG\nGCACCTACTGACGATGATAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAAC\nAGTAATAACTAA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['transmembrane signaling receptor activity']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}, {'id': ['BE0002097'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor III-A'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13085'], 'pubmed-id': ['15457442'], 'citation': ['Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6.']}, {'ref-id': ['A13086'], 'pubmed-id': ['15526004'], 'citation': ['Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7.']}, {'ref-id': ['A202010'], 'pubmed-id': ['27463856'], 'citation': ['Hofmann HP, Kronthaler U, Fritsch C, Grau R, Muller SO, Mayer R, Seidl A, Da Silva A: Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel((R))). Expert Opin Biol Ther. 2016 Oct;16(10):1185-95. doi: 10.1080/14712598.2016.1217329. Epub 2016 Aug 16.']}, {'ref-id': ['A203909'], 'pubmed-id': ['19128982'], 'citation': ['Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T: Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009 Feb;45(2):124-31. doi: 10.1016/j.cyto.2008.11.008. Epub 2009 Jan 6.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor III-A'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.'], 'gene-name': ['FCGR3A'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['209-229'], 'signal-regions': ['1-16'], 'theoretical-pi': ['8.21'], 'molecular-weight': ['29088.895'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3619']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR3A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X52645']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31324']}, {'resource': ['UniProtKB'], 'identifier': ['P08637']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG3A_HUMAN']}]}], 'synonyms': [{'synonym': ['CD16A', 'CD16a antigen', 'Fc-gamma RIII', 'Fc-gamma RIII-alpha', 'Fc-gamma RIIIa', 'FCG3', 'FCGR3', 'FcR-10', 'FcRIII', 'FcRIIIa', 'IGFR3', 'IgG Fc receptor III-2']}], 'amino-acid-sequence': ['>lcl|BSEQ0004112|Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK'], 'gene-sequence': ['>lcl|BSEQ0011522|Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A)\nATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCT\nTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTG\nCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCA\nAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACT\nCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAG\nAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCGACGACAGT\nGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTGCAGCTAGAAGTC\nCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAGGAAGACCCTATT\nCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACATATTTACAGAAT\nGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCAAAAGCCACACTC\nAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAATGTGTCTTCAGAG\nACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCATCATTCTTTCCA\nCCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCAGTGGACACAGGA\nCTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGGAAGGACCATAAA\nTTTAAATGGAGAAAGGACCCTCAAGACAAATGA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['regulation of immune response']}]}]}]}, {'id': ['BE0000901'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor III-B'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13083'], 'pubmed-id': ['10800083'], 'citation': ['Hart SP, Ross JA, Ross K, Haslett C, Dransfield I: Molecular characterization of the surface of apoptotic neutrophils: implications for functional downregulation and recognition by phagocytes. Cell Death Differ. 2000 May;7(5):493-503.']}, {'ref-id': ['A13084'], 'pubmed-id': ['17387033'], 'citation': ['Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F: Acute-phase response, clinical measures and disease activity in ankylosing spondylitis. Joint Bone Spine. 2007 May;74(3):249-53. Epub 2007 Mar 5.']}, {'ref-id': ['A13085'], 'pubmed-id': ['15457442'], 'citation': ['Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6.']}, {'ref-id': ['A13086'], 'pubmed-id': ['15526004'], 'citation': ['Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7.']}, {'ref-id': ['A203909'], 'pubmed-id': ['19128982'], 'citation': ['Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T: Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009 Feb;45(2):124-31. doi: 10.1016/j.cyto.2008.11.008. Epub 2009 Jan 6.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor III-B'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.'], 'gene-name': ['FCGR3B'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': [None], 'signal-regions': ['1-16'], 'theoretical-pi': ['6.71'], 'molecular-weight': ['26215.64'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3620']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR3B']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X16863']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31322']}, {'resource': ['UniProtKB'], 'identifier': ['O75015']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG3B_HUMAN']}]}], 'synonyms': [{'synonym': ['CD16B', 'Fc-gamma RIII', 'Fc-gamma RIII-beta', 'Fc-gamma RIIIb', 'FCG3', 'FCGR3', 'FcR-10', 'FcRIII', 'FcRIIIb', 'IGFR3', 'IgG Fc receptor III-1']}], 'amino-acid-sequence': ['>lcl|BSEQ0010635|Low affinity immunoglobulin gamma Fc region receptor III-B\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI'], 'gene-sequence': ['>lcl|BSEQ0010636|Low affinity immunoglobulin gamma Fc region receptor III-B (FCGR3B)\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['anchored component of membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['mitophagy in response to mitochondrial depolarization']}, {'category': ['process'], 'description': ['positive regulation of defense response to virus by host']}, {'category': ['process'], 'description': ['xenophagy']}]}]}]}, {'id': ['BE0009995'], 'name': ['Complement component 1q (C1q)'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A202010'], 'pubmed-id': ['27463856'], 'citation': ['Hofmann HP, Kronthaler U, Fritsch C, Grau R, Muller SO, Mayer R, Seidl A, Da Silva A: Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel((R))). Expert Opin Biol Ther. 2016 Oct;16(10):1185-95. doi: 10.1080/14712598.2016.1217329. Epub 2016 Aug 16.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Complement C1q subcomponent subunit A'], 'general-function': [None], 'specific-function': ['C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.'], 'gene-name': ['C1QA'], 'locus': ['1p36.12'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-22'], 'theoretical-pi': ['9.45'], 'molecular-weight': ['26016.47'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1241']}, {'resource': ['GenAtlas'], 'identifier': ['C1QA']}, {'resource': ['GenBank Gene Database'], 'identifier': ['AF135157']}, {'resource': ['GenBank Protein Database'], 'identifier': ['4894854']}, {'resource': ['UniProtKB'], 'identifier': ['P02745']}, {'resource': ['UniProt Accession'], 'identifier': ['C1QA_HUMAN']}]}], 'synonyms': [{'synonym': ['Complement C1q subcomponent subunit A precursor']}], 'amino-acid-sequence': ['>lcl|BSEQ0016678|Complement C1q subcomponent subunit A\nMEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR\nTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI\nRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR\nGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL\nIFPSA'], 'gene-sequence': ['>lcl|BSEQ0016679|Complement C1q subcomponent subunit A (C1QA)\nATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG\nGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC\nAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG\nACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC\nAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGAGCCCGTGGCATCCCGGGAATTAAA\nGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT\nCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG\nGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC\nTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG\nGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG\nGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC\nCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC\nATCTTCCCATCTGCCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF01391'], 'name': ['Collagen']}, {'identifier': ['PF00386'], 'name': ['C1q']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['collagen trimer']}, {'category': ['component'], 'description': ['complement component C1 complex']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['process'], 'description': ['cell-cell signaling']}, {'category': ['process'], 'description': ['complement activation']}, {'category': ['process'], 'description': ['complement activation, classical pathway']}, {'category': ['process'], 'description': ['innate immune response']}]}]}, {'name': ['Complement C1q subcomponent subunit B'], 'general-function': [None], 'specific-function': ['C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.'], 'gene-name': ['C1QB'], 'locus': ['1p36.12'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-27'], 'theoretical-pi': ['8.87'], 'molecular-weight': ['26721.62'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1242']}, {'resource': ['GenAtlas'], 'identifier': ['C1QB']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X03084']}, {'resource': ['GenBank Protein Database'], 'identifier': ['573114']}, {'resource': ['UniProtKB'], 'identifier': ['P02746']}, {'resource': ['UniProt Accession'], 'identifier': ['C1QB_HUMAN']}]}], 'synonyms': [{'synonym': ['Complement C1q subcomponent subunit B precursor']}], 'amino-acid-sequence': ['>lcl|BSEQ0016676|Complement C1q subcomponent subunit B\nMMMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKG\nEKGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQ\nKIAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNL\nCVNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANS\nIFSGFLLFPDMEA'], 'gene-sequence': ['>lcl|BSEQ0016677|Complement C1q subcomponent subunit B (C1QB)\nATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGC\nCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATC\nCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGA\nGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCA\nGGGATTCCTGGGAATCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGC\nCCAGGGGCCCCTGGAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAG\nAAAATCGCCTTCTCTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATC\nCGCTTCGACCACGTGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTC\nACCTGCAAGGTGCCCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTG\nTGCGTGAACCTCATGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTAT\nGCCTACAACACCTTCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAG\nAACGTCTTCCTGCAGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGC\nATCTTTTCCGGGTTCCTGCTCTTTCCAGATATGGAGGCCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF01391'], 'name': ['Collagen']}, {'identifier': ['PF00386'], 'name': ['C1q']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['collagen trimer']}, {'category': ['component'], 'description': ['complement component C1 complex']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['process'], 'description': ['complement activation']}, {'category': ['process'], 'description': ['complement activation, classical pathway']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['inner ear development']}]}]}, {'name': ['Complement C1q subcomponent subunit C'], 'general-function': [None], 'specific-function': ['C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.'], 'gene-name': ['C1QC'], 'locus': ['1p36.11'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-28'], 'theoretical-pi': ['8.58'], 'molecular-weight': ['25773.56'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1245']}, {'resource': ['GenAtlas'], 'identifier': ['C1QC']}, {'resource': ['GenBank Gene Database'], 'identifier': ['AF087892']}, {'resource': ['GenBank Protein Database'], 'identifier': ['33150626']}, {'resource': ['UniProtKB'], 'identifier': ['P02747']}, {'resource': ['UniProt Accession'], 'identifier': ['C1QC_HUMAN']}]}], 'synonyms': [{'synonym': ['C1QG']}], 'amino-acid-sequence': ['>lcl|BSEQ0011520|Complement C1q subcomponent subunit C\nMDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP\nGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS\nVFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV\nLLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF\nLLFPD'], 'gene-sequence': ['>lcl|BSEQ0011521|Complement C1q subcomponent subunit C (C1QC)\nATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG\nCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC\nCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA\nGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA\nCCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC\nCCCATGGGCATCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA\nGTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC\nAACGCGGTCCTCACCAACCCGCAGGGAGATTATGACACGAGCACTGGCAAGTTCACCTGC\nAAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG\nCTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT\nCAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT\nGTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC\nCTGCTCTTCCCCGACTAG'], 'pfams': [{'pfam': [{'identifier': ['PF01391'], 'name': ['Collagen']}, {'identifier': ['PF00386'], 'name': ['C1q']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['collagen trimer']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['process'], 'description': ['complement activation']}, {'category': ['process'], 'description': ['complement activation, classical pathway']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['negative regulation of granulocyte differentiation']}, {'category': ['process'], 'description': ['negative regulation of macrophage differentiation']}]}]}]}]}]"
"['DB00006', 'BTD00076', 'EXPT03302', 'BIOD00076', 'DB02351']",['Bivalirudin'],small molecule,"['Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.']",['solid'],"['For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.']","['Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.']","[{'food-interaction': ['Avoid echinacea.', 'Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.']}]","[{'target': [{'id': ['BE0000048'], 'name': ['Prothrombin'], 'organism': ['Humans'], 'actions': [{'action': ['inhibitor']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1733'], 'pubmed-id': ['11060732'], 'citation': ['Scatena R: Bivalirudin: a new generation antithrombotic drug. Expert Opin Investig Drugs. 2000 May;9(5):1119-27.']}, {'ref-id': ['A1736'], 'pubmed-id': ['11504570'], 'citation': ['Bates ER: Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes. Curr Cardiol Rep. 2001 Sep;3(5):348-54.']}, {'ref-id': ['A1738'], 'pubmed-id': ['11833835'], 'citation': ['Gladwell TD: Bivalirudin: a direct thrombin inhibitor. Clin Ther. 2002 Jan;24(1):38-58.']}, {'ref-id': ['A1739'], 'pubmed-id': ['11923794'], 'citation': ['Kleiman NS, Klem J, Fernandes LS, Rubin H, Challa S, Solomon S, Maresh K, Arora U, Klem E, Buergler J, Mathew S, Browning A, DeLao T: Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J. 2002 Apr;143(4):585-93.']}, {'ref-id': ['A1741'], 'pubmed-id': ['11929334'], 'citation': ['Carswell CI, Plosker GL: Bivalirudin: a review of its potential place in the management of acute coronary syndromes. Drugs. 2002;62(5):841-70.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Prothrombin'], 'general-function': ['Thrombospondin receptor activity'], 'specific-function': ['Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.'], 'gene-name': ['F2'], 'locus': ['11p11-q12'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-24'], 'theoretical-pi': ['5.7'], 'molecular-weight': ['70036.295'], 'chromosome-location': ['11'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3535']}, {'resource': ['GenAtlas'], 'identifier': ['F2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M17262']}, {'resource': ['GenBank Protein Database'], 'identifier': ['339641']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2362']}, {'resource': ['UniProtKB'], 'identifier': ['P00734']}, {'resource': ['UniProt Accession'], 'identifier': ['THRB_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.21.5', 'Coagulation factor II']}], 'amino-acid-sequence': ['>lcl|BSEQ0016004|Prothrombin\nMAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC\nVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV\nNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE\nCSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA\nQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG\nDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI\nDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN\nDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP\nVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST\nRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY\nGFYTHVFRLKKWIQKVIDQFGE'], 'gene-sequence': ['>lcl|BSEQ0016005|Prothrombin (F2)\nATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC\nCTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG\nGTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGC\nGTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG\nGATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT\nGCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG\nAACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT\nGAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC\nGACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA\nTGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA\nGGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG\nTACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA\nCAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC\nTTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT\nGGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA\nGATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC\nCAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT\nCTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC\nGACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG\nCTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG\nGTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT\nGACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACCAGGTACGAGCGAAACATTGAAAAG\nATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC\nCGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT\nGTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG\nGTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC\nAGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC\nCGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA\nGGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC\nCGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT\nGGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT\nGGAGAGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00594'], 'name': ['Gla']}, {'identifier': ['PF00051'], 'name': ['Kringle']}, {'identifier': ['PF00089'], 'name': ['Trypsin']}, {'identifier': ['PF09396'], 'name': ['Thrombin_light']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular matrix']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['Golgi lumen']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['growth factor activity']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase activity']}, {'category': ['function'], 'description': ['thrombospondin receptor activity']}, {'category': ['process'], 'description': ['acute-phase response']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, intrinsic pathway']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['cellular response to mechanical stimulus']}, {'category': ['process'], 'description': ['cytosolic calcium ion homeostasis']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['multicellular organismal development']}, {'category': ['process'], 'description': ['negative regulation of astrocyte differentiation']}, {'category': ['process'], 'description': ['negative regulation of fibrinolysis']}, {'category': ['process'], 'description': ['negative regulation of platelet activation']}, {'category': ['process'], 'description': ['negative regulation of proteolysis']}, {'category': ['process'], 'description': ['peptidyl-glutamic acid carboxylation']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['positive regulation of blood coagulation']}, {'category': ['process'], 'description': ['positive regulation of cell growth']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of collagen biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of phosphatidylinositol 3-kinase signaling']}, {'category': ['process'], 'description': ['positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of reactive oxygen species metabolic process']}, {'category': ['process'], 'description': ['positive regulation of release of sequestered calcium ion into cytosol']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['proteolysis']}, {'category': ['process'], 'description': ['regulation of blood coagulation']}, {'category': ['process'], 'description': ['regulation of cell shape']}, {'category': ['process'], 'description': ['regulation of gene expression']}, {'category': ['process'], 'description': ['response to inactivity']}, {'category': ['process'], 'description': ['response to wounding']}]}]}]}]}]"
"['DB00007', 'BTD00009', 'BIOD00009']",['Leuprolide'],small molecule,"['Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours.[A203222] As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132]\r\n\r\nLeuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron by Abbvie Endocrine Inc.[L13850] Since this initial approval, various long-acting intramuscular and subcutaneous products have been developed such that patients can be dosed once every six months.[L13781, L13790] Leuprolide remains frontline therapy in all conditions for which it is indicated for use.']",['solid'],"['Leuprolide is indicated for the treatment of advanced prostate cancer [L13781, L34415] and as palliative treatment of advanced prostate cancer.[L13790] \r\n\r\nIt is also used for the treatment of pediatric patients with central precocious puberty (CPP).[L13784, L13787] \r\n\r\nIn combination with oral [norethisterone] (also known as norethindrone), leuprolide is also indicated for the initial treatment of the symptoms of endometriosis.[L10310] Finally, in combination with iron supplementation, leuprolide is indicated for the preoperative hematological improvement of anemic patients with uterine leiomyomata (uterine fibroids).[L13814]']","['Gonadotropin-releasing hormone (GnRH) is a naturally occurring decapeptide that modulates the hypothalamic-pituitary-gonadal (HPG) axis. GnRH binds to corresponding receptors (GnRHRs) on the anterior pituitary gonadotropes, which in turn release luteinizing hormone (LH) and follicle-stimulating hormone (FSH); these, in turn, affect the downstream synthesis and release of the sex hormones testosterone, dihydrotestosterone, estrone, and estradiol.[A203126, A203132]\r\n\r\nDespite the variety of conditions indicated for treatment with leuprolide, the mechanism of action underlying efficacy is the same in all cases. As a GnRHR agonist, leuprolide binds to and initially activates downstream LH and FSH release; this initial spike in gonadotropin levels is responsible for some of the adverse effects associated with treatment. After 2-4 weeks of treatment, continuous stimulation of GnRHR results in feedback inhibition and significant downregulation of LH, FSH, and their corresponding downstream effects, producing a therapeutic benefit. These effects are reversible upon treatment discontinuation.[A203126, A203129, A203132, A203222, L10310, L13781, L13784, L13787, L13790, L13814]']",[None],"[{'target': [{'id': ['BE0000203'], 'name': ['Gonadotropin-releasing hormone receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1743'], 'pubmed-id': ['16809153'], 'citation': ['Castellon E, Clementi M, Hitschfeld C, Sanchez C, Benitez D, Saenz L, Contreras H, Huidobro C: Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest. 2006 Apr-May;24(3):261-8.']}, {'ref-id': ['A1746'], 'pubmed-id': ['10687850'], 'citation': ['Borroni R, Di Blasio AM, Gaffuri B, Santorsola R, Busacca M, Vigano P, Vignali M: Expression of GnRH receptor gene in human ectopic endometrial cells and inhibition of their proliferation by leuprolide acetate. Mol Cell Endocrinol. 2000 Jan 25;159(1-2):37-43.']}, {'ref-id': ['A1748'], 'pubmed-id': ['9625809'], 'citation': ['Imai A, Takagi A, Horibe S, Takagi H, Tamaya T: Fas and Fas ligand system may mediate antiproliferative activity of gonadotropin-releasing hormone receptor in endometrial cancer cells. Int J Oncol. 1998 Jul;13(1):97-100.']}, {'ref-id': ['A1750'], 'pubmed-id': ['15758569'], 'citation': ['Murase M, Uemura T, Gao M, Inada M, Funabashi T, Hirahara F: GnRH antagonist-induced down-regulation of the mRNA expression of pituitary receptors: comparisons with GnRH agonist effects. Endocr J. 2005 Feb;52(1):131-7.']}, {'ref-id': ['A1751'], 'pubmed-id': ['10394541'], 'citation': ['Khurana KK, Singh SB, Tatum AH, Schulz V, Badawy SZ: Maintenance of increased Bcl-2 expression in uterine leiomyomas after GnRH agonist therapy. J Reprod Med. 1999 Jun;44(6):487-92.']}]}], 'textbooks': [None], 'links': [{'link': [{'ref-id': ['L10310'], 'title': ['FDA Approved Drug Products: Lupaneta Pack for intramuscular and oral use'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203696s001lbl.pdf']}, {'ref-id': ['L13781'], 'title': ['FDA Approved Drug Products: Lupron Depot (leuprolide acetate) depot suspension, for intramuscular injection'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/019732s045,020517s043lbl.pdf']}, {'ref-id': ['L13784'], 'title': ['FDA Approved Drug Products: Lupron Depot-Ped (leuprolide acetate) depot suspension'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020263s046lbl.pdf']}, {'ref-id': ['L13787'], 'title': ['FDA Approved Drug Products: Fensolvi (leuprolide acetate) suspension'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213150s000lbl.pdf']}, {'ref-id': ['L13790'], 'title': ['FDA Approved Drug Products: ELIGARD (leuprolide acetate) for injectable suspension, for subcutaneous use'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021343s039,021379s041,021488s036,021731s037lbl.pdf']}, {'ref-id': ['L13814'], 'title': ['FDA Approved Drug Products: Lupron Depot 3.75mg (leuprolide acetate) depot suspension'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019943s034lbl.pdf']}]}], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Gonadotropin-releasing hormone receptor'], 'general-function': ['Peptide binding'], 'specific-function': ['Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This receptor mediates its action by association with G-proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act as an inhibitor of GnRH-R signaling.'], 'gene-name': ['GNRHR'], 'locus': ['4q21.2'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['39-58\n78-97\n116-137\n165-184\n213-232\n282-300\n307-326'], 'signal-regions': [None], 'theoretical-pi': ['9.93'], 'molecular-weight': ['37730.355'], 'chromosome-location': ['4'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:4421']}, {'resource': ['GenAtlas'], 'identifier': ['GNRHR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L03380']}, {'resource': ['GenBank Protein Database'], 'identifier': ['183422']}, {'resource': ['IUPHAR'], 'identifier': ['256']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['256']}, {'resource': ['UniProtKB'], 'identifier': ['P30968']}, {'resource': ['UniProt Accession'], 'identifier': ['GNRHR_HUMAN']}]}], 'synonyms': [{'synonym': ['GnRH receptor', 'GRHR']}], 'amino-acid-sequence': ['>lcl|BSEQ0000405|Gonadotropin-releasing hormone receptor\nMANSASPEQNQNHCSAINNSIPLMQGNLPTLTLSGKIRVTVTFFLFLLSATFNASFLLKL\nQKWTQKKEKGKKLSRMKLLLKHLTLANLLETLIVMPLDGMWNITVQWYAGELLCKVLSYL\nKLFSMYAPAFMMVVISLDRSLAITRPLALKSNSKVGQSMVGLAWILSSVFAGPQLYIFRM\nIHLADSSGQTKVFSQCVTHCSFSQWWHQAFYNFFTFSCLFIIPLFIMLICNAKIIFTLTR\nVLHQDPHELQLNQSKNNIPRARLKTLKMTVAFATSFTVCWTPYYVLGIWYWFDPEMLNRL\nSDPVNHFFFLFAFLNPCFDPLIYGYFSL'], 'gene-sequence': ['>lcl|BSEQ0018926|Gonadotropin-releasing hormone receptor (GNRHR)\nATGGCAAACAGTGCCTCTCCTGAACAGAATCAAAATCACTGTTCAGCCATCAACAACAGC\nATCCCACTGATGCAGGGCAACCTCCCCACTCTGACCTTGTCTGGAAAGATCCGAGTGACG\nGTTACTTTCTTCCTTTTTCTGCTCTCTGCGACCTTTAATGCTTCTTTCTTGTTGAAACTT\nCAGAAGTGGACACAGAAGAAAGAGAAAGGGAAAAAGCTCTCAAGAATGAAGCTGCTCTTA\nAAACATCTGACCTTAGCCAACCTGTTGGAGACTCTGATTGTCATGCCACTGGATGGGATG\nTGGAACATTACAGTCCAATGGTATGCTGGAGAGTTACTCTGCAAAGTTCTCAGTTATCTA\nAAGCTTTTCTCCATGTATGCCCCAGCCTTCATGATGGTGGTGATCAGCCTGGACCGCTCC\nCTGGCTATCACGAGGCCCCTAGCTTTGAAAAGCAACAGCAAAGTCGGACAGTCCATGGTT\nGGCCTGGCCTGGATCCTCAGTAGTGTCTTTGCAGGACCACAGTTATACATCTTCAGGATG\nATTCATCTAGCAGACAGCTCTGGACAGACAAAAGTTTTCTCTCAATGTGTAACACACTGC\nAGTTTTTCACAATGGTGGCATCAAGCATTTTATAACTTTTTCACCTTCAGCTGCCTCTTC\nATCATCCCTCTTTTCATCATGCTGATCTGCAATGCAAAAATCATCTTCACCCTGACACGG\nGTCCTTCATCAGGACCCCCACGAACTACAACTGAATCAGTCCAAGAACAATATACCAAGA\nGCACGGCTGAAGACTCTAAAAATGACGGTTGCATTTGCCACTTCATTTACTGTCTGCTGG\nACTCCCTACTATGTCCTAGGAATTTGGTATTGGTTTGATCCTGAAATGTTAAACAGGTTG\nTCAGACCCAGTAAATCACTTCTTCTTTCTCTTTGCCTTTTTAAACCCATGCTTTGATCCA\nCTTATCTATGGATATTTTTCTCTGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['gonadotropin-releasing hormone receptor activity']}, {'category': ['function'], 'description': ['peptide binding']}, {'category': ['process'], 'description': ['cellular response to gonadotropin-releasing hormone']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['multicellular organismal development']}]}]}]}]}]"
"['DB00008', 'BTD00043', 'BIOD00043']",['Peginterferon alfa-2a'],biotech,"[""Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852]. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2a. Peginterferon alfa-2a is derived from the alfa-2a moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Use of Peginterferon alfa-2a is associated with a wide range of severe adverse effects including the aggravation and development of endocrine and autoimmune disorders, retinopathies, cardiovascular and neuropsychiatric complications, and increased risk of hepatic decompensation in patients with cirrhosis. The use of Peginterferon alfa-2a has largely declined since newer interferon-free antiviral therapies have been developed.\r\n\r\nIn a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) no longer recommend Peginterferon alfa-2a for the treatment of Hepatitis C [A19593]. Peginterferon alfa-2a was used alongside [DB00811] with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality [A19626].\r\n\r\nPeginterferon alfa-2a is available as a fixed dose injector (tradename Pegasys) used for the treatment of chronic Hepatitis C. Approved in 2002 by the FDA, Pegasys is indicated for the treatment of HCV with [DB00811] or other antiviral drugs [FDA Label]. When combined together, Peginterferon alfa-2a and [DB00811] have been shown to achieve a SVR between 36% for genotype 1 and 59% for genotypes 2-6 after 48 weeks of treatment.""]",['liquid'],['Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.\r\n\r\nPeginterferon alfa-2a is also indicated as a monotherapy for adult patients with HBeAg positive and HBeAg negative chronic hepatitis B infection who have compensated liver disease and evidence of viral replication and liver inflammation [FDA Label].'],"[""Peginterferon alfa-2a is derived from recombinant human interferon's alfa-2a moeity [FDA Label]. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway. Activation of the JAK/STAT pathway increases expression of multiple genes in multiple tissues involved in the innate antiviral response.""]",[{'food-interaction': ['Drink plenty of fluids.']}],"[{'target': [{'id': ['BE0000385'], 'name': ['Interferon alpha/beta receptor 2'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1754'], 'pubmed-id': ['15898717'], 'citation': ['Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27.']}, {'ref-id': ['A1755'], 'pubmed-id': ['16953837'], 'citation': ['Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75.']}, {'ref-id': ['A1758'], 'pubmed-id': ['19955815'], 'citation': ['Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interferon alpha/beta receptor 2'], 'general-function': ['Type i interferon receptor activity'], 'specific-function': ['Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.'], 'gene-name': ['IFNAR2'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['244-264'], 'signal-regions': ['1-26'], 'theoretical-pi': ['4.11'], 'molecular-weight': ['57758.24'], 'chromosome-location': ['21'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5433']}, {'resource': ['GenAtlas'], 'identifier': ['IFNAR2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L42243']}, {'resource': ['GenBank Protein Database'], 'identifier': ['995300']}, {'resource': ['UniProtKB'], 'identifier': ['P48551']}, {'resource': ['UniProt Accession'], 'identifier': ['INAR2_HUMAN']}]}], 'synonyms': [{'synonym': ['IFN-R-2', 'IFNABR', 'IFNARB', 'Interferon alpha binding protein', 'Type I interferon receptor 2']}], 'amino-acid-sequence': ['>lcl|BSEQ0000767|Interferon alpha/beta receptor 2\nMLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS\nIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF\nSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK\nHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE\nSAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD\nMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI\nDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR\nITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT\nFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR'], 'gene-sequence': ['>lcl|BSEQ0018941|Interferon alpha/beta receptor 2 (IFNAR2)\nATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT\nATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT\nTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC\nATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG\nGTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA\nAGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC\nAGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG\nATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA\nGAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG\nCATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA\nATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA\nATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA\nTCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC\nATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG\nAGGCAAGGTCTCGCTAAGGGCTGGAATGCAGTGGCTATTCACAGGTGCAGTCATAATGCA\nCTACAGTCTGAAACTCCTGAGCTCAAACAGTCGTCCTGCCTAAGCTTCCCCAGTAGCTGG\nGATTACAAGCGTGCATCCCTGTGCCCCAGTGATTAA'], 'pfams': [{'pfam': [{'identifier': ['PF01108'], 'name': ['Tissue_fac']}, {'identifier': ['PF09294'], 'name': ['Interfer-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['protein kinase binding']}, {'category': ['function'], 'description': ['type I interferon binding']}, {'category': ['function'], 'description': ['type I interferon receptor activity']}, {'category': ['process'], 'description': ['cell proliferation']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['JAK-STAT cascade']}, {'category': ['process'], 'description': ['regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['regulation of type I interferon-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to interferon-alpha']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['type I interferon signaling pathway']}]}]}]}, {'id': ['BE0000661'], 'name': ['Interferon alpha/beta receptor 1'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1754'], 'pubmed-id': ['15898717'], 'citation': ['Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27.']}, {'ref-id': ['A1755'], 'pubmed-id': ['16953837'], 'citation': ['Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75.']}, {'ref-id': ['A1758'], 'pubmed-id': ['19955815'], 'citation': ['Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interferon alpha/beta receptor 1'], 'general-function': ['Type i interferon receptor activity'], 'specific-function': ['Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.'], 'gene-name': ['IFNAR1'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['437-457'], 'signal-regions': ['1-27'], 'theoretical-pi': ['5.56'], 'molecular-weight': ['63524.81'], 'chromosome-location': ['21'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5432']}, {'resource': ['GenAtlas'], 'identifier': ['IFNAR1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['J03171']}, {'resource': ['GenBank Protein Database'], 'identifier': ['306914']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1723']}, {'resource': ['UniProtKB'], 'identifier': ['P17181']}, {'resource': ['UniProt Accession'], 'identifier': ['INAR1_HUMAN']}]}], 'synonyms': [{'synonym': ['CRF2-1', 'Cytokine receptor class-II member 1', 'Cytokine receptor family 2 member 1', 'IFN-R-1', 'IFNAR', 'Type I interferon receptor 1']}], 'amino-acid-sequence': ['>lcl|BSEQ0001318|Interferon alpha/beta receptor 1\nMMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT\nFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF\nTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI\nENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ\nNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK\nGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP\nVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV\nFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE\nYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN\nEDESESKTSEELQQDFV'], 'gene-sequence': ['>lcl|BSEQ0018987|Interferon alpha/beta receptor 1 (IFNAR1)\nATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTG\nTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC\nATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT\nTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG\nAATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT\nAAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT\nACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG\nGCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT\nTTAAGCTTTACATATAGCTTAGTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT\nGAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA\nAAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT\nATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA\nAATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG\nTGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA\nCCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA\nGGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA\nGAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA\nTCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT\nGTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT\nGAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT\nGTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT\nTTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA\nGTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC\nTTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG\nTATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA\nAAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT\nGATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT\nGAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA'], 'pfams': [{'pfam': [{'identifier': ['PF01108'], 'name': ['Tissue_fac']}, {'identifier': ['PF09294'], 'name': ['Interfer-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['type I interferon receptor activity']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['defense response to virus']}, {'category': ['process'], 'description': ['JAK-STAT cascade']}, {'category': ['process'], 'description': ['positive regulation of interferon-beta production']}, {'category': ['process'], 'description': ['positive regulation of interferon-gamma production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-1 beta secretion']}, {'category': ['process'], 'description': ['positive regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['regulation of type I interferon-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['T cell activation']}, {'category': ['process'], 'description': ['type I interferon biosynthetic process']}, {'category': ['process'], 'description': ['type I interferon signaling pathway']}]}]}]}]}]"
"['DB00009', 'BTD00050', 'BIOD00050']",['Alteplase'],biotech,"['Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent.[L43125] It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin.[A252330,L43125] Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells.[A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).[A252270] The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting. However, its use for the treatment of acute ischemic stroke (AIS) has increased over the years.[A252340] New thrombolytic agents derived from tissue plasminogen activator, such as [desmoteplase], [tenecteplase] and [reteplase], have also been developed.[A252270,A252345] Alteplase is also available as Cathflo Activase (intracatheter instillation) for the restoration of function to central venous access devices.[L34864]']",['liquid'],"['Alteplase is indicated for the treatment of acute ischemic stroke (AIS) and for use in acute myocardial infarction (AMI) for the reduction of mortality and incidence of heart failure. Alteplase is also indicated for the lysis of acute massive pulmonary embolism, defined as acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segments, and acute pulmonary emboli accompanied by unstable hemodynamics.[L43125]']","['Alteplase is a recombinant tissue plasminogen activator (rt-PA) that converts plasminogen to plasmin in a fibrin-dependent process. In the absence of fibrin, alteplase converts a limited amount of plasminogen. However, in the presence of fibrin clots, alteplase binds to fibrin and cleaves the arginine-valine bond at positions 560 and 561 of plasminogen, converting it into its active form, plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus and promotes clot dissolution.[A252270] Alteplase initiates local fibrinolysis with limited systemic proteolysis.[L43125]']","[{'food-interaction': ['Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.']}]","[{'target': [{'id': ['BE0000211'], 'name': ['Plasminogen'], 'organism': ['Humans'], 'actions': [{'action': ['activator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A6689'], 'pubmed-id': ['18673235'], 'citation': ['Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.']}, {'ref-id': ['A6691'], 'pubmed-id': ['17963464'], 'citation': ['Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.']}, {'ref-id': ['A252270'], 'pubmed-id': ['22248305'], 'citation': ['Acheampong P, Ford GA: Pharmacokinetics of alteplase in the treatment of ischaemic stroke. Expert Opin Drug Metab Toxicol. 2012 Feb;8(2):271-81. doi: 10.1517/17425255.2012.652615. Epub 2012 Jan 17.']}]}], 'textbooks': [None], 'links': [{'link': [{'ref-id': ['L43125'], 'title': ['FDA Approved Drug Products: ACTIVASE (alteplase) injection for intravenous use'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/103172s5268lbl.pdf']}]}], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Plasminogen'], 'general-function': ['Serine-type peptidase activity'], 'specific-function': ['Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.'], 'gene-name': ['PLG'], 'locus': ['6q26'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-19'], 'theoretical-pi': ['7.25'], 'molecular-weight': ['90568.415'], 'chromosome-location': ['6'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:9071']}, {'resource': ['GenAtlas'], 'identifier': ['PLG']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X05199']}, {'resource': ['GenBank Protein Database'], 'identifier': ['387026']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2394']}, {'resource': ['UniProtKB'], 'identifier': ['P00747']}, {'resource': ['UniProt Accession'], 'identifier': ['PLMN_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.21.7']}], 'amino-acid-sequence': ['>lcl|BSEQ0016037|Plasminogen\nMEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT\nCRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN\nGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE\nCEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE\nLRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS\nAQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE\nQLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG\nLTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED\nCMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG\nPWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT\nRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE\nPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ\nLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW\nGLGCARPNKPGVYVRVSRFVTWIEGVMRNN'], 'gene-sequence': ['>lcl|BSEQ0016038|Plasminogen (PLG)\nATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG\nCCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG\nCTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC\nTGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG\nAAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC\nTCAGAGTGCAAGACTGGGAATGGAAAGAACTACAGAGGGACGATGTCCAAAACAAAAAAT\nGGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT\nACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG\nGGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG\nTGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC\nATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT\nCCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG\nCTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGTGACATCCCC\nCGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT\nGAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT\nGCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTCCCCTGCAAAAATTTGGAT\nGAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC\nCAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA\nCAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT\nGATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT\nTGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC\nCTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA\nGACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT\nGTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAGATGTAGAGACTCCTTCCGAAGAAGAC\nTGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG\nCCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA\nAATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT\nCCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT\nGCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG\nGTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA\nAGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT\nGCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC\nCAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG\nCCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA\nGTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC\nATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG\nCTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA\nTCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT\nGGAGGTCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG\nGGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT\nACTTGGATTGAGGGAGTGATGAGAAATAATTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00051'], 'name': ['Kringle']}, {'identifier': ['PF00089'], 'name': ['Trypsin']}, {'identifier': ['PF00024'], 'name': ['PAN_1']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['extrinsic component of external side of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['function'], 'description': ['apolipoprotein binding']}, {'category': ['function'], 'description': ['protein domain specific binding']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase activity']}, {'category': ['function'], 'description': ['serine-type peptidase activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['extracellular matrix disassembly']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['negative regulation of cell proliferation']}, {'category': ['process'], 'description': ['negative regulation of cell-cell adhesion mediated by cadherin']}, {'category': ['process'], 'description': ['negative regulation of cell-substrate adhesion']}, {'category': ['process'], 'description': ['negative regulation of fibrinolysis']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of fibrinolysis']}, {'category': ['process'], 'description': ['proteolysis']}, {'category': ['process'], 'description': ['tissue remodeling']}]}]}]}, {'id': ['BE0000538'], 'name': ['Fibrinogen alpha chain'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A6689'], 'pubmed-id': ['18673235'], 'citation': ['Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.']}, {'ref-id': ['A6691'], 'pubmed-id': ['17963464'], 'citation': ['Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.']}, {'ref-id': ['A252270'], 'pubmed-id': ['22248305'], 'citation': ['Acheampong P, Ford GA: Pharmacokinetics of alteplase in the treatment of ischaemic stroke. Expert Opin Drug Metab Toxicol. 2012 Feb;8(2):271-81. doi: 10.1517/17425255.2012.652615. Epub 2012 Jan 17.']}]}], 'textbooks': [None], 'links': [{'link': [{'ref-id': ['L43125'], 'title': ['FDA Approved Drug Products: ACTIVASE (alteplase) injection for intravenous use'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/103172s5268lbl.pdf']}]}], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Fibrinogen alpha chain'], 'general-function': ['Structural molecule activity'], 'specific-function': ['Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the immune response via both innate and T-cell mediated pathways.'], 'gene-name': ['FGA'], 'locus': ['4q28'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-19'], 'theoretical-pi': ['5.87'], 'molecular-weight': ['94972.455'], 'chromosome-location': ['4'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3661']}, {'resource': ['GenAtlas'], 'identifier': ['FGA']}, {'resource': ['GenBank Gene Database'], 'identifier': ['AF361104']}, {'resource': ['GenBank Protein Database'], 'identifier': ['13591824']}, {'resource': ['UniProtKB'], 'identifier': ['P02671']}, {'resource': ['UniProt Accession'], 'identifier': ['FIBA_HUMAN']}]}], 'synonyms': [{'synonym': ['Fibrinogen alpha chain precursor']}], 'amino-acid-sequence': ['>lcl|BSEQ0001074|Fibrinogen alpha chain\nMFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW\nNYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA\nNNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC\nRGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQ\nLQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSS\nGPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTW\nNPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV\nSPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTK\nEVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEF\nVSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKS\nYKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFS\nVYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQR\nGSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSH\nNNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENG\nVVWVSFRGADYSLRAVRMKIRPLVTQ'], 'gene-sequence': ['>lcl|BSEQ0021267|Fibrinogen alpha chain (FGA)\nATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCA\nGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTG\nGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGG\nAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGAT\nTTTACAAACAGAATAAATAAGCTCAAAAATTCACTATTTGAATATCAGAAGAACAATAAG\nGATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCCTCAGCC\nAATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTGAAGTC\nCTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAGAAAAATGTTAGA\nGCTCAGTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGT\nCGAGGGTCATGCAGTAGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAG\nCAGAAGCAACTTGAACAGGTCATTGCCAAAGACTTACTTCCCTCTAGAGATAGGCAACAC\nTTACCACTGATAAAAATGAAACCAGTTCCAGACTTGGTTCCCGGAAATTTTAAGAGCCAG\nCTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCGCAGATGAGAATGGAG\nTTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAACCGGA\nTCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCT\nGGACCTGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACC\nTGGAAACCTGGGAGCTCTGGACCTGGAAGTACTGGAAGCTGGAACTCTGGGAGCTCTGGA\nACTGGAAGTACTGGAAACCAAAACCCTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGG\nAATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCACTGGACCTCTGAGAGCTCTGTATCT\nGGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCAGATAGCCCAGGCTCT\nGGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAAATGTA\nAGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAA\nGAGCTCAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCA\nTGCTCTAAAACCGTTACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAA\nGAAGTGGTGACCTCCGAAGATGGTTCTGACTGTCCCGAGGCAATGGATTTAGGCACATTG\nTCTGGCATAGGTACTCTGGATGGGTTCCGCCATAGGCACCCTGATGAAGCTGCCTTCTTC\nGACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCTATGTTAGGAGAGTTT\nGTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGGAATCC\nAGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGC\nAAACAATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGC\nTATAAAATGGCAGATGAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAG\nAGAGGCCATGCTAAATCTCGCCCTGTCAGAGACTGTGATGATGTCCTCCAAACACATCCT\nTCAGGTACCCAAAGTGGCATTTTCAATATCAAGCTACCGGGATCCAGTAAGATTTTTTCT\nGTTTATTGCGATCAAGAGACCAGTTTGGGAGGATGGCTTTTGATCCAGCAAAGAATGGAT\nGGATCACTGAATTTTAACCGGACCTGGCAAGACTACAAGAGAGGTTTCGGCAGCCTGAAT\nGACGAGGGGGAAGGAGAATTCTGGCTAGGCAATGACTACCTCCACTTACTAACCCAAAGG\nGGCTCTGTTCTTAGGGTTGAATTAGAGGACTGGGCTGGGAATGAAGCTTATGCAGAATAT\nCACTTCCGGGTAGGCTCTGAGGCTGAAGGCTATGCCCTCCAAGTCTCCTCCTATGAAGGC\nACTGCGGGTGATGCTCTGATTGAGGGTTCCGTAGAGGAAGGGGCAGAGTACACCTCTCAC\nAACAACATGCAGTTCAGCACCTTTGACAGGGATGCAGACCAGTGGGAAGAGAACTGTGCA\nGAAGTCTATGGGGGAGGCTGGTGGTATAATAACTGCCAAGCAGCCAATCTCAATGGAATC\nTACTACCCTGGGGGCTCCTATGACCCAAGGAATAACAGTCCTTATGAGATTGAGAATGGA\nGTGGTCTGGGTTTCCTTTAGAGGGGCAGATTATTCCCTCAGGGCTGTTCGCATGAAAATT\nAGGCCCCTTGTGACCCAATAG'], 'pfams': [{'pfam': [{'identifier': ['PF00147'], 'name': ['Fibrinogen_C']}, {'identifier': ['PF08702'], 'name': ['Fib_alpha']}, {'identifier': ['PF12160'], 'name': ['Fibrinogen_aC']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['cell cortex']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['extracellular vesicle']}, {'category': ['component'], 'description': ['fibrinogen complex']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['component'], 'description': ['rough endoplasmic reticulum']}, {'category': ['function'], 'description': ['structural molecule activity']}, {'category': ['process'], 'description': ['acute-phase response']}, {'category': ['process'], 'description': ['adaptive immune response']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, common pathway']}, {'category': ['process'], 'description': ['blood coagulation, fibrin clot formation']}, {'category': ['process'], 'description': ['cell-matrix adhesion']}, {'category': ['process'], 'description': ['cellular protein complex assembly']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['cellular response to granulocyte colony-stimulating factor']}, {'category': ['process'], 'description': ['cellular response to interleukin-6']}, {'category': ['process'], 'description': ['cellular response to organic cyclic compound']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['induction of bacterial agglutination']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['liver regeneration']}, {'category': ['process'], 'description': ['negative regulation of blood coagulation, common pathway']}, {'category': ['process'], 'description': ['negative regulation of endothelial cell apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of extrinsic apoptotic signaling pathway via death domain receptors']}, {'category': ['process'], 'description': ['plasminogen activation']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet aggregation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['positive regulation of exocytosis']}, {'category': ['process'], 'description': ['positive regulation of heterotypic cell-cell adhesion']}, {'category': ['process'], 'description': ['positive regulation of peptide hormone secretion']}, {'category': ['process'], 'description': ['positive regulation of protein secretion']}, {'category': ['process'], 'description': ['positive regulation of substrate adhesion-dependent cell spreading']}, {'category': ['process'], 'description': ['positive regulation of vasoconstriction']}, {'category': ['process'], 'description': ['protein complex assembly']}, {'category': ['process'], 'description': ['protein polymerization']}, {'category': ['process'], 'description': ['response to calcium ion']}, {'category': ['process'], 'description': ['response to cycloheximide']}, {'category': ['process'], 'description': ['response to estradiol']}, {'category': ['process'], 'description': ['response to genistein']}, {'category': ['process'], 'description': ['response to morphine']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}, {'id': ['BE0002092'], 'name': ['Fibrinogen gamma chain'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A6689'], 'pubmed-id': ['18673235'], 'citation': ['Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.']}, {'ref-id': ['A6691'], 'pubmed-id': ['17963464'], 'citation': ['Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.']}, {'ref-id': ['A252270'], 'pubmed-id': ['22248305'], 'citation': ['Acheampong P, Ford GA: Pharmacokinetics of alteplase in the treatment of ischaemic stroke. Expert Opin Drug Metab Toxicol. 2012 Feb;8(2):271-81. doi: 10.1517/17425255.2012.652615. Epub 2012 Jan 17.']}]}], 'textbooks': [None], 'links': [{'link': [{'ref-id': ['L43125'], 'title': ['FDA Approved Drug Products: ACTIVASE (alteplase) injection for intravenous use'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/103172s5268lbl.pdf']}]}], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Fibrinogen gamma chain'], 'general-function': ['Structural molecule activity'], 'specific-function': ['Together with fibrinogen alpha (FGA) and fibrinogen beta (FGB), polymerizes to form an insoluble fibrin matrix. Has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the antibacterial immune response via both innate and T-cell mediated pathways.'], 'gene-name': ['FGG'], 'locus': ['4q28'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-26'], 'theoretical-pi': ['5.32'], 'molecular-weight': ['51511.29'], 'chromosome-location': ['4'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3694']}, {'resource': ['GenAtlas'], 'identifier': ['FGG']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M10014']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182439']}, {'resource': ['UniProtKB'], 'identifier': ['P02679']}, {'resource': ['UniProt Accession'], 'identifier': ['FIBG_HUMAN']}]}], 'synonyms': [{'synonym': ['Fibrinogen gamma chain  precursor']}], 'amino-acid-sequence': ['>lcl|BSEQ0004102|Fibrinogen gamma chain\nMSWSLHPRNLILYFYALLFLSSTCVAYVATRDNCCILDERFGSYCPTTCGIADFLSTYQT\nKVDKDLQSLEDILHQVENKTSEVKQLIKAIQLTYNPDESSKPNMIDAATLKSRKMLEEIM\nKYEASILTHDSSIRYLQEIYNSNNQKIVNLKEKVAQLEAQCQEPCKDTVQIHDITGKDCQ\nDIANKGAKQSGLYFIKPLKANQQFLVYCEIDGSGNGWTVFQKRLDGSVDFKKNWIQYKEG\nFGHLSPTGTTEFWLGNEKIHLISTQSAIPYALRVELEDWNGRTSTADYAMFKVGPEADKY\nRLTYAYFAGGDAGDAFDGFDFGDDPSDKFFTSHNGMQFSTWDNDNDKFEGNCAEQDGSGW\nWMNKCHAGHLNGVYYQGGTYSKASTPNGYDNGIIWATWKTRWYSMKKTTMKIIPFNRLTI\nGEGQQHHLGGAKQVRPEHPAETEYDSLYPEDDL'], 'gene-sequence': ['>lcl|BSEQ0011517|Fibrinogen gamma chain (FGG)\nATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTC\nTCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGA\nTTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACC\nAAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACA\nTCAGAAGTCAAACAGCTGATAAAAGCAATCCAACTCACTTATAATCCTGATGAATCATCA\nAAACCAAATATGATAGACGCTGCTACTTTGAAGTCCAGGAAAATGTTAGAAGAAATTATG\nAAATATGAAGCATCGATTTTAACACATGACTCAAGTATTCGATATTTGCAGGAAATATAT\nAATTCAAATAATCAAAAGATTGTTAACCTGAAAGAGAAGGTAGCCCAGCTTGAAGCACAG\nTGCCAGGAACCTTGCAAAGACACGGTGCAAATCCATGATATCACTGGGAAAGATTGTCAA\nGACATTGCCAATAAGGGAGCTAAACAGAGCGGGCTTTACTTTATTAAACCTCTGAAAGCT\nAACCAGCAATTCTTAGTCTACTGTGAAATCGATGGGTCTGGAAATGGATGGACTGTGTTT\nCAGAAGAGACTTGATGGCAGTGTAGATTTCAAGAAAAACTGGATTCAATATAAAGAAGGA\nTTTGGACATCTGTCTCCTACTGGCACAACAGAATTTTGGCTGGGAAATGAGAAGATTCAT\nTTGATAAGCACACAGTCTGCCATCCCATATGCATTAAGAGTGGAACTGGAAGACTGGAAT\nGGCAGAACCAGTACTGCAGACTATGCCATGTTCAAGGTGGGACCTGAAGCTGACAAGTAC\nCGCCTAACATATGCCTACTTCGCTGGTGGGGATGCTGGAGATGCCTTTGATGGCTTTGAT\nTTTGGCGATGATCCTAGTGACAAGTTTTTCACATCCCATAATGGCATGCAGTTCAGTACC\nTGGGACAATGACAATGATAAGTTTGAAGGCAACTGTGCTGAACAGGATGGATCTGGTTGG\nTGGATGAACAAGTGTCACGCTGGCCATCTCAATGGAGTTTATTACCAAGGTGGCACTTAC\nTCAAAAGCATCTACTCCTAATGGTTATGATAATGGCATTATTTGGGCCACTTGGAAAACC\nCGGTGGTATTCCATGAAGAAAACCACTATGAAGATAATCCCATTCAACAGACTCACAATT\nGGAGAAGGACAGCAACACCACCTGGGGGGAGCCAAACAGGCTGGAGACGTTTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00147'], 'name': ['Fibrinogen_C']}, {'identifier': ['PF08702'], 'name': ['Fib_alpha']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['cell cortex']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['fibrinogen complex']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['function'], 'description': ['cell adhesion molecule binding']}, {'category': ['function'], 'description': ['metal ion binding']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['structural molecule activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, fibrin clot formation']}, {'category': ['process'], 'description': ['cell-matrix adhesion']}, {'category': ['process'], 'description': ['cellular protein complex assembly']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['negative regulation of endothelial cell apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of extrinsic apoptotic signaling pathway via death domain receptors']}, {'category': ['process'], 'description': ['plasminogen activation']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet aggregation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['positive regulation of exocytosis']}, {'category': ['process'], 'description': ['positive regulation of heterotypic cell-cell adhesion']}, {'category': ['process'], 'description': ['positive regulation of peptide hormone secretion']}, {'category': ['process'], 'description': ['positive regulation of protein secretion']}, {'category': ['process'], 'description': ['positive regulation of substrate adhesion-dependent cell spreading']}, {'category': ['process'], 'description': ['positive regulation of vasoconstriction']}, {'category': ['process'], 'description': ['protein polymerization']}, {'category': ['process'], 'description': ['protein secretion']}, {'category': ['process'], 'description': ['response to calcium ion']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}, {'id': ['BE0000240'], 'name': ['Plasminogen activator inhibitor 1'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A6691'], 'pubmed-id': ['17963464'], 'citation': ['Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Plasminogen activator inhibitor 1'], 'general-function': ['Serine-type endopeptidase inhibitor activity'], 'specific-function': [""Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis.""], 'gene-name': ['SERPINE1'], 'locus': ['7q21.3-q22'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-23'], 'theoretical-pi': ['7.22'], 'molecular-weight': ['45059.695'], 'chromosome-location': ['7'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:8583']}, {'resource': ['GenAtlas'], 'identifier': ['SERPINE1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X04429']}, {'resource': ['GenBank Protein Database'], 'identifier': ['35272']}, {'resource': ['UniProtKB'], 'identifier': ['P05121']}, {'resource': ['UniProt Accession'], 'identifier': ['PAI1_HUMAN']}]}], 'synonyms': [{'synonym': ['Endothelial plasminogen activator inhibitor', 'PAI', 'PAI1', 'PLANH1', 'Serpin E1']}], 'amino-acid-sequence': ['>lcl|BSEQ0000479|Plasminogen activator inhibitor 1\nMQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY\nGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI\nFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV\nDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD\nGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK\nFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS\nSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP'], 'gene-sequence': ['>lcl|BSEQ0010214|Plasminogen activator inhibitor 1 (SERPINE1)\nATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA\nGGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG\nAGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT\nGGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG\nATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT\nCTGTACAAGGAGCTCATGGGGCCATGGAACAAGGATGAGATCAGCACCACAGACGCGATC\nTTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC\nCGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT\nGACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG\nGACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT\nCCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC\nTCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT\nGGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT\nGCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG\nCTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG\nTTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC\nATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC\nGCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA\nTCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC\nTTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG\nGAACCCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00079'], 'name': ['Serpin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular matrix']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase inhibitor activity']}, {'category': ['process'], 'description': ['angiogenesis']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cellular response to lipopolysaccharide']}, {'category': ['process'], 'description': ['chronological cell aging']}, {'category': ['process'], 'description': ['circadian rhythm']}, {'category': ['process'], 'description': ['defense response to Gram-negative bacterium']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['gene expression']}, {'category': ['process'], 'description': ['negative regulation of blood coagulation']}, {'category': ['process'], 'description': ['negative regulation of cell adhesion mediated by integrin']}, {'category': ['process'], 'description': ['negative regulation of cell migration']}, {'category': ['process'], 'description': ['negative regulation of endopeptidase activity']}, {'category': ['process'], 'description': ['negative regulation of endothelial cell apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of extrinsic apoptotic signaling pathway via death domain receptors']}, {'category': ['process'], 'description': ['negative regulation of fibrinolysis']}, {'category': ['process'], 'description': ['negative regulation of plasminogen activation']}, {'category': ['process'], 'description': ['negative regulation of smooth muscle cell migration']}, {'category': ['process'], 'description': ['negative regulation of smooth muscle cell-matrix adhesion']}, {'category': ['process'], 'description': ['negative regulation of vascular wound healing']}, {'category': ['process'], 'description': ['negative regulation of wound healing']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of angiogenesis']}, {'category': ['process'], 'description': ['positive regulation of blood coagulation']}, {'category': ['process'], 'description': ['positive regulation of inflammatory response']}, {'category': ['process'], 'description': ['positive regulation of interleukin-8 production']}, {'category': ['process'], 'description': ['positive regulation of leukotriene production involved in inflammatory response']}, {'category': ['process'], 'description': ['positive regulation of monocyte chemotaxis']}, {'category': ['process'], 'description': ['positive regulation of receptor-mediated endocytosis']}, {'category': ['process'], 'description': ['positive regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['regulation of receptor activity']}, {'category': ['process'], 'description': ['transcription initiation from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['transcription, DNA-templated']}, {'category': ['process'], 'description': ['transforming growth factor beta receptor signaling pathway']}]}]}]}]}]"
"['DB00010', 'BTD00033', 'BIOD00033']",['Sermorelin'],biotech,['Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues'],['liquid'],"['For the treatment of dwarfism, prevention of HIV-induced weight loss']",['Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.'],[None],"[{'target': [{'id': ['BE0000625'], 'name': ['Growth hormone-releasing hormone receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1760'], 'pubmed-id': ['14499707'], 'citation': [""Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, Veronese FM: PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003 Sep 26;55(10):1279-91.""]}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Growth hormone-releasing hormone receptor'], 'general-function': ['Peptide hormone binding'], 'specific-function': ['Receptor for GRF, coupled to G proteins which activate adenylyl cyclase. Stimulates somatotroph cell growth, growth hormone gene transcription and growth hormone secretion.'], 'gene-name': ['GHRHR'], 'locus': ['7p14'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['133-152\n163-181\n205-227\n241-262\n281-304\n330-348\n362-381'], 'signal-regions': ['1-22'], 'theoretical-pi': ['6.73'], 'molecular-weight': ['47401.53'], 'chromosome-location': ['7'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:4266']}, {'resource': ['GenAtlas'], 'identifier': ['GHRHR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L01406']}, {'resource': ['GenBank Protein Database'], 'identifier': ['183173']}, {'resource': ['IUPHAR'], 'identifier': ['247']}, {'resource': ['UniProtKB'], 'identifier': ['Q02643']}, {'resource': ['UniProt Accession'], 'identifier': ['GHRHR_HUMAN']}]}], 'synonyms': [{'synonym': ['GHRH receptor', 'GRF receptor', 'GRFR', 'Growth hormone-releasing factor receptor']}], 'amino-acid-sequence': ['>lcl|BSEQ0016157|Growth hormone-releasing hormone receptor\nMDRRMWGAHVFCVLSPLPTVLGHMHPECDFITQLREDESACLQAAEEMPNTTLGCPATWD\nGLLCWPTAGSGEWVTLPCPDFFSHFSSESGAVKRDCTITGWSEPFPPYPVACPVPLELLA\nEEESYFSTVKIIYTVGHSISIVALFVAITILVALRRLHCPRNYVHTQLFTTFILKAGAVF\nLKDAALFHSDDTDHCSFSTVLCKVSVAASHFATMTNFSWLLAEAVYLNCLLASTSPSSRR\nAFWWLVLAGWGLPVLFTGTWVSCKLAFEDIACWDLDDTSPYWWIIKGPIVLSVGVNFGLF\nLNIIRILVRKLEPAQGSLHTQSQYWRLSKSTLFLIPLFGIHYIIFNFLPDNAGLGIRLPL\nELGLGSFQGFIVAILYCFLNQEVRTEISRKWHGHDPELLPAWRTRAKWTTPSRSAAKVLT\nSMC'], 'gene-sequence': ['>lcl|BSEQ0016158|Growth hormone-releasing hormone receptor (GHRHR)\nATGGACCGCCGGATGTGGGGGGCCCACGTCTTCTGCGTGTTGAGCCCGTTACCGACCGTA\nTTGGGCCACATGCACCCAGAATGTGACTTCATCACCCAGCTGAGAGAGGATGAGAGTGCC\nTGTCTACAAGCAGCAGAGGAGATGCCCAACACCACCCTGGGCTGCCCTGCGACCTGGGAT\nGGGCTGCTGTGCTGGCCAACGGCAGGCTCTGGCGAGTGGGTCACCCTCCCCTGCCCGGAT\nTTCTTCTCTCACTTCAGCTCAGAGTCAGGGGCTGTGAAACGGGATTGTACTATCACTGGC\nTGGTCTGAGCCCTTTCCACCTTACCCTGTGGCCTGCCCTGTGCCTCTGGAGCTGCTGGCT\nGAGGAGGAATCTTACTTCTCCACAGTGAAGATTATCTACACCGTGGGCCATAGCATCTCT\nATTGTAGCCCTCTTCGTGGCCATCACCATCCTGGTTGCTCTCAGGAGGCTCCACTGCCCC\nCGGAACTACGTCCACACCCAGCTGTTCACCACTTTTATCCTCAAGGCGGGAGCTGTGTTC\nCTGAAGGATGCTGCCCTTTTCCACAGCGACGACACTGACCACTGCAGCTTCTCCACTGTT\nCTATGCAAGGTCTCTGTGGCCGCCTCCCATTTCGCCACCATGACCAACTTCAGCTGGCTG\nTTGGCAGAAGCCGTCTACCTGAACTGCCTCCTGGCCTCCACCTCCCCCAGCTCAAGGAGA\nGCCTTCTGGTGGCTGGTTCTCGCTGGCTGGGGGCTGCCCGTGCTCTTCACTGGCACGTGG\nGTGAGCTGCAAACTGGCCTTCGAGGACATCGCGTGCTGGGACCTGGACGACACCTCCCCC\nTACTGGTGGATCATCAAAGGGCCCATTGTCCTCTCGGTCGGGGTGAACTTTGGGCTTTTT\nCTCAATATTATCCGCATCCTGGTGAGGAAACTGGAGCCAGCTCAGGGCAGCCTCCATACC\nCAGTCTCAGTATTGGCGTCTCTCCAAGTCGACACTTTTCCTGATCCCACTCTTTGGAATT\nCACTACATCATCTTCAACTTCCTGCCAGACAATGCTGGCCTGGGCATCCGCCTCCCCCTG\nGAGCTGGGACTGGGTTCCTTCCAGGGCTTCATTGTTGCCATCCTCTACTGCTTCCTCAAC\nCAAGAGGTGAGGACTGAGATCTCACGGAAGTGGCATGGCCATGACCCTGAGCTTCTGCCA\nGCCTGGAGGACCCGTGCTAAGTGGACCACGCCTTCCCGCTCGGCGGCAAAGGTGCTGACA\nTCTATGTGCTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00002'], 'name': ['7tm_2']}, {'identifier': ['PF02793'], 'name': ['HRM']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['nuclear inner membrane']}, {'category': ['component'], 'description': ['nuclear matrix']}, {'category': ['component'], 'description': ['nuclear outer membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['secretory granule']}, {'category': ['function'], 'description': ['G-protein coupled receptor activity']}, {'category': ['function'], 'description': ['growth factor binding']}, {'category': ['function'], 'description': ['growth hormone-releasing hormone receptor activity']}, {'category': ['function'], 'description': ['peptide hormone binding']}, {'category': ['process'], 'description': ['activation of adenylate cyclase activity']}, {'category': ['process'], 'description': ['adenylate cyclase-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['cAMP-mediated signaling']}, {'category': ['process'], 'description': ['cell maturation']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular response to insulin stimulus']}, {'category': ['process'], 'description': ['determination of adult lifespan']}, {'category': ['process'], 'description': ['growth hormone secretion']}, {'category': ['process'], 'description': ['hormone metabolic process']}, {'category': ['process'], 'description': ['lactation']}, {'category': ['process'], 'description': ['multicellular organismal reproductive process']}, {'category': ['process'], 'description': ['positive regulation of cAMP biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of growth hormone secretion']}, {'category': ['process'], 'description': ['positive regulation of insulin-like growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of multicellular organism growth']}, {'category': ['process'], 'description': ['regulation of intracellular steroid hormone receptor signaling pathway']}, {'category': ['process'], 'description': ['regulation of protein metabolic process']}, {'category': ['process'], 'description': ['response to estrogen']}, {'category': ['process'], 'description': ['response to glucocorticoid']}, {'category': ['process'], 'description': ['response to insulin']}, {'category': ['process'], 'description': ['somatotropin secreting cell development']}, {'category': ['process'], 'description': ['water homeostasis']}]}]}]}]}]"
"['DB00011', 'BTD00096', 'BIOD00096', 'DB00084']",['Interferon alfa-n1'],biotech,"['Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.']",['liquid'],['For the treatment of venereal or genital warts caused by the Human Papiloma Virus.'],"['Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.']",[{'food-interaction': ['Avoid alcohol.']}],"[{'target': [{'id': ['BE0000661'], 'name': ['Interferon alpha/beta receptor 1'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A1762'], 'pubmed-id': ['10822464'], 'citation': ['Krown SE: Interferon treatment of renal cell carcinoma. Current status and future prospects. Cancer. 1987 Feb 1;59(3 Suppl):647-51.']}, {'ref-id': ['A1758'], 'pubmed-id': ['19955815'], 'citation': ['Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interferon alpha/beta receptor 1'], 'general-function': ['Type i interferon receptor activity'], 'specific-function': ['Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.'], 'gene-name': ['IFNAR1'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['437-457'], 'signal-regions': ['1-27'], 'theoretical-pi': ['5.56'], 'molecular-weight': ['63524.81'], 'chromosome-location': ['21'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5432']}, {'resource': ['GenAtlas'], 'identifier': ['IFNAR1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['J03171']}, {'resource': ['GenBank Protein Database'], 'identifier': ['306914']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1723']}, {'resource': ['UniProtKB'], 'identifier': ['P17181']}, {'resource': ['UniProt Accession'], 'identifier': ['INAR1_HUMAN']}]}], 'synonyms': [{'synonym': ['CRF2-1', 'Cytokine receptor class-II member 1', 'Cytokine receptor family 2 member 1', 'IFN-R-1', 'IFNAR', 'Type I interferon receptor 1']}], 'amino-acid-sequence': ['>lcl|BSEQ0001318|Interferon alpha/beta receptor 1\nMMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT\nFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF\nTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI\nENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ\nNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK\nGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP\nVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV\nFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE\nYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN\nEDESESKTSEELQQDFV'], 'gene-sequence': ['>lcl|BSEQ0018987|Interferon alpha/beta receptor 1 (IFNAR1)\nATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTG\nTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC\nATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT\nTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG\nAATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT\nAAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT\nACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG\nGCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT\nTTAAGCTTTACATATAGCTTAGTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT\nGAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA\nAAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT\nATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA\nAATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG\nTGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA\nCCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA\nGGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA\nGAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA\nTCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT\nGTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT\nGAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT\nGTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT\nTTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA\nGTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC\nTTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG\nTATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA\nAAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT\nGATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT\nGAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA'], 'pfams': [{'pfam': [{'identifier': ['PF01108'], 'name': ['Tissue_fac']}, {'identifier': ['PF09294'], 'name': ['Interfer-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['type I interferon receptor activity']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['defense response to virus']}, {'category': ['process'], 'description': ['JAK-STAT cascade']}, {'category': ['process'], 'description': ['positive regulation of interferon-beta production']}, {'category': ['process'], 'description': ['positive regulation of interferon-gamma production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-1 beta secretion']}, {'category': ['process'], 'description': ['positive regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['regulation of type I interferon-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['T cell activation']}, {'category': ['process'], 'description': ['type I interferon biosynthetic process']}, {'category': ['process'], 'description': ['type I interferon signaling pathway']}]}]}]}, {'id': ['BE0000385'], 'name': ['Interferon alpha/beta receptor 2'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A1762'], 'pubmed-id': ['10822464'], 'citation': ['Krown SE: Interferon treatment of renal cell carcinoma. Current status and future prospects. Cancer. 1987 Feb 1;59(3 Suppl):647-51.']}, {'ref-id': ['A1758'], 'pubmed-id': ['19955815'], 'citation': ['Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interferon alpha/beta receptor 2'], 'general-function': ['Type i interferon receptor activity'], 'specific-function': ['Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.'], 'gene-name': ['IFNAR2'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['244-264'], 'signal-regions': ['1-26'], 'theoretical-pi': ['4.11'], 'molecular-weight': ['57758.24'], 'chromosome-location': ['21'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5433']}, {'resource': ['GenAtlas'], 'identifier': ['IFNAR2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L42243']}, {'resource': ['GenBank Protein Database'], 'identifier': ['995300']}, {'resource': ['UniProtKB'], 'identifier': ['P48551']}, {'resource': ['UniProt Accession'], 'identifier': ['INAR2_HUMAN']}]}], 'synonyms': [{'synonym': ['IFN-R-2', 'IFNABR', 'IFNARB', 'Interferon alpha binding protein', 'Type I interferon receptor 2']}], 'amino-acid-sequence': ['>lcl|BSEQ0000767|Interferon alpha/beta receptor 2\nMLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS\nIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF\nSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK\nHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE\nSAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD\nMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI\nDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR\nITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT\nFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR'], 'gene-sequence': ['>lcl|BSEQ0018941|Interferon alpha/beta receptor 2 (IFNAR2)\nATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT\nATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT\nTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC\nATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG\nGTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA\nAGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC\nAGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG\nATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA\nGAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG\nCATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA\nATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA\nATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA\nTCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC\nATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG\nAGGCAAGGTCTCGCTAAGGGCTGGAATGCAGTGGCTATTCACAGGTGCAGTCATAATGCA\nCTACAGTCTGAAACTCCTGAGCTCAAACAGTCGTCCTGCCTAAGCTTCCCCAGTAGCTGG\nGATTACAAGCGTGCATCCCTGTGCCCCAGTGATTAA'], 'pfams': [{'pfam': [{'identifier': ['PF01108'], 'name': ['Tissue_fac']}, {'identifier': ['PF09294'], 'name': ['Interfer-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['protein kinase binding']}, {'category': ['function'], 'description': ['type I interferon binding']}, {'category': ['function'], 'description': ['type I interferon receptor activity']}, {'category': ['process'], 'description': ['cell proliferation']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['JAK-STAT cascade']}, {'category': ['process'], 'description': ['regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['regulation of type I interferon-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to interferon-alpha']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['type I interferon signaling pathway']}]}]}]}]}]"
"['DB00012', 'BTD00032', 'BIOD00032']",['Darbepoetin alfa'],biotech,"['Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.']",['liquid'],['For the treatment of anemia (from renal transplants or certain HIV treatment)'],"['Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with\r\nprogenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.']","[{'food-interaction': ['Administer iron supplement. When initiating an erythropoiesis-stimulating agent, evaluate iron stores and start iron supplementation if indicated. Most patients with chronic kidney disease require iron supplementation while taking an erythropoiesis-stimulating agent.']}]","[{'target': [{'id': ['BE0000654'], 'name': ['Erythropoietin receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1764'], 'pubmed-id': ['16505108'], 'citation': ['LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C, Meshaw A, Farrell FX: Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther. 2006 Feb;5(2):347-55.']}, {'ref-id': ['A1766'], 'pubmed-id': ['17575216'], 'citation': ['Kokhaei P, Abdalla AO, Hansson L, Mikaelsson E, Kubbies M, Haselbeck A, Jernberg-Wiklund H, Mellstedt H, Osterborg A: Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies. Clin Cancer Res. 2007 Jun 15;13(12):3536-44.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Erythropoietin receptor'], 'general-function': ['Identical protein binding'], 'specific-function': ['Receptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase.Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.'], 'gene-name': ['EPOR'], 'locus': ['19p13.3-p13.2'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['251-273'], 'signal-regions': ['1-24'], 'theoretical-pi': ['4.37'], 'molecular-weight': ['55064.725'], 'chromosome-location': ['19'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3416']}, {'resource': ['GenAtlas'], 'identifier': ['EPOR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M60459']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182245']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1718']}, {'resource': ['UniProtKB'], 'identifier': ['P19235']}, {'resource': ['UniProt Accession'], 'identifier': ['EPOR_HUMAN']}]}], 'synonyms': [{'synonym': ['EPO-R']}], 'amino-acid-sequence': ['>lcl|BSEQ0001304|Erythropoietin receptor\nMDHLGASLWPQVGSLCLLLAGAAWAPPPNLPDPKFESKAALLAARGPEELLCFTERLEDL\nVCFWEEAASAGVGPGNYSFSYQLEDEPWKLCRLHQAPTARGAVRFWCSLPTADTSSFVPL\nELRVTAASGAPRYHRVIHINEVVLLDAPVGLVARLADESGHVVLRWLPPPETPMTSHIRY\nEVDVSAGNGAGSVQRVEILEGRTECVLSNLRGRTRYTFAVRARMAEPSFGGFWSAWSEPV\nSLLTPSDLDPLILTLSLILVVILVLLTVLALLSHRRALKQKIWPGIPSPESEFEGLFTTH\nKGNFQLWLYQNDGCLWWSPCTPFTEDPPASLEVLSERCWGTMQAVEPGTDDEGPLLEPVG\nSEHAQDTYLVLDKWLLPRNPPSEDLPGPGGSVDIVAMDEGSEASSCSSALASKPSPEGAS\nAASFEYTILDPSSQLLRPWTLCPELPPTPPHLKYLYLVVSDSGISTDYSSGDSQGAQGGL\nSDGPYSNPYENSLIPAAEPLPPSYVACS'], 'gene-sequence': ['>lcl|BSEQ0010455|Erythropoietin receptor (EPOR)\nATGGACCACCTCGGGGCGTCCCTCTGGCCCCAGGTCGGCTCCCTTTGTCTCCTGCTCGCT\nGGGGCCGCCTGGGCGCCCCCGCCTAACCTCCCGGACCCCAAGTTCGAGAGCAAAGCGGCC\nTTGCTGGCGGCCCGGGGGCCCGAAGAGCTTCTGTGCTTCACCGAGCGGTTGGAGGACTTG\nGTGTGTTTCTGGGAGGAAGCGGCGAGCGCTGGGGTGGGCCCGGGCAACTACAGCTTCTCC\nTACCAGCTCGAGGATGAGCCATGGAAGCTGTGTCGCCTGCACCAGGCTCCCACGGCTCGT\nGGTGCGGTGCGCTTCTGGTGTTCGCTGCCTACAGCCGACACGTCGAGCTTCGTGCCCCTA\nGAGTTGCGCGTCACAGCAGCCTCCGGCGCTCCGCGATATCACCGTGTCATCCACATCAAT\nGAAGTAGTGCTCCTAGACGCCCCCGTGGGGCTGGTGGCGCGGTTGGCTGACGAGAGCGGC\nCACGTAGTGTTGCGCTGGCTCCCGCCGCCTGAGACACCCATGACGTCTCACATCCGCTAC\nGAGGTGGACGTCTCGGCCGGCAACGGCGCAGGGAGCGTACAGAGGGTGGAGATCCTGGAG\nGGCCGCACCGAGTGTGTGCTGAGCAACCTGCGGGGCCGGACGCGCTACACCTTCGCCGTC\nCGCGCGCGTATGGCTGAGCCGAGCTTCGGCGGCTTCTGGAGCGCCTGGTCGGAGCCTGTG\nTCGCTGCTGACGCCTAGCGACCTGGACCCCCTCATCCTGACGCTCTCCCTCATCCTCGTG\nGTCATCCTGGTGCTGCTGACCGTGCTCGCGCTGCTCTCCCACCGCCGGGCTCTGAAGCAG\nAAGATCTGGCCTGGCATCCCGAGCCCAGAGAGCGAGTTTGAAGGCCTCTTCACCACCCAC\nAAGGGTAACTTCCAGCTGTGGCTGTACCAGAATGATGGCTGCCTGTGGTGGAGCCCCTGC\nACCCCCTTCACGGAGGACCCACCTGCTTCCCTGGAAGTCCTCTCAGAGCGCTGCTGGGGG\nACGATGCAGGCAGTGGAGCCGGGGACAGATGATGAGGGCCCCCTGCTGGAGCCAGTGGGC\nAGTGAGCATGCCCAGGATACCTATCTGGTGCTGGACAAATGGTTGCTGCCCCGGAACCCG\nCCCAGTGAGGACCTCCCAGGGCCTGGTGGCAGTGTGGACATAGTGGCCATGGATGAAGGC\nTCAGAAGCATCCTCCTGCTCATCTGCTTTGGCCTCGAAGCCCAGCCCAGAGGGAGCCTCT\nGCTGCCAGCTTTGAGTACACTATCCTGGACCCCAGCTCCCAGCTCTTGCGTCCATGGACA\nCTGTGCCCTGAGCTGCCCCCTACCCCACCCCACCTAAAGTACCTGTACCTTGTGGTATCT\nGACTCTGGCATCTCAACTGACTACAGCTCAGGGGACTCCCAGGGAGCCCAAGGGGGCTTA\nTCCGATGGCCCCTACTCCAACCCTTATGAGAACAGCCTTATCCCAGCCGCTGAGCCTCTG\nCCCCCCAGCTATGTGGCTTGCTCTTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00041'], 'name': ['fn3']}, {'identifier': ['PF09067'], 'name': ['EpoR_lig-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['function'], 'description': ['erythropoietin receptor activity']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['process'], 'description': ['brain development']}, {'category': ['process'], 'description': ['decidualization']}, {'category': ['process'], 'description': ['erythropoietin-mediated signaling pathway']}, {'category': ['process'], 'description': ['heart development']}, {'category': ['process'], 'description': ['negative regulation of neuron apoptotic process']}, {'category': ['process'], 'description': ['positive regulation of cytosolic calcium ion concentration']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}]}]"
"['DB00013', 'BTD00030', 'BIOD00030']",['Urokinase'],biotech,['Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase.[A191943] Urokinase remains connected between these 2 chains by a sulfhydryl bond.[A191943]\r\n\r\nUrokinase was granted FDA approval on 16 January 1978.[L12138]'],['liquid'],"['In Canada, urokinase is indicated for lysis of acute massive pulmonary emboli, acute thrombi obstructing coronary arteries, occlusive thromboemboli in peripheral arteries and grafts, and restoration of patency to intravenous catheters.[L12141]']","['Urokinase is a serine protease.[A191928] It cleaves plasminogen to form the active fibrinolytic protease, plasmin.[A191928]']","[{'food-interaction': ['Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.']}]","[{'target': [{'id': ['BE0000211'], 'name': ['Plasminogen'], 'organism': ['Humans'], 'actions': [{'action': ['activator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A11586'], 'pubmed-id': ['12658774'], 'citation': ['Zhang X, Zhou H, Shen G, Liu Z, Hu Y, Wei W, Song S: Study on the mechanism of the annexin II-mediated co-assembly of t-PA and plasminogen. J Huazhong Univ Sci Technolog Med Sci. 2002;22(1):21-3, 76.']}, {'ref-id': ['A11587'], 'pubmed-id': ['12666133'], 'citation': ['Lopez-Alemany R, Longstaff C, Hawley S, Mirshahi M, Fabregas P, Jardi M, Merton E, Miles LA, Felez J: Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-Enolase. Am J Hematol. 2003 Apr;72(4):234-42.']}, {'ref-id': ['A11588'], 'pubmed-id': ['12719778'], 'citation': ['Hashimoto M, Oiwa K, Matsuo O, Ueshima S, Okada K, Okada Y, Okamoto S, Giddings JC, Yamamoto J: Suppression of argatroban-induced endogenous thrombolysis by PKSI-527, and antibodies to TPA and UPA, evaluated in a rat arterial thrombolysis model. Thromb Haemost. 2003 May;89(5):820-5.']}, {'ref-id': ['A11589'], 'pubmed-id': ['12720300'], 'citation': ['Guda K, Claffey KP, Dong M, Nambiar PR, Rosenberg DW: Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors. Mol Carcinog. 2003 May;37(1):51-9.']}, {'ref-id': ['A11590'], 'pubmed-id': ['12745435'], 'citation': ['Chang H, Shyu KG, Lin S, Wang BW, Liu YC, Lee CC: Cell adhesion induces the plasminogen activator inhibitor-1 gene expression through phosphatidylinositol 3-kinase/Akt activation in anchorage dependent cells. Cell Commun Adhes. 2002 Sep-Dec;9(5-6):239-47.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [{'link': [{'ref-id': ['L12138'], 'title': ['FDA Approved Drug Products: Kinlytic Urokinase Injection (Discontinued)'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021846s101lbl.pdf']}]}], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Plasminogen'], 'general-function': ['Serine-type peptidase activity'], 'specific-function': ['Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.'], 'gene-name': ['PLG'], 'locus': ['6q26'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-19'], 'theoretical-pi': ['7.25'], 'molecular-weight': ['90568.415'], 'chromosome-location': ['6'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:9071']}, {'resource': ['GenAtlas'], 'identifier': ['PLG']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X05199']}, {'resource': ['GenBank Protein Database'], 'identifier': ['387026']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2394']}, {'resource': ['UniProtKB'], 'identifier': ['P00747']}, {'resource': ['UniProt Accession'], 'identifier': ['PLMN_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.21.7']}], 'amino-acid-sequence': ['>lcl|BSEQ0016037|Plasminogen\nMEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT\nCRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN\nGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE\nCEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE\nLRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS\nAQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE\nQLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG\nLTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED\nCMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG\nPWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT\nRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE\nPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ\nLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW\nGLGCARPNKPGVYVRVSRFVTWIEGVMRNN'], 'gene-sequence': ['>lcl|BSEQ0016038|Plasminogen (PLG)\nATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG\nCCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG\nCTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC\nTGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG\nAAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC\nTCAGAGTGCAAGACTGGGAATGGAAAGAACTACAGAGGGACGATGTCCAAAACAAAAAAT\nGGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT\nACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG\nGGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG\nTGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC\nATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT\nCCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG\nCTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGTGACATCCCC\nCGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT\nGAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT\nGCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTCCCCTGCAAAAATTTGGAT\nGAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC\nCAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA\nCAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT\nGATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT\nTGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC\nCTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA\nGACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT\nGTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAGATGTAGAGACTCCTTCCGAAGAAGAC\nTGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG\nCCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA\nAATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT\nCCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT\nGCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG\nGTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA\nAGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT\nGCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC\nCAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG\nCCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA\nGTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC\nATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG\nCTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA\nTCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT\nGGAGGTCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG\nGGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT\nACTTGGATTGAGGGAGTGATGAGAAATAATTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00051'], 'name': ['Kringle']}, {'identifier': ['PF00089'], 'name': ['Trypsin']}, {'identifier': ['PF00024'], 'name': ['PAN_1']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['extrinsic component of external side of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['function'], 'description': ['apolipoprotein binding']}, {'category': ['function'], 'description': ['protein domain specific binding']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase activity']}, {'category': ['function'], 'description': ['serine-type peptidase activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['extracellular matrix disassembly']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['negative regulation of cell proliferation']}, {'category': ['process'], 'description': ['negative regulation of cell-cell adhesion mediated by cadherin']}, {'category': ['process'], 'description': ['negative regulation of cell-substrate adhesion']}, {'category': ['process'], 'description': ['negative regulation of fibrinolysis']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of fibrinolysis']}, {'category': ['process'], 'description': ['proteolysis']}, {'category': ['process'], 'description': ['tissue remodeling']}]}]}]}, {'id': ['BE0000717'], 'name': ['Urokinase plasminogen activator surface receptor'], 'organism': ['Humans'], 'actions': [{'action': ['inducer', 'modulator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1769'], 'pubmed-id': ['12615913'], 'citation': ['Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ: Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol. 2003 Mar 3;160(5):781-91.']}, {'ref-id': ['A1774'], 'pubmed-id': ['12817472'], 'citation': ['Fuchs T, Allgayer H: Transcriptional regulation of the urokinase receptor (u-PAR)--a central molecule of invasion and metastasis. Biol Chem. 2003 May;384(5):755-61.']}, {'ref-id': ['A1776'], 'pubmed-id': ['14679304'], 'citation': ['Kanse SM, Chavakis T, Al-Fakhri N, Hersemeyer K, Monard D, Preissner KT: Reciprocal regulation of urokinase receptor (CD87)-mediated cell adhesion by plasminogen activator inhibitor-1 and protease nexin-1. J Cell Sci. 2004 Jan 26;117(Pt 3):477-85. Epub 2003 Dec 16.']}, {'ref-id': ['A1778'], 'pubmed-id': ['14688365'], 'citation': ['Beaufort N, Leduc D, Rousselle JC, Magdolen V, Luther T, Namane A, Chignard M, Pidard D: Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J Immunol. 2004 Jan 1;172(1):540-9.']}, {'ref-id': ['A1780'], 'pubmed-id': ['14720519'], 'citation': ['Guerrero J, Santibanez JF, Gonzalez A, Martinez J: EGF receptor transactivation by urokinase receptor stimulus through a mechanism involving Src and matrix metalloproteinases. Exp Cell Res. 2004 Jan 1;292(1):201-8.']}, {'ref-id': ['A1782'], 'pubmed-id': ['17327908'], 'citation': ['Gutova M, Najbauer J, Gevorgyan A, Metz MZ, Weng Y, Shih CC, Aboody KS: Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS One. 2007 Feb 28;2(2):e243.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Urokinase plasminogen activator surface receptor'], 'general-function': ['Urokinase plasminogen activator receptor activity'], 'specific-function': ['Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form.'], 'gene-name': ['PLAUR'], 'locus': ['19q13'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': [None], 'signal-regions': ['1-22'], 'theoretical-pi': ['6.64'], 'molecular-weight': ['36977.62'], 'chromosome-location': ['19'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:9053']}, {'resource': ['GenAtlas'], 'identifier': ['PLAUR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X51675']}, {'resource': ['GenBank Protein Database'], 'identifier': ['37605']}, {'resource': ['UniProtKB'], 'identifier': ['Q03405']}, {'resource': ['UniProt Accession'], 'identifier': ['UPAR_HUMAN']}]}], 'synonyms': [{'synonym': ['MO3', 'Monocyte activation antigen Mo3', 'U-PAR', 'UPAR']}], 'amino-acid-sequence': ['>lcl|BSEQ0001430|Urokinase plasminogen activator surface receptor\nMGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL\nELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISC\nGSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNG\nFHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGP\nMNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDV\nQYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT'], 'gene-sequence': ['>lcl|BSEQ0016188|Urokinase plasminogen activator surface receptor (PLAUR)\nATGGGTCACCCGCCGCTGCTGCCGCTGCTGCTGCTGCTCCACACCTGCGTCCCAGCCTCT\nTGGGGCCTGCGGTGCATGCAGTGTAAGACCAACGGGGATTGCCGTGTGGAAGAGTGCGCC\nCTGGGACAGGACCTCTGCAGGACCACGATCGTGCGCTTGTGGGAAGAAGGAGAAGAGCTG\nGAGCTGGTGGAGAAAAGCTGTACCCACTCAGAGAAGACCAACAGGACCCTGAGCTATCGG\nACTGGCTTGAAGATCACCAGCCTTACCGAGGTTGTGTGTGGGTTAGACTTGTGCAACCAG\nGGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCGTTACCTCGAATGCATTTCCTGT\nGGCTCATCAGACATGAGCTGTGAGAGGGGCCGGCACCAGAGCCTGCAGTGCCGCAGCCCT\nGAAGAACAGTGCCTGGATGTGGTGACCCACTGGATCCAGGAAGGTGAAGAAGGGCGTCCA\nAAGGATGACCGCCACCTCCGTGGCTGTGGCTACCTTCCCGGCTGCCCGGGCTCCAATGGT\nTTCCACAACAACGACACCTTCCACTTCCTGAAATGCTGCAACACCACCAAATGCAACGAG\nGGCCCAATCCTGGAGCTTGAAAATCTGCCGCAGAATGGCCGCCAGTGTTACAGCTGCAAG\nGGGAACAGCACCCATGGATGCTCCTCTGAAGAGACTTTCCTCATTGACTGCCGAGGCCCC\nATGAATCAATGTCTGGTAGCCACCGGCACTCACGAACGCTCACTCTGGGGAAGCTGGTTG\nCCATGTAAAAGTACTACTGCCCTGAGACCACCATGCTGTGAGGAAGCCCAAGCTACTCAT\nGTATAA'], 'pfams': [{'pfam': [{'identifier': ['PF00021'], 'name': ['UPAR_LY6']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['anchored component of membrane']}, {'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['endoplasmic reticulum membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extrinsic component of membrane']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['invadopodium membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['enzyme binding']}, {'category': ['function'], 'description': ['protein domain specific binding']}, {'category': ['function'], 'description': ['receptor activity']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['urokinase plasminogen activator receptor activity']}, {'category': ['process'], 'description': ['attachment of GPI anchor to protein']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['C-terminal protein lipidation']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['chemotaxis']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['movement of cell or subcellular component']}, {'category': ['process'], 'description': ['negative regulation of apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway']}, {'category': ['process'], 'description': ['negative regulation of intrinsic apoptotic signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of DNA binding']}, {'category': ['process'], 'description': ['positive regulation of epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of release of cytochrome c from mitochondria']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['regulation of proteolysis']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['urokinase plasminogen activator signaling pathway']}]}]}]}, {'id': ['BE0000240'], 'name': ['Plasminogen activator inhibitor 1'], 'organism': ['Humans'], 'actions': [{'action': ['substrate', 'inducer']}], 'references': [{'articles': [{'article': [{'ref-id': ['A11592'], 'pubmed-id': ['12579271'], 'citation': ['Gamberi G, Serra M, Ragazzini P, Magagnoli G, Pazzaglia L, Ponticelli F, Ferrari C, Zanasi M, Bertoni F, Picci P, Benassi MS: Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep. 2003 Mar-Apr;10(2):351-6.']}, {'ref-id': ['A11604'], 'pubmed-id': ['12642587'], 'citation': ['Shetty S, Bdeir K, Cines DB, Idell S: Induction of plasminogen activator inhibitor-1 by urokinase in lung epithelial cells. J Biol Chem. 2003 May 16;278(20):18124-31. Epub 2003 Mar 17.']}, {'ref-id': ['A11605'], 'pubmed-id': ['12709915'], 'citation': ['Hellgren M: Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003 Apr;29(2):125-30.']}, {'ref-id': ['A11590'], 'pubmed-id': ['12745435'], 'citation': ['Chang H, Shyu KG, Lin S, Wang BW, Liu YC, Lee CC: Cell adhesion induces the plasminogen activator inhibitor-1 gene expression through phosphatidylinositol 3-kinase/Akt activation in anchorage dependent cells. Cell Commun Adhes. 2002 Sep-Dec;9(5-6):239-47.']}, {'ref-id': ['A11606'], 'pubmed-id': ['12785198'], 'citation': [""Gerstein ES, Shcherbakov AM, Kaz'min AI, Ognerubov NA, Kushlinskii NE: [Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer]. Vopr Onkol. 2003;49(2):165-9.""]}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Plasminogen activator inhibitor 1'], 'general-function': ['Serine-type endopeptidase inhibitor activity'], 'specific-function': [""Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis.""], 'gene-name': ['SERPINE1'], 'locus': ['7q21.3-q22'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-23'], 'theoretical-pi': ['7.22'], 'molecular-weight': ['45059.695'], 'chromosome-location': ['7'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:8583']}, {'resource': ['GenAtlas'], 'identifier': ['SERPINE1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X04429']}, {'resource': ['GenBank Protein Database'], 'identifier': ['35272']}, {'resource': ['UniProtKB'], 'identifier': ['P05121']}, {'resource': ['UniProt Accession'], 'identifier': ['PAI1_HUMAN']}]}], 'synonyms': [{'synonym': ['Endothelial plasminogen activator inhibitor', 'PAI', 'PAI1', 'PLANH1', 'Serpin E1']}], 'amino-acid-sequence': ['>lcl|BSEQ0000479|Plasminogen activator inhibitor 1\nMQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY\nGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI\nFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV\nDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD\nGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK\nFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS\nSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP'], 'gene-sequence': ['>lcl|BSEQ0010214|Plasminogen activator inhibitor 1 (SERPINE1)\nATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA\nGGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG\nAGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT\nGGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG\nATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT\nCTGTACAAGGAGCTCATGGGGCCATGGAACAAGGATGAGATCAGCACCACAGACGCGATC\nTTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC\nCGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT\nGACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG\nGACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT\nCCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC\nTCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT\nGGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT\nGCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG\nCTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG\nTTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC\nATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC\nGCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA\nTCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC\nTTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG\nGAACCCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00079'], 'name': ['Serpin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular matrix']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase inhibitor activity']}, {'category': ['process'], 'description': ['angiogenesis']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cellular response to lipopolysaccharide']}, {'category': ['process'], 'description': ['chronological cell aging']}, {'category': ['process'], 'description': ['circadian rhythm']}, {'category': ['process'], 'description': ['defense response to Gram-negative bacterium']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['gene expression']}, {'category': ['process'], 'description': ['negative regulation of blood coagulation']}, {'category': ['process'], 'description': ['negative regulation of cell adhesion mediated by integrin']}, {'category': ['process'], 'description': ['negative regulation of cell migration']}, {'category': ['process'], 'description': ['negative regulation of endopeptidase activity']}, {'category': ['process'], 'description': ['negative regulation of endothelial cell apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of extrinsic apoptotic signaling pathway via death domain receptors']}, {'category': ['process'], 'description': ['negative regulation of fibrinolysis']}, {'category': ['process'], 'description': ['negative regulation of plasminogen activation']}, {'category': ['process'], 'description': ['negative regulation of smooth muscle cell migration']}, {'category': ['process'], 'description': ['negative regulation of smooth muscle cell-matrix adhesion']}, {'category': ['process'], 'description': ['negative regulation of vascular wound healing']}, {'category': ['process'], 'description': ['negative regulation of wound healing']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of angiogenesis']}, {'category': ['process'], 'description': ['positive regulation of blood coagulation']}, {'category': ['process'], 'description': ['positive regulation of inflammatory response']}, {'category': ['process'], 'description': ['positive regulation of interleukin-8 production']}, {'category': ['process'], 'description': ['positive regulation of leukotriene production involved in inflammatory response']}, {'category': ['process'], 'description': ['positive regulation of monocyte chemotaxis']}, {'category': ['process'], 'description': ['positive regulation of receptor-mediated endocytosis']}, {'category': ['process'], 'description': ['positive regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['regulation of receptor activity']}, {'category': ['process'], 'description': ['transcription initiation from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['transcription, DNA-templated']}, {'category': ['process'], 'description': ['transforming growth factor beta receptor signaling pathway']}]}]}]}, {'id': ['BE0000969'], 'name': ['Plasminogen activator inhibitor 2'], 'organism': ['Humans'], 'actions': [{'action': ['substrate', 'inducer']}], 'references': [{'articles': [{'article': [{'ref-id': ['A11599'], 'pubmed-id': ['15277569'], 'citation': ['Swartz JM, Bystrom J, Dyer KD, Nitto T, Wynn TA, Rosenberg HF: Plasminogen activator inhibitor-2 (PAI-2) in eosinophilic leukocytes. J Leukoc Biol. 2004 Oct;76(4):812-9. Epub 2004 Jul 26.']}, {'ref-id': ['A11600'], 'pubmed-id': ['15351849'], 'citation': ['Wygrecka M, Markart P, Ruppert C, Kuchenbuch T, Fink L, Bohle RM, Grimminger F, Seeger W, Gunther A: Compartment- and cell-specific expression of coagulation and fibrinolysis factors in the murine lung undergoing inhalational versus intravenous endotoxin application. Thromb Haemost. 2004 Sep;92(3):529-40.']}, {'ref-id': ['A11601'], 'pubmed-id': ['15640330'], 'citation': ['Iglesias D, Alegre J, Aleman C, Ruiz E, Soriano T, Armadans LI, Segura RM, Angles A, Monasterio J, de Sevilla TF: Metalloproteinases and tissue inhibitors of metalloproteinases in exudative pleural effusions. Eur Respir J. 2005 Jan;25(1):104-9.']}, {'ref-id': ['A11602'], 'pubmed-id': ['15944795'], 'citation': [""Grebenchtchikov N, Maguire TM, Riisbro R, Geurts-Moespot A, O'Donovan N, Schmitt M, McGreal G, McDermott E, O'Higgins N, Brunner N, Sweep CG, Duffy MJ: Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Oncol Rep. 2005 Jul;14(1):235-9.""]}, {'ref-id': ['A11603'], 'pubmed-id': ['16327990'], 'citation': ['Fernandez-Soria V, Lleonart ME, Diaz-Fuertes M, Villuendas R, Sanchez-Prieto R, Fabra A, Ramon Y Cajal S: Adenovirus E1A orchestrates the urokinase-plasminogen activator system and upregulates PAI-2 expression, supporting a tumor suppressor effect. Int J Oncol. 2006 Jan;28(1):143-8.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Plasminogen activator inhibitor 2'], 'general-function': ['Serine-type endopeptidase inhibitor activity'], 'specific-function': ['Inhibits urokinase-type plasminogen activator. The monocyte derived PAI-2 is distinct from the endothelial cell-derived PAI-1.'], 'gene-name': ['SERPINB2'], 'locus': ['18q21.3'], 'cellular-location': ['Cytoplasm'], 'transmembrane-regions': [None], 'signal-regions': ['1-'], 'theoretical-pi': ['5.34'], 'molecular-weight': ['46595.84'], 'chromosome-location': ['18'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:8584']}, {'resource': ['GenAtlas'], 'identifier': ['SERPINB2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['J02685']}, {'resource': ['GenBank Protein Database'], 'identifier': ['189545']}, {'resource': ['UniProtKB'], 'identifier': ['P05120']}, {'resource': ['UniProt Accession'], 'identifier': ['PAI2_HUMAN']}]}], 'synonyms': [{'synonym': ['Monocyte Arg-serpin', 'PAI-2', 'PAI2', 'Placental plasminogen activator inhibitor', 'PLANH2', 'Serpin B2', 'Urokinase inhibitor']}], 'amino-acid-sequence': ['>lcl|BSEQ0016268|Plasminogen activator inhibitor 2\nMEDLCVANTLFALNLFKHLAKASPTQNLFLSPWSISSTMAMVYMGSRGSTEDQMAKVLQF\nNEVGANAVTPMTPENFTSCGFMQQIQKGSYPDAILQAQAADKIHSSFRSLSSAINASTGN\nYLLESVNKLFGEKSASFREEYIRLCQKYYSSEPQAVDFLECAEEARKKINSWVKTQTKGK\nIPNLLPEGSVDGDTRMVLVNAVYFKGKWKTPFEKKLNGLYPFRVNSAQRTPVQMMYLREK\nLNIGYIEDLKAQILELPYAGDVSMFLLLPDEIADVSTGLELLESEITYDKLNKWTSKDKM\nAEDEVEVYIPQFKLEEHYELRSILRSMGMEDAFNKGRANFSGMSERNDLFLSEVFHQAMV\nDVNEEGTEAAAGTGGVMTGRTGHGGPQFVADHPFLFLIMHKITNCILFFGRFSSP'], 'gene-sequence': ['>lcl|BSEQ0016269|Plasminogen activator inhibitor 2 (SERPINB2)\nATGGAGGATCTTTGTGTGGCAAACACACTCTTTGCCCTCAATTTATTCAAGCATCTGGCA\nAAAGCAAGCCCCACCCAGAACCTCTTCCTCTCCCCATGGAGCATCTCGTCCACCATGGCC\nATGGTCTACATGGGCTCCAGGGGCAGCACCGAAGACCAGATGGCCAAGGTGCTTCAGTTT\nAATGAAGTGGGAGCCAATGCAGTTACCCCCATGACTCCAGAGAACTTTACCAGCTGTGGG\nTTCATGCAGCAGATCCAGAAGGGTAGTTATCCTGATGCGATTTTGCAGGCACAAGCTGCA\nGATAAAATCCATTCATCCTTCCGCTCTCTCAGCTCTGCAATCAATGCATCCACAGGGAAT\nTATTTACTGGAAAGTGTCAATAAGCTGTTTGGTGAGAAGTCTGCGAGCTTCCGGGAAGAA\nTATATTCGACTCTGTCAGAAATATTACTCCTCAGAACCCCAGGCAGTAGACTTCCTAGAA\nTGTGCAGAAGAAGCTAGAAAAAAGATTAATTCCTGGGTCAAGACTCAAACCAAAGGCAAA\nATCCCAAACTTGTTACCTGAAGGTTCTGTAGATGGGGATACCAGGATGGTCCTGGTGAAT\nGCTGTCTACTTCAAAGGAAAGTGGAAAACTCCATTTGAGAAGAAACTAAATGGGCTTTAT\nCCTTTCCGTGTAAACTCGGCTCAGCGCACACCTGTACAGATGATGTACTTGCGTGAAAAG\nCTAAACATTGGATACATAGAAGACCTAAAGGCTCAGATTCTAGAACTCCCATATGCTGGA\nGATGTTAGCATGTTCTTGTTGCTTCCAGATGAAATTGCCGATGTGTCCACTGGCTTGGAG\nCTGCTGGAAAGTGAAATAACCTATGACAAACTCAACAAGTGGACCAGCAAAGACAAAATG\nGCTGAAGATGAAGTTGAGGTATACATACCCCAGTTCAAATTAGAAGAGCATTATGAACTC\nAGATCCATTCTGAGAAGCATGGGCATGGAGGACGCCTTCAACAAGGGACGGGCCAATTTC\nTCAGGGATGTCGGAGAGGAATGACCTGTTTCTTTCTGAAGTGTTCCACCAAGCCATGGTG\nGATGTGAATGAGGAGGGCACTGAAGCAGCCGCTGGCACAGGAGGTGTTATGACAGGGAGA\nACTGGACATGGAGGCCCACAGTTTGTGGCAGATCATCCTTTTCTTTTTCTTATTATGCAT\nAAGATAACCAACTGCATTTTATTTTTCGGCAGATTTTCCTCACCCTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00079'], 'name': ['Serpin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['serine-type endopeptidase inhibitor activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['negative regulation of apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of endopeptidase activity']}]}]}]}, {'id': ['BE0002112'], 'name': ['Plasma serine protease inhibitor'], 'organism': ['Humans'], 'actions': [{'action': ['substrate']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13088'], 'pubmed-id': ['17434507'], 'citation': ['Uhrin P, Schofer C, Zaujec J, Ryban L, Hilpert M, Weipoltshammer K, Jerabek I, Pirtzkall I, Furtmuller M, Dewerchin M, Binder BR, Geiger M: Male fertility and protein C inhibitor/plasminogen activator inhibitor-3 (PCI): localization of PCI in mouse testis and failure of single plasminogen activator knockout to restore spermatogenesis in PCI-deficient mice. Fertil Steril. 2007 Oct;88(4 Suppl):1049-57. Epub 2007 Apr 16.']}, {'ref-id': ['A13089'], 'pubmed-id': ['17253188'], 'citation': ['Espana F, Navarro S, Medina P, Zorio E, Estelles A: The role of protein C inhibitor in human reproduction. Semin Thromb Hemost. 2007 Feb;33(1):41-5.']}, {'ref-id': ['A13090'], 'pubmed-id': ['14645112'], 'citation': ['Odet F, Guyot R, Leduque P, Le Magueresse-Battistoni B: Evidence for similar expression of protein C inhibitor and the urokinase-type plasminogen activator system during mouse testis development. Endocrinology. 2004 Mar;145(3):1481-9. Epub 2003 Nov 26.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Plasma serine protease inhibitor'], 'general-function': ['Serine-type endopeptidase inhibitor activity'], 'specific-function': ['Heparin-dependent serine protease inhibitor acting in body fluids and secretions. Inactivates serine proteases by binding irreversibly to their serine activation site. Involved in the regulation of intravascular and extravascular proteolytic activities. Plays hemostatic roles in the blood plasma. Acts as a procoagulant and proinflammatory factor by inhibiting the anticoagulant activated protein C factor as well as the generation of activated protein C factor by the thrombin/thrombomodulin complex. Acts as an anticoagulant factor by inhibiting blood coagulation factors like prothrombin, factor XI, factor Xa, plasma kallikrein and fibrinolytic enzymes such as tissue- and urinary-type plasminogen activators. In seminal plasma, inactivates several serine proteases implicated in the reproductive system. Inhibits the serpin acrosin; indirectly protects component of the male genital tract from being degraded by excessive released acrosin. Inhibits tissue-and urinary-type plasminogen activator, prostate-specific antigen and kallikrein activities; has a control on the sperm motility and fertilization. Inhibits the activated protein C-catalyzed degradation of SEMG1 and SEMG2; regulates the degradation of semenogelin during the process of transfer of spermatozoa from the male reproductive tract into the female tract. In urine, inhibits urinary-type plasminogen activator and kallikrein activities. Inactivates membrane-anchored serine proteases activities such as MPRSS7 and TMPRSS11E. Inhibits urinary-type plasminogen activator-dependent tumor cell invasion and metastasis. May also play a non-inhibitory role in seminal plasma and urine as a hydrophobic hormone carrier by its binding to retinoic acid.'], 'gene-name': ['SERPINA5'], 'locus': ['14q32.1'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-19'], 'theoretical-pi': ['9.76'], 'molecular-weight': ['45674.315'], 'chromosome-location': ['14'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:8723']}, {'resource': ['GenAtlas'], 'identifier': ['SERPINA5']}, {'resource': ['GenBank Gene Database'], 'identifier': ['J02639']}, {'resource': ['GenBank Protein Database'], 'identifier': ['180550']}, {'resource': ['UniProtKB'], 'identifier': ['P05154']}, {'resource': ['UniProt Accession'], 'identifier': ['IPSP_HUMAN']}]}], 'synonyms': [{'synonym': ['Acrosomal serine protease inhibitor', 'PAI-3', 'PAI3', 'PCI', 'PLANH3', 'Plasminogen activator inhibitor 3', 'PROCI', 'Protein C inhibitor', 'Serpin A5']}], 'amino-acid-sequence': ['>lcl|BSEQ0011531|Plasma serine protease inhibitor\nMQLFLLLCLVLLSPQGASLHRHHPREMKKRVEDLHVGATVAPSSRRDFTFDLYRALASAA\nPSQSIFFSPVSISMSLAMLSLGAGSSTKMQILEGLGLNLQKSSEKELHRGFQQLLQELNQ\nPRDGFQLSLGNALFTDLVVDLQDTFVSAMKTLYLADTFPTNFRDSAGAMKQINDYVAKQT\nKGKIVDLLKNLDSNAVVIMVNYIFFKAKWETSFNHKGTQEQDFYVTSETVVRVPMMSRED\nQYHYLLDRNLSCRVVGVPYQGNATALFILPSEGKMQQVENGLSEKTLRKWLKMFKKRQLE\nLYLPKFSIEGSYQLEKVLPSLGISNVFTSHADLSGISNHSNIQVSEMVHKAVVEVDESGT\nRAAAATGTIFTFRSARLNSQRLVFNRPFLMFIVDNNILFLGKVNRP'], 'gene-sequence': ['>lcl|BSEQ0011532|Plasma serine protease inhibitor (SERPINA5)\nATGCAGCTCTTCCTCCTCTTGTGCCTGGTGCTTCTCAGCCCTCAGGGGGCCTCCCTTCAC\nCGCCACCACCCCCGGGAGATGAAGAAGAGAGTCGAGGACCTCCATGTAGGTGCCACGGTG\nGCCCCCAGCAGCAGAAGGGACTTTACCTTTGACCTCTACAGGGCCTTGGCTTCCGCTGCC\nCCCAGCCAGAGCATCTTCTTCTCCCCTGTGAGCATCTCCATGAGCCTGGCCATGCTCTCC\nCTGGGGGCTGGGTCCAGCACAAAGATGCAGATCCTGGAGGGCCTGGGCCTCAACCTCCAG\nAAAAGCTCAGAGAAGGAGCTGCACAGAGGCTTTCAGCAGCTCCTTCAGGAACTCAACCAG\nCCCAGAGATGGCTTCCAGCTGAGCCTCGGCAATGCCCTTTTCACCGACCTGGTGGTAGAC\nCTGCAGGACACCTTCGTAAGTGCCATGAAGACGCTGTACCTGGCAGACACTTTCCCTACC\nAACTTTAGGGACTCTGCAGGGGCCATGAAGCAGATCAATGATTATGTGGCAAAGCAAACG\nAAGGGCAAGATTGTGGACTTGCTTAAGAACCTCGATAGCAATGCGGTCGTGATCATGGTG\nAATTACATCTTCTTTAAAGCTAAGTGGGAGACAAGCTTCAACCACAAAGGCACCCAAGAG\nCAAGACTTCTACGTGACCTCGGAGACTGTGGTGCGGGTACCCATGATGAGCCGCGAGGAT\nCAGTATCACTACCTCCTGGACCGGAACCTCTCCTGCAGGGTGGTGGGGGTCCCCTACCAA\nGGCAATGCCACGGCTTTGTTCATTCTCCCCAGTGAGGGAAAGATGCAGCAGGTGGAGAAT\nGGACTGAGTGAGAAAACGCTGAGGAAGTGGCTTAAGATGTTCAAAAAGAGGCAGCTCGAG\nCTTTACCTTCCCAAATTCTCCATTGAGGGCTCCTATCAGCTGGAGAAAGTCCTCCCCAGT\nCTGGGGATCAGTAACGTCTTCACCTCCCATGCTGATCTGTCCGGCATCAGCAACCACTCA\nAATATCCAGGTGTCTGAGATGGTGCACAAAGCTGTGGTGGAGGTGGACGAGTCGGGAACC\nAGAGCAGCGGCAGCCACGGGGACAATATTCACTTTCAGGTCGGCCCGCCTGAACTCTCAG\nAGGCTAGTGTTCAACAGGCCCTTTCTGATGTTCATTGTGGATAACAACATCCTCTTCCTT\nGGCAAAGTGAACCGCCCCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00079'], 'name': ['Serpin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['acrosomal membrane']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['platelet alpha granule']}, {'category': ['component'], 'description': ['platelet dense tubular network']}, {'category': ['component'], 'description': ['protein C inhibitor-coagulation factor V complex']}, {'category': ['component'], 'description': ['protein C inhibitor-coagulation factor Xa complex']}, {'category': ['component'], 'description': ['protein C inhibitor-coagulation factor XI complex']}, {'category': ['component'], 'description': ['protein C inhibitor-KLK3 complex']}, {'category': ['component'], 'description': ['protein C inhibitor-plasma kallikrein complex']}, {'category': ['component'], 'description': ['protein C inhibitor-PLAT complex']}, {'category': ['component'], 'description': ['protein C inhibitor-PLAU complex']}, {'category': ['component'], 'description': ['protein C inhibitor-thrombin complex']}, {'category': ['component'], 'description': ['protein C inhibitor-TMPRSS11E complex']}, {'category': ['component'], 'description': ['protein C inhibitor-TMPRSS7 complex']}, {'category': ['component'], 'description': ['protein complex']}, {'category': ['function'], 'description': ['acrosin binding']}, {'category': ['function'], 'description': ['glycosaminoglycan binding']}, {'category': ['function'], 'description': ['heparin binding']}, {'category': ['function'], 'description': ['phosphatidylcholine binding']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['function'], 'description': ['retinoic acid binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase inhibitor activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['fusion of sperm to egg plasma membrane']}, {'category': ['process'], 'description': ['lipid transport']}, {'category': ['process'], 'description': ['negative regulation of endopeptidase activity']}, {'category': ['process'], 'description': ['negative regulation of hydrolase activity']}, {'category': ['process'], 'description': ['spermatogenesis']}]}]}]}, {'id': ['BE0000942'], 'name': ['Low-density lipoprotein receptor-related protein 2'], 'organism': ['Humans'], 'actions': [{'action': ['substrate']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A13092'], 'pubmed-id': ['8241286'], 'citation': [""Kanalas JJ: Effect of the nephritogenic autoantibody of Heymann's nephritis on plasminogen-binding to gp330 and activation by urokinase. Biochim Biophys Acta. 1993 Nov 25;1225(1):101-6.""]}, {'ref-id': ['A5042'], 'pubmed-id': ['1280065'], 'citation': ['Kanalas JJ: Analysis of plasmin binding and urokinase activation of plasminogen bound to the Heymann nephritis autoantigen, gp330. Arch Biochem Biophys. 1992 Dec;299(2):255-60.']}, {'ref-id': ['A13093'], 'pubmed-id': ['7959795'], 'citation': ['Korenberg JR, Argraves KM, Chen XN, Tran H, Strickland DK, Argraves WS: Chromosomal localization of human genes for the LDL receptor family member glycoprotein 330 (LRP2) and its associated protein RAP (LRPAP1). Genomics. 1994 Jul 1;22(1):88-93.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low-density lipoprotein receptor-related protein 2'], 'general-function': ['Calcium ion binding'], 'specific-function': ['Acts together with cubilin to mediate HDL endocytosis (By similarity). May participate in regulation of parathyroid-hormone and para-thyroid-hormone-related protein release.'], 'gene-name': ['LRP2'], 'locus': ['2q24-q31'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['4424-4446'], 'signal-regions': ['1-25'], 'theoretical-pi': ['4.68'], 'molecular-weight': ['521952.77'], 'chromosome-location': ['2'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6694']}, {'resource': ['GenAtlas'], 'identifier': ['LRP2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['U33837']}, {'resource': ['GenBank Protein Database'], 'identifier': ['1809240']}, {'resource': ['UniProtKB'], 'identifier': ['P98164']}, {'resource': ['UniProt Accession'], 'identifier': ['LRP2_HUMAN']}]}], 'synonyms': [{'synonym': ['Glycoprotein 330', 'gp330', 'LRP-2', 'Megalin']}], 'amino-acid-sequence': ['>lcl|BSEQ0010661|Low-density lipoprotein receptor-related protein 2\nMDRGPAAVACTLLLALVACLAPASGQECDSAHFRCGSGHCIPADWRCDGTKDCSDDADEI\nGCAVVTCQQGYFKCQSEGQCIPNSWVCDQDQDCDDGSDERQDCSQSTCSSHQITCSNGQC\nIPSEYRCDHVRDCPDGADENDCQYPTCEQLTCDNGACYNTSQKCDWKVDCRDSSDEINCT\nEICLHNEFSCGNGECIPRAYVCDHDNDCQDGSDEHACNYPTCGGYQFTCPSGRCIYQNWV\nCDGEDDCKDNGDEDGCESGPHDVHKCSPREWSCPESGRCISIYKVCDGILDCPGREDENN\nTSTGKYCSMTLCSALNCQYQCHETPYGGACFCPPGYIINHNDSRTCVEFDDCQIWGICDQ\nKCESRPGRHLCHCEEGYILERGQYCKANDSFGEASIIFSNGRDLLIGDIHGRSFRILVES\nQNRGVAVGVAFHYHLQRVFWTDTVQNKVFSVDINGLNIQEVLNVSVETPENLAVDWVNNK\nIYLVETKVNRIDMVNLDGSYRVTLITENLGHPRGIAVDPTVGYLFFSDWESLSGEPKLER\nAFMDGSNRKDLVKTKLGWPAGVTLDMISKRVYWVDSRFDYIETVTYDGIQRKTVVHGGSL\nIPHPFGVSLFEGQVFFTDWTKMAVLKANKFTETNPQVYYQASLRPYGVTVYHSLRQPYAT\nNPCKDNNGGCEQVCVLSHRTDNDGLGFRCKCTFGFQLDTDERHCIAVQNFLIFSSQVAIR\nGIPFTLSTQEDVMVPVSGNPSFFVGIDFDAQDSTIFFSDMSKHMIFKQKIDGTGREILAA\nNRVENVESLAFDWISKNLYWTDSHYKSISVMRLADKTRRTVVQYLNNPRSVVVHPFAGYL\nFFTDWFRPAKIMRAWSDGSHLLPVINTTLGWPNGLAIDWAASRLYWVDAYFDKIEHSTFD\nGLDRRRLGHIEQMTHPFGLAIFGEHLFFTDWRLGAIIRVRKADGGEMTVIRSGIAYILHL\nKSYDVNIQTGSNACNQPTHPNGDCSHFCFPVPNFQRVCGCPYGMRLASNHLTCEGDPTNE\nPPTEQCGLFSFPCKNGRCVPNYYLCDGVDDCHDNSDEQLCGTLNNTCSSSAFTCGHGECI\nPAHWRCDKRNDCVDGSDEHNCPTHAPASCLDTQYTCDNHQCISKNWVCDTDNDCGDGSDE\nKNCNSTETCQPSQFNCPNHRCIDLSFVCDGDKDCVDGSDEVGCVLNCTASQFKCASGDKC\nIGVTNRCDGVFDCSDNSDEAGCPTRPPGMCHSDEFQCQEDGICIPNFWECDGHPDCLYGS\nDEHNACVPKTCPSSYFHCDNGNCIHRAWLCDRDNDCGDMSDEKDCPTQPFRCPSWQWQCL\nGHNICVNLSVVCDGIFDCPNGTDESPLCNGNSCSDFNGGCTHECVQEPFGAKCLCPLGFL\nLANDSKTCEDIDECDILGSCSQHCYNMRGSFRCSCDTGYMLESDGRTCKVTASESLLLLV\nASQNKIIADSVTSQVHNIYSLVENGSYIVAVDFDSISGRIFWSDATQGKTWSAFQNGTDR\nRVVFDSSIILTETIAIDWVGRNLYWTDYALETIEVSKIDGSHRTVLISKNLTNPRGLALD\nPRMNEHLLFWSDWGHHPRIERASMDGSMRTVIVQDKIFWPCGLTIDYPNRLLYFMDSYLD\nYMDFCDYNGHHRRQVIASDLIIRHPYALTLFEDSVYWTDRATRRVMRANKWHGGNQSVVM\nYNIQWPLGIVAVHPSKQPNSVNPCAFSRCSHLCLLSSQGPHFYSCVCPSGWSLSPDLLNC\nLRDDQPFLITVRQHIIFGISLNPEVKSNDAMVPIAGIQNGLDVEFDDAEQYIYWVENPGE\nIHRVKTDGTNRTVFASISMVGPSMNLALDWISRNLYSTNPRTQSIEVLTLHGDIRYRKTL\nIANDGTALGVGFPIGITVDPARGKLYWSDQGTDSGVPAKIASANMDGTSVKTLFTGNLEH\nLECVTLDIEEQKLYWAVTGRGVIERGNVDGTDRMILVHQLSHPWGIAVHDSFLYYTDEQY\nEVIERVDKATGANKIVLRDNVPNLRGLQVYHRRNAAESSNGCSNNMNACQQICLPVPGGL\nFSCACATGFKLNPDNRSCSPYNSFIVVSMLSAIRGFSLELSDHSETMVPVAGQGRNALHV\nDVDVSSGFIYWCDFSSSVASDNAIRRIKPDGSSLMNIVTHGIGENGVRGIAVDWVAGNLY\nFTNAFVSETLIEVLRINTTYRRVLLKVTVDMPRHIVVDPKNRYLFWADYGQRPKIERSFL\nDCTNRTVLVSEGIVTPRGLAVDRSDGYVYWVDDSLDIIARIRINGENSEVIRYGSRYPTP\nYGITVFENSIIWVDRNLKKIFQASKEPENTEPPTVIRDNINWLRDVTIFDKQVQPRSPAE\nVNNNPCLENNGGCSHLCFALPGLHTPKCDCAFGTLQSDGKNCAISTENFLIFALSNSLRS\nLHLDPENHSPPFQTINVERTVMSLDYDSVSDRIYFTQNLASGVGQISYATLSSGIHTPTV\nIASGIGTADGIAFDWITRRIYYSDYLNQMINSMAEDGSNRTVIARVPKPRAIVLDPCQGY\nLYWADWDTHAKIERATLGGNFRVPIVNSSLVMPSGLTLDYEEDLLYWVDASLQRIERSTL\nTGVDREVIVNAAVHAFGLTLYGQYIYWTDLYTQRIYRANKYDGSGQIAMTTNLLSQPRGI\nNTVVKNQKQQCNNPCEQFNGGCSHICAPGPNGAECQCPHEGNWYLANNRKHCIVDNGERC\nGASSFTCSNGRCISEEWKCDNDNDCGDGSDEMESVCALHTCSPTAFTCANGRCVQYSYRC\nDYYNDCGDGSDEAGCLFRDCNATTEFMCNNRRCIPREFICNGVDNCHDNNTSDEKNCPDR\nTCQSGYTKCHNSNICIPRVYLCDGDNDCGDNSDENPTYCTTHTCSSSEFQCASGRCIPQH\nWYCDQETDCFDASDEPASCGHSERTCLADEFKCDGGRCIPSEWICDGDNDCGDMSDEDKR\nHQCQNQNCSDSEFLCVNDRPPDRRCIPQSWVCDGDVDCTDGYDENQNCTRRTCSENEFTC\nGYGLCIPKIFRCDRHNDCGDYSDERGCLYQTCQQNQFTCQNGRCISKTFVCDEDNDCGDG\nSDELMHLCHTPEPTCPPHEFKCDNGRCIEMMKLCNHLDDCLDNSDEKGCGINECHDPSIS\nGCDHNCTDTLTSFYCSCRPGYKLMSDKRTCVDIDECTEMPFVCSQKCENVIGSYICKCAP\nGYLREPDGKTCRQNSNIEPYLIFSNRYYLRNLTIDGYFYSLILEGLDNVVALDFDRVEKR\nLYWIDTQRQVIERMFLNKTNKETIINHRLPAAESLAVDWVSRKLYWLDARLDGLFVSDLN\nGGHRRMLAQHCVDANNTFCFDNPRGLALHPQYGYLYWADWGHRAYIGRVGMDGTNKSVII\nSTKLEWPNGITIDYTNDLLYWADAHLGYIEYSDLEGHHRHTVYDGALPHPFAITIFEDTI\nYWTDWNTRTVEKGNKYDGSNRQTLVNTTHRPFDIHVYHPYRQPIVSNPCGTNNGGCSHLC\nLIKPGGKGFTCECPDDFRTLQLSGSTYCMPMCSSTQFLCANNEKCIPIWWKCDGQKDCSD\nGSDELALCPQRFCRLGQFQCSDGNCTSPQTLCNAHQNCPDGSDEDRLLCENHHCDSNEWQ\nCANKRCIPESWQCDTFNDCEDNSDEDSSHCASRTCRPGQFRCANGRCIPQAWKCDVDNDC\nGDHSDEPIEECMSSAHLCDNFTEFSCKTNYRCIPKWAVCNGVDDCRDNSDEQGCEERTCH\nPVGDFRCKNHHCIPLRWQCDGQNDCGDNSDEENCAPRECTESEFRCVNQQCIPSRWICDH\nYNDCGDNSDERDCEMRTCHPEYFQCTSGHCVHSELKCDGSADCLDASDEADCPTRFPDGA\nYCQATMFECKNHVCIPPYWKCDGDDDCGDGSDEELHLCLDVPCNSPNRFRCDNNRCIYSH\nEVCNGVDDCGDGTDETEEHCRKPTPKPCTEYEYKCGNGHCIPHDNVCDDADDCGDWSDEL\nGCNKGKERTCAENICEQNCTQLNEGGFICSCTAGFETNVFDRTSCLDINECEQFGTCPQH\nCRNTKGSYECVCADGFTSMSDRPGKRCAAEGSSPLLLLPDNVRIRKYNLSSERFSEYLQD\nEEYIQAVDYDWDPKDIGLSVVYYTVRGEGSRFGAIKRAYIPNFESGRNNLVQEVDLKLKY\nVMQPDGIAVDWVGRHIYWSDVKNKRIEVAKLDGRYRKWLISTDLDQPAAIAVNPKLGLMF\nWTDWGKEPKIESAWMNGEDRNILVFEDLGWPTGLSIDYLNNDRIYWSDFKEDVIETIKYD\nGTDRRVIAKEAMNPYSLDIFEDQLYWISKEKGEVWKQNKFGQGKKEKTLVVNPWLTQVRI\nFHQLRYNKSVPNLCKQICSHLCLLRPGGYSCACPQGSSFIEGSTTECDAAIELPINLPPP\nCRCMHGGNCYFDETDLPKCKCPSGYTGKYCEMAFSKGISPGTTAVAVLLTILLIVVIGAL\nAIAGFFHYRRTGSLLPALPKLPSLSSLVKPSENGNGVTFRSGADLNMDIGVSGFGPETAI\nDRSMAMSEDFVMEMGKQPIIFENPMYSARDSAVKVVQPIQVTVSENVDNKNYGSPINPSE\nIVPETNPTSPAADGTQVTKWNLFKRKSKQTTNFENPIYAQMENEQKESVAATPPPSPSLP\nAKPKPPSRRDPTPTYSATEDTFKDTANLVKEDSEV'], 'gene-sequence': ['>lcl|BSEQ0010662|Low-density lipoprotein receptor-related protein 2 (LRP2)\nATGGATCGCGGGCCGGCAGCAGTGGCGTGCACGCTGCTCCTGGCTCTCGTCGCCTGCCTA\nGCGCCGGCCAGTGGCCAAGAATGTGACAGTGCGCATTTTCGCTGTGGAAGTGGGCATTGC\nATCCCTGCAGACTGGAGGTGTGATGGGACCAAAGACTGTTCAGATGACGCGGATGAAATT\nGGCTGCGCTGTTGTGACCTGCCAGCAGGGCTATTTCAAGTGCCAGAGTGAGGGACAATGC\nATCCCCAACTCCTGGGTGTGTGACCAAGATCAAGACTGTGATGATGGCTCAGATGAACGT\nCAAGATTGCTCACAAAGTACATGCTCAAGTCATCAGATAACATGCTCCAATGGTCAGTGT\nATCCCAAGTGAATACAGGTGCGACCACGTCAGAGACTGCCCCGATGGAGCTGATGAGAAT\nGACTGCCAGTACCCAACATGTGAGCAGCTTACTTGTGACAATGGGGCCTGCTATAACACC\nAGTCAGAAGTGTGATTGGAAAGTTGATTGCAGGGACTCCTCAGATGAAATCAACTGCACT\nGAGATATGCTTGCACAATGAGTTTTCATGTGGCAATGGAGAGTGTATCCCTCGTGCTTAT\nGTCTGTGACCATGACAATGATTGCCAAGACGGCAGTGACGAACATGCTTGCAACTATCCG\nACCTGCGGTGGTTACCAGTTCACTTGCCCCAGTGGCCGATGCATTTATCAAAACTGGGTT\nTGTGATGGAGAAGATGACTGTAAAGATAATGGAGATGAAGATGGATGTGAAAGCGGTCCT\nCATGATGTTCATAAATGTTCCCCAAGAGAATGGTCTTGCCCAGAGTCGGGACGATGCATC\nTCCATTTATAAAGTTTGTGATGGGATTTTAGATTGCCCAGGAAGAGAAGATGAAAACAAC\nACTAGTACCGGAAAATACTGTAGTATGACTCTGTGCTCTGCCTTGAACTGCCAGTACCAG\nTGCCATGAGACGCCGTATGGAGGAGCGTGTTTTTGTCCCCCAGGTTATATCATCAACCAC\nAATGACAGCCGTACCTGTGTTGAGTTTGATGATTGCCAGATATGGGGAATTTGTGACCAG\nAAGTGTGAAAGCCGACCTGGCCGTCACCTGTGCCACTGTGAAGAAGGGTATATCTTGGAG\nCGTGGACAGTATTGCAAAGCTAATGATTCCTTTGGCGAGGCCTCCATTATCTTCTCCAAT\nGGTCGGGATTTGTTAATTGGTGATATTCATGGAAGGAGCTTCCGGATCCTAGTGGAGTCT\nCAGAATCGTGGAGTGGCCGTGGGTGTGGCTTTCCACTATCACCTGCAAAGAGTTTTTTGG\nACAGACACCGTGCAAAATAAGGTTTTTTCAGTTGACATTAATGGTTTAAATATCCAAGAG\nGTTCTCAATGTTTCTGTTGAAACCCCAGAGAACCTGGCTGTGGACTGGGTTAATAATAAA\nATCTATCTAGTGGAAACCAAGGTCAACCGCATAGATATGGTAAATTTGGATGGAAGCTAT\nCGGGTTACCCTTATAACTGAAAACTTGGGGCATCCTAGAGGAATTGCCGTGGACCCAACT\nGTTGGTTATTTATTTTTCTCAGATTGGGAGAGCCTTTCTGGGGAACCTAAGCTGGAAAGG\nGCATTCATGGATGGCAGCAACCGTAAAGACTTGGTGAAAACAAAGCTGGGATGGCCTGCT\nGGGGTAACTCTGGATATGATATCGAAGCGTGTTTACTGGGTTGACTCTCGGTTTGATTAC\nATTGAAACTGTAACTTATGATGGAATTCAAAGGAAGACTGTAGTTCATGGAGGCTCCCTC\nATTCCTCATCCCTTTGGAGTAAGCTTATTTGAAGGTCAGGTGTTCTTTACAGATTGGACA\nAAGATGGCCGTGCTGAAGGCAAACAAGTTCACAGAGACCAACCCACAAGTGTACTACCAG\nGCTTCCCTGAGGCCCTATGGAGTGACTGTTTACCATTCCCTCAGACAGCCCTATGCTACC\nAATCCGTGTAAAGATAACAATGGGGGCTGTGAGCAGGTCTGTGTCCTCAGCCACAGAACA\nGATAATGATGGTTTGGGTTTCCGTTGCAAGTGCACATTCGGCTTCCAACTGGATACAGAT\nGAGCGCCACTGCATTGCTGTTCAGAATTTCCTCATTTTTTCATCCCAAGTTGCTATTCGT\nGGGATCCCGTTCACCTTGTCTACCCAGGAAGATGTCATGGTTCCAGTTTCGGGGAATCCT\nTCTTTCTTTGTCGGGATTGATTTTGACGCCCAGGACAGCACTATCTTTTTTTCAGATATG\nTCAAAACACATGATTTTTAAGCAAAAGATTGATGGCACAGGAAGAGAAATTCTCGCAGCT\nAACAGGGTGGAAAATGTTGAAAGTTTGGCTTTTGATTGGATTTCAAAGAATCTCTATTGG\nACAGACTCTCATTACAAGAGTATCAGTGTCATGAGGCTAGCTGATAAAACGAGACGCACA\nGTAGTTCAGTATTTAAATAACCCACGGTCGGTGGTAGTTCATCCTTTTGCCGGGTATCTA\nTTCTTCACTGATTGGTTCCGTCCTGCTAAAATTATGAGAGCATGGAGTGACGGATCTCAC\nCTCTTGCCTGTAATAAACACTACTCTTGGATGGCCCAATGGCTTGGCCATCGATTGGGCT\nGCTTCACGATTGTACTGGGTAGATGCCTATTTTGATAAAATTGAGCACAGCACCTTTGAT\nGGTTTAGACAGAAGAAGACTGGGCCATATAGAGCAGATGACACATCCGTTTGGACTTGCC\nATCTTTGGAGAGCATTTATTTTTTACTGACTGGAGACTGGGTGCCATTATTCGAGTCAGG\nAAAGCAGATGGTGGAGAAATGACAGTTATCCGAAGTGGCATTGCTTACATACTGCATTTG\nAAATCGTATGATGTCAACATCCAGACTGGTTCTAACGCCTGTAATCAACCCACGCATCCT\nAACGGTGACTGCAGCCACTTCTGCTTCCCGGTGCCAAATTTCCAGCGAGTGTGTGGGTGC\nCCTTATGGAATGAGGCTGGCTTCCAATCACTTGACATGCGAGGGGGACCCAACCAATGAA\nCCACCCACAGAGCAGTGTGGCTTATTTTCCTTCCCCTGTAAAAATGGCAGATGTGTGCCC\nAATTACTATCTCTGTGATGGAGTCGATGATTGTCATGATAACAGTGATGAGCAACTATGT\nGGCACACTTAATAATACCTGTTCATCTTCGGCGTTCACCTGTGGCCATGGGGAGTGCATT\nCCTGCACACTGGCGCTGTGACAAACGCAACGACTGTGTGGATGGCAGTGATGAGCACAAC\nTGCCCCACCCACGCACCTGCTTCCTGCCTTGACACCCAATACACCTGTGATAATCACCAG\nTGTATCTCAAAGAACTGGGTCTGTGACACAGACAATGATTGTGGGGATGGATCTGATGAA\nAAGAACTGCAATTCGACAGAGACATGCCAACCTAGTCAGTTTAATTGCCCCAATCATCGA\nTGTATTGACCTATCGTTTGTCTGTGATGGTGACAAGGATTGTGTTGATGGATCTGATGAG\nGTTGGTTGTGTATTAAACTGTACTGCTTCTCAATTCAAGTGTGCCAGTGGGGATAAATGT\nATTGGCGTCACAAATCGTTGTGATGGTGTTTTTGATTGCAGTGACAACTCGGATGAAGCA\nGGCTGTCCAACCAGGCCTCCTGGTATGTGCCACTCAGATGAATTTCAGTGCCAAGAAGAT\nGGTATCTGCATCCCGAACTTCTGGGAATGTGATGGGCATCCAGACTGCCTCTATGGATCT\nGATGAGCACAATGCCTGTGTCCCCAAGACTTGCCCTTCATCATATTTCCACTGTGACAAC\nGGAAACTGCATCCACAGGGCATGGCTCTGTGATCGGGACAATGACTGCGGGGATATGAGT\nGATGAGAAGGACTGCCCTACTCAGCCCTTTCGCTGTCCTAGTTGGCAATGGCAGTGTCTT\nGGCCATAACATCTGTGTGAATCTGAGTGTAGTGTGTGATGGCATCTTTGACTGCCCCAAT\nGGGACAGATGAGTCCCCACTTTGCAATGGGAACAGCTGCTCAGATTTCAATGGTGGTTGT\nACTCACGAGTGTGTTCAAGAGCCCTTTGGGGCTAAATGCCTATGTCCATTGGGATTCTTA\nCTTGCCAATGATTCTAAGACCTGTGAAGACATAGATGAATGTGATATTCTAGGCTCTTGT\nAGCCAGCACTGTTACAATATGAGAGGTTCTTTCCGGTGCTCGTGTGATACAGGCTACATG\nTTAGAAAGTGATGGGAGGACTTGCAAAGTTACAGCATCTGAGAGTCTGCTGTTACTTGTG\nGCAAGTCAGAACAAAATTATTGCCGACAGTGTCACCTCCCAGGTCCACAATATCTATTCA\nTTGGTCGAGAATGGTTCTTACATTGTAGCTGTTGATTTTGATTCAATTAGTGGTCGTATC\nTTTTGGTCTGATGCAACTCAGGGTAAAACCTGGAGTGCGTTTCAAAATGGAACGGACAGA\nAGAGTGGTATTTGACAGTAGCATCATCTTGACTGAAACTATTGCAATAGATTGGGTAGGT\nCGTAATCTTTACTGGACAGACTATGCTCTGGAAACAATTGAAGTCTCCAAAATTGATGGG\nAGCCACAGGACTGTGCTGATTAGTAAAAACCTAACAAATCCAAGAGGACTAGCATTAGAT\nCCCAGAATGAATGAGCATCTACTGTTCTGGTCTGACTGGGGCCACCACCCTCGCATCGAG\nCGAGCCAGCATGGACGGCAGCATGCGCACTGTCATTGTCCAGGACAAGATCTTCTGGCCC\nTGCGGCTTAACTATTGACTACCCCAACAGACTGCTCTACTTCATGGACTCCTATCTTGAT\nTACATGGACTTTTGTGATTATAATGGACACCATCGGAGACAGGTGATAGCCAGTGATTTG\nATTATACGGCACCCCTATGCCCTAACTCTCTTTGAAGACTCTGTGTACTGGACTGACCGT\nGCTACTCGTCGGGTTATGCGAGCCAACAAGTGGCATGGAGGGAACCAGTCAGTTGTAATG\nTATAATATTCAATGGCCCCTTGGGATTGTTGCGGTTCATCCTTCGAAACAACCAAATTCC\nGTGAATCCATGTGCCTTTTCCCGCTGCAGCCATCTCTGCCTGCTTTCCTCACAGGGGCCT\nCATTTTTACTCCTGTGTTTGTCCTTCAGGATGGAGTCTGTCTCCTGATCTCCTGAATTGC\nTTGAGAGATGATCAACCTTTCTTAATAACTGTAAGGCAACATATAATTTTTGGAATCTCC\nCTTAATCCTGAGGTGAAGAGCAATGATGCTATGGTCCCCATAGCAGGGATACAGAATGGT\nTTAGATGTTGAATTTGATGATGCTGAGCAATACATCTATTGGGTTGAAAATCCAGGTGAA\nATTCACAGAGTGAAGACAGATGGCACCAACAGGACAGTATTTGCTTCTATATCTATGGTG\nGGGCCTTCTATGAACCTGGCCTTAGATTGGATTTCAAGAAACCTTTATTCTACCAATCCT\nAGAACTCAGTCAATCGAGGTTTTGACACTCCACGGAGATATCAGATACAGAAAAACATTG\nATTGCCAATGATGGGACAGCTCTTGGAGTTGGCTTTCCAATTGGCATAACTGTTGATCCT\nGCTCGTGGGAAGCTGTACTGGTCAGACCAAGGAACTGACAGTGGGGTTCCTGCCAAGATC\nGCCAGTGCTAACATGGATGGCACATCTGTGAAAACTCTCTTTACTGGGAACCTCGAACAC\nCTGGAGTGTGTCACTCTTGACATCGAAGAGCAGAAACTCTACTGGGCAGTCACTGGAAGA\nGGAGTGATTGAAAGAGGAAACGTGGATGGAACAGATCGAATGATCCTGGTACACCAGCTT\nTCCCACCCCTGGGGAATTGCAGTCCATGATTCTTTCCTTTATTATACTGATGAACAGTAT\nGAGGTCATTGAAAGAGTTGATAAGGCCACTGGGGCCAACAAAATAGTCTTGAGAGATAAT\nGTTCCAAATCTGAGGGGTCTTCAAGTTTATCACAGACGCAATGCCGCCGAATCCTCAAAT\nGGCTGTAGCAACAACATGAATGCCTGTCAGCAGATTTGCCTGCCTGTACCAGGAGGATTG\nTTTTCCTGCGCCTGTGCCACTGGATTTAAACTCAATCCTGATAATCGGTCCTGCTCTCCA\nTATAACTCTTTCATTGTTGTTTCAATGCTGTCTGCAATCAGAGGCTTTAGCTTGGAATTG\nTCAGATCATTCAGAAACCATGGTGCCGGTGGCAGGCCAAGGACGAAACGCACTGCATGTG\nGATGTGGATGTGTCCTCTGGCTTTATTTATTGGTGTGATTTTAGCAGCTCAGTGGCATCT\nGATAATGCGATCCGTAGAATTAAACCAGATGGATCTTCTCTGATGAACATTGTGACACAT\nGGAATAGGAGAAAATGGAGTCCGGGGTATTGCAGTGGATTGGGTAGCAGGAAATCTTTAT\nTTCACCAATGCCTTTGTTTCTGAAACACTGATAGAAGTTCTGCGGATCAATACTACTTAC\nCGCCGTGTTCTTCTTAAAGTCACAGTGGACATGCCTAGGCATATTGTTGTAGATCCCAAG\nAACAGATACCTCTTCTGGGCTGACTATGGGCAGAGACCAAAGATTGAGCGTTCTTTCCTT\nGACTGTACCAATCGAACAGTGCTTGTGTCAGAGGGCATTGTCACACCACGGGGCTTGGCA\nGTGGACCGAAGTGATGGCTACGTTTATTGGGTTGATGATTCTTTAGATATAATTGCAAGG\nATTCGTATCAATGGAGAGAACTCTGAAGTGATTCGTTATGGCAGTCGTTACCCAACTCCT\nTATGGCATCACTGTTTTTGAAAATTCTATCATATGGGTAGATAGGAATTTGAAAAAGATC\nTTCCAAGCCAGCAAGGAACCAGAGAACACAGAGCCACCCACAGTGATAAGAGACAATATC\nAACTGGCTAAGAGATGTGACCATCTTTGACAAGCAAGTCCAGCCCCGGTCACCAGCAGAG\nGTCAACAACAACCCTTGCTTGGAAAACAATGGTGGGTGCTCTCATCTCTGCTTTGCTCTG\nCCTGGATTGCACACCCCAAAATGTGACTGTGCCTTTGGGACCCTGCAAAGTGATGGCAAG\nAATTGTGCCATTTCAACAGAAAATTTCCTCATCTTTGCCTTGTCTAATTCCTTGAGAAGC\nTTACACTTGGACCCTGAAAACCATAGCCCACCTTTCCAAACAATAAATGTGGAAAGAACT\nGTCATGTCTCTAGACTATGACAGTGTAAGTGATAGAATCTACTTCACACAAAATTTAGCC\nTCTGGAGTTGGACAGATTTCCTATGCCACCCTGTCTTCAGGGATCCATACTCCAACTGTC\nATTGCTTCAGGTATAGGGACTGCTGATGGCATTGCCTTTGACTGGATTACTAGAAGAATT\nTATTACAGTGACTACCTCAACCAGATGATTAATTCCATGGCTGAAGATGGGTCTAACCGC\nACTGTGATAGCCCGCGTTCCAAAACCAAGAGCAATTGTGTTAGATCCCTGCCAAGGGTAC\nCTGTACTGGGCTGACTGGGATACACATGCCAAAATCGAGAGAGCCACATTGGGAGGAAAC\nTTCCGCGTACCCATTGTGAACAGCAGTCTGGTCATGCCCAGTGGGCTGACTCTGGACTAT\nGAAGAGGACCTTCTCTACTGGGTGGATGCTAGTCTGCAGAGGATTGAACGCAGCACTCTG\nACGGGCGTGGATCGTGAAGTCATTGTCAATGCAGCCGTTCATGCTTTTGGCTTGACTCTC\nTATGGCCAGTATATTTACTGGACTGACTTGTACACACAAAGAATTTACCGAGCTAACAAA\nTATGACGGGTCAGGTCAGATTGCAATGACCACAAATTTGCTCTCCCAGCCCAGGGGAATC\nAACACTGTTGTGAAGAACCAGAAACAACAGTGTAACAATCCTTGTGAACAGTTTAATGGG\nGGCTGCAGCCATATCTGTGCACCAGGTCCAAATGGTGCCGAGTGCCAGTGTCCACATGAG\nGGCAACTGGTATTTGGCCAACAACAGGAAGCACTGCATTGTGGACAATGGTGAACGATGT\nGGTGCATCTTCCTTCACCTGCTCCAATGGGCGCTGCATCTCGGAAGAGTGGAAGTGTGAT\nAATGACAACGACTGTGGGGATGGCAGTGATGAGATGGAAAGTGTCTGTGCACTTCACACC\nTGCTCACCGACAGCCTTCACCTGTGCCAATGGGCGATGTGTCCAATACTCTTACCGCTGT\nGATTACTACAATGACTGTGGTGATGGCAGTGATGAGGCAGGGTGCCTGTTCAGGGACTGC\nAATGCCACCACGGAGTTTATGTGCAATAACAGAAGGTGCATACCTCGTGAGTTTATCTGC\nAATGGTGTAGACAACTGCCATGATAATAACACTTCAGATGAGAAAAATTGCCCTGATCGC\nACTTGCCAGTCTGGATACACAAAATGTCATAATTCAAATATTTGTATTCCTCGCGTTTAT\nTTGTGTGACGGAGACAATGACTGTGGAGATAACAGTGATGAAAACCCTACTTATTGCACC\nACTCACACGTGCAGCAGCAGTGAGTTCCAATGCGCATCTGGGCGCTGTATTCCTCAACAT\nTGGTATTGTGATCAAGAAACAGATTGTTTTGATGCCTCTGATGAACCTGCCTCTTGTGGT\nCACTCTGAGCGAACATGCCTAGCTGATGAGTTCAAGTGTGATGGTGGGAGGTGCATCCCA\nAGCGAATGGATCTGTGACGGTGATAATGACTGTGGGGATATGAGTGACGAGGATAAAAGG\nCACCAGTGTCAGAATCAAAACTGCTCGGATTCCGAGTTTCTCTGTGTAAATGACAGACCT\nCCGGACAGGAGGTGCATTCCCCAGTCTTGGGTCTGTGATGGCGATGTGGATTGTACTGAC\nGGCTACGATGAGAATCAGAATTGCACCAGGAGAACTTGCTCTGAAAATGAATTCACCTGT\nGGTTACGGACTGTGTATCCCAAAGATATTCAGGTGTGACCGGCACAATGACTGTGGTGAC\nTATAGCGACGAGAGGGGCTGCTTATACCAGACTTGCCAACAGAATCAGTTTACCTGTCAG\nAACGGGCGCTGCATTAGTAAAACCTTCGTCTGTGATGAGGATAATGACTGTGGAGACGGA\nTCTGATGAGCTGATGCACCTGTGCCACACCCCAGAACCCACGTGTCCACCTCACGAGTTC\nAAGTGTGACAATGGGCGCTGCATCGAGATGATGAAACTCTGCAACCACCTAGATGACTGT\nTTGGACAACAGCGATGAGAAAGGCTGTGGCATTAATGAATGCCATGACCCTTCAATCAGT\nGGCTGCGATCACAACTGCACAGACACCTTAACCAGTTTCTATTGTTCCTGTCGTCCTGGT\nTACAAGCTCATGTCTGACAAGCGGACTTGTGTTGATATTGATGAATGCACAGAGATGCCT\nTTTGTCTGTAGCCAGAAGTGTGAGAATGTAATAGGCTCCTACATCTGTAAGTGTGCCCCA\nGGCTACCTCCGAGAACCAGATGGAAAGACCTGCCGGCAAAACAGTAACATCGAACCCTAT\nCTCATTTTTAGCAACCGTTACTATTTGAGAAATTTAACTATAGATGGCTATTTTTACTCC\nCTCATCTTGGAAGGACTGGACAATGTTGTGGCATTAGATTTTGACCGAGTAGAGAAGAGA\nTTGTATTGGATTGATACACAGAGGCAAGTCATTGAGAGAATGTTTCTGAATAAGACAAAC\nAAGGAGACAATCATAAACCACAGACTACCAGCTGCAGAAAGTCTGGCTGTAGACTGGGTT\nTCCAGAAAGCTCTACTGGTTGGATGCCCGCCTGGATGGCCTCTTTGTCTCTGACCTCAAT\nGGTGGACACCGCCGCATGCTGGCCCAGCACTGTGTGGATGCCAACAACACCTTCTGCTTT\nGATAATCCCAGAGGACTTGCCCTTCACCCTCAATATGGGTACCTCTACTGGGCAGACTGG\nGGTCACCGCGCATACATTGGGAGAGTAGGCATGGATGGAACCAACAAGTCTGTGATAATC\nTCCACCAAGTTAGAGTGGCCTAATGGCATCACCATTGATTACACCAATGATCTACTCTAC\nTGGGCAGATGCCCACCTGGGTTACATAGAGTACTCTGATTTGGAGGGCCACCATCGACAC\nACGGTGTATGATGGGGCACTGCCTCACCCTTTCGCTATTACCATTTTTGAAGACACTATT\nTATTGGACAGATTGGAATACAAGGACAGTGGAAAAGGGAAACAAATATGATGGATCAAAT\nAGACAGACACTGGTGAACACAACACACAGACCATTTGACATCCATGTGTACCATCCATAT\nAGGCAGCCCATTGTGAGCAATCCCTGTGGTACCAACAATGGTGGCTGTTCTCATCTCTGC\nCTCATCAAGCCAGGAGGAAAAGGGTTCACTTGCGAGTGTCCAGATGACTTCCGCACCCTT\nCAGCTGAGTGGCAGCACCTACTGCATGCCCATGTGCTCCAGCACCCAGTTCCTGTGCGCT\nAACAATGAAAAGTGCATTCCTATCTGGTGGAAATGTGATGGACAGAAAGACTGCTCAGAT\nGGCTCTGATGAACTGGCCCTTTGCCCGCAGCGCTTCTGCCGACTGGGACAGTTCCAGTGC\nAGTGACGGCAACTGCACCAGCCCGCAGACTTTATGCAATGCTCACCAAAATTGCCCTGAT\nGGGTCTGATGAAGACCGTCTTCTTTGTGAGAATCACCACTGTGACTCCAATGAATGGCAG\nTGCGCCAACAAACGTTGCATCCCAGAATCCTGGCAGTGTGACACATTTAACGACTGTGAG\nGATAACTCAGATGAAGACAGTTCCCACTGTGCCAGCAGGACCTGCCGGCCGGGCCAGTTT\nCGGTGTGCTAATGGCCGCTGCATCCCGCAGGCCTGGAAGTGTGATGTGGATAATGATTGT\nGGAGACCACTCGGATGAGCCCATTGAAGAATGCATGAGCTCTGCCCATCTCTGTGACAAC\nTTCACAGAATTCAGCTGCAAAACAAATTACCGCTGCATCCCAAAGTGGGCCGTGTGCAAT\nGGTGTAGATGACTGCAGGGACAACAGTGATGAGCAAGGCTGTGAGGAGAGGACATGCCAT\nCCTGTGGGGGATTTCCGCTGTAAAAATCACCACTGCATCCCTCTTCGTTGGCAGTGTGAT\nGGGCAAAATGACTGTGGAGATAACTCAGATGAGGAAAACTGTGCTCCCCGGGAGTGCACA\nGAGAGCGAGTTTCGATGTGTCAATCAGCAGTGCATTCCCTCGCGATGGATCTGTGACCAT\nTACAACGACTGTGGGGACAACTCAGATGAACGGGACTGTGAGATGAGGACCTGCCATCCT\nGAATATTTTCAGTGTACAAGTGGACATTGTGTACACAGTGAACTGAAATGCGATGGATCC\nGCTGACTGTTTGGATGCGTCTGATGAAGCTGATTGTCCCACACGCTTTCCTGATGGTGCA\nTACTGCCAGGCTACTATGTTCGAATGCAAAAACCATGTTTGTATCCCGCCATATTGGAAA\nTGTGATGGCGATGATGACTGTGGCGATGGTTCAGATGAAGAACTTCACCTGTGCTTGGAT\nGTTCCCTGTAATTCACCAAACCGTTTCCGGTGTGACAACAATCGCTGCATTTATAGTCAT\nGAGGTGTGCAATGGTGTGGATGACTGTGGAGATGGAACTGATGAGACAGAGGAGCACTGT\nAGAAAACCGACCCCTAAACCTTGTACAGAATATGAATATAAGTGTGGCAATGGGCATTGC\nATTCCACATGACAATGTGTGTGATGATGCCGATGACTGTGGTGACTGGTCCGATGAACTG\nGGTTGCAATAAAGGAAAAGAAAGAACATGTGCTGAAAATATATGCGAGCAAAATTGTACC\nCAATTAAATGAAGGAGGATTTATCTGCTCCTGTACAGCTGGGTTCGAAACCAATGTTTTT\nGACAGAACCTCCTGTCTAGATATCAATGAATGTGAACAATTTGGGACTTGTCCCCAGCAC\nTGCAGAAATACCAAAGGAAGTTATGAGTGTGTCTGTGCTGATGGCTTCACGTCTATGAGT\nGACCGCCCTGGAAAACGATGTGCAGCTGAGGGTAGCTCTCCTTTGTTGCTACTGCCTGAC\nAATGTCCGAATTCGAAAATATAATCTCTCATCTGAGAGGTTCTCAGAGTATCTTCAAGAT\nGAGGAATATATCCAAGCTGTTGATTATGATTGGGATCCCAAGGACATAGGCCTCAGTGTT\nGTGTATTACACTGTGCGAGGGGAGGGCTCTAGGTTTGGTGCTATCAAACGTGCCTACATC\nCCCAACTTTGAATCCGGCCGCAATAATCTTGTGCAGGAAGTTGACCTGAAACTGAAATAC\nGTAATGCAGCCAGATGGAATAGCAGTGGACTGGGTTGGAAGGCATATTTACTGGTCAGAT\nGTCAAGAATAAACGCATTGAGGTGGCTAAACTTGATGGAAGGTACAGAAAGTGGCTGATT\nTCCACTGACCTGGACCAACCAGCTGCTATTGCTGTGAATCCCAAACTAGGGCTTATGTTC\nTGGACTGACTGGGGAAAGGAACCTAAAATCGAGTCTGCCTGGATGAATGGAGAGGACCGC\nAACATCCTGGTTTTCGAGGACCTTGGTTGGCCAACTGGCCTTTCTATCGATTATTTGAAC\nAATGACCGAATCTACTGGAGTGACTTCAAGGAGGACGTTATTGAAACCATAAAATATGAT\nGGGACTGATAGGAGAGTCATTGCAAAGGAAGCAATGAACCCTTACAGCCTGGACATCTTT\nGAAGACCAGTTATACTGGATATCTAAGGAAAAGGGAGAAGTATGGAAACAAAATAAATTT\nGGGCAAGGAAAGAAAGAGAAAACGCTGGTAGTGAACCCTTGGCTCACTCAAGTTCGAATC\nTTTCATCAACTCAGATACAATAAGTCAGTGCCCAACCTTTGCAAACAGATCTGCAGCCAC\nCTCTGCCTTCTGAGACCTGGAGGATACAGCTGTGCCTGTCCCCAAGGCTCCAGCTTTATA\nGAGGGGAGCACCACTGAGTGTGATGCAGCCATCGAACTGCCTATCAACCTGCCCCCCCCA\nTGCAGGTGCATGCACGGAGGAAATTGCTATTTTGATGAGACTGACCTCCCCAAATGCAAG\nTGTCCTAGCGGCTACACCGGAAAATATTGTGAAATGGCGTTTTCAAAAGGCATCTCTCCA\nGGAACAACCGCAGTAGCTGTGCTGTTGACAATCCTCTTGATCGTCGTAATTGGAGCTCTG\nGCAATTGCAGGATTCTTCCACTATAGAAGGACCGGCTCCCTTTTGCCTGCTCTGCCCAAG\nCTGCCAAGCTTAAGCAGTCTCGTCAAGCCCTCTGAAAATGGGAATGGGGTGACCTTCAGA\nTCAGGGGCAGATCTTAACATGGATATTGGAGTGTCTGGTTTTGGACCTGAGACTGCTATT\nGACAGGTCAATGGCAATGAGTGAAGACTTTGTCATGGAAATGGGGAAGCAGCCCATAATA\nTTTGAAAACCCAATGTACTCAGCCAGAGACAGTGCTGTCAAAGTGGTTCAGCCAATCCAG\nGTGACTGTATCTGAAAATGTGGATAATAAGAATTATGGAAGTCCCATAAACCCTTCTGAG\nATAGTTCCAGAGACAAACCCAACTTCACCAGCTGCTGATGGAACTCAGGTGACAAAATGG\nAATCTCTTCAAACGAAAATCTAAACAAACTACCAACTTTGAAAATCCAATCTATGCACAG\nATGGAGAACGAGCAAAAGGAAAGTGTTGCTGCGACACCACCTCCATCACCTTCGCTCCCT\nGCTAAGCCTAAGCCTCCTTCGAGAAGAGACCCAACTCCAACCTATTCTGCAACAGAAGAC\nACTTTTAAAGACACCGCAAATCTTGTTAAAGAAGACTCTGAAGTATAG'], 'pfams': [{'pfam': [{'identifier': ['PF07645'], 'name': ['EGF_CA']}, {'identifier': ['PF00057'], 'name': ['Ldl_recept_a']}, {'identifier': ['PF00058'], 'name': ['Ldl_recept_b']}, {'identifier': ['PF12662'], 'name': ['cEGF']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['apical plasma membrane']}, {'category': ['component'], 'description': ['brush border membrane']}, {'category': ['component'], 'description': ['coated pit']}, {'category': ['component'], 'description': ['endocytic vesicle']}, {'category': ['component'], 'description': ['endoplasmic reticulum']}, {'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['Golgi apparatus']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['lysosomal membrane']}, {'category': ['component'], 'description': ['lysosome']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['process'], 'description': ['cell proliferation']}, {'category': ['process'], 'description': ['endocytosis']}, {'category': ['process'], 'description': ['forebrain development']}, {'category': ['process'], 'description': ['lipid metabolic process']}, {'category': ['process'], 'description': ['phototransduction, visible light']}, {'category': ['process'], 'description': ['protein glycosylation']}, {'category': ['process'], 'description': ['receptor-mediated endocytosis']}, {'category': ['process'], 'description': ['retinoid metabolic process']}, {'category': ['process'], 'description': ['small molecule metabolic process']}, {'category': ['process'], 'description': ['steroid metabolic process']}, {'category': ['process'], 'description': ['vitamin D metabolic process']}]}]}]}, {'id': ['BE0001656'], 'name': ['Suppressor of tumorigenicity 14 protein'], 'organism': ['Humans'], 'actions': [{'action': ['substrate']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13094'], 'pubmed-id': ['14747469'], 'citation': ['Suzuki M, Kobayashi H, Kanayama N, Saga Y, Suzuki M, Lin CY, Dickson RB, Terao T: Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase. J Biol Chem. 2004 Apr 9;279(15):14899-908. Epub 2004 Jan 27.']}, {'ref-id': ['A13095'], 'pubmed-id': ['12815039'], 'citation': ['Kirchhofer D, Peek M, Li W, Stamos J, Eigenbrot C, Kadkhodayan S, Elliott JM, Corpuz RT, Lazarus RA, Moran P: Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1. J Biol Chem. 2003 Sep 19;278(38):36341-9. Epub 2003 Jun 18.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Suppressor of tumorigenicity 14 protein'], 'general-function': ['Serine-type peptidase activity'], 'specific-function': ['Degrades extracellular matrix. Proposed to play a role in breast cancer invasion and metastasis. Exhibits trypsin-like activity as defined by cleavage of synthetic substrates with Arg or Lys as the P1 site. Involved in the terminal differentiation of keratinocytes through prostasin (PRSS8) activation and filaggrin (FLG) processing.'], 'gene-name': ['ST14'], 'locus': ['11q24-q25'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['56-76'], 'signal-regions': [None], 'theoretical-pi': ['6.53'], 'molecular-weight': ['94769.01'], 'chromosome-location': ['11'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:11344']}, {'resource': ['GenAtlas'], 'identifier': ['ST14']}, {'resource': ['GenBank Gene Database'], 'identifier': ['AF118224']}, {'resource': ['GenBank Protein Database'], 'identifier': ['6647302']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2418']}, {'resource': ['UniProtKB'], 'identifier': ['Q9Y5Y6']}, {'resource': ['UniProt Accession'], 'identifier': ['ST14_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.21.109', 'Matriptase', 'Membrane-type serine protease 1', 'MT-SP1', 'Prostamin', 'PRSS14', 'Serine protease 14', 'Serine protease TADG-15', 'SNC19', 'TADG15', 'Tumor-associated differentially-expressed gene 15 protein']}], 'amino-acid-sequence': ['>lcl|BSEQ0016512|Suppressor of tumorigenicity 14 protein\nMGSDRARKGGGGPKDFGAGLKYNSRHEKVNGLEEGVEFLPVNNVKKVEKHGPGRWVVLAA\nVLIGLLLVLLGIGFLVWHLQYRDVRVQKVFNGYMRITNENFVDAYENSNSTEFVSLASKV\nKDALKLLYSGVPFLGPYHKESAVTAFSEGSVIAYYWSEFSIPQHLVEEAERVMAEERVVM\nLPPRARSLKSFVVTSVVAFPTDSKTVQRTQDNSCSFGLHARGVELMRFTTPGFPDSPYPA\nHARCQWALRGDADSVLSLTFRSFDLASCDERGSDLVTVYNTLSPMEPHALVQLCGTYPPS\nYNLTFHSSQNVLLITLITNTERRHPGFEATFFQLPRMSSCGGRLRKAQGTFNSPYYPGHY\nPPNIDCTWNIEVPNNQHVKVRFKFFYLLEPGVPAGTCPKDYVEINGEKYCGERSQFVVTS\nNSNKITVRFHSDQSYTDTGFLAEYLSYDSSDPCPGQFTCRTGRCIRKELRCDGWADCTDH\nSDELNCSCDAGHQFTCKNKFCKPLFWVCDSVNDCGDNSDEQGCSCPAQTFRCSNGKCLSK\nSQQCNGKDDCGDGSDEASCPKVNVVTCTKHTYRCLNGLCLSKGNPECDGKEDCSDGSDEK\nDCDCGLRSFTRQARVVGGTDADEGEWPWQVSLHALGQGHICGASLISPNWLVSAAHCYID\nDRGFRYSDPTQWTAFLGLHDQSQRSAPGVQERRLKRIISHPFFNDFTFDYDIALLELEKP\nAEYSSMVRPICLPDASHVFPAGKAIWVTGWGHTQYGGTGALILQKGEIRVINQTTCENLL\nPQQITPRMMCVGFLSGGVDSCQGDSGGPLSSVEADGRIFQAGVVSWGDGCAQRNKPGVYT\nRLPLFRDWIKENTGV'], 'gene-sequence': ['>lcl|BSEQ0016513|Suppressor of tumorigenicity 14 protein (ST14)\nATGGGGAGCGATCGGGCCCGCAAGGGCGGAGGGGGCCCGAAGGACTTCGGCGCGGGACTC\nAAGTACAACTCCCGGCACGAGAAAGTGAATGGCTTGGAGGAAGGCGTGGAGTTCCTGCCA\nGTCAACAACGTCAAGAAGGTGGAAAAGCATGGCCCGGGGCGCTGGGTGGTGCTGGCAGCC\nGTGCTGATCGGCCTCCTCTTGGTCTTGCTGGGGATCGGCTTCCTGGTGTGGCATTTGCAG\nTACCGGGACGTGCGTGTCCAGAAGGTCTTCAATGGCTACATGAGGATCACAAATGAGAAT\nTTTGTGGATGCCTACGAGAACTCCAACTCCACTGAGTTTGTAAGCCTGGCCAGCAAGGTG\nAAGGACGCGCTGAAGCTGCTGTACAGCGGAGTCCCATTCCTGGGCCCCTACCACAAGGAG\nTCGGCTGTGACGGCCTTCAGCGAGGGCAGCGTCATCGCCTACTACTGGTCTGAGTTCAGC\nATCCCGCAGCACCTGGTGGAGGAGGCCGAGCGCGTCATGGCCGAGGAGCGCGTAGTCATG\nCTGCCCCCGCGGGCGCGCTCCCTGAAGTCCTTTGTGGTCACCTCAGTGGTGGCTTTCCCC\nACGGACTCCAAAACAGTACAGAGGACCCAGGACAACAGCTGCAGCTTTGGCCTGCACGCC\nCGCGGTGTGGAGCTGATGCGCTTCACCACGCCCGGCTTCCCTGACAGCCCCTACCCCGCT\nCATGCCCGCTGCCAGTGGGCCCTGCGGGGGGACGCCGACTCAGTGCTGAGCCTCACCTTC\nCGCAGCTTTGACCTTGCGTCCTGCGACGAGCGCGGCAGCGACCTGGTGACGGTGTACAAC\nACCCTGAGCCCCATGGAGCCCCACGCCCTGGTGCAGTTGTGTGGCACCTACCCTCCCTCC\nTACAACCTGACCTTCCACTCCTCCCAGAACGTCCTGCTCATCACACTGATAACCAACACT\nGAGCGGCGGCATCCCGGCTTTGAGGCCACCTTCTTCCAGCTGCCTAGGATGAGCAGCTGT\nGGAGGCCGCTTACGTAAAGCCCAGGGGACATTCAACAGCCCCTACTACCCAGGCCACTAC\nCCACCCAACATTGACTGCACATGGAACATTGAGGTGCCCAACAACCAGCATGTGAAGGTG\nCGCTTCAAATTCTTCTACCTGCTGGAGCCCGGCGTGCCTGCGGGCACCTGCCCCAAGGAC\nTACGTGGAGATCAACGGGGAGAAATACTGCGGAGAGAGGTCCCAGTTCGTCGTCACCAGC\nAACAGCAACAAGATCACAGTTCGCTTCCACTCAGATCAGTCCTACACCGACACCGGCTTC\nTTAGCTGAATACCTCTCCTACGACTCCAGTGACCCATGCCCGGGGCAGTTCACGTGCCGC\nACGGGGCGGTGTATCCGGAAGGAGCTGCGCTGTGATGGCTGGGCCGACTGCACCGACCAC\nAGCGATGAGCTCAACTGCAGTTGCGACGCCGGCCACCAGTTCACGTGCAAGAACAAGTTC\nTGCAAGCCCCTCTTCTGGGTCTGCGACAGTGTGAACGACTGCGGAGACAACAGCGACGAG\nCAGGGGTGCAGTTGTCCGGCCCAGACCTTCAGGTGTTCCAATGGGAAGTGCCTCTCGAAA\nAGCCAGCAGTGCAATGGGAAGGACGACTGTGGGGACGGGTCCGACGAGGCCTCCTGCCCC\nAAGGTGAACGTCGTCACTTGTACCAAACACACCTACCGCTGCCTCAATGGGCTCTGCTTG\nAGCAAGGGCAACCCTGAGTGTGACGGGAAGGAGGACTGTAGCGACGGCTCAGATGAGAAG\nGACTGCGACTGTGGGCTGCGGTCATTCACGAGACAGGCTCGTGTTGTTGGGGGCACGGAT\nGCGGATGAGGGCGAGTGGCCCTGGCAGGTAAGCCTGCATGCTCTGGGCCAGGGCCACATC\nTGCGGTGCTTCCCTCATCTCTCCCAACTGGCTGGTCTCTGCCGCACACTGCTACATCGAT\nGACAGAGGATTCAGGTACTCAGACCCCACGCAGTGGACGGCCTTCCTGGGCTTGCACGAC\nCAGAGCCAGCGCAGCGCCCCTGGGGTGCAGGAGCGCAGGCTCAAGCGCATCATCTCCCAC\nCCCTTCTTCAATGACTTCACCTTCGACTATGACATCGCGCTGCTGGAGCTGGAGAAACCG\nGCAGAGTACAGCTCCATGGTGCGGCCCATCTGCCTGCCGGACGCCTCCCATGTCTTCCCT\nGCCGGCAAGGCCATCTGGGTCACGGGCTGGGGACACACCCAGTATGGAGGCACTGGCGCG\nCTGATCCTGCAAAAGGGTGAGATCCGCGTCATCAACCAGACCACCTGCGAGAACCTCCTG\nCCGCAGCAGATCACGCCGCGCATGATGTGCGTGGGCTTCCTCAGCGGCGGCGTGGACTCC\nTGCCAGGGTGATTCCGGGGGACCCCTGTCCAGCGTGGAGGCGGATGGGCGGATCTTCCAG\nGCCGGTGTGGTGAGCTGGGGAGACGGCTGCGCTCAGAGGAACAAGCCAGGCGTGTACACA\nAGGCTCCCTCTGTTTCGGGACTGGATCAAAGAGAACACTGGGGTATAG'], 'pfams': [{'pfam': [{'identifier': ['PF00089'], 'name': ['Trypsin']}, {'identifier': ['PF00057'], 'name': ['Ldl_recept_a']}, {'identifier': ['PF00431'], 'name': ['CUB']}, {'identifier': ['PF01390'], 'name': ['SEA']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['basolateral plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['extrinsic component of plasma membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['serine-type endopeptidase activity']}, {'category': ['function'], 'description': ['serine-type peptidase activity']}, {'category': ['process'], 'description': ['cell morphogenesis']}, {'category': ['process'], 'description': ['epithelial cell morphogenesis involved in placental branching']}, {'category': ['process'], 'description': ['keratinocyte differentiation']}, {'category': ['process'], 'description': ['neural tube closure']}, {'category': ['process'], 'description': ['proteolysis']}]}]}]}, {'id': ['BE0002113'], 'name': ['Nidogen-1'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A13091'], 'pubmed-id': ['1499567'], 'citation': ['Stephens RW, Aumailley M, Timpl R, Reisberg T, Tapiovaara H, Myohanen H, Murphy-Ullrich J, Vaheri A: Urokinase binding to laminin-nidogen. Structural requirements and interactions with heparin. Eur J Biochem. 1992 Aug 1;207(3):937-42.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Nidogen-1'], 'general-function': ['Proteoglycan binding'], 'specific-function': ['Sulfated glycoprotein widely distributed in basement membranes and tightly associated with laminin. Also binds to collagen IV and perlecan. It probably has a role in cell-extracellular matrix interactions.'], 'gene-name': ['NID1'], 'locus': ['1q43'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-28'], 'theoretical-pi': ['4.96'], 'molecular-weight': ['136375.93'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:7821']}, {'resource': ['GenAtlas'], 'identifier': ['NID1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M30269']}, {'resource': ['GenBank Protein Database'], 'identifier': ['189209']}, {'resource': ['UniProtKB'], 'identifier': ['P14543']}, {'resource': ['UniProt Accession'], 'identifier': ['NID1_HUMAN']}]}], 'synonyms': [{'synonym': ['Entactin', 'NID', 'NID-1']}], 'amino-acid-sequence': ['>lcl|BSEQ0037160|Nidogen-1\nMLASSSRIRAAWTRALLLPLLLAGPVGCLSRQELFPFGPGQGDLELEDGDDFVSPALELS\nGALRFYDRSDIDAVYVTTNGIIATSEPPAKESHPGLFPPTFGAVAPFLADLDTTDGLGKV\nYYREDLSPSITQRAAECVHRGFPEISFQPSSAVVVTWESVAPYQGPSRDPDQKGKRNTFQ\nAVLASSDSSSYAIFLYPEDGLQFHTTFSKKENNQVPAVVAFSQGSVGFLWKSNGAYNIFA\nNDRESVENLAKSSNSGQQGVWVFEIGSPATTNGVVPADVILGTEDGAEYDDEDEDYDLAT\nTRLGLEDVGTTPFSYKALRRGGADTYSVPSVLSPRRAATERPLGPPTERTRSFQLAVETF\nHQQHPQVIDVDEVEETGVVFSYNTDSRQTCANNRHQCSVHAECRDYATGFCCSCVAGYTG\nNGRQCVAEGSPQRVNGKVKGRIFVGSSQVPIVFENTDLHSYVVMNHGRSYTAISTIPETV\nGYSLLPLAPVGGIIGWMFAVEQDGFKNGFSITGGEFTRQAEVTFVGHPGNLVIKQRFSGI\nDEHGHLTIDTELEGRVPQIPFGSSVHIEPYTELYHYSTSVITSSSTREYTVTEPERDGAS\nPSRIYTYQWRQTITFQECVHDDSRPALPSTQQLSVDSVFVLYNQEEKILRYALSNSIGPV\nREGSPDALQNPCYIGTHGCDTNAACRPGPRTQFTCECSIGFRGDGRTCYDIDECSEQPSV\nCGSHTICNNHPGTFRCECVEGYQFSDEGTCVAVVDQRPINYCETGLHNCDIPQRAQCIYT\nGGSSYTCSCLPGFSGDGQACQDVDECQPSRCHPDAFCYNTPGSFTCQCKPGYQGDGFRCV\nPGEVEKTRCQHEREHILGAAGATDPQRPIPPGLFVPECDAHGHYAPTQCHGSTGYCWCVD\nRDGREVEGTRTRPGMTPPCLSTVAPPIHQGPAVPTAVIPLPPGTHLLFAQTGKIERLPLE\nGNTMRKTEAKAFLHVPAKVIIGLAFDCVDKMVYWTDITEPSIGRASLHGGEPTTIIRQDL\nGSPEGIAVDHLGRNIFWTDSNLDRIEVAKLDGTQRRVLFETDLVNPRGIVTDSVRGNLYW\nTDWNRDNPKIETSYMDGTNRRILVQDDLGLPNGLTFDAFSSQLCWVDAGTNRAECLNPSQ\nPSRRKALEGLQYPFAVTSYGKNLYFTDWKMNSVVALDLAISKETDAFQPHKQTRLYGITT\nALSQCPQGHNYCSVNNGGCTHLCLATPGSRTCRCPDNTLGVDCIEQK'], 'gene-sequence': ['>lcl|BSEQ0016685|Nidogen-1 (NID1)\nATGTTGGCCTCGAGCAGCCGGATCCGGGCTGCGTGGACGCGGGCGCTGCTGCTGCCGCTG\nCTGCTGGCGGGGCCTGTGGGCTGCCTGAGCCGCCAGGAGCTCTTTCCCTTCGGCCCCGGA\nCAGGGGGACCTGGAGCTGGAGGACGGGGATGACTTCGTCTCTCCTGCCCTGGAGCTGAGT\nGGGGCGCTCCGCTTCTACGACAGATCCGACATCGACGCAGTCTACGTCACCACAAATGGC\nATCATTGCTACGAGTGAACCCCCGGCCAAAGAATCCCATCCCGGGCTCTTCCCACCAACA\nTTCGGTGCAGTCGCCCCTTTCCTGGCGGACTTGGACACGACCGATGGCCTGGGGAAGGTT\nTATTATCGAGAAGACTTATCCCCCTCCATCACTCAGCGAGCAGCAGAGTGTGTCCACAGA\nGGGTTCCCGGAGATCTCTTTCCAGCCTAGTAGCGCGGTGGTTGTCACTTGGGAATCCGTG\nGCCCCCTACCAAGGGCCCAGCAGGGACCCAGACCAGAAAGGCAAGAGAAACACGTTCCAG\nGCTGTTCTAGCCTCCTCTGATTCCAGCTCCTATGCCATTTTCCTTTATCCTGAGGATGGT\nCTGCAGTTCCATACGACATTCTCAAAGAAGGAAAACAACCAAGTTCCTGCCGTGGTTGCA\nTTCAGTCAAGGTTCAGTGGGATTCTTATGGAAGAGCAACGGAGCTTATAACATATTTGCT\nAATGACAGGGAATCAGTTGAAAATTTGGCCAAGAGTAGTAACTCTGGGCAGCAGGGTGTC\nTGGGTGTTTGAGATTGGGAGTCCAGCCACCACCAATGGCGTGGTGCCTGCAGACGTGATC\nCTCGGAACTGAAGATGGGGCAGAGTATGATGATGAGGATGAAGATTATGACCTGGCGACC\nACTCGTCTGGGCCTGGAGGATGTGGGCACCACGCCCTTCTCCTACAAGGCTCTGAGAAGG\nGGAGGTGCTGACACATACAGTGTGCCCAGCGTCCTCTCCCCGCGCCGGGCAGCTACCGAA\nAGGCCCCTTGGACCTCCCACAGAGAGAACCAGGTCTTTCCAGTTGGCAGTGGAGACTTTT\nCACCAGCAGCACCCTCAGGTCATAGATGTGGATGAAGTTGAGGAAACAGGAGTTGTTTTC\nAGCTATAACACGGATTCCCGCCAGACGTGTGCTAACAACAGACACCAGTGCTCGGTGCAC\nGCAGAGTGCAGGGACTACGCCACGGGCTTCTGCTGCAGCTGTGTCGCTGGCTATACGGGC\nAATGGCAGGCAATGTGTTGCAGAAGGTTCCCCCCAGCGAGTCAATGGCAAGGTGAAAGGA\nAGGATCTTTGTGGGGAGCAGCCAGGTCCCCATTGTCTTTGAGAACACTGACCTCCACTCT\nTACGTAGTAATGAACCACGGGCGCTCCTACACAGCCATCAGCACCATTCCCGAGACCGTT\nGGATATTCTCTGCTTCCACTGGCCCCAGTTGGAGGCATCATTGGATGGATGTTTGCAGTG\nGAGCAGGACGGATTCAAGAATGGGTTCAGCATCACCGGGGGTGAGTTCACTCGCCAGGCT\nGAGGTGACCTTCGTGGGGCACCCGGGCAATCTGGTCATTAAGCAGCGGTTCAGCGGCATC\nGATGAGCATGGGCACCTGACCATCGACACGGAGCTGGAGGGCCGCGTGCCGCAGATTCCG\nTTCGGCTCCTCCGTGCACATTGAGCCCTACACGGAGCTGTACCACTACTCCACCTCAGTG\nATCACTTCCTCCTCCACCCGGGAGTACACGGTGACTGAGCCCGAGCGAGATGGGGCATCT\nCCTTCACGCATCTACACTTACCAGTGGCGCCAGACCATCACCTTCCAGGAATGCGTCCAC\nGATGACTCCCGGCCAGCCCTGCCCAGCACCCAGCAGCTCTCGGTGGACAGCGTGTTCGTC\nCTGTACAACCAGGAGGAGAAGATCTTGCGCTATGCTCTCAGCAACTCCATTGGGCCTGTG\nAGGGAAGGCTCCCCTGATGCTCTTCAGAATCCCTGCTACATCGGCACTCATGGGTGTGAC\nACCAACGCGGCCTGTCGCCCTGGTCCCAGGACACAGTTCACCTGCGAGTGCTCCATCGGC\nTTCCGAGGAGACGGGCGAACCTGCTATGATATTGATGAATGTTCAGAACAACCCTCAGTG\nTGTGGGAGCCACACAATCTGCAATAATCACCCAGGAACCTTCCGCTGCGAGTGTGTGGAG\nGGCTACCAGTTTTCAGATGAGGGAACGTGTGTGGCTGTCGTGGACCAGCGCCCCATCAAC\nTACTGTGAAACTGGCCTTCATAACTGCGACATACCCCAGCGGGCCCAGTGTATCTACACA\nGGAGGCTCCTCCTACACCTGTTCCTGCTTGCCAGGCTTTTCTGGGGATGGCCAAGCCTGC\nCAAGATGTAGATGAATGCCAGCCAAGCCGATGTCACCCTGACGCCTTCTGCTACAACACT\nCCAGGCTCTTTCACGTGCCAGTGCAAACCTGGTTATCAGGGAGACGGCTTCCGTTGCGTG\nCCCGGAGAGGTGGAGAAAACCCGGTGCCAGCACGAGCGAGAACACATTCTCGGGGCAGCG\nGGGGCGACAGACCCACAGCGACCCATTCCTCCGGGGCTGTTCGTTCCTGAGTGCGATGCG\nCACGGGCACTACGCGCCCACCCAGTGCCACGGCAGCACCGGCTACTGCTGGTGCGTGGAT\nCGCGACGGCCGCGAGGTGGAGGGCACCAGGACCAGGCCCGGGATGACGCCCCCGTGTCTG\nAGTACAGTGGCTCCCCCGATTCACCAAGGACCTGCGGTGCCTACCGCCGTGATCCCCTTG\nCCTCCTGGGACCCATTTACTCTTTGCCCAGACTGGGAAGATTGAGCGCCTGCCCCTGGAG\nGGAAATACCATGAGGAAGACAGAAGCAAAGGCGTTCCTTCATGTCCCGGCTAAAGTCATC\nATTGGACTGGCCTTTGACTGCGTGGACAAGATGGTTTACTGGACGGACATCACTGAGCCT\nTCCATTGGGAGAGCTAGTCTACATGGTGGAGAGCCAACCACCATCATTAGACAAGATCTT\nGGAAGTCCAGAAGGTATCGCTGTTGATCACCTTGGCCGCAACATCTTCTGGACAGACTCT\nAACCTGGATCGAATAGAAGTGGCGAAGCTGGACGGCACGCAGCGCCGGGTGCTCTTTGAG\nACTGACTTGGTGAATCCCAGAGGCATTGTAACGGATTCCGTGAGAGGGAACCTTTACTGG\nACAGACTGGAACAGAGATAACCCCAAGATTGAAACTTCCTACATGGACGGCACGAACCGG\nAGGATCCTTGTGCAGGATGACCTGGGCTTGCCCAATGGACTGACCTTCGATGCGTTCTCA\nTCTCAGCTCTGCTGGGTGGATGCAGGCACCAATCGGGCGGAATGCCTGAACCCCAGTCAG\nCCCAGCAGACGCAAGGCTCTCGAAGGGCTCCAGTATCCTTTTGCTGTGACGAGCTACGGG\nAAGAATCTGTATTTCACAGACTGGAAGATGAATTCCGTGGTTGCTCTCGATCTTGCAATT\nTCCAAGGAGACGGATGCTTTCCAACCCCACAAGCAGACCCGGCTGTATGGCATCACCACG\nGCCCTGTCTCAGTGTCCGCAAGGCCATAACTACTGCTCAGTGAACAATGGCGGCTGCACC\nCACCTATGCTTGGCCACCCCAGGGAGCAGGACCTGCCGTTGCCCTGACAACACCTTGGGA\nGTTGACTGTATCGAACAGAAATGA'], 'pfams': [{'pfam': [{'identifier': ['PF07645'], 'name': ['EGF_CA']}, {'identifier': ['PF00058'], 'name': ['Ldl_recept_b']}, {'identifier': ['PF00086'], 'name': ['Thyroglobulin_1']}, {'identifier': ['PF06119'], 'name': ['NIDO']}, {'identifier': ['PF07474'], 'name': ['G2F']}, {'identifier': ['PF12662'], 'name': ['cEGF']}, {'identifier': ['PF12947'], 'name': ['EGF_3']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['basal lamina']}, {'category': ['component'], 'description': ['basement membrane']}, {'category': ['component'], 'description': ['cell periphery']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular matrix']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['collagen binding']}, {'category': ['function'], 'description': ['laminin binding']}, {'category': ['function'], 'description': ['proteoglycan binding']}, {'category': ['process'], 'description': ['basement membrane organization']}, {'category': ['process'], 'description': ['cell-matrix adhesion']}, {'category': ['process'], 'description': ['extracellular matrix disassembly']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['glomerular basement membrane development']}, {'category': ['process'], 'description': ['positive regulation of cell-substrate adhesion']}]}]}]}]}]"
"['DB00014', 'BTD00113', 'BIOD00113']",['Goserelin'],small molecule,"['Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.']",['solid'],['Goserelin is indicated for:\r\n\r\n- Use in combination with flutamide for the management of locally confined carcinoma of the prostate\r\n- Palliative treatment of advanced carcinoma of the prostate\r\n- The management of endometriosis\r\n- Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding\r\n- Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women'],['Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.'],[None],"[{'target': [{'id': ['BE0000134'], 'name': ['Lutropin-choriogonadotropic hormone receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A1784'], 'pubmed-id': ['20053189'], 'citation': ['Kirby RS, Fitzpatrick JM, Clarke N: Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104(11):1580-4. doi: 10.1111/j.1464-410X.2009.08924.x.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Lutropin-choriogonadotropic hormone receptor'], 'general-function': ['Luteinizing hormone receptor activity'], 'specific-function': ['Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase.'], 'gene-name': ['LHCGR'], 'locus': ['2p21'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['364-385\n396-416\n440-462\n483-505\n526-549\n571-594\n606-627'], 'signal-regions': ['1-26'], 'theoretical-pi': ['8.58'], 'molecular-weight': ['78642.01'], 'chromosome-location': ['2'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6585']}, {'resource': ['GenAtlas'], 'identifier': ['LHCGR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M73746']}, {'resource': ['GenBank Protein Database'], 'identifier': ['903746']}, {'resource': ['IUPHAR'], 'identifier': ['254']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['254']}, {'resource': ['UniProtKB'], 'identifier': ['P22888']}, {'resource': ['UniProt Accession'], 'identifier': ['LSHR_HUMAN']}]}], 'synonyms': [{'synonym': ['LCGR', 'LGR2', 'LH/CG-R', 'LHR', 'LHRHR', 'LSH-R', 'Luteinizing hormone receptor']}], 'amino-acid-sequence': ['>lcl|BSEQ0036957|Lutropin-choriogonadotropic hormone receptor\nMKQRFSALQLLKLLLLLQPPLPRALREALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLP\nVKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFI\nNLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLK\nLYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSY\nGLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENF\nSKQCESTVRKVNNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYD\nFLRVLIWLINILAIMGNMTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIASVDS\nQTKGQYYNHAIDWQTGSGCSTAGFFTVFASELSVYTLTVITLERWHTITYAIHLDQKLRL\nRHAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETTLSQVYILTILILNVVAFF\nIICACYIKIYFAVRNPELMATNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKVPLIT\nVTNSKVLLVLFYPINSCANPFLYAIFTKTFQRDFFLLLSKFGCCKRRAELYRRKDFSAYT\nSNCKNGFTGSNKPSQSTLKLSTLHCQGTALLDKTRYTEC'], 'gene-sequence': ['>lcl|BSEQ0010174|Lutropin-choriogonadotropic hormone receptor (LHCGR)\nATGAAGCAGCGGTTCTCGGCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGCCGCCG\nCTGCCACGAGCGCTGCGCGAGGCGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGC\nGCCCTGCGCTGCCCCGGCCCCACGGCCGGTCTCACTCGACTATCACTTGCCTACCTCCCT\nGTCAAAGTGATCCCATCTCAAGCTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATC\nTCTCAGATTGATTCCCTGGAAAGGATAGAAGCTAATGCCTTTGACAACCTCCTCAATTTG\nTCTGAAATACTGATCCAGAACACCAAAAATCTGAGATACATTGAGCCCGGAGCATTTATA\nAATCTTCCCCGATTAAAATACTTGAGCATCTGTAACACAGGCATCAGAAAGTTTCCAGAT\nGTTACGAAGGTCTTCTCCTCTGAATCAAATTTCATTCTGGAAATTTGTGATAACTTACAC\nATAACCACCATACCAGGAAATGCTTTTCAAGGGATGAATAATGAATCTGTAACACTCAAA\nCTATATGGAAATGGATTTGAAGAAGTACAAAGTCATGCATTCAATGGGACGACACTGACT\nTCACTGGAGCTAAAGGAAAACGTACATCTGGAGAAGATGCACAATGGAGCCTTCCGTGGG\nGCCACAGGGCCGAAAACCTTGGATATTTCTTCCACCAAATTGCAGGCCCTGCCGAGCTAT\nGGCCTAGAGTCCATTCAGAGGCTAATTGCCACGTCATCCTATTCTCTAAAAAAATTGCCA\nTCAAGAGAAACATTTGTCAATCTCCTGGAGGCCACGTTGACTTACCCCAGCCACTGCTGT\nGCTTTTAGAAACTTGCCAACAAAAGAACAGAATTTTTCACATTCCATTTCTGAAAACTTT\nTCCAAACAATGTGAAAGCACAGTAAGGAAAGTGAATAACAAAACACTTTATTCTTCCATG\nCTTGCTGAGAGTGAACTGAGTGGCTGGGACTATGAATATGGTTTCTGCTTACCCAAGACA\nCCCCGATGTGCTCCTGAACCAGATGCTTTTAATCCCTGTGAAGATATTATGGGCTATGAC\nTTCCTTAGGGTCCTGATTTGGCTGATTAATATTCTAGCCATCATGGGAAACATGACTGTT\nCTTTTTGTTCTCCTGACAAGTCGTTACAAACTTACAGTGCCTCGTTTTCTCATGTGCAAT\nCTCTCCTTTGCAGACTTTTGCATGGGGCTCTATCTGCTGCTCATAGCCTCAGTTGATTCC\nCAAACCAAGGGCCAGTACTATAACCATGCCATAGACTGGCAGACAGGGAGTGGGTGCAGC\nACTGCTGGCTTTTTCACTGTATTCGCAAGTGAACTTTCTGTCTACACCCTCACCGTCATC\nACTCTAGAAAGATGGCACACCATCACCTATGCTATTCACCTGGACCAAAAGCTGCGATTA\nAGACATGCCATTCTGATTATGCTTGGAGGATGGCTCTTTTCTTCTCTAATTGCTATGTTG\nCCCCTTGTCGGTGTCAGCAATTACATGAAGGTCAGTATTTGCTTCCCCATGGATGTGGAA\nACCACTCTCTCACAAGTCTATATATTAACCATCCTGATTCTCAATGTGGTGGCCTTCTTC\nATAATTTGTGCTTGCTACATTAAAATTTATTTTGCAGTTCGAAACCCAGAATTAATGGCT\nACCAATAAAGATACAAAGATTGCTAAGAAAATGGCAATCCTCATCTTCACCGATTTCACC\nTGCATGGCACCTATCTCTTTTTTTGCCATCTCAGCTGCCTTCAAAGTACCTCTTATCACA\nGTAACCAACTCTAAAGTTTTACTGGTTCTTTTTTATCCCATCAATTCTTGTGCCAATCCA\nTTTCTGTATGCAATATTCACTAAGACATTCCAAAGAGATTTCTTTCTTTTGCTGAGCAAA\nTTTGGCTGCTGTAAACGTCGGGCTGAACTTTATAGAAGGAAAGATTTTTCAGCTTACACC\nTCCAACTGCAAAAATGGCTTCACTGGATCAAATAAGCCTTCTCAATCCACCTTGAAGTTG\nTCCACATTGCACTGTCAAGGTACAGCTCTCCTAGACAAGACTCGCTACACAGAGTGTTAA\n'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}, {'identifier': ['PF13306'], 'name': ['LRR_5']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['choriogonadotropin hormone binding']}, {'category': ['function'], 'description': ['choriogonadotropin hormone receptor activity']}, {'category': ['function'], 'description': ['G-protein coupled peptide receptor activity']}, {'category': ['function'], 'description': ['luteinizing hormone receptor activity']}, {'category': ['process'], 'description': ['activation of adenylate cyclase activity']}, {'category': ['process'], 'description': ['adenylate cyclase-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular response to gonadotropin stimulus']}, {'category': ['process'], 'description': ['cognition']}, {'category': ['process'], 'description': ['female gonad development']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger']}, {'category': ['process'], 'description': ['hormone-mediated signaling pathway']}, {'category': ['process'], 'description': ['luteinizing hormone signaling pathway']}, {'category': ['process'], 'description': ['male genitalia development']}, {'category': ['process'], 'description': ['male gonad development']}, {'category': ['process'], 'description': ['ovulation cycle process']}, {'category': ['process'], 'description': ['phospholipase C-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of cAMP-mediated signaling']}, {'category': ['process'], 'description': ['positive regulation of inositol trisphosphate biosynthetic process']}, {'category': ['process'], 'description': ['spermatogenesis']}, {'category': ['process'], 'description': ['uterus development']}]}]}]}, {'id': ['BE0000203'], 'name': ['Gonadotropin-releasing hormone receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1784'], 'pubmed-id': ['20053189'], 'citation': ['Kirby RS, Fitzpatrick JM, Clarke N: Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104(11):1580-4. doi: 10.1111/j.1464-410X.2009.08924.x.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Gonadotropin-releasing hormone receptor'], 'general-function': ['Peptide binding'], 'specific-function': ['Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This receptor mediates its action by association with G-proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act as an inhibitor of GnRH-R signaling.'], 'gene-name': ['GNRHR'], 'locus': ['4q21.2'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['39-58\n78-97\n116-137\n165-184\n213-232\n282-300\n307-326'], 'signal-regions': [None], 'theoretical-pi': ['9.93'], 'molecular-weight': ['37730.355'], 'chromosome-location': ['4'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:4421']}, {'resource': ['GenAtlas'], 'identifier': ['GNRHR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L03380']}, {'resource': ['GenBank Protein Database'], 'identifier': ['183422']}, {'resource': ['IUPHAR'], 'identifier': ['256']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['256']}, {'resource': ['UniProtKB'], 'identifier': ['P30968']}, {'resource': ['UniProt Accession'], 'identifier': ['GNRHR_HUMAN']}]}], 'synonyms': [{'synonym': ['GnRH receptor', 'GRHR']}], 'amino-acid-sequence': ['>lcl|BSEQ0000405|Gonadotropin-releasing hormone receptor\nMANSASPEQNQNHCSAINNSIPLMQGNLPTLTLSGKIRVTVTFFLFLLSATFNASFLLKL\nQKWTQKKEKGKKLSRMKLLLKHLTLANLLETLIVMPLDGMWNITVQWYAGELLCKVLSYL\nKLFSMYAPAFMMVVISLDRSLAITRPLALKSNSKVGQSMVGLAWILSSVFAGPQLYIFRM\nIHLADSSGQTKVFSQCVTHCSFSQWWHQAFYNFFTFSCLFIIPLFIMLICNAKIIFTLTR\nVLHQDPHELQLNQSKNNIPRARLKTLKMTVAFATSFTVCWTPYYVLGIWYWFDPEMLNRL\nSDPVNHFFFLFAFLNPCFDPLIYGYFSL'], 'gene-sequence': ['>lcl|BSEQ0018926|Gonadotropin-releasing hormone receptor (GNRHR)\nATGGCAAACAGTGCCTCTCCTGAACAGAATCAAAATCACTGTTCAGCCATCAACAACAGC\nATCCCACTGATGCAGGGCAACCTCCCCACTCTGACCTTGTCTGGAAAGATCCGAGTGACG\nGTTACTTTCTTCCTTTTTCTGCTCTCTGCGACCTTTAATGCTTCTTTCTTGTTGAAACTT\nCAGAAGTGGACACAGAAGAAAGAGAAAGGGAAAAAGCTCTCAAGAATGAAGCTGCTCTTA\nAAACATCTGACCTTAGCCAACCTGTTGGAGACTCTGATTGTCATGCCACTGGATGGGATG\nTGGAACATTACAGTCCAATGGTATGCTGGAGAGTTACTCTGCAAAGTTCTCAGTTATCTA\nAAGCTTTTCTCCATGTATGCCCCAGCCTTCATGATGGTGGTGATCAGCCTGGACCGCTCC\nCTGGCTATCACGAGGCCCCTAGCTTTGAAAAGCAACAGCAAAGTCGGACAGTCCATGGTT\nGGCCTGGCCTGGATCCTCAGTAGTGTCTTTGCAGGACCACAGTTATACATCTTCAGGATG\nATTCATCTAGCAGACAGCTCTGGACAGACAAAAGTTTTCTCTCAATGTGTAACACACTGC\nAGTTTTTCACAATGGTGGCATCAAGCATTTTATAACTTTTTCACCTTCAGCTGCCTCTTC\nATCATCCCTCTTTTCATCATGCTGATCTGCAATGCAAAAATCATCTTCACCCTGACACGG\nGTCCTTCATCAGGACCCCCACGAACTACAACTGAATCAGTCCAAGAACAATATACCAAGA\nGCACGGCTGAAGACTCTAAAAATGACGGTTGCATTTGCCACTTCATTTACTGTCTGCTGG\nACTCCCTACTATGTCCTAGGAATTTGGTATTGGTTTGATCCTGAAATGTTAAACAGGTTG\nTCAGACCCAGTAAATCACTTCTTCTTTCTCTTTGCCTTTTTAAACCCATGCTTTGATCCA\nCTTATCTATGGATATTTTTCTCTGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['gonadotropin-releasing hormone receptor activity']}, {'category': ['function'], 'description': ['peptide binding']}, {'category': ['process'], 'description': ['cellular response to gonadotropin-releasing hormone']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['multicellular organismal development']}]}]}]}]}]"
"['DB00015', 'BTD00013', 'BIOD00013']",['Reteplase'],biotech,"['Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a ""third-generation"" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).']",['liquid'],"['For lysis of acute pulmonary emboli, intracoronary emboli, and management of myocardial infarction.']","['Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. ']","[{'food-interaction': ['Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.']}]","[{'target': [{'id': ['BE0000211'], 'name': ['Plasminogen'], 'organism': ['Humans'], 'actions': [{'action': ['activator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A6691'], 'pubmed-id': ['17963464'], 'citation': ['Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.']}, {'ref-id': ['A6689'], 'pubmed-id': ['18673235'], 'citation': ['Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.']}, {'ref-id': ['A6690'], 'pubmed-id': ['19436656'], 'citation': ['Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Plasminogen'], 'general-function': ['Serine-type peptidase activity'], 'specific-function': ['Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.'], 'gene-name': ['PLG'], 'locus': ['6q26'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-19'], 'theoretical-pi': ['7.25'], 'molecular-weight': ['90568.415'], 'chromosome-location': ['6'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:9071']}, {'resource': ['GenAtlas'], 'identifier': ['PLG']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X05199']}, {'resource': ['GenBank Protein Database'], 'identifier': ['387026']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2394']}, {'resource': ['UniProtKB'], 'identifier': ['P00747']}, {'resource': ['UniProt Accession'], 'identifier': ['PLMN_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.21.7']}], 'amino-acid-sequence': ['>lcl|BSEQ0016037|Plasminogen\nMEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT\nCRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN\nGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE\nCEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE\nLRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS\nAQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE\nQLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG\nLTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED\nCMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG\nPWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT\nRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE\nPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ\nLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW\nGLGCARPNKPGVYVRVSRFVTWIEGVMRNN'], 'gene-sequence': ['>lcl|BSEQ0016038|Plasminogen (PLG)\nATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG\nCCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG\nCTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC\nTGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG\nAAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC\nTCAGAGTGCAAGACTGGGAATGGAAAGAACTACAGAGGGACGATGTCCAAAACAAAAAAT\nGGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT\nACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG\nGGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG\nTGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC\nATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT\nCCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG\nCTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGTGACATCCCC\nCGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT\nGAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT\nGCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTCCCCTGCAAAAATTTGGAT\nGAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC\nCAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA\nCAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT\nGATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT\nTGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC\nCTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA\nGACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT\nGTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAGATGTAGAGACTCCTTCCGAAGAAGAC\nTGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG\nCCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA\nAATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT\nCCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT\nGCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG\nGTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA\nAGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT\nGCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC\nCAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG\nCCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA\nGTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC\nATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG\nCTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA\nTCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT\nGGAGGTCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG\nGGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT\nACTTGGATTGAGGGAGTGATGAGAAATAATTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00051'], 'name': ['Kringle']}, {'identifier': ['PF00089'], 'name': ['Trypsin']}, {'identifier': ['PF00024'], 'name': ['PAN_1']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['extrinsic component of external side of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['function'], 'description': ['apolipoprotein binding']}, {'category': ['function'], 'description': ['protein domain specific binding']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase activity']}, {'category': ['function'], 'description': ['serine-type peptidase activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['extracellular matrix disassembly']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['negative regulation of cell proliferation']}, {'category': ['process'], 'description': ['negative regulation of cell-cell adhesion mediated by cadherin']}, {'category': ['process'], 'description': ['negative regulation of cell-substrate adhesion']}, {'category': ['process'], 'description': ['negative regulation of fibrinolysis']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of fibrinolysis']}, {'category': ['process'], 'description': ['proteolysis']}, {'category': ['process'], 'description': ['tissue remodeling']}]}]}]}, {'id': ['BE0000538'], 'name': ['Fibrinogen alpha chain'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A6689'], 'pubmed-id': ['18673235'], 'citation': ['Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.']}, {'ref-id': ['A6690'], 'pubmed-id': ['19436656'], 'citation': ['Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8.']}, {'ref-id': ['A6691'], 'pubmed-id': ['17963464'], 'citation': ['Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Fibrinogen alpha chain'], 'general-function': ['Structural molecule activity'], 'specific-function': ['Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the immune response via both innate and T-cell mediated pathways.'], 'gene-name': ['FGA'], 'locus': ['4q28'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-19'], 'theoretical-pi': ['5.87'], 'molecular-weight': ['94972.455'], 'chromosome-location': ['4'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3661']}, {'resource': ['GenAtlas'], 'identifier': ['FGA']}, {'resource': ['GenBank Gene Database'], 'identifier': ['AF361104']}, {'resource': ['GenBank Protein Database'], 'identifier': ['13591824']}, {'resource': ['UniProtKB'], 'identifier': ['P02671']}, {'resource': ['UniProt Accession'], 'identifier': ['FIBA_HUMAN']}]}], 'synonyms': [{'synonym': ['Fibrinogen alpha chain precursor']}], 'amino-acid-sequence': ['>lcl|BSEQ0001074|Fibrinogen alpha chain\nMFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW\nNYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA\nNNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC\nRGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQ\nLQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSS\nGPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTW\nNPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV\nSPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTK\nEVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEF\nVSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKS\nYKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFS\nVYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQR\nGSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSH\nNNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENG\nVVWVSFRGADYSLRAVRMKIRPLVTQ'], 'gene-sequence': ['>lcl|BSEQ0021267|Fibrinogen alpha chain (FGA)\nATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCA\nGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTG\nGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGG\nAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGAT\nTTTACAAACAGAATAAATAAGCTCAAAAATTCACTATTTGAATATCAGAAGAACAATAAG\nGATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCCTCAGCC\nAATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTGAAGTC\nCTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAGAAAAATGTTAGA\nGCTCAGTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGT\nCGAGGGTCATGCAGTAGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAG\nCAGAAGCAACTTGAACAGGTCATTGCCAAAGACTTACTTCCCTCTAGAGATAGGCAACAC\nTTACCACTGATAAAAATGAAACCAGTTCCAGACTTGGTTCCCGGAAATTTTAAGAGCCAG\nCTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCGCAGATGAGAATGGAG\nTTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAACCGGA\nTCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCT\nGGACCTGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACC\nTGGAAACCTGGGAGCTCTGGACCTGGAAGTACTGGAAGCTGGAACTCTGGGAGCTCTGGA\nACTGGAAGTACTGGAAACCAAAACCCTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGG\nAATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCACTGGACCTCTGAGAGCTCTGTATCT\nGGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCAGATAGCCCAGGCTCT\nGGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAAATGTA\nAGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAA\nGAGCTCAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCA\nTGCTCTAAAACCGTTACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAA\nGAAGTGGTGACCTCCGAAGATGGTTCTGACTGTCCCGAGGCAATGGATTTAGGCACATTG\nTCTGGCATAGGTACTCTGGATGGGTTCCGCCATAGGCACCCTGATGAAGCTGCCTTCTTC\nGACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCTATGTTAGGAGAGTTT\nGTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGGAATCC\nAGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGC\nAAACAATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGC\nTATAAAATGGCAGATGAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAG\nAGAGGCCATGCTAAATCTCGCCCTGTCAGAGACTGTGATGATGTCCTCCAAACACATCCT\nTCAGGTACCCAAAGTGGCATTTTCAATATCAAGCTACCGGGATCCAGTAAGATTTTTTCT\nGTTTATTGCGATCAAGAGACCAGTTTGGGAGGATGGCTTTTGATCCAGCAAAGAATGGAT\nGGATCACTGAATTTTAACCGGACCTGGCAAGACTACAAGAGAGGTTTCGGCAGCCTGAAT\nGACGAGGGGGAAGGAGAATTCTGGCTAGGCAATGACTACCTCCACTTACTAACCCAAAGG\nGGCTCTGTTCTTAGGGTTGAATTAGAGGACTGGGCTGGGAATGAAGCTTATGCAGAATAT\nCACTTCCGGGTAGGCTCTGAGGCTGAAGGCTATGCCCTCCAAGTCTCCTCCTATGAAGGC\nACTGCGGGTGATGCTCTGATTGAGGGTTCCGTAGAGGAAGGGGCAGAGTACACCTCTCAC\nAACAACATGCAGTTCAGCACCTTTGACAGGGATGCAGACCAGTGGGAAGAGAACTGTGCA\nGAAGTCTATGGGGGAGGCTGGTGGTATAATAACTGCCAAGCAGCCAATCTCAATGGAATC\nTACTACCCTGGGGGCTCCTATGACCCAAGGAATAACAGTCCTTATGAGATTGAGAATGGA\nGTGGTCTGGGTTTCCTTTAGAGGGGCAGATTATTCCCTCAGGGCTGTTCGCATGAAAATT\nAGGCCCCTTGTGACCCAATAG'], 'pfams': [{'pfam': [{'identifier': ['PF00147'], 'name': ['Fibrinogen_C']}, {'identifier': ['PF08702'], 'name': ['Fib_alpha']}, {'identifier': ['PF12160'], 'name': ['Fibrinogen_aC']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['cell cortex']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['extracellular vesicle']}, {'category': ['component'], 'description': ['fibrinogen complex']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['component'], 'description': ['rough endoplasmic reticulum']}, {'category': ['function'], 'description': ['structural molecule activity']}, {'category': ['process'], 'description': ['acute-phase response']}, {'category': ['process'], 'description': ['adaptive immune response']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, common pathway']}, {'category': ['process'], 'description': ['blood coagulation, fibrin clot formation']}, {'category': ['process'], 'description': ['cell-matrix adhesion']}, {'category': ['process'], 'description': ['cellular protein complex assembly']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['cellular response to granulocyte colony-stimulating factor']}, {'category': ['process'], 'description': ['cellular response to interleukin-6']}, {'category': ['process'], 'description': ['cellular response to organic cyclic compound']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['induction of bacterial agglutination']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['liver regeneration']}, {'category': ['process'], 'description': ['negative regulation of blood coagulation, common pathway']}, {'category': ['process'], 'description': ['negative regulation of endothelial cell apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of extrinsic apoptotic signaling pathway via death domain receptors']}, {'category': ['process'], 'description': ['plasminogen activation']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet aggregation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['positive regulation of exocytosis']}, {'category': ['process'], 'description': ['positive regulation of heterotypic cell-cell adhesion']}, {'category': ['process'], 'description': ['positive regulation of peptide hormone secretion']}, {'category': ['process'], 'description': ['positive regulation of protein secretion']}, {'category': ['process'], 'description': ['positive regulation of substrate adhesion-dependent cell spreading']}, {'category': ['process'], 'description': ['positive regulation of vasoconstriction']}, {'category': ['process'], 'description': ['protein complex assembly']}, {'category': ['process'], 'description': ['protein polymerization']}, {'category': ['process'], 'description': ['response to calcium ion']}, {'category': ['process'], 'description': ['response to cycloheximide']}, {'category': ['process'], 'description': ['response to estradiol']}, {'category': ['process'], 'description': ['response to genistein']}, {'category': ['process'], 'description': ['response to morphine']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}, {'id': ['BE0000240'], 'name': ['Plasminogen activator inhibitor 1'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A6691'], 'pubmed-id': ['17963464'], 'citation': ['Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Plasminogen activator inhibitor 1'], 'general-function': ['Serine-type endopeptidase inhibitor activity'], 'specific-function': [""Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis.""], 'gene-name': ['SERPINE1'], 'locus': ['7q21.3-q22'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-23'], 'theoretical-pi': ['7.22'], 'molecular-weight': ['45059.695'], 'chromosome-location': ['7'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:8583']}, {'resource': ['GenAtlas'], 'identifier': ['SERPINE1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X04429']}, {'resource': ['GenBank Protein Database'], 'identifier': ['35272']}, {'resource': ['UniProtKB'], 'identifier': ['P05121']}, {'resource': ['UniProt Accession'], 'identifier': ['PAI1_HUMAN']}]}], 'synonyms': [{'synonym': ['Endothelial plasminogen activator inhibitor', 'PAI', 'PAI1', 'PLANH1', 'Serpin E1']}], 'amino-acid-sequence': ['>lcl|BSEQ0000479|Plasminogen activator inhibitor 1\nMQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY\nGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI\nFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV\nDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD\nGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK\nFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS\nSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP'], 'gene-sequence': ['>lcl|BSEQ0010214|Plasminogen activator inhibitor 1 (SERPINE1)\nATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA\nGGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG\nAGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT\nGGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG\nATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT\nCTGTACAAGGAGCTCATGGGGCCATGGAACAAGGATGAGATCAGCACCACAGACGCGATC\nTTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC\nCGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT\nGACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG\nGACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT\nCCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC\nTCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT\nGGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT\nGCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG\nCTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG\nTTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC\nATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC\nGCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA\nTCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC\nTTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG\nGAACCCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00079'], 'name': ['Serpin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular matrix']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase inhibitor activity']}, {'category': ['process'], 'description': ['angiogenesis']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cellular response to lipopolysaccharide']}, {'category': ['process'], 'description': ['chronological cell aging']}, {'category': ['process'], 'description': ['circadian rhythm']}, {'category': ['process'], 'description': ['defense response to Gram-negative bacterium']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['gene expression']}, {'category': ['process'], 'description': ['negative regulation of blood coagulation']}, {'category': ['process'], 'description': ['negative regulation of cell adhesion mediated by integrin']}, {'category': ['process'], 'description': ['negative regulation of cell migration']}, {'category': ['process'], 'description': ['negative regulation of endopeptidase activity']}, {'category': ['process'], 'description': ['negative regulation of endothelial cell apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of extrinsic apoptotic signaling pathway via death domain receptors']}, {'category': ['process'], 'description': ['negative regulation of fibrinolysis']}, {'category': ['process'], 'description': ['negative regulation of plasminogen activation']}, {'category': ['process'], 'description': ['negative regulation of smooth muscle cell migration']}, {'category': ['process'], 'description': ['negative regulation of smooth muscle cell-matrix adhesion']}, {'category': ['process'], 'description': ['negative regulation of vascular wound healing']}, {'category': ['process'], 'description': ['negative regulation of wound healing']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of angiogenesis']}, {'category': ['process'], 'description': ['positive regulation of blood coagulation']}, {'category': ['process'], 'description': ['positive regulation of inflammatory response']}, {'category': ['process'], 'description': ['positive regulation of interleukin-8 production']}, {'category': ['process'], 'description': ['positive regulation of leukotriene production involved in inflammatory response']}, {'category': ['process'], 'description': ['positive regulation of monocyte chemotaxis']}, {'category': ['process'], 'description': ['positive regulation of receptor-mediated endocytosis']}, {'category': ['process'], 'description': ['positive regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['regulation of receptor activity']}, {'category': ['process'], 'description': ['transcription initiation from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['transcription, DNA-templated']}, {'category': ['process'], 'description': ['transforming growth factor beta receptor signaling pathway']}]}]}]}]}]"
"['DB00016', 'BTD00103', 'BIOD00103', 'DB08923']",['Erythropoietin'],biotech,"['Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow [FDA Label]. Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alfa and beta formulations. Epoetin alfa is a 165-amino acid erythropoiesis-stimulating glycoprotein produced in cell culture using recombinant DNA technology and is used for the treatment of patients with anemia associated with various clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high risk for perioperative blood loss from surgical procedures [FDA Label]. It has a molecular weight of approximately 30,400 daltons and is produced by mammalian cells into which the human erythropoietin gene has been introduced. The product contains the identical amino acid sequence of isolated natural erythropoietin and has the same biological activity as the endogenous erythropoietin. Epoetin alfa biosimilar, such as Retacrit (epoetin alfa-epbx or epoetin zeta), has been formulated to allow more access to treatment options for patients in the market [L2784]. The biosimilar is approved by the FDA and EMA as a safe, effective and affordable biological product and displays equivalent clinical efficacy, potency, and purity to the reference product [A7504]. Epoetin alfa formulations can be administered intravenously or subcutaneously.']",['liquid'],"['Indicated in adult and paediatric patients for the: \r\n\r\n- treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis.\r\n- treatment of anemia due to zidovudine in patients with HIV-infection. \r\n- treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.\r\n- reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery.']","['Erythropoietin or exogenous epoetin alfa binds to the erythropoietin receptor (EPO-R) and activates intracellular signal transduction pathways [A33079]. The affinity (Kd) of EPO for its receptor on human cells is 100 to 200 pM [A33080]. Upon binding to EPO-R on the surface of erythroid progenitor cells, a conformational change is induced which brings EPO-R-associated Janus family tyrosine protein kinase 2 (JAK2) molecules into close proximity. JAK2 molecules are subsequently activated via phosphorylation, then phosphorylate tyrosine residues in the cytoplasmic domain of the EPO-R that serve as docking sites for Src homology 2-domain-containing intracellular signaling proteins [A33079]. The signalling proteins include STAT5 that once phosphorylated by JAK2, dissociates from the EPO-R, dimerizes, and translocates to the nucleus where they serve as transcription factors to activate target genes involved in cell division or differentiation, including the apoptosis inhibitor Bcl-x [A33079]. The inhibition of apoptosis by the EPO-activated JAK2/STAT5/Bcl-x pathway is critical in erythroid differentiation. Via JAK2-mediated tyrosine phosphorylation, erythropoietin and epoetin alfa also activates other intracellular proteins involved in erythroid cell proliferation and survival, such as Shc , phosphatidylinositol 3-kinase (PI3K), and phospholipase C-1 [A33079]. ']","[{'food-interaction': ['Administer iron supplement. When initiating an erythropoiesis-stimulating agent, evaluate iron stores and start iron supplementation if indicated. Most patients with chronic kidney disease require iron supplementation while taking an erythropoiesis-stimulating agent.']}]","[{'target': [{'id': ['BE0000654'], 'name': ['Erythropoietin receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1764'], 'pubmed-id': ['16505108'], 'citation': ['LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C, Meshaw A, Farrell FX: Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther. 2006 Feb;5(2):347-55.']}, {'ref-id': ['A1766'], 'pubmed-id': ['17575216'], 'citation': ['Kokhaei P, Abdalla AO, Hansson L, Mikaelsson E, Kubbies M, Haselbeck A, Jernberg-Wiklund H, Mellstedt H, Osterborg A: Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies. Clin Cancer Res. 2007 Jun 15;13(12):3536-44.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Erythropoietin receptor'], 'general-function': ['Identical protein binding'], 'specific-function': ['Receptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase.Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.'], 'gene-name': ['EPOR'], 'locus': ['19p13.3-p13.2'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['251-273'], 'signal-regions': ['1-24'], 'theoretical-pi': ['4.37'], 'molecular-weight': ['55064.725'], 'chromosome-location': ['19'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3416']}, {'resource': ['GenAtlas'], 'identifier': ['EPOR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M60459']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182245']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1718']}, {'resource': ['UniProtKB'], 'identifier': ['P19235']}, {'resource': ['UniProt Accession'], 'identifier': ['EPOR_HUMAN']}]}], 'synonyms': [{'synonym': ['EPO-R']}], 'amino-acid-sequence': ['>lcl|BSEQ0001304|Erythropoietin receptor\nMDHLGASLWPQVGSLCLLLAGAAWAPPPNLPDPKFESKAALLAARGPEELLCFTERLEDL\nVCFWEEAASAGVGPGNYSFSYQLEDEPWKLCRLHQAPTARGAVRFWCSLPTADTSSFVPL\nELRVTAASGAPRYHRVIHINEVVLLDAPVGLVARLADESGHVVLRWLPPPETPMTSHIRY\nEVDVSAGNGAGSVQRVEILEGRTECVLSNLRGRTRYTFAVRARMAEPSFGGFWSAWSEPV\nSLLTPSDLDPLILTLSLILVVILVLLTVLALLSHRRALKQKIWPGIPSPESEFEGLFTTH\nKGNFQLWLYQNDGCLWWSPCTPFTEDPPASLEVLSERCWGTMQAVEPGTDDEGPLLEPVG\nSEHAQDTYLVLDKWLLPRNPPSEDLPGPGGSVDIVAMDEGSEASSCSSALASKPSPEGAS\nAASFEYTILDPSSQLLRPWTLCPELPPTPPHLKYLYLVVSDSGISTDYSSGDSQGAQGGL\nSDGPYSNPYENSLIPAAEPLPPSYVACS'], 'gene-sequence': ['>lcl|BSEQ0010455|Erythropoietin receptor (EPOR)\nATGGACCACCTCGGGGCGTCCCTCTGGCCCCAGGTCGGCTCCCTTTGTCTCCTGCTCGCT\nGGGGCCGCCTGGGCGCCCCCGCCTAACCTCCCGGACCCCAAGTTCGAGAGCAAAGCGGCC\nTTGCTGGCGGCCCGGGGGCCCGAAGAGCTTCTGTGCTTCACCGAGCGGTTGGAGGACTTG\nGTGTGTTTCTGGGAGGAAGCGGCGAGCGCTGGGGTGGGCCCGGGCAACTACAGCTTCTCC\nTACCAGCTCGAGGATGAGCCATGGAAGCTGTGTCGCCTGCACCAGGCTCCCACGGCTCGT\nGGTGCGGTGCGCTTCTGGTGTTCGCTGCCTACAGCCGACACGTCGAGCTTCGTGCCCCTA\nGAGTTGCGCGTCACAGCAGCCTCCGGCGCTCCGCGATATCACCGTGTCATCCACATCAAT\nGAAGTAGTGCTCCTAGACGCCCCCGTGGGGCTGGTGGCGCGGTTGGCTGACGAGAGCGGC\nCACGTAGTGTTGCGCTGGCTCCCGCCGCCTGAGACACCCATGACGTCTCACATCCGCTAC\nGAGGTGGACGTCTCGGCCGGCAACGGCGCAGGGAGCGTACAGAGGGTGGAGATCCTGGAG\nGGCCGCACCGAGTGTGTGCTGAGCAACCTGCGGGGCCGGACGCGCTACACCTTCGCCGTC\nCGCGCGCGTATGGCTGAGCCGAGCTTCGGCGGCTTCTGGAGCGCCTGGTCGGAGCCTGTG\nTCGCTGCTGACGCCTAGCGACCTGGACCCCCTCATCCTGACGCTCTCCCTCATCCTCGTG\nGTCATCCTGGTGCTGCTGACCGTGCTCGCGCTGCTCTCCCACCGCCGGGCTCTGAAGCAG\nAAGATCTGGCCTGGCATCCCGAGCCCAGAGAGCGAGTTTGAAGGCCTCTTCACCACCCAC\nAAGGGTAACTTCCAGCTGTGGCTGTACCAGAATGATGGCTGCCTGTGGTGGAGCCCCTGC\nACCCCCTTCACGGAGGACCCACCTGCTTCCCTGGAAGTCCTCTCAGAGCGCTGCTGGGGG\nACGATGCAGGCAGTGGAGCCGGGGACAGATGATGAGGGCCCCCTGCTGGAGCCAGTGGGC\nAGTGAGCATGCCCAGGATACCTATCTGGTGCTGGACAAATGGTTGCTGCCCCGGAACCCG\nCCCAGTGAGGACCTCCCAGGGCCTGGTGGCAGTGTGGACATAGTGGCCATGGATGAAGGC\nTCAGAAGCATCCTCCTGCTCATCTGCTTTGGCCTCGAAGCCCAGCCCAGAGGGAGCCTCT\nGCTGCCAGCTTTGAGTACACTATCCTGGACCCCAGCTCCCAGCTCTTGCGTCCATGGACA\nCTGTGCCCTGAGCTGCCCCCTACCCCACCCCACCTAAAGTACCTGTACCTTGTGGTATCT\nGACTCTGGCATCTCAACTGACTACAGCTCAGGGGACTCCCAGGGAGCCCAAGGGGGCTTA\nTCCGATGGCCCCTACTCCAACCCTTATGAGAACAGCCTTATCCCAGCCGCTGAGCCTCTG\nCCCCCCAGCTATGTGGCTTGCTCTTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00041'], 'name': ['fn3']}, {'identifier': ['PF09067'], 'name': ['EpoR_lig-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['function'], 'description': ['erythropoietin receptor activity']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['process'], 'description': ['brain development']}, {'category': ['process'], 'description': ['decidualization']}, {'category': ['process'], 'description': ['erythropoietin-mediated signaling pathway']}, {'category': ['process'], 'description': ['heart development']}, {'category': ['process'], 'description': ['negative regulation of neuron apoptotic process']}, {'category': ['process'], 'description': ['positive regulation of cytosolic calcium ion concentration']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}]}]"
"['DB00017', 'BTD00025', 'BIOD00025']",['Salmon calcitonin'],biotech,"['Synthetic peptide, 32 residues long formulated as a nasal spray.']",['liquid'],"[""Used in the treatment of symptomatic Paget's disease for patients unresponsive to alternate treatments or intolerant to such treatments. In addition, it is used in emergency situations when serum calcium levels must be decreased quickly until the underlying condition is identified. It can also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents. Calcitonin can be used in patients with azotemia and cases where intravenous fluids would be contraindicated due to limited cardiac reserves. Also for the treatment of post-menopausal osteoporosis in women more than 5 years post-menopause.  ""]","['Calcitonin binds to the calcitonin receptor (found primarily in osteoclasts) which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.']","[{'food-interaction': ['Administer calcium supplement. Individuals who are taking salmon calcitonin for the treatment of postmenopausal osteoporosis should ingest at least 1000mg of elemental calcium daily (by food or through supplementation).', 'Administer vitamin supplements. Individuals who are taking salmon calcitonin for the treatment of postmenopausal osteoporosis should take at least 400 international units of vitamin D daily.']}]","[{'target': [{'id': ['BE0000431'], 'name': ['Calcitonin receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1786'], 'pubmed-id': ['3004987'], 'citation': ['Bouizar Z, Fouchereau-Peron M, Taboulet J, Moukhtar MS, Milhaud G: Purification and characterization of calcitonin receptors in rat kidney membranes by covalent cross-linking techniques. Eur J Biochem. 1986 Feb 17;155(1):141-7.']}, {'ref-id': ['A1788'], 'pubmed-id': ['7610922'], 'citation': ['Stroop SD, Moore EE: Intracellular calcium increases mediated by a recombinant human calcitonin receptor. J Bone Miner Res. 1995 Apr;10(4):524-32.']}, {'ref-id': ['A1790'], 'pubmed-id': ['9231703'], 'citation': ['Sarkar A, Dickerson IM: Cloning, characterization, and expression of a calcitonin receptor from guinea pig brain. J Neurochem. 1997 Aug;69(2):455-64.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Calcitonin receptor'], 'general-function': ['Receptor activity'], 'specific-function': ['This is a receptor for calcitonin. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. The calcitonin receptor is thought to couple to the heterotrimeric guanosine triphosphate-binding protein that is sensitive to cholera toxin.'], 'gene-name': ['CALCR'], 'locus': ['7q21.3'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['172-191\n215-234\n255-277\n295-314\n331-354\n378-395\n408-429'], 'signal-regions': ['1-42'], 'theoretical-pi': ['8.71'], 'molecular-weight': ['59351.865'], 'chromosome-location': ['7'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1440']}, {'resource': ['GenAtlas'], 'identifier': ['CALCR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L00587']}, {'resource': ['GenBank Protein Database'], 'identifier': ['179880']}, {'resource': ['IUPHAR'], 'identifier': ['43']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['43']}, {'resource': ['UniProtKB'], 'identifier': ['P30988']}, {'resource': ['UniProt Accession'], 'identifier': ['CALCR_HUMAN']}]}], 'synonyms': [{'synonym': ['CT-R']}], 'amino-acid-sequence': ['>lcl|BSEQ0037016|Calcitonin receptor\nMQFSGEKISGQRDLQKSKMRFTFTSRCLALFLLLNHPTPILPAFSNQTYPTIEPKPFLYV\nVGRKKMMDAQYKCYDRMQQLPAYQGEGPYCNRTWDGWLCWDDTPAGVLSYQFCPDYFPDF\nDPSEKVTKYCDEKGVWFKHPENNRTWSNYTMCNAFTPEKLKNAYVLYYLAIVGHSLSIFT\nLVISLGIFVFFRKLTTIFPLNWKYRKALSLGCQRVTLHKNMFLTYILNSMIIIIHLVEVV\nPNGELVRRDPVSCKILHFFHQYMMACNYFWMLCEGIYLHTLIVVAVFTEKQRLRWYYLLG\nWGFPLVPTTIHAITRAVYFNDNCWLSVETHLLYIIHGPVMAALVVNFFFLLNIVRVLVTK\nMRETHEAESHMYLKAVKATMILVPLLGIQFVVFPWRPSNKMLGKIYDYVMHSLIHFQGFF\nVATIYCFCNNEVQTTVKRQWAQFKIQWNQRWGRRPSNRSARAAAAAAEAGDIPIYICHQE\nPRNEPANNQGEESAEIIPLNIIEQESSA'], 'gene-sequence': ['>lcl|BSEQ0010301|Calcitonin receptor (CALCR)\nATGCAATTTTCTGGAGAGAAGATTAGTGGACAAAGAGATCTTCAAAAATCAAAAATGAGG\nTTCACATTTACAAGCCGGTGCTTGGCACTGTTTCTTCTTCTAAATCACCCAACCCCAATT\nCTTCCTGCCTTTTCAAATCAAACCTATCCAACAATAGAGCCCAAGCCATTTCTTTACGTC\nGTAGGACGAAAGAAGATGATGGATGCACAGTACAAATGCTATGACCGAATGCAGCAGTTA\nCCCGCATACCAAGGAGAAGGTCCATATTGCAATCGCACCTGGGATGGATGGCTGTGCTGG\nGATGACACACCGGCTGGAGTATTGTCCTATCAGTTCTGCCCAGATTATTTTCCGGATTTT\nGATCCATCAGAAAAGGTTACAAAATACTGTGATGAAAAAGGTGTTTGGTTTAAACATCCT\nGAAAACAATCGAACCTGGTCCAACTATACTATGTGCAATGCTTTCACTCCTGAGAAACTG\nAAGAATGCATATGTTCTGTACTATTTGGCTATTGTGGGTCATTCTTTGTCAATTTTCACC\nCTAGTGATTTCCCTGGGGATTTTCGTGTTTTTCAGAAAATTGACAACTATTTTTCCTTTG\nAATTGGAAATATAGGAAGGCATTGAGCCTTGGCTGCCAAAGGGTAACCCTGCACAAGAAC\nATGTTTCTTACTTACATTCTGAATTCTATGATTATCATCATCCACCTGGTTGAAGTAGTA\nCCCAATGGAGAGCTCGTGCGAAGGGACCCGGTGAGCTGCAAGATTTTGCATTTTTTCCAC\nCAGTACATGATGGCCTGCAACTATTTCTGGATGCTCTGTGAAGGGATCTATCTTCATACA\nCTCATTGTCGTGGCTGTGTTTACTGAGAAGCAACGCTTGCGGTGGTATTATCTCTTGGGC\nTGGGGGTTCCCGCTGGTGCCAACCACTATCCATGCTATTACCAGGGCCGTGTACTTCAAT\nGACAACTGCTGGCTGAGTGTGGAAACCCATTTGCTTTACATAATCCATGGACCTGTCATG\nGCGGCACTTGTGGTCAATTTCTTCTTTTTGCTCAACATTGTCCGGGTGCTTGTGACCAAA\nATGAGGGAAACCCATGAGGCGGAATCCCACATGTACCTGAAGGCTGTGAAGGCCACCATG\nATCCTTGTGCCCCTGCTGGGAATCCAGTTTGTCGTCTTTCCCTGGAGACCTTCCAACAAG\nATGCTTGGGAAGATATATGATTACGTGATGCACTCTCTGATTCATTTCCAGGGCTTCTTT\nGTTGCGACCATCTACTGCTTCTGCAACAATGAGGTCCAAACCACCGTGAAGCGCCAATGG\nGCCCAATTCAAAATTCAGTGGAACCAGCGTTGGGGGAGGCGCCCCTCCAACCGCTCTGCT\nCGCGCTGCAGCCGCTGCTGCGGAGGCTGGCGACATCCCAATTTACATCTGCCATCAGGAG\nCTGAGGAATGAACCAGCCAACAACCAAGGCGAGGAGAGTGCTGAGATCATCCCTTTGAAT\nATCATAGAGCAAGAGTCATCTGCTTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00002'], 'name': ['7tm_2']}, {'identifier': ['PF02793'], 'name': ['HRM']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['calcitonin binding']}, {'category': ['function'], 'description': ['calcitonin receptor activity']}, {'category': ['function'], 'description': ['protein transporter activity']}, {'category': ['function'], 'description': ['receptor activity']}, {'category': ['process'], 'description': ['adenylate cyclase-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of adenylate cyclase activity']}, {'category': ['process'], 'description': ['positive regulation of cAMP biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of cytosolic calcium ion concentration']}, {'category': ['process'], 'description': ['protein localization to plasma membrane']}, {'category': ['process'], 'description': ['protein transport']}, {'category': ['process'], 'description': ['receptor internalization']}, {'category': ['process'], 'description': ['response to glucocorticoid']}]}]}]}]}]"
"['DB00018', 'BTD00023', 'BIOD00023']",['Interferon alfa-n3'],biotech,"['Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).']",['liquid'],['For the intralesional treatment of refractory or recurring external condylomata acuminata.'],"['Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.']",[None],"[{'target': [{'id': ['BE0000661'], 'name': ['Interferon alpha/beta receptor 1'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A1754'], 'pubmed-id': ['15898717'], 'citation': ['Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27.']}, {'ref-id': ['A1758'], 'pubmed-id': ['19955815'], 'citation': ['Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interferon alpha/beta receptor 1'], 'general-function': ['Type i interferon receptor activity'], 'specific-function': ['Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.'], 'gene-name': ['IFNAR1'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['437-457'], 'signal-regions': ['1-27'], 'theoretical-pi': ['5.56'], 'molecular-weight': ['63524.81'], 'chromosome-location': ['21'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5432']}, {'resource': ['GenAtlas'], 'identifier': ['IFNAR1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['J03171']}, {'resource': ['GenBank Protein Database'], 'identifier': ['306914']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1723']}, {'resource': ['UniProtKB'], 'identifier': ['P17181']}, {'resource': ['UniProt Accession'], 'identifier': ['INAR1_HUMAN']}]}], 'synonyms': [{'synonym': ['CRF2-1', 'Cytokine receptor class-II member 1', 'Cytokine receptor family 2 member 1', 'IFN-R-1', 'IFNAR', 'Type I interferon receptor 1']}], 'amino-acid-sequence': ['>lcl|BSEQ0001318|Interferon alpha/beta receptor 1\nMMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT\nFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF\nTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI\nENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ\nNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK\nGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP\nVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV\nFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE\nYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN\nEDESESKTSEELQQDFV'], 'gene-sequence': ['>lcl|BSEQ0018987|Interferon alpha/beta receptor 1 (IFNAR1)\nATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTG\nTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC\nATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT\nTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG\nAATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT\nAAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT\nACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG\nGCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT\nTTAAGCTTTACATATAGCTTAGTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT\nGAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA\nAAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT\nATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA\nAATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG\nTGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA\nCCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA\nGGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA\nGAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA\nTCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT\nGTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT\nGAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT\nGTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT\nTTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA\nGTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC\nTTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG\nTATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA\nAAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT\nGATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT\nGAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA'], 'pfams': [{'pfam': [{'identifier': ['PF01108'], 'name': ['Tissue_fac']}, {'identifier': ['PF09294'], 'name': ['Interfer-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['type I interferon receptor activity']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['defense response to virus']}, {'category': ['process'], 'description': ['JAK-STAT cascade']}, {'category': ['process'], 'description': ['positive regulation of interferon-beta production']}, {'category': ['process'], 'description': ['positive regulation of interferon-gamma production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-1 beta secretion']}, {'category': ['process'], 'description': ['positive regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['regulation of type I interferon-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['T cell activation']}, {'category': ['process'], 'description': ['type I interferon biosynthetic process']}, {'category': ['process'], 'description': ['type I interferon signaling pathway']}]}]}]}, {'id': ['BE0000385'], 'name': ['Interferon alpha/beta receptor 2'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A1754'], 'pubmed-id': ['15898717'], 'citation': ['Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27.']}, {'ref-id': ['A1758'], 'pubmed-id': ['19955815'], 'citation': ['Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3.']}, {'ref-id': ['A1755'], 'pubmed-id': ['16953837'], 'citation': ['Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interferon alpha/beta receptor 2'], 'general-function': ['Type i interferon receptor activity'], 'specific-function': ['Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.'], 'gene-name': ['IFNAR2'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['244-264'], 'signal-regions': ['1-26'], 'theoretical-pi': ['4.11'], 'molecular-weight': ['57758.24'], 'chromosome-location': ['21'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5433']}, {'resource': ['GenAtlas'], 'identifier': ['IFNAR2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L42243']}, {'resource': ['GenBank Protein Database'], 'identifier': ['995300']}, {'resource': ['UniProtKB'], 'identifier': ['P48551']}, {'resource': ['UniProt Accession'], 'identifier': ['INAR2_HUMAN']}]}], 'synonyms': [{'synonym': ['IFN-R-2', 'IFNABR', 'IFNARB', 'Interferon alpha binding protein', 'Type I interferon receptor 2']}], 'amino-acid-sequence': ['>lcl|BSEQ0000767|Interferon alpha/beta receptor 2\nMLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS\nIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF\nSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK\nHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE\nSAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD\nMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI\nDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR\nITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT\nFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR'], 'gene-sequence': ['>lcl|BSEQ0018941|Interferon alpha/beta receptor 2 (IFNAR2)\nATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT\nATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT\nTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC\nATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG\nGTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA\nAGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC\nAGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG\nATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA\nGAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG\nCATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA\nATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA\nATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA\nTCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC\nATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG\nAGGCAAGGTCTCGCTAAGGGCTGGAATGCAGTGGCTATTCACAGGTGCAGTCATAATGCA\nCTACAGTCTGAAACTCCTGAGCTCAAACAGTCGTCCTGCCTAAGCTTCCCCAGTAGCTGG\nGATTACAAGCGTGCATCCCTGTGCCCCAGTGATTAA'], 'pfams': [{'pfam': [{'identifier': ['PF01108'], 'name': ['Tissue_fac']}, {'identifier': ['PF09294'], 'name': ['Interfer-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['protein kinase binding']}, {'category': ['function'], 'description': ['type I interferon binding']}, {'category': ['function'], 'description': ['type I interferon receptor activity']}, {'category': ['process'], 'description': ['cell proliferation']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['JAK-STAT cascade']}, {'category': ['process'], 'description': ['regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['regulation of type I interferon-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to interferon-alpha']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['type I interferon signaling pathway']}]}]}]}]}]"
"['DB00019', 'BTD00094', 'BIOD00094']",['Pegfilgrastim'],biotech,"['Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim].[A187601] The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment.[L9746] Although the risk of developing febrile neutropenia is less than 20% in many readily used chemotherapy regimens,[A248855] infections pose risks of hospitalization and mortalities.[A187631] Due to the relatively short circulating half-life of filgrastim, a 20 kDa PEG moiety was covalently conjugated to the N-terminus of filgrastim (at the methionine residue) to develop longer-acting pegfilgrastim.[A29,A187607] Due to a longer half-life and slower elimination rate than filgrastim, pegfilgrastim requires less frequent dosing than filgrastim; however, pegfilgrastim has a comparable pharmacological activity to filgrastim and binds to the G-CSF receptor to stimulate the proliferation, differentiation, and activation of neutrophils.[A187607]\r\n\r\nFirst developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection. There are several pegfilgrastim biosimilars (Fulphila, Pelgraz or Lapelga, Pelmeg, Udenyca, Ziextenzo, Grasustek, Fylnetra, Stimufend) by Health Canada, European Union (EU), and FDA that are approved to reduce infection risk.[L9779,L9785,L43050] These biosimilars are highly similar to the reference product, Neulasta, in terms of pharmacological and pharmacokinetic profile and conditions of use.[L9974]']",['liquid'],"['Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non\xad myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.[L44221]\r\n\r\nIt is also indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).[L44221]']","['Neutrophils are short-lived immune cells that are highly susceptible to cell death following myelosuppressive chemotherapy. This marked reduction in neutrophil numbers during chemotherapy increases the risk of hospitalization, infection, and infection-related mortality. It also directly impacts the clinical outcome of patients if cases of febrile neutropenia requires dose reductions or schedule delay of chemotherapy, thus reducing the clinical efficacy of chemotherapy and patient benefit from receiving appropriate treatment.[A187631] \r\n\r\nG-CSF is an endogenous haematopoietic growth factor that stimulates granulopoietic cells of the neutrophil lineage. Pegfilgrastim mimics its biological actions and binds to the same G-CSF receptor expressed on cells of myeloid lineage, such as granulocytic precursors and mature neutrophils.[A29] Upon binding of the ligand, G-CSF receptor undergoes a conformational change and activates several downstream signalling pathways including JAK/STAT, PI3K/AKT and MAPK/ERK.[A187868] These pathways work to increase proliferation and differentiation of granulocyte progenitor cells, induce maturation of the progenitor cells, and enhance survival and function of mature neutrophils.[A29]']",[None],"[{'target': [{'id': ['BE0000793'], 'name': ['Granulocyte colony-stimulating factor receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1792'], 'pubmed-id': ['17001306'], 'citation': ['Erkeland SJ, Aarts LH, Irandoust M, Roovers O, Klomp A, Valkhof M, Gits J, Eyckerman S, Tavernier J, Touw IP: Novel role of WD40 and SOCS box protein-2 in steady-state distribution of granulocyte colony-stimulating factor receptor and G-CSF-controlled proliferation and differentiation signaling. Oncogene. 2007 Mar 29;26(14):1985-94. Epub 2006 Sep 25.']}, {'ref-id': ['A1794'], 'pubmed-id': ['12944913'], 'citation': ['Elsasser A, Franzen M, Kohlmann A, Weisser M, Schnittger S, Schoch C, Reddy VA, Burel S, Zhang DE, Ueffing M, Tenen DG, Hiddemann W, Behre G: The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner. Oncogene. 2003 Aug 28;22(36):5646-57.']}, {'ref-id': ['A1797'], 'pubmed-id': ['17127322'], 'citation': ['Ward AC: The role of the granulocyte colony-stimulating factor receptor (G-CSF-R) in disease. Front Biosci. 2007 Jan 1;12:608-18.']}, {'ref-id': ['A1798'], 'pubmed-id': ['16033816'], 'citation': ['Zhuang D, Qiu Y, Haque SJ, Dong F: Tyrosine 729 of the G-CSF receptor controls the duration of receptor signaling: involvement of SOCS3 and SOCS1. J Leukoc Biol. 2005 Oct;78(4):1008-15. Epub 2005 Jul 20.']}, {'ref-id': ['A1800'], 'pubmed-id': ['15949269'], 'citation': ['Cao YR, Shao ZH, Liu H, Shi J, Bai J, Tu MF, Wang HQ, Xing LM, Cui ZZ, Sun J, Jia HR, Yang TY: [The response of bone marrow hematopoietic cells to G-CSF in paroxysmal nocturnal hemoglobinuria patients]. Zhonghua Xue Ye Xue Za Zhi. 2005 Apr;26(4):235-8.']}, {'ref-id': ['A1802'], 'pubmed-id': ['15082029'], 'citation': ['Kotto-Kome AC, Fox SE, Lu W, Yang BB, Christensen RD, Calhoun DA: Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol Res. 2004 Jul;50(1):55-8.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Granulocyte colony-stimulating factor receptor'], 'general-function': ['Receptor activity'], 'specific-function': ['Receptor for granulocyte colony-stimulating factor (CSF3), essential for granulocytic maturation. Plays a crucial role in the proliferation, differientation and survival of cells along the neutrophilic lineage. In addition it may function in some adhesion or recognition events at the cell surface.'], 'gene-name': ['CSF3R'], 'locus': ['1p35-p34.3'], 'cellular-location': ['Secreted'], 'transmembrane-regions': ['628-650'], 'signal-regions': ['1-24'], 'theoretical-pi': ['6.14'], 'molecular-weight': ['92155.615'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:2439']}, {'resource': ['GenAtlas'], 'identifier': ['CSF3R']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X55721']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31697']}, {'resource': ['UniProtKB'], 'identifier': ['Q99062']}, {'resource': ['UniProt Accession'], 'identifier': ['CSF3R_HUMAN']}]}], 'synonyms': [{'synonym': ['G-CSF receptor', 'GCSFR']}], 'amino-acid-sequence': ['>lcl|BSEQ0001582|Granulocyte colony-stimulating factor receptor\nMARLGNCSLTWAALIILLLPGSLEECGHISVSAPIVHLGDPITASCIIKQNCSHLDPEPQ\nILWRLGAELQPGGRQQRLSDGTQESIITLPHLNHTQAFLSCCLNWGNSLQILDQVELRAG\nYPPAIPHNLSCLMNLTTSSLICQWEPGPETHLPTSFTLKSFKSRGNCQTQGDSILDCVPK\nDGQSHCCIPRKHLLLYQNMGIWVQAENALGTSMSPQLCLDPMDVVKLEPPMLRTMDPSPE\nAAPPQAGCLQLCWEPWQPGLHINQKCELRHKPQRGEASWALVGPLPLEALQYELCGLLPA\nTAYTLQIRCIRWPLPGHWSDWSPSLELRTTERAPTVRLDTWWRQRQLDPRTVQLFWKPVP\nLEEDSGRIQGYVVSWRPSGQAGAILPLCNTTELSCTFHLPSEAQEVALVAYNSAGTSRPT\nPVVFSESRGPALTRLHAMARDPHSLWVGWEPPNPWPQGYVIEWGLGPPSASNSNKTWRME\nQNGRATGFLLKENIRPFQLYEIIVTPLYQDTMGPSQHVYAYSQEMAPSHAPELHLKHIGK\nTWAQLEWVPEPPELGKSPLTHYTIFWTNAQNQSFSAILNASSRGFVLHGLEPASLYHIHL\nMAASQAGATNSTVLTLMTLTPEGSELHIILGLFGLLLLLTCLCGTAWLCCSPNRKNPLWP\nSVPDPAHSSLGSWVPTIMEEDAFQLPGLGTPPITKLTVLEEDEKKPVPWESHNSSETCGL\nPTLVQTYVLQGDPRAVSTQPQSQSGTSDQVLYGQLLGSPTSPGPGHYLRCDSTQPLLAGL\nTPSPKSYENLWFQASPLGTLVTPAPSQEDDCVFGPLLNFPLLQGIRVHGMEALGSF'], 'gene-sequence': ['>lcl|BSEQ0010560|Granulocyte colony-stimulating factor receptor (CSF3R)\nATGGCAAGGCTGGGAAACTGCAGCCTGACTTGGGCTGCCCTGATCATCCTGCTGCTCCCC\nGGAAGTCTGGAGGAGTGCGGGCACATCAGTGTCTCAGCCCCCATCGTCCACCTGGGGGAT\nCCCATCACAGCCTCCTGCATCATCAAGCAGAACTGCAGCCATCTGGACCCGGAGCCACAG\nATTCTGTGGAGACTGGGAGCAGAGCTTCAGCCCGGGGGCAGGCAGCAGCGTCTGTCTGAT\nGGGACCCAGGAATCTATCATCACCCTGCCCCACCTCAACCACACTCAGGCCTTTCTCTCC\nTGCTGCCTGAACTGGGGCAACAGCCTGCAGATCCTGGACCAGGTTGAGCTGCGCGCAGGC\nTACCCTCCAGCCATACCCCACAACCTCTCCTGCCTCATGAACCTCACAACCAGCAGCCTC\nATCTGCCAGTGGGAGCCAGGACCTGAGACCCACCTACCCACCAGCTTCACTCTGAAGAGT\nTTCAAGAGCCGGGGCAACTGTCAGACCCAAGGGGACTCCATCCTGGACTGCGTGCCCAAG\nGACGGGCAGAGCCACTGCTGCATCCCACGCAAACACCTGCTGTTGTACCAGAATATGGGC\nATCTGGGTGCAGGCAGAGAATGCGCTGGGGACCAGCATGTCCCCACAACTGTGTCTTGAT\nCCCATGGATGTTGTGAAACTGGAGCCCCCCATGCTGCGGACCATGGACCCCAGCCCTGAA\nGCGGCCCCTCCCCAGGCAGGCTGCCTACAGCTGTGCTGGGAGCCATGGCAGCCAGGCCTG\nCACATAAATCAGAAGTGTGAGCTGCGCCACAAGCCGCAGCGTGGAGAAGCCAGCTGGGCA\nCTGGTGGGCCCCCTCCCCTTGGAGGCCCTTCAGTATGAGCTCTGCGGGCTCCTCCCAGCC\nACGGCCTACACCCTGCAGATACGCTGCATCCGCTGGCCCCTGCCTGGCCACTGGAGCGAC\nTGGAGCCCCAGCCTGGAGCTGAGAACTACCGAACGGGCCCCCACTGTCAGACTGGACACA\nTGGTGGCGGCAGAGGCAGCTGGACCCCAGGACAGTGCAGCTGTTCTGGAAGCCAGTGCCC\nCTGGAGGAAGACAGCGGACGGATCCAAGGTTATGTGGTTTCTTGGAGACCCTCAGGCCAG\nGCTGGGGCCATCCTGCCCCTCTGCAACACCACAGAGCTCAGCTGCACCTTCCACCTGCCT\nTCAGAAGCCCAGGAGGTGGCCCTTGTGGCCTATAACTCAGCCGGGACCTCTCGTCCCACT\nCCGGTGGTCTTCTCAGAAAGCAGAGGCCCAGCTCTGACCAGACTCCATGCCATGGCCCGA\nGACCCTCACAGCCTCTGGGTAGGCTGGGAGCCCCCCAATCCATGGCCTCAGGGCTATGTG\nATTGAGTGGGGCCTGGGCCCCCCCAGCGCGAGCAATAGCAACAAGACCTGGAGGATGGAA\nCAGAATGGGAGAGCCACGGGGTTTCTGCTGAAGGAGAACATCAGGCCCTTTCAGCTCTAT\nGAGATCATCGTGACTCCCTTGTACCAGGACACCATGGGACCCTCCCAGCATGTCTATGCC\nTACTCTCAAGAAATGGCTCCCTCCCATGCCCCAGAGCTGCATCTAAAGCACATTGGCAAG\nACCTGGGCACAGCTGGAGTGGGTGCCTGAGCCCCCTGAGCTGGGGAAGAGCCCCCTTACC\nCACTACACCATCTTCTGGACCAACGCTCAGAACCAGTCCTTCTCCGCCATCCTGAATGCC\nTCCTCCCGTGGCTTTGTCCTCCATGGCCTGGAGCCCGCCAGTCTGTATCACATCCACCTC\nATGGCTGCCAGCCAGGCTGGGGCCACCAACAGTACAGTCCTCACCCTGATGACCTTGACC\nCCAGAGGGGTCGGAGCTACACATCATCCTGGGCCTGTTCGGCCTCCTGCTGTTGCTCACC\nTGCCTCTGTGGAACTGCCTGGCTCTGTTGCAGCCCCAACAGGAAGAATCCCCTCTGGCCA\nAGTGTCCCAGACCCAGCTCACAGCAGCCTGGGCTCCTGGGTGCCCACAATCATGGAGGAG\nGATGCCTTCCAGCTGCCCGGCCTTGGCACGCCACCCATCACCAAGCTCACAGTGCTGGAG\nGAGGATGAAAAGAAGCCGGTGCCCTGGGAGTCCCATAACAGCTCAGAGACCTGTGGCCTC\nCCCACTCTGGTCCAGACCTATGTGCTCCAGGGGGACCCAAGAGCAGTTTCCACCCAGCCC\nCAATCCCAGTCTGGCACCAGCGATCAGGTCCTTTATGGGCAGCTGCTGGGCAGCCCCACA\nAGCCCAGGGCCAGGGCACTATCTCCGCTGTGACTCCACTCAGCCCCTCTTGGCGGGCCTC\nACCCCCAGCCCCAAGTCCTATGAGAACCTCTGGTTCCAGGCCAGCCCCTTGGGGACCCTG\nGTAACCCCAGCCCCAAGCCAGGAGGACGACTGTGTCTTTGGGCCACTGCTCAACTTCCCC\nCTCCTGCAGGGGATCCGGGTCCATGGGATGGAGGCGCTGGGGAGCTTCTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00041'], 'name': ['fn3']}, {'identifier': ['PF06328'], 'name': ['Lep_receptor_Ig']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['function'], 'description': ['cytokine receptor activity']}, {'category': ['function'], 'description': ['receptor activity']}, {'category': ['process'], 'description': ['amelogenesis']}, {'category': ['process'], 'description': ['cell adhesion']}, {'category': ['process'], 'description': ['defense response']}, {'category': ['process'], 'description': ['neutrophil chemotaxis']}, {'category': ['process'], 'description': ['regulation of myeloid cell differentiation']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}]}]"
"['DB00020', 'BTD00035', 'BIOD00035']",['Sargramostim'],biotech,['Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.'],['liquid'],['For the treatment of cancer and bone marrow transplant'],['Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway. This leads to the production of hemopoietic cells and neutrophils'],[None],"[{'target': [{'id': ['BE0000628'], 'name': ['Granulocyte-macrophage colony-stimulating factor receptor subunit alpha'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1804'], 'pubmed-id': ['17090651'], 'citation': ['Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW, Hochhaus A, Neubauer A, Burchert A: Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood. 2007 Mar 1;109(5):2147-55. Epub 2006 Nov 7.']}, {'ref-id': ['A1806'], 'pubmed-id': ['16760463'], 'citation': ['Chen J, Carcamo JM, Golde DW: The alpha subunit of the granulocyte-macrophage colony-stimulating factor receptor interacts with c-Kit and inhibits c-Kit signaling. J Biol Chem. 2006 Aug 4;281(31):22421-6. Epub 2006 Jun 7.']}, {'ref-id': ['A1808'], 'pubmed-id': ['17522711'], 'citation': ['Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane JM, Kucherlapati R, Malhotra AK: Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry. 2007 Jun;12(6):572-80. Epub 2007 Mar 20.']}, {'ref-id': ['A1809'], 'pubmed-id': ['16638185'], 'citation': ['Xiao R, Zhang R, Wang YL, Zhu ZL, Chen T, Yang JH: [Expression of soluble GM-CSF-Ralpha in patients with acute myeloid leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Apr;14(2):225-7.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Granulocyte-macrophage colony-stimulating factor receptor subunit alpha'], 'general-function': ['Receptor activity'], 'specific-function': ['Low affinity receptor for granulocyte-macrophage colony-stimulating factor. Transduces a signal that results in the proliferation, differentiation, and functional activation of hematopoietic cells.'], 'gene-name': ['CSF2RA'], 'locus': ['Xp22.32 and Yp11.3'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['321-346'], 'signal-regions': ['1-22'], 'theoretical-pi': ['7.81'], 'molecular-weight': ['46206.185'], 'chromosome-location': ['X, Y'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:2435']}, {'resource': ['GenAtlas'], 'identifier': ['CSF2RA']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X17648']}, {'resource': ['GenBank Protein Database'], 'identifier': ['32089']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1707']}, {'resource': ['UniProtKB'], 'identifier': ['P15509']}, {'resource': ['UniProt Accession'], 'identifier': ['CSF2R_HUMAN']}]}], 'synonyms': [{'synonym': ['CDw116', 'CSF2R', 'CSF2RY', 'GM-CSF-R-alpha']}], 'amino-acid-sequence': ['>lcl|BSEQ0001252|Granulocyte-macrophage colony-stimulating factor receptor subunit alpha\nMLLLVTSLLLCELPHPAFLLIPEKSDLRTVAPASSLNVRFDSRTMNLSWDCQENTTFSKC\nFLTDKKNRVVEPRLSNNECSCTFREICLHEGVTFEVHVNTSQRGFQQKLLYPNSGREGTA\nAQNFSCFIYNADLMNCTWARGPTAPRDVQYFLYIRNSKRRREIRCPYYIQDSGTHVGCHL\nDNLSGLTSRNYFLVNGTSREIGIQFFDSLLDTKKIERFNPPSNVTVRCNTTHCLVRWKQP\nRTYQKLSYLDFQYQLDVHRKNTQPGTENLLINVSGDLENRYNFPSSEPRAKHSVKIRAAD\nVRILNWSSWSEAIEFGSDDGNLGSVYIYVLLIVGTLVCGIVLGFLFKRFLRIQRLFPPVP\nQIKDKLNDNHEVEDEIIWEEFTPEEGKGYREEVLTVKEIT'], 'gene-sequence': ['>lcl|BSEQ0016159|Granulocyte-macrophage colony-stimulating factor receptor subunit alpha (CSF2RA)\nATGCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCCTCCTG\nATCCCAGAGAAATCGGATCTGCGAACAGTGGCACCAGCCTCTAGTCTCAATGTGAGGTTT\nGACTCCAGGACGATGAATTTAAGCTGGGACTGCCAAGAAAACACAACCTTCAGCAAGTGT\nTTCTTAACTGACAAGAAGAACAGAGTCGTGGAACCCAGGCTCAGTAACAACGAATGTTCG\nTGCACATTTCGTGAAATTTGTCTGCATGAAGGAGTCACATTTGAGGTTCACGTGAATACT\nAGTCAAAGAGGATTTCAACAGAAACTGCTTTATCCAAATTCAGGAAGGGAGGGTACCGCT\nGCTCAGAATTTCTCCTGTTTCATCTACAATGCGGATTTAATGAACTGTACCTGGGCGAGG\nGGTCCGACGGCCCCCCGTGACGTCCAGTATTTTTTGTACATACGAAACTCAAAGAGAAGG\nAGGGAGATCCGGTGTCCTTATTACATACAAGACTCAGGAACCCATGTGGGATGTCACCTG\nGATAACCTGTCAGGATTAACGTCTCGCAATTACTTTCTGGTTAACGGAACCAGCCGAGAA\nATTGGCATCCAATTCTTTGATTCACTTTTGGACACAAAGAAAATAGAACGATTCAACCCT\nCCCAGCAATGTCACCGTACGTTGCAACACGACGCACTGCCTCGTACGGTGGAAACAGCCC\nAGGACCTATCAGAAGCTGTCGTACCTGGACTTTCAGTACCAGCTGGACGTCCACAGAAAG\nAATACCCAGCCTGGCACGGAAAACCTACTGATTAATGTTTCTGGTGATTTGGAAAATAGA\nTACAACTTTCCAAGCTCTGAGCCCAGAGCAAAACACAGTGTGAAGATCAGAGCTGCAGAC\nGTCCGCATCTTGAATTGGAGCTCCTGGAGTGAAGCCATTGAATTTGGTTCTGACGACGGG\nAACCTCGGCTCTGTGTACATTTATGTGCTCCTAATCGTGGGAACCCTTGTCTGTGGCATC\nGTCCTCGGCTTCCTCTTTAAAAGGTTCCTTAGGATACAGCGGCTGTTCCCGCCAGTTCCA\nCAGATCAAAGACAAACTGAATGATAACCATGAGGTGGAAGACGAGATCATCTGGGAGGAA\nTTCACCCCAGAGGAAGGGAAAGGCTACCGCGAAGAGGTCTTGACCGTGAAGGAAATTACC\nTGA'], 'pfams': [{'pfam': [{'identifier': ['PF09240'], 'name': ['IL6Ra-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['granulocyte colony-stimulating factor receptor activity']}, {'category': ['function'], 'description': ['receptor activity']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['cellular response to granulocyte macrophage colony-stimulating factor stimulus']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['Ras protein signal transduction']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}]}]}]}, {'id': ['BE0001036'], 'name': ['Interleukin-3 receptor subunit alpha'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13104'], 'pubmed-id': ['17562355'], 'citation': ['Eksioglu EA, Mahmood SS, Chang M, Reddy V: GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinflammatory response. Exp Hematol. 2007 Aug;35(8):1163-71. Epub 2007 Jun 11.']}, {'ref-id': ['A13105'], 'pubmed-id': ['17500228'], 'citation': ['Sakhno LV, Leplina OIu, Tikhonova MA, Raspai ZhM, Gileva IP, Nikonov SD, Zhdanov OA, Ostanin AA, Chernykh ER: [Characteristics of A-interferon-generated dendritic cells in patients with pulmonary tuberculosis]. Probl Tuberk Bolezn Legk. 2007;(3):42-6.']}, {'ref-id': ['A13106'], 'pubmed-id': ['16698686'], 'citation': ['Ward KA, Stewart LA, Schwarer AP: CD34+-derived CD11c+ + + BDCA-1+ + CD123+ + DC: expansion of a phenotypically undescribed myeloid DC1 population for use in adoptive immunotherapy. Cytotherapy. 2006;8(2):130-40.']}, {'ref-id': ['A1808'], 'pubmed-id': ['17522711'], 'citation': ['Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane JM, Kucherlapati R, Malhotra AK: Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry. 2007 Jun;12(6):572-80. Epub 2007 Mar 20.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interleukin-3 receptor subunit alpha'], 'general-function': ['Interleukin-3 receptor activity'], 'specific-function': ['This is a receptor for interleukin-3.'], 'gene-name': ['IL3RA'], 'locus': ['Xp22.3 or Yp11.3'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['306-325'], 'signal-regions': ['1-18'], 'theoretical-pi': ['8.32'], 'molecular-weight': ['43329.585'], 'chromosome-location': ['X, Y'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6012']}, {'resource': ['GenAtlas'], 'identifier': ['IL3RA']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M74782']}, {'resource': ['GenBank Protein Database'], 'identifier': ['186331']}, {'resource': ['UniProtKB'], 'identifier': ['P26951']}, {'resource': ['UniProt Accession'], 'identifier': ['IL3RA_HUMAN']}]}], 'synonyms': [{'synonym': ['IL-3 receptor subunit alpha', 'IL3R']}], 'amino-acid-sequence': ['>lcl|BSEQ0002063|Interleukin-3 receptor subunit alpha\nMVLLWLTLLLIALPCLLQTKEDPNPPITNLRMKAKAQQLTWDLNRNVTDIECVKDADYSM\nPAVNNSYCQFGAISLCEVTNYTVRVANPPFSTWILFPENSGKPWAGAENLTCWIHDVDFL\nSCSWAVGPGAPADVQYDLYLNVANRRQQYECLHYKTDAQGTRIGCRFDDISRLSSGSQSS\nHILVRGRSAAFGIPCTDKFVVFSQIEILTPPNMTAKCNKTHSFMHWKMRSHFNRKFRYEL\nQIQKRMQPVITEQVRDRTSFQLLNPGTYTVQIRARERVYEFLSAWSTPQRFECDQEEGAN\nTRAWRTSLLIALGTLLALVCVFVICRRYLVMQRLFPRIPHMKDPIGDSFQNDKLVVWEAG\nKAGLEECLVTEVQVVQKT'], 'gene-sequence': ['>lcl|BSEQ0020503|Interleukin-3 receptor subunit alpha (IL3RA)\nATGGTCCTCCTTTGGCTCACGCTGCTCCTGATCGCCCTGCCCTGTCTCCTGCAAACGAAG\nGAAGGTGGGAAGCCTTGGGCAGGTGCGGAGAATCTGACCTGCTGGATTCATGACGTGGAT\nTTCTTGAGCTGCAGCTGGGCGGTAGGCCCGGGGGCCCCCGCGGACGTCCAGTACGACCTG\nTACTTGAACGTTGCCAACAGGCGTCAACAGTACGAGTGTCTTCACTACAAAACGGATGCT\nCAGGGAACACGTATCGGGTGTCGTTTCGATGACATCTCTCGACTCTCCAGCGGTTCTCAA\nAGTTCCCACATCCTGGTGCGGGGCAGGAGCGCAGCCTTCGGTATCCCCTGCACAGATAAG\nTTTGTCGTCTTTTCACAGATTGAGATATTAACTCCACCCAACATGACTGCAAAGTGTAAT\nAAGACACATTCCTTTATGCACTGGAAAATGAGAAGTCATTTCAATCGCAAATTTCGCTAT\nGAGCTTCAGATACAAAAGAGAATGCAGCCTGTAATCACAGAACAGGTCAGAGACAGAACC\nTCCTTCCAGCTACTCAATCCTGGAACGTACACAGTACAAATAAGAGCCCGGGAAAGAGTG\nTATGAATTCTTGAGCGCCTGGAGCACCCCCCAGCGCTTCGAGTGCGACCAGGAGGAGGGC\nGCAAACACACGTGCCTGGCGGACGTCGCTGCTGATCGCGCTGGGGACGCTGCTGGCCCTG\nGTCTGTGTCTTCGTGATCTGCAGAAGGTATCTGGTGATGCAGAGACTCTTTCCCCGCATC\nCCTCACATGAAAGACCCCATCGGTGACAGCTTCCAAAACGACAAGCTGGTGGTCTGGGAG\nGCGGGCAAAGCCGGCCTGGAGGAGTGTCTGGTGACTGAAGTACAGGTCGTGCAGAAAACT\nTGA'], 'pfams': [{'pfam': [{'identifier': ['PF09240'], 'name': ['IL6Ra-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['interleukin-3 receptor activity']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['cellular response to interleukin-3']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['interleukin-3-mediated signaling pathway']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['Ras protein signal transduction']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}]}]}]}, {'id': ['BE0002115'], 'name': ['Cytokine receptor common subunit beta'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A13107'], 'pubmed-id': ['1424804'], 'citation': ['Shen Y, Baker E, Callen DF, Sutherland GR, Willson TA, Rakar S, Gough NM: Localization of the human GM-CSF receptor beta chain gene (CSF2RB) to chromosome 22q12.2-->q13.1. Cytogenet Cell Genet. 1992;61(3):175-7.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Cytokine receptor common subunit beta'], 'general-function': ['Receptor activity'], 'specific-function': ['High affinity receptor for interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor.'], 'gene-name': ['CSF2RB'], 'locus': ['22q13.1'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['444-460'], 'signal-regions': ['1-16'], 'theoretical-pi': ['5.21'], 'molecular-weight': ['97334.89'], 'chromosome-location': ['22'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:2436']}, {'resource': ['GenAtlas'], 'identifier': ['CSF2RB']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M59941']}, {'resource': ['GenBank Protein Database'], 'identifier': ['487425']}, {'resource': ['UniProtKB'], 'identifier': ['P32927']}, {'resource': ['UniProt Accession'], 'identifier': ['IL3RB_HUMAN']}]}], 'synonyms': [{'synonym': ['CDw131', 'GM-CSF/IL-3/IL-5 receptor common beta subunit', 'IL3RB', 'IL5RB']}], 'amino-acid-sequence': ['>lcl|BSEQ0004148|Cytokine receptor common subunit beta\nMVLAQGLLSMALLALCWERSLAGAEETIPLQTLRCYNDYTSHITCRWADTQDAQRLVNVT\nLIRRVNEDLLEPVSCDLSDDMPWSACPHPRCVPRRCVIPCQSFVVTDVDYFSFQPDRPLG\nTRLTVTLTQHVQPPEPRDLQISTDQDHFLLTWSVALGSPQSHWLSPGDLEFEVVYKRLQD\nSWEDAAILLSNTSQATLGPEHLMPSSTYVARVRTRLAPGSRLSGRPSKWSPEVCWDSQPG\nDEAQPQNLECFFDGAAVLSCSWEVRKEVASSVSFGLFYKPSPDAGEEECSPVLREGLGSL\nHTRHHCQIPVPDPATHGQYIVSVQPRRAEKHIKSSVNIQMAPPSLNVTKDGDSYSLRWET\nMKMRYEHIDHTFEIQYRKDTATWKDSKTETLQNAHSMALPALEPSTRYWARVRVRTSRTG\nYNGIWSEWSEARSWDTESVLPMWVLALIVIFLTIAVLLALRFCGIYGYRLRRKWEEKIPN\nPSKSHLFQNGSAELWPPGSMSAFTSGSPPHQGPWGSRFPELEGVFPVGFGDSEVSPLTIE\nDPKHVCDPPSGPDTTPAASDLPTEQPPSPQPGPPAASHTPEKQASSFDFNGPYLGPPHSR\nSLPDILGQPEPPQEGGSQKSPPPGSLEYLCLPAGGQVQLVPLAQAMGPGQAVEVERRPSQ\nGAAGSPSLESGGGPAPPALGPRVGGQDQKDSPVAIPMSSGDTEDPGVASGYVSSADLVFT\nPNSGASSVSLVPSLGLPSDQTPSLCPGLASGPPGAPGPVKSGFEGYVELPPIEGRSPRSP\nRNNPVPPEAKSPVLNPGERPADVSPTSPQPEGLLVLQQVGDYCFLPGLGPGPLSLRSKPS\nSPGPGPEIKNLDQAFQVKKPPGQAVPQVPVIQLFKALKQQDYLSLPPWEVNKPGEVC'], 'gene-sequence': ['>lcl|BSEQ0011533|Cytokine receptor common subunit beta (CSF2RB)\nATGGTGCTGGCCCAGGGGCTGCTCTCCATGGCCCTGCTGGCCCTGTGCTGGGAGCGCAGC\nCTGGCAGGGGCAGAAGAAACCATCCCGCTGCAGACCCTGCGCTGCTACAACGACTACACC\nAGCCACATCACCTGCAGGTGGGCAGACACCCAGGATGCCCAGCGGCTCGTCAACGTGACC\nCTCATTCGCCGGGTGAATGAGGACCTCCTGGAGCCAGTGTCCTGTGACCTCAGTGATGAC\nATGCCCTGGTCAGCCTGCCCCCATCCCCGCTGCGTGCCCAGGAGATGTGTCATTCCCTGC\nCAGAGTTTTGTCGTCACTGACGTTGACTACTTCTCATTCCAACCAGACAGGCCTCTGGGC\nACCCGGCTCACCGTCACTCTGACCCAGCATGTCCAGCCTCCTGAGCCCAGGGACCTGCAG\nATCAGCACCGACCAGGACCACTTCCTGCTGACCTGGAGTGTGGCCCTTGGGAGTCCCCAG\nAGCCACTGGTTGTCCCCAGGGGATCTGGAGTTTGAGGTGGTCTACAAGCGGCTTCAGGAC\nTCTTGGGAGGACGCAGCCATCCTCCTCTCCAACACCTCCCAGGCCACCCTGGGGCCAGAG\nCACCTCATGCCCAGCAGCACCTACGTGGCCCGAGTACGGACCCGCCTGGCCCCAGGTTCT\nCGGCTCTCAGGACGTCCCAGCAAGTGGAGCCCAGAGGTTTGCTGGGACTCCCAGCCAGGG\nGATGAGGCCCAGCCCCAGAACCTGGAGTGCTTCTTTGACGGGGCCGCCGTGCTCAGCTGC\nTCCTGGGAGGTGAGGAAGGAGGTGGCCAGCTCGGTCTCCTTTGGCCTATTCTACAAGCCC\nAGCCCAGATGCAGGGGAGGAAGAGTGCTCCCCAGTGCTGAGGGAGGGGCTCGGCAGCCTC\nCACACCAGGCACCACTGCCAGATTCCCGTGCCCGACCCCGCGACCCACGGCCAATACATC\nGTCTCTGTTCAGCCAAGGAGGGCAGAGAAACACATAAAGAGCTCAGTGAACATCCAGATG\nGCCCCTCCATCCCTCAACGTGACCAAGGATGGAGACAGCTACAGCCTGCGCTGGGAAACA\nATGAAAATGCGATACGAACACATAGACCACACATTTGAGATCCAGTACAGGAAAGACACG\nGCCACGTGGAAGGACAGCAAGACCGAGACCCTCCAGAACGCCCACAGCATGGCCCTGCCA\nGCCCTGGAGCCCTCCACCAGGTACTGGGCCAGGGTGAGGGTCAGGACCTCCCGCACCGGC\nTACAACGGGATCTGGAGCGAGTGGAGTGAGGCGCGCTCCTGGGACACCGAGTCGGTGCTG\nCCTATGTGGGTGCTGGCCCTCATCGTGATCTTCCTCACCATCGCTGTGCTCCTGGCCCTC\nCGCTTCTGTGGCATCTACGGGTACAGGCTGCGCAGAAAGTGGGAGGAGAAGATCCCCAAC\nCCCAGCAAGAGCCACCTGTTCCAGAACGGGAGCGCAGAGCTTTGGCCCCCAGGCAGCATG\nTCGGCCTTCACTAGCGGGAGTCCCCCACACCAGGGGCCGTGGGGCAGCCGCTTCCCTGAG\nCTGGAGGGGGTGTTCCCTGTAGGATTCGGGGACAGCGAGGTGTCACCTCTCACCATAGAG\nGACCCCAAGCATGTCTGTGATCCACCATCTGGGCCTGACACGACTCCAGCTGCCTCAGAT\nCTACCCACAGAGCAGCCCCCCAGCCCCCAGCCAGGCCCGCCTGCCGCCTCCCACACACCT\nGAGAAACAGGCTTCCAGCTTTGACTTCAATGGGCCCTACCTGGGGCCGCCCCACAGCCGC\nTCCCTACCTGACATCCTGGGCCAGCCGGAGCCCCCACAGGAGGGTGGGAGCCAGAAGTCC\nCCACCTCCAGGGTCCCTGGAGTACCTGTGTCTGCCTGCTGGGGGGCAGGTGCAACTGGTC\nCCTCTGGCCCAGGCGATGGGACCAGGACAGGCCGTGGAAGTGGAGAGAAGGCCGAGCCAG\nGGGGCTGCAGGGAGTCCCTCCCTGGAGTCCGGGGGAGGCCCTGCCCCTCCTGCTCTTGGG\nCCAAGGGTGGGAGGACAGGACCAAAAGGACAGCCCTGTGGCTATACCCATGAGCTCTGGG\nGACACTGAGGACCCTGGAGTGGCCTCTGGTTATGTCTCCTCTGCAGACCTGGTATTCACC\nCCAAACTCAGGGGCCTCGTCTGTCTCCCTAGTTCCCTCTCTGGGCCTCCCCTCAGACCAG\nACCCCCAGCTTATGTCCTGGGCTGGCCAGTGGACCCCCTGGAGCCCCAGGCCCTGTGAAG\nTCAGGGTTTGAGGGCTATGTGGAGCTCCCTCCAATTGAGGGCCGGTCCCCCAGGTCACCA\nAGGAACAATCCTGTCCCCCCTGAGGCCAAAAGCCCTGTCCTGAACCCAGGGGAACGCCCG\nGCAGATGTGTCCCCAACATCCCCACAGCCCGAGGGCCTCCTTGTCCTGCAGCAAGTGGGC\nGACTATTGCTTCCTCCCCGGCCTGGGGCCCGGCCCTCTCTCGCTCCGGAGTAAACCTTCT\nTCCCCGGGACCCGGTCCTGAGATCAAGAACCTAGACCAGGCTTTTCAAGTCAAGAAGCCC\nCCAGGCCAGGCTGTGCCCCAGGTGCCCGTCATTCAGCTCTTCAAAGCCCTGAAGCAGCAG\nGACTACCTGTCTCTGCCCCCTTGGGAGGTCAACAAGCCTGGGGAGGTGTGTTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00041'], 'name': ['fn3']}, {'identifier': ['PF09240'], 'name': ['IL6Ra-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['granulocyte macrophage colony-stimulating factor receptor complex']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['cytokine receptor activity']}, {'category': ['function'], 'description': ['receptor activity']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['cellular response to interleukin-3']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['interleukin-3-mediated signaling pathway']}, {'category': ['process'], 'description': ['interleukin-5-mediated signaling pathway']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['Ras protein signal transduction']}, {'category': ['process'], 'description': ['respiratory gaseous exchange']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}]}]}]}, {'id': ['BE0002116'], 'name': ['Syndecan-2'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A13108'], 'pubmed-id': ['10734053'], 'citation': ['Modrowski D, Basle M, Lomri A, Marie PJ: Syndecan-2 is involved in the mitogenic activity and signaling of granulocyte-macrophage colony-stimulating factor in osteoblasts. J Biol Chem. 2000 Mar 31;275(13):9178-85.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Syndecan-2'], 'general-function': ['Pdz domain binding'], 'specific-function': ['Cell surface proteoglycan that bears heparan sulfate. Regulates dendritic arbor morphogenesis (By similarity).'], 'gene-name': ['SDC2'], 'locus': ['8q22-q23'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['145-169'], 'signal-regions': ['1-18'], 'theoretical-pi': ['4.48'], 'molecular-weight': ['22159.62'], 'chromosome-location': ['8'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:10659']}, {'resource': ['GenAtlas'], 'identifier': ['SDC2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['J04621']}, {'resource': ['GenBank Protein Database'], 'identifier': ['386787']}, {'resource': ['UniProtKB'], 'identifier': ['P34741']}, {'resource': ['UniProt Accession'], 'identifier': ['SDC2_HUMAN']}]}], 'synonyms': [{'synonym': ['Fibroglycan', 'Heparan sulfate proteoglycan core protein', 'HSPG', 'HSPG1', 'SYND2']}], 'amino-acid-sequence': ['>lcl|BSEQ0037162|Syndecan-2\nMRRAWILLTLGLVACVSAESRAELTSDKDMYLDNSSIEEASGVYPIDDDDYASASGSGAD\nEDVESPELTTSRPLPKILLTSAAPKVETTTLNIQNKIPAQTKSPEETDKEKVHLSDSERK\nMDPAEEDTNVYTEKHSDSLFKRTEVLAAVIAGGVIGFLFAIFLILLLVYRMRKKDEGSYD\nLGERKPSSAAYQKAPTKEFYA'], 'gene-sequence': ['>lcl|BSEQ0011534|Syndecan-2 (SDC2)\nATGCGGCGCGCGTGGATCCTGCTCACCTTGGGCTTGGTGGCCTGCGTGTCGGCGGAGTCG\nAGAGCAGAGCTGACATCTGATAAAGACATGTACCTTGACAACAGCTCCATTGAAGAAGCT\nTCAGGAGTGTATCCTATTGATGACGATGACTACGCTTCTGCGTCTGGCTCGGGAGCTGAT\nGAGGATGTAGAGAGTCCAGAGCTGACAACATCTCGACCACTTCCAAAGATACTGTTGACT\nAGTGCTGCTCCAAAAGTGGAAACCACGACGCTGAATATACAGAACAAGATACCTGCTCAG\nACAAAGTCACCTGAAGAAACTGATAAAGAGAAAGTTCACCTCTCTGACTCAGAAAGGAAA\nATGGACCCAGCCGAAGAGGATACAAATGTGTATACTGAGAAACACTCAGACAGTCTGTTT\nAAACGGACAGAAGTCCTAGCAGCTGTCATTGCTGGTGGAGTTATTGGCTTTCTCTTTGCA\nATTTTTCTTATCCTGCTGTTGGTGTATCGCATGAGAAAGAAGGATGAAGGAAGCTATGAC\nCTTGGAGAACGCAAACCATCCAGTGCTGCTTATCAGAAGGCACCTACTAAGGAGTTTTAT\nGCGTAA'], 'pfams': [{'pfam': [{'identifier': ['PF01034'], 'name': ['Syndecan']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['Golgi lumen']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['lysosomal lumen']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['PDZ domain binding']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['bioluminescence']}, {'category': ['process'], 'description': ['carbohydrate metabolic process']}, {'category': ['process'], 'description': ['cell migration']}, {'category': ['process'], 'description': ['chondroitin sulfate metabolic process']}, {'category': ['process'], 'description': ['dendrite morphogenesis']}, {'category': ['process'], 'description': ['ephrin receptor signaling pathway']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['glycosaminoglycan biosynthetic process']}, {'category': ['process'], 'description': ['glycosaminoglycan catabolic process']}, {'category': ['process'], 'description': ['glycosaminoglycan metabolic process']}, {'category': ['process'], 'description': ['phototransduction, visible light']}, {'category': ['process'], 'description': ['regulation of dendrite morphogenesis']}, {'category': ['process'], 'description': ['retinoid metabolic process']}, {'category': ['process'], 'description': ['small molecule metabolic process']}]}]}]}, {'id': ['BE0002114'], 'name': ['Bone marrow proteoglycan'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13101'], 'pubmed-id': ['17383764'], 'citation': ['Menon K, Wu Y, Haas J, Sahu SK, Yang B, Zaheer A: Diminished degradation of myelin basic protein by anti-sulfatide antibody and interferon-gamma in myelin from glia maturation factor-deficient mice. Neurosci Res. 2007 Jun;58(2):156-63. Epub 2007 Feb 22.']}, {'ref-id': ['A13102'], 'pubmed-id': ['16522458'], 'citation': ['Letuve S, Lajoie-Kadoch S, Audusseau S, Rothenberg ME, Fiset PO, Ludwig MS, Hamid Q: IL-17E upregulates the expression of proinflammatory cytokines in lung fibroblasts. J Allergy Clin Immunol. 2006 Mar;117(3):590-6. Epub 2006 Feb 8.']}, {'ref-id': ['A13103'], 'pubmed-id': ['17600316'], 'citation': ['Kang JH, Lee da H, Seo H, Park JS, Nam KH, Shin SY, Park CS, Chung IY: Regulation of functional phenotypes of cord blood derived eosinophils by gamma-secretase inhibitor. Am J Respir Cell Mol Biol. 2007 Nov;37(5):571-7. Epub 2007 Jun 28.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Bone marrow proteoglycan'], 'general-function': ['Heparin binding'], 'specific-function': ['Cytotoxin and helminthotoxin. Also induces non-cytolytic histamine release from human basophils. Involved in antiparasitic defense mechanisms and immune hypersensitivity reactions. The proform acts as a proteinase inhibitor, reducing the activity of PAPPA.'], 'gene-name': ['PRG2'], 'locus': ['11q12'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-16'], 'theoretical-pi': ['6.64'], 'molecular-weight': ['25205.345'], 'chromosome-location': ['11'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:9362']}, {'resource': ['GenAtlas'], 'identifier': ['PRG2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['Y00809']}, {'resource': ['GenBank Protein Database'], 'identifier': ['34476']}, {'resource': ['UniProtKB'], 'identifier': ['P13727']}, {'resource': ['UniProt Accession'], 'identifier': ['PRG2_HUMAN']}]}], 'synonyms': [{'synonym': ['BMPG', 'MBP', 'Proteoglycan 2']}], 'amino-acid-sequence': ['>lcl|BSEQ0037161|Bone marrow proteoglycan\nMKLPLLLALLFGAVSALHLRSETSTFETPLGAKTLPEDEETPEQEMEETPCRELEEEEEW\nGSGSEDASKKDGAVESISVPDMVDKNLTCPEEEDTVKVVGIPGCQTCRYLLVRSLQTFSQ\nAWFTCRRCYRGNLVSIHNFNINYRIQCSVSALNQGQVWIGGRITGSGRCRRFQWVDGSRW\nNFAYWAAHQPWSRGGHCVALCTRGGHWRRAHCLRRLPFICSY'], 'gene-sequence': ['>lcl|BSEQ0019238|Bone marrow proteoglycan (PRG2)\nATGAAACTCCCCTTACTTCTGGCTCTTCTATTTGGGGCAGTTTCTGCTCTTCATCTAAGG\nTCTGAGACTTCCACCTTTGAGACCCCTTTGGGTGCTAAGACGCTGCCTGAGGATGAGGAG\nACACCAGAGCAGGAGATGGAGGAGACCCCTTGCAGGGAGCTGGAGGAAGAGGAGGAGTGG\nGGCTCTGGAAGTGAAGATGCCTCCAAGAAAGATGGGGCTGTTGAGTCTATCTCAGTGCCA\nGATATGGTGGACAAAAACCTTACGTGTCCTGAGGAAGAGGACACAGTAAAAGTGGTGGGC\nATCCCTGGGTGCCAGACCTGCCGCTACCTCCTGTTTACTTGCCGGAGGTGCTACAGGGGC\nAACCTGGTTTCCATCCACAACTTCAATATTAATTATCGAATCCAGTGTTCTGTCAGCGCG\nCTCAACCAGGGTCAAGTCTGGATTGGAGGCAGGATCACAGGCTCGGGTCGCTGCAGACGC\nTTTCAGTGGGTTGACGGCAGCCGCTGGAACTTTGCGTACTGGGCTGCTCACCAGCCCTGG\nTCCCGCGGTGGTCACTGCGTGGCCCTGTGTACCCGAGGAGGCCACTGGCGTCGAGCCCAC\nTGCCTCAGAAGACTTCCTTTCATCTGTTCCTACTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00059'], 'name': ['Lectin_C']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['transport vesicle']}, {'category': ['function'], 'description': ['carbohydrate binding']}, {'category': ['function'], 'description': ['heparin binding']}, {'category': ['process'], 'description': ['defense response to bacterium']}, {'category': ['process'], 'description': ['defense response to nematode']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['negative regulation of interleukin-10 production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-4 production']}, {'category': ['process'], 'description': ['regulation of cytokine biosynthetic process']}]}]}]}]}]"
"['DB00022', 'BTD00048', 'BIOD00048']",['Peginterferon alfa-2b'],biotech,"[""Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852]. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2b. Peginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Use of Peginterferon alfa-2b is associated with a wide range of severe adverse effects including the aggravation and development of endocrine and autoimmune disorders, retinopathies, cardiovascular and neuropsychiatric complications, and increased risk of hepatic decompensation in patients with cirrhosis. The use of Peginterferon alfa-2b has largely declined since newer interferon-free antiviral therapies have been developed.\r\n\r\nIn a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) no longer recommend Peginterferon alfa-2b for the treatment of Hepatitis C [A19593]. Peginterferon alfa-2b was used alongside [DB00811] with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality [A19626].\r\n\r\nPeginterferon alfa-2b is available as a variable dose injectable product (tradename Pegintron) used for the treatment of chronic Hepatitis C. Approved in 2001 by the FDA, Pegintron is indicated for the treatment of HCV with [Ribavirin] or other antiviral drugs [FDA Label]. When combined together, Peginterferon alfa-2b and [Ribavirin] have been shown to achieve a SVR between 41% for genotype 1 and 75% for genotypes 2-6 after 48 weeks of treatment.""]",['liquid'],"['Peginterferon alfa-2b is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.\r\n\r\nIt is also indicated for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection, including complete lymphadenectomy.[L45334]']","[""Peginterferon alfa-2b is derived from recombinant human interferon's alfa-2b moeity [FDA Label]. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway. Activation of the JAK/STAT pathway increases expression of multiple genes in multiple tissues involved in the innate antiviral response. Peginterferon alfa-2b may also acitvate the nuclear factor B pathway.""]",[{'food-interaction': ['Limit caffeine intake. Peginterferon alfa-2b can increase the serum levels of caffeine by inhibiting its metabolism through the CYP1A2 pathway.']}],"[{'target': [{'id': ['BE0000661'], 'name': ['Interferon alpha/beta receptor 1'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A1754'], 'pubmed-id': ['15898717'], 'citation': ['Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27.']}, {'ref-id': ['A1758'], 'pubmed-id': ['19955815'], 'citation': ['Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3.']}, {'ref-id': ['A1755'], 'pubmed-id': ['16953837'], 'citation': ['Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interferon alpha/beta receptor 1'], 'general-function': ['Type i interferon receptor activity'], 'specific-function': ['Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.'], 'gene-name': ['IFNAR1'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['437-457'], 'signal-regions': ['1-27'], 'theoretical-pi': ['5.56'], 'molecular-weight': ['63524.81'], 'chromosome-location': ['21'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5432']}, {'resource': ['GenAtlas'], 'identifier': ['IFNAR1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['J03171']}, {'resource': ['GenBank Protein Database'], 'identifier': ['306914']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1723']}, {'resource': ['UniProtKB'], 'identifier': ['P17181']}, {'resource': ['UniProt Accession'], 'identifier': ['INAR1_HUMAN']}]}], 'synonyms': [{'synonym': ['CRF2-1', 'Cytokine receptor class-II member 1', 'Cytokine receptor family 2 member 1', 'IFN-R-1', 'IFNAR', 'Type I interferon receptor 1']}], 'amino-acid-sequence': ['>lcl|BSEQ0001318|Interferon alpha/beta receptor 1\nMMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT\nFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF\nTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI\nENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ\nNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK\nGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP\nVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV\nFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE\nYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN\nEDESESKTSEELQQDFV'], 'gene-sequence': ['>lcl|BSEQ0018987|Interferon alpha/beta receptor 1 (IFNAR1)\nATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTG\nTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC\nATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT\nTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG\nAATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT\nAAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT\nACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG\nGCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT\nTTAAGCTTTACATATAGCTTAGTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT\nGAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA\nAAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT\nATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA\nAATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG\nTGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA\nCCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA\nGGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA\nGAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA\nTCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT\nGTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT\nGAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT\nGTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT\nTTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA\nGTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC\nTTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG\nTATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA\nAAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT\nGATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT\nGAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA'], 'pfams': [{'pfam': [{'identifier': ['PF01108'], 'name': ['Tissue_fac']}, {'identifier': ['PF09294'], 'name': ['Interfer-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['type I interferon receptor activity']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['defense response to virus']}, {'category': ['process'], 'description': ['JAK-STAT cascade']}, {'category': ['process'], 'description': ['positive regulation of interferon-beta production']}, {'category': ['process'], 'description': ['positive regulation of interferon-gamma production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-1 beta secretion']}, {'category': ['process'], 'description': ['positive regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['regulation of type I interferon-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['T cell activation']}, {'category': ['process'], 'description': ['type I interferon biosynthetic process']}, {'category': ['process'], 'description': ['type I interferon signaling pathway']}]}]}]}, {'id': ['BE0000385'], 'name': ['Interferon alpha/beta receptor 2'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A1754'], 'pubmed-id': ['15898717'], 'citation': ['Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27.']}, {'ref-id': ['A1758'], 'pubmed-id': ['19955815'], 'citation': ['Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3.']}, {'ref-id': ['A1755'], 'pubmed-id': ['16953837'], 'citation': ['Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interferon alpha/beta receptor 2'], 'general-function': ['Type i interferon receptor activity'], 'specific-function': ['Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.'], 'gene-name': ['IFNAR2'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['244-264'], 'signal-regions': ['1-26'], 'theoretical-pi': ['4.11'], 'molecular-weight': ['57758.24'], 'chromosome-location': ['21'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5433']}, {'resource': ['GenAtlas'], 'identifier': ['IFNAR2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L42243']}, {'resource': ['GenBank Protein Database'], 'identifier': ['995300']}, {'resource': ['UniProtKB'], 'identifier': ['P48551']}, {'resource': ['UniProt Accession'], 'identifier': ['INAR2_HUMAN']}]}], 'synonyms': [{'synonym': ['IFN-R-2', 'IFNABR', 'IFNARB', 'Interferon alpha binding protein', 'Type I interferon receptor 2']}], 'amino-acid-sequence': ['>lcl|BSEQ0000767|Interferon alpha/beta receptor 2\nMLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS\nIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF\nSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK\nHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE\nSAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD\nMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI\nDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR\nITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT\nFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR'], 'gene-sequence': ['>lcl|BSEQ0018941|Interferon alpha/beta receptor 2 (IFNAR2)\nATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT\nATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT\nTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC\nATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG\nGTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA\nAGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC\nAGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG\nATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA\nGAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG\nCATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA\nATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA\nATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA\nTCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC\nATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG\nAGGCAAGGTCTCGCTAAGGGCTGGAATGCAGTGGCTATTCACAGGTGCAGTCATAATGCA\nCTACAGTCTGAAACTCCTGAGCTCAAACAGTCGTCCTGCCTAAGCTTCCCCAGTAGCTGG\nGATTACAAGCGTGCATCCCTGTGCCCCAGTGATTAA'], 'pfams': [{'pfam': [{'identifier': ['PF01108'], 'name': ['Tissue_fac']}, {'identifier': ['PF09294'], 'name': ['Interfer-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['protein kinase binding']}, {'category': ['function'], 'description': ['type I interferon binding']}, {'category': ['function'], 'description': ['type I interferon receptor activity']}, {'category': ['process'], 'description': ['cell proliferation']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['JAK-STAT cascade']}, {'category': ['process'], 'description': ['regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['regulation of type I interferon-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to interferon-alpha']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['type I interferon signaling pathway']}]}]}]}]}]"
"['DB00023', 'BTD00011', 'BIOD00011']",['Asparaginase Escherichia coli'],biotech,"['Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997]. L-asparaginase of _E. coli_ is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It is available as intramuscular or intravenous injections. Therapeutic L-asparaginase from _E. coli_ works by depleting the levels of non-essential amino acid, asparagine, in lymphoblastic leukemic cells thus promoting apoptotic cell death [A31999]. For patients who develop hypersensitivity to _E. coli_-derived formulations of L-asparaginase, the use of PEGylated or non-PEGylated [DB08886] is recommended [A31999].']",['liquid'],['Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL).[L39809]'],"['Asparagine is a non-essential amino acid that maintains DNA, RNA and protein synthesis and promotes cell growth. While healthy and normal cells are capable of obtaining asparagine via dietary intake or synthesizing the asparagine from aspartate via asparagine synthetase activity, lymphoblastic leukemic cells lack the asparagine synthetase enzyme and cannot produce asparagine _de novo_ [A31999]. Thus, leukemic cells rely on exogenous source of asparagine for protein synthesis and cell survival [A31999]. L-asparagine from E. coli serves to deplete plasma levels of asparagine in leukemic cells by converting L-asparagine to L-aspartic acid and ammonia [A31999], leading to reduced reduced DNA, RNA and protein synthesis; inhibition of cell growth; and ultimately the activation of apoptotic cell-death mechanisms [A31999]. Normal cells, however, are able to synthesize asparagine and thus are affected less by the rapid depletion produced by treatment with the enzyme asparaginase [FDA Label].']",[None],"[{'target': [{'id': ['BE0004798'], 'name': ['L-asparagine'], 'organism': ['Humans'], 'actions': [{'action': ['other/unknown']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A6670'], 'pubmed-id': ['17264295'], 'citation': ['Wetzler M, Sanford BL, Kurtzberg J, DeOliveira D, Frankel SR, Powell BL, Kolitz JE, Bloomfield CD, Larson RA: Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood. 2007 May 15;109(10):4164-7. Epub 2007 Jan 30.']}, {'ref-id': ['A6671'], 'pubmed-id': ['16307417'], 'citation': ['Wenner KA, Vieira Pinheiro JP, Escherich G, Wessalowski R, Jorch N, Wolff J, Stehn M, Kohlschutter A, Boos J, Janka-Schaub GE: Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia. Klin Padiatr. 2005 Nov-Dec;217(6):321-6.']}, {'ref-id': ['A6672'], 'pubmed-id': ['14523472'], 'citation': ['Appel IM, Pinheiro JP, den Boer ML, Lanvers C, Reniers NC, Boos J, Pieters R: Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Leukemia. 2003 Nov;17(11):2254-6.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes']}]}]"
"['DB00024', 'BTD00020', 'BIOD00020']",['Thyrotropin alfa'],biotech,"['Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer. It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one N-linked glycosylation site. The alpha subunit of thyrotropin alfa, which is the effector region responsible for the stimulation of adenylate cyclase, displays close structural similarity with the alpha subunit of human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). The beta subunit (TSHB) bestows its receptor specificity due to the uniqueness to TSH. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.']",['liquid'],['For detection of residueal or recurrent thyroid cancer'],['Thyrotropin Alfa binds to the thyrotropin receptors found on any residual thyroid cells or tissues. This stimulates radioactive iodine uptake for better radiodiagnostic imaging.'],[None],"[{'target': [{'id': ['BE0000490'], 'name': ['Thyrotropin receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1812'], 'pubmed-id': ['15571461'], 'citation': ['Szkudlinski MW: Recombinant human thyrotropins of the twenty-first century. Expert Opin Pharmacother. 2004 Dec;5(12):2435-40.']}, {'ref-id': ['A1814'], 'pubmed-id': ['9039330'], 'citation': ['Conway GS: Clinical manifestations of genetic defects affecting gonadotrophins and their receptors. Clin Endocrinol (Oxf). 1996 Dec;45(6):657-63.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Thyrotropin receptor'], 'general-function': ['Thyroid-stimulating hormone receptor activity'], 'specific-function': ['Receptor for thyrothropin. Plays a central role in controlling thyroid cell metabolism. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Also acts as a receptor for thyrostimulin (GPA2+GPB5).'], 'gene-name': ['TSHR'], 'locus': ['14q31'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['414-441\n451-473\n495-517\n538-560\n581-602\n626-649\n661-682'], 'signal-regions': ['1-20'], 'theoretical-pi': ['6.98'], 'molecular-weight': ['86828.965'], 'chromosome-location': ['14'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:12373']}, {'resource': ['GenAtlas'], 'identifier': ['TSHR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M73747']}, {'resource': ['GenBank Protein Database'], 'identifier': ['903760']}, {'resource': ['IUPHAR'], 'identifier': ['255']}, {'resource': ['UniProtKB'], 'identifier': ['P16473']}, {'resource': ['UniProt Accession'], 'identifier': ['TSHR_HUMAN']}]}], 'synonyms': [{'synonym': ['LGR3', 'Thyroid-stimulating hormone receptor', 'TSH-R']}], 'amino-acid-sequence': ['>lcl|BSEQ0000978|Thyrotropin receptor\nMRPADLLQLVLLLDLPRDLGGMGCSSPPCECHQEEDFRVTCKDIQRIPSLPPSTQTLKLI\nETHLRTIPSHAFSNLPNISRIYVSIDVTLQQLESHSFYNLSKVTHIEIRNTRNLTYIDPD\nALKELPLLKFLGIFNTGLKMFPDLTKVYSTDIFFILEITDNPYMTSIPVNAFQGLCNETL\nTLKLYNNGFTSVQGYAFNGTKLDAVYLNKNKYLTVIDKDAFGGVYSGPSLLDVSQTSVTA\nLPSKGLEHLKELIARNTWTLKKLPLSLSFLHLTRADLSYPSHCCAFKNQKKIRGILESLM\nCNESSMQSLRQRKSVNALNSPLHQEYEENLGDSIVGYKEKSKFQDTHNNAHYYVFFEEQE\nDEIIGFGQELKNPQEETLQAFDSHYDYTICGDSEDMVCTPKSDEFNPCEDIMGYKFLRIV\nVWFVSLLALLGNVFVLLILLTSHYKLNVPRFLMCNLAFADFCMGMYLLLIASVDLYTHSE\nYYNHAIDWQTGPGCNTAGFFTVFASELSVYTLTVITLERWYAITFAMRLDRKIRLRHACA\nIMVGGWVCCFLLALLPLVGISSYAKVSICLPMDTETPLALAYIVFVLTLNIVAFVIVCCC\nYVKIYITVRNPQYNPGDKDTKIAKRMAVLIFTDFICMAPISFYALSAILNKPLITVSNSK\nILLVLFYPLNSCANPFLYAIFTKAFQRDVFILLSKFGICKRQAQAYRGQRVPPKNSTDIQ\nVQKVTHDMRQGLHNMEDVYELIENSHLTPKKQGQISEEYMQTVL'], 'gene-sequence': ['>lcl|BSEQ0010345|Thyrotropin receptor (TSHR)\nATGAGGCCGGCGGACTTGCTGCAGCTGGTGCTGCTGCTCGACCTGCCCAGGGACCTGGGC\nGGAATGGGGTGTTCGTCTCCACCCTGCGAGTGCCATCAGGAGGAGGACTTCAGAGTCACC\nTGCAAGGATATTCAACGCATCCCCAGCTTACCGCCCAGTACGCAGACTCTGAAGCTTATT\nGAGACTCACCTGAGAACTATTCCAAGTCATGCATTTTCTAATCTGCCCAATATTTCCAGA\nATCTACGTATCTATAGATGTGACTCTGCAGCAGCTGGAATCACACTCCTTCTACAATTTG\nAGTAAAGTGACTCACATAGAAATTCGGAATACCAGGAACTTAACTTACATAGACCCTGAT\nGCCCTCAAAGAGCTCCCCCTCCTAAAGTTCCTTGGCATTTTCAACACTGGACTTAAAATG\nTTCCCTGACCTGACCAAAGTTTATTCCACTGATATATTCTTTATACTTGAAATTACAGAC\nAACCCTTACATGACGTCAATCCCTGTGAATGCTTTTCAGGGACTATGCAATGAAACCTTG\nACACTGAAGCTGTACAACAATGGCTTTACTTCAGTCCAAGGATATGCTTTCAATGGGACA\nAAGCTGGATGCTGTTTACCTAAACAAGAATAAATACCTGACAGTTATTGACAAAGATGCA\nTTTGGAGGAGTATACAGTGGACCAAGCTTGCTGGACGTGTCTCAAACCAGTGTCACTGCC\nCTTCCATCCAAAGGCCTGGAGCACCTGAAGGAACTGATAGCAAGAAACACCTGGACTCTT\nAAGAAACTTCCACTTTCCTTGAGTTTCCTTCACCTCACACGGGCTGACCTTTCTTACCCA\nAGCCACTGCTGTGCTTTTAAGAATCAGAAGAAAATCAGAGGAATCCTTGAGTCCTTGATG\nTGTAATGAGAGCAGTATGCAGAGCTTGCGCCAGAGAAAATCTGTGAATGCCTTGAATAGC\nCCCCTCCACCAGGAATATGAAGAGAATCTGGGTGACAGCATTGTTGGGTACAAGGAAAAG\nTCCAAGTTCCAGGATACTCATAACAACGCTCATTATTACGTCTTCTTTGAAGAACAAGAG\nGATGAGATCATTGGTTTTGGCCAGGAGCTCAAAAACCCCCAGGAAGAGACTCTACAAGCT\nTTTGACAGCCATTATGACTACACCATATGTGGGGACAGTGAAGACATGGTGTGTACCCCC\nAAGTCCGATGAGTTCAACCCGTGTGAAGACATAATGGGCTACAAGTTCCTGAGAATTGTG\nGTGTGGTTCGTTAGTCTGCTGGCTCTCCTGGGCAATGTCTTTGTCCTGCTTATTCTCCTC\nACCAGCCACTACAAACTGAACGTCCCCCGCTTTCTCATGTGCAACCTGGCCTTTGCGGAT\nTTCTGCATGGGGATGTACCTGCTCCTCATCGCCTCTGTAGACCTCTACACTCACTCTGAG\nTACTACAACCATGCCATCGACTGGCAGACAGGCCCTGGGTGCAACACGGCTGGTTTCTTC\nACTGTCTTTGCAAGCGAGTTATCGGTGTATACGCTGACGGTCATCACCCTGGAGCGCTGG\nTATGCCATCACCTTCGCCATGCGCCTGGACCGGAAGATCCGCCTCAGGCACGCATGTGCC\nATCATGGTTGGGGGCTGGGTTTGCTGCTTCCTTCTCGCCCTGCTTCCTTTGGTGGGAATA\nAGTAGCTATGCCAAAGTCAGTATCTGCCTGCCCATGGACACCGAGACCCCTCTTGCTCTG\nGCATATATTGTTTTTGTTCTGACGCTCAACATAGTTGCCTTCGTCATCGTCTGCTGCTGT\nTATGTGAAGATCTACATCACAGTCCGAAATCCGCAGTACAACCCAGGGGACAAAGATACC\nAAAATTGCCAAGAGGATGGCTGTGTTGATCTTCACCGACTTCATATGCATGGCCCCAATC\nTCATTCTATGCTCTGTCAGCAATTCTGAACAAGCCTCTCATCACTGTTAGCAACTCCAAA\nATCTTGCTGGTACTCTTCTATCCACTTAACTCCTGTGCCAATCCATTCCTCTATGCTATT\nTTCACCAAGGCCTTCCAGAGGGATGTGTTCATCCTACTCAGCAAGTTTGGCATCTGTAAA\nCGCCAGGCTCAGGCATACCGGGGGCAGAGGGTTCCTCCAAAGAACAGCACTGATATTCAG\nGTTCAAAAGGTTACCCACGAGATGAGGCAGGGTCTCCACAACATGGAAGATGTCTATGAA\nCTGATTGAAAACTCCCATCTAACCCCAAAGAAGCAAGGCCAAATCTCAGAAGAGTATATG\nCAAACGGTTTTGTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}, {'identifier': ['PF13306'], 'name': ['LRR_5']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['function'], 'description': ['G-protein coupled peptide receptor activity']}, {'category': ['function'], 'description': ['thyroid-stimulating hormone receptor activity']}, {'category': ['process'], 'description': ['activation of adenylate cyclase activity']}, {'category': ['process'], 'description': ['adenylate cyclase-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['cell-cell signaling']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger']}, {'category': ['process'], 'description': ['hormone-mediated signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['thyroid-stimulating hormone signaling pathway']}]}]}]}]}]"
"['DB00025', 'BTD00029', 'BIOD00029', 'DB13162', 'DBSALT002413']","['Antihemophilic factor, human recombinant']",biotech,"['Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells']",['solid'],"['The human recombinant antihemophilic factor is indicated for use in adults and children with hemophilia A for the control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.[L41025, L36130]']",['Antihemophilic factor (AHF) is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A (classical hemophilia).'],[None],"[{'target': [{'id': ['BE0000216'], 'name': ['Coagulation factor X'], 'organism': ['Humans'], 'actions': [{'action': ['activator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1816'], 'pubmed-id': ['13801371'], 'citation': ['BLATRIX C, SOULIER JP: [Preparation of a fraction rich in prothrombin, proconvertin, Stuart factor and antihemophilic factor B (P.P.B. fraction)]. Pathol Biol (Paris). 1959 Dec;7:2477-86.']}, {'ref-id': ['A1818'], 'pubmed-id': ['14285227'], 'citation': ['LUNDBLAD RL, DAVIE EW: THE ACTIVATION OF STUART FACTOR (FACTOR X) BY ACTIVATED ANTIHEMOPHILIC FACTOR (ACTIVATED FACTOR 8). Biochemistry. 1965 Jan;4:113-20.']}, {'ref-id': ['A1820'], 'pubmed-id': ['236567'], 'citation': ['Radnoff OD, Saito H: Inhibition of Hageman factor, plasma thromboplastin antecedent, thrombin and other clotting factors by phenylglyoxal hydrate (38500). Proc Soc Exp Biol Med. 1975 Jan;148(1):177-82.']}, {'ref-id': ['A1823'], 'pubmed-id': ['6436416'], 'citation': ['Orthner CL: Characterization of proteases in AHF concentrates: effect on factor VIII:von Willebrand protein as assessed by high-pressure gel permeation chromatography. J Lab Clin Med. 1984 Nov;104(5):816-28.']}, {'ref-id': ['A1824'], 'pubmed-id': ['11891806'], 'citation': ['Freedman J, Mody M, Lazarus AH, Dewar L, Song S, Blanchette VS, Garvey MB, Ofosu FA: Platelet activation and hypercoagulability following treatment with porcine factor VIII (HYATE:C). Am J Hematol. 2002 Mar;69(3):192-9.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Coagulation factor X'], 'general-function': ['Serine-type endopeptidase activity'], 'specific-function': ['Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.'], 'gene-name': ['F10'], 'locus': ['13q34'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-31'], 'theoretical-pi': ['5.74'], 'molecular-weight': ['54731.255'], 'chromosome-location': ['13'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3528']}, {'resource': ['GenAtlas'], 'identifier': ['F10']}, {'resource': ['GenBank Gene Database'], 'identifier': ['K03194']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182841']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2359']}, {'resource': ['UniProtKB'], 'identifier': ['P00742']}, {'resource': ['UniProt Accession'], 'identifier': ['FA10_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.21.6', 'Stuart factor', 'Stuart-Prower factor']}], 'amino-acid-sequence': ['>lcl|BSEQ0010204|Coagulation factor X\nMGRPLHLVLLSASLAGLLLLGESLFIRREQANNILARVTRANSFLEEMKKGHLERECMEE\nTCSYEEAREVFEDSDKTNEFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKN\nCELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLERR\nKRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFDLLDFNQTQPERGDNNLTRIVGGQE\nCKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGE\nAVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGI\nVSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSG\nGPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPE\nVITSSPLK'], 'gene-sequence': ['>lcl|BSEQ0010205|Coagulation factor X (F10)\nATGGGGCGCCCACTGCACCTCGTCCTGCTCAGTGCCTCCCTGGCTGGCCTCCTGCTGCTC\nGGGGAAAGTCTGTTCATCCGCAGGGAGCAGGCCAACAACATCCTGGCGAGGGTCACGAGG\nGCCAATTCCTTTCTTGAAGAGATGAAGAAAGGACACCTCGAAAGAGAGTGCATGGAAGAG\nACCTGCTCATACGAAGAGGCCCGCGAGGTCTTTGAGGACAGCGACAAGACGAATGAATTC\nTGGAATAAATACAAAGATGGCGACCAGTGTGAGACCAGTCCTTGCCAGAACCAGGGCAAA\nTGTAAAGACGGCCTCGGGGAATACACCTGCACCTGTTTAGAAGGATTCGAAGGCAAAAAC\nTGTGAATTATTCACACGGAAGCTCTGCAGCCTGGACAACGGGGACTGTGACCAGTTCTGC\nCACGAGGAACAGAACTCTGTGGTGTGCTCCTGCGCCCGCGGGTACACCCTGGCTGACAAC\nGGCAAGGCCTGCATTCCCACAGGGCCCTACCCCTGTGGGAAACAGACCCTGGAACGCAGG\nAAGAGGTCAGTGGCCCAGGCCACCAGCAGCAGCGGGGAGGCCCCTGACAGCATCACATGG\nAAGCCATATGATGCAGCCGACCTGGACCCCACCGAGAACCCCTTCGACCTGCTTGACTTC\nAACCAGACGCAGCCTGAGAGGGGCGACAACAACCTCACCAGGATCGTGGGAGGCCAGGAA\nTGCAAGGACGGGGAGTGTCCCTGGCAGGCCCTGCTCATCAATGAGGAAAACGAGGGTTTC\nTGTGGTGGAACCATTCTGAGCGAGTTCTACATCCTAACGGCAGCCCACTGTCTCTACCAA\nGCCAAGAGATTCAAGGTGAGGGTAGGGGACCGGAACACGGAGCAGGAGGAGGGCGGTGAG\nGCGGTGCACGAGGTGGAGGTGGTCATCAAGCACAACCGGTTCACAAAGGAGACCTATGAC\nTTCGACATCGCCGTGCTCCGGCTCAAGACCCCCATCACCTTCCGCATGAACGTGGCGCCT\nGCCTGCCTCCCCGAGCGTGACTGGGCCGAGTCCACGCTGATGACGCAGAAGACGGGGATT\nGTGAGCGGCTTCGGGCGCACCCACGAGAAGGGCCGGCAGTCCACCAGGCTCAAGATGCTG\nGAGGTGCCCTACGTGGACCGCAACAGCTGCAAGCTGTCCAGCAGCTTCATCATCACCCAG\nAACATGTTCTGTGCCGGCTACGACACCAAGCAGGAGGATGCCTGCCAGGGGGACAGCGGG\nGGCCCGCACGTCACCCGCTTCAAGGACACCTACTTCGTGACAGGCATCGTCAGCTGGGGA\nGAGGGCTGTGCCCGTAAGGGGAAGTACGGGATCTACACCAAGGTCACCGCCTTCCTCAAG\nTGGATCGACAGGTCCATGAAAACCAGGGGCTTGCCCAAGGCCAAGAGCCATGCCCCGGAG\nGTCATAACGTCCTCTCCATTAAAGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00008'], 'name': ['EGF']}, {'identifier': ['PF00594'], 'name': ['Gla']}, {'identifier': ['PF00089'], 'name': ['Trypsin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['Golgi lumen']}, {'category': ['component'], 'description': ['intrinsic component of external side of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['phospholipid binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, extrinsic pathway']}, {'category': ['process'], 'description': ['blood coagulation, intrinsic pathway']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['peptidyl-glutamic acid carboxylation']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['proteolysis']}]}]}]}, {'id': ['BE0000364'], 'name': ['Coagulation factor IX'], 'organism': ['Humans'], 'actions': [{'action': ['cofactor']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13110'], 'pubmed-id': ['1119107'], 'citation': ['Hule V: [Factor IX inhibitor (antihemophilic factor B, PTC) in a woman]. Vnitr Lek. 1975 Mar;21(3):274-7.']}, {'ref-id': ['A13111'], 'pubmed-id': ['2994716'], 'citation': ['Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K: Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry. 1985 Jul 2;24(14):3736-50.']}, {'ref-id': ['A13112'], 'pubmed-id': ['14240634'], 'citation': ['LUNDBLAD RL, DAVIE EW: THE ACTIVATION OF ANTIHEMOPHILIC FACTOR (FACTOR 8) BY ACTIVATED CHRISTMAS FACTOR (ACTIVATED FACTOR9 9). Biochemistry. 1964 Nov;3:1720-5.']}, {'ref-id': ['A13113'], 'pubmed-id': ['932529'], 'citation': ['Hoofnagle JH, Gerety RJ, Thiel J, Barker LF: The prevalence of hepatitis B surface antigen in commercially prepared plasma products. J Lab Clin Med. 1976 Jul;88(1):102-13.']}, {'ref-id': ['A13114'], 'pubmed-id': ['6422634'], 'citation': ['Prince AM, Horowitz B, Brotman B, Huima T, Richardson L, van den Ende MC: Inactivation of hepatitis B and Hutchinson strain non-A, non-B hepatitis viruses by exposure to Tween 80 and ether. Vox Sang. 1984;46(1):36-43.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Coagulation factor IX'], 'general-function': ['Serine-type endopeptidase activity'], 'specific-function': ['Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca(2+) ions, phospholipids, and factor VIIIa.'], 'gene-name': ['F9'], 'locus': ['Xq27.1-q27.2'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-28'], 'theoretical-pi': ['5.16'], 'molecular-weight': ['51778.11'], 'chromosome-location': ['X'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3551']}, {'resource': ['GenAtlas'], 'identifier': ['F9']}, {'resource': ['GenBank Gene Database'], 'identifier': ['K02402']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182609']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2364']}, {'resource': ['UniProtKB'], 'identifier': ['P00740']}, {'resource': ['UniProt Accession'], 'identifier': ['FA9_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.21.22', 'Christmas factor', 'Plasma thromboplastin component', 'PTC']}], 'amino-acid-sequence': ['>lcl|BSEQ0000725|Coagulation factor IX\nMQRVNMIMAESPGLITICLLGYLLSAECTVFLDHENANKILNRPKRYNSGKLEEFVQGNL\nERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCP\nFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGR\nVSVSQTSKLTRAETVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPW\nQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRII\nPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVF\nHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVE\nGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT'], 'gene-sequence': ['>lcl|BSEQ0010262|Coagulation factor IX (F9)\nATGCAGCGCGTGAACATGATCATGGCAGAATCACCAGGCCTCATCACCATCTGCCTTTTA\nGGATATCTACTCAGTGCTGAATGTACAGTTTTTCTTGATCATGAAAACGCCAACAAAATT\nCTGAATCGGCCAAAGAGGTATAATTCAGGTAAATTGGAAGAGTTTGTTCAAGGGAACCTT\nGAGAGAGAATGTATGGAAGAAAAGTGTAGTTTTGAAGAAGCACGAGAAGTTTTTGAAAAC\nACTGAAAGAACAACTGAATTTTGGAAGCAGTATGTTGATGGAGATCAGTGTGAGTCCAAT\nCCATGTTTAAATGGCGGCAGTTGCAAGGATGACATTAATTCCTATGAATGTTGGTGTCCC\nTTTGGATTTGAAGGAAAGAACTGTGAATTAGATGTAACATGTAACATTAAGAATGGCAGA\nTGCGAGCAGTTTTGTAAAAATAGTGCTGATAACAAGGTGGTTTGCTCCTGTACTGAGGGA\nTATCGACTTGCAGAAAACCAGAAGTCCTGTGAACCAGCAGTGCCATTTCCATGTGGAAGA\nGTTTCTGTTTCACAAACTTCTAAGCTCACCCGTGCTGAGACTGTTTTTCCTGATGTGGAC\nTATGTAAATTCTACTGAAGCTGAAACCATTTTGGATAACATCACTCAAAGCACCCAATCA\nTTTAATGACTTCACTCGGGTTGTTGGTGGAGAAGATGCCAAACCAGGTCAATTCCCTTGG\nCAGGTTGTTTTGAATGGTAAAGTTGATGCATTCTGTGGAGGCTCTATCGTTAATGAAAAA\nTGGATTGTAACTGCTGCCCACTGTGTTGAAACTGGTGTTAAAATTACAGTTGTCGCAGGT\nGAACATAATATTGAGGAGACAGAACATACAGAGCAAAAGCGAAATGTGATTCGAATTATT\nCCTCACCACAACTACAATGCAGCTATTAATAAGTACAACCATGACATTGCCCTTCTGGAA\nCTGGACGAACCCTTAGTGCTAAACAGCTACGTTACACCTATTTGCATTGCTGACAAGGAA\nTACACGAACATCTTCCTCAAATTTGGATCTGGCTATGTAAGTGGCTGGGGAAGAGTCTTC\nCACAAAGGGAGATCAGCTTTAGTTCTTCAGTACCTTAGAGTTCCACTTGTTGACCGAGCC\nACATGTCTTCGATCTACAAAGTTCACCATCTATAACAACATGTTCTGTGCTGGCTTCCAT\nGAAGGAGGTAGAGATTCATGTCAAGGAGATAGTGGGGGACCCCATGTTACTGAAGTGGAA\nGGGACCAGTTTCTTAACTGGAATTATTAGCTGGGGTGAAGAGTGTGCAATGAAAGGCAAA\nTATGGAATATATACCAAGGTATCCCGGTATGTCAACTGGATTAAGGAAAAAACAAAGCTC\nACTTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00008'], 'name': ['EGF']}, {'identifier': ['PF00594'], 'name': ['Gla']}, {'identifier': ['PF00089'], 'name': ['Trypsin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['Golgi lumen']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['endopeptidase activity']}, {'category': ['function'], 'description': ['serine-type endopeptidase activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, extrinsic pathway']}, {'category': ['process'], 'description': ['blood coagulation, intrinsic pathway']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['peptidyl-glutamic acid carboxylation']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['proteolysis']}, {'category': ['process'], 'description': ['zymogen activation']}]}]}]}, {'id': ['BE0001043'], 'name': ['von Willebrand factor'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13157'], 'pubmed-id': ['10938981'], 'citation': ['Shord SS, Lindley CM: Coagulation products and their uses. Am J Health Syst Pharm. 2000 Aug 1;57(15):1403-17; quiz 1418-20.']}, {'ref-id': ['A13158'], 'pubmed-id': ['11858481'], 'citation': ['Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA: Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost. 2002 Feb;87(2):224-30.']}, {'ref-id': ['A13159'], 'pubmed-id': ['14750934'], 'citation': ['Gill JC, Ewenstein BM, Thompson AR, Mueller-Velten G, Schwartz BA: Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia. 2003 Nov;9(6):688-95.']}, {'ref-id': ['A13160'], 'pubmed-id': ['2128855'], 'citation': ['Smith KJ, Lusher JM, Cohen AR, Salzman P: Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC. Semin Hematol. 1990 Apr;27(2 Suppl 2):25-9.']}, {'ref-id': ['A13161'], 'pubmed-id': ['2942172'], 'citation': ['Altieri DC, Capitanio AM, Mannucci PM: von Willebrand factor contaminating porcine factor VIII concentrate (Hyate:C) causes platelet aggregation. Br J Haematol. 1986 Aug;63(4):703-11.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['von Willebrand factor'], 'general-function': ['Protein n-terminus binding'], 'specific-function': ['Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.'], 'gene-name': ['VWF'], 'locus': ['12p13.3'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-22'], 'theoretical-pi': ['5.21'], 'molecular-weight': ['309261.83'], 'chromosome-location': ['12'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:12726']}, {'resource': ['GenAtlas'], 'identifier': ['VWF']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X04385']}, {'resource': ['GenBank Protein Database'], 'identifier': ['37947']}, {'resource': ['UniProtKB'], 'identifier': ['P04275']}, {'resource': ['UniProt Accession'], 'identifier': ['VWF_HUMAN']}]}], 'synonyms': [{'synonym': ['F8VWF', 'vWF']}], 'amino-acid-sequence': ['>lcl|BSEQ0037116|von Willebrand factor\nMIPARFAGVLLALALILPGTLCAEGTRGRSSTARCSLFGSDFVNTFDGSMYSFAGYCSYL\nLAGGCQKRSFSIIGDFQNGKRVSLSVYLGEFFDIHLFVNGTVTQGDQRVSMPYASKGLYL\nETEAGYYKLSGEAYGFVARIDGSGNFQVLLSDRYFNKTCGLCGNFNIFAEDDFMTQEGTL\nTSDPYDFANSWALSSGEQWCERASPPSSSCNISSGEMQKGLWEQCQLLKSTSVFARCHPL\nVDPEPFVALCEKTLCECAGGLECACPALLEYARTCAQEGMVLYGWTDHSACSPVCPAGME\nYRQCVSPCARTCQSLHINEMCQERCVDGCSCPEGQLLDEGLCVESTECPCVHSGKRYPPG\nTSLSRDCNTCICRNSQWICSNEECPGECLVTGQSHFKSFDNRYFTFSGICQYLLARDCQD\nHSFSIVIETVQCADDRDAVCTRSVTVRLPGLHNSLVKLKHGAGVAMDGQDVQLPLLKGDL\nRIQHTVTASVRLSYGEDLQMDWDGRGRLLVKLSPVYAGKTCGLCGNYNGNQGDDFLTPSG\nLAEPRVEDFGNAWKLHGDCQDLQKQHSDPCALNPRMTRFSEEACAVLTSPTFEACHRAVS\nPLPYLRNCRYDVCSCSDGRECLCGALASYAAACAGRGVRVAWREPGRCELNCPKGQVYLQ\nCGTPCNLTCRSLSYPDEECNEACLEGCFCPPGLYMDERGDCVPKAQCPCYYDGEIFQPED\nIFSDHHTMCYCEDGFMHCTMSGVPGSLLPDAVLSSPLSHRSKRSLSCRPPMVKLVCPADN\nLRAEGLECTKTCQNYDLECMSMGCVSGCLCPPGMVRHENRCVALERCPCFHQGKEYAPGE\nTVKIGCNTCVCQDRKWNCTDHVCDATCSTIGMAHYLTFDGLKYLFPGECQYVLVQDYCGS\nNPGTFRILVGNKGCSHPSVKCKKRVTILVEGGEIELFDGEVNVKRPMKDETHFEVVESGR\nYIILLLGKALSVVWDRHLSISVVLKQTYQEKVCGLCGNFDGIQNNDLTSSNLQVEEDPVD\nFGNSWKVSSQCADTRKVPLDSSPATCHNNIMKQTMVDSSCRILTSDVFQDCNKLVDPEPY\nLDVCIYDTCSCESIGDCACFCDTIAAYAHVCAQHGKVVTWRTATLCPQSCEERNLRENGY\nECEWRYNSCAPACQVTCQHPEPLACPVQCVEGCHAHCPPGKILDELLQTCVDPEDCPVCE\nVAGRRFASGKKVTLNPSDPEHCQICHCDVVNLTCEACQEPGGLVVPPTDAPVSPTTLYVE\nDISEPPLHDFYCSRLLDLVFLLDGSSRLSEAEFEVLKAFVVDMMERLRISQKWVRVAVVE\nYHDGSHAYIGLKDRKRPSELRRIASQVKYAGSQVASTSEVLKYTLFQIFSKIDRPEASRI\nTLLLMASQEPQRMSRNFVRYVQGLKKKKVIVIPVGIGPHANLKQIRLIEKQAPENKAFVL\nSSVDELEQQRDEIVSYLCDLAPEAPPPTLPPDMAQVTVGPGLLGVSTLGPKRNSMVLDVA\nFVLEGSDKIGEADFNRSKEFMEEVIQRMDVGQDSIHVTVLQYSYMVTVEYPFSEAQSKGD\nILQRVREIRYQGGNRTNTGLALRYLSDHSFLVSQGDREQAPNLVYMVTGNPASDEIKRLP\nGDIQVVPIGVGPNANVQELERIGWPNAPILIQDFETLPREAPDLVLQRCCSGEGLQIPTL\nSPAPDCSQPLDVILLLDGSSSFPASYFDEMKSFAKAFISKANIGPRLTQVSVLQYGSITT\nIDVPWNVVPEKAHLLSLVDVMQREGGPSQIGDALGFAVRYLTSEMHGARPGASKAVVILV\nTDVSVDSVDAAADAARSNRVTVFPIGIGDRYDAAQLRILAGPAGDSNVVKLQRIEDLPTM\nVTLGNSFLHKLCSGFVRICMDEDGNEKRPGDVWTLPDQCHTVTCQPDGQTLLKSHRVNCD\nRGLRPSCPNSQSPVKVEETCGCRWTCPCVCTGSSTRHIVTFDGQNFKLTGSCSYVLFQNK\nEQDLEVILHNGACSPGARQGCMKSIEVKHSALSVELHSDMEVTVNGRLVSVPYVGGNMEV\nNVYGAIMHEVRFNHLGHIFTFTPQNNEFQLQLSPKTFASKTYGLCGICDENGANDFMLRD\nGTVTTDWKTLVQEWTVQRPGQTCQPILEEQCLVPDSSHCQVLLLPLFAECHKVLAPATFY\nAICQQDSCHQEQVCEVIASYAHLCRTNGVCVDWRTPDFCAMSCPPSLVYNHCEHGCPRHC\nDGNVSSCGDHPSEGCFCPPDKVMLEGSCVPEEACTQCIGEDGVQHQFLEAWVPDHQPCQI\nCTCLSGRKVNCTTQPCPTAKAPTCGLCEVARLRQNADQCCPEYECVCDPVSCDLPPVPHC\nERGLQPTLTNPGECRPNFTCACRKEECKRVSPPSCPPHRLPTLRKTQCCDEYECACNCVN\nSTVSCPLGYLASTATNDCGCTTTTCLPDKVCVHRSTIYPVGQFWEEGCDVCTCTDMEDAV\nMGLRVAQCSQKPCEDSCRSGFTYVLHEGECCGRCLPSACEVVTGSPRGDSQSSWKSVGSQ\nWASPENPCLINECVRVKEEVFIQQRNVSCPQLEVPVCPSGFQLSCKTSACCPSCRCERME\nACMLNGTVIGPGKTVMIDVCTTCRCMVQVGVISGFKLECRKTTCNPCPLGYKEENNTGEC\nCGRCLPTACTIQLRGGQIMTLKRDETLQDGCDTHFCKVNERGEYFWEKRVTGCPPFDEHK\nCLAEGGKIMKIPGTCCDTCEEPECNDITARLQYVKVGSCKSEVEVDIHYCQGKCASKAMY\nSIDINDVQDQCSCCSPTRTEPMQVALHCTNGSVVYHEVLNAMECKCSPRKCSK'], 'gene-sequence': ['>lcl|BSEQ0016295|von Willebrand factor (VWF)\nATGATTCCTGCCAGATTTGCCGGGGTGCTGCTTGCTCTGGCCCTCATTTTGCCAGGGACC\nCTTTGTGCAGAAGGAACTCGCGGCAGGTCATCCACGGCCCGATGCAGCCTTTTCGGAAGT\nGACTTCGTCAACACCTTTGATGGGAGCATGTACAGCTTTGCGGGATACTGCAGTTACCTC\nCTGGCAGGGGGCTGCCAGAAACGCTCCTTCTCGATTATTGGGGACTTCCAGAATGGCAAG\nAGAGTGAGCCTCTCCGTGTATCTTGGGGAATTTTTTGACATCCATTTGTTTGTCAATGGT\nACCGTGACACAGGGGGACCAAAGAGTCTCCATGCCCTATGCCTCCAAAGGGCTGTATCTA\nGAAACTGAGGCTGGGTACTACAAGCTGTCCGGTGAGGCCTATGGCTTTGTGGCCAGGATC\nGATGGCAGCGGCAACTTTCAAGTCCTGCTGTCAGACAGATACTTCAACAAGACCTGCGGG\nCTGTGTGGCAACTTTAACATCTTTGCTGAAGATGACTTTATGACCCAAGAAGGGACCTTG\nACCTCGGACCCTTATGACTTTGCCAACTCATGGGCTCTGAGCAGTGGAGAACAGTGGTGT\nGAACGGGCATCTCCTCCCAGCAGCTCATGCAACATCTCCTCTGGGGAAATGCAGAAGGGC\nCTGTGGGAGCAGTGCCAGCTTCTGAAGAGCACCTCGGTGTTTGCCCGCTGCCACCCTCTG\nGTGGACCCCGAGCCTTTTGTGGCCCTGTGTGAGAAGACTTTGTGTGAGTGTGCTGGGGGG\nCTGGAGTGCGCCTGCCCTGCCCTCCTGGAGTACGCCCGGACCTGTGCCCAGGAGGGAATG\nGTGCTGTACGGCTGGACCGACCACAGCGCGTGCAGCCCAGTGTGCCCTGCTGGTATGGAG\nTATAGGCAGTGTGTGTCCCCTTGCGCCAGGACCTGCCAGAGCCTGCACATCAATGAAATG\nTGTCAGGAGCGATGCGTGGATGGCTGCAGCTGCCCTGAGGGACAGCTCCTGGATGAAGGC\nCTCTGCGTGGAGAGCACCGAGTGTCCCTGCGTGCATTCCGGAAAGCGCTACCCTCCCGGC\nACCTCCCTCTCTCGAGACTGCAACACCTGCATTTGCCGAAACAGCCAGTGGATCTGCAGC\nAATGAAGAATGTCCAGGGGAGTGCCTTGTCACAGGTCAATCACACTTCAAGAGCTTTGAC\nAACAGATACTTCACCTTCAGTGGGATCTGCCAGTACCTGCTGGCCCGGGATTGCCAGGAC\nCACTCCTTCTCCATTGTCATTGAGACTGTCCAGTGTGCTGATGACCGCGACGCTGTGTGC\nACCCGCTCCGTCACCGTCCGGCTGCCTGGCCTGCACAACAGCCTTGTGAAACTGAAGCAT\nGGGGCAGGAGTTGCCATGGATGGCCAGGACGTCCAGCTCCCCCTCCTGAAAGGTGACCTC\nCGCATCCAGCATACAGTGACGGCCTCCGTGCGCCTCAGCTACGGGGAGGACCTGCAGATG\nGACTGGGATGGCCGCGGGAGGCTGCTGGTGAAGCTGTCCCCCGTCTATGCCGGGAAGACC\nTGCGGCCTGTGTGGGAATTACAATGGCAACCAGGGCGACGACTTCCTTACCCCCTCTGGG\nCTGGCGGAGCCCCGGGTGGAGGACTTCGGGAACGCCTGGAAGCTGCACGGGGACTGCCAG\nGACCTGCAGAAGCAGCACAGCGATCCCTGCGCCCTCAACCCGCGCATGACCAGGTTCTCC\nGAGGAGGCGTGCGCGGTCCTGACGTCCCCCACATTCGAGGCCTGCCATCGTGCCGTCAGC\nCCGCTGCCCTACCTGCGGAACTGCCGCTACGACGTGTGCTCCTGCTCGGACGGCCGCGAG\nTGCCTGTGCGGCGCCCTGGCCAGCTATGCCGCGGCCTGCGCGGGGAGAGGCGTGCGCGTC\nGCGTGGCGCGAGCCAGGCCGCTGTGAGCTGAACTGCCCGAAAGGCCAGGTGTACCTGCAG\nTGCGGGACCCCCTGCAACCTGACCTGCCGCTCTCTCTCTTACCCGGATGAGGAATGCAAT\nGAGGCCTGCCTGGAGGGCTGCTTCTGCCCCCCAGGGCTCTACATGGATGAGAGGGGGGAC\nTGCGTGCCCAAGGCCCAGTGCCCCTGTTACTATGACGGTGAGATCTTCCAGCCAGAAGAC\nATCTTCTCAGACCATCACACCATGTGCTACTGTGAGGATGGCTTCATGCACTGTACCATG\nAGTGGAGTCCCCGGAAGCTTGCTGCCTGACGCTGTCCTCAGCAGTCCCCTGTCTCATCGC\nAGCAAAAGGAGCCTATCCTGTCGGCCCCCCATGGTCAAGCTGGTGTGTCCCGCTGACAAC\nCTGCGGGCTGAAGGGCTCGAGTGTACCAAAACGTGCCAGAACTATGACCTGGAGTGCATG\nAGCATGGGCTGTGTCTCTGGCTGCCTCTGCCCCCCGGGCATGGTCCGGCATGAGAACAGA\nTGTGTGGCCCTGGAAAGGTGTCCCTGCTTCCATCAGGGCAAGGAGTATGCCCCTGGAGAA\nACAGTGAAGATTGGCTGCAACACTTGTGTCTGTCGGGACCGGAAGTGGAACTGCACAGAC\nCATGTGTGTGATGCCACGTGCTCCACGATCGGCATGGCCCACTACCTCACCTTCGACGGG\nCTCAAATACCTGTTCCCCGGGGAGTGCCAGTACGTTCTGGTGCAGGATTACTGCGGCAGT\nAACCCTGGGACCTTTCGGATCCTAGTGGGGAATAAGGGATGCAGCCACCCCTCAGTGAAA\nTGCAAGAAACGGGTCACCATCCTGGTGGAGGGAGGAGAGATTGAGCTGTTTGACGGGGAG\nGTGAATGTGAAGAGGCCCATGAAGGATGAGACTCACTTTGAGGTGGTGGAGTCTGGCCGG\nTACATCATTCTGCTGCTGGGCAAAGCCCTCTCCGTGGTCTGGGACCGCCACCTGAGCATC\nTCCGTGGTCCTGAAGCAGACATACCAGGAGAAAGTGTGTGGCCTGTGTGGGAATTTTGAT\nGGCATCCAGAACAATGACCTCACCAGCAGCAACCTCCAAGTGGAGGAAGACCCTGTGGAC\nTTTGGGAACTCCTGGAAAGTGAGCTCGCAGTGTGCTGACACCAGAAAAGTGCCTCTGGAC\nTCATCCCCTGCCACCTGCCATAACAACATCATGAAGCAGACGATGGTGGATTCCTCCTGT\nAGAATCCTTACCAGTGACGTCTTCCAGGACTGCAACAAGCTGGTGGACCCCGAGCCATAT\nCTGGATGTCTGCATTTACGACACCTGCTCCTGTGAGTCCATTGGGGACTGCGCCTGCTTC\nTGCGACACCATTGCTGCCTATGCCCACGTGTGTGCCCAGCATGGCAAGGTGGTGACCTGG\nAGGACGGCCACATTGTGCCCCCAGAGCTGCGAGGAGAGGAATCTCCGGGAGAACGGGTAT\nGAGTGTGAGTGGCGCTATAACAGCTGTGCACCTGCCTGTCAAGTCACGTGTCAGCACCCT\nGAGCCACTGGCCTGCCCTGTGCAGTGTGTGGAGGGCTGCCATGCCCACTGCCCTCCAGGG\nAAAATCCTGGATGAGCTTTTGCAGACCTGCGTTGACCCTGAAGACTGTCCAGTGTGTGAG\nGTGGCTGGCCGGCGTTTTGCCTCAGGAAAGAAAGTCACCTTGAATCCCAGTGACCCTGAG\nCACTGCCAGATTTGCCACTGTGATGTTGTCAACCTCACCTGTGAAGCCTGCCAGGAGCCG\nGGAGGCCTGGTGGTGCCTCCCACAGATGCCCCGGTGAGCCCCACCACTCTGTATGTGGAG\nGACATCTCGGAACCGCCGTTGCACGATTTCTACTGCAGCAGGCTACTGGACCTGGTCTTC\nCTGCTGGATGGCTCCTCCAGGCTGTCCGAGGCTGAGTTTGAAGTGCTGAAGGCCTTTGTG\nGTGGACATGATGGAGCGGCTGCGCATCTCCCAGAAGTGGGTCCGCGTGGCCGTGGTGGAG\nTACCACGACGGCTCCCACGCCTACATCGGGCTCAAGGACCGGAAGCGACCGTCAGAGCTG\nCGGCGCATTGCCAGCCAGGTGAAGTATGCGGGCAGCCAGGTGGCCTCCACCAGCGAGGTC\nTTGAAATACACACTGTTCCAAATCTTCAGCAAGATCGACCGCCCTGAAGCCTCCCGCATC\nACCCTGCTCCTGATGGCCAGCCAGGAGCCCCAACGGATGTCCCGGAACTTTGTCCGCTAC\nGTCCAGGGCCTGAAGAAGAAGAAGGTCATTGTGATCCCGGTGGGCATTGGGCCCCATGCC\nAACCTCAAGCAGATCCGCCTCATCGAGAAGCAGGCCCCTGAGAACAAGGCCTTCGTGCTG\nAGCAGTGTGGATGAGCTGGAGCAGCAAAGGGACGAGATCGTTAGCTACCTCTGTGACCTT\nGCCCCTGAAGCCCCTCCTCCTACTCTGCCCCCCGACATGGCACAAGTCACTGTGGGCCCG\nGGGCTCTTGGGGGTTTCGACCCTGGGGCCCAAGAGGAACTCCATGGTTCTGGATGTGGCG\nTTCGTCCTGGAAGGATCGGACAAAATTGGTGAAGCCGACTTCAACAGGAGCAAGGAGTTC\nATGGAGGAGGTGATTCAGCGGATGGATGTGGGCCAGGACAGCATCCACGTCACGGTGCTG\nCAGTACTCCTACATGGTGACTGTGGAGTACCCCTTCAGCGAGGCACAGTCCAAAGGGGAC\nATCCTGCAGCGGGTGCGAGAGATCCGCTACCAGGGCGGCAACAGGACCAACACTGGGCTG\nGCCCTGCGGTACCTCTCTGACCACAGCTTCTTGGTCAGCCAGGGTGACCGGGAGCAGGCG\nCCCAACCTGGTCTACATGGTCACCGGAAATCCTGCCTCTGATGAGATCAAGAGGCTGCCT\nGGAGACATCCAGGTGGTGCCCATTGGAGTGGGCCCTAATGCCAACGTGCAGGAGCTGGAG\nAGGATTGGCTGGCCCAATGCCCCTATCCTCATCCAGGACTTTGAGACGCTCCCCCGAGAG\nGCTCCTGACCTGGTGCTGCAGAGGTGCTGCTCCGGAGAGGGGCTGCAGATCCCCACCCTC\nTCCCCTGCACCTGACTGCAGCCAGCCCCTGGACGTGATCCTTCTCCTGGATGGCTCCTCC\nAGTTTCCCAGCTTCTTATTTTGATGAAATGAAGAGTTTCGCCAAGGCTTTCATTTCAAAA\nGCCAATATAGGGCCTCGTCTCACTCAGGTGTCAGTGCTGCAGTATGGAAGCATCACCACC\nATTGACGTGCCATGGAACGTGGTCCCGGAGAAAGCCCATTTGCTGAGCCTTGTGGACGTC\nATGCAGCGGGAGGGAGGCCCCAGCCAAATCGGGGATGCCTTGGGCTTTGCTGTGCGATAC\nTTGACTTCAGAAATGCATGGTGCCAGGCCGGGAGCCTCAAAGGCGGTGGTCATCCTGGTC\nACGGACGTCTCTGTGGATTCAGTGGATGCAGCAGCTGATGCCGCCAGGTCCAACAGAGTG\nACAGTGTTCCCTATTGGAATTGGAGATCGCTACGATGCAGCCCAGCTACGGATCTTGGCA\nGGCCCAGCAGGCGACTCCAACGTGGTGAAGCTCCAGCGAATCGAAGACCTCCCTACCATG\nGTCACCTTGGGCAATTCCTTCCTCCACAAACTGTGCTCTGGATTTGTTAGGATTTGCATG\nGATGAGGATGGGAATGAGAAGAGGCCCGGGGACGTCTGGACCTTGCCAGACCAGTGCCAC\nACCGTGACTTGCCAGCCAGATGGCCAGACCTTGCTGAAGAGTCATCGGGTCAACTGTGAC\nCGGGGGCTGAGGCCTTCGTGCCCTAACAGCCAGTCCCCTGTTAAAGTGGAAGAGACCTGT\nGGCTGCCGCTGGACCTGCCCCTGCGTGTGCACAGGCAGCTCCACTCGGCACATCGTGACC\nTTTGATGGGCAGAATTTCAAGCTGACTGGCAGCTGTTCTTATGTCCTATTTCAAAACAAG\nGAGCAGGACCTGGAGGTGATTCTCCATAATGGTGCCTGCAGCCCTGGAGCAAGGCAGGGC\nTGCATGAAATCCATCGAGGTGAAGCACAGTGCCCTCTCCGTCGAGCTGCACAGTGACATG\nGAGGTGACGGTGAATGGGAGACTGGTCTCTGTTCCTTACGTGGGTGGGAACATGGAAGTC\nAACGTTTATGGTGCCATCATGCATGAGGTCAGATTCAATCACCTTGGTCACATCTTCACA\nTTCACTCCACAAAACAATGAGTTCCAACTGCAGCTCAGCCCCAAGACTTTTGCTTCAAAG\nACGTATGGTCTGTGTGGGATCTGTGATGAGAACGGAGCCAATGACTTCATGCTGAGGGAT\nGGCACAGTCACCACAGACTGGAAAACACTTGTTCAGGAATGGACTGTGCAGCGGCCAGGG\nCAGACGTGCCAGCCCATCCTGGAGGAGCAGTGTCTTGTCCCCGACAGCTCCCACTGCCAG\nGTCCTCCTCTTACCACTGTTTGCTGAATGCCACAAGGTCCTGGCTCCAGCCACATTCTAT\nGCCATCTGCCAGCAGGACAGTTGCCACCAGGAGCAAGTGTGTGAGGTGATCGCCTCTTAT\nGCCCACCTCTGTCGGACCAACGGGGTCTGCGTTGACTGGAGGACACCTGATTTCTGTGCT\nATGTCATGCCCACCATCTCTGGTCTACAACCACTGTGAGCATGGCTGTCCCCGGCACTGT\nGATGGCAACGTGAGCTCCTGTGGGGACCATCCCTCCGAAGGCTGTTTCTGCCCTCCAGAT\nAAAGTCATGTTGGAAGGCAGCTGTGTCCCTGAAGAGGCCTGCACTCAGTGCATTGGTGAG\nGATGGAGTCCAGCACCAGTTCCTGGAAGCCTGGGTCCCGGACCACCAGCCCTGTCAGATC\nTGCACATGCCTCAGCGGGCGGAAGGTCAACTGCACAACGCAGCCCTGCCCCACGGCCAAA\nGCTCCCACGTGTGGCCTGTGTGAAGTAGCCCGCCTCCGCCAGAATGCAGACCAGTGCTGC\nCCCGAGTATGAGTGTGTGTGTGACCCAGTGAGCTGTGACCTGCCCCCAGTGCCTCACTGT\nGAACGTGGCCTCCAGCCCACACTGACCAACCCTGGCGAGTGCAGACCCAACTTCACCTGC\nGCCTGCAGGAAGGAGGAGTGCAAAAGAGTGTCCCCACCCTCCTGCCCCCCGCACCGTTTG\nCCCACCCTTCGGAAGACCCAGTGCTGTGATGAGTATGAGTGTGCCTGCAACTGTGTCAAC\nTCCACAGTGAGCTGTCCCCTTGGGTACTTGGCCTCAACTGCCACCAATGACTGTGGCTGT\nACCACAACCACCTGCCTTCCCGACAAGGTGTGTGTCCACCGAAGCACCATCTACCCTGTG\nGGCCAGTTCTGGGAGGAGGGCTGCGATGTGTGCACCTGCACCGACATGGAGGATGCCGTG\nATGGGCCTCCGCGTGGCCCAGTGCTCCCAGAAGCCCTGTGAGGACAGCTGTCGGTCGGGC\nTTCACTTACGTTCTGCATGAAGGCGAGTGCTGTGGAAGGTGCCTGCCATCTGCCTGTGAG\nGTGGTGACTGGCTCACCGCGGGGGGACTCCCAGTCTTCCTGGAAGAGTGTCGGCTCCCAG\nTGGGCCTCCCCGGAGAACCCCTGCCTCATCAATGAGTGTGTCCGAGTGAAGGAGGAGGTC\nTTTATACAACAAAGGAACGTCTCCTGCCCCCAGCTGGAGGTCCCTGTCTGCCCCTCGGGC\nTTTCAGCTGAGCTGTAAGACCTCAGCGTGCTGCCCAAGCTGTCGCTGTGAGCGCATGGAG\nGCCTGCATGCTCAATGGCACTGTCATTGGGCCCGGGAAGACTGTGATGATCGATGTGTGC\nACGACCTGCCGCTGCATGGTGCAGGTGGGGGTCATCTCTGGATTCAAGCTGGAGTGCAGG\nAAGACCACCTGCAACCCCTGCCCCCTGGGTTACAAGGAAGAAAATAACACAGGTGAATGT\nTGTGGGAGATGTTTGCCTACGGCTTGCACCATTCAGCTAAGAGGAGGACAGATCATGACA\nCTGAAGCGTGATGAGACGCTCCAGGATGGCTGTGATACTCACTTCTGCAAGGTCAATGAG\nAGAGGAGAGTACTTCTGGGAGAAGAGGGTCACAGGCTGCCCACCCTTTGATGAACACAAG\nTGTCTGGCTGAGGGAGGTAAAATTATGAAAATTCCAGGCACCTGCTGTGACACATGTGAG\nGAGCCTGAGTGCAACGACATCACTGCCAGGCTGCAGTATGTCAAGGTGGGAAGCTGTAAG\nTCTGAAGTAGAGGTGGATATCCACTACTGCCAGGGCAAATGTGCCAGCAAAGCCATGTAC\nTCCATTGACATCAACGATGTGCAGGACCAGTGCTCCTGCTGCTCTCCGACACGGACGGAG\nCCCATGCAGGTGGCCCTGCACTGCACCAATGGCTCTGTTGTGTACCATGAGGTTCTCAAT\nGCCATGGAGTGCAAATGCTCCCCCAGGAAGTGCAGCAAGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00093'], 'name': ['VWC']}, {'identifier': ['PF00092'], 'name': ['VWA']}, {'identifier': ['PF00094'], 'name': ['VWD']}, {'identifier': ['PF08742'], 'name': ['C8']}, {'identifier': ['PF01826'], 'name': ['TIL']}, {'identifier': ['PF16164'], 'name': ['VWA_N2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endoplasmic reticulum']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular matrix']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['platelet alpha granule']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['component'], 'description': ['proteinaceous extracellular matrix']}, {'category': ['component'], 'description': ['Weibel-Palade body']}, {'category': ['function'], 'description': ['chaperone binding']}, {'category': ['function'], 'description': ['collagen binding']}, {'category': ['function'], 'description': ['glycoprotein binding']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['function'], 'description': ['immunoglobulin binding']}, {'category': ['function'], 'description': ['integrin binding']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['function'], 'description': ['protein homodimerization activity']}, {'category': ['function'], 'description': ['protein N-terminus binding']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, intrinsic pathway']}, {'category': ['process'], 'description': ['cell adhesion']}, {'category': ['process'], 'description': ['cell-substrate adhesion']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['hemostasis']}, {'category': ['process'], 'description': ['liver development']}, {'category': ['process'], 'description': ['placenta development']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['protein homooligomerization']}, {'category': ['process'], 'description': ['response to wounding']}]}]}]}, {'id': ['BE0002117'], 'name': ['Phytanoyl-CoA dioxygenase, peroxisomal'], 'organism': ['Humans'], 'actions': [{'action': ['antagonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13109'], 'pubmed-id': ['11574539'], 'citation': ['Chen C, Wang Q, Fang X, Xu Q, Chi C, Gu J: Roles of phytanoyl-CoA alpha-hydroxylase in mediating the expression of human coagulation factor VIII. J Biol Chem. 2001 Dec 7;276(49):46340-6.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Phytanoyl-CoA dioxygenase, peroxisomal'], 'general-function': ['Phytanoyl-coa dioxygenase activity'], 'specific-function': ['Converts phytanoyl-CoA to 2-hydroxyphytanoyl-CoA.'], 'gene-name': ['PHYH'], 'locus': ['10pter-p11.2'], 'cellular-location': ['Peroxisome'], 'transmembrane-regions': [None], 'signal-regions': [None], 'theoretical-pi': ['8.65'], 'molecular-weight': ['38538.065'], 'chromosome-location': ['10'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:8940']}, {'resource': ['GenAtlas'], 'identifier': ['PHYH']}, {'resource': ['GenBank Gene Database'], 'identifier': ['AF023462']}, {'resource': ['GenBank Protein Database'], 'identifier': ['2564671']}, {'resource': ['UniProtKB'], 'identifier': ['O14832']}, {'resource': ['UniProt Accession'], 'identifier': ['PAHX_HUMAN']}]}], 'synonyms': [{'synonym': ['1.14.11.18', 'PAHX', 'PhyH', 'Phytanic acid oxidase', 'Phytanoyl-CoA alpha-hydroxylase']}], 'amino-acid-sequence': ['>lcl|BSEQ0004152|Phytanoyl-CoA dioxygenase, peroxisomal\nMEQLRAAARLQIVLGHLGRPSAGAVVAHPTSGTISSASFHPQQFQYTLDNNVLTLEQRKF\nYEENGFLVIKNLVPDADIQRFRNEFEKICRKEVKPLGLTVMRDVTISKSEYAPSEKMITK\nVQDFQEDKELFRYCTLPEILKYVECFTGPNIMAMHTMLINKPPDSGKKTSRHPLHQDLHY\nFPFRPSDLIVCAWTAMEHISRNNGCLVVLPGTHKGSLKPHDYPKWEGGVNKMFHGIQDYE\nENKARVHLVMEKGDTVFFHPLLIHGSGQNKTQGFRKAISCHFASADCHYIDVKGTSQENI\nEKEVVGIAHKFFGAENSVNLKDIWMFRARLVKGERTNL'], 'gene-sequence': ['>lcl|BSEQ0016686|Phytanoyl-CoA dioxygenase, peroxisomal (PHYH)\nATGAGAGATGTGACCATTTCGAAATCCGAATATGCTCCAAGTGAGAAGATGATCACGAAG\nGTCCAGGATTTCCAGGAAGATAAGGAGCTCTTCAGATACTGCACTCTCCCCGAGATTCTG\nAAATATGTGGAGTGCTTCACTGGACCTAATATTATGGCCATGCACACAATGTTGATAAAC\nAAACCTCCAGATTCTGGCAAGAAGACGTCCCGTCACCCCCTGCACCAGGACCTGCACTAT\nTTCCCCTTCAGGCCCAGCGATCTCATCGTTTGCGCCTGGACGGCGATGGAGCACATCAGC\nCGGAACAACGGCTGTCTGGTTGTGCTCCCAGGCACACACAAGGGCTCCCTGAAGCCCCAC\nGATTACCCCAAGTGGGAGGGGGGAGTTAACAAAATGTTCCACGGGATCCAGGACTACGAG\nGAAAACAAGGCCCGGGTGCACCTGGTGATGGAGAAGGGCGACACTGTTTTCTTCCATCCT\nTTGCTCATCCACGGATCTGGTCAGAATAAAACCCAGGGATTCCGGAAGGCAATTTCCTGC\nCATTTCGCCAGTGCCGATTGCCACTACATTGACGTGAAGGGCACCAGTCAAGAAAACATC\nGAGAAGGAAGTTGTAGGAATAGCACATAAATTCTTTGGAGCTGAAAATAGCGTGAACTTG\nAAGGATATTTGGATGTTTCGAGCTCGACTTGTGAAAGGAGAAAGAACCAATCTTTGA'], 'pfams': [{'pfam': [{'identifier': ['PF05721'], 'name': ['PhyH']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['mitochondrion']}, {'category': ['component'], 'description': ['peroxisomal matrix']}, {'category': ['component'], 'description': ['peroxisome']}, {'category': ['function'], 'description': ['cofactor binding']}, {'category': ['function'], 'description': ['L-ascorbic acid binding']}, {'category': ['function'], 'description': ['metal ion binding']}, {'category': ['function'], 'description': ['phytanoyl-CoA dioxygenase activity']}, {'category': ['process'], 'description': ['cellular lipid metabolic process']}, {'category': ['process'], 'description': ['fatty acid alpha-oxidation']}, {'category': ['process'], 'description': ['isoprenoid metabolic process']}, {'category': ['process'], 'description': ['methyl-branched fatty acid metabolic process']}, {'category': ['process'], 'description': ['small molecule metabolic process']}]}]}]}, {'id': ['BE0002118'], 'name': ['Asialoglycoprotein receptor 2'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13115'], 'pubmed-id': ['15946216'], 'citation': ['Bovenschen N, Rijken DC, Havekes LM, van Vlijmen BJ, Mertens K: The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost. 2005 Jun;3(6):1257-65.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Asialoglycoprotein receptor 2'], 'general-function': ['Carbohydrate binding'], 'specific-function': ['Mediates the endocytosis of plasma glycoproteins to which the terminal sialic acid residue on their complex carbohydrate moieties has been removed. The receptor recognizes terminal galactose and N-acetylgalactosamine units. After ligand binding to the receptor, the resulting complex is internalized and transported to a sorting organelle, where receptor and ligand are disassociated. The receptor then returns to the cell membrane surface.'], 'gene-name': ['ASGR2'], 'locus': ['17p'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['59-79'], 'signal-regions': [None], 'theoretical-pi': ['6.34'], 'molecular-weight': ['35092.04'], 'chromosome-location': ['17'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:743']}, {'resource': ['GenAtlas'], 'identifier': ['ASGR2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M11025']}, {'resource': ['GenBank Protein Database'], 'identifier': ['179081']}, {'resource': ['UniProtKB'], 'identifier': ['P07307']}, {'resource': ['UniProt Accession'], 'identifier': ['ASGR2_HUMAN']}]}], 'synonyms': [{'synonym': ['ASGP-R 2', 'C-type lectin domain family 4 member H2', 'CLEC4H2', 'Hepatic lectin H2', 'HL-2']}], 'amino-acid-sequence': ['>lcl|BSEQ0037163|Asialoglycoprotein receptor 2\nMAKDFQDIQQLSSEENDHPFHQGEGPGTRRLNPRRGNPFLKGPPPAQPLAQRLCSMVCFS\nLLALSFNILLLVVICVTGSQSEGHGGAQLQAELRSLKEAFSNFSSSTLTEVQAISTHGGS\nVGDKITSLGAKLEKQQQDLKADHDALLFHLKHFPVDLRFVACQMELLHSNGSQRTCCPVN\nWVEHQGSCYWFSHSGKAWAEAEKYCQLENAHLVVINSWEEQKFIVQHTNPFNTWIGLTDS\nDGSWKWVDGTDYRHNYKNWAVTQPDNWHGHELGGSEDCVEVQPDGRWNDDFCLQVYRWVC\nEKRRNATGEVA'], 'gene-sequence': ['>lcl|BSEQ0011535|Asialoglycoprotein receptor 2 (ASGR2)\nATGGCCAAGGACTTTCAAGATATCCAGCAGCTGAGCTCGGAGGAAAATGACCATCCTTTC\nCATCAAGGTGAGGGGCCAGGCACTCGCAGGCTGAATCCCAGGAGAGGAAATCCATTTTTG\nAAAGGGCCACCTCCTGCCCAGCCCCTGGCACAGCGTCTCTGCTCCATGGTCTGCTTCAGT\nCTGCTTGCCCTGAGCTTCAACATCCTGCTGCTGGTGGTCATCTGTGTGACTGGGTCCCAA\nAGTGAGGGTCACAGGGGTGCACAGCTGCAAGCCGAGCTGCGGAGCCTGAAGGAAGCTTTC\nAGCAACTTCTCCTCGAGCACCCTGACGGAGGTCCAGGCAATCAGCACCCACGGAGGCAGC\nGTGGGTGACAAGATCACATCCCTAGGAGCCAAGCTGGAGAAACAGCAGCAGGACCTGAAA\nGCAGATCACGATGCCCTGCTCTTCCATCTGAAGCACTTCCCCGTGGACCTGCGCTTCGTG\nGCCTGCCAGATGGAGCTCCTCCACAGCAACGGCTCCCAAAGGACCTGCTGCCCCGTCAAC\nTGGGTGGAGCACCAAGGCAGCTGCTACTGGTTCTCTCACTCCGGGAAGGCCTGGGCTGAG\nGCGGAGAAGTACTGCCAGCTGGAGAACGCACACCTGGTGGTCATCAACTCCTGGGAGGAG\nCAGAAATTCATTGTACAACACACGAACCCCTTCAATACCTGGATAGGTCTCACGGACAGT\nGATGGCTCTTGGAAATGGGTGGATGGCACAGACTATAGGCACAACTACAAGAACTGGGCT\nGTCACTCAGCCAGATAATTGGCACGGGCACGAGCTGGGTGGAAGTGAAGACTGTGTTGAA\nGTCCAGCCGGATGGCCGCTGGAACGATGACTTCTGCCTGCAGGTGTACCGCTGGGTGTGT\nGAGAAAAGGCGGAATGCCACCGGCGAGGTGGCCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00059'], 'name': ['Lectin_C']}, {'identifier': ['PF03954'], 'name': ['Lectin_N']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['function'], 'description': ['asialoglycoprotein receptor activity']}, {'category': ['function'], 'description': ['carbohydrate binding']}, {'category': ['process'], 'description': ['bone mineralization']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['glycoprotein metabolic process']}, {'category': ['process'], 'description': ['lipid homeostasis']}, {'category': ['process'], 'description': ['receptor-mediated endocytosis']}, {'category': ['process'], 'description': ['regulation of protein stability']}]}]}]}, {'id': ['BE0001098'], 'name': ['78 kDa glucose-regulated protein'], 'organism': ['Humans'], 'actions': [{'action': ['chaperone']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13116'], 'pubmed-id': ['9607108'], 'citation': ['Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S3-14.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['78 kDa glucose-regulated protein'], 'general-function': ['Unfolded protein binding'], 'specific-function': ['Probably plays a role in facilitating the assembly of multimeric protein complexes inside the endoplasmic reticulum. Involved in the correct folding of proteins and degradation of misfolded proteins via its interaction with DNAJC10, probably to facilitate the release of DNAJC10 from its substrate.'], 'gene-name': ['HSPA5'], 'locus': ['9q33-q34.1'], 'cellular-location': ['Endoplasmic reticulum lumen'], 'transmembrane-regions': [None], 'signal-regions': ['1-18'], 'theoretical-pi': ['4.8'], 'molecular-weight': ['72332.425'], 'chromosome-location': ['9'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5238']}, {'resource': ['GenAtlas'], 'identifier': ['HSPA5']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M19645']}, {'resource': ['GenBank Protein Database'], 'identifier': ['386758']}, {'resource': ['UniProtKB'], 'identifier': ['P11021']}, {'resource': ['UniProt Accession'], 'identifier': ['GRP78_HUMAN']}]}], 'synonyms': [{'synonym': ['BiP', 'Endoplasmic reticulum lumenal Ca(2+)-binding protein grp78', 'GRP-78', 'GRP78', 'Heat shock 70 kDa protein 5', 'Immunoglobulin heavy chain-binding protein']}], 'amino-acid-sequence': ['>lcl|BSEQ0019062|78 kDa glucose-regulated protein\nMKLSLVAAMLLLLSAARAEEEDKKEDVGTVVGIDLGTTYSCVGVFKNGRVEIIANDQGNR\nITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDAKRLIGRTWNDPSVQQDIKFLPFKVV\nEKKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAEAYLGKKVTHAVVTVPAYFNDAQ\nRQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEKNILVFDLGGGTFDVSLLTIDNG\nVFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNRAVQKLRREVEKAKRALS\nSQHQARIEIESFYEGEDFSETLTRAKFEELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIV\nLVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSGDQDTGDLVLLDVC\nPLTLGIETVGGVMTKLIPRNTVVPTKKSQIFSTASDNQPTVTIKVYEGERPLTKDNHLLG\nTFDLTGIPPAPRGVPQIEVTFEIDVNGILRVTAEDKGTGNKNKITITNDQNRLTPEEIER\nMVNDAEKFAEEDKKLKERIDTRNELESYAYSLKNQIGDKEKLGGKLSSEDKETMEKAVEE\nKIEWLESHQDADIEDFKAKKKELEEIVQPIISKLYGSAGPPPTGEEDTAEKDEL'], 'gene-sequence': ['>lcl|BSEQ0019063|78 kDa glucose-regulated protein (HSPA5)\nATGAAGCTCTCCCTGGTGGCCGCGATGCTGCTGCTGCTCAGCGCGGCGCGGGCCGAGGAG\nGAGGACAAGAAGGAGGACGTGGGCACGGTGGTCGGCATCGACCTGGGGACCACCTACTCC\nTGCGTCGGCGTGTTCAAGAACGGCCGCGTGGAGATCATCGCCAACGATCAGGGCAACCGC\nATCACGCCGTCCTATGTCGCCTTCACTCCTGAAGGGGAACGTCTGATTGGCGATGCCGCC\nAAGAACCAGCTCACCTCCAACCCCGAGAACACGGTCTTTGACGCCAAGCGGCTCATCGGC\nCGCACGTGGAATGACCCGTCTGTGCAGCAGGACATCAAGTTCTTGCCGTTCAAGGTGGTT\nGAAAAGAAAACTAAACCATACATTCAAGTTGATATTGGAGGTGGGCAAACAAAGACATTT\nGCTCCTGAAGAAATTTCTGCCATGGTTCTCACTAAAATGAAAGAAACCGCTGAGGCTTAT\nTTGGGAAAGAAGGTTACCCATGCAGTTGTTACTGTACCAGCCTATTTTAATGATGCCCAA\nCGCCAAGCAACCAAAGACGCTGGAACTATTGCTGGCCTAAATGTTATGAGGATCATCAAC\nGAGCCTACGGCAGCTGCTATTGCTTATGGCCTGGATAAGAGGGAGGGGGAGAAGAACATC\nCTGGTGTTTGACCTGGGTGGCGGAACCTTCGATGTGTCTCTTCTCACCATTGACAATGGT\nGTCTTCGAAGTTGTGGCCACTAATGGAGATACTCATCTGGGTGGAGAAGACTTTGACCAG\nCGTGTCATGGAACACTTCATCAAACTGTACAAAAAGAAGACGGGCAAAGATGTCAGGAAA\nGACAATAGAGCTGTGCAGAAACTCCGGCGCGAGGTAGAAAAGGCCAAACGGGCCCTGTCT\nTCTCAGCATCAAGCAAGAATTGAAATTGAGTCCTTCTATGAAGGAGAAGACTTTTCTGAG\nACCCTGACTCGGGCCAAATTTGAAGAGCTCAACATGGATCTGTTCCGGTCTACTATGAAG\nCCCGTCCAGAAAGTGTTGGAAGATTCTGATTTGAAGAAGTCTGATATTGATGAAATTGTT\nCTTGTTGGTGGCTCGACTCGAATTCCAAAGATTCAGCAACTGGTTAAAGAGTTCTTCAAT\nGGCAAGGAACCATCCCGTGGCATAAACCCAGATGAAGCTGTAGCGTATGGTGCTGCTGTC\nCAGGCTGGTGTGCTCTCTGGTGATCAAGATACAGGTGACCTGGTACTGCTTGATGTATGT\nCCCCTTACACTTGGTATTGAAACTGTGGGAGGTGTCATGACCAAACTGATTCCAAGGAAC\nACAGTGGTGCCTACCAAGAAGTCTCAGATCTTTTCTACAGCTTCTGATAATCAACCAACT\nGTTACAATCAAGGTCTATGAAGGTGAAAGACCCCTGACAAAAGACAATCATCTTCTGGGT\nACATTTGATCTGACTGGAATTCCTCCTGCTCCTCGTGGGGTCCCACAGATTGAAGTCACC\nTTTGAGATAGATGTGAATGGTATTCTTCGAGTGACAGCTGAAGACAAGGGTACAGGGAAC\nAAAAATAAGATCACAATCACCAATGACCAGAATCGCCTGACACCTGAAGAAATCGAAAGG\nATGGTTAATGATGCTGAGAAGTTTGCTGAGGAAGACAAAAAGCTCAAGGAGCGCATTGAT\nACTAGAAATGAGTTGGAAAGCTATGCCTATTCTCTAAAGAATCAGATTGGAGATAAAGAA\nAAGCTGGGAGGTAAACTTTCCTCTGAAGATAAGGAGACCATGGAAAAAGCTGTAGAAGAA\nAAGATTGAATGGCTGGAAAGCCACCAAGATGCTGACATTGAAGACTTCAAAGCTAAGAAG\nAAGGAACTGGAAGAAATTGTTCAACCAATTATCAGCAAACTCTATGGAAGTGCAGGCCCT\nCCCCCAACTGGTGAAGAGGATACAGCAGAAAAAGATGAGTTGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00012'], 'name': ['HSP70']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['endoplasmic reticulum']}, {'category': ['component'], 'description': ['endoplasmic reticulum chaperone complex']}, {'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['endoplasmic reticulum membrane']}, {'category': ['component'], 'description': ['endoplasmic reticulum-Golgi intermediate compartment']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['integral component of endoplasmic reticulum membrane']}, {'category': ['component'], 'description': ['melanosome']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['midbody']}, {'category': ['component'], 'description': ['mitochondrion']}, {'category': ['component'], 'description': ['myelin sheath']}, {'category': ['component'], 'description': ['nucleus']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['smooth endoplasmic reticulum']}, {'category': ['function'], 'description': ['ATP binding']}, {'category': ['function'], 'description': ['ATPase activity']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['chaperone binding']}, {'category': ['function'], 'description': ['enzyme binding']}, {'category': ['function'], 'description': ['glycoprotein binding']}, {'category': ['function'], 'description': ['misfolded protein binding']}, {'category': ['function'], 'description': ['protein domain specific binding']}, {'category': ['function'], 'description': ['ribosome binding']}, {'category': ['function'], 'description': ['ubiquitin protein ligase binding']}, {'category': ['function'], 'description': ['unfolded protein binding']}, {'category': ['process'], 'description': ['activation of signaling protein activity involved in unfolded protein response']}, {'category': ['process'], 'description': ['ATF6-mediated unfolded protein response']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['cellular response to antibiotic']}, {'category': ['process'], 'description': ['cellular response to glucose starvation']}, {'category': ['process'], 'description': ['cellular response to interleukin-4']}, {'category': ['process'], 'description': ['cerebellar Purkinje cell layer development']}, {'category': ['process'], 'description': ['cerebellum structural organization']}, {'category': ['process'], 'description': ['endoplasmic reticulum unfolded protein response']}, {'category': ['process'], 'description': ['ER overload response']}, {'category': ['process'], 'description': ['ER-associated ubiquitin-dependent protein catabolic process']}, {'category': ['process'], 'description': ['IRE1-mediated unfolded protein response']}, {'category': ['process'], 'description': ['maintenance of protein localization in endoplasmic reticulum']}, {'category': ['process'], 'description': ['negative regulation of apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of protein homodimerization activity']}, {'category': ['process'], 'description': ['negative regulation of transforming growth factor beta receptor signaling pathway']}, {'category': ['process'], 'description': ['PERK-mediated unfolded protein response']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of protein ubiquitination']}, {'category': ['process'], 'description': ['positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress']}, {'category': ['process'], 'description': ['protein folding in endoplasmic reticulum']}, {'category': ['process'], 'description': ['regulation of ATF6-mediated unfolded protein response']}, {'category': ['process'], 'description': ['regulation of IRE1-mediated unfolded protein response']}, {'category': ['process'], 'description': ['regulation of PERK-mediated unfolded protein response']}, {'category': ['process'], 'description': ['regulation of protein folding in endoplasmic reticulum']}, {'category': ['process'], 'description': ['substantia nigra development']}, {'category': ['process'], 'description': ['toxin transport']}]}]}]}, {'id': ['BE0002109'], 'name': ['Calreticulin'], 'organism': ['Humans'], 'actions': [{'action': ['chaperone']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13117'], 'pubmed-id': ['9525969'], 'citation': ['Pipe SW, Morris JA, Shah J, Kaufman RJ: Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem. 1998 Apr 3;273(14):8537-44.']}, {'ref-id': ['A13118'], 'pubmed-id': ['17899080'], 'citation': ['Srour MA, Grupp J, Aburubaiha Z, Albert T, Brondke H, Oldenburg J, Schwaab R: Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein. Ann Hematol. 2008 Feb;87(2):107-12. Epub 2007 Sep 26.']}, {'ref-id': ['A13116'], 'pubmed-id': ['9607108'], 'citation': ['Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S3-14.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Calreticulin'], 'general-function': ['Zinc ion binding'], 'specific-function': ['Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. This lectin interacts transiently with almost all of the monoglucosylated glycoproteins that are synthesized in the ER. Interacts with the DNA-binding domain of NR3C1 and mediates its nuclear export. Involved in maternal gene expression regulation. May participate in oocyte maturation via the regulation of calcium homeostasis (By similarity).'], 'gene-name': ['CALR'], 'locus': ['19p13.3-p13.2'], 'cellular-location': ['Endoplasmic reticulum lumen'], 'transmembrane-regions': [None], 'signal-regions': ['1-17'], 'theoretical-pi': ['4.04'], 'molecular-weight': ['48141.2'], 'chromosome-location': ['19'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1455']}, {'resource': ['GenAtlas'], 'identifier': ['CALR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M32294']}, {'resource': ['GenBank Protein Database'], 'identifier': ['337487']}, {'resource': ['UniProtKB'], 'identifier': ['P27797']}, {'resource': ['UniProt Accession'], 'identifier': ['CALR_HUMAN']}]}], 'synonyms': [{'synonym': ['Calregulin', 'CRP55', 'CRTC', 'Endoplasmic reticulum resident protein 60', 'ERp60', 'grp60', 'HACBP']}], 'amino-acid-sequence': ['>lcl|BSEQ0011528|Calreticulin\nMLLSVPLLLGLLGLAVAEPAVYFKEQFLDGDGWTSRWIESKHKSDFGKFVLSSGKFYGDE\nEKDKGLQTSQDARFYALSASFEPFSNKGQTLVVQFTVKHEQNIDCGGGYVKLFPNSLDQT\nDMHGDSEYNIMFGPDICGPGTKKVHVIFNYKGKNVLINKDIRCKDDEFTHLYTLIVRPDN\nTYEVKIDNSQVESGSLEDDWDFLPPKKIKDPDASKPEDWDERAKIDDPTDSKPEDWDKPE\nHIPDPDAKKPEDWDEEMDGEWEPPVIQNPEYKGEWKPRQIDNPDYKGTWIHPEIDNPEYS\nPDPSIYAYDNFGVLGLDLWQVKSGTIFDNFLITNDEAYAEEFGNETWGVTKAAEKQMKDK\nQDEEQRLKEEEEDKKRKEEEEAEDKEDDEDKDEDEEDEEDKEEDEEEDVPGQAKDEL'], 'gene-sequence': ['>lcl|BSEQ0011529|Calreticulin (CALR)\nATGCTGCTATCCGTGCCGCTGCTGCTCGGCCTCCTCGGCCTGGCCGTCGCCGAGCCTGCC\nGTCTACTTCAAGGAGCAGTTTCTGGACGGAGACGGGTGGACTTCCCGCTGGATCGAATCC\nAAACACAAGTCAGATTTTGGCAAATTCGTTCTCAGTTCCGGCAAGTTCTACGGTGACGAG\nGAGAAAGATAAAGGTTTGCAGACAAGCCAGGATGCACGCTTTTATGCTCTGTCGGCCAGT\nTTCGAGCCTTTCAGCAACAAAGGCCAGACGCTGGTGGTGCAGTTCACGGTGAAACATGAG\nCAGAACATCGACTGTGGGGGCGGCTATGTGAAGCTGTTTCCTAATAGTTTGGACCAGACA\nGACATGCACGGAGACTCAGAATACAACATCATGTTTGGTCCCGACATCTGTGGCCCTGGC\nACCAAGAAGGTTCATGTCATCTTCAACTACAAGGGCAAGAACGTGCTGATCAACAAGGAC\nATCCGTTGCAAGGATGATGAGTTTACACACCTGTACACACTGATTGTGCGGCCAGACAAC\nACCTATGAGGTGAAGATTGACAACAGCCAGGTGGAGTCCGGCTCCTTGGAAGACGATTGG\nGACTTCCTGCCACCCAAGAAGATAAAGGATCCTGATGCTTCAAAACCGGAAGACTGGGAT\nGAGCGGGCCAAGATCGATGATCCCACAGACTCCAAGCCTGAGGACTGGGACAAGCCCGAG\nCATATCCCTGACCCTGATGCTAAGAAGCCCGAGGACTGGGATGAAGAGATGGACGGAGAG\nTGGGAACCCCCAGTGATTCAGAACCCTGAGTACAAGGGTGAGTGGAAGCCCCGGCAGATC\nGACAACCCAGATTACAAGGGCACTTGGATCCACCCAGAAATTGACAACCCCGAGTATTCT\nCCCGATCCCAGTATCTATGCCTATGATAACTTTGGCGTGCTGGGCCTGGACCTCTGGCAG\nGTCAAGTCTGGCACCATCTTTGACAACTTCCTCATCACCAACGATGAGGCATACGCTGAG\nGAGTTTGGCAACGAGACGTGGGGCGTAACAAAGGCAGCAGAGAAACAAATGAAGGACAAA\nCAGGACGAGGAGCAGAGGCTTAAGGAGGAGGAAGAAGACAAGAAACGCAAAGAGGAGGAG\nGAGGCAGAGGACAAGGAGGATGATGAGGACAAAGATGAGGATGAGGAGGATGAGGAGGAC\nAAGGAGGAAGATGAGGAGGAAGATGTCCCCGGCCAGGCCAAGGACGAGCTGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00262'], 'name': ['Calreticulin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['acrosomal vesicle']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['endocytic vesicle lumen']}, {'category': ['component'], 'description': ['endoplasmic reticulum']}, {'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['Golgi apparatus']}, {'category': ['component'], 'description': ['integral component of lumenal side of endoplasmic reticulum membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['MHC class I peptide loading complex']}, {'category': ['component'], 'description': ['nucleus']}, {'category': ['component'], 'description': ['perinuclear region of cytoplasm']}, {'category': ['component'], 'description': ['polysome']}, {'category': ['component'], 'description': ['proteinaceous extracellular matrix']}, {'category': ['component'], 'description': ['sarcoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['smooth endoplasmic reticulum']}, {'category': ['function'], 'description': ['androgen receptor binding']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['carbohydrate binding']}, {'category': ['function'], 'description': ['chaperone binding']}, {'category': ['function'], 'description': ['complement component C1q binding']}, {'category': ['function'], 'description': ['DNA binding']}, {'category': ['function'], 'description': ['glycoprotein binding']}, {'category': ['function'], 'description': ['hormone binding']}, {'category': ['function'], 'description': ['integrin binding']}, {'category': ['function'], 'description': ['iron ion binding']}, {'category': ['function'], 'description': ['mRNA binding']}, {'category': ['function'], 'description': ['peptide binding']}, {'category': ['function'], 'description': ['poly(A) RNA binding']}, {'category': ['function'], 'description': ['protein binding involved in protein folding']}, {'category': ['function'], 'description': ['ubiquitin protein ligase binding']}, {'category': ['function'], 'description': ['unfolded protein binding']}, {'category': ['function'], 'description': ['zinc ion binding']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent']}, {'category': ['process'], 'description': ['antigen processing and presentation of peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['ATF6-mediated unfolded protein response']}, {'category': ['process'], 'description': ['cardiac muscle cell differentiation']}, {'category': ['process'], 'description': ['cell cycle arrest']}, {'category': ['process'], 'description': ['cellular calcium ion homeostasis']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['cellular response to lithium ion']}, {'category': ['process'], 'description': ['cellular senescence']}, {'category': ['process'], 'description': ['chaperone-mediated protein folding']}, {'category': ['process'], 'description': ['cortical actin cytoskeleton organization']}, {'category': ['process'], 'description': ['endoplasmic reticulum unfolded protein response']}, {'category': ['process'], 'description': ['glucocorticoid receptor signaling pathway']}, {'category': ['process'], 'description': ['negative regulation of intracellular steroid hormone receptor signaling pathway']}, {'category': ['process'], 'description': ['negative regulation of neuron differentiation']}, {'category': ['process'], 'description': ['negative regulation of retinoic acid receptor signaling pathway']}, {'category': ['process'], 'description': ['negative regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['negative regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['negative regulation of translation']}, {'category': ['process'], 'description': ['peptide antigen assembly with MHC class I protein complex']}, {'category': ['process'], 'description': ['positive regulation of cell cycle']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of dendritic cell chemotaxis']}, {'category': ['process'], 'description': ['positive regulation of DNA replication']}, {'category': ['process'], 'description': ['positive regulation of gene expression']}, {'category': ['process'], 'description': ['positive regulation of phagocytosis']}, {'category': ['process'], 'description': ['positive regulation of substrate adhesion-dependent cell spreading']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['protein export from nucleus']}, {'category': ['process'], 'description': ['protein folding']}, {'category': ['process'], 'description': ['protein folding in endoplasmic reticulum']}, {'category': ['process'], 'description': ['protein localization to nucleus']}, {'category': ['process'], 'description': ['protein maturation by protein folding']}, {'category': ['process'], 'description': ['protein N-linked glycosylation via asparagine']}, {'category': ['process'], 'description': ['protein stabilization']}, {'category': ['process'], 'description': ['receptor-mediated endocytosis']}, {'category': ['process'], 'description': ['regulation of apoptotic process']}, {'category': ['process'], 'description': ['regulation of meiotic nuclear division']}, {'category': ['process'], 'description': ['regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['response to drug']}, {'category': ['process'], 'description': ['response to estradiol']}, {'category': ['process'], 'description': ['response to testosterone']}, {'category': ['process'], 'description': ['sequestering of calcium ion']}, {'category': ['process'], 'description': ['spermatogenesis']}]}]}]}, {'id': ['BE0001011'], 'name': ['Calnexin'], 'organism': ['Humans'], 'actions': [{'action': ['chaperone']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13117'], 'pubmed-id': ['9525969'], 'citation': ['Pipe SW, Morris JA, Shah J, Kaufman RJ: Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem. 1998 Apr 3;273(14):8537-44.']}, {'ref-id': ['A13119'], 'pubmed-id': ['15213841'], 'citation': ['Becker S, Simpson JC, Pepperkok R, Heinz S, Herder C, Grez M, Seifried E, Tonn T: Confocal microscopy analysis of native, full length and B-domain deleted coagulation factor VIII trafficking in mammalian cells. Thromb Haemost. 2004 Jul;92(1):23-35.']}, {'ref-id': ['A13118'], 'pubmed-id': ['17899080'], 'citation': ['Srour MA, Grupp J, Aburubaiha Z, Albert T, Brondke H, Oldenburg J, Schwaab R: Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein. Ann Hematol. 2008 Feb;87(2):107-12. Epub 2007 Sep 26.']}, {'ref-id': ['A13116'], 'pubmed-id': ['9607108'], 'citation': ['Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S3-14.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Calnexin'], 'general-function': ['Poly(a) rna binding'], 'specific-function': ['Calcium-binding protein that interacts with newly synthesized glycoproteins in the endoplasmic reticulum. It may act in assisting protein assembly and/or in the retention within the ER of unassembled protein subunits. It seems to play a major role in the quality control apparatus of the ER by the retention of incorrectly folded proteins. Associated with partial T-cell antigen receptor complexes that escape the ER of immature thymocytes, it may function as a signaling complex regulating thymocyte maturation. Additionally it may play a role in receptor-mediated endocytosis at the synapse.'], 'gene-name': ['CANX'], 'locus': ['5q35'], 'cellular-location': ['Endoplasmic reticulum membrane'], 'transmembrane-regions': ['482-502'], 'signal-regions': ['1-20'], 'theoretical-pi': ['4.21'], 'molecular-weight': ['67567.695'], 'chromosome-location': ['5'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1473']}, {'resource': ['GenAtlas'], 'identifier': ['CANX']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L10284']}, {'resource': ['GenBank Protein Database'], 'identifier': ['186523']}, {'resource': ['UniProtKB'], 'identifier': ['P27824']}, {'resource': ['UniProt Accession'], 'identifier': ['CALX_HUMAN']}]}], 'synonyms': [{'synonym': ['IP90', 'Major histocompatibility complex class I antigen-binding protein p88', 'p90']}], 'amino-acid-sequence': ['>lcl|BSEQ0002013|Calnexin\nMEGKWLLCMLLVLGTAIVEAHDGHDDDVIDIEDDLDDVIEEVEDSKPDTTAPPSSPKVTY\nKAPVPTGEVYFADSFDRGTLSGWILSKAKKDDTDDEIAKYDGKWEVEEMKESKLPGDKGL\nVLMSRAKHHAISAKLNKPFLFDTKPLIVQYEVNFQNGIECGGAYVKLLSKTPELNLDQFH\nDKTPYTIMFGPDKCGEDYKLHFIFRHKNPKTGIYEEKHAKRPDADLKTYFTDKKTHLYTL\nILNPDNSFEILVDQSVVNSGNLLNDMTPPVNPSREIEDPEDRKPEDWDERPKIPDPEAVK\nPDDWDEDAPAKIPDEEATKPEGWLDDEPEYVPDPDAEKPEDWDEDMDGEWEAPQIANPRC\nESAPGCGVWQRPVIDNPNYKGKWKPPMIDNPSYQGIWKPRKIPNPDFFEDLEPFRMTPFS\nAIGLELWSMTSDIFFDNFIICADRRIVDDWANDGWGLKKAADGAAEPGVVGQMIEAAEER\nPWLWVVYILTVALPVFLVILFCCSGKKQTSGMEYKKTDAPQPDVKEEEEEKEEEKDKGDE\nEEEGEEKLEEKQKSDAEEDGGTVSQEEEDRKPKAEEDEILNRSPRNRKPRRE'], 'gene-sequence': ['>lcl|BSEQ0016282|Calnexin (CANX)\nATGGAAGGGAAGTGGTTGCTGTGTATGTTACTGGTGCTTGGAACTGCTATTGTTGAGGCT\nCATGATGGACATGATGATGATGTGATTGATATTGAGGATGACCTTGACGATGTCATTGAA\nGAGGTAGAAGACTCAAAACCAGATACCACTGCTCCTCCTTCATCTCCCAAGGTTACTTAC\nAAAGCTCCAGTTCCAACAGGGGAAGTATATTTTGCTGATTCTTTTGACAGAGGAACTCTG\nTCAGGGTGGATTTTATCCAAAGCCAAGAAAGACGATACCGATGATGAAATTGCCAAATAT\nGATGGAAAGTGGGAGGTAGAGGAAATGAAGGAGTCAAAGCTTCCAGGTGATAAAGGACTT\nGTGTTGATGTCTCGGGCCAAGCATCATGCCATCTCTGCTAAACTGAACAAGCCCTTCCTG\nTTTGACACCAAGCCTCTCATTGTTCAGTATGAGGTTAATTTCCAAAATGGAATAGAATGT\nGGTGGTGCCTATGTGAAACTGCTTTCTAAAACACCAGAACTCAACCTGGATCAGTTCCAT\nGACAAGACCCCTTATACGATTATGTTTGGTCCAGATAAATGTGGAGAGGACTATAAACTG\nCACTTCATCTTCCGACACAAAAACCCCAAAACGGGTATCTATGAAGAAAAACATGCTAAG\nAGGCCAGATGCAGATCTGAAGACCTATTTTACTGATAAGAAAACACATCTTTACACACTA\nATCTTGAATCCAGATAATAGTTTTGAAATACTGGTTGACCAATCTGTGGTGAATAGTGGA\nAATCTGCTCAATGACATGACTCCTCCTGTAAATCCTTCACGTGAAATTGAGGACCCAGAA\nGACCGGAAGCCCGAGGATTGGGATGAAAGACCAAAAATCCCAGATCCAGAAGCTGTCAAG\nCCAGATGACTGGGATGAAGATGCCCCTGCTAAGATTCCAGATGAAGAGGCCACAAAACCC\nGAAGGCTGGTTAGATGATGAGCCTGAGTACGTACCTGATCCAGACGCAGAGAAACCTGAG\nGATTGGGATGAAGACATGGATGGAGAATGGGAGGCTCCTCAGATTGCCAACCCTAGATGT\nGAGTCAGCTCCTGGATGTGGTGTCTGGCAGCGACCTGTGATTGACAACCCCAATTATAAA\nGGCAAATGGAAGCCTCCTATGATTGACAATCCCAGTTACCAGGGAATCTGGAAACCCAGG\nAAAATACCAAATCCAGATTTCTTTGAAGATCTGGAACCTTTCAGAATGACTCCTTTTAGT\nGCTATTGGTTTGGAGCTGTGGTCCATGACCTCTGACATTTTTTTTGACAACTTTATCATT\nTGTGCTGATCGAAGAATAGTTGATGATTGGGCCAATGATGGATGGGGCCTGAAGAAAGCT\nGCTGATGGGGCTGCTGAGCCAGGCGTTGTGGGGCAGATGATCGAGGCAGCTGAAGAGCGC\nCCGTGGCTGTGGGTAGTCTATATTCTAACTGTAGCCCTTCCTGTGTTCCTGGTTATCCTC\nTTCTGCTGTTCTGGAAAGAAACAGACCAGTGGTATGGAGTATAAGAAAACTGATGCACCT\nCAACCGGATGTGAAGGAAGAGGAAGAAGAGAAGGAAGAGGAAAAGGACAAGGGAGATGAG\nGAGGAGGAAGGAGAAGAGAAACTTGAAGAGAAACAGAAAAGTGATGCTGAAGAAGATGGT\nGGCACTGTCAGTCAAGAGGAGGAAGACAGAAAACCTAAAGCAGAGGAGGATGAAATTTTG\nAACAGATCACCAAGAAACAGAAAGCCACGAAGAGAGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00262'], 'name': ['Calreticulin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['axon']}, {'category': ['component'], 'description': ['dendrite cytoplasm']}, {'category': ['component'], 'description': ['dendritic spine']}, {'category': ['component'], 'description': ['endoplasmic reticulum']}, {'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['endoplasmic reticulum membrane']}, {'category': ['component'], 'description': ['ER-mitochondrion membrane contact site']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['integral component of lumenal side of endoplasmic reticulum membrane']}, {'category': ['component'], 'description': ['melanosome']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['myelin sheath']}, {'category': ['component'], 'description': ['neuronal cell body']}, {'category': ['component'], 'description': ['protein complex']}, {'category': ['component'], 'description': ['ribosome']}, {'category': ['component'], 'description': ['rough endoplasmic reticulum']}, {'category': ['component'], 'description': ['smooth endoplasmic reticulum']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['carbohydrate binding']}, {'category': ['function'], 'description': ['poly(A) RNA binding']}, {'category': ['process'], 'description': ['aging']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class II']}, {'category': ['process'], 'description': ['antigen processing and presentation of peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['chaperone-mediated protein folding']}, {'category': ['process'], 'description': ['clathrin-mediated endocytosis']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['protein folding']}, {'category': ['process'], 'description': ['protein folding in endoplasmic reticulum']}, {'category': ['process'], 'description': ['protein N-linked glycosylation via asparagine']}, {'category': ['process'], 'description': ['protein secretion']}, {'category': ['process'], 'description': ['synaptic vesicle endocytosis']}]}]}]}, {'id': ['BE0002119'], 'name': ['Protein ERGIC-53'], 'organism': ['Humans'], 'actions': [{'action': ['chaperone']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13120'], 'pubmed-id': ['14629470'], 'citation': ['Cunningham MA, Pipe SW, Zhang B, Hauri HP, Ginsburg D, Kaufman RJ: LMAN1 is a molecular chaperone for the secretion of coagulation factor VIII. J Thromb Haemost. 2003 Nov;1(11):2360-7.']}, {'ref-id': ['A13121'], 'pubmed-id': ['14726380'], 'citation': ['Miao HZ, Sirachainan N, Palmer L, Kucab P, Cunningham MA, Kaufman RJ, Pipe SW: Bioengineering of coagulation factor VIII for improved secretion. Blood. 2004 May 1;103(9):3412-9. Epub 2004 Jan 15.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Protein ERGIC-53'], 'general-function': ['Unfolded protein binding'], 'specific-function': ['Mannose-specific lectin. May recognize sugar residues of glycoproteins, glycolipids, or glycosylphosphatidyl inositol anchors and may be involved in the sorting or recycling of proteins, lipids, or both. The LMAN1-MCFD2 complex forms a specific cargo receptor for the ER-to-Golgi transport of selected proteins.'], 'gene-name': ['LMAN1'], 'locus': ['18q21.3-q22'], 'cellular-location': ['Endoplasmic reticulum-Golgi intermediate compartment membrane'], 'transmembrane-regions': ['478-498'], 'signal-regions': ['1-30'], 'theoretical-pi': ['6.76'], 'molecular-weight': ['57548.665'], 'chromosome-location': ['18'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6631']}, {'resource': ['GenAtlas'], 'identifier': ['LMAN1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X71661']}, {'resource': ['GenBank Protein Database'], 'identifier': ['433938']}, {'resource': ['UniProtKB'], 'identifier': ['P49257']}, {'resource': ['UniProt Accession'], 'identifier': ['LMAN1_HUMAN']}]}], 'synonyms': [{'synonym': ['ER-Golgi intermediate compartment 53 kDa protein', 'ERGIC53', 'F5F8D', 'Gp58', 'Intracellular mannose-specific lectin MR60', 'Lectin mannose-binding 1']}], 'amino-acid-sequence': ['>lcl|BSEQ0019239|Protein ERGIC-53\nMAGSRQRGLRARVRPLFCALLLSLGRFVRGDGVGGDPAVALPHRRFEYKYSFKGPHLVQS\nDGTVPFWAHAGNAIPSSDQIRVAPSLKSQRGSVWTKTKAAFENWEVEVTFRVTGRGRIGA\nDGLAIWYAENQGLEGPVFGSADLWNGVGIFFDSFDNDGKKNNPAIVIIGNNGQIHYDHQN\nDGASQALASCQRDFRNKPYPVRAKITYYQNTLTVMINNGFTPDKNDYEFCAKVENMIIPA\nQGHFGISAATGGLADDHDVLSFLTFQLTEPGKEPPTPDKEISEKEKEKYQEEFEHFQQEL\nDKKKEEFQKGHPDLQGQPAEEIFESVGDRELRQVFEGQNRIHLEIKQLNRQLDMILDEQR\nRYVSSLTEEISKRGAGMPGQHGQITQQELDTVVKTQHEILRQVNEMKNSMSETVRLVSGM\nQHPGSAGGVYETTQHFIDIKEHLHIVKRDIDNLVQRNMPSNEKPKCPELPPFPSCLSTVH\nFIIFVVVQTVLFIGYIMYRSQQEAAAKKFF'], 'gene-sequence': ['>lcl|BSEQ0019240|Protein ERGIC-53 (LMAN1)\nATGGCGGGATCCAGGCAAAGGGGTCTCCGGGCCAGAGTTCGGCCGCTGTTCTGCGCCTTG\nCTGCTGTCACTCGGTCGCTTCGTCCGGGGCGACGGCGTGGGAGGAGACCCCGCGGTCGCG\nTTGCCACATCGCCGTTTCGAGTACAAATACAGCTTCAAGGGGCCGCACCTGGTGCAGAGC\nGACGGGACCGTGCCCTTCTGGGCCCACGCGGGGAATGCTATTCCAAGTTCAGATCAAATT\nCGAGTAGCACCATCTTTAAAAAGCCAAAGAGGCTCAGTGTGGACAAAGACAAAAGCGGCC\nTTTGAGAACTGGGAAGTTGAGGTGACATTTCGAGTGACTGGAAGAGGTCGAATTGGAGCT\nGATGGCCTAGCAATTTGGTATGCAGAAAATCAAGGCTTGGAGGGCCCTGTGTTTGGATCA\nGCTGATCTGTGGAATGGTGTTGGAATATTTTTTGATTCTTTTGACAATGATGGAAAGAAA\nAATAATCCTGCTATAGTAATTATAGGCAACAATGGACAAATCCATTATGACCATCAAAAT\nGACGGGGCTAGTCAAGCTTTGGCAAGTTGCCAGAGGGACTTCCGCAACAAACCCTATCCT\nGTCCGAGCAAAGATTACCTATTACCAGAACACACTGACAGTAATGATCAATAATGGCTTT\nACACCAGATAAAAATGATTATGAATTTTGTGCCAAAGTGGAAAATATGATTATCCCTGCA\nCAAGGGCATTTTGGAATATCTGCTGCAACTGGAGGTCTTGCAGATGACCATGATGTCCTT\nTCTTTTCTGACTTTCCAGTTGACTGAACCTGGAAAAGAGCCGCCCACACCAGATAAAGAA\nATTTCGGAAAAGGAAAAAGAAAAGTATCAGGAGGAATTTGAGCACTTTCAACAAGAATTG\nGATAAAAAAAAAGAGGAATTCCAGAAGGGCCACCCCGACCTCCAAGGGCAGCCTGCGGAG\nGAAATATTTGAGAGTGTAGGAGATCGAGAGCTAAGACAAGTCTTTGAAGGACAGAATCGT\nATTCATCTTGAAATCAAGCAGCTGAACCGGCAGTTAGATATGATTCTTGATGAACAGAGA\nAGATATGTCTCTTCCTTAACAGAGGAAATCTCTAAAAGAGGAGCAGGAATGCCTGGGCAG\nCATGGGCAGATTACTCAACAAGAACTGGATACTGTTGTGAAAACTCAGCATGAGATTCTG\nAGACAAGTAAATGAAATGAAAAATTCCATGAGTGAAACCGTCAGACTGGTCAGTGGAATG\nCAGCACCCTGGCTCTGCTGGAGGCGTCTATGAGACAACACAGCACTTCATTGACATCAAA\nGAGCACCTGCACATAGTAAAGAGGGACATAGATAACTTAGTGCAGCGAAATATGCCATCA\nAATGAAAAGCCGAAATGCCCAGAACTACCACCATTTCCATCATGTTTGTCTACGGTCCAC\nTTCATTATATTTGTTGTGGTGCAAACTGTATTATTCATTGGTTATATCATGTATAGGTCT\nCAGCAAGAAGCAGCTGCCAAAAAATTCTTTTGA'], 'pfams': [{'pfam': [{'identifier': ['PF03388'], 'name': ['Lectin_leg-like']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endoplasmic reticulum membrane']}, {'category': ['component'], 'description': ['endoplasmic reticulum-Golgi intermediate compartment']}, {'category': ['component'], 'description': ['endoplasmic reticulum-Golgi intermediate compartment membrane']}, {'category': ['component'], 'description': ['ER to Golgi transport vesicle membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['Golgi membrane']}, {'category': ['component'], 'description': ['host cell perinuclear region of cytoplasm']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['sarcomere']}, {'category': ['function'], 'description': ['mannose binding']}, {'category': ['function'], 'description': ['metal ion binding']}, {'category': ['function'], 'description': ['unfolded protein binding']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['COPII vesicle coating']}, {'category': ['process'], 'description': ['endoplasmic reticulum organization']}, {'category': ['process'], 'description': ['ER to Golgi vesicle-mediated transport']}, {'category': ['process'], 'description': ['Golgi organization']}, {'category': ['process'], 'description': ['membrane organization']}, {'category': ['process'], 'description': ['positive regulation of organelle organization']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['protein folding']}, {'category': ['process'], 'description': ['protein N-linked glycosylation via asparagine']}, {'category': ['process'], 'description': ['protein transport']}]}]}]}, {'id': ['BE0002110'], 'name': ['Prolow-density lipoprotein receptor-related protein 1'], 'organism': ['Humans'], 'actions': [{'action': ['modulator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13122'], 'pubmed-id': ['21391865'], 'citation': ['Franchini M, Montagnana M: Low-density lipoprotein receptor-related protein 1: new functions for an old molecule. Clin Chem Lab Med. 2011 Jun;49(6):967-70. doi: 10.1515/CCLM.2011.154. Epub 2011 Mar 11.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Prolow-density lipoprotein receptor-related protein 1'], 'general-function': ['Receptor activity'], 'specific-function': ['Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells. Required for early embryonic development. Involved in cellular lipid homeostasis. Involved in the plasma clearance of chylomicron remnants and activated LRPAP1 (alpha 2-macroglobulin), as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate cellular events, such as APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission.Functions as a receptor for Pseudomonas aeruginosa exotoxin A.'], 'gene-name': ['LRP1'], 'locus': ['12q13-q14'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['4420-4444'], 'signal-regions': ['1-19'], 'theoretical-pi': ['5.02'], 'molecular-weight': ['504601.695'], 'chromosome-location': ['12'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6692']}, {'resource': ['GenAtlas'], 'identifier': ['LRP1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X13916']}, {'resource': ['GenBank Protein Database'], 'identifier': ['34339']}, {'resource': ['UniProtKB'], 'identifier': ['Q07954']}, {'resource': ['UniProt Accession'], 'identifier': ['LRP1_HUMAN']}]}], 'synonyms': [{'synonym': ['A2MR', 'Alpha-2-macroglobulin receptor', 'APOER', 'Apolipoprotein E receptor', 'APR', 'LRP-1']}], 'amino-acid-sequence': ['>lcl|BSEQ0037158|Prolow-density lipoprotein receptor-related protein 1\nMLTPPLLLLLPLLSALVAAAIDAPKTCSPKQFACRDQITCISKGWRCDGERDCPDGSDEA\nPEICPQSKAQRCQPNEHNCLGTELCVPMSRLCNGVQDCMDGSDEGPHCRELQGNCSRLGC\nQHHCVPTLDGPTCYCNSSFQLQADGKTCKDFDECSVYGTCSQLCTNTDGSFICGCVEGYL\nLQPDNRSCKAKNEPVDRPPVLLIANSQNILATYLSGAQVSTITPTSTRQTTAMDFSYANE\nTVCWVHVGDSAAQTQLKCARMPGLKGFVDEHTINISLSLHHVEQMAIDWLTGNFYFVDDI\nDDRIFVCNRNGDTCVTLLDLELYNPKGIALDPAMGKVFFTDYGQIPKVERCDMDGQNRTK\nLVDSKIVFPHGITLDLVSRLVYWADAYLDYIEVVDYEGKGRQTIIQGILIEHLYGLTVFE\nNYLYATNSDNANAQQKTSVIRVNRFNSTEYQVVTRVDKGGALHIYHQRRQPRVRSHACEN\nDQYGKPGGCSDICLLANSHKARTCRCRSGFSLGSDGKSCKKPEHELFLVYGKGRPGIIRG\nMDMGAKVPDEHMIPIENLMNPRALDFHAETGFIYFADTTSYLIGRQKIDGTERETILKDG\nIHNVEGVAVDWMGDNLYWTDDGPKKTISVARLEKAAQTRKTLIEGKMTHPRAIVVDPLNG\nWMYWTDWEEDPKDSRRGRLERAWMDGSHRDIFVTSKTVLWPNGLSLDIPAGRLYWVDAFY\nDRIETILLNGTDRKIVYEGPELNHAFGLCHHGNYLFWTEYRSGSVYRLERGVGGAPPTVT\nLLRSERPPIFEIRMYDAQQQQVGTNKCRVNNGGCSSLCLATPGSRQCACAEDQVLDADGV\nTCLANPSYVPPPQCQPGEFACANSRCIQERWKCDGDNDCLDNSDEAPALCHQHTCPSDRF\nKCENNRCIPNRWLCDGDNDCGNSEDESNATCSARTCPPNQFSCASGRCIPISWTCDLDDD\nCGDRSDESASCAYPTCFPLTQFTCNNGRCININWRCDNDNDCGDNSDEAGCSHSCSSTQF\nKCNSGRCIPEHWTCDGDNDCGDYSDETHANCTNQATRPPGGCHTDEFQCRLDGLCIPLRW\nRCDGDTDCMDSSDEKSCEGVTHVCDPSVKFGCKDSARCISKAWVCDGDNDCEDNSDEENC\nESLACRPPSHPCANNTSVCLPPDKLCDGNDDCGDGSDEGELCDQCSLNNGGCSHNCSVAP\nGEGIVCSCPLGMELGPDNHTCQIQSYCAKHLKCSQKCDQNKFSVKCSCYEGWVLEPDGES\nCRSLDPFKPFIIFSNRHEIRRIDLHKGDYSVLVPGLRNTIALDFHLSQSALYWTDVVEDK\nIYRGKLLDNGALTSFEVVIQYGLATPEGLAVDWIAGNIYWVESNLDQIEVAKLDGTLRTT\nLLAGDIEHPRAIALDPRDGILFWTDWDASLPRIEAASMSGAGRRTVHRETGSGGWPNGLT\nVDYLEKRILWIDARSDAIYSARYDGSGHMEVLRGHEFLSHPFAVTLYGGEVYWTDWRTNT\nLAKANKWTGHNVTVVQRTNTQPFDLQVYHPSRQPMAPNPCEANGGQGPCSHLCLINYNRT\nVSCACPHLMKLHKDNTTCYEFKKFLLYARQMEIRGVDLDAPYYNYIISFTVPDIDNVTVL\nDYDAREQRVYWSDVRTQAIKRAFINGTGVETVVSADLPNAHGLAVDWVSRNLFWTSYDTN\nKKQINVARLDGSFKNAVVQGLEQPHGLVVHPLRGKLYWTDGDNISMANMDGSNRTLLFSG\nQKGPVGLAIDFPESKLYWISSGNHTINRCNLDGSGLEVIDAMRSQLGKATALAIMGDKLW\nWADQVSEKMGTCSKADGSGSVVLRNSTTLVMHMKVYDESIQLDHKGTNPCSVNNGDCSQL\nCLPTSETTRSCMCTAGYSLRSGQQACEGVGSFLLYSVHEGIRGIPLDPNDKSDALVPVSG\nTSLAVGIDFHAENDTIYWVDMGLSTISRAKRDQTWREDVVTNGIGRVEGIAVDWIAGNIY\nWTDQGFDVIEVARLNGSFRYVVISQGLDKPRAITVHPEKGYLFWTEWGQYPRIERSRLDG\nTERVVLVNVSISWPNGISVDYQDGKLYWCDARTDKIERIDLETGENREVVLSSNNMDMFS\nVSVFEDFIYWSDRTHANGSIKRGSKDNATDSVPLRTGIGVQLKDIKVFNRDRQKGTNVCA\nVANGGCQQLCLYRGRGQRACACAHGMLAEDGASCREYAGYLLYSERTILKSIHLSDERNL\nNAPVQPFEDPEHMKNVIALAFDYRAGTSPGTPNRIFFSDIHFGNIQQINDDGSRRITIVE\nNVGSVEGLAYHRGWDTLYWTSYTTSTITRHTVDQTRPGAFERETVITMSGDDHPRAFVLD\nECQNLMFWTNWNEQHPSIMRAALSGANVLTLIEKDIRTPNGLAIDHRAEKLYFSDATLDK\nIERCEYDGSHRYVILKSEPVHPFGLAVYGEHIFWTDWVRRAVQRANKHVGSNMKLLRVDI\nPQQPMGIIAVANDTNSCELSPCRINNGGCQDLCLLTHQGHVNCSCRGGRILQDDLTCRAV\nNSSCRAQDEFECANGECINFSLTCDGVPHCKDKSDEKPSYCNSRRCKKTFRQCSNGRCVS\nNMLWCNGADDCGDGSDEIPCNKTACGVGEFRCRDGTCIGNSSRCNQFVDCEDASDEMNCS\nATDCSSYFRLGVKGVLFQPCERTSLCYAPSWVCDGANDCGDYSDERDCPGVKRPRCPLNY\nFACPSGRCIPMSWTCDKEDDCEHGEDETHCNKFCSEAQFECQNHRCISKQWLCDGSDDCG\nDGSDEAAHCEGKTCGPSSFSCPGTHVCVPERWLCDGDKDCADGADESIAAGCLYNSTCDD\nREFMCQNRQCIPKHFVCDHDRDCADGSDESPECEYPTCGPSEFRCANGRCLSSRQWECDG\nENDCHDQSDEAPKNPHCTSQEHKCNASSQFLCSSGRCVAEALLCNGQDDCGDSSDERGCH\nINECLSRKLSGCSQDCEDLKIGFKCRCRPGFRLKDDGRTCADVDECSTTFPCSQRCINTH\nGSYKCLCVEGYAPRGGDPHSCKAVTDEEPFLIFANRYYLRKLNLDGSNYTLLKQGLNNAV\nALDFDYREQMIYWTDVTTQGSMIRRMHLNGSNVQVLHRTGLSNPDGLAVDWVGGNLYWCD\nKGRDTIEVSKLNGAYRTVLVSSGLREPRALVVDVQNGYLYWTDWGDHSLIGRIGMDGSSR\nSVIVDTKITWPNGLTLDYVTERIYWADAREDYIEFASLDGSNRHVVLSQDIPHIFALTLF\nEDYVYWTDWETKSINRAHKTTGTNKTLLISTLHRPMDLHVFHALRQPDVPNHPCKVNNGG\nCSNLCLLSPGGGHKCACPTNFYLGSDGRTCVSNCTASQFVCKNDKCIPFWWKCDTEDDCG\nDHSDEPPDCPEFKCRPGQFQCSTGICTNPAFICDGDNDCQDNSDEANCDIHVCLPSQFKC\nTNTNRCIPGIFRCNGQDNCGDGEDERDCPEVTCAPNQFQCSITKRCIPRVWVCDRDNDCV\nDGSDEPANCTQMTCGVDEFRCKDSGRCIPARWKCDGEDDCGDGSDEPKEECDERTCEPYQ\nFRCKNNRCVPGRWQCDYDNDCGDNSDEESCTPRPCSESEFSCANGRCIAGRWKCDGDHDC\nADGSDEKDCTPRCDMDQFQCKSGHCIPLRWRCDADADCMDGSDEEACGTGVRTCPLDEFQ\nCNNTLCKPLAWKCDGEDDCGDNSDENPEECARFVCPPNRPFRCKNDRVCLWIGRQCDGTD\nNCGDGTDEEDCEPPTAHTTHCKDKKEFLCRNQRCLSSSLRCNMFDDCGDGSDEEDCSIDP\nKLTSCATNASICGDEARCVRTEKAAYCACRSGFHTVPGQPGCQDINECLRFGTCSQLCNN\nTKGGHLCSCARNFMKTHNTCKAEGSEYQVLYIADDNEIRSLFPGHPHSAYEQAFQGDESV\nRIDAMDVHVKAGRVYWTNWHTGTISYRSLPPAAPPTTSNRHRRQIDRGVTHLNISGLKMP\nRGIAIDWVAGNVYWTDSGRDVIEVAQMKGENRKTLISGMIDEPHAIVVDPLRGTMYWSDW\nGNHPKIETAAMDGTLRETLVQDNIQWPTGLAVDYHNERLYWADAKLSVIGSIRLNGTDPI\nVAADSKRGLSHPFSIDVFEDYIYGVTYINNRVFKIHKFGHSPLVNLTGGLSHASDVVLYH\nQHKQPEVTNPCDRKKCEWLCLLSPSGPVCTCPNGKRLDNGTCVPVPSPTPPPDAPRPGTC\nNLQCFNGGSCFLNARRQPKCRCQPRYTGDKCELDQCWEHCRNGGTCAASPSGMPTCRCPT\nGFTGPKCTQQVCAGYCANNSTCTVNQGNQPQCRCLPGFLGDRCQYRQCSGYCENFGTCQM\nAADGSRQCRCTAYFEGSRCEVNKCSRCLEGACVVNKQSGDVTCNCTDGRVAPSCLTCVGH\nCSNGGSCTMNSKMMPECQCPPHMTGPRCEEHVFSQQQPGHIASILIPLLLLLLLVLVAGV\nVFWYKRRVQGAKGFQHQRMTNGAMNVEIGNPTYKMYEGGEPDDVGGLLDADFALDPDKPT\nNFTNPVYATLYMGGHGSRHSLASTDEKRELLGRGPEDEIGDPLA'], 'gene-sequence': ['>lcl|BSEQ0019236|Prolow-density lipoprotein receptor-related protein 1 (LRP1)\nATGCTGACCCCGCCGTTGCTCCTGCTGCTGCCCCTGCTCTCAGCTCTGGTCGCGGCGGCT\nATCGACGCCCCTAAGACTTGCAGCCCCAAGCAGTTTGCCTGCAGAGATCAAATAACCTGT\nATCTCAAAGGGCTGGCGGTGCGACGGTGAGAGGGACTGCCCAGACGGATCTGACGAGGCC\nCCTGAGATTTGTCCACAGAGTAAGGCCCAGCGATGCCAGCCAAACGAGCATAACTGCCTG\nGGTACTGAGCTGTGTGTTCCCATGTCCCGCCTCTGCAATGGGGTCCAGGACTGCATGGAC\nGGCTCAGATGAGGGGCCCCACTGCCGAGAGCTCCAAGGCAACTGCTCTCGCCTGGGCTGC\nCAGCACCATTGTGTCCCCACACTCGATGGGCCCACCTGCTACTGCAACAGCAGCTTTCAG\nCTTCAGGCAGATGGCAAGACCTGCAAAGATTTTGATGAGTGCTCAGTGTACGGCACCTGC\nAGCCAGCTATGCACCAACACAGACGGCTCCTTCATATGTGGCTGTGTTGAAGGATACCTC\nCTGCAGCCGGATAACCGCTCCTGCAAGGCCAAGAACGAGCCAGTAGACCGGCCCCCTGTG\nCTGTTGATAGCCAACTCCCAGAACATCTTGGCCACGTACCTGAGTGGGGCCCAGGTGTCT\nACCATCACACCTACGAGCACGCGGCAGACCACAGCCATGGACTTCAGCTATGCCAACGAG\nACCGTATGCTGGGTGCATGTTGGGGACAGTGCTGCTCAGACGCAGCTCAAGTGTGCCCGC\nATGCCTGGCCTAAAGGGCTTCGTGGATGAGCACACCATCAACATCTCCCTCAGTCTGCAC\nCACGTGGAACAGATGGCCATCGACTGGCTGACAGGCAACTTCTACTTTGTGGATGACATC\nGATGATAGGATCTTTGTCTGCAACAGAAATGGGGACACATGTGTCACATTGCTAGACCTG\nGAACTCTACAACCCCAAGGGCATTGCCCTGGACCCTGCCATGGGGAAGGTGTTTTTCACT\nGACTATGGGCAGATCCCAAAGGTGGAACGCTGTGACATGGATGGGCAGAACCGCACCAAG\nCTCGTCGACAGCAAGATTGTGTTTCCTCATGGCATCACGCTGGACCTGGTCAGCCGCCTT\nGTCTACTGGGCAGATGCCTATCTGGACTATATTGAAGTGGTGGACTATGAGGGCAAGGGC\nCGCCAGACCATCATCCAGGGCATCCTGATTGAGCACCTGTACGGCCTGACTGTGTTTGAG\nAATTATCTCTATGCCACCAACTCGGACAATGCCAATGCCCAGCAGAAGACGAGTGTGATC\nCGTGTGAACCGCTTTAACAGCACCGAGTACCAGGTTGTCACCCGGGTGGACAAGGGTGGT\nGCCCTCCACATCTACCACCAGAGGCGTCAGCCCCGAGTGAGGAGCCATGCCTGTGAAAAC\nGACCAGTATGGGAAGCCGGGTGGCTGCTCTGACATCTGCCTGCTGGCCAACAGCCACAAG\nGCGCGGACCTGCCGCTGCCGTTCCGGCTTCAGCCTGGGCAGTGACGGGAAGTCATGCAAG\nAAGCCGGAGCATGAGCTGTTCCTCGTGTATGGCAAGGGCCGGCCAGGCATCATCCGGGGC\nATGGATATGGGGGCCAAGGTCCCGGATGAGCACATGATCCCCATTGAAAACCTCATGAAC\nCCCCGAGCCCTGGACTTCCACGCTGAGACCGGCTTCATCTACTTTGCCGACACCACCAGC\nTACCTCATTGGCCGCCAGAAGATTGATGGCACTGAGCGGGAGACCATCCTGAAGGACGGC\nATCCACAATGTGGAGGGTGTGGCCGTGGACTGGATGGGAGACAATCTGTACTGGACGGAC\nGATGGGCCCAAAAAGACAATCAGCGTGGCCAGGCTGGAGAAAGCTGCTCAGACCCGCAAG\nACTTTAATCGAGGGCAAAATGACACACCCCAGGGCTATTGTGGTGGATCCACTCAATGGG\nTGGATGTACTGGACAGACTGGGAGGAGGACCCCAAGGACAGTCGGCGTGGGCGGCTGGAG\nAGGGCGTGGATGGATGGCTCACACCGAGACATCTTTGTCACCTCCAAGACAGTGCTTTGG\nCCCAATGGGCTAAGCCTGGACATCCCGGCTGGGCGCCTCTACTGGGTGGATGCCTTCTAC\nGACCGCATCGAGACGATACTGCTCAATGGCACAGACCGGAAGATTGTGTATGAAGGTCCT\nGAGCTGAACCACGCCTTTGGCCTGTGTCACCATGGCAACTACCTCTTCTGGACTGAGTAT\nCGGAGTGGCAGTGTCTACCGCTTGGAACGGGGTGTAGGAGGCGCACCCCCCACTGTGACC\nCTTCTGCGCAGTGAGCGGCCCCCCATCTTTGAGATCCGAATGTATGATGCCCAGCAGCAG\nCAAGTTGGCACCAACAAATGCCGGGTGAACAATGGCGGCTGCAGCAGCCTGTGCTTGGCC\nACCCCTGGGAGCCGCCAGTGCGCCTGTGCTGAGGACCAGGTGTTGGACGCAGACGGCGTC\nACTTGCTTGGCGAACCCATCCTACGTGCCTCCACCCCAGTGCCAGCCAGGCGAGTTTGCC\nTGTGCCAACAGCCGCTGCATCCAGGAGCGCTGGAAGTGTGACGGAGACAACGATTGCCTG\nGACAACAGTGATGAGGCCCCAGCCCTCTGCCATCAGCACACCTGCCCCTCGGACCGATTC\nAAGTGCGAGAACAACCGGTGCATCCCCAACCGCTGGCTCTGCGACGGGGACAATGACTGT\nGGGAACAGTGAAGATGAGTCCAATGCCACTTGTTCAGCCCGCACCTGCCCCCCCAACCAG\nTTCTCCTGTGCCAGTGGCCGCTGCATCCCCATCTCCTGGACGTGTGATCTGGATGACGAC\nTGTGGGGACCGCTCTGATGAGTCTGCTTCGTGTGCCTATCCCACCTGCTTCCCCCTGACT\nCAGTTTACCTGCAACAATGGCAGATGTATCAACATCAACTGGAGATGCGACAATGACAAT\nGACTGTGGGGACAACAGTGACGAAGCCGGCTGCAGCCACTCCTGTTCTAGCACCCAGTTC\nAAGTGCAACAGCGGGCGTTGCATCCCCGAGCACTGGACCTGCGATGGGGACAATGACTGC\nGGAGACTACAGTGATGAGACACACGCCAACTGCACCAACCAGGCCACGAGGCCCCCTGGT\nGGCTGCCACACTGATGAGTTCCAGTGCCGGCTGGATGGACTATGCATCCCCCTGCGGTGG\nCGCTGCGATGGGGACACTGACTGCATGGACTCCAGCGATGAGAAGAGCTGTGAGGGAGTG\nACCCACGTCTGCGATCCCAGTGTCAAGTTTGGCTGCAAGGACTCAGCTCGGTGCATCAGC\nAAAGCGTGGGTGTGTGATGGCGACAATGACTGTGAGGATAACTCGGACGAGGAGAACTGC\nGAGTCCCTGGCCTGCAGGCCACCCTCGCACCCTTGTGCCAACAACACCTCAGTCTGCCTG\nCCCCCTGACAAGCTGTGTGATGGCAACGACGACTGTGGCGACGGCTCAGATGAGGGCGAG\nCTCTGCGACCAGTGCTCTCTGAATAACGGTGGCTGCAGCCACAACTGCTCAGTGGCACCT\nGGCGAAGGCATTGTGTGTTCCTGCCCTCTGGGCATGGAGCTGGGGCCCGACAACCACACC\nTGCCAGATCCAGAGCTACTGTGCCAAGCATCTCAAATGCAGCCAAAAGTGCGACCAGAAC\nAAGTTCAGCGTGAAGTGCTCCTGCTACGAGGGCTGGGTCCTGGAACCTGACGGCGAGAGC\nTGCCGCAGCCTGGACCCCTTCAAGCCGTTCATCATTTTCTCCAACCGCCATGAAATCCGG\nCGCATCGATCTTCACAAAGGAGACTACAGCGTCCTGGTGCCCGGCCTGCGCAACACCATC\nGCCCTGGACTTCCACCTCAGCCAGAGCGCCCTCTACTGGACCGACGTGGTGGAGGACAAG\nATCTACCGCGGGAAGCTGCTGGACAACGGAGCCCTGACTAGTTTCGAGGTGGTGATTCAG\nTATGGCCTGGCCACACCCGAGGGCCTGGCTGTAGACTGGATTGCAGGCAACATCTACTGG\nGTGGAGAGTAACCTGGATCAGATCGAGGTGGCCAAGCTGGATGGGACCCTCCGGACCACC\nCTGCTGGCCGGTGACATTGAGCACCCAAGGGCAATCGCACTGGATCCCCGGGATGGGATC\nCTGTTTTGGACAGACTGGGATGCCAGCCTGCCCCGCATTGAGGCAGCCTCCATGAGTGGG\nGCTGGGCGCCGCACCGTGCACCGGGAGACCGGCTCTGGGGGCTGGCCCAACGGGCTCACC\nGTGGACTACCTGGAGAAGCGCATCCTTTGGATTGACGCCAGGTCAGATGCCATTTACTCA\nGCCCGTTACGACGGCTCTGGCCACATGGAGGTGCTTCGGGGACACGAGTTCCTGTCGCAC\nCCGTTTGCAGTGACGCTGTACGGGGGGGAGGTCTACTGGACTGACTGGCGAACAAACACA\nCTGGCTAAGGCCAACAAGTGGACCGGCCACAATGTCACCGTGGTACAGAGGACCAACACC\nCAGCCCTTTGACCTGCAGGTGTACCACCCCTCCCGCCAGCCCATGGCTCCCAATCCCTGT\nGAGGCCAATGGGGGCCAGGGCCCCTGCTCCCACCTGTGTCTCATCAACTACAACCGGACC\nGTGTCCTGCGCCTGCCCCCACCTCATGAAGCTCCACAAGGACAACACCACCTGCTATGAG\nTTTAAGAAGTTCCTGCTGTACGCACGTCAGATGGAGATCCGAGGTGTGGACCTGGATGCT\nCCCTACTACAACTACATCATCTCCTTCACGGTGCCCGACATCGACAACGTCACAGTGCTA\nGACTACGATGCCCGCGAGCAGCGTGTGTACTGGTCTGACGTGCGGACACAGGCCATCAAG\nCGGGCCTTCATCAACGGCACAGGCGTGGAGACAGTCGTCTCTGCAGACTTGCCAAATGCC\nCACGGGCTGGCTGTGGACTGGGTCTCCCGAAACCTGTTCTGGACAAGCTATGACACCAAT\nAAGAAGCAGATCAATGTGGCCCGGCTGGATGGCTCCTTCAAGAACGCAGTGGTGCAGGGC\nCTGGAGCAGCCCCATGGCCTTGTCGTCCACCCTCTGCGTGGGAAGCTCTACTGGACCGAT\nGGTGACAACATCAGCATGGCCAACATGGATGGCAGCAATCGCACCCTGCTCTTCAGTGGC\nCAGAAGGGCCCCGTGGGCCTGGCTATTGACTTCCCTGAAAGCAAACTCTACTGGATCAGC\nTCCGGGAACCATACCATCAACCGCTGCAACCTGGATGGGAGTGGGCTGGAGGTCATCGAT\nGCCATGCGGAGCCAGCTGGGCAAGGCCACCGCCCTGGCCATCATGGGGGACAAGCTGTGG\nTGGGCTGATCAGGTGTCGGAAAAGATGGGCACATGCAGCAAGGCTGACGGCTCGGGCTCC\nGTGGTCCTTCGGAACAGCACCACCCTGGTGATGCACATGAAGGTCTATGACGAGAGCATC\nCAGCTGGACCATAAGGGCACCAACCCCTGCAGTGTCAACAACGGTGACTGCTCCCAGCTC\nTGCCTGCCCACGTCAGAGACGACCCGCTCCTGCATGTGCACAGCCGGCTATAGCCTCCGG\nAGTGGCCAGCAGGCCTGCGAGGGCGTAGGTTCCTTTCTCCTGTACTCTGTGCATGAGGGA\nATCAGGGGAATTCCCCTGGATCCCAATGACAAGTCAGATGCCCTGGTCCCAGTGTCCGGG\nACCTCGCTGGCTGTCGGCATCGACTTCCACGCTGAAAATGACACCATCTACTGGGTGGAC\nATGGGCCTGAGCACGATCAGCCGGGCCAAGCGGGACCAGACGTGGCGTGAAGACGTGGTG\nACCAATGGCATTGGCCGTGTGGAGGGCATTGCAGTGGACTGGATCGCAGGCAACATCTAC\nTGGACAGACCAGGGCTTTGATGTCATCGAGGTCGCCCGGCTCAATGGCTCCTTCCGCTAC\nGTGGTGATCTCCCAGGGTCTAGACAAGCCCCGGGCCATCACCGTCCACCCGGAGAAAGGG\nTACTTGTTCTGGACTGAGTGGGGTCAGTATCCGCGTATTGAGCGGTCTCGGCTAGATGGC\nACGGAGCGTGTGGTGCTGGTCAACGTCAGCATCAGCTGGCCCAACGGCATCTCAGTGGAC\nTACCAGGATGGGAAGCTGTACTGGTGCGATGCACGGACAGACAAGATTGAACGGATCGAC\nCTGGAGACAGGTGAGAACCGCGAGGTGGTTCTGTCCAGCAACAACATGGACATGTTTTCA\nGTGTCTGTGTTTGAGGATTTCATCTACTGGAGTGACAGGACTCATGCCAACGGCTCTATC\nAAGCGCGGGAGCAAAGACAATGCCACAGACTCCGTGCCCCTGCGAACCGGCATCGGCGTC\nCAGCTTAAAGACATCAAAGTCTTCAACCGGGACCGGCAGAAAGGCACCAACGTGTGCGCG\nGTGGCCAATGGCGGGTGCCAGCAGCTGTGCCTGTACCGGGGCCGTGGGCAGCGGGCCTGC\nGCCTGTGCCCACGGGATGCTGGCTGAAGACGGAGCATCGTGCCGCGAGTATGCCGGCTAC\nCTGCTCTACTCAGAGCGCACCATTCTCAAGAGTATCCACCTGTCGGATGAGCGCAACCTC\nAATGCGCCCGTGCAGCCCTTCGAGGACCCTGAGCACATGAAGAACGTCATCGCCCTGGCC\nTTTGACTACCGGGCAGGCACCTCTCCGGGCACCCCCAATCGCATCTTCTTCAGCGACATC\nCACTTTGGGAACATCCAACAGATCAACGACGATGGCTCCAGGAGGATCACCATTGTGGAA\nAACGTGGGCTCCGTGGAAGGCCTGGCCTATCACCGTGGCTGGGACACTCTCTATTGGACA\nAGCTACACGACATCCACCATCACGCGCCACACAGTGGACCAGACCCGCCCAGGGGCCTTC\nGAGCGTGAGACCGTCATCACTATGTCTGGAGATGACCACCCACGGGCCTTCGTTTTGGAC\nGAGTGCCAGAACCTCATGTTCTGGACCAACTGGAATGAGCAGCATCCCAGCATCATGCGG\nGCGGCGCTCTCGGGAGCCAATGTCCTGACCCTTATCGAGAAGGACATCCGTACCCCCAAT\nGGCCTGGCCATCGACCACCGTGCCGAGAAGCTCTACTTCTCTGACGCCACCCTGGACAAG\nATCGAGCGGTGCGAGTATGACGGCTCCCACCGCTATGTGATCCTAAAGTCAGAGCCTGTC\nCACCCCTTCGGGCTGGCCGTGTATGGGGAGCACATTTTCTGGACTGACTGGGTGCGGCGG\nGCAGTGCAGCGGGCCAACAAGCACGTGGGCAGCAACATGAAGCTGCTGCGCGTGGACATC\nCCCCAGCAGCCCATGGGCATCATCGCCGTGGCCAACGACACCAACAGCTGTGAACTCTCT\nCCATGCCGAATCAACAACGGTGGCTGCCAGGACCTGTGTCTGCTCACTCACCAGGGCCAT\nGTCAACTGCTCATGCCGAGGGGGCCGAATCCTCCAGGATGACCTCACCTGCCGAGCGGTG\nAATTCCTCTTGCCGAGCACAAGATGAGTTTGAGTGTGCCAATGGCGAGTGCATCAACTTC\nAGCCTGACCTGCGACGGCGTCCCCCACTGCAAGGACAAGTCCGATGAGAAGCCATCCTAC\nTGCAACTCCCGCCGCTGCAAGAAGACTTTCCGGCAGTGCAGCAATGGGCGCTGTGTGTCC\nAACATGCTGTGGTGCAACGGGGCCGACGACTGTGGGGATGGCTCTGACGAGATCCCTTGC\nAACAAGACAGCCTGTGGTGTGGGCGAGTTCCGCTGCCGGGACGGGACCTGCATCGGGAAC\nTCCAGCCGCTGCAACCAGTTTGTGGATTGTGAGGACGCCTCAGATGAGATGAACTGCAGT\nGCCACCGACTGCAGCAGCTACTTCCGCCTGGGCGTGAAGGGCGTGCTCTTCCAGCCCTGC\nGAGCGGACCTCACTCTGCTACGCACCCAGCTGGGTGTGTGATGGCGCCAATGACTGTGGG\nGACTACAGTGATGAGCGCGACTGCCCAGGTGTGAAACGCCCCAGATGCCCTCTGAATTAC\nTTCGCCTGCCCTAGTGGGCGCTGCATCCCCATGAGCTGGACGTGTGACAAAGAGGATGAC\nTGTGAACATGGCGAGGACGAGACCCACTGCAACAAGTTCTGCTCAGAGGCCCAGTTTGAG\nTGCCAGAACCATCGCTGCATCTCCAAGCAGTGGCTGTGTGACGGCAGCGATGACTGTGGG\nGATGGCTCAGACGAGGCTGCTCACTGTGAAGGCAAGACGTGCGGCCCCTCCTCCTTCTCC\nTGCCCTGGCACCCACGTGTGCGTCCCCGAGCGCTGGCTCTGTGACGGTGACAAAGACTGT\nGCTGATGGTGCAGACGAGAGCATCGCAGCTGGTTGCTTGTACAACAGCACTTGTGACGAC\nCGTGAGTTCATGTGCCAGAACCGCCAGTGCATCCCCAAGCACTTCGTGTGTGACCACGAC\nCGTGACTGTGCAGATGGCTCTGATGAGTCCCCCGAGTGTGAGTACCCGACCTGCGGCCCC\nAGTGAGTTCCGCTGTGCCAATGGGCGCTGTCTGAGCTCCCGCCAGTGGGAGTGTGATGGC\nGAGAATGACTGCCACGACCAGAGTGACGAGGCTCCCAAGAACCCACACTGCACCAGCCAA\nGAGCACAAGTGCAATGCCTCGTCACAGTTCCTGTGCAGCAGTGGGCGCTGTGTGGCTGAG\nGCACTGCTCTGCAACGGCCAGGATGACTGTGGCGACAGCTCGGACGAGCGTGGCTGCCAC\nATCAATGAGTGTCTCAGCCGCAAGCTCAGTGGCTGCAGCCAGGACTGTGAGGACCTCAAG\nATCGGCTTCAAGTGCCGCTGTCGCCCTGGCTTCCGGCTGAAGGACGACGGCCGGACGTGT\nGCTGATGTGGACGAGTGCAGCACCACCTTCCCCTGCAGCCAGCGCTGCATCAACACTCAT\nGGCAGCTATAAGTGTCTGTGTGTGGAGGGCTATGCACCCCGCGGCGGCGACCCCCACAGC\nTGCAAGGCTGTGACTGACGAGGAACCGTTTCTGATCTTCGCCAACCGGTACTACCTGCGC\nAAGCTCAACCTGGACGGGTCCAACTACACGTTACTTAAGCAGGGCCTGAACAACGCCGTT\nGCCTTGGATTTTGACTACCGAGAGCAGATGATCTACTGGACAGATGTGACCACCCAGGGC\nAGCATGATCCGAAGGATGCACCTTAACGGGAGCAATGTGCAGGTCCTACACCGTACAGGC\nCTCAGCAACCCCGATGGGCTGGCTGTGGACTGGGTGGGTGGCAACCTGTACTGGTGCGAC\nAAAGGCCGGGACACCATCGAGGTGTCCAAGCTCAATGGGGCCTATCGGACGGTGCTGGTC\nAGCTCTGGCCTCCGTGAGCCCAGGGCTCTGGTGGTGGATGTGCAGAATGGGTACCTGTAC\nTGGACAGACTGGGGTGACCATTCACTGATCGGCCGCATCGGCATGGATGGGTCCAGCCGC\nAGCGTCATCGTGGACACCAAGATCACATGGCCCAATGGCCTGACGCTGGACTATGTCACT\nGAGCGCATCTACTGGGCCGACGCCCGCGAGGACTACATTGAATTTGCCAGCCTGGATGGC\nTCCAATCGCCACGTTGTGCTGAGCCAGGACATCCCGCACATCTTTGCACTGACCCTGTTT\nGAGGACTACGTCTACTGGACCGACTGGGAAACAAAGTCCATTAACCGAGCCCACAAGACC\nACGGGCACCAACAAAACGCTCCTCATCAGCACGCTGCACCGGCCCATGGACCTGCATGTC\nTTCCATGCCCTGCGCCAGCCAGACGTGCCCAATCACCCCTGCAAGGTCAACAATGGTGGC\nTGCAGCAACCTGTGCCTGCTGTCCCCCGGGGGAGGGCACAAATGTGCCTGCCCCACCAAC\nTTCTACCTGGGCAGCGATGGGCGCACCTGTGTGTCCAACTGCACGGCTAGCCAGTTTGTA\nTGCAAGAACGACAAGTGCATCCCCTTCTGGTGGAAGTGTGACACCGAGGACGACTGCGGG\nGACCACTCAGACGAGCCCCCGGACTGCCCTGAGTTCAAGTGCCGGCCCGGACAGTTCCAG\nTGCTCCACAGGTATCTGCACAAACCCTGCCTTCATCTGCGATGGCGACAATGACTGCCAG\nGACAACAGTGACGAGGCCAACTGTGACATCCACGTCTGCTTGCCCAGTCAGTTCAAATGC\nACCAACACCAACCGCTGTATTCCCGGCATCTTCCGCTGCAATGGGCAGGACAACTGCGGA\nGATGGGGAGGATGAGAGGGACTGCCCCGAGGTGACCTGCGCCCCCAACCAGTTCCAGTGC\nTCCATTACCAAACGGTGCATCCCCCGGGTCTGGGTCTGCGACCGGGACAATGACTGTGTG\nGATGGCAGTGATGAGCCCGCCAACTGCACCCAGATGACCTGTGGTGTGGACGAGTTCCGC\nTGCAAGGATTCGGGCCGCTGCATCCCAGCGCGTTGGAAGTGTGACGGAGAGGATGACTGT\nGGGGATGGCTCGGATGAGCCCAAGGAAGAGTGTGATGAACGCACCTGTGAGCCATACCAG\nTTCCGCTGCAAGAACAACCGCTGCGTGCCCGGCCGCTGGCAGTGCGACTACGACAACGAT\nTGCGGTGACAACTCCGATGAAGAGAGCTGCACCCCTCGGCCCTGCTCCGAGAGTGAGTTC\nTCCTGTGCCAACGGCCGCTGCATCGCGGGGCGCTGGAAATGCGATGGAGACCACGACTGC\nGCGGACGGCTCGGACGAGAAAGACTGCACCCCCCGCTGTGACATGGACCAGTTCCAGTGC\nAAGAGCGGCCACTGCATCCCCCTGCGCTGGCGCTGTGACGCAGACGCCGACTGCATGGAC\nGGCAGCGACGAGGAGGCCTGCGGCACTGGCGTGCGGACCTGCCCCCTGGACGAGTTCCAG\nTGCAACAACACCTTGTGCAAGCCGCTGGCCTGGAAGTGCGATGGCGAGGATGACTGTGGG\nGACAACTCAGATGAGAACCCCGAGGAGTGTGCCCGGTTCGTGTGCCCTCCCAACCGGCCC\nTTCCGTTGCAAGAATGACCGCGTCTGTCTGTGGATCGGGCGCCAATGCGATGGCACGGAC\nAACTGTGGGGATGGGACTGATGAAGAGGACTGTGAGCCCCCCACAGCCCACACCACCCAC\nTGCAAAGACAAGAAGGAGTTTCTGTGCCGGAACCAGCGCTGCCTCTCCTCCTCCCTGCGC\nTGCAACATGTTCGATGACTGCGGGGACGGCTCTGACGAGGAGGACTGCAGCATCGACCCC\nAAGCTGACCAGCTGCGCCACCAATGCCAGCATCTGTGGGGACGAGGCACGCTGCGTGCGC\nACCGAGAAAGCGGCCTACTGTGCCTGCCGCTCGGGCTTCCACACCGTGCCCGGCCAGCCC\nGGATGCCAAGACATCAACGAGTGCCTGCGCTTCGGCACCTGCTCCCAGCTCTGCAACAAC\nACCAAGGGCGGCCACCTCTGCAGCTGCGCTCGGAACTTCATGAAGACGCACAACACCTGC\nAAGGCCGAAGGCTCTGAGTACCAGGTCCTGTACATCGCTGATGACAATGAGATCCGCAGC\nCTGTTCCCCGGCCACCCCCATTCGGCTTACGAGCAGGCATTCCAGGGTGACGAGAGTGTC\nCGCATTGATGCTATGGATGTCCATGTCAAGGCTGGCCGTGTCTATTGGACCAACTGGCAC\nACGGGCACCATCTCCTACCGCAGCCTGCCACCTGCTGCGCCTCCTACCACTTCCAACCGC\nCACCGGCGACAGATTGACCGGGGTGTCACCCACCTCAACATTTCAGGGCTGAAGATGCCC\nAGAGGCATCGCCATCGACTGGGTGGCCGGAAACGTGTACTGGACCGACTCGGGCCGAGAT\nGTGATTGAGGTGGCGCAGATGAAGGGCGAGAACCGCAAGACGCTCATCTCGGGCATGATT\nGACGAGCCCCACGCCATTGTGGTGGACCCACTGAGGGGGACCATGTACTGGTCAGACTGG\nGGCAACCACCCCAAGATTGAGACGGCAGCGATGGATGGGACGCTTCGGGAGACACTGGTG\nCAGGACAACATTCAGTGGCCCACAGGCCTGGCCGTGGATTATCACAATGAGCGGCTGTAC\nTGGGCAGACGCCAAGCTTTCAGTCATCGGCAGCATCCGGCTCAATGGCACGGACCCCATT\nGTGGCTGCTGACAGCAAACGAGGCCTAAGTCACCCCTTCAGCATCGACGTCTTTGAGGAT\nTACATCTATGGTGTCACCTACATCAATAATCGTGTCTTCAAGATCCATAAGTTTGGCCAC\nAGCCCCTTGGTCAACCTGACAGGGGGCCTGAGCCACGCCTCTGACGTGGTCCTTTACCAT\nCAGCACAAGCAGCCCGAAGTGACCAACCCATGTGACCGCAAGAAATGCGAGTGGCTCTGC\nCTGCTGAGCCCCAGTGGGCCTGTCTGCACCTGTCCCAATGGGAAGCGGCTGGACAACGGC\nACATGCGTGCCTGTGCCCTCTCCAACGCCCCCCCCAGATGCTCCCCGGCCTGGAACCTGT\nAACCTGCAGTGCTTCAACGGTGGCAGCTGTTTCCTCAATGCACGGAGGCAGCCCAAGTGC\nCGCTGCCAACCCCGCTACACGGGTGACAAGTGTGAACTGGACCAGTGCTGGGAGCACTGT\nCGCAATGGGGGCACCTGTGCTGCCTCCCCCTCTGGCATGCCCACGTGCCGGTGCCCCACG\nGGCTTCACGGGCCCCAAATGCACCCAGCAGGTGTGTGCGGGCTACTGTGCCAACAACAGC\nACCTGCACTGTCAACCAGGGCAACCAGCCCCAGTGCCGATGCCTACCCGGCTTCCTGGGC\nGACCGCTGCCAGTACCGGCAGTGCTCTGGCTACTGTGAGAACTTTGGCACATGCCAGATG\nGCTGCTGATGGCTCCCGACAATGCCGCTGCACTGCCTACTTTGAGGGATCGAGGTGTGAG\nGTGAACAAGTGCAGCCGCTGTCTCGAAGGGGCCTGTGTGGTCAACAAGCAGAGTGGGGAT\nGTCACCTGCAACTGCACGGATGGCCGGGTGGCCCCCAGCTGTCTGACCTGCGTCGGCCAC\nTGCAGCAATGGCGGCTCCTGTACCATGAACAGCAAAATGATGCCTGAGTGCCAGTGCCCA\nCCCCACATGACAGGGCCCCGGTGTGAGGAGCACGTCTTCAGCCAGCAGCAGCCAGGACAT\nATAGCCTCCATCCTAATCCCTCTGCTGTTGCTGCTGCTGCTGGTTCTGGTGGCCGGAGTG\nGTATTCTGGTATAAGCGGCGAGTCCAAGGGGCTAAGGGCTTCCAGCACCAACGGATGACC\nAACGGGGCCATGAACGTGGAGATTGGAAACCCCACCTACAAGATGTACGAAGGCGGAGAG\nCCTGATGATGTGGGAGGCCTACTGGACGCTGACTTTGCCCTGGACCCTGACAAGCCCACC\nAACTTCACCAACCCCGTGTATGCCACACTCTACATGGGGGGCCATGGCAGTCGCCACTCC\nCTGGCCAGCACGGACGAGAAGCGAGAACTCCTGGGCCGGGGCCCTGAGGACGAGATAGGG\nGACCCCTTGGCATAG'], 'pfams': [{'pfam': [{'identifier': ['PF07645'], 'name': ['EGF_CA']}, {'identifier': ['PF00057'], 'name': ['Ldl_recept_a']}, {'identifier': ['PF00058'], 'name': ['Ldl_recept_b']}, {'identifier': ['PF12662'], 'name': ['cEGF']}, {'identifier': ['PF16472'], 'name': ['DUF5050']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['clathrin-coated vesicle']}, {'category': ['component'], 'description': ['coated pit']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['dendrite']}, {'category': ['component'], 'description': ['endocytic vesicle membrane']}, {'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['lysosomal membrane']}, {'category': ['component'], 'description': ['neuronal cell body']}, {'category': ['component'], 'description': ['nucleolus']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['function'], 'description': ['apolipoprotein binding']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['lipoprotein particle receptor binding']}, {'category': ['function'], 'description': ['lipoprotein transporter activity']}, {'category': ['function'], 'description': ['poly(A) RNA binding']}, {'category': ['function'], 'description': ['protein complex binding']}, {'category': ['function'], 'description': ['receptor activity']}, {'category': ['process'], 'description': ['aging']}, {'category': ['process'], 'description': ['aorta morphogenesis']}, {'category': ['process'], 'description': ['apoptotic cell clearance']}, {'category': ['process'], 'description': ['beta-amyloid clearance']}, {'category': ['process'], 'description': ['cell proliferation']}, {'category': ['process'], 'description': ['lipoprotein metabolic process']}, {'category': ['process'], 'description': ['lipoprotein transport']}, {'category': ['process'], 'description': ['negative regulation of neuron apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of neuron projection development']}, {'category': ['process'], 'description': ['negative regulation of platelet-derived growth factor receptor-beta signaling pathway']}, {'category': ['process'], 'description': ['negative regulation of smooth muscle cell migration']}, {'category': ['process'], 'description': ['negative regulation of Wnt signaling pathway']}, {'category': ['process'], 'description': ['phototransduction, visible light']}, {'category': ['process'], 'description': ['positive regulation of cholesterol efflux']}, {'category': ['process'], 'description': ['positive regulation of lipid transport']}, {'category': ['process'], 'description': ['positive regulation of protein transport']}, {'category': ['process'], 'description': ['protein kinase C-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['receptor-mediated endocytosis']}, {'category': ['process'], 'description': ['regulation of actin cytoskeleton organization']}, {'category': ['process'], 'description': ['regulation of cholesterol transport']}, {'category': ['process'], 'description': ['regulation of phospholipase A2 activity']}, {'category': ['process'], 'description': ['retinoid metabolic process']}]}]}]}, {'id': ['BE0002120'], 'name': ['Multiple coagulation factor deficiency protein 2'], 'organism': ['Humans'], 'actions': [{'action': ['modulator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13123'], 'pubmed-id': ['15886209'], 'citation': ['Zhang B, Kaufman RJ, Ginsburg D: LMAN1 and MCFD2 form a cargo receptor complex and interact with coagulation factor VIII in the early secretory pathway. J Biol Chem. 2005 Jul 8;280(27):25881-6. Epub 2005 May 10.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Multiple coagulation factor deficiency protein 2'], 'general-function': ['Calcium ion binding'], 'specific-function': ['The MCFD2-LMAN1 complex forms a specific cargo receptor for the ER-to-Golgi transport of selected proteins. Plays a role in the secretion of coagulation factors.'], 'gene-name': ['MCFD2'], 'locus': ['2p21'], 'cellular-location': ['Endoplasmic reticulum-Golgi intermediate compartment'], 'transmembrane-regions': [None], 'signal-regions': ['1-26'], 'theoretical-pi': ['4.25'], 'molecular-weight': ['16390.175'], 'chromosome-location': ['2'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:18451']}, {'resource': ['GenAtlas'], 'identifier': ['MCFD2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['AF475284']}, {'resource': ['GenBank Protein Database'], 'identifier': ['20799383']}, {'resource': ['UniProtKB'], 'identifier': ['Q8NI22']}, {'resource': ['UniProt Accession'], 'identifier': ['MCFD2_HUMAN']}]}], 'synonyms': [{'synonym': ['Neural stem cell-derived neuronal survival protein', 'SDNSF']}], 'amino-acid-sequence': ['>lcl|BSEQ0004158|Multiple coagulation factor deficiency protein 2\nMTMRSLLRTPFLCGLLWAFCAPGARAEEPAASFSQPGSMGLDKNTVHDQEHIMEHLEGVI\nNKPEAEMSPQELQLHYFKMHDYDGNNLLDGLELSTAITHVHKEEGSEQAPLMSEDELINI\nIDGVLRDDDKNNDGYIDYAEFAKSLQ'], 'gene-sequence': ['>lcl|BSEQ0016687|Multiple coagulation factor deficiency protein 2 (MCFD2)\nATGACCATGAGATCCCTGCTCAGAACCCCCTTCCTGTGTGGCCTGCTCTGGGCCTTTTGT\nGCCCCAGGCGCCAGGGCTGAGGAGCCTGCAGCCAGCTTCTCCCAACCCGGCAGCATGGGC\nCTGGATAAGAACACAGTGCACGACCAAGAGCATATCATGGAGCATCTAGAAGGTGTCATC\nAACAAACCAGAGGCGGAGATGTCGCCACAAGAATTGCAGCTCCATTACTTCAAAATGCAT\nGATTATGATGGCAATAATTTGCTTGATGGCTTAGAACTCTCCACAGCCATCACTCATGTC\nCATAAGGAGGAAGGGAGTGAACAGGCACCACTAATGAGTGAAGATGAACTGATTAACATA\nATAGATGGTGTTTTGAGAGATGATGACAAGAACAATGATGGATACATTGACTATGCTGAA\nTTTGCAAAATCACTGCAGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF13499'], 'name': ['EF-hand_7']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endoplasmic reticulum membrane']}, {'category': ['component'], 'description': ['endoplasmic reticulum-Golgi intermediate compartment membrane']}, {'category': ['component'], 'description': ['ER to Golgi transport vesicle membrane']}, {'category': ['component'], 'description': ['Golgi membrane']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['COPII vesicle coating']}, {'category': ['process'], 'description': ['ER to Golgi vesicle-mediated transport']}, {'category': ['process'], 'description': ['membrane organization']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['protein N-linked glycosylation via asparagine']}, {'category': ['process'], 'description': ['protein transport']}]}]}]}]}]"
"['DB00026', 'BTD00060', 'BIOD00060']",['Anakinra'],biotech,"['Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.[L35415] Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA).[L35415] Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases.[A247000]\r\n\r\nAnakinra is produced using the _E. Coli_ bacterial expression system. On November 14, 2001, it was approved by the FDA for the treatment of rheumatoid arthritis. It was later approved for the treatment of NOMID and DIRA on December 21, 2012, and December 18, 2020, respectively. A few studies have evaluated the use of anakinra for the treatment of coronavirus disease 2019 (COVID-19).[A247265] On November 8, 2022, the FDA issued an emergency use authorization (EUA) of anakinra for the treatment of COVID-19 in hospitalized patients who are at risk of progressing to severe respiratory failure.[L43932]']",['liquid'],"['Anakinra is an interleukin-1 receptor antagonist indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis (RA), in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs). Anakinra can be used alone or in combination with DMARDs other than Tumor Necrosis Factor (TNF) blocking agents.[L35415]\r\n\r\nAnakinra is also indicated for the treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID) and the treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA).[L35415] Anakinra is also used off-label for the treatment of several inflammatory diseases.[A247000]\r\n\r\nThe FDA has issued an emergency use authorization (EUA) for the emergency use of anakinra for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults with positive results of direct SARS-CoV-2 viral testing with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure and likely to have an elevated plasma soluble urokinase plasminogen activator receptor (suPAR). Since anakinra is approved for this condition under EUA, the drug should only be used when there are no alternative treatment available.[L43927]']","['Interleukin-1 (IL-1) plays an important role in inflammation and immunological responses. Inflammatory stimuli trigger its production, and it binds to the IL-1 receptor to activate a wide variety of mechanisms. The activity of the IL-1 receptor is also regulated by a naturally occurring IL-1 receptor antagonist (IL-1Ra) that competes for the binding sites of the IL-1 receptor.[L35415] In rheumatoid arthritis (RA) patients, IL-1 levels are elevated, inducing cartilage degradation and the stimulation of bone resorption, and the amount of IL-1Ra in the synovium and synovial fluid of RA patients cannot compete with the high level of IL-1 present.[L35415] Anakinra is a recombinant, non-glycosylated form of IL-1Ra that competes with and inhibits IL-1 by binding to the IL-1 receptor; therefore, the administration of this drug reduces the inflammatory response in RA patients.[A246908,L35415] \r\n\r\nAnakinra can also be used in the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA).[L35415] Patients with NOMID have spontaneous mutations in CIAS1/NLRP3, a gene that encodes cryopyrin, an inflammasome component. When activated, the inflammasome enhances and promotes the production of IL-1, an isoform of IL-1.[A246898,L35415] DIRA is an autoinflammatory disease caused by mutations in the IL1RN gene. These mutations reduce the amount of IL-1Ra that is secreted, leading to the unopposed action of IL-1.[L35415] Anakinra controls NOMID and DIRA symptoms by inhibiting IL-1 activity.[L35415]']",[None],"[{'target': [{'id': ['BE0000565'], 'name': ['Interleukin-1 receptor type 1'], 'organism': ['Humans'], 'actions': [{'action': ['antagonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1826'], 'pubmed-id': ['17498496'], 'citation': ['Tang YH, Zhang SP, Liang Y, Deng CQ: [Effects of Panax notoginseng saponins on mRNA expressions of interleukin-1 beta, its correlative factors and cysteinyl-aspartate specific protease after cerebral ischemia-reperfusion in rats]. Zhong Xi Yi Jie He Xue Bao. 2007 May;5(3):328-32.']}, {'ref-id': ['A1828'], 'pubmed-id': ['12817089'], 'citation': ['Dayer JM: The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford). 2003 May;42 Suppl 2:ii3-10.']}, {'ref-id': ['A1830'], 'pubmed-id': ['12355453'], 'citation': ['Vamvakopoulos J, Green C, Metcalfe S: Genetic control of IL-1beta bioactivity through differential regulation of the IL-1 receptor antagonist. Eur J Immunol. 2002 Oct;32(10):2988-96.']}, {'ref-id': ['A1832'], 'pubmed-id': ['17083033'], 'citation': ['Do H, Vasilescu A, Carpentier W, Meyer L, Diop G, Hirtzig T, Coulonges C, Labib T, Spadoni JL, Therwath A, Lathrop M, Matsuda F, Zagury JF: Exhaustive genotyping of the interleukin-1 family genes and associations with AIDS progression in a French cohort. J Infect Dis. 2006 Dec 1;194(11):1492-504. Epub 2006 Oct 26.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A1835'], 'pubmed-id': ['17352828'], 'citation': ['So A, De Smedt T, Revaz S, Tschopp J: A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28.']}, {'ref-id': ['A1837'], 'pubmed-id': ['10210771'], 'citation': ['Vannier E, Kaser A, Atkins MB, Fantuzzi G, Dinarello CA, Mier JW, Tilg H: Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy. Eur Cytokine Netw. 1999 Mar;10(1):37-42.']}]}], 'textbooks': [None], 'links': [{'link': [{'ref-id': ['L35415'], 'title': ['FDA Approved Drug Products: KINERET (anakinra) subcutaneous injection'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/103950s5189lbl.pdf']}]}], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interleukin-1 receptor type 1'], 'general-function': ['Transmembrane signaling receptor activity'], 'specific-function': ['Receptor for IL1A, IL1B and IL1RN. After binding to interleukin-1 associates with the corecptor IL1RAP to form the high affinity interleukin-1 receptor complex which mediates interleukin-1-dependent activation of NF-kappa-B, MAPK and other pathways. Signaling involves the recruitment of adapter molecules such as TOLLIP, MYD88, and IRAK1 or IRAK2 via the respective TIR domains of the receptor/coreceptor subunits. Binds ligands with comparable affinity and binding of antagonist IL1RN prevents association with IL1RAP to form a signaling complex.'], 'gene-name': ['IL1R1'], 'locus': ['2q12'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['337-356'], 'signal-regions': ['1-17'], 'theoretical-pi': ['7.89'], 'molecular-weight': ['65401.91'], 'chromosome-location': ['2'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5993']}, {'resource': ['GenAtlas'], 'identifier': ['IL1R1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X16896']}, {'resource': ['GenBank Protein Database'], 'identifier': ['33801']}, {'resource': ['UniProtKB'], 'identifier': ['P14778']}, {'resource': ['UniProt Accession'], 'identifier': ['IL1R1_HUMAN']}]}], 'synonyms': [{'synonym': ['CD121 antigen-like family member A', 'IL-1R-1', 'IL-1R-alpha', 'IL1R', 'IL1RA', 'IL1RT1', 'Interleukin-1 receptor alpha', 'Interleukin-1 receptor type I', 'p80']}], 'amino-acid-sequence': ['>lcl|BSEQ0018975|Interleukin-1 receptor type 1\nMKVLLRLICFIALLISSLEADKCKEREEKIILVSSANEIDVRPCPLNPNEHKGTITWYKD\nDSKTPVSTEQASRIHQHKEKLWFVPAKVEDSGHYYCVVRNSSYCLRIKISAKFVENEPNL\nCYNAQAIFKQKLPVAGDGGLVCPYMEFFKNENNELPKLQWYKDCKPLLLDNIHFSGVKDR\nLIVMNVAEKHRGNYTCHASYTYLGKQYPITRVIEFITLEENKPTRPVIVSPANETMEVDL\nGSQIQLICNVTGQLSDIAYWKWNGSVIDEDDPVLGEDYYSVENPANKRRSTLITVLNISE\nIESRFYKHPFTCFAKNTHGIDAAYIQLIYPVTNFQKHMIGICVTLTVIIVCSVFIYKIFK\nIDIVLWYRDSCYDFLPIKASDGKTYDAYILYPKTVGEGSTSDCDIFVFKVLPEVLEKQCG\nYKLFIYGRDDYVGEDIVEVINENVKKSRRLIIILVRETSGFSWLGGSSEEQIAMYNALVQ\nDGIKVVLLELEKIQDYEKMPESIKFIKQKHGAIRWSGDFTQGPQSAKTRFWKNVRYHMPV\nQRRSPSSKHQLLSPATKEKLQREAHVPLG'], 'gene-sequence': ['>lcl|BSEQ0018976|Interleukin-1 receptor type 1 (IL1R1)\nATGAAAGTGTTACTCAGACTTATTTGTTTCATAGCTCTACTGATTTCTTCTCTGGAGGCT\nGATAAATGCAAGGAACGTGAAGAAAAAATAATTTTAGTGTCATCTGCAAATGAAATTGAT\nGTTCGTCCCTGTCCTCTTAACCCAAATGAACACAAAGGCACTATAACTTGGTATAAAGAT\nGACAGCAAGACACCTGTATCTACAGAACAAGCCTCCAGGATTCATCAACACAAAGAGAAA\nCTTTGGTTTGTTCCTGCTAAGGTGGAGGATTCAGGACATTACTATTGCGTGGTAAGAAAT\nTCATCTTACTGCCTCAGAATTAAAATAAGTGCAAAATTTGTGGAGAATGAGCCTAACTTA\nTGTTATAATGCACAAGCCATATTTAAGCAGAAACTACCCGTTGCAGGAGACGGAGGACTT\nGTGTGCCCTTATATGGAGTTTTTTAAAAATGAAAATAATGAGTTACCTAAATTACAGTGG\nTATAAGGATTGCAAACCTCTACTTCTTGACAATATACACTTTAGTGGAGTCAAAGATAGG\nCTCATCGTGATGAATGTGGCTGAAAAGCATAGAGGGAACTATACTTGTCATGCATCCTAC\nACATACTTGGGCAAGCAATATCCTATTACCCGGGTAATAGAATTTATTACTCTAGAGGAA\nAACAAACCCACAAGGCCTGTGATTGTGAGCCCAGCTAATGAGACAATGGAAGTAGACTTG\nGGATCCCAGATACAATTGATCTGTAATGTCACCGGCCAGTTGAGTGACATTGCTTACTGG\nAAGTGGAATGGGTCAGTAATTGATGAAGATGACCCAGTGCTAGGGGAAGACTATTACAGT\nGTGGAAAATCCTGCAAACAAAAGAAGGAGTACCCTCATCACAGTGCTTAATATATCGGAA\nATTGAAAGTAGATTTTATAAACATCCATTTACCTGTTTTGCCAAGAATACACATGGTATA\nGATGCAGCATATATCCAGTTAATATATCCAGTCACTAATTTCCAGAAGCACATGATTGGT\nATATGTGTCACGTTGACAGTCATAATTGTGTGTTCTGTTTTCATCTATAAAATCTTCAAG\nATTGACATTGTGCTTTGGTACAGGGATTCCTGCTATGATTTTCTCCCAATAAAAGCTTCA\nGATGGAAAGACCTATGACGCATATATACTGTATCCAAAGACTGTTGGGGAAGGGTCTACC\nTCTGACTGTGATATTTTTGTGTTTAAAGTCTTGCCTGAGGTCTTGGAAAAACAGTGTGGA\nTATAAGCTGTTCATTTATGGAAGGGATGACTACGTTGGGGAAGACATTGTTGAGGTCATT\nAATGAAAACGTAAAGAAAAGCAGAAGACTGATTATCATTTTAGTCAGAGAAACATCAGGC\nTTCAGCTGGCTGGGTGGTTCATCTGAAGAGCAAATAGCCATGTATAATGCTCTTGTTCAG\nGATGGAATTAAAGTTGTCCTGCTTGAGCTGGAGAAAATCCAAGACTATGAGAAAATGCCA\nGAATCGATTAAATTCATTAAGCAGAAACATGGGGCTATCCGCTGGTCAGGGGACTTTACA\nCAGGGACCACAGTCTGCAAAGACAAGGTTCTGGAAGAATGTCAGGTACCACATGCCAGTC\nCAGCGACGGTCACCTTCATCTAAACACCAGTTACTGTCACCAGCCACTAAGGAGAAACTG\nCAAAGAGAGGCTCACGTGCCTCTCGGGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF07679'], 'name': ['I-set']}, {'identifier': ['PF01582'], 'name': ['TIR']}, {'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['axon']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['nucleus']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['postsynaptic density']}, {'category': ['component'], 'description': ['protein complex']}, {'category': ['function'], 'description': ['interleukin-1 receptor activity']}, {'category': ['function'], 'description': ['interleukin-1, Type I, activating receptor activity']}, {'category': ['function'], 'description': ['platelet-derived growth factor receptor binding']}, {'category': ['function'], 'description': ['signal transducer activity']}, {'category': ['function'], 'description': ['transmembrane signaling receptor activity']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular response to glucose stimulus']}, {'category': ['process'], 'description': ['heat acclimation']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['interleukin-1-mediated signaling pathway']}, {'category': ['process'], 'description': ['ovulation']}, {'category': ['process'], 'description': ['regulation of inflammatory response']}, {'category': ['process'], 'description': ['response to epidermal growth factor']}, {'category': ['process'], 'description': ['response to interleukin-1']}, {'category': ['process'], 'description': ['response to nitric oxide']}, {'category': ['process'], 'description': ['response to radiation']}, {'category': ['process'], 'description': ['response to transforming growth factor beta']}]}]}]}]}]"
"['DB00027', 'BTD00036', 'BIOD00036']",['Gramicidin D'],small molecule,"['Gramcidin D is a heterogeneous mixture of three antibiotic compounds, gramicidins A, B and C, making up 80%, 6%, and 14% respectively all of which are obtained from the soil bacterial species Bacillus brevis and called collectively gramicidin D. Gramcidins are 15 residue peptides with alternating D and L amino acids, which assemble inside of the hydrophobic interior of the cellular lipid bilayer to form a -helix. Active against most Gram-positive bacteria and some Gram-negative organisms, Gramicidin D is used primarily as a topical antibiotic and is also found in Polysporin ophthalmic solution.']",['liquid'],"['For treatment of skin lesions, surface wounds and eye infections.']","['Gramicidin D binds to and inserts itself into bacterial membranes (with a strong preference to gram-positive cell membranes). This results in membrane disruption and permeabilization (it acts as a channel). This leads to (i) loss of intracellular solutes (e.g., K+ and amino acids); (ii) dissipation of the transmembrane potential; (iii) inhibition of respiration; (iv) a reduction in ATP pools; and (v) inhibition of DNA, RNA, and protein synthesis, which leads to cell death.']",[None],[None]
"['DB00028', 'BTD00091', 'BIOD00091']",['Human immunoglobulin G'],biotech,"['Intravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and ion exchange chromatography. IVIg contains the same distribution of IgG antibody subclasses as is found in the general human population. IgG subclasses are fully represented in the following proportions: 70.3% IgG1, 24.7% IgG2, 3.1% IgG3, and 1.9% IgG4. IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders.']",['liquid'],"['Human immunoglobulin G is indicated for the following conditions:\r\n\r\n### Primary Immunodeficiency\r\n- for the treatment of primary immunodeficiency in adult and pediatric patients[L39920, L39930, L39935, L39940, L39945, L39950, L39955, L39960, L39965, L39975, L39980, L40029, L40034, L40044]\r\n- in combination with [hyaluronidase (human recombinant)] for the treatment of primary immunodeficiency in patients 2 years of age.[L42760]\r\n\r\n### Immune Thrombocytopenic Purpura (ITP)\r\n- for the treatment of acute or chronic immune thrombocytopenic purpura in adult and pediatric patients[L39940, L39950, L39960, L39965, L39970, L39975, L39980]\r\n\r\n### Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)\r\n- for the treatment of CIDP in adult patients[L39955, L39965, L39975, L39980, L40034]\r\n- in combination with hyaluronidase (human recombinant) as a maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)[L40039]\r\n\r\n### Multifocal Motor Neuropathy (MMN)\r\n- for maintenance therapy to improve muscle strength and disability in adult patients with MMN[L39955]\r\n\r\n### Prophylaxis of Bacterial Infection\r\n- for the prevention of bacterial infections in patients with hypogammaglobulinemia and/or B-cell chronic lymphocytic leukemia[L39960]\r\n\r\n### Coronary Artery Aneurysm Associated With Kawasaki Syndrome\r\n- for the prevention of coronary artery aneurysms in pediatric patients with Kawasaki syndrome[L39960]\r\n\r\n### Dermatomyositis\r\n- for the treatment of dermatomyositis in adult patients[L39970]\r\n']","[""IVIg interacts with a number of different components of the immune system, including cytokines, complement, Fc receptors and several cell surface immunocompetent molecules. IVIg also impacts different effector cells of the immune system (B and T lymphocytes, dendritic cells, etc.) and regulates a wide range of genes. Its main mechanism of actions are believed to be Fc-dependent and F(ab')2-dependent. IVIg competitively blocks gamma Fc receptors, preventing the binding and ingestion of phagocytes and suppressing platelet depletion. IVIg contains a number of different antobodies, which prevent infection by attaching to the surface of invading pathogens and aiding in their disposal before they can infect cells. Antibodies remove pathogens via complement activation, agglutination or precipitation, pathogen receptor blocking, macrophage tagging or neutralization (via binding) of pathogen toxins. Intact IVIg and F(ab)2 fragments of IVIg can also neutralize the activity of various autoantibodies. By triggering the production of interleukin-1 receptor antagonist, IVIg modulates of the production of cytokines and cytokine antagonists. It also prevents the generation of the C5b-9 membrane attack complex and subsequent complement-mediated tissue damage by binding active complement components.""]",[None],"[{'target': [{'id': ['BE0000710'], 'name': ['High affinity immunoglobulin gamma Fc receptor I'], 'organism': ['Humans'], 'actions': [{'action': ['antagonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A37'], 'pubmed-id': ['17911465'], 'citation': ['Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.']}, {'ref-id': ['A13124'], 'pubmed-id': ['20441428'], 'citation': ['Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.']}, {'ref-id': ['A13125'], 'pubmed-id': ['17351760'], 'citation': ['Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['High affinity immunoglobulin gamma Fc receptor I'], 'general-function': ['Receptor signaling protein activity'], 'specific-function': ['High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.'], 'gene-name': ['FCGR1A'], 'locus': ['1q21.2-q21.3'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['293-313'], 'signal-regions': ['1-15'], 'theoretical-pi': ['8.08'], 'molecular-weight': ['42631.525'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3613']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR1A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X14356']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31332']}, {'resource': ['UniProtKB'], 'identifier': ['P12314']}, {'resource': ['UniProt Accession'], 'identifier': ['FCGR1_HUMAN']}]}], 'synonyms': [{'synonym': ['Fc-gamma RI', 'Fc-gamma RIA', 'FCG1', 'FcgammaRIa', 'FCGR1', 'FcRI', 'IGFR1', 'IgG Fc receptor I']}], 'amino-acid-sequence': ['>lcl|BSEQ0001416|High affinity immunoglobulin gamma Fc receptor I\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT'], 'gene-sequence': ['>lcl|BSEQ0016183|High affinity immunoglobulin gamma Fc receptor I (FCGR1A)\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAATTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00047'], 'name': ['ig']}, {'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['clathrin-coated endocytic vesicle membrane']}, {'category': ['component'], 'description': ['early endosome membrane']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['receptor signaling protein activity']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent']}, {'category': ['process'], 'description': ['antigen processing and presentation of peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['interferon-gamma-mediated signaling pathway']}, {'category': ['process'], 'description': ['intracellular signal transduction']}, {'category': ['process'], 'description': ['phagocytosis, engulfment']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}, {'id': ['BE0004684'], 'name': ['High affinity immunoglobulin gamma Fc receptor IB'], 'organism': ['Humans'], 'actions': [{'action': ['antagonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A37'], 'pubmed-id': ['17911465'], 'citation': ['Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.']}, {'ref-id': ['A13124'], 'pubmed-id': ['20441428'], 'citation': ['Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.']}, {'ref-id': ['A13125'], 'pubmed-id': ['17351760'], 'citation': ['Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['High affinity immunoglobulin gamma Fc receptor IB'], 'general-function': ['Immunoglobulin receptor activity'], 'specific-function': ['May bind to the Fc region of immunoglobulins gamma with a low affinity compared to FCGR1A. May function in the humoral immune response.'], 'gene-name': ['FCGR1B'], 'locus': [None], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['199-219'], 'signal-regions': ['1-15'], 'theoretical-pi': [None], 'molecular-weight': ['32231.795'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3614']}, {'resource': ['UniProtKB'], 'identifier': ['Q92637']}, {'resource': ['UniProt Accession'], 'identifier': ['FCGRB_HUMAN']}]}], 'synonyms': [{'synonym': ['Fc-gamma RIB', 'FcRIB', 'hFcgammaRIB', 'IGFRB', 'IgG Fc receptor IB']}], 'amino-acid-sequence': ['>lcl|BSEQ0009601|High affinity immunoglobulin gamma Fc receptor IB\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFMEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISQYTVKGLQLPTPVWFHVLFYLAVGIMFLVNTVLWVTIRKELKRKKKWNLEISLDSGHE\nKKVISSLQEDRHLEEELKCQEQKEEQLQEGVHRKEPQGAT'], 'gene-sequence': ['>lcl|BSEQ0020794|High affinity immunoglobulin gamma Fc receptor IB (FCGR1B)\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGGCTGGCTACTACTGCAGGTCTCCAGCAGA\nGTCTTCATGGAAGGAGAACCTCTGGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTG\nTACAATGTGCTTTACTATCGAAATGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAAC\nCTCACCATTCTGAAAACCAACATAAGTCACAATGGCACCTACCATTGCTCAGGCATGGGA\nAAGCATCGCTACACATCAGCAGGAATATCACAATACACTGTGAAAGGCCTCCAGTTACCA\nACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGAATAATGTTTTTAGTGAAC\nACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAGAAAAAGTGGAATTTAGAA\nATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAATTTCCAGCCTTCAAGAAGACAGACAT\nTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAGCTGCAGGAAGGGGTGCAC\nCGGAAGGAGCCCCAGGGGGCCACGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['clathrin-coated endocytic vesicle membrane']}, {'category': ['component'], 'description': ['early endosome membrane']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['immunoglobulin receptor activity']}, {'category': ['process'], 'description': ['adaptive immune response']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent']}, {'category': ['process'], 'description': ['antigen processing and presentation of peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['Fc receptor signaling pathway']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['interferon-gamma-mediated signaling pathway']}]}]}]}, {'id': ['BE0002098'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor II-a'], 'organism': ['Humans'], 'actions': [{'action': ['antagonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A37'], 'pubmed-id': ['17911465'], 'citation': ['Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.']}, {'ref-id': ['A13124'], 'pubmed-id': ['20441428'], 'citation': ['Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.']}, {'ref-id': ['A13125'], 'pubmed-id': ['17351760'], 'citation': ['Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor II-a'], 'general-function': [None], 'specific-function': ['Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens.'], 'gene-name': ['FCGR2A'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['218-240'], 'signal-regions': ['1-33'], 'theoretical-pi': ['6.78'], 'molecular-weight': ['35000.42'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3616']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR2A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M31932']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182474']}, {'resource': ['UniProtKB'], 'identifier': ['P12318']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG2A_HUMAN']}]}], 'synonyms': [{'synonym': ['CD32', 'CDw32', 'Fc-gamma RII-a', 'Fc-gamma-RIIa', 'FCG2', 'FCGR2A1', 'FcRII-a', 'IGFR2', 'IgG Fc receptor II-a']}], 'amino-acid-sequence': ['>lcl|BSEQ0037156|Low affinity immunoglobulin gamma Fc region receptor II-a\nMTMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSHLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN'], 'gene-sequence': ['>lcl|BSEQ0019233|Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A)\nATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCATTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['innate immune response']}]}]}]}, {'id': ['BE0002099'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor II-b'], 'organism': ['Humans'], 'actions': [{'action': ['antagonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A37'], 'pubmed-id': ['17911465'], 'citation': ['Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.']}, {'ref-id': ['A13124'], 'pubmed-id': ['20441428'], 'citation': ['Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.']}, {'ref-id': ['A13125'], 'pubmed-id': ['17351760'], 'citation': ['Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor II-b'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis.'], 'gene-name': ['FCGR2B'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['218-240'], 'signal-regions': ['1-42'], 'theoretical-pi': ['6.12'], 'molecular-weight': ['34043.355'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3618']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR2B']}, {'resource': ['GenBank Gene Database'], 'identifier': ['U87560']}, {'resource': ['GenBank Protein Database'], 'identifier': ['4099445']}, {'resource': ['UniProtKB'], 'identifier': ['P31994']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG2B_HUMAN']}]}], 'synonyms': [{'synonym': ['CD32', 'CDw32', 'Fc-gamma RII-b', 'Fc-gamma-RIIb', 'FCG2', 'FcRII-b', 'IGFR2', 'IgG Fc receptor II-b']}], 'amino-acid-sequence': ['>lcl|BSEQ0004116|Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI'], 'gene-sequence': ['>lcl|BSEQ0019237|Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B)\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTG\nCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCC\nATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTC\nAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGC\nGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTGGAG\nTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTC\nAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAACTTC\nTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATAGGC\nTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCACCG\nATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCTGTA\nGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATTTAG'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['viral process']}]}]}]}, {'id': ['BE0002100'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor II-c'], 'organism': ['Humans'], 'actions': [{'action': ['antagonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A37'], 'pubmed-id': ['17911465'], 'citation': ['Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.']}, {'ref-id': ['A13124'], 'pubmed-id': ['20441428'], 'citation': ['Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.']}, {'ref-id': ['A13125'], 'pubmed-id': ['17351760'], 'citation': ['Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor II-c'], 'general-function': ['Transmembrane signaling receptor activity'], 'specific-function': ['Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells.'], 'gene-name': ['FCGR2C'], 'locus': ['1q23.3'], 'cellular-location': ['Cytoplasm'], 'transmembrane-regions': ['224-246'], 'signal-regions': ['1-42'], 'theoretical-pi': ['6.9'], 'molecular-weight': ['35577.96'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:15626']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR2C']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X17652']}, {'resource': ['GenBank Protein Database'], 'identifier': ['32074']}, {'resource': ['UniProtKB'], 'identifier': ['P31995']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG2C_HUMAN']}]}], 'synonyms': [{'synonym': ['CD32', 'CDw32', 'Fc-gamma RII-c', 'Fc-gamma-RIIc', 'FCG2', 'FcRII-c', 'IGFR2', 'IgG Fc receptor II-c']}], 'amino-acid-sequence': ['>lcl|BSEQ0004118|Low affinity immunoglobulin gamma Fc region receptor II-c\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR\nAPTDDDKNIYLTLPPNDHVNSNN'], 'gene-sequence': ['>lcl|BSEQ0011523|Low affinity immunoglobulin gamma Fc region receptor II-c (FCGR2C)\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCCGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG\nAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT\nGAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG\nGCACCTACTGACGATGATAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAAC\nAGTAATAACTAA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['transmembrane signaling receptor activity']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}, {'id': ['BE0002097'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor III-A'], 'organism': ['Humans'], 'actions': [{'action': ['antagonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A37'], 'pubmed-id': ['17911465'], 'citation': ['Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.']}, {'ref-id': ['A13124'], 'pubmed-id': ['20441428'], 'citation': ['Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.']}, {'ref-id': ['A13125'], 'pubmed-id': ['17351760'], 'citation': ['Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor III-A'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.'], 'gene-name': ['FCGR3A'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['209-229'], 'signal-regions': ['1-16'], 'theoretical-pi': ['8.21'], 'molecular-weight': ['29088.895'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3619']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR3A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X52645']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31324']}, {'resource': ['UniProtKB'], 'identifier': ['P08637']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG3A_HUMAN']}]}], 'synonyms': [{'synonym': ['CD16A', 'CD16a antigen', 'Fc-gamma RIII', 'Fc-gamma RIII-alpha', 'Fc-gamma RIIIa', 'FCG3', 'FCGR3', 'FcR-10', 'FcRIII', 'FcRIIIa', 'IGFR3', 'IgG Fc receptor III-2']}], 'amino-acid-sequence': ['>lcl|BSEQ0004112|Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK'], 'gene-sequence': ['>lcl|BSEQ0011522|Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A)\nATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCT\nTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTG\nCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCA\nAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACT\nCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAG\nAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCGACGACAGT\nGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTGCAGCTAGAAGTC\nCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAGGAAGACCCTATT\nCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACATATTTACAGAAT\nGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCAAAAGCCACACTC\nAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAATGTGTCTTCAGAG\nACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCATCATTCTTTCCA\nCCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCAGTGGACACAGGA\nCTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGGAAGGACCATAAA\nTTTAAATGGAGAAAGGACCCTCAAGACAAATGA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['regulation of immune response']}]}]}]}, {'id': ['BE0000901'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor III-B'], 'organism': ['Humans'], 'actions': [{'action': ['antagonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A37'], 'pubmed-id': ['17911465'], 'citation': ['Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.']}, {'ref-id': ['A13124'], 'pubmed-id': ['20441428'], 'citation': ['Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.']}, {'ref-id': ['A13125'], 'pubmed-id': ['17351760'], 'citation': ['Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor III-B'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.'], 'gene-name': ['FCGR3B'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': [None], 'signal-regions': ['1-16'], 'theoretical-pi': ['6.71'], 'molecular-weight': ['26215.64'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3620']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR3B']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X16863']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31322']}, {'resource': ['UniProtKB'], 'identifier': ['O75015']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG3B_HUMAN']}]}], 'synonyms': [{'synonym': ['CD16B', 'Fc-gamma RIII', 'Fc-gamma RIII-beta', 'Fc-gamma RIIIb', 'FCG3', 'FCGR3', 'FcR-10', 'FcRIII', 'FcRIIIb', 'IGFR3', 'IgG Fc receptor III-1']}], 'amino-acid-sequence': ['>lcl|BSEQ0010635|Low affinity immunoglobulin gamma Fc region receptor III-B\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI'], 'gene-sequence': ['>lcl|BSEQ0010636|Low affinity immunoglobulin gamma Fc region receptor III-B (FCGR3B)\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['anchored component of membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['mitophagy in response to mitochondrial depolarization']}, {'category': ['process'], 'description': ['positive regulation of defense response to virus by host']}, {'category': ['process'], 'description': ['xenophagy']}]}]}]}, {'id': ['BE0003455'], 'name': ['Complement C3'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13124'], 'pubmed-id': ['20441428'], 'citation': ['Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.']}, {'ref-id': ['A13125'], 'pubmed-id': ['17351760'], 'citation': ['Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.']}, {'ref-id': ['A37'], 'pubmed-id': ['17911465'], 'citation': ['Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Complement C3'], 'general-function': ['Receptor binding'], 'specific-function': ['C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. In chronic inflammation, acts as a chemoattractant for neutrophils (By similarity). It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.C3-beta-c: Acts as a chemoattractant for neutrophils in chronic inflammation.Acylation stimulating protein: adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of C5AR2 (PubMed:8376604, PubMed:2909530, PubMed:9059512, PubMed:10432298, PubMed:15833747, PubMed:16333141, PubMed:19615750).'], 'gene-name': ['C3'], 'locus': [None], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-22'], 'theoretical-pi': ['6.34'], 'molecular-weight': ['187146.73'], 'chromosome-location': ['19'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1318']}, {'resource': ['GenAtlas'], 'identifier': ['C3']}, {'resource': ['GenBank Gene Database'], 'identifier': ['AY513239']}, {'resource': ['UniProtKB'], 'identifier': ['P01024']}, {'resource': ['UniProt Accession'], 'identifier': ['CO3_HUMAN']}]}], 'synonyms': [{'synonym': ['C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1', 'CPAMD1']}], 'amino-acid-sequence': ['>lcl|BSEQ0020692|Complement C3\nMGPTSGPSLLLLLLTHLPLALGSPMYSIITPNILRLESEETMVLEAHDAQGDVPVTVTVH\nDFPGKKLVLSSEKTVLTPATNHMGNVTFTIPANREFKSEKGRNKFVTVQATFGTQVVEKV\nVLVSLQSGYLFIQTDKTIYTPGSTVLYRIFTVNHKLLPVGRTVMVNIENPEGIPVKQDSL\nSSQNQLGVLPLSWDIPELVNMGQWKIRAYYENSPQQVFSTEFEVKEYVLPSFEVIVEPTE\nKFYYIYNEKGLEVTITARFLYGKKVEGTAFVIFGIQDGEQRISLPESLKRIPIEDGSGEV\nVLSRKVLLDGVQNPRAEDLVGKSLYVSATVILHSGSDMVQAERSGIPIVTSPYQIHFTKT\nPKYFKPGMPFDLMVFVTNPDGSPAYRVPVAVQGEDTVQSLTQGDGVAKLSINTHPSQKPL\nSITVRTKKQELSEAEQATRTMQALPYSTVGNSNNYLHLSVLRTELRPGETLNVNFLLRMD\nRAHEAKIRYYTYLIMNKGRLLKAGRQVREPGQDLVVLPLSITTDFIPSFRLVAYYTLIGA\nSGQREVVADSVWVDVKDSCVGSLVVKSGQSEDRQPVPGQQMTLKIEGDHGARVVLVAVDK\nGVFVLNKKNKLTQSKIWDVVEKADIGCTPGSGKDYAGVFSDAGLTFTSSSGQQTAQRAEL\nQCPQPAARRRRSVQLTEKRMDKVGKYPKELRKCCEDGMRENPMRFSCQRRTRFISLGEAC\nKKVFLDCCNYITELRRQHARASHLGLARSNLDEDIIAEENIVSRSEFPESWLWNVEDLKE\nPPKNGISTKLMNIFLKDSITTWEILAVSMSDKKGICVADPFEVTVMQDFFIDLRLPYSVV\nRNEQVEIRAVLYNYRQNQELKVRVELLHNPAFCSLATTKRRHQQTVTIPPKSSLSVPYVI\nVPLKTGLQEVEVKAAVYHHFISDGVRKSLKVVPEGIRMNKTVAVRTLDPERLGREGVQKE\nDIPPADLSDQVPDTESETRILLQGTPVAQMTEDAVDAERLKHLIVTPSGCGEQNMIGMTP\nTVIAVHYLDETEQWEKFGLEKRQGALELIKKGYTQQLAFRQPSSAFAAFVKRAPSTWLTA\nYVVKVFSLAVNLIAIDSQVLCGAVKWLILEKQKPDGVFQEDAPVIHQEMIGGLRNNNEKD\nMALTAFVLISLQEAKDICEEQVNSLPGSITKAGDFLEANYMNLQRSYTVAIAGYALAQMG\nRLKGPLLNKFLTTAKDKNRWEDPGKQLYNVEATSYALLALLQLKDFDFVPPVVRWLNEQR\nYYGGGYGSTQATFMVFQALAQYQKDAPDHQELNLDVSLQLPSRSSKITHRIHWESASLLR\nSEETKENEGFTVTAEGKGQGTLSVVTMYHAKAKDQLTCNKFDLKVTIKPAPETEKRPQDA\nKNTMILEICTRYRGDQDATMSILDISMMTGFAPDTDDLKQLANGVDRYISKYELDKAFSD\nRNTLIIYLDKVSHSEDDCLAFKVHQYFNVELIQPGAVKVYAYYNLEESCTRFYHPEKEDG\nKLNKLCRDELCRCAEENCFIQKSDDKVTLEERLDKACEPGVDYVYKTRLVKVQLSNDFDE\nYIMAIEQTIKSGSDEVQVGQQRTFISPIKCREALKLEEKKHYLMWGLSSDFWGEKPNLSY\nIIGKDTWVEHWPEEDECQDEENQKQCQDLGAFTESMVVFGCPN'], 'gene-sequence': ['>lcl|BSEQ0020693|Complement C3 (C3)\nATGGGACCCACCTCAGGTCCCAGCCTGCTGCTCCTGCTACTAACCCACCTCCCCCTGGCT\nCTGGGGAGTCCCATGTACTCTATCATCACCCCCAACATCTTGCGGCTGGAGAGCGAGGAG\nACCATGGTGCTGGAGGCCCACGACGCGCAAGGGGATGTTCCAGTCACTGTTACTGTCCAC\nGACTTCCCAGGCAAAAAACTAGTGCTGTCCAGTGAGAAGACTGTGCTGACCCCTGCCACC\nAACCACATGGGCAACGTCACCTTCACGATCCCAGCCAACAGGGAGTTCAAGTCAGAAAAG\nGGGCGCAACAAGTTCGTGACCGTGCAGGCCACCTTCGGGACCCAAGTGGTGGAGAAGGTG\nGTGCTGGTCAGCCTGCAGAGCGGGTACCTCTTCATCCAGACAGACAAGACCATCTACACC\nCCTGGCTCCACAGTTCTCTATCGGATCTTCACCGTCAACCACAAGCTGCTACCCGTGGGC\nCGGACGGTCATGGTCAACATTGAGAACCCGGAAGGCATCCCGGTCAAGCAGGACTCCTTG\nTCTTCTCAGAACCAGCTTGGCGTCTTGCCCTTGTCTTGGGACATTCCGGAACTCGTCAAC\nATGGGCCAGTGGAAGATCCGAGCCTACTATGAAAACTCACCACAGCAGGTCTTCTCCACT\nGAGTTTGAGGTGAAGGAGTACGTGCTGCCCAGTTTCGAGGTCATAGTGGAGCCTACAGAG\nAAATTCTACTACATCTATAACGAGAAGGGCCTGGAGGTCACCATCACCGCCAGGTTCCTC\nTACGGGAAGAAAGTGGAGGGAACTGCCTTTGTCATCTTCGGGATCCAGGATGGCGAACAG\nAGGATTTCCCTGCCTGAATCCCTCAAGCGCATTCCGATTGAGGATGGCTCGGGGGAGGTT\nGTGCTGAGCCGGAAGGTACTGCTGGACGGGGTGCAGAACCCCCGAGCAGAAGACCTGGTG\nGGGAAGTCTTTGTACGTGTCTGCCACCGTCATCTTGCACTCAGGCAGTGACATGGTGCAG\nGCAGAGCGCAGCGGGATCCCCATCGTGACCTCTCCCTACCAGATCCACTTCACCAAGACA\nCCCAAGTACTTCAAACCAGGAATGCCCTTTGACCTCATGGTGTTCGTGACGAACCCTGAT\nGGCTCTCCAGCCTACCGAGTCCCCGTGGCAGTCCAGGGCGAGGACACTGTGCAGTCTCTA\nACCCAGGGAGATGGCGTGGCCAAACTCAGCATCAACACACACCCCAGCCAGAAGCCCTTG\nAGCATCACGGTGCGCACGAAGAAGCAGGAGCTCTCGGAGGCAGAGCAGGCTACCAGGACC\nATGCAGGCTCTGCCCTACAGCACCGTGGGCAACTCCAACAATTACCTGCATCTCTCAGTG\nCTACGTACAGAGCTCAGACCCGGGGAGACCCTCAACGTCAACTTCCTCCTGCGAATGGAC\nCGCGCCCACGAGGCCAAGATCCGCTACTACACCTACCTGATCATGAACAAGGGCAGGCTG\nTTGAAGGCGGGACGCCAGGTGCGAGAGCCCGGCCAGGACCTGGTGGTGCTGCCCCTGTCC\nATCACCACCGACTTCATCCCTTCCTTCCGCCTGGTGGCGTACTACACGCTGATCGGTGCC\nAGCGGCCAGAGGGAGGTGGTGGCCGACTCCGTGTGGGTGGACGTCAAGGACTCCTGCGTG\nGGCTCGCTGGTGGTAAAAAGCGGCCAGTCAGAAGACCGGCAGCCTGTACCTGGGCAGCAG\nATGACCCTGAAGATAGAGGGTGACCACGGGGCCCGGGTGGTACTGGTGGCCGTGGACAAG\nGGCGTGTTCGTGCTGAATAAGAAGAACAAACTGACGCAGAGTAAGATCTGGGACGTGGTG\nGAGAAGGCAGACATCGGCTGCACCCCGGGCAGTGGGAAGGATTACGCCGGTGTCTTCTCC\nGACGCAGGGCTGACCTTCACGAGCAGCAGTGGCCAGCAGACCGCCCAGAGGGCAGAACTT\nCAGTGCCCGCAGCCAGCCGCCCGCCGACGCCGTTCCGTGCAGCTCACGGAGAAGCGAATG\nGACAAAGTCGGCAAGTACCCCAAGGAGCTGCGCAAGTGCTGCGAGGACGGCATGCGGGAG\nAACCCCATGAGGTTCTCGTGCCAGCGCCGGACCCGTTTCATCTCCCTGGGCGAGGCGTGC\nAAGAAGGTCTTCCTGGACTGCTGCAACTACATCACAGAGCTGCGGCGGCAGCACGCGCGG\nGCCAGCCACCTGGGCCTGGCCAGGAGTAACCTGGATGAGGACATCATTGCAGAAGAGAAC\nATCGTTTCCCGAAGTGAGTTCCCAGAGAGCTGGCTGTGGAACGTTGAGGACTTGAAAGAG\nCCACCGAAAAATGGAATCTCTACGAAGCTCATGAATATATTTTTGAAAGACTCCATCACC\nACGTGGGAGATTCTGGCTGTGAGCATGTCGGACAAGAAAGGGATCTGTGTGGCAGACCCC\nTTCGAGGTCACAGTAATGCAGGACTTCTTCATCGACCTGCGGCTACCCTACTCTGTTGTT\nCGAAACGAGCAGGTGGAAATCCGAGCCGTTCTCTACAATTACCGGCAGAACCAAGAGCTC\nAAGGTGAGGGTGGAACTACTCCACAATCCAGCCTTCTGCAGCCTGGCCACCACCAAGAGG\nCGTCACCAGCAGACCGTAACCATCCCCCCCAAGTCCTCGTTGTCCGTTCCATATGTCATC\nGTGCCGCTAAAGACCGGCCTGCAGGAAGTGGAAGTCAAGGCTGCTGTCTACCATCATTTC\nATCAGTGACGGTGTCAGGAAGTCCCTGAAGGTCGTGCCGGAAGGAATCAGAATGAACAAA\nACTGTGGCTGTTCGCACCCTGGATCCAGAACGCCTGGGCCGTGAAGGAGTGCAGAAAGAG\nGACATCCCACCTGCAGACCTCAGTGACCAAGTCCCGGACACCGAGTCTGAGACCAGAATT\nCTCCTGCAAGGGACCCCAGTGGCCCAGATGACAGAGGATGCCGTCGACGCGGAACGGCTG\nAAGCACCTCATTGTGACCCCCTCGGGCTGCGGGGAACAGAACATGATCGGCATGACGCCC\nACGGTCATCGCTGTGCATTACCTGGATGAAACGGAGCAGTGGGAGAAGTTCGGCCTAGAG\nAAGCGGCAGGGGGCCTTGGAGCTCATCAAGAAGGGGTACACCCAGCAGCTGGCCTTCAGA\nCAACCCAGCTCTGCCTTTGCGGCCTTCGTGAAACGGGCACCCAGCACCTGGCTGACCGCC\nTACGTGGTCAAGGTCTTCTCTCTGGCTGTCAACCTCATCGCCATCGACTCCCAAGTCCTC\nTGCGGGGCTGTTAAATGGCTGATCCTGGAGAAGCAGAAGCCCGACGGGGTCTTCCAGGAG\nGATGCGCCCGTGATACACCAAGAAATGATTGGTGGATTACGGAACAACAACGAGAAAGAC\nATGGCCCTCACGGCCTTTGTTCTCATCTCGCTGCAGGAGGCTAAAGATATTTGCGAGGAG\nCAGGTCAACAGCCTGCCAGGCAGCATCACTAAAGCAGGAGACTTCCTTGAAGCCAACTAC\nATGAACCTACAGAGATCCTACACTGTGGCCATTGCTGGCTATGCTCTGGCCCAGATGGGC\nAGGCTGAAGGGGCCTCTTCTTAACAAATTTCTGACCACAGCCAAAGATAAGAACCGCTGG\nGAGGACCCTGGTAAGCAGCTCTACAACGTGGAGGCCACATCCTATGCCCTCTTGGCCCTA\nCTGCAGCTAAAAGACTTTGACTTTGTGCCTCCCGTCGTGCGTTGGCTCAATGAACAGAGA\nTACTACGGTGGTGGCTATGGCTCTACCCAGGCCACCTTCATGGTGTTCCAAGCCTTGGCT\nCAATACCAAAAGGACGCCCCTGACCACCAGGAACTGAACCTTGATGTGTCCCTCCAACTG\nCCCAGCCGCAGCTCCAAGATCACCCACCGTATCCACTGGGAATCTGCCAGCCTCCTGCGA\nTCAGAAGAGACCAAGGAAAATGAGGGTTTCACAGTCACAGCTGAAGGAAAAGGCCAAGGC\nACCTTGTCGGTGGTGACAATGTACCATGCTAAGGCCAAAGATCAACTCACCTGTAATAAA\nTTCGACCTCAAGGTCACCATAAAACCAGCACCGGAAACAGAAAAGAGGCCTCAGGATGCC\nAAGAACACTATGATCCTTGAGATCTGTACCAGGTACCGGGGAGACCAGGATGCCACTATG\nTCTATATTGGACATATCCATGATGACTGGCTTTGCTCCAGACACAGATGACCTGAAGCAG\nCTGGCCAATGGTGTTGACAGATACATCTCCAAGTATGAGCTGGACAAAGCCTTCTCCGAT\nAGGAACACCCTCATCATCTACCTGGACAAGGTCTCACACTCTGAGGATGACTGTCTAGCT\nTTCAAAGTTCACCAATACTTTAATGTAGAGCTTATCCAGCCTGGAGCAGTCAAGGTCTAC\nGCCTATTACAACCTGGAGGAAAGCTGTACCCGGTTCTACCATCCGGAAAAGGAGGATGGA\nAAGCTGAACAAGCTCTGCCGTGATGAACTGTGCCGCTGTGCTGAGGAGAATTGCTTCATA\nCAAAAGTCGGATGACAAGGTCACCCTGGAAGAACGGCTGGACAAGGCCTGTGAGCCAGGA\nGTGGACTATGTGTACAAGACCCGACTGGTCAAGGTTCAGCTGTCCAATGACTTTGACGAG\nTACATCATGGCCATTGAGCAGACCATCAAGTCAGGCTCGGATGAGGTGCAGGTTGGACAG\nCAGCGCACGTTCATCAGCCCCATCAAGTGCAGAGAAGCCCTGAAGCTGGAGGAGAAGAAA\nCACTACCTCATGTGGGGTCTCTCCTCCGATTTCTGGGGAGAGAAGCCCAACCTCAGCTAC\nATCATCGGGAAGGACACTTGGGTGGAGCACTGGCCCGAGGAGGACGAATGCCAAGACGAA\nGAGAACCAGAAACAATGCCAGGACCTCGGCGCCTTCACCGAGAGCATGGTTGTCTTTGGG\nTGCCCCAACTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00207'], 'name': ['A2M']}, {'identifier': ['PF07678'], 'name': ['A2M_comp']}, {'identifier': ['PF01835'], 'name': ['A2M_N']}, {'identifier': ['PF07703'], 'name': ['A2M_N_2']}, {'identifier': ['PF07677'], 'name': ['A2M_recep']}, {'identifier': ['PF01821'], 'name': ['ANATO']}, {'identifier': ['PF01759'], 'name': ['NTR']}, {'identifier': ['PF10569'], 'name': ['Thiol-ester_cl']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['C5L2 anaphylatoxin chemotactic receptor binding']}, {'category': ['function'], 'description': ['cofactor binding']}, {'category': ['function'], 'description': ['endopeptidase inhibitor activity']}, {'category': ['function'], 'description': ['lipid binding']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['complement activation']}, {'category': ['process'], 'description': ['complement activation, alternative pathway']}, {'category': ['process'], 'description': ['complement activation, classical pathway']}, {'category': ['process'], 'description': ['fatty acid metabolic process']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['inflammatory response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['positive regulation of activation of membrane attack complex']}, {'category': ['process'], 'description': ['positive regulation of angiogenesis']}, {'category': ['process'], 'description': ['positive regulation of apoptotic cell clearance']}, {'category': ['process'], 'description': ['positive regulation of developmental growth']}, {'category': ['process'], 'description': ['positive regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['positive regulation of G-protein coupled receptor protein signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of glucose transport']}, {'category': ['process'], 'description': ['positive regulation of lipid storage']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of type IIa hypersensitivity']}, {'category': ['process'], 'description': ['positive regulation of vascular endothelial growth factor production']}, {'category': ['process'], 'description': ['regulation of complement activation']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['regulation of triglyceride biosynthetic process']}, {'category': ['process'], 'description': ['response to estradiol']}, {'category': ['process'], 'description': ['response to glucocorticoid']}, {'category': ['process'], 'description': ['response to magnesium ion']}, {'category': ['process'], 'description': ['response to progesterone']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['tolerance induction']}]}]}]}, {'id': ['BE0004685'], 'name': ['Complement C4-A'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13124'], 'pubmed-id': ['20441428'], 'citation': ['Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.']}, {'ref-id': ['A13125'], 'pubmed-id': ['17351760'], 'citation': ['Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.']}, {'ref-id': ['A37'], 'pubmed-id': ['17911465'], 'citation': ['Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Complement C4-A'], 'general-function': ['Endopeptidase inhibitor activity'], 'specific-function': ['Non-enzymatic component of C3 and C5 convertases and thus essential for the propagation of the classical complement pathway. Covalently binds to immunoglobulins and immune complexes and enhances the solubilization of immune aggregates and the clearance of IC through CR1 on erythrocytes. C4A isotype is responsible for effective binding to form amide bonds with immune aggregates or protein antigens, while C4B isotype catalyzes the transacylation of the thioester carbonyl group to form ester bonds with carbohydrate antigens.Derived from proteolytic degradation of complement C4, C4a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.'], 'gene-name': ['C4A'], 'locus': [None], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-19'], 'theoretical-pi': [None], 'molecular-weight': ['192783.805'], 'chromosome-location': ['6'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1323']}, {'resource': ['UniProtKB'], 'identifier': ['P0C0L4']}, {'resource': ['UniProt Accession'], 'identifier': ['CO4A_HUMAN']}]}], 'synonyms': [{'synonym': ['Acidic complement C4', 'C3 and PZP-like alpha-2-macroglobulin domain-containing protein 2', 'CO4', 'CPAMD2']}], 'amino-acid-sequence': ['>lcl|BSEQ0009602|Complement C4-A\nMRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLRN\nPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLKDS\nLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMVEN\nSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPN\nFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE\nSQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAELTSW\nYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVPEVQD\nIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPDS\nRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPS\nFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA\nLGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAGLAFSDGDQW\nTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTRLPMMRSCEQRA\nARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLIDEDDIPVRSFFPE\nNWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLP\nMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS\nVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNPLDHRGRTLEI\nPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASLLRLPRGCGEQTMIYLAP\nTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRKADGSYAAWLSRDSSTWLTA\nFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVA\nLTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKANSFLGEKASAGLLGAHAAAITAYAL\nTLTKAPVDLLGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNPSDPMPQAPAL\nWIETTAYALLHLLLHEGKAEMADQASAWLTRQGSFQGGFRSTQDTVIALDALSAYWIASH\nTTEERGLNVTLSSTGRNGFKSHALQLNNRQIRGLEEELQFSLGSKINVKVGGNSKGTLKV\nLRTYNVLDMKNTTCQDLQIEVTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTP\nLQLFEGRRNRRRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD\nLEKLTSLSDRYVSHFETEGPHVLLYFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYY\nNPERRCSVFYGAPSKSRLLATLCSAEVCQCAEGKCPRQRRALERGLQDEDGYRMKFACYY\nPRVEYGFQVKVLREDSRAAFRLFETKITQVLHFTKDVKAAANQMRNFLVRASCRLRLEPG\nKEYLIMGLDGATYDLEGHPQYLLDSNSWIEEMPSERLCRSTRQRAACAQLNDFLQEYGTQ\nGCQV'], 'gene-sequence': ['>lcl|BSEQ0013260|Complement C4-A (C4A)\nATGAGGCTGCTCTGGGGGCTGATCTGGGCATCCAGCTTCTTCACCTTATCTCTGCAGAAG\nCCCAGGTTGCTCTTGTTCTCTCCTTCTGTGGTTCATCTGGGGGTCCCCCTATCGGTGGGG\nGTGCAGCTCCAGGATGTGCCCCGAGGACAGGTAGTGAAAGGATCAGTGTTCCTGAGAAAC\nCCATCTCGTAATAATGTCCCCTGCTCCCCAAAGGTGGACTTCACCCTTAGCTCAGAAAGA\nGACTTCGCACTCCTCAGTCTCCAGGTGCCCTTGAAAGATGCGAAGAGCTGTGGCCTCCAT\nCAACTCCTCAGAGGCCCTGAGGTCCAGCTGGTGGCCCATTCGCCATGGCTAAAGGACTCT\nCTGTCCAGAACGACAAACATCCAGGGTATCAACCTGCTCTTCTCCTCTCGCCGGGGGCAC\nCTCTTTTTGCAGACGGACCAGCCCATTTACAACCCTGGCCAGCGGGTTCGGTACCGGGTC\nTTTGCTCTGGATCAGAAGATGCGCCCGAGCACTGACACCATCACAGTCATGGTGGAGAAC\nTCTCACGGCCTCCGCGTGCGGAAGAAGGAGGTGTACATGCCCTCGTCCATCTTCCAGGAT\nGACTTTGTGATCCCAGACATCTCAGAGCCAGGGACCTGGAAGATCTCAGCCCGATTCTCA\nGATGGCCTGGAATCCAACAGCAGCACCCAGTTTGAGGTGAAGAAATATGTCCTTCCCAAC\nTTTGAGGTGAAGATCACCCCTGGAAAGCCCTACATCCTGACGGTGCCAGGCCATCTTGAT\nGAAATGCAGTTAGACATCCAGGCCAGGTACATCTATGGGAAGCCAGTGCAGGGGGTGGCA\nTATGTGCGCTTTGGGCTCCTAGATGAGGATGGTAAGAAGACTTTCTTTCGGGGGCTGGAG\nAGTCAGACCAAGCTGGTGAATGGACAGAGCCACATTTCCCTCTCAAAGGCAGAGTTCCAG\nGACGCCCTGGAGAAGCTGAATATGGGCATTACTGACCTCCAGGGGCTGCGCCTCTACGTT\nGCTGCAGCCATCATTGAGTCTCCAGGTGGGGAGATGGAGGAGGCAGAGCTCACATCCTGG\nTATTTTGTGTCATCTCCCTTCTCCTTGGATCTTAGCAAGACCAAGCGACACCTTGTGCCT\nGGGGCCCCCTTCCTGCTGCAGGCCTTGGTCCGTGAGATGTCAGGCTCCCCAGCTTCTGGC\nATTCCTGTCAAAGTTTCTGCCACGGTGTCTTCTCCTGGGTCTGTTCCTGAAGTCCAGGAC\nATTCAGCAAAACACAGACGGGAGCGGCCAAGTCAGCATTCCAATAATTATCCCTCAGACC\nATCTCAGAGCTGCAGCTCTCAGTATCTGCAGGCTCCCCACATCCAGCGATAGCCAGGCTC\nACTGTGGCAGCCCCACCTTCAGGAGGCCCCGGGTTTCTGTCTATTGAGCGGCCGGATTCT\nCGACCTCCTCGTGTTGGGGACACTCTGAACCTGAACTTGCGAGCCGTGGGCAGTGGGGCC\nACCTTTTCTCATTACTACTACATGATCCTATCCCGAGGGCAGATCGTGTTCATGAATCGA\nGAGCCCAAGAGGACCCTGACCTCGGTCTCGGTGTTTGTGGACCATCACCTGGCACCCTCC\nTTCTACTTTGTGGCCTTCTACTACCATGGAGACCACCCAGTGGCCAACTCCCTGCGAGTG\nGATGTCCAGGCTGGGGCCTGCGAGGGCAAGCTGGAGCTCAGCGTGGACGGTGCCAAGCAG\nTACCGGAACGGGGAGTCCGTGAAGCTCCACTTAGAAACCGACTCCCTAGCCCTGGTGGCG\nCTGGGAGCCTTGGACACAGCTCTGTATGCTGCAGGCAGCAAGTCCCACAAGCCCCTCAAC\nATGGGCAAGGTCTTTGAAGCTATGAACAGCTATGACCTCGGCTGTGGTCCTGGGGGTGGG\nGACAGTGCCCTTCAGGTGTTCCAGGCAGCGGGCCTGGCCTTTTCTGATGGAGACCAGTGG\nACCTTATCCAGAAAGAGACTAAGCTGTCCCAAGGAGAAGACAACCCGGAAAAAGAGAAAC\nGTGAACTTCCAAAAGGCGATTAATGAGAAATTGGGTCAGTATGCTTCCCCGACAGCCAAG\nCGCTGCTGCCAGGATGGGGTGACACGTCTGCCCATGATGCGTTCCTGCGAGCAGCGGGCA\nGCCCGCGTGCAGCAGCCGGACTGCCGGGAGCCCTTCCTGTCCTGCTGCCAATTTGCTGAG\nAGTCTGCGCAAGAAGAGCAGGGACAAGGGCCAGGCGGGCCTCCAACGAGCCCTGGAGATC\nCTGCAGGAGGAGGACCTGATTGATGAGGATGACATTCCCGTGCGCAGCTTCTTCCCAGAG\nAACTGGCTCTGGAGAGTGGAAACAGTGGACCGCTTTCAAATATTGACACTGTGGCTCCCC\nGACTCTCTGACCACGTGGGAGATCCATGGCCTGAGCCTGTCCAAAACCAAAGGCCTATGT\nGTGGCCACCCCAGTCCAGCTCCGGGTGTTCCGCGAGTTCCACCTGCACCTCCGCCTGCCC\nATGTCTGTCCGCCGCTTTGAGCAGCTGGAGCTGCGGCCTGTCCTCTATAACTACCTGGAT\nAAAAACCTGACTGTGAGCGTCCACGTGTCCCCAGTGGAGGGGCTGTGCCTGGCTGGGGGC\nGGAGGGCTGGCCCAGCAGGTGCTGGTGCCTGCGGGCTCTGCCCGGCCTGTTGCCTTCTCT\nGTGGTGCCCACGGCAGCCGCCGCTGTGTCTCTGAAGGTGGTGGCTCGAGGGTCCTTCGAA\nTTCCCTGTGGGAGATGCGGTGTCCAAGGTTCTGCAGATTGAGAAGGAAGGGGCCATCCAT\nAGAGAGGAGCTGGTCTATGAACTCAACCCCTTGGACCACCGAGGCCGGACCTTGGAAATA\nCCTGGCAACTCTGATCCCAATATGATCCCTGATGGGGACTTTAACAGCTACGTCAGGGTT\nACAGCCTCAGATCCATTGGACACTTTAGGCTCTGAGGGGGCCTTGTCACCAGGAGGCGTG\nGCCTCCCTCTTGAGGCTTCCTCGAGGCTGTGGGGAGCAAACCATGATCTACTTGGCTCCG\nACACTGGCTGCTTCCCGCTACCTGGACAAGACAGAGCAGTGGAGCACACTGCCTCCCGAG\nACCAAGGACCACGCCGTGGATCTGATCCAGAAAGGCTACATGCGGATCCAGCAGTTTCGG\nAAGGCGGATGGTTCCTATGCGGCTTGGTTGTCACGGGACAGCAGCACCTGGCTCACAGCC\nTTTGTGTTGAAGGTCCTGAGTTTGGCCCAGGAGCAGGTAGGAGGCTCGCCTGAGAAACTG\nCAGGAGACATCTAACTGGCTTCTGTCCCAGCAGCAGGCTGACGGCTCGTTCCAGGACCCC\nTGTCCAGTGTTAGACAGGAGCATGCAGGGGGGTTTGGTGGGCAATGATGAGACTGTGGCA\nCTCACAGCCTTTGTGACCATCGCCCTTCATCATGGGCTGGCCGTCTTCCAGGATGAGGGT\nGCAGAGCCATTGAAGCAGAGAGTGGAAGCCTCCATCTCAAAGGCAAACTCATTTTTGGGG\nGAGAAAGCAAGTGCTGGGCTCCTGGGTGCCCACGCAGCTGCCATCACGGCCTATGCCCTG\nACACTGACCAAGGCGCCTGTGGACCTGCTCGGTGTTGCCCACAACAACCTCATGGCAATG\nGCCCAGGAGACTGGAGATAACCTGTACTGGGGCTCAGTCACTGGTTCTCAGAGCAATGCC\nGTGTCGCCCACCCCGGCTCCTCGCAACCCATCCGACCCCATGCCCCAGGCCCCAGCCCTG\nTGGATTGAAACCACAGCCTACGCCCTGCTGCACCTCCTGCTTCACGAGGGCAAAGCAGAG\nATGGCAGACCAGGCTTCGGCCTGGCTCACCCGTCAGGGCAGCTTCCAAGGGGGATTCCGC\nAGTACCCAAGACACGGTGATTGCCCTGGATGCCCTGTCTGCCTACTGGATTGCCTCCCAC\nACCACTGAGGAGAGGGGTCTCAATGTGACTCTCAGCTCCACAGGCCGGAATGGGTTCAAG\nTCCCACGCGCTGCAGCTGAACAACCGCCAGATTCGCGGCCTGGAGGAGGAGCTGCAGTTT\nTCCTTGGGCAGCAAGATCAATGTGAAGGTGGGAGGAAACAGCAAAGGAACCCTGAAGGTC\nCTTCGTACCTACAATGTCCTGGACATGAAGAACACGACCTGCCAGGACCTACAGATAGAA\nGTGACAGTCAAAGGCCACGTCGAGTACACGATGGAAGCAAACGAGGACTATGAGGACTAT\nGAGTACGATGAGCTTCCAGCCAAGGATGACCCAGATGCCCCTCTGCAGCCCGTGACACCC\nCTGCAGCTGTTTGAGGGTCGGAGGAACCGCCGCAGGAGGGAGGCGCCCAAGCTGACCTCC\nCTCTCTGACCGTTACGTGAGTCACTTTGAGACCGAGGGGCCCCACGTCCTGCTGTATTTT\nGACTCGGTCCCCACCTCCCGGGAGTGCGTGGGCTTTGAGGCTGTGCAGGAAGTGCCGGTG\nGGGCTGGTGCAGCCGGCCAGCGCAACCCTGTACGACTACTACAACCCCGAGCGCAGATGT\nTCTGTGTTTTACGGGGCACCAAGTAAGAGCAGACTCTTGGCCACCTTGTGTTCTGCTGAA\nGTCTGCCAGTGTGCTGAGGGGAAGTGCCCTCGCCAGCGTCGCGCCCTGGAGCGGGGTCTG\nCAGGACGAGGATGGCTACAGGATGAAGTTTGCCTGCTACTACCCCCGTGTGGAGTACGGC\nTTCCAGGTTAAGGTTCTCCGAGAAGACAGCAGAGCTGCTTTCCGCCTCTTTGAGACCAAG\nATCACCCAAGTCCTGCACTTCACCAAGGATGTCAAGGCCGCTGCTAATCAGATGCGCAAC\nTTCCTGGTTCGAGCCTCCTGCCGCCTTCGCTTGGAACCTGGGAAAGAATATTTGATCATG\nGGTCTGGATGGGGCCACCTATGACCTCGAGGGACACCCCCAGTACCTGCTGGACTCGAAT\nAGCTGGATCGAGGAGATGCCCTCTGAACGCCTGTGCCGGAGCACCCGCCAGCGGGCAGCC\nTGTGCCCAGCTCAACGACTTCCTCCAGGAGTATGGCACTCAGGGGTGCCAGGTGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00207'], 'name': ['A2M']}, {'identifier': ['PF07678'], 'name': ['A2M_comp']}, {'identifier': ['PF01835'], 'name': ['A2M_N']}, {'identifier': ['PF07703'], 'name': ['A2M_N_2']}, {'identifier': ['PF07677'], 'name': ['A2M_recep']}, {'identifier': ['PF01821'], 'name': ['ANATO']}, {'identifier': ['PF01759'], 'name': ['NTR']}, {'identifier': ['PF10569'], 'name': ['Thiol-ester_cl']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['complement component C1q binding']}, {'category': ['function'], 'description': ['endopeptidase inhibitor activity']}, {'category': ['process'], 'description': ['complement activation']}, {'category': ['process'], 'description': ['complement activation, classical pathway']}, {'category': ['process'], 'description': ['inflammatory response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['positive regulation of apoptotic cell clearance']}, {'category': ['process'], 'description': ['regulation of complement activation']}]}]}]}, {'id': ['BE0004686'], 'name': ['Complement C4-B'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13124'], 'pubmed-id': ['20441428'], 'citation': ['Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.']}, {'ref-id': ['A13125'], 'pubmed-id': ['17351760'], 'citation': ['Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.']}, {'ref-id': ['A37'], 'pubmed-id': ['17911465'], 'citation': ['Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Complement C4-B'], 'general-function': ['Non-enzymatic component of the C3 and C5 convertases and thus essential for the propagation of the classical complement pathway. Covalently binds to immunoglobulins and immune complexes and enhances the solubilization of immune aggregates and the clearance of IC through CR1 on erythrocytes. C4A isotype is responsible for effective binding to form amide bonds with immune aggregates or protein antigens, while C4B isotype catalyzes the transacylation of the thioester carbonyl group to form ester bonds with carbohydrate antigens.'], 'specific-function': ['Carbohydrate binding'], 'gene-name': ['C4B'], 'locus': [None], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-19'], 'theoretical-pi': [None], 'molecular-weight': ['192749.785'], 'chromosome-location': [None], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1324']}, {'resource': ['UniProtKB'], 'identifier': ['P0C0L5']}, {'resource': ['UniProt Accession'], 'identifier': ['CO4B_HUMAN']}]}], 'synonyms': [{'synonym': ['Basic complement C4', 'C3 and PZP-like alpha-2-macroglobulin domain-containing protein 3', 'CO4', 'CPAMD3']}], 'amino-acid-sequence': ['>lcl|BSEQ0009603|Complement C4-B\nMRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLRN\nPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLKDS\nLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMVEN\nSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPN\nFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE\nSQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAELTSW\nYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVPEVQD\nIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPDS\nRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPS\nFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA\nLGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAGLAFSDGDQW\nTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTRLPMMRSCEQRA\nARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLIDEDDIPVRSFFPE\nNWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLP\nMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS\nVVPTAATAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNPLDHRGRTLEI\nPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASLLRLPRGCGEQTMIYLAP\nTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRKADGSYAAWLSRGSSTWLTA\nFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQDLSPVIHRSMQGGLVGNDETVA\nLTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL\nTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNPSDPMPQAPAL\nWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFRSTQDTVIALDALSAYWIASH\nTTEERGLNVTLSSTGRNGFKSHALQLNNRQIRGLEEELQFSLGSKINVKVGGNSKGTLKV\nLRTYNVLDMKNTTCQDLQIEVTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTP\nLQLFEGRRNRRRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD\nLEKLTSLSDRYVSHFETEGPHVLLYFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYY\nNPERRCSVFYGAPSKSRLLATLCSAEVCQCAEGKCPRQRRALERGLQDEDGYRMKFACYY\nPRVEYGFQVKVLREDSRAAFRLFETKITQVLHFTKDVKAAANQMRNFLVRASCRLRLEPG\nKEYLIMGLDGATYDLEGHPQYLLDSNSWIEEMPSERLCRSTRQRAACAQLNDFLQEYGTQ\nGCQV'], 'gene-sequence': ['>lcl|BSEQ0017510|Complement C4-B (C4B)\nATGAGGCTGCTCTGGGGGCTGATCTGGGCATCCAGCTTCTTCACCTTATCTCTGCAGAAG\nCCCAGGTTGCTCTTGTTCTCTCCTTCTGTGGTTCATCTGGGGGTCCCCCTATCGGTGGGG\nGTGCAGCTCCAGGATGTGCCCCGAGGACAGGTAGTGAAAGGATCAGTGTTCCTGAGAAAC\nCCATCTCGTAATAATGTCCCCTGCTCCCCAAAGGTGGACTTCACCCTTAGCTCAGAAAGA\nGACTTCGCACTCCTCAGTCTCCAGGTGCCCTTGAAAGATGCGAAGAGCTGTGGCCTCCAT\nCAACTCCTCAGAGGCCCTGAGGTCCAGCTGGTGGCCCATTCGCCATGGCTAAAGGACTCT\nCTGTCCAGAACGACAAACATCCAGGGTATCAACCTGCTCTTCTCCTCTCGCCGGGGGCAC\nCTCTTTTTGCAGACGGACCAGCCCATTTACAACCCTGGCCAGCGGGTTCGGTACCGGGTC\nTTTGCTCTGGATCAGAAGATGCGCCCGAGCACTGACACCATCACAGTCATGGTGGAGAAC\nTCTCACGGCCTCCGCGTGCGGAAGAAGGAGGTGTACATGCCCTCGTCCATCTTCCAGGAT\nGACTTTGTGATCCCAGACATCTCAGAGCCAGGGACCTGGAAGATCTCAGCCCGATTCTCA\nGATGGCCTGGAATCCAACAGCAGCACCCAGTTTGAGGTGAAGAAATATGTCCTTCCCAAC\nTTTGAGGTGAAGATCACCCCTGGAAAGCCCTACATCCTGACGGTGCCAGGCCATCTTGAT\nGAAATGCAGTTAGACATCCAGGCCAGGTACATCTATGGGAAGCCAGTGCAGGGGGTGGCA\nTATGTGCGCTTTGGGCTCCTAGATGAGGATGGTAAGAAGACTTTCTTTCGGGGGCTGGAG\nAGTCAGACCAAGCTGGTGAATGGACAGAGCCACATTTCCCTCTCAAAGGCAGAGTTCCAG\nGACGCCCTGGAGAAGCTGAATATGGGCATTACTGACCTCCAGGGGCTGCGCCTCTACGTT\nGCTGCAGCCATCATTGAGTATCCAGGTGGGGAGATGGAGGAGGCAGAGCTCACATCCTGG\nTATTTTGTGTCATCTCCCTTCTCCTTGGATCTTAGCAAGACCAAGCGACACCTTGTGCCT\nGGGGCCCCCTTCCTGCTGCAGGCCTTGGTCCGTGAGATGTCAGGCTCCCCAGCTTCTGGC\nATTCCTGTCAAAGTTTCTGCCACGGTGTCTTCTCCTGGGTCTGTTCCTGAAGTCCAGGAC\nATTCAGCAAAACACAGACGGGAGCGGCCAAGTCAGCATTCCAATAATTATCCCTCAGACC\nATCTCAGAGCTGCAGCTCTCAGTATCTGCAGGCTCCCCACATCCAGCGATAGCCAGGCTC\nACTGTGGCAGCCCCACCTTCAGGAGGCCCCGGGTTTCTGTCTATTGAGCGGCCGGATTCT\nCGACCTCCTCGTGTTGGGGACACTCTGAACCTGAACTTGCGAGCCGTGGGCAGTGGGGCC\nACCTTTTCTCATTACTACTACATGATCCTATCCCGAGGGCAGATCGTGTTCATGAATCGA\nGAGCCCAAGAGGACCCTGACCTCGGTCTCGGTGTTTGTGGACCATCACCTGGCACCCTCC\nTTCTACTTTGTGGCCTTCTACTACCATGGAGACCACCCAGTGGCCAACTCCCTGCGAGTG\nGATGTCCAGGCTGGGGCCTGCGAGGGCAAGCTGGAGCTCAGCGTGGACGGTGCCAAGCAG\nTACCGGAACGGGGAGTCCGTGAAGCTCCACTTAGAAACCGACTCCCTAGCCCTGGTGGCG\nCTGGGAGCCTTGGACACAGCTCTGTATGCTGCAGGCAGCAAGTCCCACAAGCCCCTCAAC\nATGGGCAAGGTCTTTGAAGCTATGAACAGCTATGACCTCGGCTGTGGTCCTGGGGGTGGG\nGACAGTGCCCTTCAGGTGTTCCAGGCAGCGGGCCTGGCCTTTTCTGATGGAGACCAGTGG\nACCTTATCCAGAAAGAGACTAAGCTGTCCCAAGGAGAAGACAACCCGGAAAAAGAGAAAC\nGTGAACTTCCAAAAGGCGATTAATGAGAAATTGGGTCAGTATGCTTCCCCGACAGCCAAG\nCGCTGCTGCCAGGATGGGGTGACACGTCTGCCCATGATGCGTTCCTGCGAGCAGCGGGCA\nGCCCGCGTGCAGCAGCCGGACTGCCGGGAGCCCTTCCTGTCCTGCTGCCAATTTGCTGAG\nAGTCTGCGCAAGAAGAGCAGGGACAAGGGCCAGGCGGGCCTCCAACGAGCCCTGGAGATC\nCTGCAGGAGGAGGACCTGATTGATGAGGATGACATTCCCGTGCGCAGCTTCTTCCCAGAG\nAACTGGCTCTGGAGAGTGGAAACAGTGGACCGCTTTCAAATATTGACACTGTGGCTCCCC\nGACTCTCTGACCACGTGGGAGATCCATGGCCTGAGCCTGTCCAAAACCAAAGGCCTATGT\nGTGGCCACCCCAGTCCAGCTCCGGGTGTTCCGCGAGTTCCACCTGCACCTCCGCCTGCCC\nATGTCTGTCCGCCGCTTTGAGCAGCTGGAGCTGCGGCCTGTCCTCTATAACTACCTGGAT\nAAAAACCTGACTGTGAGCGTCCACGTGTCCCCAGTGGAGGGGCTGTGCCTGGCTGGGGGC\nGGAGGGCTGGCCCAGCAGGTGCTGGTGCCTGCGGGCTCTGCCCGGCCTGTTGCCTTCTCT\nGTGGTGCCCACGGCAGCCGCCGCTGTGTCTCTGAAGGTGGTGGCTCGAGGGTCCTTCGAA\nTTCCCTGTGGGAGATGCGGTGTCCAAGGTTCTGCAGATTGAGAAGGAAGGGGCCATCCAT\nAGAGAGGAGCTGGTCTATGAACTCAACCCCTTGGACCACCGAGGCCGGACCTTGGAAATA\nCCTGGCAACTCTGATCCCAATATGATCCCTGATGGGGACTTTAACAGCTACGTCAGGGTT\nACAGCCTCAGATCCATTGGACACTTTAGGCTCTGAGGGGGCCTTGTCACCAGGAGGCGTG\nGCCTCCCTCTTGAGGCTTCCTCGAGGCTGTGGGGAGCAAACCATGATCTACTTGGCTCCG\nACACTGGCTGCTTCCCGCTACCTGGACAAGACAGAGCAGTGGAGCACACTGCCTCCCGAG\nACCAAGGACCACGCCGTGGATCTGATCCAGAAAGGCTACATGCGGATCCAGCAGTTTCGG\nAAGGCGGATGGTTCCTATGCGGCTTGGTTGTCACGGGGCAGCAGCACCTGGCTCACAGCC\nTTTGTGTTGAAGGTCCTGAGTTTGGCCCAGGAGCAGGTAGGAGGCTCGCCTGAGAAACTG\nCAGGAGACATCTAACTGGCTTCTGTCCCAGCAGCAGGCTGACGGCTCGTTCCAGGACCTC\nTCTCCAGTGATACATAGGAGCATGCAGGGGGGTTTGGTGGGCAATGATGAGACTGTGGCA\nCTCACAGCCTTTGTGACCATCGCCCTTCATCATGGGCTGGCCGTCTTCCAGGATGAGGGT\nGCAGAGCCATTGAAGCAGAGAGTGGAAGCCTCCATCTCAAAGGCAAGCTCATTTTTGGGG\nGAGAAAGCAAGTGCTGGGCTCCTGGGTGCCCACGCAGCTGCCATCACGGCCTATGCCCTG\nACACTGACCAAGGCCCCTGCGGACCTGCGGGGTGTTGCCCACAACAACCTCATGGCAATG\nGCCCAGGAGACTGGAGATAACCTGTACTGGGGCTCAGTCACTGGTTCTCAGAGCAATGCC\nGTGTCGCCCACCCCAGCTCCTCGCAACCCATCCGACCCCATGCCCCAGGCCCCAGCCCTG\nTGGATTGAAACCACAGCCTACGCCCTGCTGCACCTCCTGCTTCACGAGGGCAAAGCAGAG\nATGGCAGACCAGGCTGCGGCCTGGCTCACCCGTCAGGGCAGCTTCCAAGGGGGATTCCGC\nAGTACCCAAGACACGGTGATTGCCCTGGATGCCCTGTCTGCCTACTGGATTGCCTCCCAC\nACCACTGAGGAGAGGGGTCTCAATGTGACTCTCAGCTCCACAGGCCGGAATGGGTTCAAG\nTCCCACGCGCTGCAGCTGAACAACCGCCAGATTCGCGGCCTGGAGGAGGAGCTGCAGTTT\nTCCTTGGGCAGCAAGATCAATGTGAAGGTGGGAGGAAACAGCAAAGGAACCCTGAAGGTC\nCTTCGTACCTACAATGTCCTGGACATGAAGAACACGACCTGCCAGGACCTACAGATAGAA\nGTGACAGTCAAAGGCCACGTCGAGTACACGATGGAAGCAAACGAGGACTATGAGGACTAT\nGAGTACGATGAGCTTCCAGCCAAGGATGACCCAGATGCCCCTCTGCAGCCCGTGACACCC\nCTGCAGCTGTTTGAGGGTCGGAGGAACCGCCGCAGGAGGGAGGCGCCCAAGGTGGTGGAG\nGAGCAGGAGTCCAGGGTGCACTACACCGTGTGCATCTGGCGGAACGGCAAGGTGGGGCTG\nTCTGGCATGGCCATCGCGGACGTCACCCTCCTGAGTGGATTCCACGCCCTGCGTGCTGAC\nCTGGAGAAGCTGACCTCCCTCTCTGACCGTTACGTGAGTCACTTTGAGACCGAGGGGCCC\nCACGTCCTGCTGTATTTTGACTCGGTCCCCACCTCCCGGGAGTGCGTGGGCTTTGAGGCT\nGTGCAGGAAGTGCCGGTGGGGCTGGTGCAGCCGGCCAGCGCAACCCTGTACGACTACTAC\nAACCCCGAGCGCAGATGTTCTGTGTTTTACGGGGCACCAAGTAAGAGCAGACTCTTGGCC\nACCTTGTGTTCTGCTGAAGTCTGCCAGTGTGCTGAGGGGAAGTGCCCTCGCCAGCGTCGC\nGCCCTGGAGCGGGGTCTGCAGGACGAGGATGGCTACAGGATGAAGTTTGCCTGCTACTAC\nCCCCGTGTGGAGTACGGCTTCCAGGTTAAGGTTCTCCGAGAAGACAGCAGAGCTGCTTTC\nCGCCTCTTTGAGACCAAGATCACCCAAGTCCTGCACTTCACCAAGGATGTCAAGGCCGCT\nGCTAATCAGATGCGCAACTTCCTGGTTCGAGCCTCCTGCCGCCTTCGCTTGGAACCTGGG\nAAAGAATATTTGATCATGGGTCTAGATGGGGCCACCTATGACCTCGAGGGACACCCCCAG\nTACCTGCTGGACTCGAATAGCTGGATCGAGGAGATGCCCTCTGAACGCCTGTGCCGGAGC\nACCCGCCAGCGGGCAGCCTGTGCCCAGCTCAACGACTTCCTCCAGGAGTATGGCACTCAG\nGGGTGCCAGGTGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00207'], 'name': ['A2M']}, {'identifier': ['PF07678'], 'name': ['A2M_comp']}, {'identifier': ['PF01835'], 'name': ['A2M_N']}, {'identifier': ['PF07703'], 'name': ['A2M_N_2']}, {'identifier': ['PF07677'], 'name': ['A2M_recep']}, {'identifier': ['PF01821'], 'name': ['ANATO']}, {'identifier': ['PF01759'], 'name': ['NTR']}, {'identifier': ['PF10569'], 'name': ['Thiol-ester_cl']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['axon']}, {'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['cell junction']}, {'category': ['component'], 'description': ['dendrite']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['other organism cell']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['synapse']}, {'category': ['function'], 'description': ['carbohydrate binding']}, {'category': ['function'], 'description': ['complement binding']}, {'category': ['function'], 'description': ['endopeptidase inhibitor activity']}, {'category': ['function'], 'description': ['serine-type endopeptidase activity']}, {'category': ['process'], 'description': ['complement activation']}, {'category': ['process'], 'description': ['complement activation, classical pathway']}, {'category': ['process'], 'description': ['detection of molecule of bacterial origin']}, {'category': ['process'], 'description': ['inflammatory response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['opsonization']}, {'category': ['process'], 'description': ['positive regulation of apoptotic cell clearance']}, {'category': ['process'], 'description': ['regulation of complement activation']}]}]}]}, {'id': ['BE0000855'], 'name': ['Complement C5'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13124'], 'pubmed-id': ['20441428'], 'citation': ['Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.']}, {'ref-id': ['A13125'], 'pubmed-id': ['17351760'], 'citation': ['Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.']}, {'ref-id': ['A37'], 'pubmed-id': ['17911465'], 'citation': ['Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Complement C5'], 'general-function': ['Receptor binding'], 'specific-function': ['Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes (PubMed:8182049). C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.'], 'gene-name': ['C5'], 'locus': ['9q33-q34'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-18'], 'theoretical-pi': ['6.49'], 'molecular-weight': ['188303.705'], 'chromosome-location': ['9'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1331']}, {'resource': ['GenAtlas'], 'identifier': ['C5']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M57729']}, {'resource': ['GenBank Protein Database'], 'identifier': ['179983']}, {'resource': ['UniProtKB'], 'identifier': ['P01031']}, {'resource': ['UniProt Accession'], 'identifier': ['CO5_HUMAN']}]}], 'synonyms': [{'synonym': ['C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4', 'CPAMD4']}], 'amino-acid-sequence': ['>lcl|BSEQ0019020|Complement C5\nMGLLGILCFLIFLGKTWGQEQTYVISAPKIFRVGASENIVIQVYGYTEAFDATISIKSYP\nDKKFSYSSGHVHLSSENKFQNSAILTIQPKQLPGGQNPVSYVYLEVVSKHFSKSKRMPIT\nYDNGFLFIHTDKPVYTPDQSVKVRVYSLNDDLKPAKRETVLTFIDPEGSEVDMVEEIDHI\nGIISFPDFKIPSNPRYGMWTIKAKYKEDFSTTGTAYFEVKEYVLPHFSVSIEPEYNFIGY\nKNFKNFEITIKARYFYNKVVTEADVYITFGIREDLKDDQKEMMQTAMQNTMLINGIAQVT\nFDSETAVKELSYYSLEDLNNKYLYIAVTVIESTGGFSEEAEIPGIKYVLSPYKLNLVATP\nLFLKPGIPYPIKVQVKDSLDQLVGGVPVTLNAQTIDVNQETSDLDPSKSVTRVDDGVASF\nVLNLPSGVTVLEFNVKTDAPDLPEENQAREGYRAIAYSSLSQSYLYIDWTDNHKALLVGE\nHLNIIVTPKSPYIDKITHYNYLILSKGKIIHFGTREKFSDASYQSINIPVTQNMVPSSRL\nLVYYIVTGEQTAELVSDSVWLNIEEKCGNQLQVHLSPDADAYSPGQTVSLNMATGMDSWV\nALAAVDSAVYGVQRGAKKPLERVFQFLEKSDLGCGAGGGLNNANVFHLAGLTFLTNANAD\nDSQENDEPCKEILRPRRTLQKKIEEIAAKYKHSVVKKCCYDGACVNNDETCEQRAARISL\nGPRCIKAFTECCVVASQLRANISHKDMQLGRLHMKTLLPVSKPEIRSYFPESWLWEVHLV\nPRRKQLQFALPDSLTTWEIQGVGISNTGICVADTVKAKVFKDVFLEMNIPYSVVRGEQIQ\nLKGTVYNYRTSGMQFCVKMSAVEGICTSESPVIDHQGTKSSKCVRQKVEGSSSHLVTFTV\nLPLEIGLHNINFSLETWFGKEILVKTLRVVPEGVKRESYSGVTLDPRGIYGTISRRKEFP\nYRIPLDLVPKTEIKRILSVKGLLVGEILSAVLSQEGINILTHLPKGSAEAELMSVVPVFY\nVFHYLETGNHWNIFHSDPLIEKQKLKKKLKEGMLSIMSYRNADYSYSVWKGGSASTWLTA\nFALRVLGQVNKYVEQNQNSICNSLLWLVENYQLDNGSFKENSQYQPIKLQGTLPVEAREN\nSLYLTAFTVIGIRKAFDICPLVKIDTALIKADNFLLENTLPAQSTFTLAISAYALSLGDK\nTHPQFRSIVSALKREALVKGNPPIYRFWKDNLQHKDSSVPNTGTARMVETTAYALLTSLN\nLKDINYVNPVIKWLSEEQRYGGGFYSTQDTINAIEGLTEYSLLVKQLRLSMDIDVSYKHK\nGALHNYKMTDKNFLGRPVEVLLNDDLIVSTGFGSGLATVHVTTVVHKTSTSEEVCSFYLK\nIDTQDIEASHYRGYGNSDYKRIVACASYKPSREESSSGSSHAVMDISLPTGISANEEDLK\nALVEGVDQLFTDYQIKDGHVILQLNSIPSSDFLCVRFRIFELFEVGFLSPATFTVYEYHR\nPDKQCTMFYSTSNIKIQKVCEGAACKCVEADCGQMQEELDLTISAETRKQTACKPEIAYA\nYKVSITSITVENVFVKYKATLLDIYKTGEAVAEKDSEITFIKKVTCTNAELVKGRQYLIM\nGKEALQIKYNFSFRYIYPLDSLTWIEYWPRDTTCSSCQAFLANLDEFAEDIFLNGC'], 'gene-sequence': ['>lcl|BSEQ0019021|Complement C5 (C5)\nATGGGCCTTTTGGGAATACTTTGTTTTTTAATCTTCCTGGGGAAAACCTGGGGACAGGAG\nCAAACATATGTCATTTCAGCACCAAAAATATTCCGTGTTGGAGCATCTGAAAATATTGTG\nATTCAAGTTTATGGATACACTGAAGCATTTGATGCAACAATCTCTATTAAAAGTTATCCT\nGATAAAAAATTTAGTTACTCCTCAGGCCATGTTCATTTATCCTCAGAGAATAAATTCCAA\nAACTCTGCAATCTTAACAATACAACCAAAACAATTGCCTGGAGGACAAAACCCAGTTTCT\nTATGTGTATTTGGAAGTTGTATCAAAGCATTTTTCAAAATCAAAAAGAATGCCAATAACC\nTATGACAATGGATTTCTCTTCATTCATACAGACAAACCTGTTTATACTCCAGACCAGTCA\nGTAAAAGTTAGAGTTTATTCGTTGAATGACGACTTGAAGCCAGCCAAAAGAGAAACTGTC\nTTAACTTTCATAGATCCTGAAGGATCAGAAGTTGACATGGTAGAAGAAATTGATCATATT\nGGAATTATCTCTTTTCCTGACTTCAAGATTCCGTCTAATCCTAGATATGGTATGTGGACG\nATCAAGGCTAAATATAAAGAGGACTTTTCAACAACTGGAACCGCATATTTTGAAGTTAAA\nGAATATGTCTTGCCACATTTTTCTGTCTCAATCGAGCCAGAATATAATTTCATTGGTTAC\nAAGAACTTTAAGAATTTTGAAATTACTATAAAAGCAAGATATTTTTATAATAAAGTAGTC\nACTGAGGCTGACGTTTATATCACATTTGGAATAAGAGAAGACTTAAAAGATGATCAAAAA\nGAAATGATGCAAACAGCAATGCAAAACACAATGTTGATAAATGGAATTGCTCAAGTCACA\nTTTGATTCTGAAACAGCAGTCAAAGAACTGTCATACTACAGTTTAGAAGATTTAAACAAC\nAAGTACCTTTATATTGCTGTAACAGTCATAGAGTCTACAGGTGGATTTTCTGAAGAGGCA\nGAAATACCTGGCATCAAATATGTCCTCTCTCCCTACAAACTGAATTTGGTTGCTACTCCT\nCTTTTCCTGAAGCCTGGGATTCCATATCCCATCAAGGTGCAGGTTAAAGATTCGCTTGAC\nCAGTTGGTAGGAGGAGTCCCAGTAACACTGAATGCACAAACAATTGATGTAAACCAAGAG\nACATCTGACTTGGATCCAAGCAAAAGTGTAACACGTGTTGATGATGGAGTAGCTTCCTTT\nGTGCTTAATCTCCCATCTGGAGTGACGGTGCTGGAGTTTAATGTCAAAACTGATGCTCCA\nGATCTTCCAGAAGAAAATCAGGCCAGGGAAGGTTACCGAGCAATAGCATACTCATCTCTC\nAGCCAAAGTTACCTTTATATTGATTGGACTGATAACCATAAGGCTTTGCTAGTGGGAGAA\nCATCTGAATATTATTGTTACCCCCAAAAGCCCATATATTGACAAAATAACTCACTATAAT\nTACTTGATTTTATCCAAGGGCAAAATTATCCACTTTGGCACGAGGGAGAAATTTTCAGAT\nGCATCTTATCAAAGTATAAACATTCCAGTAACACAGAACATGGTTCCTTCATCCCGACTT\nCTGGTCTATTACATCGTCACAGGAGAACAGACAGCAGAATTAGTGTCTGATTCAGTCTGG\nTTAAATATTGAAGAAAAATGTGGCAACCAGCTCCAGGTTCATCTGTCTCCTGATGCAGAT\nGCATATTCTCCAGGCCAAACTGTGTCTCTTAATATGGCAACTGGAATGGATTCCTGGGTG\nGCATTAGCAGCAGTGGACAGTGCTGTGTATGGAGTCCAAAGAGGAGCCAAAAAGCCCTTG\nGAAAGAGTATTTCAATTCTTAGAGAAGAGTGATCTGGGCTGTGGGGCAGGTGGTGGCCTC\nAACAATGCCAATGTGTTCCACCTAGCTGGACTTACCTTCCTCACTAATGCAAATGCAGAT\nGACTCCCAAGAAAATGATGAACCTTGTAAAGAAATTCTCAGGCCAAGAAGAACGCTGCAA\nAAGAAGATAGAAGAAATAGCTGCTAAATATAAACATTCAGTAGTGAAGAAATGTTGTTAC\nGATGGAGCCTGCGTTAATAATGATGAAACCTGTGAGCAGCGAGCTGCACGGATTAGTTTA\nGGGCCAAGATGCATCAAAGCTTTCACTGAATGTTGTGTCGTCGCAAGCCAGCTCCGTGCT\nAATATCTCTCATAAAGACATGCAATTGGGAAGGCTACACATGAAGACCCTGTTACCAGTA\nAGCAAGCCAGAAATTCGGAGTTATTTTCCAGAAAGCTGGTTGTGGGAAGTTCATCTTGTT\nCCCAGAAGAAAACAGTTGCAGTTTGCCCTACCTGATTCTCTAACCACCTGGGAAATTCAA\nGGCGTTGGCATTTCAAACACTGGTATATGTGTTGCTGATACTGTCAAGGCAAAGGTGTTC\nAAAGATGTCTTCCTGGAAATGAATATACCATATTCTGTTGTACGAGGAGAACAGATCCAA\nTTGAAAGGAACTGTTTACAACTATAGGACTTCTGGGATGCAGTTCTGTGTTAAAATGTCT\nGCTGTGGAGGGAATCTGCACTTCGGAAAGCCCAGTCATTGATCATCAGGGCACAAAGTCC\nTCCAAATGTGTGCGCCAGAAAGTAGAGGGCTCCTCCAGTCACTTGGTGACATTCACTGTG\nCTTCCTCTGGAAATTGGCCTTCACAACATCAATTTTTCACTGGAGACTTGGTTTGGAAAA\nGAAATCTTAGTAAAAACATTACGAGTGGTGCCAGAAGGTGTCAAAAGGGAAAGCTATTCT\nGGTGTTACTTTGGATCCTAGGGGTATTTATGGTACCATTAGCAGACGAAAGGAGTTCCCA\nTACAGGATACCCTTAGATTTGGTCCCCAAAACAGAAATCAAAAGGATTTTGAGTGTAAAA\nGGACTGCTTGTAGGTGAGATCTTGTCTGCAGTTCTAAGTCAGGAAGGCATCAATATCCTA\nACCCACCTCCCCAAAGGGAGTGCAGAGGCGGAGCTGATGAGCGTTGTCCCAGTATTCTAT\nGTTTTTCACTACCTGGAAACAGGAAATCATTGGAACATTTTTCATTCTGACCCATTAATT\nGAAAAGCAGAAACTGAAGAAAAAATTAAAAGAAGGGATGTTGAGCATTATGTCCTACAGA\nAATGCTGACTACTCTTACAGTGTGTGGAAGGGTGGAAGTGCTAGCACTTGGTTAACAGCT\nTTTGCTTTAAGAGTACTTGGACAAGTAAATAAATACGTAGAGCAGAACCAAAATTCAATT\nTGTAATTCTTTATTGTGGCTAGTTGAGAATTATCAATTAGATAATGGATCTTTCAAGGAA\nAATTCACAGTATCAACCAATAAAATTACAGGGTACCTTGCCTGTTGAAGCCCGAGAGAAC\nAGCTTATATCTTACAGCCTTTACTGTGATTGGAATTAGAAAGGCTTTCGATATATGCCCC\nCTGGTGAAAATCGACACAGCTCTAATTAAAGCTGACAACTTTCTGCTTGAAAATACACTG\nCCAGCCCAGAGCACCTTTACATTGGCCATTTCTGCGTATGCTCTTTCCCTGGGAGATAAA\nACTCACCCACAGTTTCGTTCAATTGTTTCAGCTTTGAAGAGAGAAGCTTTGGTTAAAGGT\nAATCCACCCATTTATCGTTTTTGGAAAGACAATCTTCAGCATAAAGACAGCTCTGTACCT\nAACACTGGTACGGCACGTATGGTAGAAACAACTGCCTATGCTTTACTCACCAGTCTGAAC\nTTGAAAGATATAAATTATGTTAACCCAGTCATCAAATGGCTATCAGAAGAGCAGAGGTAT\nGGAGGTGGCTTTTATTCAACCCAGGACACAATCAATGCCATTGAGGGCCTGACGGAATAT\nTCACTCCTGGTTAAACAACTCCGCTTGAGTATGGACATCGATGTTTCTTACAAGCATAAA\nGGTGCCTTACATAATTATAAAATGACAGACAAGAATTTCCTTGGGAGGCCAGTAGAGGTG\nCTTCTCAATGATGACCTCATTGTCAGTACAGGATTTGGCAGTGGCTTGGCTACAGTACAT\nGTAACAACTGTAGTTCACAAAACCAGTACCTCTGAGGAAGTTTGCAGCTTTTATTTGAAA\nATCGATACTCAGGATATTGAAGCATCCCACTACAGAGGCTACGGAAACTCTGATTACAAA\nCGCATAGTAGCATGTGCCAGCTACAAGCCCAGCAGGGAAGAATCATCATCTGGATCCTCT\nCATGCGGTGATGGACATCTCCTTGCCTACTGGAATCAGTGCAAATGAAGAAGACTTAAAA\nGCCCTTGTGGAAGGGGTGGATCAACTATTCACTGATTACCAAATCAAAGATGGACATGTT\nATTCTGCAACTGAATTCGATTCCCTCCAGTGATTTCCTTTGTGTACGATTCCGGATATTT\nGAACTCTTTGAAGTTGGGTTTCTCAGTCCTGCCACTTTCACAGTGTACGAATACCACAGA\nCCAGATAAACAGTGTACCATGTTTTATAGCACTTCCAATATCAAAATTCAGAAAGTCTGT\nGAAGGAGCCGCGTGCAAGTGTGTAGAAGCTGATTGTGGGCAAATGCAGGAAGAATTGGAT\nCTGACAATCTCTGCAGAGACAAGAAAACAAACAGCATGTAAACCAGAGATTGCATATGCT\nTATAAAGTTAGCATCACATCCATCACTGTAGAAAATGTTTTTGTCAAGTACAAGGCAACC\nCTTCTGGATATCTACAAAACTGGGGAAGCTGTTGCTGAGAAAGACTCTGAGATTACCTTC\nATTAAAAAGGTAACCTGTACTAACGCTGAGCTGGTAAAAGGAAGACAGTACTTAATTATG\nGGTAAAGAAGCCCTCCAGATAAAATACAATTTCAGTTTCAGGTACATCTACCCTTTAGAT\nTCCTTGACCTGGATTGAATACTGGCCTAGAGACACAACATGTTCATCGTGTCAAGCATTT\nTTAGCTAATTTAGATGAATTTGCCGAAGATATCTTTTTAAATGGATGCTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00207'], 'name': ['A2M']}, {'identifier': ['PF07678'], 'name': ['A2M_comp']}, {'identifier': ['PF01835'], 'name': ['A2M_N']}, {'identifier': ['PF07703'], 'name': ['A2M_N_2']}, {'identifier': ['PF07677'], 'name': ['A2M_recep']}, {'identifier': ['PF01821'], 'name': ['ANATO']}, {'identifier': ['PF01759'], 'name': ['NTR']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['membrane attack complex']}, {'category': ['function'], 'description': ['chemokine activity']}, {'category': ['function'], 'description': ['endopeptidase inhibitor activity']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['process'], 'description': ['activation of MAPK activity']}, {'category': ['process'], 'description': ['cell chemotaxis']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['chemotaxis']}, {'category': ['process'], 'description': ['complement activation']}, {'category': ['process'], 'description': ['complement activation, alternative pathway']}, {'category': ['process'], 'description': ['complement activation, classical pathway']}, {'category': ['process'], 'description': ['cytolysis']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['in utero embryonic development']}, {'category': ['process'], 'description': ['inflammatory response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['mitophagy in response to mitochondrial depolarization']}, {'category': ['process'], 'description': ['negative regulation of macrophage chemotaxis']}, {'category': ['process'], 'description': ['positive regulation of angiogenesis']}, {'category': ['process'], 'description': ['positive regulation of chemokine secretion']}, {'category': ['process'], 'description': ['positive regulation of vascular endothelial growth factor production']}, {'category': ['process'], 'description': ['regulation of complement activation']}, {'category': ['process'], 'description': ['response to stress']}]}]}]}]}]"
"['DB00029', 'BTD00102', 'BIOD00102']",['Anistreplase'],biotech,"['Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl group is chemically conjugated to a complex of bacterial-derived streptokinase and human Plasma-derived Lys-plasminogen proteins.']",['liquid'],"['For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction']",['Anistreplase cleaves the Arg/Val bond in plasminogen to form plasmin. This in turn leads to the degradation of blood clots.'],"[{'food-interaction': ['Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.']}]","[{'target': [{'id': ['BE0000211'], 'name': ['Plasminogen'], 'organism': ['Humans'], 'actions': [{'action': ['activator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A6689'], 'pubmed-id': ['18673235'], 'citation': ['Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.']}, {'ref-id': ['A6690'], 'pubmed-id': ['19436656'], 'citation': ['Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8.']}, {'ref-id': ['A6691'], 'pubmed-id': ['17963464'], 'citation': ['Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Plasminogen'], 'general-function': ['Serine-type peptidase activity'], 'specific-function': ['Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.'], 'gene-name': ['PLG'], 'locus': ['6q26'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-19'], 'theoretical-pi': ['7.25'], 'molecular-weight': ['90568.415'], 'chromosome-location': ['6'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:9071']}, {'resource': ['GenAtlas'], 'identifier': ['PLG']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X05199']}, {'resource': ['GenBank Protein Database'], 'identifier': ['387026']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2394']}, {'resource': ['UniProtKB'], 'identifier': ['P00747']}, {'resource': ['UniProt Accession'], 'identifier': ['PLMN_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.21.7']}], 'amino-acid-sequence': ['>lcl|BSEQ0016037|Plasminogen\nMEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT\nCRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN\nGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE\nCEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE\nLRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS\nAQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE\nQLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG\nLTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED\nCMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG\nPWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT\nRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE\nPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ\nLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW\nGLGCARPNKPGVYVRVSRFVTWIEGVMRNN'], 'gene-sequence': ['>lcl|BSEQ0016038|Plasminogen (PLG)\nATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG\nCCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG\nCTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC\nTGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG\nAAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC\nTCAGAGTGCAAGACTGGGAATGGAAAGAACTACAGAGGGACGATGTCCAAAACAAAAAAT\nGGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT\nACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG\nGGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG\nTGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC\nATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT\nCCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG\nCTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGTGACATCCCC\nCGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT\nGAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT\nGCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTCCCCTGCAAAAATTTGGAT\nGAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC\nCAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA\nCAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT\nGATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT\nTGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC\nCTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA\nGACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT\nGTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAGATGTAGAGACTCCTTCCGAAGAAGAC\nTGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG\nCCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA\nAATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT\nCCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT\nGCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG\nGTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA\nAGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT\nGCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC\nCAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG\nCCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA\nGTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC\nATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG\nCTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA\nTCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT\nGGAGGTCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG\nGGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT\nACTTGGATTGAGGGAGTGATGAGAAATAATTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00051'], 'name': ['Kringle']}, {'identifier': ['PF00089'], 'name': ['Trypsin']}, {'identifier': ['PF00024'], 'name': ['PAN_1']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['extrinsic component of external side of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['function'], 'description': ['apolipoprotein binding']}, {'category': ['function'], 'description': ['protein domain specific binding']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase activity']}, {'category': ['function'], 'description': ['serine-type peptidase activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['extracellular matrix disassembly']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['negative regulation of cell proliferation']}, {'category': ['process'], 'description': ['negative regulation of cell-cell adhesion mediated by cadherin']}, {'category': ['process'], 'description': ['negative regulation of cell-substrate adhesion']}, {'category': ['process'], 'description': ['negative regulation of fibrinolysis']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of fibrinolysis']}, {'category': ['process'], 'description': ['proteolysis']}, {'category': ['process'], 'description': ['tissue remodeling']}]}]}]}, {'id': ['BE0000538'], 'name': ['Fibrinogen alpha chain'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A202223'], 'pubmed-id': ['6750837'], 'citation': ['Prowse CV, Dawes J, Lane DA, Ireland H, Knight I: Proteolysis of fibrinogen in healthy volunteers following major and minor vivo plasminogen activation. Thromb Res. 1982 Jul 1;27(1):91-7. doi: 10.1016/0049-3848(82)90282-1.']}, {'ref-id': ['A202226'], 'pubmed-id': ['7798503'], 'citation': ['Merlini PA, Bauer KA, Oltrona L, Ardissino D, Spinola A, Cattaneo M, Broccolino M, Mannucci PM, Rosenberg RD: Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol. 1995 Jan;25(1):203-9. doi: 10.1016/0735-1097(94)00360-3.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Fibrinogen alpha chain'], 'general-function': ['Structural molecule activity'], 'specific-function': ['Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the immune response via both innate and T-cell mediated pathways.'], 'gene-name': ['FGA'], 'locus': ['4q28'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-19'], 'theoretical-pi': ['5.87'], 'molecular-weight': ['94972.455'], 'chromosome-location': ['4'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3661']}, {'resource': ['GenAtlas'], 'identifier': ['FGA']}, {'resource': ['GenBank Gene Database'], 'identifier': ['AF361104']}, {'resource': ['GenBank Protein Database'], 'identifier': ['13591824']}, {'resource': ['UniProtKB'], 'identifier': ['P02671']}, {'resource': ['UniProt Accession'], 'identifier': ['FIBA_HUMAN']}]}], 'synonyms': [{'synonym': ['Fibrinogen alpha chain precursor']}], 'amino-acid-sequence': ['>lcl|BSEQ0001074|Fibrinogen alpha chain\nMFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW\nNYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA\nNNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC\nRGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQ\nLQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSS\nGPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTW\nNPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV\nSPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTK\nEVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEF\nVSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKS\nYKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFS\nVYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQR\nGSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSH\nNNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENG\nVVWVSFRGADYSLRAVRMKIRPLVTQ'], 'gene-sequence': ['>lcl|BSEQ0021267|Fibrinogen alpha chain (FGA)\nATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCA\nGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTG\nGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGG\nAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGAT\nTTTACAAACAGAATAAATAAGCTCAAAAATTCACTATTTGAATATCAGAAGAACAATAAG\nGATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCCTCAGCC\nAATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTGAAGTC\nCTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAGAAAAATGTTAGA\nGCTCAGTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGT\nCGAGGGTCATGCAGTAGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAG\nCAGAAGCAACTTGAACAGGTCATTGCCAAAGACTTACTTCCCTCTAGAGATAGGCAACAC\nTTACCACTGATAAAAATGAAACCAGTTCCAGACTTGGTTCCCGGAAATTTTAAGAGCCAG\nCTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCGCAGATGAGAATGGAG\nTTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAACCGGA\nTCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCT\nGGACCTGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACC\nTGGAAACCTGGGAGCTCTGGACCTGGAAGTACTGGAAGCTGGAACTCTGGGAGCTCTGGA\nACTGGAAGTACTGGAAACCAAAACCCTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGG\nAATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCACTGGACCTCTGAGAGCTCTGTATCT\nGGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCAGATAGCCCAGGCTCT\nGGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAAATGTA\nAGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAA\nGAGCTCAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCA\nTGCTCTAAAACCGTTACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAA\nGAAGTGGTGACCTCCGAAGATGGTTCTGACTGTCCCGAGGCAATGGATTTAGGCACATTG\nTCTGGCATAGGTACTCTGGATGGGTTCCGCCATAGGCACCCTGATGAAGCTGCCTTCTTC\nGACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCTATGTTAGGAGAGTTT\nGTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGGAATCC\nAGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGC\nAAACAATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGC\nTATAAAATGGCAGATGAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAG\nAGAGGCCATGCTAAATCTCGCCCTGTCAGAGACTGTGATGATGTCCTCCAAACACATCCT\nTCAGGTACCCAAAGTGGCATTTTCAATATCAAGCTACCGGGATCCAGTAAGATTTTTTCT\nGTTTATTGCGATCAAGAGACCAGTTTGGGAGGATGGCTTTTGATCCAGCAAAGAATGGAT\nGGATCACTGAATTTTAACCGGACCTGGCAAGACTACAAGAGAGGTTTCGGCAGCCTGAAT\nGACGAGGGGGAAGGAGAATTCTGGCTAGGCAATGACTACCTCCACTTACTAACCCAAAGG\nGGCTCTGTTCTTAGGGTTGAATTAGAGGACTGGGCTGGGAATGAAGCTTATGCAGAATAT\nCACTTCCGGGTAGGCTCTGAGGCTGAAGGCTATGCCCTCCAAGTCTCCTCCTATGAAGGC\nACTGCGGGTGATGCTCTGATTGAGGGTTCCGTAGAGGAAGGGGCAGAGTACACCTCTCAC\nAACAACATGCAGTTCAGCACCTTTGACAGGGATGCAGACCAGTGGGAAGAGAACTGTGCA\nGAAGTCTATGGGGGAGGCTGGTGGTATAATAACTGCCAAGCAGCCAATCTCAATGGAATC\nTACTACCCTGGGGGCTCCTATGACCCAAGGAATAACAGTCCTTATGAGATTGAGAATGGA\nGTGGTCTGGGTTTCCTTTAGAGGGGCAGATTATTCCCTCAGGGCTGTTCGCATGAAAATT\nAGGCCCCTTGTGACCCAATAG'], 'pfams': [{'pfam': [{'identifier': ['PF00147'], 'name': ['Fibrinogen_C']}, {'identifier': ['PF08702'], 'name': ['Fib_alpha']}, {'identifier': ['PF12160'], 'name': ['Fibrinogen_aC']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['cell cortex']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['extracellular vesicle']}, {'category': ['component'], 'description': ['fibrinogen complex']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['component'], 'description': ['rough endoplasmic reticulum']}, {'category': ['function'], 'description': ['structural molecule activity']}, {'category': ['process'], 'description': ['acute-phase response']}, {'category': ['process'], 'description': ['adaptive immune response']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, common pathway']}, {'category': ['process'], 'description': ['blood coagulation, fibrin clot formation']}, {'category': ['process'], 'description': ['cell-matrix adhesion']}, {'category': ['process'], 'description': ['cellular protein complex assembly']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['cellular response to granulocyte colony-stimulating factor']}, {'category': ['process'], 'description': ['cellular response to interleukin-6']}, {'category': ['process'], 'description': ['cellular response to organic cyclic compound']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['induction of bacterial agglutination']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['liver regeneration']}, {'category': ['process'], 'description': ['negative regulation of blood coagulation, common pathway']}, {'category': ['process'], 'description': ['negative regulation of endothelial cell apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of extrinsic apoptotic signaling pathway via death domain receptors']}, {'category': ['process'], 'description': ['plasminogen activation']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet aggregation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['positive regulation of exocytosis']}, {'category': ['process'], 'description': ['positive regulation of heterotypic cell-cell adhesion']}, {'category': ['process'], 'description': ['positive regulation of peptide hormone secretion']}, {'category': ['process'], 'description': ['positive regulation of protein secretion']}, {'category': ['process'], 'description': ['positive regulation of substrate adhesion-dependent cell spreading']}, {'category': ['process'], 'description': ['positive regulation of vasoconstriction']}, {'category': ['process'], 'description': ['protein complex assembly']}, {'category': ['process'], 'description': ['protein polymerization']}, {'category': ['process'], 'description': ['response to calcium ion']}, {'category': ['process'], 'description': ['response to cycloheximide']}, {'category': ['process'], 'description': ['response to estradiol']}, {'category': ['process'], 'description': ['response to genistein']}, {'category': ['process'], 'description': ['response to morphine']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}, {'id': ['BE0000240'], 'name': ['Plasminogen activator inhibitor 1'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A6691'], 'pubmed-id': ['17963464'], 'citation': ['Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Plasminogen activator inhibitor 1'], 'general-function': ['Serine-type endopeptidase inhibitor activity'], 'specific-function': [""Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis.""], 'gene-name': ['SERPINE1'], 'locus': ['7q21.3-q22'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-23'], 'theoretical-pi': ['7.22'], 'molecular-weight': ['45059.695'], 'chromosome-location': ['7'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:8583']}, {'resource': ['GenAtlas'], 'identifier': ['SERPINE1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X04429']}, {'resource': ['GenBank Protein Database'], 'identifier': ['35272']}, {'resource': ['UniProtKB'], 'identifier': ['P05121']}, {'resource': ['UniProt Accession'], 'identifier': ['PAI1_HUMAN']}]}], 'synonyms': [{'synonym': ['Endothelial plasminogen activator inhibitor', 'PAI', 'PAI1', 'PLANH1', 'Serpin E1']}], 'amino-acid-sequence': ['>lcl|BSEQ0000479|Plasminogen activator inhibitor 1\nMQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY\nGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI\nFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV\nDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD\nGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK\nFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS\nSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP'], 'gene-sequence': ['>lcl|BSEQ0010214|Plasminogen activator inhibitor 1 (SERPINE1)\nATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA\nGGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG\nAGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT\nGGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG\nATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT\nCTGTACAAGGAGCTCATGGGGCCATGGAACAAGGATGAGATCAGCACCACAGACGCGATC\nTTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC\nCGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT\nGACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG\nGACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT\nCCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC\nTCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT\nGGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT\nGCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG\nCTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG\nTTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC\nATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC\nGCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA\nTCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC\nTTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG\nGAACCCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00079'], 'name': ['Serpin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular matrix']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase inhibitor activity']}, {'category': ['process'], 'description': ['angiogenesis']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cellular response to lipopolysaccharide']}, {'category': ['process'], 'description': ['chronological cell aging']}, {'category': ['process'], 'description': ['circadian rhythm']}, {'category': ['process'], 'description': ['defense response to Gram-negative bacterium']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['gene expression']}, {'category': ['process'], 'description': ['negative regulation of blood coagulation']}, {'category': ['process'], 'description': ['negative regulation of cell adhesion mediated by integrin']}, {'category': ['process'], 'description': ['negative regulation of cell migration']}, {'category': ['process'], 'description': ['negative regulation of endopeptidase activity']}, {'category': ['process'], 'description': ['negative regulation of endothelial cell apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of extrinsic apoptotic signaling pathway via death domain receptors']}, {'category': ['process'], 'description': ['negative regulation of fibrinolysis']}, {'category': ['process'], 'description': ['negative regulation of plasminogen activation']}, {'category': ['process'], 'description': ['negative regulation of smooth muscle cell migration']}, {'category': ['process'], 'description': ['negative regulation of smooth muscle cell-matrix adhesion']}, {'category': ['process'], 'description': ['negative regulation of vascular wound healing']}, {'category': ['process'], 'description': ['negative regulation of wound healing']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of angiogenesis']}, {'category': ['process'], 'description': ['positive regulation of blood coagulation']}, {'category': ['process'], 'description': ['positive regulation of inflammatory response']}, {'category': ['process'], 'description': ['positive regulation of interleukin-8 production']}, {'category': ['process'], 'description': ['positive regulation of leukotriene production involved in inflammatory response']}, {'category': ['process'], 'description': ['positive regulation of monocyte chemotaxis']}, {'category': ['process'], 'description': ['positive regulation of receptor-mediated endocytosis']}, {'category': ['process'], 'description': ['positive regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['regulation of receptor activity']}, {'category': ['process'], 'description': ['transcription initiation from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['transcription, DNA-templated']}, {'category': ['process'], 'description': ['transforming growth factor beta receptor signaling pathway']}]}]}]}]}]"
"['DB00030', 'BTD00105', 'BIOD00105', 'DB01383', 'DB05278', 'DB05215', 'DB05283', 'DB08914']",['Insulin human'],biotech,"['Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mellitus, insulin is a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.\r\n\r\nInsulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after trying several oral medications such as [DB00331], [DB01120], or [DB01261] have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own. \r\n\r\nMarketed as the brand name product Humulin R or Novolin R, human insulin begins to exert its effects within 30 minutes of subcutaneous administration, while peak levels occur 3-4 hours after administration. Due to its quick onset of action, human insulin is considered ""bolus insulin"" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals. Bolus insulin is often combined with once daily, long-acting ""basal insulin"" such as [DB01307], [DB09564], and [DB00047] to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Use of basal and bolus insulin together is intended to mimic the pancreas\' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia.\r\n\r\nHuman insulin is also available in an inhalable form, intended to be used as a bolus meal-time insulin. Exubera was the first inhaled insulin available on the market and was developed by Inhale Therapeutics (later named Nektar Therapeutics). Unfortunately, limited uptake by physicians and patients, poor sales, bulky packaging, and concerns over the possible impact on lung cancer development resulted in Exubera products being withdrawn from the US markets [A176005]. Exubera was followed by Afrezza, a monomeric inhaled insulin developed by Mannkind Corporation, which received FDA approval in 2016. While still available in the US, Afrezza has had similar concerns associated with its use, and had an FDA ""black box"" warning added to it to warn about use in patients with chronic lung disease. Afrezza does not currently have Health Canada or European Medicines Agency approval for marketing in Canada or the EU. \r\n\r\nHuman Insulin is a 51 residue peptide hormone produced by recombinant DNA technology by inserting the human insulin gene into Escherichia coli bacteria or Saccharomyces cerevisiae. The structure is identical to native human insulin, with two amino acid chains covalently linked by disulfide bonds. \r\n\r\nHuman insulin is also available in an intermediate-acting form as NPH (Neutral Protamine Hagedorn) as the marketed products Novolin N and Humulin N. NPH insulin is provided as a crystalline suspension of insulin with protamine and zinc, resulting in an onset of action in 1 to 3 hours, duration of action up to 24 hours, and peak action from 6 to 8 hours. Due to the added crystals, NPH insulin is typically cloudy when compared to other forms of insulin and has a neutral pH.\r\n\r\nWithout an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.']",['liquid'],['Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.'],"['The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.\r\nInsulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.']",[{'food-interaction': ['Avoid alcohol. Alcohol may impair blood glucose control.']}],"[{'target': [{'id': ['BE0000033'], 'name': ['Insulin receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1839'], 'pubmed-id': ['12970169'], 'citation': ['Desbuquois B, Chauvet G, Kouach M, Authier F: Cell itinerary and metabolic fate of proinsulin in rat liver: in vivo and in vitro studies. Endocrinology. 2003 Dec;144(12):5308-21. Epub 2003 Sep 11.']}, {'ref-id': ['A1840'], 'pubmed-id': ['12038982'], 'citation': ['Chen LM, Yang XW, Tang JG: Acidic residues on the N-terminus of proinsulin C-Peptide are important for the folding of insulin precursor. J Biochem. 2002 Jun;131(6):855-9.']}, {'ref-id': ['A1843'], 'pubmed-id': ['17722952'], 'citation': ['Bell DS: Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised? Drugs. 2007;67(13):1813-27.']}, {'ref-id': ['A1845'], 'pubmed-id': ['19683471'], 'citation': ['Tanti JF, Jager J: Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol. 2009 Dec;9(6):753-62. doi: 10.1016/j.coph.2009.07.004. Epub  2009 Aug 13.']}, {'ref-id': ['A1847'], 'pubmed-id': ['20230616'], 'citation': ['Chiu SL, Cline HT: Insulin receptor signaling in the development of neuronal structure and function. Neural Dev. 2010 Mar 15;5:7. doi: 10.1186/1749-8104-5-7.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A231659'], 'pubmed-id': ['27512793'], 'citation': ['De Meyts P: The Insulin Receptor and Its Signal Transduction Network .']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Insulin receptor'], 'general-function': ['Receptor signaling protein tyrosine kinase activity'], 'specific-function': ['Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosines residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.'], 'gene-name': ['INSR'], 'locus': ['19p13.3-p13.2'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['957-979'], 'signal-regions': ['1-27'], 'theoretical-pi': ['6.18'], 'molecular-weight': ['156331.465'], 'chromosome-location': ['19'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6091']}, {'resource': ['GenAtlas'], 'identifier': ['INSR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M10051']}, {'resource': ['GenBank Protein Database'], 'identifier': ['307070']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1800']}, {'resource': ['UniProtKB'], 'identifier': ['P06213']}, {'resource': ['UniProt Accession'], 'identifier': ['INSR_HUMAN']}]}], 'synonyms': [{'synonym': ['2.7.10.1', 'IR']}], 'amino-acid-sequence': ['>lcl|BSEQ0036940|Insulin receptor\nMATGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHL\nQILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYAL\nVIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNE\nECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECL\nGNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQG\nCHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGC\nTVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETL\nEIGNYSFYALDNQNLRQLWDWSKHNLTITQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQE\nRNDIALKTNGDQASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQ\nNVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFS\nDERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWE\nRQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQIL\nKELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAF\nPNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYV\nSARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCV\nSRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIG\nPLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSR\nEKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKG\nFTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMA\nAEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPV\nRWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDN\nCPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEME\nFEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSN\nPS'], 'gene-sequence': ['>lcl|BSEQ0020443|Insulin receptor (INSR)\nATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCG\nCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATC\nCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTG\nCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAA\nCTCATCATGATCACTGATTACTTGCTGCTCTTCCGGGTCTATGGGCTCGAGAGCCTGAAG\nGACCTGTTCCCCAACCTCACGGTCATCCGGGGATCACGACTGTTCTTTAACTACGCGCTG\nGTCATCTTCGAGATGGTTCACCTCAAGGAACTCGGCCTCTACAACCTGATGAACATCACC\nCGGGGTTCTGTCCGCATCGAGAAGAACAATGAGCTCTGTTACTTGGCCACTATCGACTGG\nTCCCGTATCCTGGATTCCGTGGAGGATAATTACATCGTGTTGAACAAAGATGACAACGAG\nGAGTGTGGAGACATCTGTCCGGGTACCGCGAAGGGCAAGACCAACTGCCCCGCCACCGTC\nATCAACGGGCAGTTTGTCGAACGATGTTGGACTCATAGTCACTGCCAGAAAGTTTGCCCG\nACCATCTGTAAGTCACACGGCTGCACCGCCGAAGGCCTCTGTTGCCACAGCGAGTGCCTG\nGGCAACTGTTCTCAGCCCGACGACCCCACCAAGTGCGTGGCCTGCCGCAACTTCTACCTG\nGACGGCAGGTGTGTGGAGACCTGCCCGCCCCCGTACTACCACTTCCAGGACTGGCGCTGT\nGTGAACTTCAGCTTCTGCCAGGACCTGCACCACAAATGCAAGAACTCGCGGAGGCAGGGC\nTGCCACCAGTACGTCATTCACAACAACAAGTGCATCCCTGAGTGTCCCTCCGGGTACACG\nATGAATTCCAGCAACTTGCTGTGCACCCCATGCCTGGGTCCCTGTCCCAAGGTGTGCCAC\nCTCCTAGAAGGCGAGAAGACCATCGACTCGGTGACGTCTGCCCAGGAGCTCCGAGGATGC\nACCGTCATCAACGGGAGTCTGATCATCAACATTCGAGGAGGCAACAATCTGGCAGCTGAG\nCTAGAAGCCAACCTCGGCCTCATTGAAGAAATTTCAGGGTATCTAAAAATCCGCCGATCC\nTACGCTCTGGTGTCACTTTCCTTCTTCCGGAAGTTACGTCTGATTCGAGGAGAGACCTTG\nGAAATTGGGAACTACTCCTTCTATGCCTTGGACAACCAGAACCTAAGGCAGCTCTGGGAC\nTGGAGCAAACACAACCTCACCATCACTCAGGGGAAACTCTTCTTCCACTATAACCCCAAA\nCTCTGCTTGTCAGAAATCCACAAGATGGAAGAAGTTTCAGGAACCAAGGGGCGCCAGGAG\nAGAAACGACATTGCCCTGAAGACCAATGGGGACCAGGCATCCTGTGAAAATGAGTTACTT\nAAATTTTCTTACATTCGGACATCTTTTGACAAGATCTTGCTGAGATGGGAGCCGTACTGG\nCCCCCCGACTTCCGAGACCTCTTGGGGTTCATGCTGTTCTACAAAGAGGCCCCTTATCAG\nAATGTGACGGAGTTCGACGGGCAGGATGCGTGTGGTTCCAACAGTTGGACGGTGGTAGAC\nATTGACCCACCCCTGAGGTCCAACGACCCCAAATCACAGAACCACCCAGGGTGGCTGATG\nCGGGGTCTCAAGCCCTGGACCCAGTATGCCATCTTTGTGAAGACCCTGGTCACCTTTTCG\nGATGAACGCCGGACCTATGGGGCCAAGAGTGACATCATTTATGTCCAGACAGATGCCACC\nAACCCCTCTGTGCCCCTGGATCCAATCTCAGTGTCTAACTCATCATCCCAGATTATTCTG\nAAGTGGAAACCACCCTCCGACCCCAATGGCAACATCACCCACTACCTGGTTTTCTGGGAG\nAGGCAGGCGGAAGACAGTGAGCTGTTCGAGCTGGATTATTGCCTCAAAGGGCTGAAGCTG\nCCCTCGAGGACCTGGTCTCCACCATTCGAGTCTGAAGATTCTCAGAAGCACAACCAGAGT\nGAGTATGAGGATTCGGCCGGCGAATGCTGCTCCTGTCCAAAGACAGACTCTCAGATCCTG\nAAGGAGCTGGAGGAGTCCTCGTTTAGGAAGACGTTTGAGGATTACCTGCACAACGTGGTT\nTTCGTCCCCAGAAAAACCTCTTCAGGCACTGGTGCCGAGGACCCTAGGCCATCTCGGAAA\nCGCAGGTCCCTTGGCGATGTTGGGAATGTGACGGTGGCCGTGCCCACGGTGGCAGCTTTC\nCCCAACACTTCCTCGACCAGCGTGCCCACGAGTCCGGAGGAGCACAGGCCTTTTGAGAAG\nGTGGTGAACAAGGAGTCGCTGGTCATCTCCGGCTTGCGACACTTCACGGGCTATCGCATC\nGAGCTGCAGGCTTGCAACCAGGACACCCCTGAGGAACGGTGCAGTGTGGCAGCCTACGTC\nAGTGCGAGGACCATGCCTGAAGCCAAGGCTGATGACATTGTTGGCCCTGTGACGCATGAA\nATCTTTGAGAACAACGTCGTCCACTTGATGTGGCAGGAGCCGAAGGAGCCCAATGGTCTG\nATCGTGCTGTATGAAGTGAGTTATCGGCGATATGGTGATGAGGAGCTGCATCTCTGCGTC\nTCCCGCAAGCACTTCGCTCTGGAACGGGGCTGCAGGCTGCGTGGGCTGTCACCGGGGAAC\nTACAGCGTGCGAATCCGGGCCACCTCCCTTGCGGGCAACGGCTCTTGGACGGAACCCACC\nTATTTCTACGTGACAGACTATTTAGACGTCCCGTCAAATATTGCAAAAATTATCATCGGC\nCCCCTCATCTTTGTCTTTCTCTTCAGTGTTGTGATTGGAAGTATTTATCTATTCCTGAGA\nAAGAGGCAGCCAGATGGGCCGCTGGGACCGCTTTACGCTTCTTCAAACCCTGAGTATCTC\nAGTGCCAGTGATGTGTTTCCATGCTCTGTGTACGTGCCGGACGAGTGGGAGGTGTCTCGA\nGAGAAGATCACCCTCCTTCGAGAGCTGGGGCAGGGCTCCTTCGGCATGGTGTATGAGGGC\nAATGCCAGGGACATCATCAAGGGTGAGGCAGAGACCCGCGTGGCGGTGAAGACGGTCAAC\nGAGTCAGCCAGTCTCCGAGAGCGGATTGAGTTCCTCAATGAGGCCTCGGTCATGAAGGGC\nTTCACCTGCCATCACGTGGTGCGCCTCCTGGGAGTGGTGTCCAAGGGCCAGCCCACGCTG\nGTGGTGATGGAGCTGATGGCTCACGGAGACCTGAAGAGCTACCTCCGTTCTCTGCGGCCA\nGAGGCTGAGAATAATCCTGGCCGCCCTCCCCCTACCCTTCAAGAGATGATTCAGATGGCG\nGCAGAGATTGCTGACGGGATGGCCTACCTGAACGCCAAGAAGTTTGTGCATCGGGACCTG\nGCAGCGAGAAACTGCATGGTCGCCCATGATTTTACTGTCAAAATTGGAGACTTTGGAATG\nACCAGAGACATCTATGAAACGGATTACTACCGGAAAGGGGGCAAGGGTCTGCTCCCTGTA\nCGGTGGATGGCACCGGAGTCCCTGAAGGATGGGGTCTTCACCACTTCTTCTGACATGTGG\nTCCTTTGGCGTGGTCCTTTGGGAAATCACCAGCTTGGCAGAACAGCCTTACCAAGGCCTG\nTCTAATGAACAGGTGTTGAAATTTGTCATGGATGGAGGGTATCTGGATCAACCCGACAAC\nTGTCCAGAGAGAGTCACTGACCTCATGCGCATGTGCTGGCAATTCAACCCCAAGATGAGG\nCCAACCTTCCTGGAGATTGTCAACCTGCTCAAGGACGACCTGCACCCCAGCTTTCCAGAG\nGTGTCGTTCTTCCACAGCGAGGAGAACAAGGCTCCCGAGAGTGAGGAGCTGGAGATGGAG\nTTTGAGGACATGGAGAATGTGCCCCTGGACCGTTCCTCGCACTGTCAGAGGGAGGAGGCG\nGGGGGCCGGGATGGAGGGTCCTCGCTGGGTTTCAAGCGGAGCTACGAGGAACACATCCCT\nTACACACACATGAACGGAGGCAAGAAAAACGGGCGGATTCTGACCTTGCCTCGGTCCAAT\nCCTTCCTAA'], 'pfams': [{'pfam': [{'identifier': ['PF07714'], 'name': ['PK_Tyr_Ser-Thr']}, {'identifier': ['PF00041'], 'name': ['fn3']}, {'identifier': ['PF00757'], 'name': ['Furin-like']}, {'identifier': ['PF01030'], 'name': ['Recep_L_domain']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['caveola']}, {'category': ['component'], 'description': ['endosome membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['insulin receptor complex']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular membrane-bounded organelle']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['function'], 'description': ['ATP binding']}, {'category': ['function'], 'description': ['GTP binding']}, {'category': ['function'], 'description': ['insulin binding']}, {'category': ['function'], 'description': ['insulin receptor substrate binding']}, {'category': ['function'], 'description': ['insulin-activated receptor activity']}, {'category': ['function'], 'description': ['insulin-like growth factor I binding']}, {'category': ['function'], 'description': ['insulin-like growth factor II binding']}, {'category': ['function'], 'description': ['insulin-like growth factor receptor binding']}, {'category': ['function'], 'description': ['phosphatidylinositol 3-kinase binding']}, {'category': ['function'], 'description': ['protein tyrosine kinase activity']}, {'category': ['function'], 'description': ['PTB domain binding']}, {'category': ['function'], 'description': ['receptor signaling protein tyrosine kinase activity']}, {'category': ['process'], 'description': ['activation of MAPK activity']}, {'category': ['process'], 'description': ['activation of protein kinase activity']}, {'category': ['process'], 'description': ['activation of protein kinase B activity']}, {'category': ['process'], 'description': ['adrenal gland development']}, {'category': ['process'], 'description': ['carbohydrate metabolic process']}, {'category': ['process'], 'description': ['cellular response to growth factor stimulus']}, {'category': ['process'], 'description': ['cellular response to insulin stimulus']}, {'category': ['process'], 'description': ['epidermis development']}, {'category': ['process'], 'description': ['exocrine pancreas development']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['glucose homeostasis']}, {'category': ['process'], 'description': ['heart morphogenesis']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['male gonad development']}, {'category': ['process'], 'description': ['male sex determination']}, {'category': ['process'], 'description': ['peptidyl-tyrosine autophosphorylation']}, {'category': ['process'], 'description': ['peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of developmental growth']}, {'category': ['process'], 'description': ['positive regulation of DNA replication']}, {'category': ['process'], 'description': ['positive regulation of glucose import']}, {'category': ['process'], 'description': ['positive regulation of glycogen biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of glycolytic process']}, {'category': ['process'], 'description': ['positive regulation of MAPK cascade']}, {'category': ['process'], 'description': ['positive regulation of meiotic cell cycle']}, {'category': ['process'], 'description': ['positive regulation of mitotic nuclear division']}, {'category': ['process'], 'description': ['positive regulation of nitric oxide biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of respiratory burst']}, {'category': ['process'], 'description': ['positive regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['protein autophosphorylation']}, {'category': ['process'], 'description': ['protein heterotetramerization']}, {'category': ['process'], 'description': ['regulation of embryonic development']}, {'category': ['process'], 'description': ['regulation of female gonad development']}, {'category': ['process'], 'description': ['regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['signal transduction by protein phosphorylation']}, {'category': ['process'], 'description': ['transformation of host cell by virus']}]}]}]}, {'id': ['BE0000858'], 'name': ['Insulin-like growth factor 1 receptor'], 'organism': ['Humans'], 'actions': [{'action': ['activator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A174958'], 'pubmed-id': ['19145584'], 'citation': ['Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H: Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev. 2009 Jan;25(1):41-9. doi: 10.1002/dmrr.912.']}, {'ref-id': ['A174961'], 'pubmed-id': ['21219237'], 'citation': ['Werner H, Weinstein D, Yehezkel E, Laron Z: Controversies in the use of insulin analogues. Expert Opin Biol Ther. 2011 Feb;11(2):199-209. doi: 10.1517/14712598.2011.540233.']}, {'ref-id': ['A174883'], 'pubmed-id': ['22420005'], 'citation': ['Varewijck AJ, Janssen JA: Insulin and its analogues and their affinities for the IGF1 receptor. Endocr Relat Cancer. 2012 Sep 5;19(5):F63-75. doi: 10.1530/ERC-12-0026. Print 2012 Oct.']}, {'ref-id': ['A231649'], 'pubmed-id': ['31771180'], 'citation': ['Sarfstein R, Nagaraj K, LeRoith D, Werner H: Differential Effects of Insulin and IGF1 Receptors on ERK and AKT Subcellular Distribution in Breast Cancer Cells. Cells. 2019 Nov 23;8(12). pii: cells8121499. doi: 10.3390/cells8121499.']}, {'ref-id': ['A231654'], 'pubmed-id': ['25905175'], 'citation': ['Donner T, Sarkar S: Insulin - Pharmacology, Therapeutic Regimens, and Principles of Intensive Insulin Therapy .']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Insulin-like growth factor 1 receptor'], 'general-function': ['Protein tyrosine kinase activity'], 'specific-function': ['Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.'], 'gene-name': ['IGF1R'], 'locus': ['15q26.3'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['936-959'], 'signal-regions': ['1-30'], 'theoretical-pi': ['5.54'], 'molecular-weight': ['154791.73'], 'chromosome-location': ['15'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5465']}, {'resource': ['GenAtlas'], 'identifier': ['IGF1R']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X04434']}, {'resource': ['GenBank Protein Database'], 'identifier': ['804990']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1801']}, {'resource': ['UniProtKB'], 'identifier': ['P08069']}, {'resource': ['UniProt Accession'], 'identifier': ['IGF1R_HUMAN']}]}], 'synonyms': [{'synonym': ['2.7.10.1', 'IGF-I receptor', 'Insulin-like growth factor I receptor']}], 'amino-acid-sequence': ['>lcl|BSEQ0001710|Insulin-like growth factor 1 receptor\nMKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLH\nILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIF\nEMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGD\nLCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCS\nAPDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHD\nGECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNL\nLINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSF\nYVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTR\nNNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDG\nQDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSE\nILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRH\nNYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRK\nVFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFES\nRVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTW\nEPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGN\nYTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHR\nKRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKG\nVVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIME\nLMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARN\nCMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGV\nVLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL\nEIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRH\nSGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC'], 'gene-sequence': ['>lcl|BSEQ0020490|Insulin-like growth factor 1 receptor (IGF1R)\nATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCC\nGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGC\nAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCAC\nATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTC\nATTACCGAGTACTTGCTGCTGTTCCGAGTGGCTGGCCTCGAGAGCCTCGGAGACCTCTTC\nCCCAACCTCACGGTCATCCGCGGCTGGAAACTCTTCTACAACTACGCCCTGGTCATCTTC\nGAGATGACCAATCTCAAGGATATTGGGCTTTACAACCTGAGGAACATTACTCGGGGGGCC\nATCAGGATTGAGAAAAATGCTGACCTCTGTTACCTCTCCACTGTGGACTGGTCCCTGATC\nCTGGATGCGGTGTCCAATAACTACATTGTGGGGAATAAGCCCCCAAAGGAATGTGGGGAC\nCTGTGTCCAGGGACCATGGAGGAGAAGCCGATGTGTGAGAAGACCACCATCAACAATGAG\nTACAACTACCGCTGCTGGACCACAAACCGCTGCCAGAAAATGTGCCCAAGCACGTGTGGG\nAAGCGGGCGTGCACCGAGAACAATGAGTGCTGCCACCCCGAGTGCCTGGGCAGCTGCAGC\nGCGCCTGACAACGACACGGCCTGTGTAGCTTGCCGCCACTACTACTATGCCGGTGTCTGT\nGTGCCTGCCTGCCCGCCCAACACCTACAGGTTTGAGGGCTGGCGCTGTGTGGACCGTGAC\nTTCTGCGCCAACATCCTCAGCGCCGAGAGCAGCGACTCCGAGGGGTTTGTGATCCACGAC\nGGCGAGTGCATGCAGGAGTGCCCCTCGGGCTTCATCCGCAACGGCAGCCAGAGCATGTAC\nTGCATCCCTTGTGAAGGTCCTTGCCCGAAGGTCTGTGAGGAAGAAAAGAAAACAAAGACC\nATTGATTCTGTTACTTCTGCTCAGATGCTCCAAGGATGCACCATCTTCAAGGGCAATTTG\nCTCATTAACATCCGACGGGGGAATAACATTGCTTCAGAGCTGGAGAACTTCATGGGGCTC\nATCGAGGTGGTGACGGGCTACGTGAAGATCCGCCATTCTCATGCCTTGGTCTCCTTGTCC\nTTCCTAAAAAACCTTCGCCTCATCCTAGGAGAGGAGCAGCTAGAAGGGAATTACTCCTTC\nTACGTCCTCGACAACCAGAACTTGCAGCAACTGTGGGACTGGGACCACCGCAACCTGACC\nATCAAAGCAGGGAAAATGTACTTTGCTTTCAATCCCAAATTATGTGTTTCCGAAATTTAC\nCGCATGGAGGAAGTGACGGGGACTAAAGGGCGCCAAAGCAAAGGGGACATAAACACCAGG\nAACAACGGGGAGAGAGCCTCCTGTGAAAGTGACGTCCTGCATTTCACCTCCACCACCACG\nTCGAAGAATCGCATCATCATAACCTGGCACCGGTACCGGCCCCCTGACTACAGGGATCTC\nATCAGCTTCACCGTTTACTACAAGGAAGCACCCTTTAAGAATGTCACAGAGTATGATGGG\nCAGGATGCCTGCGGCTCCAACAGCTGGAACATGGTGGACGTGGACCTCCCGCCCAACAAG\nGACGTGGAGCCCGGCATCTTACTACATGGGCTGAAGCCCTGGACTCAGTACGCCGTTTAC\nGTCAAGGCTGTGACCCTCACCATGGTGGAGAACGACCATATCCGTGGGGCCAAGAGTGAG\nATCTTGTACATTCGCACCAATGCTTCAGTTCCTTCCATTCCCTTGGACGTTCTTTCAGCA\nTCGAACTCCTCTTCTCAGTTAATCGTGAAGTGGAACCCTCCCTCTCTGCCCAACGGCAAC\nCTGAGTTACTACATTGTGCGCTGGCAGCGGCAGCCTCAGGACGGCTACCTTTACCGGCAC\nAATTACTGCTCCAAAGACAAAATCCCCATCAGGAAGTATGCCGACGGCACCATCGACATT\nGAGGAGGTCACAGAGAACCCCAAGACTGAGGTGTGTGGTGGGGAGAAAGGGCCTTGCTGC\nGCCTGCCCCAAAACTGAAGCCGAGAAGCAGGCCGAGAAGGAGGAGGCTGAATACCGCAAA\nGTCTTTGAGAATTTCCTGCACAACTCCATCTTCGTGCCCAGACCTGAAAGGAAGCGGAGA\nGATGTCATGCAAGTGGCCAACACCACCATGTCCAGCCGAAGCAGGAACACCACGGCCGCA\nGACACCTACAACATCACCGACCCGGAAGAGCTGGAGACAGAGTACCCTTTCTTTGAGAGC\nAGAGTGGATAACAAGGAGAGAACTGTCATTTCTAACCTTCGGCCTTTCACATTGTACCGC\nATCGATATCCACAGCTGCAACCACGAGGCTGAGAAGCTGGGCTGCAGCGCCTCCAACTTC\nGTCTTTGCAAGGACTATGCCCGCAGAAGGAGCAGATGACATTCCTGGGCCAGTGACCTGG\nGAGCCAAGGCCTGAAAACTCCATCTTTTTAAAGTGGCCGGAACCTGAGAATCCCAATGGA\nTTGATTCTAATGTATGAAATAAAATACGGATCACAAGTTGAGGATCAGCGAGAATGTGTG\nTCCAGACAGGAATACAGGAAGTATGGAGGGGCCAAGCTAAACCGGCTAAACCCGGGGAAC\nTACACAGCCCGGATTCAGGCCACATCTCTCTCTGGGAATGGGTCGTGGACAGATCCTGTG\nTTCTTCTATGTCCAGGCCAAAACAGGATATGAAAACTTCATCCATCTGATCATCGCTCTG\nCCCGTCGCTGTCCTGTTGATCGTGGGAGGGTTGGTGATTATGCTGTACGTCTTCCATAGA\nAAGAGAAATAACAGCAGGCTGGGGAATGGAGTGCTGTATGCCTCTGTGAACCCGGAGTAC\nTTCAGCGCTGCTGATGTGTACGTTCCTGATGAGTGGGAGGTGGCTCGGGAGAAGATCACC\nATGAGCCGGGAACTTGGGCAGGGGTCGTTTGGGATGGTCTATGAAGGAGTTGCCAAGGGT\nGTGGTGAAAGATGAACCTGAAACCAGAGTGGCCATTAAAACAGTGAACGAGGCCGCAAGC\nATGCGTGAGAGGATTGAGTTTCTCAACGAAGCTTCTGTGATGAAGGAGTTCAATTGTCAC\nCATGTGGTGCGATTGCTGGGTGTGGTGTCCCAAGGCCAGCCAACACTGGTCATCATGGAA\nCTGATGACACGGGGCGATCTCAAAAGTTATCTCCGGTCTCTGAGGCCAGAAATGGAGAAT\nAATCCAGTCCTAGCACCTCCAAGCCTGAGCAAGATGATTCAGATGGCCGGAGAGATTGCA\nGACGGCATGGCATACCTCAACGCCAATAAGTTCGTCCACAGAGACCTTGCTGCCCGGAAT\nTGCATGGTAGCCGAAGATTTCACAGTCAAAATCGGAGATTTTGGTATGACGCGAGATATC\nTATGAGACAGACTATTACCGGAAAGGAGGGAAAGGGCTGCTGCCCGTGCGCTGGATGTCT\nCCTGAGTCCCTCAAGGATGGAGTCTTCACCACTTACTCGGACGTCTGGTCCTTCGGGGTC\nGTCCTCTGGGAGATCGCCACACTGGCCGAGCAGCCCTACCAGGGCTTGTCCAACGAGCAA\nGTCCTTCGCTTCGTCATGGAGGGCGGCCTTCTGGACAAGCCAGACAACTGTCCTGACATG\nCTGTTTGAACTGATGCGCATGTGCTGGCAGTATAACCCCAAGATGAGGCCTTCCTTCCTG\nGAGATCATCAGCAGCATCAAAGAGGAGATGGAGCCTGGCTTCCGGGAGGTCTCCTTCTAC\nTACAGCGAGGAGAACAAGCTGCCCGAGCCGGAGGAGCTGGACCTGGAGCCAGAGAACATG\nGAGAGCGTCCCCCTGGACCCCTCGGCCTCCTCGTCCTCCCTGCCACTGCCCGACAGACAC\nTCAGGACACAAGGCCGAGAACGGCCCCGGCCCTGGGGTGCTGGTCCTCCGCGCCAGCTTC\nGACGAGAGACAGCCTTACGCCCACATGAACGGGGGCCGCAAGAACGAGCGGGCCTTGCCG\nCTGCCCCAGTCTTCGACCTGCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF07714'], 'name': ['PK_Tyr_Ser-Thr']}, {'identifier': ['PF00757'], 'name': ['Furin-like']}, {'identifier': ['PF01030'], 'name': ['Recep_L_domain']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['caveola']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular membrane-bounded organelle']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['neuron projection']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['function'], 'description': ['ATP binding']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['function'], 'description': ['insulin binding']}, {'category': ['function'], 'description': ['insulin receptor binding']}, {'category': ['function'], 'description': ['insulin receptor substrate binding']}, {'category': ['function'], 'description': ['insulin-like growth factor binding']}, {'category': ['function'], 'description': ['insulin-like growth factor I binding']}, {'category': ['function'], 'description': ['insulin-like growth factor-activated receptor activity']}, {'category': ['function'], 'description': ['phosphatidylinositol 3-kinase binding']}, {'category': ['function'], 'description': ['protein tyrosine kinase activity']}, {'category': ['process'], 'description': ['axonogenesis']}, {'category': ['process'], 'description': ['brain development']}, {'category': ['process'], 'description': ['epidermis development']}, {'category': ['process'], 'description': ['establishment of cell polarity']}, {'category': ['process'], 'description': ['exocrine pancreas development']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['inactivation of MAPKK activity']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['insulin-like growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['male sex determination']}, {'category': ['process'], 'description': ['mammary gland development']}, {'category': ['process'], 'description': ['negative regulation of apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of muscle cell apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['negative regulation of sequence-specific DNA binding transcription factor activity']}, {'category': ['process'], 'description': ['peptidyl-tyrosine autophosphorylation']}, {'category': ['process'], 'description': ['phosphatidylinositol 3-kinase signaling']}, {'category': ['process'], 'description': ['phosphatidylinositol-mediated signaling']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of cytokinesis']}, {'category': ['process'], 'description': ['positive regulation of DNA replication']}, {'category': ['process'], 'description': ['positive regulation of MAPK cascade']}, {'category': ['process'], 'description': ['positive regulation of mitotic nuclear division']}, {'category': ['process'], 'description': ['positive regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['positive regulation of steroid hormone biosynthetic process']}, {'category': ['process'], 'description': ['prostate gland epithelium morphogenesis']}, {'category': ['process'], 'description': ['protein autophosphorylation']}, {'category': ['process'], 'description': ['protein heterooligomerization']}, {'category': ['process'], 'description': ['protein tetramerization']}, {'category': ['process'], 'description': ['regulation of JNK cascade']}, {'category': ['process'], 'description': ['response to vitamin E']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}, {'id': ['BE0001123'], 'name': ['Carboxypeptidase E'], 'organism': ['Humans'], 'actions': [{'action': ['modulator', 'product of']}], 'references': [{'articles': [{'article': [{'ref-id': ['A185351'], 'pubmed-id': ['24843127'], 'citation': ['Liew CW, Assmann A, Templin AT, Raum JC, Lipson KL, Rajan S, Qiang G, Hu J, Kawamori D, Lindberg I, Philipson LH, Sonenberg N, Goldfine AB, Stoffers DA, Mirmira RG, Urano F, Kulkarni RN: Insulin regulates carboxypeptidase E by modulating translation initiation scaffolding protein eIF4G1 in pancreatic beta cells. Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):E2319-28. doi: 10.1073/pnas.1323066111. Epub 2014 May 19.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Carboxypeptidase E'], 'general-function': ['Zinc ion binding'], 'specific-function': ['Removes residual C-terminal Arg or Lys remaining after initial endoprotease cleavage during prohormone processing. Processes proinsulin.'], 'gene-name': ['CPE'], 'locus': ['4q32.3'], 'cellular-location': ['Cytoplasmic vesicle'], 'transmembrane-regions': [None], 'signal-regions': ['1-25'], 'theoretical-pi': ['4.78'], 'molecular-weight': ['53150.185'], 'chromosome-location': ['4'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:2303']}, {'resource': ['GenAtlas'], 'identifier': ['CPE']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X51405']}, {'resource': ['GenBank Protein Database'], 'identifier': ['29667']}, {'resource': ['UniProtKB'], 'identifier': ['P16870']}, {'resource': ['UniProt Accession'], 'identifier': ['CBPE_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.17.10', 'Carboxypeptidase H', 'CPE', 'CPH', 'Enkephalin convertase', 'Prohormone-processing carboxypeptidase']}], 'amino-acid-sequence': ['>lcl|BSEQ0002234|Carboxypeptidase E\nMAGRGGSALLALCGALAACGWLLGAEAQEPGAPAAGMRRRRRLQQEDGISFEYHRYPELR\nEALVSVWLQCTAISRIYTVGRSFEGRELLVIELSDNPGVHEPGEPEFKYIGNMHGNEAVG\nRELLIFLAQYLCNEYQKGNETIVNLIHSTRIHIMPSLNPDGFEKAASQPGELKDWFVGRS\nNAQGIDLNRNFPDLDRIVYVNEKEGGPNNHLLKNMKKIVDQNTKLAPETKAVIHWIMDIP\nFVLSANLHGGDLVANYPYDETRSGSAHEYSSSPDDAIFQSLARAYSSFNPAMSDPNRPPC\nRKNDDDSSFVDGTTNGGAWYSVPGGMQDFNYLSSNCFEITVELSCEKFPPEETLKTYWED\nNKNSLISYLEQIHRGVKGFVRDLQGNPIANATISVEGIDHDVTSAKDGDYWRLLIPGNYK\nLTASAPGYLAITKKVAVPYSPAAGVDFELESFSERKEEEKEELMEWWKMMSETLNF'], 'gene-sequence': ['>lcl|BSEQ0016324|Carboxypeptidase E (CPE)\nATGGCCGGGCGAGGGGGCAGCGCGCTGCTGGCTCTGTGCGGGGCACTGGCTGCCTGCGGG\nTGGCTCCTGGGCGCCGAAGCCCAGGAGCCCGGGGCGCCCGCGGCGGGCATGAGGCGGCGC\nCGGCGGCTGCAGCAAGAGGACGGCATCTCCTTCGAGTACCACCGCTACCCCGAGCTGCGC\nGAGGCGCTCGTGTCCGTGTGGCTGCAGTGCACCGCCATCAGCAGGATTTACACGGTGGGG\nCGCAGCTTCGAGGGCCGGGAGCTCCTGGTCATCGAGCTGTCCGACAACCCTGGCGTCCAT\nGAGCCTGGTGAGCCTGAATTTAAATACATTGGGAATATGCATGGGAATGAGGCTGTTGGA\nCGAGAACTGCTCATTTTCTTGGCCCAGTACCTATGCAACGAATACCAGAAGGGGAACGAG\nACAATTGTCAACCTGATCCACAGTACCCGCATTCACATCATGCCTTCCCTGAACCCAGAT\nGGCTTTGAGAAGGCAGCGTCTCAGCCTGGTGAACTCAAGGACTGGTTTGTGGGTCGAAGC\nAATGCCCAGGGAATAGATCTGAACCGGAACTTTCCAGACCTGGATAGGATAGTGTACGTG\nAATGAGAAAGAAGGTGGTCCAAATAATCATCTGTTGAAAAATATGAAGAAAATTGTGGAT\nCAAAACACAAAGCTTGCTCCTGAGACCAAGGCTGTCATTCATTGGATTATGGATATTCCT\nTTTGTGCTTTCTGCCAATCTCCATGGAGGAGACCTTGTGGCCAATTATCCATATGATGAG\nACGCGGAGTGGTAGTGCTCACGAATACAGCTCCTCCCCAGATGACGCCATTTTCCAAAGC\nTTGGCCCGGGCATACTCTTCTTTCAACCCGGCCATGTCTGACCCCAATCGGCCACCATGT\nCGCAAGAATGATGATGACAGCAGCTTTGTAGATGGAACCACCAACGGTGGTGCTTGGTAC\nAGCGTACCTGGAGGGATGCAAGACTTCAATTACCTTAGCAGCAACTGTTTTGAGATCACC\nGTGGAGCTTAGCTGTGAGAAGTTCCCACCTGAAGAGACTCTGAAGACCTACTGGGAGGAT\nAACAAAAACTCCCTCATTAGCTACCTTGAGCAGATACACCGAGGAGTTAAAGGATTTGTC\nCGAGACCTTCAAGGTAACCCAATTGCGAATGCCACCATCTCCGTGGAAGGAATAGACCAC\nGATGTTACATCCGCAAAGGATGGTGATTACTGGAGATTGCTTATACCTGGAAACTATAAA\nCTTACAGCCTCAGCTCCAGGCTATCTGGCAATAACAAAGAAAGTGGCAGTTCCTTACAGC\nCCTGCTGCTGGGGTTGATTTTGAACTGGAGTCATTTTCTGAAAGGAAAGAAGAGGAGAAG\nGAAGAATTGATGGAATGGTGGAAAATGATGTCAGAAACTTTAAATTTTTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00246'], 'name': ['Peptidase_M14']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['Golgi apparatus']}, {'category': ['component'], 'description': ['neuronal cell body']}, {'category': ['component'], 'description': ['nucleus']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['secretory granule']}, {'category': ['component'], 'description': ['secretory granule membrane']}, {'category': ['component'], 'description': ['synaptic membrane']}, {'category': ['component'], 'description': ['transport vesicle membrane']}, {'category': ['function'], 'description': ['carboxypeptidase activity']}, {'category': ['function'], 'description': ['cell adhesion molecule binding']}, {'category': ['function'], 'description': ['metallocarboxypeptidase activity']}, {'category': ['function'], 'description': ['neurexin family protein binding']}, {'category': ['function'], 'description': ['serine-type carboxypeptidase activity']}, {'category': ['function'], 'description': ['zinc ion binding']}, {'category': ['process'], 'description': ['cardiac left ventricle morphogenesis']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['cellular protein modification process']}, {'category': ['process'], 'description': ['insulin processing']}, {'category': ['process'], 'description': ['metabolic process']}, {'category': ['process'], 'description': ['neuropeptide signaling pathway']}, {'category': ['process'], 'description': ['protein localization to membrane']}, {'category': ['process'], 'description': ['Wnt signaling pathway']}]}]}]}, {'id': ['BE0001147'], 'name': ['Protein NOV homolog'], 'organism': ['Humans'], 'actions': [{'action': ['downregulator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A231599'], 'pubmed-id': ['23705021'], 'citation': ['Paradis R, Lazar N, Antinozzi P, Perbal B, Buteau J: Nov/Ccn3, a novel transcriptional target of FoxO1, impairs pancreatic beta-cell function. PLoS One. 2013 May 21;8(5):e64957. doi: 10.1371/journal.pone.0064957. Print 2013.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Protein NOV homolog'], 'general-function': ['Notch binding'], 'specific-function': ['Immediate-early protein playing a role in various cellular processes including proliferation, adhesion, migration, differentiation and survival (PubMed:15181016, PubMed:15611078, PubMed:12695522, PubMed:21344378, PubMed:12050162). Acts by binding to integrins or membrane receptors such as NOTCH1 (PubMed:12695522, PubMed:21344378, PubMed:15611078). Essential regulator of hematopoietic stem and progenitor cell function (PubMed:17463287). Inhibits myogenic differentiation through the activation of Notch-signaling pathway (PubMed:12050162). Inhibits vascular smooth muscle cells proliferation by increasing expression of cell-cycle regulators such as CDKN2B or CDKN1A independently of TGFB1 signaling (PubMed:20139355). Ligand of integrins ITGAV:ITGB3 and ITGA5:ITGB1, acts directly upon endothelial cells to stimulate pro-angiogenic activities and induces angiogenesis. In endothelial cells, supports cell adhesion, induces directed cell migration (chemotaxis) and promotes cell survival (PubMed:12695522). Plays also a role in cutaneous wound healing acting as integrin receptor ligand. Supports skin fibroblast adhesion through ITGA5:ITGB1 and ITGA6:ITGB1 and induces fibroblast chemotaxis through ITGAV:ITGB5. Seems to enhance bFGF-induced DNA synthesis in fibroblasts (PubMed:15611078). Involved in bone regeneration as a negative regulator (By similarity). Enhances the articular chondrocytic phenotype, whereas it repressed the one representing endochondral ossification (PubMed:21871891). Impairs pancreatic beta-cell function, inhibits beta-cell proliferation and insulin secretion (By similarity). Plays a role as negative regulator of endothelial pro-inflammatory activation reducing monocyte adhesion, its anti-inflammatory effects occur secondary to the inhibition of NF-kappaB signaling pathway (PubMed:21063504). Contributes to the control and coordination of inflammatory processes in atherosclerosis (By similarity). Attenuates inflammatory pain through regulation of IL1B- and TNF-induced MMP9, MMP2 and CCL2 expression. Inhibits MMP9 expression through ITGB1 engagement (PubMed:21871891).'], 'gene-name': ['NOV'], 'locus': ['8q24.1'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-31'], 'theoretical-pi': ['7.74'], 'molecular-weight': ['39161.82'], 'chromosome-location': ['8'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:7885']}, {'resource': ['GenAtlas'], 'identifier': ['NOV']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X78351']}, {'resource': ['GenBank Protein Database'], 'identifier': ['825696']}, {'resource': ['UniProtKB'], 'identifier': ['P48745']}, {'resource': ['UniProt Accession'], 'identifier': ['NOV_HUMAN']}]}], 'synonyms': [{'synonym': ['CCN family member 3', 'CCN3', 'IBP-9', 'IGF-binding protein 9', 'IGFBP-9', 'IGFBP9', 'Insulin-like growth factor-binding protein 9', 'Nephroblastoma-overexpressed gene protein homolog', 'NOVH']}], 'amino-acid-sequence': ['>lcl|BSEQ0019069|Protein NOV homolog\nMQSVQSTSFCLRKQCLCLTFLLLHLLGQVAATQRCPPQCPGRCPATPPTCAPGVRAVLDG\nCSCCLVCARQRGESCSDLEPCDESSGLYCDRSADPSNQTGICTAVEGDNCVFDGVIYRSG\nEKFQPSCKFQCTCRDGQIGCVPRCQLDVLLPEPNCPAPRKVEVPGECCEKWICGPDEEDS\nLGGLTLAAYRPEATLGVEVSDSSVNCIEQTTEWTACSKSCGMGFSTRVTNRNRQCEMLKQ\nTRLCMVRPCEQEPEQPTDKKGKKCLRTKKSLKAIHLQFKNCTSLHTYKPRFCGVCSDGRC\nCTPHNTKTIQAEFQCSPGQIVKKPVMVIGTCTCHTNCPKNNEAFLQELELKTTRGKM'], 'gene-sequence': ['>lcl|BSEQ0019070|Protein NOV homolog (NOV)\nATGCAGAGTGTGCAGAGCACGAGCTTTTGTCTCCGAAAGCAGTGCCTTTGCCTGACCTTC\nCTGCTTCTCCATCTCCTGGGACAGGTCGCTGCGACTCAGCGCTGCCCTCCCCAGTGCCCG\nGGCCGGTGCCCTGCGACGCCGCCGACCTGCGCCCCCGGGGTGCGCGCGGTGCTGGACGGC\nTGCTCATGCTGTCTGGTGTGTGCCCGCCAGCGTGGCGAGAGCTGCTCAGATCTGGAGCCA\nTGCGACGAGAGCAGTGGCCTCTACTGTGATCGCAGCGCGGACCCCAGCAACCAGACTGGC\nATCTGCACGGCGGTAGAGGGAGATAACTGTGTGTTCGATGGGGTCATCTACCGCAGTGGA\nGAGAAATTTCAGCCAAGCTGCAAATTCCAGTGCACCTGCAGAGATGGGCAGATTGGCTGT\nGTGCCCCGCTGTCAGCTGGATGTGCTACTGCCTGAGCCTAACTGCCCAGCTCCAAGAAAA\nGTTGAGGTGCCTGGAGAGTGCTGTGAAAAGTGGATCTGTGGCCCAGATGAGGAGGATTCA\nCTGGGAGGCCTTACCCTTGCAGCTTACAGGCCAGAAGCCACCCTAGGAGTAGAAGTCTCT\nGACTCAAGTGTCAACTGCATTGAACAGACCACAGAGTGGACAGCATGCTCCAAGAGCTGT\nGGTATGGGGTTCTCCACCCGGGTCACCAATAGGAACCGTCAATGTGAGATGCTGAAACAG\nACTCGGCTCTGCATGGTGCGGCCCTGTGAACAAGAGCCAGAGCAGCCAACAGATAAGAAA\nGGAAAAAAGTGTCTCCGCACCAAGAAGTCACTCAAAGCCATCCACCTGCAGTTCAAGAAC\nTGCACCAGCCTGCACACCTACAAGCCCAGGTTCTGTGGGGTCTGCAGTGATGGCCGCTGC\nTGCACTCCCCACAATACCAAAACCATCCAGGCAGAGTTTCAGTGCTCCCCAGGGCAAATA\nGTCAAGAAGCCAGTGATGGTCATTGGGACCTGCACCTGTCACACCAACTGTCCTAAGAAC\nAATGAGGCCTTCCTCCAGGAGCTGGAGCTGAAGACTACCAGAGGGAAAATGTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00093'], 'name': ['VWC']}, {'identifier': ['PF00219'], 'name': ['IGFBP']}, {'identifier': ['PF00007'], 'name': ['Cys_knot']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['axon']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['dendrite']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['gap junction']}, {'category': ['component'], 'description': ['intracellular membrane-bounded organelle']}, {'category': ['component'], 'description': ['neuronal cell body']}, {'category': ['component'], 'description': ['proteinaceous extracellular matrix']}, {'category': ['function'], 'description': ['heparin binding']}, {'category': ['function'], 'description': ['integrin binding']}, {'category': ['function'], 'description': ['Notch binding']}, {'category': ['process'], 'description': ['angiogenesis']}, {'category': ['process'], 'description': ['bone regeneration']}, {'category': ['process'], 'description': ['cell adhesion']}, {'category': ['process'], 'description': ['cell adhesion mediated by integrin']}, {'category': ['process'], 'description': ['cell chemotaxis']}, {'category': ['process'], 'description': ['cell-cell signaling']}, {'category': ['process'], 'description': ['chondrocyte differentiation']}, {'category': ['process'], 'description': ['endothelial cell chemotaxis']}, {'category': ['process'], 'description': ['endothelial cell-cell adhesion']}, {'category': ['process'], 'description': ['fibroblast migration']}, {'category': ['process'], 'description': ['hematopoietic stem cell homeostasis']}, {'category': ['process'], 'description': ['negative regulation of cell death']}, {'category': ['process'], 'description': ['negative regulation of cell growth']}, {'category': ['process'], 'description': ['negative regulation of chondrocyte proliferation']}, {'category': ['process'], 'description': ['negative regulation of inflammatory response']}, {'category': ['process'], 'description': ['negative regulation of insulin secretion']}, {'category': ['process'], 'description': ['negative regulation of monocyte chemotaxis']}, {'category': ['process'], 'description': ['negative regulation of myotube differentiation']}, {'category': ['process'], 'description': ['negative regulation of NF-kappaB import into nucleus']}, {'category': ['process'], 'description': ['negative regulation of sensory perception of pain']}, {'category': ['process'], 'description': ['negative regulation of SMAD protein import into nucleus']}, {'category': ['process'], 'description': ['positive regulation of Notch signaling pathway']}, {'category': ['process'], 'description': ['regulation of gene expression']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['smooth muscle cell migration']}, {'category': ['process'], 'description': ['smooth muscle cell proliferation']}, {'category': ['process'], 'description': ['type B pancreatic cell proliferation']}]}]}]}, {'id': ['BE0000942'], 'name': ['Low-density lipoprotein receptor-related protein 2'], 'organism': ['Humans'], 'actions': [{'action': ['substrate']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13258'], 'pubmed-id': ['9773776'], 'citation': ['Orlando RA, Rader K, Authier F, Yamazaki H, Posner BI, Bergeron JJ, Farquhar MG: Megalin is an endocytic receptor for insulin. J Am Soc Nephrol. 1998 Oct;9(10):1759-66.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low-density lipoprotein receptor-related protein 2'], 'general-function': ['Calcium ion binding'], 'specific-function': ['Acts together with cubilin to mediate HDL endocytosis (By similarity). May participate in regulation of parathyroid-hormone and para-thyroid-hormone-related protein release.'], 'gene-name': ['LRP2'], 'locus': ['2q24-q31'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['4424-4446'], 'signal-regions': ['1-25'], 'theoretical-pi': ['4.68'], 'molecular-weight': ['521952.77'], 'chromosome-location': ['2'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6694']}, {'resource': ['GenAtlas'], 'identifier': ['LRP2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['U33837']}, {'resource': ['GenBank Protein Database'], 'identifier': ['1809240']}, {'resource': ['UniProtKB'], 'identifier': ['P98164']}, {'resource': ['UniProt Accession'], 'identifier': ['LRP2_HUMAN']}]}], 'synonyms': [{'synonym': ['Glycoprotein 330', 'gp330', 'LRP-2', 'Megalin']}], 'amino-acid-sequence': ['>lcl|BSEQ0010661|Low-density lipoprotein receptor-related protein 2\nMDRGPAAVACTLLLALVACLAPASGQECDSAHFRCGSGHCIPADWRCDGTKDCSDDADEI\nGCAVVTCQQGYFKCQSEGQCIPNSWVCDQDQDCDDGSDERQDCSQSTCSSHQITCSNGQC\nIPSEYRCDHVRDCPDGADENDCQYPTCEQLTCDNGACYNTSQKCDWKVDCRDSSDEINCT\nEICLHNEFSCGNGECIPRAYVCDHDNDCQDGSDEHACNYPTCGGYQFTCPSGRCIYQNWV\nCDGEDDCKDNGDEDGCESGPHDVHKCSPREWSCPESGRCISIYKVCDGILDCPGREDENN\nTSTGKYCSMTLCSALNCQYQCHETPYGGACFCPPGYIINHNDSRTCVEFDDCQIWGICDQ\nKCESRPGRHLCHCEEGYILERGQYCKANDSFGEASIIFSNGRDLLIGDIHGRSFRILVES\nQNRGVAVGVAFHYHLQRVFWTDTVQNKVFSVDINGLNIQEVLNVSVETPENLAVDWVNNK\nIYLVETKVNRIDMVNLDGSYRVTLITENLGHPRGIAVDPTVGYLFFSDWESLSGEPKLER\nAFMDGSNRKDLVKTKLGWPAGVTLDMISKRVYWVDSRFDYIETVTYDGIQRKTVVHGGSL\nIPHPFGVSLFEGQVFFTDWTKMAVLKANKFTETNPQVYYQASLRPYGVTVYHSLRQPYAT\nNPCKDNNGGCEQVCVLSHRTDNDGLGFRCKCTFGFQLDTDERHCIAVQNFLIFSSQVAIR\nGIPFTLSTQEDVMVPVSGNPSFFVGIDFDAQDSTIFFSDMSKHMIFKQKIDGTGREILAA\nNRVENVESLAFDWISKNLYWTDSHYKSISVMRLADKTRRTVVQYLNNPRSVVVHPFAGYL\nFFTDWFRPAKIMRAWSDGSHLLPVINTTLGWPNGLAIDWAASRLYWVDAYFDKIEHSTFD\nGLDRRRLGHIEQMTHPFGLAIFGEHLFFTDWRLGAIIRVRKADGGEMTVIRSGIAYILHL\nKSYDVNIQTGSNACNQPTHPNGDCSHFCFPVPNFQRVCGCPYGMRLASNHLTCEGDPTNE\nPPTEQCGLFSFPCKNGRCVPNYYLCDGVDDCHDNSDEQLCGTLNNTCSSSAFTCGHGECI\nPAHWRCDKRNDCVDGSDEHNCPTHAPASCLDTQYTCDNHQCISKNWVCDTDNDCGDGSDE\nKNCNSTETCQPSQFNCPNHRCIDLSFVCDGDKDCVDGSDEVGCVLNCTASQFKCASGDKC\nIGVTNRCDGVFDCSDNSDEAGCPTRPPGMCHSDEFQCQEDGICIPNFWECDGHPDCLYGS\nDEHNACVPKTCPSSYFHCDNGNCIHRAWLCDRDNDCGDMSDEKDCPTQPFRCPSWQWQCL\nGHNICVNLSVVCDGIFDCPNGTDESPLCNGNSCSDFNGGCTHECVQEPFGAKCLCPLGFL\nLANDSKTCEDIDECDILGSCSQHCYNMRGSFRCSCDTGYMLESDGRTCKVTASESLLLLV\nASQNKIIADSVTSQVHNIYSLVENGSYIVAVDFDSISGRIFWSDATQGKTWSAFQNGTDR\nRVVFDSSIILTETIAIDWVGRNLYWTDYALETIEVSKIDGSHRTVLISKNLTNPRGLALD\nPRMNEHLLFWSDWGHHPRIERASMDGSMRTVIVQDKIFWPCGLTIDYPNRLLYFMDSYLD\nYMDFCDYNGHHRRQVIASDLIIRHPYALTLFEDSVYWTDRATRRVMRANKWHGGNQSVVM\nYNIQWPLGIVAVHPSKQPNSVNPCAFSRCSHLCLLSSQGPHFYSCVCPSGWSLSPDLLNC\nLRDDQPFLITVRQHIIFGISLNPEVKSNDAMVPIAGIQNGLDVEFDDAEQYIYWVENPGE\nIHRVKTDGTNRTVFASISMVGPSMNLALDWISRNLYSTNPRTQSIEVLTLHGDIRYRKTL\nIANDGTALGVGFPIGITVDPARGKLYWSDQGTDSGVPAKIASANMDGTSVKTLFTGNLEH\nLECVTLDIEEQKLYWAVTGRGVIERGNVDGTDRMILVHQLSHPWGIAVHDSFLYYTDEQY\nEVIERVDKATGANKIVLRDNVPNLRGLQVYHRRNAAESSNGCSNNMNACQQICLPVPGGL\nFSCACATGFKLNPDNRSCSPYNSFIVVSMLSAIRGFSLELSDHSETMVPVAGQGRNALHV\nDVDVSSGFIYWCDFSSSVASDNAIRRIKPDGSSLMNIVTHGIGENGVRGIAVDWVAGNLY\nFTNAFVSETLIEVLRINTTYRRVLLKVTVDMPRHIVVDPKNRYLFWADYGQRPKIERSFL\nDCTNRTVLVSEGIVTPRGLAVDRSDGYVYWVDDSLDIIARIRINGENSEVIRYGSRYPTP\nYGITVFENSIIWVDRNLKKIFQASKEPENTEPPTVIRDNINWLRDVTIFDKQVQPRSPAE\nVNNNPCLENNGGCSHLCFALPGLHTPKCDCAFGTLQSDGKNCAISTENFLIFALSNSLRS\nLHLDPENHSPPFQTINVERTVMSLDYDSVSDRIYFTQNLASGVGQISYATLSSGIHTPTV\nIASGIGTADGIAFDWITRRIYYSDYLNQMINSMAEDGSNRTVIARVPKPRAIVLDPCQGY\nLYWADWDTHAKIERATLGGNFRVPIVNSSLVMPSGLTLDYEEDLLYWVDASLQRIERSTL\nTGVDREVIVNAAVHAFGLTLYGQYIYWTDLYTQRIYRANKYDGSGQIAMTTNLLSQPRGI\nNTVVKNQKQQCNNPCEQFNGGCSHICAPGPNGAECQCPHEGNWYLANNRKHCIVDNGERC\nGASSFTCSNGRCISEEWKCDNDNDCGDGSDEMESVCALHTCSPTAFTCANGRCVQYSYRC\nDYYNDCGDGSDEAGCLFRDCNATTEFMCNNRRCIPREFICNGVDNCHDNNTSDEKNCPDR\nTCQSGYTKCHNSNICIPRVYLCDGDNDCGDNSDENPTYCTTHTCSSSEFQCASGRCIPQH\nWYCDQETDCFDASDEPASCGHSERTCLADEFKCDGGRCIPSEWICDGDNDCGDMSDEDKR\nHQCQNQNCSDSEFLCVNDRPPDRRCIPQSWVCDGDVDCTDGYDENQNCTRRTCSENEFTC\nGYGLCIPKIFRCDRHNDCGDYSDERGCLYQTCQQNQFTCQNGRCISKTFVCDEDNDCGDG\nSDELMHLCHTPEPTCPPHEFKCDNGRCIEMMKLCNHLDDCLDNSDEKGCGINECHDPSIS\nGCDHNCTDTLTSFYCSCRPGYKLMSDKRTCVDIDECTEMPFVCSQKCENVIGSYICKCAP\nGYLREPDGKTCRQNSNIEPYLIFSNRYYLRNLTIDGYFYSLILEGLDNVVALDFDRVEKR\nLYWIDTQRQVIERMFLNKTNKETIINHRLPAAESLAVDWVSRKLYWLDARLDGLFVSDLN\nGGHRRMLAQHCVDANNTFCFDNPRGLALHPQYGYLYWADWGHRAYIGRVGMDGTNKSVII\nSTKLEWPNGITIDYTNDLLYWADAHLGYIEYSDLEGHHRHTVYDGALPHPFAITIFEDTI\nYWTDWNTRTVEKGNKYDGSNRQTLVNTTHRPFDIHVYHPYRQPIVSNPCGTNNGGCSHLC\nLIKPGGKGFTCECPDDFRTLQLSGSTYCMPMCSSTQFLCANNEKCIPIWWKCDGQKDCSD\nGSDELALCPQRFCRLGQFQCSDGNCTSPQTLCNAHQNCPDGSDEDRLLCENHHCDSNEWQ\nCANKRCIPESWQCDTFNDCEDNSDEDSSHCASRTCRPGQFRCANGRCIPQAWKCDVDNDC\nGDHSDEPIEECMSSAHLCDNFTEFSCKTNYRCIPKWAVCNGVDDCRDNSDEQGCEERTCH\nPVGDFRCKNHHCIPLRWQCDGQNDCGDNSDEENCAPRECTESEFRCVNQQCIPSRWICDH\nYNDCGDNSDERDCEMRTCHPEYFQCTSGHCVHSELKCDGSADCLDASDEADCPTRFPDGA\nYCQATMFECKNHVCIPPYWKCDGDDDCGDGSDEELHLCLDVPCNSPNRFRCDNNRCIYSH\nEVCNGVDDCGDGTDETEEHCRKPTPKPCTEYEYKCGNGHCIPHDNVCDDADDCGDWSDEL\nGCNKGKERTCAENICEQNCTQLNEGGFICSCTAGFETNVFDRTSCLDINECEQFGTCPQH\nCRNTKGSYECVCADGFTSMSDRPGKRCAAEGSSPLLLLPDNVRIRKYNLSSERFSEYLQD\nEEYIQAVDYDWDPKDIGLSVVYYTVRGEGSRFGAIKRAYIPNFESGRNNLVQEVDLKLKY\nVMQPDGIAVDWVGRHIYWSDVKNKRIEVAKLDGRYRKWLISTDLDQPAAIAVNPKLGLMF\nWTDWGKEPKIESAWMNGEDRNILVFEDLGWPTGLSIDYLNNDRIYWSDFKEDVIETIKYD\nGTDRRVIAKEAMNPYSLDIFEDQLYWISKEKGEVWKQNKFGQGKKEKTLVVNPWLTQVRI\nFHQLRYNKSVPNLCKQICSHLCLLRPGGYSCACPQGSSFIEGSTTECDAAIELPINLPPP\nCRCMHGGNCYFDETDLPKCKCPSGYTGKYCEMAFSKGISPGTTAVAVLLTILLIVVIGAL\nAIAGFFHYRRTGSLLPALPKLPSLSSLVKPSENGNGVTFRSGADLNMDIGVSGFGPETAI\nDRSMAMSEDFVMEMGKQPIIFENPMYSARDSAVKVVQPIQVTVSENVDNKNYGSPINPSE\nIVPETNPTSPAADGTQVTKWNLFKRKSKQTTNFENPIYAQMENEQKESVAATPPPSPSLP\nAKPKPPSRRDPTPTYSATEDTFKDTANLVKEDSEV'], 'gene-sequence': ['>lcl|BSEQ0010662|Low-density lipoprotein receptor-related protein 2 (LRP2)\nATGGATCGCGGGCCGGCAGCAGTGGCGTGCACGCTGCTCCTGGCTCTCGTCGCCTGCCTA\nGCGCCGGCCAGTGGCCAAGAATGTGACAGTGCGCATTTTCGCTGTGGAAGTGGGCATTGC\nATCCCTGCAGACTGGAGGTGTGATGGGACCAAAGACTGTTCAGATGACGCGGATGAAATT\nGGCTGCGCTGTTGTGACCTGCCAGCAGGGCTATTTCAAGTGCCAGAGTGAGGGACAATGC\nATCCCCAACTCCTGGGTGTGTGACCAAGATCAAGACTGTGATGATGGCTCAGATGAACGT\nCAAGATTGCTCACAAAGTACATGCTCAAGTCATCAGATAACATGCTCCAATGGTCAGTGT\nATCCCAAGTGAATACAGGTGCGACCACGTCAGAGACTGCCCCGATGGAGCTGATGAGAAT\nGACTGCCAGTACCCAACATGTGAGCAGCTTACTTGTGACAATGGGGCCTGCTATAACACC\nAGTCAGAAGTGTGATTGGAAAGTTGATTGCAGGGACTCCTCAGATGAAATCAACTGCACT\nGAGATATGCTTGCACAATGAGTTTTCATGTGGCAATGGAGAGTGTATCCCTCGTGCTTAT\nGTCTGTGACCATGACAATGATTGCCAAGACGGCAGTGACGAACATGCTTGCAACTATCCG\nACCTGCGGTGGTTACCAGTTCACTTGCCCCAGTGGCCGATGCATTTATCAAAACTGGGTT\nTGTGATGGAGAAGATGACTGTAAAGATAATGGAGATGAAGATGGATGTGAAAGCGGTCCT\nCATGATGTTCATAAATGTTCCCCAAGAGAATGGTCTTGCCCAGAGTCGGGACGATGCATC\nTCCATTTATAAAGTTTGTGATGGGATTTTAGATTGCCCAGGAAGAGAAGATGAAAACAAC\nACTAGTACCGGAAAATACTGTAGTATGACTCTGTGCTCTGCCTTGAACTGCCAGTACCAG\nTGCCATGAGACGCCGTATGGAGGAGCGTGTTTTTGTCCCCCAGGTTATATCATCAACCAC\nAATGACAGCCGTACCTGTGTTGAGTTTGATGATTGCCAGATATGGGGAATTTGTGACCAG\nAAGTGTGAAAGCCGACCTGGCCGTCACCTGTGCCACTGTGAAGAAGGGTATATCTTGGAG\nCGTGGACAGTATTGCAAAGCTAATGATTCCTTTGGCGAGGCCTCCATTATCTTCTCCAAT\nGGTCGGGATTTGTTAATTGGTGATATTCATGGAAGGAGCTTCCGGATCCTAGTGGAGTCT\nCAGAATCGTGGAGTGGCCGTGGGTGTGGCTTTCCACTATCACCTGCAAAGAGTTTTTTGG\nACAGACACCGTGCAAAATAAGGTTTTTTCAGTTGACATTAATGGTTTAAATATCCAAGAG\nGTTCTCAATGTTTCTGTTGAAACCCCAGAGAACCTGGCTGTGGACTGGGTTAATAATAAA\nATCTATCTAGTGGAAACCAAGGTCAACCGCATAGATATGGTAAATTTGGATGGAAGCTAT\nCGGGTTACCCTTATAACTGAAAACTTGGGGCATCCTAGAGGAATTGCCGTGGACCCAACT\nGTTGGTTATTTATTTTTCTCAGATTGGGAGAGCCTTTCTGGGGAACCTAAGCTGGAAAGG\nGCATTCATGGATGGCAGCAACCGTAAAGACTTGGTGAAAACAAAGCTGGGATGGCCTGCT\nGGGGTAACTCTGGATATGATATCGAAGCGTGTTTACTGGGTTGACTCTCGGTTTGATTAC\nATTGAAACTGTAACTTATGATGGAATTCAAAGGAAGACTGTAGTTCATGGAGGCTCCCTC\nATTCCTCATCCCTTTGGAGTAAGCTTATTTGAAGGTCAGGTGTTCTTTACAGATTGGACA\nAAGATGGCCGTGCTGAAGGCAAACAAGTTCACAGAGACCAACCCACAAGTGTACTACCAG\nGCTTCCCTGAGGCCCTATGGAGTGACTGTTTACCATTCCCTCAGACAGCCCTATGCTACC\nAATCCGTGTAAAGATAACAATGGGGGCTGTGAGCAGGTCTGTGTCCTCAGCCACAGAACA\nGATAATGATGGTTTGGGTTTCCGTTGCAAGTGCACATTCGGCTTCCAACTGGATACAGAT\nGAGCGCCACTGCATTGCTGTTCAGAATTTCCTCATTTTTTCATCCCAAGTTGCTATTCGT\nGGGATCCCGTTCACCTTGTCTACCCAGGAAGATGTCATGGTTCCAGTTTCGGGGAATCCT\nTCTTTCTTTGTCGGGATTGATTTTGACGCCCAGGACAGCACTATCTTTTTTTCAGATATG\nTCAAAACACATGATTTTTAAGCAAAAGATTGATGGCACAGGAAGAGAAATTCTCGCAGCT\nAACAGGGTGGAAAATGTTGAAAGTTTGGCTTTTGATTGGATTTCAAAGAATCTCTATTGG\nACAGACTCTCATTACAAGAGTATCAGTGTCATGAGGCTAGCTGATAAAACGAGACGCACA\nGTAGTTCAGTATTTAAATAACCCACGGTCGGTGGTAGTTCATCCTTTTGCCGGGTATCTA\nTTCTTCACTGATTGGTTCCGTCCTGCTAAAATTATGAGAGCATGGAGTGACGGATCTCAC\nCTCTTGCCTGTAATAAACACTACTCTTGGATGGCCCAATGGCTTGGCCATCGATTGGGCT\nGCTTCACGATTGTACTGGGTAGATGCCTATTTTGATAAAATTGAGCACAGCACCTTTGAT\nGGTTTAGACAGAAGAAGACTGGGCCATATAGAGCAGATGACACATCCGTTTGGACTTGCC\nATCTTTGGAGAGCATTTATTTTTTACTGACTGGAGACTGGGTGCCATTATTCGAGTCAGG\nAAAGCAGATGGTGGAGAAATGACAGTTATCCGAAGTGGCATTGCTTACATACTGCATTTG\nAAATCGTATGATGTCAACATCCAGACTGGTTCTAACGCCTGTAATCAACCCACGCATCCT\nAACGGTGACTGCAGCCACTTCTGCTTCCCGGTGCCAAATTTCCAGCGAGTGTGTGGGTGC\nCCTTATGGAATGAGGCTGGCTTCCAATCACTTGACATGCGAGGGGGACCCAACCAATGAA\nCCACCCACAGAGCAGTGTGGCTTATTTTCCTTCCCCTGTAAAAATGGCAGATGTGTGCCC\nAATTACTATCTCTGTGATGGAGTCGATGATTGTCATGATAACAGTGATGAGCAACTATGT\nGGCACACTTAATAATACCTGTTCATCTTCGGCGTTCACCTGTGGCCATGGGGAGTGCATT\nCCTGCACACTGGCGCTGTGACAAACGCAACGACTGTGTGGATGGCAGTGATGAGCACAAC\nTGCCCCACCCACGCACCTGCTTCCTGCCTTGACACCCAATACACCTGTGATAATCACCAG\nTGTATCTCAAAGAACTGGGTCTGTGACACAGACAATGATTGTGGGGATGGATCTGATGAA\nAAGAACTGCAATTCGACAGAGACATGCCAACCTAGTCAGTTTAATTGCCCCAATCATCGA\nTGTATTGACCTATCGTTTGTCTGTGATGGTGACAAGGATTGTGTTGATGGATCTGATGAG\nGTTGGTTGTGTATTAAACTGTACTGCTTCTCAATTCAAGTGTGCCAGTGGGGATAAATGT\nATTGGCGTCACAAATCGTTGTGATGGTGTTTTTGATTGCAGTGACAACTCGGATGAAGCA\nGGCTGTCCAACCAGGCCTCCTGGTATGTGCCACTCAGATGAATTTCAGTGCCAAGAAGAT\nGGTATCTGCATCCCGAACTTCTGGGAATGTGATGGGCATCCAGACTGCCTCTATGGATCT\nGATGAGCACAATGCCTGTGTCCCCAAGACTTGCCCTTCATCATATTTCCACTGTGACAAC\nGGAAACTGCATCCACAGGGCATGGCTCTGTGATCGGGACAATGACTGCGGGGATATGAGT\nGATGAGAAGGACTGCCCTACTCAGCCCTTTCGCTGTCCTAGTTGGCAATGGCAGTGTCTT\nGGCCATAACATCTGTGTGAATCTGAGTGTAGTGTGTGATGGCATCTTTGACTGCCCCAAT\nGGGACAGATGAGTCCCCACTTTGCAATGGGAACAGCTGCTCAGATTTCAATGGTGGTTGT\nACTCACGAGTGTGTTCAAGAGCCCTTTGGGGCTAAATGCCTATGTCCATTGGGATTCTTA\nCTTGCCAATGATTCTAAGACCTGTGAAGACATAGATGAATGTGATATTCTAGGCTCTTGT\nAGCCAGCACTGTTACAATATGAGAGGTTCTTTCCGGTGCTCGTGTGATACAGGCTACATG\nTTAGAAAGTGATGGGAGGACTTGCAAAGTTACAGCATCTGAGAGTCTGCTGTTACTTGTG\nGCAAGTCAGAACAAAATTATTGCCGACAGTGTCACCTCCCAGGTCCACAATATCTATTCA\nTTGGTCGAGAATGGTTCTTACATTGTAGCTGTTGATTTTGATTCAATTAGTGGTCGTATC\nTTTTGGTCTGATGCAACTCAGGGTAAAACCTGGAGTGCGTTTCAAAATGGAACGGACAGA\nAGAGTGGTATTTGACAGTAGCATCATCTTGACTGAAACTATTGCAATAGATTGGGTAGGT\nCGTAATCTTTACTGGACAGACTATGCTCTGGAAACAATTGAAGTCTCCAAAATTGATGGG\nAGCCACAGGACTGTGCTGATTAGTAAAAACCTAACAAATCCAAGAGGACTAGCATTAGAT\nCCCAGAATGAATGAGCATCTACTGTTCTGGTCTGACTGGGGCCACCACCCTCGCATCGAG\nCGAGCCAGCATGGACGGCAGCATGCGCACTGTCATTGTCCAGGACAAGATCTTCTGGCCC\nTGCGGCTTAACTATTGACTACCCCAACAGACTGCTCTACTTCATGGACTCCTATCTTGAT\nTACATGGACTTTTGTGATTATAATGGACACCATCGGAGACAGGTGATAGCCAGTGATTTG\nATTATACGGCACCCCTATGCCCTAACTCTCTTTGAAGACTCTGTGTACTGGACTGACCGT\nGCTACTCGTCGGGTTATGCGAGCCAACAAGTGGCATGGAGGGAACCAGTCAGTTGTAATG\nTATAATATTCAATGGCCCCTTGGGATTGTTGCGGTTCATCCTTCGAAACAACCAAATTCC\nGTGAATCCATGTGCCTTTTCCCGCTGCAGCCATCTCTGCCTGCTTTCCTCACAGGGGCCT\nCATTTTTACTCCTGTGTTTGTCCTTCAGGATGGAGTCTGTCTCCTGATCTCCTGAATTGC\nTTGAGAGATGATCAACCTTTCTTAATAACTGTAAGGCAACATATAATTTTTGGAATCTCC\nCTTAATCCTGAGGTGAAGAGCAATGATGCTATGGTCCCCATAGCAGGGATACAGAATGGT\nTTAGATGTTGAATTTGATGATGCTGAGCAATACATCTATTGGGTTGAAAATCCAGGTGAA\nATTCACAGAGTGAAGACAGATGGCACCAACAGGACAGTATTTGCTTCTATATCTATGGTG\nGGGCCTTCTATGAACCTGGCCTTAGATTGGATTTCAAGAAACCTTTATTCTACCAATCCT\nAGAACTCAGTCAATCGAGGTTTTGACACTCCACGGAGATATCAGATACAGAAAAACATTG\nATTGCCAATGATGGGACAGCTCTTGGAGTTGGCTTTCCAATTGGCATAACTGTTGATCCT\nGCTCGTGGGAAGCTGTACTGGTCAGACCAAGGAACTGACAGTGGGGTTCCTGCCAAGATC\nGCCAGTGCTAACATGGATGGCACATCTGTGAAAACTCTCTTTACTGGGAACCTCGAACAC\nCTGGAGTGTGTCACTCTTGACATCGAAGAGCAGAAACTCTACTGGGCAGTCACTGGAAGA\nGGAGTGATTGAAAGAGGAAACGTGGATGGAACAGATCGAATGATCCTGGTACACCAGCTT\nTCCCACCCCTGGGGAATTGCAGTCCATGATTCTTTCCTTTATTATACTGATGAACAGTAT\nGAGGTCATTGAAAGAGTTGATAAGGCCACTGGGGCCAACAAAATAGTCTTGAGAGATAAT\nGTTCCAAATCTGAGGGGTCTTCAAGTTTATCACAGACGCAATGCCGCCGAATCCTCAAAT\nGGCTGTAGCAACAACATGAATGCCTGTCAGCAGATTTGCCTGCCTGTACCAGGAGGATTG\nTTTTCCTGCGCCTGTGCCACTGGATTTAAACTCAATCCTGATAATCGGTCCTGCTCTCCA\nTATAACTCTTTCATTGTTGTTTCAATGCTGTCTGCAATCAGAGGCTTTAGCTTGGAATTG\nTCAGATCATTCAGAAACCATGGTGCCGGTGGCAGGCCAAGGACGAAACGCACTGCATGTG\nGATGTGGATGTGTCCTCTGGCTTTATTTATTGGTGTGATTTTAGCAGCTCAGTGGCATCT\nGATAATGCGATCCGTAGAATTAAACCAGATGGATCTTCTCTGATGAACATTGTGACACAT\nGGAATAGGAGAAAATGGAGTCCGGGGTATTGCAGTGGATTGGGTAGCAGGAAATCTTTAT\nTTCACCAATGCCTTTGTTTCTGAAACACTGATAGAAGTTCTGCGGATCAATACTACTTAC\nCGCCGTGTTCTTCTTAAAGTCACAGTGGACATGCCTAGGCATATTGTTGTAGATCCCAAG\nAACAGATACCTCTTCTGGGCTGACTATGGGCAGAGACCAAAGATTGAGCGTTCTTTCCTT\nGACTGTACCAATCGAACAGTGCTTGTGTCAGAGGGCATTGTCACACCACGGGGCTTGGCA\nGTGGACCGAAGTGATGGCTACGTTTATTGGGTTGATGATTCTTTAGATATAATTGCAAGG\nATTCGTATCAATGGAGAGAACTCTGAAGTGATTCGTTATGGCAGTCGTTACCCAACTCCT\nTATGGCATCACTGTTTTTGAAAATTCTATCATATGGGTAGATAGGAATTTGAAAAAGATC\nTTCCAAGCCAGCAAGGAACCAGAGAACACAGAGCCACCCACAGTGATAAGAGACAATATC\nAACTGGCTAAGAGATGTGACCATCTTTGACAAGCAAGTCCAGCCCCGGTCACCAGCAGAG\nGTCAACAACAACCCTTGCTTGGAAAACAATGGTGGGTGCTCTCATCTCTGCTTTGCTCTG\nCCTGGATTGCACACCCCAAAATGTGACTGTGCCTTTGGGACCCTGCAAAGTGATGGCAAG\nAATTGTGCCATTTCAACAGAAAATTTCCTCATCTTTGCCTTGTCTAATTCCTTGAGAAGC\nTTACACTTGGACCCTGAAAACCATAGCCCACCTTTCCAAACAATAAATGTGGAAAGAACT\nGTCATGTCTCTAGACTATGACAGTGTAAGTGATAGAATCTACTTCACACAAAATTTAGCC\nTCTGGAGTTGGACAGATTTCCTATGCCACCCTGTCTTCAGGGATCCATACTCCAACTGTC\nATTGCTTCAGGTATAGGGACTGCTGATGGCATTGCCTTTGACTGGATTACTAGAAGAATT\nTATTACAGTGACTACCTCAACCAGATGATTAATTCCATGGCTGAAGATGGGTCTAACCGC\nACTGTGATAGCCCGCGTTCCAAAACCAAGAGCAATTGTGTTAGATCCCTGCCAAGGGTAC\nCTGTACTGGGCTGACTGGGATACACATGCCAAAATCGAGAGAGCCACATTGGGAGGAAAC\nTTCCGCGTACCCATTGTGAACAGCAGTCTGGTCATGCCCAGTGGGCTGACTCTGGACTAT\nGAAGAGGACCTTCTCTACTGGGTGGATGCTAGTCTGCAGAGGATTGAACGCAGCACTCTG\nACGGGCGTGGATCGTGAAGTCATTGTCAATGCAGCCGTTCATGCTTTTGGCTTGACTCTC\nTATGGCCAGTATATTTACTGGACTGACTTGTACACACAAAGAATTTACCGAGCTAACAAA\nTATGACGGGTCAGGTCAGATTGCAATGACCACAAATTTGCTCTCCCAGCCCAGGGGAATC\nAACACTGTTGTGAAGAACCAGAAACAACAGTGTAACAATCCTTGTGAACAGTTTAATGGG\nGGCTGCAGCCATATCTGTGCACCAGGTCCAAATGGTGCCGAGTGCCAGTGTCCACATGAG\nGGCAACTGGTATTTGGCCAACAACAGGAAGCACTGCATTGTGGACAATGGTGAACGATGT\nGGTGCATCTTCCTTCACCTGCTCCAATGGGCGCTGCATCTCGGAAGAGTGGAAGTGTGAT\nAATGACAACGACTGTGGGGATGGCAGTGATGAGATGGAAAGTGTCTGTGCACTTCACACC\nTGCTCACCGACAGCCTTCACCTGTGCCAATGGGCGATGTGTCCAATACTCTTACCGCTGT\nGATTACTACAATGACTGTGGTGATGGCAGTGATGAGGCAGGGTGCCTGTTCAGGGACTGC\nAATGCCACCACGGAGTTTATGTGCAATAACAGAAGGTGCATACCTCGTGAGTTTATCTGC\nAATGGTGTAGACAACTGCCATGATAATAACACTTCAGATGAGAAAAATTGCCCTGATCGC\nACTTGCCAGTCTGGATACACAAAATGTCATAATTCAAATATTTGTATTCCTCGCGTTTAT\nTTGTGTGACGGAGACAATGACTGTGGAGATAACAGTGATGAAAACCCTACTTATTGCACC\nACTCACACGTGCAGCAGCAGTGAGTTCCAATGCGCATCTGGGCGCTGTATTCCTCAACAT\nTGGTATTGTGATCAAGAAACAGATTGTTTTGATGCCTCTGATGAACCTGCCTCTTGTGGT\nCACTCTGAGCGAACATGCCTAGCTGATGAGTTCAAGTGTGATGGTGGGAGGTGCATCCCA\nAGCGAATGGATCTGTGACGGTGATAATGACTGTGGGGATATGAGTGACGAGGATAAAAGG\nCACCAGTGTCAGAATCAAAACTGCTCGGATTCCGAGTTTCTCTGTGTAAATGACAGACCT\nCCGGACAGGAGGTGCATTCCCCAGTCTTGGGTCTGTGATGGCGATGTGGATTGTACTGAC\nGGCTACGATGAGAATCAGAATTGCACCAGGAGAACTTGCTCTGAAAATGAATTCACCTGT\nGGTTACGGACTGTGTATCCCAAAGATATTCAGGTGTGACCGGCACAATGACTGTGGTGAC\nTATAGCGACGAGAGGGGCTGCTTATACCAGACTTGCCAACAGAATCAGTTTACCTGTCAG\nAACGGGCGCTGCATTAGTAAAACCTTCGTCTGTGATGAGGATAATGACTGTGGAGACGGA\nTCTGATGAGCTGATGCACCTGTGCCACACCCCAGAACCCACGTGTCCACCTCACGAGTTC\nAAGTGTGACAATGGGCGCTGCATCGAGATGATGAAACTCTGCAACCACCTAGATGACTGT\nTTGGACAACAGCGATGAGAAAGGCTGTGGCATTAATGAATGCCATGACCCTTCAATCAGT\nGGCTGCGATCACAACTGCACAGACACCTTAACCAGTTTCTATTGTTCCTGTCGTCCTGGT\nTACAAGCTCATGTCTGACAAGCGGACTTGTGTTGATATTGATGAATGCACAGAGATGCCT\nTTTGTCTGTAGCCAGAAGTGTGAGAATGTAATAGGCTCCTACATCTGTAAGTGTGCCCCA\nGGCTACCTCCGAGAACCAGATGGAAAGACCTGCCGGCAAAACAGTAACATCGAACCCTAT\nCTCATTTTTAGCAACCGTTACTATTTGAGAAATTTAACTATAGATGGCTATTTTTACTCC\nCTCATCTTGGAAGGACTGGACAATGTTGTGGCATTAGATTTTGACCGAGTAGAGAAGAGA\nTTGTATTGGATTGATACACAGAGGCAAGTCATTGAGAGAATGTTTCTGAATAAGACAAAC\nAAGGAGACAATCATAAACCACAGACTACCAGCTGCAGAAAGTCTGGCTGTAGACTGGGTT\nTCCAGAAAGCTCTACTGGTTGGATGCCCGCCTGGATGGCCTCTTTGTCTCTGACCTCAAT\nGGTGGACACCGCCGCATGCTGGCCCAGCACTGTGTGGATGCCAACAACACCTTCTGCTTT\nGATAATCCCAGAGGACTTGCCCTTCACCCTCAATATGGGTACCTCTACTGGGCAGACTGG\nGGTCACCGCGCATACATTGGGAGAGTAGGCATGGATGGAACCAACAAGTCTGTGATAATC\nTCCACCAAGTTAGAGTGGCCTAATGGCATCACCATTGATTACACCAATGATCTACTCTAC\nTGGGCAGATGCCCACCTGGGTTACATAGAGTACTCTGATTTGGAGGGCCACCATCGACAC\nACGGTGTATGATGGGGCACTGCCTCACCCTTTCGCTATTACCATTTTTGAAGACACTATT\nTATTGGACAGATTGGAATACAAGGACAGTGGAAAAGGGAAACAAATATGATGGATCAAAT\nAGACAGACACTGGTGAACACAACACACAGACCATTTGACATCCATGTGTACCATCCATAT\nAGGCAGCCCATTGTGAGCAATCCCTGTGGTACCAACAATGGTGGCTGTTCTCATCTCTGC\nCTCATCAAGCCAGGAGGAAAAGGGTTCACTTGCGAGTGTCCAGATGACTTCCGCACCCTT\nCAGCTGAGTGGCAGCACCTACTGCATGCCCATGTGCTCCAGCACCCAGTTCCTGTGCGCT\nAACAATGAAAAGTGCATTCCTATCTGGTGGAAATGTGATGGACAGAAAGACTGCTCAGAT\nGGCTCTGATGAACTGGCCCTTTGCCCGCAGCGCTTCTGCCGACTGGGACAGTTCCAGTGC\nAGTGACGGCAACTGCACCAGCCCGCAGACTTTATGCAATGCTCACCAAAATTGCCCTGAT\nGGGTCTGATGAAGACCGTCTTCTTTGTGAGAATCACCACTGTGACTCCAATGAATGGCAG\nTGCGCCAACAAACGTTGCATCCCAGAATCCTGGCAGTGTGACACATTTAACGACTGTGAG\nGATAACTCAGATGAAGACAGTTCCCACTGTGCCAGCAGGACCTGCCGGCCGGGCCAGTTT\nCGGTGTGCTAATGGCCGCTGCATCCCGCAGGCCTGGAAGTGTGATGTGGATAATGATTGT\nGGAGACCACTCGGATGAGCCCATTGAAGAATGCATGAGCTCTGCCCATCTCTGTGACAAC\nTTCACAGAATTCAGCTGCAAAACAAATTACCGCTGCATCCCAAAGTGGGCCGTGTGCAAT\nGGTGTAGATGACTGCAGGGACAACAGTGATGAGCAAGGCTGTGAGGAGAGGACATGCCAT\nCCTGTGGGGGATTTCCGCTGTAAAAATCACCACTGCATCCCTCTTCGTTGGCAGTGTGAT\nGGGCAAAATGACTGTGGAGATAACTCAGATGAGGAAAACTGTGCTCCCCGGGAGTGCACA\nGAGAGCGAGTTTCGATGTGTCAATCAGCAGTGCATTCCCTCGCGATGGATCTGTGACCAT\nTACAACGACTGTGGGGACAACTCAGATGAACGGGACTGTGAGATGAGGACCTGCCATCCT\nGAATATTTTCAGTGTACAAGTGGACATTGTGTACACAGTGAACTGAAATGCGATGGATCC\nGCTGACTGTTTGGATGCGTCTGATGAAGCTGATTGTCCCACACGCTTTCCTGATGGTGCA\nTACTGCCAGGCTACTATGTTCGAATGCAAAAACCATGTTTGTATCCCGCCATATTGGAAA\nTGTGATGGCGATGATGACTGTGGCGATGGTTCAGATGAAGAACTTCACCTGTGCTTGGAT\nGTTCCCTGTAATTCACCAAACCGTTTCCGGTGTGACAACAATCGCTGCATTTATAGTCAT\nGAGGTGTGCAATGGTGTGGATGACTGTGGAGATGGAACTGATGAGACAGAGGAGCACTGT\nAGAAAACCGACCCCTAAACCTTGTACAGAATATGAATATAAGTGTGGCAATGGGCATTGC\nATTCCACATGACAATGTGTGTGATGATGCCGATGACTGTGGTGACTGGTCCGATGAACTG\nGGTTGCAATAAAGGAAAAGAAAGAACATGTGCTGAAAATATATGCGAGCAAAATTGTACC\nCAATTAAATGAAGGAGGATTTATCTGCTCCTGTACAGCTGGGTTCGAAACCAATGTTTTT\nGACAGAACCTCCTGTCTAGATATCAATGAATGTGAACAATTTGGGACTTGTCCCCAGCAC\nTGCAGAAATACCAAAGGAAGTTATGAGTGTGTCTGTGCTGATGGCTTCACGTCTATGAGT\nGACCGCCCTGGAAAACGATGTGCAGCTGAGGGTAGCTCTCCTTTGTTGCTACTGCCTGAC\nAATGTCCGAATTCGAAAATATAATCTCTCATCTGAGAGGTTCTCAGAGTATCTTCAAGAT\nGAGGAATATATCCAAGCTGTTGATTATGATTGGGATCCCAAGGACATAGGCCTCAGTGTT\nGTGTATTACACTGTGCGAGGGGAGGGCTCTAGGTTTGGTGCTATCAAACGTGCCTACATC\nCCCAACTTTGAATCCGGCCGCAATAATCTTGTGCAGGAAGTTGACCTGAAACTGAAATAC\nGTAATGCAGCCAGATGGAATAGCAGTGGACTGGGTTGGAAGGCATATTTACTGGTCAGAT\nGTCAAGAATAAACGCATTGAGGTGGCTAAACTTGATGGAAGGTACAGAAAGTGGCTGATT\nTCCACTGACCTGGACCAACCAGCTGCTATTGCTGTGAATCCCAAACTAGGGCTTATGTTC\nTGGACTGACTGGGGAAAGGAACCTAAAATCGAGTCTGCCTGGATGAATGGAGAGGACCGC\nAACATCCTGGTTTTCGAGGACCTTGGTTGGCCAACTGGCCTTTCTATCGATTATTTGAAC\nAATGACCGAATCTACTGGAGTGACTTCAAGGAGGACGTTATTGAAACCATAAAATATGAT\nGGGACTGATAGGAGAGTCATTGCAAAGGAAGCAATGAACCCTTACAGCCTGGACATCTTT\nGAAGACCAGTTATACTGGATATCTAAGGAAAAGGGAGAAGTATGGAAACAAAATAAATTT\nGGGCAAGGAAAGAAAGAGAAAACGCTGGTAGTGAACCCTTGGCTCACTCAAGTTCGAATC\nTTTCATCAACTCAGATACAATAAGTCAGTGCCCAACCTTTGCAAACAGATCTGCAGCCAC\nCTCTGCCTTCTGAGACCTGGAGGATACAGCTGTGCCTGTCCCCAAGGCTCCAGCTTTATA\nGAGGGGAGCACCACTGAGTGTGATGCAGCCATCGAACTGCCTATCAACCTGCCCCCCCCA\nTGCAGGTGCATGCACGGAGGAAATTGCTATTTTGATGAGACTGACCTCCCCAAATGCAAG\nTGTCCTAGCGGCTACACCGGAAAATATTGTGAAATGGCGTTTTCAAAAGGCATCTCTCCA\nGGAACAACCGCAGTAGCTGTGCTGTTGACAATCCTCTTGATCGTCGTAATTGGAGCTCTG\nGCAATTGCAGGATTCTTCCACTATAGAAGGACCGGCTCCCTTTTGCCTGCTCTGCCCAAG\nCTGCCAAGCTTAAGCAGTCTCGTCAAGCCCTCTGAAAATGGGAATGGGGTGACCTTCAGA\nTCAGGGGCAGATCTTAACATGGATATTGGAGTGTCTGGTTTTGGACCTGAGACTGCTATT\nGACAGGTCAATGGCAATGAGTGAAGACTTTGTCATGGAAATGGGGAAGCAGCCCATAATA\nTTTGAAAACCCAATGTACTCAGCCAGAGACAGTGCTGTCAAAGTGGTTCAGCCAATCCAG\nGTGACTGTATCTGAAAATGTGGATAATAAGAATTATGGAAGTCCCATAAACCCTTCTGAG\nATAGTTCCAGAGACAAACCCAACTTCACCAGCTGCTGATGGAACTCAGGTGACAAAATGG\nAATCTCTTCAAACGAAAATCTAAACAAACTACCAACTTTGAAAATCCAATCTATGCACAG\nATGGAGAACGAGCAAAAGGAAAGTGTTGCTGCGACACCACCTCCATCACCTTCGCTCCCT\nGCTAAGCCTAAGCCTCCTTCGAGAAGAGACCCAACTCCAACCTATTCTGCAACAGAAGAC\nACTTTTAAAGACACCGCAAATCTTGTTAAAGAAGACTCTGAAGTATAG'], 'pfams': [{'pfam': [{'identifier': ['PF07645'], 'name': ['EGF_CA']}, {'identifier': ['PF00057'], 'name': ['Ldl_recept_a']}, {'identifier': ['PF00058'], 'name': ['Ldl_recept_b']}, {'identifier': ['PF12662'], 'name': ['cEGF']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['apical plasma membrane']}, {'category': ['component'], 'description': ['brush border membrane']}, {'category': ['component'], 'description': ['coated pit']}, {'category': ['component'], 'description': ['endocytic vesicle']}, {'category': ['component'], 'description': ['endoplasmic reticulum']}, {'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['Golgi apparatus']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['lysosomal membrane']}, {'category': ['component'], 'description': ['lysosome']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['process'], 'description': ['cell proliferation']}, {'category': ['process'], 'description': ['endocytosis']}, {'category': ['process'], 'description': ['forebrain development']}, {'category': ['process'], 'description': ['lipid metabolic process']}, {'category': ['process'], 'description': ['phototransduction, visible light']}, {'category': ['process'], 'description': ['protein glycosylation']}, {'category': ['process'], 'description': ['receptor-mediated endocytosis']}, {'category': ['process'], 'description': ['retinoid metabolic process']}, {'category': ['process'], 'description': ['small molecule metabolic process']}, {'category': ['process'], 'description': ['steroid metabolic process']}, {'category': ['process'], 'description': ['vitamin D metabolic process']}]}]}]}, {'id': ['BE0002126'], 'name': ['Insulin-like growth factor-binding protein 7'], 'organism': ['Humans'], 'actions': [{'action': ['inhibitor', 'binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13262'], 'pubmed-id': ['17475416'], 'citation': ['Radulescu RT: One for all and all for one: RB defends the cell while IDE, PTEN and IGFBP-7 antagonize insulin and IGFs to protect RB. Med Hypotheses. 2007;69(5):1018-20. Epub 2007 May 1.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Insulin-like growth factor-binding protein 7'], 'general-function': [None], 'specific-function': ['Binds IGF-I and IGF-II with a relatively low affinity. Stimulates prostacyclin (PGI2) production. Stimulates cell adhesion.'], 'gene-name': ['IGFBP7'], 'locus': ['4q12'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-26'], 'theoretical-pi': ['7.94'], 'molecular-weight': ['29130.055'], 'chromosome-location': ['4'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5476']}, {'resource': ['GenAtlas'], 'identifier': ['IGFBP7']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L19182']}, {'resource': ['GenBank Protein Database'], 'identifier': ['307151']}, {'resource': ['UniProtKB'], 'identifier': ['Q16270']}, {'resource': ['UniProt Accession'], 'identifier': ['IBP7_HUMAN']}]}], 'synonyms': [{'synonym': ['IBP-7', 'IGFBP-rP1', 'MAC25', 'MAC25 protein', 'PGI2-stimulating factor', 'Prostacyclin-stimulating factor', 'PSF', 'TAF', 'Tumor-derived adhesion factor']}], 'amino-acid-sequence': ['>lcl|BSEQ0004170|Insulin-like growth factor-binding protein 7\nMERPSLRALLLGAAGLLLLLLPLSSSSSSDTCGPCEPASCPPLPPLGCLLGETRDACGCC\nPMCARGEGEPCGGGGAGRGYCAPGMECVKSRKRRKGKAGAAAGGPGVSGVCVCKSRYPVC\nGSDGTTYPSGCQLRAASQRAESRGEKAITQVSKGTCEQGPSIVTPPKDIWNVTGAQVYLS\nCEVIGIPTPVLIWNKVKRGHYGVQRTELLPGDRDNLAIQTRGGPEKHEVTGWVLVSPLSK\nEDAGEYECHASNSQGQASASAKITVVDALHEIPVKKGEGAEL'], 'gene-sequence': ['>lcl|BSEQ0011540|Insulin-like growth factor-binding protein 7 (IGFBP7)\nATGGAGCGGCCGTCGCTGCGCGCCCTGCTCCTCGGCGCCGCTGGGCTGCTGCTCCTGCTC\nCTGCCCCTCTCCTCTTCCTCCTCTTCGGACACCTGCGGCCCCTGCGAGCCGGCCTCCTGC\nCCGCCCCTGCCCCCGCTGGGCTGCCTGCTGGGCGAGACCCGCGACGCGTGCGGCTGCTGC\nCCTATGTGCGCCCGCGGCGAGGGCGAGCCGTGCGGGGGTGGCGGCGCCGGCAGGGGGTAC\nTGCGCGCCGGGCATGGAGTGCGTGAAGAGCCGCAAGAGGCGGAAGGGTAAAGCCGGGGCA\nGCAGCCGGCGGTCCGGGTGTAAGCGGCGTGTGCGTGTGCAAGAGCCGCTACCCGGTGTGC\nGGCAGCGACGGCACCACCTACCCGAGCGGCTGCCAGCTGCGCGCCGCCAGCCAGAGGGCC\nGAGAGCCGCGGGGAGAAGGCCATCACCCAGGTCAGCAAGGGCACCTGCGAGCAAGGTCCT\nTCCATAGTGACGCCCCCCAAGGACATCTGGAATGTCACTGGTGCCCAGGTGTACTTGAGC\nTGTGAGGTCATCGGAATCCCGACACCTGTCCTCATCTGGAACAAGGTAAAAAGGGGTCAC\nTATGGAGTTCAAAGGACAGAACTCCTGCCTGGTGACCGGGACAACCTGGCCATTCAGACC\nCGGGGTGGCCCAGAAAAGCATGAAGTAACTGGCTGGGTGCTGGTATCTCCTCTAAGTAAG\nGAAGATGCTGGAGAATATGAGTGCCATGCATCCAATTCCCAAGGACAGGCTTCAGCATCA\nGCAAAAATTACAGTGGTTGATGCCTTACATGAAATACCAGTGAAAAAAGGTACACAATAA\n'], 'pfams': [{'pfam': [{'identifier': ['PF07679'], 'name': ['I-set']}, {'identifier': ['PF00219'], 'name': ['IGFBP']}, {'identifier': ['PF07648'], 'name': ['Kazal_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['process'], 'description': ['cell adhesion']}, {'category': ['process'], 'description': ['negative regulation of cell proliferation']}, {'category': ['process'], 'description': ['regulation of cell growth']}]}]}]}]}]"
"['DB00031', 'BTD00019', 'BIOD00019']",['Tenecteplase'],biotech,"['Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain.']",['liquid'],['For treatment of myocardial infarction and lysis of intracoronary emboli'],"['Tenecteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. ']","[{'food-interaction': ['Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.']}]","[{'target': [{'id': ['BE0000211'], 'name': ['Plasminogen'], 'organism': ['Humans'], 'actions': [{'action': ['activator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A6689'], 'pubmed-id': ['18673235'], 'citation': ['Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.']}, {'ref-id': ['A6690'], 'pubmed-id': ['19436656'], 'citation': ['Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8.']}, {'ref-id': ['A6691'], 'pubmed-id': ['17963464'], 'citation': ['Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Plasminogen'], 'general-function': ['Serine-type peptidase activity'], 'specific-function': ['Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.'], 'gene-name': ['PLG'], 'locus': ['6q26'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-19'], 'theoretical-pi': ['7.25'], 'molecular-weight': ['90568.415'], 'chromosome-location': ['6'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:9071']}, {'resource': ['GenAtlas'], 'identifier': ['PLG']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X05199']}, {'resource': ['GenBank Protein Database'], 'identifier': ['387026']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2394']}, {'resource': ['UniProtKB'], 'identifier': ['P00747']}, {'resource': ['UniProt Accession'], 'identifier': ['PLMN_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.21.7']}], 'amino-acid-sequence': ['>lcl|BSEQ0016037|Plasminogen\nMEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT\nCRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN\nGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE\nCEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE\nLRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS\nAQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE\nQLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG\nLTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED\nCMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG\nPWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT\nRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE\nPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ\nLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW\nGLGCARPNKPGVYVRVSRFVTWIEGVMRNN'], 'gene-sequence': ['>lcl|BSEQ0016038|Plasminogen (PLG)\nATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG\nCCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG\nCTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC\nTGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG\nAAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC\nTCAGAGTGCAAGACTGGGAATGGAAAGAACTACAGAGGGACGATGTCCAAAACAAAAAAT\nGGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT\nACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG\nGGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG\nTGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC\nATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT\nCCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG\nCTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGTGACATCCCC\nCGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT\nGAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT\nGCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTCCCCTGCAAAAATTTGGAT\nGAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC\nCAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA\nCAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT\nGATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT\nTGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC\nCTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA\nGACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT\nGTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAGATGTAGAGACTCCTTCCGAAGAAGAC\nTGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG\nCCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA\nAATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT\nCCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT\nGCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG\nGTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA\nAGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT\nGCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC\nCAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG\nCCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA\nGTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC\nATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG\nCTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA\nTCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT\nGGAGGTCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG\nGGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT\nACTTGGATTGAGGGAGTGATGAGAAATAATTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00051'], 'name': ['Kringle']}, {'identifier': ['PF00089'], 'name': ['Trypsin']}, {'identifier': ['PF00024'], 'name': ['PAN_1']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['extrinsic component of external side of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['function'], 'description': ['apolipoprotein binding']}, {'category': ['function'], 'description': ['protein domain specific binding']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase activity']}, {'category': ['function'], 'description': ['serine-type peptidase activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['extracellular matrix disassembly']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['negative regulation of cell proliferation']}, {'category': ['process'], 'description': ['negative regulation of cell-cell adhesion mediated by cadherin']}, {'category': ['process'], 'description': ['negative regulation of cell-substrate adhesion']}, {'category': ['process'], 'description': ['negative regulation of fibrinolysis']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of fibrinolysis']}, {'category': ['process'], 'description': ['proteolysis']}, {'category': ['process'], 'description': ['tissue remodeling']}]}]}]}, {'id': ['BE0000538'], 'name': ['Fibrinogen alpha chain'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A6690'], 'pubmed-id': ['19436656'], 'citation': ['Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8.']}, {'ref-id': ['A6689'], 'pubmed-id': ['18673235'], 'citation': ['Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.']}, {'ref-id': ['A6691'], 'pubmed-id': ['17963464'], 'citation': ['Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Fibrinogen alpha chain'], 'general-function': ['Structural molecule activity'], 'specific-function': ['Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the immune response via both innate and T-cell mediated pathways.'], 'gene-name': ['FGA'], 'locus': ['4q28'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-19'], 'theoretical-pi': ['5.87'], 'molecular-weight': ['94972.455'], 'chromosome-location': ['4'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3661']}, {'resource': ['GenAtlas'], 'identifier': ['FGA']}, {'resource': ['GenBank Gene Database'], 'identifier': ['AF361104']}, {'resource': ['GenBank Protein Database'], 'identifier': ['13591824']}, {'resource': ['UniProtKB'], 'identifier': ['P02671']}, {'resource': ['UniProt Accession'], 'identifier': ['FIBA_HUMAN']}]}], 'synonyms': [{'synonym': ['Fibrinogen alpha chain precursor']}], 'amino-acid-sequence': ['>lcl|BSEQ0001074|Fibrinogen alpha chain\nMFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW\nNYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA\nNNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC\nRGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQ\nLQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSS\nGPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTW\nNPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV\nSPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTK\nEVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEF\nVSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKS\nYKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFS\nVYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQR\nGSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSH\nNNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENG\nVVWVSFRGADYSLRAVRMKIRPLVTQ'], 'gene-sequence': ['>lcl|BSEQ0021267|Fibrinogen alpha chain (FGA)\nATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCA\nGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTG\nGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGG\nAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGAT\nTTTACAAACAGAATAAATAAGCTCAAAAATTCACTATTTGAATATCAGAAGAACAATAAG\nGATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCCTCAGCC\nAATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTGAAGTC\nCTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAGAAAAATGTTAGA\nGCTCAGTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGT\nCGAGGGTCATGCAGTAGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAG\nCAGAAGCAACTTGAACAGGTCATTGCCAAAGACTTACTTCCCTCTAGAGATAGGCAACAC\nTTACCACTGATAAAAATGAAACCAGTTCCAGACTTGGTTCCCGGAAATTTTAAGAGCCAG\nCTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCGCAGATGAGAATGGAG\nTTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAACCGGA\nTCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCT\nGGACCTGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACC\nTGGAAACCTGGGAGCTCTGGACCTGGAAGTACTGGAAGCTGGAACTCTGGGAGCTCTGGA\nACTGGAAGTACTGGAAACCAAAACCCTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGG\nAATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCACTGGACCTCTGAGAGCTCTGTATCT\nGGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCAGATAGCCCAGGCTCT\nGGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAAATGTA\nAGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAA\nGAGCTCAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCA\nTGCTCTAAAACCGTTACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAA\nGAAGTGGTGACCTCCGAAGATGGTTCTGACTGTCCCGAGGCAATGGATTTAGGCACATTG\nTCTGGCATAGGTACTCTGGATGGGTTCCGCCATAGGCACCCTGATGAAGCTGCCTTCTTC\nGACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCTATGTTAGGAGAGTTT\nGTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGGAATCC\nAGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGC\nAAACAATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGC\nTATAAAATGGCAGATGAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAG\nAGAGGCCATGCTAAATCTCGCCCTGTCAGAGACTGTGATGATGTCCTCCAAACACATCCT\nTCAGGTACCCAAAGTGGCATTTTCAATATCAAGCTACCGGGATCCAGTAAGATTTTTTCT\nGTTTATTGCGATCAAGAGACCAGTTTGGGAGGATGGCTTTTGATCCAGCAAAGAATGGAT\nGGATCACTGAATTTTAACCGGACCTGGCAAGACTACAAGAGAGGTTTCGGCAGCCTGAAT\nGACGAGGGGGAAGGAGAATTCTGGCTAGGCAATGACTACCTCCACTTACTAACCCAAAGG\nGGCTCTGTTCTTAGGGTTGAATTAGAGGACTGGGCTGGGAATGAAGCTTATGCAGAATAT\nCACTTCCGGGTAGGCTCTGAGGCTGAAGGCTATGCCCTCCAAGTCTCCTCCTATGAAGGC\nACTGCGGGTGATGCTCTGATTGAGGGTTCCGTAGAGGAAGGGGCAGAGTACACCTCTCAC\nAACAACATGCAGTTCAGCACCTTTGACAGGGATGCAGACCAGTGGGAAGAGAACTGTGCA\nGAAGTCTATGGGGGAGGCTGGTGGTATAATAACTGCCAAGCAGCCAATCTCAATGGAATC\nTACTACCCTGGGGGCTCCTATGACCCAAGGAATAACAGTCCTTATGAGATTGAGAATGGA\nGTGGTCTGGGTTTCCTTTAGAGGGGCAGATTATTCCCTCAGGGCTGTTCGCATGAAAATT\nAGGCCCCTTGTGACCCAATAG'], 'pfams': [{'pfam': [{'identifier': ['PF00147'], 'name': ['Fibrinogen_C']}, {'identifier': ['PF08702'], 'name': ['Fib_alpha']}, {'identifier': ['PF12160'], 'name': ['Fibrinogen_aC']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['cell cortex']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['extracellular vesicle']}, {'category': ['component'], 'description': ['fibrinogen complex']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['component'], 'description': ['rough endoplasmic reticulum']}, {'category': ['function'], 'description': ['structural molecule activity']}, {'category': ['process'], 'description': ['acute-phase response']}, {'category': ['process'], 'description': ['adaptive immune response']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, common pathway']}, {'category': ['process'], 'description': ['blood coagulation, fibrin clot formation']}, {'category': ['process'], 'description': ['cell-matrix adhesion']}, {'category': ['process'], 'description': ['cellular protein complex assembly']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['cellular response to granulocyte colony-stimulating factor']}, {'category': ['process'], 'description': ['cellular response to interleukin-6']}, {'category': ['process'], 'description': ['cellular response to organic cyclic compound']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['induction of bacterial agglutination']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['liver regeneration']}, {'category': ['process'], 'description': ['negative regulation of blood coagulation, common pathway']}, {'category': ['process'], 'description': ['negative regulation of endothelial cell apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of extrinsic apoptotic signaling pathway via death domain receptors']}, {'category': ['process'], 'description': ['plasminogen activation']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet aggregation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['positive regulation of exocytosis']}, {'category': ['process'], 'description': ['positive regulation of heterotypic cell-cell adhesion']}, {'category': ['process'], 'description': ['positive regulation of peptide hormone secretion']}, {'category': ['process'], 'description': ['positive regulation of protein secretion']}, {'category': ['process'], 'description': ['positive regulation of substrate adhesion-dependent cell spreading']}, {'category': ['process'], 'description': ['positive regulation of vasoconstriction']}, {'category': ['process'], 'description': ['protein complex assembly']}, {'category': ['process'], 'description': ['protein polymerization']}, {'category': ['process'], 'description': ['response to calcium ion']}, {'category': ['process'], 'description': ['response to cycloheximide']}, {'category': ['process'], 'description': ['response to estradiol']}, {'category': ['process'], 'description': ['response to genistein']}, {'category': ['process'], 'description': ['response to morphine']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}, {'id': ['BE0000717'], 'name': ['Urokinase plasminogen activator surface receptor'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A1849'], 'pubmed-id': ['15231724'], 'citation': ['Maupas-Schwalm F, Auge N, Robinet C, Cambus JP, Parsons SJ, Salvayre R, Negre-Salvayre A: The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue-type plasminogen activator. FASEB J. 2004 Sep;18(12):1398-400. Epub 2004 Jul 1.']}, {'ref-id': ['A1850'], 'pubmed-id': ['11447759'], 'citation': ['Bankl HC, Samorapoompichit P, Pikula B, Latinovic L, Bankl H, Lechner K, Valent P: Characterization of human prostate mast cells and their increase in periprostatic vein thrombosis. Am J Clin Pathol. 2001 Jul;116(1):97-106.']}, {'ref-id': ['A1852'], 'pubmed-id': ['12210068'], 'citation': ['Ferrier CM, Van Geloof WL, Straatman H, Van De Molengraft FJ, Van Muijen GN, Ruiter DJ: Spitz naevi may express components of the plasminogen activation system. J Pathol. 2002 Sep;198(1):92-9.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Urokinase plasminogen activator surface receptor'], 'general-function': ['Urokinase plasminogen activator receptor activity'], 'specific-function': ['Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form.'], 'gene-name': ['PLAUR'], 'locus': ['19q13'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': [None], 'signal-regions': ['1-22'], 'theoretical-pi': ['6.64'], 'molecular-weight': ['36977.62'], 'chromosome-location': ['19'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:9053']}, {'resource': ['GenAtlas'], 'identifier': ['PLAUR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X51675']}, {'resource': ['GenBank Protein Database'], 'identifier': ['37605']}, {'resource': ['UniProtKB'], 'identifier': ['Q03405']}, {'resource': ['UniProt Accession'], 'identifier': ['UPAR_HUMAN']}]}], 'synonyms': [{'synonym': ['MO3', 'Monocyte activation antigen Mo3', 'U-PAR', 'UPAR']}], 'amino-acid-sequence': ['>lcl|BSEQ0001430|Urokinase plasminogen activator surface receptor\nMGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL\nELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISC\nGSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNG\nFHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGP\nMNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDV\nQYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT'], 'gene-sequence': ['>lcl|BSEQ0016188|Urokinase plasminogen activator surface receptor (PLAUR)\nATGGGTCACCCGCCGCTGCTGCCGCTGCTGCTGCTGCTCCACACCTGCGTCCCAGCCTCT\nTGGGGCCTGCGGTGCATGCAGTGTAAGACCAACGGGGATTGCCGTGTGGAAGAGTGCGCC\nCTGGGACAGGACCTCTGCAGGACCACGATCGTGCGCTTGTGGGAAGAAGGAGAAGAGCTG\nGAGCTGGTGGAGAAAAGCTGTACCCACTCAGAGAAGACCAACAGGACCCTGAGCTATCGG\nACTGGCTTGAAGATCACCAGCCTTACCGAGGTTGTGTGTGGGTTAGACTTGTGCAACCAG\nGGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCGTTACCTCGAATGCATTTCCTGT\nGGCTCATCAGACATGAGCTGTGAGAGGGGCCGGCACCAGAGCCTGCAGTGCCGCAGCCCT\nGAAGAACAGTGCCTGGATGTGGTGACCCACTGGATCCAGGAAGGTGAAGAAGGGCGTCCA\nAAGGATGACCGCCACCTCCGTGGCTGTGGCTACCTTCCCGGCTGCCCGGGCTCCAATGGT\nTTCCACAACAACGACACCTTCCACTTCCTGAAATGCTGCAACACCACCAAATGCAACGAG\nGGCCCAATCCTGGAGCTTGAAAATCTGCCGCAGAATGGCCGCCAGTGTTACAGCTGCAAG\nGGGAACAGCACCCATGGATGCTCCTCTGAAGAGACTTTCCTCATTGACTGCCGAGGCCCC\nATGAATCAATGTCTGGTAGCCACCGGCACTCACGAACGCTCACTCTGGGGAAGCTGGTTG\nCCATGTAAAAGTACTACTGCCCTGAGACCACCATGCTGTGAGGAAGCCCAAGCTACTCAT\nGTATAA'], 'pfams': [{'pfam': [{'identifier': ['PF00021'], 'name': ['UPAR_LY6']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['anchored component of membrane']}, {'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['endoplasmic reticulum membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extrinsic component of membrane']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['invadopodium membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['enzyme binding']}, {'category': ['function'], 'description': ['protein domain specific binding']}, {'category': ['function'], 'description': ['receptor activity']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['urokinase plasminogen activator receptor activity']}, {'category': ['process'], 'description': ['attachment of GPI anchor to protein']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['C-terminal protein lipidation']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['chemotaxis']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['movement of cell or subcellular component']}, {'category': ['process'], 'description': ['negative regulation of apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway']}, {'category': ['process'], 'description': ['negative regulation of intrinsic apoptotic signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of DNA binding']}, {'category': ['process'], 'description': ['positive regulation of epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of release of cytochrome c from mitochondria']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['regulation of proteolysis']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['urokinase plasminogen activator signaling pathway']}]}]}]}, {'id': ['BE0000240'], 'name': ['Plasminogen activator inhibitor 1'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A11607'], 'pubmed-id': ['11163592'], 'citation': ['Lindberg P, Kinnby B, Lecander I, Lang NP, Matsson L: Increasing expression of tissue plasminogen activator and plasminogen activator inhibitor type 2 in dog gingival tissues with progressive inflammation. Arch Oral Biol. 2001 Jan;46(1):23-31.']}, {'ref-id': ['A11608'], 'pubmed-id': ['14564902'], 'citation': ['Hattori M, Azami Y: Searching for preventive measures of cardiovascular events in aged Japanese taxi drivers--the daily rhythm of cardiovascular risk factors during a night duty day. J Hum Ergol (Tokyo). 2001 Dec;30(1-2):321-6.']}, {'ref-id': ['A6691'], 'pubmed-id': ['17963464'], 'citation': ['Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Plasminogen activator inhibitor 1'], 'general-function': ['Serine-type endopeptidase inhibitor activity'], 'specific-function': [""Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis.""], 'gene-name': ['SERPINE1'], 'locus': ['7q21.3-q22'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-23'], 'theoretical-pi': ['7.22'], 'molecular-weight': ['45059.695'], 'chromosome-location': ['7'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:8583']}, {'resource': ['GenAtlas'], 'identifier': ['SERPINE1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X04429']}, {'resource': ['GenBank Protein Database'], 'identifier': ['35272']}, {'resource': ['UniProtKB'], 'identifier': ['P05121']}, {'resource': ['UniProt Accession'], 'identifier': ['PAI1_HUMAN']}]}], 'synonyms': [{'synonym': ['Endothelial plasminogen activator inhibitor', 'PAI', 'PAI1', 'PLANH1', 'Serpin E1']}], 'amino-acid-sequence': ['>lcl|BSEQ0000479|Plasminogen activator inhibitor 1\nMQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY\nGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI\nFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV\nDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD\nGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK\nFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS\nSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP'], 'gene-sequence': ['>lcl|BSEQ0010214|Plasminogen activator inhibitor 1 (SERPINE1)\nATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA\nGGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG\nAGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT\nGGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG\nATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT\nCTGTACAAGGAGCTCATGGGGCCATGGAACAAGGATGAGATCAGCACCACAGACGCGATC\nTTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC\nCGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT\nGACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG\nGACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT\nCCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC\nTCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT\nGGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT\nGCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG\nCTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG\nTTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC\nATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC\nGCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA\nTCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC\nTTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG\nGAACCCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00079'], 'name': ['Serpin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular matrix']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase inhibitor activity']}, {'category': ['process'], 'description': ['angiogenesis']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cellular response to lipopolysaccharide']}, {'category': ['process'], 'description': ['chronological cell aging']}, {'category': ['process'], 'description': ['circadian rhythm']}, {'category': ['process'], 'description': ['defense response to Gram-negative bacterium']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['gene expression']}, {'category': ['process'], 'description': ['negative regulation of blood coagulation']}, {'category': ['process'], 'description': ['negative regulation of cell adhesion mediated by integrin']}, {'category': ['process'], 'description': ['negative regulation of cell migration']}, {'category': ['process'], 'description': ['negative regulation of endopeptidase activity']}, {'category': ['process'], 'description': ['negative regulation of endothelial cell apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of extrinsic apoptotic signaling pathway via death domain receptors']}, {'category': ['process'], 'description': ['negative regulation of fibrinolysis']}, {'category': ['process'], 'description': ['negative regulation of plasminogen activation']}, {'category': ['process'], 'description': ['negative regulation of smooth muscle cell migration']}, {'category': ['process'], 'description': ['negative regulation of smooth muscle cell-matrix adhesion']}, {'category': ['process'], 'description': ['negative regulation of vascular wound healing']}, {'category': ['process'], 'description': ['negative regulation of wound healing']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of angiogenesis']}, {'category': ['process'], 'description': ['positive regulation of blood coagulation']}, {'category': ['process'], 'description': ['positive regulation of inflammatory response']}, {'category': ['process'], 'description': ['positive regulation of interleukin-8 production']}, {'category': ['process'], 'description': ['positive regulation of leukotriene production involved in inflammatory response']}, {'category': ['process'], 'description': ['positive regulation of monocyte chemotaxis']}, {'category': ['process'], 'description': ['positive regulation of receptor-mediated endocytosis']}, {'category': ['process'], 'description': ['positive regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['regulation of receptor activity']}, {'category': ['process'], 'description': ['transcription initiation from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['transcription, DNA-templated']}, {'category': ['process'], 'description': ['transforming growth factor beta receptor signaling pathway']}]}]}]}, {'id': ['BE0000969'], 'name': ['Plasminogen activator inhibitor 2'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13126'], 'pubmed-id': ['17141398'], 'citation': ['Verkleij-Hagoort AC, Ursem NT, Hop WC, Geurts-Moespot A, Steegers EA, Sweep FC, Steegers-Theunissen RP: Complex congenital malformations and the impact of the plasminogen activator system and beta-hCG in amniotic fluid. Eur J Obstet Gynecol Reprod Biol. 2007 Nov;135(1):47-52. Epub 2006 Dec 1.']}, {'ref-id': ['A13127'], 'pubmed-id': ['7958159'], 'citation': ['Bremer HA, Brommer EJ, Wallenburg HC: Effects of labor and delivery on fibrinolysis. Eur J Obstet Gynecol Reprod Biol. 1994 Jun 30;55(3):163-8.']}, {'ref-id': ['A13128'], 'pubmed-id': ['3091604'], 'citation': ['Stump DC, Thienpont M, Collen D: Purification and characterization of a novel inhibitor of urokinase from human urine. Quantitation and preliminary characterization in plasma. J Biol Chem. 1986 Sep 25;261(27):12759-66.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Plasminogen activator inhibitor 2'], 'general-function': ['Serine-type endopeptidase inhibitor activity'], 'specific-function': ['Inhibits urokinase-type plasminogen activator. The monocyte derived PAI-2 is distinct from the endothelial cell-derived PAI-1.'], 'gene-name': ['SERPINB2'], 'locus': ['18q21.3'], 'cellular-location': ['Cytoplasm'], 'transmembrane-regions': [None], 'signal-regions': ['1-'], 'theoretical-pi': ['5.34'], 'molecular-weight': ['46595.84'], 'chromosome-location': ['18'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:8584']}, {'resource': ['GenAtlas'], 'identifier': ['SERPINB2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['J02685']}, {'resource': ['GenBank Protein Database'], 'identifier': ['189545']}, {'resource': ['UniProtKB'], 'identifier': ['P05120']}, {'resource': ['UniProt Accession'], 'identifier': ['PAI2_HUMAN']}]}], 'synonyms': [{'synonym': ['Monocyte Arg-serpin', 'PAI-2', 'PAI2', 'Placental plasminogen activator inhibitor', 'PLANH2', 'Serpin B2', 'Urokinase inhibitor']}], 'amino-acid-sequence': ['>lcl|BSEQ0016268|Plasminogen activator inhibitor 2\nMEDLCVANTLFALNLFKHLAKASPTQNLFLSPWSISSTMAMVYMGSRGSTEDQMAKVLQF\nNEVGANAVTPMTPENFTSCGFMQQIQKGSYPDAILQAQAADKIHSSFRSLSSAINASTGN\nYLLESVNKLFGEKSASFREEYIRLCQKYYSSEPQAVDFLECAEEARKKINSWVKTQTKGK\nIPNLLPEGSVDGDTRMVLVNAVYFKGKWKTPFEKKLNGLYPFRVNSAQRTPVQMMYLREK\nLNIGYIEDLKAQILELPYAGDVSMFLLLPDEIADVSTGLELLESEITYDKLNKWTSKDKM\nAEDEVEVYIPQFKLEEHYELRSILRSMGMEDAFNKGRANFSGMSERNDLFLSEVFHQAMV\nDVNEEGTEAAAGTGGVMTGRTGHGGPQFVADHPFLFLIMHKITNCILFFGRFSSP'], 'gene-sequence': ['>lcl|BSEQ0016269|Plasminogen activator inhibitor 2 (SERPINB2)\nATGGAGGATCTTTGTGTGGCAAACACACTCTTTGCCCTCAATTTATTCAAGCATCTGGCA\nAAAGCAAGCCCCACCCAGAACCTCTTCCTCTCCCCATGGAGCATCTCGTCCACCATGGCC\nATGGTCTACATGGGCTCCAGGGGCAGCACCGAAGACCAGATGGCCAAGGTGCTTCAGTTT\nAATGAAGTGGGAGCCAATGCAGTTACCCCCATGACTCCAGAGAACTTTACCAGCTGTGGG\nTTCATGCAGCAGATCCAGAAGGGTAGTTATCCTGATGCGATTTTGCAGGCACAAGCTGCA\nGATAAAATCCATTCATCCTTCCGCTCTCTCAGCTCTGCAATCAATGCATCCACAGGGAAT\nTATTTACTGGAAAGTGTCAATAAGCTGTTTGGTGAGAAGTCTGCGAGCTTCCGGGAAGAA\nTATATTCGACTCTGTCAGAAATATTACTCCTCAGAACCCCAGGCAGTAGACTTCCTAGAA\nTGTGCAGAAGAAGCTAGAAAAAAGATTAATTCCTGGGTCAAGACTCAAACCAAAGGCAAA\nATCCCAAACTTGTTACCTGAAGGTTCTGTAGATGGGGATACCAGGATGGTCCTGGTGAAT\nGCTGTCTACTTCAAAGGAAAGTGGAAAACTCCATTTGAGAAGAAACTAAATGGGCTTTAT\nCCTTTCCGTGTAAACTCGGCTCAGCGCACACCTGTACAGATGATGTACTTGCGTGAAAAG\nCTAAACATTGGATACATAGAAGACCTAAAGGCTCAGATTCTAGAACTCCCATATGCTGGA\nGATGTTAGCATGTTCTTGTTGCTTCCAGATGAAATTGCCGATGTGTCCACTGGCTTGGAG\nCTGCTGGAAAGTGAAATAACCTATGACAAACTCAACAAGTGGACCAGCAAAGACAAAATG\nGCTGAAGATGAAGTTGAGGTATACATACCCCAGTTCAAATTAGAAGAGCATTATGAACTC\nAGATCCATTCTGAGAAGCATGGGCATGGAGGACGCCTTCAACAAGGGACGGGCCAATTTC\nTCAGGGATGTCGGAGAGGAATGACCTGTTTCTTTCTGAAGTGTTCCACCAAGCCATGGTG\nGATGTGAATGAGGAGGGCACTGAAGCAGCCGCTGGCACAGGAGGTGTTATGACAGGGAGA\nACTGGACATGGAGGCCCACAGTTTGTGGCAGATCATCCTTTTCTTTTTCTTATTATGCAT\nAAGATAACCAACTGCATTTTATTTTTCGGCAGATTTTCCTCACCCTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00079'], 'name': ['Serpin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['serine-type endopeptidase inhibitor activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['negative regulation of apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of endopeptidase activity']}]}]}]}, {'id': ['BE0002104'], 'name': ['Tetranectin'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13129'], 'pubmed-id': ['12694198'], 'citation': ['Westergaard UB, Andersen MH, Heegaard CW, Fedosov SN, Petersen TE: Tetranectin binds hepatocyte growth factor and tissue-type plasminogen activator. Eur J Biochem. 2003 Apr;270(8):1850-4.']}, {'ref-id': ['A13130'], 'pubmed-id': ['9034981'], 'citation': ['Kamper EF, Kopeikina LT, Koutsoukos V, Stavridis J: Plasma tetranectin levels and disease activity in patients with rheumatoid arthritis. J Rheumatol. 1997 Feb;24(2):262-8.']}, {'ref-id': ['A13131'], 'pubmed-id': ['17853709'], 'citation': ['Vuckovic B, Deric M: [Lipoprotein(a): a link between thrombogenesis and atherogenesis]. Med Pregl. 2007 Jan-Feb;60(1-2):37-41.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Tetranectin'], 'general-function': ['Kringle domain binding'], 'specific-function': ['Tetranectin binds to plasminogen and to isolated kringle 4. May be involved in the packaging of molecules destined for exocytosis.'], 'gene-name': ['CLEC3B'], 'locus': ['3p22-p21.3'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-21'], 'theoretical-pi': ['5.36'], 'molecular-weight': ['22536.665'], 'chromosome-location': [None], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:11891']}, {'resource': ['GenAtlas'], 'identifier': ['CLEC3B']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X64559']}, {'resource': ['GenBank Protein Database'], 'identifier': ['37409']}, {'resource': ['UniProtKB'], 'identifier': ['P05452']}, {'resource': ['UniProt Accession'], 'identifier': ['TETN_HUMAN']}]}], 'synonyms': [{'synonym': ['C-type lectin domain family 3 member B', 'Plasminogen kringle 4-binding protein', 'TN', 'TNA']}], 'amino-acid-sequence': ['>lcl|BSEQ0011525|Tetranectin\nMELWGAYLLLCLFSLLTQVTTEPPTQKPKKIVNAKKDVVNTKMFEELKSRLDTLAQEVAL\nLKEQQALQTVCLKGTKVHMKCFLAFTQTKTFHEASEDCISRGGTLGTPQTGSENDALYEY\nLRQSVGNEAEIWLGLNDMAAEGTWVDMTGARIAYKNWETEITAQPDGGKTENCAVLSGAA\nNGKWFDKRCRDQLPYICQFGIV'], 'gene-sequence': ['>lcl|BSEQ0004125|609 bp\nATGGAGCTCTGGGGGGCCTACCTCCTCCTCTGCCTCTTCTCCCTCCTGACCCAGGTCACC\nACCGAGCCACCAACCCAGAAGCCCAAGAAGATTGTAAATGCCAAGAAAGATGTTGTGAAC\nACAAAGATGTTTGAGGAGCTCAAGAGCCGTCTGGACACCCTGGCCCAGGAGGTGGCCCTG\nCTGAAGGAGCAGCAGGCCCTGCAGACGGTCTGCCTGAAGGGGACCAAGGTGCACATGAAA\nTGCTTTCTGGCCTTCACCCAGACGAAGACCTTCCACGAGGCCAGCGAGGACTGCATCTCG\nCGCGGGGGCACCCTGAGCACCCCTCAGACTGGCTCGGAGAACGACGCCCTGTATGAGTAC\nCTGCGCCAGAGCGTGGGCAACGAGGCCGAGATCTGGCTGGGCCTCAACGACATGGCGGCC\nGAGGGCACCTGGGTGGACATGACCGGCGCCCGCATCGCCTACAAGAACTGGGAGACTGAG\nATCACCGCGCAACCCGATGGCGGCAAGACCGAGAACTGCGCGGTCCTGTCAGGCGCGGCC\nAACGGCAAGTGGTTCGACAAGCGCTGCCGCGATCAGCTGCCCTACATCTGCCAGTTCGGG\nATCGTGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00059'], 'name': ['Lectin_C']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['granular component']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['carbohydrate binding']}, {'category': ['function'], 'description': ['heparin binding']}, {'category': ['function'], 'description': ['kringle domain binding']}, {'category': ['process'], 'description': ['bone mineralization']}, {'category': ['process'], 'description': ['cellular response to organic substance']}, {'category': ['process'], 'description': ['cellular response to transforming growth factor beta stimulus']}, {'category': ['process'], 'description': ['ossification']}, {'category': ['process'], 'description': ['positive regulation of plasminogen activation']}, {'category': ['process'], 'description': ['skeletal system development']}]}]}]}, {'id': ['BE0002105'], 'name': ['Keratin, type II cytoskeletal 8'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13132'], 'pubmed-id': ['9988531'], 'citation': ['Kralovich KR, Li L, Hembrough TA, Webb DJ, Karns LR, Gonias SL: Characterization of the binding sites for plasminogen and tissue-type plasminogen activator in cytokeratin 8 and cytokeratin 18. J Protein Chem. 1998 Nov;17(8):845-54.']}, {'ref-id': ['A13133'], 'pubmed-id': ['8760360'], 'citation': ['Hembrough TA, Kralovich KR, Li L, Gonias SL: Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation. Biochem J. 1996 Aug 1;317 ( Pt 3):763-9.']}, {'ref-id': ['A13134'], 'pubmed-id': ['8810346'], 'citation': ['Hembrough TA, Li L, Gonias SL: Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator. J Biol Chem. 1996 Oct 11;271(41):25684-91.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Keratin, type II cytoskeletal 8'], 'general-function': ['Structural molecule activity'], 'specific-function': ['Together with KRT19, helps to link the contractile apparatus to dystrophin at the costameres of striated muscle.'], 'gene-name': ['KRT8'], 'locus': ['12q13'], 'cellular-location': ['Cytoplasm'], 'transmembrane-regions': [None], 'signal-regions': [None], 'theoretical-pi': ['5.26'], 'molecular-weight': ['53703.76'], 'chromosome-location': [None], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6446']}, {'resource': ['GenAtlas'], 'identifier': ['KRT8']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M34482']}, {'resource': ['GenBank Protein Database'], 'identifier': ['181573']}, {'resource': ['UniProtKB'], 'identifier': ['P05787']}, {'resource': ['UniProt Accession'], 'identifier': ['K2C8_HUMAN']}]}], 'synonyms': [{'synonym': ['CK-8', 'CYK8', 'Cytokeratin-8', 'K8', 'Keratin-8', 'Type-II keratin Kb8']}], 'amino-acid-sequence': ['>lcl|BSEQ0004128|Keratin, type II cytoskeletal 8\nMSIRVTQKSYKVSTSGPRAFSSRSYTSGPGSRISSSSFSRVGSSNFRGGLGGGYGGASGM\nGGITAVTVNQSLLSPLVLEVDPNIQAVRTQEKEQIKTLNNKFASFIDKVRFLEQQNKMLE\nTKWSLLQQQKTARSNMDNMFESYINNLRRQLETLGQEKLKLEAELGNMQGLVEDFKNKYE\nDEINKRTEMENEFVLIKKDVDEAYMNKVELESRLEGLTDEINFLRQLYEEEIRELQSQIS\nDTSVVLSMDNSRSLDMDSIIAEVKAQYEDIANRSRAEAESMYQIKYEELQSLAGKHGDDL\nRRTKTEISEMNRNISRLQAEIEGLKGQRASLEAAIADAEQRGELAIKDANAKLSELEAAL\nQRAKQDMARQLREYQELMNVKLALDIEIATYRKLLEGEESRLESGMQNMSIHTKTTSGYA\nGGLSSAYGGLTSPGLSYSLGSSFGSGAGSSSFSRTSSSRAVVVKKIETRDGKLVSESSDV\nLPK'], 'gene-sequence': ['>lcl|BSEQ0004127|1449 bp\nATGTCCATCAGGGTGACCCAGAAGTCCTACAAGGTGTCCACCTCTGGCCCCCGGGCCTTC\nAGCAGCCGCTCCTACACGAGTGGGCCCGGTTCCCGCATCAGCTCCTCGAGCTTCTCCCGA\nGTGGGCAGCAGCAACTTTCGCGGTGGCCTGGGCGGCGGCTATGGTGGGGCCAGCGGCATG\nGGAGGCATCACCGCAGTTACGGTCAACCAGAGCCTGCTGAGCCCCCTTGTCCTGGAGGTG\nGACCCCAACATCCAGGCCGTGCGCACCCAGGAGAAGGAGCAGATCAAGACCCTCAACAAC\nAAGTTTGCCTCCTTCATAGACAAGGTACGGTTCCTGGAGCAGCAGAACAAGATGCTGGAG\nACCAAGTGGAGCCTCCTGCAGCAGCAGAAGACGGCTCGAAGCAACATGGACAACATGTTC\nGAGAGCTACATCAACAACCTTAGGCGGCAGCTGGAGACTCTGGGCCAGGAGAAGCTGAAG\nCTGGAGGCGGAGCTTGGCAACATGCAGGGGCTGGTGGAGGACTTCAAGAACAAGTATGAG\nGATGAGATCAATAAGCGTACAGAGATGGAGAACGAATTTGTCCTCATCAAGAAGGATGTG\nGATGAAGCTTACATGAACAAGGTAGAGCTGGAGTCTCGCCTGGAAGGGCTGACCGACGAG\nATCAACTTCCTCAGGCAGCTATATGAAGAGGAGATCCGGGAGCTGCAGTCCCAGATCTCG\nGACACATCTGTGGTGCTGTCCATGGACAACAGCCGCTCCCTGGACATGGACAGCATCATT\nGCTGAGGTCAAGGCACAGTACGAGGATATTGCCAACCGCAGCCGGGCTGAGGCTGAGAGC\nATGTACCAGATCAAGTATGAGGAGCTGCAGAGCCTGGCTGGGAAGCACGGGGATGACCTG\nCGGCGCACAAAGACTGAGATCTCTGAGATGAACCGGAACATCAGCCGGCTCCAGGCTGAG\nATTGAGGGCCTCAAAGGCCAGAGGGCTTCCCTGGAGGCCGCCATTGCAGATGCCGAGCAG\nCGTGGAGAGCTGGCCATTAAGGATGCCAACGCCAAGTTGTCCGAGCTGGAGGCCGCCCTG\nCAGCGGGCCAAGCAGGACATGGCGCGGCAGCTGCGTGAGTACCAGGAGCTGATGAACGTC\nAAGCTGGCCCTGGACATCGAGATCGCCACCTACAGGAAGCTGCTGGAGGGCGAGGAGAGC\nCGGCTGGAGTCTGGGATGCAGAACATGAGTATTCATACGAAGACCACCGGCGGCTATGCA\nGGTGGTCTGAGCTCGGCCTATGGGGGCTCACAAGCCGGCCTCAGCTACAGCCTGGGCTCC\nAGCTTTGGCTCTGGCGCGGGCTCCAGCTCCTTCAGCCGCACCAGCTCCTCCAGGGCCGTG\nGTTGTGAAGAAGATCGAGACACGTGATGGGAAGCTGGTGTCTGAGTCCTCTGACGTCCTG\nCCCAAGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00038'], 'name': ['Filament']}, {'identifier': ['PF16208'], 'name': ['Keratin_2_head']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell-cell junction']}, {'category': ['component'], 'description': ['costamere']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['dystrophin-associated glycoprotein complex']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['intermediate filament']}, {'category': ['component'], 'description': ['keratin filament']}, {'category': ['component'], 'description': ['nuclear matrix']}, {'category': ['component'], 'description': ['nucleoplasm']}, {'category': ['component'], 'description': ['nucleus']}, {'category': ['component'], 'description': ['sarcolemma']}, {'category': ['component'], 'description': ['Z disc']}, {'category': ['function'], 'description': ['scaffold protein binding']}, {'category': ['function'], 'description': ['structural molecule activity']}, {'category': ['process'], 'description': ['cell differentiation involved in embryonic placenta development']}, {'category': ['process'], 'description': ['extrinsic apoptotic signaling pathway']}, {'category': ['process'], 'description': ['hepatocyte apoptotic process']}, {'category': ['process'], 'description': ['response to hydrostatic pressure']}, {'category': ['process'], 'description': ['response to other organism']}, {'category': ['process'], 'description': ['sarcomere organization']}, {'category': ['process'], 'description': ['tumor necrosis factor-mediated signaling pathway']}, {'category': ['process'], 'description': ['viral process']}]}]}]}, {'id': ['BE0001170'], 'name': ['Annexin A2'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13135'], 'pubmed-id': ['15194650'], 'citation': ['Diaz VM, Hurtado M, Thomson TM, Reventos J, Paciucci R: Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut. 2004 Jul;53(7):993-1000.']}, {'ref-id': ['A13136'], 'pubmed-id': ['10578524'], 'citation': ['Kang HM, Choi KS, Kassam G, Fitzpatrick SL, Kwon M, Waisman DM: Role of annexin II tetramer in plasminogen activation. Trends Cardiovasc Med. 1999 Apr-May;9(3-4):92-102.']}, {'ref-id': ['A13137'], 'pubmed-id': ['12730231'], 'citation': ['MacLeod TJ, Kwon M, Filipenko NR, Waisman DM: Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits: characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin. J Biol Chem. 2003 Jul 11;278(28):25577-84. Epub 2003 Apr 30.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Annexin A2'], 'general-function': ['S100 protein binding'], 'specific-function': ['Calcium-regulated membrane-binding protein whose affinity for calcium is greatly enhanced by anionic phospholipids. It binds two calcium ions with high affinity. May be involved in heat-stress response. Inhibits PCSK9-enhanced LDLR degradation, probably reduces PCSK9 protein levels via a translational mechanism but also competes with LDLR for binding with PCSK9 (PubMed:18799458, PubMed:24808179, PubMed:22848640).'], 'gene-name': ['ANXA2'], 'locus': ['15q21-q22'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': [None], 'theoretical-pi': ['7.91'], 'molecular-weight': ['38603.63'], 'chromosome-location': ['15'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:537']}, {'resource': ['GenAtlas'], 'identifier': ['ANXA2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['D00017']}, {'resource': ['GenBank Protein Database'], 'identifier': ['219910']}, {'resource': ['UniProtKB'], 'identifier': ['P07355']}, {'resource': ['UniProt Accession'], 'identifier': ['ANXA2_HUMAN']}]}], 'synonyms': [{'synonym': ['Annexin II', 'Annexin-2', 'ANX2', 'ANX2L4', 'CAL1H', 'Calpactin I heavy chain', 'Calpactin-1 heavy chain', 'Chromobindin-8', 'Lipocortin II', 'LPC2D', 'p36', 'PAP-IV', 'Placental anticoagulant protein IV', 'Protein I']}], 'amino-acid-sequence': ['>lcl|BSEQ0002327|Annexin A2\nMSTVHEILCKLSLEGDHSTPPSAYGSVKAYTNFDAERDALNIETAIKTKGVDEVTIVNIL\nTNRSNAQRQDIAFAYQRRTKKELASALKSALSGHLETVILGLLKTPAQYDASELKASMKG\nLGTDEDSLIEIICSRTNQELQEINRVYKEMYKTDLEKDIISDTSGDFRKLMVALAKGRRA\nEDGSVIDYELIDQDARDLYDAGVKRKGTDVPKWISIMTERSVPHLQKVFDRYKSYSPYDM\nLESIRKEVKGDLENAFLNLVQCIQNKPLYFADRLYDSMKGKGTRDKVLIRIMVSRSEVDM\nLKIRSEFKRKYGKSLYYYIQQDTKGDYQKALLYLCGGDD'], 'gene-sequence': ['>lcl|BSEQ0010817|Annexin A2 (ANXA2)\nATGTCTACTGTTCACGAAATCCTGTGCAAGCTCAGCTTGGAGGGTGATCACTCTACACCC\nCCAAGTGCATATGGGTCTGTCAAAGCCTATACTAACTTTGATGCTGAGCGGGATGCTTTG\nAACATTGAAACAGCCATCAAGACCAAAGGTGTGGATGAGGTCACCATTGTCAACATTTTG\nACCAACCGCAGCAATGCACAGAGACAGGATATTGCCTTCGCCTACCAGAGAAGGACCAAA\nAAGGAACTTGCATCAGCACTGAAGTCAGCCTTATCTGGCCACCTGGAGACGGTGATTTTG\nGGCCTATTGAAGACACCTGCTCAGTATGACGCTTCTGAGCTAAAAGCTTCCATGAAGGGG\nCTGGGAACCGACGAGGACTCTCTCATTGAGATCATCTGCTCCAGAACCAACCAGGAGCTG\nCAGGAAATTAACAGAGTCTACAAGGAAATGTACAAGACTGATCTGGAGAAGGACATTATT\nTCGGACACATCTGGTGACTTCCGCAAGCTGATGGTTGCCCTGGCAAAGGGTAGAAGAGCA\nGAGGATGGCTCTGTCATTGATTATGAACTGATTGACCAAGATGCTCGGGATCTCTATGAC\nGCTGGAGTGAAGAGGAAAGGAACTGATGTTCCCAAGTGGATCAGCATCATGACCGAGCGG\nAGCGTGCCCCACCTCCAGAAAGTATTTGATAGGTACAAGAGTTACAGCCCTTATGACATG\nTTGGAAAGCATCAGGAAAGAGGTTAAAGGAGACCTGGAAAATGCTTTCCTGAACCTGGTT\nCAGTGCATTCAGAACAAGCCCCTGTATTTTGCTGATCGGCTGTATGACTCCATGAAGGGC\nAAGGGGACGCGAGATAAGGTCCTGATCAGAATCATGGTCTCCCGCAGTGAAGTGGACATG\nTTGAAAATTAGGTCTGAATTCAAGAGAAAGTACGGCAAGTCCCTGTACTATTATATCCAG\nCAAGACACTAAGGGCGACTACCAGAAAGCGCTGCTGTACCTGTGTGGTGGAGATGACTGA\n'], 'pfams': [{'pfam': [{'identifier': ['PF00191'], 'name': ['Annexin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['basement membrane']}, {'category': ['component'], 'description': ['basolateral plasma membrane']}, {'category': ['component'], 'description': ['cell cortex']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['early endosome']}, {'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['extrinsic component of plasma membrane']}, {'category': ['component'], 'description': ['late endosome membrane']}, {'category': ['component'], 'description': ['lipid particle']}, {'category': ['component'], 'description': ['lysosomal membrane']}, {'category': ['component'], 'description': ['macropinosome']}, {'category': ['component'], 'description': ['melanosome']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['midbody']}, {'category': ['component'], 'description': ['myelin sheath adaxonal region']}, {'category': ['component'], 'description': ['nucleus']}, {'category': ['component'], 'description': ['PCSK9-AnxA2 complex']}, {'category': ['component'], 'description': ['perinuclear region of cytoplasm']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['ruffle']}, {'category': ['component'], 'description': ['sarcolemma']}, {'category': ['component'], 'description': ['Schmidt-Lanterman incisure']}, {'category': ['component'], 'description': ['vesicle']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['calcium-dependent phospholipid binding']}, {'category': ['function'], 'description': ['calcium-dependent protein binding']}, {'category': ['function'], 'description': ['phosphatidylinositol-4,5-bisphosphate binding']}, {'category': ['function'], 'description': ['phospholipase A2 inhibitor activity']}, {'category': ['function'], 'description': ['poly(A) RNA binding']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['function'], 'description': ['S100 protein binding']}, {'category': ['process'], 'description': ['angiogenesis']}, {'category': ['process'], 'description': ['body fluid secretion']}, {'category': ['process'], 'description': ['collagen fibril organization']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['membrane budding']}, {'category': ['process'], 'description': ['membrane raft assembly']}, {'category': ['process'], 'description': ['negative regulation of catalytic activity']}, {'category': ['process'], 'description': ['negative regulation of low-density lipoprotein particle receptor catabolic process']}, {'category': ['process'], 'description': ['negative regulation of receptor binding']}, {'category': ['process'], 'description': ['negative regulation of receptor internalization']}, {'category': ['process'], 'description': ['osteoclast development']}, {'category': ['process'], 'description': ['positive regulation of binding']}, {'category': ['process'], 'description': ['positive regulation of fibroblast proliferation']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of receptor activity']}, {'category': ['process'], 'description': ['positive regulation of vesicle fusion']}, {'category': ['process'], 'description': ['protein heterotetramerization']}, {'category': ['process'], 'description': ['protein targeting to plasma membrane']}]}]}]}, {'id': ['BE0002109'], 'name': ['Calreticulin'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13138'], 'pubmed-id': ['9359841'], 'citation': ['Allen S, Bulleid NJ: Calnexin and calreticulin bind to enzymically active tissue-type plasminogen activator during biosynthesis and are not required for folding to the native conformation. Biochem J. 1997 Nov 15;328 ( Pt 1):113-9.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Calreticulin'], 'general-function': ['Zinc ion binding'], 'specific-function': ['Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. This lectin interacts transiently with almost all of the monoglucosylated glycoproteins that are synthesized in the ER. Interacts with the DNA-binding domain of NR3C1 and mediates its nuclear export. Involved in maternal gene expression regulation. May participate in oocyte maturation via the regulation of calcium homeostasis (By similarity).'], 'gene-name': ['CALR'], 'locus': ['19p13.3-p13.2'], 'cellular-location': ['Endoplasmic reticulum lumen'], 'transmembrane-regions': [None], 'signal-regions': ['1-17'], 'theoretical-pi': ['4.04'], 'molecular-weight': ['48141.2'], 'chromosome-location': ['19'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1455']}, {'resource': ['GenAtlas'], 'identifier': ['CALR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M32294']}, {'resource': ['GenBank Protein Database'], 'identifier': ['337487']}, {'resource': ['UniProtKB'], 'identifier': ['P27797']}, {'resource': ['UniProt Accession'], 'identifier': ['CALR_HUMAN']}]}], 'synonyms': [{'synonym': ['Calregulin', 'CRP55', 'CRTC', 'Endoplasmic reticulum resident protein 60', 'ERp60', 'grp60', 'HACBP']}], 'amino-acid-sequence': ['>lcl|BSEQ0011528|Calreticulin\nMLLSVPLLLGLLGLAVAEPAVYFKEQFLDGDGWTSRWIESKHKSDFGKFVLSSGKFYGDE\nEKDKGLQTSQDARFYALSASFEPFSNKGQTLVVQFTVKHEQNIDCGGGYVKLFPNSLDQT\nDMHGDSEYNIMFGPDICGPGTKKVHVIFNYKGKNVLINKDIRCKDDEFTHLYTLIVRPDN\nTYEVKIDNSQVESGSLEDDWDFLPPKKIKDPDASKPEDWDERAKIDDPTDSKPEDWDKPE\nHIPDPDAKKPEDWDEEMDGEWEPPVIQNPEYKGEWKPRQIDNPDYKGTWIHPEIDNPEYS\nPDPSIYAYDNFGVLGLDLWQVKSGTIFDNFLITNDEAYAEEFGNETWGVTKAAEKQMKDK\nQDEEQRLKEEEEDKKRKEEEEAEDKEDDEDKDEDEEDEEDKEEDEEEDVPGQAKDEL'], 'gene-sequence': ['>lcl|BSEQ0011529|Calreticulin (CALR)\nATGCTGCTATCCGTGCCGCTGCTGCTCGGCCTCCTCGGCCTGGCCGTCGCCGAGCCTGCC\nGTCTACTTCAAGGAGCAGTTTCTGGACGGAGACGGGTGGACTTCCCGCTGGATCGAATCC\nAAACACAAGTCAGATTTTGGCAAATTCGTTCTCAGTTCCGGCAAGTTCTACGGTGACGAG\nGAGAAAGATAAAGGTTTGCAGACAAGCCAGGATGCACGCTTTTATGCTCTGTCGGCCAGT\nTTCGAGCCTTTCAGCAACAAAGGCCAGACGCTGGTGGTGCAGTTCACGGTGAAACATGAG\nCAGAACATCGACTGTGGGGGCGGCTATGTGAAGCTGTTTCCTAATAGTTTGGACCAGACA\nGACATGCACGGAGACTCAGAATACAACATCATGTTTGGTCCCGACATCTGTGGCCCTGGC\nACCAAGAAGGTTCATGTCATCTTCAACTACAAGGGCAAGAACGTGCTGATCAACAAGGAC\nATCCGTTGCAAGGATGATGAGTTTACACACCTGTACACACTGATTGTGCGGCCAGACAAC\nACCTATGAGGTGAAGATTGACAACAGCCAGGTGGAGTCCGGCTCCTTGGAAGACGATTGG\nGACTTCCTGCCACCCAAGAAGATAAAGGATCCTGATGCTTCAAAACCGGAAGACTGGGAT\nGAGCGGGCCAAGATCGATGATCCCACAGACTCCAAGCCTGAGGACTGGGACAAGCCCGAG\nCATATCCCTGACCCTGATGCTAAGAAGCCCGAGGACTGGGATGAAGAGATGGACGGAGAG\nTGGGAACCCCCAGTGATTCAGAACCCTGAGTACAAGGGTGAGTGGAAGCCCCGGCAGATC\nGACAACCCAGATTACAAGGGCACTTGGATCCACCCAGAAATTGACAACCCCGAGTATTCT\nCCCGATCCCAGTATCTATGCCTATGATAACTTTGGCGTGCTGGGCCTGGACCTCTGGCAG\nGTCAAGTCTGGCACCATCTTTGACAACTTCCTCATCACCAACGATGAGGCATACGCTGAG\nGAGTTTGGCAACGAGACGTGGGGCGTAACAAAGGCAGCAGAGAAACAAATGAAGGACAAA\nCAGGACGAGGAGCAGAGGCTTAAGGAGGAGGAAGAAGACAAGAAACGCAAAGAGGAGGAG\nGAGGCAGAGGACAAGGAGGATGATGAGGACAAAGATGAGGATGAGGAGGATGAGGAGGAC\nAAGGAGGAAGATGAGGAGGAAGATGTCCCCGGCCAGGCCAAGGACGAGCTGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00262'], 'name': ['Calreticulin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['acrosomal vesicle']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['endocytic vesicle lumen']}, {'category': ['component'], 'description': ['endoplasmic reticulum']}, {'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['Golgi apparatus']}, {'category': ['component'], 'description': ['integral component of lumenal side of endoplasmic reticulum membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['MHC class I peptide loading complex']}, {'category': ['component'], 'description': ['nucleus']}, {'category': ['component'], 'description': ['perinuclear region of cytoplasm']}, {'category': ['component'], 'description': ['polysome']}, {'category': ['component'], 'description': ['proteinaceous extracellular matrix']}, {'category': ['component'], 'description': ['sarcoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['smooth endoplasmic reticulum']}, {'category': ['function'], 'description': ['androgen receptor binding']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['carbohydrate binding']}, {'category': ['function'], 'description': ['chaperone binding']}, {'category': ['function'], 'description': ['complement component C1q binding']}, {'category': ['function'], 'description': ['DNA binding']}, {'category': ['function'], 'description': ['glycoprotein binding']}, {'category': ['function'], 'description': ['hormone binding']}, {'category': ['function'], 'description': ['integrin binding']}, {'category': ['function'], 'description': ['iron ion binding']}, {'category': ['function'], 'description': ['mRNA binding']}, {'category': ['function'], 'description': ['peptide binding']}, {'category': ['function'], 'description': ['poly(A) RNA binding']}, {'category': ['function'], 'description': ['protein binding involved in protein folding']}, {'category': ['function'], 'description': ['ubiquitin protein ligase binding']}, {'category': ['function'], 'description': ['unfolded protein binding']}, {'category': ['function'], 'description': ['zinc ion binding']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent']}, {'category': ['process'], 'description': ['antigen processing and presentation of peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['ATF6-mediated unfolded protein response']}, {'category': ['process'], 'description': ['cardiac muscle cell differentiation']}, {'category': ['process'], 'description': ['cell cycle arrest']}, {'category': ['process'], 'description': ['cellular calcium ion homeostasis']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['cellular response to lithium ion']}, {'category': ['process'], 'description': ['cellular senescence']}, {'category': ['process'], 'description': ['chaperone-mediated protein folding']}, {'category': ['process'], 'description': ['cortical actin cytoskeleton organization']}, {'category': ['process'], 'description': ['endoplasmic reticulum unfolded protein response']}, {'category': ['process'], 'description': ['glucocorticoid receptor signaling pathway']}, {'category': ['process'], 'description': ['negative regulation of intracellular steroid hormone receptor signaling pathway']}, {'category': ['process'], 'description': ['negative regulation of neuron differentiation']}, {'category': ['process'], 'description': ['negative regulation of retinoic acid receptor signaling pathway']}, {'category': ['process'], 'description': ['negative regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['negative regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['negative regulation of translation']}, {'category': ['process'], 'description': ['peptide antigen assembly with MHC class I protein complex']}, {'category': ['process'], 'description': ['positive regulation of cell cycle']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of dendritic cell chemotaxis']}, {'category': ['process'], 'description': ['positive regulation of DNA replication']}, {'category': ['process'], 'description': ['positive regulation of gene expression']}, {'category': ['process'], 'description': ['positive regulation of phagocytosis']}, {'category': ['process'], 'description': ['positive regulation of substrate adhesion-dependent cell spreading']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['protein export from nucleus']}, {'category': ['process'], 'description': ['protein folding']}, {'category': ['process'], 'description': ['protein folding in endoplasmic reticulum']}, {'category': ['process'], 'description': ['protein localization to nucleus']}, {'category': ['process'], 'description': ['protein maturation by protein folding']}, {'category': ['process'], 'description': ['protein N-linked glycosylation via asparagine']}, {'category': ['process'], 'description': ['protein stabilization']}, {'category': ['process'], 'description': ['receptor-mediated endocytosis']}, {'category': ['process'], 'description': ['regulation of apoptotic process']}, {'category': ['process'], 'description': ['regulation of meiotic nuclear division']}, {'category': ['process'], 'description': ['regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['response to drug']}, {'category': ['process'], 'description': ['response to estradiol']}, {'category': ['process'], 'description': ['response to testosterone']}, {'category': ['process'], 'description': ['sequestering of calcium ion']}, {'category': ['process'], 'description': ['spermatogenesis']}]}]}]}, {'id': ['BE0001011'], 'name': ['Calnexin'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13138'], 'pubmed-id': ['9359841'], 'citation': ['Allen S, Bulleid NJ: Calnexin and calreticulin bind to enzymically active tissue-type plasminogen activator during biosynthesis and are not required for folding to the native conformation. Biochem J. 1997 Nov 15;328 ( Pt 1):113-9.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Calnexin'], 'general-function': ['Poly(a) rna binding'], 'specific-function': ['Calcium-binding protein that interacts with newly synthesized glycoproteins in the endoplasmic reticulum. It may act in assisting protein assembly and/or in the retention within the ER of unassembled protein subunits. It seems to play a major role in the quality control apparatus of the ER by the retention of incorrectly folded proteins. Associated with partial T-cell antigen receptor complexes that escape the ER of immature thymocytes, it may function as a signaling complex regulating thymocyte maturation. Additionally it may play a role in receptor-mediated endocytosis at the synapse.'], 'gene-name': ['CANX'], 'locus': ['5q35'], 'cellular-location': ['Endoplasmic reticulum membrane'], 'transmembrane-regions': ['482-502'], 'signal-regions': ['1-20'], 'theoretical-pi': ['4.21'], 'molecular-weight': ['67567.695'], 'chromosome-location': ['5'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1473']}, {'resource': ['GenAtlas'], 'identifier': ['CANX']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L10284']}, {'resource': ['GenBank Protein Database'], 'identifier': ['186523']}, {'resource': ['UniProtKB'], 'identifier': ['P27824']}, {'resource': ['UniProt Accession'], 'identifier': ['CALX_HUMAN']}]}], 'synonyms': [{'synonym': ['IP90', 'Major histocompatibility complex class I antigen-binding protein p88', 'p90']}], 'amino-acid-sequence': ['>lcl|BSEQ0002013|Calnexin\nMEGKWLLCMLLVLGTAIVEAHDGHDDDVIDIEDDLDDVIEEVEDSKPDTTAPPSSPKVTY\nKAPVPTGEVYFADSFDRGTLSGWILSKAKKDDTDDEIAKYDGKWEVEEMKESKLPGDKGL\nVLMSRAKHHAISAKLNKPFLFDTKPLIVQYEVNFQNGIECGGAYVKLLSKTPELNLDQFH\nDKTPYTIMFGPDKCGEDYKLHFIFRHKNPKTGIYEEKHAKRPDADLKTYFTDKKTHLYTL\nILNPDNSFEILVDQSVVNSGNLLNDMTPPVNPSREIEDPEDRKPEDWDERPKIPDPEAVK\nPDDWDEDAPAKIPDEEATKPEGWLDDEPEYVPDPDAEKPEDWDEDMDGEWEAPQIANPRC\nESAPGCGVWQRPVIDNPNYKGKWKPPMIDNPSYQGIWKPRKIPNPDFFEDLEPFRMTPFS\nAIGLELWSMTSDIFFDNFIICADRRIVDDWANDGWGLKKAADGAAEPGVVGQMIEAAEER\nPWLWVVYILTVALPVFLVILFCCSGKKQTSGMEYKKTDAPQPDVKEEEEEKEEEKDKGDE\nEEEGEEKLEEKQKSDAEEDGGTVSQEEEDRKPKAEEDEILNRSPRNRKPRRE'], 'gene-sequence': ['>lcl|BSEQ0016282|Calnexin (CANX)\nATGGAAGGGAAGTGGTTGCTGTGTATGTTACTGGTGCTTGGAACTGCTATTGTTGAGGCT\nCATGATGGACATGATGATGATGTGATTGATATTGAGGATGACCTTGACGATGTCATTGAA\nGAGGTAGAAGACTCAAAACCAGATACCACTGCTCCTCCTTCATCTCCCAAGGTTACTTAC\nAAAGCTCCAGTTCCAACAGGGGAAGTATATTTTGCTGATTCTTTTGACAGAGGAACTCTG\nTCAGGGTGGATTTTATCCAAAGCCAAGAAAGACGATACCGATGATGAAATTGCCAAATAT\nGATGGAAAGTGGGAGGTAGAGGAAATGAAGGAGTCAAAGCTTCCAGGTGATAAAGGACTT\nGTGTTGATGTCTCGGGCCAAGCATCATGCCATCTCTGCTAAACTGAACAAGCCCTTCCTG\nTTTGACACCAAGCCTCTCATTGTTCAGTATGAGGTTAATTTCCAAAATGGAATAGAATGT\nGGTGGTGCCTATGTGAAACTGCTTTCTAAAACACCAGAACTCAACCTGGATCAGTTCCAT\nGACAAGACCCCTTATACGATTATGTTTGGTCCAGATAAATGTGGAGAGGACTATAAACTG\nCACTTCATCTTCCGACACAAAAACCCCAAAACGGGTATCTATGAAGAAAAACATGCTAAG\nAGGCCAGATGCAGATCTGAAGACCTATTTTACTGATAAGAAAACACATCTTTACACACTA\nATCTTGAATCCAGATAATAGTTTTGAAATACTGGTTGACCAATCTGTGGTGAATAGTGGA\nAATCTGCTCAATGACATGACTCCTCCTGTAAATCCTTCACGTGAAATTGAGGACCCAGAA\nGACCGGAAGCCCGAGGATTGGGATGAAAGACCAAAAATCCCAGATCCAGAAGCTGTCAAG\nCCAGATGACTGGGATGAAGATGCCCCTGCTAAGATTCCAGATGAAGAGGCCACAAAACCC\nGAAGGCTGGTTAGATGATGAGCCTGAGTACGTACCTGATCCAGACGCAGAGAAACCTGAG\nGATTGGGATGAAGACATGGATGGAGAATGGGAGGCTCCTCAGATTGCCAACCCTAGATGT\nGAGTCAGCTCCTGGATGTGGTGTCTGGCAGCGACCTGTGATTGACAACCCCAATTATAAA\nGGCAAATGGAAGCCTCCTATGATTGACAATCCCAGTTACCAGGGAATCTGGAAACCCAGG\nAAAATACCAAATCCAGATTTCTTTGAAGATCTGGAACCTTTCAGAATGACTCCTTTTAGT\nGCTATTGGTTTGGAGCTGTGGTCCATGACCTCTGACATTTTTTTTGACAACTTTATCATT\nTGTGCTGATCGAAGAATAGTTGATGATTGGGCCAATGATGGATGGGGCCTGAAGAAAGCT\nGCTGATGGGGCTGCTGAGCCAGGCGTTGTGGGGCAGATGATCGAGGCAGCTGAAGAGCGC\nCCGTGGCTGTGGGTAGTCTATATTCTAACTGTAGCCCTTCCTGTGTTCCTGGTTATCCTC\nTTCTGCTGTTCTGGAAAGAAACAGACCAGTGGTATGGAGTATAAGAAAACTGATGCACCT\nCAACCGGATGTGAAGGAAGAGGAAGAAGAGAAGGAAGAGGAAAAGGACAAGGGAGATGAG\nGAGGAGGAAGGAGAAGAGAAACTTGAAGAGAAACAGAAAAGTGATGCTGAAGAAGATGGT\nGGCACTGTCAGTCAAGAGGAGGAAGACAGAAAACCTAAAGCAGAGGAGGATGAAATTTTG\nAACAGATCACCAAGAAACAGAAAGCCACGAAGAGAGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00262'], 'name': ['Calreticulin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['axon']}, {'category': ['component'], 'description': ['dendrite cytoplasm']}, {'category': ['component'], 'description': ['dendritic spine']}, {'category': ['component'], 'description': ['endoplasmic reticulum']}, {'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['endoplasmic reticulum membrane']}, {'category': ['component'], 'description': ['ER-mitochondrion membrane contact site']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['integral component of lumenal side of endoplasmic reticulum membrane']}, {'category': ['component'], 'description': ['melanosome']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['myelin sheath']}, {'category': ['component'], 'description': ['neuronal cell body']}, {'category': ['component'], 'description': ['protein complex']}, {'category': ['component'], 'description': ['ribosome']}, {'category': ['component'], 'description': ['rough endoplasmic reticulum']}, {'category': ['component'], 'description': ['smooth endoplasmic reticulum']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['carbohydrate binding']}, {'category': ['function'], 'description': ['poly(A) RNA binding']}, {'category': ['process'], 'description': ['aging']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class II']}, {'category': ['process'], 'description': ['antigen processing and presentation of peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['chaperone-mediated protein folding']}, {'category': ['process'], 'description': ['clathrin-mediated endocytosis']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['protein folding']}, {'category': ['process'], 'description': ['protein folding in endoplasmic reticulum']}, {'category': ['process'], 'description': ['protein N-linked glycosylation via asparagine']}, {'category': ['process'], 'description': ['protein secretion']}, {'category': ['process'], 'description': ['synaptic vesicle endocytosis']}]}]}]}, {'id': ['BE0002110'], 'name': ['Prolow-density lipoprotein receptor-related protein 1'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13139'], 'pubmed-id': ['8344937'], 'citation': ['Moestrup SK, Nielsen S, Andreasen P, Jorgensen KE, Nykjaer A, Roigaard H, Gliemann J, Christensen EI: Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes. J Biol Chem. 1993 Aug 5;268(22):16564-70.']}, {'ref-id': ['A13140'], 'pubmed-id': ['1378833'], 'citation': ['Nykjaer A, Petersen CM, Moller B, Jensen PH, Moestrup SK, Holtet TL, Etzerodt M, Thogersen HC, Munch M, Andreasen PA, et al.: Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem. 1992 Jul 25;267(21):14543-6.']}, {'ref-id': ['A13141'], 'pubmed-id': ['16303771'], 'citation': ['Hu K, Yang J, Tanaka S, Gonias SL, Mars WM, Liu Y: Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem. 2006 Jan 27;281(4):2120-7. Epub 2005 Nov 22.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Prolow-density lipoprotein receptor-related protein 1'], 'general-function': ['Receptor activity'], 'specific-function': ['Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells. Required for early embryonic development. Involved in cellular lipid homeostasis. Involved in the plasma clearance of chylomicron remnants and activated LRPAP1 (alpha 2-macroglobulin), as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate cellular events, such as APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission.Functions as a receptor for Pseudomonas aeruginosa exotoxin A.'], 'gene-name': ['LRP1'], 'locus': ['12q13-q14'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['4420-4444'], 'signal-regions': ['1-19'], 'theoretical-pi': ['5.02'], 'molecular-weight': ['504601.695'], 'chromosome-location': ['12'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6692']}, {'resource': ['GenAtlas'], 'identifier': ['LRP1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X13916']}, {'resource': ['GenBank Protein Database'], 'identifier': ['34339']}, {'resource': ['UniProtKB'], 'identifier': ['Q07954']}, {'resource': ['UniProt Accession'], 'identifier': ['LRP1_HUMAN']}]}], 'synonyms': [{'synonym': ['A2MR', 'Alpha-2-macroglobulin receptor', 'APOER', 'Apolipoprotein E receptor', 'APR', 'LRP-1']}], 'amino-acid-sequence': ['>lcl|BSEQ0037158|Prolow-density lipoprotein receptor-related protein 1\nMLTPPLLLLLPLLSALVAAAIDAPKTCSPKQFACRDQITCISKGWRCDGERDCPDGSDEA\nPEICPQSKAQRCQPNEHNCLGTELCVPMSRLCNGVQDCMDGSDEGPHCRELQGNCSRLGC\nQHHCVPTLDGPTCYCNSSFQLQADGKTCKDFDECSVYGTCSQLCTNTDGSFICGCVEGYL\nLQPDNRSCKAKNEPVDRPPVLLIANSQNILATYLSGAQVSTITPTSTRQTTAMDFSYANE\nTVCWVHVGDSAAQTQLKCARMPGLKGFVDEHTINISLSLHHVEQMAIDWLTGNFYFVDDI\nDDRIFVCNRNGDTCVTLLDLELYNPKGIALDPAMGKVFFTDYGQIPKVERCDMDGQNRTK\nLVDSKIVFPHGITLDLVSRLVYWADAYLDYIEVVDYEGKGRQTIIQGILIEHLYGLTVFE\nNYLYATNSDNANAQQKTSVIRVNRFNSTEYQVVTRVDKGGALHIYHQRRQPRVRSHACEN\nDQYGKPGGCSDICLLANSHKARTCRCRSGFSLGSDGKSCKKPEHELFLVYGKGRPGIIRG\nMDMGAKVPDEHMIPIENLMNPRALDFHAETGFIYFADTTSYLIGRQKIDGTERETILKDG\nIHNVEGVAVDWMGDNLYWTDDGPKKTISVARLEKAAQTRKTLIEGKMTHPRAIVVDPLNG\nWMYWTDWEEDPKDSRRGRLERAWMDGSHRDIFVTSKTVLWPNGLSLDIPAGRLYWVDAFY\nDRIETILLNGTDRKIVYEGPELNHAFGLCHHGNYLFWTEYRSGSVYRLERGVGGAPPTVT\nLLRSERPPIFEIRMYDAQQQQVGTNKCRVNNGGCSSLCLATPGSRQCACAEDQVLDADGV\nTCLANPSYVPPPQCQPGEFACANSRCIQERWKCDGDNDCLDNSDEAPALCHQHTCPSDRF\nKCENNRCIPNRWLCDGDNDCGNSEDESNATCSARTCPPNQFSCASGRCIPISWTCDLDDD\nCGDRSDESASCAYPTCFPLTQFTCNNGRCININWRCDNDNDCGDNSDEAGCSHSCSSTQF\nKCNSGRCIPEHWTCDGDNDCGDYSDETHANCTNQATRPPGGCHTDEFQCRLDGLCIPLRW\nRCDGDTDCMDSSDEKSCEGVTHVCDPSVKFGCKDSARCISKAWVCDGDNDCEDNSDEENC\nESLACRPPSHPCANNTSVCLPPDKLCDGNDDCGDGSDEGELCDQCSLNNGGCSHNCSVAP\nGEGIVCSCPLGMELGPDNHTCQIQSYCAKHLKCSQKCDQNKFSVKCSCYEGWVLEPDGES\nCRSLDPFKPFIIFSNRHEIRRIDLHKGDYSVLVPGLRNTIALDFHLSQSALYWTDVVEDK\nIYRGKLLDNGALTSFEVVIQYGLATPEGLAVDWIAGNIYWVESNLDQIEVAKLDGTLRTT\nLLAGDIEHPRAIALDPRDGILFWTDWDASLPRIEAASMSGAGRRTVHRETGSGGWPNGLT\nVDYLEKRILWIDARSDAIYSARYDGSGHMEVLRGHEFLSHPFAVTLYGGEVYWTDWRTNT\nLAKANKWTGHNVTVVQRTNTQPFDLQVYHPSRQPMAPNPCEANGGQGPCSHLCLINYNRT\nVSCACPHLMKLHKDNTTCYEFKKFLLYARQMEIRGVDLDAPYYNYIISFTVPDIDNVTVL\nDYDAREQRVYWSDVRTQAIKRAFINGTGVETVVSADLPNAHGLAVDWVSRNLFWTSYDTN\nKKQINVARLDGSFKNAVVQGLEQPHGLVVHPLRGKLYWTDGDNISMANMDGSNRTLLFSG\nQKGPVGLAIDFPESKLYWISSGNHTINRCNLDGSGLEVIDAMRSQLGKATALAIMGDKLW\nWADQVSEKMGTCSKADGSGSVVLRNSTTLVMHMKVYDESIQLDHKGTNPCSVNNGDCSQL\nCLPTSETTRSCMCTAGYSLRSGQQACEGVGSFLLYSVHEGIRGIPLDPNDKSDALVPVSG\nTSLAVGIDFHAENDTIYWVDMGLSTISRAKRDQTWREDVVTNGIGRVEGIAVDWIAGNIY\nWTDQGFDVIEVARLNGSFRYVVISQGLDKPRAITVHPEKGYLFWTEWGQYPRIERSRLDG\nTERVVLVNVSISWPNGISVDYQDGKLYWCDARTDKIERIDLETGENREVVLSSNNMDMFS\nVSVFEDFIYWSDRTHANGSIKRGSKDNATDSVPLRTGIGVQLKDIKVFNRDRQKGTNVCA\nVANGGCQQLCLYRGRGQRACACAHGMLAEDGASCREYAGYLLYSERTILKSIHLSDERNL\nNAPVQPFEDPEHMKNVIALAFDYRAGTSPGTPNRIFFSDIHFGNIQQINDDGSRRITIVE\nNVGSVEGLAYHRGWDTLYWTSYTTSTITRHTVDQTRPGAFERETVITMSGDDHPRAFVLD\nECQNLMFWTNWNEQHPSIMRAALSGANVLTLIEKDIRTPNGLAIDHRAEKLYFSDATLDK\nIERCEYDGSHRYVILKSEPVHPFGLAVYGEHIFWTDWVRRAVQRANKHVGSNMKLLRVDI\nPQQPMGIIAVANDTNSCELSPCRINNGGCQDLCLLTHQGHVNCSCRGGRILQDDLTCRAV\nNSSCRAQDEFECANGECINFSLTCDGVPHCKDKSDEKPSYCNSRRCKKTFRQCSNGRCVS\nNMLWCNGADDCGDGSDEIPCNKTACGVGEFRCRDGTCIGNSSRCNQFVDCEDASDEMNCS\nATDCSSYFRLGVKGVLFQPCERTSLCYAPSWVCDGANDCGDYSDERDCPGVKRPRCPLNY\nFACPSGRCIPMSWTCDKEDDCEHGEDETHCNKFCSEAQFECQNHRCISKQWLCDGSDDCG\nDGSDEAAHCEGKTCGPSSFSCPGTHVCVPERWLCDGDKDCADGADESIAAGCLYNSTCDD\nREFMCQNRQCIPKHFVCDHDRDCADGSDESPECEYPTCGPSEFRCANGRCLSSRQWECDG\nENDCHDQSDEAPKNPHCTSQEHKCNASSQFLCSSGRCVAEALLCNGQDDCGDSSDERGCH\nINECLSRKLSGCSQDCEDLKIGFKCRCRPGFRLKDDGRTCADVDECSTTFPCSQRCINTH\nGSYKCLCVEGYAPRGGDPHSCKAVTDEEPFLIFANRYYLRKLNLDGSNYTLLKQGLNNAV\nALDFDYREQMIYWTDVTTQGSMIRRMHLNGSNVQVLHRTGLSNPDGLAVDWVGGNLYWCD\nKGRDTIEVSKLNGAYRTVLVSSGLREPRALVVDVQNGYLYWTDWGDHSLIGRIGMDGSSR\nSVIVDTKITWPNGLTLDYVTERIYWADAREDYIEFASLDGSNRHVVLSQDIPHIFALTLF\nEDYVYWTDWETKSINRAHKTTGTNKTLLISTLHRPMDLHVFHALRQPDVPNHPCKVNNGG\nCSNLCLLSPGGGHKCACPTNFYLGSDGRTCVSNCTASQFVCKNDKCIPFWWKCDTEDDCG\nDHSDEPPDCPEFKCRPGQFQCSTGICTNPAFICDGDNDCQDNSDEANCDIHVCLPSQFKC\nTNTNRCIPGIFRCNGQDNCGDGEDERDCPEVTCAPNQFQCSITKRCIPRVWVCDRDNDCV\nDGSDEPANCTQMTCGVDEFRCKDSGRCIPARWKCDGEDDCGDGSDEPKEECDERTCEPYQ\nFRCKNNRCVPGRWQCDYDNDCGDNSDEESCTPRPCSESEFSCANGRCIAGRWKCDGDHDC\nADGSDEKDCTPRCDMDQFQCKSGHCIPLRWRCDADADCMDGSDEEACGTGVRTCPLDEFQ\nCNNTLCKPLAWKCDGEDDCGDNSDENPEECARFVCPPNRPFRCKNDRVCLWIGRQCDGTD\nNCGDGTDEEDCEPPTAHTTHCKDKKEFLCRNQRCLSSSLRCNMFDDCGDGSDEEDCSIDP\nKLTSCATNASICGDEARCVRTEKAAYCACRSGFHTVPGQPGCQDINECLRFGTCSQLCNN\nTKGGHLCSCARNFMKTHNTCKAEGSEYQVLYIADDNEIRSLFPGHPHSAYEQAFQGDESV\nRIDAMDVHVKAGRVYWTNWHTGTISYRSLPPAAPPTTSNRHRRQIDRGVTHLNISGLKMP\nRGIAIDWVAGNVYWTDSGRDVIEVAQMKGENRKTLISGMIDEPHAIVVDPLRGTMYWSDW\nGNHPKIETAAMDGTLRETLVQDNIQWPTGLAVDYHNERLYWADAKLSVIGSIRLNGTDPI\nVAADSKRGLSHPFSIDVFEDYIYGVTYINNRVFKIHKFGHSPLVNLTGGLSHASDVVLYH\nQHKQPEVTNPCDRKKCEWLCLLSPSGPVCTCPNGKRLDNGTCVPVPSPTPPPDAPRPGTC\nNLQCFNGGSCFLNARRQPKCRCQPRYTGDKCELDQCWEHCRNGGTCAASPSGMPTCRCPT\nGFTGPKCTQQVCAGYCANNSTCTVNQGNQPQCRCLPGFLGDRCQYRQCSGYCENFGTCQM\nAADGSRQCRCTAYFEGSRCEVNKCSRCLEGACVVNKQSGDVTCNCTDGRVAPSCLTCVGH\nCSNGGSCTMNSKMMPECQCPPHMTGPRCEEHVFSQQQPGHIASILIPLLLLLLLVLVAGV\nVFWYKRRVQGAKGFQHQRMTNGAMNVEIGNPTYKMYEGGEPDDVGGLLDADFALDPDKPT\nNFTNPVYATLYMGGHGSRHSLASTDEKRELLGRGPEDEIGDPLA'], 'gene-sequence': ['>lcl|BSEQ0019236|Prolow-density lipoprotein receptor-related protein 1 (LRP1)\nATGCTGACCCCGCCGTTGCTCCTGCTGCTGCCCCTGCTCTCAGCTCTGGTCGCGGCGGCT\nATCGACGCCCCTAAGACTTGCAGCCCCAAGCAGTTTGCCTGCAGAGATCAAATAACCTGT\nATCTCAAAGGGCTGGCGGTGCGACGGTGAGAGGGACTGCCCAGACGGATCTGACGAGGCC\nCCTGAGATTTGTCCACAGAGTAAGGCCCAGCGATGCCAGCCAAACGAGCATAACTGCCTG\nGGTACTGAGCTGTGTGTTCCCATGTCCCGCCTCTGCAATGGGGTCCAGGACTGCATGGAC\nGGCTCAGATGAGGGGCCCCACTGCCGAGAGCTCCAAGGCAACTGCTCTCGCCTGGGCTGC\nCAGCACCATTGTGTCCCCACACTCGATGGGCCCACCTGCTACTGCAACAGCAGCTTTCAG\nCTTCAGGCAGATGGCAAGACCTGCAAAGATTTTGATGAGTGCTCAGTGTACGGCACCTGC\nAGCCAGCTATGCACCAACACAGACGGCTCCTTCATATGTGGCTGTGTTGAAGGATACCTC\nCTGCAGCCGGATAACCGCTCCTGCAAGGCCAAGAACGAGCCAGTAGACCGGCCCCCTGTG\nCTGTTGATAGCCAACTCCCAGAACATCTTGGCCACGTACCTGAGTGGGGCCCAGGTGTCT\nACCATCACACCTACGAGCACGCGGCAGACCACAGCCATGGACTTCAGCTATGCCAACGAG\nACCGTATGCTGGGTGCATGTTGGGGACAGTGCTGCTCAGACGCAGCTCAAGTGTGCCCGC\nATGCCTGGCCTAAAGGGCTTCGTGGATGAGCACACCATCAACATCTCCCTCAGTCTGCAC\nCACGTGGAACAGATGGCCATCGACTGGCTGACAGGCAACTTCTACTTTGTGGATGACATC\nGATGATAGGATCTTTGTCTGCAACAGAAATGGGGACACATGTGTCACATTGCTAGACCTG\nGAACTCTACAACCCCAAGGGCATTGCCCTGGACCCTGCCATGGGGAAGGTGTTTTTCACT\nGACTATGGGCAGATCCCAAAGGTGGAACGCTGTGACATGGATGGGCAGAACCGCACCAAG\nCTCGTCGACAGCAAGATTGTGTTTCCTCATGGCATCACGCTGGACCTGGTCAGCCGCCTT\nGTCTACTGGGCAGATGCCTATCTGGACTATATTGAAGTGGTGGACTATGAGGGCAAGGGC\nCGCCAGACCATCATCCAGGGCATCCTGATTGAGCACCTGTACGGCCTGACTGTGTTTGAG\nAATTATCTCTATGCCACCAACTCGGACAATGCCAATGCCCAGCAGAAGACGAGTGTGATC\nCGTGTGAACCGCTTTAACAGCACCGAGTACCAGGTTGTCACCCGGGTGGACAAGGGTGGT\nGCCCTCCACATCTACCACCAGAGGCGTCAGCCCCGAGTGAGGAGCCATGCCTGTGAAAAC\nGACCAGTATGGGAAGCCGGGTGGCTGCTCTGACATCTGCCTGCTGGCCAACAGCCACAAG\nGCGCGGACCTGCCGCTGCCGTTCCGGCTTCAGCCTGGGCAGTGACGGGAAGTCATGCAAG\nAAGCCGGAGCATGAGCTGTTCCTCGTGTATGGCAAGGGCCGGCCAGGCATCATCCGGGGC\nATGGATATGGGGGCCAAGGTCCCGGATGAGCACATGATCCCCATTGAAAACCTCATGAAC\nCCCCGAGCCCTGGACTTCCACGCTGAGACCGGCTTCATCTACTTTGCCGACACCACCAGC\nTACCTCATTGGCCGCCAGAAGATTGATGGCACTGAGCGGGAGACCATCCTGAAGGACGGC\nATCCACAATGTGGAGGGTGTGGCCGTGGACTGGATGGGAGACAATCTGTACTGGACGGAC\nGATGGGCCCAAAAAGACAATCAGCGTGGCCAGGCTGGAGAAAGCTGCTCAGACCCGCAAG\nACTTTAATCGAGGGCAAAATGACACACCCCAGGGCTATTGTGGTGGATCCACTCAATGGG\nTGGATGTACTGGACAGACTGGGAGGAGGACCCCAAGGACAGTCGGCGTGGGCGGCTGGAG\nAGGGCGTGGATGGATGGCTCACACCGAGACATCTTTGTCACCTCCAAGACAGTGCTTTGG\nCCCAATGGGCTAAGCCTGGACATCCCGGCTGGGCGCCTCTACTGGGTGGATGCCTTCTAC\nGACCGCATCGAGACGATACTGCTCAATGGCACAGACCGGAAGATTGTGTATGAAGGTCCT\nGAGCTGAACCACGCCTTTGGCCTGTGTCACCATGGCAACTACCTCTTCTGGACTGAGTAT\nCGGAGTGGCAGTGTCTACCGCTTGGAACGGGGTGTAGGAGGCGCACCCCCCACTGTGACC\nCTTCTGCGCAGTGAGCGGCCCCCCATCTTTGAGATCCGAATGTATGATGCCCAGCAGCAG\nCAAGTTGGCACCAACAAATGCCGGGTGAACAATGGCGGCTGCAGCAGCCTGTGCTTGGCC\nACCCCTGGGAGCCGCCAGTGCGCCTGTGCTGAGGACCAGGTGTTGGACGCAGACGGCGTC\nACTTGCTTGGCGAACCCATCCTACGTGCCTCCACCCCAGTGCCAGCCAGGCGAGTTTGCC\nTGTGCCAACAGCCGCTGCATCCAGGAGCGCTGGAAGTGTGACGGAGACAACGATTGCCTG\nGACAACAGTGATGAGGCCCCAGCCCTCTGCCATCAGCACACCTGCCCCTCGGACCGATTC\nAAGTGCGAGAACAACCGGTGCATCCCCAACCGCTGGCTCTGCGACGGGGACAATGACTGT\nGGGAACAGTGAAGATGAGTCCAATGCCACTTGTTCAGCCCGCACCTGCCCCCCCAACCAG\nTTCTCCTGTGCCAGTGGCCGCTGCATCCCCATCTCCTGGACGTGTGATCTGGATGACGAC\nTGTGGGGACCGCTCTGATGAGTCTGCTTCGTGTGCCTATCCCACCTGCTTCCCCCTGACT\nCAGTTTACCTGCAACAATGGCAGATGTATCAACATCAACTGGAGATGCGACAATGACAAT\nGACTGTGGGGACAACAGTGACGAAGCCGGCTGCAGCCACTCCTGTTCTAGCACCCAGTTC\nAAGTGCAACAGCGGGCGTTGCATCCCCGAGCACTGGACCTGCGATGGGGACAATGACTGC\nGGAGACTACAGTGATGAGACACACGCCAACTGCACCAACCAGGCCACGAGGCCCCCTGGT\nGGCTGCCACACTGATGAGTTCCAGTGCCGGCTGGATGGACTATGCATCCCCCTGCGGTGG\nCGCTGCGATGGGGACACTGACTGCATGGACTCCAGCGATGAGAAGAGCTGTGAGGGAGTG\nACCCACGTCTGCGATCCCAGTGTCAAGTTTGGCTGCAAGGACTCAGCTCGGTGCATCAGC\nAAAGCGTGGGTGTGTGATGGCGACAATGACTGTGAGGATAACTCGGACGAGGAGAACTGC\nGAGTCCCTGGCCTGCAGGCCACCCTCGCACCCTTGTGCCAACAACACCTCAGTCTGCCTG\nCCCCCTGACAAGCTGTGTGATGGCAACGACGACTGTGGCGACGGCTCAGATGAGGGCGAG\nCTCTGCGACCAGTGCTCTCTGAATAACGGTGGCTGCAGCCACAACTGCTCAGTGGCACCT\nGGCGAAGGCATTGTGTGTTCCTGCCCTCTGGGCATGGAGCTGGGGCCCGACAACCACACC\nTGCCAGATCCAGAGCTACTGTGCCAAGCATCTCAAATGCAGCCAAAAGTGCGACCAGAAC\nAAGTTCAGCGTGAAGTGCTCCTGCTACGAGGGCTGGGTCCTGGAACCTGACGGCGAGAGC\nTGCCGCAGCCTGGACCCCTTCAAGCCGTTCATCATTTTCTCCAACCGCCATGAAATCCGG\nCGCATCGATCTTCACAAAGGAGACTACAGCGTCCTGGTGCCCGGCCTGCGCAACACCATC\nGCCCTGGACTTCCACCTCAGCCAGAGCGCCCTCTACTGGACCGACGTGGTGGAGGACAAG\nATCTACCGCGGGAAGCTGCTGGACAACGGAGCCCTGACTAGTTTCGAGGTGGTGATTCAG\nTATGGCCTGGCCACACCCGAGGGCCTGGCTGTAGACTGGATTGCAGGCAACATCTACTGG\nGTGGAGAGTAACCTGGATCAGATCGAGGTGGCCAAGCTGGATGGGACCCTCCGGACCACC\nCTGCTGGCCGGTGACATTGAGCACCCAAGGGCAATCGCACTGGATCCCCGGGATGGGATC\nCTGTTTTGGACAGACTGGGATGCCAGCCTGCCCCGCATTGAGGCAGCCTCCATGAGTGGG\nGCTGGGCGCCGCACCGTGCACCGGGAGACCGGCTCTGGGGGCTGGCCCAACGGGCTCACC\nGTGGACTACCTGGAGAAGCGCATCCTTTGGATTGACGCCAGGTCAGATGCCATTTACTCA\nGCCCGTTACGACGGCTCTGGCCACATGGAGGTGCTTCGGGGACACGAGTTCCTGTCGCAC\nCCGTTTGCAGTGACGCTGTACGGGGGGGAGGTCTACTGGACTGACTGGCGAACAAACACA\nCTGGCTAAGGCCAACAAGTGGACCGGCCACAATGTCACCGTGGTACAGAGGACCAACACC\nCAGCCCTTTGACCTGCAGGTGTACCACCCCTCCCGCCAGCCCATGGCTCCCAATCCCTGT\nGAGGCCAATGGGGGCCAGGGCCCCTGCTCCCACCTGTGTCTCATCAACTACAACCGGACC\nGTGTCCTGCGCCTGCCCCCACCTCATGAAGCTCCACAAGGACAACACCACCTGCTATGAG\nTTTAAGAAGTTCCTGCTGTACGCACGTCAGATGGAGATCCGAGGTGTGGACCTGGATGCT\nCCCTACTACAACTACATCATCTCCTTCACGGTGCCCGACATCGACAACGTCACAGTGCTA\nGACTACGATGCCCGCGAGCAGCGTGTGTACTGGTCTGACGTGCGGACACAGGCCATCAAG\nCGGGCCTTCATCAACGGCACAGGCGTGGAGACAGTCGTCTCTGCAGACTTGCCAAATGCC\nCACGGGCTGGCTGTGGACTGGGTCTCCCGAAACCTGTTCTGGACAAGCTATGACACCAAT\nAAGAAGCAGATCAATGTGGCCCGGCTGGATGGCTCCTTCAAGAACGCAGTGGTGCAGGGC\nCTGGAGCAGCCCCATGGCCTTGTCGTCCACCCTCTGCGTGGGAAGCTCTACTGGACCGAT\nGGTGACAACATCAGCATGGCCAACATGGATGGCAGCAATCGCACCCTGCTCTTCAGTGGC\nCAGAAGGGCCCCGTGGGCCTGGCTATTGACTTCCCTGAAAGCAAACTCTACTGGATCAGC\nTCCGGGAACCATACCATCAACCGCTGCAACCTGGATGGGAGTGGGCTGGAGGTCATCGAT\nGCCATGCGGAGCCAGCTGGGCAAGGCCACCGCCCTGGCCATCATGGGGGACAAGCTGTGG\nTGGGCTGATCAGGTGTCGGAAAAGATGGGCACATGCAGCAAGGCTGACGGCTCGGGCTCC\nGTGGTCCTTCGGAACAGCACCACCCTGGTGATGCACATGAAGGTCTATGACGAGAGCATC\nCAGCTGGACCATAAGGGCACCAACCCCTGCAGTGTCAACAACGGTGACTGCTCCCAGCTC\nTGCCTGCCCACGTCAGAGACGACCCGCTCCTGCATGTGCACAGCCGGCTATAGCCTCCGG\nAGTGGCCAGCAGGCCTGCGAGGGCGTAGGTTCCTTTCTCCTGTACTCTGTGCATGAGGGA\nATCAGGGGAATTCCCCTGGATCCCAATGACAAGTCAGATGCCCTGGTCCCAGTGTCCGGG\nACCTCGCTGGCTGTCGGCATCGACTTCCACGCTGAAAATGACACCATCTACTGGGTGGAC\nATGGGCCTGAGCACGATCAGCCGGGCCAAGCGGGACCAGACGTGGCGTGAAGACGTGGTG\nACCAATGGCATTGGCCGTGTGGAGGGCATTGCAGTGGACTGGATCGCAGGCAACATCTAC\nTGGACAGACCAGGGCTTTGATGTCATCGAGGTCGCCCGGCTCAATGGCTCCTTCCGCTAC\nGTGGTGATCTCCCAGGGTCTAGACAAGCCCCGGGCCATCACCGTCCACCCGGAGAAAGGG\nTACTTGTTCTGGACTGAGTGGGGTCAGTATCCGCGTATTGAGCGGTCTCGGCTAGATGGC\nACGGAGCGTGTGGTGCTGGTCAACGTCAGCATCAGCTGGCCCAACGGCATCTCAGTGGAC\nTACCAGGATGGGAAGCTGTACTGGTGCGATGCACGGACAGACAAGATTGAACGGATCGAC\nCTGGAGACAGGTGAGAACCGCGAGGTGGTTCTGTCCAGCAACAACATGGACATGTTTTCA\nGTGTCTGTGTTTGAGGATTTCATCTACTGGAGTGACAGGACTCATGCCAACGGCTCTATC\nAAGCGCGGGAGCAAAGACAATGCCACAGACTCCGTGCCCCTGCGAACCGGCATCGGCGTC\nCAGCTTAAAGACATCAAAGTCTTCAACCGGGACCGGCAGAAAGGCACCAACGTGTGCGCG\nGTGGCCAATGGCGGGTGCCAGCAGCTGTGCCTGTACCGGGGCCGTGGGCAGCGGGCCTGC\nGCCTGTGCCCACGGGATGCTGGCTGAAGACGGAGCATCGTGCCGCGAGTATGCCGGCTAC\nCTGCTCTACTCAGAGCGCACCATTCTCAAGAGTATCCACCTGTCGGATGAGCGCAACCTC\nAATGCGCCCGTGCAGCCCTTCGAGGACCCTGAGCACATGAAGAACGTCATCGCCCTGGCC\nTTTGACTACCGGGCAGGCACCTCTCCGGGCACCCCCAATCGCATCTTCTTCAGCGACATC\nCACTTTGGGAACATCCAACAGATCAACGACGATGGCTCCAGGAGGATCACCATTGTGGAA\nAACGTGGGCTCCGTGGAAGGCCTGGCCTATCACCGTGGCTGGGACACTCTCTATTGGACA\nAGCTACACGACATCCACCATCACGCGCCACACAGTGGACCAGACCCGCCCAGGGGCCTTC\nGAGCGTGAGACCGTCATCACTATGTCTGGAGATGACCACCCACGGGCCTTCGTTTTGGAC\nGAGTGCCAGAACCTCATGTTCTGGACCAACTGGAATGAGCAGCATCCCAGCATCATGCGG\nGCGGCGCTCTCGGGAGCCAATGTCCTGACCCTTATCGAGAAGGACATCCGTACCCCCAAT\nGGCCTGGCCATCGACCACCGTGCCGAGAAGCTCTACTTCTCTGACGCCACCCTGGACAAG\nATCGAGCGGTGCGAGTATGACGGCTCCCACCGCTATGTGATCCTAAAGTCAGAGCCTGTC\nCACCCCTTCGGGCTGGCCGTGTATGGGGAGCACATTTTCTGGACTGACTGGGTGCGGCGG\nGCAGTGCAGCGGGCCAACAAGCACGTGGGCAGCAACATGAAGCTGCTGCGCGTGGACATC\nCCCCAGCAGCCCATGGGCATCATCGCCGTGGCCAACGACACCAACAGCTGTGAACTCTCT\nCCATGCCGAATCAACAACGGTGGCTGCCAGGACCTGTGTCTGCTCACTCACCAGGGCCAT\nGTCAACTGCTCATGCCGAGGGGGCCGAATCCTCCAGGATGACCTCACCTGCCGAGCGGTG\nAATTCCTCTTGCCGAGCACAAGATGAGTTTGAGTGTGCCAATGGCGAGTGCATCAACTTC\nAGCCTGACCTGCGACGGCGTCCCCCACTGCAAGGACAAGTCCGATGAGAAGCCATCCTAC\nTGCAACTCCCGCCGCTGCAAGAAGACTTTCCGGCAGTGCAGCAATGGGCGCTGTGTGTCC\nAACATGCTGTGGTGCAACGGGGCCGACGACTGTGGGGATGGCTCTGACGAGATCCCTTGC\nAACAAGACAGCCTGTGGTGTGGGCGAGTTCCGCTGCCGGGACGGGACCTGCATCGGGAAC\nTCCAGCCGCTGCAACCAGTTTGTGGATTGTGAGGACGCCTCAGATGAGATGAACTGCAGT\nGCCACCGACTGCAGCAGCTACTTCCGCCTGGGCGTGAAGGGCGTGCTCTTCCAGCCCTGC\nGAGCGGACCTCACTCTGCTACGCACCCAGCTGGGTGTGTGATGGCGCCAATGACTGTGGG\nGACTACAGTGATGAGCGCGACTGCCCAGGTGTGAAACGCCCCAGATGCCCTCTGAATTAC\nTTCGCCTGCCCTAGTGGGCGCTGCATCCCCATGAGCTGGACGTGTGACAAAGAGGATGAC\nTGTGAACATGGCGAGGACGAGACCCACTGCAACAAGTTCTGCTCAGAGGCCCAGTTTGAG\nTGCCAGAACCATCGCTGCATCTCCAAGCAGTGGCTGTGTGACGGCAGCGATGACTGTGGG\nGATGGCTCAGACGAGGCTGCTCACTGTGAAGGCAAGACGTGCGGCCCCTCCTCCTTCTCC\nTGCCCTGGCACCCACGTGTGCGTCCCCGAGCGCTGGCTCTGTGACGGTGACAAAGACTGT\nGCTGATGGTGCAGACGAGAGCATCGCAGCTGGTTGCTTGTACAACAGCACTTGTGACGAC\nCGTGAGTTCATGTGCCAGAACCGCCAGTGCATCCCCAAGCACTTCGTGTGTGACCACGAC\nCGTGACTGTGCAGATGGCTCTGATGAGTCCCCCGAGTGTGAGTACCCGACCTGCGGCCCC\nAGTGAGTTCCGCTGTGCCAATGGGCGCTGTCTGAGCTCCCGCCAGTGGGAGTGTGATGGC\nGAGAATGACTGCCACGACCAGAGTGACGAGGCTCCCAAGAACCCACACTGCACCAGCCAA\nGAGCACAAGTGCAATGCCTCGTCACAGTTCCTGTGCAGCAGTGGGCGCTGTGTGGCTGAG\nGCACTGCTCTGCAACGGCCAGGATGACTGTGGCGACAGCTCGGACGAGCGTGGCTGCCAC\nATCAATGAGTGTCTCAGCCGCAAGCTCAGTGGCTGCAGCCAGGACTGTGAGGACCTCAAG\nATCGGCTTCAAGTGCCGCTGTCGCCCTGGCTTCCGGCTGAAGGACGACGGCCGGACGTGT\nGCTGATGTGGACGAGTGCAGCACCACCTTCCCCTGCAGCCAGCGCTGCATCAACACTCAT\nGGCAGCTATAAGTGTCTGTGTGTGGAGGGCTATGCACCCCGCGGCGGCGACCCCCACAGC\nTGCAAGGCTGTGACTGACGAGGAACCGTTTCTGATCTTCGCCAACCGGTACTACCTGCGC\nAAGCTCAACCTGGACGGGTCCAACTACACGTTACTTAAGCAGGGCCTGAACAACGCCGTT\nGCCTTGGATTTTGACTACCGAGAGCAGATGATCTACTGGACAGATGTGACCACCCAGGGC\nAGCATGATCCGAAGGATGCACCTTAACGGGAGCAATGTGCAGGTCCTACACCGTACAGGC\nCTCAGCAACCCCGATGGGCTGGCTGTGGACTGGGTGGGTGGCAACCTGTACTGGTGCGAC\nAAAGGCCGGGACACCATCGAGGTGTCCAAGCTCAATGGGGCCTATCGGACGGTGCTGGTC\nAGCTCTGGCCTCCGTGAGCCCAGGGCTCTGGTGGTGGATGTGCAGAATGGGTACCTGTAC\nTGGACAGACTGGGGTGACCATTCACTGATCGGCCGCATCGGCATGGATGGGTCCAGCCGC\nAGCGTCATCGTGGACACCAAGATCACATGGCCCAATGGCCTGACGCTGGACTATGTCACT\nGAGCGCATCTACTGGGCCGACGCCCGCGAGGACTACATTGAATTTGCCAGCCTGGATGGC\nTCCAATCGCCACGTTGTGCTGAGCCAGGACATCCCGCACATCTTTGCACTGACCCTGTTT\nGAGGACTACGTCTACTGGACCGACTGGGAAACAAAGTCCATTAACCGAGCCCACAAGACC\nACGGGCACCAACAAAACGCTCCTCATCAGCACGCTGCACCGGCCCATGGACCTGCATGTC\nTTCCATGCCCTGCGCCAGCCAGACGTGCCCAATCACCCCTGCAAGGTCAACAATGGTGGC\nTGCAGCAACCTGTGCCTGCTGTCCCCCGGGGGAGGGCACAAATGTGCCTGCCCCACCAAC\nTTCTACCTGGGCAGCGATGGGCGCACCTGTGTGTCCAACTGCACGGCTAGCCAGTTTGTA\nTGCAAGAACGACAAGTGCATCCCCTTCTGGTGGAAGTGTGACACCGAGGACGACTGCGGG\nGACCACTCAGACGAGCCCCCGGACTGCCCTGAGTTCAAGTGCCGGCCCGGACAGTTCCAG\nTGCTCCACAGGTATCTGCACAAACCCTGCCTTCATCTGCGATGGCGACAATGACTGCCAG\nGACAACAGTGACGAGGCCAACTGTGACATCCACGTCTGCTTGCCCAGTCAGTTCAAATGC\nACCAACACCAACCGCTGTATTCCCGGCATCTTCCGCTGCAATGGGCAGGACAACTGCGGA\nGATGGGGAGGATGAGAGGGACTGCCCCGAGGTGACCTGCGCCCCCAACCAGTTCCAGTGC\nTCCATTACCAAACGGTGCATCCCCCGGGTCTGGGTCTGCGACCGGGACAATGACTGTGTG\nGATGGCAGTGATGAGCCCGCCAACTGCACCCAGATGACCTGTGGTGTGGACGAGTTCCGC\nTGCAAGGATTCGGGCCGCTGCATCCCAGCGCGTTGGAAGTGTGACGGAGAGGATGACTGT\nGGGGATGGCTCGGATGAGCCCAAGGAAGAGTGTGATGAACGCACCTGTGAGCCATACCAG\nTTCCGCTGCAAGAACAACCGCTGCGTGCCCGGCCGCTGGCAGTGCGACTACGACAACGAT\nTGCGGTGACAACTCCGATGAAGAGAGCTGCACCCCTCGGCCCTGCTCCGAGAGTGAGTTC\nTCCTGTGCCAACGGCCGCTGCATCGCGGGGCGCTGGAAATGCGATGGAGACCACGACTGC\nGCGGACGGCTCGGACGAGAAAGACTGCACCCCCCGCTGTGACATGGACCAGTTCCAGTGC\nAAGAGCGGCCACTGCATCCCCCTGCGCTGGCGCTGTGACGCAGACGCCGACTGCATGGAC\nGGCAGCGACGAGGAGGCCTGCGGCACTGGCGTGCGGACCTGCCCCCTGGACGAGTTCCAG\nTGCAACAACACCTTGTGCAAGCCGCTGGCCTGGAAGTGCGATGGCGAGGATGACTGTGGG\nGACAACTCAGATGAGAACCCCGAGGAGTGTGCCCGGTTCGTGTGCCCTCCCAACCGGCCC\nTTCCGTTGCAAGAATGACCGCGTCTGTCTGTGGATCGGGCGCCAATGCGATGGCACGGAC\nAACTGTGGGGATGGGACTGATGAAGAGGACTGTGAGCCCCCCACAGCCCACACCACCCAC\nTGCAAAGACAAGAAGGAGTTTCTGTGCCGGAACCAGCGCTGCCTCTCCTCCTCCCTGCGC\nTGCAACATGTTCGATGACTGCGGGGACGGCTCTGACGAGGAGGACTGCAGCATCGACCCC\nAAGCTGACCAGCTGCGCCACCAATGCCAGCATCTGTGGGGACGAGGCACGCTGCGTGCGC\nACCGAGAAAGCGGCCTACTGTGCCTGCCGCTCGGGCTTCCACACCGTGCCCGGCCAGCCC\nGGATGCCAAGACATCAACGAGTGCCTGCGCTTCGGCACCTGCTCCCAGCTCTGCAACAAC\nACCAAGGGCGGCCACCTCTGCAGCTGCGCTCGGAACTTCATGAAGACGCACAACACCTGC\nAAGGCCGAAGGCTCTGAGTACCAGGTCCTGTACATCGCTGATGACAATGAGATCCGCAGC\nCTGTTCCCCGGCCACCCCCATTCGGCTTACGAGCAGGCATTCCAGGGTGACGAGAGTGTC\nCGCATTGATGCTATGGATGTCCATGTCAAGGCTGGCCGTGTCTATTGGACCAACTGGCAC\nACGGGCACCATCTCCTACCGCAGCCTGCCACCTGCTGCGCCTCCTACCACTTCCAACCGC\nCACCGGCGACAGATTGACCGGGGTGTCACCCACCTCAACATTTCAGGGCTGAAGATGCCC\nAGAGGCATCGCCATCGACTGGGTGGCCGGAAACGTGTACTGGACCGACTCGGGCCGAGAT\nGTGATTGAGGTGGCGCAGATGAAGGGCGAGAACCGCAAGACGCTCATCTCGGGCATGATT\nGACGAGCCCCACGCCATTGTGGTGGACCCACTGAGGGGGACCATGTACTGGTCAGACTGG\nGGCAACCACCCCAAGATTGAGACGGCAGCGATGGATGGGACGCTTCGGGAGACACTGGTG\nCAGGACAACATTCAGTGGCCCACAGGCCTGGCCGTGGATTATCACAATGAGCGGCTGTAC\nTGGGCAGACGCCAAGCTTTCAGTCATCGGCAGCATCCGGCTCAATGGCACGGACCCCATT\nGTGGCTGCTGACAGCAAACGAGGCCTAAGTCACCCCTTCAGCATCGACGTCTTTGAGGAT\nTACATCTATGGTGTCACCTACATCAATAATCGTGTCTTCAAGATCCATAAGTTTGGCCAC\nAGCCCCTTGGTCAACCTGACAGGGGGCCTGAGCCACGCCTCTGACGTGGTCCTTTACCAT\nCAGCACAAGCAGCCCGAAGTGACCAACCCATGTGACCGCAAGAAATGCGAGTGGCTCTGC\nCTGCTGAGCCCCAGTGGGCCTGTCTGCACCTGTCCCAATGGGAAGCGGCTGGACAACGGC\nACATGCGTGCCTGTGCCCTCTCCAACGCCCCCCCCAGATGCTCCCCGGCCTGGAACCTGT\nAACCTGCAGTGCTTCAACGGTGGCAGCTGTTTCCTCAATGCACGGAGGCAGCCCAAGTGC\nCGCTGCCAACCCCGCTACACGGGTGACAAGTGTGAACTGGACCAGTGCTGGGAGCACTGT\nCGCAATGGGGGCACCTGTGCTGCCTCCCCCTCTGGCATGCCCACGTGCCGGTGCCCCACG\nGGCTTCACGGGCCCCAAATGCACCCAGCAGGTGTGTGCGGGCTACTGTGCCAACAACAGC\nACCTGCACTGTCAACCAGGGCAACCAGCCCCAGTGCCGATGCCTACCCGGCTTCCTGGGC\nGACCGCTGCCAGTACCGGCAGTGCTCTGGCTACTGTGAGAACTTTGGCACATGCCAGATG\nGCTGCTGATGGCTCCCGACAATGCCGCTGCACTGCCTACTTTGAGGGATCGAGGTGTGAG\nGTGAACAAGTGCAGCCGCTGTCTCGAAGGGGCCTGTGTGGTCAACAAGCAGAGTGGGGAT\nGTCACCTGCAACTGCACGGATGGCCGGGTGGCCCCCAGCTGTCTGACCTGCGTCGGCCAC\nTGCAGCAATGGCGGCTCCTGTACCATGAACAGCAAAATGATGCCTGAGTGCCAGTGCCCA\nCCCCACATGACAGGGCCCCGGTGTGAGGAGCACGTCTTCAGCCAGCAGCAGCCAGGACAT\nATAGCCTCCATCCTAATCCCTCTGCTGTTGCTGCTGCTGCTGGTTCTGGTGGCCGGAGTG\nGTATTCTGGTATAAGCGGCGAGTCCAAGGGGCTAAGGGCTTCCAGCACCAACGGATGACC\nAACGGGGCCATGAACGTGGAGATTGGAAACCCCACCTACAAGATGTACGAAGGCGGAGAG\nCCTGATGATGTGGGAGGCCTACTGGACGCTGACTTTGCCCTGGACCCTGACAAGCCCACC\nAACTTCACCAACCCCGTGTATGCCACACTCTACATGGGGGGCCATGGCAGTCGCCACTCC\nCTGGCCAGCACGGACGAGAAGCGAGAACTCCTGGGCCGGGGCCCTGAGGACGAGATAGGG\nGACCCCTTGGCATAG'], 'pfams': [{'pfam': [{'identifier': ['PF07645'], 'name': ['EGF_CA']}, {'identifier': ['PF00057'], 'name': ['Ldl_recept_a']}, {'identifier': ['PF00058'], 'name': ['Ldl_recept_b']}, {'identifier': ['PF12662'], 'name': ['cEGF']}, {'identifier': ['PF16472'], 'name': ['DUF5050']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['clathrin-coated vesicle']}, {'category': ['component'], 'description': ['coated pit']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['dendrite']}, {'category': ['component'], 'description': ['endocytic vesicle membrane']}, {'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['lysosomal membrane']}, {'category': ['component'], 'description': ['neuronal cell body']}, {'category': ['component'], 'description': ['nucleolus']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['function'], 'description': ['apolipoprotein binding']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['lipoprotein particle receptor binding']}, {'category': ['function'], 'description': ['lipoprotein transporter activity']}, {'category': ['function'], 'description': ['poly(A) RNA binding']}, {'category': ['function'], 'description': ['protein complex binding']}, {'category': ['function'], 'description': ['receptor activity']}, {'category': ['process'], 'description': ['aging']}, {'category': ['process'], 'description': ['aorta morphogenesis']}, {'category': ['process'], 'description': ['apoptotic cell clearance']}, {'category': ['process'], 'description': ['beta-amyloid clearance']}, {'category': ['process'], 'description': ['cell proliferation']}, {'category': ['process'], 'description': ['lipoprotein metabolic process']}, {'category': ['process'], 'description': ['lipoprotein transport']}, {'category': ['process'], 'description': ['negative regulation of neuron apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of neuron projection development']}, {'category': ['process'], 'description': ['negative regulation of platelet-derived growth factor receptor-beta signaling pathway']}, {'category': ['process'], 'description': ['negative regulation of smooth muscle cell migration']}, {'category': ['process'], 'description': ['negative regulation of Wnt signaling pathway']}, {'category': ['process'], 'description': ['phototransduction, visible light']}, {'category': ['process'], 'description': ['positive regulation of cholesterol efflux']}, {'category': ['process'], 'description': ['positive regulation of lipid transport']}, {'category': ['process'], 'description': ['positive regulation of protein transport']}, {'category': ['process'], 'description': ['protein kinase C-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['receptor-mediated endocytosis']}, {'category': ['process'], 'description': ['regulation of actin cytoskeleton organization']}, {'category': ['process'], 'description': ['regulation of cholesterol transport']}, {'category': ['process'], 'description': ['regulation of phospholipase A2 activity']}, {'category': ['process'], 'description': ['retinoid metabolic process']}]}]}]}]}]"
"['DB00032', 'BTD00018', 'BIOD00018']",['Menotropins'],biotech,"['Menotropins contains follicle stimulating hormone (FSH) and luteinizing hormone (LH) purified from the urine of postmenopausal women.  It is used as a fertility medication that is injected either subcutaneously or intramuscularly. It is composed of LH with 2 subunits, alpha = 92 residues, beta = 121 residues and FSH with 2 subunits, alpha = 92 residues, beta=111 residues.']",['liquid'],['For the treatment of female infertility'],"['Being a combination drug, Menotropins bind to the follicle stimulating hormone receptor (FSH), which results in ovulation in the absence of sufficient endogenous luteinizing hormone (LH). It also binds the LH receptor, thereby stimulating proper hormone release. The drug contains both FSH and LH, therefore, it induces ovarian follicular growth and development as well as gonadal steroid production in women who do not have ovarian failure. FSH is the primary driver of follicular recruitment and growth in early folliculogenesis, while LH is important for ovarian steroidogenesis and is involved in the physiological events leading to development of a competent pre-ovulatory follicle.']",[None],"[{'target': [{'id': ['BE0000387'], 'name': ['Follicle-stimulating hormone receptor'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A1855'], 'pubmed-id': ['14680547'], 'citation': ['van de Weijer BH, Mulders JW, Bos ES, Verhaert PD, van den Hooven HW: Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reprod Biomed Online. 2003 Nov;7(5):547-57.']}, {'ref-id': ['A1856'], 'pubmed-id': ['7872378'], 'citation': ['Olive DL: The role of gonadotropins in ovulation induction. Am J Obstet Gynecol. 1995 Feb;172(2 Pt 2):759-65.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Follicle-stimulating hormone receptor'], 'general-function': ['G-protein coupled peptide receptor activity'], 'specific-function': ['Receptor for follicle-stimulating hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Induces cAMP production through the activation of PI3K-AKT and SRC-ERK1/2 signaling pathways.'], 'gene-name': ['FSHR'], 'locus': ['2p21-p16'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['367-387\n399-421\n444-465\n486-508\n529-550\n574-597\n609-630'], 'signal-regions': ['1-17'], 'theoretical-pi': ['7.19'], 'molecular-weight': ['78264.07'], 'chromosome-location': ['2'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3969']}, {'resource': ['GenAtlas'], 'identifier': ['FSHR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M65085']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182771']}, {'resource': ['IUPHAR'], 'identifier': ['253']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['253']}, {'resource': ['UniProtKB'], 'identifier': ['P23945']}, {'resource': ['UniProt Accession'], 'identifier': ['FSHR_HUMAN']}]}], 'synonyms': [{'synonym': ['Follitropin receptor', 'FSH-R', 'LGR1']}], 'amino-acid-sequence': ['>lcl|BSEQ0037007|Follicle-stimulating hormone receptor\nMALLLVSLLAFLSLGSGCHHRICHCSNRVFLCQESKVTEIPSDLPRNAIELRFVLTKLRV\nIQKGAFSGFGDLEKIEISQNDVLEVIEADVFSNLPKLHEIRIEKANNLLYINPEAFQNLP\nNLQYLLISNTGIKHLPDVHKIHSLQKVLLDIQDNINIHTIERNSFVGLSFESVILWLNKN\nGIQEIHNCAFNGTQLDELNLSDNNNLEELPNDVFHGASGPVILDISRTRIHSLPSYGLEN\nLKKLRARSTYNLKKLPTLEKLVALMEASLTYPSHCCAFANWRRQISELHPICNKSILRQE\nVDYMTQARGQRSSLAEDNESSYSRGFDMTYTEFDYDLCNEVVDVTCSPKPDAFNPCEDIM\nGYNILRVLIWFISILAITGNIIVLVILTTSQYKLTVPRFLMCNLAFADLCIGIYLLLIAS\nVDIHTKSQYHNYAIDWQTGAGCDAAGFFTVFASELSVYTLTAITLERWHTITHAMQLDCK\nVQLRHAASVMVMGWIFAFAAALFPIFGISSYMKVSICLPMDIDSPLSQLYVMSLLVLNVL\nAFVVICGCYIHIYLTVRNPNIVSSSSDTRIAKRMAMLIFTDFLCMAPISFFAISASLKVP\nLITVSKAKILLVLFHPINSCANPFLYAIFTKNFRRDFFILLSKCGCYEMQAQIYRTETSS\nTVHNTHPRNGHCSSAPRVTNGSTYILVPLSHLAQN'], 'gene-sequence': ['>lcl|BSEQ0018946|Follicle-stimulating hormone receptor (FSHR)\nATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCAT\nCGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATT\nCCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTC\nATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAAT\nGATGTCTTGGAGGTGATAGAGGCAGATGTGTTCTCCAACCTTCCCAAATTACATGAAATT\nAGAATTGAAAAGGCCAACAACCTGCTCTACATCAACCCTGAGGCCTTCCAGAACCTTCCC\nAACCTTCAATATCTGTTAATATCCAACACAGGTATTAAGCACCTTCCAGATGTTCACAAG\nATTCATTCTCTCCAAAAAGTTTTACTTGACATTCAAGATAACATAAACATCCACACAATT\nGAAAGAAATTCTTTCGTGGGGCTGAGCTTTGAAAGTGTGATTCTATGGCTGAATAAGAAT\nGGGATTCAAGAAATACACAACTGTGCATTCAATGGAACCCAACTAGATGAGCTGAATCTA\nAGCGATAATAATAATTTAGAAGAATTGCCTAATGATGTTTTCCACGGAGCCTCTGGACCA\nGTCATTCTAGATATTTCAAGAACAAGGATCCATTCCCTGCCTAGCTATGGCTTAGAAAAT\nCTTAAGAAGCTGAGGGCCAGGTCGACTTACAACTTAAAAAAGCTGCCTACTCTGGAAAAG\nCTTGTCGCCCTCATGGAAGCCAGCCTCACCTATCCCAGCCATTGCTGTGCCTTTGCAAAC\nTGGAGACGGCAAATCTCTGAGCTTCATCCAATTTGCAACAAATCTATTTTAAGGCAAGAA\nGTTGATTATATGACTCAGGCTAGGGGTCAGAGATCCTCTCTGGCAGAAGACAATGAGTCC\nAGCTACAGCAGAGGATTTGACATGACGTACACTGAGTTTGACTATGACTTATGCAATGAA\nGTGGTTGACGTGACCTGCTCCCCTAAGCCAGATGCATTCAACCCATGTGAAGATATCATG\nGGGTACAACATCCTCAGAGTCCTGATATGGTTTATCAGCATCCTGGCCATCACTGGGAAC\nATCATAGTGCTAGTGATCCTAACTACCAGCCAATATAAACTCACAGTCCCCAGGTTCCTT\nATGTGCAACCTGGCCTTTGCTGATCTCTGCATTGGAATCTACCTGCTGCTCATTGCATCA\nGTTGATATCCATACCAAGAGCCAATATCACAACTATGCCATTGACTGGCAAACTGGGGCA\nGGCTGTGATGCTGCTGGCTTTTTCACTGTCTTTGCCAGTGAGCTGTCAGTCTACACTCTG\nACAGCTATCACCTTGGAAAGATGGCATACCATCACGCATGCCATGCAGCTGGACTGCAAG\nGTGCAGCTCCGCCATGCTGCCAGTGTCATGGTGATGGGCTGGATTTTTGCTTTTGCAGCT\nGCCCTCTTTCCCATCTTTGGCATCAGCAGCTACATGAAGGTGAGCATCTGCCTGCCCATG\nGATATTGACAGCCCTTTGTCACAGCTGTATGTCATGTCCCTCCTTGTGCTCAATGTCCTG\nGCCTTTGTGGTCATCTGTGGCTGCTATATCCACATCTACCTCACAGTGCGGAACCCCAAC\nATCGTGTCCTCCTCTAGTGACACCAGGATCGCCAAGCGCATGGCCATGCTCATCTTCACT\nGACTTCCTCTGCATGGCACCCATTTCTTTCTTTGCCATTTCTGCCTCCCTCAAGGTGCCC\nCTCATCACTGTGTCCAAAGCAAAGATTCTGCTGGTTCTGTTTCACCCCATCAACTCCTGT\nGCCAACCCCTTCCTCTATGCCATCTTTACCAAAAACTTTCGCAGAGATTTCTTCATTCTG\nCTGAGCAAGTGTGGCTGCTATGAAATGCAAGCCCAAATTTATAGGACAGAAACTTCATCC\nACTGTCCACAACACCCATCCAAGGAATGGCCACTGCTCTTCAGCTCCCAGAGTCACCAGT\nGGTTCCACTTACATACTTGTCCCTCTAAGTCATTTAGCCCAAAACTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}, {'identifier': ['PF01462'], 'name': ['LRRNT']}, {'identifier': ['PF13306'], 'name': ['LRR_5']}, {'identifier': ['PF12369'], 'name': ['GnHR_trans']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['follicle-stimulating hormone receptor activity']}, {'category': ['function'], 'description': ['G-protein coupled peptide receptor activity']}, {'category': ['process'], 'description': ['activation of adenylate cyclase activity']}, {'category': ['process'], 'description': ['adenylate cyclase-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['female gamete generation']}, {'category': ['process'], 'description': ['female gonad development']}, {'category': ['process'], 'description': ['follicle-stimulating hormone signaling pathway']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['gonad development']}, {'category': ['process'], 'description': ['hormone-mediated signaling pathway']}, {'category': ['process'], 'description': ['male gonad development']}, {'category': ['process'], 'description': ['positive regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['positive regulation of phosphatidylinositol 3-kinase signaling']}, {'category': ['process'], 'description': ['primary ovarian follicle growth']}, {'category': ['process'], 'description': ['regulation of osteoclast differentiation']}, {'category': ['process'], 'description': ['regulation of protein kinase A signaling']}, {'category': ['process'], 'description': ['spermatogenesis']}, {'category': ['process'], 'description': ['uterus development']}]}]}]}, {'id': ['BE0000134'], 'name': ['Lutropin-choriogonadotropic hormone receptor'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A1855'], 'pubmed-id': ['14680547'], 'citation': ['van de Weijer BH, Mulders JW, Bos ES, Verhaert PD, van den Hooven HW: Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reprod Biomed Online. 2003 Nov;7(5):547-57.']}, {'ref-id': ['A1856'], 'pubmed-id': ['7872378'], 'citation': ['Olive DL: The role of gonadotropins in ovulation induction. Am J Obstet Gynecol. 1995 Feb;172(2 Pt 2):759-65.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Lutropin-choriogonadotropic hormone receptor'], 'general-function': ['Luteinizing hormone receptor activity'], 'specific-function': ['Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase.'], 'gene-name': ['LHCGR'], 'locus': ['2p21'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['364-385\n396-416\n440-462\n483-505\n526-549\n571-594\n606-627'], 'signal-regions': ['1-26'], 'theoretical-pi': ['8.58'], 'molecular-weight': ['78642.01'], 'chromosome-location': ['2'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6585']}, {'resource': ['GenAtlas'], 'identifier': ['LHCGR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M73746']}, {'resource': ['GenBank Protein Database'], 'identifier': ['903746']}, {'resource': ['IUPHAR'], 'identifier': ['254']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['254']}, {'resource': ['UniProtKB'], 'identifier': ['P22888']}, {'resource': ['UniProt Accession'], 'identifier': ['LSHR_HUMAN']}]}], 'synonyms': [{'synonym': ['LCGR', 'LGR2', 'LH/CG-R', 'LHR', 'LHRHR', 'LSH-R', 'Luteinizing hormone receptor']}], 'amino-acid-sequence': ['>lcl|BSEQ0036957|Lutropin-choriogonadotropic hormone receptor\nMKQRFSALQLLKLLLLLQPPLPRALREALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLP\nVKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFI\nNLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLK\nLYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSY\nGLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENF\nSKQCESTVRKVNNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYD\nFLRVLIWLINILAIMGNMTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIASVDS\nQTKGQYYNHAIDWQTGSGCSTAGFFTVFASELSVYTLTVITLERWHTITYAIHLDQKLRL\nRHAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETTLSQVYILTILILNVVAFF\nIICACYIKIYFAVRNPELMATNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKVPLIT\nVTNSKVLLVLFYPINSCANPFLYAIFTKTFQRDFFLLLSKFGCCKRRAELYRRKDFSAYT\nSNCKNGFTGSNKPSQSTLKLSTLHCQGTALLDKTRYTEC'], 'gene-sequence': ['>lcl|BSEQ0010174|Lutropin-choriogonadotropic hormone receptor (LHCGR)\nATGAAGCAGCGGTTCTCGGCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGCCGCCG\nCTGCCACGAGCGCTGCGCGAGGCGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGC\nGCCCTGCGCTGCCCCGGCCCCACGGCCGGTCTCACTCGACTATCACTTGCCTACCTCCCT\nGTCAAAGTGATCCCATCTCAAGCTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATC\nTCTCAGATTGATTCCCTGGAAAGGATAGAAGCTAATGCCTTTGACAACCTCCTCAATTTG\nTCTGAAATACTGATCCAGAACACCAAAAATCTGAGATACATTGAGCCCGGAGCATTTATA\nAATCTTCCCCGATTAAAATACTTGAGCATCTGTAACACAGGCATCAGAAAGTTTCCAGAT\nGTTACGAAGGTCTTCTCCTCTGAATCAAATTTCATTCTGGAAATTTGTGATAACTTACAC\nATAACCACCATACCAGGAAATGCTTTTCAAGGGATGAATAATGAATCTGTAACACTCAAA\nCTATATGGAAATGGATTTGAAGAAGTACAAAGTCATGCATTCAATGGGACGACACTGACT\nTCACTGGAGCTAAAGGAAAACGTACATCTGGAGAAGATGCACAATGGAGCCTTCCGTGGG\nGCCACAGGGCCGAAAACCTTGGATATTTCTTCCACCAAATTGCAGGCCCTGCCGAGCTAT\nGGCCTAGAGTCCATTCAGAGGCTAATTGCCACGTCATCCTATTCTCTAAAAAAATTGCCA\nTCAAGAGAAACATTTGTCAATCTCCTGGAGGCCACGTTGACTTACCCCAGCCACTGCTGT\nGCTTTTAGAAACTTGCCAACAAAAGAACAGAATTTTTCACATTCCATTTCTGAAAACTTT\nTCCAAACAATGTGAAAGCACAGTAAGGAAAGTGAATAACAAAACACTTTATTCTTCCATG\nCTTGCTGAGAGTGAACTGAGTGGCTGGGACTATGAATATGGTTTCTGCTTACCCAAGACA\nCCCCGATGTGCTCCTGAACCAGATGCTTTTAATCCCTGTGAAGATATTATGGGCTATGAC\nTTCCTTAGGGTCCTGATTTGGCTGATTAATATTCTAGCCATCATGGGAAACATGACTGTT\nCTTTTTGTTCTCCTGACAAGTCGTTACAAACTTACAGTGCCTCGTTTTCTCATGTGCAAT\nCTCTCCTTTGCAGACTTTTGCATGGGGCTCTATCTGCTGCTCATAGCCTCAGTTGATTCC\nCAAACCAAGGGCCAGTACTATAACCATGCCATAGACTGGCAGACAGGGAGTGGGTGCAGC\nACTGCTGGCTTTTTCACTGTATTCGCAAGTGAACTTTCTGTCTACACCCTCACCGTCATC\nACTCTAGAAAGATGGCACACCATCACCTATGCTATTCACCTGGACCAAAAGCTGCGATTA\nAGACATGCCATTCTGATTATGCTTGGAGGATGGCTCTTTTCTTCTCTAATTGCTATGTTG\nCCCCTTGTCGGTGTCAGCAATTACATGAAGGTCAGTATTTGCTTCCCCATGGATGTGGAA\nACCACTCTCTCACAAGTCTATATATTAACCATCCTGATTCTCAATGTGGTGGCCTTCTTC\nATAATTTGTGCTTGCTACATTAAAATTTATTTTGCAGTTCGAAACCCAGAATTAATGGCT\nACCAATAAAGATACAAAGATTGCTAAGAAAATGGCAATCCTCATCTTCACCGATTTCACC\nTGCATGGCACCTATCTCTTTTTTTGCCATCTCAGCTGCCTTCAAAGTACCTCTTATCACA\nGTAACCAACTCTAAAGTTTTACTGGTTCTTTTTTATCCCATCAATTCTTGTGCCAATCCA\nTTTCTGTATGCAATATTCACTAAGACATTCCAAAGAGATTTCTTTCTTTTGCTGAGCAAA\nTTTGGCTGCTGTAAACGTCGGGCTGAACTTTATAGAAGGAAAGATTTTTCAGCTTACACC\nTCCAACTGCAAAAATGGCTTCACTGGATCAAATAAGCCTTCTCAATCCACCTTGAAGTTG\nTCCACATTGCACTGTCAAGGTACAGCTCTCCTAGACAAGACTCGCTACACAGAGTGTTAA\n'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}, {'identifier': ['PF13306'], 'name': ['LRR_5']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['choriogonadotropin hormone binding']}, {'category': ['function'], 'description': ['choriogonadotropin hormone receptor activity']}, {'category': ['function'], 'description': ['G-protein coupled peptide receptor activity']}, {'category': ['function'], 'description': ['luteinizing hormone receptor activity']}, {'category': ['process'], 'description': ['activation of adenylate cyclase activity']}, {'category': ['process'], 'description': ['adenylate cyclase-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular response to gonadotropin stimulus']}, {'category': ['process'], 'description': ['cognition']}, {'category': ['process'], 'description': ['female gonad development']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger']}, {'category': ['process'], 'description': ['hormone-mediated signaling pathway']}, {'category': ['process'], 'description': ['luteinizing hormone signaling pathway']}, {'category': ['process'], 'description': ['male genitalia development']}, {'category': ['process'], 'description': ['male gonad development']}, {'category': ['process'], 'description': ['ovulation cycle process']}, {'category': ['process'], 'description': ['phospholipase C-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of cAMP-mediated signaling']}, {'category': ['process'], 'description': ['positive regulation of inositol trisphosphate biosynthetic process']}, {'category': ['process'], 'description': ['spermatogenesis']}, {'category': ['process'], 'description': ['uterus development']}]}]}]}]}]"
"['DB00033', 'BTD00017', 'BIOD00017']",['Interferon gamma-1b'],biotech,"['Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography. \r\nThe sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b.']",['liquid'],['Interferon gamma-1b is used for the treatment of Chronic granulomatous disease and Osteopetrosis.'],"['Binds directly to the type II interferon gamma receptor IFNGR1, leading to a complex of IFNGR1 and IFNGR2. This activates JAK1 and JAK2 kinases which form a STAT1 docking site. This leads to STAT1 phosphorylation, nuclear translocation and initiation of gene transcription of multiple immune-related genes.']","[{'food-interaction': ['Avoid excessive or chronic alcohol consumption. Interferon gamma-1b may cause fatigue, drowsiness, and confusion. These effects may be exacerbated by alcohol consumption.']}]","[{'target': [{'id': ['BE0000711'], 'name': ['Interferon gamma receptor 1'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1859'], 'pubmed-id': ['17251453'], 'citation': ['Matsuda A, Ebihara N, Kumagai N, Fukuda K, Ebe K, Hirano K, Sotozono C, Tei M, Hasegawa K, Shimizu M, Tamari M, Namba K, Ohno S, Mizuki N, Ikezawa Z, Shirakawa T, Hamuro J, Kinoshita S: Genetic polymorphisms in the promoter of the interferon gamma receptor 1 gene are associated with atopic cataracts. Invest Ophthalmol Vis Sci. 2007 Feb;48(2):583-9.']}, {'ref-id': ['A1861'], 'pubmed-id': ['17618444'], 'citation': ['Yao X, Chen ZQ, Gong JQ, Chen M, Li AS, Liu J: The interferon-gamma receptor gene polymorphisms (Val14Met and Gln64Arg) are not associated with systemic lupus erythematosus in Chinese patients. Arch Dermatol Res. 2007 Oct;299(8):367-71. Epub 2007 Jul 6.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interferon gamma receptor 1'], 'general-function': ['Interferon-gamma receptor activity'], 'specific-function': ['Receptor for interferon gamma. Two receptors bind one interferon gamma dimer.'], 'gene-name': ['IFNGR1'], 'locus': ['6q23-q24'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['246-266'], 'signal-regions': ['1-17'], 'theoretical-pi': ['4.56'], 'molecular-weight': ['54404.07'], 'chromosome-location': ['6'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5439']}, {'resource': ['GenAtlas'], 'identifier': ['IFNGR1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['J03143']}, {'resource': ['GenBank Protein Database'], 'identifier': ['306915']}, {'resource': ['UniProtKB'], 'identifier': ['P15260']}, {'resource': ['UniProt Accession'], 'identifier': ['INGR1_HUMAN']}]}], 'synonyms': [{'synonym': ['CDw119', 'IFN-gamma receptor 1']}], 'amino-acid-sequence': ['>lcl|BSEQ0001418|Interferon gamma receptor 1\nMALLFLLPLVMQGVSRAEMGTADLGPSSVPTPTNVTIESYNMNPIVYWEYQIMPQVPVFT\nVEVKNYGVKNSEWIDACINISHHYCNISDHVGDPSNSLWVRVKARVGQKESAYAKSEEFA\nVCRDGKIGPPKLDIRKEEKQIMIDIFHPSVFVNGDEQEVDYDPETTCYIRVYNVYVRMNG\nSEIQYKILTQKEDDCDEIQCQLAIPVSSLNSQYCVSAEGVLHVWGVTTEKSKEVCITIFN\nSSIKGSLWIPVVAALLLFLVLSLVFICFYIKKINPLKEKSIILPKSLISVVRSATLETKP\nESKYVSLITSYQPFSLEKEVVCEEPLSPATVPGMHTEDNPGKVEHTEELSSITEVVTTEE\nNIPDVVPGSHLTPIERESSSPLSSNQSEPGSIALNSYHSRNCSESDHSRNGFDTDSSCLE\nSHSSLSDSEFPPNNKGEIKTEGQELITVIKAPTSFGYDKPHVLVDLLVDDSGKESLIGYR\nPTEDSKEFS'], 'gene-sequence': ['>lcl|BSEQ0010499|Interferon gamma receptor 1 (IFNGR1)\nATGGCTCTCCTCTTTCTCCTACCCCTTGTCATGCAGGGTGTGAGCAGGGCTGAGATGGGC\nACCGCGGATCTGGGGCCGTCCTCAGTGCCTACACCAACTAATGTTACAATTGAATCCTAT\nAACATGAACCCTATCGTATATTGGGAGTACCAGATCATGCCACAGGTCCCTGTTTTTACC\nGTAGAGGTAAAGAACTATGGTGTTAAGAATTCAGAATGGATTGATGCCTGCATCAATATT\nTCTCATCATTATTGTAATATTTCTGATCATGTTGGTGATCCATCAAATTCTCTTTGGGTC\nAGAGTTAAAGCCAGGGTTGGACAAAAAGAATCTGCCTATGCAAAGTCAGAAGAATTTGCT\nGTATGCCGAGATGGAAAAATTGGACCACCTAAACTGGATATCAGAAAGGAGGAGAAGCAA\nATCATGATTGACATATTTCACCCTTCAGTTTTTGTAAATGGAGACGAGCAGGAAGTCGAT\nTATGATCCCGAAACTACCTGTTACATTAGGGTGTACAATGTGTATGTGAGAATGAACGGA\nAGTGAGATCCAGTATAAAATACTCACGCAGAAGGAAGATGATTGTGACGAGATTCAGTGC\nCAGTTAGCGATTCCAGTATCCTCACTGAATTCTCAGTACTGTGTTTCAGCAGAAGGAGTC\nTTACATGTGTGGGGTGTTACAACTGAAAAGTCAAAAGAAGTTTGTATTACCATTTTCAAT\nAGCAGTATAAAAGGTTCTCTTTGGATTCCAGTTGTTGCTGCTTTACTACTCTTTCTAGTG\nCTTAGCCTGGTATTCATCTGTTTTTATATTAAGAAAATTAATCCATTGAAGGAAAAAAGC\nATAATATTACCCAAGTCCTTGATCTCTGTGGTAAGAAGTGCTACTTTAGAGACAAAACCT\nGAATCAAAATATGTATCACTCATCACGTCATACCAGCCATTTTCCTTAGAAAAGGAGGTG\nGTCTGTGAAGAGCCGTTGTCTCCAGCAACAGTTCCAGGCATGCATACCGAAGACAATCCA\nGGAAAAGTGGAACATACAGAAGAACTTTCTAGTATAACAGAAGTGGTGACTACTGAAGAA\nAATATTCCTGACGTGGTCCCGGGCAGCCATCTGACTCCAATAGAGAGAGAGAGTTCTTCA\nCCTTTAAGTAGTAACCAGTCTGAACCTGGCAGCATCGCTTTAAACTCGTATCACTCCAGA\nAATTGTTCTGAGAGTGATCACTCCAGAAATGGTTTTGATACTGATTCCAGCTGTCTGGAA\nTCACATAGCTCCTTATCTGACTCAGAATTTCCCCCAAATAATAAAGGTGAAATAAAAACA\nGAAGGACAAGAGCTCATAACCGTAATAAAAGCCCCCACCTCCTTTGGTTATGATAAACCA\nCATGTGCTAGTGGATCTACTTGTGGATGATAGCGGTAAAGAGTCCTTGATTGGTTATAGA\nCCAACAGAAGATTCCAAAGAATTTTCATGA'], 'pfams': [{'pfam': [{'identifier': ['PF07140'], 'name': ['IFNGR1']}, {'identifier': ['PF01108'], 'name': ['Tissue_fac']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['interferon-gamma receptor activity']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['interferon-gamma-mediated signaling pathway']}, {'category': ['process'], 'description': ['regulation of interferon-gamma-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}, {'id': ['BE0000467'], 'name': ['Interferon gamma receptor 2'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A6692'], 'pubmed-id': ['17239631'], 'citation': ['Park-Min KH, Serbina NV, Yang W, Ma X, Krystal G, Neel BG, Nutt SL, Hu X, Ivashkiv LB: FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity. 2007 Jan;26(1):67-78.']}, {'ref-id': ['A1861'], 'pubmed-id': ['17618444'], 'citation': ['Yao X, Chen ZQ, Gong JQ, Chen M, Li AS, Liu J: The interferon-gamma receptor gene polymorphisms (Val14Met and Gln64Arg) are not associated with systemic lupus erythematosus in Chinese patients. Arch Dermatol Res. 2007 Oct;299(8):367-71. Epub 2007 Jul 6.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interferon gamma receptor 2'], 'general-function': ['Interferon-gamma receptor activity'], 'specific-function': ['Part of the receptor for interferon gamma. Required for signal transduction. This accessory factor is an integral part of the IFN-gamma signal transduction pathway and is likely to interact with GAF, JAK1, and/or JAK2.'], 'gene-name': ['IFNGR2'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['248-268'], 'signal-regions': ['1-27'], 'theoretical-pi': ['5.35'], 'molecular-weight': ['37805.97'], 'chromosome-location': ['21'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5440']}, {'resource': ['GenAtlas'], 'identifier': ['IFNGR2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['U05875']}, {'resource': ['GenBank Protein Database'], 'identifier': ['463550']}, {'resource': ['UniProtKB'], 'identifier': ['P38484']}, {'resource': ['UniProt Accession'], 'identifier': ['INGR2_HUMAN']}]}], 'synonyms': [{'synonym': ['AF-1', 'IFN-gamma receptor 2', 'IFNGT1', 'Interferon gamma receptor accessory factor 1', 'Interferon gamma transducer 1']}], 'amino-acid-sequence': ['>lcl|BSEQ0010328|Interferon gamma receptor 2\nMRPTLLWSLLLLLGVFAAAAAAPPDPLSQLPAPQHPKIRLYNAEQVLSWEPVALSNSTRP\nVVYQVQFKYTDSKWFTADIMSIGVNCTQITATECDFTAASPSAGFPMDFNVTLRLRAELG\nALHSAWVTMPWFQHYRNVTVGPPENIEVTPGEGSLIIRFSSPFDIADTSTAFFCYYVHYW\nEKGGIQQVKGPFRSNSISLDNLKPSRVYCLQVQAQLLWNKSNIFRVGHLSNISCYETMAD\nASTELQQVILISVGTFSLLSVLAGACFFLVLKYRGLIKYWFHTPPSIPLQIEEYLKDPTQ\nPILEALDKDSSPKDDVWDSVSIISFPEKEQEDVLQTL'], 'gene-sequence': ['>lcl|BSEQ0010329|Interferon gamma receptor 2 (IFNGR2)\nATGCGACCGACGCTGCTGTGGTCGCTGCTGCTGCTGCTCGGAGTCTTCGCCGCCGCCGCC\nGCGGCCCCGCCAGACCCTCTTTCCCAGCTGCCCGCTCCTCAGCACCCGAAGATTCGCCTG\nTACAACGCAGAGCAGGTCCTGAGTTGGGAGCCAGTGGCCCTGAGCAATAGCACGAGGCCT\nGTTGTCTACCAAGTGCAGTTTAAATACACCGACAGTAAATGGTTCACGGCCGACATCATG\nTCCATAGGGGTGAATTGTACACAGATCACAGCAACAGAGTGTGACTTCACTGCCGCCAGT\nCCCTCAGCAGGCTTCCCAATGGATTTCAATGTCACTCTACGCCTTCGAGCTGAGCTGGGA\nGCACTCCATTCTGCCTGGGTGACAATGCCTTGGTTTCAACACTATCGGAATGTGACTGTC\nGGGCCTCCAGAAAACATTGAGGTGACCCCAGGAGAAGGCTCCCTCATCATCAGGTTCTCC\nTCTCCCTTTGACATCGCTGATACCTCCACGGCCTTTTTTTGTTATTATGTCCATTACTGG\nGAAAAAGGAGGAATCCAACAGGTCAAAGGCCCTTTCAGAAGCAACTCCATTTCATTGGAT\nAACTTAAAACCCTCCAGAGTGTACTGTTTACAAGTCCAGGCACAACTGCTTTGGAACAAA\nAGTAACATCTTTAGAGTCGGGCATTTAAGCAACATATCTTGCTACGAAACAATGGCAGAT\nGCCTCCACTGAGCTTCAGCAAGTCATCCTGATCTCCGTGGGAACATTTTCGTTGCTGTCG\nGTGCTGGCAGGAGCCTGTTTCTTCCTGGTCCTGAAATATAGAGGCCTGATTAAATACTGG\nTTTCACACTCCACCAAGCATCCCATTACAGATAGAAGAGTATTTAAAAGACCCAACTCAG\nCCCATCTTAGAGGCCTTGGACAAGGACAGCTCACCAAAGGATGACGTCTGGGACTCTGTG\nTCCATTATCTCGTTTCCGGAAAAGGAGCAAGAAGATGTTCTCCAAACGCTTTGA'], 'pfams': [{'pfam': [{'identifier': ['PF01108'], 'name': ['Tissue_fac']}, {'identifier': ['PF09294'], 'name': ['Interfer-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endoplasmic reticulum']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['interferon-gamma receptor activity']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['interferon-gamma-mediated signaling pathway']}, {'category': ['process'], 'description': ['regulation of interferon-gamma-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to virus']}]}]}]}]}]"
"['DB00034', 'BTD00095', 'BTD00012', 'BIOD00095', 'BIOD00012', 'DB00037']",['Interferon alfa-2a'],biotech,['Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.'],['liquid'],"[""For the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection.""]","['Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.']",[{'food-interaction': ['Avoid alcohol.']}],"[{'target': [{'id': ['BE0000661'], 'name': ['Interferon alpha/beta receptor 1'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A1754'], 'pubmed-id': ['15898717'], 'citation': ['Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27.']}, {'ref-id': ['A1863'], 'pubmed-id': ['18230610'], 'citation': ['Cironi P, Swinburne IA, Silver PA: Enhancement of cell type specificity by quantitative modulation of a chimeric ligand. J Biol Chem. 2008 Mar 28;283(13):8469-76. doi: 10.1074/jbc.M708502200. Epub 2008  Jan 29.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interferon alpha/beta receptor 1'], 'general-function': ['Type i interferon receptor activity'], 'specific-function': ['Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.'], 'gene-name': ['IFNAR1'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['437-457'], 'signal-regions': ['1-27'], 'theoretical-pi': ['5.56'], 'molecular-weight': ['63524.81'], 'chromosome-location': ['21'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5432']}, {'resource': ['GenAtlas'], 'identifier': ['IFNAR1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['J03171']}, {'resource': ['GenBank Protein Database'], 'identifier': ['306914']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1723']}, {'resource': ['UniProtKB'], 'identifier': ['P17181']}, {'resource': ['UniProt Accession'], 'identifier': ['INAR1_HUMAN']}]}], 'synonyms': [{'synonym': ['CRF2-1', 'Cytokine receptor class-II member 1', 'Cytokine receptor family 2 member 1', 'IFN-R-1', 'IFNAR', 'Type I interferon receptor 1']}], 'amino-acid-sequence': ['>lcl|BSEQ0001318|Interferon alpha/beta receptor 1\nMMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT\nFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF\nTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI\nENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ\nNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK\nGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP\nVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV\nFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE\nYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN\nEDESESKTSEELQQDFV'], 'gene-sequence': ['>lcl|BSEQ0018987|Interferon alpha/beta receptor 1 (IFNAR1)\nATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTG\nTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC\nATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT\nTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG\nAATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT\nAAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT\nACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG\nGCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT\nTTAAGCTTTACATATAGCTTAGTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT\nGAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA\nAAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT\nATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA\nAATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG\nTGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA\nCCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA\nGGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA\nGAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA\nTCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT\nGTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT\nGAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT\nGTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT\nTTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA\nGTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC\nTTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG\nTATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA\nAAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT\nGATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT\nGAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA'], 'pfams': [{'pfam': [{'identifier': ['PF01108'], 'name': ['Tissue_fac']}, {'identifier': ['PF09294'], 'name': ['Interfer-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['type I interferon receptor activity']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['defense response to virus']}, {'category': ['process'], 'description': ['JAK-STAT cascade']}, {'category': ['process'], 'description': ['positive regulation of interferon-beta production']}, {'category': ['process'], 'description': ['positive regulation of interferon-gamma production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-1 beta secretion']}, {'category': ['process'], 'description': ['positive regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['regulation of type I interferon-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['T cell activation']}, {'category': ['process'], 'description': ['type I interferon biosynthetic process']}, {'category': ['process'], 'description': ['type I interferon signaling pathway']}]}]}]}, {'id': ['BE0000385'], 'name': ['Interferon alpha/beta receptor 2'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A1754'], 'pubmed-id': ['15898717'], 'citation': ['Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27.']}, {'ref-id': ['A1863'], 'pubmed-id': ['18230610'], 'citation': ['Cironi P, Swinburne IA, Silver PA: Enhancement of cell type specificity by quantitative modulation of a chimeric ligand. J Biol Chem. 2008 Mar 28;283(13):8469-76. doi: 10.1074/jbc.M708502200. Epub 2008  Jan 29.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interferon alpha/beta receptor 2'], 'general-function': ['Type i interferon receptor activity'], 'specific-function': ['Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.'], 'gene-name': ['IFNAR2'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['244-264'], 'signal-regions': ['1-26'], 'theoretical-pi': ['4.11'], 'molecular-weight': ['57758.24'], 'chromosome-location': ['21'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5433']}, {'resource': ['GenAtlas'], 'identifier': ['IFNAR2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L42243']}, {'resource': ['GenBank Protein Database'], 'identifier': ['995300']}, {'resource': ['UniProtKB'], 'identifier': ['P48551']}, {'resource': ['UniProt Accession'], 'identifier': ['INAR2_HUMAN']}]}], 'synonyms': [{'synonym': ['IFN-R-2', 'IFNABR', 'IFNARB', 'Interferon alpha binding protein', 'Type I interferon receptor 2']}], 'amino-acid-sequence': ['>lcl|BSEQ0000767|Interferon alpha/beta receptor 2\nMLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS\nIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF\nSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK\nHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE\nSAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD\nMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI\nDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR\nITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT\nFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR'], 'gene-sequence': ['>lcl|BSEQ0018941|Interferon alpha/beta receptor 2 (IFNAR2)\nATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT\nATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT\nTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC\nATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG\nGTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA\nAGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC\nAGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG\nATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA\nGAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG\nCATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA\nATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA\nATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA\nTCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC\nATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG\nAGGCAAGGTCTCGCTAAGGGCTGGAATGCAGTGGCTATTCACAGGTGCAGTCATAATGCA\nCTACAGTCTGAAACTCCTGAGCTCAAACAGTCGTCCTGCCTAAGCTTCCCCAGTAGCTGG\nGATTACAAGCGTGCATCCCTGTGCCCCAGTGATTAA'], 'pfams': [{'pfam': [{'identifier': ['PF01108'], 'name': ['Tissue_fac']}, {'identifier': ['PF09294'], 'name': ['Interfer-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['protein kinase binding']}, {'category': ['function'], 'description': ['type I interferon binding']}, {'category': ['function'], 'description': ['type I interferon receptor activity']}, {'category': ['process'], 'description': ['cell proliferation']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['JAK-STAT cascade']}, {'category': ['process'], 'description': ['regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['regulation of type I interferon-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to interferon-alpha']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['type I interferon signaling pathway']}]}]}]}]}]"
"['DB00035', 'BTD00112', 'BTD00061', 'BIOD00112', 'BIOD00061']",['Desmopressin'],small molecule,"[""Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release from the stimulation of increased plasma osmolarity or decreased circulating blood volume, ADH mainly acts on the cells of the distal part of the nephron and the collecting tubules in the kidney [T28]. The hormone interacts with V1, V2 or V3 receptors with differing signal cascade systems.\r\n\r\nDesmopressin displays enhanced antidiuretic potency, fewer pressor effects due to V2-selective actions, and a prolonged half-life and duration of action compared to endogenous ADH [A31661]. It has been employed clinically since 1972 and is available in various formulations including intranasal solution, intravenous solution, oral tablet and oral lyophilisate [A31662]. Desmopressin is indicated for the treatment of polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus. It was also newly approved for the treatment of mild classical hemophilia and von Willebrand's disease for minor surgeries. The active ingredient in most formulations is desmopressin acetate. Nocdurna, or desmopressin acetate, was approved by the FDA on June 21st, 2018 for the treatment of nocturia due to nocturnal polyuria in adults. It is available as a sublingual tablet.""]",['solid'],"[""- Indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void (intranasal). \r\n\r\n- Indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region (intranasal/parenteral).\r\n\r\n- Indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5% or mild to moderate classic von Willebrand's Disease (Type I) with factor VIII levels greater than 5% during surgical procedures and postoperatively to maintain hemostasis (parenteral).""]","['Upon binding of desmopressin to V2 receptors in the basolateral membrane of the cells of the distal tubule and collecting ducts of the nephron, adenylyl cyclase is stimulated. The resulting intracellular cascades in the collecting duct lead to increased rate of insertion of water channels, called aquaporins, into the lumenal membrane and enhanced the permeability of the membrane to water [T28]. ']",[None],"[{'target': [{'id': ['BE0000293'], 'name': ['Vasopressin V2 receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A15384'], 'pubmed-id': ['18761325'], 'citation': ['Del Tredici AL, Vanover KE, Knapp AE, Bertozzi SM, Nash NR, Burstein ES, Lameh J, Currier EA, Davis RE, Brann MR, Mohell N, Olsson R, Piu F: Identification of novel selective V2 receptor non-peptide agonists. Biochem Pharmacol. 2008 Oct 30;76(9):1134-41. doi: 10.1016/j.bcp.2008.08.004. Epub 2008 Aug 12.']}, {'ref-id': ['A6713'], 'pubmed-id': ['16333859'], 'citation': ['Slusarz MJ, Slusarz R, Ciarkowski J: Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system. Biopolymers. 2006 Apr 5;81(5):321-38.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Vasopressin V2 receptor'], 'general-function': ['Vasopressin receptor activity'], 'specific-function': ['Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Involved in renal water reabsorption.'], 'gene-name': ['AVPR2'], 'locus': ['Xq28'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['39-63\n78-98\n114-135\n160-180\n201-220\n272-293\n309-328'], 'signal-regions': [None], 'theoretical-pi': ['9.41'], 'molecular-weight': ['40278.57'], 'chromosome-location': ['X'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:897']}, {'resource': ['GenAtlas'], 'identifier': ['AVPR2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['U04357']}, {'resource': ['GenBank Protein Database'], 'identifier': ['28418']}, {'resource': ['IUPHAR'], 'identifier': ['368']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['368']}, {'resource': ['UniProtKB'], 'identifier': ['P30518']}, {'resource': ['UniProt Accession'], 'identifier': ['V2R_HUMAN']}]}], 'synonyms': [{'synonym': ['ADHR', 'Antidiuretic hormone receptor', 'AVPR V2', 'DIR', 'DIR3', 'Renal-type arginine vasopressin receptor', 'V2R']}], 'amino-acid-sequence': ['>lcl|BSEQ0000583|Vasopressin V2 receptor\nMLMASTTSAVPGHPSLPSLPSNSSQERPLDTRDPLLARAELALLSIVFVAVALSNGLVLA\nALARRGRRGHWAPIHVFIGHLCLADLAVALFQVLPQLAWKATDRFRGPDALCRAVKYLQM\nVGMYASSYMILAMTLDRHRAICRPMLAYRHGSGAHWNRPVLVAWAFSLLLSLPQLFIFAQ\nRNVEGGSGVTDCWACFAEPWGRRTYVTWIALMVFVAPTLGIAACQVLIFREIHASLVPGP\nSERPGGRRRGRRTGSPGEGAHVSAAVAKTVRMTLVIVVVYVLCWAPFFLVQLWAAWDPEA\nPLEGAPFVLLMLLASLNSCTNPWIYASFSSSVSSELRSLLCCARGRTPPSLGPQDESCTT\nASSSLAKDTSS'], 'gene-sequence': ['>lcl|BSEQ0010065|Vasopressin V2 receptor (AVPR2)\nATGCTCATGGCGTCCACCACTTCCGCTGTGCCTGGGCATCCCTCTCTGCCCAGCCTGCCC\nAGCAACAGCAGCCAGGAGAGGCCACTGGACACCCGGGACCCGCTGCTAGCCCGGGCGGAG\nCTGGCGCTGCTCTCCATAGTCTTTGTGGCTGTGGCCCTGAGCAATGGCCTGGTGCTGGCG\nGCCCTAGCTCGGCGGGGCCGGCGGGGCCACTGGGCACCCATACACGTCTTCATTGGCCAC\nTTGTGCCTGGCCGACCTGGCCGTGGCTCTGTTCCAAGTGCTGCCCCAGCTGGCCTGGAAG\nGCCACCGACCGCTTCCGTGGGCCAGATGCCCTGTGTCGGGCCGTGAAGTATCTGCAGATG\nGTGGGCATGTATGCCTCCTCCTACATGATCCTGGCCATGACGCTGGACCGCCACCGTGCC\nATCTGCCGTCCCATGCTGGCGTACCGCCATGGAAGTGGGGCTCACTGGAACCGGCCGGTG\nCTAGTGGCTTGGGCCTTCTCGCTCCTTCTCAGCCTGCCCCAGCTCTTCATCTTCGCCCAG\nCGCAACGTGGAAGGTGGCAGCGGGGTCACTGACTGCTGGGCCTGCTTTGCGGAGCCCTGG\nGGCCGTCGCACCTATGTCACCTGGATTGCCCTGATGGTGTTCGTGGCACCTACCCTGGGT\nATCGCCGCCTGCCAGGTGCTCATCTTCCGGGAGATTCATGCCAGTCTGGTGCCAGGGCCA\nTCAGAGAGGCCTGGGGGGCGCCGCAGGGGACGCCGGACAGGCAGCCCCGGTGAGGGAGCC\nCACGTGTCAGCAGCTGTGGCCAAGACTGTGAGGATGACGCTAGTGATTGTGGTCGTCTAT\nGTGCTGTGCTGGGCACCCTTCTTCCTGGTGCAGCTGTGGGCCGCGTGGGACCCGGAGGCA\nCCTCTGGAAGGGGCGCCCTTTGTGCTACTCATGTTGCTGGCCAGCCTCAACAGCTGCACC\nAACCCCTGGATCTATGCATCTTTCAGCAGCAGCGTGTCCTCAGAGCTGCGAAGCTTGCTC\nTGCTGTGCCCGGGGACGCACCCCACCCAGCCTGGGTCCCCAAGATGAGTCCTGCACCACC\nGCCAGCTCCTCCCTGGCCAAGGACACTTCATCGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endoplasmic reticulum']}, {'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['Golgi apparatus']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['peptide binding']}, {'category': ['function'], 'description': ['vasopressin receptor activity']}, {'category': ['process'], 'description': ['activation of adenylate cyclase activity']}, {'category': ['process'], 'description': ['adenylate cyclase-modulating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular response to hormone stimulus']}, {'category': ['process'], 'description': ['excretion']}, {'category': ['process'], 'description': ['hemostasis']}, {'category': ['process'], 'description': ['I-kappaB kinase/NF-kappaB signaling']}, {'category': ['process'], 'description': ['interferon-gamma production']}, {'category': ['process'], 'description': ['negative regulation of renal sodium excretion']}, {'category': ['process'], 'description': ['negative regulation of urine volume']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of gene expression']}, {'category': ['process'], 'description': ['positive regulation of protein ubiquitination']}, {'category': ['process'], 'description': ['positive regulation of systemic arterial blood pressure']}, {'category': ['process'], 'description': ['positive regulation of vasoconstriction']}, {'category': ['process'], 'description': ['regulation of systemic arterial blood pressure by vasopressin']}, {'category': ['process'], 'description': ['renal water homeostasis']}, {'category': ['process'], 'description': ['response to cytokine']}, {'category': ['process'], 'description': ['response to peptide']}, {'category': ['process'], 'description': ['telencephalon development']}, {'category': ['process'], 'description': ['transmembrane transport']}, {'category': ['process'], 'description': ['water transport']}]}]}]}, {'id': ['BE0000165'], 'name': ['Vasopressin V1a receptor'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13142'], 'pubmed-id': ['10731046'], 'citation': ['Loichot C, Cazaubon C, De Jong W, Helwig JJ, Nisato D, Imbs JL, Barthelmebs M: Nitric oxide, but not vasopressin V2 receptor-mediated vasodilation, modulates vasopressin-induced renal vasoconstriction in rats. Naunyn Schmiedebergs Arch Pharmacol. 2000 Mar;361(3):319-26.']}, {'ref-id': ['A13143'], 'pubmed-id': ['10594321'], 'citation': ['Mechaly I, Laurent F, Portet K, Serrano J, Cros G: Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 Nov 3;383(3):287-90.']}, {'ref-id': ['A13144'], 'pubmed-id': ['8957254'], 'citation': ['Barthelmebs M, Krieger JP, Grima M, Nisato D, Imbs JL: Vascular effects of [Arg8]vasopressin in the isolated perfused rat kidney. Eur J Pharmacol. 1996 Oct 31;314(3):325-32.']}, {'ref-id': ['A13145'], 'pubmed-id': ['15613460'], 'citation': ['Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004 Dec;11(4):871-85.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Vasopressin V1a receptor'], 'general-function': ['Vasopressin receptor activity'], 'specific-function': ['Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. Has been involved in social behaviors, including affiliation and attachment.'], 'gene-name': ['AVPR1A'], 'locus': ['12q14-q15'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['53-76\n89-110\n126-147\n169-190\n219-239\n294-313\n332-351'], 'signal-regions': [None], 'theoretical-pi': ['9.67'], 'molecular-weight': ['46799.105'], 'chromosome-location': ['12'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:895']}, {'resource': ['GenAtlas'], 'identifier': ['AVPR1A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L25615']}, {'resource': ['GenBank Protein Database'], 'identifier': ['667068']}, {'resource': ['IUPHAR'], 'identifier': ['366']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['366']}, {'resource': ['UniProtKB'], 'identifier': ['P37288']}, {'resource': ['UniProt Accession'], 'identifier': ['V1AR_HUMAN']}]}], 'synonyms': [{'synonym': ['Antidiuretic hormone receptor 1a', 'AVPR V1a', 'AVPR1', 'V1aR', 'Vascular/hepatic-type arginine vasopressin receptor']}], 'amino-acid-sequence': ['>lcl|BSEQ0009979|Vasopressin V1a receptor\nMRLSAGPDAGPSGNSSPWWPLATGAGNTSREAEALGEGNGPPRDVRNEELAKLEIAVLAV\nTFAVAVLGNSSVLLALHRTPRKTSRMHLFIRHLSLADLAVAFFQVLPQMCWDITYRFRGP\nDWLCRVVKHLQVFGMFASAYMLVVMTADRYIAVCHPLKTLQQPARRSRLMIAAAWVLSFV\nLSTPQYFVFSMIEVNNVTKARDCWATFIQPWGSRAYVTWMTGGIFVAPVVILGTCYGFIC\nYNIWCNVRGKTASRQSKGAEQAGVAFQKGFLLAPCVSSVKSISRAKIRTVKMTFVIVTAY\nIVCWAPFFIIQMWSVWDPMSVWTESENPTITITALLGSLNSCCNPWIYMFFSGHLLQDCV\nQSFPCCQNMKEKFNKEDTDSMSRRQTFYSNNRSPTNSTGMWKDSPKSSKSIKFIPVST'], 'gene-sequence': ['>lcl|BSEQ0009980|Vasopressin V1a receptor (AVPR1A)\nATGCGTCTCTCCGCCGGTCCCGACGCGGGGCCCTCGGGCAACTCCAGCCCATGGTGGCCT\nCTGGCCACCGGCGCTGGCAACACAAGCCGGGAGGCCGAAGCCCTCGGGGAGGGCAACGGC\nCCACCGAGGGACGTGCGCAACGAGGAGCTGGCCAAACTGGAGATCGCCGTGCTGGCGGTG\nACTTTCGCGGTGGCCGTGCTGGGCAACAGCAGCGTACTGCTGGCTCTGCACCGGACGCCG\nCGCAAGACGTCCCGCATGCACCTCTTCATCCGACACCTCAGCCTGGCCGACCTGGCCGTG\nGCATTCTTCCAGGTGCTGCCGCAAATGTGCTGGGACATCACCTACCGCTTCCGCGGCCCC\nGACTGGCTGTGCCGCGTGGTGAAGCACCTGCAGGTGTTCGGCATGTTTGCGTCGGCCTAC\nATGCTGGTAGTCATGACAGCCGACCGCTACATCGCGGTGTGCCACCCGCTCAAGACTCTG\nCAACAGCCCGCGCGCCGCTCGCGCCTCATGATCGCGGCCGCCTGGGTGCTGAGCTTCGTG\nCTGAGCACGCCGCAGTACTTCGTCTTCTCCATGATCGAGGTGAACAATGTCACCAAGGCC\nCGCGACTGCTGGGCCACCTTCATCCAGCCCTGGGGTTCTCGTGCCTACGTGACCTGGATG\nACGGGCGGCATCTTTGTGGCGCCCGTGGTCATCTTGGGTACCTGCTACGGCTTCATCTGC\nTACAACATCTGGTGCAACGTCCGCGGGAAGACGGCGTCGCGCCAGAGCAAGGGTGCAGAG\nCAAGCGGGTGTGGCCTTCCAAAAGGGGTTCCTGCTCGCACCCTGTGTCAGCAGCGTGAAG\nTCCATTTCCCGGGCCAAGATCCGCACGGTGAAGATGACTTTTGTGATCGTGACGGCTTAC\nATCGTCTGCTGGGCGCCTTTCTTCATCATCCAGATGTGGTCTGTCTGGGATCCCATGTCC\nGTCTGGACCGAATCGGAAAACCCTACCATCACCATCACTGCATTACTGGGTTCCTTGAAT\nAGCTGCTGTAATCCCTGGATATACATGTTTTTTAGTGGCCATCTCCTTCAAGACTGTGTT\nCAAAGCTTCCCATGCTGCCAAAACATGAAGGAAAAATTCAACAAAGAAGATACTGACAGT\nATGAGCAGAAGACAGACTTTTTATTCTAACAATCGAAGCCCAACAAACAGTACGGGTATG\nTGGAAGGACTCGCCTAAATCTTCCAAGTCCATCAAATTCATTCCTGTTTCAACTTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}, {'identifier': ['PF08983'], 'name': ['DUF1856']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cytoplasmic vesicle']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['peptide binding']}, {'category': ['function'], 'description': ['peptide hormone binding']}, {'category': ['function'], 'description': ['protein kinase C binding']}, {'category': ['function'], 'description': ['vasopressin receptor activity']}, {'category': ['process'], 'description': ['activation of phospholipase C activity']}, {'category': ['process'], 'description': ['blood circulation']}, {'category': ['process'], 'description': ['calcium-mediated signaling']}, {'category': ['process'], 'description': ['cellular response to hormone stimulus']}, {'category': ['process'], 'description': ['cellular response to water deprivation']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['generation of precursor metabolites and energy']}, {'category': ['process'], 'description': ['grooming behavior']}, {'category': ['process'], 'description': ['maternal aggressive behavior']}, {'category': ['process'], 'description': ['maternal behavior']}, {'category': ['process'], 'description': ['myotube differentiation']}, {'category': ['process'], 'description': ['negative regulation of female receptivity']}, {'category': ['process'], 'description': ['negative regulation of transmission of nerve impulse']}, {'category': ['process'], 'description': ['penile erection']}, {'category': ['process'], 'description': ['positive regulation of cell growth']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of cellular pH reduction']}, {'category': ['process'], 'description': ['positive regulation of cytosolic calcium ion concentration']}, {'category': ['process'], 'description': ['positive regulation of glutamate secretion']}, {'category': ['process'], 'description': ['positive regulation of heart rate']}, {'category': ['process'], 'description': ['positive regulation of prostaglandin biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of renal sodium excretion']}, {'category': ['process'], 'description': ['positive regulation of systemic arterial blood pressure']}, {'category': ['process'], 'description': ['positive regulation of vasoconstriction']}, {'category': ['process'], 'description': ['regulation of systemic arterial blood pressure by vasopressin']}, {'category': ['process'], 'description': ['response to corticosterone']}, {'category': ['process'], 'description': ['response to peptide']}, {'category': ['process'], 'description': ['social behavior']}, {'category': ['process'], 'description': ['sperm ejaculation']}, {'category': ['process'], 'description': ['telencephalon development']}]}]}]}, {'id': ['BE0000773'], 'name': ['Vasopressin V1b receptor'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13145'], 'pubmed-id': ['15613460'], 'citation': ['Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004 Dec;11(4):871-85.']}, {'ref-id': ['A13146'], 'pubmed-id': ['14971638'], 'citation': [""Dinan TG, O'Brien S, Lavelle E, Scott LV: Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression. Psychol Med. 2004 Jan;34(1):169-72.""]}, {'ref-id': ['A13147'], 'pubmed-id': ['18655906'], 'citation': ['Craighead M, Milne R, Campbell-Wan L, Watson L, Presland J, Thomson FJ, Marston HM, Macsweeney CP: Characterization of a novel and selective V1B receptor antagonist. Prog Brain Res. 2008;170:527-35. doi: 10.1016/S0079-6123(08)00440-8.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Vasopressin V1b receptor'], 'general-function': ['Vasopressin receptor activity'], 'specific-function': ['Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system.'], 'gene-name': ['AVPR1B'], 'locus': ['1q32'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['36-59\n72-93\n109-130\n152-173\n202-222\n284-303\n322-341'], 'signal-regions': [None], 'theoretical-pi': ['9.05'], 'molecular-weight': ['46970.345'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:896']}, {'resource': ['GenAtlas'], 'identifier': ['AVPR1B']}, {'resource': ['GenBank Gene Database'], 'identifier': ['D31833']}, {'resource': ['GenBank Protein Database'], 'identifier': ['563982']}, {'resource': ['IUPHAR'], 'identifier': ['367']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['367']}, {'resource': ['UniProtKB'], 'identifier': ['P47901']}, {'resource': ['UniProt Accession'], 'identifier': ['V1BR_HUMAN']}]}], 'synonyms': [{'synonym': ['Antidiuretic hormone receptor 1b', 'AVPR V1b', 'AVPR V3', 'AVPR3', 'V1bR', 'Vasopressin V3 receptor', 'VPR3']}], 'amino-acid-sequence': ['>lcl|BSEQ0010547|Vasopressin V1b receptor\nMDSGPLWDANPTPRGTLSAPNATTPWLGRDEELAKVEIGVLATVLVLATGGNLAVLLTLG\nQLGRKRSRMHLFVLHLALTDLAVALFQVLPQLLWDITYRFQGPDLLCRAVKYLQVLSMFA\nSTYMLLAMTLDRYLAVCHPLRSLQQPGQSTYLLIAAPWLLAAIFSLPQVFIFSLREVIQG\nSGVLDCWADFGFPWGPRAYLTWTTLAIFVLPVTMLTACYSLICHEICKNLKVKTQAWRVG\nGGGWRTWDRPSPSTLAATTRGLPSRVSSINTISRAKIRTVKMTFVIVLAYIACWAPFFSV\nQMWSVWDKNAPDEDSTNVAFTISMLLGNLNSCCNPWIYMGFNSHLLPRPLRHLACCGGPQ\nPRMRRRLSDGSLSSRHTTLLTRSSCPATLSLSLSLTLSGRPRPEESPRDLELADGEGTAE\nTIIF'], 'gene-sequence': ['>lcl|BSEQ0010548|Vasopressin V1b receptor (AVPR1B)\nATGGATTCTGGGCCTCTGTGGGATGCCAACCCCACCCCTCGGGGCACCCTCTCTGCCCCC\nAATGCCACAACACCCTGGCTGGGCCGGGATGAGGAGCTGGCCAAGGTGGAGATCGGAGTC\nCTGGCCACTGTCCTGGTGCTGGCGACCGGGGGCAACCTGGCTGTGCTGCTGACCCTGGGC\nCAGCTGGGCCGCAAGCGCTCCCGCATGCACCTGTTCGTGCTGCACTTAGCCCTGACAGAC\nCTGGCCGTGGCGCTCTTCCAGGTGCTGCCACAGCTGCTGTGGGACATCACCTACCGCTTC\nCAGGGCCCCGACCTCCTGTGCAGGGCCGTCAAGTACCTGCAGGTGCTCAGCATGTTTGCC\nTCCACCTACATGCTGCTGGCCATGACGCTGGACCGCTACCTGGCTGTCTGTCACCCCCTG\nCGCAGCCTCCAGCAGCCAGGCCAGTCCACCTACCTGCTCATCGCTGCTCCCTGGCTGCTG\nGCCGCCATCTTCAGCCTCCCTCAAGTCTTCATTTTTTCCCTGCGGGAGGTGATCCAGGGC\nTCAGGGGTGCTGGACTGCTGGGCAGACTTCGGCTTCCCTTGGGGGCCACGGGCCTACCTC\nACCTGGACCACCCTGGCTATCTTCGTTCTGCCGGTGACCATGCTCACGGCCTGCTACAGC\nCTCATCTGCCATGAGATCTGTAAAAACCTAAAAGTCAAGACACAGGCCTGGCGGGTGGGA\nGGAGGGGGCTGGAGGACTTGGGACAGGCCCTCACCTTCCACCTTAGCTGCCACCACTCGG\nGGGCTGCCATCTCGGGTCAGCAGCATCAACACCATCTCACGGGCCAAGATCCGAACAGTG\nAAGATGACCTTTGTCATCGTGCTGGCCTACATCGCTTGCTGGGCTCCCTTCTTCAGTGTC\nCAGATGTGGTCCGTGTGGGACAAGAATGCCCCTGATGAAGATTCCACCAATGTGGCTTTC\nACCATCTCTATGCTTTTGGGCAACCTCAACAGCTGCTGCAACCCCTGGATCTACATGGGC\nTTCAACAGCCACCTGTTACCGCGGCCCCTGCGTCACCTTGCCTGCTGTGGGGGTCCCCAG\nCCCAGGATGCGCCGGCGGCTCTCCGACGGCAGCCTCTCGAGCCGCCACACCACGCTGCTG\nACCCGCTCCAGCTGCCCGGCCACCCTCAGCCTCAGCCTCAGCCTAACCCTCAGTGGGAGG\nCCCAGGCCTGAAGAGTCACCAAGGGACTTGGAGCTGGCAGATGGGGAAGGCACCGCTGAG\nACCATCATCTTTTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}, {'identifier': ['PF08983'], 'name': ['DUF1856']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['peptide binding']}, {'category': ['function'], 'description': ['protein kinase C binding']}, {'category': ['function'], 'description': ['vasopressin receptor activity']}, {'category': ['process'], 'description': ['activation of phospholipase C activity']}, {'category': ['process'], 'description': ['cellular response to hormone stimulus']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of cytosolic calcium ion concentration']}, {'category': ['process'], 'description': ['positive regulation of vasoconstriction']}, {'category': ['process'], 'description': ['regulation of systemic arterial blood pressure by vasopressin']}, {'category': ['process'], 'description': ['response to peptide']}]}]}]}]}]"
"['DB00036', 'BTD00006', 'BIOD00006']",['Coagulation factor VIIa Recombinant Human'],biotech,"['Recombinant human coagulation Factor VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues. Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.']",['liquid'],['For treatment of hemorrhagic complications in hemophilia A and B.'],"['NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.']",[None],"[{'target': [{'id': ['BE0000216'], 'name': ['Coagulation factor X'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A6693'], 'pubmed-id': ['5969560'], 'citation': ['Malinvaud G: [Reflections on the use of PPSB fraction (Prothrombin-proconvertin-Stuart factor-antihemophilic factor B)]. Transfusion (Paris). 1966;9(3):245-54.']}, {'ref-id': ['A1816'], 'pubmed-id': ['13801371'], 'citation': ['BLATRIX C, SOULIER JP: [Preparation of a fraction rich in prothrombin, proconvertin, Stuart factor and antihemophilic factor B (P.P.B. fraction)]. Pathol Biol (Paris). 1959 Dec;7:2477-86.']}, {'ref-id': ['A6694'], 'pubmed-id': ['13713641'], 'citation': ['HERMANSKY F, VITEK J: The role of proconvertin and Stuart factor in the inactivation of tissue thromboplastin by serum. Experientia. 1960 Oct 15;16:455-6.']}, {'ref-id': ['A6695'], 'pubmed-id': ['14227143'], 'citation': ['GAERTNER H, CAEN J: [FUNCTIONAL RELATION BETWEEN ERYTHROPLASTIN (ERYTHROCYTE COAGULANT FACTOR) AND PLASMA FACTORS: PROACCELERIN (V), PROCONVERTIN (VII) AND STUART FACTOR(X)]. Acta Physiol Pol. 1964 Mar-Apr;15:237-43.']}, {'ref-id': ['A6696'], 'pubmed-id': ['13621053'], 'citation': ['DIDISHEIM P, LOEB J, BLATRIX C, SOULIER JP: Preparation of a human plasma fraction rich in prothrombin, proconvertin, Stuart factor, and PTC and a study of its activity and toxicity in rabbits and man. J Lab Clin Med. 1959 Feb;53(2):322-30.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Coagulation factor X'], 'general-function': ['Serine-type endopeptidase activity'], 'specific-function': ['Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.'], 'gene-name': ['F10'], 'locus': ['13q34'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-31'], 'theoretical-pi': ['5.74'], 'molecular-weight': ['54731.255'], 'chromosome-location': ['13'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3528']}, {'resource': ['GenAtlas'], 'identifier': ['F10']}, {'resource': ['GenBank Gene Database'], 'identifier': ['K03194']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182841']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2359']}, {'resource': ['UniProtKB'], 'identifier': ['P00742']}, {'resource': ['UniProt Accession'], 'identifier': ['FA10_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.21.6', 'Stuart factor', 'Stuart-Prower factor']}], 'amino-acid-sequence': ['>lcl|BSEQ0010204|Coagulation factor X\nMGRPLHLVLLSASLAGLLLLGESLFIRREQANNILARVTRANSFLEEMKKGHLERECMEE\nTCSYEEAREVFEDSDKTNEFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKN\nCELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLERR\nKRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFDLLDFNQTQPERGDNNLTRIVGGQE\nCKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGE\nAVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGI\nVSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSG\nGPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPE\nVITSSPLK'], 'gene-sequence': ['>lcl|BSEQ0010205|Coagulation factor X (F10)\nATGGGGCGCCCACTGCACCTCGTCCTGCTCAGTGCCTCCCTGGCTGGCCTCCTGCTGCTC\nGGGGAAAGTCTGTTCATCCGCAGGGAGCAGGCCAACAACATCCTGGCGAGGGTCACGAGG\nGCCAATTCCTTTCTTGAAGAGATGAAGAAAGGACACCTCGAAAGAGAGTGCATGGAAGAG\nACCTGCTCATACGAAGAGGCCCGCGAGGTCTTTGAGGACAGCGACAAGACGAATGAATTC\nTGGAATAAATACAAAGATGGCGACCAGTGTGAGACCAGTCCTTGCCAGAACCAGGGCAAA\nTGTAAAGACGGCCTCGGGGAATACACCTGCACCTGTTTAGAAGGATTCGAAGGCAAAAAC\nTGTGAATTATTCACACGGAAGCTCTGCAGCCTGGACAACGGGGACTGTGACCAGTTCTGC\nCACGAGGAACAGAACTCTGTGGTGTGCTCCTGCGCCCGCGGGTACACCCTGGCTGACAAC\nGGCAAGGCCTGCATTCCCACAGGGCCCTACCCCTGTGGGAAACAGACCCTGGAACGCAGG\nAAGAGGTCAGTGGCCCAGGCCACCAGCAGCAGCGGGGAGGCCCCTGACAGCATCACATGG\nAAGCCATATGATGCAGCCGACCTGGACCCCACCGAGAACCCCTTCGACCTGCTTGACTTC\nAACCAGACGCAGCCTGAGAGGGGCGACAACAACCTCACCAGGATCGTGGGAGGCCAGGAA\nTGCAAGGACGGGGAGTGTCCCTGGCAGGCCCTGCTCATCAATGAGGAAAACGAGGGTTTC\nTGTGGTGGAACCATTCTGAGCGAGTTCTACATCCTAACGGCAGCCCACTGTCTCTACCAA\nGCCAAGAGATTCAAGGTGAGGGTAGGGGACCGGAACACGGAGCAGGAGGAGGGCGGTGAG\nGCGGTGCACGAGGTGGAGGTGGTCATCAAGCACAACCGGTTCACAAAGGAGACCTATGAC\nTTCGACATCGCCGTGCTCCGGCTCAAGACCCCCATCACCTTCCGCATGAACGTGGCGCCT\nGCCTGCCTCCCCGAGCGTGACTGGGCCGAGTCCACGCTGATGACGCAGAAGACGGGGATT\nGTGAGCGGCTTCGGGCGCACCCACGAGAAGGGCCGGCAGTCCACCAGGCTCAAGATGCTG\nGAGGTGCCCTACGTGGACCGCAACAGCTGCAAGCTGTCCAGCAGCTTCATCATCACCCAG\nAACATGTTCTGTGCCGGCTACGACACCAAGCAGGAGGATGCCTGCCAGGGGGACAGCGGG\nGGCCCGCACGTCACCCGCTTCAAGGACACCTACTTCGTGACAGGCATCGTCAGCTGGGGA\nGAGGGCTGTGCCCGTAAGGGGAAGTACGGGATCTACACCAAGGTCACCGCCTTCCTCAAG\nTGGATCGACAGGTCCATGAAAACCAGGGGCTTGCCCAAGGCCAAGAGCCATGCCCCGGAG\nGTCATAACGTCCTCTCCATTAAAGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00008'], 'name': ['EGF']}, {'identifier': ['PF00594'], 'name': ['Gla']}, {'identifier': ['PF00089'], 'name': ['Trypsin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['Golgi lumen']}, {'category': ['component'], 'description': ['intrinsic component of external side of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['phospholipid binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, extrinsic pathway']}, {'category': ['process'], 'description': ['blood coagulation, intrinsic pathway']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['peptidyl-glutamic acid carboxylation']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['proteolysis']}]}]}]}, {'id': ['BE0001178'], 'name': ['Tissue factor'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A6694'], 'pubmed-id': ['13713641'], 'citation': ['HERMANSKY F, VITEK J: The role of proconvertin and Stuart factor in the inactivation of tissue thromboplastin by serum. Experientia. 1960 Oct 15;16:455-6.']}, {'ref-id': ['A11609'], 'pubmed-id': ['1586032'], 'citation': ['Rogers KS, Barton CL, Benson PA, Green RA: Effects of single-dose L-asparaginase on coagulation values in healthy dogs and dogs with lymphoma. Am J Vet Res. 1992 Apr;53(4):580-4.']}, {'ref-id': ['A11610'], 'pubmed-id': ['6658368'], 'citation': ['Christensen NJ: Measurements of some blood clotting factors using a centrifugal analyser (Multistat III). Scand J Clin Lab Invest. 1983 Oct;43(6):521-6.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Tissue factor'], 'general-function': ['Protease binding'], 'specific-function': ['Initiates blood coagulation by forming a complex with circulating factor VII or VIIa. The [TF:VIIa] complex activates factors IX or X by specific limited protolysis. TF plays a role in normal hemostasis by initiating the cell-surface assembly and propagation of the coagulation protease cascade.'], 'gene-name': ['F3'], 'locus': ['1p22-p21'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['252-274'], 'signal-regions': ['1-32'], 'theoretical-pi': ['7.09'], 'molecular-weight': ['33067.3'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3541']}, {'resource': ['GenAtlas'], 'identifier': ['F3']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M16553']}, {'resource': ['GenBank Protein Database'], 'identifier': ['339504']}, {'resource': ['UniProtKB'], 'identifier': ['P13726']}, {'resource': ['UniProt Accession'], 'identifier': ['TF_HUMAN']}]}], 'synonyms': [{'synonym': ['Coagulation factor III', 'TF', 'Thromboplastin']}], 'amino-acid-sequence': ['>lcl|BSEQ0002343|Tissue factor\nMETPAWPRVPRPETAVARTLLLGWVFAQVAGASGTTNTVAAYNLTWKSTNFKTILEWEPK\nPVNQVYTVQISTKSGDWKSKCFYTTDTECDLTDEIVKDVKQTYLARVFSYPAGNVESTGS\nAGEPLYENSPEFTPYLETNLGQPTIQSFEQVGTKVNVTVEDERTLVRRNNTFLSLRDVFG\nKDLIYTLYYWKSSSSGKKTAKTNTNEFLIDVDKGENYCFSVQAVIPSRTVNRKSTDSPVE\nCMGQEKGEFREIFYIIGAVVFVVIILVIILAISLHKCRKAGVGQSWKENSPLNVS'], 'gene-sequence': ['>lcl|BSEQ0021656|Tissue factor (F3)\nATGGAGACCCCTGCCTGGCCCCGGGTCCCGCGCCCCGAGACCGCCGTCGCTCGGACGCTC\nCTGCTCGGCTGGGTCTTCGCCCAGGTGGCCGGCGCTTCAGGCACTACAAATACTGTGGCA\nGCATATAATTTAACTTGGAAATCAACTAATTTCAAGACAATTTTGGAGTGGGAACCCAAA\nCCCGTCAATCAAGTCTACACTGTTCAAATAAGCACTAAGTCAGGAGATTGGAAAAGCAAA\nTGCTTTTACACAACAGACACAGAGTGTGACCTCACCGACGAGATTGTGAAGGATGTGAAG\nCAGACGTACTTGGCACGGGTCTTCTCCTACCCGGCAGGGAATGTGGAGAGCACCGGTTCT\nGCTGGGGAGCCTCTGTATGAGAACTCCCCAGAGTTCACACCTTACCTGGAGACAAACCTC\nGGACAGCCAACAATTCAGAGTTTTGAACAGGTGGGAACAAAAGTGAATGTGACCGTAGAA\nGATGAACGGACTTTAGTCAGAAGGAACAACACTTTCCTAAGCCTCCGGGATGTTTTTGGC\nAAGGACTTAATTTATACACTTTATTATTGGAAATCTTCAAGTTCAGGAAAGAAATATTCT\nACATCATTGGAGCTGTGGTATTTGTGGTCATCATCCTTGTCATCATCCTGGCTATATCTC\nTACACAAGTGTAGAAAGGCAGGAGTGGGGCAGAGCTGGAAGGAGAACTCCCCACTGA'], 'pfams': [{'pfam': [{'identifier': ['PF01108'], 'name': ['Tissue_fac']}, {'identifier': ['PF09294'], 'name': ['Interfer-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular matrix']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['intrinsic component of external side of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['cytokine receptor activity']}, {'category': ['function'], 'description': ['phospholipid binding']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['process'], 'description': ['activation of blood coagulation via clotting cascade']}, {'category': ['process'], 'description': ['activation of cysteine-type endopeptidase activity involved in apoptotic process']}, {'category': ['process'], 'description': ['activation of plasma proteins involved in acute inflammatory response']}, {'category': ['process'], 'description': ['aging']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, extrinsic pathway']}, {'category': ['process'], 'description': ['cellular response to hydrogen peroxide']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of angiogenesis']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of endothelial cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of platelet-derived growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of positive chemotaxis']}, {'category': ['process'], 'description': ['positive regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['positive regulation of smooth muscle cell migration']}, {'category': ['process'], 'description': ['response to estradiol']}, {'category': ['process'], 'description': ['response to fluid shear stress']}, {'category': ['process'], 'description': ['response to lipopolysaccharide']}, {'category': ['process'], 'description': ['response to low-density lipoprotein particle']}, {'category': ['process'], 'description': ['response to mechanical stimulus']}, {'category': ['process'], 'description': ['response to temperature stimulus']}]}]}]}, {'id': ['BE0000967'], 'name': ['Tissue factor pathway inhibitor'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13148'], 'pubmed-id': ['11772005'], 'citation': ['Mine S, Yamazaki T, Miyata T, Hara S, Kato H: Structural mechanism for heparin-binding of the third Kunitz domain of human tissue factor pathway inhibitor. Biochemistry. 2002 Jan 8;41(1):78-85.']}, {'ref-id': ['A13149'], 'pubmed-id': ['7559599'], 'citation': ['Narita M, Bu G, Olins GM, Higuchi DA, Herz J, Broze GJ Jr, Schwartz AL: Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo. J Biol Chem. 1995 Oct 20;270(42):24800-4.']}, {'ref-id': ['A13150'], 'pubmed-id': ['8700900'], 'citation': ['Stassens P, Bergum PW, Gansemans Y, Jespers L, Laroche Y, Huang S, Maki S, Messens J, Lauwereys M, Cappello M, Hotez PJ, Lasters I, Vlasuk GP: Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2149-54.']}, {'ref-id': ['A13151'], 'pubmed-id': ['12974870'], 'citation': ['Lee AY, Vlasuk GP: Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor. J Intern Med. 2003 Oct;254(4):313-21.']}, {'ref-id': ['A13152'], 'pubmed-id': ['11238112'], 'citation': ['Hansen CB, Pyke C, Petersen LC, Rao LV: Tissue factor-mediated endocytosis, recycling, and degradation of factor VIIa by a clathrin-independent mechanism not requiring the cytoplasmic domain of tissue factor. Blood. 2001 Mar 15;97(6):1712-20.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Tissue factor pathway inhibitor'], 'general-function': ['Serine-type endopeptidase inhibitor activity'], 'specific-function': ['Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action and also the ability to associate with lipoproteins in plasma.'], 'gene-name': ['TFPI'], 'locus': ['2q32'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-28'], 'theoretical-pi': ['8.31'], 'molecular-weight': ['35014.835'], 'chromosome-location': ['2'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:11760']}, {'resource': ['GenAtlas'], 'identifier': ['TFPI']}, {'resource': ['GenBank Gene Database'], 'identifier': ['J03225']}, {'resource': ['GenBank Protein Database'], 'identifier': ['180546']}, {'resource': ['UniProtKB'], 'identifier': ['P10646']}, {'resource': ['UniProt Accession'], 'identifier': ['TFPI1_HUMAN']}]}], 'synonyms': [{'synonym': ['EPI', 'Extrinsic pathway inhibitor', 'LACI', 'Lipoprotein-associated coagulation inhibitor', 'TFPI', 'TFPI1']}], 'amino-acid-sequence': ['>lcl|BSEQ0001925|Tissue factor pathway inhibitor\nMIYTMKKVHALWASVCLLLNLAPAPLNADSEEDEEHTIITDTELPPLKLMHSFCAFKADD\nGPCKAIMKRFFFNIFTRQCEEFIYGGCEGNQNRFESLEECKKMCTRDNANRIIKTTLQQE\nKPDFCFLEEDPGICRGYITRYFYNNQTKQCERFKYGGCLGNMNNFETLEECKNICEDGPN\nGFQVDNYGTQLNAVNNSLTPQSTKVPSLFEFHGPSWCLTPADRGLCRANENRFYYNSVIG\nKCRPFKYSGCGGNENNFTSKQECLRACKKGFIQRISKGGLIKTKRKRKKQRVKIAYEEIF\nVKNM'], 'gene-sequence': ['>lcl|BSEQ0010679|Tissue factor pathway inhibitor (TFPI)\nATGATTTACACAATGAAGAAAGTACATGCACTTTGGGCTTCTGTATGCCTGCTGCTTAAT\nCTTGCCCCTGCCCCTCTTAATGCTGATTCTGAGGAAGATGAAGAACACACAATTATCACA\nGATACGGAGTTGCCACCACTGAAACTTATGCATTCATTTTGTGCATTCAAGGCGGATGAT\nGGCCCATGTAAAGCAATCATGAAAAGATTTTTCTTCAATATTTTCACTCGACAGTGCGAA\nGAATTTATATATGGGGGATGTGAAGGAAATCAGAATCGATTTGAAAGTCTGGAAGAGTGC\nAAAAAAATGTGTACAAGAGATAATGCAAACAGGATTATAAAGACAACATTGCAACAAGAA\nAAGCCAGATTTCTGCTTTTTGGAAGAAGATCCTGGAATATGTCGAGGTTATATTACCAGG\nTATTTTTATAACAATCAGACAAAACAGTGTGAACGTTTCAAGTATGGTGGATGCCTGGGC\nAATATGAACAATTTTGAGACACTGGAAGAATGCAAGAACATTTGTGAAGATGGTCCGAAT\nGGTTTCCAGGTGGATAATTATGGAACCCAGCTCAATGCTGTGAATAACTCCCTGACTCCG\nCAATCAACCAAGGTTCCCAGCCTTTTTGTTACAAAAGAAGGAACAAATGATGGTTGGAAG\nAATGCGGCTCATATTTACCAAGTCTTTCTGAACGCCTTCTGCATTCATGCATCCATGTTC\nTTTCTAGGATTGGATAGCATTTCATGCCTATGTTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00014'], 'name': ['Kunitz_BPTI']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['anchored component of membrane']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['endoplasmic reticulum']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['organelle membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['endopeptidase inhibitor activity']}, {'category': ['function'], 'description': ['serine-type endopeptidase inhibitor activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, extrinsic pathway']}, {'category': ['process'], 'description': ['negative regulation of endopeptidase activity']}]}]}]}, {'id': ['BE0000403'], 'name': ['Vitamin K-dependent gamma-carboxylase'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A13153'], 'pubmed-id': ['10901669'], 'citation': [""Bouwman CA, Van Dam E, Fase KM, Koppe JG, Seinen W, Thijssen HH, Vermeer C, Van den Berg M: Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin or 2,2',4,4',5,5'-hexachlorobiphenyl on vitamin K-dependent blood coagulation in male and female WAG/Rij-rats. Chemosphere. 1999 Feb;38(3):489-505.""]}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Vitamin K-dependent gamma-carboxylase'], 'general-function': ['Gamma-glutamyl carboxylase activity'], 'specific-function': ['Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium-binding gamma-carboxyglutamate (Gla) residues with the concomitant conversion of the reduced hydroquinone form of vitamin K to vitamin K epoxide.'], 'gene-name': ['GGCX'], 'locus': ['2p12'], 'cellular-location': ['Endoplasmic reticulum membrane'], 'transmembrane-regions': ['61-81\n114-134\n137-157\n293-313\n362-382'], 'signal-regions': [None], 'theoretical-pi': ['8.1'], 'molecular-weight': ['87560.065'], 'chromosome-location': ['2'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:4247']}, {'resource': ['GenAtlas'], 'identifier': ['GGCX']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M81592']}, {'resource': ['GenBank Protein Database'], 'identifier': ['184028']}, {'resource': ['UniProtKB'], 'identifier': ['P38435']}, {'resource': ['UniProt Accession'], 'identifier': ['VKGC_HUMAN']}]}], 'synonyms': [{'synonym': ['4.1.1.90', 'Gamma-glutamyl carboxylase', 'GC', 'Peptidyl-glutamate 4-carboxylase', 'Vitamin K gamma glutamyl carboxylase']}], 'amino-acid-sequence': ['>lcl|BSEQ0000803|Vitamin K-dependent gamma-carboxylase\nMAVSAGSARTSPSSDKVQKDKAELISGPRQDSRIGKLLGFEWTDLSSWRRLVTLLNRPTD\nPASLAVFRFLFGFLMVLDIPQERGLSSLDRKYLDGLDVCRFPLLDALRPLPLDWMYLVYT\nIMFLGALGMMLGLCYRISCVLFLLPYWYVFLLDKTSWNNHSYLYGLLAFQLTFMDANHYW\nSVDGLLNAHRRNAHVPLWNYAVLRGQIFIVYFIAGVKKLDADWVEGYSMEYLSRHWLFSP\nFKLLLSEELTSLLVVHWGGLLLDLSAGFLLFFDVSRSIGLFFVSYFHCMNSQLFSIGMFS\nYVMLASSPLFCSPEWPRKLVSYCPRRLQQLLPLKAAPQPSVSCVYKRSRGKSGQKPGLRH\nQLGAAFTLLYLLEQLFLPYSHFLTQGYNNWTNGLYGYSWDMMVHSRSHQHVKITYRDGRT\nGELGYLNPGVFTQSRRWKDHADMLKQYATCLSRLLPKYNVTEPQIYFDIWVSINDRFQQR\nIFDPRVDIVQAAWSPFQRTSWVQPLLMDLSPWRAKLQEIKSSLDNHTEVVFIADFPGLHL\nENFVSEDLGNTSIQLLQGEVTVELVAEQKNQTLREGEKMQLPAGEYHKVYTTSPSPSCYM\nYVYVNTTELALEQDLAYLQELKEKVENGSETGPLPPELQPLLEGEVKGGPEPTPLVQTFL\nRRQQRLQEIERRRNTPFHERFFRFLLRKLYVFRRSFLMTCISLRNLILGRPSLEQLAQEV\nTYANLRPFEAVGELNPSNTDSSHSNPPESNPDPVHSEF'], 'gene-sequence': ['>lcl|BSEQ0018949|Vitamin K-dependent gamma-carboxylase (GGCX)\nATGGCGGTGTCTGCCGGGTCCGCGCGGACCTCGCCCAGCTCAGATAAAGTACAGAAAGAC\nAAGGCTGAACTGATCTCAGGGCCCAGGCAGGACAGCCGAATAGGGAAACTCTTGGGTTTT\nGAGTGGACAGATTTGTCCAGTTGGCGGAGGCTGGTGACCCTGCTGAATCGACCAACGGAC\nCCTGCAAGCTTAGCTGTCTTTCGTTTTCTTTTTGGGTTCTTGATGGTGCTAGACATTCCC\nCAGGAGCGGGGGCTCAGCTCTCTGGACCGGAAATACCTTGATGGGCTGGATGTGTGCCGC\nTTCCCCTTGCTGGATGCCCTACGCCCACTGCCACTTGACTGGATGTATCTTGTCTACACC\nATCATGTTTCTGGGGGCACTGGGCATGATGCTGGGCCTGTGCTACCGGATAAGCTGTGTG\nTTATTCCTGCTGCCATACTGGTATGTGTTTCTCCTGGACAAGACATCATGGAACAACCAC\nTCCTATCTGTATGGGTTGTTGGCCTTTCAGCTAACATTCATGGATGCAAACCACTACTGG\nTCTGTGGACGGTCTGCTGAATGCCCATAGGAGGAATGCCCACGTGCCCCTTTGGAACTAT\nGCAGTGCTCCGTGGCCAGATCTTCATTGTGTACTTCATTGCGGGTGTGAAAAAGCTGGAT\nGCAGACTGGGTTGAAGGCTATTCCATGGAATATTTGTCCCGGCACTGGCTCTTCAGTCCC\nTTCAAACTGCTGTTGTCTGAGGAGCTGACTAGCCTGCTGGTCGTGCACTGGGGTGGGCTG\nCTGCTTGACCTCTCAGCTGGTTTCCTGCTCTTTTTTGATGTCTCAAGATCCATTGGCCTG\nTTCTTTGTGTCCTACTTCCACTGCATGAATTCCCAGCTTTTCAGCATTGGTATGTTCTCC\nTACGTCATGCTGGCCAGCAGCCCTCTCTTCTGCTCCCCTGAGTGGCCTCGGAAGCTGGTG\nTCCTACTGCCCCCGAAGGTTGCAACAACTGTTGCCCCTCAAGGCAGCCCCTCAGCCCAGT\nGTTTCCTGTGTGTATAAGAGGAGCCGGGGCAAAAGTGGCCAGAAGCCAGGGCTGCGCCAT\nCAGCTGGGAGCTGCCTTCACCCTGCTCTACCTCCTGGAGCAGCTATTCCTGCCCTATTCT\nCATTTTCTCACCCAGGGCTATAACAACTGGACAAATGGGCTGTATGGCTATTCCTGGGAC\nATGATGGTGCACTCCCGCTCCCACCAGCACGTGAAGATCACCTACCGTGATGGCCGCACT\nGGCGAACTGGGCTACCTTAACCCTGGGGTATTTACACAGAGTCGGCGATGGAAGGATCAT\nGCAGACATGCTGAAGCAATATGCCACTTGCCTGAGCCGCCTGCTTCCCAAGTATAATGTC\nACTGAGCCCCAGATCTACTTTGATATTTGGGTCTCCATCAATGACCGCTTCCAGCAGAGG\nATTTTTGACCCTCGTGTGGACATCGTGCAGGCCGCTTGGTCACCCTTTCAGCGCACATCC\nTGGGTGCAACCACTCTTGATGGACCTGTCTCCCTGGAGGGCCAAGTTACAGGAAATCAAG\nAGCAGCCTAGACAACCACACTGAGGTGGTCTTCATTGCAGATTTCCCTGGACTGCACTTG\nGAGAATTTTGTGAGTGAAGACCTGGGCAACACTAGCATCCAGCTGCTGCAGGGGGAAGTG\nACTGTGGAGCTTGTGGCAGAACAGAAGAACCAGACTCTTCGAGAGGGAGAAAAAATGCAG\nTTGCCTGCTGGTGAGTACCATAAGGTGTATACGACATCACCTAGCCCTTCTTGCTACATG\nTACGTCTATGTCAACACTACAGAGCTTGCACTGGAGCAAGACCTGGCATATCTGCAAGAA\nTTAAAGGAAAAGGTGGAGAATGGAAGTGAAACAGGGCCTCTACCCCCAGAGCTGCAGCCT\nCTGTTGGAAGGGGAAGTAAAAGGGGGCCCTGAGCCAACACCTCTGGTTCAGACCTTTCTT\nAGACGCCAACAAAGGCTCCAGGAGATTGAACGCCGGCGAAATACTCCTTTCCATGAGCGA\nTTCTTCCGCTTCTTGTTGCGAAAGCTCTATGTCTTTCGCCGCAGCTTCCTGATGACTTGT\nATCTCACTTCGAAATCTGATATTAGGCCGTCCTTCCCTGGAGCAGCTGGCCCAGGAGGTG\nACTTATGCAAACTTGAGACCCTTTGAGGCAGTTGGAGAACTGAATCCCTCAAACACGGAT\nTCTTCACATTCTAATCCTCCTGAGTCAAATCCTGATCCTGTCCACTCAGAGTTCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF05090'], 'name': ['VKG_Carbox']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endoplasmic reticulum membrane']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['function'], 'description': ['gamma-glutamyl carboxylase activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['cellular protein modification process']}, {'category': ['process'], 'description': ['peptidyl-glutamic acid carboxylation']}, {'category': ['process'], 'description': ['post-translational protein modification']}]}]}]}, {'id': ['BE0000333'], 'name': ['Coagulation factor VII'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13162'], 'pubmed-id': ['10388743'], 'citation': ['Perera L, Darden TA, Pedersen LG: Probing the structural changes in the light chain of human coagulation factor VIIa due to tissue factor association. Biophys J. 1999 Jul;77(1):99-113.']}, {'ref-id': ['A13163'], 'pubmed-id': ['11735107'], 'citation': ['Shapiro A: Inhibitor treatment: state of the art. Semin Hematol. 2001 Oct;38(4 Suppl 12):26-34.']}, {'ref-id': ['A13164'], 'pubmed-id': ['12525826'], 'citation': ['Shapiro A: Inhibitor treatment: state of the art. Dis Mon. 2003 Jan;49(1):22-38.']}, {'ref-id': ['A13165'], 'pubmed-id': ['15907148'], 'citation': ['Siddiqui MA, Scott LJ: Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders. Drugs. 2005;65(8):1161-77.']}, {'ref-id': ['A13166'], 'pubmed-id': ['16370916'], 'citation': ['Rizoli SB, Chughtai T: The emerging role of recombinant activated Factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage. Expert Opin Biol Ther. 2006 Jan;6(1):73-81.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Coagulation factor VII'], 'general-function': ['Serine-type peptidase activity'], 'specific-function': ['Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X to factor Xa by limited proteolysis. Factor VIIa will also convert factor IX to factor IXa in the presence of tissue factor and calcium.'], 'gene-name': ['F7'], 'locus': ['13q34'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-20'], 'theoretical-pi': ['7.23'], 'molecular-weight': ['51593.465'], 'chromosome-location': ['13'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3544']}, {'resource': ['GenAtlas'], 'identifier': ['F7']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M13232']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182801']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2363']}, {'resource': ['UniProtKB'], 'identifier': ['P08709']}, {'resource': ['UniProt Accession'], 'identifier': ['FA7_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.21.21', 'Proconvertin', 'Serum prothrombin conversion accelerator', 'SPCA']}], 'amino-acid-sequence': ['>lcl|BSEQ0000663|Coagulation factor VII\nMVSQALRLLCLLLGLQGCLAAGGVAKASGGETRDMPWKPGPHRVFVTQEEAHGVLHRRRR\nANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGS\nCKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSL\nLADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGG\nTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTN\nHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVL\nNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTG\nIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP'], 'gene-sequence': ['>lcl|BSEQ0016066|Coagulation factor VII (F7)\nATGGTCTCCCAGGCCCTCAGGCTCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCCTGGCT\nGCAGGCGGGGTCGCTAAGGCCTCAGGAGGAGAAACACGGGACATGCCGTGGAAGCCGGGG\nCCTCACAGAGTCTTCGTAACCCAGGAGGAAGCCCACGGCGTCCTGCACCGGCGCCGGCGC\nGCCAACGCGTTCCTGGAGGAGCTGCGGCCGGGCTCCCTGGAGAGGGAGTGCAAGGAGGAG\nCAGTGCTCCTTCGAGGAGGCCCGGGAGATCTTCAAGGACGCGGAGAGGACGAAGCTGTTC\nTGGATTTCTTACAGTGATGGGGACCAGTGTGCCTCAAGTCCATGCCAGAATGGGGGCTCC\nTGCAAGGACCAGCTCCAGTCCTATATCTGCTTCTGCCTCCCTGCCTTCGAGGGCCGGAAC\nTGTGAGACGCACAAGGATGACCAGCTGATCTGTGTGAACGAGAACGGCGGCTGTGAGCAG\nTACTGCAGTGACCACACGGGCACCAAGCGCTCCTGTCGGTGCCACGAGGGGTACTCTCTG\nCTGGCAGACGGGGTGTCCTGCACACCCACAGTTGAATATCCATGTGGAAAAATACCTATT\nCTAGAAAAAAGAAATGCCAGCAAACCCCAAGGCCGAATTGTGGGGGGCAAGGTGTGCCCC\nAAAGGGGAGTGTCCATGGCAGGTCCTGTTGTTGGTGAATGGAGCTCAGTTGTGTGGGGGG\nACCCTGATCAACACCATCTGGGTGGTCTCCGCGGCCCACTGTTTCGACAAAATCAAGAAC\nTGGAGGAACCTGATCGCGGTGCTGGGCGAGCACGACCTCAGCGAGCACGACGGGGATGAG\nCAGAGCCGGCGGGTGGCGCAGGTCATCATCCCCAGCACGTACGTCCCGGGCACCACCAAC\nCACGACATCGCGCTGCTCCGCCTGCACCAGCCCGTGGTCCTCACTGACCATGTGGTGCCC\nCTCTGCCTGCCCGAACGGACGTTCTCTGAGAGGACGCTGGCCTTCGTGCGCTTCTCATTG\nGTCAGCGGCTGGGGCCAGCTGCTGGACCGTGGCGCCACGGCCCTGGAGCTCATGGTCCTC\nAACGTGCCCCGGCTGATGACCCAGGACTGCCTGCAGCAGTCACGGAAGGTGGGAGACTCC\nCCAAATATCACGGAGTACATGTTCTGTGCCGGCTACTCGGATGGCAGCAAGGACTCCTGC\nAAGGGGGACAGTGGAGGCCCACATGCCACCCACTACCGGGGCACGTGGTACCTGACGGGC\nATCGTCAGCTGGGGCCAGGGCTGCGCAACCGTGGGCCACTTTGGGGTGTACACCAGGGTC\nTCCCAGTACATCGAGTGGCTGCAAAAGCTCATGCGCTCAGAGCCACGCCCAGGAGTCCTC\nCTGCGAGCCCCATTTCCCTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00008'], 'name': ['EGF']}, {'identifier': ['PF00594'], 'name': ['Gla']}, {'identifier': ['PF00089'], 'name': ['Trypsin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['Golgi lumen']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['vesicle']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['glycoprotein binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase activity']}, {'category': ['function'], 'description': ['serine-type peptidase activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, extrinsic pathway']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['circadian rhythm']}, {'category': ['process'], 'description': ['organ regeneration']}, {'category': ['process'], 'description': ['peptidyl-glutamic acid carboxylation']}, {'category': ['process'], 'description': ['positive regulation of blood coagulation']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of leukocyte chemotaxis']}, {'category': ['process'], 'description': ['positive regulation of platelet-derived growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of positive chemotaxis']}, {'category': ['process'], 'description': ['positive regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['proteolysis']}, {'category': ['process'], 'description': ['response to estrogen']}, {'category': ['process'], 'description': ['response to growth hormone']}, {'category': ['process'], 'description': ['response to vitamin K']}]}]}]}]}]"
"['DB00038', 'BTD00021', 'BIOD00021']",['Oprelvekin'],biotech,"['Oprelvekin, the active ingredient in Neumega, is recombinant Interleukin-11 (IL-11), which is produced in Escherichia coli (E. coli) by recombinant DNA technology. With a molecular mass of approximately 19,000 daltons, the non-glycosylated protein is 177 amino acids in length in comparison to the natural IL-11, which is 178 amino acid long. However, it displays comparable biological activity compared to the natural IL-11 _in vitro_ and _in vivo_. Oprelvekin works by stimulating megakaryocytopoiesis and thrombopoiesis. In mice and nonhuman primate studies of animals with moderate and severe myelosuppression, in addition to compromised hematopoiesis, oprelvekin was shown to potently induce thrombopoiesis and improve platelet nadirs and accelerated platelet recoveries compared to controls. In animal studies, oprelvekin was also shown to regulate intestinal epithelium growth by enhancing healing of gastrointestinal lesions, inhibit adiopegenesis and macrophageal released pro-inflammatory cytokines, and induce acute phase protein synthesis.']",['liquid'],['Indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia.[Label]'],"['Oprelvekin binds to the interleukin 11 receptor which leads to a cascade of signal transduction events. Its pharmacological action mimics the biological activity of endogenous IL-11, which is a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production.']",[None],"[{'target': [{'id': ['BE0000416'], 'name': ['Interleukin-11 receptor subunit alpha'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1865'], 'pubmed-id': ['11012177'], 'citation': ['Nandurkar HH, Robb L, Begley CG: The role of IL-II in hematopoiesis as revealed by a targeted mutation of its receptor. Stem Cells. 1998;16 Suppl 2:53-65.']}, {'ref-id': ['A1867'], 'pubmed-id': ['11570967'], 'citation': ['Li R, Hartley L, Robb L: Cloning of rat interleukin 11 and interleukin 11 receptor alpha chain and analysis of their expression in rat uterus in the peri-implantation period. Reproduction. 2001 Oct;122(4):593-600.']}, {'ref-id': ['A1869'], 'pubmed-id': ['8637716'], 'citation': ['Nandurkar HH, Hilton DJ, Nathan P, Willson T, Nicola N, Begley CG: The human IL-11 receptor requires gp130 for signalling: demonstration by molecular cloning of the receptor. Oncogene. 1996 Feb 1;12(3):585-93.']}, {'ref-id': ['A1871'], 'pubmed-id': ['8676079'], 'citation': ['Romas E, Udagawa N, Zhou H, Tamura T, Saito M, Taga T, Hilton DJ, Suda T, Ng KW, Martin TJ: The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J Exp Med. 1996 Jun 1;183(6):2581-91.']}, {'ref-id': ['A1873'], 'pubmed-id': ['9310465'], 'citation': ['Nandurkar HH, Robb L, Tarlinton D, Barnett L, Kontgen F, Begley CG: Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis. Blood. 1997 Sep 15;90(6):2148-59.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interleukin-11 receptor subunit alpha'], 'general-function': ['Transmembrane signaling receptor activity'], 'specific-function': ['Receptor for interleukin-11. The receptor systems for IL6, LIF, OSM, CNTF, IL11 and CT1 can utilize IL6ST for initiating signal transmission. The IL11/IL11RA/IL6ST complex may be involved in the control of proliferation and/or differentiation of skeletogenic progenitor or other mesenchymal cells. Essential for the normal development of craniofacial bones and teeth. Restricts suture fusion and tooth number.'], 'gene-name': ['IL11RA'], 'locus': ['9p13'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['371-391'], 'signal-regions': ['1-22'], 'theoretical-pi': ['7.91'], 'molecular-weight': ['45221.925'], 'chromosome-location': ['9'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5967']}, {'resource': ['GenAtlas'], 'identifier': ['IL11RA']}, {'resource': ['GenBank Gene Database'], 'identifier': ['Z38102']}, {'resource': ['GenBank Protein Database'], 'identifier': ['995654']}, {'resource': ['UniProtKB'], 'identifier': ['Q14626']}, {'resource': ['UniProt Accession'], 'identifier': ['I11RA_HUMAN']}]}], 'synonyms': [{'synonym': ['IL-11 receptor subunit alpha']}], 'amino-acid-sequence': ['>lcl|BSEQ0000829|Interleukin-11 receptor subunit alpha\nMSSSCSGLSRVLVAVATALVSASSPCPQAWGPPGVQYGQPGRSVKLCCPGVTAGDPVSWF\nRDGEPKLLQGPDSGLGHELVLAQADSTDEGTYICQTLDGALGGTVTLQLGYPPARPVVSC\nQAADYENFSCTWSPSQISGLPTRYLTSYRKKTVLGADSQRRSPSTGPWPCPQDPLGAARC\nVVHGAEFWSQYRINVTEVNPLGASTRLLDVSLQSILRPDPPQGLRVESVPGYPRRLRASW\nTYPASWPCQPHFLLKFRLQYRPAQHPAWSTVEPAGLEEVITDAVAGLPHAVRVSARDFLD\nAGTWSTWSPEAWGTPSTGTIPKEIPAWGQLHTQPEVEPQVDSPAPPRPSLQPHPRLLDHR\nDSVEQVAVLASLGILSFLGLVAGALALGLWLRLRRGGKDGSPKPGFLASVIPVDRRPGAP\nNL'], 'gene-sequence': ['>lcl|BSEQ0016088|Interleukin-11 receptor subunit alpha (IL11RA)\nATGAGCAGCAGCTGCTCAGGGCTGAGCAGGGTCCTGGTGGCCGTGGCTACAGCCCTGGTG\nTCTGCCTCCTCCCCCTGCCCCCAGGCCTGGGGCCCCCCAGGGGTCCAGTATGGGCAGCCA\nGGCAGGTCCGTGAAGCTGTGTTGTCCTGGAGTGACTGCCGGGGACCCAGTGTCCTGGTTT\nCGGGATGGGGAGCCAAAGCTGCTCCAGGGACCTGACTCTGGGCTAGGGCATGAACTGGTC\nCTGGCCCAGGCAGACAGCACTGATGAGGGCACCTACATCTGCCAGACCCTGGATGGTGCA\nCTTGGGGGCACAGTGACCCTGCAGCTGGGCTACCCTCCAGCCCGCCCTGTTGTCTCCTGC\nCAAGCAGCCGACTATGAGAACTTCTCTTGCACTTGGAGTCCCAGCCAGATCAGCGGTTTA\nCCCACCCGCTACCTCACCTCCTACAGGAAGAAGACAGTCCTAGGAGCTGATAGCCAGAGG\nAGGAGTCCATCCACAGGGCCCTGGCCATGCCCACAGGATCCCCTAGGGGCTGCCCGCTGT\nGTTGTCCACGGGGCTGAGTTCTGGAGCCAGTACCGGATTAATGTGACTGAGGTGAACCCA\nCTGGGTGCCAGCACACGCCTGCTGGATGTGAGCTTGCAGAGCATCTTGCGCCCTGACCCA\nCCCCAGGGCCTGCGGGTAGAGTCAGTACCAGGTTACCCCCGACGCCTGCGAGCCAGCTGG\nACATACCCTGCCTCCTGGCCGTGCCAGCCCCACTTCCTGCTCAAGTTCCGTTTGCAGTAC\nCGTCCGGCGCAGCATCCAGCCTGGTCCACGGTGGAGCCAGCTGGACTGGAGGAGGTGATC\nACAGATGCTGTGGCTGGGCTGCCCCATGCTGTACGAGTCAGTGCCCGGGACTTTCTAGAT\nGCTGGCACCTGGAGCACCTGGAGCCCGGAGGCCTGGGGAACTCCGAGCACTGGGACCATA\nCCAAAGGAGATACCAGCATGGGGCCAGCTACACACGCAGCCAGAGGTGGAGCCTCAGGTG\nGACAGCCCTGCTCCTCCAAGGCCCTCCCTCCAACCACACCCTCGGCTACTTGATCACAGG\nGACTCTGTGGAGCAGGTAGCTGTGCTGGCGTCTTTGGGAATCCTTTCTTTCCTGGGACTG\nGTGGCTGGGGCCCTGGCACTGGGGCTCTGGCTGAGGCTGAGACGGGGTGGGAAGGATGGA\nTCCCCAAAGCCTGGGTTCTTGGCCTCAGTGATTCCAGTGGACAGGCGTCCAGGAGCTCCA\nAACCTGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00047'], 'name': ['ig']}, {'identifier': ['PF00041'], 'name': ['fn3']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['function'], 'description': ['cytokine receptor activity']}, {'category': ['function'], 'description': ['signal transducer activity']}, {'category': ['function'], 'description': ['transmembrane signaling receptor activity']}, {'category': ['process'], 'description': ['developmental process']}, {'category': ['process'], 'description': ['embryo implantation']}, {'category': ['process'], 'description': ['head development']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}]}]"
"['DB00039', 'BTD00042', 'BIOD00042']",['Palifermin'],biotech,"['Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli.\r\n\r\nPalifermin was granted FDA approval on 15 December 2004.[L17933]']",['liquid'],['For treatment of oral mucositis associated with chemotherapy and radiation therapy.'],"['Palifermin has been shown to protect oral and intestinal epithelia from the effects of radiation and chemotherapy, though the exact mechanism is not well understood.[A222248] As a recombinant keratinocyte growth factor (KGF), palifermin may promote cell proliferation, reducing the severity of oral mucositis in patients in the relevant treatment groups.[A222248] Agonism of fibroblast growth factor 2 may be predominantly responsible for this effect.[A52198] The endogenous form if palifermin is expressed in the kidney of rats.[A13175]']",[None],"[{'target': [{'id': ['BE0000748'], 'name': ['Fibroblast growth factor receptor 2'], 'organism': ['Humans'], 'actions': [{'action': ['agonist', 'binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1875'], 'pubmed-id': ['17728847'], 'citation': ['Beaven AW, Shea TC: Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant. Drugs Today (Barc). 2007 Jul;43(7):461-73.']}, {'ref-id': ['A1877'], 'pubmed-id': ['16390600'], 'citation': ['Radtke ML, Kolesar JM: Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support. J Oncol Pharm Pract. 2005 Sep;11(3):121-5.']}, {'ref-id': ['A1878'], 'pubmed-id': ['16854582'], 'citation': ['Huang YW, Wang LS, Chang HL, Ye W, Shu S, Sugimoto Y, Lin YC: Effect of keratinocyte growth factor on cell viability in primary cultured human prostate cancer stromal cells. J Steroid Biochem Mol Biol. 2006 Jul;100(1-3):24-33. Epub 2006 Jul 18.']}, {'ref-id': ['A1880'], 'pubmed-id': ['7499435'], 'citation': ['Patrie KM, Kudla AJ, Olwin BB, Chiu IM: Conservation of ligand specificity between the mammalian and amphibian fibroblast growth factor receptors. J Biol Chem. 1995 Dec 1;270(48):29018-24.']}, {'ref-id': ['A1882'], 'pubmed-id': ['9056643'], 'citation': ['Cardoso WV, Itoh A, Nogawa H, Mason I, Brody JS: FGF-1 and FGF-7 induce distinct patterns of growth and differentiation in embryonic lung epithelium. Dev Dyn. 1997 Mar;208(3):398-405.']}, {'ref-id': ['A1884'], 'pubmed-id': ['10593896'], 'citation': ['Berman B, Ostrovsky O, Shlissel M, Lang T, Regan D, Vlodavsky I, Ishai-Michaeli R, Ron D: Similarities and differences between the effects of heparin and glypican-1 on the bioactivity of acidic fibroblast growth factor and the keratinocyte growth factor. J Biol Chem. 1999 Dec 17;274(51):36132-8.']}, {'ref-id': ['A1887'], 'pubmed-id': ['17456767'], 'citation': ['Zhu X, Lee K, Asa SL, Ezzat S: Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells. Am J Pathol. 2007 May;170(5):1618-28.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A52198'], 'pubmed-id': ['8663044'], 'citation': ['Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M: Receptor specificity of the fibroblast growth factor family. J Biol Chem. 1996 Jun 21;271(25):15292-7.']}]}], 'textbooks': [None], 'links': [{'link': [{'ref-id': ['L17933'], 'title': ['FDA Approved Drug Product: Kepivance (Palifermin) Intravenous Injection'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125103s176lbl.pdf']}]}], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Fibroblast growth factor receptor 2'], 'general-function': ['Protein tyrosine kinase activity'], 'specific-function': ['Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.'], 'gene-name': ['FGFR2'], 'locus': ['10q26'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['378-398'], 'signal-regions': ['1-21'], 'theoretical-pi': ['5.68'], 'molecular-weight': ['92024.29'], 'chromosome-location': ['10'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3689']}, {'resource': ['GenAtlas'], 'identifier': ['FGFR2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X52832']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31374']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1809']}, {'resource': ['UniProtKB'], 'identifier': ['P21802']}, {'resource': ['UniProt Accession'], 'identifier': ['FGFR2_HUMAN']}]}], 'synonyms': [{'synonym': ['2.7.10.1', 'BEK', 'FGFR-2', 'K-sam', 'Keratinocyte growth factor receptor', 'KGFR', 'KSAM']}], 'amino-acid-sequence': ['>lcl|BSEQ0001492|Fibroblast growth factor receptor 2\nMVSWGRFICLVVVTMATLSLARPSFSLVEDTTLEPEEPPTKYQISQPEVYVAAPGESLEV\nRCLLKDAAVISWTKDGVHLGPNNRTVLIGEYLQIKGATPRDSGLYACTASRTVDSETWYF\nMVNVTDAISSGDDEDDTDGAEDFVSENSNNKRAPYWTNTEKMEKRLHAVPAANTVKFRCP\nAGGNPMPTMRWLKNGKEFKQEHRIGGYKVRNQHWSLIMESVVPSDKGNYTCVVENEYGSI\nNHTYHLDVVERSPHRPILQAGLPANASTVVGGDVEFVCKVYSDAQPHIQWIKHVEKNGSK\nYGPDGLPYLKVLKAAGVNTTDKEIEVLYIRNVTFEDAGEYTCLAGNSIGISFHSAWLTVL\nPAPGREKEITASPDYLEIAIYCIGVFLIACMVVTVILCRMKNTTKKPDFSSQPAVHKLTK\nRIPLRRQVTVSAESSSSMNSNTPLVRITTRLSSTADTPMLAGVSEYELPEDPKWEFPRDK\nLTLGKPLGEGCFGQVVMAEAVGIDKDKPKEAVTVAVKMLKDDATEKDLSDLVSEMEMMKM\nIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLRARRPPGMEYSYDINRVPEEQMTF\nKDLVSCTYQLARGMEYLASQKCIHRDLAARNVLVTENNVMKIADFGLARDINNIDYYKKT\nTNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLMWEIFTLGGSPYPGIPVEELFKLLKEGH\nRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLDLSQPLEQYS\nPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSVKT'], 'gene-sequence': ['>lcl|BSEQ0010527|Fibroblast growth factor receptor 2 (FGFR2)\nATGGTCAGCTGGGGTCGTTTCATCTGCCTGGTCGTGGTCACCATGGCAACCTTGTCCCTG\nGCCCGGCCCTCCTTCAGTTTAGTTGAGGATACCACATTAGAGCCAGAAGAGCCACCAACC\nAAATACCAAATCTCTCAACCAGAAGTGTACGTGGCTGCGCCAGGGGAGTCGCTAGAGGTG\nCGCTGCCTGTTGAAAGATGCCGCCGTGATCAGTTGGACTAAGGATGGGGTGCACTTGGGG\nCCCAACAATAGGACAGTGCTTATTGGGGAGTACTTGCAGATAAAGGGCGCCACGCCTAGA\nGACTCCGGCCTCTATGCTTGTACTGCCAGTAGGACTGTAGACAGTGAAACTTGGTACTTC\nATGGTGAATGTCACAGATGCCATCTCATCCGGAGATGATGAGGATGACACCGATGGTGCG\nGAAGATTTTGTCAGTGAGAACAGTAACAACAAGAGAGCACCATACTGGACCAACACAGAA\nAAGATGGAAAAGCGGCTCCATGCTGTGCCTGCGGCCAACACTGTCAAGTTTCGCTGCCCA\nGCCGGGGGGAACCCAATGCCAACCATGCGGTGGCTGAAAAACGGGAAGGAGTTTAAGCAG\nGAGCATCGCATTGGAGGCTACAAGGTACGAAACCAGCACTGGAGCCTCATTATGGAAAGT\nGTGGTCCCATCTGACAAGGGAAATTATACCTGTGTAGTGGAGAATGAATACGGGTCCATC\nAATCACACGTACCACCTGGATGTTGTGGAGCGATCGCCTCACCGGCCCATCCTCCAAGCC\nGGACTGCCGGCAAATGCCTCCACAGTGGTCGGAGGAGACGTAGAGTTTGTCTGCAAGGTT\nTACAGTGATGCCCAGCCCCACATCCAGTGGATCAAGCACGTGGAAAAGAACGGCAGTAAA\nTACGGGCCCGACGGGCTGCCCTACCTCAAGGTTCTCAAGGCCGCCGGTGTTAACACCACG\nGACAAAGAGATTGAGGTTCTCTATATTCGGAATGTAACTTTTGAGGACGCTGGGGAATAT\nACGTGCTTGGCGGGTAATTCTATTGGGATATCCTTTCACTCTGCATGGTTGACAGTTCTG\nCCAGCGCCTGGAAGAGAAAAGGAGATTACAGCTTCCCCAGACTACCTGGAGATAGCCATT\nTACTGCATAGGGGTCTTCTTAATCGCCTGTATGGTGGTAACAGTCATCCTGTGCCGAATG\nAAGAACACGACCAAGAAGCCAGACTTCAGCAGCCAGCCGGCTGTGCACAAGCTGACCAAA\nCGTATCCCCCTGCGGAGACAGGTAACAGTTTCGGCTGAGTCCAGCTCCTCCATGAACTCC\nAACACCCCGCTGGTGAGGATAACAACACGCCTCTCTTCAACGGCAGACACCCCCATGCTG\nGCAGGGGTCTCCGAGTATGAACTTCCAGAGGACCCAAAATGGGAGTTTCCAAGAGATAAG\nCTGACACTGGGCAAGCCCCTGGGAGAAGGTTGCTTTGGGCAAGTGGTCATGGCGGAAGCA\nGTGGGAATTGACAAAGACAAGCCCAAGGAGGCGGTCACCGTGGCCGTGAAGATGTTGAAA\nGATGATGCCACAGAGAAAGACCTTTCTGATCTGGTGTCAGAGATGGAGATGATGAAGATG\nATTGGGAAACACAAGAATATCATAAATCTTCTTGGAGCCTGCACACAGGATGGGCCTCTC\nTATGTCATAGTTGAGTATGCCTCTAAAGGCAACCTCCGAGAATACCTCCGAGCCCGGAGG\nCCACCCGGGATGGAGTACTCCTATGACATTAACCGTGTTCCTGAGGAGCAGATGACCTTC\nAAGGACTTGGTGTCATGCACCTACCAGCTGGCCAGAGGCATGGAGTACTTGGCTTCCCAA\nAAATGTATTCATCGAGATTTAGCAGCCAGAAATGTTTTGGTAACAGAAAACAATGTGATG\nAAAATAGCAGACTTTGGACTCGCCAGAGATATCAACAATATAGACTATTACAAAAAGACC\nACCAATGGGCGGCTTCCAGTCAAGTGGATGGCTCCAGAAGCCCTGTTTGATAGAGTATAC\nACTCATCAGAGTGATGTCTGGTCCTTCGGGGTGTTAATGTGGGAGATCTTCACTTTAGGG\nGGCTCGCCCTACCCAGGGATTCCCGTGGAGGAACTTTTTAAGCTGCTGAAGGAAGGACAC\nAGAATGGATAAGCCAGCCAACTGCACCAACGAACTGTACATGATGATGAGGGACTGTTGG\nCATGCAGTGCCCTCCCAGAGACCAACGTTCAAGCAGTTGGTAGAAGACTTGGATCGAATT\nCTCACTCTCACAACCAATGAGGAATACTTGGACCTCAGCCAACCTCTCGAACAGTATTCA\nCCTAGTTACCCTGACACAAGAAGTTCTTGTTCTTCAGGAGATGATTCTGTTTTTTCTCCA\nGACCCCATGCCTTACGAACCATGCCTTCCTCAGTATCCACACATAAACGGCAGTGTTAAA\nACATGA'], 'pfams': [{'pfam': [{'identifier': ['PF07714'], 'name': ['PK_Tyr_Ser-Thr']}, {'identifier': ['PF07679'], 'name': ['I-set']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell cortex']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['cytoplasmic membrane-bounded vesicle']}, {'category': ['component'], 'description': ['excitatory synapse']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['Golgi apparatus']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular membrane-bounded organelle']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['nucleoplasm']}, {'category': ['component'], 'description': ['nucleus']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['ATP binding']}, {'category': ['function'], 'description': ['fibroblast growth factor binding']}, {'category': ['function'], 'description': ['fibroblast growth factor-activated receptor activity']}, {'category': ['function'], 'description': ['heparin binding']}, {'category': ['function'], 'description': ['protein homodimerization activity']}, {'category': ['function'], 'description': ['protein tyrosine kinase activity']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['angiogenesis']}, {'category': ['process'], 'description': ['apoptotic process']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['axonogenesis']}, {'category': ['process'], 'description': ['bone development']}, {'category': ['process'], 'description': ['bone mineralization']}, {'category': ['process'], 'description': ['bone morphogenesis']}, {'category': ['process'], 'description': ['branch elongation involved in salivary gland morphogenesis']}, {'category': ['process'], 'description': ['branching involved in labyrinthine layer morphogenesis']}, {'category': ['process'], 'description': ['branching involved in prostate gland morphogenesis']}, {'category': ['process'], 'description': ['branching involved in salivary gland morphogenesis']}, {'category': ['process'], 'description': ['branching morphogenesis of a nerve']}, {'category': ['process'], 'description': ['bud elongation involved in lung branching']}, {'category': ['process'], 'description': ['cell fate commitment']}, {'category': ['process'], 'description': ['cell-cell signaling']}, {'category': ['process'], 'description': ['coronal suture morphogenesis']}, {'category': ['process'], 'description': ['digestive tract development']}, {'category': ['process'], 'description': ['embryonic cranial skeleton morphogenesis']}, {'category': ['process'], 'description': ['embryonic digestive tract morphogenesis']}, {'category': ['process'], 'description': ['embryonic organ development']}, {'category': ['process'], 'description': ['embryonic organ morphogenesis']}, {'category': ['process'], 'description': ['embryonic pattern specification']}, {'category': ['process'], 'description': ['endodermal digestive tract morphogenesis']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['epidermis morphogenesis']}, {'category': ['process'], 'description': ['epithelial cell differentiation']}, {'category': ['process'], 'description': ['epithelial cell proliferation involved in salivary gland morphogenesis']}, {'category': ['process'], 'description': ['epithelial to mesenchymal transition']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway involved in hemopoiesis']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway involved in mammary gland specification']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow']}, {'category': ['process'], 'description': ['gland morphogenesis']}, {'category': ['process'], 'description': ['hair follicle morphogenesis']}, {'category': ['process'], 'description': ['in utero embryonic development']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['inner ear morphogenesis']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['lacrimal gland development']}, {'category': ['process'], 'description': ['lateral sprouting from an epithelium']}, {'category': ['process'], 'description': ['lens fiber cell development']}, {'category': ['process'], 'description': ['limb bud formation']}, {'category': ['process'], 'description': ['lung alveolus development']}, {'category': ['process'], 'description': ['lung development']}, {'category': ['process'], 'description': ['lung lobe morphogenesis']}, {'category': ['process'], 'description': ['lung-associated mesenchyme development']}, {'category': ['process'], 'description': ['mammary gland bud formation']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['membranous septum morphogenesis']}, {'category': ['process'], 'description': ['mesenchymal cell differentiation']}, {'category': ['process'], 'description': ['mesenchymal cell differentiation involved in lung development']}, {'category': ['process'], 'description': ['mesenchymal cell proliferation involved in lung development']}, {'category': ['process'], 'description': ['mesodermal cell differentiation']}, {'category': ['process'], 'description': ['midbrain development']}, {'category': ['process'], 'description': ['morphogenesis of embryonic epithelium']}, {'category': ['process'], 'description': ['multicellular organism growth']}, {'category': ['process'], 'description': ['negative regulation of epithelial cell proliferation']}, {'category': ['process'], 'description': ['negative regulation of mitotic nuclear division']}, {'category': ['process'], 'description': ['negative regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['neuromuscular junction development']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['odontogenesis']}, {'category': ['process'], 'description': ['orbitofrontal cortex development']}, {'category': ['process'], 'description': ['organ growth']}, {'category': ['process'], 'description': ['organ morphogenesis']}, {'category': ['process'], 'description': ['otic vesicle formation']}, {'category': ['process'], 'description': ['outflow tract septum morphogenesis']}, {'category': ['process'], 'description': ['peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['phosphatidylinositol-mediated signaling']}, {'category': ['process'], 'description': ['positive regulation of canonical Wnt signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of cardiac muscle cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of cell cycle']}, {'category': ['process'], 'description': ['positive regulation of cell division']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of epithelial cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of epithelial cell proliferation involved in lung morphogenesis']}, {'category': ['process'], 'description': ['positive regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['positive regulation of MAPK cascade']}, {'category': ['process'], 'description': ['positive regulation of mesenchymal cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of phospholipase activity']}, {'category': ['process'], 'description': ['positive regulation of smooth muscle cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['positive regulation of Wnt signaling pathway']}, {'category': ['process'], 'description': ['post-embryonic development']}, {'category': ['process'], 'description': ['prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis']}, {'category': ['process'], 'description': ['prostate epithelial cord elongation']}, {'category': ['process'], 'description': ['prostate gland morphogenesis']}, {'category': ['process'], 'description': ['protein autophosphorylation']}, {'category': ['process'], 'description': ['pyramidal neuron development']}, {'category': ['process'], 'description': ['Ras protein signal transduction']}, {'category': ['process'], 'description': ['regulation of branching involved in prostate gland morphogenesis']}, {'category': ['process'], 'description': ['regulation of cell fate commitment']}, {'category': ['process'], 'description': ['regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['regulation of fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['regulation of morphogenesis of a branching structure']}, {'category': ['process'], 'description': ['regulation of multicellular organism growth']}, {'category': ['process'], 'description': ['regulation of osteoblast differentiation']}, {'category': ['process'], 'description': ['regulation of osteoblast proliferation']}, {'category': ['process'], 'description': ['regulation of smooth muscle cell differentiation']}, {'category': ['process'], 'description': ['regulation of smoothened signaling pathway']}, {'category': ['process'], 'description': ['reproductive structure development']}, {'category': ['process'], 'description': ['skeletal system morphogenesis']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['squamous basal epithelial stem cell differentiation involved in prostate gland acinus development']}, {'category': ['process'], 'description': ['synaptic vesicle transport']}, {'category': ['process'], 'description': ['ureteric bud development']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['ventricular cardiac muscle tissue morphogenesis']}, {'category': ['process'], 'description': ['ventricular zone neuroblast division']}]}]}]}, {'id': ['BE0002131'], 'name': ['Fibroblast growth factor receptor 1'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13167'], 'pubmed-id': ['11714710'], 'citation': ['Ostrovsky O, Berman B, Gallagher J, Mulloy B, Fernig DG, Delehedde M, Ron D: Differential effects of heparin saccharides on the formation of specific fibroblast growth factor (FGF) and FGF receptor complexes. J Biol Chem. 2002 Jan 25;277(4):2444-53. Epub 2001 Nov 19.']}, {'ref-id': ['A13168'], 'pubmed-id': ['10950949'], 'citation': ['Sher I, Lang T, Lubinsky-Mink S, Kuhn J, Adir N, Chatterjee S, Schomburg D, Ron D: Identification of residues important both for primary receptor binding and specificity in fibroblast growth factor-7. J Biol Chem. 2000 Nov 10;275(45):34881-6.']}, {'ref-id': ['A13169'], 'pubmed-id': ['11091737'], 'citation': ['Matsubara A, Yasumoto H, Usui T: Hormone Refractory Prostate Cancer and Fibroblast Growth Factor Receptor. Breast Cancer. 1999 Oct 25;6(4):320-324.']}, {'ref-id': ['A13170'], 'pubmed-id': ['10212269'], 'citation': ['Lu W, Luo Y, Kan M, McKeehan WL: Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem. 1999 Apr 30;274(18):12827-34.']}, {'ref-id': ['A13156'], 'pubmed-id': ['9890894'], 'citation': ['Wang F, Lu W, McKeehan K, Mohamedali K, Gabriel JL, Kan M, McKeehan WL: Common and specific determinants for fibroblast growth factors in the ectodomain of the receptor kinase complex. Biochemistry. 1999 Jan 5;38(1):160-71.']}, {'ref-id': ['A52198'], 'pubmed-id': ['8663044'], 'citation': ['Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M: Receptor specificity of the fibroblast growth factor family. J Biol Chem. 1996 Jun 21;271(25):15292-7.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Fibroblast growth factor receptor 1'], 'general-function': ['Protein tyrosine kinase activity'], 'specific-function': ['Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration. Required for normal mesoderm patterning and correct axial organization during embryonic development, normal skeletogenesis and normal development of the gonadotropin-releasing hormone (GnRH) neuronal system. Phosphorylates PLCG1, FRS2, GAB1 and SHB. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes phosphorylation of SHC1, STAT1 and PTPN11/SHP2. In the nucleus, enhances RPS6KA1 and CREB1 activity and contributes to the regulation of transcription. FGFR1 signaling is down-regulated by IL17RD/SEF, and by FGFR1 ubiquitination, internalization and degradation.'], 'gene-name': ['FGFR1'], 'locus': ['8p11.2-p11.1'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['377-397'], 'signal-regions': ['1-21'], 'theoretical-pi': ['6.14'], 'molecular-weight': ['91866.935'], 'chromosome-location': ['8'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3688']}, {'resource': ['GenAtlas'], 'identifier': ['FGFR1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X51803']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31368']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1808']}, {'resource': ['UniProtKB'], 'identifier': ['P11362']}, {'resource': ['UniProt Accession'], 'identifier': ['FGFR1_HUMAN']}]}], 'synonyms': [{'synonym': ['2.7.10.1', 'Basic fibroblast growth factor receptor 1', 'bFGF-R-1', 'BFGFR', 'CEK', 'FGFBR', 'FGFR-1', 'FLG', 'FLT-2', 'FLT2', 'Fms-like tyrosine kinase 2', 'HBGFR', 'N-sam', 'Proto-oncogene c-Fgr']}], 'amino-acid-sequence': ['>lcl|BSEQ0004180|Fibroblast growth factor receptor 1\nMWSWKCLLFWAVLVTATLCTARPSPTLPEQAQPWGAPVEVESFLVHPGDLLQLRCRLRDD\nVQSINWLRDGVQLAESNRTRITGEEVEVQDSVPADSGLYACVTSSPSGSDTTYFSVNVSD\nALPSSEDDDDDDDSSSEEKETDNTKPNRMPVAPYWTSPEKMEKKLHAVPAAKTVKFKCPS\nSGTPNPTLRWLKNGKEFKPDHRIGGYKVRYATWSIIMDSVVPSDKGNYTCIVENEYGSIN\nHTYQLDVVERSPHRPILQAGLPANKTVALGSNVEFMCKVYSDPQPHIQWLKHIEVNGSKI\nGPDNLPYVQILKTAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHSAWLTVLE\nALEERPAVMTSPLYLEIIIYCTGAFLISCMVGSVIVYKMKSGTKKSDFHSQMAVHKLAKS\nIPLRRQVTVSADSSASMNSGVLLVRPSRLSSSGTPMLAGVSEYELPEDPRWELPRDRLVL\nGKPLGEGCFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEMMKMIGK\nHKNIINLLGACTQDGPLYVIVEYASKGNLREYLQARRPPGLEYCYNPSHNPEEQLSSKDL\nVSCAYQVARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNG\nRLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKLLKEGHRMD\nKPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQEYLDLSMPLDQYSPSF\nPDTRSSTCSSGEDSVFSHEPLPEEPCLPRHPAQLANGGLKRR'], 'gene-sequence': ['>lcl|BSEQ0021960|Fibroblast growth factor receptor 1 (FGFR1)\nATGTGGAGCTGGAAGTGCCTCCTCTTCTGGGCTGTGCTGGTCACAGCCACACTCTGCACC\nGCTAGGCCGTCCCCGACCTTGCCTGAACAAGCCCAGCCCTGGGGAGCCCCTGTGGAAGTG\nGAGTCCTTCCTGGTCCACCCCGGTGACCTGCTGCAGCTTCGCTGTCGGCTGCGGGACGAT\nGTGCAGAGCATCAACTGGCTGCGGGACGGGGTGCAGCTGGCGGAAAGCAACCGCACCCGC\nATCACAGGGGAGGAGGTGGAGGTGCAGGACTCCGTGCCCGCAGACTCCGGCCTCTATGCT\nTGCGTAACCAGCAGCCCCTCGGGCAGTGACACCACCTACTTCTCCGTCAATGTTTCAGAT\nGCTCTCCCCTCCTCGGAGGATGATGATGATGATGATGACTCCTCTTCAGAGGAGAAAGAA\nACAGATAACACCAAACCAAACCGTATGCCCGTAGCTCCATATTGGACATCCCCAGAAAAG\nATGGAAAAGAAATTGCATGCAGTGCCGGCTGCCAAGACAGTGAAGTTCAAATGCCCTTCC\nAGTGGGACCCCAAACCCCACACTGCGCTGGTTGAAAAATGGCAAAGAATTCAAACCTGAC\nCACAGAATTGGAGGCTACAAGGTCCGTTATGCCACCTGGAGCATCATAATGGACTCTGTG\nGTGCCCTCTGACAAGGGCAACTACACCTGCATTGTGGAGAATGAGTACGGCAGCATCAAC\nCACACATACCAGCTGGATGTCGTGGAGCGGTCCCCTCACCGGCCCATCCTGCAAGCAGGG\nTTGCCCGCCAACAAAACAGTGGCCCTGGGTAGCAACGTGGAGTTCATGTGTAAGGTGTAC\nAGTGACCCGCAGCCGCACATCCAGTGGCTAAAGCACATCGAGGTGAATGGGAGCAAGATT\nGGCCCAGACAACCTGCCTTATGTCCAGATCTTGAAGACTGCTGGAGTTAATACCACCGAC\nAAAGAGATGGAGGTGCTTCACTTAAGAAATGTCTCCTTTGAGGACGCAGGGGAGTATACG\nTGCTTGGCGGGTAACTCTATCGGACTCTCCCATCACTCTGCATGGTTGACCGTTCTGGAA\nGCCCTGGAAGAGAGGCCGGCAGTGATGACCTCGCCCCTGTACCTGGAGATCATCATCTAT\nTGCACAGGGGCCTTCCTCATCTCCTGCATGGTGGGGTCGGTCATCGTCTACAAGATGAAG\nAGTGGTACCAAGAAGAGTGACTTCCACAGCCAGATGGCTGTGCACAAGCTGGCCAAGAGC\nATCCCTCTGCGCAGACAGGTGTCTGCTGACTCCAGTGCATCCATGAACTCTGGGGTTCTT\nCTGGTTCGGCCATCACGGCTCTCCTCCAGTGGGACTCCCATGCTAGCAGGGGTCTCTGAG\nTATGAGCTTCCCGAAGACCCTCGCTGGGAGCTGCCTCGGGACAGACTGGTCTTAGGCAAA\nCCCCTGGGAGAGGGCTGCTTTGGGCAGGTGGTGTTGGCAGAGGCTATCGGGCTGGACAAG\nGACAAACCCAACCGTGTGACCAAAGTGGCTGTGAAGATGTTGAAGTCGGACGCAACAGAG\nAAAGACTTGTCAGACCTGATCTCAGAAATGGAGATGATGAAGATGATCGGGAAGCATAAG\nAATATCATCAACCTGCTGGGGGCCTGCACGCAGGATGGTCCCTTGTATGTCATCGTGGAG\nTATGCCTCCAAGGGCAACCTGCGGGAGTACCTGCAGGCCCGGAGGCCCCCAGGGCTGGAA\nTACTGCTACAACCCCAGCCACAACCCAGAGGAGCAGCTCTCCTCCAAGGACCTGGTGTCC\nTGCGCCTACCAGGTGGCCCGAGGCATGGAGTATCTGGCCTCCAAGAAGTGCATACACCGA\nGACCTGGCAGCCAGGAATGTCCTGGTGACAGAGGACAATGTGATGAAGATAGCAGACTTT\nGGCCTCGCACGGGACATTCACCACATCGACTACTATAAAAAGACAACCAACGGCCGACTG\nCCTGTGAAGTGGATGGCACCCGAGGCATTATTTGACCGGATCTACACCCACCAGAGTGAT\nGTGTGGTCTTTCGGGGTGCTCCTGTGGGAGATCTTCACTCTGGGCGGCTCCCCATACCCC\nGGTGTGCCTGTGGAGGAACTTTTCAAGCTGCTGAAGGAGGGTCACCGCATGGACAAGCCC\nAGTAACTGCACCAACGAGCTGTACATGATGATGCGGGACTGCTGGCATGCAGTGCCCTCA\nCAGAGACCCACCTTCAAGCAGCTGGTGGAAGACCTGGACCGCATCGTGGCCTTGACCTCC\nAACCAGGAGTACCTGGACCTGTCCATGCCCCTGGACCAGTACTCCCCCAGCTTTCCCGAC\nACCCGGAGCTCTACGTGCTCCTCAGGGGAGGATTCCGTCTTCTCTCATGAGCCGCTGCCC\nGAGGAGCCCTGCCTGCCCCGACACCCAGCCCAGCTTGCCAATGGCGGACTCAAACGCCGC\nTGA'], 'pfams': [{'pfam': [{'identifier': ['PF07714'], 'name': ['PK_Tyr_Ser-Thr']}, {'identifier': ['PF00047'], 'name': ['ig']}, {'identifier': ['PF07679'], 'name': ['I-set']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cytoplasmic membrane-bounded vesicle']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['nucleus']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['function'], 'description': ['ATP binding']}, {'category': ['function'], 'description': ['fibroblast growth factor binding']}, {'category': ['function'], 'description': ['fibroblast growth factor-activated receptor activity']}, {'category': ['function'], 'description': ['heparin binding']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['function'], 'description': ['protein homodimerization activity']}, {'category': ['function'], 'description': ['protein tyrosine kinase activity']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['angiogenesis']}, {'category': ['process'], 'description': ['auditory receptor cell development']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['branching involved in salivary gland morphogenesis']}, {'category': ['process'], 'description': ['cell maturation']}, {'category': ['process'], 'description': ['cell migration']}, {'category': ['process'], 'description': ['chondrocyte differentiation']}, {'category': ['process'], 'description': ['chordate embryonic development']}, {'category': ['process'], 'description': ['embryonic limb morphogenesis']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development']}, {'category': ['process'], 'description': ['in utero embryonic development']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['inner ear morphogenesis']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['lung-associated mesenchyme development']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['mesenchymal cell differentiation']}, {'category': ['process'], 'description': ['midbrain development']}, {'category': ['process'], 'description': ['middle ear morphogenesis']}, {'category': ['process'], 'description': ['motogenic signaling involved in postnatal olfactory bulb interneuron migration']}, {'category': ['process'], 'description': ['negative regulation of osteoblast differentiation']}, {'category': ['process'], 'description': ['negative regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['neuron migration']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['organ induction']}, {'category': ['process'], 'description': ['outer ear morphogenesis']}, {'category': ['process'], 'description': ['paraxial mesoderm development']}, {'category': ['process'], 'description': ['peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['phosphatidylinositol-mediated signaling']}, {'category': ['process'], 'description': ['positive regulation of cardiac muscle cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of cell cycle']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of MAP kinase activity']}, {'category': ['process'], 'description': ['positive regulation of MAPK cascade']}, {'category': ['process'], 'description': ['positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of mesenchymal cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of neuron differentiation']}, {'category': ['process'], 'description': ['positive regulation of neuron projection development']}, {'category': ['process'], 'description': ['positive regulation of phosphatidylinositol 3-kinase signaling']}, {'category': ['process'], 'description': ['positive regulation of phospholipase activity']}, {'category': ['process'], 'description': ['positive regulation of phospholipase C activity']}, {'category': ['process'], 'description': ['protein autophosphorylation']}, {'category': ['process'], 'description': ['protein phosphorylation']}, {'category': ['process'], 'description': ['Ras protein signal transduction']}, {'category': ['process'], 'description': ['regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling']}, {'category': ['process'], 'description': ['regulation of cell differentiation']}, {'category': ['process'], 'description': ['regulation of extrinsic apoptotic signaling pathway in absence of ligand']}, {'category': ['process'], 'description': ['regulation of lateral mesodermal cell fate specification']}, {'category': ['process'], 'description': ['regulation of sensory perception of pain']}, {'category': ['process'], 'description': ['sensory perception of sound']}, {'category': ['process'], 'description': ['skeletal system development']}, {'category': ['process'], 'description': ['skeletal system morphogenesis']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['stem cell population maintenance']}, {'category': ['process'], 'description': ['transcription, DNA-templated']}, {'category': ['process'], 'description': ['ureteric bud development']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['ventricular zone neuroblast division']}]}]}]}, {'id': ['BE0001031'], 'name': ['Basement membrane-specific heparan sulfate proteoglycan core protein'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1884'], 'pubmed-id': ['10593896'], 'citation': ['Berman B, Ostrovsky O, Shlissel M, Lang T, Regan D, Vlodavsky I, Ishai-Michaeli R, Ron D: Similarities and differences between the effects of heparin and glypican-1 on the bioactivity of acidic fibroblast growth factor and the keratinocyte growth factor. J Biol Chem. 1999 Dec 17;274(51):36132-8.']}, {'ref-id': ['A13178'], 'pubmed-id': ['9788974'], 'citation': ['Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA, Iozzo RV: Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest. 1998 Oct 15;102(8):1599-608.']}, {'ref-id': ['A13179'], 'pubmed-id': ['16989989'], 'citation': ['Iwabuchi T, Goetinck PF: Syndecan-4 dependent FGF stimulation of mouse vibrissae growth. Mech Dev. 2006 Nov;123(11):831-41. Epub 2006 Aug 12.']}, {'ref-id': ['A13180'], 'pubmed-id': ['14753849'], 'citation': ['Asada N, Tanaka Y, Hayashido Y, Toratani S, Kan M, Kitamoto M, Nakanishi T, Kajiyama G, Chayama K, Okamoto T: Expression of fibroblast growth factor receptor genes in human hepatoma-derived cell lines. In Vitro Cell Dev Biol Anim. 2003 Jul-Aug;39(7):321-8.']}, {'ref-id': ['A13155'], 'pubmed-id': ['9094999'], 'citation': ['Friedl A, Chang Z, Tierney A, Rapraeger AC: Differential binding of fibroblast growth factor-2 and -7 to basement membrane heparan sulfate: comparison of normal and abnormal human tissues. Am J Pathol. 1997 Apr;150(4):1443-55.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Basement membrane-specific heparan sulfate proteoglycan core protein'], 'general-function': ['Protein c-terminus binding'], 'specific-function': ['Integral component of basement membranes. Component of the glomerular basement membrane (GBM), responsible for the fixed negative electrostatic membrane charge, and which provides a barrier which is both size- and charge-selective. It serves as an attachment substrate for cells. Plays essential roles in vascularization. Critical for normal heart development and for regulating the vascular response to injury. Also required for avascular cartilage development.Endorepellin in an anti-angiogenic and anti-tumor peptide that inhibits endothelial cell migration, collagen-induced endothelial tube morphogenesis and blood vessel growth in the chorioallantoic membrane. Blocks endothelial cell adhesion to fibronectin and type I collagen. Anti-tumor agent in neovascularization. Interaction with its ligand, integrin alpha2/beta1, is required for the anti-angiogenic properties. Evokes a reduction in phosphorylation of receptor tyrosine kinases via alpha2/beta1 integrin-mediated activation of the tyrosine phosphatase, PTPN6.The LG3 peptide has anti-angiogenic properties that require binding of calcium ions for full activity.'], 'gene-name': ['HSPG2'], 'locus': ['1p36.1-p34'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-21'], 'theoretical-pi': ['6.49'], 'molecular-weight': ['468826.45'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5273']}, {'resource': ['GenAtlas'], 'identifier': ['HSPG2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X62515']}, {'resource': ['GenBank Protein Database'], 'identifier': ['29470']}, {'resource': ['UniProtKB'], 'identifier': ['P98160']}, {'resource': ['UniProt Accession'], 'identifier': ['PGBM_HUMAN']}]}], 'synonyms': [{'synonym': ['HSPG', 'Perlecan', 'PLC']}], 'amino-acid-sequence': ['>lcl|BSEQ0010721|Basement membrane-specific heparan sulfate proteoglycan core protein\nMGWRAAGALLLALLLHGRLLAVTHGLRAYDGLSLPEDIETVTASQMRWTHSYLSDDEDML\nADSISGDDLGSGDLGSGDFQMVYFRALVNFTRSIEYSPQLEDAGSREFREVSEAVVDTLE\nSEYLKIPGDQVVSVVFIKELDGWVFVELDVGSEGNADGAQIQEMLLRVISSGSVASYVTS\nPQGFQFRRLGTVPQFPRACTEAEFACHSYNECVALEYRCDRRPDCRDMSDELNCEEPVLG\nISPTFSLLVETTSLPPRPETTIMRQPPVTHAPQPLLPGSVRPLPCGPQEAACRNGHCIPR\nDYLCDGQEDCEDGSDELDCGPPPPCEPNEFPCGNGHCALKLWRCDGDFDCEDRTDEANCP\nTKRPEEVCGPTQFRCVSTNMCIPASFHCDEESDCPDRSDEFGCMPPQVVTPPRESIQASR\nGQTVTFTCVAIGVPTPIINWRLNWGHIPSHPRVTVTSEGGRGTLIIRDVKESDQGAYTCE\nAMNARGMVFGIPDGVLELVPQRGPCPDGHFYLEHSAACLPCFCFGITSVCQSTRRFRDQI\nRLRFDQPDDFKGVNVTMPAQPGTPPLSSTQLQIDPSLHEFQLVDLSRRFLVHDSFWALPE\nQFLGNKVDSYGGSLRYNVRYELARGMLEPVQRPDVVLMGAGYRLLSRGHTPTQPGALNQR\nQVQFSEEHWVHESGRPVQRAELLQVLQSLEAVLIQTVYNTKMASVGLSDIAMDTTVTHAT\nSHGRAHSVEECRCPIGYSGLSCESCDAHFTRVPGGPYLGTCSGCNCNGHASSCDPVYGHC\nLNCQHNTEGPQCNKCKAGFFGDAMKATATSCRPCPCPYIDASRRFSDTCFLDTDGQATCD\nACAPGYTGRRCESCAPGYEGNPIQPGGKCRPVNQEIVRCDERGSMGTSGEACRCKNNVVG\nRLCNECADGSFHLSTRNPDGCLKCFCMGVSRHCTSSSWSRAQLHGASEEPGHFSLTNAAS\nTHTTNEGIFSPTPGELGFSSFHRLLSGPYFWSLPSRFLGDKVTSYGGELRFTVTQRSQPG\nSTPLHGQPLVVLQGNNIILEHHVAQEPSPGQPSTFIVPFREQAWQRPDGQPATREHLLMA\nLAGIDTLLIRASYAQQPAESRVSGISMDVAVPEETGQDPALEVEQCSCPPGYRGPSCQDC\nDTGYTRTPSGLYLGTCERCSCHGHSEACEPETGACQGCQHHTEGPRCEQCQPGYYGDAQR\nGTPQDCQLCPCYGDPAAGQAAHTCFLDTDGHPTCDACSPGHSGRHCERCAPGYYGNPSQG\nQPCQRDSQVPGPIGCNCDPQGSVSSQCDAAGQCQCKAQVEGLTCSHCRPHHFHLSASNPD\nGCLPCFCMGITQQCASSAYTRHLISTHFAPGDFQGFALVNPQRNSRLTGEFTVEPVPEGA\nQLSFGNFAQLGHESFYWQLPETYQGDKVAAYGGKLRYTLSYTAGPQGSPLSDPDVQITGN\nNIMLVASQPALQGPERRSYEIMFREEFWRRPDGQPATREHLLMALADLDELLIRATFSSV\nPLAASISAVSLEVAQPGPSNRPRALEVEECRCPPGYIGLSCQDCAPGYTRTGSGLYLGHC\nELCECNGHSDLCHPETGACSQCQHNAAGEFCELCAPGYYGDATAGTPEDCQPCACPLTNP\nENMFSRTCESLGAGGYRCTACEPGYTGQYCEQCGPGYVGNPSVQGGQCLPETNQAPLVVE\nVHPARSIVPQGGSHSLRCQVSGSPPHYFYWSREDGRPVPSGTQQRHQGSELHFPSVQPSD\nAGVYICTCRNLHQSNTSRAELLVTEAPSKPITVTVEEQRSQSVRPGADVTFICTAKSKSP\nAYTLVWTRLHNGKLPTRAMDFNGILTIRNVQLSDAGTYVCTGSNMFAMDQGTATLHVQAS\nGTLSAPVVSIHPPQLTVQPGQLAEFRCSATGSPTPTLEWTGGPGGQLPAKAQIHGGILRL\nPAVEPTDQAQYLCRAHSSAGQQVARAVLHVHGGGGPRVQVSPERTQVHAGRTVRLYCRAA\nGVPSATITWRKEGGSLPPQARSERTDIATLLIPAITTADAGFYLCVATSPAGTAQARIQV\nVVLSASDASPPPVKIESSSPSVTEGQTLDLNCVVAGSAHAQVTWYRRGGSLPPHTQVHGS\nRLRLPQVSPADSGEYVCRVENGSGPKEASITVSVLHGTHSGPSYTPVPGSTRPIRIEPSS\nSHVAEGQTLDLNCVVPGQAHAQVTWHKRGGSLPARHQTHGSLLRLHQVTPADSGEYVCHV\nVGTSGPLEASVLVTIEASVIPGPIPPVRIESSSSTVAEGQTLDLSCVVAGQAHAQVTWYK\nRGGSLPARHQVRGSRLYIFQASPADAGQYVCRASNGMEASITVTVTGTQGANLAYPAGST\nQPIRIEPSSSQVAEGQTLDLNCVVPGQSHAQVTWHKRGGSLPVRHQTHGSLLRLYQASPA\nDSGEYVCRVLGSSVPLEASVLVTIEPAGSVPALGVTPTVRIESSSSQVAEGQTLDLNCLV\nAGQAHAQVTWHKRGGSLPARHQVHGSRLRLLQVTPADSGEYVCRVVGSSGTQEASVLVTI\nQQRLSGSHSQGVAYPVRIESSSASLANGHTLDLNCLVASQAPHTITWYKRGGSLPSRHQI\nVGSRLRIPQVTPADSGEYVCHVSNGAGSRETSLIVTIQGSGSSHVPSVSPPIRIESSSPT\nVVEGQTLDLNCVVARQPQAIITWYKRGGSLPSRHQTHGSHLRLHQMSVADSGEYVCRANN\nNIDALEASIVISVSPSAGSPSAPGSSMPIRIESSSSHVAEGETLDLNCVVPGQAHAQVTW\nHKRGGSLPSHHQTRGSRLRLHHVSPADSGEYVCRVMGSSGPLEASVLVTIEASGSSAVHV\nPAPGGAPPIRIEPSSSRVAEGQTLDLKCVVPGQAHAQVTWHKRGGNLPARHQVHGPLLRL\nNQVSPADSGEYSCQVTGSSGTLEASVLVTIEPSSPGPIPAPGLAQPIYIEASSSHVTEGQ\nTLDLNCVVPGQAHAQVTWYKRGGSLPARHQTHGSQLRLHLVSPADSGEYVCRAASGPGPE\nQEASFTVTVPPSEGSSYRLRSPVISIDPPSSTVQQGQDASFKCLIHDGAAPISLEWKTRN\nQELEDNVHISPNGSIITIVGTRPSNHGTYRCVASNAYGVAQSVVNLSVHGPPTVSVLPEG\nPVWVKVGKAVTLECVSAGEPRSSARWTRISSTPAKLEQRTYGLMDSHAVLQISSAKPSDA\nGTYVCLAQNALGTAQKQVEVIVDTGAMAPGAPQVQAEEAELTVEAGHTATLRCSATGSPA\nPTIHWSKLRSPLPWQHRLEGDTLIIPRVAQQDSGQYICNATSPAGHAEATIILHVESPPY\nATTVPEHASVQAGETVQLQCLAHGTPPLTFQWSRVGSSLPGRATARNELLHFERAAPEDS\nGRYRCRVTNKVGSAEAFAQLLVQGPPGSLPATSIPAGSTPTVQVTPQLETKSIGASVEFH\nCAVPSDRGTQLRWFKEGGQLPPGHSVQDGVLRIQNLDQSCQGTYICQAHGPWGKAQASAQ\nLVIQALPSVLINIRTSVQTVVVGHAVEFECLALGDPKPQVTWSKVGGHLRPGIVQSGGVV\nRIAHVELADAGQYRCTATNAAGTTQSHVLLLVQALPQISMPQEVRVPAGSAAVFPCIASG\nYPTPDISWSKLDGSLPPDSRLENNMLMLPSVRPQDAGTYVCTATNRQGKVKAFAHLQVPE\nRVVPYFTQTPYSFLPLPTIKDAYRKFEIKITFRPDSADGMLLYNGQKRVPGSPTNLANRQ\nPDFISFGLVGGRPEFRFDAGSGMATIRHPTPLALGHFHTVTLLRSLTQGSLIVGDLAPVN\nGTSQGKFQGLDLNEELYLGGYPDYGAIPKAGLSSGFIGCVRELRIQGEEIVFHDLNLTAH\nGISHCPTCRDRPCQNGGQCHDSESSSYVCVCPAGFTGSRCEHSQALHCHPEACGPDATCV\nNRPDGRGYTCRCHLGRSGLRCEEGVTVTTPSLSGAGSYLALPALTNTHHELRLDVEFKPL\nAPDGVLLFSGGKSGPVEDFVSLAMVGGHLEFRYELGSGLAVLRSAEPLALGRWHRVSAER\nLNKDGSLRVNGGRPVLRSSPGKSQGLNLHTLLYLGGVEPSVPLSPATNMSAHFRGCVGEV\nSVNGKRLDLTYSFLGSQGIGQCYDSSPCERQPCQHGATCMPAGEYEFQCLCRDGFKGDLC\nEHEENPCQLREPCLHGGTCQGTRCLCLPGFSGPRCQQGSGHGIAESDWHLEGSGGNDAPG\nQYGAYFHDDGFLAFPGHVFSRSLPEVPETIELEVRTSTASGLLLWQGVEVGEAGQGKDFI\nSLGLQDGHLVFRYQLGSGEARLVSEDPINDGEWHRVTALREGRRGSIQVDGEELVSGRSP\nGPNVAVNAKGSVYIGGAPDVATLTGGRFSSGITGCVKNLVLHSARPGAPPPQPLDLQHRA\nQAGANTRPCPS'], 'gene-sequence': ['>lcl|BSEQ0010722|Basement membrane-specific heparan sulfate proteoglycan core protein (HSPG2)\nATGGGGTGGCGGGCGGCGGGCGCGCTGCTGCTGGCGCTGCTGCTGCACGGGCGGCTGCTG\nGCGGTGACCCATGGGCTGAGGGCATACGATGGCTTGTCTCTGCCTGAGGACATAGAGACC\nGTCACAGCAAGCCAAATGCGCTGGACACATTCGTACCTTTCTGATGATGAGGACATGCTG\nGCTGACAGCATCTCAGGAGACGACCTGGGCAGTGGGGACCTGGGCAGCGGGGACTTCCAG\nATGGTTTATTTCCGAGCCCTGGTGAATTTCACTCGCTCCATCGAGTACAGCCCTCAGCTG\nGAGGATGCAGGCTCCAGAGAGTTCCGAGAGGTGTCCGAGGCTGTGGTAGACACGCTGGAG\nTCGGAGTACTTGAAAATTCCCGGAGACCAGGTTGTCAGTGTGGTGTTCATCAAGGAGCTG\nGATGGCTGGGTTTTTGTGGAGCTGGATGTGGGCTCGGAAGGGAATGCGGATGGGGCTCAG\nATTCAGGAGATGCTGCTCAGGGTCATCTCCAGCGGCTCTGTGGCCTCCTACGTCACCTCT\nCCCCAGGGATTCCAGTTCCGACGCCTGGGCACAGTGCCCCAGTTCCCAAGAGCCTGCACG\nGAGGCCGAGTTTGCCTGCCACAGCTACAATGAGTGTGTGGCCCTGGAGTATCGCTGTGAC\nCGGCGGCCCGACTGCAGGGACATGTCTGATGAGCTCAATTGTGAGGAGCCAGTCCTGGGT\nATCAGCCCCACATTCTCTCTCCTTGTGGAGACGACATCTTTACCGCCCCGGCCAGAGACA\nACCATCATGCGACAGCCACCAGTCACCCACGCTCCTCAGCCCCTGCTTCCCGGTTCCGTC\nAGGCCCCTGCCCTGTGGGCCCCAGGAGGCCGCATGCCGCAATGGGCACTGCATCCCCAGA\nGACTACCTCTGCGACGGACAGGAGGACTGCGAGGACGGCAGCGATGAGCTAGACTGTGGC\nCCCCCGCCACCCTGTGAGCCCAACGAGTTCCCCTGCGGGAATGGACATTGTGCCCTCAAG\nCTGTGGCGCTGCGATGGTGACTTTGACTGTGAGGACCGAACTGATGAAGCCAACTGCCCC\nACCAAGCGTCCTGAGGAAGTGTGCGGGCCCACACAGTTCCGATGCGTCTCTACCAACATG\nTGCATCCCAGCCAGCTTCCACTGTGACGAGGAGAGCGACTGTCCTGACCGGAGCGACGAG\nTTTGGCTGCATGCCCCCCCAGGTGGTGACACCTCCCCGGGAGTCCATCCAGGCTTCCCGG\nGGCCAGACAGTGACCTTCACCTGCGTGGCCATTGGCGTCCCCACCCCCATCATCAATTGG\nAGGCTCAACTGGGGCCACATCCCCTCTCATCCCAGGGTGACAGTGACCAGCGAGGGTGGC\nCGTGGCACACTGATCATCCGTGATGTGAAGGAGTCAGACCAGGGTGCCTACACCTGTGAG\nGCCATGAACGCCCGGGGCATGGTGTTTGGCATTCCTGACGGTGTCCTTGAGCTCGTCCCA\nCAACGAGCAGGCCCCTGCCCTGACGGCCACTTCTACCTGGAGCACAGCGCCGCCTGCCTG\nCCCTGCTTCTGCTTTGGCATCACCAGCGTGTGCCAGAGCACCCGCCGCTTCCGGGACCAG\nATCAGGCTGCGCTTTGACCAACCCGATGACTTCAAGGGTGTGAATGTGACAATGCCTGCG\nCAGCCCGGCACGCCACCCCTCTCCTCCACGCAGCTGCAGATCGACCCATCCCTGCACGAG\nTTCCAGCTAGTCGACCTGTCCCGCCGCTTCCTCGTCCACGACTCCTTCTGGGCTCTGCCT\nGAACAGTTCCTGGGCAACAAGGTGGACTCCTATGGCGGCTCCCTGCGTTACAACGTGCGC\nTACGAGTTGGCCCGTGGCATGCTGGAGCCAGTGCAGCGGCCGGACGTGGTCCTCATGGGT\nGCCGGGTACCGCCTCCTCTCCCGAGGCCACACACCCACCCAACCTGGTGCTCTGAACCAG\nCGCCAGGTCCAGTTCTCTGAGGAGCACTGGGTCCATGAGTCTGGCCGGCCGGTGCAGCGC\nGCGGAGCTGCTGCAGGTGCTGCAGAGCCTGGAGGCCGTGCTCATCCAGACCGTGTACAAC\nACCAAGATGGCCAGCGTGGGACTTAGCGACATCGCCATGGATACCACCGTCACCCATGCC\nACCAGCCATGGCCGTGCCCACAGTGTGGAGGAGTGCAGATGCCCCATTGGCTATTCTGGC\nTTGTCCTGCGAGAGCTGTGATGCCCACTTCACTCGGGTGCCTGGTGGGCCCTACCTGGGC\nACCTGCTCTGGTTGCAATTGCAATGGCCATGCCAGCTCCTGTGACCCTGTGTATGGCCAC\nTGCCTGAATTGCCAGCACAACACGGAGGGGCCACAGTGCAACAAGTGCAAGGCTGGCTTC\nTTTGGGGACGCCATGAAGGCCACGGCCACTTCCTGCCGGCCCTGCCCTTGCCCATACATC\nGATGCCTCCCGCAGATTCTCAGACACTTGCTTCCTGGACACGGATGGCCAAGCCACATGT\nGACGCCTGTGCCCCAGGCTACACTGGCCGCCGCTGTGAGAGCTGTGCCCCCGGATACGAG\nGGCAACCCCATCCAGCCCGGCGGGAAGTGCAGGCCCGTCAACCAGGAGATTGTGCGCTGT\nGACGAGCGTGGCAGCATGGGGACCTCCGGGGAGGCCTGCCGCTGTAAGAACAATGTGGTG\nGGGCGCTTGTGCAATGAATGTGCTGACGGCTCTTTCCACCTGAGTACCCGAAACCCCGAT\nGGCTGCCTCAAGTGCTTCTGCATGGGTGTCAGTCGCCACTGCACCAGCTCTTCATGGAGC\nCGTGCCCAGTTGCATGGGGCCTCTGAGGAGCCTGGTCACTTCAGCCTGACCAACGCCGCA\nAGCACCCACACCACCAACGAGGGCATCTTCTCCCCCACGCCCGGGGAACTGGGATTCTCC\nTCCTTCCACAGACTCTTATCTGGACCCTACTTCTGGAGCCTCCCTTCACGCTTCCTGGGG\nGACAAGGTGACCTCCTATGGAGGAGAGCTGCGCTTCACAGTGACCCAGAGGTCCCAGCCG\nGGCTCCACACCCCTGCACGGGCAGCCGTTGGTGGTGCTGCAAGGTAACAACATCATCCTA\nGAGCACCATGTGGCCCAGGAGCCCAGCCCCGGCCAGCCCAGCACCTTCATTGTGCCTTTC\nCGGGAGCAAGCATGGCAGCGGCCCGATGGGCAGCCAGCCACACGGGAGCACCTGCTGATG\nGCACTGGCAGGCATCGACACCCTCCTGATCCGAGCATCCTACGCCCAGCAGCCCGCTGAG\nAGCAGGGTCTCTGGCATCAGCATGGACGTGGCTGTGCCCGAGGAAACCGGCCAGGACCCC\nGCGCTGGAAGTGGAACAGTGCTCCTGCCCACCCGGGTACCGTGGGCCGTCCTGCCAGGAC\nTGTGACACAGGCTACACACGCACGCCCAGTGGCCTCTACCTGGGTACCTGTGAACGCTGC\nAGCTGCCATGGCCACTCAGAGGCCTGCGAGCCAGAAACAGGTGCCTGCCAGGGCTGCCAG\nCATCACACGGAGGGCCCTCGGTGTGAGCAGTGCCAGCCAGGATACTACGGGGACGCCCAG\nCGGGGGACACCACAGGACTGCCAGCTGTGCCCCTGCTACGGAGACCCTGCTGCCGGCCAG\nGCTGCCCACACTTGTTTTCTGGACACAGACGGCCACCCCACCTGTGATGCGTGCTCCCCA\nGGCCACAGTGGGCGTCACTGTGAGAGGTGCGCCCCTGGCTACTATGGCAACCCCAGCCAG\nGGCCAGCCATGCCAGAGAGACAGCCAGGTGCCAGGGCCCATAGGCTGCAACTGTGACCCC\nCAAGGCAGCGTCAGCAGCCAGTGTGATGCTGCTGGTCAGTGCCAGTGCAAGGCCCAGGTG\nGAAGGCCTCACTTGCAGCCACTGCCGGCCCCACCACTTCCACCTGAGTGCCAGCAACCCA\nGACGGCTGCCTGCCCTGCTTCTGTATGGGCATCACCCAGCAGTGCGCCAGCTCTGCCTAC\nACACGCCACCTGATCTCCACCCACTTTGCCCCTGGGGACTTCCAAGGCTTTGCCCTGGTG\nAACCCACAGCGAAACAGCCGCCTGACAGGAGAATTCACTGTGGAACCCGTGCCCGAGGGT\nGCCCAGCTCTCTTTTGGCAACTTTGCCCAACTCGGCCATGAGTCCTTCTACTGGCAGCTG\nCCGGAGACATACCAGGGAGACAAGGTGGCGGCCTACGGTGGGAAGTTGCGATACACCCTC\nTCCTACACAGCAGGCCCACAGGGCAGCCCACTCTCTGACCCCGATGTGCAGATCACGGGC\nAACAACATCATGCTAGTGGCCTCCCAGCCAGCGCTGCAGGGCCCTGAGAGGAGGAGCTAC\nGAGATCATGTTCCGAGAGGAATTCTGGCGCCGGCCCGATGGGCAGCCGGCCACACGCGAG\nCACCTCCTGATGGCACTGGCCGACCTGGATGAGCTCCTGATCCGGGCCACGTTCTCCTCC\nGTGCCGCTGGCGGCCAGCATCAGCGCAGTCAGCCTGGAGGTCGCCCAGCCGGGGCCCTCA\nAACAGACCCCGCGCCCTCGAGGTGGAGGAGTGCCGCTGCCCGCCAGGCTACATCGGTCTG\nTCCTGCCAGGACTGTGCCCCCGGCTACACGCGCACCGGGAGTGGGCTCTACCTCGGCCAC\nTGCGAGCTATGTGAATGCAATGGCCACTCAGACCTGTGCCACCCAGAGACTGGGGCCTGC\nTCGCAATGCCAGCACAACGCCGCAGGGGAGTTCTGCGAGCTTTGTGCCCCTGGCTACTAC\nGGAGATGCCACAGCCGGGACGCCTGAGGACTGCCAGCCCTGTGCCTGCCCACTGACCAAC\nCCAGAGAACATGTTTTCCCGCACCTGTGAGAGCCTGGGAGCCGGCGGGTACCGCTGCACG\nGCCTGCGAACCCGGCTACACTGGCCAGTACTGTGAGCAGTGTGGCCCAGGTTACGTGGGT\nAACCCCAGTGTGCAAGGGGGCCAGTGCCTGCCAGAGACAAACCAAGCCCCACTGGTGGTC\nGAGGTCCATCCTGCTCGAAGCATAGTGCCCCAAGGTGGCTCCCACTCCCTGCGGTGTCAG\nGTCAGTGGGAGCCCACCCCACTACTTCTATTGGTCCCGTGAGGATGGGCGGCCTGTGCCC\nAGCGGCACCCAGCAGCGACATCAAGGCTCCGAGCTCCACTTCCCCAGCGTCCAGCCCTCG\nGATGCTGGGGTCTACATTTGCACCTGCCGTAATCTCCACCAATCCAATACCAGCCGGGCA\nGAGCTGCTGGTCACTGAGGCTCCAAGCAAGCCCATCACAGTGACTGTGGAGGAGCAGCGG\nAGCCAGAGCGTGCGCCCCGGAGCTGACGTCACCTTCATCTGCACAGCCAAAAGCAAGTCC\nCCAGCCTATACCCTGGTGTGGACCCGCCTGCACAACGGGAAACTGCCCACCCGAGCCATG\nGATTTCAATGGCATCCTGACCATTCGCAACGTCCAGCTGAGTGATGCAGGCACCTACGTG\nTGCACCGGCTCCAACATGTTTGCCATGGACCAGGGCACAGCCACTCTACATGTGCAGGCC\nTCGGGCACCTTGTCCGCCCCCGTGGTCTCCATCCATCCGCCACAGCTCACAGTGCAGCCC\nGGGCAACTGGCGGAGTTCCGCTGCAGCGCCACAGGGAGCCCCACGCCCACCCTCGAGTGG\nACAGGGGGCCCCGGCGGCCAGCTCCCTGCGAAGGCACAAATCCACGGCGGCATCCTGCGC\nCTGCCAGCTGTCGAGCCCACGGATCAGGCCCAGTACTTGTGCCGAGCCCACAGCAGCGCT\nGGGCAGCAGGTGGCCAGGGCTGTGCTCCACGTGCATGGGGGCGGTGGGCCCAGAGTCCAA\nGTGAGCCCAGAGAGGACCCAGGTCCACGCAGGCCGCACCGTCAGGCTGTACTGCAGGGCT\nGCAGGCGTGCCTAGCGCCACCATCACCTGGAGGAAGGAAGGGGGCAGCCTCCCACCACAG\nGCCCGGTCAGAGCGCACAGACATCGCGACACTGCTCATCCCAGCCATCACGACTGCTGAC\nGCCGGCTTCTACCTCTGCGTGGCCACCAGCCCTGCAGGCACTGCCCAGGCCCGGATCCAA\nGTGGTTGTCCTTTCAGCCTCAGATGCCAGCCCACCGCCGGTCAAGATTGAGTCCTCATCG\nCCTTCTGTGACAGAAGGGCAAACACTCGACCTCAACTGTGTGGTGGCAGGGTCAGCCCAT\nGCCCAGGTCACCTGGTACAGGCGAGGGGGTAGCCTGCCTCCCCACACCCAGGTGCACGGC\nTCCCGTCTGCGGCTCCCCCAGGTCTCACCAGCTGATTCTGGAGAATATGTGTGCCGTGTG\nGAGAATGGATCGGGCCCCAAGGAGGCCTCCATTACTGTGTCTGTGCTCCACGGCACCCAT\nTCTGGCCCCAGCTACACCCCAGTGCCCGGCAGCACCCGGCCCATCCGCATCGAGCCCTCC\nTCCTCACACGTGGCGGAAGGGCAGACCCTGGATCTGAACTGCGTGGTGCCCGGGCAGGCC\nCACGCCCAGGTCACGTGGCACAAGCGTGGGGGCAGCCTCCCTGCCCGGCACCAGACCCAC\nGGCTCGCTGCTGCGGCTGCACCAGGTGACCCCGGCCGACTCAGGCGAGTATGTGTGCCAT\nGTGGTGGGCACCTCCGGCCCCCTAGAGGCCTCAGTCCTGGTCACCATCGAAGCCTCTGTC\nATCCCTGGACCCATCCCACCTGTCAGGATCGAGTCTTCATCCTCCACAGTGGCCGAGGGC\nCAGACCCTGGATCTGAGCTGCGTGGTGGCAGGGCAGGCCCACGCCCAGGTCACATGGTAC\nAAGCGTGGGGGCAGCCTCCCTGCCCGGCACCAGGTTCGTGGCTCCCGCCTGTACATCTTC\nCAGGCCTCACCTGCCGATGCGGGACAGTACGTCTGCCGGGCCAGCAACGGCATGGAGGCC\nTCCATCACGGTCACAGTAACTGGGACCCAGGGGGCCAACTTAGCCTACCCTGCCGGCAGC\nACCCAGCCCATCCGCATCGAGCCCTCCTCCTCGCAAGTGGCGGAAGGGCAGACCCTGGAT\nCTGAACTGCGTGGTGCCCGGGCAGTCCCATGCCCAGGTCACGTGGCACAAGCGTGGGGGC\nAGCCTCCCTGTCCGGCACCAGACCCACGGCTCCCTGCTGAGACTCTACCAAGCGTCCCCC\nGCCGACTCGGGCGAGTACGTGTGCCGAGTGTTGGGCAGCTCCGTGCCTCTAGAGGCCTCT\nGTCCTGGTCACCATTGAGCCTGCGGGCTCAGTGCCTGCACTTGGGGTCACCCCCACGGTC\nCGGATCGAGTCATCGTCTTCGCAAGTGGCCGAGGGGCAGACCCTGGACCTGAACTGCCTC\nGTTGCTGGTCAGGCCCATGCCCAGGTCACGTGGCACAAGCGCGGGGGCAGCCTCCCGGCC\nCGGCACCAGGTGCATGGCTCGAGGCTACGCCTGCTCCAGGTGACCCCAGCTGATTCAGGG\nGAGTACGTGTGCCGTGTGGTCGGCAGCTCAGGTACCCAGGAAGCCTCAGTCCTTGTCACC\nATCCAGCAGCGCCTTAGTGGCTCCCACTCCCAGGGTGTGGCGTACCCCGTCCGCATCGAG\nTCCTCCTCAGCCTCCCTGGCCAATGGACACACCCTGGACCTCAACTGCCTGGTTGCCAGC\nCAGGCTCCCCACACCATCACCTGGTATAAGCGTGGAGGCAGCTTACCCAGCCGGCACCAG\nATCGTGGGCTCCCGGCTGCGGATCCCTCAGGTGACTCCGGCAGACTCGGGCGAGTACGTG\nTGTCACGTCAGTAACGGTGCAGGCTCCCGGGAGACCTCGCTCATCGTCACCATCCAGGGC\nAGCGGTTCCTCCCACGTGCCCAGCGTCTCCCCACCGATCAGGATCGAGTCGTCTTCCCCC\nACGGTGGTGGAAGGGCAGACCTTGGATCTGAACTGCGTGGTCGCCAGGCAGCCCCAGGCT\nATCATCACATGGTACAAGCGTGGGGGCAGCCTTCCCTCCCGACACCAGACCCATGGCTCC\nCACCTGCGGTTGCACCAAATGTCTGTGGCTGACTCGGGCGAGTATGTGTGCCGGGCCAAC\nAACAACATCGATGCCCTGGAGGCCTCCATCGTCATCTCCGTCTCCCCTAGCGCCGGCAGC\nCCCTCCGCCCCTGGCAGCTCCATGCCCATCAGAATTGAGTCATCCTCCTCACACGTGGCC\nGAAGGGGAGACCCTGGATCTGAACTGCGTGGTCCCCGGGCAGGCCCATGCCCAGGTCACT\nTGGCACAAGCGTGGGGGCAGCCTCCCCAGTCACCATCAGACCCGCGGCTCACGGCTGCGG\nCTGCACCATGTGTCCCCGGCCGACTCGGGTGAATACGTGTGCCGGGTGATGGGCAGCTCT\nGGCCCCCTGGAGGCCTCAGTCCTGGTCACCATCGAAGCCTCTGGCTCAAGTGCTGTCCAC\nGTCCCCGCCCCAGGTGGAGCCCCACCCATCCGCATCGAGCCCTCCTCCTCCCGAGTGGCA\nGAAGGGCAGACCCTGGATCTGAAGTGCGTGGTGCCCGGGCAGGCCCACGCCCAGGTCACG\nTGGCACAAGCGTGGAGGAAACCTCCCTGCCCGGCACCAGGTCCACGGCCCACTGCTGAGG\nCTGAACCAGGTGTCCCCGGCTGACTCTGGCGAGTACTCGTGCCAAGTGACCGGAAGCTCA\nGGCACCCTGGAGGCATCTGTCCTGGTCACAATTGAGCCCTCCAGCCCAGGACCCATTCCT\nGCTCCAGGACTGGCCCAGCCCATCTACATCGAGGCCTCCTCTTCACACGTGACTGAAGGG\nCAGACTCTGGATCTGAACTGTGTGGTGCCCGGGCAGGCCCATGCCCAGGTCACGTGGTAC\nAAGCGCGGGGGCAGCCTCCCCGCCCGGCACCAGACCCATGGCTCCCAGCTGCGGCTCCAC\nCTCGTCTCCCCTGCCGACTCAGGCGAGTATGTGTGTCGTGCAGCCAGCGGCCCAGGCCCT\nGAGCAAGAAGCCTCCTTCACAGTCACCGTCCCGCCCAGTGAGGGGTCTTCCTACCGCCTT\nAGGAGCCCGGTCATCTCCATCGACCCGCCCAGCAGCACCGTGCAGCAGGGCCAGGATGCC\nAGCTTCAAGTGCCTCATCCATGACGGGGCAGCCCCCATCAGCCTCGAGTGGAAGACCCGG\nAACCAGGAGCTGGAGGACAACGTCCACATCAGTCCCAATGGCTCCATCATCACCATCGTG\nGGCACCCGGCCCAGCAACCACGGTACCTACCGCTGCGTGGCCTCCAATGCCTACGGTGTG\nGCCCAGAGTGTGGTGAACCTCAGTGTGCACGGGCCCCCTACAGTGTCCGTGCTCCCCGAG\nGGCCCCGTGTGGGTGAAAGTGGGAAAGGCTGTCACCCTGGAGTGTGTCAGTGCCGGGGAG\nCCCCGCTCCTCTGCTCGTTGGACCCGGATCAGCAGCACCCCTGCCAAGTTGGAGCAGCGG\nACATATGGGCTCATGGACAGCCACGCGGTGCTGCAGATTTCATCAGCTAAACCATCAGAT\nGCGGGCACTTATGTGTGCCTTGCTCAGAATGCACTAGGCACAGCACAGAAGCAGGTGGAG\nGTGATCGTGGACACGGGCGCCATGGCCCCAGGGGCCCCTCAGGTCCAAGCTGAAGAAGCT\nGAGCTGACTGTGGAGGCTGGACACACGGCCACCTTGCGCTGCTCAGCCACAGGCAGCCCC\nGCGCCCACCATCCACTGGTCCAAGCTGCGTTCCCCACTGCCCTGGCAGCACCGGCTGGAA\nGGTGACACACTCATCATACCCCGGGTAGCCCAGCAGGACTCGGGCCAGTACATCTGCAAT\nGCCACTAGCCCTGCTGGGCACGCTGAGGCCACCATCATCCTGCACGTGGAGAGCCCACCA\nTATGCCACCACGGTCCCAGAGCACGCTTCGGTGCAGGCAGGGGAGACGGTGCAGCTCCAG\nTGCCTGGCTCACGGGACACCCCCACTCACCTTCCAGTGGAGCCGCGTGGGCAGCAGCCTT\nCCTGGGAGGGCGACCGCCAGGAACGAGCTGCTGCACTTTGAGCGTGCAGCCCCTGAGGAC\nTCAGGCCGCTACCGCTGCCGGGTCACCAACAAGGTGGGCTCAGCCGAGGCCTTTGCCCAG\nCTGCTCGTCCAAGGCCCTCCCGGCTCTCTCCCTGCCACCTCCATCCCAGCAGGGTCCACG\nCCCACCGTGCAGGTCACGCCTCAGCTAGAGACCAAGAGCATTGGGGCCAGCGTTGAGTTC\nCACTGTGCTGTGCCCAGCGACCGGGGTACCCAGCTCCGTTGGTTCAAGGAAGGGGGTCAG\nCTGCCTCCGGGTCACAGCGTGCAGGATGGGGTGCTCCGAATCCAGAACTTGGACCAGAGC\nTGCCAAGGGACGTATATATGCCAGGCCCATGGACCTTGGGGGAAGGCCCAGGCCAGTGCC\nCAGCTGGTTATCCAAGCCCTGCCCTCGGTGCTCATCAACATCCGGACCTCTGTGCAGACC\nGTGGTGGTTGGCCACGCCGTGGAGTTCGAATGCCTGGCACTGGGTGACCCCAAGCCTCAG\nGTGACATGGAGCAAAGTTGGAGGGCACCTGCGGCCAGGCATTGTGCAGAGCGGAGGTGTC\nGTCAGGATCGCCCACGTAGAGCTGGCTGATGCGGGACAGTATCGCTGCACTGCCACCAAC\nGCAGCTGGCACCACACAATCCCACGTCCTGCTGCTTGTGCAAGCCTTGCCCCAGATCTCA\nATGCCCCAAGAAGTCCGTGTGCCTGCTGGTTCTGCAGCTGTCTTCCCCTGCATAGCCTCA\nGGCTACCCCACTCCTGACATCAGCTGGAGCAAGCTGGATGGCAGCCTGCCACCTGACAGC\nCGCCTGGAGAACAACATGCTGATGCTGCCCTCAGTCCGACCCCAGGACGCAGGTACCTAC\nGTCTGCACCGCCACTAACCGCCAGGGCAAGGTCAAAGCCTTTGCCCACCTGCAGGTGCCA\nGAGCGGGTGGTGCCCTACTTCACGCAGACCCCCTACTCCTTCCTACCGCTGCCCACCATC\nAAGGATGCCTACAGGAAGTTCGAGATCAAGATCACCTTCCGGCCCGACTCAGCCGATGGG\nATGCTGCTGTACAATGGGCAGAAGCGAGTCCCAGGGAGCCCCACCAACCTGGCCAACCGG\nCAGCCCGACTTCATCTCCTTCGGCCTCGTGGGGGGAAGGCCCGAGTTCCGGTTCGATGCA\nGGCTCAGGCATGGCCACCATCCGCCATCCCACACCACTGGCCCTGGGCCATTTCCACACC\nGTGACCCTGCTGCGCAGCCTCACCCAGGGCTCCCTGATTGTGGGTGACCTGGCCCCGGTC\nAATGGGACCTCCCAGGGCAAGTTCCAGGGCCTGGATCTGAACGAGGAACTCTACCTGGGT\nGGCTATCCTGACTATGGTGCCATCCCCAAGGCGGGGCTGAGCAGCGGCTTCATAGGCTGT\nGTCCGGGAGCTGCGCATCCAGGGCGAGGAGATCGTCTTCCATGACCTCAACCTCACGGCG\nCACGGCATCTCCCACTGCCCCACCTGTCGGGACCGGCCCTGCCAGAATGGCGGTCAGTGC\nCATGACTCTGAGAGCAGCAGCTACGTGTGCGTCTGCCCAGCTGGCTTCACCGGGAGCCGC\nTGTGAGCACTCGCAGGCCCTGCACTGCCATCCAGAGGCCTGTGGGCCCGACGCCACCTGT\nGTGAACCGGCCTGACGGTCGAGGCTACACCTGCCGCTGCCACCTGGGCCGCTCGGGGTTG\nCGGTGTGAGGAAGGTGTGACAGTGACCACCCCCTCGCTGTCGGGTGCTGGCTCCTACCTG\nGCACTGCCCGCCCTCACCAACACACACCACGAGCTACGCCTGGACGTGGAGTTCAAGCCA\nCTCGCCCCTGACGGGGTCCTGCTGTTCAGCGGGGGGAAGAGCGGGCCTGTGGAGGACTTC\nGTGTCCCTGGCGATGGTGGGCGGCCACCTGGAGTTCCGCTATGAGTTGGGGTCAGGGCTG\nGCCGTTCTGCGGAGCGCCGAGCCGCTGGCCCTGGGCCGCTGGCACCGTGTGTCTGCAGAG\nCGTCTCAACAAGGACGGCAGCCTGCGGGTGAATGGTGGACGCCCTGTGCTGCGCTCCTCG\nCCCGGCAAGAGCCAGGGCCTCAACCTGCACACCCTGCTCTACCTGGGGGGTGTGGAGCCT\nTCCGTGCCACTGTCCCCGGCCACCAACATGAGCGCTCACTTCCGCGGCTGTGTGGGCGAG\nGTGTCAGTGAATGGCAAACGGCTGGACCTCACCTACAGTTTCCTAGGCAGCCAGGGCATC\nGGGCAATGCTATGATAGCTCCCCATGTGAGCGCCAGCCTTGCCAACATGGTGCCACGTGC\nATGCCCGCTGGCGAGTATGAGTTCCAGTGCCTGTGTCGAGATGGATTCAAAGGAGACCTG\nTGTGAGCACGAGGAGAACCCCTGCCAGCTCCGTGAACCCTGTCTGCATGGGGGCACCTGC\nCAGGGCACCCGCTGCCTCTGCCTCCCTGGCTTCTCTGGCCCACGCTGCCAACAAGGCTCT\nGGACATGGCATAGCAGAGTCCGACTGGCATCTTGAAGGCAGCGGGGGCAATGATGCCCCT\nGGGCAGTACGGAGCCTATTTCCACGATGATGGCTTCCTCGCCTTCCCTGGCCATGTCTTC\nTCCAGGAGCCTGCCCGAGGTGCCCGAGACCATCGAGCTGGAGGTTCGGACCAGCACAGCC\nAGTGGCCTCCTGCTCTGGCAGGGTGTGGAGGTGGGAGAGGCCGGCCAAGGCAAGGACTTC\nATCAGCCTCGGGCTTCAAGACGGGCACCTTGTCTTCAGGTACCAGCTGGGTAGTGGGGAG\nGCCCGCCTGGTCTCTGAGGACCCCATCAATGACGGCGAGTGGCACCGGGTGACAGCACTG\nCGGGAGGGCCGCAGAGGTTCCATCCAAGTCGACGGTGAGGAGCTGGTCAGCGGCCGGTCC\nCCAGGTCCCAACGTGGCAGTCAACGCCAAGGGCAGCGTCTACATCGGCGGAGCCCCTGAC\nGTGGCCACGCTGACCGGGGGCAGATTCTCCTCAGGCATCACAGGCTGTGTCAAGAACCTG\nGTGCTGCACTCGGCCCGACCCGGCGCCCCGCCCCCACAGCCCCTGGACCTGCAGCACCGC\nGCCCAGGCCGGGGCCAACACACGCCCCTGCCCCTCGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00047'], 'name': ['ig']}, {'identifier': ['PF00008'], 'name': ['EGF']}, {'identifier': ['PF07679'], 'name': ['I-set']}, {'identifier': ['PF00057'], 'name': ['Ldl_recept_a']}, {'identifier': ['PF00054'], 'name': ['Laminin_G_1']}, {'identifier': ['PF00052'], 'name': ['Laminin_B']}, {'identifier': ['PF00053'], 'name': ['Laminin_EGF']}, {'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['basal lamina']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular matrix']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['Golgi lumen']}, {'category': ['component'], 'description': ['lysosomal lumen']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['metal ion binding']}, {'category': ['function'], 'description': ['protein C-terminus binding']}, {'category': ['process'], 'description': ['angiogenesis']}, {'category': ['process'], 'description': ['brain development']}, {'category': ['process'], 'description': ['carbohydrate metabolic process']}, {'category': ['process'], 'description': ['cardiac muscle tissue development']}, {'category': ['process'], 'description': ['cartilage development involved in endochondral bone morphogenesis']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['chondrocyte differentiation']}, {'category': ['process'], 'description': ['chondroitin sulfate metabolic process']}, {'category': ['process'], 'description': ['embryonic skeletal system morphogenesis']}, {'category': ['process'], 'description': ['endochondral ossification']}, {'category': ['process'], 'description': ['extracellular matrix disassembly']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['glycosaminoglycan biosynthetic process']}, {'category': ['process'], 'description': ['glycosaminoglycan catabolic process']}, {'category': ['process'], 'description': ['glycosaminoglycan metabolic process']}, {'category': ['process'], 'description': ['lipoprotein metabolic process']}, {'category': ['process'], 'description': ['phototransduction, visible light']}, {'category': ['process'], 'description': ['protein localization']}, {'category': ['process'], 'description': ['retinoid metabolic process']}, {'category': ['process'], 'description': ['small molecule metabolic process']}]}]}]}]}]"
"['DB00040', 'BTD00057', 'BIOD00057']",['Glucagon'],biotech,"['Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.[L7634,L7637,L7640,L7643,L8519] Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.[L7640,L7643]\r\n\r\nGlucagon was granted FDA approval on 14 November 1960.[L7631]']",['liquid'],"['Glucagon is indicated as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.[L7634,L7637,L7640,L7643,L8519]']","['Glucagon binds to the glucagon receptor activating G<sub>s</sub> and G<sub>q</sub>.[A19402] This activation activates adenylate cyclase, which increases intracellular cyclic AMP and activates protein kinase A.[A19402] Activating G<sub>q</sub> activates phospholipase C, increases production of inositol 1,4,5-triphosphate, and releases intracellular calcium.[A19402] Protein kinase A phosphorylates glycogen phosphorylase kinase, which phosphorylates glycogen phosphorylase, which phosphorylates glycogen, causing its breakdown.[A19402]\r\n\r\nGlucagon also relaxes smooth muscle of the stomach, duodenum, small bowel, and colon.[L7634,L7643]']",[None],"[{'target': [{'id': ['BE0000527'], 'name': ['Glucagon receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1889'], 'pubmed-id': ['17462598'], 'citation': ['Katayama T, Shimamoto S, Oda H, Nakahara K, Kangawa K, Murakami N: Glucagon receptor expression and glucagon stimulation of ghrelin secretion in rat stomach. Biochem Biophys Res Commun. 2007 Jun 15;357(4):865-70. Epub 2007 Apr 9.']}, {'ref-id': ['A1895'], 'pubmed-id': ['17620721'], 'citation': ['Li P, Rogers T, Smiley D, DiMarchi RD, Zhang F: Design, synthesis and crystallization of a novel glucagon analog as a therapeutic agent. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Jul 1;63(Pt 7):599-601. Epub 2007 Jun 15.']}, {'ref-id': ['A1897'], 'pubmed-id': ['17623014'], 'citation': ['Li XC, Zhuo JL: Targeting glucagon receptor signalling in treating metabolic syndrome and renal injury in Type 2 diabetes: theory versus promise. Clin Sci (Lond). 2007 Aug;113(4):183-93.']}, {'ref-id': ['A1898'], 'pubmed-id': ['17534934'], 'citation': ['Fischer AJ, Stanke JJ, Ghai K, Scott M, Omar G: Development of bullwhip neurons in the embryonic chicken retina. J Comp Neurol. 2007 Aug 1;503(4):538-49.']}, {'ref-id': ['A1900'], 'pubmed-id': ['17479245'], 'citation': ['Winzell MS, Brand CL, Wierup N, Sidelmann UG, Sundler F, Nishimura E, Ahren B: Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet. Diabetologia. 2007 Jul;50(7):1453-62. Epub 2007 May 4.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A1902'], 'pubmed-id': ['8020989'], 'citation': ['Menzel S, Stoffel M, Espinosa R 3rd, Fernald AA, Le Beau MM, Bell GI: Localization of the glucagon receptor gene to human chromosome band 17q25. Genomics. 1994 Mar 15;20(2):327-8.']}, {'ref-id': ['A1905'], 'pubmed-id': ['12529935'], 'citation': ['Brubaker PL, Drucker DJ: Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels. 2002;8(3-4):179-88.']}, {'ref-id': ['A1907'], 'pubmed-id': ['8144028'], 'citation': ['Lok S, Kuijper JL, Jelinek LJ, Kramer JM, Whitmore TE, Sprecher CA, Mathewes S, Grant FJ, Biggs SH, Rosenberg GB, et al.: The human glucagon receptor encoding gene: structure, cDNA sequence and chromosomal localization. Gene. 1994 Mar 25;140(2):203-9.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Glucagon receptor'], 'general-function': ['Peptide hormone binding'], 'specific-function': ['G-protein coupled receptor for glucagon that plays a central role in the regulation of blood glucose levels and glucose homeostasis. Regulates the rate of hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. Plays an important role in mediating the responses to fasting. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Promotes activation of adenylate cyclase. Besides, plays a role in signaling via a phosphatidylinositol-calcium second messenger system.'], 'gene-name': ['GCGR'], 'locus': ['17q25'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['137-161\n174-198\n226-249\n264-285\n304-326\n351-369\n382-402'], 'signal-regions': ['1-25'], 'theoretical-pi': ['8.83'], 'molecular-weight': ['54008.44'], 'chromosome-location': ['17'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:4192']}, {'resource': ['GenAtlas'], 'identifier': ['GCGR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['U03469']}, {'resource': ['GenBank Protein Database'], 'identifier': ['439690']}, {'resource': ['IUPHAR'], 'identifier': ['251']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['251']}, {'resource': ['UniProtKB'], 'identifier': ['P47871']}, {'resource': ['UniProt Accession'], 'identifier': ['GLR_HUMAN']}]}], 'synonyms': [{'synonym': ['GL-R']}], 'amino-acid-sequence': ['>lcl|BSEQ0016117|Glucagon receptor\nMPPCQPQRPLLLLLLLLACQPQVPSAQVMDFLFEKWKLYGDQCHHNLSLLPPPTELVCNR\nTFDKYSCWPDTPANTTANISCPWYLPWHHKVQHRFVFKRCGPDGQWVRGPRGQPWRDASQ\nCQMDGEEIEVQKEVAKMYSSFQVMYTVGYSLSLGALLLALAILGGLSKLHCTRNAIHANL\nFASFVLKASSVLVIDGLLRTRYSQKIGDDLSVSTWLSDGAVAGCRVAAVFMQYGIVANYC\nWLLVEGLYLHNLLGLATLPERSFFSLYLGIGWGAPMLFVVPWAVVKCLFENVQCWTSNDN\nMGFWWILRFPVFLAILINFFIFVRIVQLLVAKLRARQMHHTDYKFRLAKSTLTLIPLLGV\nHEVVFAFVTDEHAQGTLRSAKLFFDLFLSSFQGLLVAVLYCFLNKEVQSELRRRWHRWRL\nGKVLWEERNTSNHRASSSPGHGPPSKELQFGRGGGSQDSSAETPLAGGLPRLAESPF'], 'gene-sequence': ['>lcl|BSEQ0016118|Glucagon receptor (GCGR)\nATGCCCCCCTGCCAGCCACAGCGACCCCTGCTGCTGTTGCTGCTGCTGCTGGCCTGCCAG\nCCACAGGTCCCCTCCGCTCAGGTGATGGACTTCCTGTTTGAGAAGTGGAAGCTCTACGGT\nGACCAGTGTCACCACAACCTGAGCCTGCTGCCCCCTCCCACGGAGCTGGTGTGCAACAGA\nACCTTCGACAAGTATTCCTGCTGGCCGGACACCCCCGCCAATACCACGGCCAACATCTCC\nTGCCCCTGGTACCTGCCTTGGCACCACAAAGTGCAACACCGCTTCGTGTTCAAGAGATGC\nGGGCCCGACGGTCAGTGGGTGCGTGGACCCCGGGGGCAGCCTTGGCGTGATGCCTCCCAG\nTGCCAGATGGATGGCGAGGAGATTGAGGTCCAGAAGGAGGTGGCCAAGATGTACAGCAGC\nTTCCAGGTGATGTACACAGTGGGCTACAGCCTGTCCCTGGGGGCCCTGCTCCTCGCCTTG\nGCCATCCTGGGGGGCCTCAGCAAGCTGCACTGCACCCGCAATGCCATCCACGCGAATCTG\nTTTGCGTCCTTCGTGCTGAAAGCCAGCTCCGTGCTGGTCATTGATGGGCTGCTCAGGACC\nCGCTACAGCCAGAAAATTGGCGACGACCTCAGTGTCAGCACCTGGCTCAGTGATGGAGCG\nGTGGCTGGCTGCCGTGTGGCCGCGGTGTTCATGCAATATGGCATCGTGGCCAACTACTGC\nTGGCTGCTGGTGGAGGGCCTGTACCTGCACAACCTGCTGGGCCTGGCCACCCTCCCCGAG\nAGGAGCTTCTTCAGCCTCTACCTGGGCATCGGCTGGGGTGCCCCCATGCTGTTCGTCGTC\nCCCTGGGCAGTGGTCAAGTGTCTGTTCGAGAACGTCCAGTGCTGGACCAGCAATGACAAC\nATGGGCTTCTGGTGGATCCTGCGGTTCCCCGTCTTCCTGGCCATCCTGATCAACTTCTTC\nATCTTCGTCCGCATCGTTCAGCTGCTCGTGGCCAAGCTGCGGGCACGGCAGATGCACCAC\nACAGACTACAAGTTCCGGCTGGCCAAGTCCACGCTGACCCTCATCCCTCTGCTGGGCGTC\nCACGAAGTGGTCTTCGCCTTCGTGACGGACGAGCACGCCCAGGGCACCCTGCGCTCCGCC\nAAGCTCTTCTTCGACCTCTTCCTCAGCTCCTTCCAGGGCCTGCTGGTGGCTGTCCTCTAC\nTGCTTCCTCAACAAGGAGGTGCAGTCGGAGCTGCGGCGGCGTTGGCACCGCTGGCGCCTG\nGGCAAAGTGCTATGGGAGGAGCGGAACACCAGCAACCACAGGGCCTCATCTTCGCCCGGC\nCACGGCCCTCCCAGCAAGGAGCTGCAGTTTGGGAGGGGTGGTGGCAGCCAGGATTCATCT\nGCGGAGACCCCCTTGGCTGGTGGCCTCCCTAGATTGGCTGAGAGCCCCTTCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00002'], 'name': ['7tm_2']}, {'identifier': ['PF02793'], 'name': ['HRM']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['glucagon receptor activity']}, {'category': ['function'], 'description': ['guanyl-nucleotide exchange factor activity']}, {'category': ['function'], 'description': ['peptide hormone binding']}, {'category': ['process'], 'description': ['adenylate cyclase-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['adenylate cyclase-modulating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular response to glucagon stimulus']}, {'category': ['process'], 'description': ['energy reserve metabolic process']}, {'category': ['process'], 'description': ['exocytosis']}, {'category': ['process'], 'description': ['generation of precursor metabolites and energy']}, {'category': ['process'], 'description': ['glucose homeostasis']}, {'category': ['process'], 'description': ['hormone-mediated signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of GTPase activity']}, {'category': ['process'], 'description': ['regulation of blood pressure']}, {'category': ['process'], 'description': ['regulation of glycogen metabolic process']}, {'category': ['process'], 'description': ['response to nutrient']}, {'category': ['process'], 'description': ['response to starvation']}, {'category': ['process'], 'description': ['small molecule metabolic process']}]}]}]}, {'id': ['BE0002134'], 'name': ['Glucagon-like peptide 2 receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A13181'], 'pubmed-id': ['11212269'], 'citation': ['Boushey RP, Yusta B, Drucker DJ: Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res. 2001 Jan 15;61(2):687-93.']}, {'ref-id': ['A13182'], 'pubmed-id': ['9990065'], 'citation': ['Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, Demchyshyn L, Yang ZJ, Kamboj RK, Chen H, McCallum K, Sumner-Smith M, Drucker DJ, Crivici A: Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1569-73.']}, {'ref-id': ['A13183'], 'pubmed-id': ['15817468'], 'citation': ['Estall JL, Koehler JA, Yusta B, Drucker DJ: The glucagon-like peptide-2 receptor C terminus modulates beta-arrestin-2 association but is dispensable for ligand-induced desensitization, endocytosis, and G-protein-dependent effector activation. J Biol Chem. 2005 Jun 10;280(23):22124-34. Epub 2005 Apr 6.']}, {'ref-id': ['A1905'], 'pubmed-id': ['12529935'], 'citation': ['Brubaker PL, Drucker DJ: Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels. 2002;8(3-4):179-88.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Glucagon-like peptide 2 receptor'], 'general-function': ['Glucagon receptor activity'], 'specific-function': ['This is a receptor for glucagon-like peptide 2. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.'], 'gene-name': ['GLP2R'], 'locus': ['17p13.3'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['174-198\n211-235\n262-285\n300-321\n340-362\n387-405\n418-438'], 'signal-regions': [None], 'theoretical-pi': ['9.03'], 'molecular-weight': ['63000.84'], 'chromosome-location': ['17'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:4325']}, {'resource': ['GenAtlas'], 'identifier': ['GLP2R']}, {'resource': ['GenBank Gene Database'], 'identifier': ['AF105367']}, {'resource': ['GenBank Protein Database'], 'identifier': ['4324491']}, {'resource': ['IUPHAR'], 'identifier': ['250']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['250']}, {'resource': ['UniProtKB'], 'identifier': ['O95838']}, {'resource': ['UniProt Accession'], 'identifier': ['GLP2R_HUMAN']}]}], 'synonyms': [{'synonym': ['GLP-2 receptor']}], 'amino-acid-sequence': ['>lcl|BSEQ0011545|Glucagon-like peptide 2 receptor\nMKLGSSRAGPGRGSAGLLPGVHELPMGIPAPWGTSPLSFHRKCSLWAPGRPFLTLVLLVS\nIKQVTGSLLEETTRKWAQYKQACLRDLLKEPSGIFCNGTFDQYVCWPHSSPGNVSVPCPS\nYLPWWSEESSGRAYRHCLAQGTWQTIENATDIWQDDSECSENHSFKQNVDRYALLSTLQL\nMYTVGYSFSLISLFLALTLLLFLRKLHCTRNYIHMNLFASFILRTLAVLVKDVVFYNSYS\nKRPDNENGWMSYLSEMSTSCRSVQVLLHYFVGANYLWLLVEGLYLHTLLEPTVLPERRLW\nPRYLLLGWAFPVLFVVPWGFARAHLENTGCWTTNGNKKIWWIIRGPMMLCVTVNFFIFLK\nILKLLISKLKAHQMCFRDYKYRLAKSTLVLIPLLGVHEILFSFITDDQVEGFAKLIRLFI\nQLTLSSFHGFLVALQYGFANGEVKAELRKYWVRFLLARHSGCRACVLGKDFRFLGKCPKK\nLSEGDGAEKLRKLQPSLNSGRLLHLAMRGLGELGAQPQQDHARWPRGSSLSECSEGDVTM\nANTMEEILEESEI'], 'gene-sequence': ['>lcl|BSEQ0011546|Glucagon-like peptide 2 receptor (GLP2R)\nATGAAGCTGGGATCGAGCAGGGCAGGGCCTGGGAGAGGAAGCGCGGGACTCCTGCCTGGC\nGTCCACGAGCTGCCCATGGGCATCCCTGCCCCCTGGGGGACCAGTCCTCTCTCCTTCCAC\nAGGAAGTGCTCTCTCTGGGCCCCTGGGAGGCCCTTCCTCACTCTGGTCCTGCTGGTTTCC\nATCAAGCAAGTTACAGGATCCCTCCTTGAGGAAACGACTCGGAAGTGGGCTCAGTACAAA\nCAGGCATGTCTGAGAGACTTACTCAAGGAACCTTCTGGCATATTTTGTAACGGGACATTT\nGATCAGTACGTGTGTTGGCCTCATTCTTCTCCTGGAAATGTCTCTGTACCCTGCCCTTCA\nTACTTACCTTGGTGGAGTGAAGAGAGCTCAGGAAGGGCCTACAGACACTGCTTGGCTCAG\nGGGACTTGGCAGACGATAGAGAACGCCACGGATATTTGGCAGGATGACTCCGAATGCTCC\nGAGAACCACAGCTTCAAGCAAAACGTGGATCGTTATGCCTTGCTGTCAACCTTGCAGCTG\nATGTACACCGTGGGATACTCCTTCTCTCTTATCTCCCTCTTCCTGGCTCTCACCCTCCTC\nTTGTTTCTTCGAAAACTCCACTGCACGCGCAACTACATCCACATGAACTTGTTTGCTTCT\nTTCATCCTGAGAACCCTGGCTGTACTGGTGAAGGACGTCGTCTTCTACAACTCTTACTCC\nAAGAGGCCTGACAATGAGAATGGGTGGATGTCCTACCTGTCAGAGATGTCCACCTCCTGC\nCGCTCAGTCCAGGTTCTCTTGCATTACTTTGTGGGTGCCAATTACTTATGGCTGCTGGTT\nGAAGGCCTCTACCTCCACACGCTGCTGGAGCCCACAGTGCTTCCTGAGAGGCGGCTGTGG\nCCCAGATACCTGCTGTTGGGTTGGGCCTTCCCTGTGCTATTTGTTGTACCCTGGGGTTTC\nGCCCGTGCACACCTGGAGAACACAGGGTGCTGGACAACAAATGGGAATAAGAAAATCTGG\nTGGATCATCCGAGGACCCATGATGCTCTGTGTAACAGTCAATTTCTTCATCTTCCTGAAA\nATTCTCAAGCTTCTCATTTCTAAGCTCAAAGCTCATCAAATGTGCTTCAGAGATTATAAA\nTACAGATTGGCAAAATCAACACTGGTCCTCATTCCTTTATTGGGCGTTCATGAGATCCTC\nTTCTCTTTCATCACTGATGATCAAGTTGAAGGATTTGCAAAACTTATACGACTTTTCATT\nCAGTTGACACTGAGCTCCTTTCATGGGTTCCTGGTGGCCTTGCAGTATGGTTTTGCCAAT\nGGAGAGGTGAAGGCTGAGCTGCGGAAATACTGGGTCCGCTTCTTGCTAGCCCGCCACTCA\nGGCTGCAGAGCCTGTGTCCTGGGGAAGGACTTCCGGTTCCTAGGAAAATGTCCCAAGAAG\nCTCTCGGAAGGAGATGGCGCTGAGAAGCTTCGGAAGCTGCAGCCCTCACTTAACAGTGGG\nCGGCTCCTACATCTAGCCATGCGAGGTCTTGGGGAGCTGGGCGCCCAGCCCCAACAGGAC\nCATGCACGCTGGCCCCGGGGCAGCAGCCTGTCCGAGTGCAGTGAGGGGGATGTCACCATG\nGCCAACACCATGGAGGAGATTCTGGAAGAGAGTGAGATCTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00002'], 'name': ['7tm_2']}, {'identifier': ['PF02793'], 'name': ['HRM']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['G-protein coupled receptor activity']}, {'category': ['function'], 'description': ['glucagon receptor activity']}, {'category': ['process'], 'description': ['adenylate cyclase-modulating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}]}]}]}, {'id': ['BE0000857'], 'name': ['Glucagon-like peptide 1 receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13184'], 'pubmed-id': ['17475961'], 'citation': ['Korner M, Stockli M, Waser B, Reubi JC: GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007 May;48(5):736-43.']}, {'ref-id': ['A13185'], 'pubmed-id': ['17498508'], 'citation': ['Baggio LL, Drucker DJ: Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007 May;132(6):2131-57.']}, {'ref-id': ['A1898'], 'pubmed-id': ['17534934'], 'citation': ['Fischer AJ, Stanke JJ, Ghai K, Scott M, Omar G: Development of bullwhip neurons in the embryonic chicken retina. J Comp Neurol. 2007 Aug 1;503(4):538-49.']}, {'ref-id': ['A1905'], 'pubmed-id': ['12529935'], 'citation': ['Brubaker PL, Drucker DJ: Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels. 2002;8(3-4):179-88.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Glucagon-like peptide 1 receptor'], 'general-function': ['Transmembrane signaling receptor activity'], 'specific-function': ['This is a receptor for glucagon-like peptide 1. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.'], 'gene-name': ['GLP1R'], 'locus': ['6p21'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['140-164\n177-201\n228-251\n266-287\n306-328\n353-371\n384-404'], 'signal-regions': ['1-23'], 'theoretical-pi': ['8.19'], 'molecular-weight': ['53025.22'], 'chromosome-location': ['6'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:4324']}, {'resource': ['GenAtlas'], 'identifier': ['GLP1R']}, {'resource': ['GenBank Gene Database'], 'identifier': ['U01104']}, {'resource': ['GenBank Protein Database'], 'identifier': ['405082']}, {'resource': ['IUPHAR'], 'identifier': ['249']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['249']}, {'resource': ['UniProtKB'], 'identifier': ['P43220']}, {'resource': ['UniProt Accession'], 'identifier': ['GLP1R_HUMAN']}]}], 'synonyms': [{'synonym': ['GLP-1 receptor']}], 'amino-acid-sequence': ['>lcl|BSEQ0010605|Glucagon-like peptide 1 receptor\nMAGAPGPLRLALLLLGMVGRAGPRPQGATVSLWETVQKWREYRRQCQRSLTEDPPPATDL\nFCNRTFDEYACWPDGEPGSFVNVSCPWYLPWASSVPQGHVYRFCTAEGLWLQKDNSSLPW\nRDLSECEESKRGERSSPEEQLLFLYIIYTVGYALSFSALVIASAILLGFRHLHCTRNYIH\nLNLFASFILRALSVFIKDAALKWMYSTAAQQHQWDGLLSYQDSLSCRLVFLLMQYCVAAN\nYYWLLVEGVYLYTLLAFSVLSEQWIFRLYVSIGWGVPLLFVVPWGIVKYLYEDEGCWTRN\nSNMNYWLIIRLPILFAIGVNFLIFVRVICIVVSKLKANLMCKTDIKCRLAKSTLTLIPLL\nGTHEVIFAFVMDEHARGTLRFIKLFTELSFTSFQGLMVAILYCFVNNEVQLEFRKSWERW\nRLEHLHIQRDSSMKPLKCPTSSLSSGATAGSSMYTATCQASCS'], 'gene-sequence': ['>lcl|BSEQ0010606|Glucagon-like peptide 1 receptor (GLP1R)\nATGGCCGGCGCCCCCGGCCCGCTGCGCCTTGCGCTGCTGCTGCTCGGGATGGTGGGCAGG\nGCCGGCCCCCGCCCCCAGGGTGCCACTGTGTCCCTCTGGGAGACGGTGCAGAAATGGCGA\nGAATACCGACGCCAGTGCCAGCGCTCCCTGACTGAGGATCCACCTCCTGCCACAGACTTG\nTTCTGCAACCGGACCTTCGATGAATACGCCTGCTGGCCAGATGGGGAGCCAGGCTCGTTC\nGTGAATGTCAGCTGCCCCTGGTACCTGCCCTGGGCCAGCAGTGTGCCGCAGGGCCACGTG\nTACCGGTTCTGCACAGCTGAAGGCCTCTGGCTGCAGAAGGACAACTCCAGCCTGCCCTGG\nAGGGACTTGTCGGAGTGCGAGGAGTCCAAGCGAGGGGAAAGAAGCTCCCCGGAGGAGCAG\nCTCCTGTTCCTCTACATCATCTACACGGTGGGCTACGCACTCTCCTTCTCTGCTCTGGTT\nATCGCCTCTGCGATCCTCCTCGGCTTCAGACACCTGCACTGCACCAGGAACTACATCCAC\nCTGAACCTGTTTGCATCCTTCATCCTGCGAGCATTGTCCGTCTTCATCAAGGACGCAGCC\nCTGAAGTGGATGTATAGCACAGCCGCCCAGCAGCACCAGTGGGATGGGCTCCTCTCCTAC\nCAGGACTCTCTGAGCTGCCGCCTGGTGTTTCTGCTCATGCAGTACTGTGTGGCGGCCAAT\nTACTACTGGCTCTTGGTGGAGGGCGTGTACCTGTACACACTGCTGGCCTTCTCGGTCTTA\nTCTGAGCAATGGATCTTCAGGCTCTACGTGAGCATAGGCTGGGGTGTTCCCCTGCTGTTT\nGTTGTCCCCTGGGGCATTGTCAAGTACCTCTATGAGGACGAGGGCTGCTGGACCAGGAAC\nTCCAACATGAACTACTGGCTCATTATCCGGCTGCCCATTCTCTTTGCCATTGGGGTGAAC\nTTCCTCATCTTTGTTCGGGTCATCTGCATCGTGGTATCCAAACTGAAGGCCAATCTCATG\nTGCAAGACAGACATCAAATGCAGACTTGCCAAGTCCACGCTGACACTCATCCCCCTGCTG\nGGGACTCATGAGGTCATCTTTGCCTTTGTGATGGACGAGCACGCCCGGGGGACCCTGCGC\nTTCATCAAGCTGTTTACAGAGCTCTCCTTCACCTCCTTCCAGGGGCTGATGGTGGCCATA\nTTATACTGCTTTGTCAACAATGAGGTCCAGCTGGAATTTCGGAAGAGCTGGGAGCGCTGG\nCGGCTTGAGCACTTGCACATCCAGAGGGACAGCAGCATGAAGCCCCTCAAGTGTCCCACC\nAGCAGCCTGAGCAGTGGAGCCACGGCGGGCAGCAGCATGTACACAGCCACTTGCCAGGCC\nTCCTGCAGCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00002'], 'name': ['7tm_2']}, {'identifier': ['PF02793'], 'name': ['HRM']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['glucagon receptor activity']}, {'category': ['function'], 'description': ['transmembrane signaling receptor activity']}, {'category': ['process'], 'description': ['activation of adenylate cyclase activity']}, {'category': ['process'], 'description': ['cAMP-mediated signaling']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['energy reserve metabolic process']}, {'category': ['process'], 'description': ['learning or memory']}, {'category': ['process'], 'description': ['positive regulation of blood pressure']}, {'category': ['process'], 'description': ['positive regulation of cytosolic calcium ion concentration']}, {'category': ['process'], 'description': ['regulation of heart contraction']}, {'category': ['process'], 'description': ['regulation of insulin secretion']}, {'category': ['process'], 'description': ['response to stress']}, {'category': ['process'], 'description': ['small molecule metabolic process']}]}]}]}]}]"
"['DB00041', 'BTD00082', 'BIOD00082']",['Aldesleukin'],biotech,"['Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.']",['liquid'],['For treatment of adults with metastatic renal cell carcinoma.'],"['Aldesleukin binds to the IL-2 receptor which leads to heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains, activation of the tyrosine kinase Jak3, and phosphorylation of tyrosine residues on the IL-2R beta chain. These events led to the creation of an activated receptor complex, to which various cytoplasmic signaling molecules are recruited and become substrates for regulatory enzymes (especially tyrosine kinases) that are associated with the receptor. These events stimulate growth and differentiation of T cells.']",[None],"[{'target': [{'id': ['BE0000651'], 'name': ['Interleukin-2 receptor subunit beta'], 'organism': ['Humans'], 'actions': [{'action': ['agonist', 'modulator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1910'], 'pubmed-id': ['16477002'], 'citation': ['Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA: Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2788-93. Epub 2006 Feb 13.']}, {'ref-id': ['A1912'], 'pubmed-id': ['16542139'], 'citation': ['Steppan S, Eckart MR, Bajsarowicz K, Sternberg LR, Greve JM, Cassell DJ: Reduced secondary cytokine induction by BAY 50-4798, a high-affinity receptor-specific interleukin-2 analog. J Interferon Cytokine Res. 2006 Mar;26(3):171-8.']}, {'ref-id': ['A1913'], 'pubmed-id': ['16569767'], 'citation': ['Cornish GH, Sinclair LV, Cantrell DA: Differential regulation of T-cell growth by IL-2 and IL-15. Blood. 2006 Jul 15;108(2):600-8. Epub 2006 Mar 28.']}, {'ref-id': ['A1916'], 'pubmed-id': ['16596189'], 'citation': ['Lee KD, Chen HW, Chen CC, Shih YC, Liu HK, Cheng ML: Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2. Oncol Rep. 2006 May;15(5):1211-6.']}, {'ref-id': ['A1917'], 'pubmed-id': ['16617454'], 'citation': ['Maclennan C, Hutchinson P, Holdsworth S, Bardin PG, Freezer NJ: Airway inflammation in asymptomatic children with episodic wheeze. Pediatr Pulmonol. 2006 Jun;41(6):577-83.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interleukin-2 receptor subunit beta'], 'general-function': ['Interleukin-2 receptor activity'], 'specific-function': ['Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2.'], 'gene-name': ['IL2RB'], 'locus': ['22q13|22q13.1'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['241-265'], 'signal-regions': ['1-26'], 'theoretical-pi': ['4.68'], 'molecular-weight': ['61116.59'], 'chromosome-location': ['22'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6009']}, {'resource': ['GenAtlas'], 'identifier': ['IL2RB']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M26062']}, {'resource': ['GenBank Protein Database'], 'identifier': ['307048']}, {'resource': ['UniProtKB'], 'identifier': ['P14784']}, {'resource': ['UniProt Accession'], 'identifier': ['IL2RB_HUMAN']}]}], 'synonyms': [{'synonym': ['High affinity IL-2 receptor subunit beta', 'IL-2 receptor subunit beta', 'p70-75', 'p75']}], 'amino-acid-sequence': ['>lcl|BSEQ0016166|Interleukin-2 receptor subunit beta\nMAAPALSWRLPLLILLLPLATSWASAAVNGTSQFTCFYNSRANISCVWSQDGALQDTSCQ\nVHAWPDRRRWNQTCELLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMA\nIQDFKPFENLRLMAPISLQVVHVETHRCNISWEISQASHYFERHLEFEARTLSPGHTWEE\nAPLLTLKQKQEWICLETLTPDTQYEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAALGKDT\nIPWLGHLLVGLSGAFGFIILVYLLINCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDV\nQKWLSSPFPSSSFSPGGLAPEISPLEVLERDKVTQLLLQQDKVPEPASLSSNHSLTSCFT\nNQGYFFFHLPDALEIEACQVYFTYDPYSEEDPDEGVAGAPTGSSPQPLQPLSGEDDAYCT\nFPSRDDLLLFSPSLLGGPSPPSTAPGGSGAGEERMPPSLQERVPRDWDPQPLGPPTPGVP\nDLVDFQPPPELVLREAGEEVPDAGPREGVSFPWSRPPGQGEFRALNARLPLNTDAYLSLQ\nELQGQDPTHLV'], 'gene-sequence': ['>lcl|BSEQ0016167|Interleukin-2 receptor subunit beta (IL2RB)\nATGGCGGCCCCTGCTCTGTCCTGGCGTCTGCCCCTCCTCATCCTCCTCCTGCCCCTGGCT\nACCTCTTGGGCATCTGCAGCGGTGAATGGCACTTCCCAGTTCACATGCTTCTACAACTCG\nAGAGCCAACATCTCCTGTGTCTGGAGCCAAGATGGGGCTCTGCAGGACACTTCCTGCCAA\nGTCCATGCCTGGCCGGACAGACGGCGGTGGAACCAAACCTGTGAGCTGCTCCCCGTGAGT\nCAAGCATCCTGGGCCTGCAACCTGATCCTCGGAGCCCCAGATTCTCAGAAACTGACCACA\nGTTGACATCGTCACCCTGAGGGTGCTGTGCCGTGAGGGGGTGCGATGGAGGGTGATGGCC\nATCCAGGACTTCAAGCCCTTTGAGAACCTTCGCCTGATGGCCCCCATCTCCCTCCAAGTT\nGTCCACGTGGAGACCCACAGATGCAACATAAGCTGGGAAATCTCCCAAGCCTCCCACTAC\nTTTGAAAGACACCTGGAGTTCGAGGCCCGGACGCTGTCCCCAGGCCACACCTGGGAGGAG\nGCCCCCCTGCTGACTCTCAAGCAGAAGCAGGAATGGATCTGCCTGGAGACGCTCACCCCA\nGACACCCAGTATGAGTTTCAGGTGCGGGTCAAGCCTCTGCAAGGCGAGTTCACGACCTGG\nAGCCCCTGGAGCCAGCCCCTGGCCTTCAGGACAAAGCCTGCAGCCCTTGGGAAGGACACC\nATTCCGTGGCTCGGCCACCTCCTCGTGGGCCTCAGCGGGGCTTTTGGCTTCATCATCTTA\nGTGTACTTGCTGATCAACTGCAGGAACACCGGGCCATGGCTGAAGAAGGTCCTGAAGTGT\nAACACCCCAGACCCCTCGAAGTTCTTTTCCCAGCTGAGCTCAGAGCATGGAGGAGACGTC\nCAGAAGTGGCTCTCTTCGCCCTTCCCCTCATCGTCCTTCAGCCCTGGCGGCCTGGCACCT\nGAGATCTCGCCACTAGAAGTGCTGGAGAGGGACAAGGTGACGCAGCTGCTCCTGCAGCAG\nGACAAGGTGCCTGAGCCCGCATCCTTAAGCAGCAACCACTCGCTGACCAGCTGCTTCACC\nAACCAGGGTTACTTCTTCTTCCACCTCCCGGATGCCTTGGAGATAGAGGCCTGCCAGGTG\nTACTTTACTTACGACCCCTACTCAGAGGAAGACCCTGATGAGGGTGTGGCCGGGGCACCC\nACAGGGTCTTCCCCCCAACCCCTGCAGCCTCTGTCAGGGGAGGACGACGCCTACTGCACC\nTTCCCCTCCAGGGATGACCTGCTGCTCTTCTCCCCCAGTCTCCTCGGTGGCCCCAGCCCC\nCCAAGCACTGCCCCTGGGGGCAGTGGGGCCGGTGAAGAGAGGATGCCCCCTTCTTTGCAA\nGAAAGAGTCCCCAGAGACTGGGACCCCCAGCCCCTGGGGCCTCCCACCCCAGGAGTCCCA\nGACCTGGTGGATTTTCAGCCACCCCCTGAGCTGGTGCTGCGAGAGGCTGGGGAGGAGGTC\nCCTGACGCTGGCCCCAGGGAGGGAGTCAGTTTCCCCTGGTCCAGGCCTCCTGGGCAGGGG\nGAGTTCAGGGCCCTTAATGCTCGCCTGCCCCTGAACACTGATGCCTACTTGTCCCTCCAA\nGAACTCCAGGGTCAGGACCCAACTCACTTGGTGTAG'], 'pfams': [None], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['interleukin-2 binding']}, {'category': ['function'], 'description': ['interleukin-2 receptor activity']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['interleukin-2-mediated signaling pathway']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['negative regulation of apoptotic process']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['protein complex assembly']}, {'category': ['process'], 'description': ['Ras protein signal transduction']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['viral process']}]}]}]}, {'id': ['BE0000658'], 'name': ['Interleukin-2 receptor subunit alpha'], 'organism': ['Humans'], 'actions': [{'action': ['agonist', 'modulator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A6697'], 'pubmed-id': ['17216565'], 'citation': ['Waldmann TA: Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol. 2007 Jan;27(1):1-18. Epub 2007 Jan 11.']}, {'ref-id': ['A6698'], 'pubmed-id': ['16767920'], 'citation': ['Recchia F, Cesta A, Rea S: Low dose interleukin-2 and 13-cis-retinoic acid as maintenance therapy in patients with solid tumors responsive to chemotherapy. J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):135-43.']}, {'ref-id': ['A6699'], 'pubmed-id': ['17530023'], 'citation': ['Waldmann TA: Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene. 2007 May 28;26(25):3699-703.']}, {'ref-id': ['A6700'], 'pubmed-id': ['17584597'], 'citation': ['Vlad G, Ho EK, Vasilescu ER, Fan J, Liu Z, Cai JW, Jin Z, Burke E, Deng M, Cadeiras M, Cortesini R, Itescu S, Marboe C, Mancini D, Suciu-Foca N: Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation. Transpl Immunol. 2007 Jul;18(1):13-21. Epub 2007 Apr 2.']}, {'ref-id': ['A6701'], 'pubmed-id': ['16864089'], 'citation': ['Liu BY, Zhu P, Luo HB, Fu N: [Screening of short peptides binding to cell surface interleukin-2 receptor alpha chain]. Nan Fang Yi Ke Da Xue Xue Bao. 2006 Jul;26(7):971-4.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A6702'], 'pubmed-id': ['10207608'], 'citation': ['Ouyang Y, Kaminski NE: Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes. Arch Toxicol. 1999 Feb;73(1):1-6.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interleukin-2 receptor subunit alpha'], 'general-function': ['Interleukin-2 receptor activity'], 'specific-function': ['Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T cells.'], 'gene-name': ['IL2RA'], 'locus': ['10p15-p14'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['241-259'], 'signal-regions': ['1-21'], 'theoretical-pi': ['6.49'], 'molecular-weight': ['30818.915'], 'chromosome-location': ['10'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6008']}, {'resource': ['GenAtlas'], 'identifier': ['IL2RA']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X01057']}, {'resource': ['GenBank Protein Database'], 'identifier': ['33813']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1695']}, {'resource': ['UniProtKB'], 'identifier': ['P01589']}, {'resource': ['UniProt Accession'], 'identifier': ['IL2RA_HUMAN']}]}], 'synonyms': [{'synonym': ['IL-2 receptor subunit alpha', 'p55', 'TAC antigen']}], 'amino-acid-sequence': ['>lcl|BSEQ0018991|Interleukin-2 receptor subunit alpha\nMDSYLLMWGLLTFIMVPGCQAELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKS\nGSLYMLCTGNSSHSSWDNQCQCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQAS\nLPGHCREPPPWENEATERIYHFVVGQMVYYQCVQGYRALHRGPAESVCKMTHGKTRWTQP\nQLICTGEMETSQFPGEEKPQASPEGRPESETSCLVTTTDFQIQTEMAATMETSIFTTEYQ\nVAVAGCVFLLISVLLLSGLTWQRRQRKSRRTI'], 'gene-sequence': ['>lcl|BSEQ0018992|Interleukin-2 receptor subunit alpha (IL2RA)\nATGGATTCATACCTGCTGATGTGGGGACTGCTCACGTTCATCATGGTGCCTGGCTGCCAG\nGCAGAGCTCTGTGACGATGACCCGCCAGAGATCCCACACGCCACATTCAAAGCCATGGCC\nTACAAGGAAGGAACCATGTTGAACTGTGAATGCAAGAGAGGTTTCCGCAGAATAAAAAGC\nGGGTCACTCTATATGCTCTGTACAGGAAACTCTAGCCACTCGTCCTGGGACAACCAATGT\nCAATGCACAAGCTCTGCCACTCGGAACACAACGAAACAAGTGACACCTCAACCTGAAGAA\nCAGAAAGAAAGGAAAACCACAGAAATGCAAAGTCCAATGCAGCCAGTGGACCAAGCGAGC\nCTTCCAGGTCACTGCAGGGAACCTCCACCATGGGAAAATGAAGCCACAGAGAGAATTTAT\nCATTTCGTGGTGGGGCAGATGGTTTATTATCAGTGCGTCCAGGGATACAGGGCTCTACAC\nAGAGGTCCTGCTGAGAGCGTCTGCAAAATGACCCACGGGAAGACAAGGTGGACCCAGCCC\nCAGCTCATATGCACAGGTGAAATGGAGACCAGTCAGTTTCCAGGTGAAGAGAAGCCTCAG\nGCAAGCCCCGAAGGCCGTCCTGAGAGTGAGACTTCCTGCCTCGTCACAACAACAGATTTT\nCAAATACAGACAGAAATGGCTGCAACCATGGAGACGTCCATATTTACAACAGAGTACCAG\nGTAGCAGTGGCCGGCTGTGTTTTCCTGCTGATCAGCGTCCTCCTCCTGAGTGGGCTCACC\nTGGCAGCGGAGACAGAGGAAGAGTAGAAGAACAATCTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00084'], 'name': ['Sushi']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['drug binding']}, {'category': ['function'], 'description': ['interleukin-2 binding']}, {'category': ['function'], 'description': ['interleukin-2 receptor activity']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['activation-induced cell death of T cells']}, {'category': ['process'], 'description': ['apoptotic process']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['cell proliferation']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['inflammatory response']}, {'category': ['process'], 'description': ['inflammatory response to antigenic stimulus']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['negative regulation of defense response to virus']}, {'category': ['process'], 'description': ['negative regulation of immune response']}, {'category': ['process'], 'description': ['negative regulation of inflammatory response']}, {'category': ['process'], 'description': ['negative regulation of T cell proliferation']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['Notch signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of activated T cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of T cell differentiation']}, {'category': ['process'], 'description': ['Ras protein signal transduction']}, {'category': ['process'], 'description': ['regulation of T cell homeostatic proliferation']}, {'category': ['process'], 'description': ['regulation of T cell tolerance induction']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}]}]}]}, {'id': ['BE0002102'], 'name': ['Cytokine receptor common subunit gamma'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1910'], 'pubmed-id': ['16477002'], 'citation': ['Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA: Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2788-93. Epub 2006 Feb 13.']}, {'ref-id': ['A13186'], 'pubmed-id': ['17598841'], 'citation': ['Shibata F, Toma T, Wada T, Inoue M, Tone Y, Ohta K, Kasahara Y, Sano F, Kimura M, Ikeno M, Koizumi S, Yachie A: Skin infiltration of CD56(bright) CD16(-) natural killer cells in a case of X-SCID with Omenn syndrome-like manifestations. Eur J Haematol. 2007 Jul;79(1):81-5.']}, {'ref-id': ['A13187'], 'pubmed-id': ['17635814'], 'citation': ['Fonseca SG, Reis MM, Coelho V, Nogueira LG, Monteiro SM, Mairena EC, Bacal F, Bocchi E, Guilherme L, Zheng XX, Liew FY, Higuchi ML, Kalil J, Cunha-Neto E: Locally produced survival cytokines IL-15 and IL-7 may be associated to the predominance of CD8+ T cells at heart lesions of human chronic Chagas disease cardiomyopathy. Scand J Immunol. 2007 Aug-Sep;66(2-3):362-71.']}, {'ref-id': ['A13188'], 'pubmed-id': ['17083048'], 'citation': ['Blank RB, Lamb EW, Tocheva AS, Crow ET, Lim KC, McKerrow JH, Davies SJ: The common gamma chain cytokines interleukin (IL)-2 and IL-7 indirectly modulate blood fluke development via effects on CD4+ T cells. J Infect Dis. 2006 Dec 1;194(11):1609-16. Epub 2006 Oct 23.']}, {'ref-id': ['A13189'], 'pubmed-id': ['17363735'], 'citation': ['Smyth CM, Ginn SL, Deakin CT, Logan GJ, Alexander IE: Limiting {gamma}c expression differentially affects signaling via the interleukin (IL)-7 and IL-15 receptors. Blood. 2007 Jul 1;110(1):91-8. Epub 2007 Mar 15.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Cytokine receptor common subunit gamma'], 'general-function': ['Interleukin-2 binding'], 'specific-function': ['Common subunit for the receptors for a variety of interleukins.'], 'gene-name': ['IL2RG'], 'locus': ['Xq13.1'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['263-283'], 'signal-regions': ['1-22'], 'theoretical-pi': ['6.31'], 'molecular-weight': ['42286.68'], 'chromosome-location': ['X'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6010']}, {'resource': ['GenAtlas'], 'identifier': ['IL2RG']}, {'resource': ['GenBank Gene Database'], 'identifier': ['D11086']}, {'resource': ['GenBank Protein Database'], 'identifier': ['219890']}, {'resource': ['UniProtKB'], 'identifier': ['P31785']}, {'resource': ['UniProt Accession'], 'identifier': ['IL2RG_HUMAN']}]}], 'synonyms': [{'synonym': ['gammaC', 'IL-2 receptor subunit gamma', 'IL-2R subunit gamma', 'IL-2RG', 'Interleukin-2 receptor subunit gamma', 'p64']}], 'amino-acid-sequence': ['>lcl|BSEQ0004122|Cytokine receptor common subunit gamma\nMLKPSLPFTSLLFLQLPLLGVGLNTTILTPNGNEDTTADFFLTTMPTDSLSVSTLPLPEV\nQCFVFNVEYMNCTWNSSSEPQPTNLTLHYWYKNSDNDKVQKCSHYLFSEEITSGCQLQKK\nEIHLYQTFVVQLQDPREPRRQATQMLKLQNLVIPWAPENLTLHKLSESQLELNWNNRFLN\nHCLEHLVQYRTDWDHSWTEQSVDYRHKFSLPSVDGQKRYTFRVRSRFNPLCGSAQHWSEW\nSHPIHWGSNTSKENPFLFALEAVVISVGSMGLIISLLCVYFWLERTMPRIPTLKNLEDLV\nTEYHGNFSAWSGVSKGLAESLQPDYSERLCLVSEIPPKGGALGEGPGASPCNQHSPYWAP\nPCYTLKPET'], 'gene-sequence': ['>lcl|BSEQ0016682|Cytokine receptor common subunit gamma (IL2RG)\nATGTTGAAGCCATCATTACCATTCACATCCCTCTTATTCCTGCAGCTGCCCCTGCTGGGA\nGTGGGGCTGAACACGACAATTCTGACGCCCAATGGGAATGAAGACACCACAGCTGATTTC\nTTCCTGACCACTATGCCCACTGACTCCCTCAGTGTTTCCACTCTGCCCCTCCCAGAGGTT\nCAGTGTTTTGTGTTCAATGTCGAGTACATGAATTGCACTTGGAACAGCAGCTCTGAGCCC\nCAGCCTACCAACCTCACTCTGCATTATTGGTACAAGAACTCGGATAATGATAAAGTCCAG\nAAGTGCAGCCACTATCTATTCTCTGAAGAAATCACTTCTGGCTGTCAGTTGCAAAAAAAG\nGAGATCCACCTCTACCAAACATTTGTTGTTCAGCTCCAGGACCCACGGGAACCCAGGAGA\nCAGGCCACACAGATGCTAAAACTGCAGAATCTGGTGATCCCCTGGGCTCCAGAGAACCTA\nACACTTCACAAACTGAGTGAATCCCAGCTAGAACTGAACTGGAACAACAGATTCTTGAAC\nCACTGTTTGGAGCACTTGGTGCAGTACCGGACTGACTGGGACCACAGCTGGACTGAACAA\nTCAGTGGATTATAGACATAAGTTCTCCTTGCCTAGTGTGGATGGGCAGAAACGCTACACG\nTTTCGTGTTCGGAGCCGCTTTAACCCACTCTGTGGAAGTGCTCAGCATTGGAGTGAATGG\nAGCCACCCAATCCACTGGGGGAGCAATACTTCAAAAGAGAATCCTTTCCTGTTTGCATTG\nGAAGCCGTGGTTATCTCTGTTGGCTCCATGGGATTGATTATCAGCCTTCTCTGTGTGTAT\nTTCTGGCTGGAACGGACGATGCCCCGAATTCCCACCCTGAAGAACCTAGAGGATCTTGTT\nACTGAATACCACGGGAACTTTTCGGCCTGGAGTGGTGTGTCTAAGGGACTGGCTGAGAGT\nCTGCAGCCAGACTACAGTGAACGACTCTGCCTCGTCAGTGAGATTCCCCCAAAAGGAGGG\nGCCCTTGGGGAGGGGCCTGGGGCCTCCCCATGCAACCAGCATAGCCCCTACTGGGCCCCC\nCCATGTTACACCCTAAAGCCTGAAACCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00041'], 'name': ['fn3']}, {'identifier': ['PF09240'], 'name': ['IL6Ra-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['cytokine receptor activity']}, {'category': ['function'], 'description': ['interleukin-2 binding']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['interleukin-2-mediated signaling pathway']}, {'category': ['process'], 'description': ['interleukin-4-mediated signaling pathway']}, {'category': ['process'], 'description': ['interleukin-7-mediated signaling pathway']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['Ras protein signal transduction']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['viral process']}]}]}]}]}]"
"['DB00042', 'BTD00070', 'BIOD00070']",['Botulinum toxin type B'],biotech,['Neurotoxin produced by fermentation of clostridium botulinum type B. The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex. The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation and chromatography steps.'],['liquid'],['For the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.'],"['Botulinum Toxin Type B binds to and cleaves the synaptic Vesicle Associated Membrane Protein (VAMP, also known as synaptobrevin) which is a component of the protein complex responsible for docking and fusion of the synaptic vesicle to the presynaptic membrane, a necessary step to neurotransmitter release.']",[None],"[{'target': [{'id': ['BE0002137'], 'name': ['Vesicle-associated membrane protein 2'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13190'], 'pubmed-id': ['14573702'], 'citation': ['Liu W, Montana V, Chapman ER, Mohideen U, Parpura V: Botulinum toxin type B micromechanosensor. Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13621-5. Epub 2003 Oct 22.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Vesicle-associated membrane protein 2'], 'general-function': ['Syntaxin-1 binding'], 'specific-function': ['Involved in the targeting and/or fusion of transport vesicles to their target membrane. Modulates the gating characteristics of the delayed rectifier voltage-dependent potassium channel KCNB1.'], 'gene-name': ['VAMP2'], 'locus': ['17p13.1'], 'cellular-location': ['Cytoplasmic vesicle'], 'transmembrane-regions': ['95-114'], 'signal-regions': [None], 'theoretical-pi': ['8.48'], 'molecular-weight': ['12662.585'], 'chromosome-location': ['17'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:12643']}, {'resource': ['GenAtlas'], 'identifier': ['VAMP2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M36205']}, {'resource': ['GenBank Protein Database'], 'identifier': ['338632']}, {'resource': ['UniProtKB'], 'identifier': ['P63027']}, {'resource': ['UniProt Accession'], 'identifier': ['VAMP2_HUMAN']}]}], 'synonyms': [{'synonym': ['SYB2', 'Synaptobrevin-2', 'VAMP-2']}], 'amino-acid-sequence': ['>lcl|BSEQ0016692|Vesicle-associated membrane protein 2\nMSATAATAPPAAPAGEGGPPAPPPNLTSNRRLQQTQAQVDEVVDIMRVNVDKVLERDQKL\nSELDDRADALQAGASQFETSAAKLKRKYWWKNLKMMIILGVICAIILIIIIVYFST'], 'gene-sequence': ['>lcl|BSEQ0016693|Vesicle-associated membrane protein 2 (VAMP2)\nATGTCTGCTACCGCTGCCACGGCCCCCCCTGCTGCCCCGGCTGGGGAGGGTGGTCCCCCT\nGCACCCCCTCCAAACCTCACCAGTAACAGGAGACTGCAGCAGACCCAGGCCCAGGTGGAT\nGAGGTGGTGGACATCATGAGGGTGAACGTGGACAAGGTCCTGGAGCGAGACCAGAAGCTG\nTCGGAGCTGGACGACCGTGCAGATGCACTCCAGGCGGGGGCCTCCCAGTTTGAAACAAGC\nGCAGCCAAGCTCAAGCGCAAATACTGGTGGAAAAACCTCAAGATGATGATCATCTTGGGA\nGTGATTTGCGCCATCATCCTCATCATCATCATAGTTTACTTCAGCACTTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00957'], 'name': ['Synaptobrevin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell junction']}, {'category': ['component'], 'description': ['clathrin-coated vesicle']}, {'category': ['component'], 'description': ['clathrin-sculpted gamma-aminobutyric acid transport vesicle membrane']}, {'category': ['component'], 'description': ['clathrin-sculpted glutamate transport vesicle membrane']}, {'category': ['component'], 'description': ['clathrin-sculpted monoamine transport vesicle membrane']}, {'category': ['component'], 'description': ['cytoplasmic vesicle']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular membrane-bounded organelle']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['neuron projection']}, {'category': ['component'], 'description': ['neuron projection terminus']}, {'category': ['component'], 'description': ['perinuclear region of cytoplasm']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['secretory granule']}, {'category': ['component'], 'description': ['secretory granule membrane']}, {'category': ['component'], 'description': ['SNARE complex']}, {'category': ['component'], 'description': ['storage vacuole']}, {'category': ['component'], 'description': ['synapse']}, {'category': ['component'], 'description': ['synaptic vesicle']}, {'category': ['component'], 'description': ['synaptic vesicle membrane']}, {'category': ['component'], 'description': ['synaptobrevin 2-SNAP-25-syntaxin-1a complex']}, {'category': ['component'], 'description': ['synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex']}, {'category': ['component'], 'description': ['synaptobrevin 2-SNAP-25-syntaxin-1a-complexin II complex']}, {'category': ['component'], 'description': ['terminal bouton']}, {'category': ['component'], 'description': ['trans-Golgi network']}, {'category': ['component'], 'description': ['vesicle']}, {'category': ['component'], 'description': ['zymogen granule membrane']}, {'category': ['function'], 'description': ['calcium-dependent protein binding']}, {'category': ['function'], 'description': ['calmodulin binding']}, {'category': ['function'], 'description': ['phospholipid binding']}, {'category': ['function'], 'description': ['protein self-association']}, {'category': ['function'], 'description': ['SNAP receptor activity']}, {'category': ['function'], 'description': ['SNARE binding']}, {'category': ['function'], 'description': ['syntaxin binding']}, {'category': ['function'], 'description': ['syntaxin-1 binding']}, {'category': ['process'], 'description': ['calcium ion-dependent exocytosis']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['cellular response to insulin stimulus']}, {'category': ['process'], 'description': ['energy reserve metabolic process']}, {'category': ['process'], 'description': ['eosinophil degranulation']}, {'category': ['process'], 'description': ['exocytosis']}, {'category': ['process'], 'description': ['glutamate secretion']}, {'category': ['process'], 'description': ['Golgi to plasma membrane protein transport']}, {'category': ['process'], 'description': ['long-term synaptic potentiation']}, {'category': ['process'], 'description': ['membrane fusion']}, {'category': ['process'], 'description': ['membrane organization']}, {'category': ['process'], 'description': ['neurotransmitter secretion']}, {'category': ['process'], 'description': ['positive regulation of intracellular protein transport']}, {'category': ['process'], 'description': ['post-Golgi vesicle-mediated transport']}, {'category': ['process'], 'description': ['protein complex assembly']}, {'category': ['process'], 'description': ['protein transport']}, {'category': ['process'], 'description': ['regulation of delayed rectifier potassium channel activity']}, {'category': ['process'], 'description': ['regulation of exocytosis']}, {'category': ['process'], 'description': ['regulation of insulin secretion']}, {'category': ['process'], 'description': ['regulation of vesicle-mediated transport']}, {'category': ['process'], 'description': ['response to glucose']}, {'category': ['process'], 'description': ['small molecule metabolic process']}, {'category': ['process'], 'description': ['synaptic transmission']}, {'category': ['process'], 'description': ['synaptic vesicle exocytosis']}, {'category': ['process'], 'description': ['vesicle fusion']}, {'category': ['process'], 'description': ['vesicle-mediated transport']}]}]}]}, {'id': ['BE0002136'], 'name': ['Vesicle-associated membrane protein 1'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Vesicle-associated membrane protein 1'], 'general-function': ['Snare binding'], 'specific-function': ['Involved in the targeting and/or fusion of transport vesicles to their target membrane.'], 'gene-name': ['VAMP1'], 'locus': ['12p'], 'cellular-location': ['Cytoplasmic vesicle'], 'transmembrane-regions': ['97-116'], 'signal-regions': [None], 'theoretical-pi': ['6.59'], 'molecular-weight': ['12901.815'], 'chromosome-location': ['12'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:12642']}, {'resource': ['GenAtlas'], 'identifier': ['VAMP1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M36200']}, {'resource': ['GenBank Protein Database'], 'identifier': ['338625']}, {'resource': ['UniProtKB'], 'identifier': ['P23763']}, {'resource': ['UniProt Accession'], 'identifier': ['VAMP1_HUMAN']}]}], 'synonyms': [{'synonym': ['SYB1', 'Synaptobrevin-1', 'VAMP-1']}], 'amino-acid-sequence': ['>lcl|BSEQ0004190|Vesicle-associated membrane protein 1\nMSAPAQPPAEGTEGTAPGGGPPGPPPNMTSNRRLQQTQAQVEEVVDIIRVNVDKVLERDQ\nKLSELDDRADALQAGASQFESSAAKLKRKYWWKNCKMMIMLGAICAIIVVVIVIYFFT'], 'gene-sequence': ['>lcl|BSEQ0016691|Vesicle-associated membrane protein 1 (VAMP1)\nATGTCTGCTCCAGCTCAGCCACCTGCTGAAGGGACAGAAGGGACTGCCCCAGGTGGGGGT\nCCCCCTGGCCCTCCTCCTAACATGACCAGTAACAGACGACTACAGCAAACCCAGGCACAA\nGTGGAGGAGGTGGTGGACATCATACGTGTGAACGTGGACAAGGTCCTGGAGAGGGACCAG\nAAGCTGTCAGAGCTGGATGACCGAGCTGATGCCTTGCAGGCAGGAGCATCACAATTTGAG\nAGCAGTGCTGCCAAGCTAAAGAGGAAGTATTGGTGGAAAAACTGCAAGATGATGATCATG\nCTGGGAGCCATCTGTGCCATCATCGTGGTAGTTATTGTAAGAAGAGGCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00957'], 'name': ['Synaptobrevin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell junction']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['mitochondrial outer membrane']}, {'category': ['component'], 'description': ['SNARE complex']}, {'category': ['component'], 'description': ['specific granule membrane']}, {'category': ['component'], 'description': ['synaptic vesicle']}, {'category': ['component'], 'description': ['synaptic vesicle membrane']}, {'category': ['component'], 'description': ['terminal bouton']}, {'category': ['component'], 'description': ['tertiary granule membrane']}, {'category': ['function'], 'description': ['SNAP receptor activity']}, {'category': ['function'], 'description': ['SNARE binding']}, {'category': ['process'], 'description': ['exocytosis']}, {'category': ['process'], 'description': ['SNARE complex assembly']}, {'category': ['process'], 'description': ['vesicle fusion']}]}]}]}, {'id': ['BE0002138'], 'name': ['Synaptotagmin-2'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A13191'], 'pubmed-id': ['19576489'], 'citation': ['Poulain B, Lonchamp E, Jover E, Popoff MR, Molgo J: [Mechanisms of action of botulinum toxins and neurotoxins]. Ann Dermatol Venereol. 2009 May;136 Suppl 4:S73-6. doi: 10.1016/S0151-9638(09)74531-4.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Synaptotagmin-2'], 'general-function': ['Syntaxin binding'], 'specific-function': ['Exhibits calcium-dependent phospholipid and inositol polyphosphate binding properties (By similarity). May have a regulatory role in the membrane interactions during trafficking of synaptic vesicles at the active zone of the synapse (By similarity). Plays a role in dendrite formation by melanocytes (PubMed:23999003).'], 'gene-name': ['SYT2'], 'locus': ['1q32.1'], 'cellular-location': ['Cytoplasmic vesicle'], 'transmembrane-regions': ['63-83'], 'signal-regions': [None], 'theoretical-pi': ['8.12'], 'molecular-weight': ['46871.95'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:11510']}, {'resource': ['GenAtlas'], 'identifier': ['SYT2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['AK090672']}, {'resource': ['GenBank Protein Database'], 'identifier': ['21748879']}, {'resource': ['UniProtKB'], 'identifier': ['Q8N9I0']}, {'resource': ['UniProt Accession'], 'identifier': ['SYT2_HUMAN']}]}], 'synonyms': [{'synonym': ['Synaptotagmin II', 'SytII']}], 'amino-acid-sequence': ['>lcl|BSEQ0011549|Synaptotagmin-2\nMRNIFKRNQEPIVAPATTTATMPIGPVDNSTESGGAGESQEDMFAKLKEKLFNEINKIPL\nPPWALIAIAVVAGLLLLTCCFCICKKCCCKKKKNKKEKGKGMKNAMNMKDMKGGQDDDDA\nETGLTEGEGEGEEEKEPENLGKLQFSLDYDFQANQLTVGVLQAAELPALDMGGTSDPYVK\nVFLLPDKKKKYETKVHRKTLNPAFNETFTFKVPYQELGGKTLVMAIYDFDRFSKHDIIGE\nVKVPMNTVDLGQPIEEWRDLQGGEKEEPEKLGDICTSLRYVPTAGKLTVCILEAKNLKKM\nDVGGLSDPYVKIHLMQNGKRLKKKKTTVKKKTLNPYFNESFSFEIPFEQIQKVQVVVTVL\nDYDKLGKNEAIGKIFVGSNATGTELRHWSDMLANPRRPIAQWHSLKPEEEVDALLGKNK'], 'gene-sequence': ['>lcl|BSEQ0011550|Synaptotagmin-2 (SYT2)\nATGAGGAACATTTTCAAGAGGAACCAGGAGCCTATTGTGGCTCCTGCCACCACCACCGCC\nACGATGCCCATTGGACCCGTGGACAACTCCACTGAGAGTGGGGGTGCTGGGGAGAGCCAG\nGAGGACATGTTTGCCAAACTGAAGGAGAAGTTATTCAATGAGATAAACAAGATTCCCTTA\nCCACCCTGGGCACTGATCGCCATTGCTGTGGTTGCTGGGCTCCTGCTTCTCACCTGCTGC\nTTCTGCATCTGCAAGAAATGCTGCTGCAAGAAGAAGAAGAACAAGAAGGAGAAGGGCAAA\nGGCATGAAGAATGCCATGAACATGAAGGACATGAAAGGGGGTCAGGATGACGACGACGCA\nGAGACAGGCCTGACTGAGGGGGAAGGTGAAGGGGAGGAGGAGAAAGAGCCAGAGAACCTG\nGGCAAACTGCAGTTTTCCCTGGACTATGATTTTCAGGCTAATCAGCTTACTGTGGGCGTT\nCTGCAGGCTGCTGAACTGCCTGCCCTGGACATGGGAGGCACCTCAGACCCTTATGTCAAG\nGTCTTCCTCCTTCCTGACAAGAAGAAGAAATATGAGACCAAAGTCCATCGGAAGACACTG\nAACCCTGCCTTCAATGAAACCTTCACCTTCAAGGTGCCATACCAGGAGCTTGGGGGCAAA\nACTCTGGTGATGGCCATCTATGACTTTGACCGCTTCTCCAAACATGACATCATTGGAGAG\nGTAAAGGTGCCTATGAACACAGTGGACCTCGGCCAGCCCATTGAGGAGTGGAGAGACCTG\nCAAGGCGGGGAAAAGGAGGAGCCGGAGAAGCTGGGCGACATCTGCACCTCCCTGCGCTAT\nGTGCCCACGGCCGGGAAGCTCACTGTCTGCATCCTGGAGGCTAAGAACCTCAAGAAGATG\nGACGTGGGCGGCCTTTCAGACCCGTACGTGAAGATCCACCTGATGCAGAATGGCAAGAGG\nCTCAAGAAGAAGAAGACAACCGTGAAGAAGAAGACCCTGAACCCATACTTCAACGAGTCC\nTTCAGCTTTGAGATCCCCTTCGAGCAGATTCAGAAAGTCCAGGTAGTGGTCACCGTGCTG\nGACTATGACAAGCTGGGCAAGAACGAAGCCATAGGCAAGATCTTCGTGGGCAGCAATGCC\nACGGGCACAGAGCTGCGGCACTGGTCCGACATGCTGGCCAACCCCCGGAGGCCCATCGCC\nCAGTGGCACTCGCTCAAGCCTGAGGAGGAGGTGGATGCACTCCTGGGCAAGAACAAGTAG\n'], 'pfams': [{'pfam': [{'identifier': ['PF00168'], 'name': ['C2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell junction']}, {'category': ['component'], 'description': ['chromaffin granule membrane']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['intracellular membrane-bounded organelle']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['synaptic vesicle membrane']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['calcium-dependent phospholipid binding']}, {'category': ['function'], 'description': ['clathrin binding']}, {'category': ['function'], 'description': ['inositol 1,3,4,5 tetrakisphosphate binding']}, {'category': ['function'], 'description': ['syntaxin binding']}, {'category': ['process'], 'description': ['calcium ion-dependent exocytosis of neurotransmitter']}, {'category': ['process'], 'description': ['positive regulation of dendrite extension']}, {'category': ['process'], 'description': ['regulation of calcium ion-dependent exocytosis']}, {'category': ['process'], 'description': ['synaptic vesicle endocytosis']}, {'category': ['process'], 'description': ['synaptic vesicle exocytosis']}, {'category': ['process'], 'description': ['vesicle fusion']}]}]}]}]}]"
"['DB00043', 'BTD00081', 'BIOD00081']",['Omalizumab'],biotech,"['Omalizumab, manufactured by _Genentech_, was first FDA approved in 2003 to treat adults and children 12 years of age and older with moderate to severe persistent allergic asthma which is not controlled by inhaled steroids [L4670]. Since its U.S. approval, more than 200,000 patients older than 12 with allergic asthma have been treated [L4670].  In September 2018, a new prefilled syringe formulation of this drug was approved by the FDA [L4671].']",['solid'],['This drug is an anti-IgE antibody indicated for:\r\n\r\n1. Moderate to severe persistent asthma in patients 6 years of age and older\r\nwith a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids [FDA label]\r\n\r\n2. Chronic idiopathic urticaria in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment [FDA label]'],"['When an environmental allergen first enters the body, is taken up by antigen-presenting cells (APCs). It is then processed, and presented to T and B immune cells. This is followed by the activation of B-lymphocyte and production of allergen-specific IgE. This IgE is then released by plasma cells (converted B lymphocytes) and is therefore available to bind to IgE receptors on several other cells [A39520].\r\n\r\nIgE binds to high-affinity (FcRI) and low-affinity (FcRII) receptors on multiple cells of the immune system. Following subsequent antigen exposure, cross-linking of the antigen occurs by several FcRI-bound IgE molecules on the surface of both basophils and mast cells. This leads to the activation of mast cells and histamine release, producing a wheal and other symptoms of urticaria [A39520].\r\n\r\nThe following are explanations of the mechanism of action for both indications of this drug:\r\n\r\n**Asthma**\r\n\r\nOmalizumab inhibits the binding of IgE to the high-affinity IgE receptor (FcRI) on the surface of both mast cells and basophils. The reduction in surface-bound IgE on FcRI-bearing cells limits the degree of release of mediators of the typical allergic response. Treatment with omalizumab also reduces the number of FcRI receptors on basophils in atopic patients [FDA label].\r\n\r\nOmalizumab binds to free IgE with a higher affinity than IgE itself binds to the high-affinity FcRI receptors found on basophils. Therefore, it decreases the availability of free IgE for binding [A39520]. Omalizumab by itself does not bind to the FcRI receptors, nor does the drug bind to receptor-bound IgE. These binding characteristics allow omalizumab to neutralize the typical IgE-mediated responses without causing the degranulation of basophils or cross-linking with basophil-bound IgE [A39520].\r\n\r\n**Chronic Idiopathic Urticaria**\r\nOmalizumab binds to IgE and decreases free IgE levels. Subsequently, IgE receptors (FcRI) on cells are down-regulated. The mechanism by which these effects of omalizumab result in an improvement of CIU symptoms is unclear[FDA label].']",[None],"[{'target': [{'id': ['BE0000015'], 'name': ['High affinity immunoglobulin epsilon receptor subunit alpha'], 'organism': ['Humans'], 'actions': [{'action': ['inhibitor']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1919'], 'pubmed-id': ['15356552'], 'citation': ['Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S: Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol. 2004 Sep;114(3):527-30.']}, {'ref-id': ['A1921'], 'pubmed-id': ['17368811'], 'citation': ['Mirkina I, Schweighoffer T, Kricek F: Inhibition of human cord blood-derived mast cell responses by anti-Fc epsilon RI mAb 15/1 versus anti-IgE Omalizumab. Immunol Lett. 2007 Apr 15;109(2):120-8. Epub 2007 Mar 1.']}, {'ref-id': ['A39520'], 'pubmed-id': ['26288408'], 'citation': ['Godse K, Mehta A, Patil S, Gautam M, Nadkarni N: Omalizumab-A Review. Indian J Dermatol. 2015 Jul-Aug;60(4):381-4. doi: 10.4103/0019-5154.160490.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['High affinity immunoglobulin epsilon receptor subunit alpha'], 'general-function': ['Ige receptor activity'], 'specific-function': ['Binds to the Fc region of immunoglobulins epsilon. High affinity receptor. Responsible for initiating the allergic response. Binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators (such as histamine) responsible for the manifestations of allergy. The same receptor also induces the secretion of important lymphokines.'], 'gene-name': ['FCER1A'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['206-224'], 'signal-regions': ['1-25'], 'theoretical-pi': ['6.67'], 'molecular-weight': ['29595.67'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3609']}, {'resource': ['GenAtlas'], 'identifier': ['FCER1A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X06948']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31318']}, {'resource': ['UniProtKB'], 'identifier': ['P12319']}, {'resource': ['UniProt Accession'], 'identifier': ['FCERA_HUMAN']}]}], 'synonyms': [{'synonym': ['Fc-epsilon RI-alpha', 'FCE1A', 'FcERI', 'IgE Fc receptor subunit alpha']}], 'amino-acid-sequence': ['>lcl|BSEQ0015997|High affinity immunoglobulin epsilon receptor subunit alpha\nMAPAMESPTLLCVALLFFAPDGVLAVPQKPKVSLNPPWNRIFKGENVTLTCNGNNFFEVS\nSTKWFHNGSLSEETNSSLNIVNAKFEDSGEYKCQHQQVNESEPVYLEVFSDWLLLQASAE\nVVMEGQPLFLRCHGWRNWDVYKVIYYKDGEALKYWYENHNISITNATVEDSGTYYCTGKV\nWQLDYESEPLNITVIKAPREKYWLQFFIPLLVVILFAVDTGLFISTQQQVTFLLKIKRTR\nKGFRLLNPHPKPNPKNN'], 'gene-sequence': ['>lcl|BSEQ0015998|High affinity immunoglobulin epsilon receptor subunit alpha (FCER1A)\nATGGCTCCTGCCATGGAATCCCCTACTCTACTGTGTGTAGCCTTACTGTTCTTCGCTCCA\nGATGGCGTGTTAGCAGTCCCTCAGAAACCTAAGGTCTCCTTGAACCCTCCATGGAATAGA\nATATTTAAAGGAGAGAATGTGACTCTTACATGTAATGGGAACAATTTCTTTGAAGTCAGT\nTCCACCAAATGGTTCCACAATGGCAGCCTTTCAGAAGAGACAAATTCAAGTTTGAATATT\nGTGAATGCCAAATTTGAAGACAGTGGAGAATACAAATGTCAGCACCAACAAGTTAATGAG\nAGTGAACCTGTGTACCTGGAAGTCTTCAGTGACTGGCTGCTCCTTCAGGCCTCTGCTGAG\nGTGGTGATGGAGGGCCAGCCCCTCTTCCTCAGGTGCCATGGTTGGAGGAACTGGGATGTG\nTACAAGGTGATCTATTATAAGGATGGTGAAGCTCTCAAGTACTGGTATGAGAACCACAAC\nATCTCCATTACAAATGCCACAGTTGAAGACAGTGGAACCTACTACTGTACGGGCAAAGTG\nTGGCAGCTGGACTATGAGTCTGAGCCCCTCAACATTACTGTAATAAAAGCTCCGCGTGAG\nAAGTACTGGCTACAATTTTTTATCCCATTGTTGGTGGTGATTCTGTTTGCTGTGGACACA\nGGATTATTTATCTCAACTCAGCAGCAGGTCACATTTCTCTTGAAGATTAAGAGAACCAGG\nAAAGGCTTCAGACTTCTGAACCCACATCCTAAGCCAAACCCCAAAAACAACTGA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['IgE receptor activity']}, {'category': ['process'], 'description': ['activation of JUN kinase activity']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['leukotriene biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of calcium-mediated signaling']}, {'category': ['process'], 'description': ['positive regulation of granulocyte macrophage colony-stimulating factor biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of interleukin-3 biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of mast cell degranulation']}, {'category': ['process'], 'description': ['positive regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of type I hypersensitivity']}, {'category': ['process'], 'description': ['serotonin secretion']}]}]}]}, {'id': ['BE0002139'], 'name': ['High affinity immunoglobulin epsilon receptor subunit beta'], 'organism': ['Humans'], 'actions': [{'action': ['inhibitor']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A13192'], 'pubmed-id': ['17073688'], 'citation': ['DuBuske LM: IgE, allergic diseases, and omalizumab. Curr Pharm Des. 2006;12(30):3929-44.']}, {'ref-id': ['A39250'], 'pubmed-id': ['11678779'], 'citation': ['Raunio H, Rautio A, Gullsten H, Pelkonen O: Polymorphisms of CYP2A6 and its practical consequences. Br J Clin Pharmacol. 2001 Oct;52(4):357-63.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['High affinity immunoglobulin epsilon receptor subunit beta'], 'general-function': ['Ige receptor activity'], 'specific-function': ['High affinity receptor that binds to the Fc region of immunoglobulins epsilon. Aggregation of FCER1 by multivalent antigens is required for the full mast cell response, including the release of preformed mediators (such as histamine) by degranulation and de novo production of lipid mediators and cytokines. Also mediates the secretion of important lymphokines. Binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators responsible for the manifestations of allergy.'], 'gene-name': ['MS4A2'], 'locus': ['11q13'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['60-79\n98-117\n131-150\n181-200'], 'signal-regions': [None], 'theoretical-pi': ['4.78'], 'molecular-weight': ['26533.365'], 'chromosome-location': ['11'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:7316']}, {'resource': ['GenAtlas'], 'identifier': ['MS4A2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['D10583']}, {'resource': ['GenBank Protein Database'], 'identifier': ['219882']}, {'resource': ['UniProtKB'], 'identifier': ['Q01362']}, {'resource': ['UniProt Accession'], 'identifier': ['FCERB_HUMAN']}]}], 'synonyms': [{'synonym': ['APY', 'Fc epsilon receptor I beta-chain', 'FCER1B', 'FcERI', 'IgE Fc receptor subunit beta', 'IGER', 'Membrane-spanning 4-domains subfamily A member 2']}], 'amino-acid-sequence': ['>lcl|BSEQ0011551|High affinity immunoglobulin epsilon receptor subunit beta\nMDTESNRRANLALPQEPSSVPAFEVLEISPQEVSSGRLLKSASSPPLHTWLTVLKKEQEF\nLGVTQILTAMICLCFGTVVCSVLDISHIEGDIFSSFKAGYPFWGAIFFSISGMLSIISER\nRNATYLVRGSLGANTASSIAGGTGITILIINLKKSLAYIHIHSCQKFFETKCFMASFSTE\nIVVMMLFLTILGLGSAVSLTICGAGEELKGNKVPEDRVYEELNIYSATYSELEDPGEMSP\nPIDL'], 'gene-sequence': ['>lcl|BSEQ0011552|High affinity immunoglobulin epsilon receptor subunit beta (MS4A2)\nATGGACACAGAAAGTAATAGGAGAGCAAATCTTGCTCTCCCACAGGAGCCTTCCAGTGTG\nCCTGCATTTGAAGTCTTGGAAATATCTCCCCAGGAAGTATCTTCAGGCAGACTATTGAAG\nTCGGCCTCATCCCCACCACTGCATACATGGCTGACAGTTTTGAAAAAAGAGCAGGAGTTC\nCTGGGGGTAACACAAATTCTGACTGCTATGATATGCCTTTGTTTTGGAACAGTTGTCTGC\nTCTGTACTTGATATTTCACACATTGAGGGAGACATTTTTTCATCATTTAAAGCAGGTTAT\nCCATTCTGGGGAGCCATATTTTTTTCTATTTCTGGAATGTTGTCAATTATATCTGAAAGG\nAGAAATGCAACATATCTGGTGAGAGGAAGCCTGGGAGCAAACACTGCCAGCAGCATAGCT\nGGGGGAACGGGAATTACCATCCTGATCATCAACCTGAAGAAGAGCTTGGCCTATATCCAC\nATCCACAGTTGCCAGAAATTTTTTGAGACCAAGTGCTTTATGGCTTCCTTTTCCACTGAA\nATTGTAGTGATGATGCTGTTTCTCACCATTCTGGGACTTGGTAGTGCTGTGTCACTCACA\nATCTGTGGAGCTGGGGAAGAACTCAAAGGAAACAAGGTTCCAGAGGATCGTGTTTATGAA\nGAATTAAACATATATTCAGCTACTTACAGTGAGTTGGAAGACCCAGGGGAAATGTCTCCT\nCCCATTGATTTATAA'], 'pfams': [{'pfam': [{'identifier': ['PF04103'], 'name': ['CD20']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['Fc-epsilon receptor I complex']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['membrane raft']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['IgE receptor activity']}, {'category': ['process'], 'description': ['activation of phospholipase C activity']}, {'category': ['process'], 'description': ['cytokine secretion']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['inflammatory response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['positive regulation of mast cell degranulation']}, {'category': ['process'], 'description': ['protein kinase C-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['regulation of release of sequestered calcium ion into cytosol']}]}]}]}]}]"
"['DB00044', 'BTD00056', 'BIOD00056']",['Lutropin alfa'],biotech,"['Lutropin alfa is a recombinant human luteinizing hormone produced in yeast with 2 subunits, alpha = 92 residues, beta = 121 residues. It is a heterodimeric glycoprotein made up of monomeric units. Lutropin alfa was the first and only recombinant human form of luteinizing hormone (LH) developed for use in the stimulation of follicular development. Its pharmacological action mimics the biological activity of endogenous LH; an acute rise of LH, or LH surge, in females triggers ovulation and the development of the corpous luteum. In males, LH stimulates Leydig cell to produce testosterone.']",['liquid'],['For treatment of infertility in women with hypothalamic or pituitary insufficiency (hypogonadotropic hypogonadism) and profound LH deficiency (LH <1.2 international units [IU]/L)'],['Luteinizing hormone binds to a receptor shared with the human chorionic gonadotropin hormone (hCG) on the ovarian theca (and granulosa) cells and testicular Leydig cells. This LH/CG transmembrane receptor is a member of the super-family of G protein-coupled receptors. Adenylate cyclase then activates many other pathways leading to steroid hormone production and other follicle maturation processes. '],[None],"[{'target': [{'id': ['BE0000134'], 'name': ['Lutropin-choriogonadotropic hormone receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A77'], 'pubmed-id': ['20161981'], 'citation': ['Gibreel A, Bhattacharya S: Recombinant follitropin alfa/lutropin alfa in fertility treatment. Biologics. 2010 Feb 4;4:5-17.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Lutropin-choriogonadotropic hormone receptor'], 'general-function': ['Luteinizing hormone receptor activity'], 'specific-function': ['Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase.'], 'gene-name': ['LHCGR'], 'locus': ['2p21'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['364-385\n396-416\n440-462\n483-505\n526-549\n571-594\n606-627'], 'signal-regions': ['1-26'], 'theoretical-pi': ['8.58'], 'molecular-weight': ['78642.01'], 'chromosome-location': ['2'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6585']}, {'resource': ['GenAtlas'], 'identifier': ['LHCGR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M73746']}, {'resource': ['GenBank Protein Database'], 'identifier': ['903746']}, {'resource': ['IUPHAR'], 'identifier': ['254']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['254']}, {'resource': ['UniProtKB'], 'identifier': ['P22888']}, {'resource': ['UniProt Accession'], 'identifier': ['LSHR_HUMAN']}]}], 'synonyms': [{'synonym': ['LCGR', 'LGR2', 'LH/CG-R', 'LHR', 'LHRHR', 'LSH-R', 'Luteinizing hormone receptor']}], 'amino-acid-sequence': ['>lcl|BSEQ0036957|Lutropin-choriogonadotropic hormone receptor\nMKQRFSALQLLKLLLLLQPPLPRALREALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLP\nVKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFI\nNLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLK\nLYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSY\nGLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENF\nSKQCESTVRKVNNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYD\nFLRVLIWLINILAIMGNMTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIASVDS\nQTKGQYYNHAIDWQTGSGCSTAGFFTVFASELSVYTLTVITLERWHTITYAIHLDQKLRL\nRHAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETTLSQVYILTILILNVVAFF\nIICACYIKIYFAVRNPELMATNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKVPLIT\nVTNSKVLLVLFYPINSCANPFLYAIFTKTFQRDFFLLLSKFGCCKRRAELYRRKDFSAYT\nSNCKNGFTGSNKPSQSTLKLSTLHCQGTALLDKTRYTEC'], 'gene-sequence': ['>lcl|BSEQ0010174|Lutropin-choriogonadotropic hormone receptor (LHCGR)\nATGAAGCAGCGGTTCTCGGCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGCCGCCG\nCTGCCACGAGCGCTGCGCGAGGCGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGC\nGCCCTGCGCTGCCCCGGCCCCACGGCCGGTCTCACTCGACTATCACTTGCCTACCTCCCT\nGTCAAAGTGATCCCATCTCAAGCTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATC\nTCTCAGATTGATTCCCTGGAAAGGATAGAAGCTAATGCCTTTGACAACCTCCTCAATTTG\nTCTGAAATACTGATCCAGAACACCAAAAATCTGAGATACATTGAGCCCGGAGCATTTATA\nAATCTTCCCCGATTAAAATACTTGAGCATCTGTAACACAGGCATCAGAAAGTTTCCAGAT\nGTTACGAAGGTCTTCTCCTCTGAATCAAATTTCATTCTGGAAATTTGTGATAACTTACAC\nATAACCACCATACCAGGAAATGCTTTTCAAGGGATGAATAATGAATCTGTAACACTCAAA\nCTATATGGAAATGGATTTGAAGAAGTACAAAGTCATGCATTCAATGGGACGACACTGACT\nTCACTGGAGCTAAAGGAAAACGTACATCTGGAGAAGATGCACAATGGAGCCTTCCGTGGG\nGCCACAGGGCCGAAAACCTTGGATATTTCTTCCACCAAATTGCAGGCCCTGCCGAGCTAT\nGGCCTAGAGTCCATTCAGAGGCTAATTGCCACGTCATCCTATTCTCTAAAAAAATTGCCA\nTCAAGAGAAACATTTGTCAATCTCCTGGAGGCCACGTTGACTTACCCCAGCCACTGCTGT\nGCTTTTAGAAACTTGCCAACAAAAGAACAGAATTTTTCACATTCCATTTCTGAAAACTTT\nTCCAAACAATGTGAAAGCACAGTAAGGAAAGTGAATAACAAAACACTTTATTCTTCCATG\nCTTGCTGAGAGTGAACTGAGTGGCTGGGACTATGAATATGGTTTCTGCTTACCCAAGACA\nCCCCGATGTGCTCCTGAACCAGATGCTTTTAATCCCTGTGAAGATATTATGGGCTATGAC\nTTCCTTAGGGTCCTGATTTGGCTGATTAATATTCTAGCCATCATGGGAAACATGACTGTT\nCTTTTTGTTCTCCTGACAAGTCGTTACAAACTTACAGTGCCTCGTTTTCTCATGTGCAAT\nCTCTCCTTTGCAGACTTTTGCATGGGGCTCTATCTGCTGCTCATAGCCTCAGTTGATTCC\nCAAACCAAGGGCCAGTACTATAACCATGCCATAGACTGGCAGACAGGGAGTGGGTGCAGC\nACTGCTGGCTTTTTCACTGTATTCGCAAGTGAACTTTCTGTCTACACCCTCACCGTCATC\nACTCTAGAAAGATGGCACACCATCACCTATGCTATTCACCTGGACCAAAAGCTGCGATTA\nAGACATGCCATTCTGATTATGCTTGGAGGATGGCTCTTTTCTTCTCTAATTGCTATGTTG\nCCCCTTGTCGGTGTCAGCAATTACATGAAGGTCAGTATTTGCTTCCCCATGGATGTGGAA\nACCACTCTCTCACAAGTCTATATATTAACCATCCTGATTCTCAATGTGGTGGCCTTCTTC\nATAATTTGTGCTTGCTACATTAAAATTTATTTTGCAGTTCGAAACCCAGAATTAATGGCT\nACCAATAAAGATACAAAGATTGCTAAGAAAATGGCAATCCTCATCTTCACCGATTTCACC\nTGCATGGCACCTATCTCTTTTTTTGCCATCTCAGCTGCCTTCAAAGTACCTCTTATCACA\nGTAACCAACTCTAAAGTTTTACTGGTTCTTTTTTATCCCATCAATTCTTGTGCCAATCCA\nTTTCTGTATGCAATATTCACTAAGACATTCCAAAGAGATTTCTTTCTTTTGCTGAGCAAA\nTTTGGCTGCTGTAAACGTCGGGCTGAACTTTATAGAAGGAAAGATTTTTCAGCTTACACC\nTCCAACTGCAAAAATGGCTTCACTGGATCAAATAAGCCTTCTCAATCCACCTTGAAGTTG\nTCCACATTGCACTGTCAAGGTACAGCTCTCCTAGACAAGACTCGCTACACAGAGTGTTAA\n'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}, {'identifier': ['PF13306'], 'name': ['LRR_5']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['choriogonadotropin hormone binding']}, {'category': ['function'], 'description': ['choriogonadotropin hormone receptor activity']}, {'category': ['function'], 'description': ['G-protein coupled peptide receptor activity']}, {'category': ['function'], 'description': ['luteinizing hormone receptor activity']}, {'category': ['process'], 'description': ['activation of adenylate cyclase activity']}, {'category': ['process'], 'description': ['adenylate cyclase-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular response to gonadotropin stimulus']}, {'category': ['process'], 'description': ['cognition']}, {'category': ['process'], 'description': ['female gonad development']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger']}, {'category': ['process'], 'description': ['hormone-mediated signaling pathway']}, {'category': ['process'], 'description': ['luteinizing hormone signaling pathway']}, {'category': ['process'], 'description': ['male genitalia development']}, {'category': ['process'], 'description': ['male gonad development']}, {'category': ['process'], 'description': ['ovulation cycle process']}, {'category': ['process'], 'description': ['phospholipase C-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of cAMP-mediated signaling']}, {'category': ['process'], 'description': ['positive regulation of inositol trisphosphate biosynthetic process']}, {'category': ['process'], 'description': ['spermatogenesis']}, {'category': ['process'], 'description': ['uterus development']}]}]}]}]}]"
"['DB00045', 'BTD00054', 'BIOD00054']",['Lyme disease vaccine (recombinant OspA)'],biotech,"['Vaccine against Lyme disease that contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli. Lipoprotein OspA is a single polypeptide chain of 257 amino acids with lipids covalently bonded to the N terminus. It is conjugated with alum (aluminum hydroxide) as an adjuvant.']",['liquid'],['For prophylactic treatment of Lyme Disease'],"['OspA lipoprotein, an outer surface protein of the bacteria Borrelia burgdorferi sensu stricto ZS7, is used to stimulate the production of specific antibodies against B. burgdorferi. It is used as a vaccination against Lyme Disease, a disease carried by ticks.']",[None],"[{'target': [{'id': ['BE0001164'], 'name': ['Toll-like receptor 2'], 'organism': ['Humans'], 'actions': [{'action': ['other/unknown']}], 'references': [{'articles': [{'article': [{'ref-id': ['A15360'], 'pubmed-id': ['14617145'], 'citation': ['Welty DM, Snyder DS: Internalization of OspA in rsCD14 complex and aggregated forms. Mol Microbiol. 2003 Nov;50(3):835-43.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Toll-like receptor 2'], 'general-function': ['Triacyl lipopeptide binding'], 'specific-function': ['Cooperates with LY96 to mediate the innate immune response to bacterial lipoproteins and other microbial cell wall components. Cooperates with TLR1 or TLR6 to mediate the innate immune response to bacterial lipoproteins or lipopeptides (PubMed:17889651). Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. May also promote apoptosis in response to lipoproteins (PubMed:10426996). Recognizes mycoplasmal macrophage-activating lipopeptide-2kD (MALP-2), soluble tuberculosis factor (STF), phenol-soluble modulin (PSM) and B.burgdorferi outer surface protein A lipoprotein (OspA-L) cooperatively with TLR6 (PubMed:11441107). Acts as a receptor for M.tuberculosis lipoproteins LprA, LprG, LpqH and PhoS1 (pstS1), some lipoproteins are dependent on other coreceptors (TLR1, CD14 and/or CD36).The lipoproteins act as agonists to modulate antigen presenting cell functions in response to the pathogen (PubMed:19362712). Forms activation clusters composed of several receptors depending on the ligand, these clusters trigger signaling from the cell surface and subsequently are targeted to the Golgi in a lipid-raft dependent pathway. Forms the cluster TLR2:TLR6:CD14:CD36 in response to diacylated lipopeptides and TLR2:TLR1:CD14 in response to triacylated lipopeptides (PubMed:16880211).'], 'gene-name': ['TLR2'], 'locus': ['4q32'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['589-609'], 'signal-regions': ['1-18'], 'theoretical-pi': ['6.59'], 'molecular-weight': ['89836.575'], 'chromosome-location': ['4'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:11848']}, {'resource': ['GenAtlas'], 'identifier': ['TLR2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['AF051152']}, {'resource': ['GenBank Protein Database'], 'identifier': ['3132528']}, {'resource': ['UniProtKB'], 'identifier': ['O60603']}, {'resource': ['UniProt Accession'], 'identifier': ['TLR2_HUMAN']}]}], 'synonyms': [{'synonym': ['TIL4', 'Toll/interleukin-1 receptor-like protein 4']}], 'amino-acid-sequence': ['>lcl|BSEQ0010812|Toll-like receptor 2\nMPHTLWMVWVLGVIISLSKEESSNQASLSCDRNGICKGSSGSLNSIPSGLTEAVKSLDLS\nNNRITYISNSDLQRCVNLQALVLTSNGINTIEEDSFSSLGSLEHLDLSYNYLSNLSSSWF\nKPLSSLTFLNLLGNPYKTLGETSLFSHLTKLQILRVGNMDTFTKIQRKDFAGLTFLEELE\nIDASDLQSYEPKSLKSIQNVSHLILHMKQHILLLEIFVDVTSSVECLELRDTDLDTFHFS\nELSTGETNSLIKKFTFRNVKITDESLFQVMKLLNQISGLLELEFDDCTLNGVGNFRASDN\nDRVIDPGKVETLTIRRLHIPRFYLFYDLSTLYSLTERVKRITVENSKVFLVPCLLSQHLK\nSLEYLDLSENLMVEEYLKNSACEDAWPSLQTLILRQNHLASLEKTGETLLTLKNLTNIDI\nSKNSFHSMPETCQWPEKMKYLNLSSTRIHSVTGCIPKTLEILDVSNNNLNLFSLNLPQLK\nELYISRNKLMTLPDASLLPMLLVLKISRNAITTFSKEQLDSFHTLKTLEAGGNNFICSCE\nFLSFTQEQQALAKVLIDWPANYLCDSPSHVRGQQVQDVRLSVSECHRTALVSGMCCALFL\nLILLTGVLCHRFHGLWYMKMMWAWLQAKRKPRKAPSRNICYDAFVSYSERDAYWVENLMV\nQELENFNPPFKLCLHKRDFIPGKWIIDNIIDSIEKSHKTVFVLSENFVKSEWCKYELDFS\nHFRLFDENNDAAILILLEPIEKKAIPQRFCKLRKIMNTKTYLEWPMDEAQREGFWVNLRA\nAIKS'], 'gene-sequence': ['>lcl|BSEQ0010813|Toll-like receptor 2 (TLR2)\nATGCCACATACTTTGTGGATGGTGTGGGTCTTGGGGGTCATCATCAGCCTCTCCAAGGAA\nGAATCCTCCAATCAGGCTTCTCTGTCTTGTGACCGCAATGGTATCTGCAAGGGCAGCTCA\nGGATCTTTAAACTCCATTCCCTCAGGGCTCACAGAAGCTGTAAAAAGCCTTGACCTGTCC\nAACAACAGGATCACCTACATTAGCAACAGTGACCTACAGAGGTGTGTGAACCTCCAGGCT\nCTGGTGCTGACATCCAATGGAATTAACACAATAGAGGAAGATTCTTTTTCTTCCCTGGGC\nAGTCTTGAACATTTAGACTTATCCTATAATTACTTATCTAATTTATCGTCTTCCTGGTTC\nAAGCCCCTTTCTTCTTTAACATTCTTAAACTTACTGGGAAATCCTTACAAAACCCTAGGG\nGAAACATCTCTTTTTTCTCATCTCACAAAATTGCAAATCCTGAGAGTGGGAAATATGGAC\nACCTTCACTAAGATTCAAAGAAAAGATTTTGCTGGACTTACCTTCCTTGAGGAACTTGAG\nATTGATGCTTCAGATCTACAGAGCTATGAGCCAAAAAGTTTGAAGTCAATTCAGAATGTA\nAGTCATCTGATCCTTCATATGAAGCAGCATATTTTACTGCTGGAGATTTTTGTAGATGTT\nACAAGTTCCGTGGAATGTTTGGAACTGCGAGATACTGATTTGGACACTTTCCATTTTTCA\nGAACTATCCACTGGTGAAACAAATTCATTGATTAAAAAGTTTACATTTAGAAATGTGAAA\nATCACCGATGAAAGTTTGTTTCAGGTTATGAAACTTTTGAATCAGATTTCTGGATTGTTA\nGAATTAGAGTTTGATGACTGTACCCTTAATGGAGTTGGTAATTTTAGAGCATCTGATAAT\nGACAGAGTTATAGATCCAGGTAAAGTGGAAACGTTAACAATCCGGAGGCTGCATATTCCA\nAGGTTTTACTTATTTTATGATCTGAGCACTTTATATTCACTTACAGAAAGAGTTAAAAGA\nATCACAGTAGAAAACAGTAAAGTTTTTCTGGTTCCTTGTTTACTTTCACAACATTTAAAA\nTCATTAGAATACTTGGATCTCAGTGAAAATTTGATGGTTGAAGAATACTTGAAAAATTCA\nGCCTGTGAGGATGCCTGGCCCTCTCTACAAACTTTAATTTTAAGGCAAAATCATTTGGCA\nTCATTGGAAAAAACCGGAGAGACTTTGCTCACTCTGAAAAACTTGACTAACATTGATATC\nAGTAAGAATAGTTTTCATTCTATGCCTGAAACTTGTCAGTGGCCAGAAAAGATGAAATAT\nTTGAACTTATCCAGCACACGAATACACAGTGTAACAGGCTGCATTCCCAAGACACTGGAA\nATTTTAGATGTTAGCAACAACAATCTCAATTTATTTTCTTTGAATTTGCCGCAACTCAAA\nGAACTTTATATTTCCAGAAATAAGTTGATGACTCTACCAGATGCCTCCCTCTTACCCATG\nTTACTAGTATTGAAAATCAGTAGGAATGCAATAACTACGTTTTCTAAGGAGCAACTTGAC\nTCATTTCACACACTGAAGACTTTGGAAGCTGGTGGCAATAACTTCATTTGCTCCTGTGAA\nTTCCTCTCCTTCACTCAGGAGCAGCAAGCACTGGCCAAAGTCTTGATTGATTGGCCAGCA\nAATTACCTGTGTGACTCTCCATCCCATGTGCGTGGCCAGCAGGTTCAGGATGTCCGCCTC\nTCGGTGTCGGAATGTCACAGGACAGCACTGGTGTCTGGCATGTGCTGTGCTCTGTTCCTG\nCTGATCCTGCTCACGGGGGTCCTGTGCCACCGTTTCCATGGCCTGTGGTATATGAAAATG\nATGTGGGCCTGGCTCCAGGCCAAAAGGAAGCCCAGGAAAGCTCCCAGCAGGAACATCTGC\nTATGATGCATTTGTTTCTTACAGTGAGCGGGATGCCTACTGGGTGGAGAACCTTATGGTC\nCAGGAGCTGGAGAACTTCAATCCCCCCTTCAAGTTGTGTCTTCATAAGCGGGACTTCATT\nCCTGGCAAGTGGATCATTGACAATATCATTGACTCCATTGAAAAGAGCCACAAAACTGTC\nTTTGTGCTTTCTGAAAACTTTGTGAAGAGTGAGTGGTGCAAGTATGAACTGGACTTCTCC\nCATTTCCGTCTTTTTGATGAGAACAATGATGCTGCCATTCTCATTCTTCTGGAGCCCATT\nGAGAAAAAAGCCATTCCCCAGCGCTTCTGCAAGCTGCGGAAGATAATGAACACCAAGACC\nTACCTGGAGTGGCCCATGGACGAGGCTCAGCGGGAAGGATTTTGGGTAAATCTGAGAGCT\nGCGATAAAGTCCTAG'], 'pfams': [{'pfam': [{'identifier': ['PF01463'], 'name': ['LRRCT']}, {'identifier': ['PF01582'], 'name': ['TIR']}, {'identifier': ['PF13855'], 'name': ['LRR_8']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['Golgi apparatus']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intrinsic component of plasma membrane']}, {'category': ['component'], 'description': ['membrane raft']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['Toll-like receptor 1-Toll-like receptor 2 protein complex']}, {'category': ['component'], 'description': ['Toll-like receptor 2-Toll-like receptor 6 protein complex']}, {'category': ['function'], 'description': ['diacyl lipopeptide binding']}, {'category': ['function'], 'description': ['lipopolysaccharide binding']}, {'category': ['function'], 'description': ['lipopolysaccharide receptor activity']}, {'category': ['function'], 'description': ['lipoteichoic acid binding']}, {'category': ['function'], 'description': ['peptidoglycan binding']}, {'category': ['function'], 'description': ['protein heterodimerization activity']}, {'category': ['function'], 'description': ['receptor activity']}, {'category': ['function'], 'description': ['signaling pattern recognition receptor activity']}, {'category': ['function'], 'description': ['Toll-like receptor binding']}, {'category': ['function'], 'description': ['transmembrane signaling receptor activity']}, {'category': ['function'], 'description': ['triacyl lipopeptide binding']}, {'category': ['process'], 'description': ['apoptotic process']}, {'category': ['process'], 'description': ['cell surface pattern recognition receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular response to bacterial lipopeptide']}, {'category': ['process'], 'description': ['cellular response to diacyl bacterial lipopeptide']}, {'category': ['process'], 'description': ['cellular response to lipoteichoic acid']}, {'category': ['process'], 'description': ['cellular response to peptidoglycan']}, {'category': ['process'], 'description': ['cellular response to triacyl bacterial lipopeptide']}, {'category': ['process'], 'description': ['chloramphenicol transport']}, {'category': ['process'], 'description': ['cytokine secretion involved in immune response']}, {'category': ['process'], 'description': ['defense response to Gram-positive bacterium']}, {'category': ['process'], 'description': ['detection of diacyl bacterial lipopeptide']}, {'category': ['process'], 'description': ['detection of triacyl bacterial lipopeptide']}, {'category': ['process'], 'description': ['I-kappaB phosphorylation']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['induction by symbiont of defense-related host nitric oxide production']}, {'category': ['process'], 'description': ['inflammatory response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['interleukin-10 production']}, {'category': ['process'], 'description': ['lipopolysaccharide-mediated signaling pathway']}, {'category': ['process'], 'description': ['MyD88-dependent toll-like receptor signaling pathway']}, {'category': ['process'], 'description': ['negative regulation of growth of symbiont in host']}, {'category': ['process'], 'description': ['negative regulation of interleukin-12 production']}, {'category': ['process'], 'description': ['negative regulation of interleukin-17 production']}, {'category': ['process'], 'description': ['positive regulation of chemokine production']}, {'category': ['process'], 'description': ['positive regulation of cytokine secretion']}, {'category': ['process'], 'description': ['positive regulation of gene expression']}, {'category': ['process'], 'description': ['positive regulation of inflammatory response']}, {'category': ['process'], 'description': ['positive regulation of interferon-beta production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-12 production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-18 production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-6 production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-8 production']}, {'category': ['process'], 'description': ['positive regulation of leukocyte migration']}, {'category': ['process'], 'description': ['positive regulation of macrophage cytokine production']}, {'category': ['process'], 'description': ['positive regulation of NF-kappaB import into nucleus']}, {'category': ['process'], 'description': ['positive regulation of NF-kappaB transcription factor activity']}, {'category': ['process'], 'description': ['positive regulation of nitric oxide biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of nitric-oxide synthase biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of toll-like receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['positive regulation of tumor necrosis factor biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of tumor necrosis factor production']}, {'category': ['process'], 'description': ['positive regulation of Wnt signaling pathway']}, {'category': ['process'], 'description': ['regulation of dendritic cell cytokine production']}, {'category': ['process'], 'description': ['response to molecule of fungal origin']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['toll-like receptor 2 signaling pathway']}, {'category': ['process'], 'description': ['toll-like receptor 4 signaling pathway']}, {'category': ['process'], 'description': ['toll-like receptor signaling pathway']}, {'category': ['process'], 'description': ['toll-like receptor TLR1']}, {'category': ['process'], 'description': ['toll-like receptor TLR6']}]}]}]}]}]"
"['DB00046', 'BTD00065', 'BIOD00065', 'DB01310']",['Insulin lispro'],biotech,"['Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.\r\n\r\nInsulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin lispro, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually cause cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after several oral medications such as [DB00331], [DB01120], or [DB01261] have been tried, and when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own. \r\n\r\nMarketed as the brand name product Humalog, insulin lispro begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. Due to its duration of action of around 5 hours, Humalog is considered ""bolus insulin"" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals. Bolus insulin is often combined with once daily, long-acting ""basal insulin"" such as [DB01307], [DB09564], or [DB00047] to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Use of basal and bolus insulin together is intended to mimic the pancreas\' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia.\r\n\r\nInsulin lispro is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli and was the first commercially available insulin analog. Formerly called LYSPRO from the chemical nomenclature [LYS(B28), PRO(B29)], insulin lispro differs from human insulin in that the amino acid proline at position B28 is replaced by lysine and the lysine in position B29 is replaced by proline. These biochemical changes result in a reduced tendency for self-association resulting in dissolution to a dimer and then to a monomer that is absorbed more rapidly after subcutaneous injection compared to endogenous human insulin. \r\n\r\nWithout an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.']",['liquid'],['Insulin lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.[L47616]'],"['Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and <i>m</i>-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties. ']",[None],"[{'target': [{'id': ['BE0000033'], 'name': ['Insulin receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A15263'], 'pubmed-id': ['8964871'], 'citation': ['Jehle PM, Fussgaenger RD, Kunze U, Dolderer M, Warchol W, Koop I: The human insulin analog insulin lispro improves insulin binding on circulating monocytes of intensively treated insulin-dependent diabetes mellitus patients. J Clin Endocrinol Metab. 1996 Jun;81(6):2319-27.']}, {'ref-id': ['A15264'], 'pubmed-id': ['8937933'], 'citation': ['Jehle PM, Fussganger RD, Seibold A, Luttke B, Bohm BO: Pharmacodynamics of insulin Lispro in 2 patients with type II diabetes mellitus. Int J Clin Pharmacol Ther. 1996 Nov;34(11):498-503.']}, {'ref-id': ['A1927'], 'pubmed-id': ['20424816'], 'citation': ['Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, Squatrito S, Vigneri R: Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia. 2010 Aug;53(8):1743-53. doi: 10.1007/s00125-010-1760-6. Epub 2010 Apr 28.']}, {'ref-id': ['A231659'], 'pubmed-id': ['27512793'], 'citation': ['De Meyts P: The Insulin Receptor and Its Signal Transduction Network .']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Insulin receptor'], 'general-function': ['Receptor signaling protein tyrosine kinase activity'], 'specific-function': ['Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosines residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.'], 'gene-name': ['INSR'], 'locus': ['19p13.3-p13.2'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['957-979'], 'signal-regions': ['1-27'], 'theoretical-pi': ['6.18'], 'molecular-weight': ['156331.465'], 'chromosome-location': ['19'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6091']}, {'resource': ['GenAtlas'], 'identifier': ['INSR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M10051']}, {'resource': ['GenBank Protein Database'], 'identifier': ['307070']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1800']}, {'resource': ['UniProtKB'], 'identifier': ['P06213']}, {'resource': ['UniProt Accession'], 'identifier': ['INSR_HUMAN']}]}], 'synonyms': [{'synonym': ['2.7.10.1', 'IR']}], 'amino-acid-sequence': ['>lcl|BSEQ0036940|Insulin receptor\nMATGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHL\nQILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYAL\nVIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNE\nECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECL\nGNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQG\nCHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGC\nTVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETL\nEIGNYSFYALDNQNLRQLWDWSKHNLTITQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQE\nRNDIALKTNGDQASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQ\nNVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFS\nDERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWE\nRQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQIL\nKELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAF\nPNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYV\nSARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCV\nSRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIG\nPLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSR\nEKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKG\nFTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMA\nAEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPV\nRWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDN\nCPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEME\nFEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSN\nPS'], 'gene-sequence': ['>lcl|BSEQ0020443|Insulin receptor (INSR)\nATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCG\nCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATC\nCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTG\nCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAA\nCTCATCATGATCACTGATTACTTGCTGCTCTTCCGGGTCTATGGGCTCGAGAGCCTGAAG\nGACCTGTTCCCCAACCTCACGGTCATCCGGGGATCACGACTGTTCTTTAACTACGCGCTG\nGTCATCTTCGAGATGGTTCACCTCAAGGAACTCGGCCTCTACAACCTGATGAACATCACC\nCGGGGTTCTGTCCGCATCGAGAAGAACAATGAGCTCTGTTACTTGGCCACTATCGACTGG\nTCCCGTATCCTGGATTCCGTGGAGGATAATTACATCGTGTTGAACAAAGATGACAACGAG\nGAGTGTGGAGACATCTGTCCGGGTACCGCGAAGGGCAAGACCAACTGCCCCGCCACCGTC\nATCAACGGGCAGTTTGTCGAACGATGTTGGACTCATAGTCACTGCCAGAAAGTTTGCCCG\nACCATCTGTAAGTCACACGGCTGCACCGCCGAAGGCCTCTGTTGCCACAGCGAGTGCCTG\nGGCAACTGTTCTCAGCCCGACGACCCCACCAAGTGCGTGGCCTGCCGCAACTTCTACCTG\nGACGGCAGGTGTGTGGAGACCTGCCCGCCCCCGTACTACCACTTCCAGGACTGGCGCTGT\nGTGAACTTCAGCTTCTGCCAGGACCTGCACCACAAATGCAAGAACTCGCGGAGGCAGGGC\nTGCCACCAGTACGTCATTCACAACAACAAGTGCATCCCTGAGTGTCCCTCCGGGTACACG\nATGAATTCCAGCAACTTGCTGTGCACCCCATGCCTGGGTCCCTGTCCCAAGGTGTGCCAC\nCTCCTAGAAGGCGAGAAGACCATCGACTCGGTGACGTCTGCCCAGGAGCTCCGAGGATGC\nACCGTCATCAACGGGAGTCTGATCATCAACATTCGAGGAGGCAACAATCTGGCAGCTGAG\nCTAGAAGCCAACCTCGGCCTCATTGAAGAAATTTCAGGGTATCTAAAAATCCGCCGATCC\nTACGCTCTGGTGTCACTTTCCTTCTTCCGGAAGTTACGTCTGATTCGAGGAGAGACCTTG\nGAAATTGGGAACTACTCCTTCTATGCCTTGGACAACCAGAACCTAAGGCAGCTCTGGGAC\nTGGAGCAAACACAACCTCACCATCACTCAGGGGAAACTCTTCTTCCACTATAACCCCAAA\nCTCTGCTTGTCAGAAATCCACAAGATGGAAGAAGTTTCAGGAACCAAGGGGCGCCAGGAG\nAGAAACGACATTGCCCTGAAGACCAATGGGGACCAGGCATCCTGTGAAAATGAGTTACTT\nAAATTTTCTTACATTCGGACATCTTTTGACAAGATCTTGCTGAGATGGGAGCCGTACTGG\nCCCCCCGACTTCCGAGACCTCTTGGGGTTCATGCTGTTCTACAAAGAGGCCCCTTATCAG\nAATGTGACGGAGTTCGACGGGCAGGATGCGTGTGGTTCCAACAGTTGGACGGTGGTAGAC\nATTGACCCACCCCTGAGGTCCAACGACCCCAAATCACAGAACCACCCAGGGTGGCTGATG\nCGGGGTCTCAAGCCCTGGACCCAGTATGCCATCTTTGTGAAGACCCTGGTCACCTTTTCG\nGATGAACGCCGGACCTATGGGGCCAAGAGTGACATCATTTATGTCCAGACAGATGCCACC\nAACCCCTCTGTGCCCCTGGATCCAATCTCAGTGTCTAACTCATCATCCCAGATTATTCTG\nAAGTGGAAACCACCCTCCGACCCCAATGGCAACATCACCCACTACCTGGTTTTCTGGGAG\nAGGCAGGCGGAAGACAGTGAGCTGTTCGAGCTGGATTATTGCCTCAAAGGGCTGAAGCTG\nCCCTCGAGGACCTGGTCTCCACCATTCGAGTCTGAAGATTCTCAGAAGCACAACCAGAGT\nGAGTATGAGGATTCGGCCGGCGAATGCTGCTCCTGTCCAAAGACAGACTCTCAGATCCTG\nAAGGAGCTGGAGGAGTCCTCGTTTAGGAAGACGTTTGAGGATTACCTGCACAACGTGGTT\nTTCGTCCCCAGAAAAACCTCTTCAGGCACTGGTGCCGAGGACCCTAGGCCATCTCGGAAA\nCGCAGGTCCCTTGGCGATGTTGGGAATGTGACGGTGGCCGTGCCCACGGTGGCAGCTTTC\nCCCAACACTTCCTCGACCAGCGTGCCCACGAGTCCGGAGGAGCACAGGCCTTTTGAGAAG\nGTGGTGAACAAGGAGTCGCTGGTCATCTCCGGCTTGCGACACTTCACGGGCTATCGCATC\nGAGCTGCAGGCTTGCAACCAGGACACCCCTGAGGAACGGTGCAGTGTGGCAGCCTACGTC\nAGTGCGAGGACCATGCCTGAAGCCAAGGCTGATGACATTGTTGGCCCTGTGACGCATGAA\nATCTTTGAGAACAACGTCGTCCACTTGATGTGGCAGGAGCCGAAGGAGCCCAATGGTCTG\nATCGTGCTGTATGAAGTGAGTTATCGGCGATATGGTGATGAGGAGCTGCATCTCTGCGTC\nTCCCGCAAGCACTTCGCTCTGGAACGGGGCTGCAGGCTGCGTGGGCTGTCACCGGGGAAC\nTACAGCGTGCGAATCCGGGCCACCTCCCTTGCGGGCAACGGCTCTTGGACGGAACCCACC\nTATTTCTACGTGACAGACTATTTAGACGTCCCGTCAAATATTGCAAAAATTATCATCGGC\nCCCCTCATCTTTGTCTTTCTCTTCAGTGTTGTGATTGGAAGTATTTATCTATTCCTGAGA\nAAGAGGCAGCCAGATGGGCCGCTGGGACCGCTTTACGCTTCTTCAAACCCTGAGTATCTC\nAGTGCCAGTGATGTGTTTCCATGCTCTGTGTACGTGCCGGACGAGTGGGAGGTGTCTCGA\nGAGAAGATCACCCTCCTTCGAGAGCTGGGGCAGGGCTCCTTCGGCATGGTGTATGAGGGC\nAATGCCAGGGACATCATCAAGGGTGAGGCAGAGACCCGCGTGGCGGTGAAGACGGTCAAC\nGAGTCAGCCAGTCTCCGAGAGCGGATTGAGTTCCTCAATGAGGCCTCGGTCATGAAGGGC\nTTCACCTGCCATCACGTGGTGCGCCTCCTGGGAGTGGTGTCCAAGGGCCAGCCCACGCTG\nGTGGTGATGGAGCTGATGGCTCACGGAGACCTGAAGAGCTACCTCCGTTCTCTGCGGCCA\nGAGGCTGAGAATAATCCTGGCCGCCCTCCCCCTACCCTTCAAGAGATGATTCAGATGGCG\nGCAGAGATTGCTGACGGGATGGCCTACCTGAACGCCAAGAAGTTTGTGCATCGGGACCTG\nGCAGCGAGAAACTGCATGGTCGCCCATGATTTTACTGTCAAAATTGGAGACTTTGGAATG\nACCAGAGACATCTATGAAACGGATTACTACCGGAAAGGGGGCAAGGGTCTGCTCCCTGTA\nCGGTGGATGGCACCGGAGTCCCTGAAGGATGGGGTCTTCACCACTTCTTCTGACATGTGG\nTCCTTTGGCGTGGTCCTTTGGGAAATCACCAGCTTGGCAGAACAGCCTTACCAAGGCCTG\nTCTAATGAACAGGTGTTGAAATTTGTCATGGATGGAGGGTATCTGGATCAACCCGACAAC\nTGTCCAGAGAGAGTCACTGACCTCATGCGCATGTGCTGGCAATTCAACCCCAAGATGAGG\nCCAACCTTCCTGGAGATTGTCAACCTGCTCAAGGACGACCTGCACCCCAGCTTTCCAGAG\nGTGTCGTTCTTCCACAGCGAGGAGAACAAGGCTCCCGAGAGTGAGGAGCTGGAGATGGAG\nTTTGAGGACATGGAGAATGTGCCCCTGGACCGTTCCTCGCACTGTCAGAGGGAGGAGGCG\nGGGGGCCGGGATGGAGGGTCCTCGCTGGGTTTCAAGCGGAGCTACGAGGAACACATCCCT\nTACACACACATGAACGGAGGCAAGAAAAACGGGCGGATTCTGACCTTGCCTCGGTCCAAT\nCCTTCCTAA'], 'pfams': [{'pfam': [{'identifier': ['PF07714'], 'name': ['PK_Tyr_Ser-Thr']}, {'identifier': ['PF00041'], 'name': ['fn3']}, {'identifier': ['PF00757'], 'name': ['Furin-like']}, {'identifier': ['PF01030'], 'name': ['Recep_L_domain']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['caveola']}, {'category': ['component'], 'description': ['endosome membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['insulin receptor complex']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular membrane-bounded organelle']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['function'], 'description': ['ATP binding']}, {'category': ['function'], 'description': ['GTP binding']}, {'category': ['function'], 'description': ['insulin binding']}, {'category': ['function'], 'description': ['insulin receptor substrate binding']}, {'category': ['function'], 'description': ['insulin-activated receptor activity']}, {'category': ['function'], 'description': ['insulin-like growth factor I binding']}, {'category': ['function'], 'description': ['insulin-like growth factor II binding']}, {'category': ['function'], 'description': ['insulin-like growth factor receptor binding']}, {'category': ['function'], 'description': ['phosphatidylinositol 3-kinase binding']}, {'category': ['function'], 'description': ['protein tyrosine kinase activity']}, {'category': ['function'], 'description': ['PTB domain binding']}, {'category': ['function'], 'description': ['receptor signaling protein tyrosine kinase activity']}, {'category': ['process'], 'description': ['activation of MAPK activity']}, {'category': ['process'], 'description': ['activation of protein kinase activity']}, {'category': ['process'], 'description': ['activation of protein kinase B activity']}, {'category': ['process'], 'description': ['adrenal gland development']}, {'category': ['process'], 'description': ['carbohydrate metabolic process']}, {'category': ['process'], 'description': ['cellular response to growth factor stimulus']}, {'category': ['process'], 'description': ['cellular response to insulin stimulus']}, {'category': ['process'], 'description': ['epidermis development']}, {'category': ['process'], 'description': ['exocrine pancreas development']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['glucose homeostasis']}, {'category': ['process'], 'description': ['heart morphogenesis']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['male gonad development']}, {'category': ['process'], 'description': ['male sex determination']}, {'category': ['process'], 'description': ['peptidyl-tyrosine autophosphorylation']}, {'category': ['process'], 'description': ['peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of developmental growth']}, {'category': ['process'], 'description': ['positive regulation of DNA replication']}, {'category': ['process'], 'description': ['positive regulation of glucose import']}, {'category': ['process'], 'description': ['positive regulation of glycogen biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of glycolytic process']}, {'category': ['process'], 'description': ['positive regulation of MAPK cascade']}, {'category': ['process'], 'description': ['positive regulation of meiotic cell cycle']}, {'category': ['process'], 'description': ['positive regulation of mitotic nuclear division']}, {'category': ['process'], 'description': ['positive regulation of nitric oxide biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of respiratory burst']}, {'category': ['process'], 'description': ['positive regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['protein autophosphorylation']}, {'category': ['process'], 'description': ['protein heterotetramerization']}, {'category': ['process'], 'description': ['regulation of embryonic development']}, {'category': ['process'], 'description': ['regulation of female gonad development']}, {'category': ['process'], 'description': ['regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['signal transduction by protein phosphorylation']}, {'category': ['process'], 'description': ['transformation of host cell by virus']}]}]}]}, {'id': ['BE0000858'], 'name': ['Insulin-like growth factor 1 receptor'], 'organism': ['Humans'], 'actions': [{'action': ['activator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A174883'], 'pubmed-id': ['22420005'], 'citation': ['Varewijck AJ, Janssen JA: Insulin and its analogues and their affinities for the IGF1 receptor. Endocr Relat Cancer. 2012 Sep 5;19(5):F63-75. doi: 10.1530/ERC-12-0026. Print 2012 Oct.']}, {'ref-id': ['A231649'], 'pubmed-id': ['31771180'], 'citation': ['Sarfstein R, Nagaraj K, LeRoith D, Werner H: Differential Effects of Insulin and IGF1 Receptors on ERK and AKT Subcellular Distribution in Breast Cancer Cells. Cells. 2019 Nov 23;8(12). pii: cells8121499. doi: 10.3390/cells8121499.']}, {'ref-id': ['A231654'], 'pubmed-id': ['25905175'], 'citation': ['Donner T, Sarkar S: Insulin - Pharmacology, Therapeutic Regimens, and Principles of Intensive Insulin Therapy .']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Insulin-like growth factor 1 receptor'], 'general-function': ['Protein tyrosine kinase activity'], 'specific-function': ['Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.'], 'gene-name': ['IGF1R'], 'locus': ['15q26.3'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['936-959'], 'signal-regions': ['1-30'], 'theoretical-pi': ['5.54'], 'molecular-weight': ['154791.73'], 'chromosome-location': ['15'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5465']}, {'resource': ['GenAtlas'], 'identifier': ['IGF1R']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X04434']}, {'resource': ['GenBank Protein Database'], 'identifier': ['804990']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1801']}, {'resource': ['UniProtKB'], 'identifier': ['P08069']}, {'resource': ['UniProt Accession'], 'identifier': ['IGF1R_HUMAN']}]}], 'synonyms': [{'synonym': ['2.7.10.1', 'IGF-I receptor', 'Insulin-like growth factor I receptor']}], 'amino-acid-sequence': ['>lcl|BSEQ0001710|Insulin-like growth factor 1 receptor\nMKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLH\nILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIF\nEMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGD\nLCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCS\nAPDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHD\nGECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNL\nLINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSF\nYVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTR\nNNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDG\nQDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSE\nILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRH\nNYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRK\nVFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFES\nRVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTW\nEPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGN\nYTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHR\nKRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKG\nVVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIME\nLMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARN\nCMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGV\nVLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL\nEIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRH\nSGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC'], 'gene-sequence': ['>lcl|BSEQ0020490|Insulin-like growth factor 1 receptor (IGF1R)\nATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCC\nGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGC\nAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCAC\nATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTC\nATTACCGAGTACTTGCTGCTGTTCCGAGTGGCTGGCCTCGAGAGCCTCGGAGACCTCTTC\nCCCAACCTCACGGTCATCCGCGGCTGGAAACTCTTCTACAACTACGCCCTGGTCATCTTC\nGAGATGACCAATCTCAAGGATATTGGGCTTTACAACCTGAGGAACATTACTCGGGGGGCC\nATCAGGATTGAGAAAAATGCTGACCTCTGTTACCTCTCCACTGTGGACTGGTCCCTGATC\nCTGGATGCGGTGTCCAATAACTACATTGTGGGGAATAAGCCCCCAAAGGAATGTGGGGAC\nCTGTGTCCAGGGACCATGGAGGAGAAGCCGATGTGTGAGAAGACCACCATCAACAATGAG\nTACAACTACCGCTGCTGGACCACAAACCGCTGCCAGAAAATGTGCCCAAGCACGTGTGGG\nAAGCGGGCGTGCACCGAGAACAATGAGTGCTGCCACCCCGAGTGCCTGGGCAGCTGCAGC\nGCGCCTGACAACGACACGGCCTGTGTAGCTTGCCGCCACTACTACTATGCCGGTGTCTGT\nGTGCCTGCCTGCCCGCCCAACACCTACAGGTTTGAGGGCTGGCGCTGTGTGGACCGTGAC\nTTCTGCGCCAACATCCTCAGCGCCGAGAGCAGCGACTCCGAGGGGTTTGTGATCCACGAC\nGGCGAGTGCATGCAGGAGTGCCCCTCGGGCTTCATCCGCAACGGCAGCCAGAGCATGTAC\nTGCATCCCTTGTGAAGGTCCTTGCCCGAAGGTCTGTGAGGAAGAAAAGAAAACAAAGACC\nATTGATTCTGTTACTTCTGCTCAGATGCTCCAAGGATGCACCATCTTCAAGGGCAATTTG\nCTCATTAACATCCGACGGGGGAATAACATTGCTTCAGAGCTGGAGAACTTCATGGGGCTC\nATCGAGGTGGTGACGGGCTACGTGAAGATCCGCCATTCTCATGCCTTGGTCTCCTTGTCC\nTTCCTAAAAAACCTTCGCCTCATCCTAGGAGAGGAGCAGCTAGAAGGGAATTACTCCTTC\nTACGTCCTCGACAACCAGAACTTGCAGCAACTGTGGGACTGGGACCACCGCAACCTGACC\nATCAAAGCAGGGAAAATGTACTTTGCTTTCAATCCCAAATTATGTGTTTCCGAAATTTAC\nCGCATGGAGGAAGTGACGGGGACTAAAGGGCGCCAAAGCAAAGGGGACATAAACACCAGG\nAACAACGGGGAGAGAGCCTCCTGTGAAAGTGACGTCCTGCATTTCACCTCCACCACCACG\nTCGAAGAATCGCATCATCATAACCTGGCACCGGTACCGGCCCCCTGACTACAGGGATCTC\nATCAGCTTCACCGTTTACTACAAGGAAGCACCCTTTAAGAATGTCACAGAGTATGATGGG\nCAGGATGCCTGCGGCTCCAACAGCTGGAACATGGTGGACGTGGACCTCCCGCCCAACAAG\nGACGTGGAGCCCGGCATCTTACTACATGGGCTGAAGCCCTGGACTCAGTACGCCGTTTAC\nGTCAAGGCTGTGACCCTCACCATGGTGGAGAACGACCATATCCGTGGGGCCAAGAGTGAG\nATCTTGTACATTCGCACCAATGCTTCAGTTCCTTCCATTCCCTTGGACGTTCTTTCAGCA\nTCGAACTCCTCTTCTCAGTTAATCGTGAAGTGGAACCCTCCCTCTCTGCCCAACGGCAAC\nCTGAGTTACTACATTGTGCGCTGGCAGCGGCAGCCTCAGGACGGCTACCTTTACCGGCAC\nAATTACTGCTCCAAAGACAAAATCCCCATCAGGAAGTATGCCGACGGCACCATCGACATT\nGAGGAGGTCACAGAGAACCCCAAGACTGAGGTGTGTGGTGGGGAGAAAGGGCCTTGCTGC\nGCCTGCCCCAAAACTGAAGCCGAGAAGCAGGCCGAGAAGGAGGAGGCTGAATACCGCAAA\nGTCTTTGAGAATTTCCTGCACAACTCCATCTTCGTGCCCAGACCTGAAAGGAAGCGGAGA\nGATGTCATGCAAGTGGCCAACACCACCATGTCCAGCCGAAGCAGGAACACCACGGCCGCA\nGACACCTACAACATCACCGACCCGGAAGAGCTGGAGACAGAGTACCCTTTCTTTGAGAGC\nAGAGTGGATAACAAGGAGAGAACTGTCATTTCTAACCTTCGGCCTTTCACATTGTACCGC\nATCGATATCCACAGCTGCAACCACGAGGCTGAGAAGCTGGGCTGCAGCGCCTCCAACTTC\nGTCTTTGCAAGGACTATGCCCGCAGAAGGAGCAGATGACATTCCTGGGCCAGTGACCTGG\nGAGCCAAGGCCTGAAAACTCCATCTTTTTAAAGTGGCCGGAACCTGAGAATCCCAATGGA\nTTGATTCTAATGTATGAAATAAAATACGGATCACAAGTTGAGGATCAGCGAGAATGTGTG\nTCCAGACAGGAATACAGGAAGTATGGAGGGGCCAAGCTAAACCGGCTAAACCCGGGGAAC\nTACACAGCCCGGATTCAGGCCACATCTCTCTCTGGGAATGGGTCGTGGACAGATCCTGTG\nTTCTTCTATGTCCAGGCCAAAACAGGATATGAAAACTTCATCCATCTGATCATCGCTCTG\nCCCGTCGCTGTCCTGTTGATCGTGGGAGGGTTGGTGATTATGCTGTACGTCTTCCATAGA\nAAGAGAAATAACAGCAGGCTGGGGAATGGAGTGCTGTATGCCTCTGTGAACCCGGAGTAC\nTTCAGCGCTGCTGATGTGTACGTTCCTGATGAGTGGGAGGTGGCTCGGGAGAAGATCACC\nATGAGCCGGGAACTTGGGCAGGGGTCGTTTGGGATGGTCTATGAAGGAGTTGCCAAGGGT\nGTGGTGAAAGATGAACCTGAAACCAGAGTGGCCATTAAAACAGTGAACGAGGCCGCAAGC\nATGCGTGAGAGGATTGAGTTTCTCAACGAAGCTTCTGTGATGAAGGAGTTCAATTGTCAC\nCATGTGGTGCGATTGCTGGGTGTGGTGTCCCAAGGCCAGCCAACACTGGTCATCATGGAA\nCTGATGACACGGGGCGATCTCAAAAGTTATCTCCGGTCTCTGAGGCCAGAAATGGAGAAT\nAATCCAGTCCTAGCACCTCCAAGCCTGAGCAAGATGATTCAGATGGCCGGAGAGATTGCA\nGACGGCATGGCATACCTCAACGCCAATAAGTTCGTCCACAGAGACCTTGCTGCCCGGAAT\nTGCATGGTAGCCGAAGATTTCACAGTCAAAATCGGAGATTTTGGTATGACGCGAGATATC\nTATGAGACAGACTATTACCGGAAAGGAGGGAAAGGGCTGCTGCCCGTGCGCTGGATGTCT\nCCTGAGTCCCTCAAGGATGGAGTCTTCACCACTTACTCGGACGTCTGGTCCTTCGGGGTC\nGTCCTCTGGGAGATCGCCACACTGGCCGAGCAGCCCTACCAGGGCTTGTCCAACGAGCAA\nGTCCTTCGCTTCGTCATGGAGGGCGGCCTTCTGGACAAGCCAGACAACTGTCCTGACATG\nCTGTTTGAACTGATGCGCATGTGCTGGCAGTATAACCCCAAGATGAGGCCTTCCTTCCTG\nGAGATCATCAGCAGCATCAAAGAGGAGATGGAGCCTGGCTTCCGGGAGGTCTCCTTCTAC\nTACAGCGAGGAGAACAAGCTGCCCGAGCCGGAGGAGCTGGACCTGGAGCCAGAGAACATG\nGAGAGCGTCCCCCTGGACCCCTCGGCCTCCTCGTCCTCCCTGCCACTGCCCGACAGACAC\nTCAGGACACAAGGCCGAGAACGGCCCCGGCCCTGGGGTGCTGGTCCTCCGCGCCAGCTTC\nGACGAGAGACAGCCTTACGCCCACATGAACGGGGGCCGCAAGAACGAGCGGGCCTTGCCG\nCTGCCCCAGTCTTCGACCTGCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF07714'], 'name': ['PK_Tyr_Ser-Thr']}, {'identifier': ['PF00757'], 'name': ['Furin-like']}, {'identifier': ['PF01030'], 'name': ['Recep_L_domain']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['caveola']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular membrane-bounded organelle']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['neuron projection']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['function'], 'description': ['ATP binding']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['function'], 'description': ['insulin binding']}, {'category': ['function'], 'description': ['insulin receptor binding']}, {'category': ['function'], 'description': ['insulin receptor substrate binding']}, {'category': ['function'], 'description': ['insulin-like growth factor binding']}, {'category': ['function'], 'description': ['insulin-like growth factor I binding']}, {'category': ['function'], 'description': ['insulin-like growth factor-activated receptor activity']}, {'category': ['function'], 'description': ['phosphatidylinositol 3-kinase binding']}, {'category': ['function'], 'description': ['protein tyrosine kinase activity']}, {'category': ['process'], 'description': ['axonogenesis']}, {'category': ['process'], 'description': ['brain development']}, {'category': ['process'], 'description': ['epidermis development']}, {'category': ['process'], 'description': ['establishment of cell polarity']}, {'category': ['process'], 'description': ['exocrine pancreas development']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['inactivation of MAPKK activity']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['insulin-like growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['male sex determination']}, {'category': ['process'], 'description': ['mammary gland development']}, {'category': ['process'], 'description': ['negative regulation of apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of muscle cell apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['negative regulation of sequence-specific DNA binding transcription factor activity']}, {'category': ['process'], 'description': ['peptidyl-tyrosine autophosphorylation']}, {'category': ['process'], 'description': ['phosphatidylinositol 3-kinase signaling']}, {'category': ['process'], 'description': ['phosphatidylinositol-mediated signaling']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of cytokinesis']}, {'category': ['process'], 'description': ['positive regulation of DNA replication']}, {'category': ['process'], 'description': ['positive regulation of MAPK cascade']}, {'category': ['process'], 'description': ['positive regulation of mitotic nuclear division']}, {'category': ['process'], 'description': ['positive regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['positive regulation of steroid hormone biosynthetic process']}, {'category': ['process'], 'description': ['prostate gland epithelium morphogenesis']}, {'category': ['process'], 'description': ['protein autophosphorylation']}, {'category': ['process'], 'description': ['protein heterooligomerization']}, {'category': ['process'], 'description': ['protein tetramerization']}, {'category': ['process'], 'description': ['regulation of JNK cascade']}, {'category': ['process'], 'description': ['response to vitamin E']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}]}]"
"['DB00047', 'BTD00045', 'BIOD00045', 'DB01308']",['Insulin glargine'],biotech,"['Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis.\r\n\r\nInsulin is an important treatment in the management of Type 1 Diabetes (T1D), which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin glargine, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after several oral medications such as [DB00331], [DB01120], or [DB01261] have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own. \r\n\r\nAvailable as the brand name product Lantus, insulin glargine has a duration of action up to 24 hours allowing for once-daily dosing, typically at bedtime. Due to its duration of action, Lantus is considered ""basal insulin"" as it provides low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Basal insulin is often combined with short-acting ""bolus insulin"" such as [DB00046], [DB01309], and [DB01306] to provide higher doses of insulin that are required following meals. Use of basal and bolus insulin together is intended to mimic the pancreas\' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia. \r\n\r\nInsulin glargine is also available as the biosimilar, or ""follow-on"" product, Basaglar in the US and as Abasaglar in the EU. As of 2015, insulin glargine was reformulated by Sanofi as the product Toujeo in an extra-concentrated form containing 300IU/mL (compared to 100IU/mL contained in Lantus). Use of the higher concentrated Toujeo as compared to Lantus results in slightly different pharmacokinetics, with a later onset (up to 6 hours) and duration of action (up to 30 hours). In 2021, another biosimilar, Semglee (insulin glargine-yfgn),[L34959] became the first interchangeable (with Lantus) biosimilar insulin to receive FDA approval.[L34964]\r\n\r\nInsulin glargine is produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism. Insulin glargine differs from endogenous human insulin by the replacement of an asparagine residue at position A21 of the A-chain with glycine and addition of two arginines to the C-terminus (positions B31 and 32) of the B-chain. The resulting protein is soluble at pH 4 and forms microprecipitates at physiological pH 7.4 allowing for the slow release of small amounts of insulin glargine, giving the drug a long duration of action and no pronounced peak concentration.\r\n\r\nWithout an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.']",['liquid'],"['Insulin glargine is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.[L12474,L43532,L43587]']","['Insulin glargine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signalling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism. Insulin glargine is completely soluble at pH 4, the pH of administered solution, and has low solubility at physiological pH 7.4. Upon subcuteous injection, the solution is neutralized resulting in the formation of microprecipitates. Small amounts of insulin glargine are released from microprecipitates giving the drug a relatively constant concentration over time profile over 24 hours with no pronounced peak. This release mechanism allows the drug to mimic basal insulin levels within the body. ']",[None],"[{'target': [{'id': ['BE0000033'], 'name': ['Insulin receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A1924'], 'pubmed-id': ['17922476'], 'citation': ['Le Roith D: Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes. Diabetes Metab Res Rev. 2007 Nov;23(8):593-9.']}, {'ref-id': ['A1927'], 'pubmed-id': ['20424816'], 'citation': ['Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, Squatrito S, Vigneri R: Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia. 2010 Aug;53(8):1743-53. doi: 10.1007/s00125-010-1760-6. Epub 2010 Apr 28.']}, {'ref-id': ['A1930'], 'pubmed-id': ['18585815'], 'citation': ['Wada T, Azegami M, Sugiyama M, Tsuneki H, Sasaoka T: Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin. Diabetes Res Clin Pract. 2008 Sep;81(3):269-77. doi: 10.1016/j.diabres.2008.05.007. Epub 2008 Jun 27.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Insulin receptor'], 'general-function': ['Receptor signaling protein tyrosine kinase activity'], 'specific-function': ['Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosines residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.'], 'gene-name': ['INSR'], 'locus': ['19p13.3-p13.2'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['957-979'], 'signal-regions': ['1-27'], 'theoretical-pi': ['6.18'], 'molecular-weight': ['156331.465'], 'chromosome-location': ['19'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6091']}, {'resource': ['GenAtlas'], 'identifier': ['INSR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M10051']}, {'resource': ['GenBank Protein Database'], 'identifier': ['307070']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1800']}, {'resource': ['UniProtKB'], 'identifier': ['P06213']}, {'resource': ['UniProt Accession'], 'identifier': ['INSR_HUMAN']}]}], 'synonyms': [{'synonym': ['2.7.10.1', 'IR']}], 'amino-acid-sequence': ['>lcl|BSEQ0036940|Insulin receptor\nMATGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHL\nQILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYAL\nVIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNE\nECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECL\nGNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQG\nCHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGC\nTVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETL\nEIGNYSFYALDNQNLRQLWDWSKHNLTITQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQE\nRNDIALKTNGDQASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQ\nNVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFS\nDERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWE\nRQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQIL\nKELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAF\nPNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYV\nSARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCV\nSRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIG\nPLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSR\nEKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKG\nFTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMA\nAEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPV\nRWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDN\nCPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEME\nFEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSN\nPS'], 'gene-sequence': ['>lcl|BSEQ0020443|Insulin receptor (INSR)\nATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCG\nCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATC\nCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTG\nCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAA\nCTCATCATGATCACTGATTACTTGCTGCTCTTCCGGGTCTATGGGCTCGAGAGCCTGAAG\nGACCTGTTCCCCAACCTCACGGTCATCCGGGGATCACGACTGTTCTTTAACTACGCGCTG\nGTCATCTTCGAGATGGTTCACCTCAAGGAACTCGGCCTCTACAACCTGATGAACATCACC\nCGGGGTTCTGTCCGCATCGAGAAGAACAATGAGCTCTGTTACTTGGCCACTATCGACTGG\nTCCCGTATCCTGGATTCCGTGGAGGATAATTACATCGTGTTGAACAAAGATGACAACGAG\nGAGTGTGGAGACATCTGTCCGGGTACCGCGAAGGGCAAGACCAACTGCCCCGCCACCGTC\nATCAACGGGCAGTTTGTCGAACGATGTTGGACTCATAGTCACTGCCAGAAAGTTTGCCCG\nACCATCTGTAAGTCACACGGCTGCACCGCCGAAGGCCTCTGTTGCCACAGCGAGTGCCTG\nGGCAACTGTTCTCAGCCCGACGACCCCACCAAGTGCGTGGCCTGCCGCAACTTCTACCTG\nGACGGCAGGTGTGTGGAGACCTGCCCGCCCCCGTACTACCACTTCCAGGACTGGCGCTGT\nGTGAACTTCAGCTTCTGCCAGGACCTGCACCACAAATGCAAGAACTCGCGGAGGCAGGGC\nTGCCACCAGTACGTCATTCACAACAACAAGTGCATCCCTGAGTGTCCCTCCGGGTACACG\nATGAATTCCAGCAACTTGCTGTGCACCCCATGCCTGGGTCCCTGTCCCAAGGTGTGCCAC\nCTCCTAGAAGGCGAGAAGACCATCGACTCGGTGACGTCTGCCCAGGAGCTCCGAGGATGC\nACCGTCATCAACGGGAGTCTGATCATCAACATTCGAGGAGGCAACAATCTGGCAGCTGAG\nCTAGAAGCCAACCTCGGCCTCATTGAAGAAATTTCAGGGTATCTAAAAATCCGCCGATCC\nTACGCTCTGGTGTCACTTTCCTTCTTCCGGAAGTTACGTCTGATTCGAGGAGAGACCTTG\nGAAATTGGGAACTACTCCTTCTATGCCTTGGACAACCAGAACCTAAGGCAGCTCTGGGAC\nTGGAGCAAACACAACCTCACCATCACTCAGGGGAAACTCTTCTTCCACTATAACCCCAAA\nCTCTGCTTGTCAGAAATCCACAAGATGGAAGAAGTTTCAGGAACCAAGGGGCGCCAGGAG\nAGAAACGACATTGCCCTGAAGACCAATGGGGACCAGGCATCCTGTGAAAATGAGTTACTT\nAAATTTTCTTACATTCGGACATCTTTTGACAAGATCTTGCTGAGATGGGAGCCGTACTGG\nCCCCCCGACTTCCGAGACCTCTTGGGGTTCATGCTGTTCTACAAAGAGGCCCCTTATCAG\nAATGTGACGGAGTTCGACGGGCAGGATGCGTGTGGTTCCAACAGTTGGACGGTGGTAGAC\nATTGACCCACCCCTGAGGTCCAACGACCCCAAATCACAGAACCACCCAGGGTGGCTGATG\nCGGGGTCTCAAGCCCTGGACCCAGTATGCCATCTTTGTGAAGACCCTGGTCACCTTTTCG\nGATGAACGCCGGACCTATGGGGCCAAGAGTGACATCATTTATGTCCAGACAGATGCCACC\nAACCCCTCTGTGCCCCTGGATCCAATCTCAGTGTCTAACTCATCATCCCAGATTATTCTG\nAAGTGGAAACCACCCTCCGACCCCAATGGCAACATCACCCACTACCTGGTTTTCTGGGAG\nAGGCAGGCGGAAGACAGTGAGCTGTTCGAGCTGGATTATTGCCTCAAAGGGCTGAAGCTG\nCCCTCGAGGACCTGGTCTCCACCATTCGAGTCTGAAGATTCTCAGAAGCACAACCAGAGT\nGAGTATGAGGATTCGGCCGGCGAATGCTGCTCCTGTCCAAAGACAGACTCTCAGATCCTG\nAAGGAGCTGGAGGAGTCCTCGTTTAGGAAGACGTTTGAGGATTACCTGCACAACGTGGTT\nTTCGTCCCCAGAAAAACCTCTTCAGGCACTGGTGCCGAGGACCCTAGGCCATCTCGGAAA\nCGCAGGTCCCTTGGCGATGTTGGGAATGTGACGGTGGCCGTGCCCACGGTGGCAGCTTTC\nCCCAACACTTCCTCGACCAGCGTGCCCACGAGTCCGGAGGAGCACAGGCCTTTTGAGAAG\nGTGGTGAACAAGGAGTCGCTGGTCATCTCCGGCTTGCGACACTTCACGGGCTATCGCATC\nGAGCTGCAGGCTTGCAACCAGGACACCCCTGAGGAACGGTGCAGTGTGGCAGCCTACGTC\nAGTGCGAGGACCATGCCTGAAGCCAAGGCTGATGACATTGTTGGCCCTGTGACGCATGAA\nATCTTTGAGAACAACGTCGTCCACTTGATGTGGCAGGAGCCGAAGGAGCCCAATGGTCTG\nATCGTGCTGTATGAAGTGAGTTATCGGCGATATGGTGATGAGGAGCTGCATCTCTGCGTC\nTCCCGCAAGCACTTCGCTCTGGAACGGGGCTGCAGGCTGCGTGGGCTGTCACCGGGGAAC\nTACAGCGTGCGAATCCGGGCCACCTCCCTTGCGGGCAACGGCTCTTGGACGGAACCCACC\nTATTTCTACGTGACAGACTATTTAGACGTCCCGTCAAATATTGCAAAAATTATCATCGGC\nCCCCTCATCTTTGTCTTTCTCTTCAGTGTTGTGATTGGAAGTATTTATCTATTCCTGAGA\nAAGAGGCAGCCAGATGGGCCGCTGGGACCGCTTTACGCTTCTTCAAACCCTGAGTATCTC\nAGTGCCAGTGATGTGTTTCCATGCTCTGTGTACGTGCCGGACGAGTGGGAGGTGTCTCGA\nGAGAAGATCACCCTCCTTCGAGAGCTGGGGCAGGGCTCCTTCGGCATGGTGTATGAGGGC\nAATGCCAGGGACATCATCAAGGGTGAGGCAGAGACCCGCGTGGCGGTGAAGACGGTCAAC\nGAGTCAGCCAGTCTCCGAGAGCGGATTGAGTTCCTCAATGAGGCCTCGGTCATGAAGGGC\nTTCACCTGCCATCACGTGGTGCGCCTCCTGGGAGTGGTGTCCAAGGGCCAGCCCACGCTG\nGTGGTGATGGAGCTGATGGCTCACGGAGACCTGAAGAGCTACCTCCGTTCTCTGCGGCCA\nGAGGCTGAGAATAATCCTGGCCGCCCTCCCCCTACCCTTCAAGAGATGATTCAGATGGCG\nGCAGAGATTGCTGACGGGATGGCCTACCTGAACGCCAAGAAGTTTGTGCATCGGGACCTG\nGCAGCGAGAAACTGCATGGTCGCCCATGATTTTACTGTCAAAATTGGAGACTTTGGAATG\nACCAGAGACATCTATGAAACGGATTACTACCGGAAAGGGGGCAAGGGTCTGCTCCCTGTA\nCGGTGGATGGCACCGGAGTCCCTGAAGGATGGGGTCTTCACCACTTCTTCTGACATGTGG\nTCCTTTGGCGTGGTCCTTTGGGAAATCACCAGCTTGGCAGAACAGCCTTACCAAGGCCTG\nTCTAATGAACAGGTGTTGAAATTTGTCATGGATGGAGGGTATCTGGATCAACCCGACAAC\nTGTCCAGAGAGAGTCACTGACCTCATGCGCATGTGCTGGCAATTCAACCCCAAGATGAGG\nCCAACCTTCCTGGAGATTGTCAACCTGCTCAAGGACGACCTGCACCCCAGCTTTCCAGAG\nGTGTCGTTCTTCCACAGCGAGGAGAACAAGGCTCCCGAGAGTGAGGAGCTGGAGATGGAG\nTTTGAGGACATGGAGAATGTGCCCCTGGACCGTTCCTCGCACTGTCAGAGGGAGGAGGCG\nGGGGGCCGGGATGGAGGGTCCTCGCTGGGTTTCAAGCGGAGCTACGAGGAACACATCCCT\nTACACACACATGAACGGAGGCAAGAAAAACGGGCGGATTCTGACCTTGCCTCGGTCCAAT\nCCTTCCTAA'], 'pfams': [{'pfam': [{'identifier': ['PF07714'], 'name': ['PK_Tyr_Ser-Thr']}, {'identifier': ['PF00041'], 'name': ['fn3']}, {'identifier': ['PF00757'], 'name': ['Furin-like']}, {'identifier': ['PF01030'], 'name': ['Recep_L_domain']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['caveola']}, {'category': ['component'], 'description': ['endosome membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['insulin receptor complex']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular membrane-bounded organelle']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['function'], 'description': ['ATP binding']}, {'category': ['function'], 'description': ['GTP binding']}, {'category': ['function'], 'description': ['insulin binding']}, {'category': ['function'], 'description': ['insulin receptor substrate binding']}, {'category': ['function'], 'description': ['insulin-activated receptor activity']}, {'category': ['function'], 'description': ['insulin-like growth factor I binding']}, {'category': ['function'], 'description': ['insulin-like growth factor II binding']}, {'category': ['function'], 'description': ['insulin-like growth factor receptor binding']}, {'category': ['function'], 'description': ['phosphatidylinositol 3-kinase binding']}, {'category': ['function'], 'description': ['protein tyrosine kinase activity']}, {'category': ['function'], 'description': ['PTB domain binding']}, {'category': ['function'], 'description': ['receptor signaling protein tyrosine kinase activity']}, {'category': ['process'], 'description': ['activation of MAPK activity']}, {'category': ['process'], 'description': ['activation of protein kinase activity']}, {'category': ['process'], 'description': ['activation of protein kinase B activity']}, {'category': ['process'], 'description': ['adrenal gland development']}, {'category': ['process'], 'description': ['carbohydrate metabolic process']}, {'category': ['process'], 'description': ['cellular response to growth factor stimulus']}, {'category': ['process'], 'description': ['cellular response to insulin stimulus']}, {'category': ['process'], 'description': ['epidermis development']}, {'category': ['process'], 'description': ['exocrine pancreas development']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['glucose homeostasis']}, {'category': ['process'], 'description': ['heart morphogenesis']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['male gonad development']}, {'category': ['process'], 'description': ['male sex determination']}, {'category': ['process'], 'description': ['peptidyl-tyrosine autophosphorylation']}, {'category': ['process'], 'description': ['peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of developmental growth']}, {'category': ['process'], 'description': ['positive regulation of DNA replication']}, {'category': ['process'], 'description': ['positive regulation of glucose import']}, {'category': ['process'], 'description': ['positive regulation of glycogen biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of glycolytic process']}, {'category': ['process'], 'description': ['positive regulation of MAPK cascade']}, {'category': ['process'], 'description': ['positive regulation of meiotic cell cycle']}, {'category': ['process'], 'description': ['positive regulation of mitotic nuclear division']}, {'category': ['process'], 'description': ['positive regulation of nitric oxide biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of respiratory burst']}, {'category': ['process'], 'description': ['positive regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['protein autophosphorylation']}, {'category': ['process'], 'description': ['protein heterotetramerization']}, {'category': ['process'], 'description': ['regulation of embryonic development']}, {'category': ['process'], 'description': ['regulation of female gonad development']}, {'category': ['process'], 'description': ['regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['signal transduction by protein phosphorylation']}, {'category': ['process'], 'description': ['transformation of host cell by virus']}]}]}]}, {'id': ['BE0000858'], 'name': ['Insulin-like growth factor 1 receptor'], 'organism': ['Humans'], 'actions': [{'action': ['activator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A174883'], 'pubmed-id': ['22420005'], 'citation': ['Varewijck AJ, Janssen JA: Insulin and its analogues and their affinities for the IGF1 receptor. Endocr Relat Cancer. 2012 Sep 5;19(5):F63-75. doi: 10.1530/ERC-12-0026. Print 2012 Oct.']}, {'ref-id': ['A174886'], 'pubmed-id': ['20938889'], 'citation': ['Ciaraldi TP, Sasaoka T: Review on the in vitro interaction of insulin glargine with the insulin/insulin-like growth factor system: potential implications for metabolic and mitogenic activities. Horm Metab Res. 2011 Jan;43(1):1-10. doi: 10.1055/s-0030-1267203. Epub 2010 Oct 11.']}, {'ref-id': ['A1924'], 'pubmed-id': ['17922476'], 'citation': ['Le Roith D: Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes. Diabetes Metab Res Rev. 2007 Nov;23(8):593-9.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Insulin-like growth factor 1 receptor'], 'general-function': ['Protein tyrosine kinase activity'], 'specific-function': ['Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.'], 'gene-name': ['IGF1R'], 'locus': ['15q26.3'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['936-959'], 'signal-regions': ['1-30'], 'theoretical-pi': ['5.54'], 'molecular-weight': ['154791.73'], 'chromosome-location': ['15'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5465']}, {'resource': ['GenAtlas'], 'identifier': ['IGF1R']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X04434']}, {'resource': ['GenBank Protein Database'], 'identifier': ['804990']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1801']}, {'resource': ['UniProtKB'], 'identifier': ['P08069']}, {'resource': ['UniProt Accession'], 'identifier': ['IGF1R_HUMAN']}]}], 'synonyms': [{'synonym': ['2.7.10.1', 'IGF-I receptor', 'Insulin-like growth factor I receptor']}], 'amino-acid-sequence': ['>lcl|BSEQ0001710|Insulin-like growth factor 1 receptor\nMKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLH\nILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIF\nEMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGD\nLCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCS\nAPDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHD\nGECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNL\nLINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSF\nYVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTR\nNNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDG\nQDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSE\nILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRH\nNYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRK\nVFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFES\nRVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTW\nEPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGN\nYTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHR\nKRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKG\nVVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIME\nLMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARN\nCMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGV\nVLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL\nEIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRH\nSGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC'], 'gene-sequence': ['>lcl|BSEQ0020490|Insulin-like growth factor 1 receptor (IGF1R)\nATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCC\nGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGC\nAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCAC\nATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTC\nATTACCGAGTACTTGCTGCTGTTCCGAGTGGCTGGCCTCGAGAGCCTCGGAGACCTCTTC\nCCCAACCTCACGGTCATCCGCGGCTGGAAACTCTTCTACAACTACGCCCTGGTCATCTTC\nGAGATGACCAATCTCAAGGATATTGGGCTTTACAACCTGAGGAACATTACTCGGGGGGCC\nATCAGGATTGAGAAAAATGCTGACCTCTGTTACCTCTCCACTGTGGACTGGTCCCTGATC\nCTGGATGCGGTGTCCAATAACTACATTGTGGGGAATAAGCCCCCAAAGGAATGTGGGGAC\nCTGTGTCCAGGGACCATGGAGGAGAAGCCGATGTGTGAGAAGACCACCATCAACAATGAG\nTACAACTACCGCTGCTGGACCACAAACCGCTGCCAGAAAATGTGCCCAAGCACGTGTGGG\nAAGCGGGCGTGCACCGAGAACAATGAGTGCTGCCACCCCGAGTGCCTGGGCAGCTGCAGC\nGCGCCTGACAACGACACGGCCTGTGTAGCTTGCCGCCACTACTACTATGCCGGTGTCTGT\nGTGCCTGCCTGCCCGCCCAACACCTACAGGTTTGAGGGCTGGCGCTGTGTGGACCGTGAC\nTTCTGCGCCAACATCCTCAGCGCCGAGAGCAGCGACTCCGAGGGGTTTGTGATCCACGAC\nGGCGAGTGCATGCAGGAGTGCCCCTCGGGCTTCATCCGCAACGGCAGCCAGAGCATGTAC\nTGCATCCCTTGTGAAGGTCCTTGCCCGAAGGTCTGTGAGGAAGAAAAGAAAACAAAGACC\nATTGATTCTGTTACTTCTGCTCAGATGCTCCAAGGATGCACCATCTTCAAGGGCAATTTG\nCTCATTAACATCCGACGGGGGAATAACATTGCTTCAGAGCTGGAGAACTTCATGGGGCTC\nATCGAGGTGGTGACGGGCTACGTGAAGATCCGCCATTCTCATGCCTTGGTCTCCTTGTCC\nTTCCTAAAAAACCTTCGCCTCATCCTAGGAGAGGAGCAGCTAGAAGGGAATTACTCCTTC\nTACGTCCTCGACAACCAGAACTTGCAGCAACTGTGGGACTGGGACCACCGCAACCTGACC\nATCAAAGCAGGGAAAATGTACTTTGCTTTCAATCCCAAATTATGTGTTTCCGAAATTTAC\nCGCATGGAGGAAGTGACGGGGACTAAAGGGCGCCAAAGCAAAGGGGACATAAACACCAGG\nAACAACGGGGAGAGAGCCTCCTGTGAAAGTGACGTCCTGCATTTCACCTCCACCACCACG\nTCGAAGAATCGCATCATCATAACCTGGCACCGGTACCGGCCCCCTGACTACAGGGATCTC\nATCAGCTTCACCGTTTACTACAAGGAAGCACCCTTTAAGAATGTCACAGAGTATGATGGG\nCAGGATGCCTGCGGCTCCAACAGCTGGAACATGGTGGACGTGGACCTCCCGCCCAACAAG\nGACGTGGAGCCCGGCATCTTACTACATGGGCTGAAGCCCTGGACTCAGTACGCCGTTTAC\nGTCAAGGCTGTGACCCTCACCATGGTGGAGAACGACCATATCCGTGGGGCCAAGAGTGAG\nATCTTGTACATTCGCACCAATGCTTCAGTTCCTTCCATTCCCTTGGACGTTCTTTCAGCA\nTCGAACTCCTCTTCTCAGTTAATCGTGAAGTGGAACCCTCCCTCTCTGCCCAACGGCAAC\nCTGAGTTACTACATTGTGCGCTGGCAGCGGCAGCCTCAGGACGGCTACCTTTACCGGCAC\nAATTACTGCTCCAAAGACAAAATCCCCATCAGGAAGTATGCCGACGGCACCATCGACATT\nGAGGAGGTCACAGAGAACCCCAAGACTGAGGTGTGTGGTGGGGAGAAAGGGCCTTGCTGC\nGCCTGCCCCAAAACTGAAGCCGAGAAGCAGGCCGAGAAGGAGGAGGCTGAATACCGCAAA\nGTCTTTGAGAATTTCCTGCACAACTCCATCTTCGTGCCCAGACCTGAAAGGAAGCGGAGA\nGATGTCATGCAAGTGGCCAACACCACCATGTCCAGCCGAAGCAGGAACACCACGGCCGCA\nGACACCTACAACATCACCGACCCGGAAGAGCTGGAGACAGAGTACCCTTTCTTTGAGAGC\nAGAGTGGATAACAAGGAGAGAACTGTCATTTCTAACCTTCGGCCTTTCACATTGTACCGC\nATCGATATCCACAGCTGCAACCACGAGGCTGAGAAGCTGGGCTGCAGCGCCTCCAACTTC\nGTCTTTGCAAGGACTATGCCCGCAGAAGGAGCAGATGACATTCCTGGGCCAGTGACCTGG\nGAGCCAAGGCCTGAAAACTCCATCTTTTTAAAGTGGCCGGAACCTGAGAATCCCAATGGA\nTTGATTCTAATGTATGAAATAAAATACGGATCACAAGTTGAGGATCAGCGAGAATGTGTG\nTCCAGACAGGAATACAGGAAGTATGGAGGGGCCAAGCTAAACCGGCTAAACCCGGGGAAC\nTACACAGCCCGGATTCAGGCCACATCTCTCTCTGGGAATGGGTCGTGGACAGATCCTGTG\nTTCTTCTATGTCCAGGCCAAAACAGGATATGAAAACTTCATCCATCTGATCATCGCTCTG\nCCCGTCGCTGTCCTGTTGATCGTGGGAGGGTTGGTGATTATGCTGTACGTCTTCCATAGA\nAAGAGAAATAACAGCAGGCTGGGGAATGGAGTGCTGTATGCCTCTGTGAACCCGGAGTAC\nTTCAGCGCTGCTGATGTGTACGTTCCTGATGAGTGGGAGGTGGCTCGGGAGAAGATCACC\nATGAGCCGGGAACTTGGGCAGGGGTCGTTTGGGATGGTCTATGAAGGAGTTGCCAAGGGT\nGTGGTGAAAGATGAACCTGAAACCAGAGTGGCCATTAAAACAGTGAACGAGGCCGCAAGC\nATGCGTGAGAGGATTGAGTTTCTCAACGAAGCTTCTGTGATGAAGGAGTTCAATTGTCAC\nCATGTGGTGCGATTGCTGGGTGTGGTGTCCCAAGGCCAGCCAACACTGGTCATCATGGAA\nCTGATGACACGGGGCGATCTCAAAAGTTATCTCCGGTCTCTGAGGCCAGAAATGGAGAAT\nAATCCAGTCCTAGCACCTCCAAGCCTGAGCAAGATGATTCAGATGGCCGGAGAGATTGCA\nGACGGCATGGCATACCTCAACGCCAATAAGTTCGTCCACAGAGACCTTGCTGCCCGGAAT\nTGCATGGTAGCCGAAGATTTCACAGTCAAAATCGGAGATTTTGGTATGACGCGAGATATC\nTATGAGACAGACTATTACCGGAAAGGAGGGAAAGGGCTGCTGCCCGTGCGCTGGATGTCT\nCCTGAGTCCCTCAAGGATGGAGTCTTCACCACTTACTCGGACGTCTGGTCCTTCGGGGTC\nGTCCTCTGGGAGATCGCCACACTGGCCGAGCAGCCCTACCAGGGCTTGTCCAACGAGCAA\nGTCCTTCGCTTCGTCATGGAGGGCGGCCTTCTGGACAAGCCAGACAACTGTCCTGACATG\nCTGTTTGAACTGATGCGCATGTGCTGGCAGTATAACCCCAAGATGAGGCCTTCCTTCCTG\nGAGATCATCAGCAGCATCAAAGAGGAGATGGAGCCTGGCTTCCGGGAGGTCTCCTTCTAC\nTACAGCGAGGAGAACAAGCTGCCCGAGCCGGAGGAGCTGGACCTGGAGCCAGAGAACATG\nGAGAGCGTCCCCCTGGACCCCTCGGCCTCCTCGTCCTCCCTGCCACTGCCCGACAGACAC\nTCAGGACACAAGGCCGAGAACGGCCCCGGCCCTGGGGTGCTGGTCCTCCGCGCCAGCTTC\nGACGAGAGACAGCCTTACGCCCACATGAACGGGGGCCGCAAGAACGAGCGGGCCTTGCCG\nCTGCCCCAGTCTTCGACCTGCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF07714'], 'name': ['PK_Tyr_Ser-Thr']}, {'identifier': ['PF00757'], 'name': ['Furin-like']}, {'identifier': ['PF01030'], 'name': ['Recep_L_domain']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['caveola']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular membrane-bounded organelle']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['neuron projection']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['function'], 'description': ['ATP binding']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['function'], 'description': ['insulin binding']}, {'category': ['function'], 'description': ['insulin receptor binding']}, {'category': ['function'], 'description': ['insulin receptor substrate binding']}, {'category': ['function'], 'description': ['insulin-like growth factor binding']}, {'category': ['function'], 'description': ['insulin-like growth factor I binding']}, {'category': ['function'], 'description': ['insulin-like growth factor-activated receptor activity']}, {'category': ['function'], 'description': ['phosphatidylinositol 3-kinase binding']}, {'category': ['function'], 'description': ['protein tyrosine kinase activity']}, {'category': ['process'], 'description': ['axonogenesis']}, {'category': ['process'], 'description': ['brain development']}, {'category': ['process'], 'description': ['epidermis development']}, {'category': ['process'], 'description': ['establishment of cell polarity']}, {'category': ['process'], 'description': ['exocrine pancreas development']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['inactivation of MAPKK activity']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['insulin-like growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['male sex determination']}, {'category': ['process'], 'description': ['mammary gland development']}, {'category': ['process'], 'description': ['negative regulation of apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of muscle cell apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['negative regulation of sequence-specific DNA binding transcription factor activity']}, {'category': ['process'], 'description': ['peptidyl-tyrosine autophosphorylation']}, {'category': ['process'], 'description': ['phosphatidylinositol 3-kinase signaling']}, {'category': ['process'], 'description': ['phosphatidylinositol-mediated signaling']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of cytokinesis']}, {'category': ['process'], 'description': ['positive regulation of DNA replication']}, {'category': ['process'], 'description': ['positive regulation of MAPK cascade']}, {'category': ['process'], 'description': ['positive regulation of mitotic nuclear division']}, {'category': ['process'], 'description': ['positive regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['positive regulation of steroid hormone biosynthetic process']}, {'category': ['process'], 'description': ['prostate gland epithelium morphogenesis']}, {'category': ['process'], 'description': ['protein autophosphorylation']}, {'category': ['process'], 'description': ['protein heterooligomerization']}, {'category': ['process'], 'description': ['protein tetramerization']}, {'category': ['process'], 'description': ['regulation of JNK cascade']}, {'category': ['process'], 'description': ['response to vitamin E']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}]}]"
"['DB00048', 'BTD00010', 'BIOD00010', 'DB11249']",['Collagenase clostridium histolyticum'],biotech,"[""Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum. It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and Peyronie's disease.[L14882] The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ulcers.[L14912]\r\n\r\nOn July 6, 2020 a combination of injectable bacterial collagenases was approved by the FDA for the treatment of cellulite in adult women.[L14872] Also known as Qwo, this injection is the first approved injectable treatment for cellulite and was developed by Endo International.[L14892]""]",['solid'],"[""Collagenase clostridium histolyticum is indicated for the treatment of adults with Dupuytren's contracture with a palpable cord. Additionally, it is used to treat men with Peyronie's disease diagnosed with a penile curvature deformity of at least a 30-degree angle at the beginning of therapy in addition to palpable plaques.[L14882] Collagenase ointment is used for the tissue debridement of chronic dermal ulcers and severely burned tissues.[L14952]\r\nThe combination collagenase product, also known as Qwo, is used for the treatment of moderate to severe cellulite in the buttocks of adult women.[L14872]""]","[""Peyronie's disease is a fibrous lesion of the tunica albuginea in the penile tissues.[A215067] Cellulite is a multifactorial condition resulting in the accumulation of fibrotic dermal septae and the expansion of subcutaneous fat.[A215062] Dupuytren's contracture is a fibroproliferative disease that results in the fibrous deposition of collagen in the hands, limiting mobility and functionality of the hands.[A215072] The collagen deposition in the abovementioned conditions is the target of collagenase enzyme therapy.[A215157,A215167]\r\n\r\nThese enzymes are proteinases acting to hydrolyze collagen's triple-helical conformation, resulting in the lysis of collagen deposits and relief from the necrotic tissue and plaques associated with several conditions.[L14882,L14912] On a molecular level, collagenases cleave polypeptide chains that make up the collagen triple helix structure at various loci, leading to solubilization from the collagen fibril.[A215197]""]",[None],"[{'target': [{'id': ['BE0000025'], 'name': ['Collagen alpha-1(I) chain'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1932'], 'pubmed-id': ['17440987'], 'citation': ['Egeblad M, Shen HC, Behonick DJ, Wilmes L, Eichten A, Korets LV, Kheradmand F, Werb Z, Coussens LM: Type I collagen is a genetic modifier of matrix metalloproteinase 2 in murine skeletal development. Dev Dyn. 2007 Jun;236(6):1683-93.']}, {'ref-id': ['A1934'], 'pubmed-id': ['12855673'], 'citation': ['Lindsey ML, Yoshioka J, MacGillivray C, Muangman S, Gannon J, Verghese A, Aikawa M, Libby P, Krane SM, Lee RT: Effect of a cleavage-resistant collagen mutation on left ventricular remodeling. Circ Res. 2003 Aug 8;93(3):238-45. Epub 2003 Jul 10.']}, {'ref-id': ['A1935'], 'pubmed-id': ['12535212'], 'citation': [""Beare AH, O'Kane S, Krane SM, Ferguson MW: Severely impaired wound healing in the collagenase-resistant mouse. J Invest Dermatol. 2003 Jan;120(1):153-63.""]}, {'ref-id': ['A1937'], 'pubmed-id': ['12101112'], 'citation': ['Chiu CJ, Chang ML, Chiang CP, Hahn LJ, Hsieh LL, Chen CJ: Interaction of collagen-related genes and susceptibility to betel quid-induced oral submucous fibrosis. Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):646-53.']}, {'ref-id': ['A1940'], 'pubmed-id': ['15659034'], 'citation': ['Beare AH, Krane SM, Ferguson MW: Variable impairment of wound healing in the heterozygous collagenase-resistant mouse. Wound Repair Regen. 2005 Jan-Feb;13(1):27-40.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Collagen alpha-1(I) chain'], 'general-function': ['Platelet-derived growth factor binding'], 'specific-function': ['Type I collagen is a member of group I collagen (fibrillar forming collagen).'], 'gene-name': ['COL1A1'], 'locus': ['17q21.33'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-22'], 'theoretical-pi': ['5.56'], 'molecular-weight': ['138941.105'], 'chromosome-location': ['17'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:2197']}, {'resource': ['GenAtlas'], 'identifier': ['COL1A1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['Z74615']}, {'resource': ['GenBank Protein Database'], 'identifier': ['1418928']}, {'resource': ['UniProtKB'], 'identifier': ['P02452']}, {'resource': ['UniProt Accession'], 'identifier': ['CO1A1_HUMAN']}]}], 'synonyms': [{'synonym': ['Alpha-1 type I collagen']}], 'amino-acid-sequence': ['>lcl|BSEQ0036937|Collagen alpha-1(I) chain\nMFSFVDLRLLLLLAATALLTHGQEEGQVEGQDEDIPPITCVQNGLRYHDRDVWKPEPCRI\nCVCDNGKVLCDDVICDETKNCPGAEVPEGECCPVCPDGSESPTDQETTGVEGPKGDTGPR\nGPRGPAGPPGRDGIPGQPGLPGPPGPPGPPGPPGLGGNFAPQLSYGYDEKSTGGISVPGP\nMGPSGPRGLPGPPGAPGPQGFQGPPGEPGEPGASGPMGPRGPPGPPGKNGDDGEAGKPGR\nPGERGPPGPQGARGLPGTAGLPGMKGHRGFSGLDGAKGDAGPAGPKGEPGSPGENGAPGQ\nMGPRGLPGERGRPGAPGPAGARGNDGATGAAGPPGPTGPAGPPGFPGAVGAKGEAGPQGP\nRGSEGPQGVRGEPGPPGPAGAAGPAGNPGADGQPGAKGANGAPGIAGAPGFPGARGPSGP\nQGPGGPPGPKGNSGEPGAPGSKGDTGAKGEPGPVGVQGPPGPAGEEGKRGARGEPGPTGL\nPGPPGERGGPGSRGFPGADGVAGPKGPAGERGSPGPAGPKGSPGEAGRPGEAGLPGAKGL\nTGSPGSPGPDGKTGPPGPAGQDGRPGPPGPPGARGQAGVMGFPGPKGAAGEPGKAGERGV\nPGPPGAVGPAGKDGEAGAQGPPGPAGPAGERGEQGPAGSPGFQGLPGPAGPPGEAGKPGE\nQGVPGDLGAPGPSGARGERGFPGERGVQGPPGPAGPRGANGAPGNDGAKGDAGAPGAPGS\nQGAPGLQGMPGERGAAGLPGPKGDRGDAGPKGADGSPGKDGVRGLTGPIGPPGPAGAPGD\nKGESGPSGPAGPTGARGAPGDRGEPGPPGPAGFAGPPGADGQPGAKGEPGDAGAKGDAGP\nPGPAGPAGPPGPIGNVGAPGAKGARGSAGPPGATGFPGAAGRVGPPGPSGNAGPPGPPGP\nAGKEGGKGPRGETGPAGRPGEVGPPGPPGPAGEKGSPGADGPAGAPGTPGPQGIAGQRGV\nVGLPGQRGERGFPGLPGPSGEPGKQGPSGASGERGPPGPMGPPGLAGPPGESGREGAPGA\nEGSPGRDGSPGAKGDRGETGPAGPPGAPGAPGAPGPVGPAGKSGDRGETGPAGPTGPVGP\nVGARGPAGPQGPRGDKGETGEQGDRGIKGHRGFSGLQGPPGPPGSPGEQGPSGASGPAGP\nRGPPGSAGAPGKDGLNGLPGPIGPPGPRGRTGDAGPVGPPGPPGPPGPPGPPSAGFDFSF\nLPQPPQEKAHDGGRYYRADDANVVRDRDLEVDTTLKSLSQQIENIRSPEGSRKNPARTCR\nDLKMCHSDWKSGEYWIDPNQGCNLDAIKVFCNMETGETCVYPTQPSVAQKNWYISKNPKD\nKRHVWFGESMTDGFQFEYGGQGSDPADVAIQLTFLRLMSTEASQNITYHCKNSVAYMDQQ\nTGNLKKALLLQGSNEIEIRAEGNSRFTYSVTVDGCTSHTGAWGKTVIEYKTTKTSRLPII\nDVAPLDVGAPDQEFGFDVGPVCFL'], 'gene-sequence': ['>lcl|BSEQ0016001|Collagen alpha-1(I) chain (COL1A1)\nATGTTCAGCTTTGTGGACCTCCGGCTCCTGCTCCTCTTAGCGGCCACCGCCCTCCTGACG\nCACGGCCAAGAGGAAGGCCAAGTCGAGGGCCAAGACGAAGACATCCCACCAATCACCTGC\nGTACAGAACGGCCTCAGGTACCATGACCGAGACGTGTGGAAACCCGAGCCCTGCCGGATC\nTGCGTCTGCGACAACGGCAAGGTGTTGTGCGATGACGTGATCTGTGACGAGACCAAGAAC\nTGCCCCGGCGCCGAAGTCCCCGAGGGCGAGTGCTGTCCCGTCTGCCCCGACGGCTCAGAG\nTCACCCACCGACCAAGAAACCACCGGCGTCGAGGGACCCAAGGGAGACACTGGCCCCCGA\nGGCCCAAGGGGACCCGCAGGCCCCCCTGGCCGAGATGGCATCCCTGGACAGCCTGGACTT\nCCCGGACCCCCCGGACCCCCCGGACCTCCCGGACCCCCTGGCCTCGGAGGAAACTTTGCT\nCCCCAGCTGTCTTATGGCTATGATGAGAAATCAACCGGAGGAATTTCCGTGCCTGGCCCC\nATGGGTCCCTCTGGTCCTCGTGGTCTCCCTGGCCCCCCTGGTGCACCTGGTCCCCAAGGC\nTTCCAAGGTCCCCCTGGTGAGCCTGGCGAGCCTGGAGCTTCAGGTCCCATGGGTCCCCGA\nGGTCCCCCAGGTCCCCCTGGAAAGAATGGAGATGATGGGGAAGCTGGAAAACCTGGTCGT\nCCTGGTGAGCGTGGGCCTCCTGGGCCTCAGGGTGCTCGAGGATTGCCCGGAACAGCTGGC\nCTCCCTGGAATGAAGGGACACAGAGGTTTCAGTGGTTTGGATGGTGCCAAGGGAGATGCT\nGGTCCTGCTGGTCCTAAGGGTGAGCCTGGCAGCCCTGGTGAAAATGGAGCTCCTGGTCAG\nATGGGCCCCCGTGGCCTGCCTGGTGAGAGAGGTCGCCCTGGAGCCCCTGGCCCTGCTGGT\nGCTCGTGGAAATGATGGTGCTACTGGTGCTGCCGGGCCCCCTGGTCCCACCGGCCCCGCT\nGGTCCTCCTGGCTTCCCTGGTGCTGTTGGTGCTAAGGGTGAAGCTGGTCCCCAAGGGCCC\nCGAGGCTCTGAAGGTCCCCAGGGTGTGCGTGGTGAGCCTGGCCCCCCTGGCCCTGCTGGT\nGCTGCTGGCCCTGCTGGAAACCCTGGTGCTGATGGACAGCCTGGTGCTAAAGGTGCCAAT\nGGTGCTCCTGGTATTGCTGGTGCTCCTGGCTTCCCTGGTGCCCGAGGCCCCTCTGGACCC\nCAGGGCCCCGGCGGCCCTCCTGGTCCCAAGGGTAACAGCGGTGAACCTGGTGCTCCTGGC\nAGCAAAGGAGACACTGGTGCTAAGGGAGAGCCTGGCCCTGTTGGTGTTCAAGGACCCCCT\nGGCCCTGCTGGAGAGGAAGGAAAGCGAGGAGCTCGAGGTGAACCCGGACCCACTGGCCTG\nCCCGGACCCCCTGGCGAGCGTGGTGGACCTGGTAGCCGTGGTTTCCCTGGCGCAGATGGT\nGTTGCTGGTCCCAAGGGTCCCGCTGGTGAACGTGGTTCTCCTGGCCCTGCTGGCCCCAAA\nGGATCTCCTGGTGAAGCTGGTCGTCCCGGTGAAGCTGGTCTGCCTGGTGCCAAGGGTCTG\nACTGGAAGCCCTGGCAGCCCTGGTCCTGATGGCAAAACTGGCCCCCCTGGTCCCGCCGGT\nCAAGATGGTCGCCCCGGACCCCCAGGCCCACCTGGTGCCCGTGGTCAGGCTGGTGTGATG\nGGATTCCCTGGACCTAAAGGTGCTGCTGGAGAGCCCGGCAAGGCTGGAGAGCGAGGTGTT\nCCCGGACCCCCTGGCGCTGTCGGTCCTGCTGGCAAAGATGGAGAGGCTGGAGCTCAGGGA\nCCCCCTGGCCCTGCTGGTCCCGCTGGCGAGAGAGGTGAACAAGGCCCTGCTGGCTCCCCC\nGGATTCCAGGGTCTCCCTGGTCCTGCTGGTCCTCCAGGTGAAGCAGGCAAACCTGGTGAA\nCAGGGTGTTCCTGGAGACCTTGGCGCCCCTGGCCCCTCTGGAGCAAGAGGCGAGAGAGGT\nTTCCCTGGCGAGCGTGGTGTGCAAGGTCCCCCTGGTCCTGCTGGTCCCCGAGGGGCCAAC\nGGTGCTCCCGGCAACGATGGTGCTAAGGGTGATGCTGGTGCCCCTGGAGCTCCCGGTAGC\nCAGGGCGCCCCTGGCCTTCAGGGAATGCCTGGTGAACGTGGTGCAGCTGGTCTTCCAGGG\nCCTAAGGGTGACAGAGGTGATGCTGGTCCCAAAGGTGCTGATGGCTCTCCTGGCAAAGAT\nGGCGTCCGTGGTCTGACTGGCCCCATTGGTCCTCCTGGCCCTGCTGGTGCCCCTGGTGAC\nAAGGGTGAAAGTGGTCCCAGCGGCCCTGCTGGTCCCACTGGAGCTCGTGGTGCCCCCGGA\nGACCGTGGTGAGCCTGGTCCCCCCGGCCCTGCTGGCTTTGCTGGCCCCCCTGGTGCTGAC\nGGCCAACCTGGTGCTAAAGGCGAACCTGGTGATGCTGGTGCTAAAGGCGATGCTGGTCCC\nCCTGGCCCTGCCGGACCCGCTGGACCCCCTGGCCCCATTGGTAATGTTGGTGCTCCTGGA\nGCCAAAGGTGCTCGCGGCAGCGCTGGTCCCCCTGGTGCTACTGGTTTCCCTGGTGCTGCT\nGGCCGAGTCGGTCCTCCTGGCCCCTCTGGAAATGCTGGACCCCCTGGCCCTCCTGGTCCT\nGCTGGCAAAGAAGGCGGCAAAGGTCCCCGTGGTGAGACTGGCCCTGCTGGACGTCCTGGT\nGAAGTTGGTCCCCCTGGTCCCCCTGGCCCTGCTGGCGAGAAAGGATCCCCTGGTGCTGAT\nGGTCCTGCTGGTGCTCCTGGTACTCCCGGGCCTCAAGGTATTGCTGGACAGCGTGGTGTG\nGTCGGCCTGCCTGGTCAGAGAGGAGAGAGAGGCTTCCCTGGTCTTCCTGGCCCCTCTGGT\nGAACCTGGCAAACAAGGTCCCTCTGGAGCAAGTGGTGAACGTGGTCCCCCTGGTCCCATG\nGGCCCCCCTGGATTGGCTGGACCCCCTGGTGAATCTGGACGTGAGGGGGCTCCTGGTGCC\nGAAGGTTCCCCTGGACGAGACGGTTCTCCTGGCGCCAAGGGTGACCGTGGTGAGACCGGC\nCCCGCTGGACCCCCTGGTGCTCCTGGTGCTCCTGGTGCCCCTGGCCCCGTTGGCCCTGCT\nGGCAAGAGTGGTGATCGTGGTGAGACTGGTCCTGCTGGTCCCGCCGGTCCTGTCGGCCCT\nGTTGGCGCCCGTGGCCCCGCCGGACCCCAAGGCCCCCGTGGTGACAAGGGTGAGACAGGC\nGAACAGGGCGACAGAGGCATAAAGGGTCACCGTGGCTTCTCTGGCCTCCAGGGTCCCCCT\nGGCCCTCCTGGCTCTCCTGGTGAACAAGGTCCCTCTGGAGCCTCTGGTCCTGCTGGTCCC\nCGAGGTCCCCCTGGCTCTGCTGGTGCTCCTGGCAAAGATGGACTCAACGGTCTCCCTGGC\nCCCATTGGGCCCCCTGGTCCTCGCGGTCGCACTGGTGATGCTGGTCCTGTTGGTCCCCCC\nGGCCCTCCTGGACCTCCTGGTCCCCCTGGTCCTCCCAGCGCTGGTTTCGACTTCAGCTTC\nCTGCCCCAGCCACCTCAAGAGAAGGCTCACGATGGTGGCCGCTACTACCGGGCTGATGAT\nGCCAATGTGGTTCGTGACCGTGACCTCGAGGTGGACACCACCCTCAAGAGCCTGAGCCAG\nCAGATCGAGAACATCCGGAGCCCAGAGGGCAGCCGCAAGAACCCCGCCCGCACCTGCCGT\nGACCTCAAGATGTGCCACTCTGACTGGAAGAGTGGAGAGTACTGGATTGACCCCAACCAA\nGGCTGCAACCTGGATGCCATCAAAGTCTTCTGCAACATGGAGACTGGTGAGACCTGCGTG\nTACCCCACTCAGCCCAGTGTGGCCCAGAAGAACTGGTACATCAGCAAGAACCCCAAGGAC\nAAGAGGCATGTCTGGTTCGGCGAGAGCATGACCGATGGATTCCAGTTCGAGTATGGCGGC\nCAGGGCTCCGACCCTGCCGATGTGGCCATCCAGCTGACCTTCCTGCGCCTGATGTCCACC\nGAGGCCTCCCAGAACATCACCTACCACTGCAAGAACAGCGTGGCCTACATGGACCAGCAG\nACTGGCAACCTCAAGAAGGCCCTGCTCCTCCAGGGCTCCAACGAGATCGAGATCCGCGCC\nGAGGGCAACAGCCGCTTCACCTACAGCGTCACTGTCGATGGCTGCACGAGTCACACCGGA\nGCCTGGGGCAAGACAGTGATTGAATACAAAACCACCAAGACCTCCCGCCTGCCCATCATC\nGATGTGGCCCCCTTGGACGTTGGTGCCCCAGACCAGGAATTCGGCTTCGACGTTGGCCCT\nGTCTGCTTCCTGTAA'], 'pfams': [{'pfam': [{'identifier': ['PF01410'], 'name': ['COLFI']}, {'identifier': ['PF01391'], 'name': ['Collagen']}, {'identifier': ['PF00093'], 'name': ['VWC']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['collagen type I trimer']}, {'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['extracellular matrix']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['Golgi apparatus']}, {'category': ['component'], 'description': ['secretory granule']}, {'category': ['function'], 'description': ['extracellular matrix structural constituent']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['function'], 'description': ['metal ion binding']}, {'category': ['function'], 'description': ['platelet-derived growth factor binding']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood vessel development']}, {'category': ['process'], 'description': ['bone trabecula formation']}, {'category': ['process'], 'description': ['cartilage development involved in endochondral bone morphogenesis']}, {'category': ['process'], 'description': ['cellular response to amino acid stimulus']}, {'category': ['process'], 'description': ['cellular response to epidermal growth factor stimulus']}, {'category': ['process'], 'description': ['cellular response to fibroblast growth factor stimulus']}, {'category': ['process'], 'description': ['cellular response to fluoride']}, {'category': ['process'], 'description': ['cellular response to mechanical stimulus']}, {'category': ['process'], 'description': ['cellular response to retinoic acid']}, {'category': ['process'], 'description': ['cellular response to transforming growth factor beta stimulus']}, {'category': ['process'], 'description': ['cellular response to tumor necrosis factor']}, {'category': ['process'], 'description': ['cellular response to vitamin E']}, {'category': ['process'], 'description': ['collagen biosynthetic process']}, {'category': ['process'], 'description': ['collagen catabolic process']}, {'category': ['process'], 'description': ['collagen fibril organization']}, {'category': ['process'], 'description': ['embryonic skeletal system development']}, {'category': ['process'], 'description': ['endochondral ossification']}, {'category': ['process'], 'description': ['extracellular matrix disassembly']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['face morphogenesis']}, {'category': ['process'], 'description': ['intramembranous ossification']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['negative regulation of cell-substrate adhesion']}, {'category': ['process'], 'description': ['osteoblast differentiation']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['positive regulation of canonical Wnt signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of epithelial to mesenchymal transition']}, {'category': ['process'], 'description': ['positive regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['protein heterotrimerization']}, {'category': ['process'], 'description': ['protein localization to nucleus']}, {'category': ['process'], 'description': ['protein transport']}, {'category': ['process'], 'description': ['receptor-mediated endocytosis']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['response to cAMP']}, {'category': ['process'], 'description': ['response to corticosteroid']}, {'category': ['process'], 'description': ['response to drug']}, {'category': ['process'], 'description': ['response to estradiol']}, {'category': ['process'], 'description': ['response to hydrogen peroxide']}, {'category': ['process'], 'description': ['response to hyperoxia']}, {'category': ['process'], 'description': ['response to peptide hormone']}, {'category': ['process'], 'description': ['sensory perception of sound']}, {'category': ['process'], 'description': ['skeletal system development']}, {'category': ['process'], 'description': ['skin morphogenesis']}, {'category': ['process'], 'description': ['tooth eruption']}, {'category': ['process'], 'description': ['tooth mineralization']}, {'category': ['process'], 'description': ['visual perception']}]}]}]}, {'id': ['BE0002140'], 'name': ['Collagen alpha-1(II) chain'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13193'], 'pubmed-id': ['14613270'], 'citation': ['Fraser A, Fearon U, Billinghurst RC, Ionescu M, Reece R, Barwick T, Emery P, Poole AR, Veale DJ: Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum. 2003 Nov;48(11):3085-95.']}, {'ref-id': ['A13194'], 'pubmed-id': ['17652426'], 'citation': [""Imai K, Dalal SS, Hambor J, Mitchell P, Okada Y, Horton WC, D'Armiento J: Bone growth retardation in mouse embryos expressing human collagenase 1. Am J Physiol Cell Physiol. 2007 Oct;293(4):C1209-15. Epub 2007 Jul 25.""]}, {'ref-id': ['A13195'], 'pubmed-id': ['16507130'], 'citation': ['Verstappen SM, Poole AR, Ionescu M, King LE, Abrahamowicz M, Hofman DM, Bijlsma JW, Lafeber FP: Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arthritis Res Ther. 2006;8(1):R31. Epub 2006 Jan 10.']}, {'ref-id': ['A13196'], 'pubmed-id': ['15299286'], 'citation': ['Martin G, Bogdanowicz P, Domagala F, Ficheux H, Pujol JP: Articular chondrocytes cultured in hypoxia: their response to interleukin-1beta and rhein, the active metabolite of diacerhein. Biorheology. 2004;41(3-4):549-61.']}, {'ref-id': ['A13197'], 'pubmed-id': ['12890681'], 'citation': ['Pratta MA, Yao W, Decicco C, Tortorella MD, Liu RQ, Copeland RA, Magolda R, Newton RC, Trzaskos JM, Arner EC: Aggrecan protects cartilage collagen from proteolytic cleavage. J Biol Chem. 2003 Nov 14;278(46):45539-45. Epub 2003 Jul 30.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Collagen alpha-1(II) chain'], 'general-function': ['Platelet-derived growth factor binding'], 'specific-function': ['Type II collagen is specific for cartilaginous tissues. It is essential for the normal embryonic development of the skeleton, for linear growth and for the ability of cartilage to resist compressive forces.'], 'gene-name': ['COL2A1'], 'locus': ['12q13.11-q13.2'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-25'], 'theoretical-pi': ['6.89'], 'molecular-weight': ['141785.08'], 'chromosome-location': ['12'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:2200']}, {'resource': ['GenAtlas'], 'identifier': ['COL2A1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X16468']}, {'resource': ['GenBank Protein Database'], 'identifier': ['29516']}, {'resource': ['UniProtKB'], 'identifier': ['P02458']}, {'resource': ['UniProt Accession'], 'identifier': ['CO2A1_HUMAN']}]}], 'synonyms': [{'synonym': ['Alpha-1 type II collagen']}], 'amino-acid-sequence': ['>lcl|BSEQ0004198|Collagen alpha-1(II) chain\nMIRLGAPQTLVLLTLLVAAVLRCQGQDVQEAGSCVQDGQRYNDKDVWKPEPCRICVCDTG\nTVLCDDIICEDVKDCLSPEIPFGECCPICPTDLATASGQPGPKGQKGEPGDIKDIVGPKG\nPPGPQGPAGEQGPRGDRGDKGEKGAPGPRGRDGEPGTPGNPGPPGPPGPPGPPGLGGNFA\nAQMAGGFDEKAGGAQLGVMQGPMGPMGPRGPPGPAGAPGPQGFQGNPGEPGEPGVSGPMG\nPRGPPGPPGKPGDDGEAGKPGKAGERGPPGPQGARGFPGTPGLPGVKGHRGYPGLDGAKG\nEAGAPGVKGESGSPGENGSPGPMGPRGLPGERGRTGPAGAAGARGNDGQPGPAGPPGPVG\nPAGGPGFPGAPGAKGEAGPTGARGPEGAQGPRGEPGTPGSPGPAGASGNPGTDGIPGAKG\nSAGAPGIAGAPGFPGPRGPPGPQGATGPLGPKGQTGEPGIAGFKGEQGPKGEPGPAGPQG\nAPGPAGEEGKRGARGEPGGVGPIGPPGERGAPGNRGFPGQDGLAGPKGAPGERGPSGLAG\nPKGANGDPGRPGEPGLPGARGLTGRPGDAGPQGKVGPSGAPGEDGRPGPPGPQGARGQPG\nVMGFPGPKGANGEPGKAGEKGLPGAPGLRGLPGKDGETGAAGPPGPAGPAGERGEQGAPG\nPSGFQGLPGPPGPPGEGGKPGDQGVPGEAGAPGLVGPRGERGFPGERGSPGAQGLQGPRG\nLPGTPGTDGPKGASGPAGPPGAQGPPGLQGMPGERGAAGIAGPKGDRGDVGEKGPEGAPG\nKDGGRGLTGPIGPPGPAGANGEKGEVGPPGPAGSAGARGAPGERGETGPPGPAGFAGPPG\nADGQPGAKGEQGEAGQKGDAGAPGPQGPSGAPGPQGPTGVTGPKGARGAQGPPGATGFPG\nAAGRVGPPGSNGNPGPPGPPGPSGKDGPKGARGDSGPPGRAGEPGLQGPAGPPGEKGEPG\nDDGPSGAEGPPGPQGLAGQRGIVGLPGQRGERGFPGLPGPSGEPGKQGAPGASGDRGPPG\nPVGPPGLTGPAGEPGREGSPGADGPPGRDGAAGVKGDRGETGAVGAPGAPGPPGSPGPAG\nPTGKQGDRGEAGAQGPMGPSGPAGARGIQGPQGPRGDKGEAGEPGERGLKGHRGFTGLQG\nLPGPPGPSGDQGASGPAGPSGPRGPPGPVGPSGKDGANGIPGPIGPPGPRGRSGETGPAG\nPPGNPGPPGPPGPPGPGIDMSAFAGLGPREKGPDPLQYMRADQAAGGLRQHDAEVDATLK\nSLNNQIESIRSPEGSRKNPARTCRDLKLCHPEWKSGDYWIDPNQGCTLDAMKVFCNMETG\nETCVYPNPANVPKKNWWSSKSKEKKHIWFGETINGGFHFSYGDDNLAPNTANVQMTFLRL\nLSTEGSQNITYHCKNSIAYLDEAAGNLKKALLIQGSNDVEIRAEGNSRFTYTALKDGCTK\nHTGKWGKTVIEYRSQKTSRLPIIDIAPMDIGGPEQEFGVDIGPVCFL'], 'gene-sequence': ['>lcl|BSEQ0019241|Collagen alpha-1(II) chain (COL2A1)\nATGATTCGCCTCGGGGCTCCCCAGACGCTGGTGCTGCTGACGCTGCTCGTCGCCGCTGTC\nCTTCGGTGTCAGGGCCAGGATGTCCAGGAGGCTGGCAGCTGTGTGCAGGATGGGCAGAGG\nTATAATGATAAGGATGTGTGGAAGCCGGAGCCCTGCCGGATCTGTGTCTGTGACACTGGG\nACTGTCCTCTGCGACGACATAATCTGTGAAGACGTGAAAGACTGCCTCAGCCCTGAGATC\nCCCTTCGGAGAGTGCTGCCCCATCTGCCCAACTGACCTCGCCACTGCCAGTGGGCAACCA\nGGACCAAAGGGACAGAAAGGAGAACCTGGAGACATCAAGGATATTGTAGGACCCAAAGGA\nCCTCCTGGGCCTCAGGGACCTGCAGGGGAACAAGGACCCAGAGGGGATCGTGGTGACAAA\nGGTGAAAAAGGTGCCCCTGGACCTCGTGGCAGAGATGGAGAACCTGGGACCCCTGGAAAT\nCCTGGCCCCCCTGGTCCTCCCGGCCCCCCTGGTCCCCCTGGTCTTGGTGGAAACTTTGCT\nGCCCAGATGGCTGGAGGATTTGATGAAAAGGCTGGTGGCGCCCAGTTGGGAGTAATGCAA\nGGACCAATGGGCCCCATGGGACCTCGAGGACCTCCAGGCCCTGCAGGTGCTCCTGGGCCT\nCAAGGATTTCAAGGCAATCCTGGTGAACCTGGTGAACCTGGTGTCTCTGGTCCCATGGGT\nCCCCGTGGTCCTCCTGGTCCCCCTGGAAAGCCTGGTGATGATGGTGAAGCTGGAAAACCT\nGGAAAAGCTGGTGAAAGGGGTCCGCCTGGTCCTCAGGGTGCTCGTGGTTTCCCAGGAACC\nCCAGGCCTTCCTGGTGTCAAAGGTCACAGAGGTTATCCAGGCCTGGACGGTGCTAAGGGA\nGAGGCGGGTGCTCCTGGTGTGAAGGGTGAGAGTGGTTCCCCGGGTGAGAACGGATCTCCG\nGGCCCAATGGGTCCTCGTGGCCTGCCTGGTGAAAGAGGACGGACTGGCCCTGCTGGCGCT\nGCGGGTGCCCGAGGCAACGATGGTCAGCCAGGCCCCGCAGGGCCTCCGGGTCCTGTCGGT\nCCTGCTGGTGGTCCTGGCTTCCCTGGTGCTCCTGGAGCCAAGGGTGAAGCCGGCCCCACT\nGGTGCCCGTGGTCCTGAAGGTGCTCAAGGTCCTCGCGGTGAACCTGGTACTCCTGGGTCC\nCCTGGGCCTGCTGGTGCCTCCGGTAACCCTGGAACAGATGGAATTCCTGGAGCCAAAGGA\nTCTGCTGGTGCTCCTGGCATTGCTGGTGCTCCTGGCTTCCCTGGGCCACGGGGCCCTCCT\nGGCCCTCAAGGTGCAACTGGTCCTCTGGGCCCGAAAGGTCAGACGGGTGAACCTGGTATT\nGCTGGCTTCAAAGGTGAACAAGGCCCCAAGGGAGAACCTGGCCCTGCTGGCCCCCAGGGA\nGCCCCTGGACCCGCTGGTGAAGAAGGCAAGAGAGGTGCCCGTGGAGAGCCTGGTGGCGTT\nGGGCCCATCGGTCCCCCTGGAGAAAGAGGTGCTCCCGGCAACCGCGGTTTCCCAGGTCAA\nGATGGTCTGGCAGGTCCCAAGGGAGCCCCTGGAGAGCGAGGGCCCAGTGGTCTTGCTGGC\nCCCAAGGGAGCCAACGGTGACCCTGGCCGTCCTGGAGAACCTGGCCTTCCTGGAGCCCGG\nGGTCTCACTGGCCGCCCTGGTGATGCTGGTCCTCAAGGCAAAGTTGGCCCTTCTGGAGCC\nCCTGGTGAAGATGGTCGTCCTGGACCTCCAGGTCCTCAGGGGGCTCGTGGGCAGCCTGGT\nGTCATGGGTTTCCCTGGCCCCAAAGGTGCCAACGGTGAGCCTGGCAAAGCTGGTGAGAAG\nGGACTGCCTGGTGCTCCTGGTCTGAGGGGTCTTCCTGGCAAAGATGGTGAGACAGGTGCT\nGCAGGACCCCCTGGCCCTGCTGGACCTGCTGGTGAACGAGGCGAGCAGGGTGCTCCTGGG\nCCATCTGGGTTCCAGGGACTTCCTGGCCCTCCTGGTCCCCCAGGTGAAGGTGGAAAACCA\nGGTGACCAGGGTGTTCCCGGTGAAGCTGGAGCCCCTGGCCTCGTGGGTCCCAGGGGTGAA\nCGAGGTTTCCCAGGTGAACGTGGCTCTCCCGGTGCCCAGGGCCTCCAGGGTCCCCGTGGC\nCTCCCCGGCACTCCTGGCACTGATGGTCCCAAAGGTGCATCTGGCCCAGCAGGCCCCCCT\nGGGGCTCAGGGCCCTCCAGGTCTTCAGGGAATGCCTGGCGAGAGGGGAGCAGCTGGTATC\nGCTGGGCCCAAAGGCGACAGGGGTGACGTTGGTGAGAAAGGCCCTGAGGGAGCCCCTGGA\nAAGGATGGTGGACGAGGCCTGACAGGTCCCATTGGCCCCCCTGGCCCAGCTGGTGCTAAT\nGGCGAGAAGGGAGAAGTTGGACCTCCTGGTCCTGCAGGAAGTGCTGGTGCTCGTGGCGCT\nCCGGGTGAACGTGGAGAGACTGGGCCCCCCGGACCAGCGGGATTTGCTGGGCCTCCTGGT\nGCTGATGGCCAGCCTGGGGCCAAGGGTGAGCAAGGAGAGGCCGGCCAGAAAGGCGATGCT\nGGTGCCCCTGGTCCTCAGGGCCCCTCTGGAGCACCTGGGCCTCAGGGTCCTACTGGAGTG\nACTGGTCCTAAAGGAGCCCGAGGTGCCCAAGGCCCCCCGGGAGCCACTGGATTCCCTGGA\nGCTGCTGGCCGCGTTGGACCCCCAGGCTCCAATGGCAACCCTGGACCCCCTGGTCCCCCT\nGGTCCTTCTGGAAAAGATGGTCCCAAAGGTGCTCGAGGAGACAGCGGCCCCCCTGGCCGA\nGCTGGTGAACCCGGCCTCCAAGGTCCTGCTGGACCCCCTGGCGAGAAGGGAGAGCCTGGA\nGATGACGGTCCCTCTGGTGCCGAAGGTCCACCAGGTCCCCAGGGTCTGGCTGGTCAGAGA\nGGCATCGTCGGTCTGCCTGGGCAACGTGGTGAGAGAGGATTCCCTGGCTTGCCTGGCCCG\nTCGGGTGAGCCCGGCAAGCAGGGTGCTCCTGGAGCATCTGGAGACAGAGGTCCTCCTGGC\nCCCGTGGGTCCTCCTGGCCTGACGGGTCCTGCAGGTGAACCTGGACGAGAGGGAAGCCCC\nGGTGCTGATGGCCCCCCTGGCAGAGATGGCGCTGCTGGAGTCAAGGGTGATCGTGGTGAG\nACTGGTGCTGTGGGAGCTCCTGGAGCCCCTGGGCCCCCTGGCTCCCCTGGCCCCGCTGGT\nCCAACTGGCAAGCAAGGAGACAGAGGAGAAGCTGGTGCACAAGGCCCCATGGGACCCTCA\nGGACCAGCTGGAGCCCGGGGAATCCAGGGTCCTCAAGGCCCCAGAGGTGACAAAGGAGAG\nGCTGGAGAGCCTGGCGAGAGAGGCCTGAAGGGACACCGTGGCTTCACTGGTCTGCAGGGT\nCTGCCCGGCCCTCCTGGTCCTTCTGGAGACCAAGGTGCTTCTGGTCCTGCTGGTCCTTCT\nGGCCCTAGAGGTCCTCCTGGCCCCGTCGGTCCCTCTGGCAAAGATGGTGCTAATGGAATC\nCCTGGCCCCATTGGGCCTCCTGGTCCCCGTGGACGATCAGGCGAAACCGGCCCTGCTGGT\nCCTCCTGGAAATCCTGGACCCCCTGGTCCTCCAGGTCCCCCTGGCCCTGGCATCGACATG\nTCCGCCTTTGCTGGCTTAGGCCCGAGAGAGAAGGGCCCCGACCCCCTGCAGTACATGCGG\nGCCGACCAGGCAGCCGGTGGCCTGAGACAGCATGACGCCGAGGTGGATGCCACACTCAAG\nTCCCTCAACAACCAGATTGAGAGCATCCGCAGCCCCGAGGGCTCCCGCAAGAACCCTGCT\nCGCACCTGCAGAGACCTGAAACTCTGCCACCCTGAGTGGAAGAGTGGAGACTACTGGATT\nGACCCCAACCAAGGCTGCACCTTGGACGCCATGAAGGTTTTCTGCAACATGGAGACTGGC\nGAGACTTGCGTCTACCCCAATCCAGCAAACGTTCCCAAGAAGAACTGGTGGAGCAGCAAG\nAGCAAGGAGAAGAAACACATCTGGTTTGGAGAAACCATCAATGGTGGCTTCCATTTCAGC\nTATGGAGATGACAATCTGGCTCCCAACACTGCCAACGTCCAGATGACCTTCCTACGCCTG\nCTGTCCACGGAAGGCTCCCAGAACATCACCTACCACTGCAAGAACAGCATTGCCTATCTG\nGACGAAGCAGCTGGCAACCTCAAGAAGGCCCTGCTCATCCAGGGCTCCAATGACGTGGAG\nATCCGGGCAGAGGGCAATAGCAGGTTCACGTACACTGCCCTGAAGGATGGCTGCACGAAA\nCATACCGGTAAGTGGGGCAAGACTGTTATCGAGTACCGGTCACAGAAGACCTCACGCCTC\nCCCATCATTGACATTGCACCCATGGACATAGGAGGGCCCGAGCAGGAATTCGGTGTGGAC\nATAGGGCCGGTCTGCTTCTTGTAA'], 'pfams': [{'pfam': [{'identifier': ['PF01410'], 'name': ['COLFI']}, {'identifier': ['PF01391'], 'name': ['Collagen']}, {'identifier': ['PF00093'], 'name': ['VWC']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['basement membrane']}, {'category': ['component'], 'description': ['collagen type II trimer']}, {'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['extracellular matrix']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['function'], 'description': ['extracellular matrix structural constituent conferring tensile strength']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['function'], 'description': ['metal ion binding']}, {'category': ['function'], 'description': ['platelet-derived growth factor binding']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['cartilage condensation']}, {'category': ['process'], 'description': ['cartilage development']}, {'category': ['process'], 'description': ['cartilage development involved in endochondral bone morphogenesis']}, {'category': ['process'], 'description': ['cellular response to BMP stimulus']}, {'category': ['process'], 'description': ['central nervous system development']}, {'category': ['process'], 'description': ['chondrocyte differentiation']}, {'category': ['process'], 'description': ['collagen catabolic process']}, {'category': ['process'], 'description': ['collagen fibril organization']}, {'category': ['process'], 'description': ['embryonic skeletal joint morphogenesis']}, {'category': ['process'], 'description': ['endochondral ossification']}, {'category': ['process'], 'description': ['extracellular matrix disassembly']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['heart morphogenesis']}, {'category': ['process'], 'description': ['inner ear morphogenesis']}, {'category': ['process'], 'description': ['limb bud formation']}, {'category': ['process'], 'description': ['negative regulation of extrinsic apoptotic signaling pathway in absence of ligand']}, {'category': ['process'], 'description': ['notochord development']}, {'category': ['process'], 'description': ['otic vesicle development']}, {'category': ['process'], 'description': ['palate development']}, {'category': ['process'], 'description': ['proteoglycan metabolic process']}, {'category': ['process'], 'description': ['regulation of gene expression']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['sensory perception of sound']}, {'category': ['process'], 'description': ['skeletal system development']}, {'category': ['process'], 'description': ['tissue homeostasis']}, {'category': ['process'], 'description': ['visual perception']}]}]}]}, {'id': ['BE0002130'], 'name': ['Collagen alpha-1(III) chain'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A13198'], 'pubmed-id': ['2145268'], 'citation': ['Cole WG, Chiodo AA, Lamande SR, Janeczko R, Ramirez F, Dahl HH, Chan D, Bateman JF: A base substitution at a splice site in the COL3A1 gene causes exon skipping and generates abnormal type III procollagen in a patient with Ehlers-Danlos syndrome type IV. J Biol Chem. 1990 Oct 5;265(28):17070-7.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Collagen alpha-1(III) chain'], 'general-function': ['Platelet-derived growth factor binding'], 'specific-function': ['Collagen type III occurs in most soft connective tissues along with type I collagen. Involved in regulation of cortical development. Is the major ligand of GPR56 in the developing brain and binding to GPR56 inhibits neuronal migration and activates the RhoA pathway by coupling GPR56 to GNA13 and possibly GNA12.'], 'gene-name': ['COL3A1'], 'locus': ['2q31'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-23'], 'theoretical-pi': ['6.57'], 'molecular-weight': ['138564.005'], 'chromosome-location': ['2'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:2201']}, {'resource': ['GenAtlas'], 'identifier': ['COL3A1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X14420']}, {'resource': ['GenBank Protein Database'], 'identifier': ['30058']}, {'resource': ['UniProtKB'], 'identifier': ['P02461']}, {'resource': ['UniProt Accession'], 'identifier': ['CO3A1_HUMAN']}]}], 'synonyms': [{'synonym': ['Collagen alpha-1(III) chain precursor', 'III']}], 'amino-acid-sequence': ['>lcl|BSEQ0004178|Collagen alpha-1(III) chain\nMMSFVQKGSWLLLALLHPTIILAQQEAVEGGCSHLGQSYADRDVWKPEPCQICVCDSGSV\nLCDDIICDDQELDCPNPEIPFGECCAVCPQPPTAPTRPPNGQGPQGPKGDPGPPGIPGRN\nGDPGIPGQPGSPGSPGPPGICESCPTGPQNYSPQYDSYDVKSGVAVGGLAGYPGPAGPPG\nPPGPPGTSGHPGSPGSPGYQGPPGEPGQAGPSGPPGPPGAIGPSGPAGKDGESGRPGRPG\nERGLPGPPGIKGPAGIPGFPGMKGHRGFDGRNGEKGETGAPGLKGENGLPGENGAPGPMG\nPRGAPGERGRPGLPGAAGARGNDGARGSDGQPGPPGPPGTAGFPGSPGAKGEVGPAGSPG\nSNGAPGQRGEPGPQGHAGAQGPPGPPGINGSPGGKGEMGPAGIPGAPGLMGARGPPGPAG\nANGAPGLRGGAGEPGKNGAKGEPGPRGERGEAGIPGVPGAKGEDGKDGSPGEPGANGLPG\nAAGERGAPGFRGPAGPNGIPGEKGPAGERGAPGPAGPRGAAGEPGRDGVPGGPGMRGMPG\nSPGGPGSDGKPGPPGSQGESGRPGPPGPSGPRGQPGVMGFPGPKGNDGAPGKNGERGGPG\nGPGPQGPPGKNGETGPQGPPGPTGPGGDKGDTGPPGPQGLQGLPGTGGPPGENGKPGEPG\nPKGDAGAPGAPGGKGDAGAPGERGPPGLAGAPGLRGGAGPPGPEGGKGAAGPPGPPGAAG\nTPGLQGMPGERGGLGSPGPKGDKGEPGGPGADGVPGKDGPRGPTGPIGPPGPAGQPGDKG\nEGGAPGLPGIAGPRGSPGERGETGPPGPAGFPGAPGQNGEPGGKGERGAPGEKGEGGPPG\nVAGPPGGSGPAGPPGPQGVKGERGSPGGPGAAGFPGARGLPGPPGSNGNPGPPGPSGSPG\nKDGPPGPAGNTGAPGSPGVSGPKGDAGQPGEKGSPGAQGPPGAPGPLGIAGITGARGLAG\nPPGMPGPRGSPGPQGVKGESGKPGANGLSGERGPPGPQGLPGLAGTAGEPGRDGNPGSDG\nLPGRDGSPGGKGDRGENGSPGAPGAPGHPGPPGPVGPAGKSGDRGESGPAGPAGAPGPAG\nSRGAPGPQGPRGDKGETGERGAAGIKGHRGFPGNPGAPGSPGPAGQQGAIGSPGPAGPRG\nPVGPSGPPGKDGTSGHPGPIGPPGPRGNRGERGSEGSPGHPGQPGPPGPPGAPGPCCGGV\nGAAAIAGIGGEKAGGFAPYYGDEPMDFKINTDEIMTSLKSVNGQIESLISPDGSRKNPAR\nNCRDLKFCHPELKSGEYWVDPNQGCKLDAIKVFCNMETGETCISANPLNVPRKHWWTDSS\nAEKKHVWFGESMDGGFQFSYGNPELPEDVLDVHLAFLRLLSSRASQNITYHCKNSIAYMD\nQASGNVKKALKLMGSNEGEFKAEGNSKFTYTVLEDGCTKHTGEWSKTVFEYRTRKAVRLP\nIVDIAPYDIGGPDQEFGVDVGPVCFL'], 'gene-sequence': ['>lcl|BSEQ0011542|Collagen alpha-1(III) chain (COL3A1)\nATGATGAGCTTTGTGCAAAAGGGGAGCTGGCTACTTCTCGCTCTGCTTCATCCCACTATT\nATTTTGGCACAACAGGAAGCTGTTGAAGGAGGATGTTCCCATCTTGGTCAGTCCTATGCG\nGATAGAGATGTCTGGAAGCCAGAACCATGCCAAATATGTGTCTGTGACTCAGGATCCGTT\nCTCTGCGATGACATAATATGTGACGATCAAGAATTAGACTGCCCCAACCCAGAAATTCCA\nTTTGGAGAATGTTGTGCAGTTTGCCCACAGCCTCCAACTGCTCCTACTCGCCCTCCTAAT\nGGTCAAGGACCTCAAGGCCCCAAGGGAGATCCAGGCCCTCCTGGTATTCCTGGGAGAAAT\nGGTGACCCTGGTATTCCAGGACAACCAGGGTCCCCTGGTTCTCCTGGCCCCCCTGGAATC\nTGTGAATCATGCCCTACTGGTCCTCAGAACTATTCTCCCCAGTATGATTCATATGATGTC\nAAGTCTGGAGTAGCAGTAGGAGGACTCGCAGGCTATCCTGGACCAGCTGGCCCCCCAGGC\nCCTCCCGGTCCCCCTGGTACATCTGGTCATCCTGGTTCCCCTGGATCTCCAGGATACCAA\nGGACCCCCTGGTGAACCTGGGCAAGCTGGTCCTTCAGGCCCTCCAGGACCTCCTGGTGCT\nATAGGTCCATCTGGTCCTGCTGGAAAAGATGGAGAATCAGGTAGACCCGGACGACCTGGA\nGAGCGAGGATTGCCTGGACCTCCAGGTATCAAAGGTCCAGCTGGGATACCTGGATTCCCT\nGGTATGAAAGGACACAGAGGCTTCGATGGACGAAATGGAGAAAAGGGTGAAACAGGTGCT\nCCTGGATTAAAGGGTGAAAATGGTCTTCCAGGCGAAAATGGAGCTCCTGGACCCATGGGT\nCCAAGAGGGGCTCCTGGTGAGCGAGGACGGCCAGGACTTCCTGGGGCTGCAGGTGCTCGG\nGGTAATGACGGTGCTCGAGGCAGTGATGGTCAACCAGGCCCTCCTGGTCCTCCTGGAACT\nGCCGGATTCCCTGGATCCCCTGGTGCTAAGGGTGAAGTTGGACCTGCAGGGTCTCCTGGT\nTCAAATGGTGCCCCTGGACAAAGAGGAGAACCTGGACCTCAGGGACACGCTGGTGCTCAA\nGGTCCTCCTGGCCCTCCTGGGATTAATGGTAGTCCTGGTGGTAAAGGCGAAATGGGTCCC\nGCTGGCATTCCTGGAGCTCCTGGACTGATGGGAGCCCGGGGTCCTCCAGGACCAGCCGGT\nGCTAATGGTGCTCCTGGACTGCGAGGTGGTGCAGGTGAGCCTGGTAAGAATGGTGCCAAA\nGGAGAGCCCGGACCACGTGGTGAACGCGGTGAGGCTGGTATTCCAGGTGTTCCAGGAGCT\nAAAGGCGAAGATGGCAAGGATGGATCACCTGGAGAACCTGGTGCAAATGGGCTTCCAGGA\nGCTGCAGGAGAAAGGGGTGCCCCTGGGTTCCGAGGACCTGCTGGACCAAATGGCATCCCA\nGGAGAAAAGGGTCCTGCTGGAGAGCGTGGTGCTCCAGGCCCTGCAGGGCCCAGAGGAGCT\nGCTGGAGAACCTGGCAGAGATGGCGTCCCTGGAGGTCCAGGAATGAGGGGCATGCCCGGA\nAGTCCAGGAGGACCAGGAAGTGATGGGAAACCAGGGCCTCCCGGAAGTCAAGGAGAAAGT\nGGTCGACCAGGTCCTCCTGGGCCATCTGGTCCCCGAGGTCAGCCTGGTGTCATGGGCTTC\nCCCGGTCCTAAAGGAAATGATGGTGCTCCTGGTAAGAATGGAGAACGAGGTGGCCCTGGA\nGGACCTGGCCCTCAGGGTCCTCCTGGAAAGAATGGTGAAACTGGACCTCAGGGACCCCCA\nGGGCCTACTGGGCCTGGTGGTGACAAAGGAGACACAGGACCCCCTGGTCCACAAGGATTA\nCAAGGCTTGCCTGGTACAGGTGGTCCTCCAGGAGAAAATGGAAAACCTGGGGAACCAGGT\nCCAAAGGGTGATGCCGGTGCACCTGGAGCTCCAGGAGGCAAGGGTGATGCTGGTGCCCCT\nGGTGAACGTGGACCTCCTGGATTGGCAGGGGCCCCAGGACTTAGAGGTGGAGCTGGTCCC\nCCTGGTCCCGAAGGAGGAAAGGGTGCTGCTGGTCCTCCTGGGCCACCTGGTGCTGCTGGT\nACTCCTGGTCTGCAAGGAATGCCTGGAGAAAGAGGAGGTCTTGGAAGTCCTGGTCCAAAG\nGGTGACAAGGGTGAACCAGGCGGTCCAGGTGCTGATGGTGTCCCAGGGAAAGATGGCCCA\nAGGGGTCCTACTGGTCCTATTGGTCCTCCTGGCCCAGCTGGCCAGCCTGGAGATAAGGGT\nGAAGGTGGTGCCCCCGGACTTCCAGGTATAGCTGGACCTCGTGGTAGCCCTGGTGAGAGA\nGGTGAAACTGGCCCTCCAGGACCTGCTGGTTTCCCTGGTGCTCCTGGACAGAATGGTGAA\nCCTGGTGGTAAAGGAGAAAGAGGGGCTCCGGGTGAGAAAGGTGAAGGAGGCCCTCCTGGA\nGTTGCAGGACCCCCTGGAGGTTCTGGACCTGCTGGTCCTCCTGGTCCCCAAGGTGTCAAA\nGGTGAACGTGGCAGTCCTGGTGGACCTGGTGCTGCTGGCTTCCCTGGTGCTCGTGGTCTT\nCCTGGTCCTCCTGGTAGTAATGGTAACCCAGGACCCCCAGGTCCCAGCGGTTCTCCAGGC\nAAGGATGGGCCCCCAGGTCCTGCGGGTAACACTGGTGCTCCTGGCAGCCCTGGAGTGTCT\nGGACCAAAAGGTGATGCTGGCCAACCAGGAGAGAAGGGATCGCCTGGTGCCCAGGGCCCA\nCCAGGAGCTCCAGGCCCACTTGGGATTGCTGGGATCACTGGAGCACGGGGTCTTGCAGGA\nCCACCAGGCATGCCAGGTCCTAGGGGAAGCCCTGGCCCTCAGGGTGTCAAGGGTGAAAGT\nGGGAAACCAGGAGCTAACGGTCTCAGTGGAGAACGTGGTCCCCCTGGACCCCAGGGTCTT\nCCTGGTCTGGCTGGTACAGCTGGTGAACCTGGAAGAGATGGAAACCCTGGATCAGATGGT\nCTTCCAGGCCGAGATGGATCTCCTGGTGGCAAGGGTGATCGTGGTGAAAATGGCTCTCCT\nGGTGCCCCTGGCGCTCCTGGTCATCCAGGCCCACCTGGTCCTGTCGGTCCAGCTGGAAAG\nAGTGGTGACAGAGGAGAAAGTGGCCCTGCTGGCCCTGCTGGTGCTCCCGGTCCTGCTGGT\nTCCCGAGGTGCTCCTGGTCCTCAAGGCCCACGTGGTGACAAAGGTGAAACAGGTGAACGT\nGGAGCTGCTGGCATCAAAGGACATCGAGGATTCCCTGGTAATCCAGGTGCCCCAGGTTCT\nCCAGGCCCTGCTGGTCAGCAGGGTGCAATCGGCAGTCCAGGACCTGCAGGCCCCAGAGGA\nCCTGTTGGACCCAGTGGACCTCCTGGCAAAGATGGAACCAGTGGACATCCAGGTCCCATT\nGGACCACCAGGGCCTCGAGGTAACAGAGGTGAAAGAGGATCTGAGGGCTCCCCAGGCCAC\nCCAGGGCAACCAGGCCCTCCTGGACCTCCTGGTGCCCCTGGTCCTTGCTGTGGTGGTGTT\nGGAGCCGCTGCCATTGCTGGGATTGGAGGTGAAAAAGCTGGCGGTTTTGCCCCGTATTAT\nGGAGATGAACCAATGGATTTCAAAATCAACACCGATGAGATTATGACTTCACTCAAGTCT\nGTTAATGGACAAATAGAAAGCCTCATTAGTCCTGATGGTTCTCGTAAAAACCCCGCTAGA\nAACTGCAGAGACCTGAAATTCTGCCATCCTGAACTCAAGAGTGGAGAATACTGGGTTGAC\nCCTAACCAAGGATGCAAATTGGATGCTATCAAGGTATTCTGTAATATGGAAACTGGGGAA\nACATGCATAAGTGCCAATCCTTTGAATGTTCCACGGAAACACTGGTGGACAGATTCTAGT\nGCTGAGAAGAAACACGTTTGGTTTGGAGAGTCCATGGATGGTGGTTTTCAGTTTAGCTAC\nGGCAATCCTGAACTTCCTGAAGATGTCCTTGATGTGCAGCTGGCATTCCTTCGACTTCTC\nTCCAGCCGAGCTTCCCAGAACATCACATATCACTGCAAAAATAGCATTGCATACATGGAT\nCAGGCCAGTGGAAATGTAAAGAAGGCCCTGAAGCTGATGGGGTCAAATGAAGGTGAATTC\nAAGGCTGAAGGAAATAGCAAATTCACCTACACAGTTCTGGAGGATGGTTGCACGAAACAC\nACTGGGGAATGGAGCAAAACAGTCTTTGAATATCGAACACGCAAGGCTGTGAGACTACCT\nATTGTAGATATTGCACCCTATGACATTGGTGGTCCTGATCAAGAATTTGGTGTGGACGTT\nGGCCCTGTTTGCTTTTTATAA'], 'pfams': [{'pfam': [{'identifier': ['PF01410'], 'name': ['COLFI']}, {'identifier': ['PF01391'], 'name': ['Collagen']}, {'identifier': ['PF00093'], 'name': ['VWC']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['collagen type III trimer']}, {'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['extracellular matrix']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['function'], 'description': ['extracellular matrix structural constituent']}, {'category': ['function'], 'description': ['integrin binding']}, {'category': ['function'], 'description': ['metal ion binding']}, {'category': ['function'], 'description': ['platelet-derived growth factor binding']}, {'category': ['process'], 'description': ['aging']}, {'category': ['process'], 'description': ['aorta smooth muscle tissue morphogenesis']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['cell-matrix adhesion']}, {'category': ['process'], 'description': ['cellular response to amino acid stimulus']}, {'category': ['process'], 'description': ['cerebral cortex development']}, {'category': ['process'], 'description': ['collagen catabolic process']}, {'category': ['process'], 'description': ['collagen fibril organization']}, {'category': ['process'], 'description': ['digestive tract development']}, {'category': ['process'], 'description': ['extracellular fibril organization']}, {'category': ['process'], 'description': ['extracellular matrix disassembly']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['heart development']}, {'category': ['process'], 'description': ['integrin-mediated signaling pathway']}, {'category': ['process'], 'description': ['negative regulation of immune response']}, {'category': ['process'], 'description': ['negative regulation of neuron migration']}, {'category': ['process'], 'description': ['peptide cross-linking']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['positive regulation of Rho protein signal transduction']}, {'category': ['process'], 'description': ['receptor-mediated endocytosis']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['response to cytokine']}, {'category': ['process'], 'description': ['response to mechanical stimulus']}, {'category': ['process'], 'description': ['response to radiation']}, {'category': ['process'], 'description': ['skeletal system development']}, {'category': ['process'], 'description': ['skin development']}, {'category': ['process'], 'description': ['transforming growth factor beta receptor signaling pathway']}, {'category': ['process'], 'description': ['wound healing']}]}]}]}]}]"
"['DB00049', 'BTD00090', 'BIOD00090']",['Rasburicase'],biotech,['Rasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified <i>Saccharomyces cerevisiae</i> strain. The cDNA coding for rasburicase was cloned from a strain of _Aspergillus flavus_.'],['liquid'],"['For treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy)']",['Rasburicase catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin).'],[None],"[{'target': [{'id': ['BE0004823'], 'name': ['Uric acid'], 'organism': ['Humans'], 'actions': [{'action': ['metabolizer']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A6675'], 'pubmed-id': ['16809136'], 'citation': ['Cete S, Yasar A, Arslan F: An amperometric biosensor for uric acid determination prepared from uricase immobilized in polypyrrole film. Artif Cells Blood Substit Immobil Biotechnol. 2006;34(3):367-80.']}, {'ref-id': ['A6676'], 'pubmed-id': ['16545381'], 'citation': [""Gabison L, Chiadmi M, Colloc'h N, Castro B, El Hajji M, Prange T: Recapture of [S]-allantoin, the product of the two-step degradation of uric acid, by urate oxidase. FEBS Lett. 2006 Apr 3;580(8):2087-91. Epub 2006 Mar 10.""]}, {'ref-id': ['A6677'], 'pubmed-id': ['16689679'], 'citation': ['Zhao Y, Zhao L, Yang G, Tao J, Bu Y, Liao F: Characterization of a uricase from Bacillus fastidious A.T.C.C. 26904 and its application to serum uric acid assay by a patented kinetic uricase method. Biotechnol Appl Biochem. 2006 Sep;45(Pt 2):75-80.']}, {'ref-id': ['A6678'], 'pubmed-id': ['20394650'], 'citation': ['Giraldez M, Puto K: A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults. Eur J Haematol. 2010 Aug;85(2):177-9. doi: 10.1111/j.1600-0609.2010.01457.x. Epub 2010 Apr 12.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes']}]}]"
"['DB00050', 'BTD00115', 'APRD00686', 'BIOD00115']",['Cetrorelix'],small molecule,"['Cetrorelix is a man-made hormone that blocks the effects of Gonadotropin Releasing Hormone (GnRH). GnRH controls another hormone that is called luteinizing hormone (LH), which is the hormone that starts ovulation during the menstrual cycle. When undergoing hormone treatment sometimes premature ovulation can occur, leading to eggs that are not ready for fertilization to be released. Cetrorelix does not allow the premature release of these eggs to occur.']",['solid'],['For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation'],['Cetrorelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion. It competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner.'],[None],"[{'target': [{'id': ['BE0000203'], 'name': ['Gonadotropin-releasing hormone receptor'], 'organism': ['Humans'], 'actions': [{'action': ['antagonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A11389'], 'pubmed-id': ['11854630'], 'citation': ['Volker P, Grundker C, Schmidt O, Schulz KD, Emons G: Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol. 2002 Feb;186(2):171-9.']}, {'ref-id': ['A11390'], 'pubmed-id': ['12606421'], 'citation': ['Zapatero-Caballero H, Sanchez-Franco F, Guerra-Perez N, Fernandez-Mendez C, Fernandez-Vazquez G: Gonadotropin-releasing hormone receptor gene expression during pubertal development of male rats. Biol Reprod. 2003 May;68(5):1764-70. Epub 2002 Dec 11.']}, {'ref-id': ['A11391'], 'pubmed-id': ['14561652'], 'citation': ['Zapatero-Caballero H, Sanchez-Franco F, Fernandez-Mendez C, Garcia-San Frutos M, Botella-Cubells LM, Fernandez-Vazquez G: Gonadotropin-releasing hormone receptor gene expression during pubertal development of female rats. Biol Reprod. 2004 Feb;70(2):348-55. Epub 2003 Oct 15.']}, {'ref-id': ['A11392'], 'pubmed-id': ['14605254'], 'citation': ['Roth C, Hegemann F, Hildebrandt J, Balzer I, Witt A, Wuttke W, Jarry H: Pituitary and gonadal effects of GnRH (gonadotropin releasing hormone) analogues in two peripubertal female rat models. Pediatr Res. 2004 Jan;55(1):126-33. Epub 2003 Nov 6.']}, {'ref-id': ['A1743'], 'pubmed-id': ['16809153'], 'citation': ['Castellon E, Clementi M, Hitschfeld C, Sanchez C, Benitez D, Saenz L, Contreras H, Huidobro C: Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest. 2006 Apr-May;24(3):261-8.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Gonadotropin-releasing hormone receptor'], 'general-function': ['Peptide binding'], 'specific-function': ['Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This receptor mediates its action by association with G-proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act as an inhibitor of GnRH-R signaling.'], 'gene-name': ['GNRHR'], 'locus': ['4q21.2'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['39-58\n78-97\n116-137\n165-184\n213-232\n282-300\n307-326'], 'signal-regions': [None], 'theoretical-pi': ['9.93'], 'molecular-weight': ['37730.355'], 'chromosome-location': ['4'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:4421']}, {'resource': ['GenAtlas'], 'identifier': ['GNRHR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L03380']}, {'resource': ['GenBank Protein Database'], 'identifier': ['183422']}, {'resource': ['IUPHAR'], 'identifier': ['256']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['256']}, {'resource': ['UniProtKB'], 'identifier': ['P30968']}, {'resource': ['UniProt Accession'], 'identifier': ['GNRHR_HUMAN']}]}], 'synonyms': [{'synonym': ['GnRH receptor', 'GRHR']}], 'amino-acid-sequence': ['>lcl|BSEQ0000405|Gonadotropin-releasing hormone receptor\nMANSASPEQNQNHCSAINNSIPLMQGNLPTLTLSGKIRVTVTFFLFLLSATFNASFLLKL\nQKWTQKKEKGKKLSRMKLLLKHLTLANLLETLIVMPLDGMWNITVQWYAGELLCKVLSYL\nKLFSMYAPAFMMVVISLDRSLAITRPLALKSNSKVGQSMVGLAWILSSVFAGPQLYIFRM\nIHLADSSGQTKVFSQCVTHCSFSQWWHQAFYNFFTFSCLFIIPLFIMLICNAKIIFTLTR\nVLHQDPHELQLNQSKNNIPRARLKTLKMTVAFATSFTVCWTPYYVLGIWYWFDPEMLNRL\nSDPVNHFFFLFAFLNPCFDPLIYGYFSL'], 'gene-sequence': ['>lcl|BSEQ0018926|Gonadotropin-releasing hormone receptor (GNRHR)\nATGGCAAACAGTGCCTCTCCTGAACAGAATCAAAATCACTGTTCAGCCATCAACAACAGC\nATCCCACTGATGCAGGGCAACCTCCCCACTCTGACCTTGTCTGGAAAGATCCGAGTGACG\nGTTACTTTCTTCCTTTTTCTGCTCTCTGCGACCTTTAATGCTTCTTTCTTGTTGAAACTT\nCAGAAGTGGACACAGAAGAAAGAGAAAGGGAAAAAGCTCTCAAGAATGAAGCTGCTCTTA\nAAACATCTGACCTTAGCCAACCTGTTGGAGACTCTGATTGTCATGCCACTGGATGGGATG\nTGGAACATTACAGTCCAATGGTATGCTGGAGAGTTACTCTGCAAAGTTCTCAGTTATCTA\nAAGCTTTTCTCCATGTATGCCCCAGCCTTCATGATGGTGGTGATCAGCCTGGACCGCTCC\nCTGGCTATCACGAGGCCCCTAGCTTTGAAAAGCAACAGCAAAGTCGGACAGTCCATGGTT\nGGCCTGGCCTGGATCCTCAGTAGTGTCTTTGCAGGACCACAGTTATACATCTTCAGGATG\nATTCATCTAGCAGACAGCTCTGGACAGACAAAAGTTTTCTCTCAATGTGTAACACACTGC\nAGTTTTTCACAATGGTGGCATCAAGCATTTTATAACTTTTTCACCTTCAGCTGCCTCTTC\nATCATCCCTCTTTTCATCATGCTGATCTGCAATGCAAAAATCATCTTCACCCTGACACGG\nGTCCTTCATCAGGACCCCCACGAACTACAACTGAATCAGTCCAAGAACAATATACCAAGA\nGCACGGCTGAAGACTCTAAAAATGACGGTTGCATTTGCCACTTCATTTACTGTCTGCTGG\nACTCCCTACTATGTCCTAGGAATTTGGTATTGGTTTGATCCTGAAATGTTAAACAGGTTG\nTCAGACCCAGTAAATCACTTCTTCTTTCTCTTTGCCTTTTTAAACCCATGCTTTGATCCA\nCTTATCTATGGATATTTTTCTCTGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['gonadotropin-releasing hormone receptor activity']}, {'category': ['function'], 'description': ['peptide binding']}, {'category': ['process'], 'description': ['cellular response to gonadotropin-releasing hormone']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['multicellular organismal development']}]}]}]}, {'id': ['BE0000134'], 'name': ['Lutropin-choriogonadotropic hormone receptor'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A1942'], 'pubmed-id': ['11943741'], 'citation': ['Ascoli M, Fanelli F, Segaloff DL: The lutropin/choriogonadotropin receptor, a 2002 perspective. Endocr Rev. 2002 Apr;23(2):141-74.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Lutropin-choriogonadotropic hormone receptor'], 'general-function': ['Luteinizing hormone receptor activity'], 'specific-function': ['Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase.'], 'gene-name': ['LHCGR'], 'locus': ['2p21'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['364-385\n396-416\n440-462\n483-505\n526-549\n571-594\n606-627'], 'signal-regions': ['1-26'], 'theoretical-pi': ['8.58'], 'molecular-weight': ['78642.01'], 'chromosome-location': ['2'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6585']}, {'resource': ['GenAtlas'], 'identifier': ['LHCGR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M73746']}, {'resource': ['GenBank Protein Database'], 'identifier': ['903746']}, {'resource': ['IUPHAR'], 'identifier': ['254']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['254']}, {'resource': ['UniProtKB'], 'identifier': ['P22888']}, {'resource': ['UniProt Accession'], 'identifier': ['LSHR_HUMAN']}]}], 'synonyms': [{'synonym': ['LCGR', 'LGR2', 'LH/CG-R', 'LHR', 'LHRHR', 'LSH-R', 'Luteinizing hormone receptor']}], 'amino-acid-sequence': ['>lcl|BSEQ0036957|Lutropin-choriogonadotropic hormone receptor\nMKQRFSALQLLKLLLLLQPPLPRALREALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLP\nVKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFI\nNLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLK\nLYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSY\nGLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENF\nSKQCESTVRKVNNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYD\nFLRVLIWLINILAIMGNMTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIASVDS\nQTKGQYYNHAIDWQTGSGCSTAGFFTVFASELSVYTLTVITLERWHTITYAIHLDQKLRL\nRHAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETTLSQVYILTILILNVVAFF\nIICACYIKIYFAVRNPELMATNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKVPLIT\nVTNSKVLLVLFYPINSCANPFLYAIFTKTFQRDFFLLLSKFGCCKRRAELYRRKDFSAYT\nSNCKNGFTGSNKPSQSTLKLSTLHCQGTALLDKTRYTEC'], 'gene-sequence': ['>lcl|BSEQ0010174|Lutropin-choriogonadotropic hormone receptor (LHCGR)\nATGAAGCAGCGGTTCTCGGCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGCCGCCG\nCTGCCACGAGCGCTGCGCGAGGCGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGC\nGCCCTGCGCTGCCCCGGCCCCACGGCCGGTCTCACTCGACTATCACTTGCCTACCTCCCT\nGTCAAAGTGATCCCATCTCAAGCTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATC\nTCTCAGATTGATTCCCTGGAAAGGATAGAAGCTAATGCCTTTGACAACCTCCTCAATTTG\nTCTGAAATACTGATCCAGAACACCAAAAATCTGAGATACATTGAGCCCGGAGCATTTATA\nAATCTTCCCCGATTAAAATACTTGAGCATCTGTAACACAGGCATCAGAAAGTTTCCAGAT\nGTTACGAAGGTCTTCTCCTCTGAATCAAATTTCATTCTGGAAATTTGTGATAACTTACAC\nATAACCACCATACCAGGAAATGCTTTTCAAGGGATGAATAATGAATCTGTAACACTCAAA\nCTATATGGAAATGGATTTGAAGAAGTACAAAGTCATGCATTCAATGGGACGACACTGACT\nTCACTGGAGCTAAAGGAAAACGTACATCTGGAGAAGATGCACAATGGAGCCTTCCGTGGG\nGCCACAGGGCCGAAAACCTTGGATATTTCTTCCACCAAATTGCAGGCCCTGCCGAGCTAT\nGGCCTAGAGTCCATTCAGAGGCTAATTGCCACGTCATCCTATTCTCTAAAAAAATTGCCA\nTCAAGAGAAACATTTGTCAATCTCCTGGAGGCCACGTTGACTTACCCCAGCCACTGCTGT\nGCTTTTAGAAACTTGCCAACAAAAGAACAGAATTTTTCACATTCCATTTCTGAAAACTTT\nTCCAAACAATGTGAAAGCACAGTAAGGAAAGTGAATAACAAAACACTTTATTCTTCCATG\nCTTGCTGAGAGTGAACTGAGTGGCTGGGACTATGAATATGGTTTCTGCTTACCCAAGACA\nCCCCGATGTGCTCCTGAACCAGATGCTTTTAATCCCTGTGAAGATATTATGGGCTATGAC\nTTCCTTAGGGTCCTGATTTGGCTGATTAATATTCTAGCCATCATGGGAAACATGACTGTT\nCTTTTTGTTCTCCTGACAAGTCGTTACAAACTTACAGTGCCTCGTTTTCTCATGTGCAAT\nCTCTCCTTTGCAGACTTTTGCATGGGGCTCTATCTGCTGCTCATAGCCTCAGTTGATTCC\nCAAACCAAGGGCCAGTACTATAACCATGCCATAGACTGGCAGACAGGGAGTGGGTGCAGC\nACTGCTGGCTTTTTCACTGTATTCGCAAGTGAACTTTCTGTCTACACCCTCACCGTCATC\nACTCTAGAAAGATGGCACACCATCACCTATGCTATTCACCTGGACCAAAAGCTGCGATTA\nAGACATGCCATTCTGATTATGCTTGGAGGATGGCTCTTTTCTTCTCTAATTGCTATGTTG\nCCCCTTGTCGGTGTCAGCAATTACATGAAGGTCAGTATTTGCTTCCCCATGGATGTGGAA\nACCACTCTCTCACAAGTCTATATATTAACCATCCTGATTCTCAATGTGGTGGCCTTCTTC\nATAATTTGTGCTTGCTACATTAAAATTTATTTTGCAGTTCGAAACCCAGAATTAATGGCT\nACCAATAAAGATACAAAGATTGCTAAGAAAATGGCAATCCTCATCTTCACCGATTTCACC\nTGCATGGCACCTATCTCTTTTTTTGCCATCTCAGCTGCCTTCAAAGTACCTCTTATCACA\nGTAACCAACTCTAAAGTTTTACTGGTTCTTTTTTATCCCATCAATTCTTGTGCCAATCCA\nTTTCTGTATGCAATATTCACTAAGACATTCCAAAGAGATTTCTTTCTTTTGCTGAGCAAA\nTTTGGCTGCTGTAAACGTCGGGCTGAACTTTATAGAAGGAAAGATTTTTCAGCTTACACC\nTCCAACTGCAAAAATGGCTTCACTGGATCAAATAAGCCTTCTCAATCCACCTTGAAGTTG\nTCCACATTGCACTGTCAAGGTACAGCTCTCCTAGACAAGACTCGCTACACAGAGTGTTAA\n'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}, {'identifier': ['PF13306'], 'name': ['LRR_5']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['choriogonadotropin hormone binding']}, {'category': ['function'], 'description': ['choriogonadotropin hormone receptor activity']}, {'category': ['function'], 'description': ['G-protein coupled peptide receptor activity']}, {'category': ['function'], 'description': ['luteinizing hormone receptor activity']}, {'category': ['process'], 'description': ['activation of adenylate cyclase activity']}, {'category': ['process'], 'description': ['adenylate cyclase-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular response to gonadotropin stimulus']}, {'category': ['process'], 'description': ['cognition']}, {'category': ['process'], 'description': ['female gonad development']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger']}, {'category': ['process'], 'description': ['hormone-mediated signaling pathway']}, {'category': ['process'], 'description': ['luteinizing hormone signaling pathway']}, {'category': ['process'], 'description': ['male genitalia development']}, {'category': ['process'], 'description': ['male gonad development']}, {'category': ['process'], 'description': ['ovulation cycle process']}, {'category': ['process'], 'description': ['phospholipase C-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of cAMP-mediated signaling']}, {'category': ['process'], 'description': ['positive regulation of inositol trisphosphate biosynthetic process']}, {'category': ['process'], 'description': ['spermatogenesis']}, {'category': ['process'], 'description': ['uterus development']}]}]}]}]}]"
"['DB00051', 'BTD00049', 'BIOD00049']",['Adalimumab'],biotech,"['Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor.[A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA.[A39983] This drug is frequently known as _Humira_. It is produced by recombinant DNA technology using a mammalian cell expression system. This drug is available in a prefilled syringe form and convenient pen form for subcutaneous self-administered doses.[A39983] \r\n\r\nSeveral biosimilars to adalimumab. Adalimumab-atto was the first adalimumab biosimilar approved by the FDA in 2016.[L44953] Adalimumab-adaz was approved by the FDA on October 31, 2018.[L4799] Other biosimilars include adalimumab-fkjp - which was approved in July 2022 -,[L42495] adalimumab-bwwd - which was approved in August 2022 -,[L42935] and adalimumab-aacf - which was approved in October 2023.[L49101] A biosimilar marketed as Hyrimoz, a high-concentration formulation of adalimumab, is also available.[L45643,L45818]']",['liquid'],"['Adalimumab is indicated for the following conditions:[L49101]\r\n\r\n- Moderately to severely active Rheumatoid Arthritis (RA) in adults, as monotherapy or in combination with [methotrexate] or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).[L42290, L42495, L42935, L44953, L45643, L45818, L49101]\r\n- Moderately to severely active polyarticular Juvenile Idiopathic Arthritis (JIA) in patients two years of age and older, as monotherapy or in combination with [methotrexate].[L42290, L42495, L42935, L44953, L45643, L45818, L49101]\r\n- Psoriatic Arthritis (PsA) in adults.[L42290, L42495, L42935, L44953, L45643, L45818, L49101]\r\n- Ankylosing Spondylitis (AS) in adults.[L42290, L42495, L42935, L44953, L45643, L45818, L49101]\r\n- Moderately to severely active Crohns Disease (CD) in adults and pediatric patients six years of age and older.[L42290, L42495, L42935, L44953, L45643, L45818, L49101]\r\n- Moderately to severely active Ulcerative Colitis (UC) in adults. Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers.[L42290, L42495, L42935, L44953, L45643, L45818, L49101]\r\n- Moderate to severe chronic plaque psoriasis in adult candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate.[L42290, L42495, L42935, L44953, L45643, L45818, L49101]\r\n- Moderate to severe Hidradenitis Suppurativa (HS) in adults.[L44953]\r\n- Non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients two years of age and older.[L35370]\r\n\r\nAdalimumab has also been used off-label to treat Pyoderma gangrenosum.[A40001,A40002]']","['Adalimumab binds with specificity to tumor necrosis factor-alpha (TNF-alpha) and inhibits its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface tumor necrosis factor expressing cells in vitro when in the presence of complement.[A39984,A39999] Adalimumab does not bind or inactivate lymphotoxin (Tumor necrosis factor-beta). TNF is a naturally occurring cytokine that plays a role in normal inflammatory and immune responses.[A39999] Increased levels of TNF are found in the joint synovial fluid of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis patients, and play an imperative role in pathologic inflammation and joint destruction that are major complications of these diseases. Increased levels of TNF are also measured in psoriasis plaques. In plaque psoriasis, treatment with adalimumab may decrease the epidermal thickness and inflammatory cell infiltration. The relationship between these pharmacodynamics and the mechanism(s) by which adalimumab achieves its clinical effects is not known. Additionally, adalimumab alters biological responses that are induced/regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration during inflammation (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 1-2 X 10-10M).[L35370]']",[None],"[{'target': [{'id': ['BE0000704'], 'name': ['Tumor necrosis factor'], 'organism': ['Humans'], 'actions': [{'action': ['inhibitor', 'antibody']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1943'], 'pubmed-id': ['12044041'], 'citation': ['Lorenz HM: Technology evaluation: adalimumab, Abbott laboratories. Curr Opin Mol Ther. 2002 Apr;4(2):185-90.']}, {'ref-id': ['A1946'], 'pubmed-id': ['14532145'], 'citation': ['Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL: Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii30-3.']}, {'ref-id': ['A1948'], 'pubmed-id': ['15022409'], 'citation': ['Aguillon JC, Contreras J, Dotte A, Cruzat A, Catalan D, Salazar L, Molina MC, Guerrero J, Lopez M, Soto L, Salazar-Onfray F, Cuchacovich M: [New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies]. Rev Med Chil. 2003 Dec;131(12):1445-53.']}, {'ref-id': ['A1951'], 'pubmed-id': ['15046527'], 'citation': ['Bang LM, Keating GM: Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs. 2004;18(2):121-39.']}, {'ref-id': ['A249125'], 'pubmed-id': ['31075754'], 'citation': ['Matusiak L, Jemec GB, Szepietowski JC: Pharmacological development in hidradenitis suppurativa. Curr Opin Pharmacol. 2019 Jun;46:65-72. doi: 10.1016/j.coph.2019.04.006. Epub 2019 May 7.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Tumor necrosis factor'], 'general-function': ['Tumor necrosis factor receptor binding'], 'specific-function': [""Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Upregulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective (PubMed:23396208). Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line (PubMed:22517918).The TNF intracellular domain (ICD) form induces IL12 production in dendritic cells.""], 'gene-name': ['TNF'], 'locus': ['6p21.3'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['36-56'], 'signal-regions': [None], 'theoretical-pi': ['6.92'], 'molecular-weight': ['25644.15'], 'chromosome-location': ['6'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:11892']}, {'resource': ['GenAtlas'], 'identifier': ['TNF']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M16441']}, {'resource': ['GenBank Protein Database'], 'identifier': ['339741']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2635']}, {'resource': ['UniProtKB'], 'identifier': ['P01375']}, {'resource': ['UniProt Accession'], 'identifier': ['TNFA_HUMAN']}]}], 'synonyms': [{'synonym': ['Cachectin', 'TNF-a', 'TNF-alpha', 'TNFA', 'TNFSF2', 'Tumor necrosis factor ligand superfamily member 2']}], 'amino-acid-sequence': ['>lcl|BSEQ0001404|Tumor necrosis factor\nMSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQR\nEEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELR\nDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRE\nTPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL'], 'gene-sequence': ['>lcl|BSEQ0021837|Tumor necrosis factor (TNF)\nATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAG\nACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATC\nGTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGG\nGAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCT\nTCTCGAACCCCGAGTGACAAGCCTGTAGCCCATGTTGTAGCAAACCCTCAAGCTGAGGGG\nCAGCTCCAGTGGCTGAACCGCCGGGCCAATGCCCTCCTGGCCAATGGCGTGGAGCTGAGA\nGATAACCAGCTGGTGGTGCCATCAGAGGGCCTGTACCTCATCTACTCCCAGGTCCTCTTC\nAAGGGCCAAGGCTGCCCCTCCACCCATGTGCTCCTCACCCACACCATCAGCCGCATCGCC\nGTCTCCTACCAGACCAAGGTCAACCTCCTCTCTGCCATCAAGAGCCCCTGCCAGAGGGAG\nACCCCAGAGGGGGCTGAGGCCAAGCCCTGGTATGAGCCCATCTATCTGGGAGGGGTCTTC\nCAGCTGGAGAAGGGTGACCGACTCAGCGCTGAGATCAATCGGCCCGACTATCTCGACTTT\nGCCGAGTCTGGGCAGGTCTACTTTGGGATCATTGCCCTGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00229'], 'name': ['TNF']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['membrane raft']}, {'category': ['component'], 'description': ['phagocytic cup']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['recycling endosome']}, {'category': ['function'], 'description': ['cytokine activity']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['function'], 'description': ['transcription regulatory region DNA binding']}, {'category': ['function'], 'description': ['tumor necrosis factor receptor binding']}, {'category': ['process'], 'description': ['activation of cysteine-type endopeptidase activity involved in apoptotic process']}, {'category': ['process'], 'description': ['activation of MAPK activity']}, {'category': ['process'], 'description': ['activation of MAPKKK activity']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular response to amino acid stimulus']}, {'category': ['process'], 'description': ['cellular response to nicotine']}, {'category': ['process'], 'description': ['cellular response to organic cyclic compound']}, {'category': ['process'], 'description': ['chronic inflammatory response to antigenic stimulus']}, {'category': ['process'], 'description': ['cortical actin cytoskeleton organization']}, {'category': ['process'], 'description': ['death-inducing signaling complex assembly']}, {'category': ['process'], 'description': ['defense response to Gram-positive bacterium']}, {'category': ['process'], 'description': ['embryonic digestive tract development']}, {'category': ['process'], 'description': ['epithelial cell proliferation involved in salivary gland morphogenesis']}, {'category': ['process'], 'description': ['establishment of protein localization to plasma membrane']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['extrinsic apoptotic signaling pathway']}, {'category': ['process'], 'description': ['extrinsic apoptotic signaling pathway via death domain receptors']}, {'category': ['process'], 'description': ['glucose metabolic process']}, {'category': ['process'], 'description': ['humoral immune response']}, {'category': ['process'], 'description': ['I-kappaB kinase/NF-kappaB signaling']}, {'category': ['process'], 'description': ['inflammatory response']}, {'category': ['process'], 'description': ['intrinsic apoptotic signaling pathway in response to DNA damage']}, {'category': ['process'], 'description': ['JNK cascade']}, {'category': ['process'], 'description': ['leukocyte tethering or rolling']}, {'category': ['process'], 'description': ['lipopolysaccharide-mediated signaling pathway']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['necroptotic signaling pathway']}, {'category': ['process'], 'description': ['negative regulation of alkaline phosphatase activity']}, {'category': ['process'], 'description': ['negative regulation of bicellular tight junction assembly']}, {'category': ['process'], 'description': ['negative regulation of branching involved in lung morphogenesis']}, {'category': ['process'], 'description': ['negative regulation of cytokine secretion involved in immune response']}, {'category': ['process'], 'description': ['negative regulation of extrinsic apoptotic signaling pathway in absence of ligand']}, {'category': ['process'], 'description': ['negative regulation of fat cell differentiation']}, {'category': ['process'], 'description': ['negative regulation of gene expression']}, {'category': ['process'], 'description': ['negative regulation of glucose import']}, {'category': ['process'], 'description': ['negative regulation of growth of symbiont in host']}, {'category': ['process'], 'description': ['negative regulation of interleukin-6 production']}, {'category': ['process'], 'description': ['negative regulation of lipid catabolic process']}, {'category': ['process'], 'description': ['negative regulation of lipid storage']}, {'category': ['process'], 'description': ['negative regulation of myoblast differentiation']}, {'category': ['process'], 'description': ['negative regulation of myosin-light-chain-phosphatase activity']}, {'category': ['process'], 'description': ['negative regulation of osteoblast differentiation']}, {'category': ['process'], 'description': ['negative regulation of protein complex disassembly']}, {'category': ['process'], 'description': ['negative regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['negative regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['negative regulation of viral genome replication']}, {'category': ['process'], 'description': ['osteoclast differentiation']}, {'category': ['process'], 'description': ['positive regulation of apoptotic process']}, {'category': ['process'], 'description': ['positive regulation of calcidiol 1-monooxygenase activity']}, {'category': ['process'], 'description': ['positive regulation of cell adhesion']}, {'category': ['process'], 'description': ['positive regulation of ceramide biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of chemokine (C-X-C motif) ligand 2 production']}, {'category': ['process'], 'description': ['positive regulation of chemokine biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of chemokine production']}, {'category': ['process'], 'description': ['positive regulation of chronic inflammatory response to antigenic stimulus']}, {'category': ['process'], 'description': ['positive regulation of cysteine-type endopeptidase activity involved in apoptotic process']}, {'category': ['process'], 'description': ['positive regulation of cytokine production']}, {'category': ['process'], 'description': ['positive regulation of cytokine secretion']}, {'category': ['process'], 'description': ['positive regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['positive regulation of fever generation']}, {'category': ['process'], 'description': ['positive regulation of gene expression']}, {'category': ['process'], 'description': ['positive regulation of hair follicle development']}, {'category': ['process'], 'description': ['positive regulation of heterotypic cell-cell adhesion']}, {'category': ['process'], 'description': ['positive regulation of humoral immune response mediated by circulating immunoglobulin']}, {'category': ['process'], 'description': ['positive regulation of I-kappaB kinase/NF-kappaB signaling']}, {'category': ['process'], 'description': ['positive regulation of interferon-gamma production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-6 production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-8 biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of interleukin-8 production']}, {'category': ['process'], 'description': ['positive regulation of JUN kinase activity']}, {'category': ['process'], 'description': ['positive regulation of MAP kinase activity']}, {'category': ['process'], 'description': ['positive regulation of membrane protein ectodomain proteolysis']}, {'category': ['process'], 'description': ['positive regulation of mononuclear cell migration']}, {'category': ['process'], 'description': ['positive regulation of NF-kappaB import into nucleus']}, {'category': ['process'], 'description': ['positive regulation of NF-kappaB transcription factor activity']}, {'category': ['process'], 'description': ['positive regulation of NFAT protein import into nucleus']}, {'category': ['process'], 'description': ['positive regulation of NIK/NF-kappaB signaling']}, {'category': ['process'], 'description': ['positive regulation of nitric oxide biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of osteoclast differentiation']}, {'category': ['process'], 'description': ['positive regulation of peptidyl-serine phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of phagocytosis']}, {'category': ['process'], 'description': ['positive regulation of podosome assembly']}, {'category': ['process'], 'description': ['positive regulation of programmed cell death']}, {'category': ['process'], 'description': ['positive regulation of protein complex assembly']}, {'category': ['process'], 'description': ['positive regulation of protein complex disassembly']}, {'category': ['process'], 'description': ['positive regulation of protein kinase activity']}, {'category': ['process'], 'description': ['positive regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['positive regulation of protein localization to cell surface']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of protein transport']}, {'category': ['process'], 'description': ['positive regulation of sequence-specific DNA binding transcription factor activity']}, {'category': ['process'], 'description': ['positive regulation of smooth muscle cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['positive regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['positive regulation of translational initiation by iron']}, {'category': ['process'], 'description': ['positive regulation of vitamin D biosynthetic process']}, {'category': ['process'], 'description': ['protein import into nucleus, translocation']}, {'category': ['process'], 'description': ['protein kinase B signaling']}, {'category': ['process'], 'description': ['receptor biosynthetic process']}, {'category': ['process'], 'description': ['regulation of branching involved in salivary gland morphogenesis']}, {'category': ['process'], 'description': ['regulation of establishment of endothelial barrier']}, {'category': ['process'], 'description': ['regulation of I-kappaB kinase/NF-kappaB signaling']}, {'category': ['process'], 'description': ['regulation of immunoglobulin secretion']}, {'category': ['process'], 'description': ['regulation of insulin secretion']}, {'category': ['process'], 'description': ['regulation of tumor necrosis factor-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to glucocorticoid']}, {'category': ['process'], 'description': ['response to salt stress']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['sequestering of triglyceride']}, {'category': ['process'], 'description': ['transformed cell apoptotic process']}, {'category': ['process'], 'description': ['tumor necrosis factor-mediated signaling pathway']}]}]}]}]}]"
"['DB00052', 'BTD00086', 'BIOD00086', 'DB06417']",['Somatotropin'],biotech,"['Human growth hormone (HGH), also known as somatotropin, is a peptide hormone that is synthesized and secreted by the somatotropic cells of the anterior pituitary gland.[A228183] Growth hormone plays an essential role in growth regulation during childhood as well as other basal metabolic functions, muscle and fat mass regulation, blood glucose level regulation, and lipid regulation in both children and adults.[A228183, L31508] Synthesized in a strain of _Escherichia coli_, recombinant HGH is a polypeptide hormone that contains 191 amino acid residues with a molecular weight of 22 kDa. It has an identical primary protein structure to endogenous human growth hormone.[A228188] Recombinant HGH has been commercially available since 1985 after its development by Genentech. [Somatrem] was the first available recombinant HGH and was largely replaced by somatropin, another form of recombinant HGH.[A228183] \r\n\r\nGrowth hormone therapy is approved for various disorders of growth hormone deficiency, growth failure, or short stature including Turner syndrome, chronic renal insufficiency before transplantation, Prader-Willi syndrome, a history of fetal growth restriction, short stature homeobox (SHOX) haploinsufficiency, Noonan syndrome, idiopathic short stature, and adult- or childhood-onset growth hormone deficiency.[A228188] Recombinant growth hormone is available as a subcutaneous injection for children and adults under a wide variety of brand names.']",['liquid'],"['Somatotropin is indicated for the treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone, short stature associated with Turner syndrome, Prader-Willi syndrome (PWS), idiopathic short stature (ISS), short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, and short stature born small for gestational age (SGA).[L31513, L31518] It is indicated for the treatment of growth failure in children associated with chronic kidney disease up to the time of renal transplantation.[L31523]\r\n\r\nIt is also indicated for adults with adult-onset growth hormone deficiency, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma. It is also used to treat childhood-onset growth hormone deficiency in adults due to congenital, genetic, acquired, or idiopathic causes.[L31518]\r\n\r\nSomatotropin is indicated for the treatment of wasting or cachexia in patients with human immunodeficiency virus (HIV) who are receiving antiretroviral therapy to increase lean body mass and body weight and improve physical endurance.[L31498]\r\n\r\nSomatotropin is indicated for the treatment of short bowel syndrome in adult patients receiving specialized nutritional support.[L31493]']","['In conditions of growth failure, growth hormone deficiency, low body mass, and malnutrition, somatotropin treatment acts to mimic and restore the actions of endogenous growth hormone of stimulating linear bone growth, increasing bone mass, increasing muscle and reduced fat mass, and regulating blood glucose and lipid levels.[A228183] Somatotropin mediates its effects both directly by somatotropin and indirectly by insulin-like growth factor-1 (IGF-1), which is upregulated by growth hormone. It binds to the human growth hormone receptor (GHR), which is a dimeric receptor expressed in target cells in the liver and cartilage.[L10971] Upon binding of growth hormone, GHR dimerizes and interacts with Janus kinase 2 (JAK2), subsequently leading to tyrosine phosphorylation of JAK2 and the GH receptor. The signal transducer activator of transcription (STAT) pathway is initiated, where transcription factors such as STAT1, STAT3, and STAT5 are translocated into the nucleus to stimulate target gene transcription.[L31508] \r\n\r\nAt the epiphysis or growth plate, growth hormone increases linear growth by promoting differentiation of prechondrocytes and expansion of osteoblasts. Growth hormone binding to its receptor in the liver and cartilage promotes the production of IGF-1, which acts on type 1 IGF receptors to also stimulate linear growth. In the liver, activated growth hormone receptor signalling leads to increased production of IGF binding protein-3 (IGFBP-3) and acid-labile subunit (ALS), which are proteins that bind to IGF-1 in a ternary complex to increase its half-life.[A228183]']",[None],"[{'target': [{'id': ['BE0000075'], 'name': ['Growth hormone receptor'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1954'], 'pubmed-id': ['16917171'], 'citation': ['Walenkamp MJ, Wit JM: Genetic disorders in the growth hormone - insulin-like growth factor-I axis. Horm Res. 2006;66(5):221-30.']}, {'ref-id': ['A1957'], 'pubmed-id': ['16965663'], 'citation': ['Wu XY, Xu Z, Chen C, Liu FK, Li JS: [Correlation of growth hormone receptor expression to preoperative radiosensitivity of rectal cancer patients]. Ai Zheng. 2006 Sep;25(9):1162-7.']}, {'ref-id': ['A1958'], 'pubmed-id': ['17082603'], 'citation': ['Adriani M, Garbi C, Amodio G, Russo I, Giovannini M, Amorosi S, Matrecano E, Cosentini E, Candotti F, Pignata C: Functional interaction of common gamma-chain and growth hormone receptor signaling apparatus. J Immunol. 2006 Nov 15;177(10):6889-95.']}, {'ref-id': ['A1961'], 'pubmed-id': ['17128263'], 'citation': ['Choi JH, Kim HS, Kim SH, Yang YR, Bae YS, Chang JS, Kwon HM, Ryu SH, Suh PG: Phospholipase Cgamma1 negatively regulates growth hormone signalling by forming a ternary complex with Jak2 and protein tyrosine phosphatase-1B. Nat Cell Biol. 2006 Dec;8(12):1389-97. Epub 2006 Nov 26.']}, {'ref-id': ['A1963'], 'pubmed-id': ['17133434'], 'citation': ['Bernstein RM, Leigh SR, Donovan SM, Monaco MH: Hormones and body size evolution in papionin primates. Am J Phys Anthropol. 2007 Feb;132(2):247-60.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A228183'], 'pubmed-id': ['22291494'], 'citation': ['Reh CS, Geffner ME: Somatotropin in the treatment of growth hormone deficiency and Turner syndrome in pediatric patients: a review. Clin Pharmacol. 2010;2:111-22. doi: 10.2147/CPAA.S6525. Epub 2010 Jun 1.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Growth hormone receptor'], 'general-function': ['Protein kinase binding'], 'specific-function': ['Receptor for pituitary gland growth hormone involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway (By similarity).The soluble form (GHBP) acts as a reservoir of growth hormone in plasma and may be a modulator/inhibitor of GH signaling.Isoform 2 up-regulates the production of GHBP and acts as a negative inhibitor of GH signaling.'], 'gene-name': ['GHR'], 'locus': ['5p13-p12'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['265-288'], 'signal-regions': ['1-18'], 'theoretical-pi': ['4.51'], 'molecular-weight': ['71498.885'], 'chromosome-location': ['5'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:4263']}, {'resource': ['GenAtlas'], 'identifier': ['GHR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X06562']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31738']}, {'resource': ['UniProtKB'], 'identifier': ['P10912']}, {'resource': ['UniProt Accession'], 'identifier': ['GHR_HUMAN']}]}], 'synonyms': [{'synonym': ['GH receptor', 'Somatotropin receptor']}], 'amino-acid-sequence': ['>lcl|BSEQ0000150|Growth hormone receptor\nMDLWQLLLTLALAGSSDAFSGSEATAAILSRAPWSLQSVNPGLKTNSSKEPKFTKCRSPE\nRETFSCHWTDEVHHGTKNLGPIQLFYTRRNTQEWTQEWKECPDYVSAGENSCYFNSSFTS\nIWIPYCIKLTSNGGTVDEKCFSVDEIVQPDPPIALNWTLLNVSLTGIHADIQVRWEAPRN\nADIQKGWMVLEYELQYKEVNETKWKMMDPILTTSVPVYSLKVDKEYEVRVRSKQRNSGNY\nGEFSEVLYVTLPQMSQFTCEEDFYFPWLLIIIFGIFGLTVMLFVFLFSKQQRIKMLILPP\nVPVPKIKGIDPDLLKEGKLEEVNTILAIHDSYKPEFHSDDSWVEFIELDIDEPDEKTEES\nDTDRLLSSDHEKSHSNLGVKDGDSGRTSCCEPDILETDFNANDIHEGTSEVAQPQRLKGE\nADLLCLDQKNQNNSPYHDACPATQQPSVIQAEKNKPQPLPTEGAESTHQAAHIQLSNPSS\nLSNIDFYAQVSDITPAGSVVLSPGQKNKAGMSQCDMHPEMVSLCQENFLMDNAYFCEADA\nKKCIPVAPHIKVESHIQPSLNQEDIYITTESLTTAAGRPGTGEHVPGSEMPVPDYTSIHI\nVQSPQGLILNATALPLPDKEFLSSCGYVSTDQLNKIMP'], 'gene-sequence': ['>lcl|BSEQ0010152|Growth hormone receptor (GHR)\nATGGATCTCTGGCAGCTGCTGTTGACCTTGGCACTGGCAGGATCAAGTGATGCTTTTTCT\nGGAAGTGAGGCCACAGCAGCTATCCTTAGCAGAGCACCCTGGAGTCTGCAAAGTGTTAAT\nCCAGGCCTAAAGACAAATTCTTCTAAGGAGCCTAAATTCACCAAGTGCCGTTCACCTGAG\nCGAGAGACTTTTTCATGCCACTGGACAGATGAGGTTCATCATGGTACAAAGAACCTAGGA\nCCCATACAGCTGTTCTATACCAGAAGGAACACTCAAGAATGGACTCAAGAATGGAAAGAA\nTGCCCTGATTATGTTTCTGCTGGGGAAAACAGCTGTTACTTTAATTCATCGTTTACCTCC\nATCTGGATACCTTATTGTATCAAGCTAACTAGCAATGGTGGTACAGTGGATGAAAAGTGT\nTTCTCTGTTGATGAAATAGTGCAACCAGATCCACCCATTGCCCTCAACTGGACTTTACTG\nAACGTCAGTTTAACTGGGATTCATGCAGATATCCAAGTGAGATGGGAAGCACCACGCAAT\nGCAGATATTCAGAAAGGATGGATGGTTCTGGAGTATGAACTTCAATACAAAGAAGTAAAT\nGAAACTAAATGGAAAATGATGGACCCTATATTGACAACATCAGTTCCAGTGTACTCATTG\nAAAGTGGATAAGGAATATGAAGTGCGTGTGAGATCCAAACAACGAAACTCTGGAAATTAT\nGGCGAGTTCAGTGAGGTGCTCTATGTAACACTTCCTCAGATGAGCCAATTTACATGTGAA\nGAAGATTTCTACTTTCCATGGCTCTTAATTATTATCTTTGGAATATTTGGGCTAACAGTG\nATGCTATTTGTATTCTTATTTTCTAAACAGCAAAGGATTAAAATGCTGATTCTGCCCCCA\nGTTCCAGTTCCAAAGATTAAAGGAATCGATCCAGATCTCCTCAAGGAAGGAAAATTAGAG\nGAGGTGAACACAATCTTAGCCATTCATGATAGCTATAAACCCGAATTCCACAGTGATGAC\nTCTTGGGTTGAATTTATTGAGCTAGATATTGATGAGCCAGATGAAAAGACTGAGGAATCA\nGACACAGACAGACTTCTAAGCAGTGACCATGAGAAATCACATAGTAACCTAGGGGTGAAG\nGATGGCGACTCTGGACGTACCAGCTGTTGTGAACCTGACATTCTGGAGACTGATTTCAAT\nGCCAATGACATACATGAGGGTACCTCAGAGGTTGCTCAGCCACAGAGGTTAAAAGGGGAA\nGCAGATCTCTTATGCCTTGACCAGAAGAATCAAAATAACTCACCTTATCATGATGCTTGC\nCCTGCTACTCAGCAGCCCAGTGTTATCCAAGCAGAGAAAAACAAACCACAACCACTTCCT\nACTGAAGGAGCTGAGTCAACTCACCAAGCTGCCCATATTCAGCTAAGCAATCCAAGTTCA\nCTGTCAAACATCGACTTTTATGCCCAGGTGAGCGACATTACACCAGCAGGTAGTGTGGTC\nCTTTCCCCGGGCCAAAAGAATAAGGCAGGGATGTCCCAATGTGACATGCACCCGGAAATG\nGTCTCACTCTGCCAAGAAAACTTCCTTATGGACAATGCCTACTTCTGTGAGGCAGATGCC\nAAAAAGTGCATCCCTGTGGCTCCTCACATCAAGGTTGAATCACACATACAGCCAAGCTTA\nAACCAAGAGGACATTTACATCACCACAGAAAGCCTTACCACTGCTGCTGGGAGGCCTGGG\nACAGGAGAACATGTTCCAGGTTCTGAGATGCCTGTCCCAGACTATACCTCCATTCATATA\nGTACAGTCCCCACAGGGCCTCATACTCAATGCGACTGCCTTGCCCTTGCCTGACAAAGAG\nTTTCTCTCATCATGTGGCTATGTGAGCACAGACCAACTGAACAAAATCATGCCTTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00041'], 'name': ['fn3']}, {'identifier': ['PF09067'], 'name': ['EpoR_lig-bind']}, {'identifier': ['PF12772'], 'name': ['GHBP']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['growth hormone receptor complex']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['function'], 'description': ['cytokine receptor activity']}, {'category': ['function'], 'description': ['growth factor binding']}, {'category': ['function'], 'description': ['peptide hormone binding']}, {'category': ['function'], 'description': ['proline-rich region binding']}, {'category': ['function'], 'description': ['protein homodimerization activity']}, {'category': ['function'], 'description': ['protein kinase binding']}, {'category': ['process'], 'description': ['2-oxoglutarate metabolic process']}, {'category': ['process'], 'description': ['activation of JAK2 kinase activity']}, {'category': ['process'], 'description': ['activation of MAPK activity']}, {'category': ['process'], 'description': ['allantoin metabolic process']}, {'category': ['process'], 'description': ['cellular response to hormone stimulus']}, {'category': ['process'], 'description': ['citrate metabolic process']}, {'category': ['process'], 'description': ['creatine metabolic process']}, {'category': ['process'], 'description': ['creatinine metabolic process']}, {'category': ['process'], 'description': ['endocytosis']}, {'category': ['process'], 'description': ['fatty acid metabolic process']}, {'category': ['process'], 'description': ['growth hormone receptor signaling pathway']}, {'category': ['process'], 'description': ['insulin-like growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['isoleucine metabolic process']}, {'category': ['process'], 'description': ['JAK-STAT cascade']}, {'category': ['process'], 'description': ['JAK-STAT cascade involved in growth hormone signaling pathway']}, {'category': ['process'], 'description': ['multicellular organismal metabolic process']}, {'category': ['process'], 'description': ['oxaloacetate metabolic process']}, {'category': ['process'], 'description': ['positive regulation of multicellular organism growth']}, {'category': ['process'], 'description': ['positive regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of tyrosine phosphorylation of Stat3 protein']}, {'category': ['process'], 'description': ['positive regulation of tyrosine phosphorylation of Stat5 protein']}, {'category': ['process'], 'description': ['receptor internalization']}, {'category': ['process'], 'description': ['regulation of multicellular organism growth']}, {'category': ['process'], 'description': ['response to cycloheximide']}, {'category': ['process'], 'description': ['response to estradiol']}, {'category': ['process'], 'description': ['succinate metabolic process']}, {'category': ['process'], 'description': ['taurine metabolic process']}, {'category': ['process'], 'description': ['valine metabolic process']}]}]}]}, {'id': ['BE0000345'], 'name': ['Prolactin receptor'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13199'], 'pubmed-id': ['17279774'], 'citation': ['Keeler C, Jablonski EM, Albert YB, Taylor BD, Myszka DG, Clevenger CV, Hodsdon ME: The kinetics of binding human prolactin, but not growth hormone, to the prolactin receptor vary over a physiologic pH range. Biochemistry. 2007 Mar 6;46(9):2398-410. Epub 2007 Feb 6.']}, {'ref-id': ['A13200'], 'pubmed-id': ['17395896'], 'citation': ['Ahmed TA, Buzzelli MD, Lang CH, Capen JB, Shumate ML, Navaratnarajah M, Nagarajan M, Cooney RN: Interleukin-6 inhibits growth hormone-mediated gene expression in hepatocytes. Am J Physiol Gastrointest Liver Physiol. 2007 Jun;292(6):G1793-803. Epub 2007 Mar 29.']}, {'ref-id': ['A13201'], 'pubmed-id': ['17317019'], 'citation': ['Moderscheim TA, Gorba T, Pathipati P, Kokay IC, Grattan DR, Williams CE, Scheepens A: Prolactin is involved in glial responses following a focal injury to the juvenile rat brain. Neuroscience. 2007 Mar 30;145(3):963-73. Epub 2007 Feb 20.']}, {'ref-id': ['A13202'], 'pubmed-id': ['2270485'], 'citation': ['Cunningham BC, Bass S, Fuh G, Wells JA: Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science. 1990 Dec 21;250(4988):1709-12.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Prolactin receptor'], 'general-function': ['Protein homodimerization activity'], 'specific-function': ['This is a receptor for the anterior pituitary hormone prolactin (PRL). Acts as a prosurvival factor for spermatozoa by inhibiting sperm capacitation through suppression of SRC kinase activation and stimulation of AKT. Isoform 4 is unable to transduce prolactin signaling. Isoform 6 is unable to transduce prolactin signaling.'], 'gene-name': ['PRLR'], 'locus': ['5p14-p13'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['235-258'], 'signal-regions': ['1-24'], 'theoretical-pi': ['5.08'], 'molecular-weight': ['69505.045'], 'chromosome-location': ['5'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:9446']}, {'resource': ['GenAtlas'], 'identifier': ['PRLR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M31661']}, {'resource': ['GenBank Protein Database'], 'identifier': ['190362']}, {'resource': ['UniProtKB'], 'identifier': ['P16471']}, {'resource': ['UniProt Accession'], 'identifier': ['PRLR_HUMAN']}]}], 'synonyms': [{'synonym': ['PRL-R']}], 'amino-acid-sequence': ['>lcl|BSEQ0000687|Prolactin receptor\nMKENVASATVFTLLLFLNTCLLNGQLPPGKPEIFKCRSPNKETFTCWWRPGTDGGLPTNY\nSLTYHREGETLMHECPDYITGGPNSCHFGKQYTSMWRTYIMMVNATNQMGSSFSDELYVD\nVTYIVQPDPPLELAVEVKQPEDRKPYLWIKWSPPTLIDLKTGWFTLLYEIRLKPEKAAEW\nEIHFAGQQTEFKILSLHPGQKYLVQVRCKPDHGYWSAWSPATFIQIPSDFTMNDTTVWIS\nVAVLSAVICLIIVWAVALKGYSMVTCIFPPVPGPKIKGFDAHLLEKGKSEELLSALGCQD\nFPPTSDYEDLLVEYLEVDDSEDQHLMSVHSKEHPSQGMKPTYLDPDTDSGRGSCDSPSLL\nSEKCEEPQANPSTFYDPEVIEKPENPETTHTWDPQCISMEGKIPYFHAGGSKCSTWPLPQ\nPSQHNPRSSYHNITDVCELAVGPAGAPATLLNEAGKDALKSSQTIKSREEGKATQQREVE\nSFHSETDQDTPWLLPQEKTPFGSAKPLDYVEIHKVNKDGALSLLPKQRENSGKPKKPGTP\nENNKEYAKVSGVMDNNILVLVPDPHAKNVACFEESAKEAPPSLEQNQAEKALANFTATSS\nKCRLQLGGLDYLDPACFTHSFH'], 'gene-sequence': ['>lcl|BSEQ0018944|Prolactin receptor (PRLR)\nATGAAGGAAAATGTGGCATCTGCAACCGTTTTCACTCTGCTACTTTTTCTCAACACCTGC\nCTTCTGAATGGACAGTTACCTCCTGGAAAACCTGAGATCTTTAAATGTCGTTCTCCCAAT\nAAGGAAACATTCACCTGCTGGTGGAGGCCTGGGACAGATGGAGGACTTCCTACCAATTAT\nTCACTGACTTACCACAGGGAAGGAGAGACACTCATGCATGAATGTCCAGACTACATAACC\nGGTGGCCCCAACTCCTGCCACTTTGGCAAGCAGTACACCTCCATGTGGAGGACATACATC\nATGATGGTCAATGCCACTAACCAGATGGGAAGCAGTTTCTCGGATGAACTTTATGTGGAC\nGTGACTTACATAGTTCAGCCAGACCCTCCTTTGGAGCTGGCTGTGGAAGTAAAACAGCCA\nGAAGACAGAAAACCCTACCTGTGGATTAAATGGTCTCCACCTACCCTGATTGACTTAAAA\nACTGGTTGGTTCACGCTCCTGTATGAAATTCGATTAAAACCCGAGAAAGCAGCTGAGTGG\nGAGATCCATTTTGCTGGGCAGCAAACAGAGTTTAAGATTCTCAGCCTACATCCAGGACAG\nAAATACCTTGTCCAGGTTCGCTGCAAACCAGACCATGGATACTGGAGTGCATGGAGTCCA\nGCGACCTTCATTCAGATACCTAGTGACTTCACCATGAATGATACAACCGTGTGGATCTCT\nGTGGCTGTCCTTTCTGCTGTCATCTGTTTGATTATTGTCTGGGCAGTGGCTTTGAAGGGC\nTATAGCATGGTGACCTGCATCTTTCCGCCAGTTCCTGGGCCAAAAATAAAAGGATTTGAT\nGCTCATCTGTTGGAGAAGGGCAAGTCTGAAGAACTACTGAGTGCCTTGGGATGCCAAGAC\nTTTCCTCCCACTTCTGACTATGAGGACTTGCTGGTGGAGTATTTAGAAGTAGATGATAGT\nGAGGACCAGCATCTAATGTCAGTCCATTCAAAAGAACACCCAAGTCAAGGTATGAAACCC\nACATACCTGGATCCTGACACTGACTCAGGCCGGGGGAGCTGTGACAGCCCTTCCCTTTTG\nTCTGAAAAGTGTGAGGAACCCCAGGCCAATCCCTCCACATTCTATGATCCTGAGGTCATT\nGAGAAGCCAGAGAATCCTGAAACAACCCACACCTGGGACCCCCAGTGCATAAGCATGGAA\nGGCAAAATCCCCTATTTTCATGCTGGTGGATCCAAATGTTCAACATGGCCCTTACCACAG\nCCCAGCCAGCACAACCCCAGATCCTCTTACCACAATATTACTGATGTGTGTGAGCTGGCT\nGTGGGCCCTGCAGGTGCACCGGCCACTCTGTTGAATGAAGCAGGTAAAGATGCTTTAAAA\nTCCTCTCAAACCATTAAGTCTAGAGAAGAGGGAAAGGCAACCCAGCAGAGGGAGGTAGAA\nAGCTTCCATTCTGAGACTGACCAGGATACGCCCTGGCTGCTGCCCCAGGAGAAAACCCCC\nTTTGGCTCCGCTAAACCCTTGGATTATGTGGAGATTCACAAGGTCAACAAAGATGGTGCA\nTTATCATTGCTACCAAAACAGAGAGAGAACAGCGGCAAGCCCAAGAAGCCCGGGACTCCT\nGAGAACAATAAGGAGTATGCCAAGGTGTCCGGGGTCATGGATAACAACATCCTGGTGTTG\nGTGCCAGATCCACATGCTAAAAACGTGGCTTGCTTTGAAGAATCAGCCAAAGAGGCCCCA\nCCATCACTTGAACAGAATCAAGCTGAGAAAGCCCTGGCCAACTTCACTGCAACATCAAGC\nAAGTGCAGGCTCCAGCTGGGTGGTTTGGATTACCTGGATCCCGCATGTTTTACACACTCC\nTTTCACTGA'], 'pfams': [{'pfam': [{'identifier': ['PF09067'], 'name': ['EpoR_lig-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['endosome lumen']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['metal ion binding']}, {'category': ['function'], 'description': ['ornithine decarboxylase activator activity']}, {'category': ['function'], 'description': ['peptide hormone binding']}, {'category': ['function'], 'description': ['prolactin receptor activity']}, {'category': ['function'], 'description': ['protein homodimerization activity']}, {'category': ['process'], 'description': ['activation of JAK2 kinase activity']}, {'category': ['process'], 'description': ['activation of transmembrane receptor protein tyrosine kinase activity']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['embryo implantation']}, {'category': ['process'], 'description': ['JAK-STAT cascade involved in growth hormone signaling pathway']}, {'category': ['process'], 'description': ['lactation']}, {'category': ['process'], 'description': ['mammary gland alveolus development']}, {'category': ['process'], 'description': ['mammary gland epithelial cell differentiation']}, {'category': ['process'], 'description': ['negative regulation of apoptotic process']}, {'category': ['process'], 'description': ['prostate gland growth']}, {'category': ['process'], 'description': ['regulation of cell adhesion']}, {'category': ['process'], 'description': ['regulation of epithelial cell differentiation']}, {'category': ['process'], 'description': ['steroid biosynthetic process']}, {'category': ['process'], 'description': ['T cell activation']}]}]}]}]}]"
"['DB00053', 'BTD00026', 'BIOD00026']",['Imiglucerase'],biotech,"['Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues.']",['liquid'],"[""For the treatment of Gaucher's disease (deficiency in glucocerebrosidase)""]","['Imiglucerase catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids.']",[None],"[{'target': [{'id': ['BE0004806'], 'name': ['Glucocerebroside'], 'organism': ['Humans'], 'actions': [{'action': ['other/unknown']}], 'references': [{'articles': [{'article': [{'ref-id': ['A95'], 'pubmed-id': ['20301446'], 'citation': ['Pastores GM, Hughes DA: Gaucher Disease .']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes']}]}]"
"['DB00054', 'BTD00041', 'BIOD00041']",['Abciximab'],biotech,"['Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (v3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.']",['liquid'],['Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended for use with aspirin and heparin and has been studied only in that setting.'],"['Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPIIb/IIIa. By binding to the vitronectin receptor (also known as the v3 integrin), abciximab blocks effects mediated by this integrin which include cell adhesion. Furthermore, abciximab blocks Mac-1 receptor on monocytes and neutrophils thus inhibiting monocyte adhesion.']","[{'food-interaction': ['Avoid herbs and supplements with anticoagulant/antiplatelet activity. Additive antiplatelet activity may increase the risk of bleeding. Examples include ginseng, ginkgo, ginger, and garlic.']}]","[{'target': [{'id': ['BE0001155'], 'name': ['Integrin beta-3'], 'organism': ['Humans'], 'actions': [{'action': ['antagonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1978'], 'pubmed-id': ['11588534'], 'citation': ['Amoroso G, van Boven AJ, van Veldhuisen DJ, Tio RA, Balje-Volkers CP, Petronio AS, van Oeveren W: Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients with coronary artery disease. J Cardiovasc Pharmacol. 2001 Oct;38(4):633-41.']}, {'ref-id': ['A11611'], 'pubmed-id': ['12165285'], 'citation': ['Weber AA, Meila D, Jacobs C, Weber S, Kelm M, Strauer BE, Zotz RB, Scharf RE, Schror K: Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors. Thromb Res. 2002 Apr 1;106(1):25-9.']}, {'ref-id': ['A11612'], 'pubmed-id': ['17441904'], 'citation': ['Hall PR, Malone L, Sillerud LO, Ye C, Hjelle BL, Larson RS: Characterization and NMR solution structure of a novel cyclic pentapeptide inhibitor of pathogenic hantaviruses. Chem Biol Drug Des. 2007 Mar;69(3):180-90.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A11613'], 'pubmed-id': ['18510478'], 'citation': ['Mazzaferri EL Jr, Young JJ: Abciximab: a review and update for clinicians. Expert Rev Cardiovasc Ther. 2008 Jun;6(5):609-18. doi: 10.1586/14779072.6.5.609.']}, {'ref-id': ['A11614'], 'pubmed-id': ['12749745'], 'citation': ['Ibbotson T, McGavin JK, Goa KL: Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs. 2003;63(11):1121-63.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Integrin beta-3'], 'general-function': ['Virus receptor activity'], 'specific-function': [""Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. Fibrinogen binding enhances SELP expression in activated platelets (By similarity).(Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for herpes virus 8/HHV-8 (PubMed:18045938). Integrin ITGAV:ITGB3 acts as a receptor for coxsackievirus A9 (PubMed:7519807). Acts as a receptor for Hantaan virus (PubMed:9618541). Integrin ITGAV:ITGB3 acts as a receptor for cytomegalovirus/HHV-5 (PubMed:15834425). Integrin ITGA5:ITGB3 acts as a receptor for human metapneumovirus (PubMed:24478423). Integrin ITGAV:ITGB3 acts aP05556s a receptor for human parechovirus 1 (PubMed:11160695). Integrin ITGAV:ITGB3 acts as a receptor for west nile virus (PubMed:23658209). In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions (PubMed:10397733).""], 'gene-name': ['ITGB3'], 'locus': ['17q21.32'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['719-741'], 'signal-regions': ['1-26'], 'theoretical-pi': ['4.85'], 'molecular-weight': ['87056.975'], 'chromosome-location': ['17'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6156']}, {'resource': ['GenAtlas'], 'identifier': ['ITGB3']}, {'resource': ['GenBank Gene Database'], 'identifier': ['J02703']}, {'resource': ['GenBank Protein Database'], 'identifier': ['306786']}, {'resource': ['UniProtKB'], 'identifier': ['P05106']}, {'resource': ['UniProt Accession'], 'identifier': ['ITB3_HUMAN']}]}], 'synonyms': [{'synonym': ['GP3A', 'GPIIIa', 'Platelet membrane glycoprotein IIIa']}], 'amino-acid-sequence': ['>lcl|BSEQ0002297|Integrin beta-3\nMRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLG\nSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRP\nDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFG\nAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSR\nNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCH\nVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLS\nMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDT\nVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGT\nFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFG\nKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLL\nCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRY\nCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDIL\nVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTF\nTNITYRGT'], 'gene-sequence': ['>lcl|BSEQ0021847|Integrin beta-3 (ITGB3)\nATGCGAGCGCGGCCGCGGCCCCGGCCGCTCTGGGCGACTGTGCTGGCGCTGGGGGCGCTG\nGCGGGCGTTGGCGTAGGAGGGCCCAACATCTGTACCACGCGAGGTGTGAGCTCCTGCCAG\nCAGTGCCTGGCTGTGAGCCCCATGTGTGCCTGGTGCTCTGATGAGGCCCTGCCTCTGGGC\nTCACCTCGCTGTGACCTGAAGGAGAATCTGCTGAAGGATAACTGTGCCCCAGAATCCATC\nGAGTTCCCAGTGAGTGAGGCCCGAGTACTAGAGGACAGGCCCCTCAGCGACAAGGGCTCT\nGGAGACAGCTCCCAGGTCACTCAAGTCAGTCCCCAGAGGATTGCACTCCGGCTCCGGCCA\nGATGATTCGAAGAATTTCTCCATCCAAGTGCGGCAGGTGGAGGATTACCCTGTGGACATC\nTACTACTTGATGGACCTGTCTTACTCCATGAAGGATGATCTGTGGAGCATCCAGAACCTG\nGGTACCAAGCTGGCCACCCAGATGCGAAAGCTCACCAGTAACCTGCGGATTGGCTTCGGG\nGCATTTGTGGACAAGCCTGTGTCACCATACATGTATATCTCCCCACCAGAGGCCCTCGAA\nAACCCCTGCTATGATATGAAGACCACCTGCTTGCCCATGTTTGGCTACAAACACGTGCTG\nACGCTAACTGACCAGGTGACCCGCTTCAATGAGGAAGTGAAGAAGCAGAGTGTGTCACGG\nAACCGAGATGCCCCAGAGGGTGGCTTTGATGCCATCATGCAGGCTACAGTCTGTGATGAA\nAAGATTGGCTGGAGGAATGATGCATCCCACTTGCTGGTGTTTACCACTGATGCCAAGACT\nCATATAGCATTGGACGGAAGGCTGGCAGGCATTGTCCAGCCTAATGACGGGCAGTGTCAT\nGTTGGTAGTGACAATCATTACTCTGCCTCCACTACCATGGATTATCCCTCTTTGGGGCTG\nATGACTGAGAAGCTATCCCAGAAAAACATCAATTTGATCTTTGCAGTGACTGAAAATGTA\nGTCAATCTCTATCAGAACTATAGTGAGCTCATCCCAGGGACCACAGTTGGGGTTCTGTCC\nATGGATTCCAGCAATGTCCTCCAGCTCATTGTTGATGCTTATGGGAAAATCCGTTCTAAA\nGTAGAGCTGGAAGTGCGTGACCTCCCTGAAGAGTTGTCTCTATCCTTCAATGCCACCTGC\nCTCAACAATGAGGTCATCCCTGGCCTCAAGTCTTGTATGGGACTCAAGATTGGAGACACG\nGTGAGCTTCAGCATTGAGGCCAAGGTGCGAGGCTGTCCCCAGGAGAAGGAGAAGTCCTTT\nACCATAAAGCCCGTGGGCTTCAAGGACAGCCTGATCGTCCAGGTCACCTTTGATTGTGAC\nTGTGCCTGCCAGGCCCAAGCTGAACCTAATAGCCATCGCTGCAACAATGGCAATGGGACC\nTTTGAGTGTGGGGTATGCCGTTGTGGGCCTGGCTGGCTGGGATCCCAGTGTGAGTGCTCA\nGAGGAGGACTATCGCCCTTCCCAGCAGGACGAATGCAGCCCCCGGGAGGGTCAGCCCGTC\nTGCAGCCAGCGGGGCGAGTGCCTCTGTGGTCAATGTGTCTGCCACAGCAGTGACTTTGGC\nAAGATCACGGGCAAGTACTGCGAGTGTGACGACTTCTCCTGTGTCCGCTACAAGGGGGAG\nATGTGCTCAGGCCATGGCCAGTGCAGCTGTGGGGACTGCCTGTGTGACTCCGACTGGACC\nGGCTACTACTGCAACTGTACCACGCGTACTGACACCTGCATGTCCAGCAATGGGCTGCTG\nTGCAGCGGCCGCGGCAAGTGTGAATGTGGCAGCTGTGTCTGTATCCAGCCGGGCTCCTAT\nGGGGACACCTGTGAGAAGTGCCCCACCTGCCCAGATGCCTGCACCTTTAAGAAAGAATGT\nGTGGAGTGTAAGAAGTTTGACCGGGGAGCCCTACATGACGAAAATACCTGCAACCGTTAC\nTGCCGTGACGAGATTGAGTCAGTGAAAGAGCTTAAGGACACTGGCAAGGATGCAGTGAAT\nTGTACCTATAAGAATGAGGATGACTGTGTCGTCAGATTCCAGTACTATGAAGATTCTAGT\nGGAAAGTCCATCCTGTATGTGGTAGAAGAGCCAGAGTGTCCCAAGGGCCCTGACATCCTG\nGTGGTCCTGCTCTCAGTGATGGGGGCCATTCTGCTCATTGGCCTTGCCGCCCTGCTCATC\nTGGAAACTCCTCATCACCATCCACGACCGAAAAGAATTCGCTAAATTTGAGGAAGAACGC\nGCCAGAGCAAAATGGGACACAGCCAACAACCCACTGTATAAAGAGGCCACGTCTACCTTC\nACCAATATCACGTACCGGGGCACTTAA'], 'pfams': [{'pfam': [{'identifier': ['PF07974'], 'name': ['EGF_2']}, {'identifier': ['PF00362'], 'name': ['Integrin_beta']}, {'identifier': ['PF08725'], 'name': ['Integrin_b_cyt']}, {'identifier': ['PF07965'], 'name': ['Integrin_B_tail']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['alphav-beta3 integrin-vitronectin complex']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['filopodium membrane']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['integrin alphav-beta3 complex']}, {'category': ['component'], 'description': ['integrin complex']}, {'category': ['component'], 'description': ['lamellipodium membrane']}, {'category': ['component'], 'description': ['melanosome']}, {'category': ['component'], 'description': ['microvillus membrane']}, {'category': ['component'], 'description': ['nucleus']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['component'], 'description': ['ruffle membrane']}, {'category': ['function'], 'description': ['cell adhesion molecule binding']}, {'category': ['function'], 'description': ['enzyme binding']}, {'category': ['function'], 'description': ['extracellular matrix binding']}, {'category': ['function'], 'description': ['fibronectin binding']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['function'], 'description': ['platelet-derived growth factor receptor binding']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['function'], 'description': ['protein disulfide isomerase activity']}, {'category': ['function'], 'description': ['vascular endothelial growth factor receptor 2 binding']}, {'category': ['function'], 'description': ['virus receptor activity']}, {'category': ['process'], 'description': ['activation of protein kinase activity']}, {'category': ['process'], 'description': ['angiogenesis involved in wound healing']}, {'category': ['process'], 'description': ['apolipoprotein A-I-mediated signaling pathway']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cell adhesion']}, {'category': ['process'], 'description': ['cell growth']}, {'category': ['process'], 'description': ['cell migration']}, {'category': ['process'], 'description': ['cell-matrix adhesion']}, {'category': ['process'], 'description': ['cell-substrate adhesion']}, {'category': ['process'], 'description': ['cell-substrate junction assembly']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['heterotypic cell-cell adhesion']}, {'category': ['process'], 'description': ['integrin-mediated signaling pathway']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['mesodermal cell differentiation']}, {'category': ['process'], 'description': ['negative chemotaxis']}, {'category': ['process'], 'description': ['negative regulation of lipid storage']}, {'category': ['process'], 'description': ['negative regulation of lipid transport']}, {'category': ['process'], 'description': ['negative regulation of lipoprotein metabolic process']}, {'category': ['process'], 'description': ['negative regulation of low-density lipoprotein particle receptor biosynthetic process']}, {'category': ['process'], 'description': ['negative regulation of macrophage derived foam cell differentiation']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet aggregation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of endothelial cell migration']}, {'category': ['process'], 'description': ['positive regulation of endothelial cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of vascular endothelial growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['protein folding']}, {'category': ['process'], 'description': ['regulation of bone resorption']}, {'category': ['process'], 'description': ['smooth muscle cell migration']}, {'category': ['process'], 'description': ['substrate adhesion-dependent cell spreading']}, {'category': ['process'], 'description': ['tube development']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['viral entry into host cell']}, {'category': ['process'], 'description': ['wound healing']}]}]}]}, {'id': ['BE0000439'], 'name': ['Integrin alpha-IIb'], 'organism': ['Humans'], 'actions': [{'action': ['antagonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A15406'], 'pubmed-id': ['19499855'], 'citation': ['Gibbs NM: Point-of-care assessment of antiplatelet agents in the perioperative period: a review. Anaesth Intensive Care. 2009 May;37(3):354-69.']}, {'ref-id': ['A11613'], 'pubmed-id': ['18510478'], 'citation': ['Mazzaferri EL Jr, Young JJ: Abciximab: a review and update for clinicians. Expert Rev Cardiovasc Ther. 2008 Jun;6(5):609-18. doi: 10.1586/14779072.6.5.609.']}, {'ref-id': ['A11614'], 'pubmed-id': ['12749745'], 'citation': ['Ibbotson T, McGavin JK, Goa KL: Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs. 2003;63(11):1121-63.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Integrin alpha-IIb'], 'general-function': ['Metal ion binding'], 'specific-function': ['Integrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. It recognizes the sequence R-G-D in a wide array of ligands. It recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial cell surface.'], 'gene-name': ['ITGA2B'], 'locus': ['17q21.32'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['994-1019'], 'signal-regions': ['1-31'], 'theoretical-pi': ['5.03'], 'molecular-weight': ['113375.96'], 'chromosome-location': ['17'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6138']}, {'resource': ['GenAtlas'], 'identifier': ['ITGA2B']}, {'resource': ['GenBank Gene Database'], 'identifier': ['J02764']}, {'resource': ['GenBank Protein Database'], 'identifier': ['190068']}, {'resource': ['UniProtKB'], 'identifier': ['P08514']}, {'resource': ['UniProt Accession'], 'identifier': ['ITA2B_HUMAN']}]}], 'synonyms': [{'synonym': ['GP2B', 'GPalpha IIb', 'GPIIb', 'ITGAB', 'Platelet membrane glycoprotein IIb']}], 'amino-acid-sequence': ['>lcl|BSEQ0037020|Integrin alpha-IIb\nMARALCPLQALWLLEWVLLLLGPCAAPPAWALNLDPVQLTFYAGPNGSQFGFSLDFHKDS\nHGRVAIVVGAPRTLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKA\nRQGLGASVVSWSDVIVACAPWQHWNVLEKTEEAEKTPVGSCFLAQPESGRRAEYSPCRGN\nTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGAPGGYYFLGLLAQAPVADIFSSYRP\nGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTTEYVVGAPTWSWTLGAVEI\nLDSYYQRLHRLRGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKLAEVGRVY\nLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGGPSGRGQV\nLVFLGQSEGLRSRPSQVLDSPFPTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYR\nAQPVVKASVQLLVQDSLNPAVKSCVLPQTKTPVSCFNIQMCVGATGHNIPQKLSLNAELQ\nLDRQKPRQGRRVLLLGSQQAGTTLNLDLGGKHSPICHTTMAFLRDEADFRDKLSPIVLSL\nNVSLPPTEAGMAPAVVLHGDTHVQEQTRIVLDCGEDDVCVPQLQLTASVTGSPLLVGADN\nVLELQMDAANEGEGAYEAELAVHLPQGAHYMRALSNVEGFERLICNQKKENETRVVLCEL\nGNPMKKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVE\nLRGNSFPASLVVAAEEGEREQNSLDSWGPKVEHTYELHNNGPGTVNGLHLSIHLPGQSQP\nSDLLYILDIQPQGGLQCFPQPPVNPLKVDWGLPIPSPSPIHPAHHKRDRRQIFLPEPEQP\nSRLQDPVLVSCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAW\nFNVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWK\nVGFFKRNRPPLEEDDEEGE'], 'gene-sequence': ['>lcl|BSEQ0010305|Integrin alpha-IIb (ITGA2B)\nATGGCCAGAGCTTTGTGTCCACTGCAAGCCCTCTGGCTTCTGGAGTGGGTGCTGCTGCTC\nTTGGGACCTTGTGCTGCCCCTCCAGCCTGGGCCTTGAACCTGGACCCAGTGCAGCTCACC\nTTCTATGCAGGCCCCAATGGCAGCCAGTTTGGATTTTCACTGGACTTCCACAAGGACAGC\nCATGGGAGAGTGGCCATCGTGGTGGGCGCCCCGCGGACCCTGGGCCCCAGCCAGGAGGAG\nACGGGCGGCGTGTTCCTGTGCCCCTGGAGGGCCGAGGGCGGCCAGTGCCCCTCGCTGCTC\nTTTGACCTCCGTGATGAGACCCGAAATGTAGGCTCCCAAACTTTACAAACCTTCAAGGCC\nCGCCAAGGACTGGGGGCGTCGGTCGTCAGCTGGAGCGACGTCATTGTGGCCTGCGCCCCC\nTGGCAGCACTGGAACGTCCTAGAAAAGACTGAGGAGGCTGAGAAGACGCCCGTAGGTAGC\nTGCTTTTTGGCTCAGCCAGAGAGCGGCCGCCGCGCCGAGTACTCCCCCTGTCGCGGGAAC\nACCCTGAGCCGCATTTACGTGGAAAATGATTTTAGCTGGGACAAGCGTTACTGTGAAGCG\nGGCTTCAGCTCCGTGGTCACTCAGGCCGGAGAGCTGGTGCTTGGGGCTCCTGGCGGCTAT\nTATTTCTTAGGTCTCCTGGCCCAGGCTCCAGTTGCGGATATTTTCTCGAGTTACCGCCCA\nGGCATCCTTTTGTGGCACGTGTCCTCCCAGAGCCTCTCCTTTGACTCCAGCAACCCAGAG\nTACTTCGACGGCTACTGGGGGTACTCGGTGGCCGTGGGCGAGTTCGACGGGGATCTCAAC\nACTACAGAATATGTCGTCGGTGCCCCCACTTGGAGCTGGACCCTGGGAGCGGTGGAAATT\nTTGGATTCCTACTACCAGAGGCTGCATCGGCTGCGCGGAGAGCAGATGGCGTCGTATTTT\nGGGCATTCAGTGGCTGTCACTGACGTCAACGGGGATGGGAGGCATGATCTGCTGGTGGGC\nGCTCCACTGTATATGGAGAGCCGGGCAGACCGAAAACTGGCCGAAGTGGGGCGTGTGTAT\nTTGTTCCTGCAGCCGCGAGGCCCCCACGCGCTGGGTGCCCCCAGCCTCCTGCTGACTGGC\nACACAGCTCTATGGGCGATTCGGCTCTGCCATCGCACCCCTGGGCGACCTCGACCGGGAT\nGGCTACAATGACATTGCAGTGGCTGCCCCCTACGGGGGTCCCAGTGGCCGGGGCCAAGTG\nCTGGTGTTCCTGGGTCAGAGTGAGGGGCTGAGGTCACGTCCCTCCCAGGTCCTGGACAGC\nCCCTTCCCCACAGGCTCTGCCTTTGGCTTCTCCCTTCGAGGTGCCGTAGACATCGATGAC\nAACGGATACCCAGACCTGATCGTGGGAGCTTACGGGGCCAACCAGGTGGCTGTGTACAGA\nGCTCAGCCAGTGGTGAAGGCCTCTGTCCAGCTACTGGTGCAAGATTCACTGAATCCTGCT\nGTGAAGAGCTGTGTCCTACCTCAGACCAAGACACCCGTGAGCTGCTTCAACATCCAGATG\nTGTGTTGGAGCCACTGGGCACAACATTCCTCAGAAGCTATCCCTAAATGCCGAGCTGCAG\nCTGGACCGGCAGAAGCCCCGCCAGGGCCGGCGGGTGCTGCTGCTGGGCTCTCAACAGGCA\nGGCACCACCCTGAACCTGGATCTGGGCGGAAAGCACAGCCCCATCTGCCACACCACCATG\nGCCTTCCTTCGAGATGAGGCAGACTTCCGGGACAAGCTGAGCCCCATTGTGCTCAGCCTC\nAATGTGTCCCTACCGCCCACGGAGGCTGGAATGGCCCCTGCTGTCGTGCTGCATGGAGAC\nACCCATGTGCAGGAGCAGACACGAATCGTCCTGGACTGTGGGGAAGATGACGTATGTGTG\nCCCCAGCTTCAGCTCACTGCCAGCGTGACGGGCTCCCCGCTCCTAGTTGGGGCAGATAAT\nGTCCTGGAGCTGCAGATGGACGCAGCCAACGAGGGCGAGGGGGCCTATGAAGCAGAGCTG\nGCCGTGCACCTGCCCCAGGGCGCCCACTACATGCGGGCCCTAAGCAATGTCGAGGGCTTT\nGAGAGACTCATCTGTAATCAGAAGAAGGAGAATGAGACCAGGGTGGTGCTGTGTGAGCTG\nGGCAACCCCATGAAGAAGAACGCCCAGATAGGAATCGCGATGTTGGTGAGCGTGGGGAAT\nCTGGAAGAGGCTGGGGAGTCTGTGTCCTTCCAGCTGCAGATACGGAGCAAGAACAGCCAG\nAATCCAAACAGCAAGATTGTGCTGCTGGACGTGCCGGTCCGGGCAGAGGCCCAAGTGGAG\nCTGCGAGGGAACTCCTTTCCAGCCTCCCTGGTGGTGGCAGCAGAAGAAGGTGAGAGGGAG\nCAGAACAGCTTGGACAGCTGGGGACCCAAAGTGGAGCACACCTATGAGCTCCACAACAAT\nGGCCCTGGGACTGTGAATGGTCTTCACCTCAGCATCCACCTTCCGGGACAGTCCCAGCCC\nTCCGACCTGCTCTACATCCTGGATATACAGCCCCAGGGGGGCCTTCAGTGCTTCCCACAG\nCCTCCTGTCAACCCTCTCAAGGTGGACTGGGGGCTGCCCATCCCCAGCCCCTCCCCCATT\nCACCCGGCCCATCACAAGCGGGATCGCAGACAGATCTTCCTGCCAGAGCCCGAGCAGCCC\nTCGAGGCTTCAGGATCCAGTTCTCGTAAGCTGCGACTCGGCGCCCTGTACTGTGGTGCAG\nTGTGACCTGCAGGAGATGGCGCGCGGGCAGCGGGCCATGGTCACGGTGCTGGCCTTCCTG\nTGGCTGCCCAGCCTCTACCAGAGGCCTCTGGATCAGTTTGTGCTGCAGTCGCACGCATGG\nTTCAACGTGTCCTCCCTCCCCTATGCGGTGCCCCCGCTCAGCCTGCCCCGAGGGGAAGCT\nCAGGTGTGGACACAGCTGCTCCGGGCCTTGGAGGAGAGGGCCATTCCAATCTGGTGGGTG\nCTGGTGGGTGTGCTGGGTGGCCTGCTGCTGCTCACCATCCTGGTCCTGGCCATGTGGAAG\nGTCGGCTTCTTCAAGCGGAACCGGCCACCCCTGGAAGAAGATGATGAAGAGGGGGAGTGA\n'], 'pfams': [{'pfam': [{'identifier': ['PF01839'], 'name': ['FG-GAP']}, {'identifier': ['PF00357'], 'name': ['Integrin_alpha']}, {'identifier': ['PF08441'], 'name': ['Integrin_alpha2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['integrin complex']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule membrane']}, {'category': ['function'], 'description': ['extracellular matrix binding']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['function'], 'description': ['metal ion binding']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cell adhesion']}, {'category': ['process'], 'description': ['cell-matrix adhesion']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['integrin-mediated signaling pathway']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet aggregation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of leukocyte migration']}]}]}]}, {'id': ['BE0002098'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor II-a'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [None], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor II-a'], 'general-function': [None], 'specific-function': ['Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens.'], 'gene-name': ['FCGR2A'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['218-240'], 'signal-regions': ['1-33'], 'theoretical-pi': ['6.78'], 'molecular-weight': ['35000.42'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3616']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR2A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M31932']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182474']}, {'resource': ['UniProtKB'], 'identifier': ['P12318']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG2A_HUMAN']}]}], 'synonyms': [{'synonym': ['CD32', 'CDw32', 'Fc-gamma RII-a', 'Fc-gamma-RIIa', 'FCG2', 'FCGR2A1', 'FcRII-a', 'IGFR2', 'IgG Fc receptor II-a']}], 'amino-acid-sequence': ['>lcl|BSEQ0037156|Low affinity immunoglobulin gamma Fc region receptor II-a\nMTMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSHLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN'], 'gene-sequence': ['>lcl|BSEQ0019233|Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A)\nATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCATTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['innate immune response']}]}]}]}, {'id': ['BE0002099'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor II-b'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [None], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor II-b'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis.'], 'gene-name': ['FCGR2B'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['218-240'], 'signal-regions': ['1-42'], 'theoretical-pi': ['6.12'], 'molecular-weight': ['34043.355'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3618']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR2B']}, {'resource': ['GenBank Gene Database'], 'identifier': ['U87560']}, {'resource': ['GenBank Protein Database'], 'identifier': ['4099445']}, {'resource': ['UniProtKB'], 'identifier': ['P31994']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG2B_HUMAN']}]}], 'synonyms': [{'synonym': ['CD32', 'CDw32', 'Fc-gamma RII-b', 'Fc-gamma-RIIb', 'FCG2', 'FcRII-b', 'IGFR2', 'IgG Fc receptor II-b']}], 'amino-acid-sequence': ['>lcl|BSEQ0004116|Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI'], 'gene-sequence': ['>lcl|BSEQ0019237|Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B)\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTG\nCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCC\nATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTC\nAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGC\nGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTGGAG\nTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTC\nAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAACTTC\nTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATAGGC\nTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCACCG\nATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCTGTA\nGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATTTAG'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['viral process']}]}]}]}, {'id': ['BE0001068'], 'name': ['Vitronectin'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A15407'], 'pubmed-id': ['17160551'], 'citation': ['Romagnoli E, Burzotta F, Trani C, Biondi-Zoccai GG, Giannico F, Crea F: Rationale for intracoronary administration of abciximab. J Thromb Thrombolysis. 2007 Feb;23(1):57-63.']}, {'ref-id': ['A11614'], 'pubmed-id': ['12749745'], 'citation': ['Ibbotson T, McGavin JK, Goa KL: Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs. 2003;63(11):1121-63.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Vitronectin'], 'general-function': ['Scavenger receptor activity'], 'specific-function': ['Vitronectin is a cell adhesion and spreading factor found in serum and tissues. Vitronectin interact with glycosaminoglycans and proteoglycans. Is recognized by certain members of the integrin family and serves as a cell-to-substrate adhesion molecule. Inhibitor of the membrane-damaging effect of the terminal cytolytic complement pathway.Somatomedin-B is a growth hormone-dependent serum factor with protease-inhibiting activity.'], 'gene-name': ['VTN'], 'locus': ['17q11'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-19'], 'theoretical-pi': ['5.54'], 'molecular-weight': ['54305.135'], 'chromosome-location': ['17'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:12724']}, {'resource': ['GenAtlas'], 'identifier': ['VTN']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X03168']}, {'resource': ['GenBank Protein Database'], 'identifier': ['36575']}, {'resource': ['UniProtKB'], 'identifier': ['P04004']}, {'resource': ['UniProt Accession'], 'identifier': ['VTNC_HUMAN']}]}], 'synonyms': [{'synonym': ['S-protein', 'Serum-spreading factor', 'V75', 'VN']}], 'amino-acid-sequence': ['>lcl|BSEQ0016301|Vitronectin\nMAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSCCTDYTAECKP\nQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTSDLQAQSKGNPEQTPVLKPEE\nEAPAPEVGASKPEGIDSRPETLHPGRPQPPAEEELCSGKPFDAFTDLKNGSLFAFRGQYC\nYELDEKAVRPGYPKLIRDVWGIEGPIDAAFTRINCQGKTYLFKGSQYWRFEDGVLDPDYP\nRNISDGFDGIPDNVDAALALPAHSYSGRERVYFFKGKQYWEYQFQHQPSQEECEGSSLSA\nVFEHFAMMQRDSWEDIFELLFWGRTSAGTRQPQFISRDWHGVPGQVDAAMAGRIYISGMA\nPRPSLAKKQRFRHRNRKGYRSQRGHSRGRNQNSRRPSRATWLSLFSSEESNLGANNYDDY\nRMDWLVPATCEPIQSVFFFSGDKYYRVNLRTRRVDTVDPPYPRSIAQYWLGCPAPGHL'], 'gene-sequence': ['>lcl|BSEQ0016302|Vitronectin (VTN)\nATGGCACCCCTGAGACCCCTTCTCATACTGGCCCTGCTGGCATGGGTTGCTCTGGCTGAC\nCAAGAGTCATGCAAGGGCCGCTGCACTGAGGGCTTCAACGTGGACAAGAAGTGCCAGTGT\nGACGAGCTCTGCTCTTACTACCAGAGCTGCTGCACAGACTATACGGCTGAGTGCAAGCCC\nCAAGTGACTCGCGGGGATGTGTTCACTATGCCGGAGGATGAGTACACGGTCTATGACGAT\nGGCGAGGAGAAAAACAATGCCACTGTCCATGAACAGGTGGGGGGCCCCTCCCTGACCTCT\nGACCTCCAGGCCCAGTCCAAAGGGAATCCTGAGCAGACACCTGTTCTGAAACCTGAGGAA\nGAGGCCCCTGCGCCTGAGGTGGGCGCCTCTAAGCCTGAGGGGATAGACTCAAGGCCTGAG\nACCCTTCATCCAGGGAGACCTCAGCCCCCAGCAGAGGAGGAGCTGTGCAGTGGGAAGCCC\nTTCGACGCCTTCACCGACCTCAAGAACGGTTCCCTCTTTGCCTTCCGAGGGCAGTACTGC\nTATGAACTGGACGAAAAGGCAGTGAGGCCTGGGTACCCCAAGCTCATCCGAGATGTCTGG\nGGCATCGAGGGCCCCATCGATGCCGCCTTCACCCGCATCAACTGTCAGGGGAAGACCTAC\nCTCTTCAAGGGTAGTCAGTACTGGCGCTTTGAGGATGGTGTCCTGGACCCTGATTACCCC\nCGAAATATCTCTGACGGCTTCGATGGCATCCCGGACAACGTGGATGCAGCCTTGGCCCTC\nCCTGCCCATAGCTACAGTGGCCGGGAGCGGGTCTACTTCTTCAAGGGGAAACAGTACTGG\nGAGTACCAGTTCCAGCACCAGCCCAGTCAGGAGGAGTGTGAAGGCAGCTCCCTGTCGGCT\nGTGTTTGAACACTTTGCCATGATGCAGCGGGACAGCTGGGAGGACATCTTCGAGCTTCTC\nTTCTGGGGCAGAACCTCTGCTGGTACCAGACAGCCCCAGTTCATTAGCCGGGACTGGCAC\nGGTGTGCCAGGGCAAGTGGACGCAGCCATGGCTGGCCGCATCTACATCTCAGGCATGGCA\nCCCCGCCCCTCCTTGGCCAAGAAACAAAGGTTTAGGCATCGCAACCGCAAAGGCTACCGT\nTCACAACGAGGCCACAGCCGTGGCCGCAACCAGAACTCCCGCCGGCCATCCCGCGCCACG\nTGGCTGTCCTTGTTCTCCAGTGAGGAGAGCAACTTGGGAGCCAACAACTATGATGACTAC\nAGGATGGACTGGCTTGTGCCTGCCACCTGTGAACCCATCCAGAGTGTCTTCTTCTTCTCT\nGGAGACAAGTACTACCGAGTCAATCTTCGCACACGGCGAGTGGACACTGTGGACCCTCCC\nTACCCACGCTCCATCGCTCAGTACTGGCTGGGCTGCCCAGCTCCTGGCCATCTGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00045'], 'name': ['Hemopexin']}, {'identifier': ['PF01033'], 'name': ['Somatomedin_B']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['alphav-beta3 integrin-vitronectin complex']}, {'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular matrix']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['proteinaceous extracellular matrix']}, {'category': ['function'], 'description': ['extracellular matrix binding']}, {'category': ['function'], 'description': ['heparin binding']}, {'category': ['function'], 'description': ['integrin binding']}, {'category': ['function'], 'description': ['polysaccharide binding']}, {'category': ['function'], 'description': ['scavenger receptor activity']}, {'category': ['process'], 'description': ['cell adhesion']}, {'category': ['process'], 'description': ['cell adhesion mediated by integrin']}, {'category': ['process'], 'description': ['cell-matrix adhesion']}, {'category': ['process'], 'description': ['endodermal cell differentiation']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['negative regulation of blood coagulation']}, {'category': ['process'], 'description': ['negative regulation of endopeptidase activity']}, {'category': ['process'], 'description': ['oligodendrocyte differentiation']}, {'category': ['process'], 'description': ['positive regulation of cell-substrate adhesion']}, {'category': ['process'], 'description': ['positive regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of protein binding']}, {'category': ['process'], 'description': ['positive regulation of receptor-mediated endocytosis']}, {'category': ['process'], 'description': ['positive regulation of smooth muscle cell migration']}, {'category': ['process'], 'description': ['positive regulation of vascular endothelial growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of wound healing']}, {'category': ['process'], 'description': ['regulation of complement activation']}, {'category': ['process'], 'description': ['smooth muscle cell-matrix adhesion']}]}]}]}]}]"
"['DB00055', 'BTD00068', 'BIOD00068']",['Drotrecogin alfa'],biotech,"['Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis.']",['liquid'],['For reduction of mortality in patients with severe sepsis.'],"['Activated protein C combines with protein S on platelet surfaces and then degrades factor Va and factor VIIIa, thereby reducing blood coagulability.']","[{'food-interaction': ['Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.']}]","[{'target': [{'id': ['BE0000016'], 'name': ['Coagulation factor VIII'], 'organism': ['Humans'], 'actions': [{'action': ['inhibitor']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1965'], 'pubmed-id': ['9184404'], 'citation': ['Geng JP, Castellino FJ: Properties of a recombinant chimeric protein in which the gamma-carboxyglutamic acid and helical stack domains of human anticoagulant protein C are replaced by those of human coagulation factor VII. Thromb Haemost. 1997 May;77(5):926-33.']}, {'ref-id': ['A1967'], 'pubmed-id': ['18954704'], 'citation': ['Colin G, Annane D: Corticosteroids and human recombinant activated protein C for septic shock. Clin Chest Med. 2008 Dec;29(4):705-12, x. doi: 10.1016/j.ccm.2008.06.009.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A241023'], 'pubmed-id': ['6419799'], 'citation': ['Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS: Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood. 1984 Feb;63(2):486-9.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Coagulation factor VIII'], 'general-function': ['Oxidoreductase activity'], 'specific-function': ['Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa.'], 'gene-name': ['F8'], 'locus': ['Xq28'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-19'], 'theoretical-pi': ['7.37'], 'molecular-weight': ['267007.42'], 'chromosome-location': ['X'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3546']}, {'resource': ['GenAtlas'], 'identifier': ['F8']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M14113']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182818']}, {'resource': ['UniProtKB'], 'identifier': ['P00451']}, {'resource': ['UniProt Accession'], 'identifier': ['FA8_HUMAN']}]}], 'synonyms': [{'synonym': ['AHF', 'Antihemophilic factor', 'F8C', 'Procoagulant component']}], 'amino-acid-sequence': ['>lcl|BSEQ0000032|Coagulation factor VIII\nMQIELSTCFFLCLLRFCFSATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFN\nTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAV\nGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSH\nVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRD\nAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNH\nRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNE\nEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLA\nPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTL\nLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGP\nTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDE\nNRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILS\nIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRG\nMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNSRHPSTRQKQFNATTI\nPENDIEKTDPWFAHRTPMPKIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKYETFSDDPS\nPGAIDSNNSLSEMTHFRPQLHHSGDMVFTPESGLQLRLNEKLGTTAATELKKLDFKVSST\nSNNLISTIPSDNLAAGTDNTSSLGPPSMPVHYDSQLDTTLFGKKSSPLTESGGPLSLSEE\nNNDSKLLESGLMNSQESSWGKNVSSTESGRLFKGKRAHGPALLTKDNALFKVSISLLKTN\nKTSNNSATNRKTHIDGPSLLIENSPSVWQNILESDTEFKKVTPLIHDRMLMDKNATALRL\nNHMSNKTTSSKNMEMVQQKKEGPIPPDAQNPDMSFFKMLFLPESARWIQRTHGKNSLNSG\nQGPSPKQLVSLGPEKSVEGQNFLSEKNKVVVGKGEFTKDVGLKEMVFPSSRNLFLTNLDN\nLHENNTHNQEKKIQEEIEKKETLIQENVVLPQIHTVTGTKNFMKNLFLLSTRQNVEGSYD\nGAYAPVLQDFRSLNDSTNRTKKHTAHFSKKGEEENLEGLGNQTKQIVEKYACTTRISPNT\nSQQNFVTQRSKRALKQFRLPLEETELEKRIIVDDTSTQWSKNMKHLTPSTLTQIDYNEKE\nKGAITQSPLSDCLTRSHSIPQANRSPLPIAKVSSFPSIRPIYLTRVLFQDNSSHLPAASY\nRKKDSGVQESSHFLQGAKKNNLSLAILTLEMTGDQREVGSLGTSATNSVTYKKVENTVLP\nKPDLPKTSGKVELLPKVHIYQKDLFPTETSNGSPGHLDLVEGSLLQGTEGAIKWNEANRP\nGKVPFLRVATESSAKTPSKLLDPLAWDNHYGTQIPKEEWKSQEKSPEKTAFKKKDTILSL\nNACESNHAIAAINEGQNKPEIEVTWAKQGRTERLCSQNPPVLKRHQREITRTTLQSDQEE\nIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNR\nAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASR\nPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDV\nDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRA\nPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGH\nVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKC\nQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMII\nHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFN\nPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFA\nTWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFL\nISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRM\nEVLGCEAQDLY'], 'gene-sequence': ['>lcl|BSEQ0015996|Coagulation factor VIII (F8)\nATGCAAATAGAGCTCTCCACCTGCTTCTTTCTGTGCCTTTTGCGATTCTGCTTTAGTGCC\nACCAGAAGATACTACCTGGGTGCAGTGGAACTGTCATGGGACTATATGCAAAGTGATCTC\nGGTGAGCTGCCTGTGGACGCAAGATTTCCTCCTAGAGTGCCAAAATCTTTTCCATTCAAC\nACCTCAGTCGTGTACAAAAAGACTCTGTTTGTAGAATTCACGGATCACCTTTTCAACATC\nGCTAAGCCAAGGCCACCCTGGATGGGTCTGCTAGGTCCTACCATCCAGGCTGAGGTTTAT\nGATACAGTGGTCATTACACTTAAGAACATGGCTTCCCATCCTGTCAGTCTTCATGCTGTT\nGGTGTATCCTACTGGAAAGCTTCTGAGGGAGCTGAATATGATGATCAGACCAGTCAAAGG\nGAGAAAGAAGATGATAAAGTCTTCCCTGGTGGAAGCCATACATATGTCTGGCAGGTCCTG\nAAAGAGAATGGTCCAATGGCCTCTGACCCACTGTGCCTTACCTACTCATATCTTTCTCAT\nGTGGACCTGGTAAAAGACTTGAATTCAGGCCTCATTGGAGCCCTACTAGTATGTAGAGAA\nGGGAGTCTGGCCAAGGAAAAGACACAGACCTTGCACAAATTTATACTACTTTTTGCTGTA\nTTTGATGAAGGGAAAAGTTGGCACTCAGAAACAAAGAACTCCTTGATGCAGGATAGGGAT\nGCTGCATCTGCTCGGGCCTGGCCTAAAATGCACACAGTCAATGGTTATGTAAACAGGTCT\nCTGCCAGGTCTGATTGGATGCCACAGGAAATCAGTCTATTGGCATGTGATTGGAATGGGC\nACCACTCCTGAAGTGCACTCAATATTCCTCGAAGGTCACACATTTCTTGTGAGGAACCAT\nCGCCAGGCGTCCTTGGAAATCTCGCCAATAACTTTCCTTACTGCTCAAACACTCTTGATG\nGACCTTGGACAGTTTCTACTGTTTTGTCATATCTCTTCCCACCAACATGATGGCATGGAA\nGCTTATGTCAAAGTAGACAGCTGTCCAGAGGAACCCCAACTACGAATGAAAAATAATGAA\nGAAGCGGAAGACTATGATGATGATCTTACTGATTCTGAAATGGATGTGGTCAGGTTTGAT\nGATGACAACTCTCCTTCCTTTATCCAAATTCGCTCAGTTGCCAAGAAGCATCCTAAAACT\nTGGGTACATTACATTGCTGCTGAAGAGGAGGACTGGGACTATGCTCCCTTAGTCCTCGCC\nCCCGATGACAGAAGTTATAAAAGTCAATATTTGAACAATGGCCCTCAGCGGATTGGTAGG\nAAGTACAAAAAAGTCCGATTTATGGCATACACAGATGAAACCTTTAAGACTCGTGAAGCT\nATTCAGCATGAATCAGGAATCTTGGGACCTTTACTTTATGGGGAAGTTGGAGACACACTG\nTTGATTATATTTAAGAATCAAGCAAGCAGACCATATAACATCTACCCTCACGGAATCACT\nGATGTCCGTCCTTTGTATTCAAGGAGATTACCAAAAGGTGTAAAACATTTGAAGGATTTT\nCCAATTCTGCCAGGAGAAATATTCAAATATAAATGGACAGTGACTGTAGAAGATGGGCCA\nACTAAATCAGATCCTCGGTGCCTGACCCGCTATTACTCTAGTTTCGTTAATATGGAGAGA\nGATCTAGCTTCAGGACTCATTGGCCCTCTCCTCATCTGCTACAAAGAATCTGTAGATCAA\nAGAGGAAACCAGATAATGTCAGACAAGAGGAATGTCATCCTGTTTTCTGTATTTGATGAG\nAACCGAAGCTGGTACCTCACAGAGAATATACAACGCTTTCTCCCCAATCCAGCTGGAGTG\nCAGCTTGAGGATCCAGAGTTCCAAGCCTCCAACATCATGCACAGCATCAATGGCTATGTT\nTTTGATAGTTTGCAGTTGTCAGTTTGTTTGCATGAGGTGGCATACTGGTACATTCTAAGC\nATTGGAGCACAGACTGACTTCCTTTCTGTCTTCTTCTCTGGATATACCTTCAAACACAAA\nATGGTCTATGAAGACACACTCACCCTATTCCCATTCTCAGGAGAAACTGTCTTCATGTCG\nATGGAAAACCCAGGTCTATGGATTCTGGGGTGCCACAACTCAGACTTTCGGAACAGAGGC\nATGACCGCCTTACTGAAGGTTTCTAGTTGTGACAAGAACACTGGTGATTATTACGAGGAC\nAGTTATGAAGATATTTCAGCATACTTGCTGAGTAAAAACAATGCCATTGAACCAAGAAGC\nTTCTCCCAGAATTCAAGACACCCTAGCACTAGGCAAAAGCAATTTAATGCCACCACAATT\nCCAGAAAATGACATAGAGAAGACTGACCCTTGGTTTGCACACAGAACACCTATGCCTAAA\nATACAAAATGTCTCCTCTAGTGATTTGTTGATGCTCTTGCGACAGAGTCCTACTCCACAT\nGGGCTATCCTTATCTGATCTCCAAGAAGCCAAATATGAGACTTTTTCTGATGATCCATCA\nCCTGGAGCAATAGACAGTAATAACAGCCTGTCTGAAATGACACACTTCAGGCCACAGCTC\nCATCACAGTGGGGACATGGTATTTACCCCTGAGTCAGGCCTCCAATTAAGATTAAATGAG\nAAACTGGGGACAACTGCAGCAACAGAGTTGAAGAAACTTGATTTCAAAGTTTCTAGTACA\nTCAAATAATCTGATTTCAACAATTCCATCAGACAATTTGGCAGCAGGTACTGATAATACA\nAGTTCCTTAGGACCCCCAAGTATGCCAGTTCATTATGATAGTCAATTAGATACCACTCTA\nTTTGGCAAAAAGTCATCTCCCCTTACTGAGTCTGGTGGACCTCTGAGCTTGAGTGAAGAA\nAATAATGATTCAAAGTTGTTAGAATCAGGTTTAATGAATAGCCAAGAAAGTTCATGGGGA\nAAAAATGTATCGTCAACAGAGAGTGGTAGGTTATTTAAAGGGAAAAGAGCTCATGGACCT\nGCTTTGTTGACTAAAGATAATGCCTTATTCAAAGTTAGCATCTCTTTGTTAAAGACAAAC\nAAAACTTCCAATAATTCAGCAACTAATAGAAAGACTCACATTGATGGCCCATCATTATTA\nATTGAGAATAGTCCATCAGTCTGGCAAAATATATTAGAAAGTGACACTGAGTTTAAAAAA\nGTGACACCTTTGATTCATGACAGAATGCTTATGGACAAAAATGCTACAGCTTTGAGGCTA\nAATCATATGTCAAATAAAACTACTTCATCAAAAAACATGGAAATGGTCCAACAGAAAAAA\nGAGGGCCCCATTCCACCAGATGCACAAAATCCAGATATGTCGTTCTTTAAGATGCTATTC\nTTGCCAGAATCAGCAAGGTGGATACAAAGGACTCATGGAAAGAACTCTCTGAACTCTGGG\nCAAGGCCCCAGTCCAAAGCAATTAGTATCCTTAGGACCAGAAAAATCTGTGGAAGGTCAG\nAATTTCTTGTCTGAGAAAAACAAAGTGGTAGTAGGAAAGGGTGAATTTACAAAGGACGTA\nGGACTCAAAGAGATGGTTTTTCCAAGCAGCAGAAACCTATTTCTTACTAACTTGGATAAT\nTTACATGAAAATAATACACACAATCAAGAAAAAAAAATTCAGGAAGAAATAGAAAAGAAG\nGAAACATTAATCCAAGAGAATGTAGTTTTGCCTCAGATACATACAGTGACTGGCACTAAG\nAATTTCATGAAGAACCTTTTCTTACTGAGCACTAGGCAAAATGTAGAAGGTTCATATGAC\nGGGGCATATGCTCCAGTACTTCAAGATTTTAGGTCATTAAATGATTCAACAAATAGAACA\nAAGAAACACACAGCTCATTTCTCAAAAAAAGGGGAGGAAGAAAACTTGGAAGGCTTGGGA\nAATCAAACCAAGCAAATTGTAGAGAAATATGCATGCACCACAAGGATATCTCCTAATACA\nAGCCAGCAGAATTTTGTCACGCAACGTAGTAAGAGAGCTTTGAAACAATTCAGACTCCCA\nCTAGAAGAAACAGAACTTGAAAAAAGGATAATTGTGGATGACACCTCAACCCAGTGGTCC\nAAAAACATGAAACATTTGACCCCGAGCACCCTCACACAGATAGACTACAATGAGAAGGAG\nAAAGGGGCCATTACTCAGTCTCCCTTATCAGATTGCCTTACGAGGAGTCATAGCATCCCT\nCAAGCAAATAGATCTCCATTACCCATTGCAAAGGTATCATCATTTCCATCTATTAGACCT\nATATATCTGACCAGGGTCCTATTCCAAGACAACTCTTCTCATCTTCCAGCAGCATCTTAT\nAGAAAGAAAGATTCTGGGGTCCAAGAAAGCAGTCATTTCTTACAAGGAGCCAAAAAAAAT\nAACCTTTCTTTAGCCATTCTAACCTTGGAGATGACTGGTGATCAAAGAGAGGTTGGCTCC\nCTGGGGACAAGTGCCACAAATTCAGTCACATACAAGAAAGTTGAGAACACTGTTCTCCCG\nAAACCAGACTTGCCCAAAACATCTGGCAAAGTTGAATTGCTTCCAAAAGTTCACATTTAT\nCAGAAGGACCTATTCCCTACGGAAACTAGCAATGGGTCTCCTGGCCATCTGGATCTCGTG\nGAAGGGAGCCTTCTTCAGGGAACAGAGGGAGCGATTAAGTGGAATGAAGCAAACAGACCT\nGGAAAAGTTCCCTTTCTGAGAGTAGCAACAGAAAGCTCTGCAAAGACTCCCTCCAAGCTA\nTTGGATCCTCTTGCTTGGGATAACCACTATGGTACTCAGATACCAAAAGAAGAGTGGAAA\nTCCCAAGAGAAGTCACCAGAAAAAACAGCTTTTAAGAAAAAGGATACCATTTTGTCCCTG\nAACGCTTGTGAAAGCAATCATGCAATAGCAGCAATAAATGAGGGACAAAATAAGCCCGAA\nATAGAAGTCACCTGGGCAAAGCAAGGTAGGACTGAAAGGCTGTGCTCTCAAAACCCACCA\nGTCTTGAAACGCCATCAACGGGAAATAACTCGTACTACTCTTCAGTCAGATCAAGAGGAA\nATTGACTATGATGATACCATATCAGTTGAAATGAAGAAGGAAGATTTTGACATTTATGAT\nGAGGATGAAAATCAGAGCCCCCGCAGCTTTCAAAAGAAAACACGACACTATTTTATTGCT\nGCAGTGGAGAGGCTCTGGGATTATGGGATGAGTAGCTCCCCACATGTTCTAAGAAACAGG\nGCTCAGAGTGGCAGTGTCCCTCAGTTCAAGAAAGTTGTTTTCCAGGAATTTACTGATGGC\nTCCTTTACTCAGCCCTTATACCGTGGAGAACTAAATGAACATTTGGGACTCCTGGGGCCA\nTATATAAGAGCAGAAGTTGAAGATAATATCATGGTAACTTTCAGAAATCAGGCCTCTCGT\nCCCTATTCCTTCTATTCTAGCCTTATTTCTTATGAGGAAGATCAGAGGCAAGGAGCAGAA\nCCTAGAAAAAACTTTGTCAAGCCTAATGAAACCAAAACTTACTTTTGGAAAGTGCAACAT\nCATATGGCACCCACTAAAGATGAGTTTGACTGCAAAGCCTGGGCTTATTTCTCTGATGTT\nGACCTGGAAAAAGATGTGCACTCAGGCCTGATTGGACCCCTTCTGGTCTGCCACACTAAC\nACACTGAACCCTGCTCATGGGAGACAAGTGACAGTACAGGAATTTGCTCTGTTTTTCACC\nATCTTTGATGAGACCAAAAGCTGGTACTTCACTGAAAATATGGAAAGAAACTGCAGGGCT\nCCCTGCAATATCCAGATGGAAGATCCCACTTTTAAAGAGAATTATCGCTTCCATGCAATC\nAATGGCTACATAATGGATACACTACCTGGCTTAGTAATGGCTCAGGATCAAAGGATTCGA\nTGGTATCTGCTCAGCATGGGCAGCAATGAAAACATCCATTCTATTCATTTCAGTGGACAT\nGTGTTCACTGTACGAAAAAAAGAGGAGTATAAAATGGCACTGTACAATCTCTATCCAGGT\nGTTTTTGAGACAGTGGAAATGTTACCATCCAAAGCTGGAATTTGGCGGGTGGAATGCCTT\nATTGGCGAGCATCTACATGCTGGGATGAGCACACTTTTTCTGGTGTACAGCAATAAGTGT\nCAGACTCCCCTGGGAATGGCTTCTGGACACATTAGAGATTTTCAGATTACAGCTTCAGGA\nCAATATGGACAGTGGGCCCCAAAGCTGGCCAGACTTCATTATTCCGGATCAATCAATGCC\nTGGAGCACCAAGGAGCCCTTTTCTTGGATCAAGGTGGATCTGTTGGCACCAATGATTATT\nCACGGCATCAAGACCCAGGGTGCCCGTCAGAAGTTCTCCAGCCTCTACATCTCTCAGTTT\nATCATCATGTATAGTCTTGATGGGAAGAAGTGGCAGACTTATCGAGGAAATTCCACTGGA\nACCTTAATGGTCTTCTTTGGCAATGTGGATTCATCTGGGATAAAACACAATATTTTTAAC\nCCTCCAATTATTGCTCGATACATCCGTTTGCACCCAACTCATTATAGCATTCGCAGCACT\nCTTCGCATGGAGTTGATGGGCTGTGATTTAAATAGTTGCAGCATGCCATTGGGAATGGAG\nAGTAAAGCAATATCAGATGCACAGATTACTGCTTCATCCTACTTTACCAATATGTTTGCC\nACCTGGTCTCCTTCAAAAGCTCGACTTCACCTCCAAGGGAGGAGTAATGCCTGGAGACCT\nCAGGTGAATAATCCAAAAGAGTGGCTGCAAGTGGACTTCCAGAAGACAATGAAAGTCACA\nGGAGTAACTACTCAGGGAGTAAAATCTCTGCTTACCAGCATGTATGTGAAGGAGTTCCTC\nATCTCCAGCAGTCAAGATGGCCATCAGTGGACTCTCTTTTTTCAGAATGGCAAAGTAAAG\nGTTTTTCAGGGAAATCAAGACTCCTTCACACCTGTGGTGAACTCTCTAGACCCACCGTTA\nCTGACTCGCTACCTTCGAATTCACCCCCAGAGTTGGGTGCACCAGATTGCCCTGAGGATG\nGAGGTTCTGGGCTGCGAGGCACAGGACCTCTACTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00394'], 'name': ['Cu-oxidase']}, {'identifier': ['PF07731'], 'name': ['Cu-oxidase_2']}, {'identifier': ['PF07732'], 'name': ['Cu-oxidase_3']}, {'identifier': ['PF00754'], 'name': ['F5_F8_type_C']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['endoplasmic reticulum-Golgi intermediate compartment membrane']}, {'category': ['component'], 'description': ['ER to Golgi transport vesicle']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['Golgi membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['function'], 'description': ['copper ion binding']}, {'category': ['function'], 'description': ['oxidoreductase activity']}, {'category': ['process'], 'description': ['acute-phase response']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, intrinsic pathway']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['COPII vesicle coating']}, {'category': ['process'], 'description': ['ER to Golgi vesicle-mediated transport']}, {'category': ['process'], 'description': ['membrane organization']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['protein N-linked glycosylation via asparagine']}]}]}]}, {'id': ['BE0000041'], 'name': ['Coagulation factor V'], 'organism': ['Humans'], 'actions': [{'action': ['inhibitor']}], 'references': [{'articles': [{'article': [{'ref-id': ['A6703'], 'pubmed-id': ['11236773'], 'citation': ['Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001 Mar 8;344(10):699-709.']}, {'ref-id': ['A6704'], 'pubmed-id': ['11714212'], 'citation': ['Kanji S, Devlin JW, Piekos KA, Racine E: Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis. Pharmacotherapy. 2001 Nov;21(11):1389-402.']}, {'ref-id': ['A6705'], 'pubmed-id': ['11893230'], 'citation': ['Lyseng-Williamson KA, Perry CM: Drotrecogin alfa (activated). Drugs. 2002;62(4):617-30; discussion 631-2.']}, {'ref-id': ['A6706'], 'pubmed-id': ['12004250'], 'citation': ['Joyce DE, Grinnell BW: Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med. 2002 May;30(5 Suppl):S288-93.']}, {'ref-id': ['A6707'], 'pubmed-id': ['12030642'], 'citation': ['Poe K: Drotrecogin alfa (activated) approved for treatment of severe sepsis. J Am Pharm Assoc (Wash). 2002 May-Jun;42(3):520-2.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A241023'], 'pubmed-id': ['6419799'], 'citation': ['Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS: Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood. 1984 Feb;63(2):486-9.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Coagulation factor V'], 'general-function': ['Copper ion binding'], 'specific-function': ['Central regulator of hemostasis. It serves as a critical cofactor for the prothrombinase activity of factor Xa that results in the activation of prothrombin to thrombin.'], 'gene-name': ['F5'], 'locus': ['1q23'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-28'], 'theoretical-pi': ['5.95'], 'molecular-weight': ['251701.245'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3542']}, {'resource': ['GenAtlas'], 'identifier': ['F5']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M16967']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182412']}, {'resource': ['UniProtKB'], 'identifier': ['P12259']}, {'resource': ['UniProt Accession'], 'identifier': ['FA5_HUMAN']}]}], 'synonyms': [{'synonym': ['Activated protein C cofactor', 'Proaccelerin, labile factor']}], 'amino-acid-sequence': ['>lcl|BSEQ0036943|Coagulation factor V\nMFPGCPRLWVLVVLGTSWVGWGSQGTEAAQLRQFYVAAQGISWSYRPEPTNSSLNLSVTS\nFKKIVYREYEPYFKKEKPQSTISGLLGPTLYAEVGDIIKVHFKNKADKPLSIHPQGIRYS\nKLSEGASYLDHTFPAEKMDDAVAPGREYTYEWSISEDSGPTHDDPPCLTHIYYSHENLIE\nDFNSGLIGPLLICKKGTLTEGGTQKTFDKQIVLLFAVFDESKSWSQSSSLMYTVNGYVNG\nTMPDITVCAHDHISWHLLGMSSGPELFSIHFNGQVLEQNHHKVSAITLVSATSTTANMTV\nGPEGKWIISSLTPKHLQAGMQAYIDIKNCPKKTRNLKKITREQRRHMKRWEYFIAAEEVI\nWDYAPVIPANMDKKYRSQHLDNFSNQIGKHYKKVMYTQYEDESFTKHTVNPNMKEDGILG\nPIIRAQVRDTLKIVFKNMASRPYSIYPHGVTFSPYEDEVNSSFTSGRNNTMIRAVQPGET\nYTYKWNILEFDEPTENDAQCLTRPYYSDVDIMRDIASGLIGLLLICKSRSLDRRGIQRAA\nDIEQQAVFAVFDENKSWYLEDNINKFCENPDEVKRDDPKFYESNIMSTINGYVPESITTL\nGFCFDDTVQWHFCSVGTQNEILTIHFTGHSFIYGKRHEDTLTLFPMRGESVTVTMDNVGT\nWMLTSMNSSPRSKKLRLKFRDVKCIPDDDEDSYEIFEPPESTVMATRKMHDRLEPEDEES\nDADYDYQNRLAAALGIRSFRNSSLNQEEEEFNLTALALENGTEFVSSNTDIIVGSNYSSP\nSNISKFTVNNLAEPQKAPSHQQATTAGSPLRHLIGKNSVLNSSTAEHSSPYSEDPIEDPL\nQPDVTGIRLLSLGAGEFKSQEHAKHKGPKVERDQAAKHRFSWMKLLAHKVGRHLSQDTGS\nPSGMRPWEDLPSQDTGSPSRMRPWKDPPSDLLLLKQSNSSKILVGRWHLASEKGSYEIIQ\nDTDEDTAVNNWLISPQNASRAWGESTPLANKPGKQSGHPKFPRVRHKSLQVRQDGGKSRL\nKKSQFLIKTRKKKKEKHTHHAPLSPRTFHPLRSEAYNTFSERRLKHSLVLHKSNETSLPT\nDLNQTLPSMDFGWIASLPDHNQNSSNDTGQASCPPGLYQTVPPEEHYQTFPIQDPDQMHS\nTSDPSHRSSSPELSEMLEYDRSHKSFPTDISQMSPSSEHEVWQTVISPDLSQVTLSPELS\nQTNLSPDLSHTTLSPELIQRNLSPALGQMPISPDLSHTTLSPDLSHTTLSLDLSQTNLSP\nELSQTNLSPALGQMPLSPDLSHTTLSLDFSQTNLSPELSHMTLSPELSQTNLSPALGQMP\nISPDLSHTTLSLDFSQTNLSPELSQTNLSPALGQMPLSPDPSHTTLSLDLSQTNLSPELS\nQTNLSPDLSEMPLFADLSQIPLTPDLDQMTLSPDLGETDLSPNFGQMSLSPDLSQVTLSP\nDISDTTLLPDLSQISPPPDLDQIFYPSESSQSLLLQEFNESFPYPDLGQMPSPSSPTLND\nTFLSKEFNPLVIVGLSKDGTDYIEIIPKEEVQSSEDDYAEIDYVPYDDPYKTDVRTNINS\nSRDPDNIAAWYLRSNNGNRRNYYIAAEEISWDYSEFVQRETDIEDSDDIPEDTTYKKVVF\nRKYLDSTFTKRDPRGEYEEHLGILGPIIRAEVDDVIQVRFKNLASRPYSLHAHGLSYEKS\nSEGKTYEDDSPEWFKEDNAVQPNSSYTYVWHATERSGPESPGSACRAWAYYSAVNPEKDI\nHSGLIGPLLICQKGILHKDSNMPMDMREFVLLFMTFDEKKSWYYEKKSRSSWRLTSSEMK\nKSHEFHAINGMIYSLPGLKMYEQEWVRLHLLNIGGSQDIHVVHFHGQTLLENGNKQHQLG\nVWPLLPGSFKTLEMKASKPGWWLLNTEVGENQRAGMQTPFLIMDRDCRMPMGLSTGIISD\nSQIKASEFLGYWEPRLARLNNGGSYNAWSVEKLAAEFASKPWIQVDMQKEVIITGIQTQG\nAKHYLKSCYTTEFYVAYSSNQINWQIFKGNSTRNVMYFNGNSDASTIKENQFDPPIVARY\nIRISPTRAYNRPTLRLELQGCEVNGCSTPLGMENGKIENKQITASSFKKSWWGDYWEPFR\nARLNAQGRVNAWQAKANNNKQWLEIDLLKIKKITAIITQGCKSLSSEMYVKSYTIHYSEQ\nGVEWKPYRLKSSMVDKIFEGNTNTKGHVKNFFNPPIISRFIRVIPKTWNQSIALRLELFG\nCDIY'], 'gene-sequence': ['>lcl|BSEQ0010139|Coagulation factor V (F5)\nATGTTCCCAGGCTGCCCACGCCTCTGGGTCCTGGTGGTCTTGGGCACCAGCTGGGTAGGC\nTGGGGGAGCCAAGGGACAGAAGCGGCACAGCTAAGGCAGTTCTACGTGGCTGCTCAGGGC\nATCAGTTGGAGCTACCGACCTGAGCCCACAAACTCAAGTTTGAATCTTTCTGTAACTTCC\nTTTAAGAAAATTGTCTACAGAGAGTATGAACCATATTTTAAGAAAGAAAAACCACAATCT\nACCATTTCAGGACTTCTTGGGCCTACTTTATATGCTGAAGTCGGAGACATCATAAAAGTT\nCACTTTAAAAATAAGGCAGATAAGCCCTTGAGCATCCATCCTCAAGGAATTAGGTACAGT\nAAATTATCAGAAGGTGCTTCTTACCTTGACCACACATTCCCTGCGGAGAAGATGGACGAC\nGCTGTGGCTCCAGGCCGAGAATACACCTATGAATGGAGTATCAGTGAGGACAGTGGACCC\nACCCATGATGACCCTCCATGCCTCACACACATCTATTACTCCCATGAAAATCTGATCGAG\nGATTTCAACTCGGGGCTGATTGGGCCCCTGCTTATCTGTAAAAAAGGGACCCTAACTGAG\nGGTGGGACACAGAAGACGTTTGACAAGCAAATCGTGCTACTATTTGCTGTGTTTGATGAA\nAGCAAGAGCTGGAGCCAGTCATCATCCCTAATGTACACAGTCAATGGATATGTGAATGGG\nACAATGCCAGATATAACAGTTTGTGCCCATGACCACATCAGCTGGCATCTGCTGGGAATG\nAGCTCGGGGCCAGAATTATTCTCCATTCATTTCAACGGCCAGGTCCTGGAGCAGAACCAT\nCATAAGGTCTCAGCCATCACCCTTGTCAGTGCTACATCCACTACCGCAAATATGACTGTG\nGGCCCAGAGGGAAAGTGGATCATATCTTCTCTCACCCCAAAACATTTGCAAGCTGGGATG\nCAGGCTTACATTGACATTAAAAACTGCCCAAAGAAAACCAGGAATCTTAAGAAAATAACT\nCGTGAGCAGAGGCGGCACATGAAGAGGTGGGAATACTTCATTGCTGCAGAGGAAGTCATT\nTGGGACTATGCACCTGTAATACCAGCGAATATGGACAAAAAATACAGGTCTCAGCATTTG\nGATAATTTCTCAAACCAAATTGGAAAACATTATAAGAAAGTTATGTACACACAGTACGAA\nGATGAGTCCTTCACCAAACATACAGTGAATCCCAATATGAAAGAAGATGGGATTTTGGGT\nCCTATTATCAGAGCCCAGGTCAGAGACACACTCAAAATCGTGTTCAAAAATATGGCCAGC\nCGCCCCTATAGCATTTACCCTCATGGAGTGACCTTCTCGCCTTATGAAGATGAAGTCAAC\nTCTTCTTTCACCTCAGGCAGGAACAACACCATGATCAGAGCAGTTCAACCAGGGGAAACC\nTATACTTATAAGTGGAACATCTTAGAGTTTGATGAACCCACAGAAAATGATGCCCAGTGC\nTTAACAAGACCATACTACAGTGACGTGGACATCATGAGAGACATCGCCTCTGGGCTAATA\nGGACTACTTCTAATCTGTAAGAGCAGATCCCTGGACAGGCGAGGAATACAGAGGGCAGCA\nGACATCGAACAGCAGGCTGTGTTTGCTGTGTTTGATGAGAACAAAAGCTGGTACCTTGAG\nGACAACATCAACAAGTTTTGTGAAAATCCTGATGAGGTGAAACGTGATGACCCCAAGTTT\nTATGAATCAAACATCATGAGCACTATCAATGGCTATGTGCCTGAGAGCATAACTACTCTT\nGGATTCTGCTTTGATGACACTGTCCAGTGGCACTTCTGTAGTGTGGGGACCCAGAATGAA\nATTTTGACCATCCACTTCACTGGGCACTCATTCATCTATGGAAAGAGGCATGAGGACACC\nTTGACCCTCTTCCCCATGCGTGGAGAATCTGTGACGGTCACAATGGATAATGTTGGAACT\nTGGATGTTAACTTCCATGAATTCTAGTCCAAGAAGCAAAAAGCTGAGGCTGAAATTCAGG\nGATGTTAAATGTATCCCAGATGATGATGAAGACTCATATGAGATTTTTGAACCTCCAGAA\nTCTACAGTCATGGCTACACGGAAAATGCATGATCGTTTAGAACCTGAAGATGAAGAGAGT\nGATGCTGACTATGATTACCAGAACAGACTGGCTGCAGCATTAGGAATCAGGTCATTCCGA\nAACTCATCATTGAATCAGGAAGAAGAAGAGTTCAATCTTACTGCCCTAGCTCTGGAGAAT\nGGCACTGAATTCGTTTCTTCAAACACAGATATAATTGTTGGTTCAAATTATTCTTCCCCA\nAGTAATATTAGTAAGTTCACTGTCAATAACCTTGCAGAACCTCAGAAAGCCCCTTCTCAC\nCAACAAGCCACCACAGCTGGTTCCCCACTGAGACACCTCATTGGCAAGAACTCAGTTCTC\nAATTCTTCCACAGCAGAGCATTCCAGCCCATATTCTGAAGACCCTATAGAGGATCCTCTA\nCAGCCAGATGTCACAGGGATACGTCTACTTTCACTTGGTGCTGGAGAATTCAAAAGTCAA\nGAACATGCTAAGCATAAGGGACCCAAGGTAGAAAGAGATCAAGCAGCAAAGCACAGGTTC\nTCCTGGATGAAATTACTAGCACATAAAGTTGGGAGACACCTAAGCCAAGACACTGGTTCT\nCCTTCCGGAATGAGGCCCTGGGAGGACCTTCCTAGCCAAGACACTGGTTCTCCTTCCAGA\nATGAGGCCCTGGAAGGACCCTCCTAGTGATCTGTTACTCTTAAAACAAAGTAACTCATCT\nAAGATTTTGGTTGGGAGATGGCATTTGGCTTCTGAGAAAGGTAGCTATGAAATAATCCAA\nGATACTGATGAAGACACAGCTGTTAACAATTGGCTGATCAGCCCCCAGAATGCCTCACGT\nGCTTGGGGAGAAAGCACCCCTCTTGCCAACAAGCCTGGAAAGCAGAGTGGCCACCCAAAG\nTTTCCTAGAGTTAGACATAAATCTCTACAAGTAAGACAGGATGGAGGAAAGAGTAGACTG\nAAGAAAAGCCAGTTTCTCATTAAGACACGAAAAAAGAAAAAAGAGAAGCACACACACCAT\nGCTCCTTTATCTCCGAGGACCTTTCACCCTCTAAGAAGTGAAGCCTACAACACATTTTCA\nGAAAGAAGACTTAAGCATTCGTTGGTGCTTCATAAATCCAATGAAACATCTCTTCCCACA\nGACCTCAATCAGACATTGCCCTCTATGGATTTTGGCTGGATAGCCTCACTTCCTGACCAT\nAATCAGAATTCCTCAAATGACACTGGTCAGGCAAGCTGTCCTCCAGGTCTTTATCAGACA\nGTGCCCCCAGAGGAACACTATCAAACATTCCCCATTCAAGACCCTGATCAAATGCACTCT\nACTTCAGACCCCAGTCACAGATCCTCTTCTCCAGAGCTCAGTGAAATGCTTGAGTATGAC\nCGAAGTCACAAGTCCTTCCCCACAGATATAAGTCAAATGTCCCCTTCCTCAGAACATGAA\nGTCTGGCAGACAGTCATCTCTCCAGACCTCAGCCAGGTGACCCTCTCTCCAGAACTCAGC\nCAGACAAACCTCTCTCCAGACCTCAGCCACACGACTCTCTCTCCAGAACTCATTCAGAGA\nAACCTTTCCCCAGCCCTCGGTCAGATGCCCATTTCTCCAGACCTCAGCCATACAACCCTT\nTCTCCAGACCTCAGCCATACAACCCTTTCTTTAGACCTCAGCCAGACAAACCTCTCTCCA\nGAACTCAGTCAGACAAACCTTTCTCCAGCCCTCGGTCAGATGCCCCTTTCTCCAGACCTC\nAGCCATACAACCCTTTCTCTAGACTTCAGCCAGACAAACCTCTCTCCAGAACTCAGCCAT\nATGACTCTCTCTCCAGAACTCAGTCAGACAAACCTTTCCCCAGCCCTCGGTCAGATGCCC\nATTTCTCCAGACCTCAGCCATACAACCCTTTCTCTAGACTTCAGCCAGACAAACCTCTCT\nCCAGAACTCAGTCAAACAAACCTTTCCCCAGCCCTCGGTCAGATGCCCCTTTCTCCAGAC\nCCCAGCCATACAACCCTTTCTCTAGACCTCAGCCAGACAAACCTCTCTCCAGAACTCAGT\nCAGACAAACCTTTCCCCAGACCTCAGTGAGATGCCCCTCTTTGCAGATCTCAGTCAAATT\nCCCCTTACCCCAGACCTCGACCAGATGACACTTTCTCCAGACCTTGGTGAGACAGATCTT\nTCCCCAAACTTTGGTCAGATGTCCCTTTCCCCAGACCTCAGCCAGGTGACTCTCTCTCCA\nGACATCAGTGACACCACCCTTCTCCCGGATCTCAGCCAGATATCACCTCCTCCAGACCTT\nGATCAGATATTCTACCCTTCTGAATCTAGTCAGTCATTGCTTCTTCAAGAATTTAATGAG\nTCTTTTCCTTATCCAGACCTTGGTCAGATGCCATCTCCTTCATCTCCTACTCTCAATGAT\nACTTTTCTATCAAAGGAATTTAATCCACTGGTTATAGTGGGCCTCAGTAAAGATGGTACA\nGATTACATTGAGATCATTCCAAAGGAAGAGGTCCAGAGCAGTGAAGATGACTATGCTGAA\nATTGATTATGTGCCCTATGATGACCCCTACAAAACTGATGTTAGGACAAACATCAACTCC\nTCCAGAGATCCTGACAACATTGCAGCATGGTACCTCCGCAGCAACAATGGAAACAGAAGA\nAATTATTACATTGCTGCTGAAGAAATATCCTGGGATTATTCAGAATTTGTACAAAGGGAA\nACAGATATTGAAGACTCTGATGATATTCCAGAAGATACCACATATAAGAAAGTAGTTTTT\nCGAAAGTACCTCGACAGCACTTTTACCAAACGTGATCCTCGAGGGGAGTATGAAGAGCAT\nCTCGGAATTCTTGGTCCTATTATCAGAGCTGAAGTGGATGATGTTATCCAAGTTCGTTTT\nAAAAATTTAGCATCCAGACCGTATTCTCTACATGCCCATGGACTTTCCTATGAAAAATCA\nTCAGAGGGAAAGACTTATGAAGATGACTCTCCTGAATGGTTTAAGGAAGATAATGCTGTT\nCAGCCAAATAGCAGTTATACCTACGTATGGCATGCCACTGAGCGATCAGGGCCAGAAAGT\nCCTGGCTCTGCCTGTCGGGCTTGGGCCTACTACTCAGCTGTGAACCCAGAAAAAGATATT\nCACTCAGGCTTGATAGGTCCCCTCCTAATCTGCCAAAAAGGAATACTACATAAGGACAGC\nAACATGCCTATGGACATGAGAGAATTTGTCTTACTATTTATGACCTTTGATGAAAAGAAG\nAGCTGGTACTATGAAAAGAAGTCCCGAAGTTCTTGGAGACTCACATCCTCAGAAATGAAA\nAAATCCCATGAGTTTCACGCCATTAATGGGATGATCTACAGCTTGCCTGGCCTGAAAATG\nTATGAGCAAGAGTGGGTGAGGTTACACCTGCTGAACATAGGCGGCTCCCAAGACATTCAC\nGTGGTTCACTTTCACGGCCAGACCTTGCTGGAAAATGGCAATAAACAGCACCAGTTAGGG\nGTCTGGCCCCTTCTGCCTGGTTCATTTAAAACTCTTGAAATGAAGGCATCAAAACCTGGC\nTGGTGGCTCCTAAACACAGAGGTTGGAGAAAACCAGAGAGCAGGGATGCAAACGCCATTT\nCTTATCATGGACAGAGACTGTAGGATGCCAATGGGACTAAGCACTGGTATCATATCTGAT\nTCACAGATCAAGGCTTCAGAGTTTCTGGGTTACTGGGAGCCCAGATTAGCAAGATTAAAC\nAATGGTGGATCTTATAATGCTTGGAGTGTAGAAAAACTTGCAGCAGAATTTGCCTCTAAA\nCCTTGGATCCAGGTGGACATGCAAAAGGAAGTCATAATCACAGGGATCCAGACCCAAGGT\nGCCAAACACTACCTGAAGTCCTGCTATACCACAGAGTTCTATGTAGCTTACAGTTCCAAC\nCAGATCAACTGGCAGATCTTCAAAGGGAACAGCACAAGGAATGTGATGTATTTTAATGGC\nAATTCAGATGCCTCTACAATAAAAGAGAATCAGTTTGACCCACCTATTGTGGCTAGATAT\nATTAGGATCTCTCCAACTCGAGCCTATAACAGACCTACCCTTCGATTGGAACTGCAAGGT\nTGTGAGGTAAATGGATGTTCCACACCCCTGGGTATGGAAAATGGAAAGATAGAAAACAAG\nCAAATCACAGCTTCTTCGTTTAAGAAATCTTGGTGGGGAGATTACTGGGAACCCTTCCGT\nGCCCGTCTGAATGCCCAGGGACGTGTGAATGCCTGGCAAGCCAAGGCAAACAACAATAAG\nCAGTGGCTAGAAATTGATCTACTCAAGATCAAGAAGATAACGGCAATTATAACACAGGGC\nTGCAAGTCTCTGTCCTCTGAAATGTATGTAAAGAGCTATACCATCCACTACAGTGAGCAG\nGGAGTGGAATGGAAACCATACAGGCTGAAATCCTCCATGGTGGACAAGATTTTTGAAGGA\nAATACTAATACCAAAGGACATGTGAAGAACTTTTTCAACCCCCCAATCATTTCCAGGTTT\nATCCGTGTCATTCCTAAAACATGGAATCAAAGTATTGCACTTCGCCTGGAACTCTTTGGC\nTGTGATATTTACTAG'], 'pfams': [{'pfam': [{'identifier': ['PF07732'], 'name': ['Cu-oxidase_3']}, {'identifier': ['PF00754'], 'name': ['F5_F8_type_C']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['endoplasmic reticulum-Golgi intermediate compartment membrane']}, {'category': ['component'], 'description': ['ER to Golgi transport vesicle']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['extracellular vesicle']}, {'category': ['component'], 'description': ['Golgi membrane']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['function'], 'description': ['copper ion binding']}, {'category': ['process'], 'description': ['blood circulation']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['COPII vesicle coating']}, {'category': ['process'], 'description': ['ER to Golgi vesicle-mediated transport']}, {'category': ['process'], 'description': ['membrane organization']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['protein N-linked glycosylation via asparagine']}]}]}]}, {'id': ['BE0000240'], 'name': ['Plasminogen activator inhibitor 1'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A6708'], 'pubmed-id': ['11259926'], 'citation': ['Carr ME: Diabetes mellitus: a hypercoagulable state. J Diabetes Complications. 2001 Jan-Feb;15(1):44-54.']}, {'ref-id': ['A6709'], 'pubmed-id': ['17566522'], 'citation': ['Cerchiara E, Tirindelli MC, Giannetti B, Dicuonzo G, Avvisati G: [The numerous properties of the anticoagulant protein C]. Clin Ter. 2007 Mar-Apr;158(2):181-7.']}, {'ref-id': ['A6710'], 'pubmed-id': ['12004248'], 'citation': ['Idell S: Endothelium and disordered fibrin turnover in the injured lung: newly recognized pathways. Crit Care Med. 2002 May;30(5 Suppl):S274-80.']}, {'ref-id': ['A6711'], 'pubmed-id': ['14515185'], 'citation': ['Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC, Spapen HD, Riess H, Basson B, Johnson G 3rd, Kinasewitz GT: Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost. 2003 Oct;90(4):642-53.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Plasminogen activator inhibitor 1'], 'general-function': ['Serine-type endopeptidase inhibitor activity'], 'specific-function': [""Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis.""], 'gene-name': ['SERPINE1'], 'locus': ['7q21.3-q22'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-23'], 'theoretical-pi': ['7.22'], 'molecular-weight': ['45059.695'], 'chromosome-location': ['7'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:8583']}, {'resource': ['GenAtlas'], 'identifier': ['SERPINE1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X04429']}, {'resource': ['GenBank Protein Database'], 'identifier': ['35272']}, {'resource': ['UniProtKB'], 'identifier': ['P05121']}, {'resource': ['UniProt Accession'], 'identifier': ['PAI1_HUMAN']}]}], 'synonyms': [{'synonym': ['Endothelial plasminogen activator inhibitor', 'PAI', 'PAI1', 'PLANH1', 'Serpin E1']}], 'amino-acid-sequence': ['>lcl|BSEQ0000479|Plasminogen activator inhibitor 1\nMQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY\nGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI\nFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV\nDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD\nGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK\nFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS\nSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP'], 'gene-sequence': ['>lcl|BSEQ0010214|Plasminogen activator inhibitor 1 (SERPINE1)\nATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA\nGGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG\nAGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT\nGGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG\nATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT\nCTGTACAAGGAGCTCATGGGGCCATGGAACAAGGATGAGATCAGCACCACAGACGCGATC\nTTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC\nCGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT\nGACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG\nGACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT\nCCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC\nTCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT\nGGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT\nGCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG\nCTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG\nTTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC\nATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC\nGCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA\nTCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC\nTTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG\nGAACCCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00079'], 'name': ['Serpin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular matrix']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase inhibitor activity']}, {'category': ['process'], 'description': ['angiogenesis']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cellular response to lipopolysaccharide']}, {'category': ['process'], 'description': ['chronological cell aging']}, {'category': ['process'], 'description': ['circadian rhythm']}, {'category': ['process'], 'description': ['defense response to Gram-negative bacterium']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['gene expression']}, {'category': ['process'], 'description': ['negative regulation of blood coagulation']}, {'category': ['process'], 'description': ['negative regulation of cell adhesion mediated by integrin']}, {'category': ['process'], 'description': ['negative regulation of cell migration']}, {'category': ['process'], 'description': ['negative regulation of endopeptidase activity']}, {'category': ['process'], 'description': ['negative regulation of endothelial cell apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of extrinsic apoptotic signaling pathway via death domain receptors']}, {'category': ['process'], 'description': ['negative regulation of fibrinolysis']}, {'category': ['process'], 'description': ['negative regulation of plasminogen activation']}, {'category': ['process'], 'description': ['negative regulation of smooth muscle cell migration']}, {'category': ['process'], 'description': ['negative regulation of smooth muscle cell-matrix adhesion']}, {'category': ['process'], 'description': ['negative regulation of vascular wound healing']}, {'category': ['process'], 'description': ['negative regulation of wound healing']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of angiogenesis']}, {'category': ['process'], 'description': ['positive regulation of blood coagulation']}, {'category': ['process'], 'description': ['positive regulation of inflammatory response']}, {'category': ['process'], 'description': ['positive regulation of interleukin-8 production']}, {'category': ['process'], 'description': ['positive regulation of leukotriene production involved in inflammatory response']}, {'category': ['process'], 'description': ['positive regulation of monocyte chemotaxis']}, {'category': ['process'], 'description': ['positive regulation of receptor-mediated endocytosis']}, {'category': ['process'], 'description': ['positive regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['regulation of receptor activity']}, {'category': ['process'], 'description': ['transcription initiation from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['transcription, DNA-templated']}, {'category': ['process'], 'description': ['transforming growth factor beta receptor signaling pathway']}]}]}]}, {'id': ['BE0001151'], 'name': ['Thrombomodulin'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A11615'], 'pubmed-id': ['11804648'], 'citation': ['Gresele P, Agnelli G: Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.']}, {'ref-id': ['A11616'], 'pubmed-id': ['15252033'], 'citation': ['Pineda AO, Chen ZW, Caccia S, Cantwell AM, Savvides SN, Waksman G, Mathews FS, Di Cera E: The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket. J Biol Chem. 2004 Sep 17;279(38):39824-8. Epub 2004 Jul 13.']}, {'ref-id': ['A11617'], 'pubmed-id': ['1660324'], 'citation': ['McCachren SS, Diggs J, Weinberg JB, Dittman WA: Thrombomodulin expression by human blood monocytes and by human synovial tissue lining macrophages. Blood. 1991 Dec 15;78(12):3128-32.']}, {'ref-id': ['A11618'], 'pubmed-id': ['2836377'], 'citation': ['Shirai T, Shiojiri S, Ito H, Yamamoto S, Kusumoto H, Deyashiki Y, Maruyama I, Suzuki K: Gene structure of human thrombomodulin, a cofactor for thrombin-catalyzed activation of protein C. J Biochem. 1988 Feb;103(2):281-5.']}, {'ref-id': ['A11619'], 'pubmed-id': ['3039877'], 'citation': ['Boffa MC, Burke B, Haudenschild C: [Different localization of thrombomodulin]. Ann Biol Clin (Paris). 1987;45(2):191-7.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Thrombomodulin'], 'general-function': ['Transmembrane signaling receptor activity'], 'specific-function': ['Thrombomodulin is a specific endothelial cell receptor that forms a 1:1 stoichiometric complex with thrombin. This complex is responsible for the conversion of protein C to the activated protein C (protein Ca). Once evolved, protein Ca scissions the activated cofactors of the coagulation mechanism, factor Va and factor VIIIa, and thereby reduces the amount of thrombin generated.'], 'gene-name': ['THBD'], 'locus': ['20p12-cen'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['516-539'], 'signal-regions': ['1-18'], 'theoretical-pi': ['4.54'], 'molecular-weight': ['60328.72'], 'chromosome-location': ['20'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:11784']}, {'resource': ['GenAtlas'], 'identifier': ['THBD']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X05495']}, {'resource': ['GenBank Protein Database'], 'identifier': ['736251']}, {'resource': ['UniProtKB'], 'identifier': ['P07204']}, {'resource': ['UniProt Accession'], 'identifier': ['TRBM_HUMAN']}]}], 'synonyms': [{'synonym': ['Fetomodulin', 'THRM', 'TM']}], 'amino-acid-sequence': ['>lcl|BSEQ0016328|Thrombomodulin\nMLGVLVLGALALAGLGFPAPAEPQPGGSQCVEHDCFALYPGPATFLNASQICDGLRGHLM\nTVRSSVAADVISLLLNGDGGVGRRRLWIGLQLPPGCGDPKRLGPLRGFQWVTGDNNTSYS\nRWARLDLNGAPLCGPLCVAVSAAEATVPSEPIWEEQQCEVKADGFLCEFHFPATCRPLAV\nEPGAAAAAVSITYGTPFAARGADFQALPVGSSAAVAPLGLQLMCTAPPGAVQGHWAREAP\nGAWDCSVENGGCEHACNAIPGAPRCQCPAGAALQADGRSCTASATQSCNDLCEHFCVPNP\nDQPGSYSCMCETGYRLAADQHRCEDVDDCILEPSPCPQRCVNTQGGFECHCYPNYDLVDG\nECVEPVDPCFRANCEYQCQPLNQTSYLCVCAEGFAPIPHEPHRCQMFCNQTACPADCDPN\nTQASCECPEGYILDDGFICTDIDECENGGFCSGVCHNLPGTFECICGPDSALARHIGTDC\nDSGKVDGGDSGSGEPPPSPTPGSTLTPPAVGLVHSGLLIGISIASLCLVVALLALLCHLR\nKKQGAARAKMEYKCAAPSKEVVLQHVRTERTPQRL'], 'gene-sequence': ['>lcl|BSEQ0016329|Thrombomodulin (THBD)\nATGCTTGGGGTCCTGGTCCTTGGCGCGCTGGCCCTGGCCGGCCTGGGGTTCCCCGCACCC\nGCAGAGCCGCAGCCGGGTGGCAGCCAGTGCGTCGAGCACGACTGCTTCGCGCTCTACCCG\nGGCCCCGCGACCTTCCTCAATGCCAGTCAGATCTGCGACGGACTGCGGGGCCACCTAATG\nACAGTGCGCTCCTCGGTGGCTGCCGATGTCATTTCCTTGCTACTGAACGGCGACGGCGGC\nGTTGGCCGCCGGCGCCTCTGGATCGGCCTGCAGCTGCCACCCGGCTGCGGCGACCCCAAG\nCGCCTCGGGCCCCTGCGCGGCTTCCAGTGGGTTACGGGAGACAACAACACCAGCTATAGC\nAGGTGGGCACGGCTCGACCTCAATGGGGCTCCCCTCTGCGGCCCGTTGTGCGTCGCTGTC\nTCCGCTGCTGAGGCCACTGTGCCCAGCGAGCCGATCTGGGAGGAGCAGCAGTGCGAAGTG\nAAGGCCGATGGCTTCCTCTGCGAGTTCCACTTCCCAGCCACCTGCAGGCCACTGGCTGTG\nGAGCCCGGCGCCGCGGCTGCCGCCGTCTCGATCACCTACGGCACCCCGTTCGCGGCCCGC\nGGAGCGGACTTCCAGGCGCTGCCGGTGGGCAGCTCCGCCGCGGTGGCTCCCCTCGGCTTA\nCAGCTAATGTGCACCGCGCCGCCCGGAGCGGTCCAGGGGCACTGGGCCAGGGAGGCGCCG\nGGCGCTTGGGACTGCAGCGTGGAGAACGGCGGCTGCGAGCACGCGTGCAATGCGATCCCT\nGGGGCTCCCCGCTGCCAGTGCCCAGCCGGCGCCGCCCTGCAGGCAGACGGGCGCTCCTGC\nACCGCATCCGCGACGCAGTCCTGCAACGACCTCTGCGAGCACTTCTGCGTTCCCAACCCC\nGACCAGCCGGGCTCCTACTCGTGCATGTGCGAGACCGGCTACCGGCTGGCGGCCGACCAA\nCACCGGTGCGAGGACGTGGATGACTGCATACTGGAGCCCAGTCCGTGTCCGCAGCGCTGT\nGTCAACACACAGGGTGGCTTCGAGTGCCACTGCTACCCTAACTACGACCTGGTGGACGGC\nGAGTGTGTGGAGCCCGTGGACCCGTGCTTCAGAGCCAACTGCGAGTACCAGTGCCAGCCC\nCTGAACCAAACTAGCTACCTCTGCGTCTGCGCCGAGGGCTTCGCGCCCATTCCCCACGAG\nCCGCACAGGTGCCAGATGTTTTGCAACCAGACTGCCTGTCCAGCCGACTGCGACCCCAAC\nACCCAGGCTAGCTGTGAGTGCCCTGAAGGCTACATCCTGGACGACGGTTTCATCTGCACG\nGACATCGACGAGTGCGAAAACGGCGGCTTCTGCTCCGGGGTGTGCCACAACCTCCCCGGT\nACCTTCGAGTGCATCTGCGGGCCCGACTCGGCCCTTGCCCGCCACATTGGCACCGACTGT\nGACTCCGGCAAGGTGGACGGTGGCGACAGCGGCTCTGGCGAGCCCCCGCCCAGCCCGACG\nCCCGGCTCCACCTTGACTCCTCCGGCCGTGGGGCTCGTGCATTCGGGCTTGCTCATAGGC\nATCTCCATCGCGAGCCTGTGCCTGGTGGTGGCGCTTTTGGCGCTCCTCTGCCACCTGCGC\nAAGAAGCAGGGCGCCGCCAGGGCCAAGATGGAGTACAAGTGCGCGGCCCCTTCCAAGGAG\nGTAGTGCTGCAGCACGTGCGGACCGAGCGGACGCCGCAGAGACTCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF07645'], 'name': ['EGF_CA']}, {'identifier': ['PF00059'], 'name': ['Lectin_C']}, {'identifier': ['PF09064'], 'name': ['Tme5_EGF_like']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['receptor activity']}, {'category': ['function'], 'description': ['transmembrane signaling receptor activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['female pregnancy']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['negative regulation of blood coagulation']}, {'category': ['process'], 'description': ['negative regulation of fibrinolysis']}, {'category': ['process'], 'description': ['negative regulation of platelet activation']}, {'category': ['process'], 'description': ['response to cAMP']}, {'category': ['process'], 'description': ['response to lipopolysaccharide']}, {'category': ['process'], 'description': ['response to X-ray']}]}]}]}, {'id': ['BE0000943'], 'name': ['Vitamin K-dependent protein S'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A11620'], 'pubmed-id': ['12062545'], 'citation': ['Cvirn G, Gallistl S, Koestenberger M, Kutschera J, Leschnik B, Muntean W: Alpha 2-macroglobulin enhances prothrombin activation and thrombin potential by inhibiting the anticoagulant protein C/protein S system in cord and adult plasma. Thromb Res. 2002 Mar 1;105(5):433-9.']}, {'ref-id': ['A11621'], 'pubmed-id': ['1828915'], 'citation': ['Hesselvik JF, Malm J, Dahlback B, Blomback M: Protein C, protein S and C4b-binding protein in severe infection and septic shock. Thromb Haemost. 1991 Feb 12;65(2):126-9.']}, {'ref-id': ['A11622'], 'pubmed-id': ['3160800'], 'citation': ['Cosio FG, Harker C, Batard MA, Brandt JT, Griffin JH: Plasma concentrations of the natural anticoagulants protein C and protein S in patients with proteinuria. J Lab Clin Med. 1985 Aug;106(2):218-22.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Vitamin K-dependent protein S'], 'general-function': ['Endopeptidase inhibitor activity'], 'specific-function': ['Anticoagulant plasma protein; it is a cofactor to activated protein C in the degradation of coagulation factors Va and VIIIa. It helps to prevent coagulation and stimulating fibrinolysis.'], 'gene-name': ['PROS1'], 'locus': ['3q11.2'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-24'], 'theoretical-pi': ['5.37'], 'molecular-weight': ['75121.905'], 'chromosome-location': ['3'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:9456']}, {'resource': ['GenAtlas'], 'identifier': ['PROS1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M15036']}, {'resource': ['GenBank Protein Database'], 'identifier': ['190289']}, {'resource': ['UniProtKB'], 'identifier': ['P07225']}, {'resource': ['UniProt Accession'], 'identifier': ['PROS_HUMAN']}]}], 'synonyms': [{'synonym': ['PROS']}], 'amino-acid-sequence': ['>lcl|BSEQ0001878|Vitamin K-dependent protein S\nMRVLGGRCGALLACLLLVLPVSEANFLSKQQASQVLVRKRRANSLLEETKQGNLERECIE\nELCNKEEAREVFENDPETDYFYPKYLVCLRSFQTGLFTAARQSTNAYPDLRSCVNAIPDQ\nCSPLPCNEDGYMSCKDGKASFTCTCKPGWQGEKCEFDINECKDPSNINGGCSQICDNTPG\nSYHCSCKNGFVMLSNKKDCKDVDECSLKPSICGTAVCKNIPGDFECECPEGYRYNLKSKS\nCEDIDECSENMCAQLCVNYPGGYTCYCDGKKGFKLAQDQKSCEVVSVCLPLNLDTKYELL\nYLAEQFAGVVLYLKFRLPEISRFSAEFDFRTYDSEGVILYAESIDHSAWLLIALRGGKIE\nVQLKNEHTSKITTGGDVINNGLWNMVSVEELEHSISIKIAKEAVMDINKPGPLFKPENGL\nLETKVYFAGFPRKVESELIKPINPRLDGCIRSWNLMKQGASGIKEIIQEKQNKHCLVTVE\nKGSYYPGSGIAQFHIDYNNVSSAEGWHVNVTLNIRPSTGTGVMLALVSGNNTVPFAVSLV\nDSTSEKSQDILLSVENTVIYRIQALSLCSDQQSHLEFRVNRNNLELSTPLKIETISHEDL\nQRQLAVLDKAMKAKVATYLGGLPDVPFSATPVNAFYNGCMEVNINGVQLDLDEAISKHND\nIRAHSCPSVWKKTKNS'], 'gene-sequence': ['>lcl|BSEQ0016264|Vitamin K-dependent protein S (PROS1)\nATGAGGGTCCTGGGTGGGCGCTGCGGGGCGCTGCTGGCGTGTCTCCTCCTAGTGCTTCCC\nGTCTCAGAGGCAAACTTTTTGTCAAAGCAACAGGCTTCACAAGTCCTGGTTAGGAAGCGT\nCGTGCAAATTCTTTACTTGAAGAAACCAAACAGGGTAATCTTGAAAGAGAATGCATCGAA\nGAACTGTGCAATAAAGAAGAAGCCAGGGAGGTCTTTGAAAATGACCCGGAAACGGATTAT\nTTTTATCCAAAATACTTAGTTTGTCTTCGCTCTTTTCAAACTGGGTTATTCACTGCTGCA\nCGTCAGTCAACTAATGCTTATCCTGACCTAAGAAGCTGTGTCAATGCCATTCCAGACCAG\nTGTAGTCCTCTGCCATGCAATGAAGATGGATATATGAGCTGCAAAGATGGAAAAGCTTCT\nTTTACTTGCACTTGTAAACCAGGTTGGCAAGGAGAAAAGTGTGAATTTGACATAAATGAA\nTGCAAAGATCCCTCAAATATAAATGGAGGTTGCAGTCAAATTTGTGATAATACACCTGGA\nAGTTACCACTGTTCCTGTAAAAATGGTTTTGTTATGCTTTCAAATAAGAAAGATTGTAAA\nGATGTGGATGAATGCTCTTTGAAGCCAAGCATTTGTGGCACAGCTGTGTGCAAGAACATC\nCCAGGAGATTTTGAATGTGAATGCCCCGAAGGCTACAGATATAATCTCAAATCAAAGTCT\nTGTGAAGATATAGATGAATGCTCTGAGAACATGTGTGCTCAGCTTTGTGTCAATTACCCT\nGGAGGTTACACTTGCTATTGTGATGGGAAGAAAGGATTCAAACTTGCCCAAGATCAGAAG\nAGTTGTGAGGTTGTTTCAGTGTGCCTTCCCTTGAACCTTGACACAAAGTATGAATTACTT\nTACTTGGCGGAGCAGTTTGCAGGGGTTGTTTTATATTTAAAATTTCGTTTGCCAGAAATC\nAGCAGATTTTCAGCAGAATTTGATTTCCGGACATATGATTCAGAAGGCGTGATACTGTAC\nGCAGAATCTATCGATCACTCAGCGTGGCTCCTGATTGCACTTCGTGGTGGAAAGATTGAA\nGTTCAGCTTAAGAATGAACATACATCCAAAATCACAACTGGAGGTGATGTTATTAATAAT\nGGTCTATGGAATATGGTGTCTGTGGAAGAATTAGAACATAGTATTAGCATTAAAATAGCT\nAAAGAAGCTGTGATGGATATAAATAAACCTGGACCCCTTTTTAAGCCGGAAAATGGATTG\nCTGGAAACCAAAGTATACTTTGCAGGATTCCCTCGGAAAGTGGAAAGTGAACTCATTAAA\nCCGATTAACCCTCGTCTAGATGGATGTATACGAAGCTGGAATTTGATGAAGCAAGGAGCT\nTCTGGAATAAAGGAAATTATTCAAGAAAAACAAAATAAGCATTGCCTGGTTACTGTGGAG\nAAGGGCTCCTACTATCCTGGTTCTGGAATTGCTCAATTTCACATAGATTATAATAATGTA\nTCCAGTGCTGAGGGTTGGCATGTAAATGTGACCTTGAATATTCGTCCATCCACGGGCACT\nGGTGTTATGCTTGCCTTGGTTTCTGGTAACAACACAGTGCCCTTTGCTGTGTCCTTGGTG\nGACTCCACCTCTGAAAAATCACAGGATATTCTGTTATCTGTTGAAAATACTGTAATATAT\nCGGATACAGGCCCTAAGTCTATGTTCCGATCAACAATCTCATCTGGAATTTAGAGTCAAC\nAGAAACAATCTGGAGTTGTCGACACCACTTAAAATAGAAACCATCTCCCATGAAGACCTT\nCAAAGACAACTTGCCGTCTTGGACAAAGCAATGAAAGCAAAAGTGGCCACATACCTGGGT\nGGCCTTCCAGATGTTCCATTCAGTGCCACACCAGTGAATGCCTTTTATAATGGCTGCATG\nGAAGTGAATATTAATGGTGTACAGTTGGATCTGGATGAAGCCATTTCTAAACATAATGAT\nATTAGAGCTCACTCATGTCCATCAGTTTGGAAAAAGACAAAGAATTCTTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00008'], 'name': ['EGF']}, {'identifier': ['PF00594'], 'name': ['Gla']}, {'identifier': ['PF07645'], 'name': ['EGF_CA']}, {'identifier': ['PF00054'], 'name': ['Laminin_G_1']}, {'identifier': ['PF02210'], 'name': ['Laminin_G_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['endoplasmic reticulum membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['Golgi lumen']}, {'category': ['component'], 'description': ['Golgi membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['component'], 'description': ['protein complex']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['endopeptidase inhibitor activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['negative regulation of endopeptidase activity']}, {'category': ['process'], 'description': ['peptidyl-glutamic acid carboxylation']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of phagocytosis']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['proteolysis']}, {'category': ['process'], 'description': ['regulation of complement activation']}, {'category': ['process'], 'description': ['response to lipopolysaccharide']}]}]}]}, {'id': ['BE0000048'], 'name': ['Prothrombin'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13203'], 'pubmed-id': ['10463819'], 'citation': ['Omar MN, Shouk TA, Khaleq MA: Activity of blood coagulation and fibrinolysis during and after hydroxyethyl starch (HES) colloidal volume replacement. Clin Biochem. 1999 Jun;32(4):269-74.']}, {'ref-id': ['A11620'], 'pubmed-id': ['12062545'], 'citation': ['Cvirn G, Gallistl S, Koestenberger M, Kutschera J, Leschnik B, Muntean W: Alpha 2-macroglobulin enhances prothrombin activation and thrombin potential by inhibiting the anticoagulant protein C/protein S system in cord and adult plasma. Thromb Res. 2002 Mar 1;105(5):433-9.']}, {'ref-id': ['A13204'], 'pubmed-id': ['12070133'], 'citation': ['Gruber A, Cantwell AM, Di Cera E, Hanson SR: The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo. J Biol Chem. 2002 Aug 2;277(31):27581-4. Epub 2002 Jun 17.']}, {'ref-id': ['A13205'], 'pubmed-id': ['12208873'], 'citation': ['Conway EM, Van de Wouwer M, Pollefeyt S, Jurk K, Van Aken H, De Vriese A, Weitz JI, Weiler H, Hellings PW, Schaeffer P, Herbert JM, Collen D, Theilmeier G: The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med. 2002 Sep 2;196(5):565-77.']}, {'ref-id': ['A13206'], 'pubmed-id': ['12296618'], 'citation': ['Levi M, De Jonge E, van der Poll T: Recombinant human activated protein C (Xigris). Int J Clin Pract. 2002 Sep;56(7):542-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Prothrombin'], 'general-function': ['Thrombospondin receptor activity'], 'specific-function': ['Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.'], 'gene-name': ['F2'], 'locus': ['11p11-q12'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-24'], 'theoretical-pi': ['5.7'], 'molecular-weight': ['70036.295'], 'chromosome-location': ['11'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3535']}, {'resource': ['GenAtlas'], 'identifier': ['F2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M17262']}, {'resource': ['GenBank Protein Database'], 'identifier': ['339641']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2362']}, {'resource': ['UniProtKB'], 'identifier': ['P00734']}, {'resource': ['UniProt Accession'], 'identifier': ['THRB_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.21.5', 'Coagulation factor II']}], 'amino-acid-sequence': ['>lcl|BSEQ0016004|Prothrombin\nMAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC\nVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV\nNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE\nCSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA\nQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG\nDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI\nDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN\nDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP\nVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST\nRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY\nGFYTHVFRLKKWIQKVIDQFGE'], 'gene-sequence': ['>lcl|BSEQ0016005|Prothrombin (F2)\nATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC\nCTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG\nGTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGC\nGTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG\nGATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT\nGCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG\nAACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT\nGAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC\nGACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA\nTGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA\nGGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG\nTACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA\nCAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC\nTTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT\nGGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA\nGATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC\nCAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT\nCTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC\nGACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG\nCTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG\nGTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT\nGACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACCAGGTACGAGCGAAACATTGAAAAG\nATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC\nCGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT\nGTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG\nGTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC\nAGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC\nCGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA\nGGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC\nCGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT\nGGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT\nGGAGAGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00594'], 'name': ['Gla']}, {'identifier': ['PF00051'], 'name': ['Kringle']}, {'identifier': ['PF00089'], 'name': ['Trypsin']}, {'identifier': ['PF09396'], 'name': ['Thrombin_light']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular matrix']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['Golgi lumen']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['growth factor activity']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase activity']}, {'category': ['function'], 'description': ['thrombospondin receptor activity']}, {'category': ['process'], 'description': ['acute-phase response']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, intrinsic pathway']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['cellular response to mechanical stimulus']}, {'category': ['process'], 'description': ['cytosolic calcium ion homeostasis']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['multicellular organismal development']}, {'category': ['process'], 'description': ['negative regulation of astrocyte differentiation']}, {'category': ['process'], 'description': ['negative regulation of fibrinolysis']}, {'category': ['process'], 'description': ['negative regulation of platelet activation']}, {'category': ['process'], 'description': ['negative regulation of proteolysis']}, {'category': ['process'], 'description': ['peptidyl-glutamic acid carboxylation']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['positive regulation of blood coagulation']}, {'category': ['process'], 'description': ['positive regulation of cell growth']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of collagen biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of phosphatidylinositol 3-kinase signaling']}, {'category': ['process'], 'description': ['positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of reactive oxygen species metabolic process']}, {'category': ['process'], 'description': ['positive regulation of release of sequestered calcium ion into cytosol']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['proteolysis']}, {'category': ['process'], 'description': ['regulation of blood coagulation']}, {'category': ['process'], 'description': ['regulation of cell shape']}, {'category': ['process'], 'description': ['regulation of gene expression']}, {'category': ['process'], 'description': ['response to inactivity']}, {'category': ['process'], 'description': ['response to wounding']}]}]}]}, {'id': ['BE0001129'], 'name': ['Platelet factor 4'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A6708'], 'pubmed-id': ['11259926'], 'citation': ['Carr ME: Diabetes mellitus: a hypercoagulable state. J Diabetes Complications. 2001 Jan-Feb;15(1):44-54.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Platelet factor 4'], 'general-function': ['Heparin binding'], 'specific-function': ['Released during platelet aggregation. Neutralizes the anticoagulant effect of heparin because it binds more strongly to heparin than to the chondroitin-4-sulfate chains of the carrier molecule. Chemotactic for neutrophils and monocytes. Inhibits endothelial cell proliferation, the short form is a more potent inhibitor than the longer form.'], 'gene-name': ['PF4'], 'locus': ['4q12-q21'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-31'], 'theoretical-pi': ['8.78'], 'molecular-weight': ['10844.78'], 'chromosome-location': ['4'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:8861']}, {'resource': ['GenAtlas'], 'identifier': ['PF4']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M25897']}, {'resource': ['GenBank Protein Database'], 'identifier': ['189851']}, {'resource': ['UniProtKB'], 'identifier': ['P02776']}, {'resource': ['UniProt Accession'], 'identifier': ['PLF4_HUMAN']}]}], 'synonyms': [{'synonym': ['C-X-C motif chemokine 4', 'CXCL4', 'Iroplact', 'Oncostatin-A', 'PF-4', 'SCYB4']}], 'amino-acid-sequence': ['>lcl|BSEQ0010788|Platelet factor 4\nMSSAAGFCASRPGLLFLGLLLLPLVVAFASAEAEEDGDLQCLCVKTTSQVRPRHITSLEV\nIKAGPHCPTAQLIATLKNGRKICLDLQAPLYKKIIKKLLES'], 'gene-sequence': ['>lcl|BSEQ0010789|Platelet factor 4 (PF4)\nATGAGCTCCGCAGCCGGGTTCTGCGCCTCACGCCCCGGGCTGCTGTTCCTGGGGTTGCTG\nCTCCTGCCACTTGTGGTCGCCTTCGCCAGCGCTGAAGCTGAAGAAGATGGGGACCTGCAG\nTGCCTGTGTGTGAAGACCACCTCCCAGGTCCGTCCCAGGCACATCACCAGCCTGGAGGTG\nATCAAGGCCGGACCCCACTGCCCCACTGCCCAACTGATAGCCACGCTGAAGAATGGAAGG\nAAAATTTGCTTGGACCTGCAAGCCCCGCTGTACAAGAAAATAATTAAGAAACTTTTGGAG\nAGTTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00048'], 'name': ['IL8']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['function'], 'description': ['chemokine activity']}, {'category': ['function'], 'description': ['CXCR3 chemokine receptor binding']}, {'category': ['function'], 'description': ['heparin binding']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['chemokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['inflammatory response']}, {'category': ['process'], 'description': ['leukocyte chemotaxis']}, {'category': ['process'], 'description': ['negative regulation of angiogenesis']}, {'category': ['process'], 'description': ['negative regulation of cytolysis']}, {'category': ['process'], 'description': ['negative regulation of extrinsic apoptotic signaling pathway in absence of ligand']}, {'category': ['process'], 'description': ['negative regulation of megakaryocyte differentiation']}, {'category': ['process'], 'description': ['negative regulation of MHC class II biosynthetic process']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of cAMP metabolic process']}, {'category': ['process'], 'description': ['positive regulation of cAMP-mediated signaling']}, {'category': ['process'], 'description': ['positive regulation of gene expression']}, {'category': ['process'], 'description': ['positive regulation of leukocyte chemotaxis']}, {'category': ['process'], 'description': ['positive regulation of macrophage derived foam cell differentiation']}, {'category': ['process'], 'description': ['positive regulation of macrophage differentiation']}, {'category': ['process'], 'description': ['positive regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['positive regulation of tumor necrosis factor production']}, {'category': ['process'], 'description': ['regulation of cell proliferation']}, {'category': ['process'], 'description': ['response to lipopolysaccharide']}]}]}]}, {'id': ['BE0002112'], 'name': ['Plasma serine protease inhibitor'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13207'], 'pubmed-id': ['10456457'], 'citation': ['Shen L, Villoutreix BO, Dahlback B: Involvement of Lys 62(217) and Lys 63(218) of human anticoagulant protein C in heparin stimulation of inhibition by the protein C inhibitor. Thromb Haemost. 1999 Jul;82(1):72-9.']}, {'ref-id': ['A13208'], 'pubmed-id': ['7769227'], 'citation': ['He X, Shen L, Bjartell A, Malm J, Lilja H, Dahlback B: The gene encoding vitamin K-dependent anticoagulant protein C is expressed in human male reproductive tissues. J Histochem Cytochem. 1995 Jun;43(6):563-70.']}, {'ref-id': ['A13209'], 'pubmed-id': ['9620917'], 'citation': ['Kobayashi H, Gabazza EC, Taguchi O, Wada H, Takeya H, Nishioka J, Yasui H, Kobayashi T, Hataji O, Suzuki K, Adachi Y: Protein C anticoagulant system in patients with interstitial lung disease. Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1850-4.']}, {'ref-id': ['A13210'], 'pubmed-id': ['8391599'], 'citation': ['Hayashi T, Suzuki K: [Molecular biology of protein C-thrombomodulin pathway. Structure and function, and basic studies on its clinical application]. Nihon Rinsho. 1993 Jun;51(6):1610-9.']}, {'ref-id': ['A13211'], 'pubmed-id': ['12671072'], 'citation': ['Berg DT, Gerlitz B, Shang J, Smith T, Santa P, Richardson MA, Kurz KD, Grinnell BW, Mace K, Jones BE: Engineering the proteolytic specificity of activated protein C improves its pharmacological properties. Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4423-8. Epub 2003 Apr 1.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Plasma serine protease inhibitor'], 'general-function': ['Serine-type endopeptidase inhibitor activity'], 'specific-function': ['Heparin-dependent serine protease inhibitor acting in body fluids and secretions. Inactivates serine proteases by binding irreversibly to their serine activation site. Involved in the regulation of intravascular and extravascular proteolytic activities. Plays hemostatic roles in the blood plasma. Acts as a procoagulant and proinflammatory factor by inhibiting the anticoagulant activated protein C factor as well as the generation of activated protein C factor by the thrombin/thrombomodulin complex. Acts as an anticoagulant factor by inhibiting blood coagulation factors like prothrombin, factor XI, factor Xa, plasma kallikrein and fibrinolytic enzymes such as tissue- and urinary-type plasminogen activators. In seminal plasma, inactivates several serine proteases implicated in the reproductive system. Inhibits the serpin acrosin; indirectly protects component of the male genital tract from being degraded by excessive released acrosin. Inhibits tissue-and urinary-type plasminogen activator, prostate-specific antigen and kallikrein activities; has a control on the sperm motility and fertilization. Inhibits the activated protein C-catalyzed degradation of SEMG1 and SEMG2; regulates the degradation of semenogelin during the process of transfer of spermatozoa from the male reproductive tract into the female tract. In urine, inhibits urinary-type plasminogen activator and kallikrein activities. Inactivates membrane-anchored serine proteases activities such as MPRSS7 and TMPRSS11E. Inhibits urinary-type plasminogen activator-dependent tumor cell invasion and metastasis. May also play a non-inhibitory role in seminal plasma and urine as a hydrophobic hormone carrier by its binding to retinoic acid.'], 'gene-name': ['SERPINA5'], 'locus': ['14q32.1'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-19'], 'theoretical-pi': ['9.76'], 'molecular-weight': ['45674.315'], 'chromosome-location': ['14'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:8723']}, {'resource': ['GenAtlas'], 'identifier': ['SERPINA5']}, {'resource': ['GenBank Gene Database'], 'identifier': ['J02639']}, {'resource': ['GenBank Protein Database'], 'identifier': ['180550']}, {'resource': ['UniProtKB'], 'identifier': ['P05154']}, {'resource': ['UniProt Accession'], 'identifier': ['IPSP_HUMAN']}]}], 'synonyms': [{'synonym': ['Acrosomal serine protease inhibitor', 'PAI-3', 'PAI3', 'PCI', 'PLANH3', 'Plasminogen activator inhibitor 3', 'PROCI', 'Protein C inhibitor', 'Serpin A5']}], 'amino-acid-sequence': ['>lcl|BSEQ0011531|Plasma serine protease inhibitor\nMQLFLLLCLVLLSPQGASLHRHHPREMKKRVEDLHVGATVAPSSRRDFTFDLYRALASAA\nPSQSIFFSPVSISMSLAMLSLGAGSSTKMQILEGLGLNLQKSSEKELHRGFQQLLQELNQ\nPRDGFQLSLGNALFTDLVVDLQDTFVSAMKTLYLADTFPTNFRDSAGAMKQINDYVAKQT\nKGKIVDLLKNLDSNAVVIMVNYIFFKAKWETSFNHKGTQEQDFYVTSETVVRVPMMSRED\nQYHYLLDRNLSCRVVGVPYQGNATALFILPSEGKMQQVENGLSEKTLRKWLKMFKKRQLE\nLYLPKFSIEGSYQLEKVLPSLGISNVFTSHADLSGISNHSNIQVSEMVHKAVVEVDESGT\nRAAAATGTIFTFRSARLNSQRLVFNRPFLMFIVDNNILFLGKVNRP'], 'gene-sequence': ['>lcl|BSEQ0011532|Plasma serine protease inhibitor (SERPINA5)\nATGCAGCTCTTCCTCCTCTTGTGCCTGGTGCTTCTCAGCCCTCAGGGGGCCTCCCTTCAC\nCGCCACCACCCCCGGGAGATGAAGAAGAGAGTCGAGGACCTCCATGTAGGTGCCACGGTG\nGCCCCCAGCAGCAGAAGGGACTTTACCTTTGACCTCTACAGGGCCTTGGCTTCCGCTGCC\nCCCAGCCAGAGCATCTTCTTCTCCCCTGTGAGCATCTCCATGAGCCTGGCCATGCTCTCC\nCTGGGGGCTGGGTCCAGCACAAAGATGCAGATCCTGGAGGGCCTGGGCCTCAACCTCCAG\nAAAAGCTCAGAGAAGGAGCTGCACAGAGGCTTTCAGCAGCTCCTTCAGGAACTCAACCAG\nCCCAGAGATGGCTTCCAGCTGAGCCTCGGCAATGCCCTTTTCACCGACCTGGTGGTAGAC\nCTGCAGGACACCTTCGTAAGTGCCATGAAGACGCTGTACCTGGCAGACACTTTCCCTACC\nAACTTTAGGGACTCTGCAGGGGCCATGAAGCAGATCAATGATTATGTGGCAAAGCAAACG\nAAGGGCAAGATTGTGGACTTGCTTAAGAACCTCGATAGCAATGCGGTCGTGATCATGGTG\nAATTACATCTTCTTTAAAGCTAAGTGGGAGACAAGCTTCAACCACAAAGGCACCCAAGAG\nCAAGACTTCTACGTGACCTCGGAGACTGTGGTGCGGGTACCCATGATGAGCCGCGAGGAT\nCAGTATCACTACCTCCTGGACCGGAACCTCTCCTGCAGGGTGGTGGGGGTCCCCTACCAA\nGGCAATGCCACGGCTTTGTTCATTCTCCCCAGTGAGGGAAAGATGCAGCAGGTGGAGAAT\nGGACTGAGTGAGAAAACGCTGAGGAAGTGGCTTAAGATGTTCAAAAAGAGGCAGCTCGAG\nCTTTACCTTCCCAAATTCTCCATTGAGGGCTCCTATCAGCTGGAGAAAGTCCTCCCCAGT\nCTGGGGATCAGTAACGTCTTCACCTCCCATGCTGATCTGTCCGGCATCAGCAACCACTCA\nAATATCCAGGTGTCTGAGATGGTGCACAAAGCTGTGGTGGAGGTGGACGAGTCGGGAACC\nAGAGCAGCGGCAGCCACGGGGACAATATTCACTTTCAGGTCGGCCCGCCTGAACTCTCAG\nAGGCTAGTGTTCAACAGGCCCTTTCTGATGTTCATTGTGGATAACAACATCCTCTTCCTT\nGGCAAAGTGAACCGCCCCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00079'], 'name': ['Serpin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['acrosomal membrane']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['platelet alpha granule']}, {'category': ['component'], 'description': ['platelet dense tubular network']}, {'category': ['component'], 'description': ['protein C inhibitor-coagulation factor V complex']}, {'category': ['component'], 'description': ['protein C inhibitor-coagulation factor Xa complex']}, {'category': ['component'], 'description': ['protein C inhibitor-coagulation factor XI complex']}, {'category': ['component'], 'description': ['protein C inhibitor-KLK3 complex']}, {'category': ['component'], 'description': ['protein C inhibitor-plasma kallikrein complex']}, {'category': ['component'], 'description': ['protein C inhibitor-PLAT complex']}, {'category': ['component'], 'description': ['protein C inhibitor-PLAU complex']}, {'category': ['component'], 'description': ['protein C inhibitor-thrombin complex']}, {'category': ['component'], 'description': ['protein C inhibitor-TMPRSS11E complex']}, {'category': ['component'], 'description': ['protein C inhibitor-TMPRSS7 complex']}, {'category': ['component'], 'description': ['protein complex']}, {'category': ['function'], 'description': ['acrosin binding']}, {'category': ['function'], 'description': ['glycosaminoglycan binding']}, {'category': ['function'], 'description': ['heparin binding']}, {'category': ['function'], 'description': ['phosphatidylcholine binding']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['function'], 'description': ['retinoic acid binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase inhibitor activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['fusion of sperm to egg plasma membrane']}, {'category': ['process'], 'description': ['lipid transport']}, {'category': ['process'], 'description': ['negative regulation of endopeptidase activity']}, {'category': ['process'], 'description': ['negative regulation of hydrolase activity']}, {'category': ['process'], 'description': ['spermatogenesis']}]}]}]}, {'id': ['BE0002142'], 'name': ['Serpin B6'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A199071'], 'pubmed-id': ['7548163'], 'citation': ['Sun J, Coughlin P, Salem HH, Bird P: Production and characterization of recombinant human proteinase inhibitor 6 expressed in Pichia pastoris. Biochim Biophys Acta. 1995 Sep 27;1252(1):28-34. doi: 10.1016/0167-4838(95)00108-7.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Serpin B6'], 'general-function': ['Serine-type endopeptidase inhibitor activity'], 'specific-function': ['May be involved in the regulation of serine proteinases present in the brain or extravasated from the blood (By similarity). Inhibitor of cathepsin G, kallikrein-8 and thrombin. May play an important role in the inner ear in the protection against leakage of lysosomal content during stress and loss of this protection results in cell death and sensorineural hearing loss.'], 'gene-name': ['SERPINB6'], 'locus': ['6p25'], 'cellular-location': ['Cytoplasm'], 'transmembrane-regions': [None], 'signal-regions': [None], 'theoretical-pi': ['4.93'], 'molecular-weight': ['42621.575'], 'chromosome-location': ['6'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:8950']}, {'resource': ['GenAtlas'], 'identifier': ['SERPINB6']}, {'resource': ['GenBank Gene Database'], 'identifier': ['Z22658']}, {'resource': ['GenBank Protein Database'], 'identifier': ['297412']}, {'resource': ['UniProtKB'], 'identifier': ['P35237']}, {'resource': ['UniProt Accession'], 'identifier': ['SPB6_HUMAN']}]}], 'synonyms': [{'synonym': ['CAP', 'Cytoplasmic antiproteinase', 'Peptidase inhibitor 6', 'PI-6', 'PI6', 'Placental thrombin inhibitor', 'PTI']}], 'amino-acid-sequence': ['>lcl|BSEQ0037166|Serpin B6\nMDVLAEANGTFALNLLKTLGKDNSKNVFFSPMSMSCALAMVYMGAKGNTAAQMAQILSFN\nKSGGGGDIHQGFQSLLTEVNKTGTQYLLRMANRLFGEKSCDFLSSFRDSCQKFYQAEMEE\nLDFISAVEKSRKHINTWVAEKTEGKIAELLSPGSVDPLTRLVLVNAVYFRGNWDEQFDKE\nNTEERLFKVSKNEEKPVQMMFKQSTFKKTYIGEIFTQILVLPYVGKELNMIIMLPDETTD\nLRTVEKELTYEKFVEWTRLDMMDEEEVEVSLPRFKLEESYDMESVLRNLGMTDAFELGKA\nDFSGMSQTDLSLSKVVHKSFVEVNEEGTEAAAATAAIMMMRCARFVPRFCADHPFLFFIQ\nHSKTNGILFCGRFSSP'], 'gene-sequence': ['>lcl|BSEQ0011553|Serpin B6 (SERPINB6)\nATGTCTGCCATCATGGATGTTCTCGCAGAAGCAAATGGCACCTTTGCCTTAAACCTTTTG\nAAAACGCTGGGTAAAGACAACTCGAAGAATGTGTTTTTCTCACCCATGAGCATGTCCTGT\nGCCCTGGCCATGGTCTACATGGGGGCAAAGGGAAACACCGCTGCACAGATGGCCCAGATA\nCTTTCTTTCAATAAAAGTGGCGGTGGTGGAGACATCCACCAGGGCTTCCAGTCTCTTCTC\nACCGAAGTGAACAAGACTGGCACGCAGTACTTGCTTAGGATGGCCAACAGGCTCTTTGGG\nGAAAAGTCTTGTGATTTCCTCTCATCTTTTAGAGATTCCTGCCAAAAATTCTACCAAGCA\nGAGATGGAGGAGCTTGACTTTATCAGCGCCGTAGAGAAGTCCAGAAAACACATAAACACC\nTGGGTAGCTGAAAAGACAGAAGGTAAAATTGCGGAGTTGCTCTCTCCGGGCTCAGTGGAT\nCCATTGACAAGGCTGGTTCTGGTGAATGCTGTCTATTTCAGAGGAAACTGGGATGAACAG\nTTTGACAAGGAGAACACCGAGGAGAGACTGTTTAAAGTCAGCAAGAATGAGGAGAAACCT\nGTGCAAATGATGTTTAAGCAATCTACTTTTAAGAAGACCTATATAGGAGAAATATTTACC\nCAAATCTTGGTGCTTCCATATGTTGGCAAGGAACTGAATATGATCATCATGCTTCCGGAC\nGAGACCACTGACTTGAGAACGGTGGAGAAAGAACTCACTTACGAGAAGTTCGTAGAATGG\nACGAGGCTGGACATGATGGATGAAGAGGAGGTGGAAGTGTCCCTCCCGCGGTTTAAACTA\nGAGGAAAGCTACGACATGGAGAGTGTCCTGCGCAACCTGGGCATGACTGATGCCTTCGAG\nCTGGGCAAGGCAGACTTCTCTGGAATGTCCCAGACAGACCTGTCTCTGTCCAAGGTCGTG\nCACAAGTCTTTTGTGGAGGTCAATGAGGAAGGCACGGAGGCTGCAGCCGCCACAGCTGCC\nATCATGATGATGCGGTGTGCCAGATTCGTCCCCCGCTTCTGCGCCGACCACCCCTTCCTT\nTTCTTCATCCAGCACAGCAAGACCAACGGGATTCTCTTCTGCGGCCGCTTTTCCTCTCCG\nTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00079'], 'name': ['Serpin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['protein complex']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase inhibitor activity']}, {'category': ['process'], 'description': ['cellular response to osmotic stress']}, {'category': ['process'], 'description': ['negative regulation of endopeptidase activity']}, {'category': ['process'], 'description': ['sensory perception of sound']}]}]}]}, {'id': ['BE0001161'], 'name': ['Endothelial protein C receptor'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13212'], 'pubmed-id': ['9529319'], 'citation': ['Fukudome K, Ye X, Tsuneyoshi N, Tokunaga O, Sugawara K, Mizokami H, Kimoto M: Activation mechanism of anticoagulant protein C in large blood vessels involving the endothelial cell protein C receptor. J Exp Med. 1998 Apr 6;187(7):1029-35.']}, {'ref-id': ['A13213'], 'pubmed-id': ['12871285'], 'citation': ['Ruf W, Dorfleutner A, Riewald M: Specificity of coagulation factor signaling. J Thromb Haemost. 2003 Jul;1(7):1495-503.']}, {'ref-id': ['A13214'], 'pubmed-id': ['12353077'], 'citation': ['Castellino FJ, Liang Z, Volkir SP, Haalboom E, Martin JA, Sandoval-Cooper MJ, Rosen ED: Mice with a severe deficiency of the endothelial protein C receptor gene develop, survive, and reproduce normally, and do not present with enhanced arterial thrombosis after challenge. Thromb Haemost. 2002 Sep;88(3):462-72.']}, {'ref-id': ['A6709'], 'pubmed-id': ['17566522'], 'citation': ['Cerchiara E, Tirindelli MC, Giannetti B, Dicuonzo G, Avvisati G: [The numerous properties of the anticoagulant protein C]. Clin Ter. 2007 Mar-Apr;158(2):181-7.']}, {'ref-id': ['A13215'], 'pubmed-id': ['15118520'], 'citation': ['Liaw PC: Endogenous protein C activation in patients with severe sepsis. Crit Care Med. 2004 May;32(5 Suppl):S214-8.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Endothelial protein C receptor'], 'general-function': ['Receptor activity'], 'specific-function': ['Binds activated protein C. Enhances protein C activation by the thrombin-thrombomodulin complex; plays a role in the protein C pathway controlling blood coagulation.'], 'gene-name': ['PROCR'], 'locus': ['20q11.2'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['211-231'], 'signal-regions': ['1-17'], 'theoretical-pi': ['7.2'], 'molecular-weight': ['26671.245'], 'chromosome-location': ['20'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:9452']}, {'resource': ['GenAtlas'], 'identifier': ['PROCR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L35545']}, {'resource': ['GenBank Protein Database'], 'identifier': ['565268']}, {'resource': ['UniProtKB'], 'identifier': ['Q9UNN8']}, {'resource': ['UniProt Accession'], 'identifier': ['EPCR_HUMAN']}]}], 'synonyms': [{'synonym': ['Activated protein C receptor', 'APC receptor', 'Endothelial cell protein C receptor', 'EPCR']}], 'amino-acid-sequence': ['>lcl|BSEQ0010810|Endothelial protein C receptor\nMLTTLLPILLLSGWAFCSQDASDGLQRLHMLQISYFRDPYHVWYQGNASLGGHLTHVLEG\nPDTNTTIIQLQPLQEPESWARTQSGLQSYLLQFHGLVRLVHQERTLAFPLTIRCFLGCEL\nPPEGSRAHVFFEVAVNGSSFVSFRPERALWQADTQVTSGVVTFTLQQLNAYNRTRYELRE\nFLEDTCVQYVQKHISAENTKGSQTSRSYTSLVLGVLVGSFIIAGVAVGIFLCTGGRRC'], 'gene-sequence': ['>lcl|BSEQ0010811|Endothelial protein C receptor (PROCR)\nATGTTGACAACATTGCTGCCGATACTGCTGCTGTCTGGCTGGGCCTTTTGTAGCCAAGAC\nGCCTCAGATGGCCTCCAAAGACTTCATATGCTCCAGATCTCCTACTTCCGCGACCCCTAT\nCACGTGTGGTACCAGGGCAACGCGTCGCTGGGGGGACACCTAACGCACGTGCTGGAAGGC\nCCAGACACCAACACCACGATCATTCAGCTGCAGCCCTTGCAGGAGCCCGAGAGCTGGGCG\nCGCACGCAGAGTGGCCTGCAGTCCTACCTGCTCCAGTTCCACGGCCTCGTGCGCCTGGTG\nCACCAGGAGCGGACCTTGGCCTTTCCTCTGACCATCCGCTGCTTCCTGGGCTGTGAGCTG\nCCTCCCGAGGGCTCTAGAGCCCATGTCTTCTTCGAAGTGGCTGTGAATGGGAGCTCCTTT\nGTGAGTTTCCGGCCGGAGAGAGCCTTGTGGCAGGCAGACACCCAGGTCACCTCCGGAGTG\nGTCACCTTCACCCTGCAGCAGCTCAATGCCTACAACCGCACTCGGTATGAACTGCGGGAA\nTTCCTGGAGGACACCTGTGTGCAGTATGTGCAGAAACATATTTCCGCGGAAAACACGAAA\nGGGAGCCAAACAAGCCGCTCCTACACTTCGCTGGTCCTGGGCGTCCTGGTGGGCAGTTTC\nATCATTGCTGGTGTGGCTGTAGGCATCTTCCTGTGCACAGGTGGACGGCGATGTTAA'], 'pfams': [{'pfam': [{'identifier': ['PF16497'], 'name': ['MHC_I_3']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['centrosome']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['receptor activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['negative regulation of coagulation']}]}]}]}]}]"
"['DB00056', 'BTD00077', 'BIOD00077']",['Gemtuzumab ozogamicin'],biotech,"['Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody [FDA Label]. The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death. \r\n\r\nMarketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy [A98]. However, it was voluntarily withdrawn from the market in 2010 due to safety concerns, increased patient deaths and insufficient evidence of clinical benefit during confirmatory trials [L941]. On September 1 2017, gemtuzumab ozogamicin was again approved for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia but with a lower dosing regimen and a different schedule in combination with chemotherapy or on its own [L941]. It is also indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory) [L941].']",['liquid'],['Indicated for the treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. Indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory). '],"['Mylotarg is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in site-specific DNA double strand breaks via formation of a p-benzene diradical [A20377]. Eventually, cell death is induced.']",[None],"[{'target': [{'id': ['BE0000674'], 'name': ['Myeloid cell surface antigen CD33'], 'organism': ['Humans'], 'actions': [{'action': ['antibody', 'regulator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1969'], 'pubmed-id': ['10942240'], 'citation': ['Naito K, Takeshita A, Shigeno K, Nakamura S, Fujisawa S, Shinjo K, Yoshida H, Ohnishi K, Mori M, Terakawa S, Ohno R: Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia. 2000 Aug;14(8):1436-43.']}, {'ref-id': ['A1970'], 'pubmed-id': ['11249747'], 'citation': ['Niculescu-Duvaz I: Technology evaluation: gemtuzumab ozogamicin, Celltech Group. Curr Opin Mol Ther. 2000 Dec;2(6):691-6.']}, {'ref-id': ['A1973'], 'pubmed-id': ['11342449'], 'citation': ['van Der Velden VH, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS, van Dongen JJ: Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood. 2001 May 15;97(10):3197-204.']}, {'ref-id': ['A98'], 'pubmed-id': ['11410481'], 'citation': ['Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001 Jun;7(6):1490-6.']}, {'ref-id': ['A1974'], 'pubmed-id': ['11432892'], 'citation': ['Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001 Jul 1;19(13):3244-54.']}, {'ref-id': ['A1976'], 'pubmed-id': ['20564405'], 'citation': ['McHayleh W, Foon K, Redner R, Sehgal R, Raptis A, Agha M, Luong TM, Schlesselman JJ, Boyiadzis M: Gemtuzumab ozogamicin as first-line treatment in patients aged 70 years or older with acute myeloid leukemia. Cancer. 2010 Jun 15;116(12):3001-5. doi: 10.1002/cncr.25078.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A247090'], 'pubmed-id': ['33807678'], 'citation': ['Kyriakidis I, Vasileiou E, Rossig C, Roilides E, Groll AH, Tragiannidis A: Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies. J Fungi (Basel). 2021 Mar 5;7(3). pii: jof7030186. doi: 10.3390/jof7030186.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Myeloid cell surface antigen CD33'], 'general-function': ['Receptor activity'], 'specific-function': ['Putative adhesion molecule of myelomonocytic-derived cells that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. Induces apoptosis in acute myeloid leukemia (in vitro).'], 'gene-name': ['CD33'], 'locus': ['19q13.3'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['260-282'], 'signal-regions': ['1-17'], 'theoretical-pi': ['8.48'], 'molecular-weight': ['39824.885'], 'chromosome-location': ['19'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1659']}, {'resource': ['GenAtlas'], 'identifier': ['CD33']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M23197']}, {'resource': ['GenBank Protein Database'], 'identifier': ['180098']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2601']}, {'resource': ['UniProtKB'], 'identifier': ['P20138']}, {'resource': ['UniProt Accession'], 'identifier': ['CD33_HUMAN']}]}], 'synonyms': [{'synonym': ['gp67', 'Sialic acid-binding Ig-like lectin 3', 'Siglec-3', 'SIGLEC3']}], 'amino-acid-sequence': ['>lcl|BSEQ0001344|Myeloid cell surface antigen CD33\nMPLLLLLPLLWAGALAMDPNFWLQVQESVTVQEGLCVLVPCTFFHPIPYYDKNSPVHGYW\nFREGAIISRDSPVATNKLDQEVQEETQGRFRLLGDPSRNNCSLSIVDARRRDNGSYFFRM\nERGSTKYSYKSPQLSVHVTDLTHRPKILIPGTLEPGHSKNLTCSVSWACEQGTPPIFSWL\nSAAPTSLGPRTTHSSVLIITPRPQDHGTNLTCQVKFAGAGVTTERTIQLNVTYVPQNPTT\nGIFPGDGSGKQETRAGVVHGAIGGAGVTALLALCLCLIFFIVKTHRRKAARTAVGRNDTH\nPTTGSASPKHQKKSKLHGPTETSSCSGAAPTVEMDEELHYASLNFHGMNPSKDTSTEYSE\nVRTQ'], 'gene-sequence': ['>lcl|BSEQ0010470|Myeloid cell surface antigen CD33 (CD33)\nATGCCGCTGCTGCTACTGCTGCCCCTGCTGTGGGCAGACTTGACCCACAGGCCCAAAATC\nCTCATCCCTGGCACTCTAGAACCCGGCCACTCCAAAAACCTGACCTGCTCTGTGTCCTGG\nGCCTGTGAGCAGGGAACACCCCCGATCTTCTCCTGGTTGTCAGCTGCCCCCACCTCCCTG\nGGCCCCAGGACTACTCACTCCTCGGTGCTCATAATCACCCCACGGCCCCAGGACCACGGC\nACCAACCTGACCTGTCAGGTGAAGTTCGCTGGAGCTGGTGTGACTACGGAGAGAACCATC\nCAGCTCAACGTCACCTATGTTCCACAGAACCCAACAACTGGTATCTTTCCAGGAGATGGC\nTCAGGGAAACAAGAGACCAGAGCAGGAGTGGTTCATGGGGCCATTGGAGGAGCTGGTGTT\nACAGCCCTGCTCGCTCTTTGTCTCTGCCTCATCTTCTTCATAGTGAAGACCCACAGGAGG\nAAAGCAGCCAGGACAGCAGTGGGCAGGAATGACACCCACCCTACCACAGGGTCAGCCTCC\nCCGAAACACCAGAAGAAGTCCAAGTTACATGGCCCCACTGAAACCTCAAGCTGTTCAGGT\nGCCGCCCCTACTGTGGAGATGGATGAGGAGCTGCATTATGCTTCCCTCAACTTTCATGGG\nATGAATCCTTCCAAGGACACCTCCACCGAATACTCAGAGGTCAGGACCCAGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00047'], 'name': ['ig']}, {'identifier': ['PF07686'], 'name': ['V-set']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['carbohydrate binding']}, {'category': ['function'], 'description': ['receptor activity']}, {'category': ['process'], 'description': ['cell adhesion']}, {'category': ['process'], 'description': ['cell-cell signaling']}, {'category': ['process'], 'description': ['negative regulation of cell proliferation']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}, {'id': ['BE0000901'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor III-B'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13216'], 'pubmed-id': ['9815888'], 'citation': ['Caron PC, Lai LT, Scheinberg DA: Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia. Clin Cancer Res. 1995 Jan;1(1):63-70.']}, {'ref-id': ['A13217'], 'pubmed-id': ['9649182'], 'citation': ['Rogler G, Hausmann M, Vogl D, Aschenbrenner E, Andus T, Falk W, Andreesen R, Scholmerich J, Gross V: Isolation and phenotypic characterization of colonic macrophages. Clin Exp Immunol. 1998 May;112(2):205-15.']}, {'ref-id': ['A13218'], 'pubmed-id': ['7509291'], 'citation': ['Ericson SG, Benoit NE, Mills LE, Fanger MW: The effect of recombinant human interleukin-3 and recombinant human granulocyte-macrophage colony-stimulating factor on Fc gamma receptor expression and antibody-dependent cellular cytotoxicity of hematopoietic progenitor cells during in vitro myeloid maturation. Exp Hematol. 1994 Mar;22(3):283-9.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor III-B'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.'], 'gene-name': ['FCGR3B'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': [None], 'signal-regions': ['1-16'], 'theoretical-pi': ['6.71'], 'molecular-weight': ['26215.64'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3620']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR3B']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X16863']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31322']}, {'resource': ['UniProtKB'], 'identifier': ['O75015']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG3B_HUMAN']}]}], 'synonyms': [{'synonym': ['CD16B', 'Fc-gamma RIII', 'Fc-gamma RIII-beta', 'Fc-gamma RIIIb', 'FCG3', 'FCGR3', 'FcR-10', 'FcRIII', 'FcRIIIb', 'IGFR3', 'IgG Fc receptor III-1']}], 'amino-acid-sequence': ['>lcl|BSEQ0010635|Low affinity immunoglobulin gamma Fc region receptor III-B\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI'], 'gene-sequence': ['>lcl|BSEQ0010636|Low affinity immunoglobulin gamma Fc region receptor III-B (FCGR3B)\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['anchored component of membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['mitophagy in response to mitochondrial depolarization']}, {'category': ['process'], 'description': ['positive regulation of defense response to virus by host']}, {'category': ['process'], 'description': ['xenophagy']}]}]}]}, {'id': ['BE0002097'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor III-A'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A13218'], 'pubmed-id': ['7509291'], 'citation': ['Ericson SG, Benoit NE, Mills LE, Fanger MW: The effect of recombinant human interleukin-3 and recombinant human granulocyte-macrophage colony-stimulating factor on Fc gamma receptor expression and antibody-dependent cellular cytotoxicity of hematopoietic progenitor cells during in vitro myeloid maturation. Exp Hematol. 1994 Mar;22(3):283-9.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor III-A'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.'], 'gene-name': ['FCGR3A'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['209-229'], 'signal-regions': ['1-16'], 'theoretical-pi': ['8.21'], 'molecular-weight': ['29088.895'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3619']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR3A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X52645']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31324']}, {'resource': ['UniProtKB'], 'identifier': ['P08637']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG3A_HUMAN']}]}], 'synonyms': [{'synonym': ['CD16A', 'CD16a antigen', 'Fc-gamma RIII', 'Fc-gamma RIII-alpha', 'Fc-gamma RIIIa', 'FCG3', 'FCGR3', 'FcR-10', 'FcRIII', 'FcRIIIa', 'IGFR3', 'IgG Fc receptor III-2']}], 'amino-acid-sequence': ['>lcl|BSEQ0004112|Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK'], 'gene-sequence': ['>lcl|BSEQ0011522|Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A)\nATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCT\nTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTG\nCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCA\nAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACT\nCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAG\nAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCGACGACAGT\nGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTGCAGCTAGAAGTC\nCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAGGAAGACCCTATT\nCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACATATTTACAGAAT\nGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCAAAAGCCACACTC\nAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAATGTGTCTTCAGAG\nACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCATCATTCTTTCCA\nCCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCAGTGGACACAGGA\nCTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGGAAGGACCATAAA\nTTTAAATGGAGAAAGGACCCTCAAGACAAATGA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['regulation of immune response']}]}]}]}, {'id': ['BE0000710'], 'name': ['High affinity immunoglobulin gamma Fc receptor I'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13218'], 'pubmed-id': ['7509291'], 'citation': ['Ericson SG, Benoit NE, Mills LE, Fanger MW: The effect of recombinant human interleukin-3 and recombinant human granulocyte-macrophage colony-stimulating factor on Fc gamma receptor expression and antibody-dependent cellular cytotoxicity of hematopoietic progenitor cells during in vitro myeloid maturation. Exp Hematol. 1994 Mar;22(3):283-9.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['High affinity immunoglobulin gamma Fc receptor I'], 'general-function': ['Receptor signaling protein activity'], 'specific-function': ['High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.'], 'gene-name': ['FCGR1A'], 'locus': ['1q21.2-q21.3'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['293-313'], 'signal-regions': ['1-15'], 'theoretical-pi': ['8.08'], 'molecular-weight': ['42631.525'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3613']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR1A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X14356']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31332']}, {'resource': ['UniProtKB'], 'identifier': ['P12314']}, {'resource': ['UniProt Accession'], 'identifier': ['FCGR1_HUMAN']}]}], 'synonyms': [{'synonym': ['Fc-gamma RI', 'Fc-gamma RIA', 'FCG1', 'FcgammaRIa', 'FCGR1', 'FcRI', 'IGFR1', 'IgG Fc receptor I']}], 'amino-acid-sequence': ['>lcl|BSEQ0001416|High affinity immunoglobulin gamma Fc receptor I\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT'], 'gene-sequence': ['>lcl|BSEQ0016183|High affinity immunoglobulin gamma Fc receptor I (FCGR1A)\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAATTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00047'], 'name': ['ig']}, {'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['clathrin-coated endocytic vesicle membrane']}, {'category': ['component'], 'description': ['early endosome membrane']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['receptor signaling protein activity']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent']}, {'category': ['process'], 'description': ['antigen processing and presentation of peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['interferon-gamma-mediated signaling pathway']}, {'category': ['process'], 'description': ['intracellular signal transduction']}, {'category': ['process'], 'description': ['phagocytosis, engulfment']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}]}]"
"['DB00057', 'BTD00108', 'BIOD00108']",['Indium In-111 satumomab pendetide'],biotech,['Tumor associated glycoprotein (TAG) 72 (B72.3) monoclonal antibody conjugated with Indium 111 for radioimaging colon tumors. Satumomab Pendetide (trade name: OncoScint) is no longer commercially available.'],['liquid'],['For diagnosis of extrahepatic malignant cancers'],"['Satumomab Pendetide is a monoclonal antibody which is attached to the chelator pentetic acid (DTPA) linked to the tripeptide  glycine  (G)  L-tyrosine (Y)  L-lysine (K), which chelates Indium 111. Satumomab pendetide binds selectively to cell-surface TAG-72 expressed on colorectal tumors. ']",[None],"[{'target': [{'id': ['BE0004842'], 'name': ['Tumor-associated glycoprotein 72 (TAG-72)'], 'organism': ['Humans'], 'actions': [{'action': ['other/unknown']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A6679'], 'pubmed-id': ['10088160'], 'citation': ['Muxi A, Pons F, Vidal-Sicart S, Setoain FJ, Herranz R, Novell F, Fernandez RM, Trias M, Setoain J: Radioimmunoguided surgery of colorectal carcinoma with an 111In-labelled anti-TAG72 monoclonal antibody. Nucl Med Commun. 1999 Feb;20(2):123-30.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes']}]}]"
"['DB00058', 'BTD00002', 'BIOD00002']",['Alpha-1-proteinase inhibitor'],biotech,"['Human alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation.']",['liquid'],['For chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.'],"['Alpha-1 proteinase inhibitor is a serine protease inhibitor (Serpin). Its primary mechanism is inhibiting the action of the serine protease called elastase (also plasmin and thrombin) in the lungs. The reactive center loop (RCL) of alpha-1 proteinase inhibitor extends out from the body of the protein and directs binding to the target protease. The protease cleaves the serpin at the reactive site, establishing a covalent linkage between the carboxyl group of the serpin reactive site and the serine hydroxyl of the protease. The resulting inactive serpin-protease complex is highly stable.']",[None],"[{'target': [{'id': ['BE0000394'], 'name': ['Neutrophil elastase'], 'organism': ['Humans'], 'actions': [{'action': ['inhibitor']}], 'references': [{'articles': [{'article': [{'ref-id': ['A14064'], 'pubmed-id': ['20521180'], 'citation': ['Topic A, Ljujic M, Nikolic A, Petrovic-Stanojevic N, Dopudja-Pantic V, Mitic-Milikic M, Radojkovic D: Alpha-1-antitrypsin phenotypes and neutrophil elastase gene promoter polymorphisms in lung cancer. Pathol Oncol Res. 2011 Mar;17(1):75-80. doi: 10.1007/s12253-010-9283-5. Epub 2010 Jun 3.']}, {'ref-id': ['A102'], 'pubmed-id': ['16773239'], 'citation': ['Karnaukhova E, Ophir Y, Golding B: Recombinant human alpha-1 proteinase inhibitor: towards therapeutic use. Amino Acids. 2006 Jun;30(4):317-32. Epub 2006 May 26.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Neutrophil elastase'], 'general-function': ['Serine-type endopeptidase activity'], 'specific-function': ['Modifies the functions of natural killer cells, monocytes and granulocytes. Inhibits C5a-dependent neutrophil enzyme release and chemotaxis.'], 'gene-name': ['ELANE'], 'locus': ['19p13.3'], 'cellular-location': ['Cytoplasmic'], 'transmembrane-regions': [None], 'signal-regions': ['1-27'], 'theoretical-pi': ['9.41'], 'molecular-weight': ['28517.81'], 'chromosome-location': ['19'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3309']}, {'resource': ['GenAtlas'], 'identifier': ['ELA2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['Y00477']}, {'resource': ['GenBank Protein Database'], 'identifier': ['296665']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2358']}, {'resource': ['UniProtKB'], 'identifier': ['P08246']}, {'resource': ['UniProt Accession'], 'identifier': ['ELNE_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.21.37', 'Bone marrow serine protease', 'ELA2', 'Elastase-2', 'HLE', 'Human leukocyte elastase', 'Medullasin', 'PMN elastase']}], 'amino-acid-sequence': ['>lcl|BSEQ0000785|Neutrophil elastase\nMTLGRRLACLFLACVLPALLLGGTALASEIVGGRRARPHAWPFMVSLQLRGGHFCGATLI\nAPNFVMSAAHCVANVNVRAVRVVLGAHNLSRREPTRQVFAVQRIFENGYDPVNLLNDIVI\nLQLNGSATINANVQVAQLPAQGRRLGNGVQCLAMGWGLLGRNRGIASVLQELNVTVVTSL\nCRRSNVCTLVRGRQAGVCFGDSGSPLVCNGLIHGIASFVRGGCASGLYPDAFAPVAQFVN\nWIDSIIQRSEDNPCPHPRDPDPASRTH'], 'gene-sequence': ['>lcl|BSEQ0010273|Neutrophil elastase (ELANE)\nATGACCCTCGGCCGCCGACTCGCGTGTCTTTTCCTCGCCTGTGTCCTGCCGGCCTTGCTG\nCTGGGGGGCACCGCGCTGGCCTCGGAGATTGTGGGGGGCCGGCGAGCGCGGCCCCACGCG\nTGGCCCTTCATGGTGTCCCTGCAGCTGCGCGGAGGCCACTTCTGCGGCGCCACCCTGATT\nGCGCCCAACTTCGTCATGTCGGCCGCGCACTGCGTGGCGAATGTAAACGTCCGCGCGGTG\nCGGGTGGTCCTGGGAGCCCATAACCTCTCGCGGCGGGAGCCCACCCGGCAGGTGTTCGCC\nGTGCAGCGCATCTTCGAAAACGGCTACGACCCCGTAAACTTGCTCAACGACATCGTGATT\nCTCCAGCTCAACGGGTCGGCCACCATCAACGCCAACGTGCAGGTGGCCCAGCTGCCGGCT\nCAGGGACGCCGCCTGGGCAACGGGGTGCAGTGCCTGGCCATGGGCTGGGGCCTTCTGGGC\nAGGAACCGTGGGATCGCCAGCGTCCTGCAGGAGCTCAACGTGACGGTGGTGACGTCCCTC\nTGCCGTCGCAGCAACGTCTGCACTCTCGTGAGGGGCCGGCAGGCCGGCGTCTGTTTCGGG\nGACTCCGGCAGCCCCTTGGTCTGCAACGGGCTAATCCACGGAATTGCCTCCTTCGTCCGG\nGGAGGCTGCGCCTCAGGGCTCTACCCCGATGCCTTTGCCCCGGTGGCACAGTTTGTAAAC\nTGGATCGACTCTATCATCCAACGCTCCGAGGACAACCCCTGTCCCCACCCCCGGGACCCG\nGACCCGGCCAGCAGGACCCACTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00089'], 'name': ['Trypsin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['secretory granule']}, {'category': ['component'], 'description': ['transcriptional repressor complex']}, {'category': ['function'], 'description': ['cytokine binding']}, {'category': ['function'], 'description': ['endopeptidase activity']}, {'category': ['function'], 'description': ['heparin binding']}, {'category': ['function'], 'description': ['peptidase activity']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['function'], 'description': ['RNA polymerase II transcription corepressor activity']}, {'category': ['function'], 'description': ['serine-type endopeptidase activity']}, {'category': ['process'], 'description': ['acute inflammatory response to antigenic stimulus']}, {'category': ['process'], 'description': ['cellular calcium ion homeostasis']}, {'category': ['process'], 'description': ['collagen catabolic process']}, {'category': ['process'], 'description': ['defense response to bacterium']}, {'category': ['process'], 'description': ['extracellular matrix disassembly']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['negative regulation of chemokine biosynthetic process']}, {'category': ['process'], 'description': ['negative regulation of chemotaxis']}, {'category': ['process'], 'description': ['negative regulation of growth of symbiont in host']}, {'category': ['process'], 'description': ['negative regulation of inflammatory response']}, {'category': ['process'], 'description': ['negative regulation of interleukin-8 biosynthetic process']}, {'category': ['process'], 'description': ['negative regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['neutrophil mediated killing of fungus']}, {'category': ['process'], 'description': ['phagocytosis']}, {'category': ['process'], 'description': ['positive regulation of immune response']}, {'category': ['process'], 'description': ['positive regulation of interleukin-8 biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of MAP kinase activity']}, {'category': ['process'], 'description': ['positive regulation of smooth muscle cell proliferation']}, {'category': ['process'], 'description': ['protein catabolic process']}, {'category': ['process'], 'description': ['proteolysis']}, {'category': ['process'], 'description': ['response to lipopolysaccharide']}, {'category': ['process'], 'description': ['response to UV']}, {'category': ['process'], 'description': ['response to yeast']}]}]}]}]}]"
"['DB00059', 'BTD00079', 'BIOD00079']",['Pegaspargase'],biotech,"[""Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia.[L44667] Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. However, leukemia cells have low levels of this enzyme and depend on exogenous sources. Therefore, the use of pegaspargase results in leukemic cell death.[A103,A255912,L44667] \r\n\r\nPegaspargase has the same mechanism of action as [L-asparaginase] derived from _Escherichia coli_, a previously developed enzyme used for the treatment of acute lymphoblastic leukemia (ALL). However, using L-asparaginase derived from _Escherichia coli_ may cause hypersensitivity in some patients and require frequent administration. The pegylation of pegaspargase allows access to the enzyme's active sites while limiting reticuloendothelial system uptake and reducing immune detection, and it also increases the half-life of L-asparaginase.[A255912,A255917] In February 1994, pegaspargase was approved by the FDA for the treatment of ALL in patients with hypersensitivity to native forms of L-asparaginase.[A255927]""]",['liquid'],['Pegaspargase is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with 1) first-line acute lymphoblastic leukemia or 2) acute lymphoblastic leukemia and hypersensitivity to asparaginase.[L44667]'],"['Pegaspargase is a pegylated L-asparaginase that catalyzes the conversion of the amino acid L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for DNA and RNA synthesis and cell division. It is not an essential amino acid in humans since most normal human tissues can produce asparagine via the enzyme asparagine synthetase. However, leukemia cells have low levels of this enzyme and are unable to synthesize asparagine, making them dependent on exogenous sources. It has been suggested that pegaspargase kills leukemic cells by depleting plasma asparagine.[A103,A255912,L44667] Both _Escherichia coli_-derived L-asparaginase and pegaspargase follow the same mechanism of action; however, _Escherichia coli_-derived L-asparaginase requires frequent administration, presents a high incidence of hypersensitivity reactions, and can be neutralized without any signs of hypersensitivity. By pegylating L-asparaginase, the circulation time of L-asparaginase can be extended, and immunogenicity is reduced.[A255917]']","[{'food-interaction': ['Avoid excessive or chronic alcohol consumption. Alcohol and pegaspargase can both cause hepatoxicity, therefore if they are used together they may have additive hepatoxic effects.']}]","[{'target': [{'id': ['BE0004798'], 'name': ['L-asparagine'], 'organism': ['Humans'], 'actions': [{'action': ['substrate']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A6673'], 'pubmed-id': ['17132721'], 'citation': ['Douer D, Yampolsky H, Cohen LJ, Watkins K, Levine AM, Periclou AP, Avramis VI: Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007 Apr 1;109(7):2744-50.']}, {'ref-id': ['A6670'], 'pubmed-id': ['17264295'], 'citation': ['Wetzler M, Sanford BL, Kurtzberg J, DeOliveira D, Frankel SR, Powell BL, Kolitz JE, Bloomfield CD, Larson RA: Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood. 2007 May 15;109(10):4164-7. Epub 2007 Jan 30.']}, {'ref-id': ['A6674'], 'pubmed-id': ['17766659'], 'citation': ['Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R: FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 2007 Aug;12(8):991-8.']}]}], 'textbooks': [None], 'links': [{'link': [{'ref-id': ['L44667'], 'title': ['FDA Approved Drug Products: ONCASPAR (pegaspargase) injection for intramuscular or intravenous use'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/103411s5205lbl.pdf']}]}], 'attachments': [None]}], 'known-action': ['yes']}]}]"
"['DB00060', 'BTD00093', 'BIOD00093']",['Interferon beta-1a'],biotech,"['Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.']",['liquid'],"['For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum']","['Interferon beta binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon beta binds more stably to type I interferon receptors than interferon alpha.']","[{'food-interaction': ['Avoid excessive or chronic alcohol consumption. Alcohol and interferon beta-1a can both cause hepatoxicity, therefore if they are used together they may have additive hepatoxic effects.']}]","[{'target': [{'id': ['BE0000661'], 'name': ['Interferon alpha/beta receptor 1'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A14065'], 'pubmed-id': ['10049744'], 'citation': ['Russell-Harde D, Wagner TC, Perez HD, Croze E: Formation of a uniquely stable type I interferon receptor complex by interferon beta is dependent upon particular interactions between interferon beta and its receptor and independent of tyrosine phosphorylation. Biochem Biophys Res Commun. 1999 Feb 16;255(2):539-44.']}, {'ref-id': ['A16953'], 'pubmed-id': ['16912135'], 'citation': ['van Koetsveld PM, Vitale G, de Herder WW, Feelders RA, van der Wansem K, Waaijers M, van Eijck CH, Speel EJ, Croze E, van der Lely AJ, Lamberts SW, Hofland LJ: Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth. J Clin Endocrinol Metab. 2006 Nov;91(11):4537-43. Epub 2006 Aug 15.']}, {'ref-id': ['A16954'], 'pubmed-id': ['12034032'], 'citation': ['Dupont SA, Goelz S, Goyal J, Green M: Mechanisms for regulation of cellular responsiveness to human IFN-beta1a. J Interferon Cytokine Res. 2002 Apr;22(4):491-501.']}, {'ref-id': ['A16955'], 'pubmed-id': ['11747625'], 'citation': ['Runkel L, De Dios C, Karpusas M, Baker D, Li Z, Zafari M, Betzenhauser M, Muldowney C, Miller S, Redlich PN, Grossberg SE, Whitty A, Hochman PS: Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis. J Interferon Cytokine Res. 2001 Nov;21(11):931-41.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interferon alpha/beta receptor 1'], 'general-function': ['Type i interferon receptor activity'], 'specific-function': ['Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.'], 'gene-name': ['IFNAR1'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['437-457'], 'signal-regions': ['1-27'], 'theoretical-pi': ['5.56'], 'molecular-weight': ['63524.81'], 'chromosome-location': ['21'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5432']}, {'resource': ['GenAtlas'], 'identifier': ['IFNAR1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['J03171']}, {'resource': ['GenBank Protein Database'], 'identifier': ['306914']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1723']}, {'resource': ['UniProtKB'], 'identifier': ['P17181']}, {'resource': ['UniProt Accession'], 'identifier': ['INAR1_HUMAN']}]}], 'synonyms': [{'synonym': ['CRF2-1', 'Cytokine receptor class-II member 1', 'Cytokine receptor family 2 member 1', 'IFN-R-1', 'IFNAR', 'Type I interferon receptor 1']}], 'amino-acid-sequence': ['>lcl|BSEQ0001318|Interferon alpha/beta receptor 1\nMMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT\nFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF\nTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI\nENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ\nNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK\nGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP\nVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV\nFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE\nYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN\nEDESESKTSEELQQDFV'], 'gene-sequence': ['>lcl|BSEQ0018987|Interferon alpha/beta receptor 1 (IFNAR1)\nATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTG\nTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC\nATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT\nTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG\nAATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT\nAAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT\nACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG\nGCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT\nTTAAGCTTTACATATAGCTTAGTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT\nGAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA\nAAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT\nATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA\nAATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG\nTGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA\nCCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA\nGGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA\nGAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA\nTCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT\nGTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT\nGAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT\nGTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT\nTTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA\nGTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC\nTTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG\nTATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA\nAAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT\nGATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT\nGAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA'], 'pfams': [{'pfam': [{'identifier': ['PF01108'], 'name': ['Tissue_fac']}, {'identifier': ['PF09294'], 'name': ['Interfer-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['type I interferon receptor activity']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['defense response to virus']}, {'category': ['process'], 'description': ['JAK-STAT cascade']}, {'category': ['process'], 'description': ['positive regulation of interferon-beta production']}, {'category': ['process'], 'description': ['positive regulation of interferon-gamma production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-1 beta secretion']}, {'category': ['process'], 'description': ['positive regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['regulation of type I interferon-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['T cell activation']}, {'category': ['process'], 'description': ['type I interferon biosynthetic process']}, {'category': ['process'], 'description': ['type I interferon signaling pathway']}]}]}]}, {'id': ['BE0000385'], 'name': ['Interferon alpha/beta receptor 2'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A16953'], 'pubmed-id': ['16912135'], 'citation': ['van Koetsveld PM, Vitale G, de Herder WW, Feelders RA, van der Wansem K, Waaijers M, van Eijck CH, Speel EJ, Croze E, van der Lely AJ, Lamberts SW, Hofland LJ: Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth. J Clin Endocrinol Metab. 2006 Nov;91(11):4537-43. Epub 2006 Aug 15.']}, {'ref-id': ['A16955'], 'pubmed-id': ['11747625'], 'citation': ['Runkel L, De Dios C, Karpusas M, Baker D, Li Z, Zafari M, Betzenhauser M, Muldowney C, Miller S, Redlich PN, Grossberg SE, Whitty A, Hochman PS: Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis. J Interferon Cytokine Res. 2001 Nov;21(11):931-41.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interferon alpha/beta receptor 2'], 'general-function': ['Type i interferon receptor activity'], 'specific-function': ['Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.'], 'gene-name': ['IFNAR2'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['244-264'], 'signal-regions': ['1-26'], 'theoretical-pi': ['4.11'], 'molecular-weight': ['57758.24'], 'chromosome-location': ['21'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5433']}, {'resource': ['GenAtlas'], 'identifier': ['IFNAR2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L42243']}, {'resource': ['GenBank Protein Database'], 'identifier': ['995300']}, {'resource': ['UniProtKB'], 'identifier': ['P48551']}, {'resource': ['UniProt Accession'], 'identifier': ['INAR2_HUMAN']}]}], 'synonyms': [{'synonym': ['IFN-R-2', 'IFNABR', 'IFNARB', 'Interferon alpha binding protein', 'Type I interferon receptor 2']}], 'amino-acid-sequence': ['>lcl|BSEQ0000767|Interferon alpha/beta receptor 2\nMLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS\nIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF\nSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK\nHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE\nSAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD\nMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI\nDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR\nITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT\nFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR'], 'gene-sequence': ['>lcl|BSEQ0018941|Interferon alpha/beta receptor 2 (IFNAR2)\nATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT\nATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT\nTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC\nATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG\nGTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA\nAGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC\nAGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG\nATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA\nGAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG\nCATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA\nATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA\nATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA\nTCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC\nATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG\nAGGCAAGGTCTCGCTAAGGGCTGGAATGCAGTGGCTATTCACAGGTGCAGTCATAATGCA\nCTACAGTCTGAAACTCCTGAGCTCAAACAGTCGTCCTGCCTAAGCTTCCCCAGTAGCTGG\nGATTACAAGCGTGCATCCCTGTGCCCCAGTGATTAA'], 'pfams': [{'pfam': [{'identifier': ['PF01108'], 'name': ['Tissue_fac']}, {'identifier': ['PF09294'], 'name': ['Interfer-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['protein kinase binding']}, {'category': ['function'], 'description': ['type I interferon binding']}, {'category': ['function'], 'description': ['type I interferon receptor activity']}, {'category': ['process'], 'description': ['cell proliferation']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['JAK-STAT cascade']}, {'category': ['process'], 'description': ['regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['regulation of type I interferon-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to interferon-alpha']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['type I interferon signaling pathway']}]}]}]}]}]"
"['DB00061', 'BTD00100', 'BIOD00100']",['Pegademase'],biotech,['Bovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life.'],['liquid'],['For treatment of adenosine deaminase deficiency'],"[""Pegademase converts adenosine (toxic) to inosine (less toxic) by deamination. It also converts 2'-deoxyadenosine to 2'-deoxyinosine via deamination.""]",[None],"[{'target': [{'id': ['BE0004828'], 'name': ['Adenosine'], 'organism': ['Humans'], 'actions': [{'action': ['metabolizer']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A6680'], 'pubmed-id': ['17727332'], 'citation': ['Van Linden A, Eltzschig HK: Role of pulmonary adenosine during hypoxia: extracellular generation, signaling and metabolism by surface adenosine deaminase/CD26. Expert Opin Biol Ther. 2007 Sep;7(9):1437-47.']}, {'ref-id': ['A6681'], 'pubmed-id': ['17574432'], 'citation': ['Kemeny-Beke A, Jakab A, Zsuga J, Vecsernyes M, Karsai D, Pasztor F, Grenczer M, Szentmiklosi AJ, Berta A, Gesztelyi R: Adenosine deaminase inhibition enhances the inotropic response mediated by A1 adenosine receptor in hyperthyroid guinea pig atrium. Pharmacol Res. 2007 Aug;56(2):124-31. Epub 2007 May 10.']}, {'ref-id': ['A6682'], 'pubmed-id': ['17601796'], 'citation': ['Mohsenin A, Mi T, Xia Y, Kellems RE, Chen JF, Blackburn MR: Genetic removal of the A2A adenosine receptor enhances pulmonary inflammation, mucin production, and angiogenesis in adenosine deaminase-deficient mice. Am J Physiol Lung Cell Mol Physiol. 2007 Sep;293(3):L753-61. Epub 2007 Jun 29.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes']}, {'id': ['BE0000917'], 'name': ['Growth factor receptor-bound protein 2'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13219'], 'pubmed-id': ['9299436'], 'citation': ['Ramos-Morales F, Dominguez A, Rios RM, Barroso SI, Infante C, Schweighoffer F, Tocque B, Pintor-Toro JA, Tortolero M: Adenosine deaminase is a specific partner for the Grb2 isoform Grb3-3. Biochem Biophys Res Commun. 1997 Aug 28;237(3):735-40.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Growth factor receptor-bound protein 2'], 'general-function': ['Sh3/sh2 adaptor activity'], 'specific-function': ['Adapter protein that provides a critical link between cell surface growth factor receptors and the Ras signaling pathway.Isoform 2 does not bind to phosphorylated epidermal growth factor receptor (EGFR) but inhibits EGF-induced transactivation of a RAS-responsive element. Isoform 2 acts as a dominant negative protein over GRB2 and by suppressing proliferative signals, may trigger active programmed cell death.'], 'gene-name': ['GRB2'], 'locus': ['17q24-q25'], 'cellular-location': ['Nucleus'], 'transmembrane-regions': [None], 'signal-regions': [None], 'theoretical-pi': ['6.25'], 'molecular-weight': ['25206.21'], 'chromosome-location': ['17'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:4566']}, {'resource': ['GenAtlas'], 'identifier': ['GRB2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M96995']}, {'resource': ['GenBank Protein Database'], 'identifier': ['181976']}, {'resource': ['UniProtKB'], 'identifier': ['P62993']}, {'resource': ['UniProt Accession'], 'identifier': ['GRB2_HUMAN']}]}], 'synonyms': [{'synonym': ['Adapter protein GRB2', 'ASH', 'Protein Ash', 'SH2/SH3 adapter GRB2']}], 'amino-acid-sequence': ['>lcl|BSEQ0001826|Growth factor receptor-bound protein 2\nMEAIAKYDFKATADDELSFKRGDILKVLNEECDQNWYKAELNGKDGFIPKNYIEMKPHPW\nFFGKIPRAKAEEMLSKQRHDGAFLIRESESAPGDFSLSVKFGNDVQHFKVLRDGAGKYFL\nWVVKFNSLNELVDYHRSTSVSRNQQIFLRDIEQVPQQPTYVQALFDFDPQEDGELGFRRG\nDFIHVMDNSDPNWWKGACHGQTGMFPRNYVTPVNRNV'], 'gene-sequence': ['>lcl|BSEQ0020493|Growth factor receptor-bound protein 2 (GRB2)\nATGGAAGCCATCGCCAAATATGACTTCAAAGCTACTGCAGACGACGAGCTGAGCTTCAAA\nAGGGGGGACATCCTCAAGGTTTTGAACGAAGAATGTGATCAGAACTGGTACAAGGCAGAG\nCTTAATGGAAAAGACGGCTTCATTCCCAAGAACTACATAGAAATGAAACCACATCCGTGG\nTTTTTTGGCAAAATCCCCAGAGCCAAGGCAGAAGAAATGCTTAGCAAACAGCGGCACGAT\nGGGGCCTTTCTTATCCGAGAGAGTGAGAGCGCTCCTGGGGACTTCTCCCTCTCTGTCAAG\nTTTGGAAACGATGTGCAGCACTTCAAGGTGCTCCGAGATGGAGCCGGGAAGTACTTCCTC\nTGGGTGGTGAAGTTCAATTCTTTGAATGAGCTGGTGGATTATCACAGATCTACATCTGTC\nTCCAGAAACCAGCAGATATTCCTGCGGGACATAGAACAGGTGCCACAGCAGCCGACATAC\nGTCCAGGCCCTCTTTGACTTTGATCCCCAGGAGGATGGAGAGCTGGGCTTCCGCCGGGGA\nGATTTTATCCATGTCATGGATAACTCAGACCCCAACTGGTGGAAAGGAGCTTGCCACGGG\nCAGACCGGCATGTTTCCCCGCAATTATGTCACCCCCGTGAACCGGAACGTCTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00017'], 'name': ['SH2']}, {'identifier': ['PF00018'], 'name': ['SH3_1']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell-cell junction']}, {'category': ['component'], 'description': ['COP9 signalosome']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['Golgi apparatus']}, {'category': ['component'], 'description': ['Grb2-EGFR complex']}, {'category': ['component'], 'description': ['nucleolus']}, {'category': ['component'], 'description': ['nucleoplasm']}, {'category': ['component'], 'description': ['nucleus']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['vesicle membrane']}, {'category': ['function'], 'description': ['ephrin receptor binding']}, {'category': ['function'], 'description': ['epidermal growth factor receptor binding']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['function'], 'description': ['insulin receptor substrate binding']}, {'category': ['function'], 'description': ['neurotrophin TRKA receptor binding']}, {'category': ['function'], 'description': ['poly(A) RNA binding']}, {'category': ['function'], 'description': ['protein kinase binding']}, {'category': ['function'], 'description': ['SH3 domain binding']}, {'category': ['function'], 'description': ['SH3/SH2 adaptor activity']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['aging']}, {'category': ['process'], 'description': ['anatomical structure formation involved in morphogenesis']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['branching involved in labyrinthine layer morphogenesis']}, {'category': ['process'], 'description': ['cell-cell signaling']}, {'category': ['process'], 'description': ['cellular response to ionizing radiation']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['negative regulation of epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['phosphatidylinositol-mediated signaling']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['positive regulation of actin filament polymerization']}, {'category': ['process'], 'description': ['positive regulation of reactive oxygen species metabolic process']}, {'category': ['process'], 'description': ['protein heterooligomerization']}, {'category': ['process'], 'description': ['Ras protein signal transduction']}, {'category': ['process'], 'description': ['receptor internalization']}, {'category': ['process'], 'description': ['signal transduction in response to DNA damage']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['T cell costimulation']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['viral process']}]}]}]}]}]"
"['DB00062', 'BTD00059', 'BTD00089', 'BTD00101', 'BIOD00059', 'BIOD00089', 'BIOD00101', 'DB00096', 'DB00064']",['Albumin human'],biotech,"['Human serum albumin is the primary protein present in human blood plasma. The main function of albumin is to maintain the oncotic pressure of blood [A33706]. It binds to water, cations (such as Ca2+, Na+ and K+), fatty acids, hormones, bilirubin, thyroxine (T4) and pharmaceuticals (including barbiturates).  Albumin represents approximately 50% of the total protein content in healthy humans [A40060].\r\n\r\nHuman albumin is a small globular protein (molecular weight: 66.5 kDa), consisting of a single chain of 585 amino acids organized in three repeated homolog domains (sites I, II, and III). Each domain comprises two separate sub-domains (A and B) [A40060]. \r\n\r\nThere are various preparations of albumin that are well established and widely available in the clinical setting [L3108], [L3109], [L3101].\r\n\r\nAlso known as _Albuminex_ 5% or 25%, one brand of human serum albumin is prepared from the pooled plasma of US donors in FDA-licensed facilities in the US [F229].  This is a biosimilar drug to existing human serum albumin and was approved for a biological license at both 5% and 25% concentrations by the FDA on June 21, 2018 [L3101].']",['solid'],"['Albuminex solution is indicated for adults and children for hypovolemia, ascites, hypoalbuminemia including from burns, acute nephrosis, acute respiratory distress syndrome and cardipulmonary bypass [F229].']","['The main function of albumin results from its contribution to plasma colloid oncotic pressure and transport function [F230].  \r\n\r\nAlbumin stabilizes circulating blood volume and carries hormones, enzymes, medicines, and toxins. Other physiological functions include antioxidant properties, free radical scavenging, in addition to maintenance capillary membrane integrity [F230].\r\n\r\nExogenously administered albumin increases the oncotic pressure of the intravascular system, moving fluids from the interstitial space, thereby decreasing edema and increasing the circulating blood volume. The increase in volume reduces the concentration and viscosity of blood in patients with decreased circulating blood volume while maintaining cardiac output in shock. In dehydrated patients, negligible effects exist on circulating blood volume. In addition to the above albumin replaces protein in patients with hypoproteinemia until the cause of the deficiency can be determined [L3104]. \r\n\r\n This drug has thousands of endogenous and exogenous targets. Human albumin also binds and carries a plethora of hydrophobic molecules, such as endogenous (i.e., cholesterol, fatty acids, bilirubin, thyroxine) or exogenous substances (for example, drugs and toxins), transition metal ions, as well as gas (nitric oxide [NO]), with resulting implications for their solubilisation, transport, metabolism, and detoxification [A40060].']",[None],"[{'target': [{'id': ['BE0009576'], 'name': ['Nitric oxide'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A40060'], 'pubmed-id': ['24333308'], 'citation': ['Caraceni P, Tufoni M, Bonavita ME: Clinical use of albumin. Blood Transfus. 2013 Sep;11 Suppl 4:s18-25. doi: 10.2450/2013.005s.']}, {'ref-id': ['A40069'], 'pubmed-id': ['19745558'], 'citation': ['Ishima Y, Kragh-Hansen U, Maruyama T, Otagiri M: Albumin as a nitric oxide-traffic protein: characterization, biochemistry and possible future therapeutic applications. Drug Metab Pharmacokinet. 2009;24(4):308-17.']}, {'ref-id': ['A40070'], 'pubmed-id': ['25732553'], 'citation': ['Lee P, Wu X: Review: modifications of human serum albumin and their binding effect. Curr Pharm Des. 2015;21(14):1862-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown']}]}]"
"['DB00063', 'BTD00063', 'BIOD00063']",['Eptifibatide'],biotech,"['Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics.']",['liquid'],['For treatment of myocardial infarction and acute coronary syndrome.'],"['Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. Inhibition of platelet aggregation occurs in a dose- and concentration-dependent manner.']","[{'food-interaction': ['Avoid herbs and supplements with anticoagulant/antiplatelet activity. The use of anticoagulant/antiplatelet herbs with eptifibatide may increase the risk of bleeding. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.']}]","[{'target': [{'id': ['BE0001155'], 'name': ['Integrin beta-3'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A1978'], 'pubmed-id': ['11588534'], 'citation': ['Amoroso G, van Boven AJ, van Veldhuisen DJ, Tio RA, Balje-Volkers CP, Petronio AS, van Oeveren W: Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients with coronary artery disease. J Cardiovasc Pharmacol. 2001 Oct;38(4):633-41.']}, {'ref-id': ['A1980'], 'pubmed-id': ['14618072'], 'citation': ['Schror K, Weber AA: Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis. 2003 Apr;15(2):71-80.']}, {'ref-id': ['A1982'], 'pubmed-id': ['15860200'], 'citation': ['Fischer TH, Thatte HS, Nichols TC, Bender-Neal DE, Bellinger AD, Vournakis JN: Synergistic platelet integrin signaling and factor XII activation in poly-N-acetyl glucosamine fiber-mediated hemostasis. Biomaterials. 2005 Sep;26(27):5433-43.']}, {'ref-id': ['A1984'], 'pubmed-id': ['12360110'], 'citation': ['Weber AA, Jacobs C, Meila D, Weber S, Zotz RB, Scharf RE, Kelm M, Strauer BE, Schror K: No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein IIb/IIIa inhibitors. Pharmacogenetics. 2002 Oct;12(7):581-3.']}, {'ref-id': ['A1987'], 'pubmed-id': ['14617694'], 'citation': ['Schwarz M, Katagiri Y, Kotani M, Bassler N, Loeffler C, Bode C, Peter K: Reversibility versus persistence of GPIIb/IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61). J Pharmacol Exp Ther. 2004 Mar;308(3):1002-11. Epub 2003 Nov 14.']}, {'ref-id': ['A1988'], 'pubmed-id': ['12928738'], 'citation': ['Auer J, Berent R, Lassnig E, Weber T, Maurer E, Eber B: [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease]. Herz. 2003 Aug;28(5):393-403.']}, {'ref-id': ['A1991'], 'pubmed-id': ['10592235'], 'citation': ['Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Integrin beta-3'], 'general-function': ['Virus receptor activity'], 'specific-function': [""Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. Fibrinogen binding enhances SELP expression in activated platelets (By similarity).(Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for herpes virus 8/HHV-8 (PubMed:18045938). Integrin ITGAV:ITGB3 acts as a receptor for coxsackievirus A9 (PubMed:7519807). Acts as a receptor for Hantaan virus (PubMed:9618541). Integrin ITGAV:ITGB3 acts as a receptor for cytomegalovirus/HHV-5 (PubMed:15834425). Integrin ITGA5:ITGB3 acts as a receptor for human metapneumovirus (PubMed:24478423). Integrin ITGAV:ITGB3 acts aP05556s a receptor for human parechovirus 1 (PubMed:11160695). Integrin ITGAV:ITGB3 acts as a receptor for west nile virus (PubMed:23658209). In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions (PubMed:10397733).""], 'gene-name': ['ITGB3'], 'locus': ['17q21.32'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['719-741'], 'signal-regions': ['1-26'], 'theoretical-pi': ['4.85'], 'molecular-weight': ['87056.975'], 'chromosome-location': ['17'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6156']}, {'resource': ['GenAtlas'], 'identifier': ['ITGB3']}, {'resource': ['GenBank Gene Database'], 'identifier': ['J02703']}, {'resource': ['GenBank Protein Database'], 'identifier': ['306786']}, {'resource': ['UniProtKB'], 'identifier': ['P05106']}, {'resource': ['UniProt Accession'], 'identifier': ['ITB3_HUMAN']}]}], 'synonyms': [{'synonym': ['GP3A', 'GPIIIa', 'Platelet membrane glycoprotein IIIa']}], 'amino-acid-sequence': ['>lcl|BSEQ0002297|Integrin beta-3\nMRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLG\nSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRP\nDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFG\nAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSR\nNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCH\nVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLS\nMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDT\nVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGT\nFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFG\nKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLL\nCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRY\nCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDIL\nVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTF\nTNITYRGT'], 'gene-sequence': ['>lcl|BSEQ0021847|Integrin beta-3 (ITGB3)\nATGCGAGCGCGGCCGCGGCCCCGGCCGCTCTGGGCGACTGTGCTGGCGCTGGGGGCGCTG\nGCGGGCGTTGGCGTAGGAGGGCCCAACATCTGTACCACGCGAGGTGTGAGCTCCTGCCAG\nCAGTGCCTGGCTGTGAGCCCCATGTGTGCCTGGTGCTCTGATGAGGCCCTGCCTCTGGGC\nTCACCTCGCTGTGACCTGAAGGAGAATCTGCTGAAGGATAACTGTGCCCCAGAATCCATC\nGAGTTCCCAGTGAGTGAGGCCCGAGTACTAGAGGACAGGCCCCTCAGCGACAAGGGCTCT\nGGAGACAGCTCCCAGGTCACTCAAGTCAGTCCCCAGAGGATTGCACTCCGGCTCCGGCCA\nGATGATTCGAAGAATTTCTCCATCCAAGTGCGGCAGGTGGAGGATTACCCTGTGGACATC\nTACTACTTGATGGACCTGTCTTACTCCATGAAGGATGATCTGTGGAGCATCCAGAACCTG\nGGTACCAAGCTGGCCACCCAGATGCGAAAGCTCACCAGTAACCTGCGGATTGGCTTCGGG\nGCATTTGTGGACAAGCCTGTGTCACCATACATGTATATCTCCCCACCAGAGGCCCTCGAA\nAACCCCTGCTATGATATGAAGACCACCTGCTTGCCCATGTTTGGCTACAAACACGTGCTG\nACGCTAACTGACCAGGTGACCCGCTTCAATGAGGAAGTGAAGAAGCAGAGTGTGTCACGG\nAACCGAGATGCCCCAGAGGGTGGCTTTGATGCCATCATGCAGGCTACAGTCTGTGATGAA\nAAGATTGGCTGGAGGAATGATGCATCCCACTTGCTGGTGTTTACCACTGATGCCAAGACT\nCATATAGCATTGGACGGAAGGCTGGCAGGCATTGTCCAGCCTAATGACGGGCAGTGTCAT\nGTTGGTAGTGACAATCATTACTCTGCCTCCACTACCATGGATTATCCCTCTTTGGGGCTG\nATGACTGAGAAGCTATCCCAGAAAAACATCAATTTGATCTTTGCAGTGACTGAAAATGTA\nGTCAATCTCTATCAGAACTATAGTGAGCTCATCCCAGGGACCACAGTTGGGGTTCTGTCC\nATGGATTCCAGCAATGTCCTCCAGCTCATTGTTGATGCTTATGGGAAAATCCGTTCTAAA\nGTAGAGCTGGAAGTGCGTGACCTCCCTGAAGAGTTGTCTCTATCCTTCAATGCCACCTGC\nCTCAACAATGAGGTCATCCCTGGCCTCAAGTCTTGTATGGGACTCAAGATTGGAGACACG\nGTGAGCTTCAGCATTGAGGCCAAGGTGCGAGGCTGTCCCCAGGAGAAGGAGAAGTCCTTT\nACCATAAAGCCCGTGGGCTTCAAGGACAGCCTGATCGTCCAGGTCACCTTTGATTGTGAC\nTGTGCCTGCCAGGCCCAAGCTGAACCTAATAGCCATCGCTGCAACAATGGCAATGGGACC\nTTTGAGTGTGGGGTATGCCGTTGTGGGCCTGGCTGGCTGGGATCCCAGTGTGAGTGCTCA\nGAGGAGGACTATCGCCCTTCCCAGCAGGACGAATGCAGCCCCCGGGAGGGTCAGCCCGTC\nTGCAGCCAGCGGGGCGAGTGCCTCTGTGGTCAATGTGTCTGCCACAGCAGTGACTTTGGC\nAAGATCACGGGCAAGTACTGCGAGTGTGACGACTTCTCCTGTGTCCGCTACAAGGGGGAG\nATGTGCTCAGGCCATGGCCAGTGCAGCTGTGGGGACTGCCTGTGTGACTCCGACTGGACC\nGGCTACTACTGCAACTGTACCACGCGTACTGACACCTGCATGTCCAGCAATGGGCTGCTG\nTGCAGCGGCCGCGGCAAGTGTGAATGTGGCAGCTGTGTCTGTATCCAGCCGGGCTCCTAT\nGGGGACACCTGTGAGAAGTGCCCCACCTGCCCAGATGCCTGCACCTTTAAGAAAGAATGT\nGTGGAGTGTAAGAAGTTTGACCGGGGAGCCCTACATGACGAAAATACCTGCAACCGTTAC\nTGCCGTGACGAGATTGAGTCAGTGAAAGAGCTTAAGGACACTGGCAAGGATGCAGTGAAT\nTGTACCTATAAGAATGAGGATGACTGTGTCGTCAGATTCCAGTACTATGAAGATTCTAGT\nGGAAAGTCCATCCTGTATGTGGTAGAAGAGCCAGAGTGTCCCAAGGGCCCTGACATCCTG\nGTGGTCCTGCTCTCAGTGATGGGGGCCATTCTGCTCATTGGCCTTGCCGCCCTGCTCATC\nTGGAAACTCCTCATCACCATCCACGACCGAAAAGAATTCGCTAAATTTGAGGAAGAACGC\nGCCAGAGCAAAATGGGACACAGCCAACAACCCACTGTATAAAGAGGCCACGTCTACCTTC\nACCAATATCACGTACCGGGGCACTTAA'], 'pfams': [{'pfam': [{'identifier': ['PF07974'], 'name': ['EGF_2']}, {'identifier': ['PF00362'], 'name': ['Integrin_beta']}, {'identifier': ['PF08725'], 'name': ['Integrin_b_cyt']}, {'identifier': ['PF07965'], 'name': ['Integrin_B_tail']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['alphav-beta3 integrin-vitronectin complex']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['filopodium membrane']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['integrin alphav-beta3 complex']}, {'category': ['component'], 'description': ['integrin complex']}, {'category': ['component'], 'description': ['lamellipodium membrane']}, {'category': ['component'], 'description': ['melanosome']}, {'category': ['component'], 'description': ['microvillus membrane']}, {'category': ['component'], 'description': ['nucleus']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['component'], 'description': ['ruffle membrane']}, {'category': ['function'], 'description': ['cell adhesion molecule binding']}, {'category': ['function'], 'description': ['enzyme binding']}, {'category': ['function'], 'description': ['extracellular matrix binding']}, {'category': ['function'], 'description': ['fibronectin binding']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['function'], 'description': ['platelet-derived growth factor receptor binding']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['function'], 'description': ['protein disulfide isomerase activity']}, {'category': ['function'], 'description': ['vascular endothelial growth factor receptor 2 binding']}, {'category': ['function'], 'description': ['virus receptor activity']}, {'category': ['process'], 'description': ['activation of protein kinase activity']}, {'category': ['process'], 'description': ['angiogenesis involved in wound healing']}, {'category': ['process'], 'description': ['apolipoprotein A-I-mediated signaling pathway']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cell adhesion']}, {'category': ['process'], 'description': ['cell growth']}, {'category': ['process'], 'description': ['cell migration']}, {'category': ['process'], 'description': ['cell-matrix adhesion']}, {'category': ['process'], 'description': ['cell-substrate adhesion']}, {'category': ['process'], 'description': ['cell-substrate junction assembly']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['heterotypic cell-cell adhesion']}, {'category': ['process'], 'description': ['integrin-mediated signaling pathway']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['mesodermal cell differentiation']}, {'category': ['process'], 'description': ['negative chemotaxis']}, {'category': ['process'], 'description': ['negative regulation of lipid storage']}, {'category': ['process'], 'description': ['negative regulation of lipid transport']}, {'category': ['process'], 'description': ['negative regulation of lipoprotein metabolic process']}, {'category': ['process'], 'description': ['negative regulation of low-density lipoprotein particle receptor biosynthetic process']}, {'category': ['process'], 'description': ['negative regulation of macrophage derived foam cell differentiation']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet aggregation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of endothelial cell migration']}, {'category': ['process'], 'description': ['positive regulation of endothelial cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of vascular endothelial growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['protein folding']}, {'category': ['process'], 'description': ['regulation of bone resorption']}, {'category': ['process'], 'description': ['smooth muscle cell migration']}, {'category': ['process'], 'description': ['substrate adhesion-dependent cell spreading']}, {'category': ['process'], 'description': ['tube development']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['viral entry into host cell']}, {'category': ['process'], 'description': ['wound healing']}]}]}]}, {'id': ['BE0009351'], 'name': ['Voltage-dependent N-type calcium channel'], 'organism': ['Humans'], 'actions': [{'action': ['antagonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A247185'], 'pubmed-id': ['9825033'], 'citation': ['Chong PH: Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases. Am J Health Syst Pharm. 1998 Nov 15;55(22):2363-86. doi: 10.1093/ajhp/55.22.2363.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Voltage-dependent N-type calcium channel subunit alpha'], 'general-function': ['Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1B gives rise to N-type calcium currents.'], 'specific-function': ['Voltage-gated calcium channel activity'], 'gene-name': ['CACNA1B'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['99-116\n136-156\n223-245\n333-355\n484-504\n510-527\n548-566\n609-631\n687-709'], 'signal-regions': [None], 'theoretical-pi': [None], 'molecular-weight': ['111676.12'], 'chromosome-location': [None], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['UniProtKB'], 'identifier': ['A0A024R8I1']}, {'resource': ['UniProt Accession'], 'identifier': ['A0A024R8I1_HUMAN']}]}], 'synonyms': [None], 'amino-acid-sequence': ['>lcl|BSEQ0052085|Voltage-dependent N-type calcium channel subunit alpha\nMVRFGDELGGRYGGPGGGERARGGGAGGAGGPGPGGLQPGQRVLYKQSIAQRARTMALYN\nPIPVKQNCFTVNRSLFVFSEDNVVRKYAKRITEWPPFEYMILATIIANCIVLALEQHLPD\nGDKTPMSERLDDTEPYFIGIFCFEAGIKIIALGFVFHKGSYLRNGWKVMDFVVVLTGILA\nTAGTDFDLRTLRAVRVLRPLKLVSGIPSLQVVLKSIMKAMVPLLQIGLLLFFAILMFAII\nGLEFYMGKFHKACFPNSTDAEPVGDFPCGKEAPARLCEGDTECREYWPGPNFGITNFDNI\nLFAILTVFQCITMEGWTDILYNTNDAAGNTWNWLYFIPLIIIGSFFMLNLVLGVLSGEFA\nKERERVENRRAFLKLRRQQQIERELNGYLEWIFKAEEVMLAEEDRNAEEKSPLDVLKRAA\nTKKSRNDLIHAEEGEDRFADLCAVGSPFARASLKSGKTESSSYFRRKEKMFRFFIRRMVK\nAQSFYWVVLCVVALNTLCVAMVHYNQPRRLTTTLYFAEFVFLGLFLTEMSLKMYGLGPRS\nYFRSSFNCFDFGVIVGSVFEVVWAAIKPGSSFGISVLRALRLLRIFKVTKYWSSLRNLVV\nSLLNSMKSIISLLFLLFLFIVVFALLGMQLFGGQFNFQDETPTTNFDTFPAAILTVFQIL\nTGEDWNAVMYHGIESQGGVSKGMFSSFYFIVLTLFGNYTLLNVFLAIAVDNLANAQELTK\nDEEEMEEAANQKLALQKAKEVAEVSPMSAANISIAARQQNSAKARSVWEQRASQLRLQNL\nRASCEALYSEMDPEERLRFATTRHLRPDMKTHLDRPLVVELGRDGARGPVGGKARPEAAE\nAPEGVDPPRRHHRHRDKDKTPAAGDQDRAEAPKAESGEPGAREERPRPHRSHSKEAAGPP\nEARSERGRGPGPEGGRRHHRRGSPEEAAEREPRRHRAHRHQDPSKESPRQGRAARAAPRR\nPPSGAPGGGERGGAGAAAPGPAQGAACSRGCGEGDHGEGGHGEGG'], 'gene-sequence': [None], 'pfams': [{'pfam': [{'identifier': ['PF00520'], 'name': ['Ion_trans']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['voltage-gated calcium channel complex']}, {'category': ['function'], 'description': ['voltage-gated calcium channel activity']}, {'category': ['process'], 'description': ['regulation of ion transmembrane transport']}]}]}, {'name': ['Voltage-dependent N-type calcium channel subunit alpha-1B'], 'general-function': ['Voltage-gated calcium channel activity'], 'specific-function': [""Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1B gives rise to N-type calcium currents. N-type calcium channels belong to the 'high-voltage activated' (HVA) group and are blocked by omega-conotoxin-GVIA (omega-CTx-GVIA) and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to dihydropyridines (DHP), and omega-agatoxin-IVA (omega-Aga-IVA). Calcium channels containing alpha-1B subunit may play a role in directed migration of immature neurons.""], 'gene-name': ['CACNA1B'], 'locus': ['9q34'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['96-114\n133-152\n164-183\n188-206\n226-245\n332-356\n483-501\n517-536\n545-562\n574-592\n612-631\n685-709\n1152-1169\n1186-1205\n1218-1236\n1247-1265\n1285-1304\n1392-1416\n1472-1490\n1506-1525\n1534-1552\n1564-1582\n1602-1621\n1684-1708'], 'signal-regions': [None], 'theoretical-pi': ['8.62'], 'molecular-weight': ['262493.84'], 'chromosome-location': ['9'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1389']}, {'resource': ['GenAtlas'], 'identifier': ['CACNA1B']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M94172']}, {'resource': ['GenBank Protein Database'], 'identifier': ['179758']}, {'resource': ['IUPHAR'], 'identifier': ['533']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['533']}, {'resource': ['UniProtKB'], 'identifier': ['Q00975']}, {'resource': ['UniProt Accession'], 'identifier': ['CAC1B_HUMAN']}]}], 'synonyms': [{'synonym': ['BIII', 'Brain calcium channel III', 'CACH5', 'CACNL1A5', 'Calcium channel, L type, alpha-1 polypeptide isoform 5', 'Voltage-gated calcium channel subunit alpha Cav2.2']}], 'amino-acid-sequence': ['>lcl|BSEQ0004369|Voltage-dependent N-type calcium channel subunit alpha-1B\nMVRFGDELGGRYGGPGGGERARGGGAGGAGGPGPGGLQPGQRVLYKQSIAQRARTMALYN\nPIPVKQNCFTVNRSLFVFSEDNVVRKYAKRITEWPPFEYMILATIIANCIVLALEQHLPD\nGDKTPMSERLDDTEPYFIGIFCFEAGIKIIALGFVFHKGSYLRNGWNVMDFVVVLTGILA\nTAGTDFDLRTLRAVRVLRPLKLVSGIPSLQVVLKSIMKAMVPLLQIGLLLFFAILMFAII\nGLEFYMGKFHKACFPNSTDAEPVGDFPCGKEAPARLCEGDTECREYWPGPNFGITNFDNI\nLFAILTVFQCITMEGWTDILYNTNDAAGNTWNWLYFIPLIIIGSFFMLNLVLGVLSGEFA\nKERERVENRRAFLKLRRQQQIERELNGYLEWIFKAEEVMLAEEDRNAEEKSPLDVLKRAA\nTKKSRNDLIHAEEGEDRFADLCAVGSPFARASLKSGKTESSSYFRRKEKMFRFFIRRMVK\nAQSFYWVVLCVVALNTLCVAMVHYNQPRRLTTTLYFAEFVFLGLFLTEMSLKMYGLGPRS\nYFRSSFNCFDFGVIVGSVFEVVWAAIKPGSSFGISVLRALRLLRIFKVTKYWSSLRNLVV\nSLLNSMKSIISLLFLLFLFIVVFALLGMQLFGGQFNFQDETPTTNFDTFPAAILTVFQIL\nTGEDWNAVMYHGIESQGGVSKGMFSSFYFIVLTLFGNYTLLNVFLAIAVDNLANAQELTK\nDEEEMEEAANQKLALQKAKEVAEVSPMSAANISIAARQQNSAKARSVWEQRASQLRLQNL\nRASCEALYSEMDPEERLRFATTRHLRPDMKTHLDRPLVVELGRDGARGPVGGKARPEAAE\nAPEGVDPPRRHHRHRDKDKTPAAGDQDRAEAPKAESGEPGAREERPRPHRSHSKEAAGPP\nEARSERGRGPGPEGGRRHHRRGSPEEAAEREPRRHRAHRHQDPSKECAGAKGERRARHRG\nGPRAGPREAESGEEPARRHRARHKAQPAHEAVEKETTEKEATEKEAEIVEADKEKELRNH\nQPREPHCDLETSGTVTVGPMHTLPSTCLQKVEEQPEDADNQRNVTRMGSQPPDPNTIVHI\nPVMLTGPLGEATVVPSGNVDLESQAEGKKEVEADDVMRSGPRPIVPYSSMFCLSPTNLLR\nRFCHYIVTMRYFEVVILVVIALSSIALAAEDPVRTDSPRNNALKYLDYIFTGVFTFEMVI\nKMIDLGLLLHPGAYFRDLWNILDFIVVSGALVAFAFSGSKGKDINTIKSLRVLRVLRPLK\nTIKRLPKLKAVFDCVVNSLKNVLNILIVYMLFMFIFAVIAVQLFKGKFFYCTDESKELER\nDCRGQYLDYEKEEVEAQPRQWKKYDFHYDNVLWALLTLFTVSTGEGWPMVLKHSVDATYE\nEQGPSPGYRMELSIFYVVYFVVFPFFFVNIFVALIIITFQEQGDKVMSECSLEKNERACI\nDFAISAKPLTRYMPQNRQSFQYKTWTFVVSPPFEYFIMAMIALNTVVLMMKFYDAPYEYE\nLMLKCLNIVFTSMFSMECVLKIIAFGVLNYFRDAWNVFDFVTVLGSITDILVTEIAETNN\nFINLSFLRLFRAARLIKLLRQGYTIRILLWTFVQSFKALPYVCLLIAMLFFIYAIIGMQV\nFGNIALDDDTSINRHNNFRTFLQALMLLFRSATGEAWHEIMLSCLSNQACDEQANATECG\nSDFAYFYFVSFIFLCSFLMLNLFVAVIMDNFEYLTRDSSILGPHHLDEFIRVWAEYDPAA\nCGRISYNDMFEMLKHMSPPLGLGKKCPARVAYKRLVRMNMPISNEDMTVHFTSTLMALIR\nTALEIKLAPAGTKQHQCDAELRKEISVVWANLPQKTLDLLVPPHKPDEMTVGKVYAALMI\nFDFYKQNKTTRDQMQQAPGGLSQMGPVSLFHPLKATLEQTQPAVLRGARVFLRQKSSTSL\nSNGGAIQNQESGIKESVSWGTQRTQDAPHEARPPLERGHSTEIPVGRSGALAVDVQMQSI\nTRRGPDGEPQPGLESQGRAASMPRLAAETQPVTDASPMKRSISTLAQRPRGTHLCSTTPD\nRPPPSQASSHHHHHRCHRRRDRKQRSLEKGPSLSADMDGAPSSAVGPGLPPGEGPTGCRR\nERERRQERGRSQERRQPSSSSSEKQRFYSCDRFGGREPPKPKPSLSSHPTSPTAGQEPGP\nHPQGSGSVNGSPLLSTSGASTPGRGGRRQLPQTPLTPRPSITYKTANSSPIHFAGAQTSL\nPAFSPGRLSRGLSEHNALLQRDPLSQPLAPGSRIGSDPYLGQRLDSEASVHALPEDTLTF\nEEAVATNSGRSSRTSYVSSLTSQSHPLRRVPNGYHCTLGLSSGGRARHSYHHPDQDHWC'], 'gene-sequence': ['>lcl|BSEQ0011606|Voltage-dependent N-type calcium channel subunit alpha-1B (CACNA1B)\nATGGTCCGCTTCGGGGACGAGCTGGGCGGCCGCTATGGGGGCCCCGGCGGCGGAGAGCGG\nGCCCGGGGCGGCGGGGCCGGCGGGGCGGGGGGCCCGGGTCCCGGGGGGCTGCAGCCCGGC\nCAGCGGGTCCTCTACAAGCAATCGATCGCGCAGCGCGCGCGGACCATGGCGCTGTACAAC\nCCCATCCCGGTCAAGCAGAACTGCTTCACCGTCAACCGCTCGCTCTTCGTCTTCAGCGAG\nGACAACGTCGTCCGCAAATACGCGAAGCGCATCACCGAGTGGCCTCCATTCGAGTATATG\nATCCTGGCCACCATCATCGCCAACTGCATCGTGCTGGCCCTGGAGCAGCACCTCCCTGAT\nGGGGACAAAACGCCCATGTCCGAGCGGCTGGACGACACGGAGCCCTATTTCATCGGGATC\nTTTTGCTTCGAGGCAGGGATCAAAATCATCGCTCTGGGCTTTGTCTTCCACAAGGGCTCT\nTACCTGCGGAACGGCTGGAACGTCATGGACTTCGTGGTCGTCCTCACAGGGATCCTTGCC\nACGGCTGGAACTGACTTCGACCTGCGAACACTGAGGGCTGTGCGTGTGCTGAGGCCCCTG\nAAGCTGGTGTCTGGGATTCCAAGTTTGCAGGTGGTGCTCAAGTCCATCATGAAGGCCATG\nGTTCCACTCCTGCAGATTGGGCTGCTTCTCTTCTTTGCCATCCTCATGTTTGCCATCATT\nGGCCTGGAGTTCTACATGGGCAAGTTCCACAAGGCCTGTTTCCCCAACAGCACAGATGCG\nGAGCCCGTGGGTGACTTCCCCTGTGGCAAGGAGGCCCCAGCCCGGCTGTGCGAGGGCGAC\nACTGAGTGCCGGGAGTACTGGCCAGGACCCAACTTTGGCATCACCAACTTTGACAATATC\nCTGTTTGCCATCTTGACGGTGTTCCAGTGCATCACCATGGAGGGCTGGACTGACATCCTC\nTATAATACAAACGATGCGGCCGGCAACACCTGGAACTGGCTCTACTTCATCCCTCTCATC\nATCATCGGCTCCTTCTTCATGCTCAACCTGGTGCTGGGCGTGCTCTCGGGGGAGTTTGCC\nAAGGAGCGAGAGAGGGTGGAGAACCGCCGCGCCTTCCTGAAGCTGCGCCGGCAGCAGCAG\nATCGAGCGAGAGCTCAACGGGTACCTGGAGTGGATCTTCAAGGCGGAGGAAGTCATGCTG\nGCCGAGGAGGACAGGAATGCAGAGGAGAAGTCCCCTTTGGACGTGCTGAAGAGAGCGGCC\nACCAAGAAGAGCAGAAATGACCTGATCCACGCAGAGGAGGGAGAGGACCGGTTTGCAGAT\nCTCTGTGCTGTTGGATCCCCCTTCGCCCGCGCCAGCCTCAAGAGCGGGAAGACAGAGAGC\nTCGTCATACTTCCGGAGGAAGGAGAAGATGTTCCGGTTTTTTATCCGGCGCATGGTGAAG\nGCTCAGAGCTTCTACTGGGTGGTGCTGTGCGTGGTGGCCCTGAACACACTGTGTGTGGCC\nATGGTGCATTACAACCAGCCGCGGCGGCTTACCACGACCCTGTATTTTGCAGAGTTTGTT\nTTCCTGGGTCTCTTCCTCACAGAGATGTCCCTGAAGATGTATGGCCTGGGGCCCAGAAGC\nTACTTCCGGTCCTCCTTCAACTGCTTCGACTTTGGGGTCATCGTGGGGAGCGTCTTTGAA\nGTGGTCTGGGCGGCCATCAAGCCGGGAAGCTCCTTTGGGATCAGTGTGCTGCGGGCCCTC\nCGCCTGCTGAGGATCTTCAAAGTCACGAAGTACTGGAGCTCCCTGCGGAACCTGGTGGTG\nTCCCTGCTGAACTCCATGAAGTCCATCATCAGCCTGCTCTTCTTGCTCTTCCTGTTCATT\nGTGGTCTTCGCCCTGCTGGGGATGCAGCTGTTTGGGGGACAGTTCAACTTCCAGGATGAG\nACTCCCACAACCAACTTCGACACCTTCCCTGCCGCCATCCTCACTGTCTTCCAGATCCTG\nACGGGAGAGGACTGGAATGCAGTGATGTATCACGGGATCGAATCGCAAGGCGGCGTCAGC\nAAAGGCATGTTCTCGTCCTTTTACTTCATTGTCCTGACACTGTTCGGAAACTACACTCTG\nCTGAATGTCTTTCTGGCCATCGCTGTGGACAACCTGGCCAACGCCCAAGAGCTGACCAAG\nGATGAAGAGGAGATGGAAGAAGCAGCCAATCAGAAGCTTGCTCTGCAAAAGGCCAAAGAA\nGTGGCTGAAGTCAGCCCCATGTCTGCCGCGAACATCTCCATCGCCGCCAGGCAGCAGAAC\nTCGGCCAAGGCGCGCTCGGTGTGGGAGCAGCGGGCCAGCCAGCTACGGCTGCAGAACCTG\nCGGGCCAGCTGCGAGGCGCTGTACAGCGAGATGGACCCCGAGGAGCGGCTGCGCTTCGCC\nACTACGCGCCACCTGCGGCCCGACATGAAGACGCACCTGGACCGGCCGCTGGTGGTGGAG\nCTGGGCCGCGACGGCGCGCGGGGGCCCGTGGGAGGCAAAGCCCGACCTGAGGCTGCGGAG\nGCCCCCGAGGGCGTCGACCCTCCGCGCAGGCACCACCGGCACCGCGACAAGGACAAGACC\nCCCGCGGCGGGGGACCAGGACCGAGCAGAGGCCCCGAAGGCGGAGAGCGGGGAGCCCGGT\nGCCCGGGAGGAGCGGCCGCGGCCGCACCGCAGCCACAGCAAGGAGGCCGCGGGGCCCCCG\nGAGGCGCGGAGCGAGCGCGGCCGAGGCCCAGGCCCCGAGGGCGGCCGGCGGCACCACCGG\nCGCGGCTCCCCGGAGGAGGCGGCCGAGCGGGAGCCCCGACGCCACCGCGCGCACCGGCAC\nCAGGATCCGAGCAAGGAGTGCGCCGGCGCCAAGGGCGAGCGGCGCGCGCGGCACCGCGGC\nGGCCCCCGAGCGGGGCCCCGGGAGGCGGAGAGCGGGGAGGAGCCGGCGCGGCGGCACCGG\nGCCCGGCACAAGGCGCAGCCTGCTCACGAGGCTGTGGAGAAGGAGACCACGGAGAAGGAG\nGCCACGGAGAAGGAGGCTGAGATAGTGGAAGCCGACAAGGAAAAGGAGCTCCGGAACCAC\nCAGCCCCGGGAGCCACACTGTGACCTGGAGACCAGTGGGACTGTGACTGTGGGTCCCATG\nCACACACTGCCCAGCACCTGTCTCCAGAAGGTGGAGGAACAGCCAGAGGATGCAGACAAT\nCAGCGGAACGTCACTCGCATGGGCAGTCAGCCCCCAGACCCGAACACTATTGTACATATC\nCCAGTGATGCTGACGGGCCCTCTTGGGGAAGCCACGGTCGTTCCCAGTGGTAACGTGGAC\nCTGGAAAGCCAAGCAGAGGGGAAGAAGGAGGTGGAAGCGGATGACGTGATGAGGAGCGGC\nCCCCGGCCTATCGTCCCATACAGCTCCATGTTCTGTTTAAGCCCCACCAACCTGCTCCGC\nCGCTTCTGCCACTACATCGTGACCATGAGGTACTTCGAGGTGGTCATTCTCGTGGTCATC\nGCCTTGAGCAGCATCGCCCTGGCTGCTGAGGACCCAGTGCGCACAGACTCGCCCAGGAAC\nAACGCTCTGAAATACCTGGATTACATTTTCACTGGTGTCTTTACCTTTGAGATGGTGATA\nAAGATGATCGACTTGGGACTGCTGCTTCACCCTGGAGCCTATTTCCGGGACTTGTGGAAC\nATTCTGGACTTCATTGTGGTCAGTGGCGCCCTGGTGGCGTTTGCTTTCTCAGGATCCAAA\nGGGAAAGACATCAATACCATCAAGTCTCTGAGAGTCCTTCGTGTCCTGCGGCCCCTCAAG\nACCATCAAACGGCTGCCCAAGCTCAAGGCTGTGTTTGACTGTGTGGTGAACTCCCTGAAG\nAATGTCCTCAACATCTTGATTGTCTACATGCTCTTCATGTTCATATTTGCCGTCATTGCG\nGTGCAGCTCTTCAAAGGGAAGTTTTTCTACTGCACAGATGAATCCAAGGAGCTGGAGAGG\nGACTGCAGGGGTCAGTATTTGGATTATGAGAAGGAGGAAGTGGAAGCTCAGCCCAGGCAG\nTGGAAGAAATACGACTTTCACTACGACAATGTGCTCTGGGCTCTGCTGACGCTGTTCACA\nGTGTCCACGGGAGAAGGCTGGCCCATGGTGCTGAAACACTCCGTGGATGCCACCTATGAG\nGAGCAGGGTCCAAGCCCTGGGTACCGCATGGAGCTGTCCATCTTCTACGTGGTCTACTTT\nGTGGTCTTTCCCTTCTTCTTCGTCAACATCTTTGTGGCTTTGATCATCATCACCTTCCAG\nGAGCAGGGGGACAAGGTGATGTCTGAATGCAGCCTGGAGAAGAACGAGAGGGCTTGCATT\nGACTTCGCCATCAGCGCCAAACCCCTGACACGGTACATGCCCCAAAACCGGCAGTCGTTC\nCAGTATAAGACGTGGACATTTGTGGTCTCCCCGCCCTTTGAATACTTCATCATGGCCATG\nATAGCCCTCAACACTGTGGTGCTGATGATGAAGTTCTATGATGCACCCTATGAGTACGAG\nCTGATGCTGAAATGCCTGAACATCGTGTTCACATCCATGTTCTCCATGGAATGCGTGCTG\nAAGATCATCGCCTTTGGGGTGCTGAACTATTTCAGAGATGCCTGGAATGTCTTTGACTTT\nGTCACTGTGTTGGGAAGTATTACTGATATTTTAGTAACAGAGATTGCGGAAACGAACAAT\nTTCATCAACCTCAGCTTCCTCCGCCTCTTTCGAGCTGCGCGGCTGATCAAGCTGCTCCGC\nCAGGGCTACACCATCCGCATCCTGCTGTGGACCTTTGTCCAGTCCTTCAAGGCCCTGCCC\nTACGTGTGTCTGCTCATTGCCATGCTGTTCTTCATCTACGCCATCATCGGCATGCAGGTG\nTTTGGGAATATTGCCCTGGATGATGACACCAGCATCAACCGCCACAACAACTTCCGGACG\nTTTTTGCAAGCCCTGATGCTGCTGTTCAGGAGCGCCACGGGGGAGGCCTGGCACGAGATC\nATGCTGTCCTGCCTGAGCAACCAGGCCTGTGATGAGCAGGCCAATGCCACCGAGTGTGGA\nAGTGACTTTGCCTACTTCTACTTCGTCTCCTTCATCTTCCTGTGCTCCTTTCTGATGTTG\nAACCTCTTTGTGGCTGTGATCATGGACAATTTTGAGTACCTCACGCGGGACTCTTCCATC\nCTAGGTCCTCACCACTTGGATGAGTTCATCCGGGTCTGGGCTGAATACGACCCGGCTGCG\nTGTGGGCGCATCAGTTACAATGACATGTTTGAGATGCTGAAACACATGTCCCCGCCTCTG\nGGGCTGGGGAAGAAATGCCCTGCTCGAGTTGCTTACAAGCGCCTGGTTCGCATGAACATG\nCCCATCTCCAACGAGGACATGACTGTTCACTTCACGTCCACGCTGATGGCCCTCATCCGG\nACGGCACTGGAGATCAAGCTGGCCCCAGCTGGGACAAAGCAGCATCAGTGTGACGCGGAG\nTTGAGGAAGGAGATTTCCGTTGTGTGGGCCAATCTGCCCCAGAAGACTTTGGACTTGCTG\nGTACCACCCCATAAGCCTGATGAGATGACAGTGGGGAAGGTTTATGCAGCTCTGATGATA\nTTCGACTTCTACAAGCAGAACAAAACCACCAGAGACCAGATGCAGCAGGCTCCTGGAGGC\nCTCTCCCAGATGGGTCCTGTGTCCCTGTTCCACCCTCTGAAGGCCACCCTGGAGCAGACA\nCAGCCGGCTGTGCTCCGAGGAGCCCGGGTTTTCCTTCGACAGAAGAGTTCCACCTCCCTC\nAGCAATGGCGGGGCCATACAAAACCAAGAGAGTGGCATCAAAGAGTCTGTCTCCTGGGGC\nACTCAAAGGACCCAGGATGCACCCCATGAGGCCAGGCCACCCCTGGAGCGTGGCCACTCC\nACAGAGATCCCTGTGGGGCGGTCAGGAGCACTGGCTGTGGACGTTCAGATGCAGAGCATA\nACCCGGAGGGGCCCTGATGGGGAGCCCCAGCCTGGGCTGGAGAGCCAGGGTCGAGCGGCC\nTCCATGCCCCGCCTTGCGGCCGAGACTCAGCCCGTCACAGATGCCAGCCCCATGAAGCGC\nTCCATCTCCACGCTGGCCCAGCGGCCCCGTGGGACTCATCTTTGCAGCACCACCCCGGAC\nCGCCCACCCCCTAGCCAGGCGTCGTCGCACCACCACCACCACCGCTGCCACCGCCGCAGG\nGACAGGAAGCAGAGGTCCCTGGAGAAGGGGCCCAGCCTGTCTGCCGATATGGATGGCGCA\nCCAAGCAGTGCTGTGGGGCCGGGGCTGCCCCCGGGAGAGGGGCCTACAGGCTGCCGGCGG\nGAACGAGAGCGCCGGCAGGAGCGGGGCCGGTCCCAGGAGCGGAGGCAGCCCTCATCCTCC\nTCCTCGGAGAAGCAGCGCTTCTACTCCTGCGACCGCTTTGGGGGCCGTGAGCCCCCGAAG\nCCCAAGCCCTCCCTCAGCAGCCACCCAACGTCGCCAACAGCTGGCCAGGAGCCGGGACCC\nCACCCACAGGGCAGTGGTTCCGTGAATGGGAGCCCCTTGCTGTCAACATCTGGTGCTAGC\nACCCCCGGCCGCGGTGGGCGGAGGCAGCTCCCCCAGACGCCCCTGACTCCCCGCCCCAGC\nATCACCTACAAGACGGCCAACTCCTCACCCATCCACTTCGCCGGGGCTCAGACCAGCCTC\nCCTGCCTTCTCCCCAGGCCGGCTCAGCCGTGGGCTTTCCGAACACAACGCCCTGCTGCAG\nAGAGACCCCCTCAGCCAGCCCCTGGCCCCTGGCTCTCGAATTGGCTCTGACCCTTACCTG\nGGGCAGCGTCTGGACAGTGAGGCCTCTGTCCACGCCCTGCCTGAGGACACTCTCACTTTC\nGAGGAGGCTGTGGCCACCAACTCGGGCCGCTCCTCCAGGACTTCCTACGTGTCCTCCCTG\nACCTCCCAGTCTCACCCTCTCCGCCGCGTGCCCAACGGTTACCACTGCACCCTGGGACTC\nAGCTCGGGTGGCCGAGCACGGCACAGCTACCACCACCCTGACCAAGACCACTGGTGCTAG\n'], 'pfams': [{'pfam': [{'identifier': ['PF00520'], 'name': ['Ion_trans']}, {'identifier': ['PF08763'], 'name': ['Ca_chan_IQ']}, {'identifier': ['PF16905'], 'name': ['GPHH']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['dendrite']}, {'category': ['component'], 'description': ['neuronal cell body']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['voltage-gated calcium channel complex']}, {'category': ['function'], 'description': ['ATP binding']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['high voltage-gated calcium channel activity']}, {'category': ['function'], 'description': ['protein C-terminus binding']}, {'category': ['function'], 'description': ['voltage-gated calcium channel activity']}, {'category': ['process'], 'description': ['calcium ion import']}, {'category': ['process'], 'description': ['locomotory behavior']}, {'category': ['process'], 'description': ['membrane depolarization']}, {'category': ['process'], 'description': ['membrane depolarization during action potential']}, {'category': ['process'], 'description': ['neurotransmitter secretion']}, {'category': ['process'], 'description': ['regulation of blood pressure']}, {'category': ['process'], 'description': ['regulation of calcium ion transport']}, {'category': ['process'], 'description': ['regulation of heart contraction']}, {'category': ['process'], 'description': ['response to pain']}, {'category': ['process'], 'description': ['synaptic transmission']}, {'category': ['process'], 'description': ['transport']}]}]}]}]}]"
"['DB00065', 'BTD00004', 'BIOD00004']",['Infliximab'],biotech,"[""Infliximab is a tumor necrosis factor (TNF-alpha or TNF-) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions [A31469]. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-) is a key proinflammatory cytokine involved in chronic inflammatory diseases [A31469]. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF- [A106], infliximab disrupts the interaction of TNF- with its receptors and may also cause lysis of cells that produce TNF- [A106].\r\n\r\nInfliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment of various inflammatory disorders such as adult or pediatric Chron's disease, adult or pediatric ulcerative colitis, rheumatoid arthritis in combination with methotrexate, ankylosing spondyliti, psoriatic arthritis, and plaque psoriasis [FDA Label]. In clinical trials, multiple infusions of infliximab displayed in a reduction of signs and symptoms of inflammatory diseases and induction of remission in patients who have had an inadequate response to alternative first-line therapies for that disorder [FDA Label]. \r\n\r\nThere are currently two biosilimars of infliximab available in the US market that demonstrate a high degree of similarity to the reference product, Remicade. They are approved for all eligible indications of the reference product. Inflectra, a first biosimilar drug product, was approved in 2016. In December 2017, Ixifi, a second biosimilar that was developed by Pfizer, was granted approval by the FDA.""]",['liquid'],"['* Indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult or pediatric ( 6 years of age) patients with moderately to severely active **Crohns disease** who have had an inadequate response to conventional therapy\r\n* Indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing **Crohns disease**. \r\n* Indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric ( 6 years of age) patients with moderately to severely active **ulcerative colitis** who have had an inadequate response to conventional therapy. \r\n* Indicated for, in combination with methotrexate, reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active **rheumatoid arthritis**. \r\n* Indicated for reducing signs and symptoms in patients with active **ankylosing spondylitis**. \r\n* Indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with **psoriatic arthritis**. \r\n* Indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) **plaque psoriasis** who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.']","['Infliximab is a IgG1 monoclonal antibody that binds to soluble and transmembrane forms of TNF- with high affinity to disrupt the pro-inflammatory cascade signalling. Binding of the antibody to TNF- prevents TNF- from interacting with its receptors. Infliximab does not neutralize TNF- (lymphotoxin-), a related cytokine that utilizes the same receptors as TNF- [FDA Label]. Blocked actions of TNF- further leads to downregulation of local and systemic pro-inflammatory cytokines (i.e. IL-1, IL-6), reduction of lymphocyte and leukocyte migration to sites of inflammation, induction of apoptosis of TNF-producing cells (i.e. activated monocytes and T lymphocytes), increased levels of nuclear factor-B inhibitor, and reduction of reduction of endothelial adhesion molecules and acute phase proteins [A31469]. Its inhibitory actions on TNF- was demonstrated in human fibroblasts, endothelial cells, neutrophils, B and Tlymphocytes and epithelial cells [FDA Label]. Infliximab also atteunates the production of tissue degrading enzymes synthesized by synoviocytes and/or chondrocytes. According to a transgenic mice study that developed polyarthritis due to consitutive levels of human TNF-, infliximab decreased synovitis and joint erosions in collagen-induced arthritis and allows eroded joints to heal [FDA Label]. ']",[None],"[{'target': [{'id': ['BE0000704'], 'name': ['Tumor necrosis factor'], 'organism': ['Humans'], 'actions': [{'action': ['inhibitor']}], 'references': [{'articles': [{'article': [{'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A1993'], 'pubmed-id': ['17642244'], 'citation': ['Mimura T: [Selection of one of the TNF blockers; infliximab and etanercept]. Nihon Rinsho. 2007 Jul;65(7):1282-6.']}, {'ref-id': ['A1994'], 'pubmed-id': ['16052578'], 'citation': ['Braun J, Baraliakos X, Listing J, Sieper J: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005 Aug;52(8):2447-51.']}, {'ref-id': ['A1996'], 'pubmed-id': ['16456024'], 'citation': [""Danese S, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A, Pique JM, Panes J, Katz JA, Gasbarrini A, Fiocchi C: TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol. 2006 Feb 15;176(4):2617-24.""]}, {'ref-id': ['A1998'], 'pubmed-id': ['15674127'], 'citation': [""Magro F, Pereira P, Carneiro F, Veloso FT: Reactive hepatitis in a patient with Crohn's disease successfully treated with infliximab: does tumor necrosis factor alpha play a role in reactive hepatitis? Inflamm Bowel Dis. 2005 Jan;11(1):88-90.""]}, {'ref-id': ['A2000'], 'pubmed-id': ['16622728'], 'citation': ['Mori S, Imamura F, Kiyofuji C, Ito K, Koga Y, Honda I, Sugimoto M: Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody. Mod Rheumatol. 2006;16(1):58-62.']}, {'ref-id': ['A2002'], 'pubmed-id': ['12110154'], 'citation': ['Maini RN, Feldmann M: How does infliximab work in rheumatoid arthritis? Arthritis Res. 2002;4 Suppl 2:S22-8. Epub 2002 Mar 27.']}, {'ref-id': ['A2004'], 'pubmed-id': ['15481318'], 'citation': [""Sapienza MS, Cohen S, Dimarino AJ: Treatment of pyoderma gangrenosum with infliximab in Crohn's disease. Dig Dis Sci. 2004 Sep;49(9):1454-7.""]}, {'ref-id': ['A2005'], 'pubmed-id': ['15691217'], 'citation': ['Tobin AM, Kirby B: TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs. 2005;19(1):47-57.']}, {'ref-id': ['A2007'], 'pubmed-id': ['15691299'], 'citation': ['Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P, Ceuppens JL: Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther. 2005 Feb 1;21(3):251-8.']}, {'ref-id': ['A2009'], 'pubmed-id': ['15804598'], 'citation': ['Popa C, Netea MG, Barrera P, Radstake TR, van Riel PL, Kullberg BJ, Van der Meer JW: Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy. Cytokine. 2005 Apr 21;30(2):72-7.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Tumor necrosis factor'], 'general-function': ['Tumor necrosis factor receptor binding'], 'specific-function': [""Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Upregulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective (PubMed:23396208). Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line (PubMed:22517918).The TNF intracellular domain (ICD) form induces IL12 production in dendritic cells.""], 'gene-name': ['TNF'], 'locus': ['6p21.3'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['36-56'], 'signal-regions': [None], 'theoretical-pi': ['6.92'], 'molecular-weight': ['25644.15'], 'chromosome-location': ['6'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:11892']}, {'resource': ['GenAtlas'], 'identifier': ['TNF']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M16441']}, {'resource': ['GenBank Protein Database'], 'identifier': ['339741']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2635']}, {'resource': ['UniProtKB'], 'identifier': ['P01375']}, {'resource': ['UniProt Accession'], 'identifier': ['TNFA_HUMAN']}]}], 'synonyms': [{'synonym': ['Cachectin', 'TNF-a', 'TNF-alpha', 'TNFA', 'TNFSF2', 'Tumor necrosis factor ligand superfamily member 2']}], 'amino-acid-sequence': ['>lcl|BSEQ0001404|Tumor necrosis factor\nMSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQR\nEEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELR\nDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRE\nTPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL'], 'gene-sequence': ['>lcl|BSEQ0021837|Tumor necrosis factor (TNF)\nATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAG\nACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATC\nGTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGG\nGAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCT\nTCTCGAACCCCGAGTGACAAGCCTGTAGCCCATGTTGTAGCAAACCCTCAAGCTGAGGGG\nCAGCTCCAGTGGCTGAACCGCCGGGCCAATGCCCTCCTGGCCAATGGCGTGGAGCTGAGA\nGATAACCAGCTGGTGGTGCCATCAGAGGGCCTGTACCTCATCTACTCCCAGGTCCTCTTC\nAAGGGCCAAGGCTGCCCCTCCACCCATGTGCTCCTCACCCACACCATCAGCCGCATCGCC\nGTCTCCTACCAGACCAAGGTCAACCTCCTCTCTGCCATCAAGAGCCCCTGCCAGAGGGAG\nACCCCAGAGGGGGCTGAGGCCAAGCCCTGGTATGAGCCCATCTATCTGGGAGGGGTCTTC\nCAGCTGGAGAAGGGTGACCGACTCAGCGCTGAGATCAATCGGCCCGACTATCTCGACTTT\nGCCGAGTCTGGGCAGGTCTACTTTGGGATCATTGCCCTGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00229'], 'name': ['TNF']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['membrane raft']}, {'category': ['component'], 'description': ['phagocytic cup']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['recycling endosome']}, {'category': ['function'], 'description': ['cytokine activity']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['function'], 'description': ['transcription regulatory region DNA binding']}, {'category': ['function'], 'description': ['tumor necrosis factor receptor binding']}, {'category': ['process'], 'description': ['activation of cysteine-type endopeptidase activity involved in apoptotic process']}, {'category': ['process'], 'description': ['activation of MAPK activity']}, {'category': ['process'], 'description': ['activation of MAPKKK activity']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular response to amino acid stimulus']}, {'category': ['process'], 'description': ['cellular response to nicotine']}, {'category': ['process'], 'description': ['cellular response to organic cyclic compound']}, {'category': ['process'], 'description': ['chronic inflammatory response to antigenic stimulus']}, {'category': ['process'], 'description': ['cortical actin cytoskeleton organization']}, {'category': ['process'], 'description': ['death-inducing signaling complex assembly']}, {'category': ['process'], 'description': ['defense response to Gram-positive bacterium']}, {'category': ['process'], 'description': ['embryonic digestive tract development']}, {'category': ['process'], 'description': ['epithelial cell proliferation involved in salivary gland morphogenesis']}, {'category': ['process'], 'description': ['establishment of protein localization to plasma membrane']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['extrinsic apoptotic signaling pathway']}, {'category': ['process'], 'description': ['extrinsic apoptotic signaling pathway via death domain receptors']}, {'category': ['process'], 'description': ['glucose metabolic process']}, {'category': ['process'], 'description': ['humoral immune response']}, {'category': ['process'], 'description': ['I-kappaB kinase/NF-kappaB signaling']}, {'category': ['process'], 'description': ['inflammatory response']}, {'category': ['process'], 'description': ['intrinsic apoptotic signaling pathway in response to DNA damage']}, {'category': ['process'], 'description': ['JNK cascade']}, {'category': ['process'], 'description': ['leukocyte tethering or rolling']}, {'category': ['process'], 'description': ['lipopolysaccharide-mediated signaling pathway']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['necroptotic signaling pathway']}, {'category': ['process'], 'description': ['negative regulation of alkaline phosphatase activity']}, {'category': ['process'], 'description': ['negative regulation of bicellular tight junction assembly']}, {'category': ['process'], 'description': ['negative regulation of branching involved in lung morphogenesis']}, {'category': ['process'], 'description': ['negative regulation of cytokine secretion involved in immune response']}, {'category': ['process'], 'description': ['negative regulation of extrinsic apoptotic signaling pathway in absence of ligand']}, {'category': ['process'], 'description': ['negative regulation of fat cell differentiation']}, {'category': ['process'], 'description': ['negative regulation of gene expression']}, {'category': ['process'], 'description': ['negative regulation of glucose import']}, {'category': ['process'], 'description': ['negative regulation of growth of symbiont in host']}, {'category': ['process'], 'description': ['negative regulation of interleukin-6 production']}, {'category': ['process'], 'description': ['negative regulation of lipid catabolic process']}, {'category': ['process'], 'description': ['negative regulation of lipid storage']}, {'category': ['process'], 'description': ['negative regulation of myoblast differentiation']}, {'category': ['process'], 'description': ['negative regulation of myosin-light-chain-phosphatase activity']}, {'category': ['process'], 'description': ['negative regulation of osteoblast differentiation']}, {'category': ['process'], 'description': ['negative regulation of protein complex disassembly']}, {'category': ['process'], 'description': ['negative regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['negative regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['negative regulation of viral genome replication']}, {'category': ['process'], 'description': ['osteoclast differentiation']}, {'category': ['process'], 'description': ['positive regulation of apoptotic process']}, {'category': ['process'], 'description': ['positive regulation of calcidiol 1-monooxygenase activity']}, {'category': ['process'], 'description': ['positive regulation of cell adhesion']}, {'category': ['process'], 'description': ['positive regulation of ceramide biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of chemokine (C-X-C motif) ligand 2 production']}, {'category': ['process'], 'description': ['positive regulation of chemokine biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of chemokine production']}, {'category': ['process'], 'description': ['positive regulation of chronic inflammatory response to antigenic stimulus']}, {'category': ['process'], 'description': ['positive regulation of cysteine-type endopeptidase activity involved in apoptotic process']}, {'category': ['process'], 'description': ['positive regulation of cytokine production']}, {'category': ['process'], 'description': ['positive regulation of cytokine secretion']}, {'category': ['process'], 'description': ['positive regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['positive regulation of fever generation']}, {'category': ['process'], 'description': ['positive regulation of gene expression']}, {'category': ['process'], 'description': ['positive regulation of hair follicle development']}, {'category': ['process'], 'description': ['positive regulation of heterotypic cell-cell adhesion']}, {'category': ['process'], 'description': ['positive regulation of humoral immune response mediated by circulating immunoglobulin']}, {'category': ['process'], 'description': ['positive regulation of I-kappaB kinase/NF-kappaB signaling']}, {'category': ['process'], 'description': ['positive regulation of interferon-gamma production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-6 production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-8 biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of interleukin-8 production']}, {'category': ['process'], 'description': ['positive regulation of JUN kinase activity']}, {'category': ['process'], 'description': ['positive regulation of MAP kinase activity']}, {'category': ['process'], 'description': ['positive regulation of membrane protein ectodomain proteolysis']}, {'category': ['process'], 'description': ['positive regulation of mononuclear cell migration']}, {'category': ['process'], 'description': ['positive regulation of NF-kappaB import into nucleus']}, {'category': ['process'], 'description': ['positive regulation of NF-kappaB transcription factor activity']}, {'category': ['process'], 'description': ['positive regulation of NFAT protein import into nucleus']}, {'category': ['process'], 'description': ['positive regulation of NIK/NF-kappaB signaling']}, {'category': ['process'], 'description': ['positive regulation of nitric oxide biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of osteoclast differentiation']}, {'category': ['process'], 'description': ['positive regulation of peptidyl-serine phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of phagocytosis']}, {'category': ['process'], 'description': ['positive regulation of podosome assembly']}, {'category': ['process'], 'description': ['positive regulation of programmed cell death']}, {'category': ['process'], 'description': ['positive regulation of protein complex assembly']}, {'category': ['process'], 'description': ['positive regulation of protein complex disassembly']}, {'category': ['process'], 'description': ['positive regulation of protein kinase activity']}, {'category': ['process'], 'description': ['positive regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['positive regulation of protein localization to cell surface']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of protein transport']}, {'category': ['process'], 'description': ['positive regulation of sequence-specific DNA binding transcription factor activity']}, {'category': ['process'], 'description': ['positive regulation of smooth muscle cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['positive regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['positive regulation of translational initiation by iron']}, {'category': ['process'], 'description': ['positive regulation of vitamin D biosynthetic process']}, {'category': ['process'], 'description': ['protein import into nucleus, translocation']}, {'category': ['process'], 'description': ['protein kinase B signaling']}, {'category': ['process'], 'description': ['receptor biosynthetic process']}, {'category': ['process'], 'description': ['regulation of branching involved in salivary gland morphogenesis']}, {'category': ['process'], 'description': ['regulation of establishment of endothelial barrier']}, {'category': ['process'], 'description': ['regulation of I-kappaB kinase/NF-kappaB signaling']}, {'category': ['process'], 'description': ['regulation of immunoglobulin secretion']}, {'category': ['process'], 'description': ['regulation of insulin secretion']}, {'category': ['process'], 'description': ['regulation of tumor necrosis factor-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to glucocorticoid']}, {'category': ['process'], 'description': ['response to salt stress']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['sequestering of triglyceride']}, {'category': ['process'], 'description': ['transformed cell apoptotic process']}, {'category': ['process'], 'description': ['tumor necrosis factor-mediated signaling pathway']}]}]}]}]}]"
"['DB00066', 'BTD00099', 'BTD00064', 'BIOD00099', 'BIOD00064', 'DB09024']",['Follitropin'],biotech,"['Follitropin is a human follicle stimulating hormone (FSH) preparation of recombinant DNA origin, which consists of two non-covalently linked, non-identical glycoproteins designated as the alpha- and beta- subunits. The alpha- and beta- subunits have 92 and 111 amino acids. The alpha subunit is glycosylated at Asn 51 and Asn 78 while the beta subunit is glycosylated at Asn 7 and Asn 24. Follitropin beta is produced in genetically engineered Chinese hamster cell lines (CHO). The nomenclature beta differentiates it from another recombinant human FSH product that was marketed earlier as follitropin alpha. Follitropin is important in the development of follicles produced by the ovaries. Given by subcutaneous injection, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility. Follitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF).  Numerous physio-chemical tests and bioassays indicate that follitropin beta and follitropin alpha are indistinguishable. However, a more recent study showed there is may be a slight clinical difference, with the alpha form tending towards a higher pregnancy rate and the beta form tending towards a lower pregnancy rate, but with significantly higher estradiol (E2) levels. Structural analysis shows that the amino acid sequence of follitropin beta is identical to that of natural human follicle stimulating hormone (FSH). Further, the ogliosaccharide side chains are very similar, but not completely identical to that of natural FSH. However, these small differences do not affect the bioactivity compared to natural FSH.']",['liquid'],"['In women having been diagnosed with primary ovarian failure, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility. In men with hypogonadotrophic hypogonadism, it is used to induce spermatogenesis. Follitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF).']","['Follitropin is a recombinant form of endogenous follicle stimulating hormone (FSH). FSH binds to the follicle stimulating hormone receptor which is a G-coupled transmembrane receptor. Binding of the FSH to its receptor seems to induce phosphorylation and activation of the PI3K (Phosphatidylinositol-3-kinase) and Akt signaling pathway, which is known to regulate many other metabolic and related survival/maturation functions in cells.']",[None],"[{'target': [{'id': ['BE0000387'], 'name': ['Follicle-stimulating hormone receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A2011'], 'pubmed-id': ['11299519'], 'citation': ['Layman LC: Mutations in the follicle-stimulating hormone-beta (FSH beta) and FSH receptor genes in mice and humans. Semin Reprod Med. 2000;18(1):5-10.']}, {'ref-id': ['A2013'], 'pubmed-id': ['7755615'], 'citation': ['Leng N, Dattatreyamurty B, Reichert LE Jr: Identification of amino acid residues 300-315 of the rat FSH receptor as a hormone binding domain: evidence for its interaction with specific regions of FSH beta-subunit. Biochem Biophys Res Commun. 1995 May 16;210(2):392-9.']}, {'ref-id': ['A2014'], 'pubmed-id': ['2108722'], 'citation': ['Santa Coloma TA, Dattatreyamurty B, Reichert LE Jr: A synthetic peptide corresponding to human FSH beta-subunit 33-53 binds to FSH receptor, stimulates basal estradiol biosynthesis, and is a partial antagonist of FSH. Biochemistry. 1990 Feb 6;29(5):1194-200.']}, {'ref-id': ['A2017'], 'pubmed-id': ['8319832'], 'citation': ['Dattatreyamurty B, Reichert LE Jr: Identification of regions of the follitropin (FSH) beta-subunit that interact with the N-terminus region (residues 9-30) of the FSH receptor. Mol Cell Endocrinol. 1993 May;93(1):39-46.']}, {'ref-id': ['A2019'], 'pubmed-id': ['8070368'], 'citation': ['Lindau-Shepard B, Roth KE, Dias JA: Identification of amino acids in the C-terminal region of human follicle-stimulating hormone (FSH) beta-subunit involved in binding to human FSH receptor. Endocrinology. 1994 Sep;135(3):1235-40.']}, {'ref-id': ['A109'], 'pubmed-id': ['18020563'], 'citation': ['Goa KL, Wagstaff AJ: Follitropin alpha in infertility: a review. BioDrugs. 1998 Mar;9(3):235-60.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Follicle-stimulating hormone receptor'], 'general-function': ['G-protein coupled peptide receptor activity'], 'specific-function': ['Receptor for follicle-stimulating hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Induces cAMP production through the activation of PI3K-AKT and SRC-ERK1/2 signaling pathways.'], 'gene-name': ['FSHR'], 'locus': ['2p21-p16'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['367-387\n399-421\n444-465\n486-508\n529-550\n574-597\n609-630'], 'signal-regions': ['1-17'], 'theoretical-pi': ['7.19'], 'molecular-weight': ['78264.07'], 'chromosome-location': ['2'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3969']}, {'resource': ['GenAtlas'], 'identifier': ['FSHR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M65085']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182771']}, {'resource': ['IUPHAR'], 'identifier': ['253']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['253']}, {'resource': ['UniProtKB'], 'identifier': ['P23945']}, {'resource': ['UniProt Accession'], 'identifier': ['FSHR_HUMAN']}]}], 'synonyms': [{'synonym': ['Follitropin receptor', 'FSH-R', 'LGR1']}], 'amino-acid-sequence': ['>lcl|BSEQ0037007|Follicle-stimulating hormone receptor\nMALLLVSLLAFLSLGSGCHHRICHCSNRVFLCQESKVTEIPSDLPRNAIELRFVLTKLRV\nIQKGAFSGFGDLEKIEISQNDVLEVIEADVFSNLPKLHEIRIEKANNLLYINPEAFQNLP\nNLQYLLISNTGIKHLPDVHKIHSLQKVLLDIQDNINIHTIERNSFVGLSFESVILWLNKN\nGIQEIHNCAFNGTQLDELNLSDNNNLEELPNDVFHGASGPVILDISRTRIHSLPSYGLEN\nLKKLRARSTYNLKKLPTLEKLVALMEASLTYPSHCCAFANWRRQISELHPICNKSILRQE\nVDYMTQARGQRSSLAEDNESSYSRGFDMTYTEFDYDLCNEVVDVTCSPKPDAFNPCEDIM\nGYNILRVLIWFISILAITGNIIVLVILTTSQYKLTVPRFLMCNLAFADLCIGIYLLLIAS\nVDIHTKSQYHNYAIDWQTGAGCDAAGFFTVFASELSVYTLTAITLERWHTITHAMQLDCK\nVQLRHAASVMVMGWIFAFAAALFPIFGISSYMKVSICLPMDIDSPLSQLYVMSLLVLNVL\nAFVVICGCYIHIYLTVRNPNIVSSSSDTRIAKRMAMLIFTDFLCMAPISFFAISASLKVP\nLITVSKAKILLVLFHPINSCANPFLYAIFTKNFRRDFFILLSKCGCYEMQAQIYRTETSS\nTVHNTHPRNGHCSSAPRVTNGSTYILVPLSHLAQN'], 'gene-sequence': ['>lcl|BSEQ0018946|Follicle-stimulating hormone receptor (FSHR)\nATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCAT\nCGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATT\nCCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTC\nATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAAT\nGATGTCTTGGAGGTGATAGAGGCAGATGTGTTCTCCAACCTTCCCAAATTACATGAAATT\nAGAATTGAAAAGGCCAACAACCTGCTCTACATCAACCCTGAGGCCTTCCAGAACCTTCCC\nAACCTTCAATATCTGTTAATATCCAACACAGGTATTAAGCACCTTCCAGATGTTCACAAG\nATTCATTCTCTCCAAAAAGTTTTACTTGACATTCAAGATAACATAAACATCCACACAATT\nGAAAGAAATTCTTTCGTGGGGCTGAGCTTTGAAAGTGTGATTCTATGGCTGAATAAGAAT\nGGGATTCAAGAAATACACAACTGTGCATTCAATGGAACCCAACTAGATGAGCTGAATCTA\nAGCGATAATAATAATTTAGAAGAATTGCCTAATGATGTTTTCCACGGAGCCTCTGGACCA\nGTCATTCTAGATATTTCAAGAACAAGGATCCATTCCCTGCCTAGCTATGGCTTAGAAAAT\nCTTAAGAAGCTGAGGGCCAGGTCGACTTACAACTTAAAAAAGCTGCCTACTCTGGAAAAG\nCTTGTCGCCCTCATGGAAGCCAGCCTCACCTATCCCAGCCATTGCTGTGCCTTTGCAAAC\nTGGAGACGGCAAATCTCTGAGCTTCATCCAATTTGCAACAAATCTATTTTAAGGCAAGAA\nGTTGATTATATGACTCAGGCTAGGGGTCAGAGATCCTCTCTGGCAGAAGACAATGAGTCC\nAGCTACAGCAGAGGATTTGACATGACGTACACTGAGTTTGACTATGACTTATGCAATGAA\nGTGGTTGACGTGACCTGCTCCCCTAAGCCAGATGCATTCAACCCATGTGAAGATATCATG\nGGGTACAACATCCTCAGAGTCCTGATATGGTTTATCAGCATCCTGGCCATCACTGGGAAC\nATCATAGTGCTAGTGATCCTAACTACCAGCCAATATAAACTCACAGTCCCCAGGTTCCTT\nATGTGCAACCTGGCCTTTGCTGATCTCTGCATTGGAATCTACCTGCTGCTCATTGCATCA\nGTTGATATCCATACCAAGAGCCAATATCACAACTATGCCATTGACTGGCAAACTGGGGCA\nGGCTGTGATGCTGCTGGCTTTTTCACTGTCTTTGCCAGTGAGCTGTCAGTCTACACTCTG\nACAGCTATCACCTTGGAAAGATGGCATACCATCACGCATGCCATGCAGCTGGACTGCAAG\nGTGCAGCTCCGCCATGCTGCCAGTGTCATGGTGATGGGCTGGATTTTTGCTTTTGCAGCT\nGCCCTCTTTCCCATCTTTGGCATCAGCAGCTACATGAAGGTGAGCATCTGCCTGCCCATG\nGATATTGACAGCCCTTTGTCACAGCTGTATGTCATGTCCCTCCTTGTGCTCAATGTCCTG\nGCCTTTGTGGTCATCTGTGGCTGCTATATCCACATCTACCTCACAGTGCGGAACCCCAAC\nATCGTGTCCTCCTCTAGTGACACCAGGATCGCCAAGCGCATGGCCATGCTCATCTTCACT\nGACTTCCTCTGCATGGCACCCATTTCTTTCTTTGCCATTTCTGCCTCCCTCAAGGTGCCC\nCTCATCACTGTGTCCAAAGCAAAGATTCTGCTGGTTCTGTTTCACCCCATCAACTCCTGT\nGCCAACCCCTTCCTCTATGCCATCTTTACCAAAAACTTTCGCAGAGATTTCTTCATTCTG\nCTGAGCAAGTGTGGCTGCTATGAAATGCAAGCCCAAATTTATAGGACAGAAACTTCATCC\nACTGTCCACAACACCCATCCAAGGAATGGCCACTGCTCTTCAGCTCCCAGAGTCACCAGT\nGGTTCCACTTACATACTTGTCCCTCTAAGTCATTTAGCCCAAAACTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}, {'identifier': ['PF01462'], 'name': ['LRRNT']}, {'identifier': ['PF13306'], 'name': ['LRR_5']}, {'identifier': ['PF12369'], 'name': ['GnHR_trans']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['follicle-stimulating hormone receptor activity']}, {'category': ['function'], 'description': ['G-protein coupled peptide receptor activity']}, {'category': ['process'], 'description': ['activation of adenylate cyclase activity']}, {'category': ['process'], 'description': ['adenylate cyclase-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['female gamete generation']}, {'category': ['process'], 'description': ['female gonad development']}, {'category': ['process'], 'description': ['follicle-stimulating hormone signaling pathway']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['gonad development']}, {'category': ['process'], 'description': ['hormone-mediated signaling pathway']}, {'category': ['process'], 'description': ['male gonad development']}, {'category': ['process'], 'description': ['positive regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['positive regulation of phosphatidylinositol 3-kinase signaling']}, {'category': ['process'], 'description': ['primary ovarian follicle growth']}, {'category': ['process'], 'description': ['regulation of osteoclast differentiation']}, {'category': ['process'], 'description': ['regulation of protein kinase A signaling']}, {'category': ['process'], 'description': ['spermatogenesis']}, {'category': ['process'], 'description': ['uterus development']}]}]}]}]}]"
"['DB00067', 'BTD00110', 'BIOD00110', 'DB09392']",['Vasopressin'],small molecule,"['Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third and eighth amino acids.[A228013] Despite a wide variety of functions, exogenous vasopressin is primarily used to control blood pressure during systemic shock by increasing vasoconstriction and renal fluid reuptake by acting through V<sub>1</sub> and V<sub>2</sub> cellular receptors.[A228008, A228013, A228018, L31413]\r\n\r\nThe vasopressive effect of posterior pituitary gland extracts was noted in 1895, while vasopressin itself was not purified until 1951. It has been used for more than five decades for varying conditions, including variceal bleeding, diabetes insipidus, and, more recently, vasodilatory shock.[A228013] It is currently marketed under the trademark VASOSTRICT by PAR Pharmaceuticals.[L31413]']",['solid'],['Vasopressin is indicated to increase blood pressure in adults in vasodilatory shock refractory to the application of fluids and catecholamines.[L31413]'],"[""Vasopressin, Cyclo (1-6) L-Cysteinyl-L-Tyrosyl-L-PhenylalanylL-Glutaminyl-L-Asparaginyl-L-Cysteinyl-L-Prolyl-L-Arginyl-L-Glycinamide, is a cyclic nonapeptide hormone primarily produced by the supraoptic and periventricular nuclei of the hypothalamus.[A228008, L31413] Vasopressin release is mediated by sensory pathways, in which either a 2% increase in plasma osmolarity or a 10% decrease in blood pressure causes the release of endogenous vasopressin.[A228013] Upon release, vasopressin mediates a variety of physiological effects, both centrally and systemically, primarily by binding to G-protein-coupled receptors termed V<sub>1</sub> (V<sub>1A</sub>), V<sub>2</sub>, and V<sub>3</sub> (V<sub>1B</sub>).\r\n\r\nV<sub>1</sub> receptors are abundantly expressed in the brain whereby vasopressin binding can increase blood pressure through autonomic pathways.[A228008] Peripherally, V<sub>1</sub> is localized in the blood vessels (vascular smooth muscle), platelets, adrenal glands, kidneys, and liver.[A228008, A228018] Vasopressin binding to V<sub>1</sub> causes hydrolysis of phosphatidylinositol-4,5-bisphosphate into inositol triphosphate (IP<sub>3</sub>) and diacylglycerol (DAG) by phospholipase C, which in turn release intracellular calcium and activate protein kinase C (PKC) to open voltage-gated calcium channels (VGCCs) while closing potassium channels. Overall, intracellular calcium levels rise, which bind calmodulin and cause muscular contraction, resulting in vasoconstriction.[A228013] This is balanced by the apparent ability of vasopressin to induce vasodilation through binding oxytocin receptors and activating endothelial nitric oxide (NO) synthase; NO acts antagonistically to reduce muscle contraction.[A228013] It is also thought that vasopressin, acting through both V<sub>1</sub> and oxytocin receptors, causes the cardiac release of atrial natriuretic peptide (ANP), which has a negative inotropic effect; indeed, vasopressin tends to decrease heart rate and cardiac output, although the opposite effect has been noted with low doses.[A228013, L31413]\r\n\r\nV<sub>2</sub> receptors are abundantly expressed in the distal convoluted tubules and the collecting ducts of the kidneys.[A228018, A228023] Vasopressin binding to V<sub>2</sub> causes activation of a G<sub>s</sub> protein that subsequently activates protein kinase A (PKA) through adenylyl cyclase-mediated increase in cyclic adenosine monophosphate (cAMP), which leads to phosphorylation of the water channel aquaporin-2 (AQP2) and its trafficking to the cell surface.[A228018, A228023] Increased AQP2 levels lead to increased water reabsorption and explains vasopressin's antidiuretic effects.[A228018]\r\n\r\nV<sub>3</sub> (formerly V<sub>1B</sub>) receptors are primarily located in the anterior pituitary and brain.[A228008, A228018] Vasopressin released during acute stress causes adrenocorticotropic hormone (ACTH) release from the pituitary through V<sub>3</sub> and by potentiating the effects of corticotrophin-releasing factor. Within the brain itself, V<sub>3</sub> activation modulates various effects, including recognition, memory, aggression, anxiety, and depression.[A228008]\r\n\r\nThus, vasopressin can affect a wide variety of physiological processes, often in apparently contradictory ways depending on the patient's dose and physiological state. Vasodilatory shock causes an immediate release of vasopressin from 20 to 200 times its normal serum concentration, which falls again to normal levels in prolonged shock; in this context, normal serum levels are insufficient to control the pathologic vasodilation.[A228013, A228018] In these cases, vasopressin acts to depolarize hyperpolarized vascular smooth muscle cells, restore sensitivity to catecholamines, and inhibit excessive nitric oxide production, primarily through acting through V<sub>1</sub> receptors. Therefore, vasopressin helps decrease the dose requirement for norepinephrine and is routinely administered together with norepinephrine to restore normal blood pressure in shock states.[A228018, L31413]""]",[None],"[{'target': [{'id': ['BE0000293'], 'name': ['Vasopressin V2 receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist', 'regulator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A6712'], 'pubmed-id': ['17020465'], 'citation': ['Boson WL, Della Manna T, Damiani D, Miranda DM, Gadelha MR, Liberman B, Correa H, Romano-Silva MA, Friedman E, Silva FF, Ribeiro PA, De Marco L: Novel vasopressin type 2 (AVPR2) gene mutations in Brazilian nephrogenic diabetes insipidus patients. Genet Test. 2006 Fall;10(3):157-62.']}, {'ref-id': ['A6713'], 'pubmed-id': ['16333859'], 'citation': ['Slusarz MJ, Slusarz R, Ciarkowski J: Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system. Biopolymers. 2006 Apr 5;81(5):321-38.']}, {'ref-id': ['A6714'], 'pubmed-id': ['16563128'], 'citation': [""Bouley R, Hawthorn G, Russo LM, Lin HY, Ausiello DA, Brown D: Aquaporin 2 (AQP2) and vasopressin type 2 receptor (V2R) endocytosis in kidney epithelial cells: AQP2 is located in 'endocytosis-resistant' membrane domains after vasopressin treatment. Biol Cell. 2006 Apr;98(4):215-32.""]}, {'ref-id': ['A6715'], 'pubmed-id': ['17287200'], 'citation': ['Yi X, Bouley R, Lin HY, Bechoua S, Sun TX, Del Re E, Shioda T, Raychowdhury MK, Lu HA, Abou-Samra AB, Brown D, Ausiello DA: Alix (AIP1) is a vasopressin receptor (V2R)-interacting protein that increases lysosomal degradation of the V2R. Am J Physiol Renal Physiol. 2007 May;292(5):F1303-13. Epub 2007 Feb 6.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A228008'], 'pubmed-id': ['29480411'], 'citation': ['Lozic M, Sarenac O, Murphy D, Japundzic-Zigon N: Vasopressin, Central Autonomic Control and Blood Pressure Regulation. Curr Hypertens Rep. 2018 Feb 26;20(2):11. doi: 10.1007/s11906-018-0811-0.']}, {'ref-id': ['A249445'], 'pubmed-id': ['33435837'], 'citation': ['Urbach J, Goldsmith SR: Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials. Ther Adv Cardiovasc Dis. 2021 Jan-Dec;15:1753944720977741. doi: 10.1177/1753944720977741.']}, {'ref-id': ['A247075'], 'pubmed-id': ['32946151'], 'citation': ['Mondritzki T, Mai TA, Vogel J, Pook E, Wasnaire P, Schmeck C, Huser J, Dinh W, Truebel H, Kolkhof P: Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure. Eur J Heart Fail. 2021 May;23(5):743-750. doi: 10.1002/ejhf.2001. Epub 2020 Oct 9.']}]}], 'textbooks': [None], 'links': [{'link': [{'ref-id': ['L31413'], 'title': ['FDA Approved Drug Products: VASOSTRICT (vasopressin) injection'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204485Orig1s013lbl.pdf']}]}], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Vasopressin V2 receptor'], 'general-function': ['Vasopressin receptor activity'], 'specific-function': ['Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Involved in renal water reabsorption.'], 'gene-name': ['AVPR2'], 'locus': ['Xq28'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['39-63\n78-98\n114-135\n160-180\n201-220\n272-293\n309-328'], 'signal-regions': [None], 'theoretical-pi': ['9.41'], 'molecular-weight': ['40278.57'], 'chromosome-location': ['X'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:897']}, {'resource': ['GenAtlas'], 'identifier': ['AVPR2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['U04357']}, {'resource': ['GenBank Protein Database'], 'identifier': ['28418']}, {'resource': ['IUPHAR'], 'identifier': ['368']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['368']}, {'resource': ['UniProtKB'], 'identifier': ['P30518']}, {'resource': ['UniProt Accession'], 'identifier': ['V2R_HUMAN']}]}], 'synonyms': [{'synonym': ['ADHR', 'Antidiuretic hormone receptor', 'AVPR V2', 'DIR', 'DIR3', 'Renal-type arginine vasopressin receptor', 'V2R']}], 'amino-acid-sequence': ['>lcl|BSEQ0000583|Vasopressin V2 receptor\nMLMASTTSAVPGHPSLPSLPSNSSQERPLDTRDPLLARAELALLSIVFVAVALSNGLVLA\nALARRGRRGHWAPIHVFIGHLCLADLAVALFQVLPQLAWKATDRFRGPDALCRAVKYLQM\nVGMYASSYMILAMTLDRHRAICRPMLAYRHGSGAHWNRPVLVAWAFSLLLSLPQLFIFAQ\nRNVEGGSGVTDCWACFAEPWGRRTYVTWIALMVFVAPTLGIAACQVLIFREIHASLVPGP\nSERPGGRRRGRRTGSPGEGAHVSAAVAKTVRMTLVIVVVYVLCWAPFFLVQLWAAWDPEA\nPLEGAPFVLLMLLASLNSCTNPWIYASFSSSVSSELRSLLCCARGRTPPSLGPQDESCTT\nASSSLAKDTSS'], 'gene-sequence': ['>lcl|BSEQ0010065|Vasopressin V2 receptor (AVPR2)\nATGCTCATGGCGTCCACCACTTCCGCTGTGCCTGGGCATCCCTCTCTGCCCAGCCTGCCC\nAGCAACAGCAGCCAGGAGAGGCCACTGGACACCCGGGACCCGCTGCTAGCCCGGGCGGAG\nCTGGCGCTGCTCTCCATAGTCTTTGTGGCTGTGGCCCTGAGCAATGGCCTGGTGCTGGCG\nGCCCTAGCTCGGCGGGGCCGGCGGGGCCACTGGGCACCCATACACGTCTTCATTGGCCAC\nTTGTGCCTGGCCGACCTGGCCGTGGCTCTGTTCCAAGTGCTGCCCCAGCTGGCCTGGAAG\nGCCACCGACCGCTTCCGTGGGCCAGATGCCCTGTGTCGGGCCGTGAAGTATCTGCAGATG\nGTGGGCATGTATGCCTCCTCCTACATGATCCTGGCCATGACGCTGGACCGCCACCGTGCC\nATCTGCCGTCCCATGCTGGCGTACCGCCATGGAAGTGGGGCTCACTGGAACCGGCCGGTG\nCTAGTGGCTTGGGCCTTCTCGCTCCTTCTCAGCCTGCCCCAGCTCTTCATCTTCGCCCAG\nCGCAACGTGGAAGGTGGCAGCGGGGTCACTGACTGCTGGGCCTGCTTTGCGGAGCCCTGG\nGGCCGTCGCACCTATGTCACCTGGATTGCCCTGATGGTGTTCGTGGCACCTACCCTGGGT\nATCGCCGCCTGCCAGGTGCTCATCTTCCGGGAGATTCATGCCAGTCTGGTGCCAGGGCCA\nTCAGAGAGGCCTGGGGGGCGCCGCAGGGGACGCCGGACAGGCAGCCCCGGTGAGGGAGCC\nCACGTGTCAGCAGCTGTGGCCAAGACTGTGAGGATGACGCTAGTGATTGTGGTCGTCTAT\nGTGCTGTGCTGGGCACCCTTCTTCCTGGTGCAGCTGTGGGCCGCGTGGGACCCGGAGGCA\nCCTCTGGAAGGGGCGCCCTTTGTGCTACTCATGTTGCTGGCCAGCCTCAACAGCTGCACC\nAACCCCTGGATCTATGCATCTTTCAGCAGCAGCGTGTCCTCAGAGCTGCGAAGCTTGCTC\nTGCTGTGCCCGGGGACGCACCCCACCCAGCCTGGGTCCCCAAGATGAGTCCTGCACCACC\nGCCAGCTCCTCCCTGGCCAAGGACACTTCATCGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endoplasmic reticulum']}, {'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['Golgi apparatus']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['peptide binding']}, {'category': ['function'], 'description': ['vasopressin receptor activity']}, {'category': ['process'], 'description': ['activation of adenylate cyclase activity']}, {'category': ['process'], 'description': ['adenylate cyclase-modulating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular response to hormone stimulus']}, {'category': ['process'], 'description': ['excretion']}, {'category': ['process'], 'description': ['hemostasis']}, {'category': ['process'], 'description': ['I-kappaB kinase/NF-kappaB signaling']}, {'category': ['process'], 'description': ['interferon-gamma production']}, {'category': ['process'], 'description': ['negative regulation of renal sodium excretion']}, {'category': ['process'], 'description': ['negative regulation of urine volume']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of gene expression']}, {'category': ['process'], 'description': ['positive regulation of protein ubiquitination']}, {'category': ['process'], 'description': ['positive regulation of systemic arterial blood pressure']}, {'category': ['process'], 'description': ['positive regulation of vasoconstriction']}, {'category': ['process'], 'description': ['regulation of systemic arterial blood pressure by vasopressin']}, {'category': ['process'], 'description': ['renal water homeostasis']}, {'category': ['process'], 'description': ['response to cytokine']}, {'category': ['process'], 'description': ['response to peptide']}, {'category': ['process'], 'description': ['telencephalon development']}, {'category': ['process'], 'description': ['transmembrane transport']}, {'category': ['process'], 'description': ['water transport']}]}]}]}, {'id': ['BE0000165'], 'name': ['Vasopressin V1a receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist', 'regulator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A2021'], 'pubmed-id': ['17275806'], 'citation': ['Hiroyama M, Wang S, Aoyagi T, Oikawa R, Sanbe A, Takeo S, Tanoue A: Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice. Eur J Pharmacol. 2007 Mar 22;559(2-3):89-97. Epub 2006 Dec 29.']}, {'ref-id': ['A2023'], 'pubmed-id': ['16532916'], 'citation': ['Liedman R, Grant L, Igidbashian S, James I, McLeod A, Skillern L, Akerlund M: Intrauterine pressure, ischemia markers, and experienced pain during administration of a vasopressin V1a receptor antagonist in spontaneous and vasopressin-induced dysmenorrhea. Acta Obstet Gynecol Scand. 2006;85(2):207-11.']}, {'ref-id': ['A2025'], 'pubmed-id': ['16511036'], 'citation': ['Adikesavan NV, Mahmood SS, Stanley N, Xu Z, Wu N, Thibonnier M, Shoham M: A C-terminal segment of the V1R vasopressin receptor is unstructured in the crystal structure of its chimera with the maltose-binding protein. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005 Apr 1;61(Pt 4):341-5. Epub 2005 Mar 24.']}, {'ref-id': ['A2026'], 'pubmed-id': ['16011575'], 'citation': ['Hammock EA, Lim MM, Nair HP, Young LJ: Association of vasopressin 1a receptor levels with a regulatory microsatellite and behavior. Genes Brain Behav. 2005 Jul;4(5):289-301.']}, {'ref-id': ['A2030'], 'pubmed-id': ['17303660'], 'citation': ['Aoyagi T, Birumachi J, Hiroyama M, Fujiwara Y, Sanbe A, Yamauchi J, Tanoue A: Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology. 2007 May;148(5):2075-84. Epub 2007 Feb 15.']}, {'ref-id': ['A228008'], 'pubmed-id': ['29480411'], 'citation': ['Lozic M, Sarenac O, Murphy D, Japundzic-Zigon N: Vasopressin, Central Autonomic Control and Blood Pressure Regulation. Curr Hypertens Rep. 2018 Feb 26;20(2):11. doi: 10.1007/s11906-018-0811-0.']}, {'ref-id': ['A249445'], 'pubmed-id': ['33435837'], 'citation': ['Urbach J, Goldsmith SR: Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials. Ther Adv Cardiovasc Dis. 2021 Jan-Dec;15:1753944720977741. doi: 10.1177/1753944720977741.']}, {'ref-id': ['A247075'], 'pubmed-id': ['32946151'], 'citation': ['Mondritzki T, Mai TA, Vogel J, Pook E, Wasnaire P, Schmeck C, Huser J, Dinh W, Truebel H, Kolkhof P: Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure. Eur J Heart Fail. 2021 May;23(5):743-750. doi: 10.1002/ejhf.2001. Epub 2020 Oct 9.']}]}], 'textbooks': [None], 'links': [{'link': [{'ref-id': ['L31413'], 'title': ['FDA Approved Drug Products: VASOSTRICT (vasopressin) injection'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204485Orig1s013lbl.pdf']}]}], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Vasopressin V1a receptor'], 'general-function': ['Vasopressin receptor activity'], 'specific-function': ['Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. Has been involved in social behaviors, including affiliation and attachment.'], 'gene-name': ['AVPR1A'], 'locus': ['12q14-q15'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['53-76\n89-110\n126-147\n169-190\n219-239\n294-313\n332-351'], 'signal-regions': [None], 'theoretical-pi': ['9.67'], 'molecular-weight': ['46799.105'], 'chromosome-location': ['12'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:895']}, {'resource': ['GenAtlas'], 'identifier': ['AVPR1A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L25615']}, {'resource': ['GenBank Protein Database'], 'identifier': ['667068']}, {'resource': ['IUPHAR'], 'identifier': ['366']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['366']}, {'resource': ['UniProtKB'], 'identifier': ['P37288']}, {'resource': ['UniProt Accession'], 'identifier': ['V1AR_HUMAN']}]}], 'synonyms': [{'synonym': ['Antidiuretic hormone receptor 1a', 'AVPR V1a', 'AVPR1', 'V1aR', 'Vascular/hepatic-type arginine vasopressin receptor']}], 'amino-acid-sequence': ['>lcl|BSEQ0009979|Vasopressin V1a receptor\nMRLSAGPDAGPSGNSSPWWPLATGAGNTSREAEALGEGNGPPRDVRNEELAKLEIAVLAV\nTFAVAVLGNSSVLLALHRTPRKTSRMHLFIRHLSLADLAVAFFQVLPQMCWDITYRFRGP\nDWLCRVVKHLQVFGMFASAYMLVVMTADRYIAVCHPLKTLQQPARRSRLMIAAAWVLSFV\nLSTPQYFVFSMIEVNNVTKARDCWATFIQPWGSRAYVTWMTGGIFVAPVVILGTCYGFIC\nYNIWCNVRGKTASRQSKGAEQAGVAFQKGFLLAPCVSSVKSISRAKIRTVKMTFVIVTAY\nIVCWAPFFIIQMWSVWDPMSVWTESENPTITITALLGSLNSCCNPWIYMFFSGHLLQDCV\nQSFPCCQNMKEKFNKEDTDSMSRRQTFYSNNRSPTNSTGMWKDSPKSSKSIKFIPVST'], 'gene-sequence': ['>lcl|BSEQ0009980|Vasopressin V1a receptor (AVPR1A)\nATGCGTCTCTCCGCCGGTCCCGACGCGGGGCCCTCGGGCAACTCCAGCCCATGGTGGCCT\nCTGGCCACCGGCGCTGGCAACACAAGCCGGGAGGCCGAAGCCCTCGGGGAGGGCAACGGC\nCCACCGAGGGACGTGCGCAACGAGGAGCTGGCCAAACTGGAGATCGCCGTGCTGGCGGTG\nACTTTCGCGGTGGCCGTGCTGGGCAACAGCAGCGTACTGCTGGCTCTGCACCGGACGCCG\nCGCAAGACGTCCCGCATGCACCTCTTCATCCGACACCTCAGCCTGGCCGACCTGGCCGTG\nGCATTCTTCCAGGTGCTGCCGCAAATGTGCTGGGACATCACCTACCGCTTCCGCGGCCCC\nGACTGGCTGTGCCGCGTGGTGAAGCACCTGCAGGTGTTCGGCATGTTTGCGTCGGCCTAC\nATGCTGGTAGTCATGACAGCCGACCGCTACATCGCGGTGTGCCACCCGCTCAAGACTCTG\nCAACAGCCCGCGCGCCGCTCGCGCCTCATGATCGCGGCCGCCTGGGTGCTGAGCTTCGTG\nCTGAGCACGCCGCAGTACTTCGTCTTCTCCATGATCGAGGTGAACAATGTCACCAAGGCC\nCGCGACTGCTGGGCCACCTTCATCCAGCCCTGGGGTTCTCGTGCCTACGTGACCTGGATG\nACGGGCGGCATCTTTGTGGCGCCCGTGGTCATCTTGGGTACCTGCTACGGCTTCATCTGC\nTACAACATCTGGTGCAACGTCCGCGGGAAGACGGCGTCGCGCCAGAGCAAGGGTGCAGAG\nCAAGCGGGTGTGGCCTTCCAAAAGGGGTTCCTGCTCGCACCCTGTGTCAGCAGCGTGAAG\nTCCATTTCCCGGGCCAAGATCCGCACGGTGAAGATGACTTTTGTGATCGTGACGGCTTAC\nATCGTCTGCTGGGCGCCTTTCTTCATCATCCAGATGTGGTCTGTCTGGGATCCCATGTCC\nGTCTGGACCGAATCGGAAAACCCTACCATCACCATCACTGCATTACTGGGTTCCTTGAAT\nAGCTGCTGTAATCCCTGGATATACATGTTTTTTAGTGGCCATCTCCTTCAAGACTGTGTT\nCAAAGCTTCCCATGCTGCCAAAACATGAAGGAAAAATTCAACAAAGAAGATACTGACAGT\nATGAGCAGAAGACAGACTTTTTATTCTAACAATCGAAGCCCAACAAACAGTACGGGTATG\nTGGAAGGACTCGCCTAAATCTTCCAAGTCCATCAAATTCATTCCTGTTTCAACTTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}, {'identifier': ['PF08983'], 'name': ['DUF1856']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cytoplasmic vesicle']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['peptide binding']}, {'category': ['function'], 'description': ['peptide hormone binding']}, {'category': ['function'], 'description': ['protein kinase C binding']}, {'category': ['function'], 'description': ['vasopressin receptor activity']}, {'category': ['process'], 'description': ['activation of phospholipase C activity']}, {'category': ['process'], 'description': ['blood circulation']}, {'category': ['process'], 'description': ['calcium-mediated signaling']}, {'category': ['process'], 'description': ['cellular response to hormone stimulus']}, {'category': ['process'], 'description': ['cellular response to water deprivation']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['generation of precursor metabolites and energy']}, {'category': ['process'], 'description': ['grooming behavior']}, {'category': ['process'], 'description': ['maternal aggressive behavior']}, {'category': ['process'], 'description': ['maternal behavior']}, {'category': ['process'], 'description': ['myotube differentiation']}, {'category': ['process'], 'description': ['negative regulation of female receptivity']}, {'category': ['process'], 'description': ['negative regulation of transmission of nerve impulse']}, {'category': ['process'], 'description': ['penile erection']}, {'category': ['process'], 'description': ['positive regulation of cell growth']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of cellular pH reduction']}, {'category': ['process'], 'description': ['positive regulation of cytosolic calcium ion concentration']}, {'category': ['process'], 'description': ['positive regulation of glutamate secretion']}, {'category': ['process'], 'description': ['positive regulation of heart rate']}, {'category': ['process'], 'description': ['positive regulation of prostaglandin biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of renal sodium excretion']}, {'category': ['process'], 'description': ['positive regulation of systemic arterial blood pressure']}, {'category': ['process'], 'description': ['positive regulation of vasoconstriction']}, {'category': ['process'], 'description': ['regulation of systemic arterial blood pressure by vasopressin']}, {'category': ['process'], 'description': ['response to corticosterone']}, {'category': ['process'], 'description': ['response to peptide']}, {'category': ['process'], 'description': ['social behavior']}, {'category': ['process'], 'description': ['sperm ejaculation']}, {'category': ['process'], 'description': ['telencephalon development']}]}]}]}, {'id': ['BE0000773'], 'name': ['Vasopressin V1b receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A6716'], 'pubmed-id': ['17027167'], 'citation': ['Young WS, Li J, Wersinger SR, Palkovits M: The vasopressin 1b receptor is prominent in the hippocampal area CA2 where it is unaffected by restraint stress or adrenalectomy. Neuroscience. 2006 Dec 28;143(4):1031-9. Epub 2006 Oct 4.']}, {'ref-id': ['A6717'], 'pubmed-id': ['16720725'], 'citation': ['Volpi S, Liu Y, Aguilera G: Vasopressin increases GAGA binding activity to the V1b receptor promoter through transactivation of the MAP kinase pathway. J Mol Endocrinol. 2006 Jun;36(3):581-90.']}, {'ref-id': ['A6718'], 'pubmed-id': ['17284170'], 'citation': ['Wersinger SR, Caldwell HK, Christiansen M, Young WS 3rd: Disruption of the vasopressin 1b receptor gene impairs the attack component of aggressive behavior in mice. Genes Brain Behav. 2007 Oct;6(7):653-60. Epub 2006 Dec 20.']}, {'ref-id': ['A6719'], 'pubmed-id': ['16114100'], 'citation': ['Slusarz MJ, Gieldon A, Slusarz R, Ciarkowski J: Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors-molecular dynamics study of the activated receptor-vasopressin-G(alpha) systems. J Pept Sci. 2006 Mar;12(3):180-9.']}, {'ref-id': ['A6720'], 'pubmed-id': ['15993108'], 'citation': ['Jurkevich A, Berghman LR, Cornett LE, Kuenzel WJ: Characterization and immunohistochemical visualization of the vasotocin VT2 receptor in the pituitary gland of the chicken, Gallus gallus. Gen Comp Endocrinol. 2005 Aug;143(1):82-91. Epub 2005 Mar 23.']}, {'ref-id': ['A228008'], 'pubmed-id': ['29480411'], 'citation': ['Lozic M, Sarenac O, Murphy D, Japundzic-Zigon N: Vasopressin, Central Autonomic Control and Blood Pressure Regulation. Curr Hypertens Rep. 2018 Feb 26;20(2):11. doi: 10.1007/s11906-018-0811-0.']}]}], 'textbooks': [None], 'links': [{'link': [{'ref-id': ['L31413'], 'title': ['FDA Approved Drug Products: VASOSTRICT (vasopressin) injection'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204485Orig1s013lbl.pdf']}]}], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Vasopressin V1b receptor'], 'general-function': ['Vasopressin receptor activity'], 'specific-function': ['Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system.'], 'gene-name': ['AVPR1B'], 'locus': ['1q32'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['36-59\n72-93\n109-130\n152-173\n202-222\n284-303\n322-341'], 'signal-regions': [None], 'theoretical-pi': ['9.05'], 'molecular-weight': ['46970.345'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:896']}, {'resource': ['GenAtlas'], 'identifier': ['AVPR1B']}, {'resource': ['GenBank Gene Database'], 'identifier': ['D31833']}, {'resource': ['GenBank Protein Database'], 'identifier': ['563982']}, {'resource': ['IUPHAR'], 'identifier': ['367']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['367']}, {'resource': ['UniProtKB'], 'identifier': ['P47901']}, {'resource': ['UniProt Accession'], 'identifier': ['V1BR_HUMAN']}]}], 'synonyms': [{'synonym': ['Antidiuretic hormone receptor 1b', 'AVPR V1b', 'AVPR V3', 'AVPR3', 'V1bR', 'Vasopressin V3 receptor', 'VPR3']}], 'amino-acid-sequence': ['>lcl|BSEQ0010547|Vasopressin V1b receptor\nMDSGPLWDANPTPRGTLSAPNATTPWLGRDEELAKVEIGVLATVLVLATGGNLAVLLTLG\nQLGRKRSRMHLFVLHLALTDLAVALFQVLPQLLWDITYRFQGPDLLCRAVKYLQVLSMFA\nSTYMLLAMTLDRYLAVCHPLRSLQQPGQSTYLLIAAPWLLAAIFSLPQVFIFSLREVIQG\nSGVLDCWADFGFPWGPRAYLTWTTLAIFVLPVTMLTACYSLICHEICKNLKVKTQAWRVG\nGGGWRTWDRPSPSTLAATTRGLPSRVSSINTISRAKIRTVKMTFVIVLAYIACWAPFFSV\nQMWSVWDKNAPDEDSTNVAFTISMLLGNLNSCCNPWIYMGFNSHLLPRPLRHLACCGGPQ\nPRMRRRLSDGSLSSRHTTLLTRSSCPATLSLSLSLTLSGRPRPEESPRDLELADGEGTAE\nTIIF'], 'gene-sequence': ['>lcl|BSEQ0010548|Vasopressin V1b receptor (AVPR1B)\nATGGATTCTGGGCCTCTGTGGGATGCCAACCCCACCCCTCGGGGCACCCTCTCTGCCCCC\nAATGCCACAACACCCTGGCTGGGCCGGGATGAGGAGCTGGCCAAGGTGGAGATCGGAGTC\nCTGGCCACTGTCCTGGTGCTGGCGACCGGGGGCAACCTGGCTGTGCTGCTGACCCTGGGC\nCAGCTGGGCCGCAAGCGCTCCCGCATGCACCTGTTCGTGCTGCACTTAGCCCTGACAGAC\nCTGGCCGTGGCGCTCTTCCAGGTGCTGCCACAGCTGCTGTGGGACATCACCTACCGCTTC\nCAGGGCCCCGACCTCCTGTGCAGGGCCGTCAAGTACCTGCAGGTGCTCAGCATGTTTGCC\nTCCACCTACATGCTGCTGGCCATGACGCTGGACCGCTACCTGGCTGTCTGTCACCCCCTG\nCGCAGCCTCCAGCAGCCAGGCCAGTCCACCTACCTGCTCATCGCTGCTCCCTGGCTGCTG\nGCCGCCATCTTCAGCCTCCCTCAAGTCTTCATTTTTTCCCTGCGGGAGGTGATCCAGGGC\nTCAGGGGTGCTGGACTGCTGGGCAGACTTCGGCTTCCCTTGGGGGCCACGGGCCTACCTC\nACCTGGACCACCCTGGCTATCTTCGTTCTGCCGGTGACCATGCTCACGGCCTGCTACAGC\nCTCATCTGCCATGAGATCTGTAAAAACCTAAAAGTCAAGACACAGGCCTGGCGGGTGGGA\nGGAGGGGGCTGGAGGACTTGGGACAGGCCCTCACCTTCCACCTTAGCTGCCACCACTCGG\nGGGCTGCCATCTCGGGTCAGCAGCATCAACACCATCTCACGGGCCAAGATCCGAACAGTG\nAAGATGACCTTTGTCATCGTGCTGGCCTACATCGCTTGCTGGGCTCCCTTCTTCAGTGTC\nCAGATGTGGTCCGTGTGGGACAAGAATGCCCCTGATGAAGATTCCACCAATGTGGCTTTC\nACCATCTCTATGCTTTTGGGCAACCTCAACAGCTGCTGCAACCCCTGGATCTACATGGGC\nTTCAACAGCCACCTGTTACCGCGGCCCCTGCGTCACCTTGCCTGCTGTGGGGGTCCCCAG\nCCCAGGATGCGCCGGCGGCTCTCCGACGGCAGCCTCTCGAGCCGCCACACCACGCTGCTG\nACCCGCTCCAGCTGCCCGGCCACCCTCAGCCTCAGCCTCAGCCTAACCCTCAGTGGGAGG\nCCCAGGCCTGAAGAGTCACCAAGGGACTTGGAGCTGGCAGATGGGGAAGGCACCGCTGAG\nACCATCATCTTTTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}, {'identifier': ['PF08983'], 'name': ['DUF1856']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['peptide binding']}, {'category': ['function'], 'description': ['protein kinase C binding']}, {'category': ['function'], 'description': ['vasopressin receptor activity']}, {'category': ['process'], 'description': ['activation of phospholipase C activity']}, {'category': ['process'], 'description': ['cellular response to hormone stimulus']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of cytosolic calcium ion concentration']}, {'category': ['process'], 'description': ['positive regulation of vasoconstriction']}, {'category': ['process'], 'description': ['regulation of systemic arterial blood pressure by vasopressin']}, {'category': ['process'], 'description': ['response to peptide']}]}]}]}, {'id': ['BE0000844'], 'name': ['Oxytocin receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A228013'], 'pubmed-id': ['24621650'], 'citation': ['Pelletier JS, Dicken B, Bigam D, Cheung PY: Cardiac effects of vasopressin. J Cardiovasc Pharmacol. 2014 Jul;64(1):100-7. doi: 10.1097/FJC.0000000000000092.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Oxytocin receptor'], 'general-function': ['Vasopressin receptor activity'], 'specific-function': ['Receptor for oxytocin. The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system.'], 'gene-name': ['OXTR'], 'locus': ['3p25'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['39-63\n75-97\n114-135\n155-175\n203-225\n276-294\n310-332'], 'signal-regions': [None], 'theoretical-pi': ['9.88'], 'molecular-weight': ['42770.99'], 'chromosome-location': ['3'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:8529']}, {'resource': ['GenAtlas'], 'identifier': ['OXTR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X64878']}, {'resource': ['GenBank Protein Database'], 'identifier': ['34765']}, {'resource': ['IUPHAR'], 'identifier': ['369']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['369']}, {'resource': ['UniProtKB'], 'identifier': ['P30559']}, {'resource': ['UniProt Accession'], 'identifier': ['OXYR_HUMAN']}]}], 'synonyms': [{'synonym': ['OT-R']}], 'amino-acid-sequence': ['>lcl|BSEQ0010596|Oxytocin receptor\nMEGALAANWSAEAANASAAPPGAEGNRTAGPPRRNEALARVEVAVLCLILLLALSGNACV\nLLALRTTRQKHSRLFFFMKHLSIADLVVAVFQVLPQLLWDITFRFYGPDLLCRLVKYLQV\nVGMFASTYLLLLMSLDRCLAICQPLRSLRRRTDRLAVLATWLGCLVASAPQVHIFSLREV\nADGVFDCWAVFIQPWGPKAYITWITLAVYIVPVIVLAACYGLISFKIWQNLRLKTAAAAA\nAEAPEGAAAGDGGRVALARVSSVKLISKAKIRTVKMTFIIVLAFIVCWTPFFFVQMWSVW\nDANAPKEASAFIIVMLLASLNSCCNPWIYMLFTGHLFHELVQRFLCCSASYLKGRRLGET\nSASKKSNSSSFVLSHRSSSQRSCSQPSTA'], 'gene-sequence': ['>lcl|BSEQ0010597|Oxytocin receptor (OXTR)\nATGGAGGGCGCGCTCGCAGCCAACTGGAGCGCCGAGGCAGCCAACGCCAGCGCCGCGCCG\nCCGGGGGCCGAGGGCAACCGCACCGCCGGACCCCCGCGGCGCAACGAGGCCCTGGCGCGC\nGTGGAGGTGGCGGTGCTGTGTCTCATCCTGCTCCTGGCGCTGAGCGGGAACGCGTGTGTG\nCTGCTGGCGCTGCGCACCACACGCCAGAAGCACTCGCGCCTCTTCTTCTTCATGAAGCAC\nCTAAGCATCGCCGACCTGGTGGTGGCAGTGTTTCAGGTGCTGCCGCAGTTGCTGTGGGAC\nATCACCTTCCGCTTCTACGGGCCCGACCTGCTGTGCCGCCTGGTCAAGTACTTGCAGGTG\nGTGGGCATGTTCGCCTCCACCTACCTGCTGCTGCTCATGTCCCTGGACCGCTGCCTGGCC\nATCTGCCAGCCGCTGCGCTCGCTGCGCCGCCGCACCGACCGCCTGGCAGTGCTCGCCACG\nTGGCTCGGCTGCCTGGTGGCCAGCGCGCCGCAGGTGCACATCTTCTCTCTGCGCGAGGTG\nGCTGACGGCGTCTTCGACTGCTGGGCCGTCTTCATCCAGCCCTGGGGACCCAAGGCCTAC\nATCACATGGATCACGCTAGCTGTCTACATCGTGCCGGTCATCGTGCTCGCTGCCTGCTAC\nGGCCTTATCAGCTTCAAGATCTGGCAGAACTTGCGGCTCAAGACCGCTGCAGCGGCGGCG\nGCCGAGGCGCCAGAGGGCGCGGCGGCTGGCGATGGGGGGCGCGTGGCCCTGGCGCGTGTC\nAGCAGCGTCAAGCTCATCTCCAAGGCCAAGATCCGCACGGTCAAGATGACTTTCATCATC\nGTGCTGGCCTTCATCGTGTGCTGGACGCCTTTCTTCTTCGTGCAGATGTGGAGCGTCTGG\nGATGCCAACGCGCCCAAGGAAGCCTCGGCCTTCATCATCGTCATGCTCCTGGCCAGCCTC\nAACAGCTGCTGCAACCCCTGGATCTACATGCTGTTCACGGGCCACCTCTTCCACGAACTC\nGTGCAGCGCTTCCTGTGCTGCTCCGCCAGCTACCTGAAGGGCAGACGCCTGGGAGAGACG\nAGTGCCAGCAAAAAGAGCAACTCGTCCTCCTTTGTCCTGAGCCATCGCAGCTCCAGCCAG\nAGGAGCTGCTCCCAGCCATCCACGGCGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['apical plasma membrane']}, {'category': ['component'], 'description': ['cell-cell adherens junction']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['microvillus']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['oxytocin receptor activity']}, {'category': ['function'], 'description': ['peptide binding']}, {'category': ['function'], 'description': ['peptide hormone binding']}, {'category': ['function'], 'description': ['vasopressin receptor activity']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular response to hormone stimulus']}, {'category': ['process'], 'description': ['digestive tract development']}, {'category': ['process'], 'description': ['eating behavior']}, {'category': ['process'], 'description': ['ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['estrous cycle']}, {'category': ['process'], 'description': ['female pregnancy']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['heart development']}, {'category': ['process'], 'description': ['lactation']}, {'category': ['process'], 'description': ['maternal behavior']}, {'category': ['process'], 'description': ['maternal process involved in parturition']}, {'category': ['process'], 'description': ['memory']}, {'category': ['process'], 'description': ['muscle contraction']}, {'category': ['process'], 'description': ['negative regulation of gastric acid secretion']}, {'category': ['process'], 'description': ['positive regulation of blood pressure']}, {'category': ['process'], 'description': ['positive regulation of cytosolic calcium ion concentration']}, {'category': ['process'], 'description': ['positive regulation of norepinephrine secretion']}, {'category': ['process'], 'description': ['positive regulation of penile erection']}, {'category': ['process'], 'description': ['positive regulation of synapse assembly']}, {'category': ['process'], 'description': ['positive regulation of synaptic transmission, GABAergic']}, {'category': ['process'], 'description': ['positive regulation of synaptic transmission, glutamatergic']}, {'category': ['process'], 'description': ['positive regulation of uterine smooth muscle contraction']}, {'category': ['process'], 'description': ['positive regulation of vasoconstriction']}, {'category': ['process'], 'description': ['regulation of systemic arterial blood pressure by vasopressin']}, {'category': ['process'], 'description': ['response to amphetamine']}, {'category': ['process'], 'description': ['response to anoxia']}, {'category': ['process'], 'description': ['response to cocaine']}, {'category': ['process'], 'description': ['response to cytokine']}, {'category': ['process'], 'description': ['response to drug']}, {'category': ['process'], 'description': ['response to estradiol']}, {'category': ['process'], 'description': ['response to peptide']}, {'category': ['process'], 'description': ['response to peptide hormone']}, {'category': ['process'], 'description': ['response to progesterone']}, {'category': ['process'], 'description': ['sleep']}, {'category': ['process'], 'description': ['social behavior']}, {'category': ['process'], 'description': ['sperm ejaculation']}, {'category': ['process'], 'description': ['suckling behavior']}, {'category': ['process'], 'description': ['telencephalon development']}]}]}]}]}]"
"['DB00068', 'BTD00078', 'BIOD00078']",['Interferon beta-1b'],biotech,"['Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD']",['liquid'],['Interferon beta-1b is a drug used for the treatment of relapsing/remitting multiple sclerosis. It has been shown to slow the advance of the disease as well as to decrease the frequency of attacks.'],['Interferon beta binds to type I interferon receptors (IFNAR1 and IFNAR2c) which activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon beta binds more stably to type I interferon receptors than interferon alpha.'],"[{'food-interaction': ['Avoid excessive or chronic alcohol consumption. Alcohol and Interferon beta-1 can both cause hepatoxicity, therefore if they are used together they may have additive hepatoxic effects.']}]","[{'target': [{'id': ['BE0000661'], 'name': ['Interferon alpha/beta receptor 1'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A14065'], 'pubmed-id': ['10049744'], 'citation': ['Russell-Harde D, Wagner TC, Perez HD, Croze E: Formation of a uniquely stable type I interferon receptor complex by interferon beta is dependent upon particular interactions between interferon beta and its receptor and independent of tyrosine phosphorylation. Biochem Biophys Res Commun. 1999 Feb 16;255(2):539-44.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interferon alpha/beta receptor 1'], 'general-function': ['Type i interferon receptor activity'], 'specific-function': ['Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.'], 'gene-name': ['IFNAR1'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['437-457'], 'signal-regions': ['1-27'], 'theoretical-pi': ['5.56'], 'molecular-weight': ['63524.81'], 'chromosome-location': ['21'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5432']}, {'resource': ['GenAtlas'], 'identifier': ['IFNAR1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['J03171']}, {'resource': ['GenBank Protein Database'], 'identifier': ['306914']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1723']}, {'resource': ['UniProtKB'], 'identifier': ['P17181']}, {'resource': ['UniProt Accession'], 'identifier': ['INAR1_HUMAN']}]}], 'synonyms': [{'synonym': ['CRF2-1', 'Cytokine receptor class-II member 1', 'Cytokine receptor family 2 member 1', 'IFN-R-1', 'IFNAR', 'Type I interferon receptor 1']}], 'amino-acid-sequence': ['>lcl|BSEQ0001318|Interferon alpha/beta receptor 1\nMMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT\nFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF\nTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI\nENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ\nNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK\nGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP\nVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV\nFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE\nYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN\nEDESESKTSEELQQDFV'], 'gene-sequence': ['>lcl|BSEQ0018987|Interferon alpha/beta receptor 1 (IFNAR1)\nATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTG\nTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC\nATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT\nTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG\nAATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT\nAAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT\nACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG\nGCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT\nTTAAGCTTTACATATAGCTTAGTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT\nGAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA\nAAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT\nATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA\nAATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG\nTGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA\nCCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA\nGGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA\nGAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA\nTCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT\nGTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT\nGAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT\nGTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT\nTTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA\nGTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC\nTTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG\nTATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA\nAAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT\nGATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT\nGAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA'], 'pfams': [{'pfam': [{'identifier': ['PF01108'], 'name': ['Tissue_fac']}, {'identifier': ['PF09294'], 'name': ['Interfer-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['type I interferon receptor activity']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['defense response to virus']}, {'category': ['process'], 'description': ['JAK-STAT cascade']}, {'category': ['process'], 'description': ['positive regulation of interferon-beta production']}, {'category': ['process'], 'description': ['positive regulation of interferon-gamma production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-1 beta secretion']}, {'category': ['process'], 'description': ['positive regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['regulation of type I interferon-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['T cell activation']}, {'category': ['process'], 'description': ['type I interferon biosynthetic process']}, {'category': ['process'], 'description': ['type I interferon signaling pathway']}]}]}]}, {'id': ['BE0000385'], 'name': ['Interferon alpha/beta receptor 2'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A14065'], 'pubmed-id': ['10049744'], 'citation': ['Russell-Harde D, Wagner TC, Perez HD, Croze E: Formation of a uniquely stable type I interferon receptor complex by interferon beta is dependent upon particular interactions between interferon beta and its receptor and independent of tyrosine phosphorylation. Biochem Biophys Res Commun. 1999 Feb 16;255(2):539-44.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interferon alpha/beta receptor 2'], 'general-function': ['Type i interferon receptor activity'], 'specific-function': ['Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.'], 'gene-name': ['IFNAR2'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['244-264'], 'signal-regions': ['1-26'], 'theoretical-pi': ['4.11'], 'molecular-weight': ['57758.24'], 'chromosome-location': ['21'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5433']}, {'resource': ['GenAtlas'], 'identifier': ['IFNAR2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L42243']}, {'resource': ['GenBank Protein Database'], 'identifier': ['995300']}, {'resource': ['UniProtKB'], 'identifier': ['P48551']}, {'resource': ['UniProt Accession'], 'identifier': ['INAR2_HUMAN']}]}], 'synonyms': [{'synonym': ['IFN-R-2', 'IFNABR', 'IFNARB', 'Interferon alpha binding protein', 'Type I interferon receptor 2']}], 'amino-acid-sequence': ['>lcl|BSEQ0000767|Interferon alpha/beta receptor 2\nMLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS\nIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF\nSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK\nHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE\nSAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD\nMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI\nDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR\nITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT\nFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR'], 'gene-sequence': ['>lcl|BSEQ0018941|Interferon alpha/beta receptor 2 (IFNAR2)\nATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT\nATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT\nTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC\nATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG\nGTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA\nAGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC\nAGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG\nATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA\nGAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG\nCATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA\nATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA\nATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA\nTCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC\nATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG\nAGGCAAGGTCTCGCTAAGGGCTGGAATGCAGTGGCTATTCACAGGTGCAGTCATAATGCA\nCTACAGTCTGAAACTCCTGAGCTCAAACAGTCGTCCTGCCTAAGCTTCCCCAGTAGCTGG\nGATTACAAGCGTGCATCCCTGTGCCCCAGTGATTAA'], 'pfams': [{'pfam': [{'identifier': ['PF01108'], 'name': ['Tissue_fac']}, {'identifier': ['PF09294'], 'name': ['Interfer-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['protein kinase binding']}, {'category': ['function'], 'description': ['type I interferon binding']}, {'category': ['function'], 'description': ['type I interferon receptor activity']}, {'category': ['process'], 'description': ['cell proliferation']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['JAK-STAT cascade']}, {'category': ['process'], 'description': ['regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['regulation of type I interferon-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to interferon-alpha']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['type I interferon signaling pathway']}]}]}]}]}]"
"['DB00069', 'BTD00062', 'BIOD00062']",['Interferon alfacon-1'],biotech,"['Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional amino acid changes were made to facilitate the molecular construction, and a corresponding synthetic DNA sequence was constructed using chemical synthesis methodology. Interferon alfacon-1 differs from interferon alfa-2b at 20/166 amino acids (88% homology), and comparison with interferon-beta shows identity at over 30% of the amino acid positions. Interferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1. Prior to final purification, Interferon alfacon-1 is allowed to oxidize to its native state, and its final purity is achieved by sequential passage over a series of chromatography columns. This protein has a molecular weight of 19,434 daltons.']",['liquid'],"[""For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma""]","['Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta. The resulting actions include gene transcription, inhibition of cellular growth, alteration of the state of cellular differentiation, interference with oncogene expression, alteration of cell surface antigen expression, increasing phagocytic activity of macrophages, and augmentation of the cytotoxicity of lymphocytes for target cells.']",[None],"[{'target': [{'id': ['BE0000661'], 'name': ['Interferon alpha/beta receptor 1'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A2033'], 'pubmed-id': ['12528473'], 'citation': ['Yasuda S, Miyata K: [Interferon alfacon-1 (Advaferon): a novel synthetic interferon for the treatment of hepatitis C, its pharmacological and clinical profile]. Nihon Yakurigaku Zasshi. 2002 Dec;120(6):421-6.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interferon alpha/beta receptor 1'], 'general-function': ['Type i interferon receptor activity'], 'specific-function': ['Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.'], 'gene-name': ['IFNAR1'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['437-457'], 'signal-regions': ['1-27'], 'theoretical-pi': ['5.56'], 'molecular-weight': ['63524.81'], 'chromosome-location': ['21'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5432']}, {'resource': ['GenAtlas'], 'identifier': ['IFNAR1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['J03171']}, {'resource': ['GenBank Protein Database'], 'identifier': ['306914']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1723']}, {'resource': ['UniProtKB'], 'identifier': ['P17181']}, {'resource': ['UniProt Accession'], 'identifier': ['INAR1_HUMAN']}]}], 'synonyms': [{'synonym': ['CRF2-1', 'Cytokine receptor class-II member 1', 'Cytokine receptor family 2 member 1', 'IFN-R-1', 'IFNAR', 'Type I interferon receptor 1']}], 'amino-acid-sequence': ['>lcl|BSEQ0001318|Interferon alpha/beta receptor 1\nMMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT\nFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF\nTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI\nENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ\nNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK\nGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP\nVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV\nFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE\nYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN\nEDESESKTSEELQQDFV'], 'gene-sequence': ['>lcl|BSEQ0018987|Interferon alpha/beta receptor 1 (IFNAR1)\nATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTG\nTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC\nATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT\nTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG\nAATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT\nAAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT\nACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG\nGCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT\nTTAAGCTTTACATATAGCTTAGTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT\nGAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA\nAAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT\nATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA\nAATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG\nTGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA\nCCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA\nGGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA\nGAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA\nTCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT\nGTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT\nGAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT\nGTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT\nTTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA\nGTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC\nTTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG\nTATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA\nAAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT\nGATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT\nGAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA'], 'pfams': [{'pfam': [{'identifier': ['PF01108'], 'name': ['Tissue_fac']}, {'identifier': ['PF09294'], 'name': ['Interfer-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['type I interferon receptor activity']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['defense response to virus']}, {'category': ['process'], 'description': ['JAK-STAT cascade']}, {'category': ['process'], 'description': ['positive regulation of interferon-beta production']}, {'category': ['process'], 'description': ['positive regulation of interferon-gamma production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-1 beta secretion']}, {'category': ['process'], 'description': ['positive regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['regulation of type I interferon-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['T cell activation']}, {'category': ['process'], 'description': ['type I interferon biosynthetic process']}, {'category': ['process'], 'description': ['type I interferon signaling pathway']}]}]}]}, {'id': ['BE0000385'], 'name': ['Interferon alpha/beta receptor 2'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A116'], 'pubmed-id': ['8836913'], 'citation': ['Blatt LM, Davis JM, Klein SB, Taylor MW: The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res. 1996 Jul;16(7):489-99.']}, {'ref-id': ['A2033'], 'pubmed-id': ['12528473'], 'citation': ['Yasuda S, Miyata K: [Interferon alfacon-1 (Advaferon): a novel synthetic interferon for the treatment of hepatitis C, its pharmacological and clinical profile]. Nihon Yakurigaku Zasshi. 2002 Dec;120(6):421-6.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interferon alpha/beta receptor 2'], 'general-function': ['Type i interferon receptor activity'], 'specific-function': ['Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.'], 'gene-name': ['IFNAR2'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['244-264'], 'signal-regions': ['1-26'], 'theoretical-pi': ['4.11'], 'molecular-weight': ['57758.24'], 'chromosome-location': ['21'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5433']}, {'resource': ['GenAtlas'], 'identifier': ['IFNAR2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L42243']}, {'resource': ['GenBank Protein Database'], 'identifier': ['995300']}, {'resource': ['UniProtKB'], 'identifier': ['P48551']}, {'resource': ['UniProt Accession'], 'identifier': ['INAR2_HUMAN']}]}], 'synonyms': [{'synonym': ['IFN-R-2', 'IFNABR', 'IFNARB', 'Interferon alpha binding protein', 'Type I interferon receptor 2']}], 'amino-acid-sequence': ['>lcl|BSEQ0000767|Interferon alpha/beta receptor 2\nMLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS\nIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF\nSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK\nHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE\nSAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD\nMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI\nDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR\nITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT\nFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR'], 'gene-sequence': ['>lcl|BSEQ0018941|Interferon alpha/beta receptor 2 (IFNAR2)\nATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT\nATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT\nTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC\nATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG\nGTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA\nAGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC\nAGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG\nATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA\nGAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG\nCATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA\nATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA\nATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA\nTCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC\nATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG\nAGGCAAGGTCTCGCTAAGGGCTGGAATGCAGTGGCTATTCACAGGTGCAGTCATAATGCA\nCTACAGTCTGAAACTCCTGAGCTCAAACAGTCGTCCTGCCTAAGCTTCCCCAGTAGCTGG\nGATTACAAGCGTGCATCCCTGTGCCCCAGTGATTAA'], 'pfams': [{'pfam': [{'identifier': ['PF01108'], 'name': ['Tissue_fac']}, {'identifier': ['PF09294'], 'name': ['Interfer-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['protein kinase binding']}, {'category': ['function'], 'description': ['type I interferon binding']}, {'category': ['function'], 'description': ['type I interferon receptor activity']}, {'category': ['process'], 'description': ['cell proliferation']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['JAK-STAT cascade']}, {'category': ['process'], 'description': ['regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['regulation of type I interferon-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to interferon-alpha']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['type I interferon signaling pathway']}]}]}]}]}]"
"['DB00070', 'BTD00022', 'BIOD00022']",['Hyaluronidase (ovine)'],biotech,['Highly purified sheep hyaluronidase for administration by injection into the vitreous of the eye.'],['liquid'],['For increase of absorption and distribution of other injected drugs and for rehydration.'],"['Hyaluronidase is a spreading or diffusing substance. It increase the permeability of connective tissue through the hydrolysis of hyaluronic acid. Hyaluronidase hydrolyzes hyaluronic acid by splitting the glucosaminidic bond between C1 of the glucosamine moiety and C4 of glucuronic acid. This temporarily decreases the viscosity of the cellular cement and increases diffusion of injected fluids or of localized transudates or exudates, thus facilitating their absorption.']",[None],"[{'target': [{'id': ['BE0004821'], 'name': ['Hyaluronan'], 'organism': ['Humans'], 'actions': [{'action': ['other']}], 'references': [{'articles': [None], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes']}, {'id': ['BE0000984'], 'name': ['Transforming growth factor beta-1'], 'organism': ['Humans'], 'actions': [{'action': ['inhibitor']}], 'references': [{'articles': [{'article': [{'ref-id': ['A11623'], 'pubmed-id': ['11327694'], 'citation': ['Chang NS: Hyaluronidase activation of c-Jun N-terminal kinase is necessary for protection of L929 fibrosarcoma cells from staurosporine-mediated cell death. Biochem Biophys Res Commun. 2001 May 4;283(2):278-86.']}, {'ref-id': ['A11624'], 'pubmed-id': ['7648625'], 'citation': ['Locci P, Marinucci L, Lilli C, Martinese D, Becchetti E: Transforming growth factor beta 1-hyaluronic acid interaction. Cell Tissue Res. 1995 Aug;281(2):317-24.']}, {'ref-id': ['A11625'], 'pubmed-id': ['9435505'], 'citation': ['Chang NS: Hyaluronidase enhancement of TNF-mediated cell death is reversed by TGF-beta 1. Am J Physiol. 1997 Dec;273(6 Pt 1):C1987-94.']}, {'ref-id': ['A11626'], 'pubmed-id': ['9850732'], 'citation': ['Chang NS: Transforming growth factor-beta protection of cancer cells against tumor necrosis factor cytotoxicity is counteracted by hyaluronidase (review). Int J Mol Med. 1998 Dec;2(6):653-9.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Transforming growth factor beta-1'], 'general-function': ['Type iii transforming growth factor beta receptor binding'], 'specific-function': ['Multifunctional protein that controls proliferation, differentiation and other functions in many cell types. Many cells synthesize TGFB1 and have specific receptors for it. It positively and negatively regulates many other growth factors. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. Can promote either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. At high concentrations, leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression, favoring Treg cell development. At low concentrations in concert with IL-6 and IL-21, leads to expression of the IL-17 and IL-23 receptors, favoring differentiation to Th17 cells.'], 'gene-name': ['TGFB1'], 'locus': ['19q13.2|19q13.1'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-29'], 'theoretical-pi': ['8.63'], 'molecular-weight': ['44340.685'], 'chromosome-location': ['19'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:11766']}, {'resource': ['GenAtlas'], 'identifier': ['TGFB1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X05839']}, {'resource': ['GenBank Protein Database'], 'identifier': ['1212989']}, {'resource': ['UniProtKB'], 'identifier': ['P01137']}, {'resource': ['UniProt Accession'], 'identifier': ['TGFB1_HUMAN']}]}], 'synonyms': [{'synonym': ['TGF-beta-1', 'TGFB']}], 'amino-acid-sequence': ['>lcl|BSEQ0021834|Transforming growth factor beta-1\nMPPSGLRLLLLLLPLLWLLVLTPGRPAAGLSTCKTIDMELVKRKRIEAIRGQILSKLRLA\nSPPSQGEVPPGPLPEAVLALYNSTRDRVAGESAEPEPEPEADYYAKEVTRVLMVETHNEI\nYDKFKQSTHSIYMFFNTSELREAVPEPVLLSRAELRLLRLKLKVEQHVELYQKYSNNSWR\nYLSNRLLAPSDSPEWLSFDVTGVVRQWLSRGGEIEGFRLSAHCSCDSRDNTLQVDINGFT\nTGRRGDLATIHGMNRPFLLLMATPLERAQHLQSSRHRRALDTNYCFSSTEKNCCVRQLYI\nDFRKDLGWKWIHEPKGYHANFCLGPCPYIWSLDTQYSKVLALYNQHNPGASAAPCCVPQA\nLEPLPIVYYVGRKPKVEQLSNMIVRSCKCS'], 'gene-sequence': ['>lcl|BSEQ0021835|Transforming growth factor beta-1 (TGFB1)\nATGCCGCCCTCCGGGCTGCGGCTGCTGCCGCTGCTGCTACCGCTGCTGTGGCTACTGGTG\nCTGACGCCTGGCCGGCCGGCCGCGGGACTATCCACCTGCAAGACTATCGACATGGAGCTG\nGTGAAGCGGAAGCGCATCGAGGCCATCCGCGGCCAGATCCTGTCCAAGCTGCGGCTCGCC\nAGCCCCCCGAGCCAGGGGGAGGTGCCGCCCGGCCCGCTGCCCGAGGCCGTGCTCGCCCTG\nTACAACAGCACCCGCGACCGGGTGGCCGGGGAGAGTGCAGAACCGGAGCCCGAGCCTGAG\nGCCGACTACTACGCCAAGGAGGTCACCCGCGTGCTAATGGTGGAAACCCACAACGAAATC\nTATGACAAGTTCAAGCAGAGTACACACAGCATATATATGTTCTTCAACACATCAGAGCTC\nCGAGAAGCGGTACCTGAACCCGTGTTGCTCTCCCGGGCAGAGCTGCGTCTGCTGAGGCTC\nAAGTTAAAAGTGGAGCAGCACGTGGAGCTGTACCAGAAATACAGCAACAATTCCTGGCGA\nTACCTCAGCAACCGGCTGCTGGCACCCAGCGACTCGCCAGAGTGGTTATCTTTTGATGTC\nACCGGAGTTGTGCGGCAGTGGTTGAGCCGTGGAGGGGAAATTGAGGGCTTTCGCCTTAGC\nGCCCACTGCTCCTGTGACAGCAGGGATAACACACTGCAAGTGGACATCAACGGGTTCACT\nACCGGCCGCCGAGGTGACCTGGCCACCATTCATGGCATGAACCGGCCTTTCCTGCTTCTC\nATGGCCACCCCGCTGGAGAGGGCCCAGCATCTGCAAAGCTCCCGGCACCGCCGAGCCCTG\nGACACCAACTATTGCTTCAGCTCCACGGAGAAGAACTGCTGCGTGCGGCAGCTGTACATT\nGACTTCCGCAAGGACCTCGGCTGGAAGTGGATCCACGAGCCCAAGGGCTACCATGCCAAC\nTTCTGCCTCGGGCCCTGCCCCTACATTTGGAGCCTGGACACGCAGTACAGCAAGGTCCTG\nGCCCTGTACAACCAGCATAACCCGGGCGCCTCGGCGGCGCCGTGCTGCGTGCCGCAGGCG\nCTGGAGCCGCTGCCCATCGTGTACTACGTGGGCCGCAAGCCCAAGGTGGAGCAGCTGTCC\nAACATGATCGTGCGCTCCTGCAAGTGCAGCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00019'], 'name': ['TGF_beta']}, {'identifier': ['PF00688'], 'name': ['TGFb_propeptide']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['axon']}, {'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['Golgi lumen']}, {'category': ['component'], 'description': ['neuronal cell body']}, {'category': ['component'], 'description': ['nucleus']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['component'], 'description': ['proteinaceous extracellular matrix']}, {'category': ['function'], 'description': ['antigen binding']}, {'category': ['function'], 'description': ['cytokine activity']}, {'category': ['function'], 'description': ['enzyme binding']}, {'category': ['function'], 'description': ['glycoprotein binding']}, {'category': ['function'], 'description': ['type I transforming growth factor beta receptor binding']}, {'category': ['function'], 'description': ['type II transforming growth factor beta receptor binding']}, {'category': ['function'], 'description': ['type III transforming growth factor beta receptor binding']}, {'category': ['process'], 'description': ['active induction of host immune response by virus']}, {'category': ['process'], 'description': ['adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains']}, {'category': ['process'], 'description': ['aging']}, {'category': ['process'], 'description': ['ATP biosynthetic process']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['branch elongation involved in mammary gland duct branching']}, {'category': ['process'], 'description': ['cell cycle arrest']}, {'category': ['process'], 'description': ['cell development']}, {'category': ['process'], 'description': ['cell growth']}, {'category': ['process'], 'description': ['cell-cell junction organization']}, {'category': ['process'], 'description': ['cellular calcium ion homeostasis']}, {'category': ['process'], 'description': ['cellular response to dexamethasone stimulus']}, {'category': ['process'], 'description': ['cellular response to organic cyclic compound']}, {'category': ['process'], 'description': ['cellular response to transforming growth factor beta stimulus']}, {'category': ['process'], 'description': ['chondrocyte differentiation']}, {'category': ['process'], 'description': ['common-partner SMAD protein phosphorylation']}, {'category': ['process'], 'description': ['connective tissue replacement involved in inflammatory response wound healing']}, {'category': ['process'], 'description': ['defense response to fungus, incompatible interaction']}, {'category': ['process'], 'description': ['digestive tract development']}, {'category': ['process'], 'description': ['endoderm development']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['epithelial to mesenchymal transition']}, {'category': ['process'], 'description': ['evasion or tolerance of host defenses by virus']}, {'category': ['process'], 'description': ['extracellular matrix assembly']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['extrinsic apoptotic signaling pathway']}, {'category': ['process'], 'description': ['face morphogenesis']}, {'category': ['process'], 'description': ['female pregnancy']}, {'category': ['process'], 'description': ['frontal suture morphogenesis']}, {'category': ['process'], 'description': ['germ cell migration']}, {'category': ['process'], 'description': ['hematopoietic progenitor cell differentiation']}, {'category': ['process'], 'description': ['hyaluronan catabolic process']}, {'category': ['process'], 'description': ['inflammatory response']}, {'category': ['process'], 'description': ['inner ear development']}, {'category': ['process'], 'description': ['lens fiber cell differentiation']}, {'category': ['process'], 'description': ['lipopolysaccharide-mediated signaling pathway']}, {'category': ['process'], 'description': ['lymph node development']}, {'category': ['process'], 'description': ['macrophage derived foam cell differentiation']}, {'category': ['process'], 'description': ['mammary gland branching involved in thelarche']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['mitotic cell cycle checkpoint']}, {'category': ['process'], 'description': ['modulation by virus of host morphology or physiology']}, {'category': ['process'], 'description': ['mononuclear cell proliferation']}, {'category': ['process'], 'description': ['myelination']}, {'category': ['process'], 'description': ['myeloid dendritic cell differentiation']}, {'category': ['process'], 'description': ['negative regulation of blood vessel endothelial cell migration']}, {'category': ['process'], 'description': ['negative regulation of cell cycle']}, {'category': ['process'], 'description': ['negative regulation of cell differentiation']}, {'category': ['process'], 'description': ['negative regulation of cell growth']}, {'category': ['process'], 'description': ['negative regulation of cell proliferation']}, {'category': ['process'], 'description': ['negative regulation of cell-cell adhesion']}, {'category': ['process'], 'description': ['negative regulation of DNA replication']}, {'category': ['process'], 'description': ['negative regulation of epithelial cell proliferation']}, {'category': ['process'], 'description': ['negative regulation of extracellular matrix disassembly']}, {'category': ['process'], 'description': ['negative regulation of fat cell differentiation']}, {'category': ['process'], 'description': ['negative regulation of gene expression']}, {'category': ['process'], 'description': ['negative regulation of gene silencing by miRNA']}, {'category': ['process'], 'description': ['negative regulation of hyaluronan biosynthetic process']}, {'category': ['process'], 'description': ['negative regulation of interleukin-17 production']}, {'category': ['process'], 'description': ['negative regulation of macrophage cytokine production']}, {'category': ['process'], 'description': ['negative regulation of mitotic cell cycle']}, {'category': ['process'], 'description': ['negative regulation of myoblast differentiation']}, {'category': ['process'], 'description': ['negative regulation of neuroblast proliferation']}, {'category': ['process'], 'description': ['negative regulation of ossification']}, {'category': ['process'], 'description': ['negative regulation of phagocytosis']}, {'category': ['process'], 'description': ['negative regulation of protein localization to plasma membrane']}, {'category': ['process'], 'description': ['negative regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['negative regulation of release of sequestered calcium ion into cytosol']}, {'category': ['process'], 'description': ['negative regulation of skeletal muscle tissue development']}, {'category': ['process'], 'description': ['negative regulation of T cell proliferation']}, {'category': ['process'], 'description': ['negative regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['negative regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['negative regulation of transforming growth factor beta receptor signaling pathway']}, {'category': ['process'], 'description': ['Notch signaling pathway']}, {'category': ['process'], 'description': ['oligodendrocyte development']}, {'category': ['process'], 'description': ['organ regeneration']}, {'category': ['process'], 'description': ['ossification involved in bone remodeling']}, {'category': ['process'], 'description': ['pathway-restricted SMAD protein phosphorylation']}, {'category': ['process'], 'description': ['phosphate-containing compound metabolic process']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of apoptotic process']}, {'category': ['process'], 'description': ['positive regulation of blood vessel endothelial cell migration']}, {'category': ['process'], 'description': ['positive regulation of bone mineralization']}, {'category': ['process'], 'description': ['positive regulation of branching involved in ureteric bud morphogenesis']}, {'category': ['process'], 'description': ['positive regulation of cell cycle arrest']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of cellular protein metabolic process']}, {'category': ['process'], 'description': ['positive regulation of chemotaxis']}, {'category': ['process'], 'description': ['positive regulation of collagen biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of epithelial cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of epithelial to mesenchymal transition']}, {'category': ['process'], 'description': ['positive regulation of exit from mitosis']}, {'category': ['process'], 'description': ['positive regulation of extracellular matrix assembly']}, {'category': ['process'], 'description': ['positive regulation of fibroblast migration']}, {'category': ['process'], 'description': ['positive regulation of fibroblast proliferation']}, {'category': ['process'], 'description': ['positive regulation of gene expression']}, {'category': ['process'], 'description': ['positive regulation of histone acetylation']}, {'category': ['process'], 'description': ['positive regulation of histone deacetylation']}, {'category': ['process'], 'description': ['positive regulation of interleukin-17 production']}, {'category': ['process'], 'description': ['positive regulation of isotype switching to IgA isotypes']}, {'category': ['process'], 'description': ['positive regulation of MAP kinase activity']}, {'category': ['process'], 'description': ['positive regulation of NAD+ ADP-ribosyltransferase activity']}, {'category': ['process'], 'description': ['positive regulation of NF-kappaB transcription factor activity']}, {'category': ['process'], 'description': ['positive regulation of odontogenesis']}, {'category': ['process'], 'description': ['positive regulation of pathway-restricted SMAD protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of peptidyl-serine phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of peptidyl-threonine phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of phosphatidylinositol 3-kinase activity']}, {'category': ['process'], 'description': ['positive regulation of protein complex assembly']}, {'category': ['process'], 'description': ['positive regulation of protein dephosphorylation']}, {'category': ['process'], 'description': ['positive regulation of protein import into nucleus']}, {'category': ['process'], 'description': ['positive regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of protein secretion']}, {'category': ['process'], 'description': ['positive regulation of SMAD protein import into nucleus']}, {'category': ['process'], 'description': ['positive regulation of smooth muscle cell differentiation']}, {'category': ['process'], 'description': ['positive regulation of superoxide anion generation']}, {'category': ['process'], 'description': ['positive regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['positive regulation of transcription regulatory region DNA binding']}, {'category': ['process'], 'description': ['positive regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['positive regulation of vascular endothelial growth factor production']}, {'category': ['process'], 'description': ['positive regulation of vascular permeability']}, {'category': ['process'], 'description': ['protein export from nucleus']}, {'category': ['process'], 'description': ['protein import into nucleus, translocation']}, {'category': ['process'], 'description': ['protein kinase B signaling']}, {'category': ['process'], 'description': ['protein phosphorylation']}, {'category': ['process'], 'description': ['receptor catabolic process']}, {'category': ['process'], 'description': ['regulation of actin cytoskeleton reorganization']}, {'category': ['process'], 'description': ['regulation of apoptotic process']}, {'category': ['process'], 'description': ['regulation of binding']}, {'category': ['process'], 'description': ['regulation of blood vessel remodeling']}, {'category': ['process'], 'description': ['regulation of branching involved in mammary gland duct morphogenesis']}, {'category': ['process'], 'description': ['regulation of cartilage development']}, {'category': ['process'], 'description': ['regulation of cell migration']}, {'category': ['process'], 'description': ['regulation of DNA binding']}, {'category': ['process'], 'description': ['regulation of interleukin-23 production']}, {'category': ['process'], 'description': ['regulation of protein import into nucleus']}, {'category': ['process'], 'description': ['regulation of sodium ion transport']}, {'category': ['process'], 'description': ['regulation of striated muscle tissue development']}, {'category': ['process'], 'description': ['regulation of transforming growth factor beta receptor signaling pathway']}, {'category': ['process'], 'description': ['regulatory T cell differentiation']}, {'category': ['process'], 'description': ['response to cholesterol']}, {'category': ['process'], 'description': ['response to drug']}, {'category': ['process'], 'description': ['response to estradiol']}, {'category': ['process'], 'description': ['response to glucose']}, {'category': ['process'], 'description': ['response to hypoxia']}, {'category': ['process'], 'description': ['response to laminar fluid shear stress']}, {'category': ['process'], 'description': ['response to progesterone']}, {'category': ['process'], 'description': ['response to radiation']}, {'category': ['process'], 'description': ['response to vitamin D']}, {'category': ['process'], 'description': ['response to wounding']}, {'category': ['process'], 'description': ['salivary gland morphogenesis']}, {'category': ['process'], 'description': ['SMAD protein complex assembly']}, {'category': ['process'], 'description': ['SMAD protein import into nucleus']}, {'category': ['process'], 'description': ['SMAD protein signal transduction']}, {'category': ['process'], 'description': ['T cell homeostasis']}, {'category': ['process'], 'description': ['tolerance induction to self antigen']}, {'category': ['process'], 'description': ['transforming growth factor beta receptor signaling pathway']}, {'category': ['process'], 'description': ['ureteric bud development']}, {'category': ['process'], 'description': ['viral life cycle']}]}]}]}]}]"
"['DB00071', 'BTD00031', 'BIOD00031']",['Insulin pork'],biotech,"['Insulin isolated from pig pancreas. Composed of alpha and beta chains, processed from pro-insulin. Forms a hexameric structure.']",['liquid'],['For the treatment of type I and II diabetes mellitus.'],"['Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.']","[{'food-interaction': [""Avoid excessive or chronic alcohol consumption. Drinking more than two standard drinks per day in women, or more than 3 standard drinks per day in men, can reduce a patient's insulin requirements, and therefore increase the risk of hypoglycemia if the insulin dosing is not adjusted.""]}]","[{'target': [{'id': ['BE0000033'], 'name': ['Insulin receptor'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1840'], 'pubmed-id': ['12038982'], 'citation': ['Chen LM, Yang XW, Tang JG: Acidic residues on the N-terminus of proinsulin C-Peptide are important for the folding of insulin precursor. J Biochem. 2002 Jun;131(6):855-9.']}, {'ref-id': ['A1839'], 'pubmed-id': ['12970169'], 'citation': ['Desbuquois B, Chauvet G, Kouach M, Authier F: Cell itinerary and metabolic fate of proinsulin in rat liver: in vivo and in vitro studies. Endocrinology. 2003 Dec;144(12):5308-21. Epub 2003 Sep 11.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Insulin receptor'], 'general-function': ['Receptor signaling protein tyrosine kinase activity'], 'specific-function': ['Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosines residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.'], 'gene-name': ['INSR'], 'locus': ['19p13.3-p13.2'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['957-979'], 'signal-regions': ['1-27'], 'theoretical-pi': ['6.18'], 'molecular-weight': ['156331.465'], 'chromosome-location': ['19'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6091']}, {'resource': ['GenAtlas'], 'identifier': ['INSR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M10051']}, {'resource': ['GenBank Protein Database'], 'identifier': ['307070']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1800']}, {'resource': ['UniProtKB'], 'identifier': ['P06213']}, {'resource': ['UniProt Accession'], 'identifier': ['INSR_HUMAN']}]}], 'synonyms': [{'synonym': ['2.7.10.1', 'IR']}], 'amino-acid-sequence': ['>lcl|BSEQ0036940|Insulin receptor\nMATGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHL\nQILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYAL\nVIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNE\nECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECL\nGNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQG\nCHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGC\nTVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETL\nEIGNYSFYALDNQNLRQLWDWSKHNLTITQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQE\nRNDIALKTNGDQASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQ\nNVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFS\nDERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWE\nRQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQIL\nKELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAF\nPNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYV\nSARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCV\nSRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIG\nPLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSR\nEKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKG\nFTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMA\nAEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPV\nRWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDN\nCPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEME\nFEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSN\nPS'], 'gene-sequence': ['>lcl|BSEQ0020443|Insulin receptor (INSR)\nATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCG\nCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATC\nCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTG\nCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAA\nCTCATCATGATCACTGATTACTTGCTGCTCTTCCGGGTCTATGGGCTCGAGAGCCTGAAG\nGACCTGTTCCCCAACCTCACGGTCATCCGGGGATCACGACTGTTCTTTAACTACGCGCTG\nGTCATCTTCGAGATGGTTCACCTCAAGGAACTCGGCCTCTACAACCTGATGAACATCACC\nCGGGGTTCTGTCCGCATCGAGAAGAACAATGAGCTCTGTTACTTGGCCACTATCGACTGG\nTCCCGTATCCTGGATTCCGTGGAGGATAATTACATCGTGTTGAACAAAGATGACAACGAG\nGAGTGTGGAGACATCTGTCCGGGTACCGCGAAGGGCAAGACCAACTGCCCCGCCACCGTC\nATCAACGGGCAGTTTGTCGAACGATGTTGGACTCATAGTCACTGCCAGAAAGTTTGCCCG\nACCATCTGTAAGTCACACGGCTGCACCGCCGAAGGCCTCTGTTGCCACAGCGAGTGCCTG\nGGCAACTGTTCTCAGCCCGACGACCCCACCAAGTGCGTGGCCTGCCGCAACTTCTACCTG\nGACGGCAGGTGTGTGGAGACCTGCCCGCCCCCGTACTACCACTTCCAGGACTGGCGCTGT\nGTGAACTTCAGCTTCTGCCAGGACCTGCACCACAAATGCAAGAACTCGCGGAGGCAGGGC\nTGCCACCAGTACGTCATTCACAACAACAAGTGCATCCCTGAGTGTCCCTCCGGGTACACG\nATGAATTCCAGCAACTTGCTGTGCACCCCATGCCTGGGTCCCTGTCCCAAGGTGTGCCAC\nCTCCTAGAAGGCGAGAAGACCATCGACTCGGTGACGTCTGCCCAGGAGCTCCGAGGATGC\nACCGTCATCAACGGGAGTCTGATCATCAACATTCGAGGAGGCAACAATCTGGCAGCTGAG\nCTAGAAGCCAACCTCGGCCTCATTGAAGAAATTTCAGGGTATCTAAAAATCCGCCGATCC\nTACGCTCTGGTGTCACTTTCCTTCTTCCGGAAGTTACGTCTGATTCGAGGAGAGACCTTG\nGAAATTGGGAACTACTCCTTCTATGCCTTGGACAACCAGAACCTAAGGCAGCTCTGGGAC\nTGGAGCAAACACAACCTCACCATCACTCAGGGGAAACTCTTCTTCCACTATAACCCCAAA\nCTCTGCTTGTCAGAAATCCACAAGATGGAAGAAGTTTCAGGAACCAAGGGGCGCCAGGAG\nAGAAACGACATTGCCCTGAAGACCAATGGGGACCAGGCATCCTGTGAAAATGAGTTACTT\nAAATTTTCTTACATTCGGACATCTTTTGACAAGATCTTGCTGAGATGGGAGCCGTACTGG\nCCCCCCGACTTCCGAGACCTCTTGGGGTTCATGCTGTTCTACAAAGAGGCCCCTTATCAG\nAATGTGACGGAGTTCGACGGGCAGGATGCGTGTGGTTCCAACAGTTGGACGGTGGTAGAC\nATTGACCCACCCCTGAGGTCCAACGACCCCAAATCACAGAACCACCCAGGGTGGCTGATG\nCGGGGTCTCAAGCCCTGGACCCAGTATGCCATCTTTGTGAAGACCCTGGTCACCTTTTCG\nGATGAACGCCGGACCTATGGGGCCAAGAGTGACATCATTTATGTCCAGACAGATGCCACC\nAACCCCTCTGTGCCCCTGGATCCAATCTCAGTGTCTAACTCATCATCCCAGATTATTCTG\nAAGTGGAAACCACCCTCCGACCCCAATGGCAACATCACCCACTACCTGGTTTTCTGGGAG\nAGGCAGGCGGAAGACAGTGAGCTGTTCGAGCTGGATTATTGCCTCAAAGGGCTGAAGCTG\nCCCTCGAGGACCTGGTCTCCACCATTCGAGTCTGAAGATTCTCAGAAGCACAACCAGAGT\nGAGTATGAGGATTCGGCCGGCGAATGCTGCTCCTGTCCAAAGACAGACTCTCAGATCCTG\nAAGGAGCTGGAGGAGTCCTCGTTTAGGAAGACGTTTGAGGATTACCTGCACAACGTGGTT\nTTCGTCCCCAGAAAAACCTCTTCAGGCACTGGTGCCGAGGACCCTAGGCCATCTCGGAAA\nCGCAGGTCCCTTGGCGATGTTGGGAATGTGACGGTGGCCGTGCCCACGGTGGCAGCTTTC\nCCCAACACTTCCTCGACCAGCGTGCCCACGAGTCCGGAGGAGCACAGGCCTTTTGAGAAG\nGTGGTGAACAAGGAGTCGCTGGTCATCTCCGGCTTGCGACACTTCACGGGCTATCGCATC\nGAGCTGCAGGCTTGCAACCAGGACACCCCTGAGGAACGGTGCAGTGTGGCAGCCTACGTC\nAGTGCGAGGACCATGCCTGAAGCCAAGGCTGATGACATTGTTGGCCCTGTGACGCATGAA\nATCTTTGAGAACAACGTCGTCCACTTGATGTGGCAGGAGCCGAAGGAGCCCAATGGTCTG\nATCGTGCTGTATGAAGTGAGTTATCGGCGATATGGTGATGAGGAGCTGCATCTCTGCGTC\nTCCCGCAAGCACTTCGCTCTGGAACGGGGCTGCAGGCTGCGTGGGCTGTCACCGGGGAAC\nTACAGCGTGCGAATCCGGGCCACCTCCCTTGCGGGCAACGGCTCTTGGACGGAACCCACC\nTATTTCTACGTGACAGACTATTTAGACGTCCCGTCAAATATTGCAAAAATTATCATCGGC\nCCCCTCATCTTTGTCTTTCTCTTCAGTGTTGTGATTGGAAGTATTTATCTATTCCTGAGA\nAAGAGGCAGCCAGATGGGCCGCTGGGACCGCTTTACGCTTCTTCAAACCCTGAGTATCTC\nAGTGCCAGTGATGTGTTTCCATGCTCTGTGTACGTGCCGGACGAGTGGGAGGTGTCTCGA\nGAGAAGATCACCCTCCTTCGAGAGCTGGGGCAGGGCTCCTTCGGCATGGTGTATGAGGGC\nAATGCCAGGGACATCATCAAGGGTGAGGCAGAGACCCGCGTGGCGGTGAAGACGGTCAAC\nGAGTCAGCCAGTCTCCGAGAGCGGATTGAGTTCCTCAATGAGGCCTCGGTCATGAAGGGC\nTTCACCTGCCATCACGTGGTGCGCCTCCTGGGAGTGGTGTCCAAGGGCCAGCCCACGCTG\nGTGGTGATGGAGCTGATGGCTCACGGAGACCTGAAGAGCTACCTCCGTTCTCTGCGGCCA\nGAGGCTGAGAATAATCCTGGCCGCCCTCCCCCTACCCTTCAAGAGATGATTCAGATGGCG\nGCAGAGATTGCTGACGGGATGGCCTACCTGAACGCCAAGAAGTTTGTGCATCGGGACCTG\nGCAGCGAGAAACTGCATGGTCGCCCATGATTTTACTGTCAAAATTGGAGACTTTGGAATG\nACCAGAGACATCTATGAAACGGATTACTACCGGAAAGGGGGCAAGGGTCTGCTCCCTGTA\nCGGTGGATGGCACCGGAGTCCCTGAAGGATGGGGTCTTCACCACTTCTTCTGACATGTGG\nTCCTTTGGCGTGGTCCTTTGGGAAATCACCAGCTTGGCAGAACAGCCTTACCAAGGCCTG\nTCTAATGAACAGGTGTTGAAATTTGTCATGGATGGAGGGTATCTGGATCAACCCGACAAC\nTGTCCAGAGAGAGTCACTGACCTCATGCGCATGTGCTGGCAATTCAACCCCAAGATGAGG\nCCAACCTTCCTGGAGATTGTCAACCTGCTCAAGGACGACCTGCACCCCAGCTTTCCAGAG\nGTGTCGTTCTTCCACAGCGAGGAGAACAAGGCTCCCGAGAGTGAGGAGCTGGAGATGGAG\nTTTGAGGACATGGAGAATGTGCCCCTGGACCGTTCCTCGCACTGTCAGAGGGAGGAGGCG\nGGGGGCCGGGATGGAGGGTCCTCGCTGGGTTTCAAGCGGAGCTACGAGGAACACATCCCT\nTACACACACATGAACGGAGGCAAGAAAAACGGGCGGATTCTGACCTTGCCTCGGTCCAAT\nCCTTCCTAA'], 'pfams': [{'pfam': [{'identifier': ['PF07714'], 'name': ['PK_Tyr_Ser-Thr']}, {'identifier': ['PF00041'], 'name': ['fn3']}, {'identifier': ['PF00757'], 'name': ['Furin-like']}, {'identifier': ['PF01030'], 'name': ['Recep_L_domain']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['caveola']}, {'category': ['component'], 'description': ['endosome membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['insulin receptor complex']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular membrane-bounded organelle']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['function'], 'description': ['ATP binding']}, {'category': ['function'], 'description': ['GTP binding']}, {'category': ['function'], 'description': ['insulin binding']}, {'category': ['function'], 'description': ['insulin receptor substrate binding']}, {'category': ['function'], 'description': ['insulin-activated receptor activity']}, {'category': ['function'], 'description': ['insulin-like growth factor I binding']}, {'category': ['function'], 'description': ['insulin-like growth factor II binding']}, {'category': ['function'], 'description': ['insulin-like growth factor receptor binding']}, {'category': ['function'], 'description': ['phosphatidylinositol 3-kinase binding']}, {'category': ['function'], 'description': ['protein tyrosine kinase activity']}, {'category': ['function'], 'description': ['PTB domain binding']}, {'category': ['function'], 'description': ['receptor signaling protein tyrosine kinase activity']}, {'category': ['process'], 'description': ['activation of MAPK activity']}, {'category': ['process'], 'description': ['activation of protein kinase activity']}, {'category': ['process'], 'description': ['activation of protein kinase B activity']}, {'category': ['process'], 'description': ['adrenal gland development']}, {'category': ['process'], 'description': ['carbohydrate metabolic process']}, {'category': ['process'], 'description': ['cellular response to growth factor stimulus']}, {'category': ['process'], 'description': ['cellular response to insulin stimulus']}, {'category': ['process'], 'description': ['epidermis development']}, {'category': ['process'], 'description': ['exocrine pancreas development']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['glucose homeostasis']}, {'category': ['process'], 'description': ['heart morphogenesis']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['male gonad development']}, {'category': ['process'], 'description': ['male sex determination']}, {'category': ['process'], 'description': ['peptidyl-tyrosine autophosphorylation']}, {'category': ['process'], 'description': ['peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of developmental growth']}, {'category': ['process'], 'description': ['positive regulation of DNA replication']}, {'category': ['process'], 'description': ['positive regulation of glucose import']}, {'category': ['process'], 'description': ['positive regulation of glycogen biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of glycolytic process']}, {'category': ['process'], 'description': ['positive regulation of MAPK cascade']}, {'category': ['process'], 'description': ['positive regulation of meiotic cell cycle']}, {'category': ['process'], 'description': ['positive regulation of mitotic nuclear division']}, {'category': ['process'], 'description': ['positive regulation of nitric oxide biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of respiratory burst']}, {'category': ['process'], 'description': ['positive regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['protein autophosphorylation']}, {'category': ['process'], 'description': ['protein heterotetramerization']}, {'category': ['process'], 'description': ['regulation of embryonic development']}, {'category': ['process'], 'description': ['regulation of female gonad development']}, {'category': ['process'], 'description': ['regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['signal transduction by protein phosphorylation']}, {'category': ['process'], 'description': ['transformation of host cell by virus']}]}]}]}, {'id': ['BE0000858'], 'name': ['Insulin-like growth factor 1 receptor'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A13240'], 'pubmed-id': ['9846170'], 'citation': ['Fottner C, Engelhardt D, Weber MM: Regulation of steroidogenesis by insulin-like growth factors (IGFs) in adult human adrenocortical cells: IGF-I and, more potently, IGF-II preferentially enhance androgen biosynthesis through interaction with the IGF-I receptor and IGF-binding proteins. J Endocrinol. 1998 Sep;158(3):409-17.']}, {'ref-id': ['A13241'], 'pubmed-id': ['9582514'], 'citation': ['Zhang Q, Berggren PO, Hansson A, Tally M: Insulin-like growth factor-I-induced DNA synthesis in insulin-secreting cell line RINm5F is associated with phosphorylation of the insulin-like growth factor-I receptor and the insulin receptor substrate-2. J Endocrinol. 1998 Mar;156(3):573-81.']}, {'ref-id': ['A13242'], 'pubmed-id': ['7476290'], 'citation': ['Sowers JR, Jacobs DB, Simpson L, al-Homsi B, Grunberger G, Sokol R: Erythrocyte insulin and insulin-like growth factor-I receptor tyrosine kinase activity in hypertension in pregnancy. Metabolism. 1995 Oct;44(10):1308-13.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Insulin-like growth factor 1 receptor'], 'general-function': ['Protein tyrosine kinase activity'], 'specific-function': ['Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.'], 'gene-name': ['IGF1R'], 'locus': ['15q26.3'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['936-959'], 'signal-regions': ['1-30'], 'theoretical-pi': ['5.54'], 'molecular-weight': ['154791.73'], 'chromosome-location': ['15'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5465']}, {'resource': ['GenAtlas'], 'identifier': ['IGF1R']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X04434']}, {'resource': ['GenBank Protein Database'], 'identifier': ['804990']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1801']}, {'resource': ['UniProtKB'], 'identifier': ['P08069']}, {'resource': ['UniProt Accession'], 'identifier': ['IGF1R_HUMAN']}]}], 'synonyms': [{'synonym': ['2.7.10.1', 'IGF-I receptor', 'Insulin-like growth factor I receptor']}], 'amino-acid-sequence': ['>lcl|BSEQ0001710|Insulin-like growth factor 1 receptor\nMKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLH\nILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIF\nEMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGD\nLCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCS\nAPDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHD\nGECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNL\nLINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSF\nYVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTR\nNNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDG\nQDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSE\nILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRH\nNYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRK\nVFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFES\nRVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTW\nEPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGN\nYTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHR\nKRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKG\nVVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIME\nLMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARN\nCMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGV\nVLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL\nEIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRH\nSGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC'], 'gene-sequence': ['>lcl|BSEQ0020490|Insulin-like growth factor 1 receptor (IGF1R)\nATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCC\nGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGC\nAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCAC\nATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTC\nATTACCGAGTACTTGCTGCTGTTCCGAGTGGCTGGCCTCGAGAGCCTCGGAGACCTCTTC\nCCCAACCTCACGGTCATCCGCGGCTGGAAACTCTTCTACAACTACGCCCTGGTCATCTTC\nGAGATGACCAATCTCAAGGATATTGGGCTTTACAACCTGAGGAACATTACTCGGGGGGCC\nATCAGGATTGAGAAAAATGCTGACCTCTGTTACCTCTCCACTGTGGACTGGTCCCTGATC\nCTGGATGCGGTGTCCAATAACTACATTGTGGGGAATAAGCCCCCAAAGGAATGTGGGGAC\nCTGTGTCCAGGGACCATGGAGGAGAAGCCGATGTGTGAGAAGACCACCATCAACAATGAG\nTACAACTACCGCTGCTGGACCACAAACCGCTGCCAGAAAATGTGCCCAAGCACGTGTGGG\nAAGCGGGCGTGCACCGAGAACAATGAGTGCTGCCACCCCGAGTGCCTGGGCAGCTGCAGC\nGCGCCTGACAACGACACGGCCTGTGTAGCTTGCCGCCACTACTACTATGCCGGTGTCTGT\nGTGCCTGCCTGCCCGCCCAACACCTACAGGTTTGAGGGCTGGCGCTGTGTGGACCGTGAC\nTTCTGCGCCAACATCCTCAGCGCCGAGAGCAGCGACTCCGAGGGGTTTGTGATCCACGAC\nGGCGAGTGCATGCAGGAGTGCCCCTCGGGCTTCATCCGCAACGGCAGCCAGAGCATGTAC\nTGCATCCCTTGTGAAGGTCCTTGCCCGAAGGTCTGTGAGGAAGAAAAGAAAACAAAGACC\nATTGATTCTGTTACTTCTGCTCAGATGCTCCAAGGATGCACCATCTTCAAGGGCAATTTG\nCTCATTAACATCCGACGGGGGAATAACATTGCTTCAGAGCTGGAGAACTTCATGGGGCTC\nATCGAGGTGGTGACGGGCTACGTGAAGATCCGCCATTCTCATGCCTTGGTCTCCTTGTCC\nTTCCTAAAAAACCTTCGCCTCATCCTAGGAGAGGAGCAGCTAGAAGGGAATTACTCCTTC\nTACGTCCTCGACAACCAGAACTTGCAGCAACTGTGGGACTGGGACCACCGCAACCTGACC\nATCAAAGCAGGGAAAATGTACTTTGCTTTCAATCCCAAATTATGTGTTTCCGAAATTTAC\nCGCATGGAGGAAGTGACGGGGACTAAAGGGCGCCAAAGCAAAGGGGACATAAACACCAGG\nAACAACGGGGAGAGAGCCTCCTGTGAAAGTGACGTCCTGCATTTCACCTCCACCACCACG\nTCGAAGAATCGCATCATCATAACCTGGCACCGGTACCGGCCCCCTGACTACAGGGATCTC\nATCAGCTTCACCGTTTACTACAAGGAAGCACCCTTTAAGAATGTCACAGAGTATGATGGG\nCAGGATGCCTGCGGCTCCAACAGCTGGAACATGGTGGACGTGGACCTCCCGCCCAACAAG\nGACGTGGAGCCCGGCATCTTACTACATGGGCTGAAGCCCTGGACTCAGTACGCCGTTTAC\nGTCAAGGCTGTGACCCTCACCATGGTGGAGAACGACCATATCCGTGGGGCCAAGAGTGAG\nATCTTGTACATTCGCACCAATGCTTCAGTTCCTTCCATTCCCTTGGACGTTCTTTCAGCA\nTCGAACTCCTCTTCTCAGTTAATCGTGAAGTGGAACCCTCCCTCTCTGCCCAACGGCAAC\nCTGAGTTACTACATTGTGCGCTGGCAGCGGCAGCCTCAGGACGGCTACCTTTACCGGCAC\nAATTACTGCTCCAAAGACAAAATCCCCATCAGGAAGTATGCCGACGGCACCATCGACATT\nGAGGAGGTCACAGAGAACCCCAAGACTGAGGTGTGTGGTGGGGAGAAAGGGCCTTGCTGC\nGCCTGCCCCAAAACTGAAGCCGAGAAGCAGGCCGAGAAGGAGGAGGCTGAATACCGCAAA\nGTCTTTGAGAATTTCCTGCACAACTCCATCTTCGTGCCCAGACCTGAAAGGAAGCGGAGA\nGATGTCATGCAAGTGGCCAACACCACCATGTCCAGCCGAAGCAGGAACACCACGGCCGCA\nGACACCTACAACATCACCGACCCGGAAGAGCTGGAGACAGAGTACCCTTTCTTTGAGAGC\nAGAGTGGATAACAAGGAGAGAACTGTCATTTCTAACCTTCGGCCTTTCACATTGTACCGC\nATCGATATCCACAGCTGCAACCACGAGGCTGAGAAGCTGGGCTGCAGCGCCTCCAACTTC\nGTCTTTGCAAGGACTATGCCCGCAGAAGGAGCAGATGACATTCCTGGGCCAGTGACCTGG\nGAGCCAAGGCCTGAAAACTCCATCTTTTTAAAGTGGCCGGAACCTGAGAATCCCAATGGA\nTTGATTCTAATGTATGAAATAAAATACGGATCACAAGTTGAGGATCAGCGAGAATGTGTG\nTCCAGACAGGAATACAGGAAGTATGGAGGGGCCAAGCTAAACCGGCTAAACCCGGGGAAC\nTACACAGCCCGGATTCAGGCCACATCTCTCTCTGGGAATGGGTCGTGGACAGATCCTGTG\nTTCTTCTATGTCCAGGCCAAAACAGGATATGAAAACTTCATCCATCTGATCATCGCTCTG\nCCCGTCGCTGTCCTGTTGATCGTGGGAGGGTTGGTGATTATGCTGTACGTCTTCCATAGA\nAAGAGAAATAACAGCAGGCTGGGGAATGGAGTGCTGTATGCCTCTGTGAACCCGGAGTAC\nTTCAGCGCTGCTGATGTGTACGTTCCTGATGAGTGGGAGGTGGCTCGGGAGAAGATCACC\nATGAGCCGGGAACTTGGGCAGGGGTCGTTTGGGATGGTCTATGAAGGAGTTGCCAAGGGT\nGTGGTGAAAGATGAACCTGAAACCAGAGTGGCCATTAAAACAGTGAACGAGGCCGCAAGC\nATGCGTGAGAGGATTGAGTTTCTCAACGAAGCTTCTGTGATGAAGGAGTTCAATTGTCAC\nCATGTGGTGCGATTGCTGGGTGTGGTGTCCCAAGGCCAGCCAACACTGGTCATCATGGAA\nCTGATGACACGGGGCGATCTCAAAAGTTATCTCCGGTCTCTGAGGCCAGAAATGGAGAAT\nAATCCAGTCCTAGCACCTCCAAGCCTGAGCAAGATGATTCAGATGGCCGGAGAGATTGCA\nGACGGCATGGCATACCTCAACGCCAATAAGTTCGTCCACAGAGACCTTGCTGCCCGGAAT\nTGCATGGTAGCCGAAGATTTCACAGTCAAAATCGGAGATTTTGGTATGACGCGAGATATC\nTATGAGACAGACTATTACCGGAAAGGAGGGAAAGGGCTGCTGCCCGTGCGCTGGATGTCT\nCCTGAGTCCCTCAAGGATGGAGTCTTCACCACTTACTCGGACGTCTGGTCCTTCGGGGTC\nGTCCTCTGGGAGATCGCCACACTGGCCGAGCAGCCCTACCAGGGCTTGTCCAACGAGCAA\nGTCCTTCGCTTCGTCATGGAGGGCGGCCTTCTGGACAAGCCAGACAACTGTCCTGACATG\nCTGTTTGAACTGATGCGCATGTGCTGGCAGTATAACCCCAAGATGAGGCCTTCCTTCCTG\nGAGATCATCAGCAGCATCAAAGAGGAGATGGAGCCTGGCTTCCGGGAGGTCTCCTTCTAC\nTACAGCGAGGAGAACAAGCTGCCCGAGCCGGAGGAGCTGGACCTGGAGCCAGAGAACATG\nGAGAGCGTCCCCCTGGACCCCTCGGCCTCCTCGTCCTCCCTGCCACTGCCCGACAGACAC\nTCAGGACACAAGGCCGAGAACGGCCCCGGCCCTGGGGTGCTGGTCCTCCGCGCCAGCTTC\nGACGAGAGACAGCCTTACGCCCACATGAACGGGGGCCGCAAGAACGAGCGGGCCTTGCCG\nCTGCCCCAGTCTTCGACCTGCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF07714'], 'name': ['PK_Tyr_Ser-Thr']}, {'identifier': ['PF00757'], 'name': ['Furin-like']}, {'identifier': ['PF01030'], 'name': ['Recep_L_domain']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['caveola']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular membrane-bounded organelle']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['neuron projection']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['function'], 'description': ['ATP binding']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['function'], 'description': ['insulin binding']}, {'category': ['function'], 'description': ['insulin receptor binding']}, {'category': ['function'], 'description': ['insulin receptor substrate binding']}, {'category': ['function'], 'description': ['insulin-like growth factor binding']}, {'category': ['function'], 'description': ['insulin-like growth factor I binding']}, {'category': ['function'], 'description': ['insulin-like growth factor-activated receptor activity']}, {'category': ['function'], 'description': ['phosphatidylinositol 3-kinase binding']}, {'category': ['function'], 'description': ['protein tyrosine kinase activity']}, {'category': ['process'], 'description': ['axonogenesis']}, {'category': ['process'], 'description': ['brain development']}, {'category': ['process'], 'description': ['epidermis development']}, {'category': ['process'], 'description': ['establishment of cell polarity']}, {'category': ['process'], 'description': ['exocrine pancreas development']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['inactivation of MAPKK activity']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['insulin-like growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['male sex determination']}, {'category': ['process'], 'description': ['mammary gland development']}, {'category': ['process'], 'description': ['negative regulation of apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of muscle cell apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['negative regulation of sequence-specific DNA binding transcription factor activity']}, {'category': ['process'], 'description': ['peptidyl-tyrosine autophosphorylation']}, {'category': ['process'], 'description': ['phosphatidylinositol 3-kinase signaling']}, {'category': ['process'], 'description': ['phosphatidylinositol-mediated signaling']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of cytokinesis']}, {'category': ['process'], 'description': ['positive regulation of DNA replication']}, {'category': ['process'], 'description': ['positive regulation of MAPK cascade']}, {'category': ['process'], 'description': ['positive regulation of mitotic nuclear division']}, {'category': ['process'], 'description': ['positive regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['positive regulation of steroid hormone biosynthetic process']}, {'category': ['process'], 'description': ['prostate gland epithelium morphogenesis']}, {'category': ['process'], 'description': ['protein autophosphorylation']}, {'category': ['process'], 'description': ['protein heterooligomerization']}, {'category': ['process'], 'description': ['protein tetramerization']}, {'category': ['process'], 'description': ['regulation of JNK cascade']}, {'category': ['process'], 'description': ['response to vitamin E']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}]}]"
"['DB00072', 'BTD00098', 'BIOD00098']",['Trastuzumab'],biotech,"['Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody [A40276] that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2).[L14015] It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic breast cancer, where there is a proven amplification of the HER-2 oncogene or over-expression of the HER-2 protein in tumours. It is suggested that the overexpression or gene amplification of HER2 has been found in about 2030% of breast cancers and elevated activation of HER2 triggers multiple downstream pathways leading to abnormal proliferation of cancer cells [A121]. Trastuzumab binds to HER2 and suppresses cancer cell growth, proliferation, and survival directly and indirectly [A121].\r\n\r\nIn December 2017, FDA approved OGIVRI (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). It displays biosimilar properties as Herceptin according to clinical data. While Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer, it is the second biosimilar approved in the U.S. for the treatment of cancer. Herzuma (trastuzumab-pkrb) is a biosimilar drug approved in December 2018 for the treatment of HER2-overexpressing breast cancer. KANJINTI (trastuzumab-anns) is another biosimilar approved by the FDA in June 2019.[L14135] ONTRUZANT, another biosimilar of Herceptin, was approved by Health Canada in February 2022.[L40303, L40308] In November 2023, trastuzumab was also approved by the EMA under the brand name Herwenda.[L49339]']",['solid'],"['For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based therapy.[L14015]\r\n\r\nTrastuzumab is indicated as a first-line treatment, in combination with paclitaxel, for metastatic HER2-overexpressing breast cancer, and as monotherapy in patients who have previously received one or more chemotherapy regimens in the metastatic setting.[L14015] In Europe, trastuzumab can also be used in combination with paclitaxel or docetaxel for the treatment of metastatic HER2-positive breast cancer in adult patients and with an aromatase inhibitor in postmenopausal patients.[L49324]\r\n\r\nFor HER2-positive early breast cancer, the EMA approved trastuzumab as monotherapy following surgery, chemotherapy (neoadjuvant or adjuvant), and radiation or following adjuvant chemotherapy with doxorubicin and cyclophosphamide in combination with paclitaxel or docetaxel. It can also be used in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin or with neoadjuvant chemotherapy followed by adjuvant trastuzumab therapy for locally advanced (including inflammatory) disease or tumors > 2 cm in diameter.[L49324]\r\n\r\nTrastuzumab is also indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease by the FDA and EMA.[L14015]\r\n\r\nTrastuzumab is indicated for subcutaneous administration - in combination with either [hyaluronidase][L14132] or both hyaluronidase and [pertuzumab][L14510] - for the treatment of adults with HER2-positive breast cancers.']","['Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene. Over-expressed in breast tumour cells, HER-2 overamplifies the signal provided by other receptors of the HER family by forming heterodimers [A121]. The HER-2 receptor is a transmembrane tyrosine kinase receptor that consists of an extracellular ligand-binding domain, a transmembrane region, and an intracellular or cytoplasmic tyrosine kinase domain. It is activated by the formation of homodimers or heterodimers with other EGFR proteins, leading to dimerization and autophosphorylation and/or transphosphorylation of specific tyrosine residues in EGFR intracellular domains [A121]. Further downstream molecular signaling cascades are activated, such as the Ras/Raf/mitogen-activated protein kinase (MAPK), the phosphoinositide 3-kinase/Akt, and the phospholipase C (PLC)/protein kinase C (PKC) pathways that promote cell growth and survival and cell cycle progression [A121]. Due to upregulation of HER-2 in tumour cells, hyperactivation of these signaling pathways and abnormal cell proliferation is observed. Trastuzumab binds to the extracellular ligand-binding domain and blocks the cleavage of the extracellular domain of HER-2 to induce its antibody-induced receptor downmodulation [A121], and subsequently inhibits HER-2-mediated intracellular signaling cascades. Inhibition of MAPK and PI3K/Akt pathways lead to an increase in cell cycle arrest, and the suppression of cell growth and proliferation [A121]. Trastuzumab also mediates the activation of antibody-dependent cell-mediated cytotoxicity (ADCC) [A40276] by attracting the immune cells, such as natural killer (NK) cells, to tumor sites that overexpress HER-2 [A121]. While the drug alone has a minimal potential to induce complement-dependent cytotoxicity (CDC),[A201902] one study demonstrated increased therapeutic effectiveness and a synergistic effect on uterine serous carcinoma cells _in vitro_ when used in combination with [pertuzumab], which also has minor effects on CDC alone. This study showed that only the combination of both cell-bound antibodies would be sufficient to bind and activate the complement component 1q (C1q) required to initiate the complement cascade reaction.[A201896]\r\n\r\nIntrinsic trastuzumab resistance has been noted for some patients with HER-2 positive breast cancer. Mechanisms involving trastuzumab resistance include deficiency of phosphatase and tensin homologue and activation of phosphoinositide 3-kinase, and the overexpression of other surface receptors, such as insulin-like growth factor [A40276].']",[None],"[{'target': [{'id': ['BE0000511'], 'name': ['Receptor tyrosine-protein kinase erbB-2'], 'organism': ['Humans'], 'actions': [{'action': ['binder', 'antibody']}], 'references': [{'articles': [{'article': [{'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A13551'], 'pubmed-id': ['18690878'], 'citation': ['Leveque D, Gigou L, Bergerat JP: Clinical pharmacology of trastuzumab. Curr Clin Pharmacol. 2008 Jan;3(1):51-5.']}, {'ref-id': ['A13552'], 'pubmed-id': ['17660958'], 'citation': ['Lin A, Rugo HS: The role of trastuzumab in early stage breast cancer: current data and treatment recommendations. Curr Treat Options Oncol. 2007 Feb;8(1):47-60.']}, {'ref-id': ['A13553'], 'pubmed-id': ['11098307'], 'citation': ['Treish I, Schwartz R, Lindley C: Pharmacology and therapeutic use of trastuzumab in breast cancer. Am J Health Syst Pharm. 2000 Nov 15;57(22):2063-76; quiz 2077-9.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Receptor tyrosine-protein kinase erbB-2'], 'general-function': ['Transmembrane signaling receptor activity'], 'specific-function': [""Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.In the nucleus is involved in transcriptional regulation. Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Implicated in transcriptional activation of CDKN1A; the function involves STAT3 and SRC. Involved in the transcription of rRNA genes by RNA Pol I and enhances protein synthesis and cell growth.""], 'gene-name': ['ERBB2'], 'locus': ['17q11.2-q12|17q21.1'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['653-675'], 'signal-regions': ['1-22'], 'theoretical-pi': ['5.76'], 'molecular-weight': ['137909.27'], 'chromosome-location': ['17'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3430']}, {'resource': ['GenAtlas'], 'identifier': ['ERBB2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M11767']}, {'resource': ['GenBank Protein Database'], 'identifier': ['553282']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2019']}, {'resource': ['UniProtKB'], 'identifier': ['P04626']}, {'resource': ['UniProt Accession'], 'identifier': ['ERBB2_HUMAN']}]}], 'synonyms': [{'synonym': ['2.7.10.1', 'HER2', 'Metastatic lymph node gene 19 protein', 'MLN 19', 'MLN19', 'NEU', 'NGL', 'p185erbB2', 'Proto-oncogene c-ErbB-2', 'Proto-oncogene Neu', 'Tyrosine kinase-type cell surface receptor HER2']}], 'amino-acid-sequence': ['>lcl|BSEQ0001020|Receptor tyrosine-protein kinase erbB-2\nMELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNL\nELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNG\nDPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLA\nLTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQC\nAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACP\nYNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSAN\nIQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLP\nDLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTV\nPWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQEC\nVEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARC\nPSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVG\nILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETEL\nRKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSP\nYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVR\nLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFT\nHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWM\nIDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDA\nEEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEG\nAGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYV\nNQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQ\nGGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV'], 'gene-sequence': ['>lcl|BSEQ0010360|Receptor tyrosine-protein kinase erbB-2 (ERBB2)\nATGAAGCTGCGGCTCCCTGCCAGTCCCGAGACCCACCTGGACATGCTCCGCCACCTCTAC\nCAGGGCTGCCAGGTGGTGCAGGGAAACCTGGAACTCACCTACCTGCCCACCAATGCCAGC\nCTGTCCTTCCTGCAGGATATCCAGGAGGTGCAGGGCTACGTGCTCATCGCTCACAACCAA\nGTGAGGCAGGTCCCACTGCAGAGGCTGCGGATTGTGCGAGGCACCCAGCTCTTTGAGGAC\nAACTATGCCCTGGCCGTGCTAGACAATGGAGACCCGCTGAACAATACCACCCCTGTCACA\nGGGGCCTCCCCAGGAGGCCTGCGGGAGCTGCAGCTTCGAAGCCTCACAGAGATCTTGAAA\nGGAGGGGTCTTGATCCAGCGGAACCCCCAGCTCTGCTACCAGGACACGATTTTGTGGAAG\nGACATCTTCCACAAGAACAACCAGCTGGCTCTCACACTGATAGACACCAACCGCTCTCGG\nGCCTGCCACCCCTGTTCTCCGATGTGTAAGGGCTCCCGCTGCTGGGGAGAGAGTTCTGAG\nGATTGTCAGAGCCTGACGCGCACTGTCTGTGCCGGTGGCTGTGCCCGCTGCAAGGGGCCA\nCTGCCCACTGACTGCTGCCATGAGCAGTGTGCTGCCGGCTGCACGGGCCCCAAGCACTCT\nGACTGCCTGGCCTGCCTCCACTTCAACCACAGTGGCATCTGTGAGCTGCACTGCCCAGCC\nCTGGTCACCTACAACACAGACACGTTTGAGTCCATGCCCAATCCCGAGGGCCGGTATACA\nTTCGGCGCCAGCTGTGTGACTGCCTGTCCCTACAACTACCTTTCTACGGACGTGGGATCC\nTGCACCCTCGTCTGCCCCCTGCACAACCAAGAGGTGACAGCAGAGGATGGAACACAGCGG\nTGTGAGAAGTGCAGCAAGCCCTGTGCCCGAGTGTGCTATGGTCTGGGCATGGAGCACTTG\nCGAGAGGTGAGGGCAGTTACCAGTGCCAATATCCAGGAGTTTGCTGGCTGCAAGAAGATC\nTTTGGGAGCCTGGCATTTCTGCCGGAGAGCTTTGATGGGGACCCAGCCTCCAACACTGCC\nCCGCTCCAGCCAGAGCAGCTCCAAGTGTTTGAGACTCTGGAAGAGATCACAGGTTACCTA\nTACATCTCAGCATGGCCGGACAGCCTGCCTGACCTCAGCGTCTTCCAGAACCTGCAAGTA\nATCCGGGGACGAATTCTGCACAATGGCGCCTACTCGCTGACCCTGCAAGGGCTGGGCATC\nAGCTGGCTGGGGCTGCGCTCACTGAGGGAACTGGGCAGTGGACTGGCCCTCATCCACCAT\nAACACCCACCTCTGCTTCGTGCACACGGTGCCCTGGGACCAGCTCTTTCGGAACCCGCAC\nCAAGCTCTGCTCCACACTGCCAACCGGCCAGAGGACGAGTGTGTGGGCGAGGGCCTGGCC\nTGCCACCAGCTGTGCGCCCGAGGGCACTGCTGGGGTCCAGGGCCCACCCAGTGTGTCAAC\nTGCAGCCAGTTCCTTCGGGGCCAGGAGTGCGTGGAGGAATGCCGAGTACTGCAGGGGCTC\nCCCAGGGAGTATGTGAATGCCAGGCACTGTTTGCCGTGCCACCCTGAGTGTCAGCCCCAG\nAATGGCTCAGTGACCTGTTTTGGACCGGAGGCTGACCAGTGTGTGGCCTGTGCCCACTAT\nAAGGACCCTCCCTTCTGCGTGGCCCGCTGCCCCAGCGGTGTGAAACCTGACCTCTCCTAC\nATGCCCATCTGGAAGTTTCCAGATGAGGAGGGCGCATGCCAGCCTTGCCCCATCAACTGC\nACCCACTCCTGTGTGGACCTGGATGACAAGGGCTGCCCCGCCGAGCAGAGAGCCAGCCCT\nCTGACGTCCATCATCTCTGCGGTGGTTGGCATTCTGCTGGTCGTGGTCTTGGGGGTGGTC\nTTTGGGATCCTCATCAAGCGACGGCAGCAGAAGATCCGGAAGTACACGATGCGGAGACTG\nCTGCAGGAAACGGAGCTGGTGGAGCCGCTGACACCTAGCGGAGCGATGCCCAACCAGGCG\nCAGATGCGGATCCTGAAAGAGACGGAGCTGAGGAAGGTGAAGGTGCTTGGATCTGGCGCT\nTTTGGCACAGTCTACAAGGGCATCTGGATCCCTGATGGGGAGAATGTGAAAATTCCAGTG\nGCCATCAAAGTGTTGAGGGAAAACACATCCCCCAAAGCCAACAAAGAAATCTTAGACGAA\nGCATACGTGATGGCTGGTGTGGGCTCCCCATATGTCTCCCGCCTTCTGGGCATCTGCCTG\nACATCCACGGTGCAGCTGGTGACACAGCTTATGCCCTATGGCTGCCTCTTAGACCATGTC\nCGGGAAAACCGCGGACGCCTGGGCTCCCAGGACCTGCTGAACTGGTGTATGCAGATTGCC\nAAGGGGATGAGCTACCTGGAGGATGTGCGGCTCGTACACAGGGACTTGGCCGCTCGGAAC\nGTGCTGGTCAAGAGTCCCAACCATGTCAAAATTACAGACTTCGGGCTGGCTCGGCTGCTG\nGACATTGACGAGACAGAGTACCATGCAGATGGGGGCAAGGTGCCCATCAAGTGGATGGCG\nCTGGAGTCCATTCTCCGCCGGCGGTTCACCCACCAGAGTGATGTGTGGAGTTATGGTGTG\nACTGTGTGGGAGCTGATGACTTTTGGGGCCAAACCTTACGATGGGATCCCAGCCCGGGAG\nATCCCTGACCTGCTGGAAAAGGGGGAGCGGCTGCCCCAGCCCCCCATCTGCACCATTGAT\nGTCTACATGATCATGGTCAAATGTTGGATGATTGACTCTGAATGTCGGCCAAGATTCCGG\nGAGTTGGTGTCTGAATTCTCCCGCATGGCCAGGGACCCCCAGCGCTTTGTGGTCATCCAG\nAATGAGGACTTGGGCCCAGCCAGTCCCTTGGACAGCACCTTCTACCGCTCACTGCTGGAG\nGACGATGACATGGGGGACCTGGTGGATGCTGAGGAGTATCTGGTACCCCAGCAGGGCTTC\nTTCTGTCCAGACCCTGCCCCGGGCGCTGGGGGCATGGTCCACCACAGGCACCGCAGCTCA\nTCTACCAGGAGTGGCGGTGGGGACCTGACACTAGGGCTGGAGCCCTCTGAAGAGGAGGCC\nCCCAGGTCTCCACTGGCACCCTCCGAAGGGGCTGGCTCCGATGTATTTGATGGTGACCTG\nGGAATGGGGGCAGCCAAGGGGCTGCAAAGCCTCCCCACACATGACCCCAGCCCTCTACAG\nCGGTACAGTGAGGACCCCACAGTACCCCTGCCCTCTGAGACTGATGGCTACGTTGCCCCC\nCTGACCTGCAGCCCCCAGCCTGAATATGTGAACCAGCCAGATGTTCGGCCCCAGCCCCCT\nTCGCCCCGAGAGGGCCCTCTGCCTGCTGCCCGACCTGCTGGTGCCACTCTGGAAAGGCCC\nAAGACTCTCTCCCCAGGGAAGAATGGGGTCGTCAAAGACGTTTTTGCCTTTGGGGGTGCC\nGTGGAGAACCCCGAGTACTTGACACCCCAGGGAGGAGCTGCCCCTCAGCCCCACCCTCCT\nCCTGCCTTCAGCCCAGCCTTCGACAACCTCTATTACTGGGACCAGGACCCACCAGAGCGG\nGGGGCTCCACCCAGCACCTTCAAAGGGACACCTACGGCAGAGAACCCAGAGTACCTGGGT\nCTGGACGTGCCAGTGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF07714'], 'name': ['PK_Tyr_Ser-Thr']}, {'identifier': ['PF00757'], 'name': ['Furin-like']}, {'identifier': ['PF01030'], 'name': ['Recep_L_domain']}, {'identifier': ['PF14843'], 'name': ['GF_recep_IV']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['apical plasma membrane']}, {'category': ['component'], 'description': ['basal plasma membrane']}, {'category': ['component'], 'description': ['basolateral plasma membrane']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['cytoplasmic vesicle']}, {'category': ['component'], 'description': ['endosome membrane']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['lateral loop']}, {'category': ['component'], 'description': ['membrane raft']}, {'category': ['component'], 'description': ['microvillus']}, {'category': ['component'], 'description': ['nucleus']}, {'category': ['component'], 'description': ['perinuclear region of cytoplasm']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['postsynaptic membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['function'], 'description': ['ATP binding']}, {'category': ['function'], 'description': ['ErbB-3 class receptor binding']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['function'], 'description': ['protein C-terminus binding']}, {'category': ['function'], 'description': ['protein dimerization activity']}, {'category': ['function'], 'description': ['protein heterodimerization activity']}, {'category': ['function'], 'description': ['protein phosphatase binding']}, {'category': ['function'], 'description': ['protein tyrosine kinase activity']}, {'category': ['function'], 'description': ['receptor signaling protein tyrosine kinase activity']}, {'category': ['function'], 'description': ['RNA polymerase I core binding']}, {'category': ['function'], 'description': ['transmembrane receptor protein tyrosine kinase activity']}, {'category': ['function'], 'description': ['transmembrane signaling receptor activity']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['cell proliferation']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular response to growth factor stimulus']}, {'category': ['process'], 'description': ['enzyme linked receptor protein signaling pathway']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['estrous cycle']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['heart development']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['liver development']}, {'category': ['process'], 'description': ['mammary gland involution']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['motor neuron axon guidance']}, {'category': ['process'], 'description': ['myelination']}, {'category': ['process'], 'description': ['negative regulation of apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of immature T cell proliferation in thymus']}, {'category': ['process'], 'description': ['neuromuscular junction development']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['oligodendrocyte differentiation']}, {'category': ['process'], 'description': ['peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['peripheral nervous system development']}, {'category': ['process'], 'description': ['phosphatidylinositol 3-kinase signaling']}, {'category': ['process'], 'description': ['phosphatidylinositol-mediated signaling']}, {'category': ['process'], 'description': ['positive regulation of cell adhesion']}, {'category': ['process'], 'description': ['positive regulation of cell growth']}, {'category': ['process'], 'description': ['positive regulation of epithelial cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of GTPase activity']}, {'category': ['process'], 'description': ['positive regulation of MAP kinase activity']}, {'category': ['process'], 'description': ['positive regulation of phosphatidylinositol 3-kinase signaling']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of protein targeting to membrane']}, {'category': ['process'], 'description': ['positive regulation of Ras protein signal transduction']}, {'category': ['process'], 'description': ['positive regulation of transcription from RNA polymerase I promoter']}, {'category': ['process'], 'description': ['positive regulation of transcription from RNA polymerase III promoter']}, {'category': ['process'], 'description': ['positive regulation of translation']}, {'category': ['process'], 'description': ['protein autophosphorylation']}, {'category': ['process'], 'description': ['protein phosphorylation']}, {'category': ['process'], 'description': ['Ras protein signal transduction']}, {'category': ['process'], 'description': ['regulation of angiogenesis']}, {'category': ['process'], 'description': ['regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['regulation of microtubule-based process']}, {'category': ['process'], 'description': ['response to axon injury']}, {'category': ['process'], 'description': ['response to drug']}, {'category': ['process'], 'description': ['response to progesterone']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['skeletal muscle tissue development']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['sympathetic nervous system development']}, {'category': ['process'], 'description': ['tongue development']}, {'category': ['process'], 'description': ['transcription, DNA-templated']}, {'category': ['process'], 'description': ['transmembrane receptor protein tyrosine kinase signaling pathway']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['wound healing']}]}]}]}]}]"
"['DB00073', 'BTD00014', 'BIOD00014']",['Rituximab'],biotech,"[""Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences [A40017], [FDA label]. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) [L4811], however, has now been approved for a variety of conditions [FDA label]. On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808].""]",['liquid'],"['Rituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkins Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.[L26641,L42025,L42030,L42035,L42040] Additionally, rituximab is indicated for the treatment of adult patients with non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy; and previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens.[L26641,L42025,L42030,L42035,L42040]\r\n\r\nRituximab, in combination with fludarabine and cyclophosphamide (FC), is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL).[L26641,L42025,L42030,L42035,L42040] In combination with methotrexate, rituximab is indicated for the treatment of adult patients with moderately-to severely-active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.[L26641,L42025,L42030,L42035] Additionally, rituximab, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA).[L26641,L42025,L42030,L42035]\r\n\r\nRITUXAN (rituximab injection for intravenous use) is indicated for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy; as well as the treatment of adult patients with moderate to severe pemphigus vulgaris.[L26641] These indications for RITUXAN are not included in the labels of rituximab biosimilar products (rituximab-arrx, rituximab-abbs, rituximab-pvvr).[L42025,L42030,L42035] The combination product RITUXAN HYCELA (rituximab and hyaluronidase human injection, for subcutaneous use) is not indicated for the treatment of non-malignant conditions.[L42040]']","['Rituximab is a monoclonal antibody that targets CD20, an antigen expressed on the surface of pre-B and mature B-lymphocytes [A124,A125,A126,L26641]. About 85% of non-Hodgkins lymphoma (NHL) cases are B-cell lymphomas, characterized by the high expression of CD19, CD20 and CD22 cell surface antigens.[A248980] CD20 is involved in cell cycle regulation, apoptosis and calcium signaling. By targeting CD20, rituximab promotes cell lysis while sparing hematopoietic and plasma cells without this surface antigen.[A40017,A248980] It has been suggested that cell lysis mechanisms triggered by rituximab include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) [L26641]. Rituximab is part of the immunoglobulin G1 (IgG1) subclass of antibodies, and is formed by a murine variable region (Fab region) and a human constant region (Fc region). The Fab region gives rituximab its specificity for CD20, while the Fc region interacts with cell surface receptors to activate the immune system, leading to the depletion of circulating B lymphocytes [A40017].\r\n\r\nIn regards to the mechanism of action in rheumatoid arthritis (RA), B-cells are thought to play a role in the pathogenesis of RA and the associated condition of chronic synovitis.[L26641] B-cells may act at various sites in the autoimmune/inflammatory process through the production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and the production of proinflammatory cytokines [L26641]. The administration of rituximab in this condition has resulted in significant clinical and symptomatic improvements [A125,L26641]. Rituximab is also indicated for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), two conditions characterized by the presence of circulating antineutrophil cytoplasmic antibodies and increased B-cell activity. It has been suggested that rituximab depletes CD20<sup>+</sup> B-cells at a higher rate in GPA and MPA patients with high levels of Fc receptor-like 5 (FCRL5).[A248985]']",[None],"[{'target': [{'id': ['BE0000066'], 'name': ['B-lymphocyte antigen CD20'], 'organism': ['Humans'], 'actions': [{'action': ['antibody', 'regulator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A13495'], 'pubmed-id': ['20350667'], 'citation': ['van Meerten T, Hagenbeek A: CD20-targeted therapy: the next generation of antibodies. Semin Hematol. 2010 Apr;47(2):199-210. doi: 10.1053/j.seminhematol.2010.01.007.']}, {'ref-id': ['A13496'], 'pubmed-id': ['20350663'], 'citation': ['Jaglowski SM, Byrd JC: Rituximab in chronic lymphocytic leukemia. Semin Hematol. 2010 Apr;47(2):156-69. doi: 10.1053/j.seminhematol.2010.01.005.']}, {'ref-id': ['A124'], 'pubmed-id': ['9704735'], 'citation': ['McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33.']}, {'ref-id': ['A234849'], 'pubmed-id': ['26883591'], 'citation': ['Phuah J, Wong EA, Gideon HP, Maiello P, Coleman MT, Hendricks MR, Ruden R, Cirrincione LR, Chan J, Lin PL, Flynn JL: Effects of B Cell Depletion on Early Mycobacterium tuberculosis Infection in Cynomolgus Macaques. Infect Immun. 2016 Apr 22;84(5):1301-1311. doi: 10.1128/IAI.00083-16. Print 2016 May.']}, {'ref-id': ['A234854'], 'pubmed-id': ['26920337'], 'citation': ['Hayashi K, Nagasaki E, Kan S, Ito M, Kamata Y, Homma S, Aiba K: Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation. Cancer Sci. 2016 May;107(5):682-9. doi: 10.1111/cas.12918. Epub 2016 Apr 7.']}, {'ref-id': ['A247090'], 'pubmed-id': ['33807678'], 'citation': ['Kyriakidis I, Vasileiou E, Rossig C, Roilides E, Groll AH, Tragiannidis A: Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies. J Fungi (Basel). 2021 Mar 5;7(3). pii: jof7030186. doi: 10.3390/jof7030186.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [{'attachment': [{'ref-id': ['F2122'], 'title': ['Rituxan FDA label'], 'url': ['//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/122/original/Rituxan_FDA_label.pdf?1543612957']}]}]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['B-lymphocyte antigen CD20'], 'general-function': ['Mhc class ii protein complex binding'], 'specific-function': ['This protein may be involved in the regulation of B-cell activation and proliferation.'], 'gene-name': ['MS4A1'], 'locus': ['11q12'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['57-78\n85-105\n121-141\n189-209'], 'signal-regions': [None], 'theoretical-pi': ['4.73'], 'molecular-weight': ['33076.99'], 'chromosome-location': ['11'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:7315']}, {'resource': ['GenAtlas'], 'identifier': ['MS4A1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X12530']}, {'resource': ['GenBank Protein Database'], 'identifier': ['29774']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2628']}, {'resource': ['UniProtKB'], 'identifier': ['P11836']}, {'resource': ['UniProt Accession'], 'identifier': ['CD20_HUMAN']}]}], 'synonyms': [{'synonym': ['B-lymphocyte surface antigen B1', 'Bp35', 'CD20', 'Leukocyte surface antigen Leu-16', 'Membrane-spanning 4-domains subfamily A member 1']}], 'amino-acid-sequence': ['>lcl|BSEQ0000132|B-lymphocyte antigen CD20\nMTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRRMSSLVGPTQSFFMRESKTLGAVQIMNG\nLFHIALGGLLMIPAGIYAPICVTVWYPLWGGIMYIISGSLLAATEKNSRKCLVKGKMIMN\nSLSLFAAISGMILSIMDILNIKISHFLKMESLNFIRAHTPYINIYNCEPANPSEKNSPST\nQYCYSIQSLFLGILSVMLIFAFFQELVIAGIVENEWKRTCSRPKSNIVLLSAEEKKEQTI\nEIKEEVVGLTETSSQPKNEEDIEIIPIQEEEEEETETNFPEPPQDQESSPIENDSSP'], 'gene-sequence': ['>lcl|BSEQ0009913|B-lymphocyte antigen CD20 (MS4A1)\nATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCT\nATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCC\nACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGG\nCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATC\nTGTGTGACTGTGTGGTACCCTCTCTGGGGAGGCATTATGTATATTATTTCCGGATCACTC\nCTGGCAGCAACGGAGAAAAACTCCAGGAAGTGTTTGGTCAAAGGAAAAATGATAATGAAT\nTCATTGAGCCTCTTTGCTGCCATTTCTGGAATGATTCTTTCAATCATGGACATACTTAAT\nATTAAAATTTCCCATTTTTTAAAAATGGAGAGTCTGAATTTTATTAGAGCTCACACACCA\nTATATTAACATATACAACTGTGAACCAGCTAATCCCTCTGAGAAAAACTCCCCATCTACC\nCAATACTGTTACAGCATACAATCTCTGTTCTTGGGCATTTTGTCAGTGATGCTGATCTTT\nGCCTTCTTCCAGGAACTTGTAATAGCTGGCATCGTTGAGAATGAATGGAAAAGAACGTGC\nTCCAGACCCAAATCTAACATAGTTCTCCTGTCAGCAGAAGAAAAAAAAGAACAGACTATT\nGAAATAAAAGAAGAAGTGGTTGGGCTAACTGAAACATCTTCCCAACCAAAGAATGAAGAA\nGACATTGAAATTATTCCAATCCAAGAAGAGGAAGAAGAAGAAACAGAGACGAACTTTCCA\nGAACCTCCCCAAGATCAGGAATCCTCACCAATAGAAAATGACAGCTCTCCTTAA'], 'pfams': [{'pfam': [{'identifier': ['PF04103'], 'name': ['CD20']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['function'], 'description': ['MHC class II protein complex binding']}, {'category': ['process'], 'description': ['B cell proliferation']}, {'category': ['process'], 'description': ['humoral immune response']}]}]}]}]}]"
"['DB00074', 'BTD00073', 'BIOD00073']",['Basiliximab'],biotech,"['A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha.']",['liquid'],['For prophylactic treatment of kidney transplant rejection'],"['Basiliximab binds with high-affinity to the alpha-subunit (CD25) of the high-affinity IL-2 receptor. This inhibits IL-2 binding, which inhibits T-cell activation and prevents the body from mounting an immune response against the foreign kidney.']",[None],"[{'target': [{'id': ['BE0000658'], 'name': ['Interleukin-2 receptor subunit alpha'], 'organism': ['Humans'], 'actions': [{'action': ['antibody']}], 'references': [{'articles': [{'article': [{'ref-id': ['A2034'], 'pubmed-id': ['12591363'], 'citation': ['Choy BY, Chan TM, Li FK, Lui SL, Lo WK, Yip T, Tse KC, Lai KN: IL2-receptor antagonist (basiliximab) induction therapy is associated with lower morbidity and mortality in renal transplant recipients. Transplant Proc. 2003 Feb;35(1):195.']}, {'ref-id': ['A2036'], 'pubmed-id': ['9695721'], 'citation': ['Kovarik J, Breidenbach T, Gerbeau C, Korn A, Schmidt AG, Nashan B: Disposition and immunodynamics of basiliximab in liver allograft recipients. Clin Pharmacol Ther. 1998 Jul;64(1):66-72.']}, {'ref-id': ['A2037'], 'pubmed-id': ['16908318'], 'citation': ['Garcia CD, Bittencourt VB, Tumelero A, Antonello JS, Malheiros D, Garcia VD: Plasmapheresis for recurrent posttransplant focal segmental glomerulosclerosis. Transplant Proc. 2006 Jul-Aug;38(6):1904-5.']}, {'ref-id': ['A2038'], 'pubmed-id': ['10512062'], 'citation': ['Berard JL, Velez RL, Freeman RB, Tsunoda SM: A review of interleukin-2 receptor antagonists in solid organ transplantation. Pharmacotherapy. 1999 Oct;19(10):1127-37.']}, {'ref-id': ['A2042'], 'pubmed-id': ['10567956'], 'citation': ['Mentre F, Kovarik J, Gerbeau C: Constructing a prediction interval for time to reach a threshold concentration based on a population pharmacokinetic analysis: an application to basiliximab in renal transplantation. J Pharmacokinet Biopharm. 1999 Apr;27(2):213-30.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interleukin-2 receptor subunit alpha'], 'general-function': ['Interleukin-2 receptor activity'], 'specific-function': ['Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T cells.'], 'gene-name': ['IL2RA'], 'locus': ['10p15-p14'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['241-259'], 'signal-regions': ['1-21'], 'theoretical-pi': ['6.49'], 'molecular-weight': ['30818.915'], 'chromosome-location': ['10'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6008']}, {'resource': ['GenAtlas'], 'identifier': ['IL2RA']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X01057']}, {'resource': ['GenBank Protein Database'], 'identifier': ['33813']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1695']}, {'resource': ['UniProtKB'], 'identifier': ['P01589']}, {'resource': ['UniProt Accession'], 'identifier': ['IL2RA_HUMAN']}]}], 'synonyms': [{'synonym': ['IL-2 receptor subunit alpha', 'p55', 'TAC antigen']}], 'amino-acid-sequence': ['>lcl|BSEQ0018991|Interleukin-2 receptor subunit alpha\nMDSYLLMWGLLTFIMVPGCQAELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKS\nGSLYMLCTGNSSHSSWDNQCQCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQAS\nLPGHCREPPPWENEATERIYHFVVGQMVYYQCVQGYRALHRGPAESVCKMTHGKTRWTQP\nQLICTGEMETSQFPGEEKPQASPEGRPESETSCLVTTTDFQIQTEMAATMETSIFTTEYQ\nVAVAGCVFLLISVLLLSGLTWQRRQRKSRRTI'], 'gene-sequence': ['>lcl|BSEQ0018992|Interleukin-2 receptor subunit alpha (IL2RA)\nATGGATTCATACCTGCTGATGTGGGGACTGCTCACGTTCATCATGGTGCCTGGCTGCCAG\nGCAGAGCTCTGTGACGATGACCCGCCAGAGATCCCACACGCCACATTCAAAGCCATGGCC\nTACAAGGAAGGAACCATGTTGAACTGTGAATGCAAGAGAGGTTTCCGCAGAATAAAAAGC\nGGGTCACTCTATATGCTCTGTACAGGAAACTCTAGCCACTCGTCCTGGGACAACCAATGT\nCAATGCACAAGCTCTGCCACTCGGAACACAACGAAACAAGTGACACCTCAACCTGAAGAA\nCAGAAAGAAAGGAAAACCACAGAAATGCAAAGTCCAATGCAGCCAGTGGACCAAGCGAGC\nCTTCCAGGTCACTGCAGGGAACCTCCACCATGGGAAAATGAAGCCACAGAGAGAATTTAT\nCATTTCGTGGTGGGGCAGATGGTTTATTATCAGTGCGTCCAGGGATACAGGGCTCTACAC\nAGAGGTCCTGCTGAGAGCGTCTGCAAAATGACCCACGGGAAGACAAGGTGGACCCAGCCC\nCAGCTCATATGCACAGGTGAAATGGAGACCAGTCAGTTTCCAGGTGAAGAGAAGCCTCAG\nGCAAGCCCCGAAGGCCGTCCTGAGAGTGAGACTTCCTGCCTCGTCACAACAACAGATTTT\nCAAATACAGACAGAAATGGCTGCAACCATGGAGACGTCCATATTTACAACAGAGTACCAG\nGTAGCAGTGGCCGGCTGTGTTTTCCTGCTGATCAGCGTCCTCCTCCTGAGTGGGCTCACC\nTGGCAGCGGAGACAGAGGAAGAGTAGAAGAACAATCTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00084'], 'name': ['Sushi']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['drug binding']}, {'category': ['function'], 'description': ['interleukin-2 binding']}, {'category': ['function'], 'description': ['interleukin-2 receptor activity']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['activation-induced cell death of T cells']}, {'category': ['process'], 'description': ['apoptotic process']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['cell proliferation']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['inflammatory response']}, {'category': ['process'], 'description': ['inflammatory response to antigenic stimulus']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['negative regulation of defense response to virus']}, {'category': ['process'], 'description': ['negative regulation of immune response']}, {'category': ['process'], 'description': ['negative regulation of inflammatory response']}, {'category': ['process'], 'description': ['negative regulation of T cell proliferation']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['Notch signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of activated T cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of T cell differentiation']}, {'category': ['process'], 'description': ['Ras protein signal transduction']}, {'category': ['process'], 'description': ['regulation of T cell homeostatic proliferation']}, {'category': ['process'], 'description': ['regulation of T cell tolerance induction']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}]}]}]}, {'id': ['BE0000651'], 'name': ['Interleukin-2 receptor subunit beta'], 'organism': ['Humans'], 'actions': [{'action': ['antibody']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13281'], 'pubmed-id': ['10188761'], 'citation': ['Onrust SV, Wiseman LR: Basiliximab. Drugs. 1999 Feb;57(2):207-13; discussion 214.']}, {'ref-id': ['A13282'], 'pubmed-id': ['10708100'], 'citation': ['Hausen B, Gummert J, Berry GJ, Christians U, Serkova N, Ikonen T, Hook L, Legay F, Schuler W, Schreier MH, Morris RE: Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin. Transplantation. 2000 Feb 27;69(4):488-96.']}, {'ref-id': ['A13283'], 'pubmed-id': ['11840795'], 'citation': ['Schmitz K, Hitzer S, Behrens-Baumann W: [Immune suppression by combination therapy with basiliximab and cyclosporin in high risk keratoplasty. A pilot study]. Ophthalmologe. 2002 Jan;99(1):38-45.']}, {'ref-id': ['A13284'], 'pubmed-id': ['12667677'], 'citation': ['Warle MC, Kwekkeboom J, Tilanus HW, Metselaar HJ: Basiliximab interferes with the detection of soluble IL-2 receptor by the Immulite Immunoassay system. J Immunol Methods. 2003 Apr 1;275(1-2):133-6.']}, {'ref-id': ['A13285'], 'pubmed-id': ['12826150'], 'citation': ['Emparan C, Laukotter M, Wolters H, Dame C, Heidenreich S, Senninger N: Calcineurin-free protocols with basiliximab induction allow patients included in ""old to old"" programs achieve standard kidney transplant function. Transplant Proc. 2003 Jun;35(4):1326-7.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Interleukin-2 receptor subunit beta'], 'general-function': ['Interleukin-2 receptor activity'], 'specific-function': ['Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2.'], 'gene-name': ['IL2RB'], 'locus': ['22q13|22q13.1'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['241-265'], 'signal-regions': ['1-26'], 'theoretical-pi': ['4.68'], 'molecular-weight': ['61116.59'], 'chromosome-location': ['22'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6009']}, {'resource': ['GenAtlas'], 'identifier': ['IL2RB']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M26062']}, {'resource': ['GenBank Protein Database'], 'identifier': ['307048']}, {'resource': ['UniProtKB'], 'identifier': ['P14784']}, {'resource': ['UniProt Accession'], 'identifier': ['IL2RB_HUMAN']}]}], 'synonyms': [{'synonym': ['High affinity IL-2 receptor subunit beta', 'IL-2 receptor subunit beta', 'p70-75', 'p75']}], 'amino-acid-sequence': ['>lcl|BSEQ0016166|Interleukin-2 receptor subunit beta\nMAAPALSWRLPLLILLLPLATSWASAAVNGTSQFTCFYNSRANISCVWSQDGALQDTSCQ\nVHAWPDRRRWNQTCELLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMA\nIQDFKPFENLRLMAPISLQVVHVETHRCNISWEISQASHYFERHLEFEARTLSPGHTWEE\nAPLLTLKQKQEWICLETLTPDTQYEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAALGKDT\nIPWLGHLLVGLSGAFGFIILVYLLINCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDV\nQKWLSSPFPSSSFSPGGLAPEISPLEVLERDKVTQLLLQQDKVPEPASLSSNHSLTSCFT\nNQGYFFFHLPDALEIEACQVYFTYDPYSEEDPDEGVAGAPTGSSPQPLQPLSGEDDAYCT\nFPSRDDLLLFSPSLLGGPSPPSTAPGGSGAGEERMPPSLQERVPRDWDPQPLGPPTPGVP\nDLVDFQPPPELVLREAGEEVPDAGPREGVSFPWSRPPGQGEFRALNARLPLNTDAYLSLQ\nELQGQDPTHLV'], 'gene-sequence': ['>lcl|BSEQ0016167|Interleukin-2 receptor subunit beta (IL2RB)\nATGGCGGCCCCTGCTCTGTCCTGGCGTCTGCCCCTCCTCATCCTCCTCCTGCCCCTGGCT\nACCTCTTGGGCATCTGCAGCGGTGAATGGCACTTCCCAGTTCACATGCTTCTACAACTCG\nAGAGCCAACATCTCCTGTGTCTGGAGCCAAGATGGGGCTCTGCAGGACACTTCCTGCCAA\nGTCCATGCCTGGCCGGACAGACGGCGGTGGAACCAAACCTGTGAGCTGCTCCCCGTGAGT\nCAAGCATCCTGGGCCTGCAACCTGATCCTCGGAGCCCCAGATTCTCAGAAACTGACCACA\nGTTGACATCGTCACCCTGAGGGTGCTGTGCCGTGAGGGGGTGCGATGGAGGGTGATGGCC\nATCCAGGACTTCAAGCCCTTTGAGAACCTTCGCCTGATGGCCCCCATCTCCCTCCAAGTT\nGTCCACGTGGAGACCCACAGATGCAACATAAGCTGGGAAATCTCCCAAGCCTCCCACTAC\nTTTGAAAGACACCTGGAGTTCGAGGCCCGGACGCTGTCCCCAGGCCACACCTGGGAGGAG\nGCCCCCCTGCTGACTCTCAAGCAGAAGCAGGAATGGATCTGCCTGGAGACGCTCACCCCA\nGACACCCAGTATGAGTTTCAGGTGCGGGTCAAGCCTCTGCAAGGCGAGTTCACGACCTGG\nAGCCCCTGGAGCCAGCCCCTGGCCTTCAGGACAAAGCCTGCAGCCCTTGGGAAGGACACC\nATTCCGTGGCTCGGCCACCTCCTCGTGGGCCTCAGCGGGGCTTTTGGCTTCATCATCTTA\nGTGTACTTGCTGATCAACTGCAGGAACACCGGGCCATGGCTGAAGAAGGTCCTGAAGTGT\nAACACCCCAGACCCCTCGAAGTTCTTTTCCCAGCTGAGCTCAGAGCATGGAGGAGACGTC\nCAGAAGTGGCTCTCTTCGCCCTTCCCCTCATCGTCCTTCAGCCCTGGCGGCCTGGCACCT\nGAGATCTCGCCACTAGAAGTGCTGGAGAGGGACAAGGTGACGCAGCTGCTCCTGCAGCAG\nGACAAGGTGCCTGAGCCCGCATCCTTAAGCAGCAACCACTCGCTGACCAGCTGCTTCACC\nAACCAGGGTTACTTCTTCTTCCACCTCCCGGATGCCTTGGAGATAGAGGCCTGCCAGGTG\nTACTTTACTTACGACCCCTACTCAGAGGAAGACCCTGATGAGGGTGTGGCCGGGGCACCC\nACAGGGTCTTCCCCCCAACCCCTGCAGCCTCTGTCAGGGGAGGACGACGCCTACTGCACC\nTTCCCCTCCAGGGATGACCTGCTGCTCTTCTCCCCCAGTCTCCTCGGTGGCCCCAGCCCC\nCCAAGCACTGCCCCTGGGGGCAGTGGGGCCGGTGAAGAGAGGATGCCCCCTTCTTTGCAA\nGAAAGAGTCCCCAGAGACTGGGACCCCCAGCCCCTGGGGCCTCCCACCCCAGGAGTCCCA\nGACCTGGTGGATTTTCAGCCACCCCCTGAGCTGGTGCTGCGAGAGGCTGGGGAGGAGGTC\nCCTGACGCTGGCCCCAGGGAGGGAGTCAGTTTCCCCTGGTCCAGGCCTCCTGGGCAGGGG\nGAGTTCAGGGCCCTTAATGCTCGCCTGCCCCTGAACACTGATGCCTACTTGTCCCTCCAA\nGAACTCCAGGGTCAGGACCCAACTCACTTGGTGTAG'], 'pfams': [None], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['interleukin-2 binding']}, {'category': ['function'], 'description': ['interleukin-2 receptor activity']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['interleukin-2-mediated signaling pathway']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['negative regulation of apoptotic process']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['protein complex assembly']}, {'category': ['process'], 'description': ['Ras protein signal transduction']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['viral process']}]}]}]}]}]"
"['DB00075', 'BTD00005', 'BIOD00005']",['Muromonab'],biotech,"['Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type 2a (IgG2a).']",['liquid'],"['For treatment of organ transplant recipients, prevention of organ rejection']","['Muromonab binds to the T-cell surface glycoprotein CD3 epsilon chain. It appears to kill CD-3 positive cells by inducing Fc mediated apoptosis, antibody mediated cytotoxicity and complement-dependent cytotoxicity.']",[None],"[{'target': [{'id': ['BE0003456'], 'name': ['T-cell surface glycoprotein CD3 delta chain'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A15421'], 'pubmed-id': ['2503348'], 'citation': ['Todd PA, Brogden RN: Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs. 1989 Jun;37(6):871-99.']}, {'ref-id': ['A15422'], 'pubmed-id': ['8861551'], 'citation': ['Wilde MI, Goa KL: Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs. 1996 May;51(5):865-94.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['T-cell surface glycoprotein CD3 delta chain'], 'general-function': ['Transmembrane signaling receptor activity'], 'specific-function': ['The CD3 complex mediates signal transduction.'], 'gene-name': ['CD3D'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['106-126'], 'signal-regions': ['1-21'], 'theoretical-pi': ['5.21'], 'molecular-weight': ['18929.38'], 'chromosome-location': ['11'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1673']}, {'resource': ['GenAtlas'], 'identifier': ['CD3D']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X01451']}, {'resource': ['UniProtKB'], 'identifier': ['P04234']}, {'resource': ['UniProt Accession'], 'identifier': ['CD3D_HUMAN']}]}], 'synonyms': [{'synonym': ['T-cell receptor T3 delta chain', 'T3D']}], 'amino-acid-sequence': ['>lcl|BSEQ0006727|T-cell surface glycoprotein CD3 delta chain\nMEHSTFLSGLVLATLLSQVSPFKIPIEELEDRVFVNCNTSITWVEGTVGTLLSDITRLDL\nGKRILDPRGIYRCNGTDIYKDKESTVQVHYRMCQSCVELDPATVAGIIVTDVIATLLLAL\nGVFCFAGHETGRLSGAADTQALLRNDQVYQPLRDRDDAQYSHLGGNWARNK'], 'gene-sequence': ['>lcl|BSEQ0017107|T-cell surface glycoprotein CD3 delta chain (CD3D)\nATGGAACATAGCACGTTTCTCTCTGGCCTGGTACTGGCTACCCTTCTCTCGCAAGTGAGC\nCCCTTCAAGATACCTATAGAGGAACTTGAGGACAGAGTGTTTGTGAATTGCAATACCAGC\nATCACATGGGTAGAGGGAACGGTGGGAACACTGCTCTCAGACATTACAAGACTGGACCTG\nGGAAAACGCATCCTGGACCCACGAGGAATATATAGGTGTAATGGGACAGATATATACAAG\nGACAAAGAATCTACCGTGCAAGTTCATTATCGAATGTGCCAGAGCTGTGTGGAGCTGGAT\nCCAGCCACCGTGGCTGGCATCATTGTCACTGATGTCATTGCCACTCTGCTCCTTGCTTTG\nGGAGTCTTCTGCTTTGCTGGACATGAGACTGGAAGGCTGTCTGGGGCTGCCGACACACAA\nGCTCTGTTGAGGAATGACCAGGTCTATCAGCCCCTCCGAGATCGAGATGATGCTCAGTAC\nAGCCACCTTGGAGGAAACTGGGCTCGGAACAAGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF02189'], 'name': ['ITAM']}, {'identifier': ['PF16680'], 'name': ['Ig_4']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['alpha-beta T cell receptor complex']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['T cell receptor complex']}, {'category': ['function'], 'description': ['protein heterodimerization activity']}, {'category': ['function'], 'description': ['transcription coactivator activity']}, {'category': ['function'], 'description': ['transmembrane signaling receptor activity']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['positive thymic T cell selection']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['T cell costimulation']}, {'category': ['process'], 'description': ['T cell differentiation']}, {'category': ['process'], 'description': ['T cell receptor signaling pathway']}]}]}]}, {'id': ['BE0000274'], 'name': ['T-cell surface glycoprotein CD3 epsilon chain'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['T-cell surface glycoprotein CD3 epsilon chain'], 'general-function': ['Transmembrane signaling receptor activity'], 'specific-function': ['The CD3 complex mediates signal transduction, resulting in T cell activation and proliferation. Required for normal immune responses (PubMed:15546002, PubMed:8490660).'], 'gene-name': ['CD3E'], 'locus': ['11q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['127-152'], 'signal-regions': ['1-22'], 'theoretical-pi': ['6.75'], 'molecular-weight': ['23147.09'], 'chromosome-location': ['11'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1674']}, {'resource': ['GenAtlas'], 'identifier': ['CD3E']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X03884']}, {'resource': ['GenBank Protein Database'], 'identifier': ['469945']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2742']}, {'resource': ['UniProtKB'], 'identifier': ['P07766']}, {'resource': ['UniProt Accession'], 'identifier': ['CD3E_HUMAN']}]}], 'synonyms': [{'synonym': ['T-cell surface antigen T3/Leu-4 epsilon chain', 'T3E']}], 'amino-acid-sequence': ['>lcl|BSEQ0016054|T-cell surface glycoprotein CD3 epsilon chain\nMQSGTHWRVLGLCLLSVGVWGQDGNEEMGGITQTPYKVSISGTTVILTCPQYPGSEILWQ\nHNDKNIGGDEDDKNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRARVCE\nNCMEMDVMSVATIVIVDICITGGLLLLVYYWSKNRKAKAKPVTRGAGAGGRQRGQNKERP\nPPVPNPDYEPIRKGQRDLYSGLNQRRI'], 'gene-sequence': ['>lcl|BSEQ0016055|T-cell surface glycoprotein CD3 epsilon chain (CD3E)\nATGCAGTCGGGCACTCACTGGAGAGTTCTGGGCCTCTGCCTCTTATCAGTTGGCGTTTGG\nGGGCAAGATGGTAATGAAGAAATGGGTGGTATTACACAGACACCATATAAAGTCTCCATC\nTCTGGAACCACAGTAATATTGACATGCCCTCAGTATCCTGGATCTGAAATACTATGGCAA\nCACAATGATAAAAACATAGGCGGTGATGAGGATGATAAAAACATAGGCAGTGATGAGGAT\nCACCTGTCACTGAAGGAATTTTCAGAATTGGAGCAAAGTGGTTATTATGTCTGCTACCCC\nAGAGGAAGCAAACCAGAAGATGCGAACTTTTATCTCTACCTGAGGGCAAGAGTGTGTGAG\nAACTGCATGGAGATGGATGTGATGTCGGTGGCCACAATTGTCATAGTGGACATCTGCATC\nACTGGGGGCTTGCTGCTGCTGGTTTACTACTGGAGCAAGAATAGAAAGGCCAAGGCCAAG\nCCTGTGACACGAGGAGCGGGTGCTGGCGGCAGGCAAAGGGGACAAAACAAGGAGAGGCCA\nCCACCTGTTCCCAACCCAGACTATGAGCCCATCCGGAAAGGCCAGCGGGACCTGTATTCT\nGGCCTGAATCAGAGACGCATCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF02189'], 'name': ['ITAM']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['alpha-beta T cell receptor complex']}, {'category': ['component'], 'description': ['cell-cell junction']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['immunological synapse']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['T cell receptor complex']}, {'category': ['function'], 'description': ['protein heterodimerization activity']}, {'category': ['function'], 'description': ['protein kinase binding']}, {'category': ['function'], 'description': ['receptor signaling complex scaffold activity']}, {'category': ['function'], 'description': ['receptor signaling protein activity']}, {'category': ['function'], 'description': ['SH3 domain binding']}, {'category': ['function'], 'description': ['T cell receptor binding']}, {'category': ['function'], 'description': ['transmembrane signaling receptor activity']}, {'category': ['process'], 'description': ['apoptotic signaling pathway']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['intracellular signal transduction']}, {'category': ['process'], 'description': ['negative regulation of gene expression']}, {'category': ['process'], 'description': ['negative regulation of smoothened signaling pathway']}, {'category': ['process'], 'description': ['negative thymic T cell selection']}, {'category': ['process'], 'description': ['positive regulation of alpha-beta T cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of calcium-mediated signaling']}, {'category': ['process'], 'description': ['positive regulation of gene expression']}, {'category': ['process'], 'description': ['positive regulation of interferon-gamma production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-2 biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of interleukin-4 production']}, {'category': ['process'], 'description': ['positive regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of T cell anergy']}, {'category': ['process'], 'description': ['positive regulation of T cell proliferation']}, {'category': ['process'], 'description': ['protein complex assembly']}, {'category': ['process'], 'description': ['regulation of apoptotic process']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['response to nutrient']}, {'category': ['process'], 'description': ['signal complex assembly']}, {'category': ['process'], 'description': ['T cell activation']}, {'category': ['process'], 'description': ['T cell costimulation']}, {'category': ['process'], 'description': ['T cell receptor signaling pathway']}, {'category': ['process'], 'description': ['transmembrane receptor protein tyrosine kinase signaling pathway']}]}]}]}, {'id': ['BE0003457'], 'name': ['T-cell surface glycoprotein CD3 gamma chain'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A15421'], 'pubmed-id': ['2503348'], 'citation': ['Todd PA, Brogden RN: Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs. 1989 Jun;37(6):871-99.']}, {'ref-id': ['A15422'], 'pubmed-id': ['8861551'], 'citation': ['Wilde MI, Goa KL: Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs. 1996 May;51(5):865-94.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['T-cell surface glycoprotein CD3 gamma chain'], 'general-function': ['Transmembrane signaling receptor activity'], 'specific-function': ['The CD3 complex mediates signal transduction.'], 'gene-name': ['CD3G'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['117-137'], 'signal-regions': ['1-22'], 'theoretical-pi': ['8.59'], 'molecular-weight': ['20469.335'], 'chromosome-location': ['11'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1675']}, {'resource': ['GenAtlas'], 'identifier': ['CD3G']}, {'resource': ['GenBank Gene Database'], 'identifier': ['BC113830']}, {'resource': ['UniProtKB'], 'identifier': ['P09693']}, {'resource': ['UniProt Accession'], 'identifier': ['CD3G_HUMAN']}]}], 'synonyms': [{'synonym': ['T-cell receptor T3 gamma chain', 'T3G']}], 'amino-acid-sequence': ['>lcl|BSEQ0012414|T-cell surface glycoprotein CD3 gamma chain\nMEQGKGLAVLILAIILLQGTLAQSIKGNHLVKVYDYQEDGSVLLTCDAEAKNITWFKDGK\nMIGFLTEDKKKWNLGSNAKDPRGMYQCKGSQNKSKPLQVYYRMCQNCIELNAATISGFLF\nAEIVSIFVLAVGVYFIAGQDGVRQSRASDKQTLLPNDQLYQPLKDREDDQYSHLQGNQLR\nRN'], 'gene-sequence': ['>lcl|BSEQ0012415|T-cell surface glycoprotein CD3 gamma chain (CD3G)\nATGGAACAGGGGAAGGGCCTGGCTGTCCTCATCCTGGCTATCATTCTTCTTCAAGGTACT\nTTGGCCCAGTCAATCAAAGGAAACCACTTGGTTAAGGTGTATGACTATCAAGAAGATGGT\nTCGGTACTTCTGACTTGTGATGCAGAAGCCAAAAATATCACATGGTTTAAAGATGGGAAG\nATGATCGGCTTCCTAACTGAAGATAAAAAAAAATGGAATCTGGGAAGTAATGCCAAGGAC\nCCTCGAGGGATGTATCAGTGTAAAGGATCACAGAACAAGTCAAAACCACTCCAAGTGTAT\nTACAGAATGTGTCAGAACTGCATTGAACTAAATGCAGCCACCATATCTGGCTTTCTCTTT\nGCTGAAATCGTCAGCATTTTCGTCCTTGCTGTTGGGGTCTACTTCATTGCTGGACAGGAT\nGGAGTTCGCCAGTCGAGAGCTTCAGACAAGCAGACTCTGTTGCCCAATGACCAGCTCTAC\nCAGCCCCTCAAGGATCGAGAAGATGACCAGTACAGCCACCTTCAAGGAAACCAGTTGAGG\nAGGAATTGA'], 'pfams': [{'pfam': [{'identifier': ['PF02189'], 'name': ['ITAM']}, {'identifier': ['PF16680'], 'name': ['Ig_4']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['alpha-beta T cell receptor complex']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['T cell receptor complex']}, {'category': ['function'], 'description': ['protein heterodimerization activity']}, {'category': ['function'], 'description': ['receptor signaling complex scaffold activity']}, {'category': ['function'], 'description': ['T cell receptor binding']}, {'category': ['function'], 'description': ['transmembrane signaling receptor activity']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['establishment or maintenance of cell polarity']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['protein complex assembly']}, {'category': ['process'], 'description': ['protein transport']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['regulation of lymphocyte apoptotic process']}, {'category': ['process'], 'description': ['T cell activation']}, {'category': ['process'], 'description': ['T cell costimulation']}, {'category': ['process'], 'description': ['T cell receptor signaling pathway']}]}]}]}, {'id': ['BE0003458'], 'name': ['T-cell surface glycoprotein CD3 zeta chain'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A15421'], 'pubmed-id': ['2503348'], 'citation': ['Todd PA, Brogden RN: Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs. 1989 Jun;37(6):871-99.']}, {'ref-id': ['A15422'], 'pubmed-id': ['8861551'], 'citation': ['Wilde MI, Goa KL: Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs. 1996 May;51(5):865-94.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['T-cell surface glycoprotein CD3 zeta chain'], 'general-function': ['Transmembrane signaling receptor activity'], 'specific-function': ['Probable role in assembly and expression of the TCR complex as well as signal transduction upon antigen triggering.'], 'gene-name': ['CD247'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['31-51'], 'signal-regions': ['1-21'], 'theoretical-pi': ['9.65'], 'molecular-weight': ['18696.275'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1677']}, {'resource': ['GenAtlas'], 'identifier': ['CD247']}, {'resource': ['GenBank Gene Database'], 'identifier': ['BC025703']}, {'resource': ['UniProtKB'], 'identifier': ['P20963']}, {'resource': ['UniProt Accession'], 'identifier': ['CD3Z_HUMAN']}]}], 'synonyms': [{'synonym': ['CD3Z', 'T-cell receptor T3 zeta chain', 'T3Z', 'TCRZ']}], 'amino-acid-sequence': ['>lcl|BSEQ0006729|T-cell surface glycoprotein CD3 zeta chain\nMKWKALFTAAILQAQLPITEAQSFGLLDPKLCYLLDGILFIYGVILTALFLRVKFSRSAD\nAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMA\nEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR'], 'gene-sequence': ['>lcl|BSEQ0017108|T-cell surface glycoprotein CD3 zeta chain (CD247)\nATGAAGTGGAAGGCGCTTTTCACCGCGGCCATCCTGCAGGCACAGTTGCCGATTACAGAG\nGCACAGAGCTTTGGCCTGCTGGATCCCAAACTCTGCTACCTGCTGGATGGAATCCTCTTC\nATCTATGGTGTCATTCTCACTGCCTTGTTCCTGAGAGTGAAGTTCAGCAGGAGCGCAGAC\nGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGA\nGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCG\nAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAG\nGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTT\nTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTG\nCCCCCTCGCTAA'], 'pfams': [{'pfam': [{'identifier': ['PF02189'], 'name': ['ITAM']}, {'identifier': ['PF11628'], 'name': ['TCR_zetazeta']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['alpha-beta T cell receptor complex']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['T cell receptor complex']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['function'], 'description': ['protein homodimerization activity']}, {'category': ['function'], 'description': ['transmembrane signaling receptor activity']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['regulation of defense response to virus by virus']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['T cell costimulation']}, {'category': ['process'], 'description': ['T cell receptor signaling pathway']}, {'category': ['process'], 'description': ['viral process']}]}]}]}, {'id': ['BE0000901'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor III-B'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13286'], 'pubmed-id': ['10851527'], 'citation': ['Pellegrini P, Berghella AM, Del Beato T, Adorno D, Casciani CU: Immunological directives for biotherapy improvement in the treatment of colorectal cancer. Cancer Biother Radiopharm. 1996 Apr;11(2):113-8.']}, {'ref-id': ['A13287'], 'pubmed-id': ['10851498'], 'citation': ['Contasta I, Pellegrini P, Berghella AM, Del Beato T, Canossi A, Di Rocco M, Adorno D, Casciani CU: Necessity of biotherapeutic treatments inducing TH1 cell functions in colorectal cancer. Cancer Biother Radiopharm. 1996 Dec;11(6):373-83.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor III-B'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.'], 'gene-name': ['FCGR3B'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': [None], 'signal-regions': ['1-16'], 'theoretical-pi': ['6.71'], 'molecular-weight': ['26215.64'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3620']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR3B']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X16863']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31322']}, {'resource': ['UniProtKB'], 'identifier': ['O75015']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG3B_HUMAN']}]}], 'synonyms': [{'synonym': ['CD16B', 'Fc-gamma RIII', 'Fc-gamma RIII-beta', 'Fc-gamma RIIIb', 'FCG3', 'FCGR3', 'FcR-10', 'FcRIII', 'FcRIIIb', 'IGFR3', 'IgG Fc receptor III-1']}], 'amino-acid-sequence': ['>lcl|BSEQ0010635|Low affinity immunoglobulin gamma Fc region receptor III-B\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI'], 'gene-sequence': ['>lcl|BSEQ0010636|Low affinity immunoglobulin gamma Fc region receptor III-B (FCGR3B)\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['anchored component of membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['mitophagy in response to mitochondrial depolarization']}, {'category': ['process'], 'description': ['positive regulation of defense response to virus by host']}, {'category': ['process'], 'description': ['xenophagy']}]}]}]}]}]"
"['DB00076', 'BTD00046', 'BTD00027', 'BIOD00046', 'BIOD00027']",['Digoxin Immune Fab (Ovine)'],biotech,['Digoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative Digoxindicarboxymethylamine. It is used as an antidote for overdose of digoxin.'],['liquid'],['For treatment of digitoxin overdose or digitalis glycoside toxicity.'],['Binds excess digoxin or digitoxin molecules circulating in the blood.'],[None],"[{'target': [{'id': ['BE0004837'], 'name': ['Digoxin'], 'organism': ['Humans'], 'actions': [{'action': ['other/unknown']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A6683'], 'pubmed-id': ['12194938'], 'citation': ['McMillin GA, Owen WE, Lambert TL, De BK, Frank EL, Bach PR, Annesley TM, Roberts WL: Comparable effects of DIGIBIND and DigiFab in thirteen digoxin immunoassays. Clin Chem. 2002 Sep;48(9):1580-4.']}, {'ref-id': ['A6684'], 'pubmed-id': ['17630695'], 'citation': ['Chhatre S, Thillaivinayagalingam P, Francis R, Titchener-Hooker NJ, Newcombe AR, Keshavarz-Moore E: Decision-support software for the industrial-scale chromatographic purification of antibodies. Biotechnol Prog. 2007 Jul-Aug;23(4):888-94. Epub 2007 Jul 13.']}, {'ref-id': ['A6685'], 'pubmed-id': ['17516918'], 'citation': [""Thillaivinayagalingam P, Newcombe AR, O'Donovan K, Francis R, Keshavarz-Moore E: Detection and quantification of affinity ligand leaching and specific antibody fragment concentration within chromatographic fractions using surface plasmon resonance. Biotechnol Appl Biochem. 2007 Dec;48(Pt 4):179-88.""]}, {'ref-id': ['A6511'], 'pubmed-id': ['16946442'], 'citation': ['Betten DP, Vohra RB, Cook MD, Matteucci MJ, Clark RF: Antidote use in the critically ill poisoned patient. J Intensive Care Med. 2006 Sep-Oct;21(5):255-77.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes']}]}]"
"['DB00078', 'BTD00069', 'BIOD00069']",['Ibritumomab tiuxetan'],biotech,"['Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.']",['liquid'],"[""For treatment of non-Hodgkin's lymphoma""]","['The Fab segment of the antibody targets the CD20 epitope on B-cells, allowing the radioactive yttrium to destroy the cell via production of beta particles.']","[{'food-interaction': ['Avoid herbs and supplements with anticoagulant/antiplatelet activity. Individuals taking these herbs/supplements while taking ibritumomab tiuxetan should be monitored for thrombocytopenia more frequently. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.']}]","[{'target': [{'id': ['BE0000066'], 'name': ['B-lymphocyte antigen CD20'], 'organism': ['Humans'], 'actions': [{'action': ['antibody', 'regulator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A2044'], 'pubmed-id': ['10541376'], 'citation': [""Wiseman GA, White CA, Witzig TE, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Grillo-Lopez AJ: Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res. 1999 Oct;5(10 Suppl):3281s-3286s.""]}, {'ref-id': ['A2046'], 'pubmed-id': ['11418316'], 'citation': [""Goldenberg DM: The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):195-201.""]}, {'ref-id': ['A2048'], 'pubmed-id': ['11879282'], 'citation': ['Dillman RO: Monoclonal antibody therapy for lymphoma: an update. Cancer Pract. 2001 Mar-Apr;9(2):71-80.']}, {'ref-id': ['A2050'], 'pubmed-id': ['12011122'], 'citation': [""Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002 May 15;20(10):2453-63.""]}, {'ref-id': ['A2052'], 'pubmed-id': ['15045033'], 'citation': [""Witzig TE: Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma. Drugs Today (Barc). 2004 Feb;40(2):111-9.""]}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A2054'], 'pubmed-id': ['20113680'], 'citation': ['Goldsmith SJ: Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med. 2010 Mar;40(2):122-35. doi: 10.1053/j.semnuclmed.2009.11.002.']}, {'ref-id': ['A247090'], 'pubmed-id': ['33807678'], 'citation': ['Kyriakidis I, Vasileiou E, Rossig C, Roilides E, Groll AH, Tragiannidis A: Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies. J Fungi (Basel). 2021 Mar 5;7(3). pii: jof7030186. doi: 10.3390/jof7030186.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['B-lymphocyte antigen CD20'], 'general-function': ['Mhc class ii protein complex binding'], 'specific-function': ['This protein may be involved in the regulation of B-cell activation and proliferation.'], 'gene-name': ['MS4A1'], 'locus': ['11q12'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['57-78\n85-105\n121-141\n189-209'], 'signal-regions': [None], 'theoretical-pi': ['4.73'], 'molecular-weight': ['33076.99'], 'chromosome-location': ['11'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:7315']}, {'resource': ['GenAtlas'], 'identifier': ['MS4A1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X12530']}, {'resource': ['GenBank Protein Database'], 'identifier': ['29774']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2628']}, {'resource': ['UniProtKB'], 'identifier': ['P11836']}, {'resource': ['UniProt Accession'], 'identifier': ['CD20_HUMAN']}]}], 'synonyms': [{'synonym': ['B-lymphocyte surface antigen B1', 'Bp35', 'CD20', 'Leukocyte surface antigen Leu-16', 'Membrane-spanning 4-domains subfamily A member 1']}], 'amino-acid-sequence': ['>lcl|BSEQ0000132|B-lymphocyte antigen CD20\nMTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRRMSSLVGPTQSFFMRESKTLGAVQIMNG\nLFHIALGGLLMIPAGIYAPICVTVWYPLWGGIMYIISGSLLAATEKNSRKCLVKGKMIMN\nSLSLFAAISGMILSIMDILNIKISHFLKMESLNFIRAHTPYINIYNCEPANPSEKNSPST\nQYCYSIQSLFLGILSVMLIFAFFQELVIAGIVENEWKRTCSRPKSNIVLLSAEEKKEQTI\nEIKEEVVGLTETSSQPKNEEDIEIIPIQEEEEEETETNFPEPPQDQESSPIENDSSP'], 'gene-sequence': ['>lcl|BSEQ0009913|B-lymphocyte antigen CD20 (MS4A1)\nATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCT\nATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCC\nACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGG\nCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATC\nTGTGTGACTGTGTGGTACCCTCTCTGGGGAGGCATTATGTATATTATTTCCGGATCACTC\nCTGGCAGCAACGGAGAAAAACTCCAGGAAGTGTTTGGTCAAAGGAAAAATGATAATGAAT\nTCATTGAGCCTCTTTGCTGCCATTTCTGGAATGATTCTTTCAATCATGGACATACTTAAT\nATTAAAATTTCCCATTTTTTAAAAATGGAGAGTCTGAATTTTATTAGAGCTCACACACCA\nTATATTAACATATACAACTGTGAACCAGCTAATCCCTCTGAGAAAAACTCCCCATCTACC\nCAATACTGTTACAGCATACAATCTCTGTTCTTGGGCATTTTGTCAGTGATGCTGATCTTT\nGCCTTCTTCCAGGAACTTGTAATAGCTGGCATCGTTGAGAATGAATGGAAAAGAACGTGC\nTCCAGACCCAAATCTAACATAGTTCTCCTGTCAGCAGAAGAAAAAAAAGAACAGACTATT\nGAAATAAAAGAAGAAGTGGTTGGGCTAACTGAAACATCTTCCCAACCAAAGAATGAAGAA\nGACATTGAAATTATTCCAATCCAAGAAGAGGAAGAAGAAGAAACAGAGACGAACTTTCCA\nGAACCTCCCCAAGATCAGGAATCCTCACCAATAGAAAATGACAGCTCTCCTTAA'], 'pfams': [{'pfam': [{'identifier': ['PF04103'], 'name': ['CD20']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['function'], 'description': ['MHC class II protein complex binding']}, {'category': ['process'], 'description': ['B cell proliferation']}, {'category': ['process'], 'description': ['humoral immune response']}]}]}]}]}]"
"['DB00080', 'BTD00111', 'BIOD00111']",['Daptomycin'],small molecule,"['Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant _Staphylococcus aureus_ (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE).[A231379, A231384, L32534] Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal tryptophan covalently bonded to decanoic acid.[A231374, L32534] Daptomycin was first discovered in the early 1980s by researchers at Eli Lilly in soil samples from Mount Ararat in Turkey.[A231384] Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing scheme reduced side effects while retaining efficacy.[A231379]\r\n\r\nDaptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN by Cubist Pharmaceuticals LLC (Merck & Co.).[L32534]']",['solid'],"['Daptomycin is indicated for the treatment of complicated skin and skin structure infections (cSSSI) in patients one year of age and older. It is also indicated for the treatment of _Staphylococcus aureus_ bloodstream infections (bacteremia) in patients one year of age and older, including in adult patients with right-sided infective endocarditis.[L32534]\r\n\r\nDaptomycin is not indicated for the treatment of pneumonia or left-sided infective endocarditis due to _S. aureus_. Use is not recommended in pediatric patients younger than one year of age due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or\r\ncentral).[L32534]\r\n\r\nAs with all antibacterial drugs, it is strongly suggested to perform sufficient testing before treatment initiation in order to confirm an infection caused by susceptible bacteria. Failure to do so may result in suboptimal treatment, treatment failure, and the development of drug-resistant bacteria.[L32534]']","[""The mechanism of action of daptomycin remains poorly understood. Studies have suggested a direct inhibition of cell membrane/cell wall constituent biosynthesis, including peptidoglycan, uridine diphosphate-N-acid, acetyl-L-alanine, and lipoteichoic acid (LTA). However, no convincing evidence has been presented for any of these models, and an effect on LTA biosynthesis has been ruled out by other studies in _S. aureus_ and _E. faecalis_.[A231384, A231394, A14171]\r\n\r\nIt is well understood that free daptomycin (apo-daptomycin) is a trianion at physiological pH, which binds Ca<sup>2+</sup> in a 1:1 stoichiometric ratio to become a monoanion, which is thought to rely primarily on the Asp(7), Asp(9), and L-3MeGlu12 residues that form a DXDG motif.[A231374, A231379, A231384] Calcium-binding facilitates daptomycin's insertion into bacterial membranes preferentially due to their high content of the acidic phospholipids phosphatidylglycerol (PG) and cardiolipin (CL), wherein it is proposed that daptomycin can bind two calcium equivalents and form oligomers.[A231379] PG is recognized as the main membrane requirement for daptomycin activity; daptomycin preferentially localizes in PG-rich membrane domains, and mutations affecting PG prevalence are linked to daptomycin resistance.[A231379] Calcium-dependent membrane binding is the generally accepted mechanism of action for daptomycin, but the precise downstream effects are unclear, and numerous models have been proposed.\r\n\r\nOne mechanism proposes that the daptomycin membrane binding alters membrane fluidity, causing dissociation of cell wall biosynthetic enzymes such as the lipid II synthase MurG and the phospholipid synthase PlsX.[A231384] This is consistent with the observed effects of daptomycin on cell shape in various bacteria at concentrations at or above the minimum inhibitory concentration (MIC).[A14171] Aberrant cell morphology is also consistent with the observed localization of daptomycin at the division septa and a hypothesized role in inhibiting cell division.[A231379] A recent study suggested the formation of tripartite complexes containing calcium-bound daptomycin, PG, and various undecaprenyl-coupled cell envelope precursors, which subsequently include lipid II. This complex is proposed to inhibit cell division, lead to the dispersion of cell wall biosynthetic machinery, and eventually cause lysis of the membrane bilayer at the septum causing cell death.[A231384, A231409]\r\n\r\nAnother popular model is based on early observations that daptomycin, in a calcium-dependent manner, caused potassium ion leakage and loss of membrane potential in treated bacterial cells.[A231394, A231419, A231424] Although this lead some to suggest that daptomycin could bind PG to form oligomeric pores in the bacterial membrane,[A231384] no cell lysis was observed in _S. aureus_ or _E. faecalis_,[A231379] and the daptomycin-induced ion conduction is inconsistent with pore formation.[A231429] Rather, it has been proposed that daptomycin forms calcium-dependent dimeric complexes in fixed ratios of Dap<sub>2</sub>Ca<sub>3</sub>PG<sub>2</sub>, which can act as transient ionophores.[A231429] The observed loss of membrane potential is suggested to result in a non-specific loss of gradient-dependent nutrient transport, ATP production, and biosynthesis, leading to cell death.[A231379, A231424]\r\n\r\nNotably, these models are not strictly mutually exclusive and are supported to varying extents by observed resistance mutations. The strict requirement for PG for daptomycin bactericidal action is supported by mutations in _mprF_, _cls2_, _pgsA_, and the _dlt_ operon in _S. aureus_, _cls_ in various enterococci, and _pgsA_, PG synthase, and the _dlt_ operon in _E. faecium_, all of which alter the bacterial membrane composition and specifically the PG content of bacterial membranes. Other noted mutations in various regulatory systems that control membrane homeostasis also support the cell membrane as the site of daptomycin action. Curiously, in _E. faecalis_, the most commonly observed form of daptomycin resistance is characterized by abnormal division septa, which supports the cell division-based mechanism of daptomycin action.[A231379, A231384]""]",[None],"[{'target': [{'id': ['BE0010021'], 'name': ['Cytoplasmic membrane'], 'organism': ['Bacteria'], 'actions': [{'action': ['incorporation into and destabilization']}], 'references': [{'articles': [{'article': [{'ref-id': ['A231374'], 'pubmed-id': ['29059358'], 'citation': ['Heidary M, Khosravi AD, Khoshnood S, Nasiri MJ, Soleimani S, Goudarzi M: Daptomycin. J Antimicrob Chemother. 2018 Jan 1;73(1):1-11. doi: 10.1093/jac/dkx349.']}, {'ref-id': ['A231379'], 'pubmed-id': ['27288182'], 'citation': ['Taylor SD, Palmer M: The action mechanism of daptomycin. Bioorg Med Chem. 2016 Dec 15;24(24):6253-6268. doi: 10.1016/j.bmc.2016.05.052. Epub 2016 May 28.']}, {'ref-id': ['A231384'], 'pubmed-id': ['32687352'], 'citation': ['Karas JA, Carter GP, Howden BP, Turner AM, Paulin OKA, Swarbrick JD, Baker MA, Li J, Velkov T: Structure-Activity Relationships of Daptomycin Lipopeptides. J Med Chem. 2020 Nov 25;63(22):13266-13290. doi: 10.1021/acs.jmedchem.0c00780. Epub 2020 Aug 6.']}, {'ref-id': ['A231394'], 'pubmed-id': ['2821889'], 'citation': ['Allen NE, Hobbs JN, Alborn WE Jr: Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032. Antimicrob Agents Chemother. 1987 Jul;31(7):1093-9. doi: 10.1128/aac.31.7.1093.']}, {'ref-id': ['A14171'], 'pubmed-id': ['2168145'], 'citation': ['Canepari P, Boaretti M, Lleo MM, Satta G: Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032). Antimicrob Agents Chemother. 1990 Jun;34(6):1220-6.']}, {'ref-id': ['A231409'], 'pubmed-id': ['32193379'], 'citation': ['Grein F, Muller A, Scherer KM, Liu X, Ludwig KC, Klockner A, Strach M, Sahl HG, Kubitscheck U, Schneider T: Ca(2+)-Daptomycin targets cell wall biosynthesis by forming a tripartite complex with undecaprenyl-coupled intermediates and membrane lipids. Nat Commun. 2020 Mar 19;11(1):1455. doi: 10.1038/s41467-020-15257-1.']}, {'ref-id': ['A231419'], 'pubmed-id': ['1666494'], 'citation': ['Alborn WE Jr, Allen NE, Preston DA: Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother. 1991 Nov;35(11):2282-7. doi: 10.1128/aac.35.11.2282.']}, {'ref-id': ['A231424'], 'pubmed-id': ['1687346'], 'citation': ['Allen NE, Alborn WE Jr, Hobbs JN Jr: Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrob Agents Chemother. 1991 Dec;35(12):2639-42. doi: 10.1128/aac.35.12.2639.']}, {'ref-id': ['A231429'], 'pubmed-id': ['32526177'], 'citation': ['Huang HW: DAPTOMYCIN, its membrane-active mechanism vs. that of other antimicrobial peptides. Biochim Biophys Acta Biomembr. 2020 Oct 1;1862(10):183395. doi: 10.1016/j.bbamem.2020.183395. Epub 2020 Jun 9.']}]}], 'textbooks': [None], 'links': [{'link': [{'ref-id': ['L32534'], 'title': ['FDA Approved Drug Products: CUBICIN (daptomycin) injection'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021572s063,064lbl.pdf']}]}], 'attachments': [None]}], 'known-action': ['yes']}]}]"
"['DB00081', 'BTD00085', 'BIOD00085', 'DB09557']",['Tositumomab'],biotech,"['Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine).']",['liquid'],"[""For treatment of non-Hodgkin's lymphoma (CD20 positive, follicular)""]","['Binds to the CD20 antigen which is found on mature B lymphocytes. The antibody binding appears to induce apoptosis, complement-dependent cytotoxicity and cell death through ionizing radiation.']",[None],"[{'target': [{'id': ['BE0000066'], 'name': ['B-lymphocyte antigen CD20'], 'organism': ['Humans'], 'actions': [{'action': ['antibody']}], 'references': [{'articles': [{'article': [{'ref-id': ['A2046'], 'pubmed-id': ['11418316'], 'citation': [""Goldenberg DM: The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):195-201.""]}, {'ref-id': ['A2048'], 'pubmed-id': ['11879282'], 'citation': ['Dillman RO: Monoclonal antibody therapy for lymphoma: an update. Cancer Pract. 2001 Mar-Apr;9(2):71-80.']}, {'ref-id': ['A2056'], 'pubmed-id': ['12899647'], 'citation': ['Authors unspecified: Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab. BioDrugs. 2003;17(4):290-5.']}, {'ref-id': ['A2058'], 'pubmed-id': ['14748653'], 'citation': [""Friedberg JW, Fisher RI: Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther. 2004 Feb;4(1):18-26.""]}, {'ref-id': ['A2060'], 'pubmed-id': ['15023434'], 'citation': ['Silverman DH, Delpassand ES, Torabi F, Goy A, McLaughlin P, Murray JL: Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues. Cancer Treat Rev. 2004 Apr;30(2):165-72.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A2063'], 'pubmed-id': ['13129395'], 'citation': ['Beeson C, Butrynski JE, Hart MJ, Nourigat C, Matthews DC, Press OW, Senter PD, Bernstein ID: Conditionally cleavable radioimmunoconjugates: a novel approach for the release of radioisotopes from radioimmunoconjugates. Bioconjug Chem. 2003 Sep-Oct;14(5):927-33.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['B-lymphocyte antigen CD20'], 'general-function': ['Mhc class ii protein complex binding'], 'specific-function': ['This protein may be involved in the regulation of B-cell activation and proliferation.'], 'gene-name': ['MS4A1'], 'locus': ['11q12'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['57-78\n85-105\n121-141\n189-209'], 'signal-regions': [None], 'theoretical-pi': ['4.73'], 'molecular-weight': ['33076.99'], 'chromosome-location': ['11'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:7315']}, {'resource': ['GenAtlas'], 'identifier': ['MS4A1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X12530']}, {'resource': ['GenBank Protein Database'], 'identifier': ['29774']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2628']}, {'resource': ['UniProtKB'], 'identifier': ['P11836']}, {'resource': ['UniProt Accession'], 'identifier': ['CD20_HUMAN']}]}], 'synonyms': [{'synonym': ['B-lymphocyte surface antigen B1', 'Bp35', 'CD20', 'Leukocyte surface antigen Leu-16', 'Membrane-spanning 4-domains subfamily A member 1']}], 'amino-acid-sequence': ['>lcl|BSEQ0000132|B-lymphocyte antigen CD20\nMTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRRMSSLVGPTQSFFMRESKTLGAVQIMNG\nLFHIALGGLLMIPAGIYAPICVTVWYPLWGGIMYIISGSLLAATEKNSRKCLVKGKMIMN\nSLSLFAAISGMILSIMDILNIKISHFLKMESLNFIRAHTPYINIYNCEPANPSEKNSPST\nQYCYSIQSLFLGILSVMLIFAFFQELVIAGIVENEWKRTCSRPKSNIVLLSAEEKKEQTI\nEIKEEVVGLTETSSQPKNEEDIEIIPIQEEEEEETETNFPEPPQDQESSPIENDSSP'], 'gene-sequence': ['>lcl|BSEQ0009913|B-lymphocyte antigen CD20 (MS4A1)\nATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCT\nATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCC\nACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGG\nCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATC\nTGTGTGACTGTGTGGTACCCTCTCTGGGGAGGCATTATGTATATTATTTCCGGATCACTC\nCTGGCAGCAACGGAGAAAAACTCCAGGAAGTGTTTGGTCAAAGGAAAAATGATAATGAAT\nTCATTGAGCCTCTTTGCTGCCATTTCTGGAATGATTCTTTCAATCATGGACATACTTAAT\nATTAAAATTTCCCATTTTTTAAAAATGGAGAGTCTGAATTTTATTAGAGCTCACACACCA\nTATATTAACATATACAACTGTGAACCAGCTAATCCCTCTGAGAAAAACTCCCCATCTACC\nCAATACTGTTACAGCATACAATCTCTGTTCTTGGGCATTTTGTCAGTGATGCTGATCTTT\nGCCTTCTTCCAGGAACTTGTAATAGCTGGCATCGTTGAGAATGAATGGAAAAGAACGTGC\nTCCAGACCCAAATCTAACATAGTTCTCCTGTCAGCAGAAGAAAAAAAAGAACAGACTATT\nGAAATAAAAGAAGAAGTGGTTGGGCTAACTGAAACATCTTCCCAACCAAAGAATGAAGAA\nGACATTGAAATTATTCCAATCCAAGAAGAGGAAGAAGAAGAAACAGAGACGAACTTTCCA\nGAACCTCCCCAAGATCAGGAATCCTCACCAATAGAAAATGACAGCTCTCCTTAA'], 'pfams': [{'pfam': [{'identifier': ['PF04103'], 'name': ['CD20']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['function'], 'description': ['MHC class II protein complex binding']}, {'category': ['process'], 'description': ['B cell proliferation']}, {'category': ['process'], 'description': ['humoral immune response']}]}]}]}, {'id': ['BE0002099'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor II-b'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A6923'], 'pubmed-id': ['17768100'], 'citation': ['Glennie MJ, French RR, Cragg MS, Taylor RP: Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007 Sep;44(16):3823-37.']}, {'ref-id': ['A202865'], 'pubmed-id': ['25568316'], 'citation': ['Vaughan AT, Chan CH, Klein C, Glennie MJ, Beers SA, Cragg MS: Activatory and inhibitory Fcgamma receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain. J Biol Chem. 2015 Feb 27;290(9):5424-37. doi: 10.1074/jbc.M114.593806. Epub 2015 Jan 7.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor II-b'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis.'], 'gene-name': ['FCGR2B'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['218-240'], 'signal-regions': ['1-42'], 'theoretical-pi': ['6.12'], 'molecular-weight': ['34043.355'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3618']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR2B']}, {'resource': ['GenBank Gene Database'], 'identifier': ['U87560']}, {'resource': ['GenBank Protein Database'], 'identifier': ['4099445']}, {'resource': ['UniProtKB'], 'identifier': ['P31994']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG2B_HUMAN']}]}], 'synonyms': [{'synonym': ['CD32', 'CDw32', 'Fc-gamma RII-b', 'Fc-gamma-RIIb', 'FCG2', 'FcRII-b', 'IGFR2', 'IgG Fc receptor II-b']}], 'amino-acid-sequence': ['>lcl|BSEQ0004116|Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI'], 'gene-sequence': ['>lcl|BSEQ0019237|Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B)\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTG\nCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCC\nATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTC\nAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGC\nGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTGGAG\nTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTC\nAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAACTTC\nTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATAGGC\nTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCACCG\nATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCTGTA\nGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATTTAG'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['viral process']}]}]}]}]}]"
"['DB00082', 'BTD00044', 'BIOD00044']",['Pegvisomant'],biotech,"['Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly.  Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.']",['liquid'],['Pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly.'],"['Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH. This leads to the normalization of serum IGF-1 levels.']",[None],"[{'target': [{'id': ['BE0000075'], 'name': ['Growth hormone receptor'], 'organism': ['Humans'], 'actions': [{'action': ['antagonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13418'], 'pubmed-id': ['19820031'], 'citation': ['Moller L, Norrelund H, Jessen N, Flyvbjerg A, Pedersen SB, Gaylinn BD, Liu J, Thorner MO, Moller N, Lunde Jorgensen JO: Impact of growth hormone receptor blockade on substrate metabolism during fasting in healthy subjects. J Clin Endocrinol Metab. 2009 Nov;94(11):4524-32. doi: 10.1210/jc.2009-0381. Epub 2009 Oct 9.']}, {'ref-id': ['A13419'], 'pubmed-id': ['17322491'], 'citation': ['Paisley AN, Hayden K, Ellis A, Anderson J, Wieringa G, Trainer PJ: Pegvisomant interference in GH assays results in underestimation of GH levels. Eur J Endocrinol. 2007 Mar;156(3):315-9.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A13420'], 'pubmed-id': ['20595800'], 'citation': ['De Martino MC, Auriemma RS, Brevetti G, Vitale G, Schiano V, Galdiero M, Grasso L, Lombardi G, Colao A, Pivonello R: The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. J Endocrinol Invest. 2010 Oct;33(9):663-70. doi: 10.3275/7143. Epub 2010 Jul 1.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Growth hormone receptor'], 'general-function': ['Protein kinase binding'], 'specific-function': ['Receptor for pituitary gland growth hormone involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway (By similarity).The soluble form (GHBP) acts as a reservoir of growth hormone in plasma and may be a modulator/inhibitor of GH signaling.Isoform 2 up-regulates the production of GHBP and acts as a negative inhibitor of GH signaling.'], 'gene-name': ['GHR'], 'locus': ['5p13-p12'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['265-288'], 'signal-regions': ['1-18'], 'theoretical-pi': ['4.51'], 'molecular-weight': ['71498.885'], 'chromosome-location': ['5'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:4263']}, {'resource': ['GenAtlas'], 'identifier': ['GHR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X06562']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31738']}, {'resource': ['UniProtKB'], 'identifier': ['P10912']}, {'resource': ['UniProt Accession'], 'identifier': ['GHR_HUMAN']}]}], 'synonyms': [{'synonym': ['GH receptor', 'Somatotropin receptor']}], 'amino-acid-sequence': ['>lcl|BSEQ0000150|Growth hormone receptor\nMDLWQLLLTLALAGSSDAFSGSEATAAILSRAPWSLQSVNPGLKTNSSKEPKFTKCRSPE\nRETFSCHWTDEVHHGTKNLGPIQLFYTRRNTQEWTQEWKECPDYVSAGENSCYFNSSFTS\nIWIPYCIKLTSNGGTVDEKCFSVDEIVQPDPPIALNWTLLNVSLTGIHADIQVRWEAPRN\nADIQKGWMVLEYELQYKEVNETKWKMMDPILTTSVPVYSLKVDKEYEVRVRSKQRNSGNY\nGEFSEVLYVTLPQMSQFTCEEDFYFPWLLIIIFGIFGLTVMLFVFLFSKQQRIKMLILPP\nVPVPKIKGIDPDLLKEGKLEEVNTILAIHDSYKPEFHSDDSWVEFIELDIDEPDEKTEES\nDTDRLLSSDHEKSHSNLGVKDGDSGRTSCCEPDILETDFNANDIHEGTSEVAQPQRLKGE\nADLLCLDQKNQNNSPYHDACPATQQPSVIQAEKNKPQPLPTEGAESTHQAAHIQLSNPSS\nLSNIDFYAQVSDITPAGSVVLSPGQKNKAGMSQCDMHPEMVSLCQENFLMDNAYFCEADA\nKKCIPVAPHIKVESHIQPSLNQEDIYITTESLTTAAGRPGTGEHVPGSEMPVPDYTSIHI\nVQSPQGLILNATALPLPDKEFLSSCGYVSTDQLNKIMP'], 'gene-sequence': ['>lcl|BSEQ0010152|Growth hormone receptor (GHR)\nATGGATCTCTGGCAGCTGCTGTTGACCTTGGCACTGGCAGGATCAAGTGATGCTTTTTCT\nGGAAGTGAGGCCACAGCAGCTATCCTTAGCAGAGCACCCTGGAGTCTGCAAAGTGTTAAT\nCCAGGCCTAAAGACAAATTCTTCTAAGGAGCCTAAATTCACCAAGTGCCGTTCACCTGAG\nCGAGAGACTTTTTCATGCCACTGGACAGATGAGGTTCATCATGGTACAAAGAACCTAGGA\nCCCATACAGCTGTTCTATACCAGAAGGAACACTCAAGAATGGACTCAAGAATGGAAAGAA\nTGCCCTGATTATGTTTCTGCTGGGGAAAACAGCTGTTACTTTAATTCATCGTTTACCTCC\nATCTGGATACCTTATTGTATCAAGCTAACTAGCAATGGTGGTACAGTGGATGAAAAGTGT\nTTCTCTGTTGATGAAATAGTGCAACCAGATCCACCCATTGCCCTCAACTGGACTTTACTG\nAACGTCAGTTTAACTGGGATTCATGCAGATATCCAAGTGAGATGGGAAGCACCACGCAAT\nGCAGATATTCAGAAAGGATGGATGGTTCTGGAGTATGAACTTCAATACAAAGAAGTAAAT\nGAAACTAAATGGAAAATGATGGACCCTATATTGACAACATCAGTTCCAGTGTACTCATTG\nAAAGTGGATAAGGAATATGAAGTGCGTGTGAGATCCAAACAACGAAACTCTGGAAATTAT\nGGCGAGTTCAGTGAGGTGCTCTATGTAACACTTCCTCAGATGAGCCAATTTACATGTGAA\nGAAGATTTCTACTTTCCATGGCTCTTAATTATTATCTTTGGAATATTTGGGCTAACAGTG\nATGCTATTTGTATTCTTATTTTCTAAACAGCAAAGGATTAAAATGCTGATTCTGCCCCCA\nGTTCCAGTTCCAAAGATTAAAGGAATCGATCCAGATCTCCTCAAGGAAGGAAAATTAGAG\nGAGGTGAACACAATCTTAGCCATTCATGATAGCTATAAACCCGAATTCCACAGTGATGAC\nTCTTGGGTTGAATTTATTGAGCTAGATATTGATGAGCCAGATGAAAAGACTGAGGAATCA\nGACACAGACAGACTTCTAAGCAGTGACCATGAGAAATCACATAGTAACCTAGGGGTGAAG\nGATGGCGACTCTGGACGTACCAGCTGTTGTGAACCTGACATTCTGGAGACTGATTTCAAT\nGCCAATGACATACATGAGGGTACCTCAGAGGTTGCTCAGCCACAGAGGTTAAAAGGGGAA\nGCAGATCTCTTATGCCTTGACCAGAAGAATCAAAATAACTCACCTTATCATGATGCTTGC\nCCTGCTACTCAGCAGCCCAGTGTTATCCAAGCAGAGAAAAACAAACCACAACCACTTCCT\nACTGAAGGAGCTGAGTCAACTCACCAAGCTGCCCATATTCAGCTAAGCAATCCAAGTTCA\nCTGTCAAACATCGACTTTTATGCCCAGGTGAGCGACATTACACCAGCAGGTAGTGTGGTC\nCTTTCCCCGGGCCAAAAGAATAAGGCAGGGATGTCCCAATGTGACATGCACCCGGAAATG\nGTCTCACTCTGCCAAGAAAACTTCCTTATGGACAATGCCTACTTCTGTGAGGCAGATGCC\nAAAAAGTGCATCCCTGTGGCTCCTCACATCAAGGTTGAATCACACATACAGCCAAGCTTA\nAACCAAGAGGACATTTACATCACCACAGAAAGCCTTACCACTGCTGCTGGGAGGCCTGGG\nACAGGAGAACATGTTCCAGGTTCTGAGATGCCTGTCCCAGACTATACCTCCATTCATATA\nGTACAGTCCCCACAGGGCCTCATACTCAATGCGACTGCCTTGCCCTTGCCTGACAAAGAG\nTTTCTCTCATCATGTGGCTATGTGAGCACAGACCAACTGAACAAAATCATGCCTTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00041'], 'name': ['fn3']}, {'identifier': ['PF09067'], 'name': ['EpoR_lig-bind']}, {'identifier': ['PF12772'], 'name': ['GHBP']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['growth hormone receptor complex']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['function'], 'description': ['cytokine receptor activity']}, {'category': ['function'], 'description': ['growth factor binding']}, {'category': ['function'], 'description': ['peptide hormone binding']}, {'category': ['function'], 'description': ['proline-rich region binding']}, {'category': ['function'], 'description': ['protein homodimerization activity']}, {'category': ['function'], 'description': ['protein kinase binding']}, {'category': ['process'], 'description': ['2-oxoglutarate metabolic process']}, {'category': ['process'], 'description': ['activation of JAK2 kinase activity']}, {'category': ['process'], 'description': ['activation of MAPK activity']}, {'category': ['process'], 'description': ['allantoin metabolic process']}, {'category': ['process'], 'description': ['cellular response to hormone stimulus']}, {'category': ['process'], 'description': ['citrate metabolic process']}, {'category': ['process'], 'description': ['creatine metabolic process']}, {'category': ['process'], 'description': ['creatinine metabolic process']}, {'category': ['process'], 'description': ['endocytosis']}, {'category': ['process'], 'description': ['fatty acid metabolic process']}, {'category': ['process'], 'description': ['growth hormone receptor signaling pathway']}, {'category': ['process'], 'description': ['insulin-like growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['isoleucine metabolic process']}, {'category': ['process'], 'description': ['JAK-STAT cascade']}, {'category': ['process'], 'description': ['JAK-STAT cascade involved in growth hormone signaling pathway']}, {'category': ['process'], 'description': ['multicellular organismal metabolic process']}, {'category': ['process'], 'description': ['oxaloacetate metabolic process']}, {'category': ['process'], 'description': ['positive regulation of multicellular organism growth']}, {'category': ['process'], 'description': ['positive regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of tyrosine phosphorylation of Stat3 protein']}, {'category': ['process'], 'description': ['positive regulation of tyrosine phosphorylation of Stat5 protein']}, {'category': ['process'], 'description': ['receptor internalization']}, {'category': ['process'], 'description': ['regulation of multicellular organism growth']}, {'category': ['process'], 'description': ['response to cycloheximide']}, {'category': ['process'], 'description': ['response to estradiol']}, {'category': ['process'], 'description': ['succinate metabolic process']}, {'category': ['process'], 'description': ['taurine metabolic process']}, {'category': ['process'], 'description': ['valine metabolic process']}]}]}]}]}]"
"['DB00083', 'BTD00092', 'BIOD00092']",['Botulinum toxin type A'],biotech,"['In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use.[A231824] With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other conditions.[A231819,L32569] A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm, and hyperhidrosis.[L32494,L32559]']",['solid'],"['Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.[L32559]\r\n\r\nIn addition to the above indications, botulinum toxin A is used for the following conditions: treatment of adults with symptomatic overactive bladder with or without incontinence,  treatment of incontinence in adult patients who are not candidates for anticholinergic therapy, treatment of Neurogenic Detrusor Overactivity (NDO) in patients over 5 years who cannot undergo anticholinergic therapy.  Botulinum toxin A is indicated for the prevention of chronic migraines, for the treatment of muscle spasms, cervical dystonia, axillary hyperhidrosis, strabismus,[L32494] and disorders of the 7th cranial nerve.[L32569]\r\n\r\nOff-label, botulinum toxin A is used for a variety of conditions such as temporomandibular joint (TMJ) disorders and myofascial pain[A231874], neurogenic thoracic outlet syndrome, epicondylitis, post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic pain, spinal cord injury, and bladder pain.[A231879]']","['Botulinum toxin is a 150-kDa molecular weight protein consisting of a light chain (50 kDa) and heavy chain (100 kDa) linked by a single disulfide bond. The crystal structure reveals 3 lobes - the light chain, the amino-terminal portion of the heavy chain, and the carboxyl-terminal portion of the heavy chain.[A231854]\r\n\r\nBotulinum toxin type A blocks neuromuscular transmission on motor or sympathetic nerve terminals, inhibiting the release of acetylcholine.[L32494] Botulinum toxins have actions on various regions: the neuromuscular junction, autonomic ganglia, and both postganglionic sympathetic and parasympathetic nerve endings. The heavy chain of the toxin binds selectively  at the presynaptic surface of cholinergic neurons in an irreversible fashion. After binding, the toxin-receptor complex is transported into the cell by endocytosis. The disulfide bond between the two chains is cleaved and the botulism toxin enters the cytoplasm. The light chain specifically interacts with SNAP-25 in the nerve terminals to block binding of acetylcholine vesicles with the cell membrane.  SNAP-25 is required for successful binding and release of acetylcholine from vesicles in nerve endings.[A231304]']",[None],"[{'target': [{'id': ['BE0000390'], 'name': ['Synaptosomal-associated protein 25'], 'organism': ['Humans'], 'actions': [{'action': ['inhibitor']}], 'references': [{'articles': [{'article': [{'ref-id': ['A2064'], 'pubmed-id': ['14644446'], 'citation': ['Zhou JY, Wang ZF, Ren XM, Tang MZ, Shi YL: Antagonism of botulinum toxin type A-induced cleavage of SNAP-25 in rat cerebral synaptosome by toosendanin. FEBS Lett. 2003 Dec 4;555(2):375-9.']}, {'ref-id': ['A2066'], 'pubmed-id': ['15222581'], 'citation': ['Flynn TC: Myobloc. Dermatol Clin. 2004 Apr;22(2):207-11, vii.']}, {'ref-id': ['A2072'], 'pubmed-id': ['16831062'], 'citation': ['Straughan D: Progress in applying the Three Rs to the potency testing of Botulinum toxin type A. Altern Lab Anim. 2006 Jun;34(3):305-13.']}, {'ref-id': ['A231814'], 'pubmed-id': ['9886085'], 'citation': ['Vaidyanathan VV, Yoshino K, Jahnz M, Dorries C, Bade S, Nauenburg S, Niemann H, Binz T: Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: domains and amino acid residues controlling the formation of enzyme-substrate complexes and cleavage. J Neurochem. 1999 Jan;72(1):327-37. doi: 10.1046/j.1471-4159.1999.0720327.x.']}]}], 'textbooks': [None], 'links': [{'link': [{'ref-id': ['L32494'], 'title': ['FDA Approved Products: Botox (onabotulinumtoxinA) for injection'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103000s5318lbl.pdf']}]}], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Synaptosomal-associated protein 25'], 'general-function': ['Syntaxin-1 binding'], 'specific-function': ['t-SNARE involved in the molecular regulation of neurotransmitter release. May play an important role in the synaptic function of specific neuronal systems. Associates with proteins involved in vesicle docking and membrane fusion. Regulates plasma membrane recycling through its interaction with CENPF. Modulates the gating characteristics of the delayed rectifier voltage-dependent potassium channel KCNB1 in pancreatic beta cells.'], 'gene-name': ['SNAP25'], 'locus': ['20p12-p11.2'], 'cellular-location': ['Cytoplasm'], 'transmembrane-regions': [None], 'signal-regions': [None], 'theoretical-pi': ['4.39'], 'molecular-weight': ['23314.905'], 'chromosome-location': ['20'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:11132']}, {'resource': ['GenAtlas'], 'identifier': ['SNAP25']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L19760']}, {'resource': ['GenBank Protein Database'], 'identifier': ['307426']}, {'resource': ['UniProtKB'], 'identifier': ['P60880']}, {'resource': ['UniProt Accession'], 'identifier': ['SNP25_HUMAN']}]}], 'synonyms': [{'synonym': ['SNAP', 'SNAP-25', 'SUP', 'Super protein', 'Synaptosomal-associated 25 kDa protein']}], 'amino-acid-sequence': ['>lcl|BSEQ0000777|Synaptosomal-associated protein 25\nMAEDADMRNELEEMQRRADQLADESLESTRRMLQLVEESKDAGIRTLVMLDEQGEQLERI\nEEGMDQINKDMKEAEKNLTDLGKFCGLCVCPCNKLKSSDAYKKAWGNNQDGVVASQPARV\nVDEREQMAISGGFIRRVTNDARENEMDENLEQVSGIIGNLRHMALDMGNEIDTQNRQIDR\nIMEKADSNKTRIDEANQRATKMLGSG'], 'gene-sequence': ['>lcl|BSEQ0018947|Synaptosomal-associated protein 25 (SNAP25)\nATGGCCGAAGACGCAGACATGCGCAATGAGCTGGAGGAGATGCAGCGAAGGGCTGACCAG\nTTGGCTGATGAGTCGCTGGAAAGCACCCGTCGTATGCTGCAACTGGTTGAAGAGAGTAAA\nGATGCTGGTATCAGGACTTTGGTTATGTTGGATGAACAAGGAGAACAACTCGATCGTGTC\nGAAGAAGGCATGAACCATATCAACCAAGACATGAAGGAGGCTGAGAAAAATTTAAAAGAT\nTTAGGGAAATGCTGTGGCCTTTTCATATGTCCTTGTAACAAGCTTAAATCAAGTGATGCT\nTACAAAAAAGCCTGGGGCAATAATCAGGACGGAGTGGTGGCCAGCCAGCCTGCTCGTGTA\nGTGGACGAACGGGAGCAGATGGCCATCAGTGGCGGCTTCATCCGCAGGGTAACAAATGAT\nGCCCGAGAAAATGAAATGGATGAAAACCTAGAGCAGGTGAGCGGCATCATCGGGAACCTC\nCGTCACATGGCCCTGGATATGGGCAATGAGATCGATACACAGAATCGCCAGATCGACAGG\nATCATGGAGAAGGCTGATTCCAACAAAACCAGAATTGATGAGGCCAACCAACGTGCAACA\nAAGATGCTGGGAAGTGGTTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00835'], 'name': ['SNAP-25']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell junction']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['growth cone']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['myelin sheath']}, {'category': ['component'], 'description': ['neuron projection']}, {'category': ['component'], 'description': ['perinuclear region of cytoplasm']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['presynaptic membrane']}, {'category': ['component'], 'description': ['SNARE complex']}, {'category': ['component'], 'description': ['synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex']}, {'category': ['component'], 'description': ['trans-Golgi network']}, {'category': ['function'], 'description': ['calcium-dependent protein binding']}, {'category': ['function'], 'description': ['SNAP receptor activity']}, {'category': ['function'], 'description': ['syntaxin-1 binding']}, {'category': ['process'], 'description': ['associative learning']}, {'category': ['process'], 'description': ['energy reserve metabolic process']}, {'category': ['process'], 'description': ['glutamate secretion']}, {'category': ['process'], 'description': ['locomotory behavior']}, {'category': ['process'], 'description': ['long-term synaptic potentiation']}, {'category': ['process'], 'description': ['neurotransmitter secretion']}, {'category': ['process'], 'description': ['neurotransmitter uptake']}, {'category': ['process'], 'description': ['regulation of insulin secretion']}, {'category': ['process'], 'description': ['regulation of neuron projection development']}, {'category': ['process'], 'description': ['small molecule metabolic process']}, {'category': ['process'], 'description': ['synaptic transmission']}, {'category': ['process'], 'description': ['synaptic vesicle docking']}, {'category': ['process'], 'description': ['synaptic vesicle exocytosis']}, {'category': ['process'], 'description': ['synaptic vesicle fusion to presynaptic membrane']}, {'category': ['process'], 'description': ['synaptic vesicle priming']}]}]}]}, {'id': ['BE0003572'], 'name': ['Rho-related GTP-binding protein RhoB'], 'organism': ['Humans'], 'actions': [{'action': ['inhibitor']}], 'references': [{'articles': [{'article': [{'ref-id': ['A15361'], 'pubmed-id': ['15140914'], 'citation': ['Ishida H, Zhang X, Erickson K, Ray P: Botulinum toxin type A targets RhoB to inhibit lysophosphatidic acid-stimulated actin reorganization and acetylcholine release in nerve growth factor-treated PC12 cells. J Pharmacol Exp Ther. 2004 Sep;310(3):881-9. Epub 2004 May 12.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Rho-related GTP-binding protein RhoB'], 'general-function': ['Gtpase activity'], 'specific-function': ['Mediates apoptosis in neoplastically transformed cells after DNA damage. Not essential for development but affects cell adhesion and growth factor signaling in transformed cells. Plays a negative role in tumorigenesis as deletion causes tumor formation. Involved in intracellular protein trafficking of a number of proteins. Targets PKN1 to endosomes and is involved in trafficking of the EGF receptor from late endosomes to lysosomes. Also required for stability and nuclear trafficking of AKT1/AKT which promotes endothelial cell survival during vascular development. Serves as a microtubule-dependent signal that is required for the myosin contractile ring formation during cell cycle cytokinesis. Required for genotoxic stress-induced cell death in breast cancer cells.'], 'gene-name': ['RHOB'], 'locus': ['2p24'], 'cellular-location': ['Late endosome membrane'], 'transmembrane-regions': [None], 'signal-regions': [None], 'theoretical-pi': ['4.85'], 'molecular-weight': ['22123.185'], 'chromosome-location': ['2'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:668']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X06820']}, {'resource': ['GenBank Protein Database'], 'identifier': ['36032']}, {'resource': ['UniProtKB'], 'identifier': ['P62745']}, {'resource': ['UniProt Accession'], 'identifier': ['RHOB_HUMAN']}]}], 'synonyms': [{'synonym': ['ARH6', 'ARHB', 'h6', 'Rho cDNA clone 6']}], 'amino-acid-sequence': ['>lcl|BSEQ0012483|Rho-related GTP-binding protein RhoB\nMAAIRKKLVVVGDGACGKTCLLIVFSKDEFPEVYVPTVFENYVADIEVDGKQVELALWDT\nAGQEDYDRLRPLSYPDTDVILMCFSVDSPDSLENIPEKWVPEVKHFCPNVPIILVANKKD\nLRSDEHVRTELARMKQEPVRTDDGRAMAVRIQAYDYLECSAKTKEGVREVFETATRAALQ\nKRYGSQNGCINCCKVL'], 'gene-sequence': ['>lcl|BSEQ0012484|Rho-related GTP-binding protein RhoB (RHOB)\nATGGCGGCCATCCGCAAGAAGCTGGTGGTGGTGGGCGACGGCGCGTGTGGCAAGACGTGC\nCTGCTGATCGTGTTCAGTAAGGACGAGTTCCCCGAGGTGTACGTGCCCACCGTCTTCGAG\nAACTATGTGGCCGACATTGAGGTGGACGGCAAGCAGGTGGAGCTGGCGCTGTGGGACACG\nGCGGGCCAGGAGGACTACGACCGCCTGCGGCCGCTCTCCTACCCGGACACCGACGTCATT\nCTCATGTGCTTCTCGGTGGACAGCCCGGACTCGCTGGAGAACATCCCCGAGAAGTGGGTC\nCCCGAGGTGAAGCACTTCTGTCCCAATGTGCCCATCATCCTGGTGGCCAACAAAAAAGAC\nCTGCGCAGCGACGAGCATGTCCGCACAGAGCTGGCCCGCATGAAGCAGGAACCCGTGCGC\nACGGATGACGGCCGCGCCATGGCCGTGCGCATCCAAGCCTACGACTACCTCGAGTGCTCT\nGCCAAGACCAAGGAAGGCGTGCGCGAGGTCTTCGAGACGGCCACGCGCGCCGCGCTGCAG\nAAGCGCTACGGCTCCCAGAACGGCTGCATCAACTGCTGCAAGGTGCTATGA'], 'pfams': [{'pfam': [{'identifier': ['PF00071'], 'name': ['Ras']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cleavage furrow']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['early endosome']}, {'category': ['component'], 'description': ['endosome membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['late endosome membrane']}, {'category': ['component'], 'description': ['nucleus']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['GDP binding']}, {'category': ['function'], 'description': ['GTP binding']}, {'category': ['function'], 'description': ['GTPase activity']}, {'category': ['process'], 'description': ['angiogenesis']}, {'category': ['process'], 'description': ['apoptotic process']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cell adhesion']}, {'category': ['process'], 'description': ['cellular response to hydrogen peroxide']}, {'category': ['process'], 'description': ['cellular response to ionizing radiation']}, {'category': ['process'], 'description': ['cytokinesis']}, {'category': ['process'], 'description': ['endosome to lysosome transport']}, {'category': ['process'], 'description': ['endothelial tube morphogenesis']}, {'category': ['process'], 'description': ['intracellular protein transport']}, {'category': ['process'], 'description': ['negative regulation of cell cycle']}, {'category': ['process'], 'description': ['negative regulation of cell migration']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['positive regulation of angiogenesis']}, {'category': ['process'], 'description': ['positive regulation of apoptotic process']}, {'category': ['process'], 'description': ['positive regulation of endothelial cell migration']}, {'category': ['process'], 'description': ['regulation of cell migration']}, {'category': ['process'], 'description': ['regulation of small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['Rho protein signal transduction']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['transformed cell apoptotic process']}]}]}]}]}]"
"['DB00085', 'BTD00067', 'BIOD00067', 'DB05356']",['Pancrelipase'],biotech,"['Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands.[L2509] The pancrelipase mixture was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510] For further information on the components of this mixture please visit [DB11065], [DB11066] and [DB13147].']",['solid'],"['The use of pancrelipase amylase is part of the pancreatic enzyme replacement therapy. This therapy is indicated for the treatment of pancreatic insufficiency attributed to cystic fibrosis, chronic pancreatitis or any other medically defined pancreatic disease that might require it.[A32721, A32736] Pancreatic diseases are associated with the deterioration of pancreatic parenchyma and of the dual physiological functions of the pancreas. Once established, pancreatic insufficiency results in malnutrition, weight loss, and steatorrhea.[A32723]']","['Pancrelipase is used to replace the deficiency of pancreatic enzymes. As abovementioned, pancrelipase is formed by a mixture of lipase, protease, and amylase which are able to break down fat, protein, and starches, respectively, in the small intestine.[T180] For a more specific description of each mechanism of action, please visit [DB11065], [DB11066] and [DB13147]. ']","[{'food-interaction': ['Drink plenty of fluids.', 'Take with fluids.', 'Take with food. If swallowing the oral capsule is not tolerated, sprinkle on acidic soft foods with a pH of 4 or less.']}]","[{'target': [{'id': ['BE0004834'], 'name': ['Dietary fat'], 'organism': ['Humans'], 'actions': [{'action': ['cleavage']}], 'references': [{'articles': [{'article': [{'ref-id': ['A17142'], 'pubmed-id': ['11150608'], 'citation': ['Svendsen A: Lipase protein engineering. Biochim Biophys Acta. 2000 Dec 29;1543(2):223-238.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes']}, {'id': ['BE0004835'], 'name': ['Dietary protein'], 'organism': ['Humans'], 'actions': [{'action': ['cleavage']}], 'references': [{'articles': [{'article': [{'ref-id': ['A17143'], 'pubmed-id': ['7845208'], 'citation': ['Rawlings ND, Barrett AJ: Families of serine peptidases. Methods Enzymol. 1994;244:19-61.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes']}, {'id': ['BE0004836'], 'name': ['Dietary starch'], 'organism': ['Humans'], 'actions': [{'action': ['cleavage']}], 'references': [{'articles': [{'article': [{'ref-id': ['A17144'], 'pubmed-id': ['15005645'], 'citation': ['Udani J, Hardy M, Madsen DC: Blocking carbohydrate absorption and weight loss: a clinical trial using Phase 2 brand proprietary fractionated white bean extract. Altern Med Rev. 2004 Mar;9(1):63-9.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes']}]}]"
"['DB00086', 'BTD00028', 'BIOD00028']",['Streptokinase'],biotech,"['Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci.']",['liquid'],"['For the treatment of acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or emolism and occlusion of arteriovenous cannulae']",['Plasminogen is an inactive molecule that becomes activated to plasmin when the Arg/Val bond is cleaved. Plasmin breaks down fibrin clots created by the blood clotting cascade. Streptokinase forms a highly specific 1:1 enzymatic complex with plasminogen which converts inactive plasminogen molecules into active plasmin. Plasmin degrades fibrin clots as well as fibrinogen and other plasma proteins. This in turn leads to the degradation of blood clots.'],"[{'food-interaction': ['Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.']}]","[{'target': [{'id': ['BE0000211'], 'name': ['Plasminogen'], 'organism': ['Humans'], 'actions': [{'action': ['activator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13288'], 'pubmed-id': ['10569766'], 'citation': ['Caballero AR, Lottenberg R, Johnston KH: Cloning, expression, sequence analysis, and characterization of streptokinases secreted by porcine and equine isolates of Streptococcus equisimilis. Infect Immun. 1999 Dec;67(12):6478-86.']}, {'ref-id': ['A13289'], 'pubmed-id': ['10581996'], 'citation': ['Alessi MC, Juhan-Vague I: [Thrombolytics and their use]. Rev Prat. 1999 Oct 1;49(15):1654-8.']}, {'ref-id': ['A13290'], 'pubmed-id': ['10631997'], 'citation': ['Chaudhary A, Vasudha S, Rajagopal K, Komath SS, Garg N, Yadav M, Mande SC, Sahni G: Function of the central domain of streptokinase in substrate plasminogen docking and processing revealed by site-directed mutagenesis. Protein Sci. 1999 Dec;8(12):2791-805.']}, {'ref-id': ['A13291'], 'pubmed-id': ['10664583'], 'citation': ['Parry MA, Zhang XC, Bode I: Molecular mechanisms of plasminogen activation: bacterial cofactors provide clues. Trends Biochem Sci. 2000 Feb;25(2):53-9.']}, {'ref-id': ['A13292'], 'pubmed-id': ['10726310'], 'citation': [""Korol'chuk VI, Makohonenko IeM, Sederkhol'm-Vil'iams SA: [Plasminogen binding with decapeptide and polypeptide fragments of streptokinase]. Ukr Biokhim Zh (1999). 1999 Sep-Oct;71(5):51-8.""]}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Plasminogen'], 'general-function': ['Serine-type peptidase activity'], 'specific-function': ['Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.'], 'gene-name': ['PLG'], 'locus': ['6q26'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-19'], 'theoretical-pi': ['7.25'], 'molecular-weight': ['90568.415'], 'chromosome-location': ['6'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:9071']}, {'resource': ['GenAtlas'], 'identifier': ['PLG']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X05199']}, {'resource': ['GenBank Protein Database'], 'identifier': ['387026']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2394']}, {'resource': ['UniProtKB'], 'identifier': ['P00747']}, {'resource': ['UniProt Accession'], 'identifier': ['PLMN_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.21.7']}], 'amino-acid-sequence': ['>lcl|BSEQ0016037|Plasminogen\nMEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT\nCRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN\nGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE\nCEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE\nLRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS\nAQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE\nQLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG\nLTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED\nCMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG\nPWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT\nRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE\nPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ\nLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW\nGLGCARPNKPGVYVRVSRFVTWIEGVMRNN'], 'gene-sequence': ['>lcl|BSEQ0016038|Plasminogen (PLG)\nATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG\nCCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG\nCTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC\nTGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG\nAAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC\nTCAGAGTGCAAGACTGGGAATGGAAAGAACTACAGAGGGACGATGTCCAAAACAAAAAAT\nGGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT\nACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG\nGGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG\nTGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC\nATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT\nCCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG\nCTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGTGACATCCCC\nCGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT\nGAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT\nGCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTCCCCTGCAAAAATTTGGAT\nGAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC\nCAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA\nCAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT\nGATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT\nTGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC\nCTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA\nGACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT\nGTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAGATGTAGAGACTCCTTCCGAAGAAGAC\nTGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG\nCCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA\nAATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT\nCCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT\nGCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG\nGTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA\nAGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT\nGCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC\nCAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG\nCCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA\nGTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC\nATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG\nCTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA\nTCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT\nGGAGGTCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG\nGGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT\nACTTGGATTGAGGGAGTGATGAGAAATAATTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00051'], 'name': ['Kringle']}, {'identifier': ['PF00089'], 'name': ['Trypsin']}, {'identifier': ['PF00024'], 'name': ['PAN_1']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['extrinsic component of external side of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['function'], 'description': ['apolipoprotein binding']}, {'category': ['function'], 'description': ['protein domain specific binding']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase activity']}, {'category': ['function'], 'description': ['serine-type peptidase activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['extracellular matrix disassembly']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['negative regulation of cell proliferation']}, {'category': ['process'], 'description': ['negative regulation of cell-cell adhesion mediated by cadherin']}, {'category': ['process'], 'description': ['negative regulation of cell-substrate adhesion']}, {'category': ['process'], 'description': ['negative regulation of fibrinolysis']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of fibrinolysis']}, {'category': ['process'], 'description': ['proteolysis']}, {'category': ['process'], 'description': ['tissue remodeling']}]}]}]}, {'id': ['BE0000928'], 'name': ['Proteinase-activated receptor 1'], 'organism': ['Humans'], 'actions': [{'action': ['activator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13293'], 'pubmed-id': ['10666203'], 'citation': ['McRedmond JP, Harriott P, Walker B, Fitzgerald DJ: Streptokinase-induced platelet activation involves antistreptokinase antibodies and cleavage of protease-activated receptor-1. Blood. 2000 Feb 15;95(4):1301-8.']}, {'ref-id': ['A70342'], 'pubmed-id': ['10079109'], 'citation': ['Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR: Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999 Mar;103(6):879-87.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Proteinase-activated receptor 1'], 'general-function': ['Thrombin receptor activity'], 'specific-function': ['High affinity receptor for activated thrombin coupled to G proteins that stimulate phosphoinositide hydrolysis. May play a role in platelets activation and in vascular development.'], 'gene-name': ['F2R'], 'locus': ['5q13'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['103-128\n138-157\n177-198\n219-239\n269-288\n312-334\n351-374'], 'signal-regions': ['1-21'], 'theoretical-pi': ['8.33'], 'molecular-weight': ['47439.83'], 'chromosome-location': ['5'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3537']}, {'resource': ['GenAtlas'], 'identifier': ['F2R']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M62424']}, {'resource': ['GenBank Protein Database'], 'identifier': ['339677']}, {'resource': ['IUPHAR'], 'identifier': ['347']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['347']}, {'resource': ['UniProtKB'], 'identifier': ['P25116']}, {'resource': ['UniProt Accession'], 'identifier': ['PAR1_HUMAN']}]}], 'synonyms': [{'synonym': ['CF2R', 'Coagulation factor II receptor', 'PAR-1', 'PAR1', 'Thrombin receptor', 'TR']}], 'amino-acid-sequence': ['>lcl|BSEQ0010652|Proteinase-activated receptor 1\nMGPRRLLLVAACFSLCGPLLSARTRARRPESKATNATLDPRSFLLRNPNDKYEPFWEDEE\nKNESGLTEYRLVSINKSSPLQKQLPAFISEDASGYLTSSWLTLFVPSVYTGVFVVSLPLN\nIMAIVVFILKMKVKKPAVVYMLHLATADVLFVSVLPFKISYYFSGSDWQFGSELCRFVTA\nAFYCNMYASILLMTVISIDRFLAVVYPMQSLSWRTLGRASFTCLAIWALAIAGVVPLLLK\nEQTIQVPGLNITTCHDVLNETLLEGYYAYYFSAFSAVFFFVPLIISTVCYVSIIRCLSSS\nAVANRSKKSRALFLSAAVFCIFIICFGPTNVLLIAHYSFLSHTSTTEAAYFAYLLCVCVS\nSISCCIDPLIYYYASSECQRYVYSILCCKESSDPSSYNSSGQLMASKMDTCSSNLNNSIY\nKKLLT'], 'gene-sequence': ['>lcl|BSEQ0010653|Proteinase-activated receptor 1 (F2R)\nATGGGGCCGCGGCGGCTGCTGCTGGTGGCCGCCTGCTTCAGTCTGTGCGGCCCGCTGTTG\nTCTGCCCGCACCCGGGCCCGCAGGCCAGAATCAAAAGCAACAAATGCCACCTTAGATCCC\nCGGTCATTTCTTCTCAGGAACCCCAATGATAAATATGAACCATTTTGGGAGGATGAGGAG\nAAAAATGAAAGTGGGTTAACTGAATACAGATTAGTCTCCATCAATAAAAGCAGTCCTCTT\nCAAAAACAACTTCCTGCATTCATCTCAGAAGATGCCTCCGGATATTTGACCAGCTCCTGG\nCTGACACTCTTTGTCCCATCTGTGTACACCGGAGTGTTTGTAGTCAGCCTCCCACTAAAC\nATCATGGCCATCGTTGTGTTCATCCTGAAAATGAAGGTCAAGAAGCCGGCGGTGGTGTAC\nATGCTGCACCTGGCCACGGCAGATGTGCTGTTTGTGTCTGTGCTCCCCTTTAAGATCAGC\nTATTACTTTTCCGGCAGTGATTGGCAGTTTGGGTCTGAATTGTGTCGCTTCGTCACTGCA\nGCATTTTACTGTAACATGTACGCCTCTATCTTGCTCATGACAGTCATAAGCATTGACCGG\nTTTCTGGCTGTGGTGTATCCCATGCAGTCCCTCTCCTGGCGTACTCTGGGAAGGGCTTCC\nTTCACTTGTCTGGCCATCTGGGCTTTGGCCATCGCAGGGGTAGTGCCTCTGCTCCTCAAG\nGAGCAAACCATCCAGGTGCCCGGGCTCAACATCACTACCTGTCATGATGTGCTCAATGAA\nACCCTGCTCGAAGGCTACTATGCCTACTACTTCTCAGCCTTCTCTGCTGTCTTCTTTTTT\nGTGCCGCTGATCATTTCCACGGTCTGTTATGTGTCTATCATTCGATGTCTTAGCTCTTCC\nGCAGTTGCCAACCGCAGCAAGAAGTCCCGGGCTTTGTTCCTGTCAGCTGCTGTTTTCTGC\nATCTTCATCATTTGCTTCGGACCCACAAACGTCCTCCTGATTGCGCATTACTCATTCCTT\nTCTCACACTTCCACCACAGAGGCTGCCTACTTTGCCTACCTCCTCTGTGTCTGTGTCAGC\nAGCATAAGCTGCTGCATCGACCCCCTAATTTACTATTACGCTTCCTCTGAGTGCCAGAGG\nTACGTCTACAGTATCTTATGCTGCAAAGAAAGTTCCGATCCCAGCAGTTATAACAGCAGT\nGGGCAGTTGATGGCAAGTAAAATGGATACCTGCTCTAGTAACCTGAATAACAGCATATAC\nAAAAAGCTGTTAACTTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['caveola']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['early endosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['Golgi apparatus']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['late endosome']}, {'category': ['component'], 'description': ['neuromuscular junction']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet dense tubular network']}, {'category': ['component'], 'description': ['postsynaptic membrane']}, {'category': ['function'], 'description': ['G-protein alpha-subunit binding']}, {'category': ['function'], 'description': ['G-protein beta-subunit binding']}, {'category': ['function'], 'description': ['G-protein coupled receptor activity']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['thrombin receptor activity']}, {'category': ['process'], 'description': ['activation of cysteine-type endopeptidase activity involved in apoptotic process']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['anatomical structure morphogenesis']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['connective tissue replacement involved in inflammatory response wound healing']}, {'category': ['process'], 'description': ['establishment of synaptic specificity at neuromuscular junction']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['homeostasis of number of cells within a tissue']}, {'category': ['process'], 'description': ['inflammatory response']}, {'category': ['process'], 'description': ['negative regulation of cell proliferation']}, {'category': ['process'], 'description': ['negative regulation of glomerular filtration']}, {'category': ['process'], 'description': ['negative regulation of neuron apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of renin secretion into blood stream']}, {'category': ['process'], 'description': ['phospholipase C-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet dense granule organization']}, {'category': ['process'], 'description': ['positive regulation of blood coagulation']}, {'category': ['process'], 'description': ['positive regulation of calcium ion transport']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of collagen biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of cysteine-type endopeptidase activity involved in apoptotic process']}, {'category': ['process'], 'description': ['positive regulation of cytosolic calcium ion concentration']}, {'category': ['process'], 'description': ['positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['positive regulation of I-kappaB kinase/NF-kappaB signaling']}, {'category': ['process'], 'description': ['positive regulation of interleukin-6 secretion']}, {'category': ['process'], 'description': ['positive regulation of interleukin-8 secretion']}, {'category': ['process'], 'description': ['positive regulation of JAK-STAT cascade']}, {'category': ['process'], 'description': ['positive regulation of MAPK cascade']}, {'category': ['process'], 'description': ['positive regulation of phosphatidylinositol 3-kinase signaling']}, {'category': ['process'], 'description': ['positive regulation of release of sequestered calcium ion into cytosol']}, {'category': ['process'], 'description': ['positive regulation of Rho protein signal transduction']}, {'category': ['process'], 'description': ['positive regulation of smooth muscle contraction']}, {'category': ['process'], 'description': ['positive regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['positive regulation of vasoconstriction']}, {'category': ['process'], 'description': ['protein kinase C-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['regulation of blood coagulation']}, {'category': ['process'], 'description': ['regulation of interleukin-1 beta production']}, {'category': ['process'], 'description': ['regulation of sensory perception of pain']}, {'category': ['process'], 'description': ['release of sequestered calcium ion into cytosol']}, {'category': ['process'], 'description': ['response to lipopolysaccharide']}, {'category': ['process'], 'description': ['response to wounding']}, {'category': ['process'], 'description': ['STAT protein import into nucleus']}, {'category': ['process'], 'description': ['tyrosine phosphorylation of STAT protein']}]}]}]}]}]"
"['DB00087', 'BTD00109', 'BIOD00109']",['Alemtuzumab'],biotech,"['Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin.[L43397]\r\n\r\nAlemtuzumab was approved by the FDA in 2001.[L43397] It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL). The dose of alemtuzumab used for B-CLL is much higher than that for MS, and also at more frequent dosing.[L43397, L30335]']",['liquid'],"['LEMTRADA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.[L43397] LEMTRADA contains the same active ingredient (alemtuzumab) found in CAMPATH, and CAMPATH is approved for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), although generally administered at higher and more frequent doses (e.g., 30 mg) than recommended in the treatment of MS.[L43397]']","['The precise mechanism by which alemtuzumab exerts its therapeutic effects in multiple sclerosis is unknown but is presumed to involve binding to CD52, a cell surface antigen present on T and B lymphocytes, and on natural killer cells, monocytes, and macrophages. Following cell surface binding to T and B lymphocytes, alemtuzumab results in antibody-dependent cellular cytolysis\r\nand complement-mediated lysis.[L43397] Research suggests that alemtuzumab can also exert immunomodulatory effects through the depletion and repopulation of lymphocytes, including alterations in the number, proportions, and properties of some lymphocyte subsets posttreatment, increasing representation of regulatory T cell subsets, and increasing representation of memory T- and B-lymphocytes.[L43418] The reduction in the level of circulating B and T cells by alemtuzumab and subsequent repopulation may reduce the potential for relapse, which ultimately delays disease progression.[L43418,L30335]']",[None],"[{'target': [{'id': ['BE0000083'], 'name': ['CAMPATH-1 antigen'], 'organism': ['Humans'], 'actions': [{'action': ['antibody']}], 'references': [{'articles': [{'article': [{'ref-id': ['A2075'], 'pubmed-id': ['10092828'], 'citation': ['Gilliland LK, Walsh LA, Frewin MR, Wise MP, Tone M, Hale G, Kioussis D, Waldmann H: Elimination of the immunogenicity of therapeutic antibodies. J Immunol. 1999 Mar 15;162(6):3663-71.']}, {'ref-id': ['A2077'], 'pubmed-id': ['10366506'], 'citation': ['James LC, Hale G, Waldmann H, Bloomer AC: 1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen. J Mol Biol. 1999 Jun 4;289(2):293-301.']}, {'ref-id': ['A2078'], 'pubmed-id': ['10520035'], 'citation': ['Rawstron AC, Rollinson SJ, Richards S, Short MA, English A, Morgan GJ, Hale G, Hillmen P: The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment. Br J Haematol. 1999 Oct;107(1):148-53.']}, {'ref-id': ['A2081'], 'pubmed-id': ['10573085'], 'citation': ['Rebello PR, Hale G, Friend PJ, Cobbold SP, Waldmann H: Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection. Transplantation. 1999 Nov 15;68(9):1417-20.']}, {'ref-id': ['A2083'], 'pubmed-id': ['10744652'], 'citation': ['Hederer RA, Guntermann C, Miller N, Nagy P, Szollosi J, Damjanovich S, Hale G, Alexander DR: The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells. Int Immunol. 2000 Apr;12(4):505-16.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A2085'], 'pubmed-id': ['19479612'], 'citation': ['Geissinger E, Bonzheim I, Roth S, Rosenwald A, Muller-Hermelink HK, Rudiger T: CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies. Leuk Lymphoma. 2009 Jun;50(6):1010-6. doi: 10.1080/10428190902926981.']}, {'ref-id': ['A2086'], 'pubmed-id': ['19343298'], 'citation': [""Quintas-Cardama A, O'Brien S: Targeted therapy for chronic lymphocytic leukemia. Target Oncol. 2009 Jan;4(1):11-21. doi: 10.1007/s11523-008-0099-0. Epub 2009 Jan  27.""]}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['CAMPATH-1 antigen'], 'general-function': [None], 'specific-function': ['May play a role in carrying and orienting carbohydrate, as well as having a more specific role.'], 'gene-name': ['CD52'], 'locus': ['1p36'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': [None], 'signal-regions': ['1-24'], 'theoretical-pi': ['8.56'], 'molecular-weight': ['6613.67'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1804']}, {'resource': ['GenAtlas'], 'identifier': ['CD52']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X62466']}, {'resource': ['GenBank Protein Database'], 'identifier': ['29646']}, {'resource': ['UniProtKB'], 'identifier': ['P31358']}, {'resource': ['UniProt Accession'], 'identifier': ['CD52_HUMAN']}]}], 'synonyms': [{'synonym': ['Cambridge pathology 1 antigen', 'CDW52', 'Epididymal secretory protein E5', 'HE5', 'Human epididymis-specific protein 5']}], 'amino-acid-sequence': ['>lcl|BSEQ0010155|CAMPATH-1 antigen\nMKRFLFLLLTISLLVMVQIQTGLSGQNDTSQTSSPSASSNISGGIFLFFVANAIIHLFCF\nS'], 'gene-sequence': ['>lcl|BSEQ0010156|CAMPATH-1 antigen (CD52)\nATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTGGTTATGGTACAGATACAA\nACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAAC\nATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTC\nAGTTGA'], 'pfams': [{'pfam': [{'identifier': ['PF15116'], 'name': ['CD52']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['anchored component of membrane']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['process'], 'description': ['positive regulation of cytosolic calcium ion concentration']}, {'category': ['process'], 'description': ['respiratory burst']}]}]}]}, {'id': ['BE0000901'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor III-B'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13294'], 'pubmed-id': ['9337053'], 'citation': ['Nagler A, Condiotti R, Lubina A, Deutsch VR: Enhancement of megakaryocytopoiesis by Campath-1G-treated natural killer cells. Bone Marrow Transplant. 1997 Oct;20(7):525-31.']}, {'ref-id': ['A13295'], 'pubmed-id': ['8707338'], 'citation': ['Brett S, Baxter G, Cooper H, Johnston JM, Tite J, Rapson N: Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H. Immunology. 1996 May;88(1):13-9.']}, {'ref-id': ['A13296'], 'pubmed-id': ['9020367'], 'citation': ['Osterborg A, Werner A, Halapi E, Lundin J, Harmenberg U, Wigzell H, Mellstedt H: Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52). Eur J Haematol. 1997 Jan;58(1):5-13.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor III-B'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.'], 'gene-name': ['FCGR3B'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': [None], 'signal-regions': ['1-16'], 'theoretical-pi': ['6.71'], 'molecular-weight': ['26215.64'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3620']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR3B']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X16863']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31322']}, {'resource': ['UniProtKB'], 'identifier': ['O75015']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG3B_HUMAN']}]}], 'synonyms': [{'synonym': ['CD16B', 'Fc-gamma RIII', 'Fc-gamma RIII-beta', 'Fc-gamma RIIIb', 'FCG3', 'FCGR3', 'FcR-10', 'FcRIII', 'FcRIIIb', 'IGFR3', 'IgG Fc receptor III-1']}], 'amino-acid-sequence': ['>lcl|BSEQ0010635|Low affinity immunoglobulin gamma Fc region receptor III-B\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI'], 'gene-sequence': ['>lcl|BSEQ0010636|Low affinity immunoglobulin gamma Fc region receptor III-B (FCGR3B)\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['anchored component of membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['mitophagy in response to mitochondrial depolarization']}, {'category': ['process'], 'description': ['positive regulation of defense response to virus by host']}, {'category': ['process'], 'description': ['xenophagy']}]}]}]}, {'id': ['BE0002097'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor III-A'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13297'], 'pubmed-id': ['15217834'], 'citation': ['Lin TS, Flinn IW, Modali R, Lehman TA, Webb J, Waymer S, Moran ME, Lucas MS, Farag SS, Byrd JC: FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood. 2005 Jan 1;105(1):289-91. Epub 2004 Jun 24.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor III-A'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.'], 'gene-name': ['FCGR3A'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['209-229'], 'signal-regions': ['1-16'], 'theoretical-pi': ['8.21'], 'molecular-weight': ['29088.895'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3619']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR3A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X52645']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31324']}, {'resource': ['UniProtKB'], 'identifier': ['P08637']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG3A_HUMAN']}]}], 'synonyms': [{'synonym': ['CD16A', 'CD16a antigen', 'Fc-gamma RIII', 'Fc-gamma RIII-alpha', 'Fc-gamma RIIIa', 'FCG3', 'FCGR3', 'FcR-10', 'FcRIII', 'FcRIIIa', 'IGFR3', 'IgG Fc receptor III-2']}], 'amino-acid-sequence': ['>lcl|BSEQ0004112|Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK'], 'gene-sequence': ['>lcl|BSEQ0011522|Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A)\nATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCT\nTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTG\nCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCA\nAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACT\nCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAG\nAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCGACGACAGT\nGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTGCAGCTAGAAGTC\nCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAGGAAGACCCTATT\nCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACATATTTACAGAAT\nGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCAAAAGCCACACTC\nAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAATGTGTCTTCAGAG\nACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCATCATTCTTTCCA\nCCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCAGTGGACACAGGA\nCTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGGAAGGACCATAAA\nTTTAAATGGAGAAAGGACCCTCAAGACAAATGA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['regulation of immune response']}]}]}]}, {'id': ['BE0000710'], 'name': ['High affinity immunoglobulin gamma Fc receptor I'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A202025'], 'pubmed-id': ['23543215'], 'citation': ['White AL, Chan HT, French RR, Beers SA, Cragg MS, Johnson PW, Glennie MJ: FcgammaRIotaIotaB controls the potency of agonistic anti-TNFR mAbs. Cancer Immunol Immunother. 2013 May;62(5):941-8. doi: 10.1007/s00262-013-1398-6. Epub 2013 Mar 31.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['High affinity immunoglobulin gamma Fc receptor I'], 'general-function': ['Receptor signaling protein activity'], 'specific-function': ['High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.'], 'gene-name': ['FCGR1A'], 'locus': ['1q21.2-q21.3'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['293-313'], 'signal-regions': ['1-15'], 'theoretical-pi': ['8.08'], 'molecular-weight': ['42631.525'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3613']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR1A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X14356']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31332']}, {'resource': ['UniProtKB'], 'identifier': ['P12314']}, {'resource': ['UniProt Accession'], 'identifier': ['FCGR1_HUMAN']}]}], 'synonyms': [{'synonym': ['Fc-gamma RI', 'Fc-gamma RIA', 'FCG1', 'FcgammaRIa', 'FCGR1', 'FcRI', 'IGFR1', 'IgG Fc receptor I']}], 'amino-acid-sequence': ['>lcl|BSEQ0001416|High affinity immunoglobulin gamma Fc receptor I\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT'], 'gene-sequence': ['>lcl|BSEQ0016183|High affinity immunoglobulin gamma Fc receptor I (FCGR1A)\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAATTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00047'], 'name': ['ig']}, {'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['clathrin-coated endocytic vesicle membrane']}, {'category': ['component'], 'description': ['early endosome membrane']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['receptor signaling protein activity']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent']}, {'category': ['process'], 'description': ['antigen processing and presentation of peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['interferon-gamma-mediated signaling pathway']}, {'category': ['process'], 'description': ['intracellular signal transduction']}, {'category': ['process'], 'description': ['phagocytosis, engulfment']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}, {'id': ['BE0002098'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor II-a'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13297'], 'pubmed-id': ['15217834'], 'citation': ['Lin TS, Flinn IW, Modali R, Lehman TA, Webb J, Waymer S, Moran ME, Lucas MS, Farag SS, Byrd JC: FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood. 2005 Jan 1;105(1):289-91. Epub 2004 Jun 24.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor II-a'], 'general-function': [None], 'specific-function': ['Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens.'], 'gene-name': ['FCGR2A'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['218-240'], 'signal-regions': ['1-33'], 'theoretical-pi': ['6.78'], 'molecular-weight': ['35000.42'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3616']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR2A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M31932']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182474']}, {'resource': ['UniProtKB'], 'identifier': ['P12318']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG2A_HUMAN']}]}], 'synonyms': [{'synonym': ['CD32', 'CDw32', 'Fc-gamma RII-a', 'Fc-gamma-RIIa', 'FCG2', 'FCGR2A1', 'FcRII-a', 'IGFR2', 'IgG Fc receptor II-a']}], 'amino-acid-sequence': ['>lcl|BSEQ0037156|Low affinity immunoglobulin gamma Fc region receptor II-a\nMTMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSHLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN'], 'gene-sequence': ['>lcl|BSEQ0019233|Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A)\nATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCATTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['innate immune response']}]}]}]}, {'id': ['BE0002099'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor II-b'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A202025'], 'pubmed-id': ['23543215'], 'citation': ['White AL, Chan HT, French RR, Beers SA, Cragg MS, Johnson PW, Glennie MJ: FcgammaRIotaIotaB controls the potency of agonistic anti-TNFR mAbs. Cancer Immunol Immunother. 2013 May;62(5):941-8. doi: 10.1007/s00262-013-1398-6. Epub 2013 Mar 31.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor II-b'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis.'], 'gene-name': ['FCGR2B'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['218-240'], 'signal-regions': ['1-42'], 'theoretical-pi': ['6.12'], 'molecular-weight': ['34043.355'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3618']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR2B']}, {'resource': ['GenBank Gene Database'], 'identifier': ['U87560']}, {'resource': ['GenBank Protein Database'], 'identifier': ['4099445']}, {'resource': ['UniProtKB'], 'identifier': ['P31994']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG2B_HUMAN']}]}], 'synonyms': [{'synonym': ['CD32', 'CDw32', 'Fc-gamma RII-b', 'Fc-gamma-RIIb', 'FCG2', 'FcRII-b', 'IGFR2', 'IgG Fc receptor II-b']}], 'amino-acid-sequence': ['>lcl|BSEQ0004116|Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI'], 'gene-sequence': ['>lcl|BSEQ0019237|Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B)\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTG\nCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCC\nATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTC\nAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGC\nGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTGGAG\nTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTC\nAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAACTTC\nTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATAGGC\nTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCACCG\nATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCTGTA\nGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATTTAG'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['viral process']}]}]}]}, {'id': ['BE0002100'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor II-c'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A202025'], 'pubmed-id': ['23543215'], 'citation': ['White AL, Chan HT, French RR, Beers SA, Cragg MS, Johnson PW, Glennie MJ: FcgammaRIotaIotaB controls the potency of agonistic anti-TNFR mAbs. Cancer Immunol Immunother. 2013 May;62(5):941-8. doi: 10.1007/s00262-013-1398-6. Epub 2013 Mar 31.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor II-c'], 'general-function': ['Transmembrane signaling receptor activity'], 'specific-function': ['Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells.'], 'gene-name': ['FCGR2C'], 'locus': ['1q23.3'], 'cellular-location': ['Cytoplasm'], 'transmembrane-regions': ['224-246'], 'signal-regions': ['1-42'], 'theoretical-pi': ['6.9'], 'molecular-weight': ['35577.96'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:15626']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR2C']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X17652']}, {'resource': ['GenBank Protein Database'], 'identifier': ['32074']}, {'resource': ['UniProtKB'], 'identifier': ['P31995']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG2C_HUMAN']}]}], 'synonyms': [{'synonym': ['CD32', 'CDw32', 'Fc-gamma RII-c', 'Fc-gamma-RIIc', 'FCG2', 'FcRII-c', 'IGFR2', 'IgG Fc receptor II-c']}], 'amino-acid-sequence': ['>lcl|BSEQ0004118|Low affinity immunoglobulin gamma Fc region receptor II-c\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR\nAPTDDDKNIYLTLPPNDHVNSNN'], 'gene-sequence': ['>lcl|BSEQ0011523|Low affinity immunoglobulin gamma Fc region receptor II-c (FCGR2C)\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCCGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG\nAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT\nGAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG\nGCACCTACTGACGATGATAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAAC\nAGTAATAACTAA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['transmembrane signaling receptor activity']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}]}]"
"['DB00088', 'BTD00037', 'BIOD00037']",['Alglucerase'],biotech,"['Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues. Alglucerase was first approved by the FDA in 1991;[A254816] however, it was later discontinued from the market.']",['liquid'],"['Alglucerase is indicated for use as a long-term enzyme replacement therapy in patients with Type I Gaucher disease who exhibit signs and symptoms that are severe enough to result in moderate-to-severe anemia, thrombocytopenia, bone disease, or significant hepato- or splenomegaly.[L44266]']","['Alglucerase catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids.']",[None],"[{'target': [{'id': ['BE0004806'], 'name': ['Glucocerebroside'], 'organism': ['Humans'], 'actions': [{'action': ['other/unknown']}], 'references': [{'articles': [{'article': [{'ref-id': ['A95'], 'pubmed-id': ['20301446'], 'citation': ['Pastores GM, Hughes DA: Gaucher Disease .']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes']}]}]"
"['DB00089', 'BTD00080', 'BIOD00080']",['Capromab pendetide'],biotech,"['Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA  also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] during imaging to evaluate the extent of prostate cancer.']",['liquid'],['For diagnosis of prostate cancer and detection of intra-pelvic metastases.'],['Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors.'],[None],"[{'target': [{'id': ['BE0000568'], 'name': ['Glutamate carboxypeptidase 2'], 'organism': ['Humans'], 'actions': [{'action': ['other/unknown']}], 'references': [{'articles': [{'article': [{'ref-id': ['A2089'], 'pubmed-id': ['11016653'], 'citation': ['Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH: In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000 Sep 15;60(18):5237-43.']}, {'ref-id': ['A2090'], 'pubmed-id': ['15882479'], 'citation': ['Sodee DB, Nelson AD, Faulhaber PF, Maclennan GT, Resnick MI, Bakale G: Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer. 2005 Mar;3(4):230-8.']}, {'ref-id': ['A2092'], 'pubmed-id': ['9508077'], 'citation': ['Gregorakis AK, Holmes EH, Murphy GP: Prostate-specific membrane antigen: current and future utility. Semin Urol Oncol. 1998 Feb;16(1):2-12.']}, {'ref-id': ['A2093'], 'pubmed-id': ['9792131'], 'citation': ['Sodee DB, Ellis RJ, Samuels MA, Spirnak JP, Poole WF, Riester C, Martanovic DM, Stonecipher R, Bellon EM: Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results. Prostate. 1998 Nov 1;37(3):140-8.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Glutamate carboxypeptidase 2'], 'general-function': ['Tetrahydrofolyl-poly(glutamate) polymer binding'], 'specific-function': ['Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Has a preference for tri-alpha-glutamate peptides. In the intestine, required for the uptake of folate. In the brain, modulates excitatory neurotransmission through the hydrolysis of the neuropeptide, N-aceylaspartylglutamate (NAAG), thereby releasing glutamate. Isoform PSM-4 and isoform PSM-5 would appear to be physiologically irrelevant. Involved in prostate tumor progression.Also exhibits a dipeptidyl-peptidase IV type activity. In vitro, cleaves Gly-Pro-AMC.'], 'gene-name': ['FOLH1'], 'locus': ['11p11.2'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['20-43'], 'signal-regions': [None], 'theoretical-pi': ['6.97'], 'molecular-weight': ['84330.015'], 'chromosome-location': ['11'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3788']}, {'resource': ['GenAtlas'], 'identifier': ['FOLH1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M99487']}, {'resource': ['GenBank Protein Database'], 'identifier': ['190664']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1606']}, {'resource': ['UniProtKB'], 'identifier': ['Q04609']}, {'resource': ['UniProt Accession'], 'identifier': ['FOLH1_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.17.21', 'Cell growth-inhibiting gene 27 protein', 'FGCP', 'Folate hydrolase 1', 'FOLH', 'Folylpoly-gamma-glutamate carboxypeptidase', 'GCPII', 'Glutamate carboxypeptidase II', 'Membrane glutamate carboxypeptidase', 'mGCP', 'N-acetylated-alpha-linked acidic dipeptidase I', 'NAALAD1', 'NAALADase I', 'Prostate-specific membrane antigen', 'PSM', 'PSMA', 'Pteroylpoly-gamma-glutamate carboxypeptidase']}], 'amino-acid-sequence': ['>lcl|BSEQ0001134|Glutamate carboxypeptidase 2\nMWNLLHETDSAVATARRPRWLCAGALVLAGGFFLLGFLFGWFIKSSNEATNITPKHNMKA\nFLDELKAENIKKFLYNFTQIPHLAGTEQNFQLAKQIQSQWKEFGLDSVELAHYDVLLSYP\nNKTHPNYISIINEDGNEIFNTSLFEPPPPGYENVSDIVPPFSAFSPQGMPEGDLVYVNYA\nRTEDFFKLERDMKINCSGKIVIARYGKVFRGNKVKNAQLAGAKGVILYSDPADYFAPGVK\nSYPDGWNLPGGGVQRGNILNLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIPVHPIGYY\nDAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVKMHIHSTNEVTRIYNVIG\nTLRGAVEPDRYVILGGHRDSWVFGGIDPQSGAAVVHEIVRSFGTLKKEGWRPRRTILFAS\nWDAEEFGLLGSTEWAEENSRLLQERGVAYINADSSIEGNYTLRVDCTPLMYSLVHNLTKE\nLKSPDEGFEGKSLYESWTKKSPSPEFSGMPRISKLGSGNDFEVFFQRLGIASGRARYTKN\nWETNKFSGYPLYHSVYETYELVEKFYDPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDY\nAVVLRKYADKIYSISMKHPQEMKTYSVSFDSLFSAVKNFTEIASKFSERLQDFDKSNPIV\nLRMMNDQLMFLERAFIDPLGLPDRPFYRHVIYAPSSHNKYAGESFPGIYDALFDIESKVD\nPSKAWGEVKRQIYVAAFTVQAAAETLSEVA'], 'gene-sequence': ['>lcl|BSEQ0016135|Glutamate carboxypeptidase 2 (FOLH1)\nATGTGGAATCTCCTTCACGAAACCGACTCGGCTGTGGCCACCGCGCGCCGCCCGCGCTGG\nCTGTGCGCTGGGGCGCTGGTGCTGGCGGGTGGCTTCTTTCTCCTCGGCTTCCTCTTCGGG\nTGGTTTATAAAATCCTCCAATGAAGCTACTAACATTACTCCAAAGCATAATATGAAAGCA\nTTTTTGGATGAATTGAAAGCTGAGAACATCAAGAAGTTCTTATATAATTTTACACAGATA\nCCACATTTAGCAGGAACAGAACAAAACTTTCAGCTTGCAAAGCAAATTCAATCCCAGTGG\nAAAGAATTTGGCCTGGATTCTGTTGAGCTAGCACATTATGATGTCCTGTTGTCCTACCCA\nAATAAGACTCATCCCAACTACATCTCAATAATTAATGAAGATGGAAATGAGATTTTCAAC\nACATCATTATTTGAACCACCTCCTCCAGGATATGAAAATGTTTCGGATATTGTACCACCT\nTTCAGTGCTTTCTCTCCTCAAGGAATGCCAGAGGGCGATCTAGTGTATGTTAACTATGCA\nCGAACTGAAGACTTCTTTAAATTGGAACGGGACATGAAAATCAATTGCTCTGGGAAAATT\nGTAATTGCCAGATATGGGAAAGTTTTCAGAGGAAATAAGGTTAAAAATGCCCAGCTGGCA\nGGGGCCAAAGGAGTCATTCTCTACTCCGACCCTGCTGACTACTTTGCTCCTGGGGTGAAG\nTCCTATCCAGATGGTTGGAATCTTCCTGGAGGTGGTGTCCAGCGTGGAAATATCCTAAAT\nCTGAATGGTGCAGGAGACCCTCTCACACCAGGTTACCCAGCAAATGAATATGCTTATAGG\nCGTGGAATTGCAGAGGCTGTTGGTCTTCCAAGTATTCCTGTTCATCCAATTGGATACTAT\nGATGCACAGAAGCTCCTAGAAAAAATGGGTGGCTCAGCACCACCAGATAGCAGCTGGAGA\nGGAAGTCTCAAAGTGCCCTACAATGTTGGACCTGGCTTTACTGGAAACTTTTCTACACAA\nAAAGTCAAGATGCACATCCACTCTACCAATGAAGTGACAAGAATTTACAATGTGATAGGT\nACTCTCAGAGGAGCAGTGGAACCAGACAGATATGTCATTCTGGGAGGTCACCGGGACTCA\nTGGGTGTTTGGTGGTATTGACCCTCAGAGTGGAGCAGCTGTTGTTCATGAAATTGTGAGG\nAGCTTTGGAACACTGAAAAAGGAAGGGTGGAGACCTAGAAGAACAATTTTGTTTGCAAGC\nTGGGATGCAGAAGAATTTGGTCTTCTTGGTTCTACTGAGTGGGCAGAGGAGAATTCAAGA\nCTCCTTCAAGAGCGTGGCGTGGCTTATATTAATGCTGACTCATCTATAGAAGGAAACTAC\nACTCTGAGAGTTGATTGTACACCGCTGATGTACAGCTTGGTACACAACCTAACAAAAGAG\nCTGAAAAGCCCTGATGAAGGCTTTGAAGGCAAATCTCTTTATGAAAGTTGGACTAAAAAA\nAGTCCTTCCCCAGAGTTCAGTGGCATGCCCAGGATAAGCAAATTGGGATCTGGAAATGAT\nTTTGAGGTGTTCTTCCAACGACTTGGAATTGCTTCAGGCAGAGCACGGTATACTAAAAAT\nTGGGAAACAAACAAATTCAGCGGCTATCCACTGTATCACAGTGTCTATGAAACATATGAG\nTTGGTGGAAAAGTTTTATGATCCAATGTTTAAATATCACCTCACTGTGGCCCAGGTTCGA\nGGAGGGATGGTGTTTGAGCTAGCCAATTCCATAGTGCTCCCTTTTGATTGTCGAGATTAT\nGCTGTAGTTTTAAGAAAGTATGCTGACAAAATCTACAGTATTTCTATGAAACATCCACAG\nGAAATGAAGACATACAGTGTATCATTTGATTCACTTTTTTCTGCAGTAAAGAATTTTACA\nGAAATTGCTTCCAAGTTCAGTGAGAGACTCCAGGACTTTGACAAAAGCAAGCATGTCATC\nTATGCTCCAAGCAGCCACAACAAGTATGCAGGGGAGTCATTCCCAGGAATTTATGATGCT\nCTGTTTGATATTGAAAGCAAAGTGGACCCTTCCAAGGCCTGGGGAGAAGTGAAGAGACAG\nATTTATGTTGCAGCCTTCACAGTGCAGGCAGCTGCAGAGACTTTGAGTGAAGTAGCCTAA\n'], 'pfams': [{'pfam': [{'identifier': ['PF02225'], 'name': ['PA']}, {'identifier': ['PF04389'], 'name': ['Peptidase_M28']}, {'identifier': ['PF04253'], 'name': ['TFR_dimer']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['Ac-Asp-Glu binding']}, {'category': ['function'], 'description': ['dipeptidase activity']}, {'category': ['function'], 'description': ['metal ion binding']}, {'category': ['function'], 'description': ['metallocarboxypeptidase activity']}, {'category': ['function'], 'description': ['peptidase activity']}, {'category': ['function'], 'description': ['tetrahydrofolyl-poly(glutamate) polymer binding']}, {'category': ['process'], 'description': ['C-terminal protein deglutamylation']}, {'category': ['process'], 'description': ['cellular amino acid biosynthetic process']}, {'category': ['process'], 'description': ['cellular nitrogen compound metabolic process']}, {'category': ['process'], 'description': ['folic acid-containing compound metabolic process']}, {'category': ['process'], 'description': ['proteolysis']}, {'category': ['process'], 'description': ['small molecule metabolic process']}]}]}]}]}]"
"['DB00090', 'BTD00008', 'BIOD00008']",['Laronidase'],biotech,"['Human recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line. Laronidase is a glycoprotein with a molecular weight of approximately 83 kD. The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human a-L-iduronidase. It contains 6 N-linked oligosaccharide modification sites.']",['liquid'],['For the treatment of mucopolysaccharidosis'],['Laronidase catalyses the hydrolysis of terminal alpha-L-iduronic acid residues of dermatan sulfate and heparin sulfate.'],[None],"[{'target': [{'id': ['BE0004822'], 'name': ['Iduronic acid'], 'organism': ['Humans'], 'actions': [{'action': ['other/unknown']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A6686'], 'pubmed-id': ['16283671'], 'citation': ['Kloska A, Bohdanowicz J, Konopa G, Tylki-Szymnska A, Jakobkiewicz-Banecka J, Czartoryska B, Liberek A, Wegrzyn A, Wegrzyn G: Changes in hair morphology of mucopolysaccharidosis I patients treated with recombinant human alpha-L-iduronidase (laronidase, Aldurazyme). Am J Med Genet A. 2005 Dec 15;139(3):199-203.']}, {'ref-id': ['A6687'], 'pubmed-id': ['4269173'], 'citation': ['Bach G, Eisenberg F Jr, Cantz M, Neufeld EF: The defect in the Hunter syndrome: deficiency of sulfoiduronate sulfatase. Proc Natl Acad Sci U S A. 1973 Jul;70(7):2134-8.']}, {'ref-id': ['A6688'], 'pubmed-id': ['1554373'], 'citation': ['Freeman C, Hopwood JJ: Human alpha-L-iduronidase. Catalytic properties and an integrated role in the lysosomal degradation of heparan sulphate. Biochem J. 1992 Mar 15;282 ( Pt 3):899-908.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes']}]}]"
"['DB00091', 'BTD00003', 'BIOD00003']",['Cyclosporine'],small molecule,"['Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_.[A174049] Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]']",['solid'],"['Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine can be used in patients who have chronic transplant rejection and have received previous immunosuppressive therapy[L3002] and to prevent or treat graft-versus-host disease (GVHD).[L11097]\r\n\r\nSecondly, cyclosporine is used for the treatment of patients with severe active rheumatoid arthritis (RA) when they no longer respond to methotrexate alone.[L3734] It can be used for the treatment of adult non-immunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated.[L3734] The ophthalmic solution of cyclosporine is indicated to increase tear production in patients suffering from keratoconjunctivitis sicca.[L11097] In addition, cyclosporine is approved for the treatment of steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases which may include minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis.[L11097]\r\n\r\nA cyclosporine ophthalmic emulsion is indicated in the treatment of vernal keratoconjunctivitis in adults and children.[L34694]\r\n\r\nOff-label, cyclosporine is commonly used for the treatment of various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, as well as idiopathic thrombocytopenic purpura.[A139,A174085,A189393,A189396,A189399]']","[""Cyclosporine is a calcineurin inhibitor that inhibits T cell activation.[A174049,A174088,A189411] Its binding to the receptor cyclophilin-1 inside cells produces a complex known as cyclosporine-cyclophilin. This complex subsequently inhibits calcineurin, which in turn stops the dephosphorylation as well as the activation of the nuclear factor of activated T cells (NF-AT) that normally cause inflammatory reactions.  NF-AT is a transcription factor that promotes the production of cytokines such as IL-2, IL-4, interferon-gamma and TNF-alpha, all of which are involved in the inflammatory process. Specifically, the inhibition of IL-2, which is necessary for T cell activation or proliferation, is believed to be responsible for cyclosporine's  immunosuppressive actions.[A174049,A189408] In addition to the above, the inhibition of NF-AT leads to lower levels of other factors associated with T helper cell function and thymocyte development.[A174049]""]","[{'food-interaction': ['Avoid grapefruit products.', 'Avoid potassium-containing products. Taking products that increase serum potassium may increase the risk of hyperkalemia.', ""Avoid St. John's Wort."", 'Take at the same time every day. Take consistently with regard to food.']}]","[{'target': [{'id': ['BE0000379'], 'name': ['Calcium signal-modulating cyclophilin ligand'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A2095'], 'pubmed-id': ['20927389'], 'citation': ['Bernasconi R, Solda T, Galli C, Pertel T, Luban J, Molinari M: Cyclosporine A-sensitive, cyclophilin B-dependent endoplasmic reticulum-associated degradation. PLoS One. 2010 Sep 28;5(9). pii: e13008. doi: 10.1371/journal.pone.0013008.']}, {'ref-id': ['A2096'], 'pubmed-id': ['20674565'], 'citation': ['Yamashita H, Ito T, Kato H, Asai S, Tanaka H, Nagai H, Inagaki N: Comparison of the efficacy of tacrolimus and cyclosporine A in a murine model of dinitrofluorobenzene-induced atopic dermatitis. Eur J Pharmacol. 2010 Oct 25;645(1-3):171-6. doi: 10.1016/j.ejphar.2010.07.031. Epub 2010 Aug 3.']}, {'ref-id': ['A2098'], 'pubmed-id': ['20602248'], 'citation': ['Galat A, Bua J: Molecular aspects of cyclophilins mediating therapeutic actions of their ligands. Cell Mol Life Sci. 2010 Oct;67(20):3467-88. doi: 10.1007/s00018-010-0437-0. Epub  2010 Jul 4.']}, {'ref-id': ['A2100'], 'pubmed-id': ['20637127'], 'citation': ['Lee J, Kim SS: Current implications of cyclophilins in human cancers. J Exp Clin Cancer Res. 2010 Jul 19;29:97. doi: 10.1186/1756-9966-29-97.']}, {'ref-id': ['A174049'], 'pubmed-id': ['24682697'], 'citation': ['Forsythe P, Paterson S: Ciclosporin 10 years on: indications and efficacy. Vet Rec. 2014 Mar;174 Suppl 2:13-21. doi: 10.1136/vr.102484.']}, {'ref-id': ['A189408'], 'pubmed-id': ['1502562'], 'citation': ['Russell G, Graveley R, Seid J, al-Humidan AK, Skjodt H: Mechanisms of action of cyclosporine and effects on connective tissues. Semin Arthritis Rheum. 1992 Jun;21(6 Suppl 3):16-22. doi: 10.1016/0049-0172(92)90009-3.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Calcium signal-modulating cyclophilin ligand'], 'general-function': [None], 'specific-function': ['Likely involved in the mobilization of calcium as a result of the TCR/CD3 complex interaction. Binds to cyclophilin B.'], 'gene-name': ['CAMLG'], 'locus': ['5q23'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['190-210\n241-257'], 'signal-regions': [None], 'theoretical-pi': ['8.19'], 'molecular-weight': ['32952.255'], 'chromosome-location': ['5'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1471']}, {'resource': ['GenAtlas'], 'identifier': ['CAMLG']}, {'resource': ['GenBank Gene Database'], 'identifier': ['U18242']}, {'resource': ['GenBank Protein Database'], 'identifier': ['619670']}, {'resource': ['UniProtKB'], 'identifier': ['P49069']}, {'resource': ['UniProt Accession'], 'identifier': ['CAMLG_HUMAN']}]}], 'synonyms': [{'synonym': ['CAML']}], 'amino-acid-sequence': ['>lcl|BSEQ0016072|Calcium signal-modulating cyclophilin ligand\nMESMAVATDGGERPGVPAGSGLSASQRRAELRRRKLLMNSEQRINRIMGFHRPGSGAEEE\nSQTKSKQQDSDKLNSLSVPSVSKRVVLGDSVSTGTTDQQGGVAEVKGTQLGDKLDSFIKP\nPECSSDVNLELRQRNRGDLTADSVQRGSRHGLEQYLSRFEEAMKLRKQLISEKPSQEDGN\nTTEEFDSFRIFRLVGCALLALGVRAFVCKYLSIFAPFLTLQLAYMGLYKYFPKSEKKIKT\nTVLTAALLLSGIPAEVINRSMDTYSKMGEVFTDLCVYFFTFIFCHELLDYWGSEVP'], 'gene-sequence': ['>lcl|BSEQ0016073|Calcium signal-modulating cyclophilin ligand (CAMLG)\nATGGAGTCGATGGCCGTCGCTACCGACGGCGGGGAGAGGCCGGGGGTCCCAGCGGGCTCA\nGGTCTGTCGGCTTCCCAGCGTCGGGCGGAGCTGCGTCGGAGAAAGCTGCTCATGAACTCG\nGAACAGCGCATCAACCGGATCATGGGCTTTCACAGGCCCGGGAGCGGCGCGGAAGAAGAA\nAGTCAAACAAAATCAAAGCAGCAGGACAGTGATAAACTGAACTCCCTCAGCGTTCCTTCC\nGTTTCAAAGCGAGTAGTGCTGGGTGATTCAGTCAGTACAGGAACAACTGACCAGCAGGGT\nGGTGTGGCCGAGGTAAAGGGGACCCAACTGGGAGACAAATTGGACTCGTTCATTAAACCA\nCCTGAGTGCAGTAGTGATGTCAACCTTGAGCTCCGGCAGCGGAACAGAGGGGACCTGACA\nGCGGACTCGGTCCAGAGGGGTTCCCGCCATGGCCTAGAGCAGTACCTTTCCAGATTCGAA\nGAAGCAATGAAGCTAAGGAAACAGCTGATTAGTGAAAAACCCAGTCAAGAGGATGGAAAT\nACAACAGAAGAATTTGACTCTTTTCGAATATTTAGATTGGTGGGATGTGCTCTTCTTGCT\nCTTGGAGTCAGAGCTTTTGTTTGCAAATACTTGTCCATATTTGCTCCATTTCTTACTTTA\nCAACTTGCGTACATGGGATTATACAAATATTTTCCCAAGAGTGAAAAGAAGATAAAGACA\nACAGTACTAACAGCTGCACTTCTATTGTCGGGAATTCCTGCCGAAGTGATAAATCGATCA\nATGGATACCTATAGCAAAATGGGCGAAGTCTTCACAGATCTCTGTGTCTACTTTTTCACT\nTTTATCTTTTGTCATGAACTGCTTGATTATTGGGGCTCTGAAGTACCATGA'], 'pfams': [{'pfam': [{'identifier': ['PF14963'], 'name': ['CAML']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endoplasmic reticulum']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['process'], 'description': ['defense response']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['receptor recycling']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['viral process']}]}]}]}, {'id': ['BE0002143'], 'name': ['Calcineurin subunit B type 2'], 'organism': ['Humans'], 'actions': [{'action': ['inhibitor']}], 'references': [{'articles': [{'article': [{'ref-id': ['A2096'], 'pubmed-id': ['20674565'], 'citation': ['Yamashita H, Ito T, Kato H, Asai S, Tanaka H, Nagai H, Inagaki N: Comparison of the efficacy of tacrolimus and cyclosporine A in a murine model of dinitrofluorobenzene-induced atopic dermatitis. Eur J Pharmacol. 2010 Oct 25;645(1-3):171-6. doi: 10.1016/j.ejphar.2010.07.031. Epub 2010 Aug 3.']}, {'ref-id': ['A189501'], 'pubmed-id': ['23468591'], 'citation': ['Grigoriu S, Bond R, Cossio P, Chen JA, Ly N, Hummer G, Page R, Cyert MS, Peti W: The molecular mechanism of substrate engagement and immunosuppressant inhibition of calcineurin. PLoS Biol. 2013;11(2):e1001492. doi: 10.1371/journal.pbio.1001492. Epub 2013 Feb 26.']}, {'ref-id': ['A189504'], 'pubmed-id': ['7529175'], 'citation': ['Cardenas ME, Hemenway C, Muir RS, Ye R, Fiorentino D, Heitman J: Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands. EMBO J. 1994 Dec 15;13(24):5944-57.']}]}], 'textbooks': [None], 'links': [{'link': [{'ref-id': ['L3734'], 'title': ['Neoral (Cyclosporine) FDA Label'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050715s027,050716s028lbl.pdf']}]}], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Calcineurin subunit B type 2'], 'general-function': ['Calcium ion binding'], 'specific-function': ['Regulatory subunit of calcineurin, a calcium-dependent, calmodulin stimulated protein phosphatase. Confers calcium sensitivity (By similarity).'], 'gene-name': ['PPP3R2'], 'locus': ['9q31.1'], 'cellular-location': [None], 'transmembrane-regions': [None], 'signal-regions': [None], 'theoretical-pi': ['4.49'], 'molecular-weight': ['19533.065'], 'chromosome-location': ['9'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:9318']}, {'resource': ['GenAtlas'], 'identifier': ['PPP3R2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['AF145026']}, {'resource': ['GenBank Protein Database'], 'identifier': ['33150800']}, {'resource': ['UniProtKB'], 'identifier': ['Q96LZ3']}, {'resource': ['UniProt Accession'], 'identifier': ['CANB2_HUMAN']}]}], 'synonyms': [{'synonym': ['Calcineurin B-like protein', 'Calcineurin BII', 'CBLP', 'CNBII', 'PPP3R1-like', 'PPP3RL', 'Protein phosphatase 2B regulatory subunit 2', 'Protein phosphatase 3 regulatory subunit B beta isoform']}], 'amino-acid-sequence': ['>lcl|BSEQ0004204|Calcineurin subunit B type 2\nMGNEASYPAEMCSHFDNDEIKRLGRRFKKLDLDKSGSLSVEEFMSLPELRHNPLVRRVID\nVFDTDGDGEVDFKEFILGTSQFSVKGDEEQKLRFAFSIYDMDKDGYISNGELFQVLKMMV\nGNNLTDWQLQQLVDKTIIILDKDGDGKISFEEFSAVVRDLEIHKKLVLIV'], 'gene-sequence': ['>lcl|BSEQ0011554|Calcineurin subunit B type 2 (PPP3R2)\nATGTCCACAATGGGAAACGAGGCCAGTTACCCGGCGGAGATGTGCTCCCACTTTGACAAT\nGATGAAATTAAAAGGCTGGGCAGGAGGTTTAAGAAGTTGGACTTGGACAAATCAGGGTCT\nCTGAGCGTGGAGGAGTTCATGTCCCTGCCGGAGCTGCGCCACAACCCGTTGGTGCGGCGA\nGTGATCGACGTCTTCGACACCGACGGTGATGGAGAAGTGGACTTCAAGGAATTCATCCTG\nGGGACCTCCCAGTTCAGCGTCAAGGGCGACGAGGAGCAGAAGTTGAGGTTTGCGTTCAGC\nATTTACGACATGGATAAAGATGGCTACATTTCCAACGGGGAGCTCTTCCAGGTGCTGAAG\nATGATGGTGGGCAACAACCTGACGGACTGGCAGCTCCAGCAGCTGGTCGACAAAACCATC\nATCATCCTGGACAAGGATGGCGATGGGAAGATATCCTTTGAGGAATTCAGTGCTGTGGTC\nAGAGACCTGGAGATCCACAAGAAGCTGGTCCTCATCGTATGA'], 'pfams': [{'pfam': [{'identifier': ['PF13499'], 'name': ['EF-hand_7']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['function'], 'description': ['calcium ion binding']}]}]}]}, {'id': ['BE0001014'], 'name': ['Peptidyl-prolyl cis-trans isomerase A'], 'organism': ['Humans'], 'actions': [{'action': ['inhibitor', 'binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A11631'], 'pubmed-id': ['17461417'], 'citation': ['Redell JB, Zhao J, Dash PK: Acutely increased cyclophilin a expression after brain injury: a role in blood-brain barrier function and tissue preservation. J Neurosci Res. 2007 Jul;85(9):1980-8.']}, {'ref-id': ['A11632'], 'pubmed-id': ['17609268'], 'citation': ['Schaller T, Ylinen LM, Webb BL, Singh S, Towers GJ: Fusion of cyclophilin A to Fv1 enables cyclosporine-sensitive restriction of human and feline immunodeficiency viruses. J Virol. 2007 Sep;81(18):10055-63. Epub 2007 Jul 3.']}, {'ref-id': ['A2100'], 'pubmed-id': ['20637127'], 'citation': ['Lee J, Kim SS: Current implications of cyclophilins in human cancers. J Exp Clin Cancer Res. 2010 Jul 19;29:97. doi: 10.1186/1756-9966-29-97.']}, {'ref-id': ['A11633'], 'pubmed-id': ['20368803'], 'citation': ['Stegmann CM, Luhrmann R, Wahl MC: The crystal structure of PPIL1 bound to cyclosporine A suggests a binding mode for a linear epitope of the SKIP protein. PLoS One. 2010 Apr 2;5(4):e10013. doi: 10.1371/journal.pone.0010013.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Peptidyl-prolyl cis-trans isomerase A'], 'general-function': ['Virion binding'], 'specific-function': ['PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides.'], 'gene-name': ['PPIA'], 'locus': ['7p13'], 'cellular-location': ['Cytoplasm'], 'transmembrane-regions': [None], 'signal-regions': [None], 'theoretical-pi': ['7.97'], 'molecular-weight': ['18012.42'], 'chromosome-location': ['7'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:9253']}, {'resource': ['GenAtlas'], 'identifier': ['PPIA']}, {'resource': ['GenBank Gene Database'], 'identifier': ['Y00052']}, {'resource': ['GenBank Protein Database'], 'identifier': ['30309']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2751']}, {'resource': ['UniProtKB'], 'identifier': ['P62937']}, {'resource': ['UniProt Accession'], 'identifier': ['PPIA_HUMAN']}]}], 'synonyms': [{'synonym': ['5.2.1.8', 'Cyclophilin A', 'Cyclosporin A-binding protein', 'CYPA', 'PPIase A', 'Rotamase A']}], 'amino-acid-sequence': ['>lcl|BSEQ0002019|Peptidyl-prolyl cis-trans isomerase A\nMVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGF\nMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTE\nWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE'], 'gene-sequence': ['>lcl|BSEQ0010711|Peptidyl-prolyl cis-trans isomerase A (PPIA)\nATGTGTCAGGGTGGTGACTTCACACGCCATAATGGCACTGGTGGCAAGTCCATCTATGGG\nGAGAAATTTGAAGATGAGAACTTCATCCTAAAGCATACGGGTCCTGGCATCTTGTCCATG\nGCAAATGCTGGACCCAACACAAATGGTTCCCAGTTTTTCATCTGCACTGCCAAGACTGAG\nTGGTTGGATGGCAAGCATGTGGTGTTTGGCAAAGTGAAAGAAGGCATGAATATTGTGGAG\nGCCATGGAGCGCTTTGGGTCCAGGAATGGCAAGACCAGCAAGAAGATCACCATTGCTGAC\nTGTGGACAACTCGAATAA'], 'pfams': [{'pfam': [{'identifier': ['PF00160'], 'name': ['Pro_isomerase']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['nucleus']}, {'category': ['function'], 'description': ['peptide binding']}, {'category': ['function'], 'description': ['peptidyl-prolyl cis-trans isomerase activity']}, {'category': ['function'], 'description': ['poly(A) RNA binding']}, {'category': ['function'], 'description': ['unfolded protein binding']}, {'category': ['function'], 'description': ['virion binding']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['entry into host cell']}, {'category': ['process'], 'description': ['establishment of integrated proviral latency']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['lipid particle organization']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of protein secretion']}, {'category': ['process'], 'description': ['positive regulation of viral genome replication']}, {'category': ['process'], 'description': ['protein folding']}, {'category': ['process'], 'description': ['protein peptidyl-prolyl isomerization']}, {'category': ['process'], 'description': ['regulation of viral genome replication']}, {'category': ['process'], 'description': ['RNA-dependent DNA replication']}, {'category': ['process'], 'description': ['uncoating of virus']}, {'category': ['process'], 'description': ['viral life cycle']}, {'category': ['process'], 'description': ['viral process']}, {'category': ['process'], 'description': ['viral release from host cell']}, {'category': ['process'], 'description': ['virion assembly']}]}]}]}, {'id': ['BE0001399'], 'name': ['Peptidyl-prolyl cis-trans isomerase F, mitochondrial'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A189495'], 'pubmed-id': ['2970139'], 'citation': ['Quesniaux VF, Schreier MH, Wenger RM, Hiestand PC, Harding MW, Van Regenmortel MH: Molecular characteristics of cyclophilin-cyclosporine interaction. Transplantation. 1988 Aug;46(2 Suppl):23S-28S. doi: 10.1097/00007890-198808001-00005.']}, {'ref-id': ['A189498'], 'pubmed-id': ['2026447'], 'citation': ['Ryffel B, Woerly G, Greiner B, Haendler B, Mihatsch MJ, Foxwell BM: Distribution of the cyclosporine binding protein cyclophilin in human tissues. Immunology. 1991 Mar;72(3):399-404.']}, {'ref-id': ['A74200'], 'pubmed-id': ['1896075'], 'citation': ['Kallen J, Spitzfaden C, Zurini MG, Wider G, Widmer H, Wuthrich K, Walkinshaw MD: Structure of human cyclophilin and its binding site for cyclosporin A determined by X-ray crystallography and NMR spectroscopy. Nature. 1991 Sep 19;353(6341):276-9.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Peptidyl-prolyl cis-trans isomerase F, mitochondrial'], 'general-function': ['Peptidyl-prolyl cis-trans isomerase activity'], 'specific-function': ['PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. Involved in regulation of the mitochondrial permeability transition pore (mPTP). It is proposed that its association with the mPTP is masking a binding site for inhibiting inorganic phosphate (Pi) and promotes the open probability of the mPTP leading to apoptosis or necrosis; the requirement of the PPIase activity for this function is debated. In cooperation with mitochondrial TP53 is involved in activating oxidative stress-induced necrosis. Involved in modulation of mitochondrial membrane F(1)F(0) ATP synthase activity and regulation of mitochondrial matrix adenine nucleotide levels. Has anti-apoptotic activity independently of mPTP and in cooperation with BCL2 inhibits cytochrome c-dependent apoptosis.'], 'gene-name': ['PPIF'], 'locus': ['10q22-q23'], 'cellular-location': ['Mitochondrion matrix'], 'transmembrane-regions': [None], 'signal-regions': [None], 'theoretical-pi': ['9.95'], 'molecular-weight': ['22040.09'], 'chromosome-location': ['10'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:9259']}, {'resource': ['GenAtlas'], 'identifier': ['PPIF']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M80254']}, {'resource': ['GenBank Protein Database'], 'identifier': ['181274']}, {'resource': ['UniProtKB'], 'identifier': ['P30405']}, {'resource': ['UniProt Accession'], 'identifier': ['PPIF_HUMAN']}]}], 'synonyms': [{'synonym': ['5.2.1.8', 'Cyclophilin D', 'Cyclophilin F', 'CyP-D', 'CyP-M', 'CYP3', 'CypD', 'Mitochondrial cyclophilin', 'PPIase F', 'Rotamase F']}], 'amino-acid-sequence': ['>lcl|BSEQ0002777|Peptidyl-prolyl cis-trans isomerase F, mitochondrial\nMLALRCGSRWLGLLSVPRSVPLRLPAARACSKGSGDPSSSSSSGNPLVYLDVDANGKPLG\nRVVLELKADVVPKTAENFRALCTGEKGFGYKGSTFHRVIPSFMCQAGDFTNHNGTGGKSI\nYGSRFPDENFTLKHVGPGVLSMANAGPNTNGSQFFICTIKTDWLDGKHVVFGHVKEGMDV\nVKKIESFGSKSGRTSKKIVITDCGQLS'], 'gene-sequence': ['>lcl|BSEQ0021846|Peptidyl-prolyl cis-trans isomerase F, mitochondrial (PPIF)\nATGCTGGCGCTGCGCTGCGGCTCCCGCTGGCTCGGCCTGCTCTCCGTCCCGCGCTCCGTG\nCCGCTGCGCCTCCCCGCGGCCCGCGCCTGCAGCAAGGGCTCCGGCGACCCGTCCTCTTCC\nTCCTCCTCCGGGAACCCGCTCGTGTACCTGGACGTGGACGCCAACGGGAAGCCGCTCGGC\nCGCGTGGTGCTGGAGCTGAAGGCAGATGTCGTCCCAAAGACAGCTGAGAACTTCAGAGCC\nCTGTGCACTGGTGAGAAGGGCTTCGGCTACAAAGGCTCCACCTTCCACAGGGTGATCCCT\nTCCTTCATGTGCCAGGCGGGCGACTTCACCAACCACAATGGCACAGGCGGGAAGTCCATC\nTACGGAAGCCGCTTTCCTGACGAGAACTTTACACTGAAGCACGTGGGGCCAGGTGTCCTG\nTCCATGGCTAATGCTGGTCCTAACACCAACGGCTCCCAGTTCTTCATCTGCACCATAAAG\nACAGACTGGTTGGATGGCAAGCATGTTGTGTTCGGTCACGTCAAAGAGGGCATGGACGTC\nGTGAAGAAAATAGAATCTTTCGGCTCTAAGAGTGGGAGGACATCCAAGAAGATTGTCATC\nACAGACTGTGGCCAGTTGAGCTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00160'], 'name': ['Pro_isomerase']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['mitochondrial inner membrane']}, {'category': ['component'], 'description': ['mitochondrial matrix']}, {'category': ['component'], 'description': ['mitochondrion']}, {'category': ['function'], 'description': ['cyclosporin A binding']}, {'category': ['function'], 'description': ['peptidyl-prolyl cis-trans isomerase activity']}, {'category': ['process'], 'description': ['apoptotic mitochondrial changes']}, {'category': ['process'], 'description': ['cellular response to arsenic-containing substance']}, {'category': ['process'], 'description': ['cellular response to calcium ion']}, {'category': ['process'], 'description': ['cellular response to hydrogen peroxide']}, {'category': ['process'], 'description': ['necroptotic process']}, {'category': ['process'], 'description': ['negative regulation of apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of ATPase activity']}, {'category': ['process'], 'description': ['negative regulation of intrinsic apoptotic signaling pathway']}, {'category': ['process'], 'description': ['negative regulation of oxidative phosphorylation']}, {'category': ['process'], 'description': ['negative regulation of oxidative phosphorylation uncoupler activity']}, {'category': ['process'], 'description': ['negative regulation of release of cytochrome c from mitochondria']}, {'category': ['process'], 'description': ['positive regulation of release of cytochrome c from mitochondria']}, {'category': ['process'], 'description': ['protein folding']}, {'category': ['process'], 'description': ['protein peptidyl-prolyl isomerization']}, {'category': ['process'], 'description': ['regulation of mitochondrial membrane permeability']}, {'category': ['process'], 'description': ['regulation of mitochondrial membrane permeability involved in programmed necrotic cell death']}, {'category': ['process'], 'description': ['regulation of necrotic cell death']}, {'category': ['process'], 'description': ['regulation of proton-transporting ATPase activity, rotational mechanism']}, {'category': ['process'], 'description': ['response to ischemia']}]}]}]}]}]"
"['DB00092', 'BTD00055', 'BIOD00055']",['Alefacept'],biotech,"['Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.']",['liquid'],"['As an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis']",['Inhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen.'],[None],"[{'target': [{'id': ['BE0000719'], 'name': ['T-cell surface antigen CD2'], 'organism': ['Humans'], 'actions': [{'action': ['inhibitor', 'antibody', 'regulator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A2102'], 'pubmed-id': ['17555598'], 'citation': ['Chamian F, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Cardinale I, Khatcherian A, Novitskaya I, Wittkowski KM, Krueger JG, Lowes MA: Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. J Transl Med. 2007 Jun 7;5:27.']}, {'ref-id': ['A2104'], 'pubmed-id': ['11970990'], 'citation': ['da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu YM, Hochman PS: Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol. 2002 May 1;168(9):4462-71.']}, {'ref-id': ['A2106'], 'pubmed-id': ['17403057'], 'citation': ['Larsen R, Ryder LP, Svejgaard A, Gniadecki R: Changes in circulating lymphocyte subpopulations following administration of the leucocyte function-associated antigen-3 (LFA-3)/IgG1 fusion protein alefacept. Clin Exp Immunol. 2007 Jul;149(1):23-30. Epub 2007 Apr 2.']}, {'ref-id': ['A2108'], 'pubmed-id': ['14968366'], 'citation': ['Goedkoop AY, de Rie MA, Picavet DI, Kraan MC, Dinant HJ, van Kuijk AW, Tak PP, Bos JD, Teunissen MB: Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch Dermatol Res. 2004 Apr;295(11):465-73. Epub 2004 Feb 14.']}, {'ref-id': ['A2110'], 'pubmed-id': ['12795770'], 'citation': ['Ortonne JP: Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2003 Jul;17 Suppl 2:12-6.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A247090'], 'pubmed-id': ['33807678'], 'citation': ['Kyriakidis I, Vasileiou E, Rossig C, Roilides E, Groll AH, Tragiannidis A: Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies. J Fungi (Basel). 2021 Mar 5;7(3). pii: jof7030186. doi: 10.3390/jof7030186.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['T-cell surface antigen CD2'], 'general-function': ['Receptor binding'], 'specific-function': ['CD2 interacts with lymphocyte function-associated antigen (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types. CD2 is implicated in the triggering of T-cells, the cytoplasmic domain is implicated in the signaling function.'], 'gene-name': ['CD2'], 'locus': ['1p13'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['210-235'], 'signal-regions': ['1-24'], 'theoretical-pi': ['10.3'], 'molecular-weight': ['39447.96'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1639']}, {'resource': ['GenAtlas'], 'identifier': ['CD2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M19806']}, {'resource': ['GenBank Protein Database'], 'identifier': ['180081']}, {'resource': ['UniProtKB'], 'identifier': ['P06729']}, {'resource': ['UniProt Accession'], 'identifier': ['CD2_HUMAN']}]}], 'synonyms': [{'synonym': ['Erythrocyte receptor', 'LFA-2', 'LFA-3 receptor', 'Rosette receptor', 'SRBC', 'T-cell surface antigen T11/Leu-5']}], 'amino-acid-sequence': ['>lcl|BSEQ0010504|T-cell surface antigen CD2\nMSFPCKFVASFLLIFNVSSKGAVSKEITNALETWGALGQDINLDIPSFQMSDDIDDIKWE\nKTSDKKKIAQFRKEKETFKEKDTYKLFKNGTLKIKHLKTDDQDIYKVSIYDTKGKNVLEK\nIFDLKIQERVSKPKISWTCINTTLTCEVMNGTDPELNLYQDGKHLKLSQRVITHKWTTSL\nSAKFKCTAGNKVSKESSVEPVSCPEKGLDIYLIIGICGGGSLLMVFVALLVFYITKRKKQ\nRSRRNDEELETRAHRVATEERGRKPHQIPASTPQNPATSQHPPPPPGHRSQAPSHRPPPP\nGHRVQHQPQKRPPAPSGTQVHQQKGPPLPRPRVQPKPPHGAAENSLSPSSN'], 'gene-sequence': ['>lcl|BSEQ0010505|T-cell surface antigen CD2 (CD2)\nATGAGCTTTCCATGTAAATTTGTAGCCAGCTTCCTTCTGATTTTCAATGTTTCTTCCAAA\nGGTGCAGTCTCCAAAGAGATTACGAATGCCTTGGAAACCTGGGGTGCCTTGGGTCAGGAC\nATCAACTTGGACATTCCTAGTTTTCAAATGAGTGATGATATTGACGATATAAAATGGGAA\nAAAACTTCAGACAAGAAAAAGATTGCACAATTCAGAAAAGAGAAAGAGACTTTCAAGGAA\nAAAGATACATATAAGCTATTTAAAAATGGAACTCTGAAAATTAAGCATCTGAAGACCGAT\nGATCAGGATATCTACAAGGTATCAATATATGATACAAAAGGAAAAAATGTGTTGGAAAAA\nATATTTGATTTGAAGATTCAAGAGAGGGTCTCAAAACCAAAGATCTCCTGGACTTGTATC\nAACACAACCCTGACCTGTGAGGTAATGAATGGAACTGACCCCGAATTAAACCTGTATCAA\nGATGGGAAACATCTAAAACTTTCTCAGAGGGTCATCACACACAAGTGGACCACCAGCCTG\nAGTGCAAAATTCAAGTGCACAGCAGGGAACAAAGTCAGCAAGGAATCCAGTGTCGAGCCT\nGTCAGCTGTCCAGAGAAAGGTCTGGACATCTATCTCATCATTGGCATATGTGGAGGAGGC\nAGCCTCTTGATGGTCTTTGTGGCACTGCTCGTTTTCTATATCACCAAAAGGAAAAAACAG\nAGGAGTCGGAGAAATGATGAGGAGCTGGAGACAAGAGCCCACAGAGTAGCTACTGAAGAA\nAGGGGCCGGAAGCCCCACCAAATTCCAGCTTCAACCCCTCAGAATCCAGCAACTTCCCAA\nCATCCTCCTCCACCACCTGGTCATCGTTCCCAGGCACCTAGTCATCGTCCCCCGCCTCCT\nGGACACCGTGTTCAGCACCAGCCTCAGAAGAGGCCTCCTGCTCCGTCGGGCACACAAGTT\nCACCAGCAGAAAGGCCCGCCCCTCCCCAGACCTCGAGTTCAGCCAAAACCTCCCCATGGG\nGCAGCAGAAAACTCATTGTCCCCTTCCTCTAATTAA'], 'pfams': [{'pfam': [{'identifier': ['PF07686'], 'name': ['V-set']}, {'identifier': ['PF05790'], 'name': ['C2-set']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['anchored component of plasma membrane']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['cell-cell junction']}, {'category': ['component'], 'description': ['cytoplasmic side of plasma membrane']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['receptor activity']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['process'], 'description': ['apoptotic process']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['heterotypic cell-cell adhesion']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['membrane raft polarization']}, {'category': ['process'], 'description': ['natural killer cell activation']}, {'category': ['process'], 'description': ['positive regulation of interferon-gamma secretion']}, {'category': ['process'], 'description': ['positive regulation of interleukin-8 secretion']}, {'category': ['process'], 'description': ['positive regulation of myeloid dendritic cell activation']}, {'category': ['process'], 'description': ['positive regulation of tumor necrosis factor production']}, {'category': ['process'], 'description': ['regulation of T cell differentiation']}, {'category': ['process'], 'description': ['single organismal cell-cell adhesion']}, {'category': ['process'], 'description': ['T cell activation']}]}]}]}, {'id': ['BE0002097'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor III-A'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A2104'], 'pubmed-id': ['11970990'], 'citation': ['da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu YM, Hochman PS: Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol. 2002 May 1;168(9):4462-71.']}, {'ref-id': ['A13298'], 'pubmed-id': ['12795239'], 'citation': ['Vaishnaw AK, TenHoor CN: Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn. 2002 Dec;29(5-6):415-26.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor III-A'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.'], 'gene-name': ['FCGR3A'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['209-229'], 'signal-regions': ['1-16'], 'theoretical-pi': ['8.21'], 'molecular-weight': ['29088.895'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3619']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR3A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X52645']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31324']}, {'resource': ['UniProtKB'], 'identifier': ['P08637']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG3A_HUMAN']}]}], 'synonyms': [{'synonym': ['CD16A', 'CD16a antigen', 'Fc-gamma RIII', 'Fc-gamma RIII-alpha', 'Fc-gamma RIIIa', 'FCG3', 'FCGR3', 'FcR-10', 'FcRIII', 'FcRIIIa', 'IGFR3', 'IgG Fc receptor III-2']}], 'amino-acid-sequence': ['>lcl|BSEQ0004112|Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK'], 'gene-sequence': ['>lcl|BSEQ0011522|Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A)\nATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCT\nTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTG\nCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCA\nAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACT\nCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAG\nAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCGACGACAGT\nGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTGCAGCTAGAAGTC\nCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAGGAAGACCCTATT\nCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACATATTTACAGAAT\nGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCAAAAGCCACACTC\nAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAATGTGTCTTCAGAG\nACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCATCATTCTTTCCA\nCCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCAGTGGACACAGGA\nCTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGGAAGGACCATAAA\nTTTAAATGGAGAAAGGACCCTCAAGACAAATGA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['regulation of immune response']}]}]}]}, {'id': ['BE0000901'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor III-B'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A2104'], 'pubmed-id': ['11970990'], 'citation': ['da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu YM, Hochman PS: Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol. 2002 May 1;168(9):4462-71.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor III-B'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.'], 'gene-name': ['FCGR3B'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': [None], 'signal-regions': ['1-16'], 'theoretical-pi': ['6.71'], 'molecular-weight': ['26215.64'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3620']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR3B']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X16863']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31322']}, {'resource': ['UniProtKB'], 'identifier': ['O75015']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG3B_HUMAN']}]}], 'synonyms': [{'synonym': ['CD16B', 'Fc-gamma RIII', 'Fc-gamma RIII-beta', 'Fc-gamma RIIIb', 'FCG3', 'FCGR3', 'FcR-10', 'FcRIII', 'FcRIIIb', 'IGFR3', 'IgG Fc receptor III-1']}], 'amino-acid-sequence': ['>lcl|BSEQ0010635|Low affinity immunoglobulin gamma Fc region receptor III-B\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI'], 'gene-sequence': ['>lcl|BSEQ0010636|Low affinity immunoglobulin gamma Fc region receptor III-B (FCGR3B)\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['anchored component of membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['mitophagy in response to mitochondrial depolarization']}, {'category': ['process'], 'description': ['positive regulation of defense response to virus by host']}, {'category': ['process'], 'description': ['xenophagy']}]}]}]}]}]"
"['DB00093', 'BTD00114', 'BIOD00114']",['Felypressin'],biotech,"['A synthetic nonapeptide comprising cysteinyl, phenylalanyl, phenylalanyl, glutaminyl, asparaginyl, cysteinyl, prolyl, lysyl, and glycinamide residues in sequence, with a disulfide bridge joining the two cysteine residues. Its antidiuretic effects are less than those of vasopressin. It is a non-catecholamine vasoconstrictor used in local anaesthetic injections for dental use, and is an ingredient of preparations that have been used for treatment of pain and inflammation of the mouth.']",['solid'],"['For use as an alternative to adrenaline as a localising agent, provided that local ischaemia is not essential.']","['Felypressin binds to the vasopressin receptor V1a. This causes contraction of the smooth muscle in the vascular bed, especially capillaries, small arterioles and venules.']",[None],"[{'target': [{'id': ['BE0000165'], 'name': ['Vasopressin V1a receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A2112'], 'pubmed-id': ['18655903'], 'citation': ['Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G: Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512. doi: 10.1016/S0079-6123(08)00437-8.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Vasopressin V1a receptor'], 'general-function': ['Vasopressin receptor activity'], 'specific-function': ['Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. Has been involved in social behaviors, including affiliation and attachment.'], 'gene-name': ['AVPR1A'], 'locus': ['12q14-q15'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['53-76\n89-110\n126-147\n169-190\n219-239\n294-313\n332-351'], 'signal-regions': [None], 'theoretical-pi': ['9.67'], 'molecular-weight': ['46799.105'], 'chromosome-location': ['12'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:895']}, {'resource': ['GenAtlas'], 'identifier': ['AVPR1A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L25615']}, {'resource': ['GenBank Protein Database'], 'identifier': ['667068']}, {'resource': ['IUPHAR'], 'identifier': ['366']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['366']}, {'resource': ['UniProtKB'], 'identifier': ['P37288']}, {'resource': ['UniProt Accession'], 'identifier': ['V1AR_HUMAN']}]}], 'synonyms': [{'synonym': ['Antidiuretic hormone receptor 1a', 'AVPR V1a', 'AVPR1', 'V1aR', 'Vascular/hepatic-type arginine vasopressin receptor']}], 'amino-acid-sequence': ['>lcl|BSEQ0009979|Vasopressin V1a receptor\nMRLSAGPDAGPSGNSSPWWPLATGAGNTSREAEALGEGNGPPRDVRNEELAKLEIAVLAV\nTFAVAVLGNSSVLLALHRTPRKTSRMHLFIRHLSLADLAVAFFQVLPQMCWDITYRFRGP\nDWLCRVVKHLQVFGMFASAYMLVVMTADRYIAVCHPLKTLQQPARRSRLMIAAAWVLSFV\nLSTPQYFVFSMIEVNNVTKARDCWATFIQPWGSRAYVTWMTGGIFVAPVVILGTCYGFIC\nYNIWCNVRGKTASRQSKGAEQAGVAFQKGFLLAPCVSSVKSISRAKIRTVKMTFVIVTAY\nIVCWAPFFIIQMWSVWDPMSVWTESENPTITITALLGSLNSCCNPWIYMFFSGHLLQDCV\nQSFPCCQNMKEKFNKEDTDSMSRRQTFYSNNRSPTNSTGMWKDSPKSSKSIKFIPVST'], 'gene-sequence': ['>lcl|BSEQ0009980|Vasopressin V1a receptor (AVPR1A)\nATGCGTCTCTCCGCCGGTCCCGACGCGGGGCCCTCGGGCAACTCCAGCCCATGGTGGCCT\nCTGGCCACCGGCGCTGGCAACACAAGCCGGGAGGCCGAAGCCCTCGGGGAGGGCAACGGC\nCCACCGAGGGACGTGCGCAACGAGGAGCTGGCCAAACTGGAGATCGCCGTGCTGGCGGTG\nACTTTCGCGGTGGCCGTGCTGGGCAACAGCAGCGTACTGCTGGCTCTGCACCGGACGCCG\nCGCAAGACGTCCCGCATGCACCTCTTCATCCGACACCTCAGCCTGGCCGACCTGGCCGTG\nGCATTCTTCCAGGTGCTGCCGCAAATGTGCTGGGACATCACCTACCGCTTCCGCGGCCCC\nGACTGGCTGTGCCGCGTGGTGAAGCACCTGCAGGTGTTCGGCATGTTTGCGTCGGCCTAC\nATGCTGGTAGTCATGACAGCCGACCGCTACATCGCGGTGTGCCACCCGCTCAAGACTCTG\nCAACAGCCCGCGCGCCGCTCGCGCCTCATGATCGCGGCCGCCTGGGTGCTGAGCTTCGTG\nCTGAGCACGCCGCAGTACTTCGTCTTCTCCATGATCGAGGTGAACAATGTCACCAAGGCC\nCGCGACTGCTGGGCCACCTTCATCCAGCCCTGGGGTTCTCGTGCCTACGTGACCTGGATG\nACGGGCGGCATCTTTGTGGCGCCCGTGGTCATCTTGGGTACCTGCTACGGCTTCATCTGC\nTACAACATCTGGTGCAACGTCCGCGGGAAGACGGCGTCGCGCCAGAGCAAGGGTGCAGAG\nCAAGCGGGTGTGGCCTTCCAAAAGGGGTTCCTGCTCGCACCCTGTGTCAGCAGCGTGAAG\nTCCATTTCCCGGGCCAAGATCCGCACGGTGAAGATGACTTTTGTGATCGTGACGGCTTAC\nATCGTCTGCTGGGCGCCTTTCTTCATCATCCAGATGTGGTCTGTCTGGGATCCCATGTCC\nGTCTGGACCGAATCGGAAAACCCTACCATCACCATCACTGCATTACTGGGTTCCTTGAAT\nAGCTGCTGTAATCCCTGGATATACATGTTTTTTAGTGGCCATCTCCTTCAAGACTGTGTT\nCAAAGCTTCCCATGCTGCCAAAACATGAAGGAAAAATTCAACAAAGAAGATACTGACAGT\nATGAGCAGAAGACAGACTTTTTATTCTAACAATCGAAGCCCAACAAACAGTACGGGTATG\nTGGAAGGACTCGCCTAAATCTTCCAAGTCCATCAAATTCATTCCTGTTTCAACTTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}, {'identifier': ['PF08983'], 'name': ['DUF1856']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cytoplasmic vesicle']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['peptide binding']}, {'category': ['function'], 'description': ['peptide hormone binding']}, {'category': ['function'], 'description': ['protein kinase C binding']}, {'category': ['function'], 'description': ['vasopressin receptor activity']}, {'category': ['process'], 'description': ['activation of phospholipase C activity']}, {'category': ['process'], 'description': ['blood circulation']}, {'category': ['process'], 'description': ['calcium-mediated signaling']}, {'category': ['process'], 'description': ['cellular response to hormone stimulus']}, {'category': ['process'], 'description': ['cellular response to water deprivation']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['generation of precursor metabolites and energy']}, {'category': ['process'], 'description': ['grooming behavior']}, {'category': ['process'], 'description': ['maternal aggressive behavior']}, {'category': ['process'], 'description': ['maternal behavior']}, {'category': ['process'], 'description': ['myotube differentiation']}, {'category': ['process'], 'description': ['negative regulation of female receptivity']}, {'category': ['process'], 'description': ['negative regulation of transmission of nerve impulse']}, {'category': ['process'], 'description': ['penile erection']}, {'category': ['process'], 'description': ['positive regulation of cell growth']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of cellular pH reduction']}, {'category': ['process'], 'description': ['positive regulation of cytosolic calcium ion concentration']}, {'category': ['process'], 'description': ['positive regulation of glutamate secretion']}, {'category': ['process'], 'description': ['positive regulation of heart rate']}, {'category': ['process'], 'description': ['positive regulation of prostaglandin biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of renal sodium excretion']}, {'category': ['process'], 'description': ['positive regulation of systemic arterial blood pressure']}, {'category': ['process'], 'description': ['positive regulation of vasoconstriction']}, {'category': ['process'], 'description': ['regulation of systemic arterial blood pressure by vasopressin']}, {'category': ['process'], 'description': ['response to corticosterone']}, {'category': ['process'], 'description': ['response to peptide']}, {'category': ['process'], 'description': ['social behavior']}, {'category': ['process'], 'description': ['sperm ejaculation']}, {'category': ['process'], 'description': ['telencephalon development']}]}]}]}]}]"
"['DB00094', 'BTD00104', 'BIOD00104']",['Urofollitropin'],biotech,"['Urofollitropin is a urinary-derived follicle-stimulating hormone (FSH) that is extracted and purified from human urine samples. It consists of two non-covalently linked, non-identical glycoproteins designated as the alpha- and beta- subunits. The alpha- and beta- subunits have 92 and 111 amino acids. The alpha subunit is glycosylated at Asn 51 and Asn 78 while the beta subunit is glycosylated at Asn 7 and Asn 24. Urofollitropin is typically used injected subcutaneously in combination with human chorionic gonadotropin (hCG) to induce ovulation. Urofollitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF).']",['liquid'],['For treatment of female infertility'],"['FSH binds to the follicle stimulating hormone receptor which is a G-coupled transmembrane receptor. Binding of the FSH to its receptor seems to induce phosphorylation and activation of the PI3K (Phosphatidylinositol-3-kinase) and Akt signaling pathway, which is known to regulate many other metabolic and related survival/maturation functions in cells.']",[None],"[{'target': [{'id': ['BE0000387'], 'name': ['Follicle-stimulating hormone receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A2011'], 'pubmed-id': ['11299519'], 'citation': ['Layman LC: Mutations in the follicle-stimulating hormone-beta (FSH beta) and FSH receptor genes in mice and humans. Semin Reprod Med. 2000;18(1):5-10.']}, {'ref-id': ['A2013'], 'pubmed-id': ['7755615'], 'citation': ['Leng N, Dattatreyamurty B, Reichert LE Jr: Identification of amino acid residues 300-315 of the rat FSH receptor as a hormone binding domain: evidence for its interaction with specific regions of FSH beta-subunit. Biochem Biophys Res Commun. 1995 May 16;210(2):392-9.']}, {'ref-id': ['A2014'], 'pubmed-id': ['2108722'], 'citation': ['Santa Coloma TA, Dattatreyamurty B, Reichert LE Jr: A synthetic peptide corresponding to human FSH beta-subunit 33-53 binds to FSH receptor, stimulates basal estradiol biosynthesis, and is a partial antagonist of FSH. Biochemistry. 1990 Feb 6;29(5):1194-200.']}, {'ref-id': ['A2017'], 'pubmed-id': ['8319832'], 'citation': ['Dattatreyamurty B, Reichert LE Jr: Identification of regions of the follitropin (FSH) beta-subunit that interact with the N-terminus region (residues 9-30) of the FSH receptor. Mol Cell Endocrinol. 1993 May;93(1):39-46.']}, {'ref-id': ['A2019'], 'pubmed-id': ['8070368'], 'citation': ['Lindau-Shepard B, Roth KE, Dias JA: Identification of amino acids in the C-terminal region of human follicle-stimulating hormone (FSH) beta-subunit involved in binding to human FSH receptor. Endocrinology. 1994 Sep;135(3):1235-40.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Follicle-stimulating hormone receptor'], 'general-function': ['G-protein coupled peptide receptor activity'], 'specific-function': ['Receptor for follicle-stimulating hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Induces cAMP production through the activation of PI3K-AKT and SRC-ERK1/2 signaling pathways.'], 'gene-name': ['FSHR'], 'locus': ['2p21-p16'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['367-387\n399-421\n444-465\n486-508\n529-550\n574-597\n609-630'], 'signal-regions': ['1-17'], 'theoretical-pi': ['7.19'], 'molecular-weight': ['78264.07'], 'chromosome-location': ['2'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3969']}, {'resource': ['GenAtlas'], 'identifier': ['FSHR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M65085']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182771']}, {'resource': ['IUPHAR'], 'identifier': ['253']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['253']}, {'resource': ['UniProtKB'], 'identifier': ['P23945']}, {'resource': ['UniProt Accession'], 'identifier': ['FSHR_HUMAN']}]}], 'synonyms': [{'synonym': ['Follitropin receptor', 'FSH-R', 'LGR1']}], 'amino-acid-sequence': ['>lcl|BSEQ0037007|Follicle-stimulating hormone receptor\nMALLLVSLLAFLSLGSGCHHRICHCSNRVFLCQESKVTEIPSDLPRNAIELRFVLTKLRV\nIQKGAFSGFGDLEKIEISQNDVLEVIEADVFSNLPKLHEIRIEKANNLLYINPEAFQNLP\nNLQYLLISNTGIKHLPDVHKIHSLQKVLLDIQDNINIHTIERNSFVGLSFESVILWLNKN\nGIQEIHNCAFNGTQLDELNLSDNNNLEELPNDVFHGASGPVILDISRTRIHSLPSYGLEN\nLKKLRARSTYNLKKLPTLEKLVALMEASLTYPSHCCAFANWRRQISELHPICNKSILRQE\nVDYMTQARGQRSSLAEDNESSYSRGFDMTYTEFDYDLCNEVVDVTCSPKPDAFNPCEDIM\nGYNILRVLIWFISILAITGNIIVLVILTTSQYKLTVPRFLMCNLAFADLCIGIYLLLIAS\nVDIHTKSQYHNYAIDWQTGAGCDAAGFFTVFASELSVYTLTAITLERWHTITHAMQLDCK\nVQLRHAASVMVMGWIFAFAAALFPIFGISSYMKVSICLPMDIDSPLSQLYVMSLLVLNVL\nAFVVICGCYIHIYLTVRNPNIVSSSSDTRIAKRMAMLIFTDFLCMAPISFFAISASLKVP\nLITVSKAKILLVLFHPINSCANPFLYAIFTKNFRRDFFILLSKCGCYEMQAQIYRTETSS\nTVHNTHPRNGHCSSAPRVTNGSTYILVPLSHLAQN'], 'gene-sequence': ['>lcl|BSEQ0018946|Follicle-stimulating hormone receptor (FSHR)\nATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCAT\nCGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATT\nCCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTC\nATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAAT\nGATGTCTTGGAGGTGATAGAGGCAGATGTGTTCTCCAACCTTCCCAAATTACATGAAATT\nAGAATTGAAAAGGCCAACAACCTGCTCTACATCAACCCTGAGGCCTTCCAGAACCTTCCC\nAACCTTCAATATCTGTTAATATCCAACACAGGTATTAAGCACCTTCCAGATGTTCACAAG\nATTCATTCTCTCCAAAAAGTTTTACTTGACATTCAAGATAACATAAACATCCACACAATT\nGAAAGAAATTCTTTCGTGGGGCTGAGCTTTGAAAGTGTGATTCTATGGCTGAATAAGAAT\nGGGATTCAAGAAATACACAACTGTGCATTCAATGGAACCCAACTAGATGAGCTGAATCTA\nAGCGATAATAATAATTTAGAAGAATTGCCTAATGATGTTTTCCACGGAGCCTCTGGACCA\nGTCATTCTAGATATTTCAAGAACAAGGATCCATTCCCTGCCTAGCTATGGCTTAGAAAAT\nCTTAAGAAGCTGAGGGCCAGGTCGACTTACAACTTAAAAAAGCTGCCTACTCTGGAAAAG\nCTTGTCGCCCTCATGGAAGCCAGCCTCACCTATCCCAGCCATTGCTGTGCCTTTGCAAAC\nTGGAGACGGCAAATCTCTGAGCTTCATCCAATTTGCAACAAATCTATTTTAAGGCAAGAA\nGTTGATTATATGACTCAGGCTAGGGGTCAGAGATCCTCTCTGGCAGAAGACAATGAGTCC\nAGCTACAGCAGAGGATTTGACATGACGTACACTGAGTTTGACTATGACTTATGCAATGAA\nGTGGTTGACGTGACCTGCTCCCCTAAGCCAGATGCATTCAACCCATGTGAAGATATCATG\nGGGTACAACATCCTCAGAGTCCTGATATGGTTTATCAGCATCCTGGCCATCACTGGGAAC\nATCATAGTGCTAGTGATCCTAACTACCAGCCAATATAAACTCACAGTCCCCAGGTTCCTT\nATGTGCAACCTGGCCTTTGCTGATCTCTGCATTGGAATCTACCTGCTGCTCATTGCATCA\nGTTGATATCCATACCAAGAGCCAATATCACAACTATGCCATTGACTGGCAAACTGGGGCA\nGGCTGTGATGCTGCTGGCTTTTTCACTGTCTTTGCCAGTGAGCTGTCAGTCTACACTCTG\nACAGCTATCACCTTGGAAAGATGGCATACCATCACGCATGCCATGCAGCTGGACTGCAAG\nGTGCAGCTCCGCCATGCTGCCAGTGTCATGGTGATGGGCTGGATTTTTGCTTTTGCAGCT\nGCCCTCTTTCCCATCTTTGGCATCAGCAGCTACATGAAGGTGAGCATCTGCCTGCCCATG\nGATATTGACAGCCCTTTGTCACAGCTGTATGTCATGTCCCTCCTTGTGCTCAATGTCCTG\nGCCTTTGTGGTCATCTGTGGCTGCTATATCCACATCTACCTCACAGTGCGGAACCCCAAC\nATCGTGTCCTCCTCTAGTGACACCAGGATCGCCAAGCGCATGGCCATGCTCATCTTCACT\nGACTTCCTCTGCATGGCACCCATTTCTTTCTTTGCCATTTCTGCCTCCCTCAAGGTGCCC\nCTCATCACTGTGTCCAAAGCAAAGATTCTGCTGGTTCTGTTTCACCCCATCAACTCCTGT\nGCCAACCCCTTCCTCTATGCCATCTTTACCAAAAACTTTCGCAGAGATTTCTTCATTCTG\nCTGAGCAAGTGTGGCTGCTATGAAATGCAAGCCCAAATTTATAGGACAGAAACTTCATCC\nACTGTCCACAACACCCATCCAAGGAATGGCCACTGCTCTTCAGCTCCCAGAGTCACCAGT\nGGTTCCACTTACATACTTGTCCCTCTAAGTCATTTAGCCCAAAACTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}, {'identifier': ['PF01462'], 'name': ['LRRNT']}, {'identifier': ['PF13306'], 'name': ['LRR_5']}, {'identifier': ['PF12369'], 'name': ['GnHR_trans']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['follicle-stimulating hormone receptor activity']}, {'category': ['function'], 'description': ['G-protein coupled peptide receptor activity']}, {'category': ['process'], 'description': ['activation of adenylate cyclase activity']}, {'category': ['process'], 'description': ['adenylate cyclase-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['female gamete generation']}, {'category': ['process'], 'description': ['female gonad development']}, {'category': ['process'], 'description': ['follicle-stimulating hormone signaling pathway']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['gonad development']}, {'category': ['process'], 'description': ['hormone-mediated signaling pathway']}, {'category': ['process'], 'description': ['male gonad development']}, {'category': ['process'], 'description': ['positive regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['positive regulation of phosphatidylinositol 3-kinase signaling']}, {'category': ['process'], 'description': ['primary ovarian follicle growth']}, {'category': ['process'], 'description': ['regulation of osteoclast differentiation']}, {'category': ['process'], 'description': ['regulation of protein kinase A signaling']}, {'category': ['process'], 'description': ['spermatogenesis']}, {'category': ['process'], 'description': ['uterus development']}]}]}]}]}]"
"['DB00095', 'BTD00074', 'BIOD00074']",['Efalizumab'],biotech,['Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797]'],['liquid'],"['For the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.']","['Efalizumab binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes. As a result efalizumab decreases cell surface expression of CD11a.']",[None],"[{'target': [{'id': ['BE0009967'], 'name': ['Integrin alpha-X'], 'organism': ['Humans'], 'actions': [{'action': ['antibody']}], 'references': [{'articles': [{'article': [{'ref-id': ['A202904'], 'pubmed-id': ['25070825'], 'citation': ['Pan WZ, Shi CX, Tian M, Yu JG: Anti-CD11c antibody, Efalizumab attenuate ventilator-induced lung injury. Eur Rev Med Pharmacol Sci. 2014;18(15):2182-90.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Integrin alpha-X'], 'general-function': ['Integrin alpha-X/beta-2 is a receptor for fibrinogen. It recognizes the sequence G-P-R in fibrinogen. It mediates cell-cell interaction during inflammatory responses. It is especially important in monocyte adhesion and chemotaxis.'], 'specific-function': ['Metal ion binding'], 'gene-name': ['ITGAX'], 'locus': ['16p11.2'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['1108-1128'], 'signal-regions': ['1-19'], 'theoretical-pi': [None], 'molecular-weight': ['127828.18'], 'chromosome-location': ['16'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6152']}, {'resource': ['UniProtKB'], 'identifier': ['P20702']}, {'resource': ['UniProt Accession'], 'identifier': ['ITAX_HUMAN']}]}], 'synonyms': [{'synonym': ['CD11 antigen-like family member C', 'CD11C', 'Leu M5', 'Leukocyte adhesion glycoprotein p150,95 alpha chain', 'Leukocyte adhesion receptor p150,95']}], 'amino-acid-sequence': ['>lcl|BSEQ0052471|Integrin alpha-X\nMTRTRAALLLFTALATSLGFNLDTEELTAFRVDSAGFGDSVVQYANSWVVVGAPQKITAA\nNQTGGLYQCGYSTGACEPIGLQVPPEAVNMSLGLSLASTTSPSQLLACGPTVHHECGRNM\nYLTGLCFLLGPTQLTQRLPVSRQECPRQEQDIVFLIDGSGSISSRNFATMMNFVRAVISQ\nFQRPSTQFSLMQFSNKFQTHFTFEEFRRSSNPLSLLASVHQLQGFTYTATAIQNVVHRLF\nHASYGARRDAAKILIVITDGKKEGDSLDYKDVIPMADAAGIIRYAIGVGLAFQNRNSWKE\nLNDIASKPSQEHIFKVEDFDALKDIQNQLKEKIFAIEGTETTSSSSFELEMAQEGFSAVF\nTPDGPVLGAVGSFTWSGGAFLYPPNMSPTFINMSQENVDMRDSYLGYSTELALWKGVQSL\nVLGAPRYQHTGKAVIFTQVSRQWRMKAEVTGTQIGSYFGASLCSVDVDSDGSTDLVLIGA\nPHYYEQTRGGQVSVCPLPRGWRRWWCDAVLYGEQGHPWGRFGAALTVLGDVNGDKLTDVV\nIGAPGEEENRGAVYLFHGVLGPSISPSHSQRIAGSQLSSRLQYFGQALSGGQDLTQDGLV\nDLAVGARGQVLLLRTRPVLWVGVSMQFIPAEIPRSAFECREQVVSEQTLVQSNICLYIDK\nRSKNLLGSRDLQSSVTLDLALDPGRLSPRATFQETKNRSLSRVRVLGLKAHCENFNLLLP\nSCVEDSVTPITLRLNFTLVGKPLLAFRNLRPMLAADAQRYFTASLPFEKNCGADHICQDN\nLGISFSFPGLKSLLVGSNLELNAEVMVWNDGEDSYGTTITFSHPAGLSYRYVAEGQKQGQ\nLRSLHLTCDSAPVGSQGTWSTSCRINHLIFRGGAQITFLATFDVSPKAVLGDRLLLTANV\nSSENNTPRTSKTTFQLELPVKYAVYTVVSSHEQFTKYLNFSESEEKESHVAMHRYQVNNL\nGQRDLPVSINFWVPVELNQEAVWMDVEVSHPQNPSLRCSSEKIAPPASDFLAHIQKNPVL\nDCSIAGCLRFRCDVPSFSVQEELDFTLKGNLSFGWVRQILQKKVSVVSVAEITFDTSVYS\nQLPGQEAFMRAQTTTVLEKYKVHNPTPLIVGSSIGGLLLLALITAVLYKVGFFKRQYKEM\nMEEANGQIAPENGTQTPSPPSEK'], 'gene-sequence': ['>lcl|BSEQ0052472|Integrin alpha-X (ITGAX)\nATGACCAGGACCAGGGCAGCACTCCTCCTGTTCACAGCCTTAGCAACTTCTCTAGGTTTC\nAACTTGGACACAGAGGAGCTGACAGCCTTCCGTGTGGACAGCGCTGGGTTTGGAGACAGC\nGTGGTCCAGTATGCCAACTCCTGGGTGGTGGTTGGAGCCCCCCAAAAGATAACAGCTGCC\nAACCAAACGGGTGGCCTCTACCAGTGTGGCTACAGCACTGGTGCCTGTGAGCCCATCGGC\nCTGCAGGTGCCCCCGGAGGCCGTGAACATGTCCCTGGGCCTGTCCCTGGCGTCTACCACC\nAGCCCTTCCCAGCTGCTGGCCTGCGGCCCCACCGTGCACCACGAGTGCGGGAGGAACATG\nTACCTCACCGGACTCTGCTTCCTCCTGGGCCCCACCCAGCTCACCCAGAGGCTCCCGGTG\nTCCAGGCAGGAGTGCCCAAGACAGGAGCAGGACATTGTGTTCCTGATCGATGGCTCAGGC\nAGCATCTCCTCCCGCAACTTTGCCACGATGATGAACTTCGTGAGAGCTGTGATAAGCCAG\nTTCCAGAGACCCAGCACCCAGTTTTCCCTGATGCAGTTCTCCAACAAATTCCAAACACAC\nTTCACTTTCGAGGAATTCAGGCGCAGCTCAAACCCCCTCAGCCTGTTGGCTTCTGTTCAC\nCAGCTGCAAGGGTTTACATACACGGCCACCGCCATCCAAAATGTCGTGCACCGATTGTTC\nCATGCCTCATATGGGGCCCGTAGGGATGCCGCCAAAATTCTCATTGTCATCACTGATGGG\nAAGAAAGAAGGCGACAGCCTGGATTATAAGGATGTCATCCCCATGGCTGATGCAGCAGGC\nATCATCCGCTATGCAATTGGGGTTGGATTAGCTTTTCAAAACAGAAATTCTTGGAAAGAA\nTTAAATGACATTGCATCGAAGCCCTCCCAGGAACACATATTTAAAGTGGAGGACTTTGAT\nGCTCTGAAAGATATTCAAAACCAACTGAAGGAGAAGATCTTTGCCATTGAGGGTACGGAG\nACCACAAGCAGTAGCTCCTTCGAATTGGAGATGGCACAGGAGGGCTTCAGCGCTGTGTTC\nACACCTGATGGCCCCGTTCTGGGGGCTGTGGGGAGCTTCACCTGGTCTGGAGGTGCCTTC\nCTGTACCCCCCAAATATGAGCCCTACCTTCATCAACATGTCTCAGGAGAATGTGGACATG\nAGGGACTCTTACCTGGGTTACTCCACCGAGCTGGCCCTCTGGAAAGGGGTGCAGAGCCTG\nGTCCTGGGGGCCCCCCGCTACCAGCACACCGGGAAGGCTGTCATCTTCACCCAGGTGTCC\nAGGCAATGGAGGATGAAGGCCGAAGTCACGGGGACTCAGATCGGCTCCTACTTCGGGGCC\nTCCCTCTGCTCCGTGGACGTAGACAGCGACGGCAGCACCGACCTGGTCCTCATCGGGGCC\nCCCCATTACTACGAGCAGACCCGAGGGGGCCAGGTGTCTGTGTGTCCCTTGCCCAGGGGG\nTGGAGAAGGTGGTGGTGTGATGCTGTTCTCTACGGGGAGCAGGGCCACCCCTGGGGTCGC\nTTTGGGGCGGCTCTGACAGTGCTGGGGGATGTGAATGGGGACAAGCTGACAGACGTGGTC\nATCGGGGCCCCAGGAGAGGAGGAGAACCGGGGTGCTGTCTACCTGTTTCACGGAGTCTTG\nGGACCCAGCATCAGCCCCTCCCACAGCCAGCGGATCGCGGGCTCCCAGCTCTCCTCCAGG\nCTGCAGTATTTTGGGCAGGCACTGAGCGGGGGTCAAGACCTCACCCAGGATGGACTGGTG\nGACCTGGCTGTGGGGGCCCGGGGCCAGGTGCTCCTGCTCAGGACCAGACCTGTGCTCTGG\nGTGGGGGTGAGCATGCAGTTCATACCTGCCGAGATCCCCAGGTCTGCGTTTGAGTGTCGG\nGAGCAGGTGGTCTCTGAGCAGACCCTGGTACAGTCCAACATCTGCCTTTACATTGACAAA\nCGTTCTAAGAACCTGCTTGGGAGCCGTGACCTCCAAAGCTCTGTGACCTTGGACCTGGCC\nCTCGACCCTGGCCGCCTGAGTCCCCGTGCCACCTTCCAGGAAACAAAGAACCGGAGTCTG\nAGCCGAGTCCGAGTCCTCGGGCTGAAGGCACACTGTGAAAACTTCAACCTGCTGCTCCCG\nAGCTGCGTGGAGGACTCTGTGACCCCCATTACCTTGCGTCTGAACTTCACGCTGGTGGGC\nAAGCCCCTCCTTGCCTTCAGAAACCTGCGGCCTATGCTGGCCGCCGATGCTCAGAGATAC\nTTCACGGCCTCCCTACCCTTTGAGAAGAACTGTGGAGCCGACCATATCTGCCAGGACAAT\nCTCGGCATCTCCTTCAGCTTCCCAGGCTTGAAGTCCCTGCTGGTGGGGAGTAACCTGGAG\nCTGAACGCAGAAGTGATGGTGTGGAATGACGGGGAAGACTCCTACGGAACCACCATCACC\nTTCTCCCACCCCGCAGGACTGTCCTACCGCTACGTGGCAGAGGGCCAGAAACAAGGGCAG\nCTGCGTTCCCTGCACCTGACATGTGACAGCGCCCCAGTTGGGAGCCAGGGCACCTGGAGC\nACCAGCTGCAGAATCAACCACCTCATCTTCCGTGGCGGCGCCCAGATCACCTTCTTGGCT\nACCTTTGACGTCTCCCCCAAGGCTGTCCTGGGAGACCGGCTGCTTCTGACAGCCAATGTG\nAGCAGTGAGAACAACACTCCCAGGACCAGCAAGACCACCTTCCAGCTGGAGCTCCCGGTG\nAAGTATGCTGTCTACACTGTGGTTAGCAGCCACGAACAATTCACCAAATACCTCAACTTC\nTCAGAGTCTGAGGAGAAGGAAAGCCATGTGGCCATGCACAGATACCAGGTCAATAACCTG\nGGACAGAGGGACCTGCCTGTCAGCATCAACTTCTGGGTGCCTGTGGAGCTGAACCAGGAG\nGCTGTGTGGATGGATGTGGAGGTCTCCCACCCCCAGAACCCATCCCTTCGGTGCTCCTCA\nGAGAAAATCGCACCCCCAGCATCTGACTTCCTGGCGCACATTCAGAAGAATCCCGTGCTG\nGACTGCTCCATTGCTGGCTGCCTGCGGTTCCGCTGTGACGTCCCCTCCTTCAGCGTCCAG\nGAGGAGCTGGATTTCACCCTGAAGGGCAACCTCAGCTTTGGCTGGGTCCGCCAGATATTG\nCAGAAGAAGGTGTCGGTCGTGAGTGTGGCTGAAATTACGTTCGACACATCCGTGTACTCC\nCAGCTTCCAGGACAGGAGGCATTTATGAGAGCTCAGACGACAACGGTGCTGGAGAAGTAC\nAAGGTCCACAACCCCACCCCCCTCATCGTAGGCAGCTCCATTGGGGGTCTGTTGCTGCTG\nGCACTCATCACAGCGGTACTGTACAAAGTTGGCTTCTTCAAGCGTCAGTACAAGGAAATG\nATGGAGGAGGCAAATGGACAAATTGCCCCAGAAAACGGGACACAGACCCCCAGCCCGCCC\nAGTGAGAAATGA'], 'pfams': [{'pfam': [{'identifier': ['PF01839'], 'name': ['FG-GAP']}, {'identifier': ['PF00357'], 'name': ['Integrin_alpha']}, {'identifier': ['PF08441'], 'name': ['Integrin_alpha2']}, {'identifier': ['PF00092'], 'name': ['VWA']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['ficolin-1-rich granule membrane']}, {'category': ['component'], 'description': ['integrin complex']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['protein-containing complex']}, {'category': ['component'], 'description': ['secretory granule membrane']}, {'category': ['component'], 'description': ['tertiary granule membrane']}, {'category': ['function'], 'description': ['metal ion binding']}, {'category': ['function'], 'description': ['protein heterodimerization activity']}, {'category': ['function'], 'description': ['receptor tyrosine kinase binding']}, {'category': ['function'], 'description': ['signaling receptor activity']}, {'category': ['process'], 'description': ['animal organ morphogenesis']}, {'category': ['process'], 'description': ['cell adhesion']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['heterotypic cell-cell adhesion']}, {'category': ['process'], 'description': ['integrin-mediated signaling pathway']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['neutrophil degranulation']}, {'category': ['process'], 'description': ['positive regulation of angiogenesis']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of cell population proliferation']}, {'category': ['process'], 'description': ['positive regulation of endothelial tube morphogenesis']}, {'category': ['process'], 'description': ['positive regulation of gene expression']}, {'category': ['process'], 'description': ['positive regulation of myelination']}]}]}]}, {'id': ['BE0000516'], 'name': ['Integrin alpha-L'], 'organism': ['Humans'], 'actions': [{'action': ['antibody']}], 'references': [{'articles': [{'article': [{'ref-id': ['A2114'], 'pubmed-id': ['19170413'], 'citation': ['Frampton JE, Plosker GL: Efalizumab: a review of its use in the management of chronic moderate-to-severe plaque psoriasis. Am J Clin Dermatol. 2009;10(1):51-72. doi: 10.2165/0128071-200910010-00009.']}, {'ref-id': ['A146'], 'pubmed-id': ['17053736'], 'citation': ['Descamps V: [Efalizumab]. Ann Dermatol Venereol. 2006 Aug-Sep;133(8-9 Pt 1):666-78.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A199125'], 'pubmed-id': ['15799683'], 'citation': ['Wellington K, Perry CM: Efalizumab. Am J Clin Dermatol. 2005;6(2):113-8; discussion 119-20. doi: 10.2165/00128071-200506020-00006.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Integrin alpha-L'], 'general-function': ['Metal ion binding'], 'specific-function': ['Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. It is involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes.'], 'gene-name': ['ITGAL'], 'locus': ['16p11.2'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['1091-1111'], 'signal-regions': ['1-25'], 'theoretical-pi': ['5.35'], 'molecular-weight': ['128768.495'], 'chromosome-location': ['16'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6148']}, {'resource': ['GenAtlas'], 'identifier': ['ITGAL']}, {'resource': ['GenBank Gene Database'], 'identifier': ['Y00796']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31422']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2451']}, {'resource': ['UniProtKB'], 'identifier': ['P20701']}, {'resource': ['UniProt Accession'], 'identifier': ['ITAL_HUMAN']}]}], 'synonyms': [{'synonym': ['CD11 antigen-like family member A', 'CD11A', 'Leukocyte adhesion glycoprotein LFA-1 alpha chain', 'Leukocyte function-associated molecule 1 alpha chain', 'LFA-1A']}], 'amino-acid-sequence': ['>lcl|BSEQ0001030|Integrin alpha-L\nMKDSCITVMAMALLSGFFFFAPASSYNLDVRGARSFSPPRAGRHFGYRVLQVGNGVIVGA\nPGEGNSTGSLYQCQSGTGHCLPVTLRGSNYTSKYLGMTLATDPTDGSILACDPGLSRTCD\nQNTYLSGLCYLFRQNLQGPMLQGRPGFQECIKGNVDLVFLFDGSMSLQPDEFQKILDFMK\nDVMKKLSNTSYQFAAVQFSTSYKTEFDFSDYVKRKDPDALLKHVKHMLLLTNTFGAINYV\nATEVFREELGARPDATKVLIIITDGEATDSGNIDAAKDIIRYIIGIGKHFQTKESQETLH\nKFASKPASEFVKILDTFEKLKDLFTELQKKIYVIEGTSKQDLTSFNMELSSSGISADLSR\nGHAVVGAVGAKDWAGGFLDLKADLQDDTFIGNEPLTPEVRAGYLGYTVTWLPSRQKTSLL\nASGAPRYQHMGRVLLFQEPQGGGHWSQVQTIHGTQIGSYFGGELCGVDVDQDGETELLLI\nGAPLFYGEQRGGRVFIYQRRQLGFEEVSELQGDPGYPLGRFGEAITALTDINGDGLVDVA\nVGAPLEEQGAVYIFNGRHGGLSPQPSQRIEGTQVLSGIQWFGRSIHGVKDLEGDGLADVA\nVGAESQMIVLSSRPVVDMVTLMSFSPAEIPVHEVECSYSTSNKMKEGVNITICFQIKSLI\nPQFQGRLVANLTYTLQLDGHRTRRRGLFPGGRHELRRNIAVTTSMSCTDFSFHFPVCVQD\nLISPINVSLNFSLWEEEGTPRDQRAQGKDIPPILRPSLHSETWEIPFEKNCGEDKKCEAN\nLRVSFSPARSRALRLTAFASLSVELSLSNLEEDAYWVQLDLHFPPGLSFRKVEMLKPHSQ\nIPVSCEELPEESRLLSRALSCNVSSPIFKAGHSVALQMMFNTLVNSSWGDSVELHANVTC\nNNEDSDLLEDNSATTIIPILYPINILIQDQEDSTLYVSFTPKGPKIHQVKHMYQVRIQPS\nIHDHNIPTLEAVVGVPQPPSEGPITHQWSVQMEPPVPCHYEDLERLPDAAEPCLPGALFR\nCPVVFRQEILVQVIGTLELVGEIEASSMFSLCSSLSISFNSSKHFHLYGSNASLAQVVMK\nVDVVYEKQMLYLYVLSGIGGLLLLLLIFIVLYKVGFFKRNLKEKMEAGRGVPNGIPAEDS\nEQLASGQEAGDPGCLKPLHEKDSESGGGKD'], 'gene-sequence': ['>lcl|BSEQ0021647|Integrin alpha-L (ITGAL)\nATGAAGGATTCCTGCATCACTGTGATGGCCATGGCGCTGCTGTCTGGGTTCTTTTTCTTC\nGCGCCGGCCTCGAGCTACAACCTGGACGTGCGGGGCGCGCGGAGCTTCTCCCCACCGCGC\nGCCGGGAGGCACTTTGGATACCGCGTCCTGCAGGTCGGAAACGGGGTCATCGTGGGAGCT\nCCAGGGGAGGGGAACAGCACAGGAAGCCTCTATCAGTGCCAGTCGGGCACAGGACACTGC\nCTGCCAGTCACCCTGAGAGGTTCCAACTATACCTCCAAGTACTTGGGAATGACCTTGGCA\nACAGACCCCACAGATGGAAGCATTTTGTTTGCTGCTGTTCAGTTTTCCACAAGCTACAAA\nACAGAATTTGATTTCTCAGATTATGTTAAACGGAAGGACCCTGATGCTCTGCTGAAGCAT\nGTAAAGCACATGTTGCTGTTGACCAATACCTTTGGTGCCATCAATTATGTCGCGACAGAG\nGTGTTCCGGGAGGAGCTGGGGGCCCGGCCAGATGCCACCAAAGTGCTTATCATCATCACG\nGATGGGGAGGCCACTGACAGTGGCAACATCGATGCGGCCAAAGACATCATCCGCTACATC\nATCGGGATTGGAAAGCATTTTCAGACCAAGGAGAGTCAGGAGACCCTCCACAAATTTGCA\nTCAAAACCCGCGAGCGAGTTTGTGAAAATTCTGGACACATTTGAGAAGCTGAAAGATCTA\nTTCACTGAGCTGCAGAAGAAGATCTATGTCATTGAGGGCACAAGCAAACAGGACCTGACT\nTCCTTCAACATGGAGCTGTCCTCCAGCGGCATCAGTGCTGACCTCAGCAGGGGCCATGCA\nGTCGTGGGGGCAGTAGGAGCCAAGGACTGGGCTGGGGGCTTTCTTGACCTGAAGGCAGAC\nCTGCAGGATGACACATTTATTGGGAATGAACCATTGACACCAGAAGTGAGAGCAGGCTAT\nTTGGGTTACACCGTGACCTGGCTGCCCTCCCGGCAAAAGACTTCGTTGCTGGCCTCGGGA\nGCCCCTCGATACCAGCACATGGGCCGAGTGCTGCTGTTCCAAGAGCCACAGGGCGGAGGA\nCACTGGAGCCAGGTCCAGACAATCCATGGGACCCAGATTGGCTCTTATTTCGGTGGGGAG\nCTGTGTGGCGTCGACGTGGACCAAGATGGGGAGACAGAGCTGCTGCTGATTGGTGCCCCA\nCTGTTCTATGGGGAGCAGAGAGGAGGCCGGGTGTTTATCTACCAGAGAAGACAGTTGGGG\nTTTGAAGAAGTCTCAGAGCTGCAGGGGGACCCCGGCTACCCACTCGGGCGGTTTGGAGAA\nGCCATCACTGCTCTGACAGACATCAACGGCGATGGGCTGGTAGACGTGGCTGTGGGGGCC\nCCTCTGGAGGAGCAGGGGGCTGTGTACATCTTCAATGGGAGGCACGGGGGGCTTAGTCCC\nCAGCCAAGTCAGCGGATAGAAGGGACCCAAGTGCTCTCAGGAATTCAGTGGTTTGGACGC\nTCCATCCATGGGGTGAAGGACCTTGAAGGGGATGGCTTGGCAGATGTGGCTGTGGGGGCT\nGAGAGCCAGATGATCGTGCTGAGCTCCCGGCCCGTGGTGGATATGGTCACCCTGATGTCC\nTTCTCTCCAGCTGAGATCCCAGTGCATGAAGTGGAGTGCTCCTATTCAACCAGTAACAAG\nATGAAAGAAGGAGTTAATATCACAATCTGTTTCCAGATCAAGTCTCTCATCCCCCAGTTC\nCAAGGCCGCCTGGTTGCCAATCTCACTTACACTCTGCAGCTGGATGGCCACCGGACCAGA\nAGACGGGGGTTGTTCCCAGGAGGGAGACATGAACTCAGAAGGAATATAGCTGTCACCACC\nAGCATGTCATGCACTGACTTCTCATTTCATTTCCCGGTATGTGTTCAAGACCTCATCTCC\nCCCATCAATGTTTCCCTGAATTTCTCTCTTTGGGAGGAGGAAGGGACACCGAGGGACCAA\nAGGGCGGGCAAGGACATACCGCCCATCCTGAGACCCTCCCTGCACTCGGAAACCTGGGAG\nATCCCTTTTGAGAAGAACTGTGGGGAGGACAAGAAGTGTGAGGCAAACTTGAGAGTGTCC\nTTCTCTCCTGCAAGATCCAGAGCCCTGCGTCTAACTGCTTTTGCCAGCCTCTCTGTGGAG\nCTGAGCCTGAGTAACTTGGAAGAAGATGCTTACTGGGTCCAGCTGGACCTGCACTTCCCC\nCCGGGACTCTCCTTCCGCAAGGTGGAGATGCTGAAGCCCCATAGCCAGATACCTGTGAGC\nTGCGAGGAGCTTCCTGAAGAGTCCAGGCTTCTGTCCAGGGCATTATCTTGCAATGTGAGC\nTCTCCCATCTTCAAAGCAGGCCACTCGGTTGCTCTGCAGATGATGTTTAATACACTGGTA\nAACAGCTCCTGGGGGGACTCGGTTGAATTGCACGCCAATGTGACCTGTAACAATGAGGAC\nTCAGACCTCCTGGAGGACAACTCAGCCACTACCATCATCCCCATCCTGTACCCCATCAAC\nATCCTCATCCAGGACCAAGAAGACTCCACACTCTATGTCAGTTTCACCCCCAAAGGCCCC\nAAGATCCACCAAGTCAAGCACATGTACCAGGTGAGGATCCAGCCTTCCATCCACGACCAC\nAACATACCCACCCTGGAGGCTGTGGTTGGGGTGCCACAGCCTCCCAGCGAGGGGCCCATC\nACACACCAGTGGAGCGTGCAGATGGAGCCTCCCGTGCCCTGCCACTATGAGGATCTGGAG\nAGGCTCCCGGATGCAGCTGAGCCTTGTCTCCCCGGAGCCCTGTTCCGCTGCCCTGTTGTC\nTTCAGGCAGGAGATCCTCGTCCAAGTGATCGGGACTCTGGAGCTGGTGGGAGAGATCGAG\nGCCTCTTCCATGTTCAGCCTCTGCAGCTCCCTCTCCATCTCCTTCAACAGCAGCAAGCAT\nTTCCACCTCTATGGCAGCAACGCCTCCCTGGCCCAGGTTGTCATGAAGGTTGACGTGGTG\nTATGAGAAGCAGATGCTCTACCTCTACGTGCTGAGCGGCATCGGGGGGCTGCTGCTGCTG\nCTGCTCATTTTCATAGTGCTGTACAAGGTTGGTTTCTTCAAACGGAACCTGAAGGAGAAG\nATGGAGGCTGGCAGAGGTGTCCCGAATGGAATCCCTGCAGAAGACTCTGAGCAGCTGGCA\nTCTGGGCAAGAGGCTGGGGATCCCGGCTGCCTGAAGCCCCTCCATGAGAAGGACTCTGAG\nAGTGGTGGTGGCAAGGACTGA'], 'pfams': [{'pfam': [{'identifier': ['PF01839'], 'name': ['FG-GAP']}, {'identifier': ['PF00357'], 'name': ['Integrin_alpha']}, {'identifier': ['PF08441'], 'name': ['Integrin_alpha2']}, {'identifier': ['PF00092'], 'name': ['VWA']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['cell-cell junction']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['immunological synapse']}, {'category': ['component'], 'description': ['integrin alphaL-beta2 complex']}, {'category': ['component'], 'description': ['integrin complex']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['cell adhesion molecule binding']}, {'category': ['function'], 'description': ['ICAM-3 receptor activity']}, {'category': ['function'], 'description': ['metal ion binding']}, {'category': ['process'], 'description': ['activated T cell proliferation']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cell adhesion']}, {'category': ['process'], 'description': ['cell-matrix adhesion']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules']}, {'category': ['process'], 'description': ['inflammatory response']}, {'category': ['process'], 'description': ['integrin-mediated signaling pathway']}, {'category': ['process'], 'description': ['leukocyte cell-cell adhesion']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['movement of cell or subcellular component']}, {'category': ['process'], 'description': ['positive regulation of calcium-mediated signaling']}, {'category': ['process'], 'description': ['positive regulation of T cell proliferation']}, {'category': ['process'], 'description': ['receptor clustering']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell']}]}]}]}]}]"
"['DB00097', 'BTD00034', 'BIOD00034']",['Choriogonadotropin alfa'],biotech,"['Recombinant human chorionic gonadotropin with 2 subunits, alpha = 92 residues, beta = 145 residues, each with N-and O-linked carbohydrate moieties linked to ASN-52 and ASN-78 (on alpha subunit) and ASN-13, ASN-30, SER-121, SER-127, SER-132 and SER-138 (on beta subunit). The primary structure of the alpha-chain of r-hCG is identical to that of the alpha-chain of hCG, FSH and LH.']",['solid'],['For the treatment of female infertility'],['Choriogonadotropin alfa binds to the Follicle stimulating hormone receptor which results in ovulation in the absence of sufficient endogenous Luteinizing hormone.'],[None],"[{'target': [{'id': ['BE0000134'], 'name': ['Lutropin-choriogonadotropic hormone receptor'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13299'], 'pubmed-id': ['15967102'], 'citation': ['Bodek G, Vierre S, Rivero-Muller A, Huhtaniemi I, Ziecik AJ, Rahman NA: A novel targeted therapy of Leydig and granulosa cell tumors through the luteinizing hormone receptor using a hecate-chorionic gonadotropin beta conjugate in transgenic mice. Neoplasia. 2005 May;7(5):497-508.']}, {'ref-id': ['A13300'], 'pubmed-id': ['12606382'], 'citation': ['Gromoll J, Wistuba J, Terwort N, Godmann M, Muller T, Simoni M: A new subclass of the luteinizing hormone/chorionic gonadotropin receptor lacking exon 10 messenger RNA in the New World monkey (Platyrrhini) lineage. Biol Reprod. 2003 Jul;69(1):75-80. Epub 2003 Feb 19.']}, {'ref-id': ['A2119'], 'pubmed-id': ['17059863'], 'citation': ['Lin W, Bernard MP, Cao D, Myers RV, Kerrigan JE, Moyle WR: Follitropin receptors contain cryptic ligand binding sites. Mol Cell Endocrinol. 2007 Jan 2;260-262:83-92. Epub 2006 Oct 23.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Lutropin-choriogonadotropic hormone receptor'], 'general-function': ['Luteinizing hormone receptor activity'], 'specific-function': ['Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase.'], 'gene-name': ['LHCGR'], 'locus': ['2p21'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['364-385\n396-416\n440-462\n483-505\n526-549\n571-594\n606-627'], 'signal-regions': ['1-26'], 'theoretical-pi': ['8.58'], 'molecular-weight': ['78642.01'], 'chromosome-location': ['2'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6585']}, {'resource': ['GenAtlas'], 'identifier': ['LHCGR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M73746']}, {'resource': ['GenBank Protein Database'], 'identifier': ['903746']}, {'resource': ['IUPHAR'], 'identifier': ['254']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['254']}, {'resource': ['UniProtKB'], 'identifier': ['P22888']}, {'resource': ['UniProt Accession'], 'identifier': ['LSHR_HUMAN']}]}], 'synonyms': [{'synonym': ['LCGR', 'LGR2', 'LH/CG-R', 'LHR', 'LHRHR', 'LSH-R', 'Luteinizing hormone receptor']}], 'amino-acid-sequence': ['>lcl|BSEQ0036957|Lutropin-choriogonadotropic hormone receptor\nMKQRFSALQLLKLLLLLQPPLPRALREALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLP\nVKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFI\nNLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLK\nLYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSY\nGLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENF\nSKQCESTVRKVNNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYD\nFLRVLIWLINILAIMGNMTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIASVDS\nQTKGQYYNHAIDWQTGSGCSTAGFFTVFASELSVYTLTVITLERWHTITYAIHLDQKLRL\nRHAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETTLSQVYILTILILNVVAFF\nIICACYIKIYFAVRNPELMATNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKVPLIT\nVTNSKVLLVLFYPINSCANPFLYAIFTKTFQRDFFLLLSKFGCCKRRAELYRRKDFSAYT\nSNCKNGFTGSNKPSQSTLKLSTLHCQGTALLDKTRYTEC'], 'gene-sequence': ['>lcl|BSEQ0010174|Lutropin-choriogonadotropic hormone receptor (LHCGR)\nATGAAGCAGCGGTTCTCGGCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGCCGCCG\nCTGCCACGAGCGCTGCGCGAGGCGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGC\nGCCCTGCGCTGCCCCGGCCCCACGGCCGGTCTCACTCGACTATCACTTGCCTACCTCCCT\nGTCAAAGTGATCCCATCTCAAGCTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATC\nTCTCAGATTGATTCCCTGGAAAGGATAGAAGCTAATGCCTTTGACAACCTCCTCAATTTG\nTCTGAAATACTGATCCAGAACACCAAAAATCTGAGATACATTGAGCCCGGAGCATTTATA\nAATCTTCCCCGATTAAAATACTTGAGCATCTGTAACACAGGCATCAGAAAGTTTCCAGAT\nGTTACGAAGGTCTTCTCCTCTGAATCAAATTTCATTCTGGAAATTTGTGATAACTTACAC\nATAACCACCATACCAGGAAATGCTTTTCAAGGGATGAATAATGAATCTGTAACACTCAAA\nCTATATGGAAATGGATTTGAAGAAGTACAAAGTCATGCATTCAATGGGACGACACTGACT\nTCACTGGAGCTAAAGGAAAACGTACATCTGGAGAAGATGCACAATGGAGCCTTCCGTGGG\nGCCACAGGGCCGAAAACCTTGGATATTTCTTCCACCAAATTGCAGGCCCTGCCGAGCTAT\nGGCCTAGAGTCCATTCAGAGGCTAATTGCCACGTCATCCTATTCTCTAAAAAAATTGCCA\nTCAAGAGAAACATTTGTCAATCTCCTGGAGGCCACGTTGACTTACCCCAGCCACTGCTGT\nGCTTTTAGAAACTTGCCAACAAAAGAACAGAATTTTTCACATTCCATTTCTGAAAACTTT\nTCCAAACAATGTGAAAGCACAGTAAGGAAAGTGAATAACAAAACACTTTATTCTTCCATG\nCTTGCTGAGAGTGAACTGAGTGGCTGGGACTATGAATATGGTTTCTGCTTACCCAAGACA\nCCCCGATGTGCTCCTGAACCAGATGCTTTTAATCCCTGTGAAGATATTATGGGCTATGAC\nTTCCTTAGGGTCCTGATTTGGCTGATTAATATTCTAGCCATCATGGGAAACATGACTGTT\nCTTTTTGTTCTCCTGACAAGTCGTTACAAACTTACAGTGCCTCGTTTTCTCATGTGCAAT\nCTCTCCTTTGCAGACTTTTGCATGGGGCTCTATCTGCTGCTCATAGCCTCAGTTGATTCC\nCAAACCAAGGGCCAGTACTATAACCATGCCATAGACTGGCAGACAGGGAGTGGGTGCAGC\nACTGCTGGCTTTTTCACTGTATTCGCAAGTGAACTTTCTGTCTACACCCTCACCGTCATC\nACTCTAGAAAGATGGCACACCATCACCTATGCTATTCACCTGGACCAAAAGCTGCGATTA\nAGACATGCCATTCTGATTATGCTTGGAGGATGGCTCTTTTCTTCTCTAATTGCTATGTTG\nCCCCTTGTCGGTGTCAGCAATTACATGAAGGTCAGTATTTGCTTCCCCATGGATGTGGAA\nACCACTCTCTCACAAGTCTATATATTAACCATCCTGATTCTCAATGTGGTGGCCTTCTTC\nATAATTTGTGCTTGCTACATTAAAATTTATTTTGCAGTTCGAAACCCAGAATTAATGGCT\nACCAATAAAGATACAAAGATTGCTAAGAAAATGGCAATCCTCATCTTCACCGATTTCACC\nTGCATGGCACCTATCTCTTTTTTTGCCATCTCAGCTGCCTTCAAAGTACCTCTTATCACA\nGTAACCAACTCTAAAGTTTTACTGGTTCTTTTTTATCCCATCAATTCTTGTGCCAATCCA\nTTTCTGTATGCAATATTCACTAAGACATTCCAAAGAGATTTCTTTCTTTTGCTGAGCAAA\nTTTGGCTGCTGTAAACGTCGGGCTGAACTTTATAGAAGGAAAGATTTTTCAGCTTACACC\nTCCAACTGCAAAAATGGCTTCACTGGATCAAATAAGCCTTCTCAATCCACCTTGAAGTTG\nTCCACATTGCACTGTCAAGGTACAGCTCTCCTAGACAAGACTCGCTACACAGAGTGTTAA\n'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}, {'identifier': ['PF13306'], 'name': ['LRR_5']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['choriogonadotropin hormone binding']}, {'category': ['function'], 'description': ['choriogonadotropin hormone receptor activity']}, {'category': ['function'], 'description': ['G-protein coupled peptide receptor activity']}, {'category': ['function'], 'description': ['luteinizing hormone receptor activity']}, {'category': ['process'], 'description': ['activation of adenylate cyclase activity']}, {'category': ['process'], 'description': ['adenylate cyclase-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular response to gonadotropin stimulus']}, {'category': ['process'], 'description': ['cognition']}, {'category': ['process'], 'description': ['female gonad development']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger']}, {'category': ['process'], 'description': ['hormone-mediated signaling pathway']}, {'category': ['process'], 'description': ['luteinizing hormone signaling pathway']}, {'category': ['process'], 'description': ['male genitalia development']}, {'category': ['process'], 'description': ['male gonad development']}, {'category': ['process'], 'description': ['ovulation cycle process']}, {'category': ['process'], 'description': ['phospholipase C-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of cAMP-mediated signaling']}, {'category': ['process'], 'description': ['positive regulation of inositol trisphosphate biosynthetic process']}, {'category': ['process'], 'description': ['spermatogenesis']}, {'category': ['process'], 'description': ['uterus development']}]}]}]}, {'id': ['BE0000387'], 'name': ['Follicle-stimulating hormone receptor'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A2116'], 'pubmed-id': ['9027352'], 'citation': ['Jameson JL: Inherited disorders of the gonadotropin hormones. Mol Cell Endocrinol. 1996 Dec 20;125(1-2):143-9.']}, {'ref-id': ['A2119'], 'pubmed-id': ['17059863'], 'citation': ['Lin W, Bernard MP, Cao D, Myers RV, Kerrigan JE, Moyle WR: Follitropin receptors contain cryptic ligand binding sites. Mol Cell Endocrinol. 2007 Jan 2;260-262:83-92. Epub 2006 Oct 23.']}, {'ref-id': ['A2120'], 'pubmed-id': ['20374735'], 'citation': ['Tao YX, Segaloff DL: Follicle stimulating hormone receptor mutations and reproductive disorders. Prog Mol Biol Transl Sci. 2009;89:115-31. doi: 10.1016/S1877-1173(09)89005-4. Epub 2009 Oct 7.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Follicle-stimulating hormone receptor'], 'general-function': ['G-protein coupled peptide receptor activity'], 'specific-function': ['Receptor for follicle-stimulating hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Induces cAMP production through the activation of PI3K-AKT and SRC-ERK1/2 signaling pathways.'], 'gene-name': ['FSHR'], 'locus': ['2p21-p16'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['367-387\n399-421\n444-465\n486-508\n529-550\n574-597\n609-630'], 'signal-regions': ['1-17'], 'theoretical-pi': ['7.19'], 'molecular-weight': ['78264.07'], 'chromosome-location': ['2'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3969']}, {'resource': ['GenAtlas'], 'identifier': ['FSHR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M65085']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182771']}, {'resource': ['IUPHAR'], 'identifier': ['253']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['253']}, {'resource': ['UniProtKB'], 'identifier': ['P23945']}, {'resource': ['UniProt Accession'], 'identifier': ['FSHR_HUMAN']}]}], 'synonyms': [{'synonym': ['Follitropin receptor', 'FSH-R', 'LGR1']}], 'amino-acid-sequence': ['>lcl|BSEQ0037007|Follicle-stimulating hormone receptor\nMALLLVSLLAFLSLGSGCHHRICHCSNRVFLCQESKVTEIPSDLPRNAIELRFVLTKLRV\nIQKGAFSGFGDLEKIEISQNDVLEVIEADVFSNLPKLHEIRIEKANNLLYINPEAFQNLP\nNLQYLLISNTGIKHLPDVHKIHSLQKVLLDIQDNINIHTIERNSFVGLSFESVILWLNKN\nGIQEIHNCAFNGTQLDELNLSDNNNLEELPNDVFHGASGPVILDISRTRIHSLPSYGLEN\nLKKLRARSTYNLKKLPTLEKLVALMEASLTYPSHCCAFANWRRQISELHPICNKSILRQE\nVDYMTQARGQRSSLAEDNESSYSRGFDMTYTEFDYDLCNEVVDVTCSPKPDAFNPCEDIM\nGYNILRVLIWFISILAITGNIIVLVILTTSQYKLTVPRFLMCNLAFADLCIGIYLLLIAS\nVDIHTKSQYHNYAIDWQTGAGCDAAGFFTVFASELSVYTLTAITLERWHTITHAMQLDCK\nVQLRHAASVMVMGWIFAFAAALFPIFGISSYMKVSICLPMDIDSPLSQLYVMSLLVLNVL\nAFVVICGCYIHIYLTVRNPNIVSSSSDTRIAKRMAMLIFTDFLCMAPISFFAISASLKVP\nLITVSKAKILLVLFHPINSCANPFLYAIFTKNFRRDFFILLSKCGCYEMQAQIYRTETSS\nTVHNTHPRNGHCSSAPRVTNGSTYILVPLSHLAQN'], 'gene-sequence': ['>lcl|BSEQ0018946|Follicle-stimulating hormone receptor (FSHR)\nATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCAT\nCGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATT\nCCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTC\nATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAAT\nGATGTCTTGGAGGTGATAGAGGCAGATGTGTTCTCCAACCTTCCCAAATTACATGAAATT\nAGAATTGAAAAGGCCAACAACCTGCTCTACATCAACCCTGAGGCCTTCCAGAACCTTCCC\nAACCTTCAATATCTGTTAATATCCAACACAGGTATTAAGCACCTTCCAGATGTTCACAAG\nATTCATTCTCTCCAAAAAGTTTTACTTGACATTCAAGATAACATAAACATCCACACAATT\nGAAAGAAATTCTTTCGTGGGGCTGAGCTTTGAAAGTGTGATTCTATGGCTGAATAAGAAT\nGGGATTCAAGAAATACACAACTGTGCATTCAATGGAACCCAACTAGATGAGCTGAATCTA\nAGCGATAATAATAATTTAGAAGAATTGCCTAATGATGTTTTCCACGGAGCCTCTGGACCA\nGTCATTCTAGATATTTCAAGAACAAGGATCCATTCCCTGCCTAGCTATGGCTTAGAAAAT\nCTTAAGAAGCTGAGGGCCAGGTCGACTTACAACTTAAAAAAGCTGCCTACTCTGGAAAAG\nCTTGTCGCCCTCATGGAAGCCAGCCTCACCTATCCCAGCCATTGCTGTGCCTTTGCAAAC\nTGGAGACGGCAAATCTCTGAGCTTCATCCAATTTGCAACAAATCTATTTTAAGGCAAGAA\nGTTGATTATATGACTCAGGCTAGGGGTCAGAGATCCTCTCTGGCAGAAGACAATGAGTCC\nAGCTACAGCAGAGGATTTGACATGACGTACACTGAGTTTGACTATGACTTATGCAATGAA\nGTGGTTGACGTGACCTGCTCCCCTAAGCCAGATGCATTCAACCCATGTGAAGATATCATG\nGGGTACAACATCCTCAGAGTCCTGATATGGTTTATCAGCATCCTGGCCATCACTGGGAAC\nATCATAGTGCTAGTGATCCTAACTACCAGCCAATATAAACTCACAGTCCCCAGGTTCCTT\nATGTGCAACCTGGCCTTTGCTGATCTCTGCATTGGAATCTACCTGCTGCTCATTGCATCA\nGTTGATATCCATACCAAGAGCCAATATCACAACTATGCCATTGACTGGCAAACTGGGGCA\nGGCTGTGATGCTGCTGGCTTTTTCACTGTCTTTGCCAGTGAGCTGTCAGTCTACACTCTG\nACAGCTATCACCTTGGAAAGATGGCATACCATCACGCATGCCATGCAGCTGGACTGCAAG\nGTGCAGCTCCGCCATGCTGCCAGTGTCATGGTGATGGGCTGGATTTTTGCTTTTGCAGCT\nGCCCTCTTTCCCATCTTTGGCATCAGCAGCTACATGAAGGTGAGCATCTGCCTGCCCATG\nGATATTGACAGCCCTTTGTCACAGCTGTATGTCATGTCCCTCCTTGTGCTCAATGTCCTG\nGCCTTTGTGGTCATCTGTGGCTGCTATATCCACATCTACCTCACAGTGCGGAACCCCAAC\nATCGTGTCCTCCTCTAGTGACACCAGGATCGCCAAGCGCATGGCCATGCTCATCTTCACT\nGACTTCCTCTGCATGGCACCCATTTCTTTCTTTGCCATTTCTGCCTCCCTCAAGGTGCCC\nCTCATCACTGTGTCCAAAGCAAAGATTCTGCTGGTTCTGTTTCACCCCATCAACTCCTGT\nGCCAACCCCTTCCTCTATGCCATCTTTACCAAAAACTTTCGCAGAGATTTCTTCATTCTG\nCTGAGCAAGTGTGGCTGCTATGAAATGCAAGCCCAAATTTATAGGACAGAAACTTCATCC\nACTGTCCACAACACCCATCCAAGGAATGGCCACTGCTCTTCAGCTCCCAGAGTCACCAGT\nGGTTCCACTTACATACTTGTCCCTCTAAGTCATTTAGCCCAAAACTAA'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}, {'identifier': ['PF01462'], 'name': ['LRRNT']}, {'identifier': ['PF13306'], 'name': ['LRR_5']}, {'identifier': ['PF12369'], 'name': ['GnHR_trans']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['follicle-stimulating hormone receptor activity']}, {'category': ['function'], 'description': ['G-protein coupled peptide receptor activity']}, {'category': ['process'], 'description': ['activation of adenylate cyclase activity']}, {'category': ['process'], 'description': ['adenylate cyclase-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['female gamete generation']}, {'category': ['process'], 'description': ['female gonad development']}, {'category': ['process'], 'description': ['follicle-stimulating hormone signaling pathway']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['gonad development']}, {'category': ['process'], 'description': ['hormone-mediated signaling pathway']}, {'category': ['process'], 'description': ['male gonad development']}, {'category': ['process'], 'description': ['positive regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['positive regulation of phosphatidylinositol 3-kinase signaling']}, {'category': ['process'], 'description': ['primary ovarian follicle growth']}, {'category': ['process'], 'description': ['regulation of osteoclast differentiation']}, {'category': ['process'], 'description': ['regulation of protein kinase A signaling']}, {'category': ['process'], 'description': ['spermatogenesis']}, {'category': ['process'], 'description': ['uterus development']}]}]}]}]}]"
"['DB00098', 'BTD00040', 'BIOD00040']",['Antithymocyte immunoglobulin (rabbit)'],biotech,['Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.'],['liquid'],['For prevention of renal transplant rejection'],"['Binds to multiple, T-cell specific antigens leading to T-lymphocyte cell death via complement mediated cytotoxicity or apoptosis.']",[None],"[{'target': [{'id': ['BE0003573'], 'name': ['Major histocompatibility complex class I-related gene protein'], 'organism': ['Humans'], 'actions': [{'action': ['antagonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A15362'], 'pubmed-id': ['12586600'], 'citation': ['Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Major histocompatibility complex class I-related gene protein'], 'general-function': ['Peptide antigen binding'], 'specific-function': ['Antigen-presenting molecule specialized in presenting microbial vitamin B metabolites. Involved in the development and expansion of a small population of T-cells expressing an invariant T-cell receptor alpha chain called mucosal-associated invariant T-cells (MAIT). MAIT lymphocytes are preferentially located in the gut lamina propria and therefore may be involved in monitoring commensal flora or serve as a distress signal. Expression and MAIT cell recognition seem to be ligand-dependent.'], 'gene-name': ['MR1'], 'locus': ['1q25.3'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['303-323'], 'signal-regions': ['1-22'], 'theoretical-pi': ['6.27'], 'molecular-weight': ['39365.76'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:4975']}, {'resource': ['GenBank Gene Database'], 'identifier': ['U22963']}, {'resource': ['GenBank Protein Database'], 'identifier': ['940354']}, {'resource': ['UniProtKB'], 'identifier': ['Q95460']}, {'resource': ['UniProt Accession'], 'identifier': ['HMR1_HUMAN']}]}], 'synonyms': [{'synonym': ['Class I histocompatibility antigen-like protein', 'MHC class I-related gene protein']}], 'amino-acid-sequence': ['>lcl|BSEQ0006881|Major histocompatibility complex class I-related gene protein\nMGELMAFLLPLIIVLMVKHSDSRTHSLRYFRLGVSDPIHGVPEFISVGYVDSHPITTYDS\nVTRQKEPRAPWMAENLAPDHWERYTQLLRGWQQMFKVELKRLQRHYNHSGSHTYQRMIGC\nELLEDGSTTGFLQYAYDGQDFLIFNKDTLSWLAVDNVAHTIKQAWEANQHELLYQKNWLE\nEECIAWLKRFLEYGKDTLQRTEPPLVRVNRKETFPGVTALFCKAHGFYPPEIYMTWMKNG\nEEIVQEIDYGDILPSGDGTYQAWASIELDPQSSNLYSCHVEHCGVHMVLQVPQESETIPL\nVMKAVSGSIVLVIVLAGVGVLVWRRRPREQNGAIYLPTPDR'], 'gene-sequence': ['>lcl|BSEQ0012485|Major histocompatibility complex class I-related gene protein (MR1)\nATGGGGGAACTGATGGCGTTCCTGTTACCTCTCATCATTGTGTTAATGGTGAAGCACAGC\nGATTCCCGGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGG\nGTCCCTGAATTTATTTCGGTTGGGTACGTGGACTCGCACCCTATCACCACATATGACAGT\nGTCACTCGGCAGAAGGAGCCACGGGCCCCATGGATGGCAGAGAACCTCGCGCCTGATCAC\nTGGGAGAGGTACACTCAGCTGCTGAGGGGCTGGCAGCAGATGTTCAAGGTGGAACTGAAG\nCGCCTACAGAGGCACTACAATCACTCAGATAATGTGGCTCACACCATCAAGCAGGCATGG\nGAGGCCAATCAGCATGAGTTGCTGTATCAAAAGAATTGGCTGGAAGAAGAATGTATTGCC\nTGGCTAAAGAGATTCCTGGAGTATGGGAAAGACACCCTACAAAGAACAGAGCCCCCACTG\nGTCAGAGTAAATCGCAAAGAAACTTTTCCAGGGGTTACAGCTCTCTTCTGCAAAGCTCAT\nGGCTTTTACCCCCCAGAAATTTACATGACATGGATGAAAAACGGGGAAGAAATTGTCCAA\nGAAATTGATTATGGAGACATTCTTCCCAGTGGGGATGGAACCTATCAGGCGTGGGCATCA\nATTGAGCTTGATCCTCAGAGCAGCAACCTTTACTCCTGTCATGTGGAGCACTGCGGTGTC\nCACATGGTTCTTCAGGTCCCCCAGGAATCAGAAACTATCCCTCTTGTGATGAAAGCTGTC\nTCTGGGTCCATTGTCCTTGTCATTGTGCTGGCTGGAGTTGGTGTTCTAGTCTGGAGAAGA\nAGGCCCCGAGAGCAAAATGGAGCCATCTACCTTCCAACACCAGATCGATGA'], 'pfams': [{'pfam': [{'identifier': ['PF07654'], 'name': ['C1-set']}, {'identifier': ['PF00129'], 'name': ['MHC_I']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endoplasmic reticulum']}, {'category': ['component'], 'description': ['endoplasmic reticulum membrane']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['MHC class I protein complex']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['MHC class I receptor activity']}, {'category': ['function'], 'description': ['peptide antigen binding']}, {'category': ['process'], 'description': ['antigen processing and presentation of peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['cytokine production involved in immune response']}, {'category': ['process'], 'description': ['defense response to Gram-negative bacterium']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['interleukin-1 beta production']}, {'category': ['process'], 'description': ['interleukin-17 production']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}, {'id': ['BE0000516'], 'name': ['Integrin alpha-L'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A15362'], 'pubmed-id': ['12586600'], 'citation': ['Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Integrin alpha-L'], 'general-function': ['Metal ion binding'], 'specific-function': ['Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. It is involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes.'], 'gene-name': ['ITGAL'], 'locus': ['16p11.2'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['1091-1111'], 'signal-regions': ['1-25'], 'theoretical-pi': ['5.35'], 'molecular-weight': ['128768.495'], 'chromosome-location': ['16'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6148']}, {'resource': ['GenAtlas'], 'identifier': ['ITGAL']}, {'resource': ['GenBank Gene Database'], 'identifier': ['Y00796']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31422']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2451']}, {'resource': ['UniProtKB'], 'identifier': ['P20701']}, {'resource': ['UniProt Accession'], 'identifier': ['ITAL_HUMAN']}]}], 'synonyms': [{'synonym': ['CD11 antigen-like family member A', 'CD11A', 'Leukocyte adhesion glycoprotein LFA-1 alpha chain', 'Leukocyte function-associated molecule 1 alpha chain', 'LFA-1A']}], 'amino-acid-sequence': ['>lcl|BSEQ0001030|Integrin alpha-L\nMKDSCITVMAMALLSGFFFFAPASSYNLDVRGARSFSPPRAGRHFGYRVLQVGNGVIVGA\nPGEGNSTGSLYQCQSGTGHCLPVTLRGSNYTSKYLGMTLATDPTDGSILACDPGLSRTCD\nQNTYLSGLCYLFRQNLQGPMLQGRPGFQECIKGNVDLVFLFDGSMSLQPDEFQKILDFMK\nDVMKKLSNTSYQFAAVQFSTSYKTEFDFSDYVKRKDPDALLKHVKHMLLLTNTFGAINYV\nATEVFREELGARPDATKVLIIITDGEATDSGNIDAAKDIIRYIIGIGKHFQTKESQETLH\nKFASKPASEFVKILDTFEKLKDLFTELQKKIYVIEGTSKQDLTSFNMELSSSGISADLSR\nGHAVVGAVGAKDWAGGFLDLKADLQDDTFIGNEPLTPEVRAGYLGYTVTWLPSRQKTSLL\nASGAPRYQHMGRVLLFQEPQGGGHWSQVQTIHGTQIGSYFGGELCGVDVDQDGETELLLI\nGAPLFYGEQRGGRVFIYQRRQLGFEEVSELQGDPGYPLGRFGEAITALTDINGDGLVDVA\nVGAPLEEQGAVYIFNGRHGGLSPQPSQRIEGTQVLSGIQWFGRSIHGVKDLEGDGLADVA\nVGAESQMIVLSSRPVVDMVTLMSFSPAEIPVHEVECSYSTSNKMKEGVNITICFQIKSLI\nPQFQGRLVANLTYTLQLDGHRTRRRGLFPGGRHELRRNIAVTTSMSCTDFSFHFPVCVQD\nLISPINVSLNFSLWEEEGTPRDQRAQGKDIPPILRPSLHSETWEIPFEKNCGEDKKCEAN\nLRVSFSPARSRALRLTAFASLSVELSLSNLEEDAYWVQLDLHFPPGLSFRKVEMLKPHSQ\nIPVSCEELPEESRLLSRALSCNVSSPIFKAGHSVALQMMFNTLVNSSWGDSVELHANVTC\nNNEDSDLLEDNSATTIIPILYPINILIQDQEDSTLYVSFTPKGPKIHQVKHMYQVRIQPS\nIHDHNIPTLEAVVGVPQPPSEGPITHQWSVQMEPPVPCHYEDLERLPDAAEPCLPGALFR\nCPVVFRQEILVQVIGTLELVGEIEASSMFSLCSSLSISFNSSKHFHLYGSNASLAQVVMK\nVDVVYEKQMLYLYVLSGIGGLLLLLLIFIVLYKVGFFKRNLKEKMEAGRGVPNGIPAEDS\nEQLASGQEAGDPGCLKPLHEKDSESGGGKD'], 'gene-sequence': ['>lcl|BSEQ0021647|Integrin alpha-L (ITGAL)\nATGAAGGATTCCTGCATCACTGTGATGGCCATGGCGCTGCTGTCTGGGTTCTTTTTCTTC\nGCGCCGGCCTCGAGCTACAACCTGGACGTGCGGGGCGCGCGGAGCTTCTCCCCACCGCGC\nGCCGGGAGGCACTTTGGATACCGCGTCCTGCAGGTCGGAAACGGGGTCATCGTGGGAGCT\nCCAGGGGAGGGGAACAGCACAGGAAGCCTCTATCAGTGCCAGTCGGGCACAGGACACTGC\nCTGCCAGTCACCCTGAGAGGTTCCAACTATACCTCCAAGTACTTGGGAATGACCTTGGCA\nACAGACCCCACAGATGGAAGCATTTTGTTTGCTGCTGTTCAGTTTTCCACAAGCTACAAA\nACAGAATTTGATTTCTCAGATTATGTTAAACGGAAGGACCCTGATGCTCTGCTGAAGCAT\nGTAAAGCACATGTTGCTGTTGACCAATACCTTTGGTGCCATCAATTATGTCGCGACAGAG\nGTGTTCCGGGAGGAGCTGGGGGCCCGGCCAGATGCCACCAAAGTGCTTATCATCATCACG\nGATGGGGAGGCCACTGACAGTGGCAACATCGATGCGGCCAAAGACATCATCCGCTACATC\nATCGGGATTGGAAAGCATTTTCAGACCAAGGAGAGTCAGGAGACCCTCCACAAATTTGCA\nTCAAAACCCGCGAGCGAGTTTGTGAAAATTCTGGACACATTTGAGAAGCTGAAAGATCTA\nTTCACTGAGCTGCAGAAGAAGATCTATGTCATTGAGGGCACAAGCAAACAGGACCTGACT\nTCCTTCAACATGGAGCTGTCCTCCAGCGGCATCAGTGCTGACCTCAGCAGGGGCCATGCA\nGTCGTGGGGGCAGTAGGAGCCAAGGACTGGGCTGGGGGCTTTCTTGACCTGAAGGCAGAC\nCTGCAGGATGACACATTTATTGGGAATGAACCATTGACACCAGAAGTGAGAGCAGGCTAT\nTTGGGTTACACCGTGACCTGGCTGCCCTCCCGGCAAAAGACTTCGTTGCTGGCCTCGGGA\nGCCCCTCGATACCAGCACATGGGCCGAGTGCTGCTGTTCCAAGAGCCACAGGGCGGAGGA\nCACTGGAGCCAGGTCCAGACAATCCATGGGACCCAGATTGGCTCTTATTTCGGTGGGGAG\nCTGTGTGGCGTCGACGTGGACCAAGATGGGGAGACAGAGCTGCTGCTGATTGGTGCCCCA\nCTGTTCTATGGGGAGCAGAGAGGAGGCCGGGTGTTTATCTACCAGAGAAGACAGTTGGGG\nTTTGAAGAAGTCTCAGAGCTGCAGGGGGACCCCGGCTACCCACTCGGGCGGTTTGGAGAA\nGCCATCACTGCTCTGACAGACATCAACGGCGATGGGCTGGTAGACGTGGCTGTGGGGGCC\nCCTCTGGAGGAGCAGGGGGCTGTGTACATCTTCAATGGGAGGCACGGGGGGCTTAGTCCC\nCAGCCAAGTCAGCGGATAGAAGGGACCCAAGTGCTCTCAGGAATTCAGTGGTTTGGACGC\nTCCATCCATGGGGTGAAGGACCTTGAAGGGGATGGCTTGGCAGATGTGGCTGTGGGGGCT\nGAGAGCCAGATGATCGTGCTGAGCTCCCGGCCCGTGGTGGATATGGTCACCCTGATGTCC\nTTCTCTCCAGCTGAGATCCCAGTGCATGAAGTGGAGTGCTCCTATTCAACCAGTAACAAG\nATGAAAGAAGGAGTTAATATCACAATCTGTTTCCAGATCAAGTCTCTCATCCCCCAGTTC\nCAAGGCCGCCTGGTTGCCAATCTCACTTACACTCTGCAGCTGGATGGCCACCGGACCAGA\nAGACGGGGGTTGTTCCCAGGAGGGAGACATGAACTCAGAAGGAATATAGCTGTCACCACC\nAGCATGTCATGCACTGACTTCTCATTTCATTTCCCGGTATGTGTTCAAGACCTCATCTCC\nCCCATCAATGTTTCCCTGAATTTCTCTCTTTGGGAGGAGGAAGGGACACCGAGGGACCAA\nAGGGCGGGCAAGGACATACCGCCCATCCTGAGACCCTCCCTGCACTCGGAAACCTGGGAG\nATCCCTTTTGAGAAGAACTGTGGGGAGGACAAGAAGTGTGAGGCAAACTTGAGAGTGTCC\nTTCTCTCCTGCAAGATCCAGAGCCCTGCGTCTAACTGCTTTTGCCAGCCTCTCTGTGGAG\nCTGAGCCTGAGTAACTTGGAAGAAGATGCTTACTGGGTCCAGCTGGACCTGCACTTCCCC\nCCGGGACTCTCCTTCCGCAAGGTGGAGATGCTGAAGCCCCATAGCCAGATACCTGTGAGC\nTGCGAGGAGCTTCCTGAAGAGTCCAGGCTTCTGTCCAGGGCATTATCTTGCAATGTGAGC\nTCTCCCATCTTCAAAGCAGGCCACTCGGTTGCTCTGCAGATGATGTTTAATACACTGGTA\nAACAGCTCCTGGGGGGACTCGGTTGAATTGCACGCCAATGTGACCTGTAACAATGAGGAC\nTCAGACCTCCTGGAGGACAACTCAGCCACTACCATCATCCCCATCCTGTACCCCATCAAC\nATCCTCATCCAGGACCAAGAAGACTCCACACTCTATGTCAGTTTCACCCCCAAAGGCCCC\nAAGATCCACCAAGTCAAGCACATGTACCAGGTGAGGATCCAGCCTTCCATCCACGACCAC\nAACATACCCACCCTGGAGGCTGTGGTTGGGGTGCCACAGCCTCCCAGCGAGGGGCCCATC\nACACACCAGTGGAGCGTGCAGATGGAGCCTCCCGTGCCCTGCCACTATGAGGATCTGGAG\nAGGCTCCCGGATGCAGCTGAGCCTTGTCTCCCCGGAGCCCTGTTCCGCTGCCCTGTTGTC\nTTCAGGCAGGAGATCCTCGTCCAAGTGATCGGGACTCTGGAGCTGGTGGGAGAGATCGAG\nGCCTCTTCCATGTTCAGCCTCTGCAGCTCCCTCTCCATCTCCTTCAACAGCAGCAAGCAT\nTTCCACCTCTATGGCAGCAACGCCTCCCTGGCCCAGGTTGTCATGAAGGTTGACGTGGTG\nTATGAGAAGCAGATGCTCTACCTCTACGTGCTGAGCGGCATCGGGGGGCTGCTGCTGCTG\nCTGCTCATTTTCATAGTGCTGTACAAGGTTGGTTTCTTCAAACGGAACCTGAAGGAGAAG\nATGGAGGCTGGCAGAGGTGTCCCGAATGGAATCCCTGCAGAAGACTCTGAGCAGCTGGCA\nTCTGGGCAAGAGGCTGGGGATCCCGGCTGCCTGAAGCCCCTCCATGAGAAGGACTCTGAG\nAGTGGTGGTGGCAAGGACTGA'], 'pfams': [{'pfam': [{'identifier': ['PF01839'], 'name': ['FG-GAP']}, {'identifier': ['PF00357'], 'name': ['Integrin_alpha']}, {'identifier': ['PF08441'], 'name': ['Integrin_alpha2']}, {'identifier': ['PF00092'], 'name': ['VWA']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['cell-cell junction']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['immunological synapse']}, {'category': ['component'], 'description': ['integrin alphaL-beta2 complex']}, {'category': ['component'], 'description': ['integrin complex']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['cell adhesion molecule binding']}, {'category': ['function'], 'description': ['ICAM-3 receptor activity']}, {'category': ['function'], 'description': ['metal ion binding']}, {'category': ['process'], 'description': ['activated T cell proliferation']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cell adhesion']}, {'category': ['process'], 'description': ['cell-matrix adhesion']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules']}, {'category': ['process'], 'description': ['inflammatory response']}, {'category': ['process'], 'description': ['integrin-mediated signaling pathway']}, {'category': ['process'], 'description': ['leukocyte cell-cell adhesion']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['movement of cell or subcellular component']}, {'category': ['process'], 'description': ['positive regulation of calcium-mediated signaling']}, {'category': ['process'], 'description': ['positive regulation of T cell proliferation']}, {'category': ['process'], 'description': ['receptor clustering']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell']}]}]}]}, {'id': ['BE0000846'], 'name': ['T-lymphocyte activation antigen CD86'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A15362'], 'pubmed-id': ['12586600'], 'citation': ['Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['T-lymphocyte activation antigen CD86'], 'general-function': ['Virus receptor activity'], 'specific-function': ['Receptor involved in the costimulatory signal essential for T-lymphocyte proliferation and interleukin-2 production, by binding CD28 or CTLA-4. May play a critical role in the early events of T-cell activation and costimulation of naive T-cells, such as deciding between immunity and anergy that is made by T-cells within 24 hours after activation. Isoform 2 interferes with the formation of CD86 clusters, and thus acts as a negative regulator of T-cell activation.(Microbial infection) Acts as a receptor for adenovirus subgroup B.'], 'gene-name': ['CD86'], 'locus': ['3q21'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['248-268'], 'signal-regions': ['1-23'], 'theoretical-pi': ['6.91'], 'molecular-weight': ['37681.97'], 'chromosome-location': ['3'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1705']}, {'resource': ['GenAtlas'], 'identifier': ['CD86']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L25259']}, {'resource': ['GenBank Protein Database'], 'identifier': ['439839']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2745']}, {'resource': ['UniProtKB'], 'identifier': ['P42081']}, {'resource': ['UniProt Accession'], 'identifier': ['CD86_HUMAN']}]}], 'synonyms': [{'synonym': ['Activation B7-2 antigen', 'B70', 'BU63', 'CD28LG2', 'CTLA-4 counter-receptor B7.2', 'FUN-1']}], 'amino-acid-sequence': ['>lcl|BSEQ0037094|T-lymphocyte activation antigen CD86\nMDPQCTMGLSNILFVMAFLLSGAAPLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQ\nENLVLNEVYLGKEKFDSVHSKYMGRTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGM\nIRIHQMNSELSVLANFSQPEIVPISNITENVYINLTCSSIHGYPEPKKMSVLLRTKNSTI\nEYDGVMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILETDKTRLLSSPFSIELEDPQ\nPPPDHIPWITAVLPTVIICVMVFCLILWKWKKKKRPRNSYKCGTNTMEREESEQTKKREK\nIHIPERSDEAQRVFKSSKTSSCDKSDTCF'], 'gene-sequence': ['>lcl|BSEQ0016227|T-lymphocyte activation antigen CD86 (CD86)\nATGGATCCCCAGTGCACTATGGGACTGAGTAACATTCTCTTTGTGATGGCCTTCCTGCTC\nTCTGCTAACTTCAGTCAACCTGAAATAGTACCAATTTCTAATATAACAGAAAATGTGTAC\nATAAATTTGACCTGCTCATCTATACACGGTTACCCAGAACCTAAGAAGATGAGTGTTTTG\nCTAAGAACCAAGAATTCAACTATCGAGTATGATGGTATTATGCAGAAATCTCAAGATAAT\nGTCACAGAACTGTACGACGTTTCCATCAGCTTGTCTGTTTCATTCCCTGATGTTACGAGC\nAATATGACCATCTTCTGTATTCTGGAAACTGACAAGACGCGGCTTTTATCTTCACCTTTC\nTCTATAGAGCTTGAGGACCCTCAGCCTCCCCCAGACCACATTCCTTGGATTACAGCTGTA\nCTTCCAACAGTTATTATATGTGTGATGGTTTTCTGTCTAATTCTATGGAAATGGAAGAAG\nAAGAAGCGGCCTCGCAACTCTTATAAATGTGGAACCAACACAATGGAGAGGGAAGAGAGT\nGAACAGACCAAGAAAAGAGAAAAAATCCATATACCTGAAAGATCTGATGAAGCCCAGCGT\nGTTTTTAAAAGTTCGAAGACATCTTCATGCGACAAAAGTGATACATGTTTTTAA'], 'pfams': [{'pfam': [{'identifier': ['PF07686'], 'name': ['V-set']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['intracellular membrane-bounded organelle']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['coreceptor activity']}, {'category': ['function'], 'description': ['receptor activity']}, {'category': ['function'], 'description': ['virus receptor activity']}, {'category': ['process'], 'description': ['adaptive immune response']}, {'category': ['process'], 'description': ['aging']}, {'category': ['process'], 'description': ['B cell activation']}, {'category': ['process'], 'description': ['cell-cell signaling']}, {'category': ['process'], 'description': ['cellular response to cytokine stimulus']}, {'category': ['process'], 'description': ['cellular response to lipopolysaccharide']}, {'category': ['process'], 'description': ['cellular response to metal ion']}, {'category': ['process'], 'description': ['defense response to virus']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['myeloid dendritic cell differentiation']}, {'category': ['process'], 'description': ['negative regulation of T cell anergy']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['phosphatidylinositol-mediated signaling']}, {'category': ['process'], 'description': ['positive regulation of activated T cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of interleukin-2 biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of interleukin-4 biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of lymphotoxin A biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of T-helper 2 cell differentiation']}, {'category': ['process'], 'description': ['positive regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['response to drug']}, {'category': ['process'], 'description': ['response to interferon-gamma']}, {'category': ['process'], 'description': ['response to yeast']}, {'category': ['process'], 'description': ['T cell activation']}, {'category': ['process'], 'description': ['T cell costimulation']}, {'category': ['process'], 'description': ['T cell proliferation involved in immune response']}, {'category': ['process'], 'description': ['toll-like receptor 3 signaling pathway']}]}]}]}, {'id': ['BE0002099'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor II-b'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A15362'], 'pubmed-id': ['12586600'], 'citation': ['Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor II-b'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis.'], 'gene-name': ['FCGR2B'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['218-240'], 'signal-regions': ['1-42'], 'theoretical-pi': ['6.12'], 'molecular-weight': ['34043.355'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3618']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR2B']}, {'resource': ['GenBank Gene Database'], 'identifier': ['U87560']}, {'resource': ['GenBank Protein Database'], 'identifier': ['4099445']}, {'resource': ['UniProtKB'], 'identifier': ['P31994']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG2B_HUMAN']}]}], 'synonyms': [{'synonym': ['CD32', 'CDw32', 'Fc-gamma RII-b', 'Fc-gamma-RIIb', 'FCG2', 'FcRII-b', 'IGFR2', 'IgG Fc receptor II-b']}], 'amino-acid-sequence': ['>lcl|BSEQ0004116|Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI'], 'gene-sequence': ['>lcl|BSEQ0019237|Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B)\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTG\nCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCC\nATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTC\nAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGC\nGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTGGAG\nTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTC\nAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAACTTC\nTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATAGGC\nTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCACCG\nATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCTGTA\nGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATTTAG'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['viral process']}]}]}]}, {'id': ['BE0003488'], 'name': ['T-cell surface glycoprotein CD4'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A15362'], 'pubmed-id': ['12586600'], 'citation': ['Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['T-cell surface glycoprotein CD4'], 'general-function': ['Zinc ion binding'], 'specific-function': ['Accessory protein for MHC class-II antigen/T-cell receptor interaction. May regulate T-cell activation. Induces the aggregation of lipid rafts.(Microbial infection) Acts as a receptor for human immunodeficiency virus-1 (PubMed:2214026, PubMed:16331979, PubMed:9641677). Down-regulated by HIV-1 Vpu (PubMed:17346169). Acts as a receptor for Human Herpes virus 7/HHV-7 (PubMed:7909607).'], 'gene-name': ['CD4'], 'locus': [None], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['397-418'], 'signal-regions': ['1-25'], 'theoretical-pi': ['10.24'], 'molecular-weight': ['51110.205'], 'chromosome-location': ['12'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1678']}, {'resource': ['GenAtlas'], 'identifier': ['CD4']}, {'resource': ['GenBank Gene Database'], 'identifier': ['BC025782']}, {'resource': ['UniProtKB'], 'identifier': ['P01730']}, {'resource': ['UniProt Accession'], 'identifier': ['CD4_HUMAN']}]}], 'synonyms': [{'synonym': ['T-cell surface antigen T4/Leu-3']}], 'amino-acid-sequence': ['>lcl|BSEQ0019431|T-cell surface glycoprotein CD4\nMNRGVPFRHLLLVLQLALLPAATQGKKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIK\nILGNQGSFLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICEVEDQKEEVQL\nLVFGLTANSDTHLLQGQSLTLTLESPPGSSPSVQCRSPRGKNIQGGKTLSVSQLELQDSG\nTWTCTVLQNQKKVEFKIDIVVLAFQKASSIVYKKEGEQVEFSFPLAFTVEKLTGSGELWW\nQAERASSSKSWITFDLKNKEVSVKRVTQDPKLQMGKKLPLHLTLPQALPQYAGSGNLTLA\nLEAKTGKLHQEVNLVVMRATQLQKNLTCEVWGPTSPKLMLSLKLENKEAKVSKREKAVWV\nLNPEAGMWQCLLSDSGQVLLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIGLGIFFCV\nRCRHRRRQAERMSQIKRLLSEKKTCQCPHRFQKTCSPI'], 'gene-sequence': ['>lcl|BSEQ0019432|T-cell surface glycoprotein CD4 (CD4)\nATGAACCGGGGAGTCCCTTTTAGGCACTTGCTTCTGGTGCTGCAACTGGCGCTCCTCCCA\nGCAGCCACTCAGGGAAAGAAAGTGGTGCTGGGCAAAAAAGGGGATACAGTGGAACTGACC\nTGTACAGCTTCCCAGAAGAAGAGCATACAATTCCACTGGAAAAACTCCAACCAGATAAAG\nATTCTGGGAAATCAGGGCTCCTTCTTAACTAAAGGTCCATCCAAGCTGAATGATCGCGCT\nGACTCAAGAAGAAGCCTTTGGGACCAAGGAAACTTTCCCCTGATCATCAAGAATCTTAAG\nATAGAAGACTCAGATACTTACATCTGTGAAGTGGAGGACCAGAAGGAGGAGGTGCAATTG\nCTAGTGTTCGGATTGACTGCCAACTCTGACACCCACCTGCTTCAGGGGCAGAGCCTGACC\nCTGACCTTGGAGAGCCCCCCTGGTAGTAGCCCCTCAGTGCAATGTAGGAGTCCAAGGGGT\nAAAAACATACAGGGGGGGAAGACCCTCTCCGTGTCTCAGCTGGAGCTCCAGGATAGTGGC\nACCTGGACATGCACTGTCTTGCAGAACCAGAAGAAGGTGGAGTTCAAAATAGACATCGTG\nGTGCTAGCTTTCCAGAAGGCCTCCAGCATAGTCTATAAGAAAGAGGGGGAACAGGTGGAG\nTTCTCCTTCCCACTCGCCTTTACAGTTGAAAAGCTGACGGGCAGTGGCGAGCTGTGGTGG\nCAGGCGGAGAGGGCTTCCTCCTCCAAGTCTTGGATCACCTTTGACCTGAAGAACAAGGAA\nGTGTCTGTAAAACGGGTTACCCAGGACCCTAAGCTCCAGATGGGCAAGAAGCTCCCGCTC\nCACCTCACCCTGCCCCAGGCCTTGCCTCAGTATGCTGGCTCTGGAAACCTCACCCTGGCC\nCTTGAAGCGAAAACAGGAAAGTTGCATCAGGAAGTGAACCTGGTGGTGATGAGAGCCACT\nCAGCTCCAGAAAAATTTGACCTGTGAGGTGTGGGGACCCACCTCCCCTAAGCTGATGCTG\nAGTTTGAAACTGGAGAACAAGGAGGCAAAGGTCTCGAAGCGGGAGAAGGCGGTGTGGGTG\nCTGAACCCTGAGGCGGGGATGTGGCAGTGTCTGCTGAGTGACTCGGGACAGGTCCTGCTG\nGAATCCAACATCAAGGTTCTGCCCACATGGTCCACCCCGGTGCAGCCAATGGCCCTGATT\nGTGCTGGGGGGCGTCGCCGGCCTCCTGCTTTTCATTGGGCTAGGCATCTTCTTCTGTGTC\nAGGTGCCGGCACCGAAGGCGCCAAGCAGAGCGGATGTCTCAGATCAAGAGACTCCTCAGT\nGAGAAGAAGACCTGCCAGTGTCCTCACCGGTTTCAGAAGACATGTAGCCCCATTTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00047'], 'name': ['ig']}, {'identifier': ['PF05790'], 'name': ['C2-set']}, {'identifier': ['PF09191'], 'name': ['CD4-extracel']}, {'identifier': ['PF12104'], 'name': ['Tcell_CD4_C']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['early endosome']}, {'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['endoplasmic reticulum membrane']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['membrane raft']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['T cell receptor complex']}, {'category': ['function'], 'description': ['coreceptor activity']}, {'category': ['function'], 'description': ['enzyme binding']}, {'category': ['function'], 'description': ['extracellular matrix structural constituent']}, {'category': ['function'], 'description': ['glycoprotein binding']}, {'category': ['function'], 'description': ['MHC class II protein binding']}, {'category': ['function'], 'description': ['protein homodimerization activity']}, {'category': ['function'], 'description': ['protein kinase binding']}, {'category': ['function'], 'description': ['receptor activity']}, {'category': ['function'], 'description': ['transmembrane signaling receptor activity']}, {'category': ['function'], 'description': ['virus receptor activity']}, {'category': ['function'], 'description': ['zinc ion binding']}, {'category': ['process'], 'description': ['adaptive immune response']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cytokine production']}, {'category': ['process'], 'description': ['defense response to Gram-negative bacterium']}, {'category': ['process'], 'description': ['entry into host cell']}, {'category': ['process'], 'description': ['enzyme linked receptor protein signaling pathway']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['induction by virus of host cell-cell fusion']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['maintenance of protein location in cell']}, {'category': ['process'], 'description': ['positive regulation of calcium-mediated signaling']}, {'category': ['process'], 'description': ['positive regulation of interleukin-2 biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of protein kinase activity']}, {'category': ['process'], 'description': ['regulation of defense response to virus by virus']}, {'category': ['process'], 'description': ['regulation of T cell activation']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['T cell costimulation']}, {'category': ['process'], 'description': ['T cell differentiation']}, {'category': ['process'], 'description': ['T cell receptor signaling pathway']}, {'category': ['process'], 'description': ['T cell selection']}, {'category': ['process'], 'description': ['transmembrane receptor protein tyrosine kinase signaling pathway']}, {'category': ['process'], 'description': ['viral process']}]}]}]}, {'id': ['BE0003575'], 'name': ['Integrin beta-1'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A15362'], 'pubmed-id': ['12586600'], 'citation': ['Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Integrin beta-1'], 'general-function': ['Virus receptor activity'], 'specific-function': [""Integrins alpha-1/beta-1, alpha-2/beta-1, alpha-10/beta-1 and alpha-11/beta-1 are receptors for collagen. Integrins alpha-1/beta-1 and alpha-2/beta-2 recognize the proline-hydroxylated sequence G-F-P-G-E-R in collagen. Integrins alpha-2/beta-1, alpha-3/beta-1, alpha-4/beta-1, alpha-5/beta-1, alpha-8/beta-1, alpha-10/beta-1, alpha-11/beta-1 and alpha-V/beta-1 are receptors for fibronectin. Alpha-4/beta-1 recognizes one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. Integrin alpha-5/beta-1 is a receptor for fibrinogen. Integrin alpha-1/beta-1, alpha-2/beta-1, alpha-6/beta-1 and alpha-7/beta-1 are receptors for lamimin. Integrin alpha-4/beta-1 is a receptor for VCAM1. It recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-9/beta-1 is a receptor for VCAM1, cytotactin and osteopontin. It recognizes the sequence A-E-I-D-G-I-E-L in cytotactin. Integrin alpha-3/beta-1 is a receptor for epiligrin, thrombospondin and CSPG4. Alpha-3/beta-1 may mediate with LGALS3 the stimulation by CSPG4 of endothelial cells migration. Integrin alpha-V/beta-1 is a receptor for vitronectin. Beta-1 integrins recognize the sequence R-G-D in a wide array of ligands. Isoform 2 interferes with isoform 1 resulting in a dominant negative effect on cell adhesion and migration (in vitro). When associated with alpha-7/beta-1 integrin, regulates cell adhesion and laminin matrix deposition. Involved in promoting endothelial cell motility and angiogenesis. Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process and the formation of mineralized bone nodules. May be involved in up-regulation of the activity of kinases such as PKC via binding to KRT1. Together with KRT1 and GNB2L1/RACK1, serves as a platform for SRC activation or inactivation. Plays a mechanistic adhesive role during telophase, required for the successful completion of cytokinesis. Integrin alpha-3/beta-1 provides a docking site for FAP (seprase) at invadopodia plasma membranes in a collagen-dependent manner and hence may participate in the adhesion, formation of invadopodia and matrix degradation processes, promoting cell invasion.Isoform 5: Isoform 5 displaces isoform 1 in striated muscles.(Microbial infection) Integrin ITGA2:ITGB1 acts as a receptor for human echoviruses 1 and 8 (PubMed:8411387). Acts as a receptor for cytomegalovirus/HHV-5 (PubMed:20660204). Acts as a receptor for Epstein-Barr virus/HHV-4 (PubMed:17945327). Integrin ITGA5:ITGB1 acts as a receptor for human parvovirus B19 (PubMed:12907437). Integrin ITGA2:ITGB1 acts as a receptor for human rotavirus (PubMed:12941907). Acts as a receptor for mammalian reovirus (PubMed:16501085). In case of HIV-1 infection, integrin ITGA5:ITGB1 binding to extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions (PubMed:10397733).""], 'gene-name': ['ITGB1'], 'locus': ['10p11.2'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['729-751'], 'signal-regions': ['1-20'], 'theoretical-pi': ['5.04'], 'molecular-weight': ['88414.575'], 'chromosome-location': ['10'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6153']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X07979']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31442']}, {'resource': ['UniProtKB'], 'identifier': ['P05556']}, {'resource': ['UniProt Accession'], 'identifier': ['ITB1_HUMAN']}]}], 'synonyms': [{'synonym': ['Fibronectin receptor subunit beta', 'FNRB', 'Glycoprotein IIa', 'GPIIA', 'MDF2', 'MSK12', 'VLA-4 subunit beta']}], 'amino-acid-sequence': ['>lcl|BSEQ0006885|Integrin beta-1\nMNLQPIFWIGLISSVCCVFAQTDENRCLKANAKSCGECIQAGPNCGWCTNSTFLQEGMPT\nSARCDDLEALKKKGCPPDDIENPRGSKDIKKNKNVTNRSKGTAEKLKPEDITQIQPQQLV\nLRLRSGEPQTFTLKFKRAEDYPIDLYYLMDLSYSMKDDLENVKSLGTDLMNEMRRITSDF\nRIGFGSFVEKTVMPYISTTPAKLRNPCTSEQNCTSPFSYKNVLSLTNKGEVFNELVGKQR\nISGNLDSPEGGFDAIMQVAVCGSLIGWRNVTRLLVFSTDAGFHFAGDGKLGGIVLPNDGQ\nCHLENNMYTMSHYYDYPSIAHLVQKLSENNIQTIFAVTEEFQPVYKELKNLIPKSAVGTL\nSANSSNVIQLIIDAYNSLSSEVILENGKLSEGVTISYKSYCKNGVNGTGENGRKCSNISI\nGDEVQFEISITSNKCPKKDSDSFKIRPLGFTEEVEVILQYICECECQSEGIPESPKCHEG\nNGTFECGACRCNEGRVGRHCECSTDEVNSEDMDAYCRKENSSEICSNNGECVCGQCVCRK\nRDNTNEIYSGKFCECDNFNCDRSNGLICGGNGVCKCRVCECNPNYTGSACDCSLDTSTCE\nASNGQICNGRGICECGVCKCTDPKFQGQTCEMCQTCLGVCAEHKECVQCRAFNKGEKKDT\nCTQECSYFNITKVESRDKLPQPVQPDPVSHCKEKDVDDCWFYFTYSVNGNNEVMVHVVEN\nPECPTGPDIIPIVAGVVAGIVLIGLALLLIWKLLMIIHDRREFAKFEKEKMNAKWDTGEN\nPIYKSAVTTVVNPKYEGK'], 'gene-sequence': ['>lcl|BSEQ0021939|Integrin beta-1 (ITGB1)\nATGAATTTACAACCAATTTTCTGGATTGGACTGATCAGTTCAGTTTGCTGTGTGTTTGCT\nCAAACAGATGAAAATAGATGTTTAAAAGCAAATGCCAAATCATGTGGAGAATGTATACAA\nGCAGGGCCAAATTGTGGGTGGTGCACAAATTCAACATTTTTACAGGAAGGAATGCCTACT\nTCTGCACGATGTGATGATTTAGAAGCCTTAAAAAAGAAGGGTTGCCCTCCAGATGACATA\nGAAAATCCCAGAGGCTCCAAAGATATAAAGAAAAATAAAAATGTAACCAACCGTAGCAAA\nGGAACAGCAGAGAAGCTCAAGCCAGAGGATATTACTCAGATCCAACCACAGCAGTTGGTT\nTTGCGATTAAGATCAGGGGAGCCACAGACATTTACATTAAAATTCAAGAGAGCTGAAGAC\nTATCCCATTGACCTCTACTACCTTATGGACCTGTCTTACTCAATGAAAGACGATTTGGAG\nAATGTAAAAAGTCTTGGAACAGATCTGATGAATGAAATGAGGAGGATTACTTCGGACTTC\nAGAATTGGATTTGGCTCATTTGTGGAAAAGACTGTGATGCCTTACATTAGCACAACACCA\nGCTAAGCTCAGGAACCCTTGCACAAGTGAACAGAACTGCACCAGCCCATTTAGCTACAAA\nAATGTGCTCAGTCTTACTAATAAAGGAGAAGTATTTAATGAACTTGTTGGAAAACAGCGC\nATATCTGGAAATTTGGATTCTCCAGAAGGTGGTTTCGATGCCATCATGCAAGTTGCAGTT\nTGTGGATCACTGATTGGCTGGAGGAATGTTACACGGCTGCTGGTGTTTTCCACAGATGCC\nGGGTTTCACTTTGCTGGAGATGGGAAACTTGGTGGCATTGTTTTACCAAATGATGGACAA\nTGTCACCTGGAAAATAATATGTACACAATGAGCCATTATTATGATTATCCTTCTATTGCT\nCACCTTGTCCAGAAACTGAGTGAAAATAATATTCAGACAATTTTTGCAGTTACTGAAGAA\nTTTCAGCCTGTTTACAAGGAGCTGAAAAACTTGATCCCTAAGTCAGCAGTAGGAACATTA\nTCTGCAAATTCTAGCAATGTAATTCAGTTGATCATTGATGCATACAATTCCCTTTCCTCA\nGAAGTCATTTTGGAAAACGGCAAATTGTCAGAAGGCGTAACAATAAGTTACAAATCTTAC\nTGCAAGAACGGGGTGAATGGAACAGGGGAAAATGGAAGAAAATGTTCCAATATTTCCATT\nGGAGATGAGGTTCAATTTGAAATTAGCATAACTTCAAATAAGTGTCCAAAAAAGGATTCT\nGACAGCTTTAAAATTAGGCCTCTGGGCTTTACGGAGGAAGTAGAGGTTATTCTTCAGTAC\nATCTGTGAATGTGAATGCCAAAGCGAAGGCATCCCTGAAAGTCCCAAGTGTCATGAAGGA\nAATGGGACATTTGAGTGTGGCGCGTGCAGGTGCAATGAAGGGCGTGTTGGTAGACATTGT\nGAATGCAGCACAGATGAAGTTAACAGTGAAGACATGGATGCTTACTGCAGGAAAGAAAAC\nAGTTCAGAAATCTGCAGTAACAATGGAGAGTGCGTCTGCGGACAGTGTGTTTGTAGGAAG\nAGGGATAATACAAATGAAATTTATTCTGGCAAATTCTGCGAGTGTGATAATTTCAACTGT\nGATAGATCCAATGGCTTAATTTGTGGAGGAAATGGTGTTTGCAAGTGTCGTGTGTGTGAG\nTGCAACCCCAACTACACTGGCAGTGCATGTGACTGTTCTTTGGATACTAGTACTTGTGAA\nGCCAGCAACGGACAGATCTGCAATGGCCGGGGCATCTGCGAGTGTGGTGTCTGTAAGTGT\nACAGATCCGAAGTTTCAAGGGCAAACGTGTGAGATGTGTCAGACCTGCCTTGGTGTCTGT\nGCTGAGCATAAAGAATGTGTTCAGTGCAGAGCCTTCAATAAAGGAGAAAAGAAAGACACA\nTGCACACAGGAATGTTCCTATTTTAACATTACCAAGGTAGAAAGTCGGGACAAATTACCC\nCAGCCGGTCCAACCTGATCCTGTGTCCCATTGTAAGGAGAAGGATGTTGACGACTGTTGG\nTTCTATTTTACGTATTCAGTGAATGGGAACAACGAGGTCATGGTTCATGTTGTGGAGAAT\nCCAGAGTGTCCCACTGGTCCAGACATCATTCCAATTGTAGCTGGTGTGGTTGCTGGAATT\nGTTCTTATTGGCCTTGCATTACTGCTGATATGGAAGCTTTTAATGATAATTCATGACAGA\nAGGGAGTTTGCTAAATTTGAAAAGGAGAAAATGAATGCCAAATGGGACACGGGTGAAAAT\nCCTATTTATAAGAGTGCCGTAACAACTGTGGTCAATCCGAAGTATGAGGGAAAATGA'], 'pfams': [{'pfam': [{'identifier': ['PF07974'], 'name': ['EGF_2']}, {'identifier': ['PF00362'], 'name': ['Integrin_beta']}, {'identifier': ['PF08725'], 'name': ['Integrin_b_cyt']}, {'identifier': ['PF07965'], 'name': ['Integrin_B_tail']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['cleavage furrow']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['dendritic spine']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['filopodium']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['integrin alpha1-beta1 complex']}, {'category': ['component'], 'description': ['integrin alpha10-beta1 complex']}, {'category': ['component'], 'description': ['integrin alpha11-beta1 complex']}, {'category': ['component'], 'description': ['integrin alpha2-beta1 complex']}, {'category': ['component'], 'description': ['integrin alpha3-beta1 complex']}, {'category': ['component'], 'description': ['integrin alpha7-beta1 complex']}, {'category': ['component'], 'description': ['integrin alpha8-beta1 complex']}, {'category': ['component'], 'description': ['integrin complex']}, {'category': ['component'], 'description': ['intercalated disc']}, {'category': ['component'], 'description': ['invadopodium membrane']}, {'category': ['component'], 'description': ['lamellipodium']}, {'category': ['component'], 'description': ['melanosome']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['membrane raft']}, {'category': ['component'], 'description': ['myelin sheath abaxonal region']}, {'category': ['component'], 'description': ['neuromuscular junction']}, {'category': ['component'], 'description': ['perinuclear region of cytoplasm']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['component'], 'description': ['recycling endosome']}, {'category': ['component'], 'description': ['ruffle']}, {'category': ['component'], 'description': ['ruffle membrane']}, {'category': ['component'], 'description': ['sarcolemma']}, {'category': ['component'], 'description': ['synaptic membrane']}, {'category': ['function'], 'description': ['actin binding']}, {'category': ['function'], 'description': ['cell adhesion molecule binding']}, {'category': ['function'], 'description': ['collagen binding involved in cell-matrix adhesion']}, {'category': ['function'], 'description': ['fibronectin binding']}, {'category': ['function'], 'description': ['metal ion binding']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['function'], 'description': ['protein complex binding']}, {'category': ['function'], 'description': ['protein heterodimerization activity']}, {'category': ['function'], 'description': ['virus receptor activity']}, {'category': ['process'], 'description': ['axon extension']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['B cell differentiation']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['calcium-independent cell-matrix adhesion']}, {'category': ['process'], 'description': ['cardiac muscle cell differentiation']}, {'category': ['process'], 'description': ['cell fate specification']}, {'category': ['process'], 'description': ['cell junction assembly']}, {'category': ['process'], 'description': ['cell migration']}, {'category': ['process'], 'description': ['cell migration involved in sprouting angiogenesis']}, {'category': ['process'], 'description': ['cell-cell adhesion mediated by integrin']}, {'category': ['process'], 'description': ['cell-matrix adhesion']}, {'category': ['process'], 'description': ['cell-substrate adhesion']}, {'category': ['process'], 'description': ['cellular defense response']}, {'category': ['process'], 'description': ['cellular response to low-density lipoprotein particle stimulus']}, {'category': ['process'], 'description': ['dendrite morphogenesis']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['formation of radial glial scaffolds']}, {'category': ['process'], 'description': ['G1/S transition of mitotic cell cycle']}, {'category': ['process'], 'description': ['germ cell migration']}, {'category': ['process'], 'description': ['heterotypic cell-cell adhesion']}, {'category': ['process'], 'description': ['homophilic cell adhesion via plasma membrane adhesion molecules']}, {'category': ['process'], 'description': ['in utero embryonic development']}, {'category': ['process'], 'description': ['integrin-mediated signaling pathway']}, {'category': ['process'], 'description': ['leukocyte cell-cell adhesion']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['leukocyte tethering or rolling']}, {'category': ['process'], 'description': ['mesodermal cell differentiation']}, {'category': ['process'], 'description': ['negative regulation of anoikis']}, {'category': ['process'], 'description': ['negative regulation of cell differentiation']}, {'category': ['process'], 'description': ['negative regulation of Rho protein signal transduction']}, {'category': ['process'], 'description': ['positive regulation of apoptotic process']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of establishment of protein localization to plasma membrane']}, {'category': ['process'], 'description': ['positive regulation of GTPase activity']}, {'category': ['process'], 'description': ['receptor internalization']}, {'category': ['process'], 'description': ['regulation of cell cycle']}, {'category': ['process'], 'description': ['regulation of collagen catabolic process']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['sarcomere organization']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['visual learning']}]}]}]}, {'id': ['BE0003576'], 'name': ['Integrin alpha-V'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A15362'], 'pubmed-id': ['12586600'], 'citation': ['Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Integrin alpha-V'], 'general-function': ['Voltage-gated calcium channel activity'], 'specific-function': [""The alpha-V (ITGAV) integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. They recognize the sequence R-G-D in a wide array of ligands.(Microbial infection) Integrin ITGAV:ITGB5 acts as a receptor for adenovirus type C (PubMed:20615244). Integrin ITGAV:ITGB5 and ITGAV:ITGB3 act as receptors for coxsackievirus A9 and B1 (PubMed:9426447, PubMed:15194773, PubMed:7519807). Integrin ITGAV:ITGB3 acts as a receptor for herpes virus 8/HHV-8 (PubMed:18045938). Integrin ITGAV:ITGB6 acts as a receptor for herpes simplex 1/HHV-1 (PubMed:24367260). Integrin ITGAV:ITGB3 acts as a receptor for Human parechovirus 1 (PubMed:11160695). Integrin ITGAV:ITGB3 acts as a receptor for West nile virus (PubMed:23658209). In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions (PubMed:10397733).""], 'gene-name': ['ITGAV'], 'locus': ['2q31-q32'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['993-1016'], 'signal-regions': ['1-30'], 'theoretical-pi': ['5.36'], 'molecular-weight': ['116036.855'], 'chromosome-location': ['2'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6150']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M14648']}, {'resource': ['GenBank Protein Database'], 'identifier': ['340307']}, {'resource': ['UniProtKB'], 'identifier': ['P06756']}, {'resource': ['UniProt Accession'], 'identifier': ['ITAV_HUMAN']}]}], 'synonyms': [{'synonym': ['MSK8', 'Vitronectin receptor subunit alpha', 'VNRA']}], 'amino-acid-sequence': ['>lcl|BSEQ0006887|Integrin alpha-V\nMAFPPRRRLRLGPRGLPLLLSGLLLPLCRAFNLDVDSPAEYSGPEGSYFGFAVDFFVPSA\nSSRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPIEFDATGNRDYAKDDPLEFKS\nHQWFGASVRSKQDKILACAPLYHWRTEMKQEREPVGTCFLQDGTKTVEYAPCRSQDIDAD\nGQGFCQGGFSIDFTKADRVLLGGPGSFYWQGQLISDQVAEIVSKYDPNVYSIKYNNQLAT\nRTAQAIFDDSYLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYIYDGKNMSSLYNFTGE\nQMAAYFGFSVAATDINGDDYADVFIGAPLFMDRGSDGKLQEVGQVSVSLQRASGDFQTTK\nLNGFEVFARFGSAIAPLGDLDQDGFNDIAIAAPYGGEDKKGIVYIFNGRSTGLNAVPSQI\nLEGQWAARSMPPSFGYSMKGATDIDKNGYPDLIVGAFGVDRAILYRARPVITVNAGLEVY\nPSILNQDNKTCSLPGTALKVSCFNVRFCLKADGKGVLPRKLNFQVELLLDKLKQKGAIRR\nALFLYSRSPSHSKNMTISRGGLMQCEELIAYLRDESEFRDKLTPITIFMEYRLDYRTAAD\nTTGLQPILNQFTPANISRQAHILLDCGEDNVCKPKLEVSVDSDQKKIYIGDDNPLTLIVK\nAQNQGEGAYEAELIVSIPLQADFIGVVRNNEALARLSCAFKTENQTRQVVCDLGNPMKAG\nTQLLAGLRFSVHQQSEMDTSVKFDLQIQSSNLFDKVSPVVSHKVDLAVLAAVEIRGVSSP\nDHVFLPIPNWEHKENPETEEDVGPVVQHIYELRNNGPSSFSKAMLHLQWPYKYNNNTLLY\nILHYDIDGPMNCTSDMEINPLRIKISSLQTTEKNDTVAGQGERDHLITKRDLALSEGDIH\nTLGCGVAQCLKIVCQVGRLDRGKSAILYVKSLLWTETFMNKENQNHSYSLKSSASFNVIE\nFPYKNLPIEDITNSTLVTTNVTWGIQPAPMPVPVWVIILAVLAGLLLLAVLVFVMYRMGF\nFKRVRPPQEEQEREQLQPHENGEGNSET'], 'gene-sequence': ['>lcl|BSEQ0012486|Integrin alpha-V (ITGAV)\nATGCTCCTAGGCACCCTCCTTCTGATCCTGTACATCTTAATGTTGTGCCGGATGTTTCTT\nCTCGTGGGAGCTCCCAAAGCAAACACCACCCAGCCTGGGATTGTGGAAGGAGGGCAGGTC\nCTCAAATGTGACTGGTCTTCTACCCGCCGGTGCCAGCCAATTGAATTTGATGCAACAGGC\nAATAGAGATTATGCCAAGGATGATCCATTGGAATTTAAGTCCCATCAGTGGTTTGGAGCA\nTCTGTGAGGTCGAAACAGGATAAAATTTTGGCCTGTGCCCCATTGTACCATTGGAGAACT\nGAGATGAAACAGGAGCGAGAGCCTGTTGGAACATGCTTTCTTCAAGATGGAACAAAGACT\nGTTGAGTATGCTCCATGTAGATCACAAGATATTGATGCTGATGGACAGGGATTTTGTCAA\nGGAGGATTCAGCATTGATTTTACTAAAGCTGACAGAGTACTTCTTGGTGGTCCTGGTAGC\nTTTTATTGGCAAGGTCAGCTTATTTCGGATCAAGTGGCAGAAATCGTATCTAAATACGAC\nCCCAATGTTTACAGCATCAAGTATAATAACCAATTAGCAACTCGGACTGCACAAGCTATT\nTTTGATGACAGCTATTTGGGTTATTCTGTGGCTGTCGGAGATTTCAATGGTGATGGCATA\nGATGACTTTGTTTCAGGAGTTCCAAGAGCAGCAAGGACTTTGGGAATGGTTTATATTTAT\nGATGGGAAGAACATGTCCTCCTTATACAATTTTACTGGCGAGCAGATGGCTGCATATTTC\nGGATTTTCTGTAGCTGCCACTGACATTAATGGAGATGATTATGCAGATGTGTTTATTGGA\nGCACCTCTCTTCATGGATCGTGGCTCTGATGGCAAACTCCAAGAGGTGGGGCAGGTCTCA\nGTGTCTCTACAGAGAGCTTCAGGAGACTTCCAGACGACAAAGCTGAATGGATTTGAGGTC\nTTTGCACGGTTTGGCAGTGCCATAGCTCCTTTGGGAGATCTGGACCAGGATGGTTTCAAT\nGATATTGCAATTGCTGCTCCATATGGGGGTGAAGATAAAAAAGGAATTGTTTATATCTTC\nAATGGAAGATCAACAGGCTTGAACGCAGTCCCATCTCAAATCCTTGAAGGGCAGTGGGCT\nGCTCGAAGCATGCCACCAAGCTTTGGCTATTCAATGAAAGGAGCCACAGATATAGACAAA\nAATGGATATCCAGACTTAATTGTAGGAGCTTTTGGTGTAGATCGAGCTATCTTATACAGG\nGCCAGACCAGTTATCACTGTAAATGCTGGTCTTGAAGTGTACCCTAGCATTTTAAATCAA\nGACAATAAAACCTGCTCACTGCCTGGAACAGCTCTCAAAGTTTCCTGTTTTAATGTTAGG\nTTCTGCTTAAAGGCAGATGGCAAAGGAGTACTTCCCAGGAAACTTAATTTCCAGGTGGAA\nCTTCTTTTGGATAAACTCAAGCAAAAGGGAGCAATTCGACGAGCACTGTTTCTCTACAGC\nAGGTCCCCAAGTCACTCCAAGAACATGACTATTTCAAGGGGGGGACTGATGCAGTGTGAG\nGAATTGATAGCGTATCTGCGGGATGAATCTGAATTTAGAGACAAACTCACTCCAATTACT\nATTTTTATGGAATATCGGTTGGATTATAGAACAGCTGCTGATACAACAGGCTTGCAACCC\nATTCTTAACCAGTTCACGCCTGCTAACATTAGTCGACAGGCTCACATTCTACTTGACTGT\nGGTGAAGACAATGTCTGTAAACCCAAGCTGGAAGTTTCTGTAGATAGTGATCAAAAGAAG\nATCTATATTGGGGATGACAACCCTCTGACATTGATTGTTAAGGCTCAGAATCAAGGAGAA\nGGTGCCTACGAAGCTGAGCTCATCGTTTCCATTCCACTGCAGGCTGATTTCATCGGGGTT\nGTCCGAAACAATGAAGCCTTAGCAAGACTTTCCTGTGCATTTAAGACAGAAAACCAAACT\nCGCCAGGTGGTATGTGACCTTGGAAACCCAATGAAGGCTGGAACTCAACTCTTAGCTGGT\nCTTCGTTTCAGTGTGCACCAGCAGTCAGAGATGGATACTTCTGTGAAATTTGACTTACAA\nATCCAAAGCTCAAATCTATTTGACAAAGTAAGCCCAGTTGTATCTCACAAAGTTGATCTT\nGCTGTTTTAGCTGCAGTTGAGATAAGAGGAGTCTCGAGTCCTGATCATATCTTTCTTCCG\nATTCCAAACTGGGAGCACAAGGAGAACCCTGAGACTGAAGAAGATGTTGGGCCAGTTGTT\nCAGCACATCTATGAGCTGAGAAACAATGGTCCAAGTTCATTCAGCAAGGCAATGCTCCAT\nCTTCAGTGGCCTTACAAATATAATAATAACACTCTGTTGTATATCCTTCATTATGATATT\nGATGGACCAATGAACTGCACTTCAGATATGGAGATCAACCCTTTGAGAATTAAGATCTCA\nTCTTTGCAAACAACTGAAAAGAATGACACGGTTGCCGGGCAAGGTGAGCGGGACCATCTC\nATCACTAAGCGGGATCTTGCCCTCAGTGAAGGAGATATTCACACTTTGGGTTGTGGAGTT\nGCTCAGTGCTTGAAGATTGTCTGCCAAGTTGGGAGATTAGACAGAGGAAAGAGTGCAATC\nTTGTACGTAAAGTCATTACTGTGGACTGAGACTTTTATGAATAAAGAAAATCAGAATCAT\nTCCTATTCTCTGAAGTCGTCTGCTTCATTTAATGTCATAGAGTTTCCTTATAAGAATCTT\nCCAATTGAGGATATCACCAACTCCACATTGGTTACCACTAATGTCACCTGGGGCATTCAG\nCCAGCGCCCATGCCTGTGCCTGTGTGGGTGATCATTTTAGCAGTTCTAGCAGGATTGTTG\nCTACTGGCTGTTTTGGTATTTGTAATGTACAGGATGGGCTTTTTTAAACGGGTCCGGCCA\nCCTCAAGAAGAACAAGAAAGGGAGCAGCTTCAACCTCATGAAAATGGTGAAGGAAACTCA\nGAAACTTAA'], 'pfams': [{'pfam': [{'identifier': ['PF01839'], 'name': ['FG-GAP']}, {'identifier': ['PF00357'], 'name': ['Integrin_alpha']}, {'identifier': ['PF08441'], 'name': ['Integrin_alpha2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['alphav-beta3 integrin-IGF-1-IGF1R complex']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['filopodium membrane']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['integrin alphav-beta3 complex']}, {'category': ['component'], 'description': ['integrin alphav-beta5 complex']}, {'category': ['component'], 'description': ['integrin alphav-beta8 complex']}, {'category': ['component'], 'description': ['integrin complex']}, {'category': ['component'], 'description': ['lamellipodium membrane']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['microvillus membrane']}, {'category': ['component'], 'description': ['phagocytic vesicle']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['ruffle membrane']}, {'category': ['function'], 'description': ['extracellular matrix binding']}, {'category': ['function'], 'description': ['extracellular matrix protein binding']}, {'category': ['function'], 'description': ['fibronectin binding']}, {'category': ['function'], 'description': ['metal ion binding']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['function'], 'description': ['transforming growth factor beta binding']}, {'category': ['function'], 'description': ['virus receptor activity']}, {'category': ['function'], 'description': ['voltage-gated calcium channel activity']}, {'category': ['process'], 'description': ['angiogenesis']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent']}, {'category': ['process'], 'description': ['antigen processing and presentation of peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['apolipoprotein A-I-mediated signaling pathway']}, {'category': ['process'], 'description': ['apoptotic cell clearance']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['calcium ion transmembrane transport']}, {'category': ['process'], 'description': ['cell adhesion']}, {'category': ['process'], 'description': ['cell growth']}, {'category': ['process'], 'description': ['cell migration']}, {'category': ['process'], 'description': ['cell-matrix adhesion']}, {'category': ['process'], 'description': ['cell-substrate adhesion']}, {'category': ['process'], 'description': ['endodermal cell differentiation']}, {'category': ['process'], 'description': ['entry of symbiont into host cell by promotion of host phagocytosis']}, {'category': ['process'], 'description': ['ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['extrinsic apoptotic signaling pathway in absence of ligand']}, {'category': ['process'], 'description': ['heterotypic cell-cell adhesion']}, {'category': ['process'], 'description': ['integrin-mediated signaling pathway']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['negative chemotaxis']}, {'category': ['process'], 'description': ['negative regulation of entry of bacterium into host cell']}, {'category': ['process'], 'description': ['negative regulation of extrinsic apoptotic signaling pathway']}, {'category': ['process'], 'description': ['negative regulation of lipid storage']}, {'category': ['process'], 'description': ['negative regulation of lipid transport']}, {'category': ['process'], 'description': ['negative regulation of lipoprotein metabolic process']}, {'category': ['process'], 'description': ['negative regulation of low-density lipoprotein particle receptor biosynthetic process']}, {'category': ['process'], 'description': ['negative regulation of macrophage derived foam cell differentiation']}, {'category': ['process'], 'description': ['positive regulation of cell adhesion']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of osteoblast proliferation']}, {'category': ['process'], 'description': ['regulation of apoptotic cell clearance']}, {'category': ['process'], 'description': ['regulation of phagocytosis']}, {'category': ['process'], 'description': ['substrate adhesion-dependent cell spreading']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['viral entry into host cell']}]}]}]}, {'id': ['BE0001155'], 'name': ['Integrin beta-3'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A15362'], 'pubmed-id': ['12586600'], 'citation': ['Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Integrin beta-3'], 'general-function': ['Virus receptor activity'], 'specific-function': [""Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. Fibrinogen binding enhances SELP expression in activated platelets (By similarity).(Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for herpes virus 8/HHV-8 (PubMed:18045938). Integrin ITGAV:ITGB3 acts as a receptor for coxsackievirus A9 (PubMed:7519807). Acts as a receptor for Hantaan virus (PubMed:9618541). Integrin ITGAV:ITGB3 acts as a receptor for cytomegalovirus/HHV-5 (PubMed:15834425). Integrin ITGA5:ITGB3 acts as a receptor for human metapneumovirus (PubMed:24478423). Integrin ITGAV:ITGB3 acts aP05556s a receptor for human parechovirus 1 (PubMed:11160695). Integrin ITGAV:ITGB3 acts as a receptor for west nile virus (PubMed:23658209). In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions (PubMed:10397733).""], 'gene-name': ['ITGB3'], 'locus': ['17q21.32'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['719-741'], 'signal-regions': ['1-26'], 'theoretical-pi': ['4.85'], 'molecular-weight': ['87056.975'], 'chromosome-location': ['17'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6156']}, {'resource': ['GenAtlas'], 'identifier': ['ITGB3']}, {'resource': ['GenBank Gene Database'], 'identifier': ['J02703']}, {'resource': ['GenBank Protein Database'], 'identifier': ['306786']}, {'resource': ['UniProtKB'], 'identifier': ['P05106']}, {'resource': ['UniProt Accession'], 'identifier': ['ITB3_HUMAN']}]}], 'synonyms': [{'synonym': ['GP3A', 'GPIIIa', 'Platelet membrane glycoprotein IIIa']}], 'amino-acid-sequence': ['>lcl|BSEQ0002297|Integrin beta-3\nMRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLG\nSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRP\nDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFG\nAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSR\nNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCH\nVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLS\nMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDT\nVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGT\nFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFG\nKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLL\nCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRY\nCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDIL\nVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTF\nTNITYRGT'], 'gene-sequence': ['>lcl|BSEQ0021847|Integrin beta-3 (ITGB3)\nATGCGAGCGCGGCCGCGGCCCCGGCCGCTCTGGGCGACTGTGCTGGCGCTGGGGGCGCTG\nGCGGGCGTTGGCGTAGGAGGGCCCAACATCTGTACCACGCGAGGTGTGAGCTCCTGCCAG\nCAGTGCCTGGCTGTGAGCCCCATGTGTGCCTGGTGCTCTGATGAGGCCCTGCCTCTGGGC\nTCACCTCGCTGTGACCTGAAGGAGAATCTGCTGAAGGATAACTGTGCCCCAGAATCCATC\nGAGTTCCCAGTGAGTGAGGCCCGAGTACTAGAGGACAGGCCCCTCAGCGACAAGGGCTCT\nGGAGACAGCTCCCAGGTCACTCAAGTCAGTCCCCAGAGGATTGCACTCCGGCTCCGGCCA\nGATGATTCGAAGAATTTCTCCATCCAAGTGCGGCAGGTGGAGGATTACCCTGTGGACATC\nTACTACTTGATGGACCTGTCTTACTCCATGAAGGATGATCTGTGGAGCATCCAGAACCTG\nGGTACCAAGCTGGCCACCCAGATGCGAAAGCTCACCAGTAACCTGCGGATTGGCTTCGGG\nGCATTTGTGGACAAGCCTGTGTCACCATACATGTATATCTCCCCACCAGAGGCCCTCGAA\nAACCCCTGCTATGATATGAAGACCACCTGCTTGCCCATGTTTGGCTACAAACACGTGCTG\nACGCTAACTGACCAGGTGACCCGCTTCAATGAGGAAGTGAAGAAGCAGAGTGTGTCACGG\nAACCGAGATGCCCCAGAGGGTGGCTTTGATGCCATCATGCAGGCTACAGTCTGTGATGAA\nAAGATTGGCTGGAGGAATGATGCATCCCACTTGCTGGTGTTTACCACTGATGCCAAGACT\nCATATAGCATTGGACGGAAGGCTGGCAGGCATTGTCCAGCCTAATGACGGGCAGTGTCAT\nGTTGGTAGTGACAATCATTACTCTGCCTCCACTACCATGGATTATCCCTCTTTGGGGCTG\nATGACTGAGAAGCTATCCCAGAAAAACATCAATTTGATCTTTGCAGTGACTGAAAATGTA\nGTCAATCTCTATCAGAACTATAGTGAGCTCATCCCAGGGACCACAGTTGGGGTTCTGTCC\nATGGATTCCAGCAATGTCCTCCAGCTCATTGTTGATGCTTATGGGAAAATCCGTTCTAAA\nGTAGAGCTGGAAGTGCGTGACCTCCCTGAAGAGTTGTCTCTATCCTTCAATGCCACCTGC\nCTCAACAATGAGGTCATCCCTGGCCTCAAGTCTTGTATGGGACTCAAGATTGGAGACACG\nGTGAGCTTCAGCATTGAGGCCAAGGTGCGAGGCTGTCCCCAGGAGAAGGAGAAGTCCTTT\nACCATAAAGCCCGTGGGCTTCAAGGACAGCCTGATCGTCCAGGTCACCTTTGATTGTGAC\nTGTGCCTGCCAGGCCCAAGCTGAACCTAATAGCCATCGCTGCAACAATGGCAATGGGACC\nTTTGAGTGTGGGGTATGCCGTTGTGGGCCTGGCTGGCTGGGATCCCAGTGTGAGTGCTCA\nGAGGAGGACTATCGCCCTTCCCAGCAGGACGAATGCAGCCCCCGGGAGGGTCAGCCCGTC\nTGCAGCCAGCGGGGCGAGTGCCTCTGTGGTCAATGTGTCTGCCACAGCAGTGACTTTGGC\nAAGATCACGGGCAAGTACTGCGAGTGTGACGACTTCTCCTGTGTCCGCTACAAGGGGGAG\nATGTGCTCAGGCCATGGCCAGTGCAGCTGTGGGGACTGCCTGTGTGACTCCGACTGGACC\nGGCTACTACTGCAACTGTACCACGCGTACTGACACCTGCATGTCCAGCAATGGGCTGCTG\nTGCAGCGGCCGCGGCAAGTGTGAATGTGGCAGCTGTGTCTGTATCCAGCCGGGCTCCTAT\nGGGGACACCTGTGAGAAGTGCCCCACCTGCCCAGATGCCTGCACCTTTAAGAAAGAATGT\nGTGGAGTGTAAGAAGTTTGACCGGGGAGCCCTACATGACGAAAATACCTGCAACCGTTAC\nTGCCGTGACGAGATTGAGTCAGTGAAAGAGCTTAAGGACACTGGCAAGGATGCAGTGAAT\nTGTACCTATAAGAATGAGGATGACTGTGTCGTCAGATTCCAGTACTATGAAGATTCTAGT\nGGAAAGTCCATCCTGTATGTGGTAGAAGAGCCAGAGTGTCCCAAGGGCCCTGACATCCTG\nGTGGTCCTGCTCTCAGTGATGGGGGCCATTCTGCTCATTGGCCTTGCCGCCCTGCTCATC\nTGGAAACTCCTCATCACCATCCACGACCGAAAAGAATTCGCTAAATTTGAGGAAGAACGC\nGCCAGAGCAAAATGGGACACAGCCAACAACCCACTGTATAAAGAGGCCACGTCTACCTTC\nACCAATATCACGTACCGGGGCACTTAA'], 'pfams': [{'pfam': [{'identifier': ['PF07974'], 'name': ['EGF_2']}, {'identifier': ['PF00362'], 'name': ['Integrin_beta']}, {'identifier': ['PF08725'], 'name': ['Integrin_b_cyt']}, {'identifier': ['PF07965'], 'name': ['Integrin_B_tail']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['alphav-beta3 integrin-vitronectin complex']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['filopodium membrane']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['integrin alphav-beta3 complex']}, {'category': ['component'], 'description': ['integrin complex']}, {'category': ['component'], 'description': ['lamellipodium membrane']}, {'category': ['component'], 'description': ['melanosome']}, {'category': ['component'], 'description': ['microvillus membrane']}, {'category': ['component'], 'description': ['nucleus']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['component'], 'description': ['ruffle membrane']}, {'category': ['function'], 'description': ['cell adhesion molecule binding']}, {'category': ['function'], 'description': ['enzyme binding']}, {'category': ['function'], 'description': ['extracellular matrix binding']}, {'category': ['function'], 'description': ['fibronectin binding']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['function'], 'description': ['platelet-derived growth factor receptor binding']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['function'], 'description': ['protein disulfide isomerase activity']}, {'category': ['function'], 'description': ['vascular endothelial growth factor receptor 2 binding']}, {'category': ['function'], 'description': ['virus receptor activity']}, {'category': ['process'], 'description': ['activation of protein kinase activity']}, {'category': ['process'], 'description': ['angiogenesis involved in wound healing']}, {'category': ['process'], 'description': ['apolipoprotein A-I-mediated signaling pathway']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cell adhesion']}, {'category': ['process'], 'description': ['cell growth']}, {'category': ['process'], 'description': ['cell migration']}, {'category': ['process'], 'description': ['cell-matrix adhesion']}, {'category': ['process'], 'description': ['cell-substrate adhesion']}, {'category': ['process'], 'description': ['cell-substrate junction assembly']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['heterotypic cell-cell adhesion']}, {'category': ['process'], 'description': ['integrin-mediated signaling pathway']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['mesodermal cell differentiation']}, {'category': ['process'], 'description': ['negative chemotaxis']}, {'category': ['process'], 'description': ['negative regulation of lipid storage']}, {'category': ['process'], 'description': ['negative regulation of lipid transport']}, {'category': ['process'], 'description': ['negative regulation of lipoprotein metabolic process']}, {'category': ['process'], 'description': ['negative regulation of low-density lipoprotein particle receptor biosynthetic process']}, {'category': ['process'], 'description': ['negative regulation of macrophage derived foam cell differentiation']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet aggregation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['positive regulation of endothelial cell migration']}, {'category': ['process'], 'description': ['positive regulation of endothelial cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of vascular endothelial growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['protein folding']}, {'category': ['process'], 'description': ['regulation of bone resorption']}, {'category': ['process'], 'description': ['smooth muscle cell migration']}, {'category': ['process'], 'description': ['substrate adhesion-dependent cell spreading']}, {'category': ['process'], 'description': ['tube development']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['viral entry into host cell']}, {'category': ['process'], 'description': ['wound healing']}]}]}]}, {'id': ['BE0000598'], 'name': ['T-cell surface glycoprotein CD1a'], 'organism': ['Humans'], 'actions': [{'action': ['inhibitor']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['T-cell surface glycoprotein CD1a'], 'general-function': ['Lipopeptide binding'], 'specific-function': ['Antigen-presenting protein that binds self and non-self lipid and glycolipid antigens and presents them to T-cell receptors on natural killer T-cells.'], 'gene-name': ['CD1A'], 'locus': ['1q22-q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['301-321'], 'signal-regions': ['1-16'], 'theoretical-pi': ['6.79'], 'molecular-weight': ['37077.1'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1634']}, {'resource': ['GenAtlas'], 'identifier': ['CD1A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M28825']}, {'resource': ['GenBank Protein Database'], 'identifier': ['180036']}, {'resource': ['UniProtKB'], 'identifier': ['P06126']}, {'resource': ['UniProt Accession'], 'identifier': ['CD1A_HUMAN']}]}], 'synonyms': [{'synonym': ['hTa1 thymocyte antigen', 'T-cell surface antigen T6/Leu-6']}], 'amino-acid-sequence': ['>lcl|BSEQ0010415|T-cell surface glycoprotein CD1a\nMLFLLLPLLAVLPGDGNADGLKEPLSFHVTWIASFYNHSWKQNLVSGWLSDLQTHTWDSN\nSSTIVFLCPWSRGNFSNEEWKELETLFRIRTIRSFEGIRRYAHELQFEYPFEIQVTGGCE\nLHSGKVSGSFLQLAYQGSDFVSFQNNSWLPYPVAGNMAKHFCKVLNQNQHENDITHNLLS\nDTCPRFILGLLDAGKAHLQRQVKPEAWLSHGPSPGPGHLQLVCHVSGFYPKPVWVMWMRG\nEQEQQGTQRGDILPSADGTWYLRATLEVAAGEAADLSCRVKHSSLEGQDIVLYWEHHSSV\nGFIILAVIVPLLLLIGLALWFRKRCFC'], 'gene-sequence': ['>lcl|BSEQ0010416|T-cell surface glycoprotein CD1a (CD1A)\nATGCTGTTTTTGCTACTTCCATTGTTAGCTGTTCTCCCAGGTGATGGCAATGCAGACGGG\nCTCAAGGAGCCTCTCTCCTTCCATGTCACCTGGATCGCATCCTTTTACAACCATTCCTGG\nAAACAAAATCTGGTCTCAGGTTGGCTGAGTGATTTGCAGACTCATACCTGGGACAGCAAT\nTCCAGCACCATCGTTTTCCTGTGCCCCTGGTCCAGGGGAAACTTCAGCAATGAGGAGTGG\nAAGGAACTGGAAACATTATTCCGTATACGCACCATTCGGTCATTTGAGGGAATTCGTAGA\nTACGCCCATGAATTGCAGTTTGAATATCCTTTTGAGATACAGGTGACAGGAGGCTGTGAG\nCTGCACTCTGGAAAGGTCTCAGGAAGCTTCTTGCAGTTAGCTTATCAAGGATCAGACTTT\nGTGAGCTTCCAGAACAATTCATGGTTGCCATATCCAGTGGCTGGGAATATGGCCAAGCAT\nTTCTGCAAAGTGCTCAATCAGAATCAGCATGAAAATGACATAACACACAATCTTCTCAGT\nGACACCTGCCCACGTTTCATCTTGGGTCTTCTTGATGCAGGAAAGGCACATCTCCAGCGG\nCAAGTGAAGCCCGAGGCCTGGCTGTCCCATGGCCCCAGTCCTGGCCCTGGCCATCTGCAG\nCTTGTGTGCCATGTCTCAGGATTCTACCCAAAGCCCGTGTGGGTGATGTGGATGCGGGGT\nGAGCAGGAGCAGCAGGGCACTCAGCGAGGGGACATCTTGCCCAGTGCTGATGGGACATGG\nTATCTCCGCGCAACCCTGGAGGTGGCCGCTGGGGAGGCAGCTGACCTGTCCTGTCGGGTG\nAAGCACAGCAGTCTAGAGGGCCAGGACATCGTCCTCTACTGGGAGCATCACAGTTCCGTG\nGGCTTCATCATCTTGGCGGTGATAGTGCCTTTACTTCTTCTGATAGGTCTTGCGCTTTGG\nTTCAGGAAACGCTGTTTCTGTTAA'], 'pfams': [{'pfam': [{'identifier': ['PF07654'], 'name': ['C1-set']}, {'identifier': ['PF16497'], 'name': ['MHC_I_3']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endosome membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['beta-2-microglobulin binding']}, {'category': ['function'], 'description': ['endogenous lipid antigen binding']}, {'category': ['function'], 'description': ['exogenous lipid antigen binding']}, {'category': ['function'], 'description': ['lipopeptide binding']}, {'category': ['process'], 'description': ['adaptive immune response']}, {'category': ['process'], 'description': ['antigen processing and presentation, exogenous lipid antigen via MHC class Ib']}, {'category': ['process'], 'description': ['immune response']}]}]}]}]}]"
"['DB00099', 'BTD00072', 'BIOD00072', 'DB09560']",['Filgrastim'],biotech,"['Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in _E. Coli_.[L40714] Human G-CSF is a glycoprotein that regulates the production and release of neutrophils from the bone marrow. Filgrastim mimics the biological actions of G-CSF to increase the levels of neutrophils in the blood.[L40719] It has a number of therapeutic uses, including the management and prevention of infections and febrile neutropenia in patients receiving myelosuppressive chemotherapy or radiation therapy. It is also used to manage severe chronic neutropenia and mobilize hematopoietic progenitor cells to the peripheral blood for collection by leukapheresis in patients undergoing peripheral blood progenitor cell collection and therapy.[L40714]\r\n\r\nFilgrastim was approved in the US in 1991 and there are biosimilars available with similar therapeutic indications.[A245858] Tbo-filgrastim was approved by the FDA on August 29, 2012.[L36325] Filgrastim-sndz was approved on March 6, 2015 [L40768] and filgrastim-ayow was approved on March 2, 2022.[L40773] A long-acting, pegylated G-CSF, [pegfilgrastim], was made available to increase the duration of action of the drug.']",['liquid'],"['Filgrastim is indicated to decrease the incidence of infection as manifested by febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.[L40714]\r\n\r\nFilgrastim is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia.[L40714]\r\n\r\nFilgrastim is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae e.g. febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation.[L40714]\r\n\r\nFilgrastim is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis.[L40714]\r\n\r\nFilgrastim is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g. fever infections oropharyngeal ulcers) in symptomatic patients with congenital neutropenia cyclic neutropenia or idiopathic neutropenia.[L40714]\r\n\r\nFilgrastim is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation.[L40714]']","['Neutrophils are critical granulocytes involved in the acute inflammatory response and host defences against bacterial infections.[A245873] They also contribute to long-term adaptive immunity by promoting immediate host immune response and attracting other cells, such as macrophages and dendritic cells. As neutrophils promote both the initiation and the maintenance of inflammation at sites of infection, suppressed neutrophil responses lead to extreme susceptibility to infection.[A35605] Low neutrophil levels, or neutropenia, caused by chronic neutropenia, myelosuppressive chemotherapy, and radiation therapy increases the risk of infection and related events.[A245868] Neutropenia caused by chemotherapy or radiation therapy can further progress into febrile neutropenia, which is associated with an elevated risk for life-threatening systemic infections and chemotherapy-associated morbidity and mortality.[A35591]\r\n\r\nThe production and release of functional neutrophils from the bone marrow are normally regulated by granulocyte colony-stimulating factors (G-CSF), which are major cytokine regulators of neutrophilic granulocytes.[A35605] G-CSFs act on hematopoietic cells by binding to specific cell surface receptors to stimulate the proliferation differentiation and maturation of neutrophil progenitors. G-CSF also induces some end-cell functional activation of neutrophils, including enhanced phagocytic ability priming of the cellular metabolism associated with respiratory burst antibody-dependent killing, and the increased expression of some cell surface antigens.[L40714]  Filgrastim is a short-acting recombinant G-CSF that mimics the biological actions of endogenous G-CSF. It also facilitates the release of neutrophils from the bone marrow into the blood to reduce the incidence of infection and manage neutropenia.[A245858, A245868]']",[None],"[{'target': [{'id': ['BE0000793'], 'name': ['Granulocyte colony-stimulating factor receptor'], 'organism': ['Humans'], 'actions': [{'action': ['stimulator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1792'], 'pubmed-id': ['17001306'], 'citation': ['Erkeland SJ, Aarts LH, Irandoust M, Roovers O, Klomp A, Valkhof M, Gits J, Eyckerman S, Tavernier J, Touw IP: Novel role of WD40 and SOCS box protein-2 in steady-state distribution of granulocyte colony-stimulating factor receptor and G-CSF-controlled proliferation and differentiation signaling. Oncogene. 2007 Mar 29;26(14):1985-94. Epub 2006 Sep 25.']}, {'ref-id': ['A2123'], 'pubmed-id': ['17494858'], 'citation': ['Link DC, Kunter G, Kasai Y, Zhao Y, Miner T, McLellan MD, Ries RE, Kapur D, Nagarajan R, Dale DC, Bolyard AA, Boxer LA, Welte K, Zeidler C, Donadieu J, Bellanne-Chantelot C, Vardiman JW, Caligiuri MA, Bloomfield CD, DiPersio JF, Tomasson MH, Graubert TA, Westervelt P, Watson M, Shannon W, Baty J, Mardis ER, Wilson RK, Ley TJ: Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood. 2007 Sep 1;110(5):1648-55. Epub 2007 May 9.']}, {'ref-id': ['A1800'], 'pubmed-id': ['15949269'], 'citation': ['Cao YR, Shao ZH, Liu H, Shi J, Bai J, Tu MF, Wang HQ, Xing LM, Cui ZZ, Sun J, Jia HR, Yang TY: [The response of bone marrow hematopoietic cells to G-CSF in paroxysmal nocturnal hemoglobinuria patients]. Zhonghua Xue Ye Xue Za Zhi. 2005 Apr;26(4):235-8.']}, {'ref-id': ['A1797'], 'pubmed-id': ['17127322'], 'citation': ['Ward AC: The role of the granulocyte colony-stimulating factor receptor (G-CSF-R) in disease. Front Biosci. 2007 Jan 1;12:608-18.']}, {'ref-id': ['A1798'], 'pubmed-id': ['16033816'], 'citation': ['Zhuang D, Qiu Y, Haque SJ, Dong F: Tyrosine 729 of the G-CSF receptor controls the duration of receptor signaling: involvement of SOCS3 and SOCS1. J Leukoc Biol. 2005 Oct;78(4):1008-15. Epub 2005 Jul 20.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [{'attachment': [{'ref-id': ['F714'], 'title': ['EMA label'], 'url': ['//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/714/original/nivestim_EMA.pdf?1532118975']}, {'ref-id': ['F719'], 'title': ['TBO filgrastim'], 'url': ['//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/719/original/TBO_filgrastim.pdf?1532124628']}]}]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Granulocyte colony-stimulating factor receptor'], 'general-function': ['Receptor activity'], 'specific-function': ['Receptor for granulocyte colony-stimulating factor (CSF3), essential for granulocytic maturation. Plays a crucial role in the proliferation, differientation and survival of cells along the neutrophilic lineage. In addition it may function in some adhesion or recognition events at the cell surface.'], 'gene-name': ['CSF3R'], 'locus': ['1p35-p34.3'], 'cellular-location': ['Secreted'], 'transmembrane-regions': ['628-650'], 'signal-regions': ['1-24'], 'theoretical-pi': ['6.14'], 'molecular-weight': ['92155.615'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:2439']}, {'resource': ['GenAtlas'], 'identifier': ['CSF3R']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X55721']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31697']}, {'resource': ['UniProtKB'], 'identifier': ['Q99062']}, {'resource': ['UniProt Accession'], 'identifier': ['CSF3R_HUMAN']}]}], 'synonyms': [{'synonym': ['G-CSF receptor', 'GCSFR']}], 'amino-acid-sequence': ['>lcl|BSEQ0001582|Granulocyte colony-stimulating factor receptor\nMARLGNCSLTWAALIILLLPGSLEECGHISVSAPIVHLGDPITASCIIKQNCSHLDPEPQ\nILWRLGAELQPGGRQQRLSDGTQESIITLPHLNHTQAFLSCCLNWGNSLQILDQVELRAG\nYPPAIPHNLSCLMNLTTSSLICQWEPGPETHLPTSFTLKSFKSRGNCQTQGDSILDCVPK\nDGQSHCCIPRKHLLLYQNMGIWVQAENALGTSMSPQLCLDPMDVVKLEPPMLRTMDPSPE\nAAPPQAGCLQLCWEPWQPGLHINQKCELRHKPQRGEASWALVGPLPLEALQYELCGLLPA\nTAYTLQIRCIRWPLPGHWSDWSPSLELRTTERAPTVRLDTWWRQRQLDPRTVQLFWKPVP\nLEEDSGRIQGYVVSWRPSGQAGAILPLCNTTELSCTFHLPSEAQEVALVAYNSAGTSRPT\nPVVFSESRGPALTRLHAMARDPHSLWVGWEPPNPWPQGYVIEWGLGPPSASNSNKTWRME\nQNGRATGFLLKENIRPFQLYEIIVTPLYQDTMGPSQHVYAYSQEMAPSHAPELHLKHIGK\nTWAQLEWVPEPPELGKSPLTHYTIFWTNAQNQSFSAILNASSRGFVLHGLEPASLYHIHL\nMAASQAGATNSTVLTLMTLTPEGSELHIILGLFGLLLLLTCLCGTAWLCCSPNRKNPLWP\nSVPDPAHSSLGSWVPTIMEEDAFQLPGLGTPPITKLTVLEEDEKKPVPWESHNSSETCGL\nPTLVQTYVLQGDPRAVSTQPQSQSGTSDQVLYGQLLGSPTSPGPGHYLRCDSTQPLLAGL\nTPSPKSYENLWFQASPLGTLVTPAPSQEDDCVFGPLLNFPLLQGIRVHGMEALGSF'], 'gene-sequence': ['>lcl|BSEQ0010560|Granulocyte colony-stimulating factor receptor (CSF3R)\nATGGCAAGGCTGGGAAACTGCAGCCTGACTTGGGCTGCCCTGATCATCCTGCTGCTCCCC\nGGAAGTCTGGAGGAGTGCGGGCACATCAGTGTCTCAGCCCCCATCGTCCACCTGGGGGAT\nCCCATCACAGCCTCCTGCATCATCAAGCAGAACTGCAGCCATCTGGACCCGGAGCCACAG\nATTCTGTGGAGACTGGGAGCAGAGCTTCAGCCCGGGGGCAGGCAGCAGCGTCTGTCTGAT\nGGGACCCAGGAATCTATCATCACCCTGCCCCACCTCAACCACACTCAGGCCTTTCTCTCC\nTGCTGCCTGAACTGGGGCAACAGCCTGCAGATCCTGGACCAGGTTGAGCTGCGCGCAGGC\nTACCCTCCAGCCATACCCCACAACCTCTCCTGCCTCATGAACCTCACAACCAGCAGCCTC\nATCTGCCAGTGGGAGCCAGGACCTGAGACCCACCTACCCACCAGCTTCACTCTGAAGAGT\nTTCAAGAGCCGGGGCAACTGTCAGACCCAAGGGGACTCCATCCTGGACTGCGTGCCCAAG\nGACGGGCAGAGCCACTGCTGCATCCCACGCAAACACCTGCTGTTGTACCAGAATATGGGC\nATCTGGGTGCAGGCAGAGAATGCGCTGGGGACCAGCATGTCCCCACAACTGTGTCTTGAT\nCCCATGGATGTTGTGAAACTGGAGCCCCCCATGCTGCGGACCATGGACCCCAGCCCTGAA\nGCGGCCCCTCCCCAGGCAGGCTGCCTACAGCTGTGCTGGGAGCCATGGCAGCCAGGCCTG\nCACATAAATCAGAAGTGTGAGCTGCGCCACAAGCCGCAGCGTGGAGAAGCCAGCTGGGCA\nCTGGTGGGCCCCCTCCCCTTGGAGGCCCTTCAGTATGAGCTCTGCGGGCTCCTCCCAGCC\nACGGCCTACACCCTGCAGATACGCTGCATCCGCTGGCCCCTGCCTGGCCACTGGAGCGAC\nTGGAGCCCCAGCCTGGAGCTGAGAACTACCGAACGGGCCCCCACTGTCAGACTGGACACA\nTGGTGGCGGCAGAGGCAGCTGGACCCCAGGACAGTGCAGCTGTTCTGGAAGCCAGTGCCC\nCTGGAGGAAGACAGCGGACGGATCCAAGGTTATGTGGTTTCTTGGAGACCCTCAGGCCAG\nGCTGGGGCCATCCTGCCCCTCTGCAACACCACAGAGCTCAGCTGCACCTTCCACCTGCCT\nTCAGAAGCCCAGGAGGTGGCCCTTGTGGCCTATAACTCAGCCGGGACCTCTCGTCCCACT\nCCGGTGGTCTTCTCAGAAAGCAGAGGCCCAGCTCTGACCAGACTCCATGCCATGGCCCGA\nGACCCTCACAGCCTCTGGGTAGGCTGGGAGCCCCCCAATCCATGGCCTCAGGGCTATGTG\nATTGAGTGGGGCCTGGGCCCCCCCAGCGCGAGCAATAGCAACAAGACCTGGAGGATGGAA\nCAGAATGGGAGAGCCACGGGGTTTCTGCTGAAGGAGAACATCAGGCCCTTTCAGCTCTAT\nGAGATCATCGTGACTCCCTTGTACCAGGACACCATGGGACCCTCCCAGCATGTCTATGCC\nTACTCTCAAGAAATGGCTCCCTCCCATGCCCCAGAGCTGCATCTAAAGCACATTGGCAAG\nACCTGGGCACAGCTGGAGTGGGTGCCTGAGCCCCCTGAGCTGGGGAAGAGCCCCCTTACC\nCACTACACCATCTTCTGGACCAACGCTCAGAACCAGTCCTTCTCCGCCATCCTGAATGCC\nTCCTCCCGTGGCTTTGTCCTCCATGGCCTGGAGCCCGCCAGTCTGTATCACATCCACCTC\nATGGCTGCCAGCCAGGCTGGGGCCACCAACAGTACAGTCCTCACCCTGATGACCTTGACC\nCCAGAGGGGTCGGAGCTACACATCATCCTGGGCCTGTTCGGCCTCCTGCTGTTGCTCACC\nTGCCTCTGTGGAACTGCCTGGCTCTGTTGCAGCCCCAACAGGAAGAATCCCCTCTGGCCA\nAGTGTCCCAGACCCAGCTCACAGCAGCCTGGGCTCCTGGGTGCCCACAATCATGGAGGAG\nGATGCCTTCCAGCTGCCCGGCCTTGGCACGCCACCCATCACCAAGCTCACAGTGCTGGAG\nGAGGATGAAAAGAAGCCGGTGCCCTGGGAGTCCCATAACAGCTCAGAGACCTGTGGCCTC\nCCCACTCTGGTCCAGACCTATGTGCTCCAGGGGGACCCAAGAGCAGTTTCCACCCAGCCC\nCAATCCCAGTCTGGCACCAGCGATCAGGTCCTTTATGGGCAGCTGCTGGGCAGCCCCACA\nAGCCCAGGGCCAGGGCACTATCTCCGCTGTGACTCCACTCAGCCCCTCTTGGCGGGCCTC\nACCCCCAGCCCCAAGTCCTATGAGAACCTCTGGTTCCAGGCCAGCCCCTTGGGGACCCTG\nGTAACCCCAGCCCCAAGCCAGGAGGACGACTGTGTCTTTGGGCCACTGCTCAACTTCCCC\nCTCCTGCAGGGGATCCGGGTCCATGGGATGGAGGCGCTGGGGAGCTTCTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00041'], 'name': ['fn3']}, {'identifier': ['PF06328'], 'name': ['Lep_receptor_Ig']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['function'], 'description': ['cytokine receptor activity']}, {'category': ['function'], 'description': ['receptor activity']}, {'category': ['process'], 'description': ['amelogenesis']}, {'category': ['process'], 'description': ['cell adhesion']}, {'category': ['process'], 'description': ['defense response']}, {'category': ['process'], 'description': ['neutrophil chemotaxis']}, {'category': ['process'], 'description': ['regulation of myeloid cell differentiation']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}]}]"
"['DB00100', 'BTD00038', 'BIOD00038']",['Coagulation Factor IX (Recombinant)'],biotech,"['Recombinant Coagulation Factor IX is a purified Factor IX glycoprotein produced by recombinant DNA technology. It has a primary amino acid sequence that is identical to the Ala148 allelic form of human factor IX, and has structural and functional characteristics similar to those of endogenous factor IX. It is not derived from human blood (unlike human Factor IX complex), and is instead produced by a genetically engineered Chinese hamster ovary (CHO) cell line that secretes recombinant Factor IX into cell medium that is then processed and purified for use as a pharmaceutical agent. \r\n\r\nRecombinant Factor IX is indicated for the control and prevention of bleeding episodes in adult and pediatric patients with congenital factor IX deficiency (Hemophilia B).']",['liquid'],['For treatment of hemophilia (Christmas disease).'],"[""Coagulation Factor IX is an important protein in the process of hemostasis and normal blood clotting as it plays a key role within the coagulation cascade. It is located within the blood plasma as a zymogen, an antecedent to enzymatic function, in its inactivated state. Factor IX is dependent on the presence of Vitamin K, and is activated to a serine protease by the function of Coagulation Factor XIa. Factor XIa cleaves the peptide bond associated with protein activation in Factor IX, leaving Factor IX with two exposed chains, a light chain and a heavy chain. These two chains are held together by several disulfide bonds that reinforce the structure of Factor IX's activated form. After being activated, Factor IX forms a complex with calcium ions, membrane phospholipids and Coagulation Factor VIII to activate Coagulation Factor X. The activation of Factor X then performs a similarly integral step in the blood coagulation cascade. The ultimate result of phenotypically normal coagulation factors is the creation of platelets for normal blood clotting.""]",[None],"[{'target': [{'id': ['BE0000216'], 'name': ['Coagulation factor X'], 'organism': ['Humans'], 'actions': [{'action': ['activator']}], 'references': [{'articles': [{'article': [{'ref-id': ['A2125'], 'pubmed-id': ['1391956'], 'citation': ['Worfolk LA, Robinson RA, Tracy PB: Factor Xa interacts with two sites on monocytes with different functional activities. Blood. 1992 Oct 15;80(8):1989-97.']}, {'ref-id': ['A2126'], 'pubmed-id': ['8083242'], 'citation': ['Jones KC, Mann KG: A model for the tissue factor pathway to thrombin. II. A mathematical simulation. J Biol Chem. 1994 Sep 16;269(37):23367-73.']}, {'ref-id': ['A2128'], 'pubmed-id': ['9079657'], 'citation': ['Ambrosini G, Plescia J, Chu KC, High KA, Altieri DC: Activation-dependent exposure of the inter-EGF sequence Leu83-Leu88 in factor Xa mediates ligand binding to effector cell protease receptor-1. J Biol Chem. 1997 Mar 28;272(13):8340-5.']}, {'ref-id': ['A2131'], 'pubmed-id': ['10933803'], 'citation': ['London FS, Walsh PN: Zymogen factor IX potentiates factor IXa-catalyzed factor X activation. Biochemistry. 2000 Aug 15;39(32):9850-8.']}, {'ref-id': ['A2133'], 'pubmed-id': ['10919405'], 'citation': ['Scandella DH: Properties of anti-factor VIII inhibitor antibodies in hemophilia A patients. Semin Thromb Hemost. 2000;26(2):137-42.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A2134'], 'pubmed-id': ['659613'], 'citation': ['Di Scipio RG, Kurachi K, Davie EW: Activation of human factor IX (Christmas factor). J Clin Invest. 1978 Jun;61(6):1528-38.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Coagulation factor X'], 'general-function': ['Serine-type endopeptidase activity'], 'specific-function': ['Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.'], 'gene-name': ['F10'], 'locus': ['13q34'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-31'], 'theoretical-pi': ['5.74'], 'molecular-weight': ['54731.255'], 'chromosome-location': ['13'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3528']}, {'resource': ['GenAtlas'], 'identifier': ['F10']}, {'resource': ['GenBank Gene Database'], 'identifier': ['K03194']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182841']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2359']}, {'resource': ['UniProtKB'], 'identifier': ['P00742']}, {'resource': ['UniProt Accession'], 'identifier': ['FA10_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.21.6', 'Stuart factor', 'Stuart-Prower factor']}], 'amino-acid-sequence': ['>lcl|BSEQ0010204|Coagulation factor X\nMGRPLHLVLLSASLAGLLLLGESLFIRREQANNILARVTRANSFLEEMKKGHLERECMEE\nTCSYEEAREVFEDSDKTNEFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKN\nCELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLERR\nKRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFDLLDFNQTQPERGDNNLTRIVGGQE\nCKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGE\nAVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGI\nVSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSG\nGPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPE\nVITSSPLK'], 'gene-sequence': ['>lcl|BSEQ0010205|Coagulation factor X (F10)\nATGGGGCGCCCACTGCACCTCGTCCTGCTCAGTGCCTCCCTGGCTGGCCTCCTGCTGCTC\nGGGGAAAGTCTGTTCATCCGCAGGGAGCAGGCCAACAACATCCTGGCGAGGGTCACGAGG\nGCCAATTCCTTTCTTGAAGAGATGAAGAAAGGACACCTCGAAAGAGAGTGCATGGAAGAG\nACCTGCTCATACGAAGAGGCCCGCGAGGTCTTTGAGGACAGCGACAAGACGAATGAATTC\nTGGAATAAATACAAAGATGGCGACCAGTGTGAGACCAGTCCTTGCCAGAACCAGGGCAAA\nTGTAAAGACGGCCTCGGGGAATACACCTGCACCTGTTTAGAAGGATTCGAAGGCAAAAAC\nTGTGAATTATTCACACGGAAGCTCTGCAGCCTGGACAACGGGGACTGTGACCAGTTCTGC\nCACGAGGAACAGAACTCTGTGGTGTGCTCCTGCGCCCGCGGGTACACCCTGGCTGACAAC\nGGCAAGGCCTGCATTCCCACAGGGCCCTACCCCTGTGGGAAACAGACCCTGGAACGCAGG\nAAGAGGTCAGTGGCCCAGGCCACCAGCAGCAGCGGGGAGGCCCCTGACAGCATCACATGG\nAAGCCATATGATGCAGCCGACCTGGACCCCACCGAGAACCCCTTCGACCTGCTTGACTTC\nAACCAGACGCAGCCTGAGAGGGGCGACAACAACCTCACCAGGATCGTGGGAGGCCAGGAA\nTGCAAGGACGGGGAGTGTCCCTGGCAGGCCCTGCTCATCAATGAGGAAAACGAGGGTTTC\nTGTGGTGGAACCATTCTGAGCGAGTTCTACATCCTAACGGCAGCCCACTGTCTCTACCAA\nGCCAAGAGATTCAAGGTGAGGGTAGGGGACCGGAACACGGAGCAGGAGGAGGGCGGTGAG\nGCGGTGCACGAGGTGGAGGTGGTCATCAAGCACAACCGGTTCACAAAGGAGACCTATGAC\nTTCGACATCGCCGTGCTCCGGCTCAAGACCCCCATCACCTTCCGCATGAACGTGGCGCCT\nGCCTGCCTCCCCGAGCGTGACTGGGCCGAGTCCACGCTGATGACGCAGAAGACGGGGATT\nGTGAGCGGCTTCGGGCGCACCCACGAGAAGGGCCGGCAGTCCACCAGGCTCAAGATGCTG\nGAGGTGCCCTACGTGGACCGCAACAGCTGCAAGCTGTCCAGCAGCTTCATCATCACCCAG\nAACATGTTCTGTGCCGGCTACGACACCAAGCAGGAGGATGCCTGCCAGGGGGACAGCGGG\nGGCCCGCACGTCACCCGCTTCAAGGACACCTACTTCGTGACAGGCATCGTCAGCTGGGGA\nGAGGGCTGTGCCCGTAAGGGGAAGTACGGGATCTACACCAAGGTCACCGCCTTCCTCAAG\nTGGATCGACAGGTCCATGAAAACCAGGGGCTTGCCCAAGGCCAAGAGCCATGCCCCGGAG\nGTCATAACGTCCTCTCCATTAAAGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00008'], 'name': ['EGF']}, {'identifier': ['PF00594'], 'name': ['Gla']}, {'identifier': ['PF00089'], 'name': ['Trypsin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['Golgi lumen']}, {'category': ['component'], 'description': ['intrinsic component of external side of plasma membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['phospholipid binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, extrinsic pathway']}, {'category': ['process'], 'description': ['blood coagulation, intrinsic pathway']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['peptidyl-glutamic acid carboxylation']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['proteolysis']}]}]}]}, {'id': ['BE0001021'], 'name': ['Coagulation factor XI'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A11634'], 'pubmed-id': ['10593931'], 'citation': ['Sun MF, Zhao M, Gailani D: Identification of amino acids in the factor XI apple 3 domain required for activation of factor IX. J Biol Chem. 1999 Dec 17;274(51):36373-8.']}, {'ref-id': ['A11635'], 'pubmed-id': ['11342438'], 'citation': ['Gailani D, Ho D, Sun MF, Cheng Q, Walsh PN: Model for a factor IX activation complex on blood platelets: dimeric conformation of factor XIa is essential. Blood. 2001 May 15;97(10):3117-22.']}, {'ref-id': ['A2134'], 'pubmed-id': ['659613'], 'citation': ['Di Scipio RG, Kurachi K, Davie EW: Activation of human factor IX (Christmas factor). J Clin Invest. 1978 Jun;61(6):1528-38.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Coagulation factor XI'], 'general-function': ['Serine-type endopeptidase activity'], 'specific-function': ['Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX.'], 'gene-name': ['F11'], 'locus': ['4q35'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-18'], 'theoretical-pi': ['8.14'], 'molecular-weight': ['70108.56'], 'chromosome-location': ['4'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3529']}, {'resource': ['GenAtlas'], 'identifier': ['F11']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M13142']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182833']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2360']}, {'resource': ['UniProtKB'], 'identifier': ['P03951']}, {'resource': ['UniProt Accession'], 'identifier': ['FA11_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.21.27', 'FXI', 'Plasma thromboplastin antecedent', 'PTA']}], 'amino-acid-sequence': ['>lcl|BSEQ0002033|Coagulation factor XI\nMIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFT\nFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDM\nKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITK\nLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFT\nFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTD\nFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKIL\nHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSI\nIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYD\nIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLV\nTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCA\nQRERPGVYTNVVEYVDWILEKTQAV'], 'gene-sequence': ['>lcl|BSEQ0010715|Coagulation factor XI (F11)\nATGATTTTCTTATATCAAGTGGTACATTTCATTTTATTTACTTCAGTTTCTGGTGAATGT\nGTGACTCAGTTGTTGAAGGACACCTGCTTTGAAGGAGGGGACATTACTACGGTCTTCACA\nCCAAGCGCCAAGTACTGCCAGGTAGTCTGCACTTACCACCCAAGATGTTTACTCTTCACT\nTTCACGGCGGAATCACCATCTGAGGATCCCACCCGATGGTTTACTTGTGTCCTGAAAGAC\nAGTGTTACAGAAACACTGCCAAGAGTGAATAGGACAGCAGCGATTTCTGGGTATTCTTTC\nAAGCAATGCTCACACCAAATAAGCGCTTGCAACAAAGACATTTATGTGGACCTAGACATG\nAAGGGCATAAACTATAACAGCTCAGTTGCCAAGAGTGCTCAAGAATGCCAAGAAAGATGC\nACGGATGACGTCCACTGCCACTTTTTCACGTACGCCACAAGGCAGTTTCCCAGCCTGGAG\nCATCGTAACATTTGTCTACTGAAGCACACCCAAACAGGGACACCAACCAGAATAACGAAG\nCTCGATAAAGTGGTGTCTGGATTTTCACTGAAATCCTGTGCACTTTCTAATCTGGCTTGT\nATTAGGGACATTTTCCCTAATACGGTGTTTGCAGACAGCAACATCGACAGTGTCATGGCT\nCCCGATGCTTTTGTCTGTGGCCGAATCTGCACTCATCATCCCGGTTGCTTGTTTTTTACC\nTTCTTTTCCCAGGAATGGCCCAAAGAATCTCAAAGAAATCTTTGTCTCCTTAAAACATCT\nGAGAGTGGATTGCCCAGTACACGCATTAAAAAGAGCAAAGCTCTTTCTGGTTTCAGTCTA\nCAAAGCTGCAGGCACAGCATCCCAGTGTTCTGCCATTCTTCATTTTACCATGACACTGAT\nTTCTTGGGAGAAGAACTGGATATTGTTGCTGCAAAAAGTCACGAGGCCTGCCAGAAACTG\nTGCACCAATGCCGTCCGCTGCCAGTTTTTTACCTATACCCCAGCCCAAGCATCCTGCAAC\nGAAGGGAAGGGCAAGTGTTACTTAAAGCTTTCTTCAAACGGATCTCCAACTAAAATACTT\nCACGGGAGAGGAGGCATCTCTGGATACACATTAAGGTTGTGTAAAATGGATAATGAGTGT\nACCACCAAAATCAAGCCCAGGATCGTTGGAGGAACTGCGTCTGTTCGTGGTGAGTGGCCG\nTGGCAGGTGACCCTGCACACAACCTCACCCACTCAGAGACACCTGTGTGGAGGCTCCATC\nATTGGAAACCAGTGGATATTAACAGCCGCTCACTGTTTCTATGGGGTAGAGTCACCTAAG\nATTTTGCGTGTCTACAGTGGCATTTTAAATCAATCTGAAATAAAAGAGGACACATCTTTC\nTTTGGGGTTCAAGAAATAATAATCCATGATCAGTATAAAATGGCAGAAAGCGGGTATGAT\nATTGCCTTGTTGAAACTGGAAACCACAGTGAATTACACAGATTCTCAACGACCCATATGC\nCTGCCTTCCAAAGGAGATAGAAATGTAATATACACTGATTGCTGGGTGACTGGATGGGGG\nTACAGAAAACTAAGAGACAAAATACAAAATACTCTCCAGAAAGCCAAGATACCCTTAGTG\nACCAACGAAGAGTGCCAGAAGAGATACAGAGGACATAAAATAACCCATAAGATGATCTGT\nGCCGGCTACAGGGAAGGAGGGAAGGACGCTTGCAAGGGAGATTCGGGAGGCCCTCTGTCC\nTGCAAACACAATGAGGTCTGGCATCTGGTAGGCATCACGAGCTGGGGCGAAGGCTGTGCT\nCAAAGGGAGCGGCCAGGTGTTTACACCAACGTGGTCGAGTACGTGGACTGGATTCTGGAG\nAAAACTCAAGCAGTGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00089'], 'name': ['Trypsin']}, {'identifier': ['PF00024'], 'name': ['PAN_1']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['heparin binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, intrinsic pathway']}, {'category': ['process'], 'description': ['plasminogen activation']}, {'category': ['process'], 'description': ['positive regulation of fibrinolysis']}]}]}]}, {'id': ['BE0000333'], 'name': ['Coagulation factor VII'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13313'], 'pubmed-id': ['10192655'], 'citation': ['Baker DC, Robbe SL, Jacobson L, Manco-Johnson MJ, Holler L, Lefkowitz J: Hereditary deficiency of vitamin-K-dependent coagulation factors in Rambouillet sheep. Blood Coagul Fibrinolysis. 1999 Mar;10(2):75-80.']}, {'ref-id': ['A13314'], 'pubmed-id': ['10381508'], 'citation': ['Hertzberg MS, Facey SL, Hogg PJ: An Arg/Ser substitution in the second epidermal growth factor-like module of factor IX introduces an O-linked carbohydrate and markedly impairs activation by factor XIa and factor VIIa/Tissue factor and catalytic efficiency of factor IXa. Blood. 1999 Jul 1;94(1):156-63.']}, {'ref-id': ['A13308'], 'pubmed-id': ['10498586'], 'citation': ['Butenas S, van\'t Veer C, Mann KG: ""Normal"" thrombin generation. Blood. 1999 Oct 1;94(7):2169-78.']}, {'ref-id': ['A13315'], 'pubmed-id': ['10617609'], 'citation': ['Celie PH, Lenting PJ, Mertens K: Hydrophobic contact between the two epidermal growth factor-like domains of blood coagulation factor IX contributes to enzymatic activity. J Biol Chem. 2000 Jan 7;275(1):229-34.']}, {'ref-id': ['A13157'], 'pubmed-id': ['10938981'], 'citation': ['Shord SS, Lindley CM: Coagulation products and their uses. Am J Health Syst Pharm. 2000 Aug 1;57(15):1403-17; quiz 1418-20.']}, {'ref-id': ['A2134'], 'pubmed-id': ['659613'], 'citation': ['Di Scipio RG, Kurachi K, Davie EW: Activation of human factor IX (Christmas factor). J Clin Invest. 1978 Jun;61(6):1528-38.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Coagulation factor VII'], 'general-function': ['Serine-type peptidase activity'], 'specific-function': ['Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X to factor Xa by limited proteolysis. Factor VIIa will also convert factor IX to factor IXa in the presence of tissue factor and calcium.'], 'gene-name': ['F7'], 'locus': ['13q34'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-20'], 'theoretical-pi': ['7.23'], 'molecular-weight': ['51593.465'], 'chromosome-location': ['13'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3544']}, {'resource': ['GenAtlas'], 'identifier': ['F7']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M13232']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182801']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2363']}, {'resource': ['UniProtKB'], 'identifier': ['P08709']}, {'resource': ['UniProt Accession'], 'identifier': ['FA7_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.21.21', 'Proconvertin', 'Serum prothrombin conversion accelerator', 'SPCA']}], 'amino-acid-sequence': ['>lcl|BSEQ0000663|Coagulation factor VII\nMVSQALRLLCLLLGLQGCLAAGGVAKASGGETRDMPWKPGPHRVFVTQEEAHGVLHRRRR\nANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGS\nCKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSL\nLADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGG\nTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTN\nHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVL\nNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTG\nIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP'], 'gene-sequence': ['>lcl|BSEQ0016066|Coagulation factor VII (F7)\nATGGTCTCCCAGGCCCTCAGGCTCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCCTGGCT\nGCAGGCGGGGTCGCTAAGGCCTCAGGAGGAGAAACACGGGACATGCCGTGGAAGCCGGGG\nCCTCACAGAGTCTTCGTAACCCAGGAGGAAGCCCACGGCGTCCTGCACCGGCGCCGGCGC\nGCCAACGCGTTCCTGGAGGAGCTGCGGCCGGGCTCCCTGGAGAGGGAGTGCAAGGAGGAG\nCAGTGCTCCTTCGAGGAGGCCCGGGAGATCTTCAAGGACGCGGAGAGGACGAAGCTGTTC\nTGGATTTCTTACAGTGATGGGGACCAGTGTGCCTCAAGTCCATGCCAGAATGGGGGCTCC\nTGCAAGGACCAGCTCCAGTCCTATATCTGCTTCTGCCTCCCTGCCTTCGAGGGCCGGAAC\nTGTGAGACGCACAAGGATGACCAGCTGATCTGTGTGAACGAGAACGGCGGCTGTGAGCAG\nTACTGCAGTGACCACACGGGCACCAAGCGCTCCTGTCGGTGCCACGAGGGGTACTCTCTG\nCTGGCAGACGGGGTGTCCTGCACACCCACAGTTGAATATCCATGTGGAAAAATACCTATT\nCTAGAAAAAAGAAATGCCAGCAAACCCCAAGGCCGAATTGTGGGGGGCAAGGTGTGCCCC\nAAAGGGGAGTGTCCATGGCAGGTCCTGTTGTTGGTGAATGGAGCTCAGTTGTGTGGGGGG\nACCCTGATCAACACCATCTGGGTGGTCTCCGCGGCCCACTGTTTCGACAAAATCAAGAAC\nTGGAGGAACCTGATCGCGGTGCTGGGCGAGCACGACCTCAGCGAGCACGACGGGGATGAG\nCAGAGCCGGCGGGTGGCGCAGGTCATCATCCCCAGCACGTACGTCCCGGGCACCACCAAC\nCACGACATCGCGCTGCTCCGCCTGCACCAGCCCGTGGTCCTCACTGACCATGTGGTGCCC\nCTCTGCCTGCCCGAACGGACGTTCTCTGAGAGGACGCTGGCCTTCGTGCGCTTCTCATTG\nGTCAGCGGCTGGGGCCAGCTGCTGGACCGTGGCGCCACGGCCCTGGAGCTCATGGTCCTC\nAACGTGCCCCGGCTGATGACCCAGGACTGCCTGCAGCAGTCACGGAAGGTGGGAGACTCC\nCCAAATATCACGGAGTACATGTTCTGTGCCGGCTACTCGGATGGCAGCAAGGACTCCTGC\nAAGGGGGACAGTGGAGGCCCACATGCCACCCACTACCGGGGCACGTGGTACCTGACGGGC\nATCGTCAGCTGGGGCCAGGGCTGCGCAACCGTGGGCCACTTTGGGGTGTACACCAGGGTC\nTCCCAGTACATCGAGTGGCTGCAAAAGCTCATGCGCTCAGAGCCACGCCCAGGAGTCCTC\nCTGCGAGCCCCATTTCCCTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00008'], 'name': ['EGF']}, {'identifier': ['PF00594'], 'name': ['Gla']}, {'identifier': ['PF00089'], 'name': ['Trypsin']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['Golgi lumen']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['vesicle']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['glycoprotein binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase activity']}, {'category': ['function'], 'description': ['serine-type peptidase activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, extrinsic pathway']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['circadian rhythm']}, {'category': ['process'], 'description': ['organ regeneration']}, {'category': ['process'], 'description': ['peptidyl-glutamic acid carboxylation']}, {'category': ['process'], 'description': ['positive regulation of blood coagulation']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of leukocyte chemotaxis']}, {'category': ['process'], 'description': ['positive regulation of platelet-derived growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of positive chemotaxis']}, {'category': ['process'], 'description': ['positive regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['proteolysis']}, {'category': ['process'], 'description': ['response to estrogen']}, {'category': ['process'], 'description': ['response to growth hormone']}, {'category': ['process'], 'description': ['response to vitamin K']}]}]}]}, {'id': ['BE0000016'], 'name': ['Coagulation factor VIII'], 'organism': ['Humans'], 'actions': [{'action': ['cofactor']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13303'], 'pubmed-id': ['11150722'], 'citation': ['Neels JG, Bovenschen N, van Zonneveld AJ, Lenting PJ: Interaction between factor VIII and LDL receptor-related protein. Modulation of coagulation? Trends Cardiovasc Med. 2000 Jan;10(1):8-14.']}, {'ref-id': ['A13304'], 'pubmed-id': ['12719776'], 'citation': ['Carr ME Jr, Martin EJ, Kuhn JG, Seremetis SV: Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion. Thromb Haemost. 2003 May;89(5):803-11.']}, {'ref-id': ['A13305'], 'pubmed-id': ['12826528'], 'citation': ['Federici AB: The factor VIII/von Willebrand factor complex: basic and clinical issues. Haematologica. 2003 Jun;88(6):EREP02.']}, {'ref-id': ['A13306'], 'pubmed-id': ['14598591'], 'citation': ['Kalashnikova LA, Berkovskii AL, Dobrynina LA, Sergeeva EV, Kozlov AA, Aleksandrova EN, Nasonov EL: [Clotting factor VIII in Sneddon syndrome]. Klin Med (Mosk). 2003;81(9):42-5.']}, {'ref-id': ['A13307'], 'pubmed-id': ['16476097'], 'citation': ['Johansen RF, Sorensen B, Ingerslev J: Acquired haemophilia: dynamic whole blood coagulation utilized to guide haemostatic therapy. Haemophilia. 2006 Mar;12(2):190-7.']}, {'ref-id': ['A2134'], 'pubmed-id': ['659613'], 'citation': ['Di Scipio RG, Kurachi K, Davie EW: Activation of human factor IX (Christmas factor). J Clin Invest. 1978 Jun;61(6):1528-38.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Coagulation factor VIII'], 'general-function': ['Oxidoreductase activity'], 'specific-function': ['Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa.'], 'gene-name': ['F8'], 'locus': ['Xq28'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-19'], 'theoretical-pi': ['7.37'], 'molecular-weight': ['267007.42'], 'chromosome-location': ['X'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3546']}, {'resource': ['GenAtlas'], 'identifier': ['F8']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M14113']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182818']}, {'resource': ['UniProtKB'], 'identifier': ['P00451']}, {'resource': ['UniProt Accession'], 'identifier': ['FA8_HUMAN']}]}], 'synonyms': [{'synonym': ['AHF', 'Antihemophilic factor', 'F8C', 'Procoagulant component']}], 'amino-acid-sequence': ['>lcl|BSEQ0000032|Coagulation factor VIII\nMQIELSTCFFLCLLRFCFSATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFN\nTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAV\nGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSH\nVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRD\nAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNH\nRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNE\nEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLA\nPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTL\nLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGP\nTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDE\nNRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILS\nIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRG\nMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNSRHPSTRQKQFNATTI\nPENDIEKTDPWFAHRTPMPKIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKYETFSDDPS\nPGAIDSNNSLSEMTHFRPQLHHSGDMVFTPESGLQLRLNEKLGTTAATELKKLDFKVSST\nSNNLISTIPSDNLAAGTDNTSSLGPPSMPVHYDSQLDTTLFGKKSSPLTESGGPLSLSEE\nNNDSKLLESGLMNSQESSWGKNVSSTESGRLFKGKRAHGPALLTKDNALFKVSISLLKTN\nKTSNNSATNRKTHIDGPSLLIENSPSVWQNILESDTEFKKVTPLIHDRMLMDKNATALRL\nNHMSNKTTSSKNMEMVQQKKEGPIPPDAQNPDMSFFKMLFLPESARWIQRTHGKNSLNSG\nQGPSPKQLVSLGPEKSVEGQNFLSEKNKVVVGKGEFTKDVGLKEMVFPSSRNLFLTNLDN\nLHENNTHNQEKKIQEEIEKKETLIQENVVLPQIHTVTGTKNFMKNLFLLSTRQNVEGSYD\nGAYAPVLQDFRSLNDSTNRTKKHTAHFSKKGEEENLEGLGNQTKQIVEKYACTTRISPNT\nSQQNFVTQRSKRALKQFRLPLEETELEKRIIVDDTSTQWSKNMKHLTPSTLTQIDYNEKE\nKGAITQSPLSDCLTRSHSIPQANRSPLPIAKVSSFPSIRPIYLTRVLFQDNSSHLPAASY\nRKKDSGVQESSHFLQGAKKNNLSLAILTLEMTGDQREVGSLGTSATNSVTYKKVENTVLP\nKPDLPKTSGKVELLPKVHIYQKDLFPTETSNGSPGHLDLVEGSLLQGTEGAIKWNEANRP\nGKVPFLRVATESSAKTPSKLLDPLAWDNHYGTQIPKEEWKSQEKSPEKTAFKKKDTILSL\nNACESNHAIAAINEGQNKPEIEVTWAKQGRTERLCSQNPPVLKRHQREITRTTLQSDQEE\nIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNR\nAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASR\nPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDV\nDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRA\nPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGH\nVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKC\nQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMII\nHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFN\nPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFA\nTWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFL\nISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRM\nEVLGCEAQDLY'], 'gene-sequence': ['>lcl|BSEQ0015996|Coagulation factor VIII (F8)\nATGCAAATAGAGCTCTCCACCTGCTTCTTTCTGTGCCTTTTGCGATTCTGCTTTAGTGCC\nACCAGAAGATACTACCTGGGTGCAGTGGAACTGTCATGGGACTATATGCAAAGTGATCTC\nGGTGAGCTGCCTGTGGACGCAAGATTTCCTCCTAGAGTGCCAAAATCTTTTCCATTCAAC\nACCTCAGTCGTGTACAAAAAGACTCTGTTTGTAGAATTCACGGATCACCTTTTCAACATC\nGCTAAGCCAAGGCCACCCTGGATGGGTCTGCTAGGTCCTACCATCCAGGCTGAGGTTTAT\nGATACAGTGGTCATTACACTTAAGAACATGGCTTCCCATCCTGTCAGTCTTCATGCTGTT\nGGTGTATCCTACTGGAAAGCTTCTGAGGGAGCTGAATATGATGATCAGACCAGTCAAAGG\nGAGAAAGAAGATGATAAAGTCTTCCCTGGTGGAAGCCATACATATGTCTGGCAGGTCCTG\nAAAGAGAATGGTCCAATGGCCTCTGACCCACTGTGCCTTACCTACTCATATCTTTCTCAT\nGTGGACCTGGTAAAAGACTTGAATTCAGGCCTCATTGGAGCCCTACTAGTATGTAGAGAA\nGGGAGTCTGGCCAAGGAAAAGACACAGACCTTGCACAAATTTATACTACTTTTTGCTGTA\nTTTGATGAAGGGAAAAGTTGGCACTCAGAAACAAAGAACTCCTTGATGCAGGATAGGGAT\nGCTGCATCTGCTCGGGCCTGGCCTAAAATGCACACAGTCAATGGTTATGTAAACAGGTCT\nCTGCCAGGTCTGATTGGATGCCACAGGAAATCAGTCTATTGGCATGTGATTGGAATGGGC\nACCACTCCTGAAGTGCACTCAATATTCCTCGAAGGTCACACATTTCTTGTGAGGAACCAT\nCGCCAGGCGTCCTTGGAAATCTCGCCAATAACTTTCCTTACTGCTCAAACACTCTTGATG\nGACCTTGGACAGTTTCTACTGTTTTGTCATATCTCTTCCCACCAACATGATGGCATGGAA\nGCTTATGTCAAAGTAGACAGCTGTCCAGAGGAACCCCAACTACGAATGAAAAATAATGAA\nGAAGCGGAAGACTATGATGATGATCTTACTGATTCTGAAATGGATGTGGTCAGGTTTGAT\nGATGACAACTCTCCTTCCTTTATCCAAATTCGCTCAGTTGCCAAGAAGCATCCTAAAACT\nTGGGTACATTACATTGCTGCTGAAGAGGAGGACTGGGACTATGCTCCCTTAGTCCTCGCC\nCCCGATGACAGAAGTTATAAAAGTCAATATTTGAACAATGGCCCTCAGCGGATTGGTAGG\nAAGTACAAAAAAGTCCGATTTATGGCATACACAGATGAAACCTTTAAGACTCGTGAAGCT\nATTCAGCATGAATCAGGAATCTTGGGACCTTTACTTTATGGGGAAGTTGGAGACACACTG\nTTGATTATATTTAAGAATCAAGCAAGCAGACCATATAACATCTACCCTCACGGAATCACT\nGATGTCCGTCCTTTGTATTCAAGGAGATTACCAAAAGGTGTAAAACATTTGAAGGATTTT\nCCAATTCTGCCAGGAGAAATATTCAAATATAAATGGACAGTGACTGTAGAAGATGGGCCA\nACTAAATCAGATCCTCGGTGCCTGACCCGCTATTACTCTAGTTTCGTTAATATGGAGAGA\nGATCTAGCTTCAGGACTCATTGGCCCTCTCCTCATCTGCTACAAAGAATCTGTAGATCAA\nAGAGGAAACCAGATAATGTCAGACAAGAGGAATGTCATCCTGTTTTCTGTATTTGATGAG\nAACCGAAGCTGGTACCTCACAGAGAATATACAACGCTTTCTCCCCAATCCAGCTGGAGTG\nCAGCTTGAGGATCCAGAGTTCCAAGCCTCCAACATCATGCACAGCATCAATGGCTATGTT\nTTTGATAGTTTGCAGTTGTCAGTTTGTTTGCATGAGGTGGCATACTGGTACATTCTAAGC\nATTGGAGCACAGACTGACTTCCTTTCTGTCTTCTTCTCTGGATATACCTTCAAACACAAA\nATGGTCTATGAAGACACACTCACCCTATTCCCATTCTCAGGAGAAACTGTCTTCATGTCG\nATGGAAAACCCAGGTCTATGGATTCTGGGGTGCCACAACTCAGACTTTCGGAACAGAGGC\nATGACCGCCTTACTGAAGGTTTCTAGTTGTGACAAGAACACTGGTGATTATTACGAGGAC\nAGTTATGAAGATATTTCAGCATACTTGCTGAGTAAAAACAATGCCATTGAACCAAGAAGC\nTTCTCCCAGAATTCAAGACACCCTAGCACTAGGCAAAAGCAATTTAATGCCACCACAATT\nCCAGAAAATGACATAGAGAAGACTGACCCTTGGTTTGCACACAGAACACCTATGCCTAAA\nATACAAAATGTCTCCTCTAGTGATTTGTTGATGCTCTTGCGACAGAGTCCTACTCCACAT\nGGGCTATCCTTATCTGATCTCCAAGAAGCCAAATATGAGACTTTTTCTGATGATCCATCA\nCCTGGAGCAATAGACAGTAATAACAGCCTGTCTGAAATGACACACTTCAGGCCACAGCTC\nCATCACAGTGGGGACATGGTATTTACCCCTGAGTCAGGCCTCCAATTAAGATTAAATGAG\nAAACTGGGGACAACTGCAGCAACAGAGTTGAAGAAACTTGATTTCAAAGTTTCTAGTACA\nTCAAATAATCTGATTTCAACAATTCCATCAGACAATTTGGCAGCAGGTACTGATAATACA\nAGTTCCTTAGGACCCCCAAGTATGCCAGTTCATTATGATAGTCAATTAGATACCACTCTA\nTTTGGCAAAAAGTCATCTCCCCTTACTGAGTCTGGTGGACCTCTGAGCTTGAGTGAAGAA\nAATAATGATTCAAAGTTGTTAGAATCAGGTTTAATGAATAGCCAAGAAAGTTCATGGGGA\nAAAAATGTATCGTCAACAGAGAGTGGTAGGTTATTTAAAGGGAAAAGAGCTCATGGACCT\nGCTTTGTTGACTAAAGATAATGCCTTATTCAAAGTTAGCATCTCTTTGTTAAAGACAAAC\nAAAACTTCCAATAATTCAGCAACTAATAGAAAGACTCACATTGATGGCCCATCATTATTA\nATTGAGAATAGTCCATCAGTCTGGCAAAATATATTAGAAAGTGACACTGAGTTTAAAAAA\nGTGACACCTTTGATTCATGACAGAATGCTTATGGACAAAAATGCTACAGCTTTGAGGCTA\nAATCATATGTCAAATAAAACTACTTCATCAAAAAACATGGAAATGGTCCAACAGAAAAAA\nGAGGGCCCCATTCCACCAGATGCACAAAATCCAGATATGTCGTTCTTTAAGATGCTATTC\nTTGCCAGAATCAGCAAGGTGGATACAAAGGACTCATGGAAAGAACTCTCTGAACTCTGGG\nCAAGGCCCCAGTCCAAAGCAATTAGTATCCTTAGGACCAGAAAAATCTGTGGAAGGTCAG\nAATTTCTTGTCTGAGAAAAACAAAGTGGTAGTAGGAAAGGGTGAATTTACAAAGGACGTA\nGGACTCAAAGAGATGGTTTTTCCAAGCAGCAGAAACCTATTTCTTACTAACTTGGATAAT\nTTACATGAAAATAATACACACAATCAAGAAAAAAAAATTCAGGAAGAAATAGAAAAGAAG\nGAAACATTAATCCAAGAGAATGTAGTTTTGCCTCAGATACATACAGTGACTGGCACTAAG\nAATTTCATGAAGAACCTTTTCTTACTGAGCACTAGGCAAAATGTAGAAGGTTCATATGAC\nGGGGCATATGCTCCAGTACTTCAAGATTTTAGGTCATTAAATGATTCAACAAATAGAACA\nAAGAAACACACAGCTCATTTCTCAAAAAAAGGGGAGGAAGAAAACTTGGAAGGCTTGGGA\nAATCAAACCAAGCAAATTGTAGAGAAATATGCATGCACCACAAGGATATCTCCTAATACA\nAGCCAGCAGAATTTTGTCACGCAACGTAGTAAGAGAGCTTTGAAACAATTCAGACTCCCA\nCTAGAAGAAACAGAACTTGAAAAAAGGATAATTGTGGATGACACCTCAACCCAGTGGTCC\nAAAAACATGAAACATTTGACCCCGAGCACCCTCACACAGATAGACTACAATGAGAAGGAG\nAAAGGGGCCATTACTCAGTCTCCCTTATCAGATTGCCTTACGAGGAGTCATAGCATCCCT\nCAAGCAAATAGATCTCCATTACCCATTGCAAAGGTATCATCATTTCCATCTATTAGACCT\nATATATCTGACCAGGGTCCTATTCCAAGACAACTCTTCTCATCTTCCAGCAGCATCTTAT\nAGAAAGAAAGATTCTGGGGTCCAAGAAAGCAGTCATTTCTTACAAGGAGCCAAAAAAAAT\nAACCTTTCTTTAGCCATTCTAACCTTGGAGATGACTGGTGATCAAAGAGAGGTTGGCTCC\nCTGGGGACAAGTGCCACAAATTCAGTCACATACAAGAAAGTTGAGAACACTGTTCTCCCG\nAAACCAGACTTGCCCAAAACATCTGGCAAAGTTGAATTGCTTCCAAAAGTTCACATTTAT\nCAGAAGGACCTATTCCCTACGGAAACTAGCAATGGGTCTCCTGGCCATCTGGATCTCGTG\nGAAGGGAGCCTTCTTCAGGGAACAGAGGGAGCGATTAAGTGGAATGAAGCAAACAGACCT\nGGAAAAGTTCCCTTTCTGAGAGTAGCAACAGAAAGCTCTGCAAAGACTCCCTCCAAGCTA\nTTGGATCCTCTTGCTTGGGATAACCACTATGGTACTCAGATACCAAAAGAAGAGTGGAAA\nTCCCAAGAGAAGTCACCAGAAAAAACAGCTTTTAAGAAAAAGGATACCATTTTGTCCCTG\nAACGCTTGTGAAAGCAATCATGCAATAGCAGCAATAAATGAGGGACAAAATAAGCCCGAA\nATAGAAGTCACCTGGGCAAAGCAAGGTAGGACTGAAAGGCTGTGCTCTCAAAACCCACCA\nGTCTTGAAACGCCATCAACGGGAAATAACTCGTACTACTCTTCAGTCAGATCAAGAGGAA\nATTGACTATGATGATACCATATCAGTTGAAATGAAGAAGGAAGATTTTGACATTTATGAT\nGAGGATGAAAATCAGAGCCCCCGCAGCTTTCAAAAGAAAACACGACACTATTTTATTGCT\nGCAGTGGAGAGGCTCTGGGATTATGGGATGAGTAGCTCCCCACATGTTCTAAGAAACAGG\nGCTCAGAGTGGCAGTGTCCCTCAGTTCAAGAAAGTTGTTTTCCAGGAATTTACTGATGGC\nTCCTTTACTCAGCCCTTATACCGTGGAGAACTAAATGAACATTTGGGACTCCTGGGGCCA\nTATATAAGAGCAGAAGTTGAAGATAATATCATGGTAACTTTCAGAAATCAGGCCTCTCGT\nCCCTATTCCTTCTATTCTAGCCTTATTTCTTATGAGGAAGATCAGAGGCAAGGAGCAGAA\nCCTAGAAAAAACTTTGTCAAGCCTAATGAAACCAAAACTTACTTTTGGAAAGTGCAACAT\nCATATGGCACCCACTAAAGATGAGTTTGACTGCAAAGCCTGGGCTTATTTCTCTGATGTT\nGACCTGGAAAAAGATGTGCACTCAGGCCTGATTGGACCCCTTCTGGTCTGCCACACTAAC\nACACTGAACCCTGCTCATGGGAGACAAGTGACAGTACAGGAATTTGCTCTGTTTTTCACC\nATCTTTGATGAGACCAAAAGCTGGTACTTCACTGAAAATATGGAAAGAAACTGCAGGGCT\nCCCTGCAATATCCAGATGGAAGATCCCACTTTTAAAGAGAATTATCGCTTCCATGCAATC\nAATGGCTACATAATGGATACACTACCTGGCTTAGTAATGGCTCAGGATCAAAGGATTCGA\nTGGTATCTGCTCAGCATGGGCAGCAATGAAAACATCCATTCTATTCATTTCAGTGGACAT\nGTGTTCACTGTACGAAAAAAAGAGGAGTATAAAATGGCACTGTACAATCTCTATCCAGGT\nGTTTTTGAGACAGTGGAAATGTTACCATCCAAAGCTGGAATTTGGCGGGTGGAATGCCTT\nATTGGCGAGCATCTACATGCTGGGATGAGCACACTTTTTCTGGTGTACAGCAATAAGTGT\nCAGACTCCCCTGGGAATGGCTTCTGGACACATTAGAGATTTTCAGATTACAGCTTCAGGA\nCAATATGGACAGTGGGCCCCAAAGCTGGCCAGACTTCATTATTCCGGATCAATCAATGCC\nTGGAGCACCAAGGAGCCCTTTTCTTGGATCAAGGTGGATCTGTTGGCACCAATGATTATT\nCACGGCATCAAGACCCAGGGTGCCCGTCAGAAGTTCTCCAGCCTCTACATCTCTCAGTTT\nATCATCATGTATAGTCTTGATGGGAAGAAGTGGCAGACTTATCGAGGAAATTCCACTGGA\nACCTTAATGGTCTTCTTTGGCAATGTGGATTCATCTGGGATAAAACACAATATTTTTAAC\nCCTCCAATTATTGCTCGATACATCCGTTTGCACCCAACTCATTATAGCATTCGCAGCACT\nCTTCGCATGGAGTTGATGGGCTGTGATTTAAATAGTTGCAGCATGCCATTGGGAATGGAG\nAGTAAAGCAATATCAGATGCACAGATTACTGCTTCATCCTACTTTACCAATATGTTTGCC\nACCTGGTCTCCTTCAAAAGCTCGACTTCACCTCCAAGGGAGGAGTAATGCCTGGAGACCT\nCAGGTGAATAATCCAAAAGAGTGGCTGCAAGTGGACTTCCAGAAGACAATGAAAGTCACA\nGGAGTAACTACTCAGGGAGTAAAATCTCTGCTTACCAGCATGTATGTGAAGGAGTTCCTC\nATCTCCAGCAGTCAAGATGGCCATCAGTGGACTCTCTTTTTTCAGAATGGCAAAGTAAAG\nGTTTTTCAGGGAAATCAAGACTCCTTCACACCTGTGGTGAACTCTCTAGACCCACCGTTA\nCTGACTCGCTACCTTCGAATTCACCCCCAGAGTTGGGTGCACCAGATTGCCCTGAGGATG\nGAGGTTCTGGGCTGCGAGGCACAGGACCTCTACTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00394'], 'name': ['Cu-oxidase']}, {'identifier': ['PF07731'], 'name': ['Cu-oxidase_2']}, {'identifier': ['PF07732'], 'name': ['Cu-oxidase_3']}, {'identifier': ['PF00754'], 'name': ['F5_F8_type_C']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['endoplasmic reticulum-Golgi intermediate compartment membrane']}, {'category': ['component'], 'description': ['ER to Golgi transport vesicle']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['Golgi membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['function'], 'description': ['copper ion binding']}, {'category': ['function'], 'description': ['oxidoreductase activity']}, {'category': ['process'], 'description': ['acute-phase response']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, intrinsic pathway']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['COPII vesicle coating']}, {'category': ['process'], 'description': ['ER to Golgi vesicle-mediated transport']}, {'category': ['process'], 'description': ['membrane organization']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['protein N-linked glycosylation via asparagine']}]}]}]}, {'id': ['BE0000048'], 'name': ['Prothrombin'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13308'], 'pubmed-id': ['10498586'], 'citation': ['Butenas S, van\'t Veer C, Mann KG: ""Normal"" thrombin generation. Blood. 1999 Oct 1;94(7):2169-78.']}, {'ref-id': ['A13309'], 'pubmed-id': ['10499904'], 'citation': ['Kohler M: Thrombogenicity of prothrombin complex concentrates. Thromb Res. 1999 Aug 15;95(4 Suppl 1):S13-7.']}, {'ref-id': ['A13310'], 'pubmed-id': ['10499905'], 'citation': ['Seitz R, Dodt J: Virus safety of prothrombin complex concentrates and factor IX concentrates. Thromb Res. 1999 Aug 15;95(4 Suppl 1):S19-23.']}, {'ref-id': ['A13311'], 'pubmed-id': ['10648407'], 'citation': ['Samis JA, Ramsey GD, Walker JB, Nesheim ME, Giles AR: Proteolytic processing of human coagulation factor IX by plasmin. Blood. 2000 Feb 1;95(3):943-51.']}, {'ref-id': ['A13312'], 'pubmed-id': ['11019961'], 'citation': ['Bauer KA, Humphries S, Smillie B, Li L, Cooper JA, Barzegar S, Rosenberg RD, Miller GJ: Prothrombin activation is increased among asymptomatic carriers of the prothrombin G20210A and factor V Arg506Gln mutations. Thromb Haemost. 2000 Sep;84(3):396-400.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Prothrombin'], 'general-function': ['Thrombospondin receptor activity'], 'specific-function': ['Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.'], 'gene-name': ['F2'], 'locus': ['11p11-q12'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-24'], 'theoretical-pi': ['5.7'], 'molecular-weight': ['70036.295'], 'chromosome-location': ['11'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3535']}, {'resource': ['GenAtlas'], 'identifier': ['F2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M17262']}, {'resource': ['GenBank Protein Database'], 'identifier': ['339641']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2362']}, {'resource': ['UniProtKB'], 'identifier': ['P00734']}, {'resource': ['UniProt Accession'], 'identifier': ['THRB_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.21.5', 'Coagulation factor II']}], 'amino-acid-sequence': ['>lcl|BSEQ0016004|Prothrombin\nMAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC\nVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV\nNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE\nCSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA\nQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG\nDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI\nDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN\nDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP\nVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST\nRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY\nGFYTHVFRLKKWIQKVIDQFGE'], 'gene-sequence': ['>lcl|BSEQ0016005|Prothrombin (F2)\nATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC\nCTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG\nGTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGC\nGTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG\nGATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT\nGCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG\nAACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT\nGAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC\nGACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA\nTGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA\nGGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG\nTACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA\nCAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC\nTTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT\nGGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA\nGATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC\nCAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT\nCTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC\nGACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG\nCTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG\nGTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT\nGACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACCAGGTACGAGCGAAACATTGAAAAG\nATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC\nCGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT\nGTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG\nGTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC\nAGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC\nCGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA\nGGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC\nCGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT\nGGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT\nGGAGAGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00594'], 'name': ['Gla']}, {'identifier': ['PF00051'], 'name': ['Kringle']}, {'identifier': ['PF00089'], 'name': ['Trypsin']}, {'identifier': ['PF09396'], 'name': ['Thrombin_light']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular matrix']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['Golgi lumen']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['growth factor activity']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase activity']}, {'category': ['function'], 'description': ['thrombospondin receptor activity']}, {'category': ['process'], 'description': ['acute-phase response']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, intrinsic pathway']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['cellular response to mechanical stimulus']}, {'category': ['process'], 'description': ['cytosolic calcium ion homeostasis']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['multicellular organismal development']}, {'category': ['process'], 'description': ['negative regulation of astrocyte differentiation']}, {'category': ['process'], 'description': ['negative regulation of fibrinolysis']}, {'category': ['process'], 'description': ['negative regulation of platelet activation']}, {'category': ['process'], 'description': ['negative regulation of proteolysis']}, {'category': ['process'], 'description': ['peptidyl-glutamic acid carboxylation']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['positive regulation of blood coagulation']}, {'category': ['process'], 'description': ['positive regulation of cell growth']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of collagen biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of phosphatidylinositol 3-kinase signaling']}, {'category': ['process'], 'description': ['positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of reactive oxygen species metabolic process']}, {'category': ['process'], 'description': ['positive regulation of release of sequestered calcium ion into cytosol']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['proteolysis']}, {'category': ['process'], 'description': ['regulation of blood coagulation']}, {'category': ['process'], 'description': ['regulation of cell shape']}, {'category': ['process'], 'description': ['regulation of gene expression']}, {'category': ['process'], 'description': ['response to inactivity']}, {'category': ['process'], 'description': ['response to wounding']}]}]}]}, {'id': ['BE0002110'], 'name': ['Prolow-density lipoprotein receptor-related protein 1'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A13321'], 'pubmed-id': ['12522212'], 'citation': ['Rohlena J, Kolkman JA, Boertjes RC, Mertens K, Lenting PJ: Residues Phe342-Asn346 of activated coagulation factor IX contribute to the interaction with low density lipoprotein receptor-related protein. J Biol Chem. 2003 Mar 14;278(11):9394-401. Epub 2003 Jan 9.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Prolow-density lipoprotein receptor-related protein 1'], 'general-function': ['Receptor activity'], 'specific-function': ['Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells. Required for early embryonic development. Involved in cellular lipid homeostasis. Involved in the plasma clearance of chylomicron remnants and activated LRPAP1 (alpha 2-macroglobulin), as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate cellular events, such as APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission.Functions as a receptor for Pseudomonas aeruginosa exotoxin A.'], 'gene-name': ['LRP1'], 'locus': ['12q13-q14'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['4420-4444'], 'signal-regions': ['1-19'], 'theoretical-pi': ['5.02'], 'molecular-weight': ['504601.695'], 'chromosome-location': ['12'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6692']}, {'resource': ['GenAtlas'], 'identifier': ['LRP1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X13916']}, {'resource': ['GenBank Protein Database'], 'identifier': ['34339']}, {'resource': ['UniProtKB'], 'identifier': ['Q07954']}, {'resource': ['UniProt Accession'], 'identifier': ['LRP1_HUMAN']}]}], 'synonyms': [{'synonym': ['A2MR', 'Alpha-2-macroglobulin receptor', 'APOER', 'Apolipoprotein E receptor', 'APR', 'LRP-1']}], 'amino-acid-sequence': ['>lcl|BSEQ0037158|Prolow-density lipoprotein receptor-related protein 1\nMLTPPLLLLLPLLSALVAAAIDAPKTCSPKQFACRDQITCISKGWRCDGERDCPDGSDEA\nPEICPQSKAQRCQPNEHNCLGTELCVPMSRLCNGVQDCMDGSDEGPHCRELQGNCSRLGC\nQHHCVPTLDGPTCYCNSSFQLQADGKTCKDFDECSVYGTCSQLCTNTDGSFICGCVEGYL\nLQPDNRSCKAKNEPVDRPPVLLIANSQNILATYLSGAQVSTITPTSTRQTTAMDFSYANE\nTVCWVHVGDSAAQTQLKCARMPGLKGFVDEHTINISLSLHHVEQMAIDWLTGNFYFVDDI\nDDRIFVCNRNGDTCVTLLDLELYNPKGIALDPAMGKVFFTDYGQIPKVERCDMDGQNRTK\nLVDSKIVFPHGITLDLVSRLVYWADAYLDYIEVVDYEGKGRQTIIQGILIEHLYGLTVFE\nNYLYATNSDNANAQQKTSVIRVNRFNSTEYQVVTRVDKGGALHIYHQRRQPRVRSHACEN\nDQYGKPGGCSDICLLANSHKARTCRCRSGFSLGSDGKSCKKPEHELFLVYGKGRPGIIRG\nMDMGAKVPDEHMIPIENLMNPRALDFHAETGFIYFADTTSYLIGRQKIDGTERETILKDG\nIHNVEGVAVDWMGDNLYWTDDGPKKTISVARLEKAAQTRKTLIEGKMTHPRAIVVDPLNG\nWMYWTDWEEDPKDSRRGRLERAWMDGSHRDIFVTSKTVLWPNGLSLDIPAGRLYWVDAFY\nDRIETILLNGTDRKIVYEGPELNHAFGLCHHGNYLFWTEYRSGSVYRLERGVGGAPPTVT\nLLRSERPPIFEIRMYDAQQQQVGTNKCRVNNGGCSSLCLATPGSRQCACAEDQVLDADGV\nTCLANPSYVPPPQCQPGEFACANSRCIQERWKCDGDNDCLDNSDEAPALCHQHTCPSDRF\nKCENNRCIPNRWLCDGDNDCGNSEDESNATCSARTCPPNQFSCASGRCIPISWTCDLDDD\nCGDRSDESASCAYPTCFPLTQFTCNNGRCININWRCDNDNDCGDNSDEAGCSHSCSSTQF\nKCNSGRCIPEHWTCDGDNDCGDYSDETHANCTNQATRPPGGCHTDEFQCRLDGLCIPLRW\nRCDGDTDCMDSSDEKSCEGVTHVCDPSVKFGCKDSARCISKAWVCDGDNDCEDNSDEENC\nESLACRPPSHPCANNTSVCLPPDKLCDGNDDCGDGSDEGELCDQCSLNNGGCSHNCSVAP\nGEGIVCSCPLGMELGPDNHTCQIQSYCAKHLKCSQKCDQNKFSVKCSCYEGWVLEPDGES\nCRSLDPFKPFIIFSNRHEIRRIDLHKGDYSVLVPGLRNTIALDFHLSQSALYWTDVVEDK\nIYRGKLLDNGALTSFEVVIQYGLATPEGLAVDWIAGNIYWVESNLDQIEVAKLDGTLRTT\nLLAGDIEHPRAIALDPRDGILFWTDWDASLPRIEAASMSGAGRRTVHRETGSGGWPNGLT\nVDYLEKRILWIDARSDAIYSARYDGSGHMEVLRGHEFLSHPFAVTLYGGEVYWTDWRTNT\nLAKANKWTGHNVTVVQRTNTQPFDLQVYHPSRQPMAPNPCEANGGQGPCSHLCLINYNRT\nVSCACPHLMKLHKDNTTCYEFKKFLLYARQMEIRGVDLDAPYYNYIISFTVPDIDNVTVL\nDYDAREQRVYWSDVRTQAIKRAFINGTGVETVVSADLPNAHGLAVDWVSRNLFWTSYDTN\nKKQINVARLDGSFKNAVVQGLEQPHGLVVHPLRGKLYWTDGDNISMANMDGSNRTLLFSG\nQKGPVGLAIDFPESKLYWISSGNHTINRCNLDGSGLEVIDAMRSQLGKATALAIMGDKLW\nWADQVSEKMGTCSKADGSGSVVLRNSTTLVMHMKVYDESIQLDHKGTNPCSVNNGDCSQL\nCLPTSETTRSCMCTAGYSLRSGQQACEGVGSFLLYSVHEGIRGIPLDPNDKSDALVPVSG\nTSLAVGIDFHAENDTIYWVDMGLSTISRAKRDQTWREDVVTNGIGRVEGIAVDWIAGNIY\nWTDQGFDVIEVARLNGSFRYVVISQGLDKPRAITVHPEKGYLFWTEWGQYPRIERSRLDG\nTERVVLVNVSISWPNGISVDYQDGKLYWCDARTDKIERIDLETGENREVVLSSNNMDMFS\nVSVFEDFIYWSDRTHANGSIKRGSKDNATDSVPLRTGIGVQLKDIKVFNRDRQKGTNVCA\nVANGGCQQLCLYRGRGQRACACAHGMLAEDGASCREYAGYLLYSERTILKSIHLSDERNL\nNAPVQPFEDPEHMKNVIALAFDYRAGTSPGTPNRIFFSDIHFGNIQQINDDGSRRITIVE\nNVGSVEGLAYHRGWDTLYWTSYTTSTITRHTVDQTRPGAFERETVITMSGDDHPRAFVLD\nECQNLMFWTNWNEQHPSIMRAALSGANVLTLIEKDIRTPNGLAIDHRAEKLYFSDATLDK\nIERCEYDGSHRYVILKSEPVHPFGLAVYGEHIFWTDWVRRAVQRANKHVGSNMKLLRVDI\nPQQPMGIIAVANDTNSCELSPCRINNGGCQDLCLLTHQGHVNCSCRGGRILQDDLTCRAV\nNSSCRAQDEFECANGECINFSLTCDGVPHCKDKSDEKPSYCNSRRCKKTFRQCSNGRCVS\nNMLWCNGADDCGDGSDEIPCNKTACGVGEFRCRDGTCIGNSSRCNQFVDCEDASDEMNCS\nATDCSSYFRLGVKGVLFQPCERTSLCYAPSWVCDGANDCGDYSDERDCPGVKRPRCPLNY\nFACPSGRCIPMSWTCDKEDDCEHGEDETHCNKFCSEAQFECQNHRCISKQWLCDGSDDCG\nDGSDEAAHCEGKTCGPSSFSCPGTHVCVPERWLCDGDKDCADGADESIAAGCLYNSTCDD\nREFMCQNRQCIPKHFVCDHDRDCADGSDESPECEYPTCGPSEFRCANGRCLSSRQWECDG\nENDCHDQSDEAPKNPHCTSQEHKCNASSQFLCSSGRCVAEALLCNGQDDCGDSSDERGCH\nINECLSRKLSGCSQDCEDLKIGFKCRCRPGFRLKDDGRTCADVDECSTTFPCSQRCINTH\nGSYKCLCVEGYAPRGGDPHSCKAVTDEEPFLIFANRYYLRKLNLDGSNYTLLKQGLNNAV\nALDFDYREQMIYWTDVTTQGSMIRRMHLNGSNVQVLHRTGLSNPDGLAVDWVGGNLYWCD\nKGRDTIEVSKLNGAYRTVLVSSGLREPRALVVDVQNGYLYWTDWGDHSLIGRIGMDGSSR\nSVIVDTKITWPNGLTLDYVTERIYWADAREDYIEFASLDGSNRHVVLSQDIPHIFALTLF\nEDYVYWTDWETKSINRAHKTTGTNKTLLISTLHRPMDLHVFHALRQPDVPNHPCKVNNGG\nCSNLCLLSPGGGHKCACPTNFYLGSDGRTCVSNCTASQFVCKNDKCIPFWWKCDTEDDCG\nDHSDEPPDCPEFKCRPGQFQCSTGICTNPAFICDGDNDCQDNSDEANCDIHVCLPSQFKC\nTNTNRCIPGIFRCNGQDNCGDGEDERDCPEVTCAPNQFQCSITKRCIPRVWVCDRDNDCV\nDGSDEPANCTQMTCGVDEFRCKDSGRCIPARWKCDGEDDCGDGSDEPKEECDERTCEPYQ\nFRCKNNRCVPGRWQCDYDNDCGDNSDEESCTPRPCSESEFSCANGRCIAGRWKCDGDHDC\nADGSDEKDCTPRCDMDQFQCKSGHCIPLRWRCDADADCMDGSDEEACGTGVRTCPLDEFQ\nCNNTLCKPLAWKCDGEDDCGDNSDENPEECARFVCPPNRPFRCKNDRVCLWIGRQCDGTD\nNCGDGTDEEDCEPPTAHTTHCKDKKEFLCRNQRCLSSSLRCNMFDDCGDGSDEEDCSIDP\nKLTSCATNASICGDEARCVRTEKAAYCACRSGFHTVPGQPGCQDINECLRFGTCSQLCNN\nTKGGHLCSCARNFMKTHNTCKAEGSEYQVLYIADDNEIRSLFPGHPHSAYEQAFQGDESV\nRIDAMDVHVKAGRVYWTNWHTGTISYRSLPPAAPPTTSNRHRRQIDRGVTHLNISGLKMP\nRGIAIDWVAGNVYWTDSGRDVIEVAQMKGENRKTLISGMIDEPHAIVVDPLRGTMYWSDW\nGNHPKIETAAMDGTLRETLVQDNIQWPTGLAVDYHNERLYWADAKLSVIGSIRLNGTDPI\nVAADSKRGLSHPFSIDVFEDYIYGVTYINNRVFKIHKFGHSPLVNLTGGLSHASDVVLYH\nQHKQPEVTNPCDRKKCEWLCLLSPSGPVCTCPNGKRLDNGTCVPVPSPTPPPDAPRPGTC\nNLQCFNGGSCFLNARRQPKCRCQPRYTGDKCELDQCWEHCRNGGTCAASPSGMPTCRCPT\nGFTGPKCTQQVCAGYCANNSTCTVNQGNQPQCRCLPGFLGDRCQYRQCSGYCENFGTCQM\nAADGSRQCRCTAYFEGSRCEVNKCSRCLEGACVVNKQSGDVTCNCTDGRVAPSCLTCVGH\nCSNGGSCTMNSKMMPECQCPPHMTGPRCEEHVFSQQQPGHIASILIPLLLLLLLVLVAGV\nVFWYKRRVQGAKGFQHQRMTNGAMNVEIGNPTYKMYEGGEPDDVGGLLDADFALDPDKPT\nNFTNPVYATLYMGGHGSRHSLASTDEKRELLGRGPEDEIGDPLA'], 'gene-sequence': ['>lcl|BSEQ0019236|Prolow-density lipoprotein receptor-related protein 1 (LRP1)\nATGCTGACCCCGCCGTTGCTCCTGCTGCTGCCCCTGCTCTCAGCTCTGGTCGCGGCGGCT\nATCGACGCCCCTAAGACTTGCAGCCCCAAGCAGTTTGCCTGCAGAGATCAAATAACCTGT\nATCTCAAAGGGCTGGCGGTGCGACGGTGAGAGGGACTGCCCAGACGGATCTGACGAGGCC\nCCTGAGATTTGTCCACAGAGTAAGGCCCAGCGATGCCAGCCAAACGAGCATAACTGCCTG\nGGTACTGAGCTGTGTGTTCCCATGTCCCGCCTCTGCAATGGGGTCCAGGACTGCATGGAC\nGGCTCAGATGAGGGGCCCCACTGCCGAGAGCTCCAAGGCAACTGCTCTCGCCTGGGCTGC\nCAGCACCATTGTGTCCCCACACTCGATGGGCCCACCTGCTACTGCAACAGCAGCTTTCAG\nCTTCAGGCAGATGGCAAGACCTGCAAAGATTTTGATGAGTGCTCAGTGTACGGCACCTGC\nAGCCAGCTATGCACCAACACAGACGGCTCCTTCATATGTGGCTGTGTTGAAGGATACCTC\nCTGCAGCCGGATAACCGCTCCTGCAAGGCCAAGAACGAGCCAGTAGACCGGCCCCCTGTG\nCTGTTGATAGCCAACTCCCAGAACATCTTGGCCACGTACCTGAGTGGGGCCCAGGTGTCT\nACCATCACACCTACGAGCACGCGGCAGACCACAGCCATGGACTTCAGCTATGCCAACGAG\nACCGTATGCTGGGTGCATGTTGGGGACAGTGCTGCTCAGACGCAGCTCAAGTGTGCCCGC\nATGCCTGGCCTAAAGGGCTTCGTGGATGAGCACACCATCAACATCTCCCTCAGTCTGCAC\nCACGTGGAACAGATGGCCATCGACTGGCTGACAGGCAACTTCTACTTTGTGGATGACATC\nGATGATAGGATCTTTGTCTGCAACAGAAATGGGGACACATGTGTCACATTGCTAGACCTG\nGAACTCTACAACCCCAAGGGCATTGCCCTGGACCCTGCCATGGGGAAGGTGTTTTTCACT\nGACTATGGGCAGATCCCAAAGGTGGAACGCTGTGACATGGATGGGCAGAACCGCACCAAG\nCTCGTCGACAGCAAGATTGTGTTTCCTCATGGCATCACGCTGGACCTGGTCAGCCGCCTT\nGTCTACTGGGCAGATGCCTATCTGGACTATATTGAAGTGGTGGACTATGAGGGCAAGGGC\nCGCCAGACCATCATCCAGGGCATCCTGATTGAGCACCTGTACGGCCTGACTGTGTTTGAG\nAATTATCTCTATGCCACCAACTCGGACAATGCCAATGCCCAGCAGAAGACGAGTGTGATC\nCGTGTGAACCGCTTTAACAGCACCGAGTACCAGGTTGTCACCCGGGTGGACAAGGGTGGT\nGCCCTCCACATCTACCACCAGAGGCGTCAGCCCCGAGTGAGGAGCCATGCCTGTGAAAAC\nGACCAGTATGGGAAGCCGGGTGGCTGCTCTGACATCTGCCTGCTGGCCAACAGCCACAAG\nGCGCGGACCTGCCGCTGCCGTTCCGGCTTCAGCCTGGGCAGTGACGGGAAGTCATGCAAG\nAAGCCGGAGCATGAGCTGTTCCTCGTGTATGGCAAGGGCCGGCCAGGCATCATCCGGGGC\nATGGATATGGGGGCCAAGGTCCCGGATGAGCACATGATCCCCATTGAAAACCTCATGAAC\nCCCCGAGCCCTGGACTTCCACGCTGAGACCGGCTTCATCTACTTTGCCGACACCACCAGC\nTACCTCATTGGCCGCCAGAAGATTGATGGCACTGAGCGGGAGACCATCCTGAAGGACGGC\nATCCACAATGTGGAGGGTGTGGCCGTGGACTGGATGGGAGACAATCTGTACTGGACGGAC\nGATGGGCCCAAAAAGACAATCAGCGTGGCCAGGCTGGAGAAAGCTGCTCAGACCCGCAAG\nACTTTAATCGAGGGCAAAATGACACACCCCAGGGCTATTGTGGTGGATCCACTCAATGGG\nTGGATGTACTGGACAGACTGGGAGGAGGACCCCAAGGACAGTCGGCGTGGGCGGCTGGAG\nAGGGCGTGGATGGATGGCTCACACCGAGACATCTTTGTCACCTCCAAGACAGTGCTTTGG\nCCCAATGGGCTAAGCCTGGACATCCCGGCTGGGCGCCTCTACTGGGTGGATGCCTTCTAC\nGACCGCATCGAGACGATACTGCTCAATGGCACAGACCGGAAGATTGTGTATGAAGGTCCT\nGAGCTGAACCACGCCTTTGGCCTGTGTCACCATGGCAACTACCTCTTCTGGACTGAGTAT\nCGGAGTGGCAGTGTCTACCGCTTGGAACGGGGTGTAGGAGGCGCACCCCCCACTGTGACC\nCTTCTGCGCAGTGAGCGGCCCCCCATCTTTGAGATCCGAATGTATGATGCCCAGCAGCAG\nCAAGTTGGCACCAACAAATGCCGGGTGAACAATGGCGGCTGCAGCAGCCTGTGCTTGGCC\nACCCCTGGGAGCCGCCAGTGCGCCTGTGCTGAGGACCAGGTGTTGGACGCAGACGGCGTC\nACTTGCTTGGCGAACCCATCCTACGTGCCTCCACCCCAGTGCCAGCCAGGCGAGTTTGCC\nTGTGCCAACAGCCGCTGCATCCAGGAGCGCTGGAAGTGTGACGGAGACAACGATTGCCTG\nGACAACAGTGATGAGGCCCCAGCCCTCTGCCATCAGCACACCTGCCCCTCGGACCGATTC\nAAGTGCGAGAACAACCGGTGCATCCCCAACCGCTGGCTCTGCGACGGGGACAATGACTGT\nGGGAACAGTGAAGATGAGTCCAATGCCACTTGTTCAGCCCGCACCTGCCCCCCCAACCAG\nTTCTCCTGTGCCAGTGGCCGCTGCATCCCCATCTCCTGGACGTGTGATCTGGATGACGAC\nTGTGGGGACCGCTCTGATGAGTCTGCTTCGTGTGCCTATCCCACCTGCTTCCCCCTGACT\nCAGTTTACCTGCAACAATGGCAGATGTATCAACATCAACTGGAGATGCGACAATGACAAT\nGACTGTGGGGACAACAGTGACGAAGCCGGCTGCAGCCACTCCTGTTCTAGCACCCAGTTC\nAAGTGCAACAGCGGGCGTTGCATCCCCGAGCACTGGACCTGCGATGGGGACAATGACTGC\nGGAGACTACAGTGATGAGACACACGCCAACTGCACCAACCAGGCCACGAGGCCCCCTGGT\nGGCTGCCACACTGATGAGTTCCAGTGCCGGCTGGATGGACTATGCATCCCCCTGCGGTGG\nCGCTGCGATGGGGACACTGACTGCATGGACTCCAGCGATGAGAAGAGCTGTGAGGGAGTG\nACCCACGTCTGCGATCCCAGTGTCAAGTTTGGCTGCAAGGACTCAGCTCGGTGCATCAGC\nAAAGCGTGGGTGTGTGATGGCGACAATGACTGTGAGGATAACTCGGACGAGGAGAACTGC\nGAGTCCCTGGCCTGCAGGCCACCCTCGCACCCTTGTGCCAACAACACCTCAGTCTGCCTG\nCCCCCTGACAAGCTGTGTGATGGCAACGACGACTGTGGCGACGGCTCAGATGAGGGCGAG\nCTCTGCGACCAGTGCTCTCTGAATAACGGTGGCTGCAGCCACAACTGCTCAGTGGCACCT\nGGCGAAGGCATTGTGTGTTCCTGCCCTCTGGGCATGGAGCTGGGGCCCGACAACCACACC\nTGCCAGATCCAGAGCTACTGTGCCAAGCATCTCAAATGCAGCCAAAAGTGCGACCAGAAC\nAAGTTCAGCGTGAAGTGCTCCTGCTACGAGGGCTGGGTCCTGGAACCTGACGGCGAGAGC\nTGCCGCAGCCTGGACCCCTTCAAGCCGTTCATCATTTTCTCCAACCGCCATGAAATCCGG\nCGCATCGATCTTCACAAAGGAGACTACAGCGTCCTGGTGCCCGGCCTGCGCAACACCATC\nGCCCTGGACTTCCACCTCAGCCAGAGCGCCCTCTACTGGACCGACGTGGTGGAGGACAAG\nATCTACCGCGGGAAGCTGCTGGACAACGGAGCCCTGACTAGTTTCGAGGTGGTGATTCAG\nTATGGCCTGGCCACACCCGAGGGCCTGGCTGTAGACTGGATTGCAGGCAACATCTACTGG\nGTGGAGAGTAACCTGGATCAGATCGAGGTGGCCAAGCTGGATGGGACCCTCCGGACCACC\nCTGCTGGCCGGTGACATTGAGCACCCAAGGGCAATCGCACTGGATCCCCGGGATGGGATC\nCTGTTTTGGACAGACTGGGATGCCAGCCTGCCCCGCATTGAGGCAGCCTCCATGAGTGGG\nGCTGGGCGCCGCACCGTGCACCGGGAGACCGGCTCTGGGGGCTGGCCCAACGGGCTCACC\nGTGGACTACCTGGAGAAGCGCATCCTTTGGATTGACGCCAGGTCAGATGCCATTTACTCA\nGCCCGTTACGACGGCTCTGGCCACATGGAGGTGCTTCGGGGACACGAGTTCCTGTCGCAC\nCCGTTTGCAGTGACGCTGTACGGGGGGGAGGTCTACTGGACTGACTGGCGAACAAACACA\nCTGGCTAAGGCCAACAAGTGGACCGGCCACAATGTCACCGTGGTACAGAGGACCAACACC\nCAGCCCTTTGACCTGCAGGTGTACCACCCCTCCCGCCAGCCCATGGCTCCCAATCCCTGT\nGAGGCCAATGGGGGCCAGGGCCCCTGCTCCCACCTGTGTCTCATCAACTACAACCGGACC\nGTGTCCTGCGCCTGCCCCCACCTCATGAAGCTCCACAAGGACAACACCACCTGCTATGAG\nTTTAAGAAGTTCCTGCTGTACGCACGTCAGATGGAGATCCGAGGTGTGGACCTGGATGCT\nCCCTACTACAACTACATCATCTCCTTCACGGTGCCCGACATCGACAACGTCACAGTGCTA\nGACTACGATGCCCGCGAGCAGCGTGTGTACTGGTCTGACGTGCGGACACAGGCCATCAAG\nCGGGCCTTCATCAACGGCACAGGCGTGGAGACAGTCGTCTCTGCAGACTTGCCAAATGCC\nCACGGGCTGGCTGTGGACTGGGTCTCCCGAAACCTGTTCTGGACAAGCTATGACACCAAT\nAAGAAGCAGATCAATGTGGCCCGGCTGGATGGCTCCTTCAAGAACGCAGTGGTGCAGGGC\nCTGGAGCAGCCCCATGGCCTTGTCGTCCACCCTCTGCGTGGGAAGCTCTACTGGACCGAT\nGGTGACAACATCAGCATGGCCAACATGGATGGCAGCAATCGCACCCTGCTCTTCAGTGGC\nCAGAAGGGCCCCGTGGGCCTGGCTATTGACTTCCCTGAAAGCAAACTCTACTGGATCAGC\nTCCGGGAACCATACCATCAACCGCTGCAACCTGGATGGGAGTGGGCTGGAGGTCATCGAT\nGCCATGCGGAGCCAGCTGGGCAAGGCCACCGCCCTGGCCATCATGGGGGACAAGCTGTGG\nTGGGCTGATCAGGTGTCGGAAAAGATGGGCACATGCAGCAAGGCTGACGGCTCGGGCTCC\nGTGGTCCTTCGGAACAGCACCACCCTGGTGATGCACATGAAGGTCTATGACGAGAGCATC\nCAGCTGGACCATAAGGGCACCAACCCCTGCAGTGTCAACAACGGTGACTGCTCCCAGCTC\nTGCCTGCCCACGTCAGAGACGACCCGCTCCTGCATGTGCACAGCCGGCTATAGCCTCCGG\nAGTGGCCAGCAGGCCTGCGAGGGCGTAGGTTCCTTTCTCCTGTACTCTGTGCATGAGGGA\nATCAGGGGAATTCCCCTGGATCCCAATGACAAGTCAGATGCCCTGGTCCCAGTGTCCGGG\nACCTCGCTGGCTGTCGGCATCGACTTCCACGCTGAAAATGACACCATCTACTGGGTGGAC\nATGGGCCTGAGCACGATCAGCCGGGCCAAGCGGGACCAGACGTGGCGTGAAGACGTGGTG\nACCAATGGCATTGGCCGTGTGGAGGGCATTGCAGTGGACTGGATCGCAGGCAACATCTAC\nTGGACAGACCAGGGCTTTGATGTCATCGAGGTCGCCCGGCTCAATGGCTCCTTCCGCTAC\nGTGGTGATCTCCCAGGGTCTAGACAAGCCCCGGGCCATCACCGTCCACCCGGAGAAAGGG\nTACTTGTTCTGGACTGAGTGGGGTCAGTATCCGCGTATTGAGCGGTCTCGGCTAGATGGC\nACGGAGCGTGTGGTGCTGGTCAACGTCAGCATCAGCTGGCCCAACGGCATCTCAGTGGAC\nTACCAGGATGGGAAGCTGTACTGGTGCGATGCACGGACAGACAAGATTGAACGGATCGAC\nCTGGAGACAGGTGAGAACCGCGAGGTGGTTCTGTCCAGCAACAACATGGACATGTTTTCA\nGTGTCTGTGTTTGAGGATTTCATCTACTGGAGTGACAGGACTCATGCCAACGGCTCTATC\nAAGCGCGGGAGCAAAGACAATGCCACAGACTCCGTGCCCCTGCGAACCGGCATCGGCGTC\nCAGCTTAAAGACATCAAAGTCTTCAACCGGGACCGGCAGAAAGGCACCAACGTGTGCGCG\nGTGGCCAATGGCGGGTGCCAGCAGCTGTGCCTGTACCGGGGCCGTGGGCAGCGGGCCTGC\nGCCTGTGCCCACGGGATGCTGGCTGAAGACGGAGCATCGTGCCGCGAGTATGCCGGCTAC\nCTGCTCTACTCAGAGCGCACCATTCTCAAGAGTATCCACCTGTCGGATGAGCGCAACCTC\nAATGCGCCCGTGCAGCCCTTCGAGGACCCTGAGCACATGAAGAACGTCATCGCCCTGGCC\nTTTGACTACCGGGCAGGCACCTCTCCGGGCACCCCCAATCGCATCTTCTTCAGCGACATC\nCACTTTGGGAACATCCAACAGATCAACGACGATGGCTCCAGGAGGATCACCATTGTGGAA\nAACGTGGGCTCCGTGGAAGGCCTGGCCTATCACCGTGGCTGGGACACTCTCTATTGGACA\nAGCTACACGACATCCACCATCACGCGCCACACAGTGGACCAGACCCGCCCAGGGGCCTTC\nGAGCGTGAGACCGTCATCACTATGTCTGGAGATGACCACCCACGGGCCTTCGTTTTGGAC\nGAGTGCCAGAACCTCATGTTCTGGACCAACTGGAATGAGCAGCATCCCAGCATCATGCGG\nGCGGCGCTCTCGGGAGCCAATGTCCTGACCCTTATCGAGAAGGACATCCGTACCCCCAAT\nGGCCTGGCCATCGACCACCGTGCCGAGAAGCTCTACTTCTCTGACGCCACCCTGGACAAG\nATCGAGCGGTGCGAGTATGACGGCTCCCACCGCTATGTGATCCTAAAGTCAGAGCCTGTC\nCACCCCTTCGGGCTGGCCGTGTATGGGGAGCACATTTTCTGGACTGACTGGGTGCGGCGG\nGCAGTGCAGCGGGCCAACAAGCACGTGGGCAGCAACATGAAGCTGCTGCGCGTGGACATC\nCCCCAGCAGCCCATGGGCATCATCGCCGTGGCCAACGACACCAACAGCTGTGAACTCTCT\nCCATGCCGAATCAACAACGGTGGCTGCCAGGACCTGTGTCTGCTCACTCACCAGGGCCAT\nGTCAACTGCTCATGCCGAGGGGGCCGAATCCTCCAGGATGACCTCACCTGCCGAGCGGTG\nAATTCCTCTTGCCGAGCACAAGATGAGTTTGAGTGTGCCAATGGCGAGTGCATCAACTTC\nAGCCTGACCTGCGACGGCGTCCCCCACTGCAAGGACAAGTCCGATGAGAAGCCATCCTAC\nTGCAACTCCCGCCGCTGCAAGAAGACTTTCCGGCAGTGCAGCAATGGGCGCTGTGTGTCC\nAACATGCTGTGGTGCAACGGGGCCGACGACTGTGGGGATGGCTCTGACGAGATCCCTTGC\nAACAAGACAGCCTGTGGTGTGGGCGAGTTCCGCTGCCGGGACGGGACCTGCATCGGGAAC\nTCCAGCCGCTGCAACCAGTTTGTGGATTGTGAGGACGCCTCAGATGAGATGAACTGCAGT\nGCCACCGACTGCAGCAGCTACTTCCGCCTGGGCGTGAAGGGCGTGCTCTTCCAGCCCTGC\nGAGCGGACCTCACTCTGCTACGCACCCAGCTGGGTGTGTGATGGCGCCAATGACTGTGGG\nGACTACAGTGATGAGCGCGACTGCCCAGGTGTGAAACGCCCCAGATGCCCTCTGAATTAC\nTTCGCCTGCCCTAGTGGGCGCTGCATCCCCATGAGCTGGACGTGTGACAAAGAGGATGAC\nTGTGAACATGGCGAGGACGAGACCCACTGCAACAAGTTCTGCTCAGAGGCCCAGTTTGAG\nTGCCAGAACCATCGCTGCATCTCCAAGCAGTGGCTGTGTGACGGCAGCGATGACTGTGGG\nGATGGCTCAGACGAGGCTGCTCACTGTGAAGGCAAGACGTGCGGCCCCTCCTCCTTCTCC\nTGCCCTGGCACCCACGTGTGCGTCCCCGAGCGCTGGCTCTGTGACGGTGACAAAGACTGT\nGCTGATGGTGCAGACGAGAGCATCGCAGCTGGTTGCTTGTACAACAGCACTTGTGACGAC\nCGTGAGTTCATGTGCCAGAACCGCCAGTGCATCCCCAAGCACTTCGTGTGTGACCACGAC\nCGTGACTGTGCAGATGGCTCTGATGAGTCCCCCGAGTGTGAGTACCCGACCTGCGGCCCC\nAGTGAGTTCCGCTGTGCCAATGGGCGCTGTCTGAGCTCCCGCCAGTGGGAGTGTGATGGC\nGAGAATGACTGCCACGACCAGAGTGACGAGGCTCCCAAGAACCCACACTGCACCAGCCAA\nGAGCACAAGTGCAATGCCTCGTCACAGTTCCTGTGCAGCAGTGGGCGCTGTGTGGCTGAG\nGCACTGCTCTGCAACGGCCAGGATGACTGTGGCGACAGCTCGGACGAGCGTGGCTGCCAC\nATCAATGAGTGTCTCAGCCGCAAGCTCAGTGGCTGCAGCCAGGACTGTGAGGACCTCAAG\nATCGGCTTCAAGTGCCGCTGTCGCCCTGGCTTCCGGCTGAAGGACGACGGCCGGACGTGT\nGCTGATGTGGACGAGTGCAGCACCACCTTCCCCTGCAGCCAGCGCTGCATCAACACTCAT\nGGCAGCTATAAGTGTCTGTGTGTGGAGGGCTATGCACCCCGCGGCGGCGACCCCCACAGC\nTGCAAGGCTGTGACTGACGAGGAACCGTTTCTGATCTTCGCCAACCGGTACTACCTGCGC\nAAGCTCAACCTGGACGGGTCCAACTACACGTTACTTAAGCAGGGCCTGAACAACGCCGTT\nGCCTTGGATTTTGACTACCGAGAGCAGATGATCTACTGGACAGATGTGACCACCCAGGGC\nAGCATGATCCGAAGGATGCACCTTAACGGGAGCAATGTGCAGGTCCTACACCGTACAGGC\nCTCAGCAACCCCGATGGGCTGGCTGTGGACTGGGTGGGTGGCAACCTGTACTGGTGCGAC\nAAAGGCCGGGACACCATCGAGGTGTCCAAGCTCAATGGGGCCTATCGGACGGTGCTGGTC\nAGCTCTGGCCTCCGTGAGCCCAGGGCTCTGGTGGTGGATGTGCAGAATGGGTACCTGTAC\nTGGACAGACTGGGGTGACCATTCACTGATCGGCCGCATCGGCATGGATGGGTCCAGCCGC\nAGCGTCATCGTGGACACCAAGATCACATGGCCCAATGGCCTGACGCTGGACTATGTCACT\nGAGCGCATCTACTGGGCCGACGCCCGCGAGGACTACATTGAATTTGCCAGCCTGGATGGC\nTCCAATCGCCACGTTGTGCTGAGCCAGGACATCCCGCACATCTTTGCACTGACCCTGTTT\nGAGGACTACGTCTACTGGACCGACTGGGAAACAAAGTCCATTAACCGAGCCCACAAGACC\nACGGGCACCAACAAAACGCTCCTCATCAGCACGCTGCACCGGCCCATGGACCTGCATGTC\nTTCCATGCCCTGCGCCAGCCAGACGTGCCCAATCACCCCTGCAAGGTCAACAATGGTGGC\nTGCAGCAACCTGTGCCTGCTGTCCCCCGGGGGAGGGCACAAATGTGCCTGCCCCACCAAC\nTTCTACCTGGGCAGCGATGGGCGCACCTGTGTGTCCAACTGCACGGCTAGCCAGTTTGTA\nTGCAAGAACGACAAGTGCATCCCCTTCTGGTGGAAGTGTGACACCGAGGACGACTGCGGG\nGACCACTCAGACGAGCCCCCGGACTGCCCTGAGTTCAAGTGCCGGCCCGGACAGTTCCAG\nTGCTCCACAGGTATCTGCACAAACCCTGCCTTCATCTGCGATGGCGACAATGACTGCCAG\nGACAACAGTGACGAGGCCAACTGTGACATCCACGTCTGCTTGCCCAGTCAGTTCAAATGC\nACCAACACCAACCGCTGTATTCCCGGCATCTTCCGCTGCAATGGGCAGGACAACTGCGGA\nGATGGGGAGGATGAGAGGGACTGCCCCGAGGTGACCTGCGCCCCCAACCAGTTCCAGTGC\nTCCATTACCAAACGGTGCATCCCCCGGGTCTGGGTCTGCGACCGGGACAATGACTGTGTG\nGATGGCAGTGATGAGCCCGCCAACTGCACCCAGATGACCTGTGGTGTGGACGAGTTCCGC\nTGCAAGGATTCGGGCCGCTGCATCCCAGCGCGTTGGAAGTGTGACGGAGAGGATGACTGT\nGGGGATGGCTCGGATGAGCCCAAGGAAGAGTGTGATGAACGCACCTGTGAGCCATACCAG\nTTCCGCTGCAAGAACAACCGCTGCGTGCCCGGCCGCTGGCAGTGCGACTACGACAACGAT\nTGCGGTGACAACTCCGATGAAGAGAGCTGCACCCCTCGGCCCTGCTCCGAGAGTGAGTTC\nTCCTGTGCCAACGGCCGCTGCATCGCGGGGCGCTGGAAATGCGATGGAGACCACGACTGC\nGCGGACGGCTCGGACGAGAAAGACTGCACCCCCCGCTGTGACATGGACCAGTTCCAGTGC\nAAGAGCGGCCACTGCATCCCCCTGCGCTGGCGCTGTGACGCAGACGCCGACTGCATGGAC\nGGCAGCGACGAGGAGGCCTGCGGCACTGGCGTGCGGACCTGCCCCCTGGACGAGTTCCAG\nTGCAACAACACCTTGTGCAAGCCGCTGGCCTGGAAGTGCGATGGCGAGGATGACTGTGGG\nGACAACTCAGATGAGAACCCCGAGGAGTGTGCCCGGTTCGTGTGCCCTCCCAACCGGCCC\nTTCCGTTGCAAGAATGACCGCGTCTGTCTGTGGATCGGGCGCCAATGCGATGGCACGGAC\nAACTGTGGGGATGGGACTGATGAAGAGGACTGTGAGCCCCCCACAGCCCACACCACCCAC\nTGCAAAGACAAGAAGGAGTTTCTGTGCCGGAACCAGCGCTGCCTCTCCTCCTCCCTGCGC\nTGCAACATGTTCGATGACTGCGGGGACGGCTCTGACGAGGAGGACTGCAGCATCGACCCC\nAAGCTGACCAGCTGCGCCACCAATGCCAGCATCTGTGGGGACGAGGCACGCTGCGTGCGC\nACCGAGAAAGCGGCCTACTGTGCCTGCCGCTCGGGCTTCCACACCGTGCCCGGCCAGCCC\nGGATGCCAAGACATCAACGAGTGCCTGCGCTTCGGCACCTGCTCCCAGCTCTGCAACAAC\nACCAAGGGCGGCCACCTCTGCAGCTGCGCTCGGAACTTCATGAAGACGCACAACACCTGC\nAAGGCCGAAGGCTCTGAGTACCAGGTCCTGTACATCGCTGATGACAATGAGATCCGCAGC\nCTGTTCCCCGGCCACCCCCATTCGGCTTACGAGCAGGCATTCCAGGGTGACGAGAGTGTC\nCGCATTGATGCTATGGATGTCCATGTCAAGGCTGGCCGTGTCTATTGGACCAACTGGCAC\nACGGGCACCATCTCCTACCGCAGCCTGCCACCTGCTGCGCCTCCTACCACTTCCAACCGC\nCACCGGCGACAGATTGACCGGGGTGTCACCCACCTCAACATTTCAGGGCTGAAGATGCCC\nAGAGGCATCGCCATCGACTGGGTGGCCGGAAACGTGTACTGGACCGACTCGGGCCGAGAT\nGTGATTGAGGTGGCGCAGATGAAGGGCGAGAACCGCAAGACGCTCATCTCGGGCATGATT\nGACGAGCCCCACGCCATTGTGGTGGACCCACTGAGGGGGACCATGTACTGGTCAGACTGG\nGGCAACCACCCCAAGATTGAGACGGCAGCGATGGATGGGACGCTTCGGGAGACACTGGTG\nCAGGACAACATTCAGTGGCCCACAGGCCTGGCCGTGGATTATCACAATGAGCGGCTGTAC\nTGGGCAGACGCCAAGCTTTCAGTCATCGGCAGCATCCGGCTCAATGGCACGGACCCCATT\nGTGGCTGCTGACAGCAAACGAGGCCTAAGTCACCCCTTCAGCATCGACGTCTTTGAGGAT\nTACATCTATGGTGTCACCTACATCAATAATCGTGTCTTCAAGATCCATAAGTTTGGCCAC\nAGCCCCTTGGTCAACCTGACAGGGGGCCTGAGCCACGCCTCTGACGTGGTCCTTTACCAT\nCAGCACAAGCAGCCCGAAGTGACCAACCCATGTGACCGCAAGAAATGCGAGTGGCTCTGC\nCTGCTGAGCCCCAGTGGGCCTGTCTGCACCTGTCCCAATGGGAAGCGGCTGGACAACGGC\nACATGCGTGCCTGTGCCCTCTCCAACGCCCCCCCCAGATGCTCCCCGGCCTGGAACCTGT\nAACCTGCAGTGCTTCAACGGTGGCAGCTGTTTCCTCAATGCACGGAGGCAGCCCAAGTGC\nCGCTGCCAACCCCGCTACACGGGTGACAAGTGTGAACTGGACCAGTGCTGGGAGCACTGT\nCGCAATGGGGGCACCTGTGCTGCCTCCCCCTCTGGCATGCCCACGTGCCGGTGCCCCACG\nGGCTTCACGGGCCCCAAATGCACCCAGCAGGTGTGTGCGGGCTACTGTGCCAACAACAGC\nACCTGCACTGTCAACCAGGGCAACCAGCCCCAGTGCCGATGCCTACCCGGCTTCCTGGGC\nGACCGCTGCCAGTACCGGCAGTGCTCTGGCTACTGTGAGAACTTTGGCACATGCCAGATG\nGCTGCTGATGGCTCCCGACAATGCCGCTGCACTGCCTACTTTGAGGGATCGAGGTGTGAG\nGTGAACAAGTGCAGCCGCTGTCTCGAAGGGGCCTGTGTGGTCAACAAGCAGAGTGGGGAT\nGTCACCTGCAACTGCACGGATGGCCGGGTGGCCCCCAGCTGTCTGACCTGCGTCGGCCAC\nTGCAGCAATGGCGGCTCCTGTACCATGAACAGCAAAATGATGCCTGAGTGCCAGTGCCCA\nCCCCACATGACAGGGCCCCGGTGTGAGGAGCACGTCTTCAGCCAGCAGCAGCCAGGACAT\nATAGCCTCCATCCTAATCCCTCTGCTGTTGCTGCTGCTGCTGGTTCTGGTGGCCGGAGTG\nGTATTCTGGTATAAGCGGCGAGTCCAAGGGGCTAAGGGCTTCCAGCACCAACGGATGACC\nAACGGGGCCATGAACGTGGAGATTGGAAACCCCACCTACAAGATGTACGAAGGCGGAGAG\nCCTGATGATGTGGGAGGCCTACTGGACGCTGACTTTGCCCTGGACCCTGACAAGCCCACC\nAACTTCACCAACCCCGTGTATGCCACACTCTACATGGGGGGCCATGGCAGTCGCCACTCC\nCTGGCCAGCACGGACGAGAAGCGAGAACTCCTGGGCCGGGGCCCTGAGGACGAGATAGGG\nGACCCCTTGGCATAG'], 'pfams': [{'pfam': [{'identifier': ['PF07645'], 'name': ['EGF_CA']}, {'identifier': ['PF00057'], 'name': ['Ldl_recept_a']}, {'identifier': ['PF00058'], 'name': ['Ldl_recept_b']}, {'identifier': ['PF12662'], 'name': ['cEGF']}, {'identifier': ['PF16472'], 'name': ['DUF5050']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['clathrin-coated vesicle']}, {'category': ['component'], 'description': ['coated pit']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['dendrite']}, {'category': ['component'], 'description': ['endocytic vesicle membrane']}, {'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['lysosomal membrane']}, {'category': ['component'], 'description': ['neuronal cell body']}, {'category': ['component'], 'description': ['nucleolus']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['function'], 'description': ['apolipoprotein binding']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['lipoprotein particle receptor binding']}, {'category': ['function'], 'description': ['lipoprotein transporter activity']}, {'category': ['function'], 'description': ['poly(A) RNA binding']}, {'category': ['function'], 'description': ['protein complex binding']}, {'category': ['function'], 'description': ['receptor activity']}, {'category': ['process'], 'description': ['aging']}, {'category': ['process'], 'description': ['aorta morphogenesis']}, {'category': ['process'], 'description': ['apoptotic cell clearance']}, {'category': ['process'], 'description': ['beta-amyloid clearance']}, {'category': ['process'], 'description': ['cell proliferation']}, {'category': ['process'], 'description': ['lipoprotein metabolic process']}, {'category': ['process'], 'description': ['lipoprotein transport']}, {'category': ['process'], 'description': ['negative regulation of neuron apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of neuron projection development']}, {'category': ['process'], 'description': ['negative regulation of platelet-derived growth factor receptor-beta signaling pathway']}, {'category': ['process'], 'description': ['negative regulation of smooth muscle cell migration']}, {'category': ['process'], 'description': ['negative regulation of Wnt signaling pathway']}, {'category': ['process'], 'description': ['phototransduction, visible light']}, {'category': ['process'], 'description': ['positive regulation of cholesterol efflux']}, {'category': ['process'], 'description': ['positive regulation of lipid transport']}, {'category': ['process'], 'description': ['positive regulation of protein transport']}, {'category': ['process'], 'description': ['protein kinase C-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['receptor-mediated endocytosis']}, {'category': ['process'], 'description': ['regulation of actin cytoskeleton organization']}, {'category': ['process'], 'description': ['regulation of cholesterol transport']}, {'category': ['process'], 'description': ['regulation of phospholipase A2 activity']}, {'category': ['process'], 'description': ['retinoid metabolic process']}]}]}]}, {'id': ['BE0000403'], 'name': ['Vitamin K-dependent gamma-carboxylase'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13316'], 'pubmed-id': ['14660587'], 'citation': ['Lin PJ, Straight DL, Stafford DW: Binding of the factor IX gamma-carboxyglutamic acid domain to the vitamin K-dependent gamma-glutamyl carboxylase active site induces an allosteric effect that may ensure processive carboxylation and regulate the release of carboxylated product. J Biol Chem. 2004 Feb 20;279(8):6560-6. Epub 2003 Dec 2.']}, {'ref-id': ['A13317'], 'pubmed-id': ['9115224'], 'citation': ['Wu SM, Mutucumarana VP, Geromanos S, Stafford DW: The propeptide binding site of the bovine gamma-glutamyl carboxylase. J Biol Chem. 1997 May 2;272(18):11718-22.']}, {'ref-id': ['A13318'], 'pubmed-id': ['8506307'], 'citation': ['Rehemtulla A, Roth DA, Wasley LC, Kuliopulos A, Walsh CT, Furie B, Furie BC, Kaufman RJ: In vitro and in vivo functional characterization of bovine vitamin K-dependent gamma-carboxylase expressed in Chinese hamster ovary cells. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4611-5.']}, {'ref-id': ['A13319'], 'pubmed-id': ['9748333'], 'citation': ['Stanley TB, Wu SM, Houben RJ, Mutucumarana VP, Stafford DW: Role of the propeptide and gamma-glutamic acid domain of factor IX for in vitro carboxylation by the vitamin K-dependent carboxylase. Biochemistry. 1998 Sep 22;37(38):13262-8.']}, {'ref-id': ['A13320'], 'pubmed-id': ['9141486'], 'citation': ['Stanley TB, Stafford DW, Olivera BM, Bandyopadhyay PK: Identification of a vitamin K-dependent carboxylase in the venom duct of a Conus snail. FEBS Lett. 1997 Apr 21;407(1):85-8.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Vitamin K-dependent gamma-carboxylase'], 'general-function': ['Gamma-glutamyl carboxylase activity'], 'specific-function': ['Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium-binding gamma-carboxyglutamate (Gla) residues with the concomitant conversion of the reduced hydroquinone form of vitamin K to vitamin K epoxide.'], 'gene-name': ['GGCX'], 'locus': ['2p12'], 'cellular-location': ['Endoplasmic reticulum membrane'], 'transmembrane-regions': ['61-81\n114-134\n137-157\n293-313\n362-382'], 'signal-regions': [None], 'theoretical-pi': ['8.1'], 'molecular-weight': ['87560.065'], 'chromosome-location': ['2'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:4247']}, {'resource': ['GenAtlas'], 'identifier': ['GGCX']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M81592']}, {'resource': ['GenBank Protein Database'], 'identifier': ['184028']}, {'resource': ['UniProtKB'], 'identifier': ['P38435']}, {'resource': ['UniProt Accession'], 'identifier': ['VKGC_HUMAN']}]}], 'synonyms': [{'synonym': ['4.1.1.90', 'Gamma-glutamyl carboxylase', 'GC', 'Peptidyl-glutamate 4-carboxylase', 'Vitamin K gamma glutamyl carboxylase']}], 'amino-acid-sequence': ['>lcl|BSEQ0000803|Vitamin K-dependent gamma-carboxylase\nMAVSAGSARTSPSSDKVQKDKAELISGPRQDSRIGKLLGFEWTDLSSWRRLVTLLNRPTD\nPASLAVFRFLFGFLMVLDIPQERGLSSLDRKYLDGLDVCRFPLLDALRPLPLDWMYLVYT\nIMFLGALGMMLGLCYRISCVLFLLPYWYVFLLDKTSWNNHSYLYGLLAFQLTFMDANHYW\nSVDGLLNAHRRNAHVPLWNYAVLRGQIFIVYFIAGVKKLDADWVEGYSMEYLSRHWLFSP\nFKLLLSEELTSLLVVHWGGLLLDLSAGFLLFFDVSRSIGLFFVSYFHCMNSQLFSIGMFS\nYVMLASSPLFCSPEWPRKLVSYCPRRLQQLLPLKAAPQPSVSCVYKRSRGKSGQKPGLRH\nQLGAAFTLLYLLEQLFLPYSHFLTQGYNNWTNGLYGYSWDMMVHSRSHQHVKITYRDGRT\nGELGYLNPGVFTQSRRWKDHADMLKQYATCLSRLLPKYNVTEPQIYFDIWVSINDRFQQR\nIFDPRVDIVQAAWSPFQRTSWVQPLLMDLSPWRAKLQEIKSSLDNHTEVVFIADFPGLHL\nENFVSEDLGNTSIQLLQGEVTVELVAEQKNQTLREGEKMQLPAGEYHKVYTTSPSPSCYM\nYVYVNTTELALEQDLAYLQELKEKVENGSETGPLPPELQPLLEGEVKGGPEPTPLVQTFL\nRRQQRLQEIERRRNTPFHERFFRFLLRKLYVFRRSFLMTCISLRNLILGRPSLEQLAQEV\nTYANLRPFEAVGELNPSNTDSSHSNPPESNPDPVHSEF'], 'gene-sequence': ['>lcl|BSEQ0018949|Vitamin K-dependent gamma-carboxylase (GGCX)\nATGGCGGTGTCTGCCGGGTCCGCGCGGACCTCGCCCAGCTCAGATAAAGTACAGAAAGAC\nAAGGCTGAACTGATCTCAGGGCCCAGGCAGGACAGCCGAATAGGGAAACTCTTGGGTTTT\nGAGTGGACAGATTTGTCCAGTTGGCGGAGGCTGGTGACCCTGCTGAATCGACCAACGGAC\nCCTGCAAGCTTAGCTGTCTTTCGTTTTCTTTTTGGGTTCTTGATGGTGCTAGACATTCCC\nCAGGAGCGGGGGCTCAGCTCTCTGGACCGGAAATACCTTGATGGGCTGGATGTGTGCCGC\nTTCCCCTTGCTGGATGCCCTACGCCCACTGCCACTTGACTGGATGTATCTTGTCTACACC\nATCATGTTTCTGGGGGCACTGGGCATGATGCTGGGCCTGTGCTACCGGATAAGCTGTGTG\nTTATTCCTGCTGCCATACTGGTATGTGTTTCTCCTGGACAAGACATCATGGAACAACCAC\nTCCTATCTGTATGGGTTGTTGGCCTTTCAGCTAACATTCATGGATGCAAACCACTACTGG\nTCTGTGGACGGTCTGCTGAATGCCCATAGGAGGAATGCCCACGTGCCCCTTTGGAACTAT\nGCAGTGCTCCGTGGCCAGATCTTCATTGTGTACTTCATTGCGGGTGTGAAAAAGCTGGAT\nGCAGACTGGGTTGAAGGCTATTCCATGGAATATTTGTCCCGGCACTGGCTCTTCAGTCCC\nTTCAAACTGCTGTTGTCTGAGGAGCTGACTAGCCTGCTGGTCGTGCACTGGGGTGGGCTG\nCTGCTTGACCTCTCAGCTGGTTTCCTGCTCTTTTTTGATGTCTCAAGATCCATTGGCCTG\nTTCTTTGTGTCCTACTTCCACTGCATGAATTCCCAGCTTTTCAGCATTGGTATGTTCTCC\nTACGTCATGCTGGCCAGCAGCCCTCTCTTCTGCTCCCCTGAGTGGCCTCGGAAGCTGGTG\nTCCTACTGCCCCCGAAGGTTGCAACAACTGTTGCCCCTCAAGGCAGCCCCTCAGCCCAGT\nGTTTCCTGTGTGTATAAGAGGAGCCGGGGCAAAAGTGGCCAGAAGCCAGGGCTGCGCCAT\nCAGCTGGGAGCTGCCTTCACCCTGCTCTACCTCCTGGAGCAGCTATTCCTGCCCTATTCT\nCATTTTCTCACCCAGGGCTATAACAACTGGACAAATGGGCTGTATGGCTATTCCTGGGAC\nATGATGGTGCACTCCCGCTCCCACCAGCACGTGAAGATCACCTACCGTGATGGCCGCACT\nGGCGAACTGGGCTACCTTAACCCTGGGGTATTTACACAGAGTCGGCGATGGAAGGATCAT\nGCAGACATGCTGAAGCAATATGCCACTTGCCTGAGCCGCCTGCTTCCCAAGTATAATGTC\nACTGAGCCCCAGATCTACTTTGATATTTGGGTCTCCATCAATGACCGCTTCCAGCAGAGG\nATTTTTGACCCTCGTGTGGACATCGTGCAGGCCGCTTGGTCACCCTTTCAGCGCACATCC\nTGGGTGCAACCACTCTTGATGGACCTGTCTCCCTGGAGGGCCAAGTTACAGGAAATCAAG\nAGCAGCCTAGACAACCACACTGAGGTGGTCTTCATTGCAGATTTCCCTGGACTGCACTTG\nGAGAATTTTGTGAGTGAAGACCTGGGCAACACTAGCATCCAGCTGCTGCAGGGGGAAGTG\nACTGTGGAGCTTGTGGCAGAACAGAAGAACCAGACTCTTCGAGAGGGAGAAAAAATGCAG\nTTGCCTGCTGGTGAGTACCATAAGGTGTATACGACATCACCTAGCCCTTCTTGCTACATG\nTACGTCTATGTCAACACTACAGAGCTTGCACTGGAGCAAGACCTGGCATATCTGCAAGAA\nTTAAAGGAAAAGGTGGAGAATGGAAGTGAAACAGGGCCTCTACCCCCAGAGCTGCAGCCT\nCTGTTGGAAGGGGAAGTAAAAGGGGGCCCTGAGCCAACACCTCTGGTTCAGACCTTTCTT\nAGACGCCAACAAAGGCTCCAGGAGATTGAACGCCGGCGAAATACTCCTTTCCATGAGCGA\nTTCTTCCGCTTCTTGTTGCGAAAGCTCTATGTCTTTCGCCGCAGCTTCCTGATGACTTGT\nATCTCACTTCGAAATCTGATATTAGGCCGTCCTTCCCTGGAGCAGCTGGCCCAGGAGGTG\nACTTATGCAAACTTGAGACCCTTTGAGGCAGTTGGAGAACTGAATCCCTCAAACACGGAT\nTCTTCACATTCTAATCCTCCTGAGTCAAATCCTGATCCTGTCCACTCAGAGTTCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF05090'], 'name': ['VKG_Carbox']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['endoplasmic reticulum membrane']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['function'], 'description': ['gamma-glutamyl carboxylase activity']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['cellular protein modification process']}, {'category': ['process'], 'description': ['peptidyl-glutamic acid carboxylation']}, {'category': ['process'], 'description': ['post-translational protein modification']}]}]}]}]}]"
"['DB00102', 'BTD00053', 'BIOD00053']",['Becaplermin'],biotech,"['Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together by disulfide bonds.']",['liquid'],['For topical treatment of skin ulcers (from diabetes)'],"['Binds to the beta platelet-derived growth factor (PDGF) receptor, a tyrosine kinase receptor. PDGF is known to exist as a dimer, and activates its signaling pathway by a ligand induced receptor dimerization and autophosphorylation. PDGF receptors also contain many auto-phosphorylation sites, which serve to mediate binding of SH2 sites and subsequently signal corresponding pathways. There are five different isoforms of PDGF that activate through two different receptors (alpha and beta).']",[None],"[{'target': [{'id': ['BE0000205'], 'name': ['Platelet-derived growth factor receptor beta'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A2136'], 'pubmed-id': ['18686746'], 'citation': ['Papanas N, Maltezos E: Becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Clin Interv Aging. 2008;3(2):233-40.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Platelet-derived growth factor receptor beta'], 'general-function': ['Vascular endothelial growth factor binding'], 'specific-function': ['Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of pericytes and smooth muscle cells to endothelial cells. Plays a role in the migration of vascular smooth muscle cells and the formation of neointima at vascular injury sites. Required for normal development of the cardiovascular system. Required for normal recruitment of pericytes (mesangial cells) in the kidney glomerulus, and for normal formation of a branched network of capillaries in kidney glomeruli. Promotes rearrangement of the actin cytoskeleton and the formation of membrane ruffles. Binding of its cognate ligands - homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFD -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PLCG1, PIK3R1, PTPN11, RASA1/GAP, CBL, SHC1 and NCK1. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leads to the activation of the AKT1 signaling pathway. Phosphorylation of SHC1, or of the C-terminus of PTPN11, creates a binding site for GRB2, resulting in the activation of HRAS, RAF1 and down-stream MAP kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation and activation of SRC family kinases. Promotes phosphorylation of PDCD6IP/ALIX and STAM. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor.'], 'gene-name': ['PDGFRB'], 'locus': ['5q31-q32'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['533-553'], 'signal-regions': ['1-32'], 'theoretical-pi': ['4.62'], 'molecular-weight': ['123966.895'], 'chromosome-location': ['5'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:8804']}, {'resource': ['GenAtlas'], 'identifier': ['PDGFRB']}, {'resource': ['GenBank Gene Database'], 'identifier': ['J03278']}, {'resource': ['GenBank Protein Database'], 'identifier': ['189732']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1804']}, {'resource': ['UniProtKB'], 'identifier': ['P09619']}, {'resource': ['UniProt Accession'], 'identifier': ['PGFRB_HUMAN']}]}], 'synonyms': [{'synonym': ['2.7.10.1', 'Beta platelet-derived growth factor receptor', 'Beta-type platelet-derived growth factor receptor', 'CD140 antigen-like family member B', 'PDGF-R-beta', 'PDGFR', 'PDGFR-1', 'PDGFR1', 'Platelet-derived growth factor receptor 1']}], 'amino-acid-sequence': ['>lcl|BSEQ0000409|Platelet-derived growth factor receptor beta\nMRLPGAMPALALKGELLLLSLLLLLEPQISQGLVVTPPGPELVLNVSSTFVLTCSGSAPV\nVWERMSQEPPQEMAKAQDGTFSSVLTLTNLTGLDTGEYFCTHNDSRGLETDERKRLYIFV\nPDPTVGFLPNDAEELFIFLTEITEITIPCRVTDPQLVVTLHEKKGDVALPVPYDHQRGFS\nGIFEDRSYICKTTIGDREVDSDAYYVYRLQVSSINVSVNAVQTVVRQGENITLMCIVIGN\nEVVNFEWTYPRKESGRLVEPVTDFLLDMPYHIRSILHIPSAELEDSGTYTCNVTESVNDH\nQDEKAINITVVESGYVRLLGEVGTLQFAELHRSRTLQVVFEAYPPPTVLWFKDNRTLGDS\nSAGEIALSTRNVSETRYVSELTLVRVKVAEAGHYTMRAFHEDAEVQLSFQLQINVPVRVL\nELSESHPDSGEQTVRCRGRGMPQPNIIWSACRDLKRCPRELPPTLLGNSSEEESQLETNV\nTYWEEEQEFEVVSTLRLQHVDRPLSVRCTLRNAVGQDTQEVIVVPHSLPFKVVVISAILA\nLVVLTIISLIILIMLWQKKPRYEIRWKVIESVSSDGHEYIYVDPMQLPYDSTWELPRDQL\nVLGRTLGSGAFGQVVEATAHGLSHSQATMKVAVKMLKSTARSSEKQALMSELKIMSHLGP\nHLNVVNLLGACTKGGPIYIITEYCRYGDLVDYLHRNKHTFLQHHSDKRRPPSAELYSNAL\nPVGLPLPSHVSLTGESDGGYMDMSKDESVDYVPMLDMKGDVKYADIESSNYMAPYDNYVP\nSAPERTCRATLINESPVLSYMDLVGFSYQVANGMEFLASKNCVHRDLAARNVLICEGKLV\nKICDFGLARDIMRDSNYISKGSTFLPLKWMAPESIFNSLYTTLSDVWSFGILLWEIFTLG\nGTPYPELPMNEQFYNAIKRGYRMAQPAHASDEIYEIMQKCWEEKFEIRPPFSQLVLLLER\nLLGEGYKKKYQQVDEEFLRSDHPAILRSQARLPGFHGLRSPLDTSSVLYTAVQPNEGDND\nYIIPLPDPKPEVADEGPLEGSPSLASSTLNEVNTSSTISCDSPLEPQDEPEPEPQLELQV\nEPEPELEQLPDSGCPAPRAEAEDSFL'], 'gene-sequence': ['>lcl|BSEQ0021922|Platelet-derived growth factor receptor beta (PDGFRB)\nATGCGGCTTCCGGGTGCGATGCCAGCTCTGGCCCTCAAAGGCGAGCTGCTGTTGCTGTCT\nCTCCTGTTACTTCTGGAACCACAGATCTCTCAGGGCCTGGTCGTCACACCCCCGGGGCCA\nGAGCTTGTCCTCAATGTCTCCAGCACCTTCGTTCTGACCTGCTCGGGTTCAGCTCCGGTG\nGTGTGGGAACGGATGTCCCAGGAGCCCCCACAGGAAATGGCCAAGGCCCAGGATGGCACC\nTTCTCCAGCGTGCTCACACTGACCAACCTCACTGGGCTAGACACGGGAGAATACTTTTGC\nACCCACAATGACTCCCGTGGACTGGAGACCGATGAGCGGAAACGGCTCTACATCTTTGTG\nCCAGATCCCACCGTGGGCTTCCTCCCTAATGATGCCGAGGAACTATTCATCTTTCTCACG\nGAAATAACTGAGATCACCATTCCATGCCGAGTAACAGACCCACAGCTGGTGGTGACACTG\nCACGAGAAGAAAGGGGACGTTGCACTGCCTGTCCCCTATGATCACCAACGTGGCTTTTCT\nGGTATCTTTGAGGACAGAAGCTACATCTGCAAAACCACCATTGGGGACAGGGAGGTGGAT\nTCTGATGCCTACTATGTCTACAGACTCCAGGTGTCATCCATCAACGTCTCTGTGAACGCA\nGTGCAGACTGTGGTCCGCCAGGGTGAGAACATCACCCTCATGTGCATTGTGATCGGGAAT\nGAGGTGGTCAACTTCGAGTGGACATACCCCCGCAAAGAAAGTGGGCGGCTGGTGGAGCCG\nGTGACTGACTTCCTCTTGGATATGCCTTACCACATCCGCTCCATCCTGCACATCCCCAGT\nGCCGAGTTAGAAGACTCGGGGACCTACACCTGCAATGTGACGGAGAGTGTGAATGACCAT\nCAGGATGAAAAGGCCATCAACATCACCGTGGTTGAGAGCGGCTACGTGCGGCTCCTGGGA\nGAGGTGGGCACACTACAATTTGCTGAGCTGCATCGGAGCCGGACACTGCAGGTAGTGTTC\nGAGGCCTACCCACCGCCCACTGTCCTGTGGTTCAAAGACAACCGCACCCTGGGCGACTCC\nAGCGCTGGCGAAATCGCCCTGTCCACGCGCAACGTGTCGGAGACCCGGTATGTGTCAGAG\nCTGACACTGGTTCGCGTGAAGGTGGCAGAGGCTGGCCACTACACCATGCGGGCCTTCCAT\nGAGGATGCTGAGGTCCAGCTCTCCTTCCAGCTACAGATCAATGTCCCTGTCCGAGTGCTG\nGAGCTAAGTGAGAGCCACCCTGACAGTGGGGAACAGACAGTCCGCTGTCGTGGCCGGGGC\nATGCCCCAGCCGAACATCATCTGGTCTGCCTGCAGAGACCTCAAAAGGTGTCCACGTGAG\nCTGCCGCCCACGCTGCTGGGGAACAGTTCCGAAGAGGAGAGCCAGCTGGAGACTAACGTG\nACGTACTGGGAGGAGGAGCAGGAGTTTGAGGTGGTGAGCACACTGCGTCTGCAGCACGTG\nGATCGGCCACTGTCGGTGCGCTGCACGCTGCGCAACGCTGTGGGCCAGGACACGCAGGAG\nGTCATCGTGGTGCCACACTCCTTGCCCTTTAAGGTGGTGGTGATCTCAGCCATCCTGGCC\nCTGGTGGTGCTCACCATCATCTCCCTTATCATCCTCATCATGCTTTGGCAGAAGAAGCCA\nCGTTACGAGATCCGATGGAAGGTGATTGAGTCTGTGAGCTCTGACGGCCATGAGTACATC\nTACGTGGACCCCATGCAGCTGCCCTATGACTCCACGTGGGAGCTGCCGCGGGACCAGCTT\nGTGCTGGGACGCACCCTCGGCTCTGGGGCCTTTGGGCAGGTGGTGGAGGCCACGGCTCAT\nGGCCTGAGCCATTCTCAGGCCACGATGAAAGTGGCCGTCAAGATGCTTAAATCCACAGCC\nCGCAGCAGTGAGAAGCAAGCCCTTATGTCGGAGCTGAAGATCATGAGTCACCTTGGGCCC\nCACCTGAACGTGGTCAACCTGTTGGGGGCCTGCACCAAAGGAGGACCCATCTATATCATC\nACTGAGTACTGCCGCTACGGAGACCTGGTGGACTACCTGCACCGCAACAAACACACCTTC\nCTGCAGCACCACTCCGACAAGCGCCGCCCGCCCAGCGCGGAGCTCTACAGCAATGCTCTG\nCCCGTTGGGCTCCCCCTGCCCAGCCATGTGTCCTTGACCGGGGAGAGCGACGGTGGCTAC\nATGGACATGAGCAAGGACGAGTCGGTGGACTATGTGCCCATGCTGGACATGAAAGGAGAC\nGTCAAATATGCAGACATCGAGTCCTCCAACTACATGGCCCCTTACGATAACTACGTTCCC\nTCTGCCCCTGAGAGGACCTGCCGAGCAACTTTGATCAACGAGTCTCCAGTGCTAAGCTAC\nATGGACCTCGTGGGCTTCAGCTACCAGGTGGCCAATGGCATGGAGTTTCTGGCCTCCAAG\nAACTGCGTCCACAGAGACCTGGCGGCTAGGAACGTGCTCATCTGTGAAGGCAAGCTGGTC\nAAGATCTGTGACTTTGGCCTGGCTCGAGACATCATGCGGGACTCGAATTACATCTCCAAA\nGGCAGCACCTTTTTGCCTTTAAAGTGGATGGCTCCGGAGAGCATCTTCAACAGCCTCTAC\nACCACCCTGAGCGACGTGTGGTCCTTCGGGATCCTGCTCTGGGAGATCTTCACCTTGGGT\nGGCACCCCTTACCCAGAGCTGCCCATGAACGAGCAGTTCTACAATGCCATCAAACGGGGT\nTACCGCATGGCCCAGCCTGCCCATGCCTCCGACGAGATCTATGAGATCATGCAGAAGTGC\nTGGGAAGAGAAGTTTGAGATTCGGCCCCCCTTCTCCCAGCTGGTGCTGCTTCTCGAGAGA\nCTGTTGGGCGAAGGTTACAAAAAGAAGTACCAGCAGGTGGATGAGGAGTTTCTGAGGAGT\nGACCACCCAGCCATCCTTCGGTCCCAGGCCCGCTTGCCTGGGTTCCATGGCCTCCGATCT\nCCCCTGGACACCAGCTCCGTCCTCTATACTGCCGTGCAGCCCAATGAGGGTGACAACGAC\nTATATCATCCCCCTGCCTGACCCCAAACCCGAGGTTGCTGACGAGGGCCCACTGGAGGGT\nTCCCCCAGCCTAGCCAGCTCCACCCTGAATGAAGTCAACACCTCCTCAACCATCTCCTGT\nGACAGCCCCCTGGAGCCCCAGGACGAACCAGAGCCAGAGCCCCAGCTTGAGCTCCAGGTG\nGAGCCGGAGCCAGAGCTGGAACAGTTGCCGGATTCGGGGTGCCCTGCGCCTCGGGCGGAA\nGCAGAGGATAGCTTCCTGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF07714'], 'name': ['PK_Tyr_Ser-Thr']}, {'identifier': ['PF00047'], 'name': ['ig']}, {'identifier': ['PF07679'], 'name': ['I-set']}, {'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['apical plasma membrane']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['cytoplasmic membrane-bounded vesicle']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['intrinsic component of plasma membrane']}, {'category': ['component'], 'description': ['lysosomal lumen']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['nucleus']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['ATP binding']}, {'category': ['function'], 'description': ['platelet activating factor receptor activity']}, {'category': ['function'], 'description': ['platelet-derived growth factor beta-receptor activity']}, {'category': ['function'], 'description': ['platelet-derived growth factor binding']}, {'category': ['function'], 'description': ['platelet-derived growth factor receptor binding']}, {'category': ['function'], 'description': ['platelet-derived growth factor-activated receptor activity']}, {'category': ['function'], 'description': ['protein kinase binding']}, {'category': ['function'], 'description': ['protein tyrosine kinase activity']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['vascular endothelial growth factor binding']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['adrenal gland development']}, {'category': ['process'], 'description': ['aorta morphogenesis']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['cardiac myofibril assembly']}, {'category': ['process'], 'description': ['cell chemotaxis']}, {'category': ['process'], 'description': ['cell migration']}, {'category': ['process'], 'description': ['cell migration involved in coronary angiogenesis']}, {'category': ['process'], 'description': ['cell migration involved in vasculogenesis']}, {'category': ['process'], 'description': ['cellular response to platelet-derived growth factor stimulus']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['glycosaminoglycan biosynthetic process']}, {'category': ['process'], 'description': ['in utero embryonic development']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['inner ear development']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['metanephric comma-shaped body morphogenesis']}, {'category': ['process'], 'description': ['metanephric glomerular capillary formation']}, {'category': ['process'], 'description': ['metanephric glomerular mesangial cell proliferation involved in metanephros development']}, {'category': ['process'], 'description': ['metanephric mesenchymal cell migration']}, {'category': ['process'], 'description': ['metanephric mesenchyme development']}, {'category': ['process'], 'description': ['metanephric S-shaped body morphogenesis']}, {'category': ['process'], 'description': ['negative regulation of apoptotic process']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['phosphatidylinositol metabolic process']}, {'category': ['process'], 'description': ['phosphatidylinositol-mediated signaling']}, {'category': ['process'], 'description': ['platelet-derived growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['platelet-derived growth factor receptor-beta signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of calcium ion import']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of chemotaxis']}, {'category': ['process'], 'description': ['positive regulation of collagen biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of DNA biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['positive regulation of MAP kinase activity']}, {'category': ['process'], 'description': ['positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of mitotic nuclear division']}, {'category': ['process'], 'description': ['positive regulation of phosphatidylinositol 3-kinase activity']}, {'category': ['process'], 'description': ['positive regulation of phosphatidylinositol 3-kinase signaling']}, {'category': ['process'], 'description': ['positive regulation of phospholipase C activity']}, {'category': ['process'], 'description': ['positive regulation of phosphoprotein phosphatase activity']}, {'category': ['process'], 'description': ['positive regulation of reactive oxygen species metabolic process']}, {'category': ['process'], 'description': ['positive regulation of smooth muscle cell migration']}, {'category': ['process'], 'description': ['positive regulation of smooth muscle cell proliferation']}, {'category': ['process'], 'description': ['protein autophosphorylation']}, {'category': ['process'], 'description': ['Ras protein signal transduction']}, {'category': ['process'], 'description': ['regulation of actin cytoskeleton organization']}, {'category': ['process'], 'description': ['regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['response to estradiol']}, {'category': ['process'], 'description': ['response to fluid shear stress']}, {'category': ['process'], 'description': ['response to hydrogen peroxide']}, {'category': ['process'], 'description': ['response to hyperoxia']}, {'category': ['process'], 'description': ['response to retinoic acid']}, {'category': ['process'], 'description': ['response to toxic substance']}, {'category': ['process'], 'description': ['retina vasculature development in camera-type eye']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['skeletal system morphogenesis']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['smooth muscle cell chemotaxis']}, {'category': ['process'], 'description': ['smooth muscle tissue development']}, {'category': ['process'], 'description': ['tissue homeostasis']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['wound healing']}]}]}]}, {'id': ['BE0000852'], 'name': ['Platelet-derived growth factor receptor alpha'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13324'], 'pubmed-id': ['10070317'], 'citation': ['Abdiu A, Walz TM, Nishikawa BK, Wingren S, Larsson SE, Wasteson A: Human malignant fibrous histiocytomas in vitro: growth characteristics and their association with expression of mRNA for platelet-derived growth factor, transforming growth factor-alpha and their receptors. Eur J Cancer. 1998 Dec;34(13):2094-100.']}, {'ref-id': ['A13325'], 'pubmed-id': ['7665222'], 'citation': ['Ebert M, Yokoyama M, Friess H, Kobrin MS, Buchler MW, Korc M: Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer. 1995 Sep 4;62(5):529-35.']}, {'ref-id': ['A13326'], 'pubmed-id': ['12632922'], 'citation': ['Miller-Kasprzak E, Niemir ZI, Czekalski S: [Structure and function of PDGF-R-alpha and its expression in normal kidney and kidney diseases]. Przegl Lek. 2002;59(10):826-31.']}, {'ref-id': ['A13327'], 'pubmed-id': ['1702511'], 'citation': ['Heidaran MA, Pierce JH, Lombardi D, Ruggiero M, Gutkind JS, Matsui T, Aaronson SA: Deletion or substitution within the alpha platelet-derived growth factor receptor kinase insert domain: effects on functional coupling with intracellular signaling pathways. Mol Cell Biol. 1991 Jan;11(1):134-42.']}, {'ref-id': ['A13328'], 'pubmed-id': ['14506245'], 'citation': ['Yu J, Liu XW, Kim HR: Platelet-derived growth factor (PDGF) receptor-alpha-activated c-Jun NH2-terminal kinase-1 is critical for PDGF-induced p21WAF1/CIP1 promoter activity independent of p53. J Biol Chem. 2003 Dec 5;278(49):49582-8. Epub 2003 Sep 23.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Platelet-derived growth factor receptor alpha'], 'general-function': ['Vascular endothelial growth factor-activated receptor activity'], 'specific-function': ['Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for normal skeleton development and cephalic closure during embryonic development. Required for normal development of the mucosa lining the gastrointestinal tract, and for recruitment of mesenchymal cells and normal development of intestinal villi. Plays a role in cell migration and chemotaxis in wound healing. Plays a role in platelet activation, secretion of agonists from platelet granules, and in thrombin-induced platelet aggregation. Binding of its cognate ligands - homodimeric PDGFA, homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFC -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylates PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and thereby mediates activation of the AKT1 signaling pathway. Mediates activation of HRAS and of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3 and STAT5A and/or STAT5B. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor.'], 'gene-name': ['PDGFRA'], 'locus': ['4q11-q13'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['529-549'], 'signal-regions': ['1-23'], 'theoretical-pi': ['4.81'], 'molecular-weight': ['122668.46'], 'chromosome-location': ['4'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:8803']}, {'resource': ['GenAtlas'], 'identifier': ['PDGFRA']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M21574']}, {'resource': ['GenBank Protein Database'], 'identifier': ['189734']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1803']}, {'resource': ['UniProtKB'], 'identifier': ['P16234']}, {'resource': ['UniProt Accession'], 'identifier': ['PGFRA_HUMAN']}]}], 'synonyms': [{'synonym': ['2.7.10.1', 'Alpha platelet-derived growth factor receptor', 'Alpha-type platelet-derived growth factor receptor', 'CD140 antigen-like family member A', 'CD140a antigen', 'PDGF-R-alpha', 'PDGFR-2', 'PDGFR2', 'Platelet-derived growth factor alpha receptor', 'Platelet-derived growth factor receptor 2', 'RHEPDGFRA']}], 'amino-acid-sequence': ['>lcl|BSEQ0001698|Platelet-derived growth factor receptor alpha\nMGTSHPAFLVLGCLLTGLSLILCQLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYP\nMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIY\nVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTTDPETPVTLHNSEGVVPASYDSRQGFNG\nTFTVGPYICEATVKGKKFQTIPFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNN\nEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVK\nEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENL\nTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDL\nVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRD\nRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKLVAPTLRSELTVAAAVLVLLVIVII\nSLIVLVVIWKQKPRYEIRWRVIESISPDGHEYIYVDPMQLPYDSRWEFPRDGLVLGRVLG\nSGAFGKVVEGTAYGLSRSQPVMKVAVKMLKPTARSSEKQALMSELKIMTHLGPHLNIVNL\nLGACTKSGPIYIITEYCFYGDLVNYLHKNRDSFLSHHPEKPKKELDIFGLNPADESTRSY\nVILSFENNGDYMDMKQADTTQYVPMLERKEVSKYSDIQRSLYDRPASYKKKSMLDSEVKN\nLLSDDNSEGLTLLDLLSFTYQVARGMEFLASKNCVHRDLAARNVLLAQGKIVKICDFGLA\nRDIMHDSNYVSKGSTFLPVKWMAPESIFDNLYTTLSDVWSYGILLWEIFSLGGTPYPGMM\nVDSTFYNKIKSGYRMAKPDHATSEVYEIMVKCWNSEPEKRPSFYHLSEIVENLLPGQYKK\nSYEKIHLDFLKSDHPAVARMRVDSDNAYIGVTYKNEEDKLKDWEGGLDEQRLSADSGYII\nPLPDIDPVPEEEDLGKRNRHSSQTSEESAIETGSSSSTFIKREDETIEDIDMMDDIGIDS\nSDLVEDSFL'], 'gene-sequence': ['>lcl|BSEQ0019023|Platelet-derived growth factor receptor alpha (PDGFRA)\nATGGGGACTTCCCATCCGGCGTTCCTGGTCTTAGGCTGTCTTCTCACAGGGCTGAGCCTA\nATCCTCTGCCAGCTTTCATTACCCTCTATCCTTCCAAATGAAAATGAAAAGGTTGTGCAG\nCTGAATTCATCCTTTTCTCTGAGATGCTTTGGGGAGAGTGAAGTGAGCTGGCAGTACCCC\nATGTCTGAAGAAGAGAGCTCCGATGTGGAAATCAGAAATGAAGAAAACAACAGCGGCCTT\nTTTGTGACGGTCTTGGAAGTGAGCAGTGCCTCGGCGGCCCACACAGGGTTGTACACTTGC\nTATTACAACCACACTCAGACAGAAGAGAATGAGCTTGAAGGCAGGCACATTTACATCTAT\nGTGCCAGACCCAGATGTAGCCTTTGTACCTCTAGGAATGACGGATTATTTAGTCATCGTG\nGAGGATGATGATTCTGCCATTATACCTTGTCGCACAACTGATCCCGAGACTCCTGTAACC\nTTACACAACAGTGAGGGGGTGGTACCTGCCTCCTACGACAGCAGACAGGGCTTTAATGGG\nACCTTCACTGTAGGGCCCTATATCTGTGAGGCCACCGTCAAAGGAAAGAAGTTCCAGACC\nATCCCATTTAATGTTTATGCTTTAAAAGCAACATCAGAGCTGGATCTAGAAATGGAAGCT\nCTTAAAACCGTGTATAAGTCAGGGGAAACGATTGTGGTCACCTGTGCTGTTTTTAACAAT\nGAGGTGGTTGACCTTCAATGGACTTACCCTGGAGAAGTGAAAGGCAAAGGCATCACAATG\nCTGGAAGAAATCAAAGTCCCATCCATCAAATTGGTGTACACTTTGACGGTCCCCGAGGCC\nACGGTGAAAGACAGTGGAGATTACGAATGTGCTGCCCGCCAGGCTACCAGGGAGGTCAAA\nGAAATGAAGAAAGTCACTATTTCTGTCCATGAGAAAGGTTTCATTGAAATCAAACCCACC\nTTCAGCCAGTTGGAAGCTGTCAACCTGCATGAAGTCAAACATTTTGTTGTAGAGGTGCGG\nGCCTACCCACCTCCCAGGATATCCTGGCTGAAAAACAATCTGACTCTGATTGAAAATCTC\nACTGAGATCACCACTGATGTGGAAAAGATTCAGGAAATAAGGTATCGAAGCAAATTAAAG\nCTGATCCGTGCTAAGGAAGAAGACAGTGGCCATTATACTATTGTAGCTCAAAATGAAGAT\nGCTGTGAAGAGCTATACTTTTGAACTGTTAACTCAAGTTCCTTCATCCATTCTGGACTTG\nGTCGATGATCACCATGGCTCAACTGGGGGACAGACGGTGAGGTGCACAGCTGAAGGCACG\nCCGCTTCCTGATATTGAGTGGATGATATGCAAAGATATTAAGAAATGTAATAATGAAACT\nTCCTGGACTATTTTGGCCAACAATGTCTCAAACATCATCACGGAGATCCACTCCCGAGAC\nAGGAGTACCGTGGAGGGCCGTGTGACTTTCGCCAAAGTGGAGGAGACCATCGCCGTGCGA\nTGCCTGGCTAAGAATCTCCTTGGAGCTGAGAACCGAGAGCTGAAGCTGGTGGCTCCCACC\nCTGCGTTCTGAACTCACGGTGGCTGCTGCAGTCCTGGTGCTGTTGGTGATTGTGATCATC\nTCACTTATTGTCCTGGTTGTCATTTGGAAACAGAAACCGAGGTATGAAATTCGCTGGAGG\nGTCATTGAATCAATCAGCCCAGATGGACATGAATATATTTATGTGGACCCGATGCAGCTG\nCCTTATGACTCAAGATGGGAGTTTCCAAGAGATGGACTAGTGCTTGGTCGGGTCTTGGGG\nTCTGGAGCGTTTGGGAAGGTGGTTGAAGGAACAGCCTATGGATTAAGCCGGTCCCAACCT\nGTCATGAAAGTTGCAGTGAAGATGCTAAAACCCACGGCCAGATCCAGTGAAAAACAAGCT\nCTCATGTCTGAACTGAAGATAATGACTCACCTGGGGCCACATTTGAACATTGTAAACTTG\nCTGGGAGCCTGCACCAAGTCAGGCCCCATTTACATCATCACAGAGTATTGCTTCTATGGA\nGATTTGGTCAACTATTTGCATAAGAATAGGGATAGCTTCCTGAGCCACCACCCAGAGAAG\nCCAAAGAAAGAGCTGGATATCTTTGGATTGAACCCTGCTGATGAAAGCACACGGAGCTAT\nGTTATTTTATCTTTTGAAAACAATGGTGACTACATGGACATGAAGCAGGCTGATACTACA\nCAGTATGTCCCCATGCTAGAAAGGAAAGAGGTTTCTAAATATTCCGACATCCAGAGATCA\nCTCTATGATCGTCCAGCCTCATATAAGAAGAAATCTATGTTAGACTCAGAAGTCAAAAAC\nCTCCTTTCAGATGATAACTCAGAAGGCCTTACTTTATTGGATTTGTTGAGCTTCACCTAT\nCAAGTTGCCCGAGGAATGGAGTTTTTGGCTTCAAAAAATTGTGTCCACCGTGATCTGGCT\nGCTCGCAACGTCCTCCTGGCACAAGGAAAAATTGTGAAGATCTGTGACTTTGGCCTGGCC\nAGAGACATCATGCATGATTCGAACTATGTGTCGAAAGGCAGTACCTTTCTGCCCGTGAAG\nTGGATGGCTCCTGAGAGCATCTTTGACAACCTCTACACCACACTGAGTGATGTCTGGTCT\nTATGGCATTCTGCTCTGGGAGATCTTTTCCCTTGGTGGCACCCCTTACCCCGGCATGATG\nGTGGATTCTACTTTCTACAATAAGATCAAGAGTGGGTACCGGATGGCCAAGCCTGACCAC\nGCTACCAGTGAAGTCTACGAGATCATGGTGAAATGCTGGAACAGTGAGCCGGAGAAGAGA\nCCCTCCTTTTACCACCTGAGTGAGATTGTGGAGAATCTGCTGCCTGGACAATATAAAAAG\nAGTTATGAAAAAATTCACCTGGACTTCCTGAAGAGTGACCATCCTGCTGTGGCACGCATG\nCGTGTGGACTCAGACAATGCATACATTGGTGTCACCTACAAAAACGAGGAAGACAAGCTG\nAAGGACTGGGAGGGTGGTCTGGATGAGCAGAGACTGAGCGCTGACAGTGGCTACATCATT\nCCTCTGCCTGACATTGACCCTGTCCCTGAGGAGGAGGACCTGGGCAAGAGGAACAGACAC\nAGCTCGCAGACCTCTGAAGAGAGTGCCATTGAGACGGGTTCCAGCAGTTCCACCTTCATC\nAAGAGAGAGGACGAGACCATTGAAGACATCGACATGATGGATGACATCGGCATAGACTCT\nTCAGACCTGGTGGAAGACAGCTTCCTGTAA'], 'pfams': [{'pfam': [{'identifier': ['PF07714'], 'name': ['PK_Tyr_Ser-Thr']}, {'identifier': ['PF07679'], 'name': ['I-set']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intrinsic component of plasma membrane']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['nucleus']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['protein complex']}, {'category': ['function'], 'description': ['ATP binding']}, {'category': ['function'], 'description': ['platelet-derived growth factor alpha-receptor activity']}, {'category': ['function'], 'description': ['platelet-derived growth factor binding']}, {'category': ['function'], 'description': ['platelet-derived growth factor receptor binding']}, {'category': ['function'], 'description': ['protein homodimerization activity']}, {'category': ['function'], 'description': ['protein kinase activity']}, {'category': ['function'], 'description': ['transmembrane receptor protein tyrosine kinase activity']}, {'category': ['function'], 'description': ['vascular endothelial growth factor binding']}, {'category': ['function'], 'description': ['vascular endothelial growth factor-activated receptor activity']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['cardiac myofibril assembly']}, {'category': ['process'], 'description': ['cell activation']}, {'category': ['process'], 'description': ['cell chemotaxis']}, {'category': ['process'], 'description': ['cellular response to reactive oxygen species']}, {'category': ['process'], 'description': ['embryonic cranial skeleton morphogenesis']}, {'category': ['process'], 'description': ['embryonic digestive tract morphogenesis']}, {'category': ['process'], 'description': ['embryonic skeletal system morphogenesis']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['luteinization']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['metanephric glomerular capillary formation']}, {'category': ['process'], 'description': ['negative regulation of platelet activation']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['phosphatidylinositol-mediated signaling']}, {'category': ['process'], 'description': ['platelet aggregation']}, {'category': ['process'], 'description': ['platelet-derived growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['platelet-derived growth factor receptor-alpha signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of cytosolic calcium ion concentration']}, {'category': ['process'], 'description': ['positive regulation of DNA replication']}, {'category': ['process'], 'description': ['positive regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['positive regulation of fibroblast proliferation']}, {'category': ['process'], 'description': ['positive regulation of phosphatidylinositol 3-kinase activity']}, {'category': ['process'], 'description': ['positive regulation of phosphatidylinositol 3-kinase signaling']}, {'category': ['process'], 'description': ['positive regulation of phospholipase C activity']}, {'category': ['process'], 'description': ['protein autophosphorylation']}, {'category': ['process'], 'description': ['Ras protein signal transduction']}, {'category': ['process'], 'description': ['regulation of actin cytoskeleton reorganization']}, {'category': ['process'], 'description': ['regulation of chemotaxis']}, {'category': ['process'], 'description': ['regulation of mesenchymal stem cell differentiation']}, {'category': ['process'], 'description': ['retina vasculature development in camera-type eye']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['viral process']}, {'category': ['process'], 'description': ['wound healing']}]}]}]}, {'id': ['BE0000910'], 'name': ['Alpha-2-macroglobulin'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13322'], 'pubmed-id': ['1697862'], 'citation': ['Lizonova A, Bizik J, Grofova M, Vaheri A: Coexpression of tumor-associated alpha 2-macroglobulin and growth factors in human melanoma cell lines. J Cell Biochem. 1990 Aug;43(4):315-25.']}, {'ref-id': ['A13323'], 'pubmed-id': ['7541796'], 'citation': ['Bonner JC, Osornio-Vargas AR: Differential binding and regulation of platelet-derived growth factor A and B chain isoforms by alpha 2-macroglobulin. J Biol Chem. 1995 Jul 7;270(27):16236-42.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Alpha-2-macroglobulin'], 'general-function': ['Tumor necrosis factor binding'], 'specific-function': [""Is able to inhibit all four classes of proteinases by a unique 'trapping' mechanism. This protein has a peptide stretch, called the 'bait region' which contains specific cleavage sites for different proteinases. When a proteinase cleaves the bait region, a conformational change is induced in the protein which traps the proteinase. The entrapped enzyme remains active against low molecular weight substrates (activity against high molecular weight substrates is greatly reduced). Following cleavage in the bait region a thioester bond is hydrolyzed and mediates the covalent binding of the protein to the proteinase.""], 'gene-name': ['A2M'], 'locus': ['12p13.3-p12.3'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-23'], 'theoretical-pi': ['6.39'], 'molecular-weight': ['163289.945'], 'chromosome-location': ['12'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:7']}, {'resource': ['GenAtlas'], 'identifier': ['A2M']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M11313']}, {'resource': ['GenBank Protein Database'], 'identifier': ['177870']}, {'resource': ['UniProtKB'], 'identifier': ['P01023']}, {'resource': ['UniProt Accession'], 'identifier': ['A2MG_HUMAN']}]}], 'synonyms': [{'synonym': ['Alpha-2-M', 'C3 and PZP-like alpha-2-macroglobulin domain-containing protein 5', 'CPAMD5']}], 'amino-acid-sequence': ['>lcl|BSEQ0037100|Alpha-2-macroglobulin\nMGKNKLLHPSLVLLLLVLLPTDASVSGKPQYMVLVPSLLHTETTEKGCVLLSYLNETVTV\nSASLESVRGNRSLFTDLEAENDVLHCVAFAVPKSSSNEEVMFLTVQVKGPTQEFKKRTTV\nMVKNEDSLVFVQTDKSIYKPGQTVKFRVVSMDENFHPLNELIPLVYIQDPKGNRIAQWQS\nFQLEGGLKQFSFPLSSEPFQGSYKVVVQKKSGGRTEHPFTVEEFVLPKFEVQVTVPKIIT\nILEEEMNVSVCGLYTYGKPVPGHVTVSICRKYSDASDCHGEDSQAFCEKFSGQLNSHGCF\nYQQVKTKVFQLKRKEYEMKLHTEAQIQEEGTVVELTGRQSSEITRTITKLSFVKVDSHFR\nQGIPFFGQVRLVDGKGVPIPNKVIFIRGNEANYYSNATTDEHGLVQFSINTTNVMGTSLT\nVRVNYKDRSPCYGYQWVSEEHEEAHHTAYLVFSPSKSFVHLEPMSHELPCGHTQTVQAHY\nILNGGTLLGLKKLSFYYLIMAKGGIVRTGTHGLLVKQEDMKGHFSISIPVKSDIAPVARL\nLIYAVLPTGDVIGDSAKYDVENCLANKVDLSFSPSQSLPASHAHLRVTAAPQSVCALRAV\nDQSVLLMKPDAELSASSVYNLLPEKDLTGFPGPLNDQDNEDCINRHNVYINGITYTPVSS\nTNEKDMYSFLEDMGLKAFTNSKIRKPKMCPQLQQYEMHGPEGLRVGFYESDVMGRGHARL\nVHVEEPHTETVRKYFPETWIWDLVVVNSAGVAEVGVTVPDTITEWKAGAFCLSEDAGLGI\nSSTASLRAFQPFFVELTMPYSVIRGEAFTLKATVLNYLPKCIRVSVQLEASPAFLAVPVE\nKEQAPHCICANGRQTVSWAVTPKSLGNVNFTVSAEALESQELCGTEVPSVPEHGRKDTVI\nKPLLVEPEGLEKETTFNSLLCPSGGEVSEELSLKLPPNVVEESARASVSVLGDILGSAMQ\nNTQNLLQMPYGCGEQNMVLFAPNIYVLDYLNETQQLTPEIKSKAIGYLNTGYQRQLNYKH\nYDGSYSTFGERYGRNQGNTWLTAFVLKTFAQARAYIFIDEAHITQALIWLSQRQKDNGCF\nRSSGSLLNNAIKGGVEDEVTLSAYITIALLEIPLTVTHPVVRNALFCLESAWKTAQEGDH\nGSHVYTKALLAYAFALAGNQDKRKEVLKSLNEEAVKKDNSVHWERPQKPKAPVGHFYEPQ\nAPSAEVEMTSYVLLAYLTAQPAPTSEDLTSATNIVKWITKQQNAQGGFSSTQDTVVALHA\nLSKYGAATFTRTGKAAQVTIQSSGTFSSKFQVDNNNRLLLQQVSLPELPGEYSMKVTGEG\nCVYLQTSLKYNILPEKEEFPFALGVQTLPQTCDEPKAHTSFQISLSVSYTGSRSASNMAI\nVDVKMVSGFIPLKPTVKMLERSNHVSRTEVSSNHVLIYLDKVSNQTLSLFFTVLQDVPVR\nDLKPAIVKVYDYYETDEFAIAEYNAPCSKDLGNA'], 'gene-sequence': ['>lcl|BSEQ0019028|Alpha-2-macroglobulin (A2M)\nATGGGGAAGAACAAACTCCTTCATCCAAGTCTGGTTCTTCTCCTCTTGGTCCTCCTGCCC\nACAGACGCCTCAGTCTCTGGAAAACCGCAGTATATGGTTCTGGTCCCCTCCCTGCTCCAC\nACTGAGACCACTGAGAAGGGCTGTGTCCTTCTGAGCTACCTGAATGAGACAGTGACTGTA\nAGTGCTTCCTTGGAGTCTGTCAGGGGAAACAGGAGCCTCTTCACTGACCTGGAGGCGGAG\nAATGACGTACTCCACTGTGTCGCCTTCGCTGTCCCAAAGTCTTCATCCAATGAGGAGGTA\nATGTTCCTCACTGTCCAAGTGAAAGGACCAACCCAAGAATTTAAGAAGCGGACCACAGTG\nATGGTTAAGAACGAGGACAGTCTGGTCTTTGTCCAGACAGACAAATCAATCTACAAACCA\nGGGCAGACAGTGAAATTTCGTGTTGTCTCCATGGATGAAAACTTTCACCCCCTGAATGAG\nTTGATTCCACTAGTATACATTCAGGATCCCAAAGGAAATCGCATCGCACAATGGCAGAGT\nTTCCAGTTAGAGGGTGGCCTCAAGCAATTTTCTTTTCCCCTCTCATCAGAGCCCTTCCAG\nGGCTCCTACAAGGTGGTGGTACAGAAGAAATCAGGTGGAAGGACAGAGCACCCTTTCACC\nGTGGAGGAATTTGTTCTTCCCAAGTTTGAAGTACAAGTAACAGTGCCAAAGATAATCACC\nATCTTGGAAGAAGAGATGAATGTATCAGTGTGTGGCCTATACACATATGGGAAGCCTGTC\nCCTGGACATGTGACTGTGAGCATTTGCAGAAAGTATAGTGACGCTTCCGACTGCCACGGT\nGAAGATTCACAGGCTTTCTGTGAGAAATTCAGTGGACAGCTAAACAGCCATGGCTGCTTC\nTATCAGCAAGTAAAAACCAAGGTCTTCCAGCTGAAGAGGAAGGAGTATGAAATGAAACTT\nCACACTGAGGCCCAGATCCAAGAAGAAGGAACAGTGGTGGAATTGACTGGAAGGCAGTCC\nAGTGAAATCACAAGAACCATAACCAAACTCTCATTTGTGAAAGTGGACTCACACTTTCGA\nCAGGGAATTCCCTTCTTTGGGCAGGTGCGCCTAGTAGATGGGAAAGGCGTCCCTATACCA\nAATAAAGTCATATTCATCAGAGGAAATGAAGCAAACTATTACTCCAATGCTACCACGGAT\nGAGCATGGCCTTGTACAGTTCTCTATCAACACCACCAATGTTATGGGTACCTCTCTTACT\nGTTAGGGTCAATTACAAGGATCGTAGTCCCTGTTACGGCTACCAGTGGGTGTCAGAAGAA\nCACGAAGAGGCACATCACACTGCTTATCTTGTGTTCTCCCCAAGCAAGAGCTTTGTCCAC\nCTTGAGCCCATGTCTCATGAACTACCCTGTGGCCATACTCAGACAGTCCAGGCACATTAT\nATTCTGAATGGAGGCACCCTGCTGGGGCTGAAGAAGCTCTCCTTCTATTATCTGATAATG\nGCAAAGGGAGGCATTGTCCGAACTGGGACTCATGGACTGCTTGTGAAGCAGGAAGACATG\nAAGGGCCATTTTTCCATCTCAATCCCTGTGAAGTCAGACATTGCTCCTGTCGCTCGGTTG\nCTCATCTATGCTGTTTTACCTACCGGGGACGTGATTGGGGATTCTGCAAAATATGATGTT\nGAAAATTGTCTGGCCAACAAGGTGGATTTGAGCTTCAGCCCATCACAAAGTCTCCCAGCC\nTCACACGCCCACCTGCGAGTCACAGCGGCTCCTCAGTCCGTCTGCGCCCTCCGTGCTGTG\nGACCAAAGCGTGCTGCTCATGAAGCCTGATGCTGAGCTCTCGGCGTCCTCGGTTTACAAC\nCTGCTACCAGAAAAGGACCTCACTGGCTTCCCTGGGCCTTTGAATGACCAGGACGATGAA\nGACTGCATCAATCGTCATAATGTCTATATTAATGGAATCACATATACTCCAGTATCAAGT\nACAAATGAAAAGGATATGTACAGCTTCCTAGAGGACATGGGCTTAAAGGCATTCACCAAC\nTCAAAGATTCGTAAACCCAAAATGTGTCCACAGCTTCAACAGTATGAAATGCATGGACCT\nGAAGGTCTACGTGTAGGTTTTTATGAGTCAGATGTAATGGGAAGAGGCCATGCACGCCTG\nGTGCATGTTGAAGAGCCTCACACGGAGACCGTACGAAAGTACTTCCCTGAGACATGGATC\nTGGGATTTGGTGGTGGTAAACTCAGCAGGTGTGGCTGAGGTAGGAGTAACAGTCCCTGAC\nACCATCACCGAGTGGAAGGCAGGGGCCTTCTGCCTGTCTGAAGATGCTGGACTTGGTATC\nTCTTCCACTGCCTCTCTCCGAGCCTTCCAGCCCTTCTTTGTGGAGCTCACAATGCCTTAC\nTCTGTGATTCGTGGAGAGGCCTTCACACTCAAGGCCACGGTCCTAAACTACCTTCCCAAA\nTGCATCCGGGTCAGTGTGCAGCTGGAAGCCTCTCCCGCCTTCCTAGCTGTCCCAGTGGAG\nAAGGAACAAGCGCCTCACTGCATCTGTGCAAACGGGCGGCAAACTGTGTCCTGGGCAGTA\nACCCCAAAGTCATTAGGAAATGTGAATTTCACTGTGAGCGCAGAGGCACTAGAGTCTCAA\nGAGCTGTGTGGGACTGAGGTGCCTTCAGTTCCTGAACACGGAAGGAAAGACACAGTCATC\nAAGCCTCTGTTGGTTGAACCTGAAGGACTAGAGAAGGAAACAACATTCAACTCCCTACTT\nTGTCCATCAGGTGGTGAGGTTTCTGAAGAATTATCCCTGAAACTGCCACCAAATGTGGTA\nGAAGAATCTGCCCGAGCTTCTGTCTCAGTTTTGGGAGACATATTAGGCTCTGCCATGCAA\nAACACACAAAATCTTCTCCAGATGCCCTATGGCTGTGGAGAGCAGAATATGGTCCTCTTT\nGCTCCTAACATCTATGTACTGGATTATCTAAATGAAACACAGCAGCTTACTCCAGAGATC\nAAGTCCAAGGCCATTGGCTATCTCAACACTGGTTACCAGAGACAGTTGAACTACAAACAC\nTATGATGGCTCCTACAGCACCTTTGGGGAGCGATATGGCAGGAACCAGGGCAACACCTGG\nCTCACAGCCTTTGTTCTGAAGACTTTTGCCCAAGCTCGAGCCTACATCTTCATCGATGAA\nGCACACATTACCCAAGCCCTCATATGGCTCTCCCAGAGGCAGAAGGACAATGGCTGTTTC\nAGGAGCTCTGGGTCACTGCTCAACAATGCCATAAAGGGAGGAGTAGAAGATGAAGTGACC\nCTCTCCGCCTATATCACCATCGCCCTTCTGGAGATTCCTCTCACAGTCACTCACCCTGTT\nGTCCGCAATGCCCTGTTTTGCCTGGAGTCAGCCTGGAAGACAGCACAAGAAGGGGACCAT\nGGCAGCCATGTATATACCAAAGCACTGCTGGCCTATGCTTTTGCCCTGGCAGGTAACCAG\nGACAAGAGGAAGGAAGTACTCAAGTCACTTAATGAGGAAGCTGTGAAGAAAGACAACTCT\nGTCCATTGGGAGCGCCCTCAGAAACCCAAGGCACCAGTGGGGCATTTTTACGAACCCCAG\nGCTCCCTCTGCTGAGGTGGAGATGACATCCTATGTGCTCCTCGCTTATCTCACGGCCCAG\nCCAGCCCCAACCTCGGAGGACCTGACCTCTGCAACCAACATCGTGAAGTGGATCACGAAG\nCAGCAGAATGCCCAGGGCGGTTTCTCCTCCACCCAGGACACAGTGGTGGCTCTCCATGCT\nCTGTCCAAATATGGAGCAGCCACATTTACCAGGACTGGGAAGGCTGCACAGGTGACTATC\nCAGTCTTCAGGGACATTTTCCAGCAAATTCCAAGTGGACAACAACAACCGCCTGTTACTG\nCAGCAGGTCTCATTGCCAGAGCTGCCTGGGGAATACAGCATGAAAGTGACAGGAGAAGGA\nTGTGTCTACCTCCAGACATCCTTGAAATACAATATTCTCCCAGAAAAGGAAGAGTTCCCC\nTTTGCTTTAGGAGTGCAGACTCTGCCTCAAACTTGTGATGAACCCAAAGCCCACACCAGC\nTTCCAAATCTCCCTAAGTGTCAGTTACACAGGGAGCCGCTCTGCCTCCAACATGGCGATC\nGTTGATGTGAAGATGGTCTCTGGCTTCATTCCCCTGAAGCCAACAGTGAAAATGCTTGAA\nAGATCTAACCATGTGAGCCGGACAGAAGTCAGCAGCAACCATGTCTTGATTTACCTTGAT\nAAGGTGTCAAATCAGACACTGAGCTTGTTCTTCACGGTTCTGCAAGATGTCCCAGTAAGA\nGATCTGAAACCAGCCATAGTGAAAGTCTATGATTACTACGAGACGGATGAGTTTGCAATT\nGCTGAGTACAATGCTCCTTGCAGCAAAGATCTTGGAAATGCTTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00207'], 'name': ['A2M']}, {'identifier': ['PF07678'], 'name': ['A2M_comp']}, {'identifier': ['PF01835'], 'name': ['A2M_N']}, {'identifier': ['PF07703'], 'name': ['A2M_N_2']}, {'identifier': ['PF07677'], 'name': ['A2M_recep']}, {'identifier': ['PF10569'], 'name': ['Thiol-ester_cl']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['platelet alpha granule lumen']}, {'category': ['function'], 'description': ['calcium-dependent protein binding']}, {'category': ['function'], 'description': ['enzyme binding']}, {'category': ['function'], 'description': ['growth factor binding']}, {'category': ['function'], 'description': ['interleukin-1 binding']}, {'category': ['function'], 'description': ['interleukin-8 binding']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase inhibitor activity']}, {'category': ['function'], 'description': ['tumor necrosis factor binding']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, intrinsic pathway']}, {'category': ['process'], 'description': ['extracellular matrix disassembly']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['negative regulation of complement activation, lectin pathway']}, {'category': ['process'], 'description': ['negative regulation of endopeptidase activity']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['platelet degranulation']}, {'category': ['process'], 'description': ['regulation of small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['stem cell differentiation']}]}]}]}]}]"
"['DB00103', 'BTD00075', 'BIOD00075']",['Agalsidase beta'],biotech,"['Agalsidase beta is a recombinant human -galactosidase A similar to [agalsidase alfa]. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009.[A220343]\r\n\r\nAgalsidase beta was granted FDA approval on 24 April 2003.[L16383]']",['liquid'],['Agalsidase beta is indicated in the treatment of Fabry disease.[L16383]'],"['-galactosidase A is uptaken by cells via the mannose 6 phosphate receptor.[A220323] Agalsidase beta hydrolyzes globotriaosylceramide and other glycosphingolipids that would normally be hydrolyzed by endogenous -galactosidase A.[L16383] Preventing the accumulation of glycosphingolipids prevents or reduces the severity of manifestations of Fabry disease such as renal failure, cardiomyopathy, or cerebrovascular events.[L16383]']",[None],"[{'target': [{'id': ['BE0004830'], 'name': ['Globotriaosylceramide'], 'organism': ['Humans'], 'actions': [{'action': ['metabolizer', 'ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A153'], 'pubmed-id': ['19852524'], 'citation': ['Schaefer RM, Tylki-Szymanska A, Hilz MJ: Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs. 2009 Nov 12;69(16):2179-205. doi: 10.2165/11318300-000000000-00000.']}, {'ref-id': ['A154'], 'pubmed-id': ['20464743'], 'citation': ['El Dib RP, Pastores GM: Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev. 2010 May 12;(5):CD006663. doi: 10.1002/14651858.CD006663.pub2.']}, {'ref-id': ['A155'], 'pubmed-id': ['19725195'], 'citation': ['Lim-Melia ER, Kronn DF: Current enzyme replacement therapy for the treatment of lysosomal storage diseases. Pediatr Ann. 2009 Aug;38(8):448-55.']}]}], 'textbooks': [None], 'links': [{'link': [{'ref-id': ['L16383'], 'title': ['FDA Approved Drug Products: Fabrazyme Agalsidase Beta Intravenous Injection'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103979s5303lbl.pdf']}]}], 'attachments': [None]}], 'known-action': ['yes']}]}]"
"['DB00104', 'BTD00088', 'BIOD00088']",['Octreotide'],biotech,"['Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction.[L14501] In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management.[L14501]\r\n\r\nOctreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone.[L14513] Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas).[L14513] In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance treatment of acromegaly. This drug was developed by Chiasma Inc.[L14495,L14507,L14528]']",['solid'],"['Octreotide by injection is used for the treatment of acromegaly and the reduction of flushing and diarrhea symptoms related to carcinoid tumors and/or vasoactive intestinal peptide (VIPoma) tumors.[L14513] The delayed-release oral formulation is used for the long-term treatment of acromegaly in patients who tolerate and respond adequately to injectable octreotide and [lanreotide].[L14507,L45528]']","[""Octreotide binds to somatostatin receptors coupled to phospholipase C through G proteins and leads to smooth muscle contraction in the blood vessels.[L14519] Downstream effects that stimulate phospholipase C, the production of 1, 4,5-inositol triphosphate, and action on the L-type calcium channels lead to the inhibition of growth hormone, treating the various growth-hormone and metabolic effects of acromegaly.[L14519]\r\n\r\nOctreotide's suppression of luteinizing hormone (LH)[A214724], reduction in splanchnic blood flow[A214727], and inhibition of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide provide relief for the gastrointestinal and flushing symptoms of carcinoid and/or VIPoma tumors.[A214721]""]","[{'food-interaction': ['Take on an empty stomach. The oral capsules should be taken on an empty stomach. Food reduces oral octreotide absorption by 90%.', 'Take with or without food. Octreotide injections may be taken with or without food.']}]","[{'target': [{'id': ['BE0010008'], 'name': ['Somatostatin receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A214673'], 'pubmed-id': ['19330452'], 'citation': ['Casarini AP, Jallad RS, Pinto EM, Soares IC, Nonogaki S, Giannella-Neto D, Musolino NR, Alves VA, Bronstein MD: Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary. 2009;12(4):297-303. doi: 10.1007/s11102-009-0175-1.']}, {'ref-id': ['A214676'], 'pubmed-id': ['25451334'], 'citation': ['Mulak A, Larauche M, Biraud M, Million M, Rivier J, Tache Y: Selective agonists of somatostatin receptor subtype 1 or 2 injected peripherally induce antihyperalgesic effect in two models of visceral hypersensitivity in mice. Peptides. 2015 Jan;63:71-80. doi: 10.1016/j.peptides.2014.10.013. Epub 2014 Nov 5.']}]}], 'textbooks': [None], 'links': [{'link': [{'ref-id': ['L14513'], 'title': ['Product monograph: Sandostatin (octreotide acetate) injection'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19667scm044_Sandostatin_lbl.pdf']}, {'ref-id': ['L14519'], 'title': ['NIH StatPearls: Octreotide'], 'url': ['https://www.ncbi.nlm.nih.gov/books/NBK544333/']}]}], 'attachments': [None]}], 'known-action': ['yes']}]}]"
"['DB00105', 'BTD00066', 'BIOD00066', 'DB05600']",['Interferon alfa-2b'],biotech,['Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.'],['liquid'],"[""For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.""]",['Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which upon dimerization activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.'],[{'food-interaction': ['Avoid alcohol.']}],"[{'target': [{'id': ['BE0000385'], 'name': ['Interferon alpha/beta receptor 2'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A2138'], 'pubmed-id': ['7584665'], 'citation': ['Eid P, Tovey MG: Characterization of a domain of a human type I interferon receptor protein involved in ligand binding. J Interferon Cytokine Res. 1995 Mar;15(3):205-11.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interferon alpha/beta receptor 2'], 'general-function': ['Type i interferon receptor activity'], 'specific-function': ['Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.'], 'gene-name': ['IFNAR2'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['244-264'], 'signal-regions': ['1-26'], 'theoretical-pi': ['4.11'], 'molecular-weight': ['57758.24'], 'chromosome-location': ['21'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5433']}, {'resource': ['GenAtlas'], 'identifier': ['IFNAR2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L42243']}, {'resource': ['GenBank Protein Database'], 'identifier': ['995300']}, {'resource': ['UniProtKB'], 'identifier': ['P48551']}, {'resource': ['UniProt Accession'], 'identifier': ['INAR2_HUMAN']}]}], 'synonyms': [{'synonym': ['IFN-R-2', 'IFNABR', 'IFNARB', 'Interferon alpha binding protein', 'Type I interferon receptor 2']}], 'amino-acid-sequence': ['>lcl|BSEQ0000767|Interferon alpha/beta receptor 2\nMLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS\nIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF\nSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK\nHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE\nSAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD\nMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI\nDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR\nITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT\nFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR'], 'gene-sequence': ['>lcl|BSEQ0018941|Interferon alpha/beta receptor 2 (IFNAR2)\nATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT\nATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT\nTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC\nATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG\nGTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA\nAGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC\nAGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG\nATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA\nGAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG\nCATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA\nATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA\nATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA\nTCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC\nATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG\nAGGCAAGGTCTCGCTAAGGGCTGGAATGCAGTGGCTATTCACAGGTGCAGTCATAATGCA\nCTACAGTCTGAAACTCCTGAGCTCAAACAGTCGTCCTGCCTAAGCTTCCCCAGTAGCTGG\nGATTACAAGCGTGCATCCCTGTGCCCCAGTGATTAA'], 'pfams': [{'pfam': [{'identifier': ['PF01108'], 'name': ['Tissue_fac']}, {'identifier': ['PF09294'], 'name': ['Interfer-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['protein kinase binding']}, {'category': ['function'], 'description': ['type I interferon binding']}, {'category': ['function'], 'description': ['type I interferon receptor activity']}, {'category': ['process'], 'description': ['cell proliferation']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['JAK-STAT cascade']}, {'category': ['process'], 'description': ['regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['regulation of type I interferon-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to interferon-alpha']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['type I interferon signaling pathway']}]}]}]}, {'id': ['BE0000661'], 'name': ['Interferon alpha/beta receptor 1'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A6726'], 'pubmed-id': ['10567921'], 'citation': ['Khine AA, Lingwood CA: Functional significance of globotriaosyl ceramide in interferon-alpha(2)/type 1 interferon receptor-mediated antiviral activity. J Cell Physiol. 2000 Jan;182(1):97-108.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interferon alpha/beta receptor 1'], 'general-function': ['Type i interferon receptor activity'], 'specific-function': ['Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.'], 'gene-name': ['IFNAR1'], 'locus': [None], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['437-457'], 'signal-regions': ['1-27'], 'theoretical-pi': ['5.56'], 'molecular-weight': ['63524.81'], 'chromosome-location': ['21'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5432']}, {'resource': ['GenAtlas'], 'identifier': ['IFNAR1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['J03171']}, {'resource': ['GenBank Protein Database'], 'identifier': ['306914']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1723']}, {'resource': ['UniProtKB'], 'identifier': ['P17181']}, {'resource': ['UniProt Accession'], 'identifier': ['INAR1_HUMAN']}]}], 'synonyms': [{'synonym': ['CRF2-1', 'Cytokine receptor class-II member 1', 'Cytokine receptor family 2 member 1', 'IFN-R-1', 'IFNAR', 'Type I interferon receptor 1']}], 'amino-acid-sequence': ['>lcl|BSEQ0001318|Interferon alpha/beta receptor 1\nMMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT\nFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF\nTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI\nENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ\nNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK\nGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP\nVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV\nFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE\nYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN\nEDESESKTSEELQQDFV'], 'gene-sequence': ['>lcl|BSEQ0018987|Interferon alpha/beta receptor 1 (IFNAR1)\nATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTG\nTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC\nATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT\nTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG\nAATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT\nAAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT\nACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG\nGCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT\nTTAAGCTTTACATATAGCTTAGTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT\nGAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA\nAAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT\nATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA\nAATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG\nTGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA\nCCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA\nGGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA\nGAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA\nTCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT\nGTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT\nGAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT\nGTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT\nTTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA\nGTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC\nTTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG\nTATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA\nAAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT\nGATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT\nGAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA'], 'pfams': [{'pfam': [{'identifier': ['PF01108'], 'name': ['Tissue_fac']}, {'identifier': ['PF09294'], 'name': ['Interfer-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['type I interferon receptor activity']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['defense response to virus']}, {'category': ['process'], 'description': ['JAK-STAT cascade']}, {'category': ['process'], 'description': ['positive regulation of interferon-beta production']}, {'category': ['process'], 'description': ['positive regulation of interferon-gamma production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-1 beta secretion']}, {'category': ['process'], 'description': ['positive regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['regulation of type I interferon-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['T cell activation']}, {'category': ['process'], 'description': ['type I interferon biosynthetic process']}, {'category': ['process'], 'description': ['type I interferon signaling pathway']}]}]}]}]}]"
"['DB00106', 'BTD00051', 'BIOD00051']",['Abarelix'],small molecule,['Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.'],['solid'],['For palliative treatment of advanced prostate cancer.'],['Abarelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion.'],[None],"[{'target': [{'id': ['BE0000203'], 'name': ['Gonadotropin-releasing hormone receptor'], 'organism': ['Humans'], 'actions': [{'action': ['antagonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A2140'], 'pubmed-id': ['16985933'], 'citation': ['Debruyne FM: Gonadotropin-releasing hormone antagonist in the management of prostate cancer. Rev Urol. 2004;6 Suppl 7:S25-32.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Gonadotropin-releasing hormone receptor'], 'general-function': ['Peptide binding'], 'specific-function': ['Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This receptor mediates its action by association with G-proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act as an inhibitor of GnRH-R signaling.'], 'gene-name': ['GNRHR'], 'locus': ['4q21.2'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['39-58\n78-97\n116-137\n165-184\n213-232\n282-300\n307-326'], 'signal-regions': [None], 'theoretical-pi': ['9.93'], 'molecular-weight': ['37730.355'], 'chromosome-location': ['4'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:4421']}, {'resource': ['GenAtlas'], 'identifier': ['GNRHR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['L03380']}, {'resource': ['GenBank Protein Database'], 'identifier': ['183422']}, {'resource': ['IUPHAR'], 'identifier': ['256']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['256']}, {'resource': ['UniProtKB'], 'identifier': ['P30968']}, {'resource': ['UniProt Accession'], 'identifier': ['GNRHR_HUMAN']}]}], 'synonyms': [{'synonym': ['GnRH receptor', 'GRHR']}], 'amino-acid-sequence': ['>lcl|BSEQ0000405|Gonadotropin-releasing hormone receptor\nMANSASPEQNQNHCSAINNSIPLMQGNLPTLTLSGKIRVTVTFFLFLLSATFNASFLLKL\nQKWTQKKEKGKKLSRMKLLLKHLTLANLLETLIVMPLDGMWNITVQWYAGELLCKVLSYL\nKLFSMYAPAFMMVVISLDRSLAITRPLALKSNSKVGQSMVGLAWILSSVFAGPQLYIFRM\nIHLADSSGQTKVFSQCVTHCSFSQWWHQAFYNFFTFSCLFIIPLFIMLICNAKIIFTLTR\nVLHQDPHELQLNQSKNNIPRARLKTLKMTVAFATSFTVCWTPYYVLGIWYWFDPEMLNRL\nSDPVNHFFFLFAFLNPCFDPLIYGYFSL'], 'gene-sequence': ['>lcl|BSEQ0018926|Gonadotropin-releasing hormone receptor (GNRHR)\nATGGCAAACAGTGCCTCTCCTGAACAGAATCAAAATCACTGTTCAGCCATCAACAACAGC\nATCCCACTGATGCAGGGCAACCTCCCCACTCTGACCTTGTCTGGAAAGATCCGAGTGACG\nGTTACTTTCTTCCTTTTTCTGCTCTCTGCGACCTTTAATGCTTCTTTCTTGTTGAAACTT\nCAGAAGTGGACACAGAAGAAAGAGAAAGGGAAAAAGCTCTCAAGAATGAAGCTGCTCTTA\nAAACATCTGACCTTAGCCAACCTGTTGGAGACTCTGATTGTCATGCCACTGGATGGGATG\nTGGAACATTACAGTCCAATGGTATGCTGGAGAGTTACTCTGCAAAGTTCTCAGTTATCTA\nAAGCTTTTCTCCATGTATGCCCCAGCCTTCATGATGGTGGTGATCAGCCTGGACCGCTCC\nCTGGCTATCACGAGGCCCCTAGCTTTGAAAAGCAACAGCAAAGTCGGACAGTCCATGGTT\nGGCCTGGCCTGGATCCTCAGTAGTGTCTTTGCAGGACCACAGTTATACATCTTCAGGATG\nATTCATCTAGCAGACAGCTCTGGACAGACAAAAGTTTTCTCTCAATGTGTAACACACTGC\nAGTTTTTCACAATGGTGGCATCAAGCATTTTATAACTTTTTCACCTTCAGCTGCCTCTTC\nATCATCCCTCTTTTCATCATGCTGATCTGCAATGCAAAAATCATCTTCACCCTGACACGG\nGTCCTTCATCAGGACCCCCACGAACTACAACTGAATCAGTCCAAGAACAATATACCAAGA\nGCACGGCTGAAGACTCTAAAAATGACGGTTGCATTTGCCACTTCATTTACTGTCTGCTGG\nACTCCCTACTATGTCCTAGGAATTTGGTATTGGTTTGATCCTGAAATGTTAAACAGGTTG\nTCAGACCCAGTAAATCACTTCTTCTTTCTCTTTGCCTTTTTAAACCCATGCTTTGATCCA\nCTTATCTATGGATATTTTTCTCTGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['gonadotropin-releasing hormone receptor activity']}, {'category': ['function'], 'description': ['peptide binding']}, {'category': ['process'], 'description': ['cellular response to gonadotropin-releasing hormone']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['multicellular organismal development']}]}]}]}]}]"
"['DB00107', 'BTD00016', 'BIOD00016']",['Oxytocin'],biotech,"['Sir Henry H. Dale first identified oxytocin and its uterine contractile properties in 1906.[A229008,A228593,A229108] Like all other neurohypophysial hormones, oxytocin is composed of nine amino acids with a disulfide bridge between the Cys 1 and 6 residues.[A229008,A228593] In the mid-1950s, synthetic oxytocin was successfully synthesized by a biochemist named Vincent du Vigneaud; he was later recognized with a Nobel prize for his work.[A229108] Oxytocin continues to be an important tool in modern obstetrics to induce labor when indicated and to manage postpartum hemorrhage.[A229108,A229113] It is estimated that labor induction with oxytocin is used in almost 10% of deliveries globally.[A228593] \r\n\r\nIt should be noted that there are risks associated with oxytocin intervention during childbirth. Oxytocin should be used judiciously only when necessary and by experienced healthcare practitioners.[A229113]\r\n\r\nAlthough most commonly linked to labor and delivery, oxytocin actually has broad peripheral and central effects.[A229008] It plays an important role in pair bonding, social cognition and functioning, and even fear conditioning.[A229013] Oxytocin also serves a role in metabolic homeostasis and cardiovascular regulation.[A228593,A229098]']",['liquid'],"['Administration of exogenous oxytocin is indicated in the antepartum period to initiate or improve uterine contractions for vaginal delivery in situations where there is fetal or maternal concern.[L31433] For example, It may be used to induce labor in cases of Rh sensitization, maternal diabetes, preeclampsia at or near term, and when delivery is indicated due to prematurely ruptured membranes.[A229018,L31433] Importantly, oxytocin is not approved or indicated for elective induction of labor. Oxytocin may be used to reinforce labor in select cases of uterine inertia and as adjunctive therapy in the management of incomplete or inevitable abortion. In the postpartum period, oxytocin may be used to induced contractions in the 3rd stage of labor and to control postpartum bleeding or hemorrhage.[L31433]']","['Oxytocin plays a vital role in labour and delivery.[A228928] The hormone is produced in the hypothalamus and is secreted from the paraventricular nucleus to the posterior pituitary where it is stored.[A228928,A228958] It is then released in pulses during childbirth to induce uterine contractions.[A228928]\r\n\r\nThe concentration of oxytocin receptors on the myometrium increases significantly during pregnancy and reaches a peak in early labor.[L31433] Activation of oxytocin receptors on the myometrium triggers a downstream cascade that leads to increased intracellular calcium in uterine myofibrils which strengthens and increases the frequency of uterine contractions.[L31433,A228958,A228718]\r\n\r\nIn humans, most hormones are regulated by negative feedback; however, oxytocin is one of the few that is regulated by positive feedback.[A228958] The head of the fetus pushing on the cervix signals the release of oxytocin from the posterior pituitary of the mother.[A228958] Oxytocin then travels to the uterus where it stimulates uterine contractions.[A228958] The elicited uterine contractions will then stimulate the release of increasing amounts of oxytocin.[A228958] This positive feedback loop will continue until parturition.[A228958]\r\n\r\nSince exogenously administered and endogenously secreted oxytocin result in the same effects on the female reproductive system, synthetic oxytocin may be used in specific instances during the antepartum and postpartum period to induce or improve uterine contractions.[A228958,L31433]']",[None],"[{'target': [{'id': ['BE0000844'], 'name': ['Oxytocin receptor'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A17259'], 'pubmed-id': ['20108008'], 'citation': ['Spyranti Z, Fragiadaki M, Magafa V, Borovickova L, Spyroulias GA, Cordopatis P, Slaninova J: In position 7 L- and D-Tic-substituted oxytocin and deamino oxytocin: NMR study and conformational insights. Amino Acids. 2010 Jul;39(2):539-48. doi: 10.1007/s00726-009-0470-1. Epub 2010 Jan 27.']}, {'ref-id': ['A17260'], 'pubmed-id': ['20104850'], 'citation': ['Frantz MC, Rodrigo J, Boudier L, Durroux T, Mouillac B, Hibert M: Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist. J Med Chem. 2010 Feb 25;53(4):1546-62. doi: 10.1021/jm901084f.']}, {'ref-id': ['A17261'], 'pubmed-id': ['18655883'], 'citation': ['Gimpl G, Reitz J, Brauer S, Trossen C: Oxytocin receptors: ligand binding, signalling and cholesterol dependence. Prog Brain Res. 2008;170:193-204. doi: 10.1016/S0079-6123(08)00417-2.']}, {'ref-id': ['A17262'], 'pubmed-id': ['15646817'], 'citation': ['Ahn TG, Han SJ, Cho YS, An TH, Pak SC, Flouret G: In vivo activity of the potent oxytocin antagonist on uterine activity in the rat. In Vivo. 2004 Nov-Dec;18(6):763-6.']}, {'ref-id': ['A17263'], 'pubmed-id': ['21208749'], 'citation': ['Furman DJ, Chen MC, Gotlib IH: Variant in oxytocin receptor gene is associated with amygdala volume. Psychoneuroendocrinology. 2011 Jul;36(6):891-7. doi: 10.1016/j.psyneuen.2010.12.004. Epub 2011 Jan 3.']}, {'ref-id': ['A228593'], 'pubmed-id': ['30253045'], 'citation': ['Ding C, Leow MK, Magkos F: Oxytocin in metabolic homeostasis: implications for obesity and diabetes management. Obes Rev. 2019 Jan;20(1):22-40. doi: 10.1111/obr.12757. Epub 2018 Sep 25.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Oxytocin receptor'], 'general-function': ['Vasopressin receptor activity'], 'specific-function': ['Receptor for oxytocin. The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system.'], 'gene-name': ['OXTR'], 'locus': ['3p25'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['39-63\n75-97\n114-135\n155-175\n203-225\n276-294\n310-332'], 'signal-regions': [None], 'theoretical-pi': ['9.88'], 'molecular-weight': ['42770.99'], 'chromosome-location': ['3'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:8529']}, {'resource': ['GenAtlas'], 'identifier': ['OXTR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X64878']}, {'resource': ['GenBank Protein Database'], 'identifier': ['34765']}, {'resource': ['IUPHAR'], 'identifier': ['369']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['369']}, {'resource': ['UniProtKB'], 'identifier': ['P30559']}, {'resource': ['UniProt Accession'], 'identifier': ['OXYR_HUMAN']}]}], 'synonyms': [{'synonym': ['OT-R']}], 'amino-acid-sequence': ['>lcl|BSEQ0010596|Oxytocin receptor\nMEGALAANWSAEAANASAAPPGAEGNRTAGPPRRNEALARVEVAVLCLILLLALSGNACV\nLLALRTTRQKHSRLFFFMKHLSIADLVVAVFQVLPQLLWDITFRFYGPDLLCRLVKYLQV\nVGMFASTYLLLLMSLDRCLAICQPLRSLRRRTDRLAVLATWLGCLVASAPQVHIFSLREV\nADGVFDCWAVFIQPWGPKAYITWITLAVYIVPVIVLAACYGLISFKIWQNLRLKTAAAAA\nAEAPEGAAAGDGGRVALARVSSVKLISKAKIRTVKMTFIIVLAFIVCWTPFFFVQMWSVW\nDANAPKEASAFIIVMLLASLNSCCNPWIYMLFTGHLFHELVQRFLCCSASYLKGRRLGET\nSASKKSNSSSFVLSHRSSSQRSCSQPSTA'], 'gene-sequence': ['>lcl|BSEQ0010597|Oxytocin receptor (OXTR)\nATGGAGGGCGCGCTCGCAGCCAACTGGAGCGCCGAGGCAGCCAACGCCAGCGCCGCGCCG\nCCGGGGGCCGAGGGCAACCGCACCGCCGGACCCCCGCGGCGCAACGAGGCCCTGGCGCGC\nGTGGAGGTGGCGGTGCTGTGTCTCATCCTGCTCCTGGCGCTGAGCGGGAACGCGTGTGTG\nCTGCTGGCGCTGCGCACCACACGCCAGAAGCACTCGCGCCTCTTCTTCTTCATGAAGCAC\nCTAAGCATCGCCGACCTGGTGGTGGCAGTGTTTCAGGTGCTGCCGCAGTTGCTGTGGGAC\nATCACCTTCCGCTTCTACGGGCCCGACCTGCTGTGCCGCCTGGTCAAGTACTTGCAGGTG\nGTGGGCATGTTCGCCTCCACCTACCTGCTGCTGCTCATGTCCCTGGACCGCTGCCTGGCC\nATCTGCCAGCCGCTGCGCTCGCTGCGCCGCCGCACCGACCGCCTGGCAGTGCTCGCCACG\nTGGCTCGGCTGCCTGGTGGCCAGCGCGCCGCAGGTGCACATCTTCTCTCTGCGCGAGGTG\nGCTGACGGCGTCTTCGACTGCTGGGCCGTCTTCATCCAGCCCTGGGGACCCAAGGCCTAC\nATCACATGGATCACGCTAGCTGTCTACATCGTGCCGGTCATCGTGCTCGCTGCCTGCTAC\nGGCCTTATCAGCTTCAAGATCTGGCAGAACTTGCGGCTCAAGACCGCTGCAGCGGCGGCG\nGCCGAGGCGCCAGAGGGCGCGGCGGCTGGCGATGGGGGGCGCGTGGCCCTGGCGCGTGTC\nAGCAGCGTCAAGCTCATCTCCAAGGCCAAGATCCGCACGGTCAAGATGACTTTCATCATC\nGTGCTGGCCTTCATCGTGTGCTGGACGCCTTTCTTCTTCGTGCAGATGTGGAGCGTCTGG\nGATGCCAACGCGCCCAAGGAAGCCTCGGCCTTCATCATCGTCATGCTCCTGGCCAGCCTC\nAACAGCTGCTGCAACCCCTGGATCTACATGCTGTTCACGGGCCACCTCTTCCACGAACTC\nGTGCAGCGCTTCCTGTGCTGCTCCGCCAGCTACCTGAAGGGCAGACGCCTGGGAGAGACG\nAGTGCCAGCAAAAAGAGCAACTCGTCCTCCTTTGTCCTGAGCCATCGCAGCTCCAGCCAG\nAGGAGCTGCTCCCAGCCATCCACGGCGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00001'], 'name': ['7tm_1']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['apical plasma membrane']}, {'category': ['component'], 'description': ['cell-cell adherens junction']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['microvillus']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['oxytocin receptor activity']}, {'category': ['function'], 'description': ['peptide binding']}, {'category': ['function'], 'description': ['peptide hormone binding']}, {'category': ['function'], 'description': ['vasopressin receptor activity']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular response to hormone stimulus']}, {'category': ['process'], 'description': ['digestive tract development']}, {'category': ['process'], 'description': ['eating behavior']}, {'category': ['process'], 'description': ['ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['estrous cycle']}, {'category': ['process'], 'description': ['female pregnancy']}, {'category': ['process'], 'description': ['G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['heart development']}, {'category': ['process'], 'description': ['lactation']}, {'category': ['process'], 'description': ['maternal behavior']}, {'category': ['process'], 'description': ['maternal process involved in parturition']}, {'category': ['process'], 'description': ['memory']}, {'category': ['process'], 'description': ['muscle contraction']}, {'category': ['process'], 'description': ['negative regulation of gastric acid secretion']}, {'category': ['process'], 'description': ['positive regulation of blood pressure']}, {'category': ['process'], 'description': ['positive regulation of cytosolic calcium ion concentration']}, {'category': ['process'], 'description': ['positive regulation of norepinephrine secretion']}, {'category': ['process'], 'description': ['positive regulation of penile erection']}, {'category': ['process'], 'description': ['positive regulation of synapse assembly']}, {'category': ['process'], 'description': ['positive regulation of synaptic transmission, GABAergic']}, {'category': ['process'], 'description': ['positive regulation of synaptic transmission, glutamatergic']}, {'category': ['process'], 'description': ['positive regulation of uterine smooth muscle contraction']}, {'category': ['process'], 'description': ['positive regulation of vasoconstriction']}, {'category': ['process'], 'description': ['regulation of systemic arterial blood pressure by vasopressin']}, {'category': ['process'], 'description': ['response to amphetamine']}, {'category': ['process'], 'description': ['response to anoxia']}, {'category': ['process'], 'description': ['response to cocaine']}, {'category': ['process'], 'description': ['response to cytokine']}, {'category': ['process'], 'description': ['response to drug']}, {'category': ['process'], 'description': ['response to estradiol']}, {'category': ['process'], 'description': ['response to peptide']}, {'category': ['process'], 'description': ['response to peptide hormone']}, {'category': ['process'], 'description': ['response to progesterone']}, {'category': ['process'], 'description': ['sleep']}, {'category': ['process'], 'description': ['social behavior']}, {'category': ['process'], 'description': ['sperm ejaculation']}, {'category': ['process'], 'description': ['suckling behavior']}, {'category': ['process'], 'description': ['telencephalon development']}]}]}]}]}]"
"['DB00108', 'BTD00083', 'BIOD00083']",['Natalizumab'],biotech,"[""Natalizumab is a recombinant humanized IgG4 monoclonal antibody that binds to 4-integrin.[L48041] While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008.[A261331]\r\n\r\nOn August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023.[L49096]""]",['liquid'],"['Natalizumab is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.[L48031, L48036, L49096] \r\n\r\nIt is also indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohns disease with evidence of inflammation who have had an inadequate response to or are unable to tolerate, conventional therapies and inhibitors of TNF-. It is not to be used in combination with immunosuppressants or inhibitors of TNF-.[L48031, L48036] ']","['Integrins are transmembrane receptors and adhesion molecules that facilitate the chemotaxis of leukocytes to inflammation sites.[A261326] Made up of multiple subunits, 4 integrins form heterodimers with -subunits to form functional molecules.[A261321] During inflammation, endothelial cells lining blood vessels are activated by cytokines. There is increased expression of cell adhesion molecules on the vascular endothelium, such as vascular cell adhesion molecule-1 (VCAM-1) and mucosal addressin cell adhesion molecule-1 (MAdCAM-1), expressed on vascular endothelial cells of the gastrointestinal tract. These cell adhesion molecules act as ligands or counter-receptors for 4 integrin receptors expressed primarily on lymphocytes, monocytes, and eosinophils. The interaction between cell adhesion molecules and 4 integrin facilitates the transmigration of leukocytes across the endothelium into inflamed parenchymal tissue, activation and proliferation of lymphocytes, and enhanced activity of local cytokines and chemokines. 4 integrin can also interact with extracellular matrix molecules such as fibronectin and osteopontin to further propagate inflammation.[A261321, L48031] Natalizumab binds to the 4 subunit of 41 and 47 integrin receptors to block the 4-mediated adhesion of leukocytes to their counter-receptors. In vitro, natalizumab also blocks 4-mediated cell binding to osteopontin and an alternatively spliced domain of fibronectin, connecting segment-1 (CS-1). In vivo, natalizumab may further inhibit the interaction of 4-expressing leukocytes with their ligand(s) in the extracellular matrix and on parenchymal cells, thereby inhibiting further recruitment and inflammatory activity of activated immune cells.[L48031]\r\n\r\nThe specific mechanism(s) by which natalizumab exerts its effects in multiple sclerosis and Crohns disease have not been fully defined. Lesions in multiple sclerosis (MS) are believed to occur when activated inflammatory cells, including T-lymphocytes, cross the blood-brain barrier (BBB). Leukocyte migration across the BBB involves the interaction between adhesion molecules on inflammatory cells and their counter-receptors expressed on endothelial cells lining blood vessels. Natalizumab blocks the molecular interaction of 41-integrin expressed by inflammatory cells with VCAM-1 on vascular endothelial cells and with CS-1 and/or osteopontin expressed by parenchymal cells in the brain; thereby, natalizumab reduces leukocyte migration into brain parenchyma and reduces plaque formation associated with MS.[A261326, L48031]\r\n\r\nThe interaction of the 47 integrin with the endothelial receptor MAdCAM1 has been implicated as an important contributor to chronic inflammation in Crohns disease (CD). MAdCAM-1 is mainly expressed on gut endothelial cells and is critical in homing T lymphocytes to gut lymph tissue found in Peyers patches. Increased MAdCAM-1 expression is often observed at active inflammation sites in patients with CD, suggesting that MAdCAM-1 may be involved in the recruitment of leukocytes to the mucosa. The clinical effect of natalizumab in CD may, therefore, be secondary to the blockade of the molecular interaction of the 47 integrin receptor with MAdCAM-1 expressed on the venular endothelium at inflammatory foci. VCAM-1 expression has been found to be upregulated on colonic endothelial cells in a mouse model of inflammatory bowel disease and appears to play a role in leukocyte recruitment to sites of inflammation; however, the role of VCAM-1 in CD is unclear.[L48031]']",[None],"[{'target': [{'id': ['BE0000590'], 'name': ['Integrin alpha-4'], 'organism': ['Humans'], 'actions': [{'action': ['antibody']}], 'references': [{'articles': [{'article': [{'ref-id': ['A2146'], 'pubmed-id': ['16268663'], 'citation': ['Sheremata WA, Minagar A, Alexander JS, Vollmer T: The role of alpha-4 integrin in the aetiology of multiple sclerosis: current knowledge and therapeutic implications. CNS Drugs. 2005;19(11):909-22.']}, {'ref-id': ['A2147'], 'pubmed-id': ['16634035'], 'citation': [""Niino M, Bodner C, Simard ML, Alatab S, Gano D, Kim HJ, Trigueiro M, Racicot D, Guerette C, Antel JP, Fournier A, Grand'Maison F, Bar-Or A: Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol. 2006 May;59(5):748-54.""]}, {'ref-id': ['A2149'], 'pubmed-id': ['17461891'], 'citation': ['Stuve O, Bennett JL: Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev. 2007 Spring;13(1):79-95.']}, {'ref-id': ['A2151'], 'pubmed-id': ['9389694'], 'citation': ['Craddock CF, Nakamoto B, Andrews RG, Priestley GV, Papayannopoulou T: Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood. 1997 Dec 15;90(12):4779-88.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [{'link': [{'ref-id': ['L48031'], 'title': ['FDA Approved Drug Products: TYSABRI (natalizumab) injection, for intravenous use (April 2023)'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125104s976s979lbl.pdf']}]}], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Integrin alpha-4'], 'general-function': ['Metal ion binding'], 'specific-function': ['Integrins alpha-4/beta-1 (VLA-4) and alpha-4/beta-7 are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1. Integrin alpha-4/beta-1 recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-4/beta-7 is also a receptor for MADCAM1. It recognizes the sequence L-D-T in MADCAM1. On activated endothelial cells integrin VLA-4 triggers homotypic aggregation for most VLA-4-positive leukocyte cell lines. It may also participate in cytolytic T-cell interactions with target cells.'], 'gene-name': ['ITGA4'], 'locus': ['2q31.3'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['978-1001'], 'signal-regions': ['1-33'], 'theoretical-pi': ['6.32'], 'molecular-weight': ['114898.745'], 'chromosome-location': ['2'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6140']}, {'resource': ['GenAtlas'], 'identifier': ['ITGA4']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X16983']}, {'resource': ['GenBank Protein Database'], 'identifier': ['33946']}, {'resource': ['UniProtKB'], 'identifier': ['P13612']}, {'resource': ['UniProt Accession'], 'identifier': ['ITA4_HUMAN']}]}], 'synonyms': [{'synonym': ['CD49 antigen-like family member D', 'CD49D', 'Integrin alpha-IV', 'VLA-4 subunit alpha']}], 'amino-acid-sequence': ['>lcl|BSEQ0037051|Integrin alpha-4\nMAWEARREPGPRRAAVRETVMLLLCLGVPTGRPYNVDTESALLYQGPHNTLFGYSVVLHS\nHGANRWLLVGAPTANWLANASVINPGAIYRCRIGKNPGQTCEQLQLGSPNGEPCGKTCLE\nERDNQWLGVTLSRQPGENGSIVTCGHRWKNIFYIKNENKLPTGGCYGVPPDLRTELSKRI\nAPCYQDYVKKFGENFASCQAGISSFYTKDLIVMGAPGSSYWTGSLFVYNITTNKYKAFLD\nKQNQVKFGSYLGYSVGAGHFRSQHTTEVVGGAPQHEQIGKAYIFSIDEKELNILHEMKGK\nKLGSYFGASVCAVDLNADGFSDLLVGAPMQSTIREEGRVFVYINSGSGAVMNAMETNLVG\nSDKYAARFGESIVNLGDIDNDGFEDVAIGAPQEDDLQGAIYIYNGRADGISSTFSQRIEG\nLQISKSLSMFGQSISGQIDADNNGYVDVAVGAFRSDSAVLLRTRPVVIVDASLSHPESVN\nRTKFDCVENGWPSVCIDLTLCFSYKGKEVPGYIVLFYNMSLDVNRKAESPPRFYFSSNGT\nSDVITGSIQVSSREANCRTHQAFMRKDVRDILTPIQIEAAYHLGPHVISKRSTEEFPPLQ\nPILQQKKEKDIMKKTINFARFCAHENCSADLQVSAKIGFLKPHENKTYLAVGSMKTLMLN\nVSLFNAGDDAYETTLHVKLPVGLYFIKILELEEKQINCEVTDNSGVVQLDCSIGYIYVDH\nLSRIDISFLLDVSSLSRAEEDLSITVHATCENEEEMDNLKHSRVTVAIPLKYEVKLTVHG\nFVNPTSFVYGSNDENEPETCMVEKMNLTFHVINTGNSMAPNVSVEIMVPNSFSPQTDKLF\nNILDVQTTTGECHFENYQRVCALEQQKSAMQTLKGIVRFLSKTDKRLLYCIKADPHCLNF\nLCNFGKMESGKEASVHIQLEGRPSILEMDETSALKFEIRATGFPEPNPRVIELNKDENVA\nHVLLEGLHHQRPKRYFTIVIISSSLLLGLIVLLLISYVMWKAGFFKRQYKSILQEENRRD\nSWSYINSKSNDD'], 'gene-sequence': ['>lcl|BSEQ0010411|Integrin alpha-4 (ITGA4)\nATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTG\nATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGC\nGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGC\nCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCT\nTCAGTGATCAATCCCGGGGCGATTTACAGATGCAGGATCGGAAAGAATCCCGGCCAGACG\nTGCGAACAGCTCCAGCTGGGTAGCCCTAATGGAGAACCTTGTGGAAAGACTTGTTTGGAA\nGAGAGAGACAATCAGTGGTTGGGGGTCACACTTTCCAGACAGCCAGGAGAAAATGGATCC\nATCGTGACTTGTGGGCATAGATGGAAAAATATATTTTACATAAAGAATGAAAATAAGCTC\nCCCACTGGTGGTTGCTATGGAGTGCCCCCTGATTTACGAACAGAACTGAGTAAAAGAATA\nGCTCCGTGTTATCAAGATTATGTGAAAAAATTTGGAGAAAATTTTGCATCATGTCAAGCT\nGGAATATCCAGTTTTTACACAAAGGATTTAATTGTGATGGGGGCCCCAGGATCATCTTAC\nTGGACTGGCTCTCTTTTTGTCTACAATATAACTACAAATAAATACAAGGCTTTTTTAGAC\nAAACAAAATCAAGTAAAATTTGGAAGTTATTTAGGATATTCAGTCGGAGCTGGTCATTTT\nCGGAGCCAGCATACTACCGAAGTAGTCGGAGGAGCTCCTCAACATGAGCAGATTGGTAAG\nGCATATATATTCAGCATTGATGAAAAAGAACTAAATATCTTACATGAAATGAAAGGTAAA\nAAGCTTGGATCGTACTTTGGAGCTTCTGTCTGTGCTGTGGACCTCAATGCAGATGGCTTC\nTCAGATCTGCTCGTGGGAGCACCCATGCAGAGCACCATCAGAGAGGAAGGAAGAGTGTTT\nGTGTACATCAACTCTGGCTCGGGAGCAGTAATGAATGCAATGGAAACAAACCTCGTTGGA\nAGTGACAAATATGCTGCAAGATTTGGGGAATCTATAGTTAATCTTGGCGACATTGACAAT\nGATGGCTTTGAAGATGTTGCTATCGGAGCTCCACAAGAAGATGACTTGCAAGGTGCTATT\nTATATTTACAATGGCCGTGCAGATGGGATCTCGTCAACCTTCTCACAGAGAATTGAAGGA\nCTTCAGATCAGCAAATCGTTAAGTATGTTTGGACAGTCTATATCAGGACAAATTGATGCA\nGATAATAATGGCTATGTAGATGTAGCAGTTGGTGCTTTTCGGTCTGATTCTGCTGTCTTG\nCTAAGGACAAGACCTGTAGTAATTGTTGACGCTTCTTTAAGCCACCCTGAGTCAGTAAAT\nAGAACGAAATTTGACTGTGTTGAAAATGGATGGCCTTCTGTGTGCATAGATCTAACACTT\nTGTTTCTCATATAAGGGCAAGGAAGTTCCAGGTTACATTGTTTTGTTTTATAACATGAGT\nTTGGATGTGAACAGAAAGGCAGAGTCTCCACCAAGATTCTATTTCTCTTCTAATGGAACT\nTCTGACGTGATTACAGGAAGCATACAGGTGTCCAGCAGAGAAGCTAACTGTAGAACACAT\nCAAGCATTTATGCGGAAAGATGTGCGGGACATCCTCACCCCAATTCAGATTGAAGCTGCT\nTACCACCTTGGTCCTCATGTCATCAGTAAACGAAGTACAGAGGAATTCCCACCACTTCAG\nCCAATTCTTCAGCAGAAGAAAGAAAAAGACATAATGAAAAAAACAATAAACTTTGCAAGG\nTTTTGTGCCCATGAAAATTGTTCTGCTGATTTACAGGTTTCTGCAAAGATTGGGTTTTTG\nAAGCCCCATGAAAATAAAACATATCTTGCTGTTGGGAGTATGAAGACATTGATGTTGAAT\nGTGTCCTTGTTTAATGCTGGAGATGATGCATATGAAACGACTCTACATGTCAAACTACCC\nGTGGGTCTTTATTTCATTAAGATTTTAGAGCTGGAAGAGAAGCAAATAAACTGTGAAGTC\nACAGATAACTCTGGCGTGGTACAACTTGACTGCAGTATTGGCTATATATATGTAGATCAT\nCTCTCAAGGATAGATATTAGCTTTCTCCTGGATGTGAGCTCACTCAGCAGAGCGGAAGAG\nGACCTCAGTATCACAGTGCATGCTACCTGTGAAAATGAAGAGGAAATGGACAATCTAAAG\nCACAGCAGAGTGACTGTAGCAATACCTTTAAAATATGAGGTTAAGCTGACTGTTCATGGG\nTTTGTAAACCCAACTTCATTTGTGTATGGATCAAATGATGAAAATGAGCCTGAAACGTGC\nATGGTGGAGAAAATGAACTTAACTTTCCATGTTATCAACACTGGCAATAGTATGGCTCCC\nAATGTTAGTGTGGAAATAATGGTACCAAATTCTTTTAGCCCCCAAACTGATAAGCTGTTC\nAACATTTTGGATGTCCAGACTACTACTGGAGAATGCCACTTTGAAAATTATCAAAGAGTG\nTGTGCATTAGAGCAGCAAAAGAGTGCAATGCAGACCTTGAAAGGCATAGTCCGGTTCTTG\nTCCAAGACTGATAAGAGGCTATTGTACTGCATAAAAGCTGATCCACATTGTTTAAATTTC\nTTGTGTAATTTTGGGAAAATGGAAAGTGGAAAAGAAGCCAGTGTTCATATCCAACTGGAA\nGGCCGGCCATCCATTTTAGAAATGGATGAGACTTCAGCACTCAAGTTTGAAATAAGAGCA\nACAGGTTTTCCAGAGCCAAATCCAAGAGTAATTGAACTAAACAAGGATGAGAATGTTGCG\nCATGTTCTACTGGAAGGACTACATCATCAAAGACCCAAACGTTATTTCACCATAGTGATT\nATTTCAAGTAGCTTGCTACTTGGACTTATTGTACTTCTGTTGATCTCATATGTTATGTGG\nAAGGCTGGCTTCTTTAAAAGACAATACAAATCTATCCTACAAGAAGAAAACAGAAGAGAC\nAGTTGGAGTTATATCAACAGTAAAAGCAATGATGATTAA'], 'pfams': [{'pfam': [{'identifier': ['PF01839'], 'name': ['FG-GAP']}, {'identifier': ['PF08441'], 'name': ['Integrin_alpha2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['cell-cell junction']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['integrin alpha4-beta7 complex']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['cell adhesion molecule binding']}, {'category': ['function'], 'description': ['metal ion binding']}, {'category': ['process'], 'description': ['B cell differentiation']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood vessel remodeling']}, {'category': ['process'], 'description': ['cell-matrix adhesion']}, {'category': ['process'], 'description': ['cell-matrix adhesion involved in ameboidal cell migration']}, {'category': ['process'], 'description': ['cellular response to cytokine stimulus']}, {'category': ['process'], 'description': ['chorio-allantoic fusion']}, {'category': ['process'], 'description': ['diapedesis']}, {'category': ['process'], 'description': ['endodermal cell differentiation']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['face development']}, {'category': ['process'], 'description': ['heart development']}, {'category': ['process'], 'description': ['heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules']}, {'category': ['process'], 'description': ['heterotypic cell-cell adhesion']}, {'category': ['process'], 'description': ['import into cell']}, {'category': ['process'], 'description': ['integrin-mediated signaling pathway']}, {'category': ['process'], 'description': ['leukocyte cell-cell adhesion']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['leukocyte tethering or rolling']}, {'category': ['process'], 'description': ['negative regulation of protein homodimerization activity']}, {'category': ['process'], 'description': ['positive regulation of leukocyte tethering or rolling']}, {'category': ['process'], 'description': ['positive regulation of T cell migration']}, {'category': ['process'], 'description': ['receptor clustering']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['substrate adhesion-dependent cell spreading']}, {'category': ['process'], 'description': ['T cell migration']}]}]}]}, {'id': ['BE0000901'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor III-B'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A201866'], 'pubmed-id': ['29951887'], 'citation': ['Weber F, Breustedt D, Schlicht S, Meyer CA, Niewoehner J, Ebeling M, Freskgard PO, Bruenker P, Singer T, Reth M, Iglesias A: First Infusion Reactions are Mediated by FcgammaRIIIb and Neutrophils. Pharm Res. 2018 Jun 27;35(9):169. doi: 10.1007/s11095-018-2448-8.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor III-B'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.'], 'gene-name': ['FCGR3B'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': [None], 'signal-regions': ['1-16'], 'theoretical-pi': ['6.71'], 'molecular-weight': ['26215.64'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3620']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR3B']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X16863']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31322']}, {'resource': ['UniProtKB'], 'identifier': ['O75015']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG3B_HUMAN']}]}], 'synonyms': [{'synonym': ['CD16B', 'Fc-gamma RIII', 'Fc-gamma RIII-beta', 'Fc-gamma RIIIb', 'FCG3', 'FCGR3', 'FcR-10', 'FcRIII', 'FcRIIIb', 'IGFR3', 'IgG Fc receptor III-1']}], 'amino-acid-sequence': ['>lcl|BSEQ0010635|Low affinity immunoglobulin gamma Fc region receptor III-B\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI'], 'gene-sequence': ['>lcl|BSEQ0010636|Low affinity immunoglobulin gamma Fc region receptor III-B (FCGR3B)\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['anchored component of membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['mitophagy in response to mitochondrial depolarization']}, {'category': ['process'], 'description': ['positive regulation of defense response to virus by host']}, {'category': ['process'], 'description': ['xenophagy']}]}]}]}, {'id': ['BE0000710'], 'name': ['High affinity immunoglobulin gamma Fc receptor I'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A201869'], 'pubmed-id': ['31002172'], 'citation': [""Dudek S, Weissmuller S, Anzaghe M, Miller L, Sterr S, Hoffmann K, Hengel H, Waibler Z: Human Fcgamma receptors compete for TGN1412 binding that determines the antibody's effector function. Eur J Immunol. 2019 Jul;49(7):1117-1126. doi: 10.1002/eji.201847924. Epub 2019 Apr 29.""]}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['High affinity immunoglobulin gamma Fc receptor I'], 'general-function': ['Receptor signaling protein activity'], 'specific-function': ['High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.'], 'gene-name': ['FCGR1A'], 'locus': ['1q21.2-q21.3'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['293-313'], 'signal-regions': ['1-15'], 'theoretical-pi': ['8.08'], 'molecular-weight': ['42631.525'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3613']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR1A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X14356']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31332']}, {'resource': ['UniProtKB'], 'identifier': ['P12314']}, {'resource': ['UniProt Accession'], 'identifier': ['FCGR1_HUMAN']}]}], 'synonyms': [{'synonym': ['Fc-gamma RI', 'Fc-gamma RIA', 'FCG1', 'FcgammaRIa', 'FCGR1', 'FcRI', 'IGFR1', 'IgG Fc receptor I']}], 'amino-acid-sequence': ['>lcl|BSEQ0001416|High affinity immunoglobulin gamma Fc receptor I\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT'], 'gene-sequence': ['>lcl|BSEQ0016183|High affinity immunoglobulin gamma Fc receptor I (FCGR1A)\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAATTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00047'], 'name': ['ig']}, {'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['clathrin-coated endocytic vesicle membrane']}, {'category': ['component'], 'description': ['early endosome membrane']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['receptor signaling protein activity']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent']}, {'category': ['process'], 'description': ['antigen processing and presentation of peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['interferon-gamma-mediated signaling pathway']}, {'category': ['process'], 'description': ['intracellular signal transduction']}, {'category': ['process'], 'description': ['phagocytosis, engulfment']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}, {'id': ['BE0001085'], 'name': ['Intercellular adhesion molecule 1'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Intercellular adhesion molecule 1'], 'general-function': ['Virus receptor activity'], 'specific-function': [""ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2). During leukocyte trans-endothelial migration, ICAM1 engagement promotes the assembly of endothelial apical cups through ARHGEF26/SGEF and RHOG activation.(Microbial infection) Acts as a receptor for major receptor group rhinovirus A-B capsid proteins (PubMed:1968231, PubMed:2538243). Acts as a receptor for Coxsackievirus A21 capsid proteins (PubMed:11160747, PubMed:16004874, PubMed:9539703). Upon Kaposi's sarcoma-associated herpesvirus/HHV-8 infection, is degraded by viral E3 ubiquitin ligase MIR2, presumably to prevent lysis of infected cells by cytotoxic T-lymphocytes and NK cell (PubMed:11413168).""], 'gene-name': ['ICAM1'], 'locus': ['19p13.3-p13.2'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['481-503'], 'signal-regions': ['1-27'], 'theoretical-pi': ['8.06'], 'molecular-weight': ['57824.785'], 'chromosome-location': ['19'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:5344']}, {'resource': ['GenAtlas'], 'identifier': ['ICAM1']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X06990']}, {'resource': ['GenBank Protein Database'], 'identifier': ['758074']}, {'resource': ['UniProtKB'], 'identifier': ['P05362']}, {'resource': ['UniProt Accession'], 'identifier': ['ICAM1_HUMAN']}]}], 'synonyms': [{'synonym': ['ICAM-1', 'Major group rhinovirus receptor']}], 'amino-acid-sequence': ['>lcl|BSEQ0020504|Intercellular adhesion molecule 1\nMAPSSPRPALPALLVLLGALFPGPGNAQTSVSPSKVILPRGGSVLVTCSTSCDQPKLLGI\nETPLPKKELLLPGNNRKVYELSNVQEDSQPMCYSNCPDGQSTAKTFLTVYWTPERVELAP\nLPSWQPVGKNLTLRCQVEGGAPRANLTVVLLRGEKELKREPAVGEPAEVTTTVLVRRDHH\nGANFSCRTELDLRPQGLELFENTSAPYQLQTFVLPATPPQLVSPRVLEVDTQGTVVCSLD\nGLFPVSEAQVHLALGDQRLNPTVTYGNDSFSAKASVSVTAEDEGTQRLTCAVILGNQSQE\nTLQTVTIYSFPAPNVILTKPEVSEGTEVTVKCEAHPRAKVTLNGVPAQPLGPRAQLLLKA\nTPEDNGRSFSCSATLEVAGQLIHKNQTRELRVLYGPRLDERDCPGNWTWPENSQQTPMCQ\nAWGNPLPELKCLKDGTFPLPIGESVTVTRDLEGTYLCRARSTQGEVTRKVTVNVLSPRYE\nIVIITVVAAAVIMGTAGLSTYLYNRQRKIKKYRLQQAQKGTPMKPNTQATPP'], 'gene-sequence': ['>lcl|BSEQ0020505|Intercellular adhesion molecule 1 (ICAM1)\nATGGCTCCCAGCAGCCCCCGGCCCGCGCTGCCCGCACTCCTGGTCCTGCTCGGGGCTCTG\nTTCCCAGGACCTGGCAATGCCCAGACATCTGTGTCCCCCTCAAAAGTCATCCTGCCCCGG\nGGAGGCTCCGTGCTGGTGACATGCAGCACCTCCTGTGACCAGCCCAAGTTGTTGGGCATA\nGAGACCCCGTTGCCTAAAAAGGAGTTGCTCCTGCCTGGGAACAACCGGAAGGTGTATGAA\nCTGAGCAATGTGCAAGAAGATAGCCAACCAATGTGCTATTCAAACTGCCCTGATGGGCAG\nTCAACAGCTAAAACCTTCCTCACCGTGTACTGGACTCCAGAACGGGTGGAACTGGCACCC\nCTCCCCTCTTGGCAGCCAGTGGGCAAGAACCTTACCCTACGCTGCCAGGTGGAGGGTGGG\nGCACCCCGGGCCAACCTCACCGTGGTGCTGCTCCGTGGGGAGAAGGAGCTGAAACGGGAG\nCCAGCTGTGGGGGAGCCCGCTGAGGTCACGACCACGGTGCTGGTGAGGAGAGATCACCAT\nGGAGCCAATTTCTCGTGCCGCACTGAACTGGACCTGCGGCCCCAAGGGCTGGAGCTGTTT\nGAGAACACCTCGGCCCCCTACCAGCTCCAGACCTTTGTCCTGCCAGCGACTCCCCCACAA\nCTTGTCAGCCCCCGGGTCCTAGAGGTGGACACGCAGGGGACCGTGGTCTGTTCCCTGGAC\nGGGCTGTTCCCAGTCTCGGAGGCCCAGGTCCACCTGGCACTGGGGGACCAGAGGTTGAAC\nCCCACAGTCACCTATGGCAACGACTCCTTCTCGGCCAAGGCCTCAGTCAGTGTGACCGCA\nGAGGACGAGGGCACCCAGCGGCTGACGTGTGCAGTAATACTGGGGAACCAGAGCCAGGAG\nACACTGCAGACAGTGACCATCTACAGCTTTCCGGCGCCCAACGTGATTCTGACGAAGCCA\nGAGGTCTCAGAAGGGACCGAGGTGACAGTGAAGTGTGAGGCCCACCCTAGAGCCAAGGTG\nACGCTGAATGGGGTTCCAGCCCAGCCACTGGGCCCGAGGGCCCAGCTCCTGCTGAAGGCC\nACCCCAGAGGACAACGGGCGCAGCTTCTCCTGCTCTGCAACCCTGGAGGTGGCCGGCCAG\nCTTATACACAAGAACCAGACCCGGGAGCTTCGTGTCCTGTATGGCCCCCGACTGGACGAG\nAGGGATTGTCCGGGAAACTGGACGTGGCCAGAAAATTCCCAGCAGACTCCAATGTGCCAG\nGCTTGGGGGAACCCATTGCCCGAGCTCAAGTGTCTAAAGGATGGCACTTTCCCACTGCCC\nATCGGGGAATCAGTGACTGTCACTCGAGATCTTGAGGGCACCTACCTCTGTCGGGCCAGG\nAGCACTCAAGGGGAGGTCACCCGCAAGGTGACCGTGAATGTGCTCTCCCCCCGGTATGAG\nATTGTCATCATCACTGTGGTAGCAGCCGCAGTCATAATGGGCACTGCAGGCCTCAGCACG\nTACCTCTATAACCGCCAGCGGAAGATCAAGAAATACAGACTACAACAGGCCCAAAAAGGG\nACCCCCATGAAACCGAACACACAAGCCACGCCTCCCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF03921'], 'name': ['ICAM_N']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['immunological synapse']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['membrane raft']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['integrin binding']}, {'category': ['function'], 'description': ['receptor activity']}, {'category': ['function'], 'description': ['transmembrane signaling receptor activity']}, {'category': ['function'], 'description': ['virus receptor activity']}, {'category': ['process'], 'description': ['acute inflammatory response to antigenic stimulus']}, {'category': ['process'], 'description': ['adhesion of symbiont to host']}, {'category': ['process'], 'description': ['cell adhesion']}, {'category': ['process'], 'description': ['cell adhesion mediated by integrin']}, {'category': ['process'], 'description': ['cell aging']}, {'category': ['process'], 'description': ['cellular response to alkaloid']}, {'category': ['process'], 'description': ['cellular response to glucose stimulus']}, {'category': ['process'], 'description': ['cellular response to hypoxia']}, {'category': ['process'], 'description': ['cellular response to interleukin-1']}, {'category': ['process'], 'description': ['cellular response to lipopolysaccharide']}, {'category': ['process'], 'description': ['cellular response to nutrient levels']}, {'category': ['process'], 'description': ['cellular response to tumor necrosis factor']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['establishment of endothelial barrier']}, {'category': ['process'], 'description': ['establishment of Sertoli cell barrier']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules']}, {'category': ['process'], 'description': ['interferon-gamma-mediated signaling pathway']}, {'category': ['process'], 'description': ['leukocyte cell-cell adhesion']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['membrane to membrane docking']}, {'category': ['process'], 'description': ['negative regulation of calcium ion transport']}, {'category': ['process'], 'description': ['negative regulation of endothelial cell apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of extrinsic apoptotic signaling pathway via death domain receptors']}, {'category': ['process'], 'description': ['ovarian follicle development']}, {'category': ['process'], 'description': ['positive regulation of actin filament polymerization']}, {'category': ['process'], 'description': ['positive regulation of cellular extravasation']}, {'category': ['process'], 'description': ['positive regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['positive regulation of GTPase activity']}, {'category': ['process'], 'description': ['positive regulation of NF-kappaB transcription factor activity']}, {'category': ['process'], 'description': ['positive regulation of nitric oxide biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of vasoconstriction']}, {'category': ['process'], 'description': ['receptor-mediated virion attachment to host cell']}, {'category': ['process'], 'description': ['regulation of cell adhesion']}, {'category': ['process'], 'description': ['regulation of cell shape']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['regulation of leukocyte mediated cytotoxicity']}, {'category': ['process'], 'description': ['regulation of ruffle assembly']}, {'category': ['process'], 'description': ['response to amino acid']}, {'category': ['process'], 'description': ['response to amphetamine']}, {'category': ['process'], 'description': ['response to copper ion']}, {'category': ['process'], 'description': ['response to drug']}, {'category': ['process'], 'description': ['response to ethanol']}, {'category': ['process'], 'description': ['response to gonadotropin']}, {'category': ['process'], 'description': ['response to ionizing radiation']}, {'category': ['process'], 'description': ['response to organic cyclic compound']}, {'category': ['process'], 'description': ['response to sulfur dioxide']}, {'category': ['process'], 'description': ['sensory perception of sound']}, {'category': ['process'], 'description': ['T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell']}, {'category': ['process'], 'description': ['T cell antigen processing and presentation']}]}]}]}]}]"
